<SEC-DOCUMENT>0001104659-26-023444.txt : 20260304
<SEC-HEADER>0001104659-26-023444.hdr.sgml : 20260304
<ACCEPTANCE-DATETIME>20260304160605
ACCESSION NUMBER:		0001104659-26-023444
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		128
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260304
DATE AS OF CHANGE:		20260304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Verastem, Inc.
		CENTRAL INDEX KEY:			0001526119
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				273269467
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35403
		FILM NUMBER:		26721184

	BUSINESS ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 500
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		(781) 292-4200

	MAIL ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 500
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>vstm-20251231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.2.0.5 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/4/2026 8:56:08 PM -->
<!-- iXBRL Library version: 1.0.9448.42501 -->
<!-- iXBRL Service Job ID: 00000000-0000-0000-0000-000000000000 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:vstm="http://www.verastem.com/20251231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>Verastem,&#160;Inc._December 31, 2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntityCentralIndexKey" id="Tc_z3XtzHMRmU2aqTv8dK6c_A_2_1">0001526119</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:DocumentFiscalYearFocus" id="Tc_95ca6b8oQ0OaAzvy6R0oFg_3_1">2025</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:DocumentFiscalPeriodFocus" id="Tc_2A0M9ug7nEOGXe-m_FUbpQ_4_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:AmendmentFlag" id="Tc_7qTXQ40-Zk-5gKhT5f-boQ_5_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_seqv11hd7kGtRU21nUUodw" decimals="-3" name="vstm:PreferredStockSharesDesignated" id="Hidden_ysfm7Z_m_EuRZVq3lctHYw">944000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_seqv11hd7kGtRU21nUUodw" decimals="-3" name="us-gaap:PreferredStockSharesIssued" id="Hidden_eYsU4ZNv00232JjNRkZteQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_edm9qWQjT0uGo3Ul1o6KTA" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_qHhHCzO2QUaDq3kIsGr8-A">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_seqv11hd7kGtRU21nUUodw" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_VjEul_4ydEymIByn90mfmg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" xs:nil="true" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" id="Hidden_4fkcjdqq20K-eWbfNX-_fQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" xs:nil="true" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" id="Hidden_sTNsB9LO6EuYGC4ZcgJfMw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" xs:nil="true" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" name="us-gaap:PreferredStockValue" id="Hidden_QmHIF05vtkW-Lf37Rt1dAg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" xs:nil="true" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" name="us-gaap:PreferredStockValue" id="Hidden_YfginUZE2EOloL1Am_w-Fw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_f0PNnUvzCUyNJXe3HQWfrg">77740000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_A0c_18zVRUq0bhgTAuwcJA">44784000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_5_30_2023_To_5_30_2023_us-gaap_TypeOfArrangementAxis_vstm_CertificateOfAmendmentMember_49ED66jM9E25MF3tUNgntg" decimals="4" name="vstm:StockholdersEquityReverseStockSplitConversionRatio" id="Hidden_mxFYjHBtZEODqcY96vbZbg">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_5_30_2023_To_5_30_2023_oisDwP2U50elPdB2XZBoCg" decimals="4" name="vstm:StockholdersEquityReverseStockSplitConversionRatio" id="Hidden_UDYzqQ6S1E630AMzLLYW3A">0.0833</ix:nonFraction><ix:nonNumeric contextRef="Duration_5_1_2022_To_5_31_2022_0S7CWDwAHkCwzDSQQTfHkw" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden_q90ZIR8th0OGZ8dK-5vu4A">http://fasb.org/us-gaap/2025#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" name="us-gaap:GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration" id="Hidden_LYd0gLsYTUK5twLVxNTSUw">http://www.verastem.com/20251231#GrantsReceivableNet</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" name="us-gaap:Depreciation" id="Hidden_W4pGquiuLUKirJceSn_YoA">30000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" name="us-gaap:Depreciation" id="Hidden_NwoIzrC_q02kziSjSvHlIw">26000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" name="us-gaap:Depreciation" id="Hidden_N2ulbwwA-UqvBSpy2gwqug">62000</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_iZI7Ie7K00GLdoRZJcm5tA" name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" id="Hidden_Jq6EAhHjvU6lCRswi0Rx2Q">http://fasb.org/us-gaap/2025#SecuredOvernightFinancingRateSofrMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_14_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_0BoN3371-EmgElNU_GJ5pw" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden__aGtVmkn9kuWPabZ5DVUXg">http://www.verastem.com/20251231#FairValueAdjustmentOfNotes</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_14_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_0BoN3371-EmgElNU_GJ5pw" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList" id="Hidden_-3F5ri1upkSXeC-rPJHM9A">http://www.verastem.com/20251231#FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk</ix:nonNumeric><ix:nonNumeric contextRef="Duration_3_22_2023_To_3_22_2023_CVN1xwustEOhPxcy3fNk7A" name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" id="Hidden_YOPMCZqEsUS3-osVGkAxWQ">http://fasb.org/us-gaap/2025#SecuredOvernightFinancingRateSofrMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_vstm_ShareBasedPaymentArrangementTrancheFiveMember_9vzgnyw0KEW9zorH509q7Q" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_Y9Qm4X9j2kKBLrWQXymdSw">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration" id="Hidden_0gfH3kQvRkeG5SIGukyrFQ">http://xbrl.sec.gov/country/2025#US</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_kZtv3Lbx3kGdnwrGa-1nxQ" name="vstm:CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod" id="Hidden_UdxKXO7ke0C6w3GjR8sZiQ">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_GkEC-M9QTUSgrlwCXKodVw" name="vstm:CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod" id="Hidden_gx1jXOcOUEaYyXuc-ygToQ">P15Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" id="Hidden_7alXqiLFbU--YfYHWYlRNA">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_8_24_2023_To_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_dsxUwW56ZECoNMCxu8ilPA" name="vstm:NumberOfDaysOfPriorNoticeToTerminateAgreement." id="Hidden_JU_oIydDdkuR8-FICIEckw">P90D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_8_24_2023_To_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_dsxUwW56ZECoNMCxu8ilPA" name="vstm:NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach" id="Hidden_AfA5SF6tv0-rw53ZSmEEFw">P60D</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" name="us-gaap:SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" id="Hidden_gxfwXUi5dECGg1py2bW53w">http://fasb.org/us-gaap/2025#SupplierFinanceProgramObligationCurrent http://fasb.org/us-gaap/2025#SupplierFinanceProgramObligationNoncurrent</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="vstm-20251231.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_VeTMKHIwC0eLyAN6WUjVXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:PrivatePlacement2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_SkzoBDCVyE253YNoI4hWww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:November2025PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_wgrwxnERa0qwi96U9x_blQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:PrivatePlacement2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_Pf0AlvNsAkKhEKrfCVhX9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:November2025PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_9kM5FIopg02NBn8H3CtCvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_9_30_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_-TqHBbCtZkCiLS7Kdk667Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_30_2023_To_5_30_2023_us-gaap_TypeOfArrangementAxis_vstm_CertificateOfAmendmentMember_49ED66jM9E25MF3tUNgntg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:CertificateOfAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-30</xbrli:startDate><xbrli:endDate>2023-05-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_30_2023_To_5_30_2023_oisDwP2U50elPdB2XZBoCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-30</xbrli:startDate><xbrli:endDate>2023-05-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2013_To_12_31_2018_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_6UYIohPWOE6apXvvQXRZUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2013_To_12_31_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_InUwV157EEmuIs833j_9kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_a-kauTSQJEW4yLfm5-WSHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2020_To_2_29_2020_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_KH8OwIiqFUWzZ49IgN-PQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueAndAllowancesReturnsMember_FTUadeq3F0WCVMRH53KrHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vstm:ProductRevenueAllowancesAndReservesTypeAxis">vstm:ProductRevenueAndAllowancesReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember_yE8fkK7qa06bC6iq6BUR2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vstm:ProductRevenueAllowancesAndReservesTypeAxis">vstm:ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember_OyYlxyJlr0W_orM9kelphA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vstm:ProductRevenueAllowancesAndReservesTypeAxis">vstm:ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember_Uvl6OFaJ0Uq4ztzlNkkoEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vstm:ProductRevenueAllowancesAndReservesTypeAxis">vstm:ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember_168XNhm2-E2OU8g_oJr-ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vstm:ProductRevenueAllowancesAndReservesTypeAxis">vstm:ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember_RoPH4kuymE2ByqNH0aMdag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vstm:ProductRevenueAllowancesAndReservesTypeAxis">vstm:ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember_sxwP1I5FCEKe9EEKt9_cgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vstm:ProductRevenueAllowancesAndReservesTypeAxis">vstm:ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueAndAllowancesReturnsMember_5FE7cQWXTUKpa-SgNguaWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vstm:ProductRevenueAllowancesAndReservesTypeAxis">vstm:ProductRevenueAndAllowancesReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_StatementScenarioAxis_vstm_AchievementOfCertainSalesMilestonesMember_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_zzkKq8OR_UOKfHUpO3ZAdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:AchievementOfCertainSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:ExclusiveLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_srt_StatementScenarioAxis_vstm_AchievementOfFdaApprovalMember_tZQwQiMhYEqbPdhEQQ5HEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:AchievementOfFdaApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_srt_StatementScenarioAxis_vstm_AchievementOfFdaApprovalAnniversaryMember_xTJSoxkVBEah1aNhnYblRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:AchievementOfFdaApprovalAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_srt_StatementScenarioAxis_vstm_AchievementOfCertainSalesMilestonesMember_31ejtZ8BeEqgLwzBvmRC6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:AchievementOfCertainSalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_srt_StatementScenarioAxis_vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_o3q236vw0keqOsqNBTnifA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:AchievementOfCertainDevelopmentAndCommercializationMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_vstm_ExerciseOfAllThreeGenFleetOptionsMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_o_C5UTUcQ0-Z9MtY_JiXjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:GenfleetTherapeuticsShanghaiIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:ExerciseOfAllThreeGenFleetOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_vstm_AchievementOfCertainSalesMilestonesMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_njuY9ME3DkeF5IZXfRJNAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:GenfleetTherapeuticsShanghaiIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:AchievementOfCertainSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_39lEE9M2vkGrczaWHlXE3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:GenfleetTherapeuticsShanghaiIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:AchievementOfCertainDevelopmentAndCommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_E2vhbuJLHEynsOukxWJq3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:GenfleetTherapeuticsShanghaiIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_pZ_a6EQacUaXNZDxp5JMNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_First100MillionNetSalesOfEachIncludedProductMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_yDuuqaiCa0qAYyrozwvzzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:First100MillionNetSalesOfEachIncludedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_13_2025_srt_StatementScenarioAxis_vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_L9jTrBAWiUuY_e_CNM8bCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_-48AVsFUBEugaVAWJ90CjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_6_30_2025_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_ouTeCHDu4Ey5RJk0ycXIKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:ExclusiveLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember_hrCFuYf1CEmedfPlJxDI9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2024_To_1_17_2024_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_9tsdrgQO-UKXsRxV5I_Sjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:StockOptionExchangeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-17</xbrli:startDate><xbrli:endDate>2024-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_MajorCustomersAxis_vstm_MajorCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_kdCTYwGzK0Wb4YPT-CMQMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vstm:MajorCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2025_To_8_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_9R4yRxA400KtN3lsZ5eH2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:AtMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_gb-CSVl9SE2eIj1tdK0XYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:AtMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_O0Rufo-BykGzNlAstqrYkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_usrikRrbhk2qFlA8-ytCWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_mTaWPJHmCU-O7Tpo-6Loaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2023_To_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_dsxUwW56ZECoNMCxu8ilPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:GenfleetTherapeuticsShanghaiIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-24</xbrli:startDate><xbrli:endDate>2023-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_pEx0srU5Ak2GiczyEYhqRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_e8TDv-L8LUauwZTI1obpiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_8uqSrXDV0EmTZ1ByOF2jBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_4eTmUVOzd0mGjZsxlu90SQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2024_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_ipNYPIX9lkyb7J4LRrkchw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_s7JVz9MorkeAVWRt5OMAbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_MdVGT0IgvUmbjCVDMtrXUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_5YDVN68wcUm0VSa7Wv493Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_m7dZCqcrSkuva19JwTUE4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_5ZISHrVDkE2EvnOvhrL_rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vstm:CopiktraLicenseAndRelatedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_K33i8h8swEuknRDePz8siA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_besuRyf8Y0a58JN5tevWUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_9WaY4ozWNUCB3Lci8zTJtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_1_31_2025_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_lGAzc-lkAkKmcWT8YEBiIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:GenfleetTherapeuticsShanghaiIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_DF8qnE1w-kGq9_Ct4jgrAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:GenfleetTherapeuticsShanghaiIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2025_To_1_13_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_ZP6M46McoESK6chF5ck0mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:First8QuartersFollowingNotePurchaseAgreementClosingDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zCbuz_b2rkCKzl31gcidKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_02A2El0zNE6rdIdZB1KSUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermDLoanMember_0YiEHyy_qUmrRNBRC-bsYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermDLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-25</xbrli:startDate><xbrli:endDate>2022-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermCLoanMember_GwB-PS6Ju0-fUVSXWFqhUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermCLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-25</xbrli:startDate><xbrli:endDate>2022-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_StatementScenarioAxis_vstm_SecondSaleMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_1vwgf71uzE-hN_Nsosf5bQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:SecondSaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_13_2025_srt_StatementScenarioAxis_vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_FQVi45q7jkSuA4lClWDejQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_13_2025_srt_StatementScenarioAxis_vstm_SecondSaleMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_kgBvIxdJtkiqAwZH4jNFMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:SecondSaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_25_2022_To_3_25_2022_srt_StatementScenarioAxis_vstm_PrepaymentAfterSecondAnniversaryMember_1PALNeli40iSsLa7t8QfSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:PrepaymentAfterSecondAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-25</xbrli:startDate><xbrli:endDate>2022-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_25_2022_To_3_25_2022_srt_StatementScenarioAxis_vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember_q8ti5S-pZU699rXFl4F2PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-25</xbrli:startDate><xbrli:endDate>2022-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember_hJCM6F5LHUKiyc_uSMcFDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-25</xbrli:startDate><xbrli:endDate>2022-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_2MBviHog-02Q7tUt8Qeq9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Lb8_EogSb0aV0xpnEYsScg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-24</xbrli:startDate><xbrli:endDate>2023-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_4_2022_To_11_4_2022_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_gfizhfrkqE64g9G7nBHm7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-04</xbrli:startDate><xbrli:endDate>2022-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_StatementScenarioAxis_vstm_PursuantToLicenseAgreementMember_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_VDan3WYf1EevGGqNXzZ9hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:PursuantToLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:ExclusiveLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_kZtv3Lbx3kGdnwrGa-1nxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_GkEC-M9QTUSgrlwCXKodVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_QfOCneyU3kuQfy4l3HkaFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_r6xwMcGjUkmR3Dp9MxTNuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_YFjHghTZW0Ch1fCZB71hlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_0A2hZA9RokujrbpWC0nGmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_7rlVb8oVn0S0Tnw4gAwhJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_5LADYlfrGUudV0Z1BYW7WA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_olbo--1GgkW245MgvwjaNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_18_2024_To_10_18_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fM5yxfUyOk2FmCtStYKMUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-18</xbrli:startDate><xbrli:endDate>2024-10-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_T__SJ-zwq0yVJL4kvpsp4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_14_2025_To_11_14_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_WUufEo4u2kmXKrrBjVvTxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-14</xbrli:startDate><xbrli:endDate>2025-11-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_25_2025_To_4_25_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_w6Qgr7wiUECKdrz2j0wQgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:PrivatePlacement2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-25</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_NZvKvAzq-k2_cBvWayCtvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_76lNElnqP0Ge645AbtZsrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_UQMJ9oLa3kmJvYGMn38KsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_L9scB89F9EeAgUmzCCgzrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:CantorFitzgeraldCo.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:AtMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_mUhVWV8WMkScZAT8JeG4VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_18_2024_To_10_18_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Kvj5joERQU2FBgyJpIJZgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-18</xbrli:startDate><xbrli:endDate>2024-10-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_tpO1jPCeLkKmH0m8Lyeh1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:CantorFitzgeraldCo.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:AtMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_24_2023_To_1_24_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_vGMn7XIAIUSBLUxCpfC0tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-24</xbrli:startDate><xbrli:endDate>2023-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_644V0cfv3U-29Mjt5jpGcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_2UfHf6a-7UekKeqNumvvTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:CantorFitzgeraldCo.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:AtMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_11_2012_To_7_11_2012_srt_CounterpartyNameAxis_vstm_PfizerIncMember_BItiDfIFn0WcHJLqHz3mqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-07-11</xbrli:startDate><xbrli:endDate>2012-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7MnmvaWWgEePqWQTjdY9HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_TAPCsw8lgkWIgfJ_mbgurQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dp0SN57cD0KXZDKWXesKDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fuhD4w1zHUO3JOvClD8XNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7Z9PHqH2q0S7RrWVtY151Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xiIip57Oi0ehdHOXQBNQkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NDL3BYU3PUuJd3uSXk_5qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_w551gdo2ok6ZEMwgbJunYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C6prOwECYEmM37Ntixav9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8HWoELe-FUKs4q6zosK0_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lrgQGYbzQEm9cGGsaWCIRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ASFttFVznUOS8yMRpJAbxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MohRnXLqbEGEo5fjQezNRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_y9BYeLeimkGfbgD3G1n6_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IVIVyZ8H2UGZjpXhTwRvWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ba-9SwGbmkucpagN-WsZYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_rXXFIzj9hUybe-4ngReB2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_W4v_8l5EHEOk8tW_t3-29w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Y_mwN22A6kGbxpRR-EAdLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_V_Epz3gmqU27y1VxbWmrEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_14_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_u5xj-WOakUigG8lS-TAocg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_25_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_RmWH6lNih0uXM3yO2Zl1qQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:PrivatePlacement2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_UBix19n6xEadDF59Ya6BCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_vstm_PublicMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_y99DVEYGyUKxX-8hVBLWvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PublicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_KXGM5R7Mj0CV9njTnuX__g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_vVu2uuQvG06s9WNMj9GHKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Qle4ZI3AIEyBN5JnaC-kDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_XEXyJOXQwU6kwc_ldYtXQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_oquxji7W7kORBWim9QZqHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_11_2024_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_-AttFnMCSU6nI2v6Vkvu9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:StockOptionExchangeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_17_2024_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_6mVNyROOJkSrg0yW3Dje3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:StockOptionExchangeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_9MQgPcH2EUCI7sWeUwpq2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_19_2020_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_7ogkiNGxH0Cudi_sLSt8Sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_18_2018_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_VfDIZ_ny_0SEOGbgvYKH1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2014_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_HTpasKVhbEijVBMXmoAR3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_29_2012_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member__U1eFLyyYUinIuRMK__m6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2025_To_9_30_2025_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_cywh5amltUm6Kt3zBqYeYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2023_To_9_30_2023_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_D0hnNXSwOkqr4_93nEPQFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_kF5MtIMMKk-IM7zcfxe9ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_ZKoZ1HtmKEOVJFeHyY-zGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_6dsoZ6DBIU6g6FY7wcduKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_sFo85W5EcE2hWIXSctPLDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_12_31_2018_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_3QOHsDLjBU6VMM7clr-E_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_hb0DPVUMikKyDJikKyOjUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_29_2012_To_2_29_2012_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_I4P8dDbjHU-7QChhWz3WUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-02-29</xbrli:startDate><xbrli:endDate>2012-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Thu2JVJXHE-NAiF2FbkbWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_H7UvvfgjnUqqlhC1ni7-Kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_PLQMRuTiiE6wbLtAwlEjMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member__JkWWHFFE02LfRdH8KCQ3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_AH-XF6rwGUWP_UuR-y8kTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_SRNGIXeB20ejdnPS4J6CHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_vstm_ShareBasedPaymentArrangementTrancheFiveMember_9vzgnyw0KEW9zorH509q7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">vstm:ShareBasedPaymentArrangementTrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_vstm_ShareBasedCompensationAwardTrancheFourMember_NWg1r4cHA0-EOBRAYidUbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">vstm:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8LF9tFy9yEe9w7E5AvqW_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_mUQePIf6k0Ox3rRBC0Wpxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DIZOBohzgUCmiDTqRAMCOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_21_2019_To_6_21_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_m3em9BxJfkWCCgCqGcDWTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-21</xbrli:startDate><xbrli:endDate>2019-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_BalanceSheetLocationAxis_vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_ursq9MeRN0yWn5gbwLYHOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vstm:RestrictedCashAndCashEquivalentsNoncurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceLeaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_BalanceSheetLocationAxis_vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_2MkKTScWkE6izafnUVQf4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vstm:RestrictedCashAndCashEquivalentsNoncurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceInNeedhamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_BalanceSheetLocationAxis_vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_10pAZepk4k-KD0pKIdmI3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vstm:RestrictedCashAndCashEquivalentsNoncurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceLeaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_BalanceSheetLocationAxis_vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_2wSiS_Brj0WdJYyQqH3Mow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vstm:RestrictedCashAndCashEquivalentsNoncurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceInNeedhamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_13_2025_To_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_8KWsZFM4mEuCXxQ0JyrXPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:November2025PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-13</xbrli:startDate><xbrli:endDate>2025-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_x-U4MebMkEusy4zb3w2UTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_VByLpZd3oUumXTdQ76R5ZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vstm:CopiktraLicenseAndRelatedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_zBiJ6bOlu0qlmuRS_OwhWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vstm:ResearchDevelopingAndCommercializationDrugsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_LArOb7j6NEaAnMIYXIPzkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_vstm_MajorCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_S7Vk9c7EfUOkiG3i3sRNMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vstm:MajorCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_ycCXXJQjykqCsZOvjuthHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vstm:CopiktraLicenseAndRelatedAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vstm:ResearchDevelopingAndCommercializationDrugsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_HA-hUtbuQkSrDIYOaGPRyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vstm:CopiktraLicenseAndRelatedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_C_jlzU3foUSnLHdbsgYZFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vstm:CopiktraLicenseAndRelatedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4zRDVYOP-0K61PPNI3Uvhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_jTuekN8itU-PCSYuKMbIDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_OkY1QtMdYk-oqCKMPg88RQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_AXOj8gL7Jk6ZdhZ0AOwscw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Gs8d_AaUlkS6G-nzgF-NEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_YUbMCLNoMEiiVq3ezSlFGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_Em0bxcv8gk6czzZLTd4Ywg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_yve5Cj4_rU-htYKKwRh69g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7S9Co7osyUKPh1S2Fr2wNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_25_2025_To_4_25_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_t2jNkx3weEK3-E4-F4tIgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:PrivatePlacement2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-25</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_22_2023_To_3_22_2023_us-gaap_DebtInstrumentAxis_vstm_TermBLoanMember_Ko01k0D9G0CisdNqaY7CwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermBLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-22</xbrli:startDate><xbrli:endDate>2023-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_n_qBs1SNYkedi6TPK_3kgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-25</xbrli:startDate><xbrli:endDate>2022-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Btgqk5RY306LVDoxcjygVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-24</xbrli:startDate><xbrli:endDate>2023-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_edm9qWQjT0uGo3Ul1o6KTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_s_eRJ_IM-EC5I5guhHo3NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_8jcz-NhL0EGmNv5s7ylAMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_seqv11hd7kGtRU21nUUodw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_1iNwjL1LvUC8CJz-JY9pGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_FENbJ6e8LUCyQO0RcrlfFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_24_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_FQWIrrRmRkCSrnKhzFgoaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_4_2022_srt_CounterpartyNameAxis_vstm_BiotechnologyValueFundMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_ZbyWkvA4UE-y5mQ7pRm7Mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:BiotechnologyValueFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ykjfpsDf9EClxEq1QlGEFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_18_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_ACFKxOC2mUGBN1ufbr5J8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_EgpHd6yzBUuaIpY-YY3qXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_3L8cmMQep0K6q--7_1jqxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:PrivatePlacement2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_jUBqmRoabkGaS293dmEkgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:November2025PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2024_To_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_oG3TWOGlW0SJkm54UqDFTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-23</xbrli:startDate><xbrli:endDate>2024-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2024_To_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_semVXOzt7UuTbjL3iSPnbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-23</xbrli:startDate><xbrli:endDate>2024-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_h5EVJwZSEkaojEFbMUpw3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_NfyaVSuOXEOBvk_0IuL8CA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_vstm_IqviaIncMember_us-gaap_BalanceSheetLocationAxis_vstm_AccountsPayableCurrentMember_EPTDxkm6dUGE_Y2j9gCeGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:IqviaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vstm:AccountsPayableCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_vstm_IqviaIncMember_sAB2nn3xb06KIRwK0qRhxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:IqviaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_EMxewkfryEW0MgeN6Ed9RQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_M65DxSkBeUWXwkv5yp4KTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2024_UMnI-wXQ0USHesrFhwgQ9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_nO8T_caZLkmO-wA1SFOP5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceInNeedhamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_15_2018_To_2_15_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_TZVH7IRG1kSvGhOZkG4XQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceInNeedhamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-15</xbrli:startDate><xbrli:endDate>2018-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_15_2018_To_2_15_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_PZfr7HL6HkyNjzMRM2PTpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceInNeedhamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-15</xbrli:startDate><xbrli:endDate>2018-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_SnnAtXkpqkWQ3yAjnYmU6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:FirstInsuranceFundingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-Ba5ewoa3EWicqSM_lHMtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TtA8P5RxPEqhMQS4CQul_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yQk4kITunkGYKm5hIqAzWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2023_To_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_us-gaap_ResearchAndDevelopmentArrangementMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_tYSyxNxH1Uuvalr8k9zyHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:GenfleetTherapeuticsShanghaiIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-24</xbrli:startDate><xbrli:endDate>2023-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_MkLIiJaJsUiWkMQbaTnydg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_fqBR8I39AkaH9nxabK_ZXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_13_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_xbPXD0-44U2IqHm7qVghXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_13_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_OGwNsXA5AUWD7GEFLnYUtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_yUvfHNVxFkOmrE7fRHax3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_13_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_kwGm2G1ANE6CxfNPRBiayA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_QSij2lq4ik6s4CjD_2yz9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_Uj6ZHm1iCka91Tq8-q7rTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:ExclusiveLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_us-gaap_GovernmentAssistanceTypeAxis_us-gaap_GovernmentAssistanceOtherMember_GBuPX_U0g0azpKLEVKIehg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">us-gaap:GovernmentAssistanceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_0S7CWDwAHkCwzDSQQTfHkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember__WavrOlweUuRmxKfUY_vSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember_RAkPieYklE2it_DAfMg6bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_6KQR_VTJyEGtpgOTeeNfig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_l6H3Xy5qKk-1R-nWGp4lrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6mJXVPDki0CwWIMRXdTM3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_14_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_0BoN3371-EmgElNU_GJ5pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-14</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_fGAFkO2I5k6tbgjWbUyMMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_FvCF6Wd2sUa1Ka_dpTtMeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_M3ZzNPTGjEyOJy5c4k1gkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_vstm_PublicMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_Jr05H4l9L0uUqAYKxs4qxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PublicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_7P_amzQ5tEm7vf5xPezzyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:StockOptionExchangeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_QxkWpkXINU6ewZdwyiOEzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aS2tcr5syUKqamx-hjW3Pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_22_2023_To_3_22_2023_CVN1xwustEOhPxcy3fNk7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-22</xbrli:startDate><xbrli:endDate>2023-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_RedemptionPriorToThirdAnniversaryMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_E6tvvCsPZ0mBoCk6DsCySg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:RedemptionPriorToThirdAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_RedemptionPriorToSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_YpTuBpiScUuxKI1zr7VhQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:RedemptionPriorToSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_RedemptionAfterYearThirdAnniversaryMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_E6iz-U49E0K1SJSRv0h8aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:RedemptionAfterYearThirdAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_1_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_cQjwjoVWG0yneJwH7D4Q0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:FirstInsuranceFundingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_Un8b41l_pEirHv8lmaIPmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_22_2023_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_75mzb7bZKkioJTv-axGvyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_8S_QmEHi20-3Bt7pN3KrWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_UhCOi_V-Yk--a9CzLZu_Og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:FirstInsuranceFundingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_13_2025_srt_StatementScenarioAxis_vstm_InitialSaleMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_TGIhGhuPoUWERtDGZhnrlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:InitialSaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_zrQB4qKfyEqQTrK2VnX_yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermELoanMember_oqIeKfAl3E-mBRkyj-y-iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermELoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermDLoanMember_w57GQ0GBSEaZmkdvKKZD1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermDLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermCLoanMember_LB9vQfFWtUOb5dJuYRvwQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermCLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_iZI7Ie7K00GLdoRZJcm5tA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_22_2023_To_3_22_2023_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_5nolpa91pE-eWxvWNTzoIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-22</xbrli:startDate><xbrli:endDate>2023-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_S54_9duti0-qFLlDHg8uag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_4_2022_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_zoyOL8-GYk65yM8gGKkE-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_4_2022_To_11_4_2022_srt_CounterpartyNameAxis_vstm_BiotechnologyValueFundMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_tMPnHLFbrkuMv8YVveCukQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:BiotechnologyValueFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-04</xbrli:startDate><xbrli:endDate>2022-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_4_2022_To_11_4_2022_srt_CounterpartyNameAxis_vstm_BiotechnologyValueFundMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fvPNrQJtrkWkJoV_MdT_gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:BiotechnologyValueFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-04</xbrli:startDate><xbrli:endDate>2022-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_MajorCustomersAxis_vstm_MajorCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_plJG3megQ0iGNmTnOb-Uvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vstm:MajorCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_6XXSqLAvakekgauvuyfFBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_KS1tXWlGL0mDHAAYpEFAqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_30_2023_us-gaap_TypeOfArrangementAxis_vstm_CertificateOfAmendmentMember_Q_y7EUi3X0K_kq-y8s1gbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:CertificateOfAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_PreFundedWarrantMember_KnGNGKDd4UaRuVatC6F9Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_v94nix69zkGeGJg-ULbs-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_WarrantMember_wbTMM7gk_U6IJSEizGwY4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_jgUB4qLkMESjHNyit_jWJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_o3QykpaT9kO0MVdafyJpUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_vstm_SeriesaConvertiblePreferredStockMember_h2EwK_J3D0yrYJTXRulnyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_vstm_PreFundedWarrantMember_Fay4PRvQWEyTg9vyJimtfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_VwswXPy6N0iYiVDwlnG78g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_WarrantMember_3vY0IAdGpE23ucHgSc6EPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_hNJYkO5IlkSxNYbhWOjEug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_LdWz0v453kS4CX1tFFGG_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_xgsOVZqDvUy1HFomyzF7Hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_21_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_kZlm7MS8p0C-2514CTT6lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_W-OWHjTX20eGOqczNgrSyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_XleLLeLgMUaEtBjxP-2klw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_n96ND7-6FkaDWs_KK9qUrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:November2025PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_NVq59xSXbE6uvQXjAgxbQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_25_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_ehT0HA0cvUW9AwZHGjQ9nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:PrivatePlacement2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_eegaa3ABKkqBRahdn4RezA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_9uZ0RStEKUaT5_5fRWamIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_qoqGwn8YFkepdjxAScNrxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_ewMMPiBO5k-cPP2IurkzMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_9JY_1UA-ZEecEwccCTRt3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_Uyhdm4_rYEOg-NEKFqTeBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_z5GNzJxej0aeNGqmRjwWLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_CashAndCashEquivalentsAxis_vstm_CashAndMoneyMarketAccountsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_vstm_CorporateBondsAndCommercialPaperMember_RPkjFi0xNEyDFZjufdCC-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vstm:CashAndMoneyMarketAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vstm:CorporateBondsAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7jjnAioBzkCDhttauz0FHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_vstm_CashAndMoneyMarketAccountsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d4Dr_eG7_EGh26Hx67k-HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vstm:CashAndMoneyMarketAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_eBqr6h4vlUOpwptV_czZMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_CashAndCashEquivalentsAxis_vstm_CashAndMoneyMarketAccountsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_vstm_CorporateBondsAndCommercialPaperMember_MWAiV7Cxnk2tfkH3USoRZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vstm:CashAndMoneyMarketAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vstm:CorporateBondsAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_12Jwxj-GpUyMjUlJbpGHrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_vstm_CashAndMoneyMarketAccountsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_2k6kDSuJ90Spe63C0ts7DA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vstm:CashAndMoneyMarketAccountsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_-gOCxHhMf0WnaIxAheCqPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0ZkUR0_jhUeO6Ak4kIOPSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AjLSxccsFEupWVwt4xkeYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5WLmwNvOF0u7-gwsjUY1fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5TQU9p2reEqK8sueEagIGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_15_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_xJV-v7FV5UyE4Ztk9gpPcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceLeaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_15_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_X8QqK4Hmd06KwW35Ix-WEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceInNeedhamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2014_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_xnA_Kvwj70evJoubr3vJJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceInNeedhamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_haNRViJSzEOTdDWixSwWZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_2Bs0lZ91y0Cmf6Th8FtUgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_YnZ3x6uu-0Wme4Fzg28ezw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_GHWd8K1WG0u-Q7uzXgEt8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_V8o_TMafXU69pWaNyC7oHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_nET5C9dUgUCwg9L0-kWvkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_YJkjgHtK7UWwDuHpo_dJVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_NV4P7J5B-UKwUVnwqEP6NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_Z7vMySuKckCsJVbZ8qZDQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_UVwviP4qFk2O79hJ4CkV4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_eu_9_6CHf0y-Lj52IH4byw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Q-P8zB2YJ0Gd2Zv66vU9Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_xY-UvU2IMkukHRCrwlS71A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_-x24TYsG3USzRfi7iWlv3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_P0DHBOoSh0iaybDJceiPYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:StockOptionExchangeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_vstm_SellingGeneralAndAdministrativeExpenseMember_GF1wQLe1cEepBDtan8hiOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">vstm:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vstm:ResearchDevelopingAndCommercializationDrugsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_81vFum6e40qPRWAKzAeYEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_HI4Ao1b7KUaKAhD6JIXWwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_vstm_SellingGeneralAndAdministrativeExpenseMember_sCAZBIHJT0aFnxlMm6H5GQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">vstm:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vstm:ResearchDevelopingAndCommercializationDrugsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_S_kTXh7xV0m8qg0cNUl6aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2rH54lHkjUGemFEv-HKuhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_oOgDU519zEqo7xvys1DGvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_vstm_SellingGeneralAndAdministrativeExpenseMember_F3TTaRhxYEqLX5MuwsstiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">vstm:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vstm:ResearchDevelopingAndCommercializationDrugsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_o06JHclHKkuBTNuWXs-wzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_M0_H0x6EIkiEVk025KKwUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_vKi2RrPfkku5amSLSGzqiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2024_To_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_hbgxBNPYbUyJb5vXdalJvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-23</xbrli:startDate><xbrli:endDate>2024-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Nx7kZA6zXkqD1bBA5afBeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_6SeiJlC4WkGCPvAYgU6Y5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H2d2wIpatEOMddtM_uXHjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_smxFsQJeIEe8LC1hRLDuYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GZ0fEHkwU0OYcLlJwZ7pfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2025_To_12_31_2025_9WuRZ5oiCEytQ-4llKR_8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_U2l50NSmAkq0-Oxfvm-ugA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_27_2026_QrdMVJO2fkqYAmK0L974Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_customer_sDaO4Ago9kCUEtrMUagxqg"><xbrli:measure>vstm:customer</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_tranche_AR7EJ57OqEq8JqHSzH8_Aw"><xbrli:measure>vstm:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_tReSOj-zJkipnhJ_-h7uBA"><xbrli:measure>vstm:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_FdbiNq8DNkeaOGqvsWqN6A"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_5quK1hZThku2W0bLLpUodA"><xbrli:measure>vstm:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_zofEUC3Xr0eG4_rh7aLMNg"><xbrli:measure>vstm:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Y_QWKc7mjBxEydJx6eMjqhZA"><xbrli:measure>vstm:Y</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_8U3XYH-pF0m6Z5I545EDwQ"><xbrli:measure>vstm:installment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_1a660d33_d051_4960_bab4_37bd8cc22564"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON,&#160;D.C.&#160;20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:DocumentType" id="Narr_m1aKTUZTAEipb9avVxcmtQ"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><a id="_30036142_276b_4148_a921_cdfa6f23efda"></a><a id="Tc_fwFhS2gCvUKAZOafCd-qdw_0_0"></a><a id="Tc_88vXDMSai0uydyjalzpjQg_1_1"></a><a id="Tc_OH9DNG3WAUqS-zMOMOR17g_2_0"></a><a id="Tc_z38x3tcLlkuxD0REDlhUPA_3_0"></a><a id="Tc_MG1bFnYlU0GwyhROx5N7wg_4_1"></a><a id="Tc_oO0NQY4SjkCORIKz4q4ESA_5_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:3.6pt;width:100%;"><tr style=""><td style="vertical-align:top;width:13.41%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p></td><td style="vertical-align:bottom;width:86.58%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:13.41%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:DocumentAnnualReport" id="Tc_QZOsYGLlXk2coQJKgqUwzw_1_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:86.58%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR&#160;15(d)&#160;OF&#160;THE SECURITIES&#160;EXCHANGE ACT OF&#160;1934</b></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:DocumentPeriodEndDate" id="Narr_uT9824eMZEyELjqihYatOQ"><ix:nonNumeric format="ixt:date-monthname-day-en" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:CurrentFiscalYearEndDate" id="Narr_j92kn5s44UGunC1S_N6V3A"><b style="font-size:7pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">, 2025</b></ix:nonNumeric></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">or</b></p></td></tr><tr style=""><td style="vertical-align:top;width:13.41%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:DocumentTransitionReport" id="Tc_MCUIjnWK90mY0Mx8-4e9RA_4_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:86.58%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR&#160;15(d)&#160;OF&#160;THE SECURITIES&#160;EXCHANGE ACT OF&#160;1934</b></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">For the transition period from                  to                  </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-size:9pt;font-weight:bold;">Commission file number&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntityFileNumber" id="Narr_EHiwa2qlzUaTLTZN8nIrug"><b style="font-size:9pt;font-weight:bold;">001-35403</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntityRegistrantName" id="Narr_q64GgQ5sq0yplVX-NHb07g"><b style="font-weight:bold;">Verastem,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 4pt 0pt;">(Exact name of registrant as specified in its charter)</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style=""><td style="vertical-align:top;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntityIncorporationStateCountryCode" id="Narr_7939X_drx02_yFD1OfYfOg"><b style="font-size:7pt;font-weight:bold;">Delaware</b></ix:nonNumeric><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">(State or other jurisdiction of</span><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">incorporation or organization)</span></p></td><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntityTaxIdentificationNumber" id="Narr_T7Nuc_ns80mc4LVppx3JiQ"><b style="font-size:7pt;font-weight:bold;">27-3269467</b></ix:nonNumeric><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">(I.R.S. Employer</span><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">Identification No.)</span></p></td></tr><tr style=""><td style="vertical-align:top;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3pt 0pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntityAddressAddressLine1" id="Narr_oJw7X6zfCkamqwE6xqV31w"><b style="font-size:7pt;font-weight:bold;">117 Kendrick Street, Suite&#160;500</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;"><br/></b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntityAddressCityOrTown" id="Narr_BAtBUl14FESnylwnWFJFGQ"><b style="font-size:7pt;font-weight:bold;">Needham</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntityAddressStateOrProvince" id="Narr_C4GbbPJJoEyJdZl4qT2j1A"><b style="font-size:7pt;font-weight:bold;">Massachusetts</b></ix:nonNumeric><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">(Address of principal executive offices)</span></p></td><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3pt 0pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntityAddressPostalZipCode" id="Narr_ty531AN7M0yIoX5tJSh1Hg"><b style="font-size:7pt;font-weight:bold;">02494</b></ix:nonNumeric><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">(Zip Code)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:CityAreaCode" id="Narr_xsonCEK1lEuMJNJXw8kyVQ"><b style="font-size:8pt;font-weight:bold;">781</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">)&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:LocalPhoneNumber" id="Narr_Oh2VH1o7IESAnxTn-x83iQ"><b style="font-size:8pt;font-weight:bold;">292-4200</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">Securities registered pursuant to Section&#160;12(b) of the Act:</p><a id="_217a83c6_2b05_4519_aee9_90bbfad2132b"></a><a id="Tc_y-HCugsd30SwzQcaO-aslg_0_0"></a><a id="Tc_x_wuAXh4NkOnpVk-PXydpQ_0_1"></a><a id="Tc_ImyD6DI4REW9Hh8BjIqzbw_0_2"></a><a id="Tc_erotj8ehykiNO58jNcDPbg_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:3.6pt;width:91.77%;"><tr style=""><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:28.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr style=""><td style="vertical-align:top;width:36.11%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:Security12bTitle" id="Tc_MaopwaNSpUm-K6GIB1NgUw_1_0"><span style="font-size:7pt;">Common Stock, $0.0001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:TradingSymbol" id="Tc_0zhkkvvkjUKOEALDO_jbaw_1_1"><span style="font-size:7pt;">VSTM</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:28.25%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;">The </span><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:SecurityExchangeName" id="Narr_LLW66hU9VEe0BpgGX83j5g"><span style="font-size:7pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:7pt;"> Capital Market</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:4pt 0pt 0pt 0pt;">Securities registered pursuant to Section&#160;12(g) of the Act: <b style="font-weight:bold;">None</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;">&#160;</span><span style="font-size:8pt;white-space:pre-wrap;">Yes  </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_osw-H4MfRUiMY9M1x4xcRw"><span style="font-size:8pt;">No</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act. </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;">&#160;</span><span style="font-size:8pt;white-space:pre-wrap;">Yes  </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntityVoluntaryFilers" id="Narr_TZY3PK1AWkeCO6n5BvA8JQ"><span style="font-size:8pt;">No</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntityCurrentReportingStatus" id="Narr_T0RwRmzcKkWxhoR64_JzkQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;white-space:pre-wrap;">  </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;">&#160;No</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit). </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntityInteractiveDataCurrent" id="Narr_33VYti6IyUa9CtQX_MNBbA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;white-space:pre-wrap;">  </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;">&#160;No</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:3.6pt;width:100%;"><tr style=""><td style="vertical-align:top;width:21.46%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:10pt;text-indent:-10pt;margin:0pt;">Large&#160;accelerated&#160;filer&#160;<span style="font-family:'Times New Roman';">&#9723;</span></p></td><td style="vertical-align:top;width:17.55%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Accelerated&#160;filer <span style="font-family:'Times New Roman';">&#9723;</span></p></td><td style="vertical-align:top;width:15.58%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntityFilerCategory" id="Narr_dxzk3qHhR0uHZL06iJhjOw"><span style="font-size:8pt;">Non-accelerated&#160;filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;"><br/></span><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.72%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">Smaller&#160;reporting&#160;company</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntitySmallBusiness" id="Narr_88T9ZX6gqU2mW7jTqAkx7Q"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:22.67%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">Emerging growth company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntityEmergingGrowthCompany" id="Narr_Bwh66ASiOk2krNqUW7TJ7g"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting&#160;under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:IcfrAuditorAttestationFlag" id="Narr_C7VZ66t2Rk2BKG4WAgcGzg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issues financial statements.</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;"> </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_cKYvsEkW7E6nQMHgXU40MQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:EntityShellCompany" id="Narr_2Ir7zo-4xk-NlmI0NwYXvQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;No</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">Aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2025 was $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_6_30_2025_U2l50NSmAkq0-Oxfvm-ugA" decimals="0" name="dei:EntityPublicFloat" id="Narr_u3NJr1E-tUiGMU8QKjWeLA">253,804,995</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">The number of shares outstanding of the registrant&#8217;s common stock as of February 27, 2026 was <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_2_27_2026_QrdMVJO2fkqYAmK0L974Jw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_qTUTmJOuyUeb3XeVGiAzBA">87,835,106</ix:nonFraction></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="Tb_kNmPeiFSL0qJLcyXzSfaTQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">Portions of the definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A relating to the Registrant&#8217;s Annual General Meeting of Shareholders, to be held on May 21, 2026 will be incorporated by reference in this Form 10-K in response to Items 10, 11, 12, 13 and 14 of Part III. The definitive proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December&#160;31, 2025.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:36pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7ec166ae_78f8_46a5_beb6_67b21d4b3e60"></a><a id="Toc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:3.6pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style=""><td colspan="4" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#PARTI_947786"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item1Business"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#ITEM1ARiskFactors_957358"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1ARiskFactors_957358"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">37</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_621403"><span style="font-style:normal;font-weight:normal;">Item&#160;1B.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_621403"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item1CCybersecurity_872844"><span style="font-style:normal;font-weight:normal;">Item 1C. </span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1CCybersecurity_872844"><span style="font-style:normal;font-weight:normal;">Cybersecurity</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item2Properties_314266"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_314266"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">81</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item3LegalProceedings_948111"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_948111"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">81</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_401479"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_401479"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">81</p></td></tr><tr style=""><td colspan="3" style="vertical-align:top;width:88.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#PARTII_454447"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td><td style="vertical-align:bottom;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuers Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">82</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item6SelectedFinancialData_957616"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6SelectedFinancialData_957616"><span style="font-style:normal;font-weight:normal;">Reserved</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;7.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item&#160;7A.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">98</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item8ConsolidatedFinancialStatementsandS"><span style="font-style:normal;font-weight:normal;">Item&#160;8.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8ConsolidatedFinancialStatementsandS"><span style="font-style:normal;font-weight:normal;">Consolidated Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">98</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item&#160;9.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">98</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_391706"><span style="font-style:normal;font-weight:normal;">Item&#160;9A.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_391706"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">98</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item9BOtherInformation_30350"><span style="font-style:normal;font-weight:normal;">Item&#160;9B.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_30350"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">99</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item9CDisclosureREgardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Item 9C.</span></a> </p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9CDisclosureREgardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">100</p></td></tr><tr style=""><td colspan="3" style="vertical-align:top;width:88.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#PARTIII_41607"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERS"><span style="font-style:normal;font-weight:normal;">Item&#160;10.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERS"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">100</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_242284"><span style="font-style:normal;font-weight:normal;">Item&#160;11.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_242284"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">101</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-style:normal;font-weight:normal;">Item&#160;12.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">101</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">Item&#160;13.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">101</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTANTFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">Item&#160;14.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTANTFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">101</p></td></tr><tr style=""><td colspan="3" style="vertical-align:top;width:88.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#PARTIV_998053"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Item&#160;15.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">102</p></td></tr><tr style=""><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Item16Form10KSummary"><span style="font-style:normal;font-weight:normal;">Item&#160;16.</span></a></p></td><td style="vertical-align:top;width:78.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">102</p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:86.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#EXHIBITINDEX_345974"><span style="font-style:normal;font-weight:normal;">EXHIBIT INDEX</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">103</p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:86.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#SIGNATURES_102162"><span style="font-style:normal;font-weight:normal;">SIGNATURES</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.28%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">109</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk186482864"></a><a id="_Hlk186484440"></a><a id="_0c63d241_04a9_4960_8034_e62605b7f6c9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORWARD LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="white-space:pre-wrap;">This Annual Report on Form 10-K contains forward-looking statements. These forward-looking statements generally can be identified by the use of words such as &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;potentially,&#8221; &#8220;project,&#8221; and other words of similar meaning All statements, other than statements related to present facts or current conditions or historical facts, contained in this Annual Report on Form 10-K are forward-looking statements, including statements regarding our strategy, future operations, future financial position, including our ability to continue as a going concern through one year from the date of the financial statements for the year ended December 31, 2025, future revenues, projected costs, prospects, plans and objectives of management. Such statements relate to, among other things, the commercial success of our marketed product AVMAPKI&#8482; FAKZYNJA&#8482; CO-PACK (avutometinib capsules; defactinib tablets), the development and activity of our programs and product candidates, avutometinib (rapidly accelerated fibrosarcoma (&#8220;RAF&#8221;)/ mitogen-activated protein kinase kinase (&#8220;MEK&#8221;) program), defactinib (focal adhesion kinase (&#8220;FAK&#8221;) program), and VS-7375 (a selective oral KRAS G12D dual ON/OFF inhibitor), the structure and potential clinical value of our completed, planned and pending clinical trials, including the RAMP 201, RAMP 201J, RAMP 205, RAMP 301 and VS-7375 trials; the timing of commencing and completing trials, including topline data reports, our interactions with regulators;  the timeline and indications for clinical development, regulatory submissions and the potential for and timing of commercialization of our product candidates; the potential for additional development programs involving the Company&#8217;s lead compound and the potential market opportunities thereof; the expected outcome and benefits of our collaboration with GenFleet Therapeutics (Shanghai), Inc. (&#8220;GenFleet&#8221;) and the estimated addressable markets for, and anticipated market opportunities of our drug candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks and uncertainties, among other things, regarding: the success in the development and potential commercialization of our product candidates, including avutometinib in combination with other compounds, including defactinib, LUMAKRAS&#174;, VS-7375 and others; the uncertainties inherent in research and development, such as negative or unexpected results of clinical trials; the occurrence or timing of applications for our product candidates that may be filed with regulatory authorities in any jurisdictions; whether and when regulatory authorities in any jurisdictions may approve applications that may be filed for our product candidates and, if approved, whether our product candidates will be commercially successful in such jurisdictions; the impact of current and future healthcare reforms, including those affecting the delivery of or payment for healthcare products and services; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the scope, timing, and outcome of any legal proceedings; decisions by regulatory authorities regarding trial design, labeling and other matters that could affect the timing, availability or commercial potential of our product candidates; whether preclinical testing of our product candidates and preliminary or interim data from clinical trials will be predictive of the results or success of ongoing or later clinical trials; that the timing, scope and rate of reimbursement for our product candidates is uncertain; actions or advice of regulatory agencies to maintain regulatory approval of AVMAPKI FAKZYNJA CO-PACK; that the market opportunities of AVMAPKI FAKZYNJA CO-PACK are based on internal and third-party estimates which may prove to be incorrect; that third- party payors (including government agencies) may not reimburse; uncertainties related to regulatory and policy changes proposed and enacted by the current U.S. presidential administration that may adversely affect our business; that there may be competitive developments affecting our product candidates; that data may not be available when expected; that enrollment of clinical trials may take longer than expected; risks associated with preliminary and interim data, which may not be representative of more mature data, including with respect to interim duration of therapy data; that our marketed products and product candidates may cause adverse safety events and/or unexpected concerns may arise from additional data or analysis, or result in unmanageable safety profiles as compared to their levels of efficacy; that we may be unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so; that we may not be able to confirm the results from the RAMP 201 study or expand the approved indication for AVMAPKI FAKZYNJA CO-PACK; that our product candidates may experience manufacturing or supply interruptions or failures; that any of our third-party contract research organizations, contract manufacturing organizations, clinical sites, or contractors, among others, who we rely on may fail to fully perform; that we face substantial competition, which may result in others developing or commercializing products before or more successfully than we do which could result in reduced market share or market potential for our product candidates; that we may be unable to successfully initiate or complete the clinical </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">development and eventual commercialization of our product candidates; that the development and commercialization of our product candidates may take longer or cost more than planned, including as a result of conducting additional studies or our decisions regarding execution of such commercialization; that we may not have sufficient cash to fund our contemplated operations, including certain of our product development programs; that we may not attract and retain high quality personnel; that we or Pfizer, Inc. (&#8220;Pfizer&#8221;) may fail to fully perform under the license agreement covering certain Pfizer FAK inhibitors, including defactinib; that we or Chugai Pharmaceutical, Co. Ltd. (&#8220;Chugai&#8221;) may fail to fully perform under the avutometinib license agreement; that we or Secura Bio, Inc. (&#8220;Secura&#8221;) may fail to fully perform under the asset purchase agreement with Secura, including in relation to milestone payments; that we may not see a return on investment on the payments we have and may continue to make pursuant to the collaboration and option agreement with GenFleet or that GenFleet may fail to fully perform under the agreement; that we may not be able to establish new or expand on existing collaborations or partnerships, including with respect to in-licensing of our product candidates, on favorable terms, or at all; that we may be unable to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity, debt financing or otherwise; that we may not pursue or submit regulatory filings for our product candidates; and that our product candidates will not receive regulatory approval, become commercially successful products, or result in new treatment options being offered to patients. Other risks and uncertainties include those identified under the heading &#8220;Risk Factors&#8221; contained in this Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 4, 2026, and in any subsequent filings with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">As a result of these and other factors, we may not achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. The forward-looking statements contained in this Annual Report on Form 10-K reflect our views as of the date hereof. We do not assume and specifically disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk221129868"></a><a id="_60247c6f_4d4a_4466_9cff_0e6577c558fd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">SUMMARY OF RISK FACTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Item 1A. Risk Factors&#8221;. You should carefully consider the risks that are summarized below and discussed in greater detail in the above mentioned section&#160;before making an investment decision. If any of the following risks and uncertainties actually occur, our business, financial condition, and results of operations could be negatively impacted, and you could lose all or part of your investment.</i></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are highly dependent on the commercial success of AVMAPKI FAKZYNJA CO-PACK (avutometinib&#160;capsules;&#160;defactinib&#160;tablets)) in the United States for the foreseeable future.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preclinical testing and clinical trials of our product candidates may not be successful. Although we have received accelerated approval from FDA for the combination of avutometinib and defactinib, if we are unable to expand the approved indication for the combination product, obtain marketing approval for or successfully commercialize any of our other product candidates, or if we experience significant delays in doing so, our business will be materially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even though&#160;avutometinib and defactinib has received marketing authorization, and even if any of our&#160;other product candidates receives marketing approval,&#160;avutometinib and defactinib and any other product candidates may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market opportunities for AVMAPKI FAKZYNJA CO-PACK and our other product candidates, if approved, may be smaller than we estimate, and the FDA and other comparable foreign regulatory authorities may approve our product candidates for a more limited patient population than we anticipate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The approval of our product candidates as single agents or part of a combination therapy for the treatment of certain cancers may be more costly than our prior clinical trials, may take longer to achieve regulatory approval, may be associated with new, more severe or serious and unanticipated adverse events, and may have a smaller market opportunity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize such candidates, and our ability to generate revenue will be materially impaired.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If serious adverse or unexpected side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant losses since our inception. We may incur losses for the foreseeable future and may never achieve or maintain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will need additional funding. If we are unable to raise capital if needed, we would be forced to delay, reduce, or eliminate our product development programs or commercialization efforts, including for avutometinib, defactinib and VS-7375.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Raising additional capital or entering into certain licensing arrangements may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face substantial competition, which may result in others developing or commercializing products before or more successfully than we do.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely in part on third parties to conduct our clinical trials and preclinical testing, and if they do not properly and successfully perform their obligations to us, we may not be able to obtain regulatory approvals for and commercialize any of our other product candidates.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:189.65pt;"><a id="_e87d6aa8_aa8a_49c9_9961_e68604235d4d"></a><a id="PARTI_947786"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART </b><b style="font-weight:bold;">I</b></p><a id="Item1Business"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OVERVIEW</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are&#160;a&#160;biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with&#160;challenging&#160;RAS/MAPK pathway-driven cancers.&#160;We&#160;market AVMAPKI FAKZYNJA CO-PACK&#160;(avutometinib&#160;capsules;&#160;defactinib&#160;tablets)&#160;in the&#160;United States (&#8220;U.S.&#8221;), the first treatment specifically FDA-approved for&#160;adults with KRAS-mutated recurrent low-grade serous ovarian cancer (&#8220;LGSOC&#8221;)&#160;who have received prior systemic therapy.&#160;AVMAPKI FAKZYNJA CO-PACK&#160;received accelerated approval in the U.S. on May 8, 2025.&#160;We are&#160;also&#160;conducting&#160;RAMP 301, a Phase 3 trial designed to evaluate avutometinib plus defactinib versus Investigator&#8217;s Choice of Treatment (&#8220;ICT&#8221;) in patients with recurrent LGSOC with and without a KRAS mutation. This trial will serve as a confirmatory study for the initial U.S. indication and has the potential to expand the indication regardless of KRAS mutation status. Results of the RAMP 301 trial may also support future regulatory filings outside of the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our pipeline&#160;includes clinical-stage programs,&#160;preclinical research&#160;programs&#160;and&#160;externally partnered&#160;early-stage programs. Our&#160;focus&#160;is&#160;on novel small molecule drugs&#160;developed both as monotherapy and in combination,&#160;which&#160;inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including&#160;targeting RAS directly with&#160;KRAS G12D inhibition, targeting the pathway downstream with&#160;RAF/MEK inhibition,&#160;and targeting the parallel pathway that drives resistance with&#160;FAK inhibition.&#160;Our focus is to expeditiously develop and deliver transformative therapies that&#160;truly change&#160;outcomes for people living with RAS/MAPK pathway-driven cancers.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For our clinical-stage pipeline programs, we are evaluating VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor,&#160;for the treatment of patients with KRAS G12D mutated cancers, including&#160;pancreatic ductal adenocarcinoma&#160;(&#8220;PDAC&#8221;),&#160;non-small cell lung cancer&#160;(&#8220;NSCLC&#8221;), colorectal cancer (&#8220;CRC&#8221;)&#160;and other KRAS G12D mutated cancers.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A summary of our commercial and pipeline products is shown below.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="vstm-20251231x10k003.jpg" alt="Graphic" style="display:inline-block;height:189.65pt;width:468pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Not shown: Two undisclosed assets at discovery phase targeting RAS/MAPK pathway-driven cancers as part of the&#8239;GenFleet&#8239;Therapeutics&#160;collaboration.&#8203;</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Segoe UI';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information below summarizes our key achievements in 2025 and the&#160;anticipated&#160;near-term milestones for&#160;our pipeline programs.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVMAPKI FAKZYNJA CO-PACK&#160;</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">AVMAPKI FAKZYNJA CO-PACK&#160;received accelerated approval by the&#160;U.S. Food and Drug Administration&#8239;(FDA) on&#8239;May 8, 2025&#160;for the treatment of adults with KRAS-mutated recurrent LGSOC who have received prior systemic therapy, approximately two months in advance of the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) action date of&#8239;June 30, 2025.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The product was&#160;commercially available&#160;within a week&#160;of approval&#160;and&#160;was&#160;subsequently&#160;listed as a&#160;Category 2A recommendation&#160;for KRAS-mutated&#160;recurrent LGSOC&#160;in the&#160;National Comprehensive Cancer Network&#174; (&#8220;NCCN&#174;&#8221;)&#160;Clinical Practice Guidelines in Oncology (&#8220;NCCN Guidelines&#174;&#8221;).&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Potential label and&#160;commercial&#160;geographic&#160;expansion of the combination therapy&#160;progressed:&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional&#160;patient enrollment for RAMP 301&#160;was completed&#160;in December 2025&#160;following a pre-planned interim analysis (&#8220;IA&#8221;)&#160;by&#160;the Independent Data Monitoring Committee&#160;(&#8220;IDMC&#8221;),&#160;which&#160;recommended a modest,&#160;one-time increase of 29 patients across KRAS mutation status based on the total enrollment achieved in October&#160;2025.&#160;We expect to report a topline readout of the primary endpoint in mid-2027.&#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The&#8239;European Commission granted Orphan Drug Designation in July 2025 for avutometinib plus defactinib for the treatment of ovarian cancer based on a positive opinion from the&#8239;European Medicines Agency Committee for Orphan Medicinal Products. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preliminary safety and efficacy data from the Phase 2 RAMP 201J trial in&#8239;Japan&#8239;was presented in November 2025 at the&#160;International Gynecologic Cancer Society&#8239;(&#8220;IGCS&#8221;) 2025 Annual Meeting&#160;and we are continuing enrollment of patients into the&#160;RAMP 301 study&#160;in Japan.&#160;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Avutometinib&#160;in combination with&#160;defactinib</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In&#160;May&#160;2025, we reported&#160;that&#160;we selected the recommended Phase 2 dose (&#8220;RP2D&#8221;) known as &#8220;dose level 1&#8221;&#160;in our RAMP 205 trial, which is&#160;evaluating&#160;avutometinib&#160;plus&#160;defactinib&#160;and in combination with standard of care chemotherapy (gemcitabine and Nab-paclitaxel)&#160;in front-line metastatic PDAC.&#160;&#160;In the study, dose level 1&#160;demonstrated&#160;a&#160;confirmed&#160;overall response rate&#160;(&#8220;ORR&#8221;) of 83% (10/12) patients.&#160;Adverse events across all dose cohorts remained&#160;generally consistent&#160;with the previously announced safety and tolerability profile, and no new safety signals have&#160;emerged.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We completed enrollment&#160;of&#160;the expansion cohort of a total of 29 patients&#160;at&#160;RP2D,&#160;and we expect to report an update on the safety and efficacy of this expansion cohort in the&#160;first half of 2026.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In September 2021, we entered into a clinical collaboration agreement with Amgen, Inc. (&#8220;Amgen&#8221;) to evaluate avutometinib in combination with Amgen&#8217;s KRAS G12C inhibitor LUMAKRAS&#174; (sotorasib) with and without defactinib in a Phase1/2 study entitled RAMP 203 in patients na&#239;ve to or previously treated with a KRAS G12C inhibitor.  Following evaluation of interim data in December 2025 we announced the discontinuation of RAMP 203 to focus resources on clinical development of VS-7375, reflecting the evolving treatment landscape for KRAS G12C inhibitors and the strategic prioritization of programs with the greatest potential impact for patients living with advanced lung cancer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">VS-7375</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In January 2025,&#160;we&#160;licensed VS-7375 from&#160;GenFleet&#160;Therapeutics&#160;(&#8220;GenFleet&#8221;)&#160;and announced in June&#160;2025&#160;that&#160;the first patient had&#160;been dosed in the monotherapy portion of VS-7375-101, the&#8239;U.S.&#8239;Phase&#160;1/2&#160;clinical trial evaluating VS-7375 in patients with advanced KRAS G12D mutant solid tumors, including PDAC, NSCLC, and CRC.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In July 2025, the&#8239;FDA&#160;granted Fast Track Designation (&#8220;FTD&#8221;) to VS-7375, for the&#160;first-line&#160;(&#8220;1L&#8221;)&#160;treatment of patients with KRAS G12D-mutated locally advanced or metastatic PDAC and for the treatment of patients with </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">KRAS G12D-mutated locally advanced or metastatic PDAC who have received at least one prior line of standard systemic therapy.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We continue to make progress with&#160;the&#160;VS-7375-101 trial, which includes&#160;both monotherapy and combination dose escalation and dose expansion cohorts,&#160;as follows:&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the&#160;monotherapy dose escalation&#160;phase, we cleared&#160;the&#160;400 mg,&#160;600 mg, and&#160;900 mg&#160;daily dose (&#8220;QD&#8221;) dose levels with no dose-limiting&#160;toxicities&#160;(&#8220;DLTs&#8221;) and no major toxicities and dose escalation continues.&#160;In October 2025, we reported promising anti-tumor activity was&#160;observed&#160;in patients with various solid tumors, including metastatic PDAC.&#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">In a&#160;pharmacokinetics (PK)&#160;analysis, doses of VS-7375 at&#160;600 mg&#160;QD&#160;and above,&#160;with feeding and anti-emetic prophylaxis,&#160;yielded similar exposures to fasted patients in China. The clinical exposures observed correspond with the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> exposures achieved in preclinical models necessary for maximal anti-tumor efficacy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">As&#160;of&#160;the&#160;January&#160;30,&#160;2026&#160;data cutoff, VS-7375&#160;demonstrated&#160;an encouraging safety profile and was&#160;generally well-tolerated&#160;across&#160;all&#160;monotherapy dose levels&#160;evaluated to date.&#160;Patients (n=23) receiving VS-7375&#160;at either 400 mg QD, 600 mg QD or 900 mg QD&#160;with a mean duration of therapy of 1.6 months (0.7-5.6),&#160;reported&#160;no&#160;drug related liver function test abnormalities.&#160;There was no&#160;drug-related neutropenia&#160;or&#160;anemia&#160;&gt;Grade 2 and rates of nausea, vomiting and diarrhea&#160;remained&#160;lower than those reported by our partner in China.&#160;No&#160;DLTs&#160;have been reported to date,&#160;and the&#160;maximum&#160;tolerated dose has not been reached.&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We&#160;initiated&#160;the&#160;monotherapy&#160;dose expansion cohorts with the&#160;600 mg&#160;QD dose and&#160;are&#160;increasing&#160;enrollment&#160;across&#160;three different cohorts:&#160;second line&#160;(&#8220;2L&#8221;) PDAC, second-&#160;and&#160;third-line&#160;(&#8220;2L/3L&#8221;) NSCLC, and other second line or greater (&#8220;2L+&#8221;) KRAS G12D mutated solid tumors.&#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In our combination cohorts we are enrolling patients into three different cohorts,&#160;including 2L+ solid tumors in combination with cetuximab,&#160;1L NSCLC in combination with carboplatin/pemetrexed/pembrolizumab, and 2L PDAC in combination with gemcitabine and Nab-paclitaxel.&#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We cleared the&#160;400 mg and 600 mg&#160;QD dose of VS-7375 in combination with cetuximab and are evaluating&#160;higher doses.&#160;&#160;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We plan to report an&#160;update on early dose-escalation data from the VS-7375-101 trial in&#160;first&#160;half of 2026.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Following recent feedback from the FDA,&#160;we are&#160;amending&#160;the&#160;VS-7375-101&#160;Phase 1/2 protocol and breaking out disease-specific Phase 2 registration-directed trials for KRAS G12D mutated 2L PDAC, 2L/3L NSCLC (monotherapy), and 2L+ CRC in&#160;combination&#160;with cetuximab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our partner,&#160;GenFleet,&#160;is&#160;developing VS-7375 as GFH375&#160;in&#160;greater&#160;China&#160;and&#160;to date&#160;has generated data in more than 150 patients with PDAC, NSCLC and other solid tumor cancers.&#160;GenFleet&#160;reported initial positive safety and anti-tumor activity&#160;in 2L&#160;PDAC&#160;(58.3% ORR in 12 patients)&#160;and&#160;2L&#160;NSCLC&#160;(68.8% ORR in 16 patients).&#160;GenFleet&#160;has an ongoing Phase&#160;1/2b&#160;trial&#160;of GFH375 in combination with cetuximab or chemotherapy&#160;in KRAS G12D-mutated solid tumors in China. The chemotherapy combination will be conducted in 1L PDAC&#160;in China.&#160;GenFleet&#160;is&#160;also&#160;conducting a&#160;Phase 3&#160;trial in China&#160;evaluating GFH375 in patients with pretreated KRAS G12D-mutated metastatic pancreatic&#160;cancer.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preclinical Programs</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We continue to progress preclinical research programs across our pipeline assets.&#160;We also have two undisclosed assets at discovery phase targeting RAS/MAPK pathway-driven cancers as part of the&#8239;GenFleet&#8239;Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:263.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OUR STRATEGY</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our&#160;goal&#160;is to&#160;deliver&#160;transformative&#160;therapies that&#160;meaningfully improve outcomes for patients living&#160;with&#160;RAS/MAPK pathway-driven cancers. We are developing small molecule therapeutics targeting&#160;this&#160;pathway&#160;and&#160;have&#160;already successfully&#160;demonstrated&#160;clinical-to-commercial success in bringing novel RAS/MAPK pathway-targeted therapies from development through FDA&#160;approval to commercialization. We&#160;are well-positioned to deliver continued commercial success and develop&#160;a&#160;potential best-in-class&#160;treatment&#160;for long-term growth.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Precision&#160;targeting of&#160;RAS/MAPK&#160;pathway-driven cancers differentiates our science. Our focus is on novel small molecule drugs developed both as monotherapy and in combination that inhibit critical signaling pathways in cancer promoting cell survival and tumor growth. This includes targeting RAS directly with KRAS G12D inhibition, targeting the pathway downstream with RAF/MEK inhibition, and targeting the parallel pathway that drives resistance with FAK inhibition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="font-family:'Segoe UI';"><img src="vstm-20251231x10k004.jpg" alt="Graphic" style="display:inline-block;height:263.15pt;width:468pt;"/></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Segoe UI';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our lead&#160;FDA-approved&#160;combination&#160;product,&#160;AVMAPKI FAKZYNJA CO-PACK, is&#160;indicated&#160;for the treatment of patients with KRAS-mutated recurrent LGSOC&#160;who have received prior&#160;systemic therapy. We have&#160;established&#160;a commercial presence&#160;in the U.S. that is&#160;scalable&#160;to&#160;maximize future oncology development programs and launches.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our innovative pipeline is anchored by VS-7375, a potential best-in-class KRAS G12D (ON/OFF) inhibitor targeting the most prevalent KRAS mutation in human cancers. We believe VS-7375&#160;addresses a significant opportunity across multiple KRAS G12D-mutated solid tumors with a differentiated profile and best-in-class anti-tumor activity. We see substantial&#160;potential to address a significant unmet medical need and&#160;establish&#160;leadership in this therapeutic area.&#160;&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our key&#160;priorities&#160;are as follows:&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Maximize&#160;and sustain commercial momentum&#160;leveraging&#160;our established engagement with the healthcare provider community and building upon the&#160;strong foundation&#160;achieved in our&#160;initial&#160;launch&#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Advance VS-7375 through development&#160;to produce&#160;topline clinical data readouts&#160;and drive toward registration-directed studies&#160;across KRAS G12D mutated solid tumors,&#160;including PDAC, NSCLC, and CRC&#160;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Rigorously&#160;follow&#160;patients&#160;to achieve data maturity&#160;in our&#160;Phase 3 confirmatory&#160;trial,&#160;RAMP 301,&#160;which&#160;may&#160;support label&#160;expansion in the U.S. and&#160;regulatory submissions outside of the U.S.&#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Maintain prudent capital management through key inflection points&#160;&#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Continue to support our people and culture&#160;through this next phase of growth</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVMAPKI FAKZYNJA CO-PACK FDA Approved&#160;for KRAS-mutated recurrent LGSOC</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">AVMAPKI FAKZYNJA CO-PACK&#160;received accelerated approval by the&#160;FDA on&#8239;May 8, 2025, approximately two months in advance of the PDUFA action date of&#8239;June 30, 2025, for the treatment of adult patients with KRAS-mutated recurrent LGSOC who have received prior systemic therapy.&#160;The product was&#160;commercially available&#160;within a week of approval and was&#160;subsequently&#160;listed as a Category 2A recommendation in the National Comprehensive Cancer Network&#174; (NCCN&#174;) Clinical Practice Guidelines in Oncology (NCCN Guidelines&#174;).&#160;Prior to this approval, there were no FDA-approved treatments specifically for KRAS-mutated recurrent LGSOC.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">LGSOC is a rare ovarian cancer that is persistent&#160;and&#160;starts in the thin layer of tissue around the ovaries (also known as the epithelium). Low-grade means the cancer cells look a lot like normal cells, and serous means the cancer started in the serous membrane, which is part of the epithelium.</span>&#160;<span style="font-size:10pt;">There are&#160;approximately 6,000&#160;to 8,000 women with LGSOC living in the U.S., and 1,000 to 2,000 cases are diagnosed each year. LGSOC is&#160;most commonly diagnosed&#160;in women between the ages of 20 to 30 and 50 to 60.&#160;More than 80% of patients experience a&#160;recurrence.&#160;The RAS/MAPK pathway is a primary driver of tumor&#160;growth&#160;and genetic mutations that activate this pathway are found in many cancers. In LGSOC, 70% of patients have a RAS/MAPK&#160;pathway-associated&#160;mutation.&#160;One&#160;of&#160;these&#160;mutations,&#160;known&#160;as&#160;</span><i style="font-size:10pt;font-style:italic;">KRAS</i><span style="font-size:10pt;">,&#160;is&#160;present in approximately 30% of patients with LGSOC.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cancer is highly dependent on the RAS/MAPK signaling pathway for its growth, and blocking any single node in this pathway is&#160;generally insufficient&#160;for deep and durable anti-cancer activity as the cancer will compensate by activating other signaling proteins within the RAS pathway or in parallel pathways. AVMAPKI (avutometinib) inhibits MEK kinase activity while also blocking the compensatory reactivation of MEK by upstream RAF. RAF and MEK proteins are regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. Blocking RAF and/or MEK activates FAK, a key mediator of drug resistance. FAKZYNJA (defactinib) is a FAK inhibitor. The&#160;avutometinib&#160;and&#160;defactinib&#160;combination was designed to provide a more complete blockade of the signaling that drives the growth and drug resistance of RAS/MAPK pathway-dependent tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Commercial Launch</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">AVMAPKI plus FAKZYNJA is only commercially available in the&#8239;U.S.&#8239;as an oral combination co-pack with the two prescription products, known as &#8220;AVMAPKI FAKZYNJA CO-PACK.&#8221;&#160;The product was&#160;available&#160;at our designated specialty pharmacies within five days of approval.&#160;Our first full&#160;seven&#160;months of commercial launch&#160;in 2025&#160;resulted in&#160;the recognition of $30.9 million in&#160;net product revenue.&#160;Over the&#8239;past few years, as part of our pre-launch efforts and educational work with our medical science liaisons, and now with the addition of our field&#160;sales team, we have&#160;generated strong awareness and&#160;built&#160;a highly experienced and motivated team.&#160;We believe our&#160;initial&#160;launch success&#160;has been&#160;driven by&#8239;consistent adoption among both academic centers and community&#160;oncologists.&#160;&#8239;&#8239;&#8239;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We&#8239;defined&#8239;three&#8239;key&#8239;strategic&#8239;launch&#8239;imperatives&#160;to drive our launch: 1) effectively reach healthcare providers,&#160;keeping in consideration&#160;that&#8239;the&#8239;top 100&#160;commercial healthcare organizations&#160;in the U.S.&#160;comprise&#8239;approximately&#8239;50% of&#8239;the&#8239;sales&#8239;opportunity;&#8239;2) engage and support patients&#8239;throughout their journey&#160;since,&#160;as&#8239;patients progress through other therapies, many will be ready for a new&#8239;treatment&#8239;option; and&#8239;3) ensure seamless access&#8239;to&#8239;support patients&#8239;and&#8239;ensure any barriers to reimbursement are removed.&#8239;Our approach is highly&#8239;targeted,&#8239;and we are&#8239;utilizing&#8239;a deliberate mix of one-on-one meetings, group discussions, and conference engagements to maximize the impact of every interaction in this rare disease&#8239;market.&#8239;We&#160;have received&#8239;a&#160;favorable&#8239;mix&#160;of orders&#160;between&#160;the two specialty&#160;pharmacies&#8239;onboarded&#8239;in&#160;the second quarter of&#160;2025&#160;and&#8239;the&#8239;four&#8239;specialty&#8239;distributors&#8239;we added&#8239;in the third quarter of 2025.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe we are well-positioned for continued growth&#160;as we aim to achieve our goal&#160;that&#160;every KRAS-mutated&#8239;LGSOC patient should not only receive this treatment but&#8239;should&#8239;do so at their first recurrence.&#8239;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accelerated Approval&#160;</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Verastem&#8239;initiated a rolling&#160;New Drug Application&#160;(&#8220;NDA&#8221;)&#160;in&#8239;May 2024&#8239;and&#160;aligned with the FDA on plans to complete the NDA submission in&#8239;October 2024&#8239;for adult patients with&#160;KRAS-mutated recurrent&#160;LGSOC, who received at least one prior systemic therapy.&#8239;The NDA included&#160;safety and efficacy results&#160;from&#160;57 patients&#160;with&#160;KRAS-mutated recurrent LGSOC&#160;enrolled in&#160;our&#160;Phase 2&#160;RAMP 201&#160;clinical&#160;trial.&#160;In the study,&#160;AVMAPKI and FAKZYNJA, in combination, showed a confirmed ORR by&#160;<span style="background:#ffffff;">blinded independent central review&#160;(&#8220;BICR&#8221;)</span>&#160;of 44% (25/57; 95%&#160;Confidence Interval (&#8220;CI&#8221;): 31-58)&#160;in patients with a KRAS mutation. The DOR ranged from 3.3 to&#160;31.1 months&#160;in the KRAS mutant population.&#160;The safety of AVMAPKI and FAKZYNJA, in combination, was evaluated in 57 patients with&#8239;KRAS<i style="font-style:italic;">-</i>mutated recurrent LGSOC. Possible serious side effects with AVMAPKI FAKZYNJA CO-PACK include ocular disorders, skin toxicities (&#8220;rash&#8221;), hepatotoxicity, rhabdomyolysis, and fetal harm when administered during pregnancy. The most common side effects, including laboratory changes, of AVMAPKI FAKZYNJA CO-PACK include increased levels of an enzyme in the blood (&#8220;CPK&#8221;), nausea, fatigue, abnormal liver test (&#8220;AST&#8221;), and rash.&#160;<span style="background:#ffffff;">The NDA also includes supportive data from&#160;our&#160;FRAME Phase 1 trial, the first study conducted with&#160;the&#160;</span>AVMAPKI and FAKZYNJA<span style="background:#ffffff;">&#160;combination therapy in recurrent LGSOC.&#160;</span>&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We completed our&#160;submission in&#8239;October 2024,&#160;and the&#160;FDA&#160;accepted&#160;the&#160;NDA under the accelerated approval pathway&#160;in December 2024. The NDA&#160;was&#160;granted Priority Review with a PDUFA action date of&#8239;June 30, 2025.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Prior to NDA acceptance, the FDA granted Breakthrough Therapy Designation&#160;(&#8220;BTD&#8221;)&#160;for the&#160;combination&#160;therapy&#160;for&#160;patients with recurrent LGSOC after one or more prior lines of therapy, including platinum-based chemotherapy, in&#8239;May 2021.&#160;BTD&#160;allows for the expedited development and review of drugs for serious or life-threatening conditions.&#160;Avutometinib&#160;alone or in combination with&#160;defactinib&#160;was also granted Orphan Drug Designation by the FDA for the treatment of LGSOC,&#160;which recognized this rare cancer as distinct from high-grade&#8239;serous ovarian cancer&#160;(&#8220;HGSOC&#8221;).&#160;These designations, combined with the early approval,&#160;underscored the urgency and importance of addressing the unmet treatment needs of women living with LGSOC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RAMP 201&#160;Clinical Trial&#160;</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">RAMP 201&#160;(ENGOTov60/GOG3052)&#160;was&#160;a Phase 2&#160;adaptive, two-part multicenter, parallel cohort, randomized, open-label trial to evaluate the efficacy and safety of&#160;avutometinib&#160;alone and in combination with&#160;defactinib&#160;in patients with recurrent low-grade serous ovarian cancer.&#160;The first part of the study determined the selection of the go forward regimen, which was the combination of&#160;avutometinib&#160;and&#160;defactinib&#160;versus&#160;avutometinib&#160;alone, based on overall response rates. The expansion phases of the trial evaluated&#160;the safety and efficacy of the go forward regimen of&#160;avutometinib&#160;3.2 mg twice weekly and&#160;defactinib&#160;200 mg&#160;twice daily.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In October 2024, we announced&#160;the primary analysis of the&#160;RAMP 201 study with a data cutoff of June 30, 2024, that was presented at the IGCS&#160;2025 Annual Meeting. The&#160;study showed a confirmed ORR&#160;by&#160;BICR&#160;of 31%&#160;(34/109; 95% CI: 23-41) in all evaluable patients with measurable disease with approximately 12 months of follow up. Among patients with KRAS-mutated&#160;LGSOC, the confirmed ORR was 44% (25/57; 95% CI: 31-58),&#160;and for patients with KRAS wild-type&#160;LGSOC the confirmed ORR was 17% (9/52; 95% CI: 8-30). The median duration of response&#160;(&#8220;mDOR&#8221;)&#160;was 31.1 months (95% CI: 14.8-31.1) in all evaluable patients, with 31.1 months (95% CI: 14.8-31.1) in the KRAS mutant&#160;population and 9.2 months (95% CI: 5.5-NEi) in the KRAS&#160;wild-type&#160;population. The median progression-free survival was 12.9 months (95% CI: 10.9-20.2) in all evaluable patients, with 22 months (95% CI: 11.1-36.6) in the KRAS mutant&#160;population and 12.8 months (95% CI: 7.4-18.4) in the KRAS wild-type&#160;population. The disease control rate&#160;(&#8220;DCR&#8221;)&#160;at six or more months was 61% in the total evaluable population, 70% in KRAS mutant&#160;population and 50% in KRAS wild-type&#160;population. The updated data&#160;demonstrated&#160;that&#160;avutometinib&#160;in combination with&#160;defactinib&#160;was&#160;generally well-tolerated, with a 10% discontinuation rate due to adverse events and no new safety signals were&#160;identified. The most common treatment-related adverse events (all grades, grade &#8805;3) for the combination were nausea (67.0%, 2.6%), diarrhea (58.3%, 7.8%), and increased blood creatine phosphokinase levels (60.0%, 24.3%).</span>&#160;</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The&#160;primary analysis of the&#160;RAMP 201 study was published in the&#160;</span><i style="font-style:italic;background:#ffffff;">Journal of Clinical Oncology</i><span style="background:#ffffff;">&#160;in July 2025. The FRAME study was published in&#160;</span><i style="font-style:italic;background:#ffffff;">Nature</i><span style="background:#ffffff;">&#160;in June 2025.&#160;</span>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RAMP 301 Phase 3 Confirmatory Clinical&#160;Trial</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">AVMAPKI FAKZYNJA CO-PACK&#160;is approved under accelerated approval based on the tumor response rate and duration of response.&#160;The FDA requires&#160;that&#160;we confirm the benefit&#160;in a confirmatory trial.&#160;In December of 2023, we&#160;initiated&#160;a&#160;global, randomized,&#160;<span style="background:#ffffff;">confirmatory Phase 3 trial&#160;known as RAMP 301&#160;in an&#160;international collaboration between&#8239;The GOG Foundation, Inc. and the European Network of&#160;Gynaecological&#160;Oncological Trial groups. RAMP 301</span>&#160;is&#160;<span style="background:#ffffff;">evaluating&#160;the combination of&#160;avutometinib&#160;and&#160;defactinib&#160;versus standard</span>&#160;of care<span style="background:#ffffff;">&#160;chemotherapy or hormonal therapy&#160;for the treatment of patients with recurrent LGSOC&#160;with and without a KRAS mutation. RAMP 301 will serve as the confirmatory study required by the FDA for the combination of&#160;avutometinib&#160;and&#160;defactinib&#160;for the&#160;initial&#160;indication&#160;of&#160;KRAS-mutated&#160;recurrent LGSOC,&#160;potentially&#160;leading to&#160;full approval,&#160;and has the potential to support an expanded&#160;indication&#160;regardless of KRAS mutation status.&#160;The primary endpoint is&#160;progression-free survival&#160;by&#160;</span>BICR<span style="background:#ffffff;">. Secondary endpoints include ORR,&#160;DOR, DCR, safety and tolerability, patient-reported outcomes, and overall survival&#160;(&#8220;OS&#8221;). RAMP 301&#160;has enrolled patients&#160;in the&#8239;United States, Australia, Canada, Europe,&#160;United Kingdom</span>,<span style="background:#ffffff;">&#160;and Korea.&#160;</span>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The&#160;planned enrollment&#160;for RAMP 301&#160;of the targeted 270 patients was completed&#160;in October 2025,&#160;a full quarter&#160;earlier&#160;than&#160;anticipated.&#160;</span>Additional&#160;patient enrollment&#160;was&#160;also&#160;completed&#160;ahead of schedule&#160;in December 2025,&#160;following a pre-planned&#160;IA&#160;by the&#160;IDMC,&#160;which recommended a modest,&#160;one-time increase of 29 patients across KRAS mutation status based on the total enrollment achieved in October 2025.&#160;We expect to report a topline readout of the primary endpoint in mid-2027.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Post-marketing Accelerated Approval Requirement and Commitments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a condition of receiving accelerated approval for the AVMAPKI FAKZYNJA CO-PACK, we are required to conduct additional studies to verify the clinical benefit of AVMAPKI FAKZYNJA CO-PACK and address post-marketing commitments as agreed upon with the FDA. We need to complete the ongoing Phase 3 RAMP 301 trial and provide the progression-free survival (&#8220;PFS&#8221;) and the final overall survival analyses, intended to describe and verify the clinical benefit of avutometinib and defactinib combination in adult patients with recurrent KRAS-mutated LGSOC with central KRAS testing results for all patients. We are also required to complete a pediatric study of avutometinib and defactinib to evaluate preliminary efficacy, and characterize dose, pharmacokinetics (&#8220;PK&#8221;) pharmacodynamics (&#8220;PD&#8221;) and preliminary safety in pediatric patients ages 2 to &lt;17 years of age with relapsed or refractory unresectable or metastatic RAS/MAPK pathway-driven pediatric cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, we are also required to: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assess drug-drug interaction risks when defactinib is taken with CYP3A4 inhibitors through a trial evaluating the effect of a moderate CYP3A4 inhibitor on defactinib PK and identify the appropriate dosing</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluate the potential risk of cardiomyopathy in adult patients with recurrent LGSOC receiving the combination of avutometinib and defactinib</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enroll at least 15 evaluable patients with moderate hepatic impairment to evaluate the potential risk of increased serious adverse reactions with avutometinib in combination with defactinib</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assess the effect of severe hepatic impairment on defactinib and its active metabolite to evaluate the potential serious risk of increased serious adverse reactions in patients with severe hepatic impairment </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assess the effect of severe hepatic impairment on avutometinib to evaluate the potential serious risk of increased serious adverse reactions in patients with severe hepatic impairment </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assess the severe renal impairment on avutometinib to evaluate the potential serious risk of increased serious adverse reactions in patients with severe renal impairment </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complete study VS-6063-108, assessing drug interactions between defactinib and BCRP inhibitor, a P-gp Inhibitor, and a moderate CYP2C9 inhibitor</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assess effects of multiple doses of defactinib on single dose pharmacokinetics of substrates of CYP3A4, CYP2C9, P-gp, BCPR, OATP1B1, and OATP1B3 to evaluate the potential serious risks of </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased serious adverse reactions from elevated levels of CYP3A4, CYP2C9, P-gp, BCPR, OATP1B1, and OATP1B3 substrates, respectively, when they are used concomitantly with defactinib </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assess the effect of defactinib on MATE2-K substrates drugs interaction risks</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct an in vitro study to assess whether additional drug interaction studies are needed for defactinib metabolite M4</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct an appropriate analytical and clinical validation study to support the development of a diagnostic device that is essential to the safe and effective use of the combination of avutometinib and defactinib in KRAS-mutated, recurrent low-grade serous ovarian cancer</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">LGSOC&#160;Geographic&#160;Commercial&#160;Expansion&#160;</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We continue to make progress on potential&#160;geographic&#160;commercial expansion of the&#160;AVMAPKI and FAKZYNJA<span style="background:#ffffff;">&#160;</span>combination therapy.&#160;The&#8239;European Commission granted Orphan Drug Designation&#160;in July 2025 for&#160;avutometinib&#160;plus&#160;defactinib&#160;for the treatment of ovarian cancer based on a positive opinion from the&#8239;European Medicines Agency Committee for Orphan Medicinal Products.&#160;Preliminary safety and efficacy data from the Phase 2 RAMP 201J trial in&#8239;Japan&#8239;was presented at the IGCS&#160;2025 Annual Meeting&#160;in November 2025&#160;and we are continuing enrollment of patients into the RAMP 301 study in Japan.&#160;Plans to engage regulatory authorities in these regions are ongoing.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Product Pipeline&#160;</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Avutometinib&#160;in&#160;Combination with&#160;Defactinib&#160;in&#160;First-line&#160;Advanced&#160;Pancreatic Cancer</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In 2025, the National&#160;Cancer Institute (&#8220;NCI&#8221;)&#160;estimated that pancreatic cancer was the tenth most common cancer diagnosed in the United States and that the disease represented the third leading cause of cancer-related death in the&#160;U.S. Pancreatic cancer often has a poor prognosis, even when diagnosed early.&#160;Early detection&#160;remains&#160;a&#160;challenge,&#160;and survival rates have not&#160;improved significantly during the past 40 years.&#160;According to the NCI, the&#160;five-year survival rate for pancreatic cancer is 13%&#160;(2015-2021)&#160;and only 3% for those with advanced&#160;disease.&#160;In 2025, the NCI estimated&#160;that more than 67,000 people in the U.S.&#160;would be diagnosed with pancreatic cancer&#160;and more than 50,000&#160;were&#160;estimated to die&#160;from this disease.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The treatment options for pancreatic cancer remain&#160;primarily&#160;limited to combinations of chemotherapy or chemotherapy plus radiation.&#160;Immuno-oncology agents have not&#160;demonstrated&#160;a significant improvement in treatment outcomes&#160;for patients with pancreatic cancer.&#160;KRAS mutations occur in up to 95% of pancreatic cancer. KRAS mutations confer constitutive activation of the KRAS protein, which activates RAF and MEK downstream supporting proliferation and survival of tumor cells. This provides the rationale for use of avutometinib to block both RAF and MEK to inhibit KRAS signaling in pancreatic cancer. Additionally, it has been previously reported that inhibition of the MAPK pathway with targeted therapies activates FAK as an adaptive resistance mechanism. Furthermore, FAK has been shown to be hyperactivated in human PDAC, and FAK activation has been correlated with high levels of fibroblasts, poor T cell infiltration and poor overall survival in these patients. Thus, there is a strong scientific rationale for combining&#160;avutometinib&#160;(to inhibit RAF and MEK to block the MAPK pathway)&#160;and&#160;defactinib&#160;(to inhibit FAK to reduce stromal density and adaptive resistance to&#160;avutometinib) to the&#160;standard&#160;of care&#160;gemcitabine/Nab-paclitaxel&#160;regimen with the&#160;objective&#160;of increasing response rate and survival. In preclinical models of pancreatic cancer, this combination of avutometinib and FAK inhibition with gemcitabine and paclitaxel has been shown to induce strong tumor regression. &#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Avutometinib&#160;and&#160;defactinib&#160;in combination with standard of care chemotherapy (gemcitabine and Nab-paclitaxel)&#160;are being evaluated&#160;in patients with previously untreated&#160;advanced&#160;PDAC&#160;in the&#160;RAMP 205&#160;clinical trial.&#160;RAMP 205 is a multicenter, open-label, single-arm Phase 1b/2a study designed to evaluate the safety,&#160;tolerability&#160;and efficacy of&#160;the&#160;combination&#160;at different doses and schedules to&#160;determine&#160;the recommended RP2D.&#160;<span style="background:#ffffff;">We received the first &#8220;Therapeutic Accelerator Award&#8221; from&#160;</span>Pancreatic Cancer Network (&#8220;PanCAN&#8221;)<span style="background:#ffffff;">&#160;for up to $3.8 million&#160;to support the&#160;RAMP 205&#160;study.&#160;</span>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In May of 2025,&#160;we announced an update on the&#160;RAMP 205&#160;trial and that&#160;we&#160;selected&#160;our&#160;RP2D&#160;as&#160;DL1. In the&#160;update,&#160;DL1 demonstrated a&#160;confirmed&#160;ORR&#160;of 83% (10/12)&#160;in&#160;patients. Adverse events across all dose cohorts </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">remained&#160;generally consistent&#160;with the previously announced safety and tolerability profile, and no new safety signals have&#160;emerged.&#160;We&#160;completed&#160;enrollment of&#160;29&#160;patients in an&#160;expansion cohort at&#160;the&#160;RP2D&#160;in 2025, and we expect to report an update on the safety and efficacy of this&#160;cohort in the first half of 2026.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">VS-7375 is a potential best-in-class, potent, and selective oral KRAS G12D dual ON/OFF inhibitor.&#160;VS-7375 has a differentiated&#160;profile&#160;compared to other RAS inhibitors. Based on preclinical data, VS-7375 offers dual, potent inhibition of both ON and OFF states of KRAS G12D. We believe&#160;this correlates with&#160;better in&#160;vivo efficacy and durability versus&#160;ON-only RAS inhibitors. VS-7375 has&#160;demonstrated&#160;a high affinity for KRAS G12D with long residence time (18-24 hours) in&#160;preclinical models. We believe this correlates with a more rapid and durable suppression of&#160;pERK&#160;signaling (which controls growth and cell survival) when compared to other&#160;ON-only KRAS G12D inhibitors in tumor cell lines. The selective inhibition of VS-7375 to KRAS G12D has shown,&#160;in&#160;preclinical models,&#160;to spare T cell proliferation&#160;to&#160;maintain&#160;a&#160;normal healthy&#160;immune response,&#160;versus&#160;a RAS-multi-inhibitor&#160;which&#160;impairs&#160;T cell proliferation at increasing concentrations of drug.&#160;The once daily oral dosing of VS-7375 achieves exposures corresponding to maximal tumor regressions across preclinical models&#160;for pancreatic, lung and colorectal cancers.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">VS-7375 Licensing</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">VS-7375 is the lead program from the discovery and development collaboration with&#160;GenFleet.&#160;We exercised the GenFleet Option (defined herein) in January 2025,&#160;announced that&#160;our&#160;IND application for VS-7375&#160;had been&#160;approved&#160;by the FDA in April 2025,&#160;and&#160;initiated&#160;a Phase 1/2a clinical trial in&#160;June 2025.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">GenFleet&#160;is developing VS-7375 as GFH375 in greater China.&#160;GenFleet&#8217;s&#160;IND for GFH375 was approved in&#8239;China&#8239;in&#8239;June 2024, and the first patient was dosed in a Phase 1/2 study in&#8239;July 2024. To date,&#160;GenFleet&#160;has generated data in more than 150 patients with PDAC, NSCLC,&#160;and other solid tumor cancers, and&#160;reported initial positive safety and anti-tumor activity in 2L PDAC (58.3% ORR in 12 patients) and 2L NSCLC (68.8% ORR in 16 patients).&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">GenFleet&#160;also has an ongoing Phase 1/2b trial of GFH375 in combination with cetuximab or chemotherapy in KRAS G12D-mutated solid tumors in China. The chemotherapy combination will be conducted in 1L PDAC.&#160;GenFleet&#160;is also conducting a Phase 3 trial in China evaluating GFH375 in patients with pretreated KRAS G12D-mutated metastatic pancreatic cancer.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">VS-7375-101 Phase 1/2 Clinical Trial KRAS G12D Solid Tumors</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In&#160;June 2025, we dosed&#160;the first patient in the monotherapy&#160;portion&#160;of VS-7375-101, the&#8239;U.S.&#8239;Phase 1/2 clinical trial evaluating VS-7375 in patients with advanced KRAS G12D mutant solid tumors, including PDAC, NSCLC, CRC&#160;and other KRAS G12D mutated solid tumors.&#160;We continue to make progress with the VS-7375-101 trial, which includes both monotherapy and combination dose escalation and dose expansion cohorts.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">VS-7375-101&#160;Phase 1/2b&#160;Monotherapy Dose Escalation and Dose Expansion Phases</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the monotherapy dose escalation phase, we cleared the&#160;400 mg,&#160;600 mg, and&#160;900 mg&#160;daily dose levels with no DLTs and no major toxicities.&#160;We reported early safety data that showed limited nausea and vomiting through feeding patients and using standard prophylaxis treatments. We also addressed&#160;diarrhea&#160;quickly with standard oral agents.&#160;Promising anti-tumor activity&#160;was&#160;observed&#160;in patients with various solid tumors, including metastatic PDAC.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We&#160;initiated&#160;dose expansion cohorts with the&#160;600 mg&#160;QD dose and are increasing enrollment across three different cohorts: 2L PDAC, 2L/3L&#160;NSCLC, and other 2L+ KRAS G12D mutated solid tumors.&#160;&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We plan to report early data from the VS-7375-101 trial in the first half of 2026.&#160;</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">VS-7375-101&#160;Phase 1/2b&#160;Combination&#160;Dose Escalation and Dose Expansion Phases</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In our combination cohorts,&#160;we are enrolling patients into three different&#160;dose escalation&#160;cohorts,&#160;including 2L+ solid tumors in combination with cetuximab, 1L NSCLC in combination with carboplatin/pemetrexed&#160;/pembrolizumab, and 2L PDAC in combination with gemcitabine and Nab-paclitaxel.&#160;&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We cleared the&#160;400 mg&#160;QD dose and 600 mg QD dose of VS-7375 in combination with cetuximab and higher doses are now being evaluated. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In our dose expansion cohorts, we&#160;plan to continue to evaluate&#160;VS-7375&#160;alone and&#160;in combination with cetuximab&#160;in 2L+ CRC. We also plan to continue to evaluate VS-7375 with chemotherapy or immunotherapy in 1L NSCLC and move into the 1L PDAC setting in combination with chemotherapy.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">VS-7375&#160;Regulatory Pathway</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In July 2025, the&#8239;FDA granted FTD to VS-7375, for 1L treatment of patients with KRAS G12D-mutated locally advanced or metastatic PDAC and for the treatment of patients with KRAS G12D-mutated locally advanced or metastatic PDAC who have received at least one prior line of standard systemic therapy.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Based on recent FDA feedback, we plan to amend the VS-7375-101 Phase 1/2 protocol to breakout disease specific Phase 2 registration-directed trials for KRAS G12D mutated 2L PDAC, 2L/3L NSCLC and 2L+ CRC. Our development focus is on the highest unmet&#160;need&#160;populations,&#160;and we plan to&#160;expedite&#160;regulatory submissions&#160;as quickly as possible.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Market Opportunity in U.S.&#160;for PDAC, NSCLC, CRC KRAS G12D&#160;Tumors&#160;</i>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">KRAS G12D&#160;represents&#160;26% of all KRAS mutations, making it the most prevalent KRAS mutation in human cancers. The KRAS G12D mutation occurs most commonly in pancreatic (40%), colorectal (15%), non-small cell lung (5%)&#160;and&#160;other cancers such as&#160;endometrial (5%),&#160;biliary tract&#160;cancer&#160;(7-15%)&#160;and&#160;small bowel cancer (16%).&#160;Across the various KRAS G12D-mutated cancers,&#160;the KRAS G12D mutation often correlates with worse outcomes. In pancreatic cancer, it is associated with shorter survival and a higher risk of progression. In lung cancer,&#160;the&#160;KRAS G12D&#160;mutation&#160;is a significant driver of the disease, especially among non-smokers and is linked to poor responses to standard of care. In colorectal cancer, which is&#160;impacting&#160;younger populations, the&#160;KRAS G12D&#160;mutation is often linked to aggressive tumors.&#160;Overall, the KRAS G12D mutation appears across many types of cancer and&#160;remains&#160;an unmet medical need.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">According to&#160;external sources, market research,&#160;and&#160;internal analyses and calculations, we estimate the potential addressable&#160;market in&#160;KRAS G12D-mutated cancers&#160;at launch in the U.S.&#160;represents a&#160;multi-billion&#160;dollar&#160;opportunity with the&#160;ability&#160;to&#160;treat&#160;approximately&#160;40,000&#160;patients&#160;annually&#160;across either&#160;1L or 2L&#160;treatment&#160;(with or without combination treatments)&#160;in PDAC, NSCLC,&#160;CRC and other solid tumors.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Currently, no therapies are approved&#160;in the U.S.,&#160;Europe&#160;or Japan,&#160;specifically targeting KRAS G12D mutations in cancer.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INTELLECTUAL PROPERTY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We strive to protect the proprietary technology that we believe is important to our business, including seeking and maintaining patents intended to cover our product candidates and compositions, their methods of use and processes for their manufacture, and any other aspects of inventions that are commercially important to the development of our business. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We plan to continue to expand our intellectual property estate by filing patent applications directed to compositions, methods of treatment, and patient selection created or identified from our ongoing development of our product candidates. Our success will depend on our ability to obtain and maintain patent and other proprietary protection for </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">commercially important technology, inventions and know-how related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets, and operate without infringing the valid and enforceable patents and proprietary rights of third parties. We also rely on know-how, continuing technological innovation, and in-licensing opportunities to develop and maintain our proprietary position. We seek to obtain domestic and international patent protection, and endeavor to promptly file patent applications for new commercially valuable inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and patent scope can be reinterpreted by the courts after issuance. Moreover, many jurisdictions permit third parties to challenge issued patents in administrative proceedings, which may result in further narrowing or even cancellation of patent claims. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because patent applications in the U.S. and certain other jurisdictions are maintained in secrecy for 18&#160;months or potentially even longer, and because publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings or derivation proceedings declared by the U.S. Patent and Trademark Office to determine priority of invention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Patents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, our patent portfolio includes issued and pending patent applications worldwide. These patents and patent applications fall into three categories: (1)&#160;the RAF/MEK inhibition program; (2) the FAK inhibition program, and (3) KRAS inhibition program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">RAF/MEK inhibition program (avutometinib)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have exclusively licensed a patent portfolio of four patent families that are owned or exclusively licensed by Chugai and therefore we have an exclusive option to exclusively license either directly from Chugai or from any party that has an exclusive license from Chugai. The first patent family has claims directed to the composition of matter of avutometinib, and includes granted patents in various jurisdictions, such as the U.S., Australia, Brazil, Canada, China, Europe (validated in several countries), Japan, Korea, Israel, and New Zealand that are expected to expire in February of 2027, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. The second patent family has claims directed to methods of making avutometinib and includes granted patents in Europe, Japan, and the U.S. that are expected to expire in September of 2032, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. The third patent family has claims directed to a dosing protocol of avutometinib, and includes two granted patents in the United States, that are expected to expire in November of 2038, granted patents in Australia, Europe, Korea, and Taiwan, and pending patent applications in various jurisdictions, such as Brazil, Canada, China, Europe, Hong Kong, Japan, Mexico, and Singapore. Patents that issue in this family will have a statutory expiration date in May of 2038, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. The fourth patent family covers a method of using avutometinib in combination with a FAK inhibitor, such as defactinib, for treating a patient, and includes two granted patents in the U.S. and granted patents in Japan, Hong Kong, Macau, Singapore, and Taiwan that are expected to expire in September of 2040, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees, and pending patent applications in Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Indonesia, Japan, Korea, Mexico, Malaysia, New Zealand, Singapore, and the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, we own one patent family covering solid forms of avutometinib, which includes two granted patents in the U.S. that are expected to expire in December of 2042, a pending patent application in the U.S., and pending foreign patent applications in various jurisdictions, such as Australia, Canada, China, Europe, Japen, Korea, and </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Singapore, that if issued are expected to expire in May of 2043, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We also own eight patent families and co-own three patent families covering various methods of using a dual RAF/MEK inhibitor for treating a patient. Our eight patent families have claims directed to using a dual RAF/MEK inhibitor in combination with various therapeutic agents, such as a KRAS G12C inhibitors, KRAS G12D inhibitors, and immunotherapeutic agents for treating a patient, and have patent applications pending in various jurisdictions, such as Australia, Canada, China, Europe, and the U.S., that if issued would expire between 2041 and 2043, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. Our three co-owned patent families have claims directed to using a dual RAF/MEK inhibitor in combination with other  therapeutics and including a pending US provisional application and patent applications pending in various jurisdictions, such as Australia, Canada, China, Europe, and the U.S., that if issued are expected to expire in 2042 to 2045, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">FAK inhibition program (defactinib)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have exclusively licensed a portfolio of patents owned by Pfizer, which are directed to FAK inhibitor compounds and methods of their use, for example in cancer. One patent family has claims directed to the composition of matter of defactinib, has a patent application pending in the United States, and patents granted in various jurisdictions, such as Australia, Canada, China, Europe (validated in various countries), Israel, Japan, Korea, Singapore, and the United States, that are expected to expire in April of 2028, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. For example, US 7,928,109 covers the composition of matter of defactinib specifically, and US 8,247,411 covers the composition of matter of defactinib generically. Also included are issued and pending patent applications having claims directed to methods of treatment and methods of making defactinib. For example, US 8,440,822 and US 10,450,297 cover methods of making defactinib. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to the issued patents exclusively licensed from Pfizer, we own or co-own three patent families with claims directed to defactinib. One patent family is co-owned with Pfizer and has claims directed to compositions (e.g.,&#160;<span style="white-space:pre-wrap;">oral dosage forms) of defactinib and certain methods of use. This family contains granted patents in various jurisdictions, such as Europe (validated in various countries), Australia, Brazil, Hong Kong, Israel, Japan, Korea, Mexico, New Zealand, and South Africa and pending patent applications in the United States, Brazil, China, Europe, Israel, and Japan. The patents and pending patent applications, if issued, are expected to expire in January of 2035, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We own a second patent family with claims directed to methods of using a FAK inhibitor, such as defactinib, in combination with a MEK inhibitor for treating a patient. Patents in this family have been granted in the U.S., Japan, Hong Kong, and Europe, and are expected to expire in February 2035, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We own a third patent family with claims directed to methods of using a FAK inhibitor, such as defactinib, in combination with an immunotherapeutic agent.  Patent applications in this family have been granted in the U.S., Europe, Canada, China, Israel, and Mexico, and are expected to expire in June 2036, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. Patent applications in this family are also pending the U.S., Australia, Canada, China, Europe, Japan, and Singapore.</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">KRAS inhibition program (VS-7375)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We in-licensed a patent portfolio from GenFleet, which includes four patent families directed to KRAS inhibitors. In regard to VS-7375, two patent families have claims directed to the composition of matter of VS-7375. One patent family includes patent applications pending in various jurisdictions, such as the United States, Europe, and Japan, that if issued would expire in August of 2042, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. The other patent family includes patent applications pending in various jurisdictions, such as Australia, Brazil, Canada, Europe, Japan, Korea, Mexico, and the U.S., that if issued, are expected to expire in September of 2043, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The other two patent families are directed to other KRAS inhibitors. One family includes patent applications in the U.S. and Europe, that if issued are expected to expire in April of 2042, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. The remaining family includes patent applications in various jurisdictions such as the U.S., Australia, Brazil, Canada, Europe, Japan, and Korea, that if issued are expected to expire in March of 2042, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Patent Term</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The base term of a U.S. patent is 20&#160;years from the filing date of the earliest-filed non-provisional patent application from which the patent claims priority. The term of a U.S. patent can be lengthened by patent term adjustment, which compensates the owner of the patent for administrative delays at the U.S. Patent and Trademark Office. In some cases, the term of a U.S. patent is shortened by terminal disclaimer that reduces its term to that of an earlier-expiring patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term of a U.S. patent may be eligible for patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act, to account for at least some of the time the drug is under development and regulatory review after the patent is granted. With regard to a drug for which FDA approval is the first permitted marketing of the active ingredient, the Hatch-Waxman Act allows for extension of the term of one United States patent that includes at least one claim covering the composition of matter of an FDA-approved drug, an FDA-approved method of treatment using the drug, and/or a method of manufacturing the FDA-approved drug. The extended patent term cannot exceed the shorter of five years beyond the non-extended expiration of the patent or 14&#160;years from the date of the FDA approval of the drug. Some foreign jurisdictions, including Europe and Japan, have analogous patent term extension provisions, which allow for extension of the term of a patent that covers a drug approved by the applicable foreign regulatory agency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LICENSES AND COMMERCIAL AGREEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GenFleet Therapeutics Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On August 24, 2023, we entered into a collaboration and option agreement (the &#8220;GenFleet Agreement&#8221;) with GenFleet pursuant to which GenFleet granted us options to&#160;obtain exclusive development and commercialization rights worldwide outside of mainland China, Hong Kong, Macau, and Taiwan (the &#8220;Verastem Territory&#8221;) for up to three oncology programs targeting RAS pathway driven cancers (the &#8220;GenFleet Options&#8221;). We may exercise our GenFleet Options on a program-by-program basis. In December 2023, we announced the lead oncology discovery program is VS-7375, a potential best-in-class oral and selective KRAS G12D (ON/OFF) inhibitor. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In January 2025, we exercised our GenFleet Option with respect to VS-7375 and made a $6.0 million payment to GenFleet. In January 2025, we entered into a supply agreement with GenFleet pursuant to which GenFleet agreed to provide us with compound and licensed product for development use for VS-7375. </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We made an upfront payment of $2.0 million to GenFleet in September 2023 and will provide $1.5 million of research support over the first three years of the GenFleet Agreement. In addition, pursuant to the GenFleet Agreement, upon achievement of certain milestones, and upon us exercising its GenFleet Options, GenFleet will be entitled to receive payments of up to $622.0 million, inclusive of (i) up to $154.0 million upon achievement of certain development and commercialization milestones, (ii) up to $450.0 million upon achievement of certain sales milestones, and (iii) up to $18.0 million upon exercise of all three GenFleet Options. We paid GenFleet a $3.0 million milestone payment in the year ended December 31, 2024, upon GenFleet achieving a development milestone. We have also agreed to pay GenFleet royalties on net sales of licensed products in the Verastem Territory ranging from the mid to high single digits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may terminate the GenFleet Agreement in its entirety or on a program-by-program basis by providing 90 days&#8217; written notice to GenFleet. Either party may terminate the GenFleet Agreement in its entirety or on a program-by-program and country-by-country basis, with 60 days&#8217; written notice for the other party&#8217;s material breach if such party fails to cure the breach. Either party may also terminate the GenFleet Agreement in its entirety upon certain insolvency events involving the other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Secura Bio, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On August 10, 2020, we and Secura signed an Asset Purchase Agreement (the &#8220;Secura APA&#8221;) and on September 30, 2020, the transaction closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Secura APA, we sold to Secura our exclusive worldwide license for the research, development, commercialization, and manufacture in oncology indications of products containing duvelisib. The sale included certain intellectual property related to duvelisib in oncology indications, certain existing duvelisib inventory, claims and rights under certain contracts pertaining to duvelisib. Pursuant to the Secura APA, Secura assumed all operational and financial responsibility for activities that were part of the duvelisib oncology program, including all commercialization efforts related to duvelisib in the United States and Europe, as well as our ongoing duvelisib clinical trials. Further, Secura assumed all obligations with existing collaboration partners developing and commercializing duvelisib, which include Yakult Honsha Co., Ltd. (&#8220;Yakult&#8221;), CSPC Pharmaceutical Group Limited (&#8220;CSPC&#8221;), and Sanofi. Additionally, Secura assumed all royalty payment obligations due under the amended and restated license agreement with Infinity Pharmaceuticals, Inc. (&#8220;Infinity&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Secura APA, Secura paid us an up-front payment of $70.0 million, and has agreed to pay us (i) regulatory milestone payments up to $45.0 million, consisting of a payment of $35.0 million upon receipt of regulatory approval of COPIKTRA in the United States for the treatment of peripheral T-cell lymphoma (&#8220;PTCL&#8221;) and a payment of $10.0 million upon receipt of the first regulatory approval for the commercial sale of COPIKTRA in the European Union for the treatment of PTCL, (ii) sales milestone payments of up to $50.0 million, consisting of $10.0 million when total worldwide net sales of COPIKTRA exceed $100.0 million, $15.0 million when total worldwide net sales of COPIKTRA exceed $200.0 million and $25.0 million when total worldwide net sales of COPIKTRA exceed $300.0 million, (iii) low double-digit royalties on the annual aggregate net sales above $100.0 million in the United States, European Union, and the United Kingdom of Great Britain and Northern Ireland and (iv) 50% of all royalty, milestone and sublicense revenue payments payable to Secura under our existing license agreements with Sanofi, Yakult, and CSPC, and 50% of all royalty, and royalty payments payable to Secura under any license or sublicense agreement entered into by Secura in certain jurisdictions. In the year ended December 31, 2024, Secura achieved $100.0 million of total worldwide net sales of COPIKTRA which triggered a $10.0 million milestone payment to us, which we received in July 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Secura&#8217;s royalty obligations remain in effect on a country-by-country basis upon the last to occur (a) 10 years from the first commercial sale of product containing duvelisib in such country or (b) the expiration of all valid patent claims covering products containing duvelisib in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December 2021, Secura announced it had voluntarily withdrawn COPIKTRA (duvelisib) from the U.S. for treatment of patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies. On June 30, 2022, the FDA issued a drug safety communication warning that resulted from a clinical trial showing a possible increased risk of death with COPIKTRA compared to another medicine to treat chronic blood cancer called leukemia and lymphoma. The clinical trial also found that COPIKTRA was associated with a higher risk of serious </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">side effects, including infections, diarrhea, inflammation of the intestines and lungs, skin reactions, and high liver enzyme levels in the blood. In September 2022, the FDA&#8217;s Oncologic Drug Advisory Committee (&#8220;ODAC&#8221;) voted eight to four against COPIKTRA&#8217;s use in patients with relapsed or refractory chronic lymphocytic leukemia/ small lymphocytic lymphoma after at least two prior therapies citing an unfavorable risk/benefit profile. In September 2022, Secura&#8217;s sublicensee, Yakult, announced it had withdrawn its NDA for duvelisib in Japan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Chugai Pharmaceutical Co., Ltd.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 7, 2020, we entered into a license agreement with Chugai (the &#8220;Chugai Agreement&#8221;) whereby Chugai granted us an exclusive worldwide license for the development, commercialization, and manufacture of products containing avutometinib.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Chugai Agreement, we received an exclusive right to develop and commercialize products containing avutometinib at our own cost and expense. In February 2020, we paid Chugai a non-refundable payment of $3.0 million. We are further obligated to pay Chugai double-digit royalties on net sales of products containing avutometinib, subject to reduction in certain circumstances. Chugai also obtained opt back rights to develop and commercialize avutometinib (a) in the European Union, and (b) in Japan and Taiwan. Chugai has communicated their intention not to exercise their opt back rights for Japan, Taiwan, or the European Union. Chugai and we have made customary representations and warranties and have agreed to certain customary covenants, including confidentiality and indemnification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Unless earlier terminated, the Chugai Agreement will expire upon the fulfillment of our royalty obligations to Chugai for the sale of any products containing the avutometinib, which royalty obligations expire on a product-by-product and country-by-country basis, upon the last to occur, in each specific country, of (a) expiration of valid licensed patent claims covering such product or (b) 12 years from the first commercial sale of such product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may terminate the Chugai Agreement upon 180 days&#8217; written notice. Subject to certain limitations, Chugai may terminate the Chugai Agreement upon written notice if we challenge any patent licensed by Chugai to us under the Chugai Agreement. Either party may terminate the license agreement in its entirety with 120 days&#8217; written notice for the other party&#8217;s material breach if such party fails to cure the breach. Either party may also terminate the Chugai Agreement in its entirety upon certain insolvency events involving the other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pfizer Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July 11, 2012, we entered into a license agreement (the &#8220;Pfizer Agreement&#8221;) with Pfizer under which Pfizer granted us worldwide, exclusive rights to research, develop, manufacture and commercialize products containing certain of Pfizer&#8217;s inhibitors of FAK, including defactinib, for all therapeutic, diagnostic and prophylactic uses in humans. We have the right to grant sublicenses under the foregoing licensed rights, subject to certain restrictions. We are solely responsible, at our own expense, for the clinical development of these products, which is to be conducted in accordance with an agreed upon development plan. We are also responsible for all manufacturing and commercialization activities at our own expense. Pfizer provided us with an initial quantity of clinical supplies of one of the products for an agreed upon price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upon entering into the Pfizer Agreement, we made a onetime cash payment to Pfizer in the amount of $1.5 million and issued 16,001 shares of our common stock, adjusted for our Reverse Stock Split (defined herein).<span style="background:#ffffff;"> In April 2025, we entered into an amendment to the Pfizer Agreement such that a $7.5 million milestone became payable upon FDA approval of AVMAPKI FAKZYNJA CO-PACK on May 8, 2025 (the &#8220;First Pfizer Milestone&#8221;), and $8.0 million milestone (the &#8220;Second Pfizer Milestone&#8221;) is payable upon the one-year anniversary of the FDA approval of AVMAPKI FAKZYNJA CO-PACK. We made the First Pfizer Milestone payment in 2025 and expect to make the Second Pfizer Milestone payment in 2026.</span> Pfizer is also eligible to receive up to $2.0 million in developmental milestones and up to an additional $110.0 million based on the successful attainment of regulatory and commercial sales milestones. Pfizer is also eligible to receive high single to mid-double-digit royalties on future net sales of the products. Our royalty obligations with respect to each product in each country begin on the date of first commercial sale of the product in that country, and end on the later of 10 years after the date of first commercial sale of the </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">product in that country or the date of expiration or abandonment of the last claim contained in any issued patent or patent application licensed by Pfizer to us that covers the product in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Pfizer Agreement will remain in effect until the expiration of all our royalty obligations to Pfizer, determined on a product by product and country by country basis. So long as we are not in breach of the Pfizer Agreement, we have the right to terminate the license agreement at will on a product by product and country by country basis, or in its entirety, upon 90 days written notice to Pfizer. Either party has the right to terminate the Pfizer Agreement in connection with an insolvency event involving the other party or a material breach of the Pfizer Agreement by the other party that remains uncured for a specified period of time. If the Pfizer Agreement is terminated by either party for any reason, worldwide rights to the research, development, manufacture and commercialization of the products revert back to Pfizer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMPETITION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The biotechnology&#160;and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. While we believe that our technology, development&#160;experience&#160;and scientific knowledge provide us with competitive advantages, we face potential competition from many&#160;different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many of our competitors may have significantly greater financial resources and&#160;expertise&#160;in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology, and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and&#160;retaining&#160;qualified scientific and management personnel and&#160;establishing&#160;clinical trial sites and patient registration for clinical trials, as well as in&#160;acquiring&#160;technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The key competitive factors affecting the success of all our product candidates, if approved, are likely to be their efficacy, safety, side effects, convenience, price, the level of generic competition, and the availability of reimbursement from government and other third-party&#160;payors.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors&#160;establishing&#160;a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other&#160;third-party&#160;payors&#160;seeking&#160;to encourage the use of generic products. There are many generic products currently on the market for the indications that we are pursuing, and&#160;additional&#160;generic&#160;products are expected to become available over the coming years. If our therapeutic product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The most common methods of treating patients with cancer are surgery, radiation, and drug therapy, including chemotherapy, hormone therapy, immunotherapy, and targeted drug therapy. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. To the extent our product candidates are&#160;ultimately used&#160;in combination with or as an adjunct to existing drug or other therapies, our product candidates will not be competitive with them. Some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well established therapies and are widely accepted by physicians,&#160;patients&#160;and&#160;third-party&#160;payors. In general, although there has been considerable progress over the past few decades in the treatment of cancer and the currently marketed therapies provide benefits to many patients, these therapies all are limited to some&#160;extent in their </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">efficacy and frequency of adverse events, and none of them are successful in treating all patients. As a result, the level of morbidity and mortality from cancer&#160;remains&#160;high.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to currently marketed therapies, there are also&#160;a number of&#160;products in late-stage clinical development to treat cancer. These products in development may provide efficacy, safety, convenience, and other benefits that are not provided by currently marketed therapies. As a result, they may provide significant competition for any of our product candidates for which we obtain market approval.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Several&#160;FDA-approved&#160;RAF and/or MEK inhibitors&#160;are&#160;commercially&#160;available;&#160;however,&#160;we are not aware of any&#160;products&#160;that are specifically&#160;approved&#160;for KRAS-mutated recurrent LGSOC.&#160;Competitors that&#160;are currently developing&#160;RAF and/or MEK inhibitors&#160;are&#160;Abbvie,&#160;AstraZeneca, Bristol Myers Squibb Company,&#160;Erasca, Genentech, Novartis AG, and Pfizer.&#160;Other&#160;competitors&#160;developing KRAS G12D inhibitors and pan-KRAS inhibitors&#160;are&#160;Astellas Pharma Inc., AstraZeneca,&#160;Bayer,&#160;BeOne, Boehringer Ingelheim, Chugai,&#160;D3 Bio,&#160;Eli Lilly,&#160;GenFleet,&#160;Genentech, Incyte Corporation,&#160;Jacobio,&#160;Jiangsu Hengrui Pharmaceuticals Company Ltd, Quanta Therapeutics,&#160;Ranok&#160;Therapeutics,&#160;Revolution Medicine,&#160;and&#160;Tyligand&#160;Bioscience; however, we are not aware of any FDA-approved treatments for the KRAS G12D&#160;mutation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MANUFACTURING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We contract with third parties for the manufacture of our product candidates for preclinical studies, clinical trials, and commercial requirements and we intend to continue to do so in the future. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:95.13%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:20.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:79.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:40pt;"><td style="vertical-align:middle;width:20.15%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Avutometinib</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(AVMAPKI)</p></td><td style="vertical-align:top;width:79.84%;background:#ffffff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.37;margin:0pt;"><span style="white-space:pre-wrap;">We work with one contract manufacturing organization (&#8220;CMO&#8221;) for the manufacture of        avutometinib drug product, two CMOs for the production of avutometinib drug substance, and one CMO for avutometinib drug packaging/labeling.</span></p></td></tr><tr style="height:35.5pt;"><td style="vertical-align:middle;width:20.15%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Defactinib</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(FAKZYNJA)</p></td><td style="vertical-align:top;width:79.84%;background:#ffffff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.37;margin:0pt;">We have one CMO for the manufacture of defactinib drug product, one CMO for the production of defactinib drug substance, and one CMO for defactinib drug packaging/labeling.</p></td></tr><tr style="height:40pt;"><td style="vertical-align:middle;width:20.15%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VS-7375</b></p></td><td style="vertical-align:middle;width:79.84%;background:#ffffff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.37;margin:0pt;">We currently are party to a supply agreement with GenFleet pursuant to which we expect to obtain VS-7375 finished product from GenFleet. We are in the process of completing tech transfers with a two domestic CMO to onshore the manufacture of both drug substance and drug product of VS-7375 to the US.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities.&#160;We have supply agreements in place with these CMOs and we obtain drug substance, drug product and packaging/labeling services from these CMOs on a purchase order basis. We may elect to pursue relationships with other CMOs for manufacturing of drug product, drug substance, and packaging/labeling for later-stage clinical trials, commercialization or for risk management. We have personnel with pharmaceutical development and manufacturing experience who are responsible for the relationships with our CMOs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All of our drug candidates are organic compounds of low molecular weight, generally called small molecules.&#160;We select compounds not only on the basis of their potential efficacy and safety, but also for their ease of synthesis and the reasonable cost of their starting materials.&#160;We expect to continue to develop drug candidates that can be produced cost-effectively at third-party CMOs.<span style="display:inline-block;width:27.45pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">APPLICABLE LAWS AND GOVERNMENT REGULATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Government authorities in the U.S., at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, including any manufacturing changes, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, import and export of pharmaceutical products, such as those we are developing.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. Drug Approval Process</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before a drug may be marketed in the U.S. generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.3pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests, animal studies, and formulation studies in compliance with the FDA&#8217;s good laboratory practice regulations and applicable requirements for the humane use of laboratory animals or other applicable requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.3pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND application, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.3pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent institutional review board (&#8220;IRB&#8221;) at each clinical site before each trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.3pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices (&#8220;GCP&#8221;) and other clinical-trial related regulations to establish the safety and efficacy of the proposed drug for each indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.3pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an NDA and payment of user fees for FDA review of NDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.3pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA advisory committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.3pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practices (&#8220;cGMP&#8221;) requirements and to assure that the facilities, methods, and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.3pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the NDA.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The U.S. Supreme Court&#8217;s June 28, 2024 decision in <i style="font-style:italic;">Loper Bright Enterprises v. Raimondo</i> (&#8220;<i style="font-style:italic;">Loper</i>&#8221;) overturned the longstanding <i style="font-style:italic;">Chevron</i> doctrine under which administrative agencies, including the FDA, were entitled to deference in the interpretation of &#8220;ambiguous&#8221; federal statutes. The full impact of the <i style="font-style:italic;">Loper</i> decision is not yet known, but it could lead to significant changes in FDA regulation of our business and the pharmaceutical industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Studies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Before testing any product candidate in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as <i style="font-style:italic;">in vitro</i> and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective thirty days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on their ClinicalTrials.gov website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase&#160;1:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase&#160;2:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase&#160;3: </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The drug is administered to an expanded patient population in adequate and well-controlled clinical trials to generate sufficient data to statistically confirm the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of a NDA or, in certain circumstances, post-approval, such as in the case of drugs approved under the accelerated approval pathway.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase&#160;1, Phase&#160;2 and Phase&#160;3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Marketing Approval</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to a substantial application user fee, scheduled in 2026 to exceed $4.6 million, and the sponsor of an approved NDA is also subject to annual program fees, based on the number of approved products. These fees are typically adjusted annually. User fee statutory authority expires every five years. The PDUFA was re-authorized for an additional five years in 2022 </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">until 2027, and negotiations are underway to re-authorize PDUFA for fiscal years 2028 through 2032. Fee waivers are available in certain circumstances, including a waiver of the application fee for an orphan drug application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA conducts a preliminary review of all NDAs within the first 60&#160;days after submission before accepting them for filing to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review of NDAs. Under these goals, the FDA has committed to review most such applications for non-priority products within 10&#160;months after accepting the application for filing, and most applications for priority review products, that is, drugs that the FDA determines represent a significant improvement over existing therapy, within six months after accepting the application for filing. The review process may be extended by the FDA for three additional months to consider certain information or clarification regarding information already provided in the submission. The FDA may also refer applications for novel drugs or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the Pediatric Research Equity Act of 2003, as amended and reauthorized by the Food and Drug Administration Amendments Act of 2007 (&#8220;FDAAA&#8221;), an NDA or supplement to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan drug designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP and integrity of the clinical data submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The testing and approval process requires substantial time, effort and financial resources, and each may take many years to complete. Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. We may encounter difficulties or unanticipated costs in our efforts to develop our product candidates and secure necessary governmental approvals, which could delay or preclude us from marketing our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">After the FDA&#8217;s evaluation of the NDA and inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If the FDA issues a complete response letter, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two to six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval and refuse to approve the NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Even if the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase&#160;4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">distribution restrictions or other risk management mechanisms, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expedited Development and Review Programs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA has various programs, including fast track designation, breakthrough therapy designation, priority review and accelerated approval, which are designed to expedite or facilitate the process for the development and FDA review of drugs and biologics that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs and biologics to patients earlier than under standard FDA review procedures.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Fast Track Designation. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that the product is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment, and demonstrates the potential to address unmet medical needs for the condition. Under the fast track program, the sponsor of a new drug candidate may request the FDA to designate the product for a specific indication as a fast track product concurrent with or after the filing of the IND for the product candidate. The FDA must determine if the product candidate qualifies for fast track designation within 60&#160;days after receipt of the sponsor&#8217;s request.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">In addition to other benefits, such as the ability to use surrogate endpoints and have greater interactions with the FDA, the FDA may initiate review of sections of a fast track product&#8217;s NDA before the application is complete. This rolling review is available if the applicant provides and the FDA approves a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA&#8217;s time period goal for reviewing a fast track application does not begin until the last section of the NDA is submitted. In addition, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Breakthrough Designation</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. A drug may be designated as a breakthrough therapy if the drug is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The breakthrough therapy designation provides all the benefits of the fast track program, including the eligibility for rolling review. The FDA may take certain administrative actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team and taking other steps to aid sponsors in designing the clinical trials. Although breakthrough designation does not affect the regulatory standards for approval, the frequent interactions with the FDA may facilitate a more efficient development program. In addition, the breakthrough designation may be withdrawn by the FDA if the FDA believes that the drug no longer meets the conditions for qualification. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Priority Review.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Under FDA policies, a product candidate may be eligible for priority review, or review within a six-month time frame, compared to the ten-month time frame for a standard review, from the time a complete application is accepted for filing. Products regulated by the FDA&#8217;s Center for Drug Evaluation and Research (&#8220;CDER&#8221;) are eligible for priority review if they provide a significant improvement compared to marketed products in the treatment, diagnosis or prevention of a disease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Accelerated Approval. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Under the FDA&#8217;s accelerated approval regulations, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit. In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A product candidate approved on </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">this basis is subject to rigorous post-marketing compliance requirements, including the completion of one or more Phase&#160;4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies or confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the drug from the market on an expedited basis. The Food and Drug Omnibus Reform Act of 2022 (&#8220;FDORA&#8221;) signed by President Biden on December 29, 2022 as part of the Consolidated Appropriations Act, 2023 (H.R. 2617) includes numerous reforms to the accelerated approval process for drugs and biologics and enables the FDA to require, as appropriate, that a post-approval study be underway prior to granting accelerated approval. FDORA also expands the expedited withdrawal procedures available to the FDA to allow the agency to use expedited procedures if a sponsor fails to conduct any required post-approval study of the product with due diligence. FDORA also adds the failure of a sponsor of a product approved under accelerated approval to conduct with due diligence any required post-approval study with respect to such product or to submit timely reports with respect to such product to the list of prohibited acts in the FDCA. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Orphan Drugs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally defined as a disease or condition that affects fewer than 200,000 individuals in the U.S. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the U.S. for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same orphan indication, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. The FDA has historically taken the position that the scope of orphan exclusivity aligns with the approved indication or use of a product, rather than the disease or condition for which the product received orphan designation. However, on September 30, 2021, the U.S. Court of Appeals for the 11<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Circuit issued a decision in <i style="font-style:italic;">Catalyst Pharms., Inc. v. Becerra</i> holding that the scope of orphan drug exclusivity must align with the disease or condition for which the product received orphan designation, even if the product&#8217;s approval was for a narrower use or indication. It remains to be seen how this decision affects orphan drug exclusivity going forward. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application user fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Hatch Waxman Act</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Abbreviated New Drug Applications</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an abbreviated New Drug Application (&#8220;ANDA&#8221;). Generally, an ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths, dosage form and route of administration as the listed drug and has been shown to be bioequivalent through <i style="font-style:italic;">in vitro</i> or <i style="font-style:italic;">in vivo</i> testing or otherwise to the listed drug. ANDA applicants are not required to conduct or submit results of preclinical or clinical tests to prove the safety or effectiveness of their drug product, other than the requirement for bioequivalence testing. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. Specifically, the applicant must certify with respect to each patent that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the required patent information has not been filed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the listed patent has expired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the listed patent is invalid, unenforceable or will not be infringed by the new product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph&#160;IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If the ANDA applicant has provided a Paragraph&#160;IV certification to the FDA, the applicant must also send notice of the Paragraph&#160;IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&#160;IV certification. The filing of a patent infringement lawsuit within 45&#160;days after the receipt of a Paragraph&#160;IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30&#160;months after the NDA or patent holder&#8217;s receipt of the Paragraph&#160;IV certification, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The ANDA also will not be approved until any applicable non-patent exclusivity period, such as exclusivity for obtaining approval of a new chemical entity, for the referenced product has expired. Federal law provides a period of five years following approval of a drug containing no previously approved active moiety during which ANDAs for generic versions of those drugs cannot be submitted unless the submission contains a Paragraph&#160;IV challenge to a listed patent, in which case the submission may be made four years following the original product approval. Federal law provides for a period of three years of exclusivity during which the FDA cannot grant effective approval of an ANDA for the conditions of use covered by the exclusivity, but FDA requires as a condition of approval new clinical trials conducted by or for the sponsor. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication. Under the Best Pharmaceuticals for Children Act, federal law also provides that periods of patent and non-patent marketing exclusivity listed in the Orange Book for a drug may be extended by six months if the NDA sponsor conducts pediatric studies identified by the FDA in a written request. For written requests issued by the FDA after September&#160;27, 2007, the date of enactment of the FDAAA, the FDA must grant pediatric exclusivity no later than nine months prior to the date of expiration of patent or non-patent exclusivity in order for the six-month pediatric extension to apply to that exclusivity period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Combination Therapy </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Combination therapy is a treatment modality that involves the use of two or more drugs to be used in combination to treat a disease or condition. If those drugs are combined in one dosage form, such as one pill, that is known as a fixed dose combination product, and it is reviewed pursuant to the FDA&#8217;s Combination Rule&#160;at 21 CFR 300.50 (&#8220;the Rule&#8221;). The Rule provides that two or more drugs may be combined in a single dosage form when each component contributes to the claimed effects and the dosage of each component (amount, frequency, duration) is such that the combination is safe and effective for a significant patient population requiring such concurrent therapy as defined in the labeling for the drug. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not all combination therapy falls under the category of a fixed dose combination. For example, the FDA recognizes that two drugs in separate dosage forms and in separate packaging, that otherwise might be administered as monotherapy for an indication, also may be used in combination for the same indication.&#160;In 2013, the FDA issued </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">guidance to assist sponsors that were developing the range of combination therapies that fall outside the category of fixed dose combinations. That guidance provides recommendations and advice on such topics as: (1) assessment at the outset whether two or more therapies are appropriate for use in combination; (2) guiding principles for nonclinical and clinical development of the combination; (3) options for regulatory pathways to seek marketing approval of the combination; and (4) post-marketing safety monitoring and reporting obligations. Given the wide range of potential combination therapy variations, the FDA indicated it intends to assess each potential combination on a case-by case basis and encouraged sponsors to engage in early and regular consultation with the relevant review division at the agency throughout the development process for its proposed combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Combination Products</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA regulates combinations of products that cross FDA centers, such as drug, biologic or medical device components that are physically, chemically or otherwise combined into a single entity, as a combination product. The FDA center with primary jurisdiction for the combination product will take the lead in the premarket review of the product, with the other center consulting or collaborating with the lead center.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA&#8217;s Office of Combination Products (&#8220;OCP&#8221;) determines which center will have primary jurisdiction for the combination product based on the combination product&#8217;s &#8220;primary mode of action.&#8221; A mode of action is the means by which a product achieves an intended therapeutic effect or action. The primary mode of action is the mode of action that provides the most important therapeutic action of the combination product, or the mode of action expected to make the greatest contribution to the overall intended therapeutic effects of the combination product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Often it is difficult for the OCP to determine with reasonable certainty the most important therapeutic action of the combination product. In those difficult cases, the OCP will consider consistency with other combination products raising similar types of safety and effectiveness questions, or which center has the most expertise to evaluate the most significant safety and effectiveness questions raised by the combination product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A sponsor may use a voluntary formal process, known as a Request for Designation, when the product classification is unclear or in dispute, to obtain a binding decision as to which center will regulate the combination product. If the sponsor objects to that decision, it may request that the agency reconsider that decision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Regulatory Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any drug manufactured or distributed by us pursuant to FDA approvals would be subject to extensive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase&#160;4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. Regulatory approval of oncology products often requires that patients in clinical trials be followed for long periods to determine the overall survival benefit of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before implementation. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain cGMP compliance.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical trials to assess new safety risks or imposition of distribution or other restrictions under a Risk Evaluation and Mitigation Strategy program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consent decrees, corporate integrity agreements, injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. The current administration announced in September 2025 that it intends to prioritize enforcement of pharmaceutical advertising requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Additional Provisions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As part of the sales and marketing process, pharmaceutical companies frequently provide samples of approved drugs to physicians. The Prescription Drug Marketing Act (&#8220;PDMA&#8221;) imposes requirements and limitations upon the provision of drug samples to physicians, as well as prohibits states from licensing distributors of prescription drugs unless the state licensing program meets certain federal guidelines that include minimum standards for storage, handling and record keeping. In addition, the PDMA sets forth civil and criminal penalties for violations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Healthcare Laws</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the U.S., pharmaceutical manufacturers are subject to numerous other federal, state and local laws designed to, for example, prevent fraud and abuse; prevent the causing of false claims to be submitted to government healthcare programs; promote transparency in interactions with others in the healthcare industry; regulate pricing of drugs; require reporting of drug prices and payment of rebates or offering of discounts to certain government programs and public and private payors; and protect the privacy of individual information. These laws are enforced by various federal and state enforcement authorities, including but not limited to, the U.S. Department of Justice, and individual U.S. Attorney offices within the Department of Justice, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;), HHS&#8217; various divisions, including but not limited to, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), and the Office of Inspector General, and state boards of pharmacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We may be subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback laws and false claims laws, for activities related to past and future sales of any products reimbursable by third-party payors such as federal health care programs (including Medicare and Medicaid) or, in some cases, commercial health plans.  Anti-kickback laws generally prohibit a pharmaceutical manufacturer from soliciting, offering, receiving, or paying anything of value to generate business, including the purchase, prescription or use of a particular drug. False claims laws generally prohibit anyone from knowingly and willingly presenting, or causing to be presented, any claims for payment for reimbursed drugs or services to third-party payors that are false or fraudulent. </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Laws and regulations have also been enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers with marketed products. The laws and regulations generally limit financial interactions between manufacturers and health care providers; require manufacturers to adopt certain compliance standards; require disclosure to the government and public of financial interactions; require disclosure of marketing expenditures or pricing information, regulate drug pricing and/or require the registration of pharmaceutical sales representatives.  Many of these laws and regulations contain ambiguous requirements or require administrative guidance for implementation. Given the lack of clarity in laws and their implementation, any future activities (if we obtain approval and/or reimbursement from federal healthcare programs for our product candidates) could be subject to challenge.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The distribution of drugs and biological products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Federal and state consumer protection and unfair competition laws and regulations broadly regulate marketplace activities and that potentially harm consumers and could apply to the activities of pharmaceutical manufacturers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may be subject to data privacy and security laws in the various jurisdictions in which we operate, obtain or store personally identifiable information. Numerous U.S. federal and state laws govern the collection, use, disclosure and storage of personal information. Various foreign countries also have, or are developing, laws governing the collection, use, disclosure and storage of personal information. Globally, there has been an increasing focus on privacy and data protection issues that may affect our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Efforts to ensure that our activities comply with applicable healthcare laws and regulations will involve substantial costs. Given the breadth of the laws and regulations, limited guidance for certain laws and regulations and evolving government interpretations of the laws and regulations, governmental authorities may possibly conclude that our business practices may not comply with such laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources.  Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Foreign Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In order to market any product outside of the U.S., we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Regardless of our current FDA approval or any future FDA approvals we may obtain for a product, we would need to obtain the necessary approvals by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pharmaceutical Coverage, Pricing and Reimbursement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of new drug products. Sales of our product candidates, if approved, will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs such as Medicare and Medicaid, commercial health insurers and managed care organizations. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the approved drugs for a particular indication.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. We may also need to provide discounts to purchasers, private health plans or government healthcare programs. Our product candidates may not be considered medically necessary or cost effective. Even if covered, third-party payors may seek to control utilization of our products through various mechanisms (e.g., requiring a prescriber to obtain prior authorization from a health plan before the product will be covered by the health plan or establishing patient copays and deductibles that encourage use of other products over our products). A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for drug products can differ significantly from payor to payor. One third-party payor&#8217;s decision to cover a particular drug product or service does not ensure that other payors will also provide coverage for the drug product or will provide coverage at an adequate reimbursement rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Within the U.S., FDA-approved drugs could potentially be covered by various government health benefit programs as well as purchased by government agencies. The participation in such programs or the sale of products to such agencies is subject to regulation. The marketability of any of our approved products may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Medicaid is a joint federal and state program that is administered by the states for low income and disabled beneficiaries. Under the Medicaid Drug Rebate Program, participating manufacturers are required to pay a rebate for each unit of product reimbursed by the state Medicaid programs. The amount of the rebate for each product is set by law and may be subject to an additional discount if certain pricing increases more than inflation. State Medicaid programs and Medicaid managed care plans can seek additional &#8220;supplemental&#8221; rebates from manufacturers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Medicare is a federal program that is administered by the federal government that covers individuals aged 65 and over, disabled individuals and certain other eligible individuals. Medicare Part D provides coverage to enrolled Medicare patients for self-administered drugs (i.e., drugs that do not need to be injected or otherwise administered by a physician). Medicare Part D is administered by private prescription drug plans approved by the U.S. government and each drug plan establishes its own Medicare Part D formulary for prescription drug coverage and pricing, which the drug plan may modify from time-to-time. The prescription drug plans negotiate rebates and other discounts with manufacturers and may condition formulary placement on the availability of manufacturer discounts. Manufacturers with marketed brand name drugs may be asked to provide discounts on brand name prescription drugs utilized by Medicare Part D beneficiaries in order for a given prescription drug plan to cover the manufacturer&#8217;s drug. Under a new manufacturer discount drug program that became effective January 1, 2025, manufacturers pay 10% of the allowed cost of the drug after a Medicare beneficiary has met the standard deductible until the beneficiary reaches the annual out-of-pocket cap ($2,100) and then 20% of the allowed cost of the drug. Additionally, as the result of recent changes under the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;), drug utilization under Medicare Part B and Part D may be subject to an additional Medicare discount if the pricing increases more than inflation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Drug products are subject to discounted pricing when purchased by federal agencies via the Federal Supply Schedule (&#8220;FSS&#8221;). FSS participation is required for a drug product to be covered and reimbursed by certain federal agencies and for coverage under the Medicaid Drug Rebate Program and Medicare Part B. FSS pricing is negotiated periodically with the Department of Veterans Affairs. FSS pricing is subject to statutory reporting requirements and is negotiated periodically with the Department of Veterans Affairs, including by reference to a manufacturer&#8217;s comparable non-federal customer pricing. In addition, prices for drugs purchased by the Veterans Administration (&#8220;VA&#8221;), Department of Defense (including drugs purchased by military personnel and dependents through the TRICARE retail pharmacy program), Coast Guard, and Public Health Service (&#8220;PHS&#8221;) through the FSS are subject to a cap on pricing (known as the &#8220;federal ceiling price&#8221;) and may be subject to an additional discount if pricing increases more than the rate of inflation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To maintain coverage of drugs under the Medicaid Drug Rebate Program and Medicare Part B, manufacturers are required to participate in and extend discounts to certain purchasers under the PHS pharmaceutical pricing program. </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Purchasers eligible for discounts include hospitals that serve a disproportionate share of financially needy patients, community health clinics and other entities that receive health services grants from the PHS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The containment of healthcare costs has become a priority for federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services and examining the medical necessity and cost effectiveness of medical products and services, in addition to their safety and efficacy. If these third-party payors do not consider our products to be cost effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. Federal and state governments in the U.S. as well as foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures, and tightening of existing controls and measures, could limit payments for pharmaceuticals such as the drug candidates that we are developing and could adversely affect our net revenue and results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular product candidate to currently available therapies. For example, the European Union provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a drug product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. There can be no assurance that any country that has price controls or reimbursement limitations for drug products will allow favorable reimbursement and pricing arrangements for any of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The marketability of products for which we may receive regulatory approval for commercial sale may suffer if the government and private third-party payors fail to provide adequate coverage and reimbursement, seek to control utilization, or create pressure to provide price concessions, coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time. Even if favorable coverage and reimbursement status is attained for a product, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">New Legislation and Regulations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, legislation is drafted, introduced and passed in the U.S. Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing and marketing of pharmaceutical products. For example, in 2016, Congress enacted and President Obama signed into law the 21<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> Century Cures Act that amends a number of sections of the FDCA. Additionally, in December 2022, President Biden signed into law the Consolidated Appropriations Act, 2023 (H.R. 2617) that contains important reforms relevant to the FDA, including the FDORA and the Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act. In addition to new legislation, FDA regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or interpretations changed or what the effect of such changes, if any, may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, in the U.S., federal and state governments continue to propose and pass legislation designed to reform delivery of, or payment for, healthcare, which include initiatives to reduce the cost of healthcare generally and drugs specifically. For example, in 2010, Congress enacted the Patient Protection and Affordable Care Act and the Healthcare and Education Reconciliation Act (collectively, &#8220;ACA&#8221;), which expanded healthcare coverage through Medicaid expansion and the implementation of the individual mandate for health insurance coverage, and included changes to the coverage and reimbursement of drug products under government healthcare programs as well as the imposition of annual fees on manufacturers of branded pharmaceuticals.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Beyond the ACA, there are ongoing and widespread healthcare reform efforts, a number of which have focused on regulation of prices or payment for drug products. Drug pricing and payment reform has been an ongoing focus. For example, the Inflation Reduction Act ("IRA") of 2022 includes several changes intended to address rising prescription drug prices in Medicare Parts B and D, with varying implementation dates. These changes include caps on Medicare Part D out-of-pocket costs, Medicare Part B and Part D drug price inflation rebates, a new Medicare Part D manufacturer discount drug program (replacing the prior Medicare Part D coverage gap discount program) and a drug price negotiation program for certain high spend Medicare Part B and D drugs (with the first set of negotiated Medicare maximum fair prices going into effect in 2026). The IRA<span style="text-decoration-line:line-through;text-decoration-style:solid;"> </span>has had a significant impact on the pharmaceutical industry and that impact is anticipated to continue. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Beyond the IRA, changes to Medicaid effective in 2024 eliminated the Medicaid rebate cap and changes to certain Medicare price reporting requirements for drugs beginning in 2026 will likely increase the administrative and compliance burden for manufacturers. In addition, recent legislation expanded the orphan drug exclusion in the IRA Medicare drug price negotiation program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the current presidential administration, there has been significant reform activity focused on drug pricing and reimbursement. For example, President Trump issued an Executive Order in April 2025 with multiple directives aimed at lowering drug prices, including refining the Medicare drug price negotiation program established by the IRA, accelerating competition for high-cost prescription drugs by accelerating approval of generics and biosimilars and facilitating the process for re-classifying prescription drugs as over-the-counter drugs, and increasing drug importation. In May 2025, President Trump issued another Executive Order that directed government agencies and officials to identify most-favored nation pricing targets for prescription drugs (and looked to pharmaceutical manufacturers to make significant progress towards delivering target prices to patients), prevent foreign countries from disproportionately shifting the cost of global pharmaceutical research and development to the U.S., and facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers to sell their products to patients at the most-favored-nation price. In the wake of the Executive Orders and related executive initiatives, a number of pharmaceutical manufacturers have announced direct-to-consumer offerings with discounted prices and/or reached agreement with the federal government regarding pricing for drugs, including prices for Medicaid drugs and newly launched products. A future website sponsored by the federal government that is anticipated to offer pharmaceutical direct-to-consumer channels has also been announced. Federal agencies are developing new drug pricing pilot programs, such as a Medicaid model that would authorize the federal government to negotiate Medicaid supplemental rebates with participating manufacturers on behalf of state Medicaid programs, in exchange for standardized coverage criteria for participating manufacturer drugs, and proposed Medicare Part B and Part D pilot models that, if finalized as proposed, would replace existing inflation-based Medicare rebates with rebates determined on the basis of international prices, for drugs and patients subject to the model. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other healthcare reform efforts or actions may affect access to healthcare coverage or the funding of health care benefits, although the full impact of such efforts or actions cannot be predicted. For example, the Congressional Budget Office has estimated that Medicaid provisions in the 2025 budget reconciliation legislation, including restrictions in eligibility and funding for Medicaid, as well as changes to the healthcare marketplace such as the elimination of certain subsidies, will increase the number of uninsured patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Individual states in the U.S. have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price and reimbursement constraints, restrictions on copayment assistance by pharmaceutical manufacturers, value-based pricing, marketing cost disclosure and other transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Healthcare reform efforts have been and may continue to be subject to scrutiny, legal challenge and subsequent amendment, creating further uncertainty. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other government actions could have an adverse effect upon, and could prevent, our products&#8217; commercial success. For example, the Trump Administration&#8217;s announced tariff on branded or patented drugs may increase the cost of drug products that are imported from abroad or manufactured using products or materials imported from abroad. The timeline for implementation of this tariff has not yet been finalized. As another example, the Budget Control Act of 2011, as amended, resulted in the imposition of reductions in Medicare (but not Medicaid) payments to providers in </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2013 and remains in effect through 2032 unless additional Congressional action is taken. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented and/or any significant taxes or fees that may be imposed on us could have an adverse impact on our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Healthcare reform initiatives at the federal or state level could affect demand for, or pricing of, our product candidates if approved for sale. We cannot predict the ultimate content, timing or effect of any such reform. There is no assurance that healthcare reform will not adversely affect our future business and financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">HUMAN CAPITAL RESOURCES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe our employees are among the most important assets to our company and are key to achieving our goals and expectations. Accordingly, we focus significant attention on attracting and retaining talented individuals. To support these objectives, our human resources programs reflect our commitment to our core values (Purposeful, Unwavering, Influential, Insightful and Symbiotic) and are designed to prioritize our employees&#8217; well-being, support their career goals, offer competitive wages and benefits, and enhance our culture through efforts aimed at making the workplace more satisfying, engaging and inclusive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In order to attract qualified applicants to Verastem and retain such employees, we offer a total rewards package consisting of base salary and cash target bonus, a comprehensive benefit package, and equity compensation for every employee.&#160;Bonus opportunity and equity compensation increase as a percentage of total compensation based on level of responsibility.&#160;Actual bonus payout is based on our achievement of corporate goals and individual performance.</span> <span style="background:#ffffff;">In addition, many of our employees are stockholders of the company through participation in our Employee Stock Purchase Plan, which aligns the interests of our employees with our stockholders by providing stock ownership on a</span> tax-deferred <span style="background:#ffffff;">basis. We also </span>provide for employer matching contributions equal to 100% of employee deferral contributions up to a deferral rate of 6% of eligible compensation to our Section 401(k) retirement savings plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, we had 102 full time equivalent employees, including a total of 23 employees with M.D. or Ph.D. degrees, and two part-time employees. Of the full time equivalent employees, 56 employees were engaged in research and development activities. We consider the intellectual capital of our employees to be an essential driver of our business and key to our success. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BUSINESS&#8212;EXECUTIVE OFFICERS OF THE REGISTRANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the name, age and position of each of our executive officers as of February&#160;27, 2026.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:49.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.25;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.25;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.25;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.25;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:32.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.25;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.25;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:top;width:49.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Executive Officers:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:49.08%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-left:10pt;text-indent:-10pt;margin:0pt;">Daniel W. Paterson</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:right;margin:0pt;">64&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">President, Chief Executive Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:49.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-left:10pt;text-indent:-10pt;margin:0pt;">Michael Kauffman</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:right;margin:0pt 2.15pt 0pt 0pt;">62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">President of Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:9.9pt;"><td style="vertical-align:top;width:49.08%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-left:10pt;text-indent:-10pt;margin:0pt;">Daniel Calkins</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:right;margin:0pt 2pt 0pt 0pt;">38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Daniel W. Paterson</i>, has served as our Chief Executive Officer since August 2023 and as our President since June 2019, in addition to serving as our Chief Operating Officer from December 2014 to July 2023, as our Chief Business Officer from July 2013 to December 2014 and as our Vice President, Head of Corporate Development and Diagnostics from March 2012 until July 2013. Prior to joining us in March 2012, Mr. Paterson was a consultant in 2011. From 2009 through 2010, Mr. Paterson was the Chief Operating Officer of On-Q-ity. Mr. Paterson was the President and Chief Executive Officer of The DNA Repair Company from 2006 until 2009, when it was acquired by On-Q-ity. Previously, he held senior level positions at IMS Health, CareTools, OnCare, and Axion. Mr. Paterson holds a B.A. in Biology from Boston University and attended the Northeastern University Graduate Pharmacology program.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk221279661"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Michael Kauffman M.D., Ph.D.</i>, has served as our President of Development since December 2025 after serving as lead director of our board of directors since June 2016. Michael has been a member of our board of directors since November 2012 and continues to serve on our board of directors.&#160;Prior to his role as President of Development, he was the Chief Executive Officer, president and board member of Nereid Therapeutics Inc from November 2023 to November 2025. Prior to this, Dr. Kauffman was the cofounding Chief Executive Officer and acting Chief Medical Officer of Karyopharm Therapeutics Inc., a publicly traded commercial stage biotechnology company, from January 2011 to April 2021 and senior clinical advisor from May 2021 to May 2022. Prior to this, Dr. Kauffman was the Chief Medical Officer of Onyx Pharmaceuticals, Inc., a publicly traded biotechnology company, from November 2009 until December 2010. Dr. Kauffman received an M.D. and Ph.D. in molecular biology and biochemistry from Johns Hopkins University and holds a B.A. in biochemistry from Amherst College. Dr. Kauffman trained in Internal Medicine at Beth Israel Deaconess and rheumatology at Massachusetts General Hospitals, and is board certified in internal medicine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Daniel Calkins,</i> has served as our Chief Financial Officer since October 2023, prior to which Mr. Calkins served as our Vice President, Finance from September 2022 to October 2023, as our Corporate Controller from March 2020 to September 2022, as our Assistant Controller from May 2019 to March 2020, and as our Associate Director, SEC Reporting and Technical Accounting from December 2018 to May 2019. Prior to joining us in December 2018, Mr. Calkins held various positions of increasing responsibility at CFGI from May 2013 to December 2018. Prior to CFGI, Mr. Calkins began his career at PwC LLP in the assurance practice. Mr. Calkins holds a B.S. in Accounting from Bryant University and M.S. in Accounting from Northeastern University. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OUR CORPORATE INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We were incorporated under the laws of the State of Delaware in August 2010. Our principal executive offices are located at 117 Kendrick Street, Suite&#160;500, Needham, Massachusetts 02494 and our telephone number is (781)&#160;292-4200.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ADDITIONAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We maintain a website at www.verastem.com. We make available, free of charge on our website, our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and all amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) as soon as reasonably practicable after we electronically file those reports with, or furnish them to, the SEC. We also make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors and 10% stockholders pursuant to Section&#160;16 under the Exchange Act as soon as reasonably practicable after copies of those filings are provided to us by those persons. The information contained on, or that can be accessed through, our website is not a part of or incorporated by reference in this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2103bdd7_0744_43cf_80c4_567aae5d9dd0"></a><a id="ITEM1ARiskFactors_957358"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">ITEM 1A.&#160; Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Careful consideration should be given to the following material risk factors, in addition to the other information set forth in this Annual Report on Form 10-K and in other documents that we file with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) in evaluating us and our business. Investing in our common stock involves a high degree of risk. If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks we face. New risk factors can emerge from time to time, and it is not possible to predict the impact that any factor or combination of factors may have on our business, prospects, financial condition and results of operations.</i></p><a id="_Hlk221117022"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Risks Related to the Development of Our Product Candidates and Commercialization of our Product Candidates</b></p><div style="margin-top:0pt;"><a id="_Hlk221116899"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We are highly dependent on the commercial success of AVMAPKI FAKZYNJA CO-PACK (avutometinib&#160;capsules;&#160;defactinib&#160;tablets) in the U.S for the foreseeable future.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">In May 2025, we received accelerated approval for AVMAPKI FAKZYNJA CO-PACK in the U.S. for treatment of adults with KRAS-mutated, recurrent LGSOC who have received prior systemic therapy. The commercial success of AVMAPKI FAKZYNJA CO-PACK depends on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of AVMAPKI FAKZYNJA CO-PACK as a treatment for adult patients with KRAS-mutated, recurrent LGSOC who have received prior systemic therapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the treatable patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of our sales and marketing efforts; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the coverage and reimbursement levels set by governmental authorities, private health insurers, and other third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the adoption of AVMAPKI FAKZYNJA CO-PACK by physicians, which depends on whether physicians view it as a safe and effective treatment for adults with KRAS-mutated, recurrent LGSOC who have received prior systemic therapy; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the occurrence of any side effects, adverse reactions, misuse or any unfavorable publicity in these or other areas associated with avutometinib and defactinib; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the development and commercialization of products or therapies that compete with AVMAPKI FAKZYNJA CO-PACK.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-indent:0pt;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk221116903"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Preclinical testing and clinical trials of our product candidates may not be successful. If we are unable to expand the approved indication for the c</i><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">ombination product, obtain marketing approval for or successfully commercialize any of our product candidates, or if we experience significant delays in doing so, our business will be materially harmed.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:5pt 0pt 0pt 18pt;">We have invested a significant portion of our efforts and financial resources in the research and development of our product candidates. Our ability to generate product revenues will depend heavily on the successful commercialization and development of our product candidates. The success of our product candidates will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation and successful enrollment and completion of our clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of marketing approvals from the FDA and other regulatory authorities for our current and future product candidates, including pricing approvals where required; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing and maintaining commercial manufacturing capabilities or making arrangements with third-party manufacturers; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing and maintaining commercial capabilities, including hiring and training a sales force, and launching commercial sales of the products, if and when approved, whether alone or in collaboration with others; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the products, if and when approved, by patients, the medical community, and third-party payors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">securing and maintaining coverage and adequate reimbursement for our products from third-party payors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively competing with other therapies; and </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-indent:0pt;background:#ffffff;margin:0pt 0pt 0pt 36pt;">a continued acceptable safety and efficacy profile of the products following approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">Many of these factors are beyond our control, including clinical development, the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any collaborator. If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business.</p><a id="_Hlk221116921"></a><a id="_Hlk220677110"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Even though&#160;AVMAPKI FAKZYNJA CO-PACK</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">has received accelerated approval in the U.S., and even if we receive marketing approval for an expanded indication for our combination product or any of our&#160;other product candidates receives marketing approval,&#160;such product candidates may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">Even though&#160;AVMAPKI FAKZYNJA CO-PACK has received accelerated approval in the U.S., and even if we receive marketing approval for an expanded indication for our combination product or any of our&#160;other product candidates receives marketing approval, our products and product candidates may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. If&#160;AVMAPKI FAKZYNJA CO-PACK does not achieve an adequate level of acceptance, or if we are unable to increase market acceptance of&#160;AVMAPKI FAKZYNJA CO-PACK as compared to existing or competitive products, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of&#160;AVMAPKI FAKZYNJA CO-PACK, or any of our other product candidates, if approved for commercial sale, will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efficacy and potential advantages compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">convenience and ease of administration compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to offer our product candidates for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the line of therapy for our product candidates is designated under physician treatment guidelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the standard of care for the targeted indications for product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings, including distribution or use restrictions, contained in the approved labeling for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficient third-party coverage and reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of the medical community to appropriately recognize and manage side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety concerns with similar products marketed by others; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects as a result of treatment with product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;background:#ffffff;margin:5pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="margin-top:5pt;"><a id="_Hlk221116927"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:5pt 0pt 0pt 0pt;">&#216;</td><td style="padding:5pt 0pt 0pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. For example, a further review and analysis of this data may change the conclusions drawn from this unaudited data indicating less promising results than we currently anticipate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, adherence to the dosing regimen and other trial protocols, and the rate of dropout among clinical trial participants. There also may be significant variability in the safety results obtained through the long-term follow-up of patients from ongoing studies. We do not know whether any clinical trial we may conduct or follow-up data we collect will demonstrate consistent or adequate efficacy and/or safety sufficient to obtain regulatory approval to market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">In addition, the design of a clinical trial may determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">A failure of one or more clinical trials could indicate a higher likelihood that subsequent clinical trials of the same product candidate in the same or other indications or subsequent clinical trials of other related product candidates will be unsuccessful for the same reasons as the unsuccessful clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may have delays in reaching or fail to reach agreement on clinical trial contracts or clinical trial protocols with prospective trial sites;</span><span style="display:inline-block;width:14.25pt;"></span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or our participants may drop out of these clinical trials at a higher rate than we anticipate; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate the trials; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant changes to the policies or regulations of the FDA or foreign regulatory authorities regarding the development, approval, and marketing of pharmaceutical products, including but not limited to as a result of the 2024 United States presidential election.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be delayed in obtaining or not obtain marketing approval for our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain approval with labeling that includes significant use or distribution restrictions including imposition of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;), or safety warnings, including boxed warnings; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be subject to additional post marketing testing requirements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have the product removed from the market after obtaining marketing approval.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:12pt 0pt 12pt 18pt;">The FDA and foreign regulatory authorities may determine that the results from our ongoing and futunew drure trials do not support regulatory approval and may require us to conduct an additional clinical trial or trials. If these agencies take such a position, the costs of development of our product candidates could increase materially and their potential market introduction could be delayed or abandoned. The regulatory agencies could also require that we conduct additional clinical, nonclinical or manufacturing validation studies and submit that data before it will consider a new drug application. Our product development costs will also increase if we experience delays in clinical testing or marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</p><div style="margin-top:5pt;"><a id="_Hlk221116935"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or foreign regulatory authorities. In addition, there are a number of ongoing clinical trials being conducted by other companies for product candidates treating cancer. Patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors' product candidates, particularly if they view such treatments to be more conventional and established.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Patient enrollment is affected by other factors including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and nature of the patient population; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">severity of the disease under investigation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eligibility criteria for the study in question; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceived risks and benefits of the product candidate under study in relation to other available treatments including any new treatments that may be approved for the indications we are investigating; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efforts to facilitate timely enrollment in clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient referral practices of physicians; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to monitor patients adequately during and after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proximity and availability of clinical trial sites for prospective patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">constraints on the healthcare system such as a pandemic.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">Furthermore, enrolled patients may drop out of a clinical trial, which could impair the validity or statistical significance of the clinical trial. A number of factors can influence the patient discontinuation rate, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inclusion of a placebo arm in a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">possible inactivity or low activity of the product candidate being tested at one or more of the dose levels being tested; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the occurrence of adverse side effects, whether or not related to the product candidate; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of numerous alternative treatment options, including clinical trials evaluating competing product candidates, that may induce patients to discontinue their participation in the trial.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</p><div style="margin-top:5pt;"><a id="_Hlk221116939"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Preclinical studies and preliminary, initial &#8220;top-line&#8221; and interim data from clinical trials of our product candidates, or statistical analyses and projections based thereon, are not necessarily predictive of the results or success of ongoing or later clinical trials of our product candidates. If we cannot replicate the results from our preclinical studies and clinical trials of our product candidates, we may be unable to successfully develop, obtain regulatory approval for, and commercialize our product candidates.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">Preclinical studies and any positive preliminary, initial &#8220;top-line,&#8221; and interim data from our clinical trials of our product candidates may not necessarily be predictive of the results of ongoing or later clinical trials. Even if we are able to complete our planned clinical trials of our product candidates according to our current development timeline, the positive results from clinical trials of our product candidates may not be replicated in subsequent clinical trial results. Also, our later stage clinical trials could differ in significant ways from earlier stage clinical trials, which could cause the outcome of the later stage trials to differ from our earlier stage clinical trials. For example, these differences may include changes to inclusion and exclusion criteria, efficacy endpoints and statistical design. Many companies in the biotechnology and pharmaceutical industries, including us, have suffered significant setbacks in late stage clinical trials after achieving positive results in an earlier stage of development. If we fail to produce positive results in our planned clinical trials of any of our product candidates, the development timeline and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects, would be materially adversely affected.</p><div style="margin-top:5pt;"><a id="_Hlk221116942"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Our approach to the treatment of cancer through cell death, inhibition of tumor growth, and disruption of the tumor microenvironment is relatively unproven, and we do not know whether we will be able to develop any products of significant commercial value.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">We are developing product candidates to treat cancer by using targeted agents to cause cell death, inhibition of tumor growth, and disruption of the tumor microenvironment, and thereby thwart the growth and proliferation of cancer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">Research on the use of small molecules to cause cell death, inhibition of tumor growth, and disruption of the tumor microenvironment is an emerging field and, consequently, there is still uncertainty about whether defactinib, avutometinib and VS-7375 are effective in improving outcomes for patients with cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Any products that we develop may not effectively cause cell death, inhibition of tumor growth, and disruption of the tumor microenvironment. While we are currently conducting clinical trials for product candidates that we believe will cause cell death, inhibition of tumor growth, and disruption of the tumor microenvironment, we may not ultimately be successful in demonstrating their efficacy, alone or in combination with other treatments.</p><div style="margin-top:5pt;"><a id="_Hlk221116946"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The market opportunities for AVMAPKI FAKZYNJA CO-PACK and our other product candidates, if approved, may be smaller than we estimate, and the FDA and other comparable foreign regulatory authorities may approve our product candidates for a more limited patient population than we anticipate.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">The potential market opportunity for our product candidates is difficult to estimate precisely. For example, the number of patients suffering from each of recurrent KRAS mutant LGSOC and recurrent KRAS wild-type LGSOC populations we are targeting near term (for KRAS mutant LGSOC) and longer term (for KRAS wild type LGSOC) is small and has not been established with precision. Due to the rarity of our target indications, there is no comprehensive patient registry or other method of establishing with precision the actual number of patients with KRAS mutant LGSOC and KRAS wild-type LGSOC. As a result, we have had to rely on other available sources to derive clinical prevalence estimates for our target indications. We make estimates regarding the incidence and prevalence of target patient populations, the rate of recurrence and the median survival for particular diseases, including with respect to LGSOC, based on various third-party sources and internally generated analysis and use such estimates in making decisions regarding our drug development strategy determining indications on which to focus in preclinical or clinical trials.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">Our estimates of the patient population, pricing and revenue opportunities for our product candidates, including for KRAS mutant patients with recurrent LGSOC, are based on a number of internal and third-party estimates, including, without limitation, internal forecasts of potential market penetration, the median duration of treatment from initial interim clinical data and the assumed prices at which we can commercialize our product candidates. These estimates may be inaccurate or based on imprecise data. The market opportunity of AVMAPKI FAKZYNJA CO-PACK and our product candidates, if approved, will depend on, among other things, acceptance by the medical community, patient access, drug pricing and reimbursement. The number of patients in the addressable market may turn out to be lower than we estimate, patients may not be otherwise amenable to treatment with our drugs, or new patients may become increasingly difficult to identify or gain access to, all of which may significantly harm our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">In addition, even if we obtain approval for any of our product candidates, such approvals may be for more limited patient populations than we had anticipated and the potential market for our product candidates will be smaller than our current estimates. Obtaining approval for only a smaller patient population of our target indications for which we anticipate seeking approval would have a materially adverse effect on our ability to achieve commercialization and generate revenues.</p><div style="margin-top:5pt;"><a id="_Hlk221116952"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The approval of our product candidates as single agents or part of a combination therapy for the treatment of certain cancers may be more costly than our prior clinical trials, may take longer to achieve regulatory approval, may be associated with new, more severe or serious and unanticipated adverse events, and may have a smaller market opportunity.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">Part of our current business model involves conducting clinical trials to study the effects of combining our product candidates with other approved and investigational targeted therapies, chemotherapies, and immunotherapies to treat patients with cancer. Regulatory approval for a combination treatment generally requires clinical trials to evaluate the activity of each component of the combination treatment. As a result, it may be more difficult and costly to obtain regulatory approval of our product candidates for use as part of a combination treatment than obtaining regulatory approval of our product candidates alone. In addition, we also risk losing the supply of any approved or investigational product being combined with our product candidate in these clinical trials. Furthermore, the potential market opportunity for our product candidates is difficult to estimate precisely. For instance, if one of our product candidates receives regulatory approval from a combination study, it may be approved solely for use in combination with the approved or investigational product in a particular indication and the market opportunity our product candidate would be dependent upon the continued use and availability of the approved or investigational product. In addition, because physicians, patients, and third-party payors may be sensitive to the addition of the cost of our product candidates to the cost of treatment with the other products, we may experience downward pressure on the price that we can charge for our product candidates if they receive regulatory approval. Further, we cannot be sure that physicians will view our product candidates, if approved as part of a combination treatment, as sufficiently superior to a treatment regimen consisting of only the approved or investigational product. Additionally, the adverse side effects of our product candidates may be enhanced when combined with other products. If such adverse side effects are experienced, we could be required to conduct additional preclinical and clinical studies, and if such adverse side effects are severe, we may not be able to continue the clinical trials of the combination therapy because the risks may outweigh the therapeutic benefit of the combination.</p><div style="margin-top:5pt;"><a id="_Hlk221116957"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We face substantial competition, which may result in others developing or commercializing products before or more successfully than we do.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we are developing our product candidates, including Abbvie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb Company, Chugai, D3 Bio, Eli Lilly, Erasca, Genentech, GenFleet, Incyte Corporation, Jacobio, Jiangsu Hengrui Pharmaceuticals </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt 0pt 0pt 18pt;">Company Ltd, Novartis AG, Pfizer, Quanta Therapeutics, Ranok Therapeutics, Revolution Medicine, Tyligand Bioscience and others. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">We are developing our product candidates for the treatment of cancer. There are a variety of available therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic products. We expect that our product candidates, if approved, will be priced at a significant premium over competitive generic products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:5pt 0pt 0pt 18pt;">Many of our competitors have significantly greater financial resources and expertise than we do in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Additionally, new developments, including the development of other drug technologies and methods of preventing the incidence of disease, occur in the pharmaceutical and medical technology industries at a rapid pace.<span style="letter-spacing:-1.5pt;">&#160;</span>These developments may render our product candidates obsolete or<span style="letter-spacing:-0.35pt;">&#160;</span>noncompetitive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">In addition, to the extent that products or product candidates of our competitors demonstrate serious adverse side effects or are determined to be ineffective in clinical trials, the commercialization and the development of our product candidates could be negatively impacted.</p><div style="margin-top:5pt;"><a id="_Hlk221116962"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">If we fail to obtain regulatory approval in jurisdictions outside the U.S., we will not be able to market our products in those jurisdictions.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5pt 0pt 0pt 18pt;">We intend to seek regulatory approval for our product candidates in countries outside of the U.S. and expect that these countries will be important markets for our products, if approved. Marketing our products in these countries will require separate regulatory approvals in each market and compliance with numerous and varying regulatory requirements. The regulations that apply to the conduct of clinical trials and approval procedures vary from country to country and may require additional testing. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. In addition, in many countries outside the U.S., a drug must be approved for reimbursement before it can be approved for sale in that country. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Failure to obtain regulatory approval in one country may have a negative effect on the regulatory approval process in others. Further, we and our collaboration partners are currently conducting clinical trials, and may in the future conduct additional clinical trials, outside the U.S., including the Phase 1/2 clinical trial evaluating VS-7375 by GenFleet in China. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to conditions imposed by the FDA. For example, the FDA will generally not approve the application unless the data are applicable to the U.S. population and U.S. medical practice and the FDA is able to validate the data through an on-site inspection or other appropriate means. The FDA or any comparable foreign regulatory authority may not accept data from trials conducted outside of the U.S. or the applicable jurisdiction, which may result in the need for additional trials that could be costly and time consuming and could result in the product candidate not receiving approval for commercialization in the applicable jurisdiction. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not obtain foreign regulatory approvals on a timely </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">basis, if at all. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any foreign market.</p><a id="_Hlk221116966"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">If serious adverse or unexpected side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates.</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">Our product candidates are in various stages of clinical development, and their risk of failure is high. It is impossible to predict when or if our other product candidates will prove effective or safe in humans or will receive marketing approval. If our product candidates are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk benefit perspective. Patients in our clinical trials have experienced serious adverse events, deemed by us and the clinical investigator to be related to our product candidates. Serious adverse events generally refer to adverse events, that result in death, are life threatening, require hospitalization or prolonging of hospitalization, or cause a significant and permanent disruption of normal life functions, congenital anomalies or birth defects, or require intervention to prevent such outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Avutometinib and defactinib are being administered and studied in our Phase 1, Phase 2, and Phase 3 clinical trials, and VS-7375 is being administered and studied in our Phase 1 and Phase 2 clinical trials and the development program continues to progress. For avutometinib, defactinib, and VS-7375 the toxicities reported to date have been predictable and appear to be manageable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5pt 0pt 12pt 18pt;">As a result of adverse events observed to date, or further safety or toxicity issues that we may experience in our clinical trials in the future, we may not receive approval to market any product candidates, which could prevent us from ever generating revenue from the sale of products or achieving profitability. Results of our trials could reveal an unacceptably high severity and prevalence of side effects. In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our products candidates for any or all targeted indications. Many compounds that initially showed promise in early stage testing for treating cancer have later been found to cause side effects that prevented further development of the compound. In addition, while we and our clinical trial investigators currently determine if serious adverse or unacceptable side effects are drug related, the FDA or other non-U.S. regulatory authorities may disagree with our or our clinical trial investigators&#8217; interpretation of data from clinical trials and the conclusion that a serious adverse effect or unacceptable side effect was not drug related.</p><div style="margin-top:5pt;"><a id="_Hlk221116970"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products.</p><div style="margin-top:5pt;"><a id="_Hlk221116975"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Any future product candidates that we commercialize may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">In both domestic and foreign markets, any product candidates that may receive marketing approval in the future will depend, in part, on favorable pricing as well as the availability of coverage and amount of reimbursement by third-party payors, including governments and private health plans. Substantial uncertainty exists regarding coverage and reimbursement by third-party payors of newly approved health care products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">Outside the United States, some countries require approval of the sale price of a drug before the product can be marketed. In many such countries, the pricing review period begins after marketing or product licensing </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in product candidates, even if those product candidates obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Cost containment is a key trend in the United States and elsewhere. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, the level of reimbursement. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize the product candidates for which we may obtain marketing approval.</p><div style="margin-top:5pt;"><a id="_Hlk221116980"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop</i><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any other products we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any product candidates or products that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend the related litigation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any products that we may develop.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">We currently hold $10.0 million in product liability insurance coverage in the aggregate, with a per incident limit of $10.0 million, which may not be adequate to cover all liabilities that we may incur. We have in the past and may in the future need to increase our insurance coverage as we commercialize future product candidates or if we initiate additional clinical trials in the United States and around the world. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</p><a id="_Hlk221116985"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">A pandemic, epidemic, or outbreak of an infectious disease, such as COVID-19, has and may in the future adversely affect our business.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Broad-based business or economic disruptions could adversely affect our ongoing or planned research and development activities, our financial condition and our results of operations. For example, United States residents and businesses in major urban centers have been hit especially hard by the global spread of COVID-19, which has resulted in certain disruptions to our business and may in the future result in additional disruptions to our business. Examples of both include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Shortages of personnel at clinical trial sites and delay in startup activities. Clinics and hospitals in Europe and United States continue to cause delays in startup and on-going activities due to the ongoing  shortages of both site coordinators and staff within the industry.  Frequent high</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"> </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">turnover of existing site staff and slower contracting, budget negotiations, and operational bottlenecks contribute to the delays.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Work-from-home limitations. Since 2020, a material portion of our workforce works remotely and we expect this to continue, which could impact our ability to effectively plan, execute, communicate, and maintain our corporate culture.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Capital markets volatility. Equity and debt markets have experienced significant volatility in recent years, which makes it more difficult to raise capital at a reasonable valuation or at all.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Business interruptions or disruptions. There may be interruptions or disruptions that directly or indirectly adversely affect our or our current or potential collaboration partners&#8217; organizations, which may delay or disrupt our business plans or impact a collaboration partner&#8217;s ability to fully perform under our agreements with them.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">Each of these factors could have a material adverse effect on our business and results of operations.</p><a id="_Hlk221117000"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:5pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Commercial Agreements</b></p><div style="margin-top:0pt;"><a id="_Hlk221116992"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We depend on Secura for the achievement and payment of the contingent consideration under the asset purchase agreement between us and Secura pursuant to which we sold the COPIKTRA assets to Secura. If Secura is unsuccessful in developing and commercializing COPIKTRA, we may not receive such payments or otherwise capitalize on the market potential of COPIKTRA. </i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">On September 30, 2020, we completed the disposition of our rights, title, and interest in and to COPIKTRA to Secura. Under the terms of the asset purchase agreement with Secura, we are entitled to contingent consideration, including milestone payments and royalties, dependent upon the further development and commercial success of COPIKTRA. Accordingly, our ability to receive the contingent consideration will depend on Secura&#8217;s ability to successfully develop and commercialize COPIKTRA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Secura&#8217;s ability to develop and commercialize COPIKTRA is subject to a number of risks and uncertainties, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Secura has significant discretion in determining how to develop further and commercialize COPIKTRA, including through potential collaborators and partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Secura may not commit sufficient resources to development, marketing or distribution of COPIKTRA; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">even if diligently pursued, Secura&#8217;s efforts to develop and commercialize COPIKTRA may not be successful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Secura may not properly maintain or defend its intellectual property rights or may use its proprietary information in such a way as to invite litigation that could jeopardize or invalidate the intellectual property of COPIKTRA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Secura may fail to maintain compliance with ongoing FDA labeling, packaging, storage, advertising, promotion, recordkeeping, safety and other post-market requirements; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Secura may not be able to obtain regulatory approval in United States for certain oncology indications or obtain approval in jurisdictions outside of the United States and as a result, will not be able to market COPIKTRA for those indications or in those jurisdictions; and</span></td></tr></table><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:5pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:5pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disputes may arise between Secura and us that result in the delay of payments or in costly litigation that diverts management attention and resources.</span></td></tr></table><div style="margin-top:12pt;"><a id="_Hlk221117083"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Our ability to receive future contingent consideration, including milestone payments and royalties, from the sale of our rights, title, and interest in COPIKTRA to Secura may be adversely affected by lower than expected COPIKTRA sales and Secura&#8217;s ability to achieve other developmental and regulatory milestones.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">On June 30, 2022, the FDA issued a drug safety communication warning that resulted from a clinical trial showing a possible increased risk of death with COPIKTRA compared to another medicine to treat chronic blood cancer called leukemia and lymphoma. The aforementioned clinical trial also found that COPIKTRA was associated with a higher risk of serious side effects, including infections, diarrhea, inflammation of the intestines and lungs, skin reactions, and high liver enzyme levels in the blood. In September 2022, the FDA&#8217;s ODAC voted eight to four against COPIKTRA&#8217;s use in patients with relapsed or refractory chronic lymphocytic </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">leukemia/ small lymphocytic lymphoma after at least two prior therapies citing an unfavorable risk/benefit profile. The FDA drug safety communication warning, the FDA&#8217;s ODAC vote, future actions by the FDA, and any safety concerns associated with COPIKTRA, perceived or real, may materially and adversely affect Secura&#8217;s development and commercialization success of COPIKTRA and, consequently, our ability to receive future contingent consideration from our sale of our right, title, and interest in COPIKTRA to Secura.</p><div style="margin-top:5pt;"><a id="_Hlk221117088"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">If we do not realize the anticipated benefits of our license agreements with Pfizer for the FAK program and Chugai for the dual RAF/MEK candidate program, or from the GenFleet Agreement, our business could be adversely affected.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">Our license agreements with Pfizer for defactinib, Chugai for avutometinib, and the GenFleet Agreement for up to three oncology programs, may fail to further our business strategy as anticipated or to achieve anticipated benefits and success. We may make or have made assumptions relating to the impact of the acquisition of defactinib and avutometinib or entering into the GenFleet Agreement on our financial results relating to numerous matters, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of development and commercialization of defactinib and avutometinib; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of development and commercialization of any of the three oncology programs; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other financial and strategic risks related to the agreements with Pfizer, Chugai and GenFleet.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 18pt;">Further, we may incur higher than expected operating and transaction costs, and we may encounter general economic and business conditions that adversely affect us relating to our agreements with Pfizer, Chugai or GenFleet. If one or more of these assumptions are incorrect, it could have an adverse effect on our business and operating results, and the benefits from our license agreements with Pfizer for defactinib and Chugai for avutometinib and the GenFleet Agreement may not be realized or be of the magnitude expected.</p><div style="margin-top:5pt;"><a id="_Hlk221117092"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We depend on GenFleet to fully perform under the GenFleet Agreement inclusive of our supply agreement with GenFleet.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">On August 24, 2023, we entered into the GenFleet Agreement pursuant to which we obtained three GenFleet Options that may be exercised on a program-by-program basis. In December 2023, we announced the selection of a potential best-in class oral and selective KRAS G12D (ON/OFF) inhibitor VS-7375 as the lead program. GenFleet is currently conducting a Phase 1/2 trial in&#160;China evaluating VS-7375 in patients with KRAS G12D-mutated advanced solid tumors. In January 2025, we exercised early the GenFleet Option for the lead compound VS-7375 and initiated a Phase 1/2a study in middle of 2025 in the U.S. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Pursuant to the GenFleet Agreement, we are reliant on GenFleet to fulfill their responsibilities including ongoing discovery and lead optimization for the second and third programs and execution of the Phase 1 clinical trials for the second and third programs. Accordingly, our ability to realize the anticipated benefits and success of the GenFleet Agreement is dependent upon GenFleet fulfilling their obligations. Furthermore, we have entered into a supply agreement with GenFleet pursuant to which we expect to obtain VS-7375 finished product from GenFleet for use in our planned clinical trial in the United States. If GenFleet does not perform under the supply agreement, our ability to obtain VS-7375 and consequently our current and planned clinical trial in the United States investigating VS-7375 will be materially adversely impacted. If GenFleet does not successfully carry out their responsibilities, the benefits of the GenFleet Agreement and our collaboration with GenFleet may not be realized.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk221117099"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</b></p><div style="margin-top:0pt;"><a id="_Hlk221117108"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We have incurred significant losses since our inception. We may incur losses for the foreseeable future and may never achieve or maintain profitability.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;"><span style="white-space:pre-wrap;">Since inception, we have incurred significant operating losses. As of December 31, 2025, we had an accumulated deficit of $1.165 billion To date, we have generated minimal product revenues and have financed our operations primarily through public and private offerings of our common stock, preferred stock, warrants and pre-funded warrants, offerings of convertible notes, sales of our common stock pursuant to our at-the-market equity offering programs, our Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;) with RGCM SA LLC, as purchaser agent, Oberland Capital Management LLC (&#8220;Oberland&#8221;) and certain funds managed by Oberland, as purchasers, (together with the other purchasers party thereto referred to as the &#8220;Note Purchase Agreement Purchasers&#8221;), former loan agreements, upfront payments under our license and collaboration agreements with Yakult, Honsha Co., Ltd. (&#8220;Yakult&#8221;), CSPC Pharmaceutical Group Limited (&#8220;CSPC&#8221;),  and Sanofi, and the upfront payment and milestone payments under the Secura APA. We have devoted substantially all of our efforts to research and development. We expect to continue to incur significant expenses and may incur operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue commercialization activities of AVMAPKI FAKZYNJA CO-PACK</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue our ongoing clinical trials with our product candidates, including with avutometinib and defactinib for wild type LGSOC, avutometinib and defactinib for other non-LGSOC cancers; and VS-7375</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate additional clinical trials for our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand, and protect our intellectual property portfolio; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license other products and technologies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional clinical, development, and scientific personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish and maintain a sales, marketing and distribution infrastructure to commercialize any products for which we obtain marketing approval.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:12pt 0pt 12pt 18pt;">To become and remain profitable, we must develop and eventually commercialize a product or products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining marketing approval for these product candidates, and manufacturing, marketing, and selling those products for which we may obtain marketing approval. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk221117134"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We will need additional funding. If we are unable to raise capital if needed, we would be forced to delay, reduce, or eliminate our product development programs or commercialization efforts, including for avutometinib, defactinib and VS-7375.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">We expect our expenses to increase in connection with our ongoing activities, particularly in connection with our commercialization of AVMAPKI FAKZYNJA CO-PACK and the continued clinical development of our other product candidates. We expect our cash and cash equivalents at December&#160;31, 2025, combined with the proceeds from exercise of warrants in January 2026 along with revenue we expect to generate from sales of AVMAPKI FAKZYNJA, will be sufficient to fund our current operating plan and capital expenditure requirements for the next 12 months from the issuance of these financial statements. We may need to obtain additional funding in connection with our continuing operations, including for our clinical development programs. Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">the costs and timing of activities of commercialization for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AVMAPKI FAKZYNJA CO-PACK</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> and product candidates for which we expect to receive marketing approval;&#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, and results of our ongoing and potential future clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we acquire or in-license other product candidates and technologies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing, and outcome of regulatory review of our product candidates (including our efforts to seek approval and fund the preparation and filing of regulatory submissions); </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">revenue received from commercial sales of AVMAPKI FAKZYNJA CO-PACK and our product candidates, should any of our product candidates also receive marketing approval; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending intellectual property related claims; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish collaborations or partnerships on favorable terms, if at all.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of milestone payments and royalties pursuant to the Secura APA including timing of such receipt. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 18pt;">Conducting clinical trials is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval of any of our product candidates. Even though the FDA has approved AVMAPKI FAKZYNJA CO-PACK it may not achieve commercial success. Our commercial revenues are derived from sales of products. Accordingly, even though we received regulatory approval for AVMAPKI FAKZYNJA CO-PACK, it may take several years to achieve a significant level of sales, and as a result we may need to continue to rely on additional financing to further our clinical development objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</p><div style="margin-top:5pt;"><a id="_Hlk221117187"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Unfavorable economic conditions could have a material adverse effect on our business, financial condition, results of operations, or cash flows.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Unfavorable macroeconomic conditions and other adverse macroeconomic factors have resulted, among other matters, in tightening in the debt and equity markets, and high levels of&#160;inflation. Similarly, changes in U.S. federal policy that affect the geopolitical landscape could give rise to circumstances outside our control that could have negative impacts on our business operations.<span style="font-size:12pt;"> </span>For example, the current presidential administration has imposed or is considering imposing tariffs on a large number of countries, reciprocal tariffs with certain countries and particularized tariffs on certain types of foreign goods, including pharmaceutical products and components manufactured outside of the U.S. Historically,&#160;tariffs&#160;have led to increased trade and political tensions. In response to&#160;tariffs, other countries have implemented retaliatory&#160;tariffs&#160;on U.S. goods. Political tensions resulting from trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. Tightening of the equity markets makes it more difficult to raise capital at a reasonable valuation or at all. Tariffs, economic sanctions, and other changes in U.S. trade policy have in the past and could in the future negatively affect our business, financial condition, and results of operations.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">In addition, the U.S. Bureau of Labor Statistics has reported for the period from December 2024 to December 2025, the Consumer Price Index for All Urban Consumers rose 2.7%, which remains above the U.S. Federal Reserve&#8217;s inflation target of 2%. If inflationary pressures increase or continue for a prolonged period, it may continue to result in increased costs of labor, cost of clinical trials, and costs of manufacturing which could adversely affect our results of operations. </p><a id="_Hlk221117192"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Our ability to use our net operating loss carryforwards may be limited.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:12pt 0pt 12pt 18pt;">As of December 31, 2025, we had U.S. federal and state NOL carryforwards of approximately $460.5 million and $99.5 million, respectively. As of December 31, 2025, we also had federal and state tax credits of $12.3 million and $0.7 million, respectively, which may be used to offset future tax liabilities. The NOL and tax credit carryforwards will expire at various dates through 2045, except for $423.3 million of federal NOL carryforwards which may be carried forward indefinitely. Sections 382 and 383 of the Internal Revenue Code (&#8220;IRC&#8221;) and similar provisions under state law limits the annual use of NOL carry-forwards and tax credit carryforwards, respectively, following an ownership change pursuant to section 382 of the IRC and similar state provisions. In general, an ownership change occurs for purposes of Section 382 if there are certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of-year period in excess of 50%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 18pt;">During 2024, we believe we triggered ownership changes under Section 382 of the IRC and similar provisions under state law. As a result, we believe that our federal NOL carryforwards, state NOL carryforwards, research and development credits, and orphan drug credits are limited by Section 382 and similar provisions under state law as of December 31, 2025. A portion of federal NOL carryforwards and state NOL carryforwards that we expect we will not be able to utilize were written off. Similarly, we wrote off all federal and state research and development credits, and federal orphan drug credits we determined we will not be able to utilize due to limitation and expiration periods. We have approximately $346.4 million of federal NOLs generated prior to such ownership changes inclusive of $309.3 million of federal NOLs <span style="background:#ffffff;">which may be carried forward indefinitely. Since the $309.3 million of federal NOLs may be carried forward indefinitely these have not been written off as of December 31, 2025, but due to the limitations under Section 382, generally we can only use $1.6 million per year against taxable income in the future. Future changes in our stock ownership, some of which are outside of our control, could result in further ownership changes under section 382 of the IRC. We may not be able to use some or all of our NOL and tax credit carryforwards, even if we attain profitability.</span></p><a id="_Hlk221117290"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Indebtedness</b></p><a id="_Hlk221117351"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Our level of indebtedness and debt service obligations could adversely affect our financial condition and may make it more difficult for us to fund our operations.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 18pt;">On January 13, 2025 (the &#8220;Note Purchase Agreement Closing Date&#8221;), we entered into the Note Purchase Agreement pursuant to which we may sell to the Note Purchase Agreement Purchasers, and the Note Purchase Agreement Purchasers may buy from us notes (the &#8220;Notes&#8221;) in an aggregate principal amount not to exceed $150.0 million. We completed an initial sale of $75.0 million principal amount of Notes on the Note Purchase Agreement Closing Date. In addition, the we may issue and sell additional Notes with aggregate principal amount of up to $75.0 million as follows:</p><div style="margin-top:14pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt 0pt 6pt 0pt;">i.</td><td style="text-align:right;width:18pt;padding:0pt 0pt 6pt 0pt;"/><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at our option, the a second purchase (the &#8220;Second Purchase&#8221;) of $25.0 million principal amount of Notes, at any time prior to December 31, 2025, upon the FDA&#8217;s approval sufficient for the promotion and sale of avutometinib and defactinib for the treatment of LGSOC and subject to certain other customary conditions precedent. In March 2026, we amended the Note Purchase Agreement to extend the date by which we may draw down the Second Purchase from December 31, 2025 to June 30, 2026; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt;">ii.</td><td style="text-align:right;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">at our option, the, a third purchase  of up to $50.0 million principal amount of Notes, at any time prior to December 31, 2026, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">provided that trailing six-month worldwide net sales of avutometinib and defactinib are at least $55.0 million and subject to certain other customary conditions precedent.</span></td></tr></table><div style="margin-top:6pt;"></div></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">The outstanding principal amount of the Notes bear interest at a rate per annum equal to the sum of (i)&#160;the greater of the Term SOFR (as defined in the Note Purchase Agreement) and 4.29%, and (ii)&#160;3.71%, subject to adjustment in certain circumstances set forth in the Note Purchase Agreement and an overall cap of 9.75%, payable quarterly in arrears until the seventh anniversary of the Note Purchase Agreement Closing Date or the date on which all amounts owing to the Note Purchase Agreement Purchasers under the Note Purchase Agreement have been paid in full (the &#8220;Note Purchase Agreement Maturity Date&#8221;). For the first eight (8)&#160;<span style="white-space:pre-wrap;">quarters following the Note Purchase Agreement Closing Date, at our option, up to 50% of the interest due may be paid-in-kind and added to the then-outstanding principal balance of the Notes. Through December 31, 2025, we have not elected to defer any interest through the paid-in-kind option.  Upon the occurrence and during the continuance of an Event of Default (as defined in the Note Purchase Agreement) under the Note Purchase Agreement, the then-applicable interest rate on all outstanding obligations may be increased by an additional 5.00%.</span></p><a id="_Hlk220702338"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:12pt 0pt 0pt 18pt;">The Note Purchase Agreement Purchasers will receive 1.00% (the &#8220;Revenue Participation Percentage&#8221;) of the first $100.0 million of net sales of each Included Product (as defined in the Note Purchase Agreement) by us or our licensees in each calendar year, payable quarterly. &#8220;Included Products&#8221; is defined in the Note Purchase Agreement to include (a)&#160;avutometinib and defactinib, including any product that contains either one of the foregoing in combination with any other active ingredient(s), and (b)&#160;all other compounds, chemical entities or pharmaceutical products being designed, developed, licensed, manufactured or commercialized by us or our subsidiaries from time to time. The Revenue Participation Percentage will increase&#160;pro rata&#160;immediately upon the occurrence of the Option Sale, such that the Revenue Participation Percentage shall increase to a maximum of 2.00% in the event that $150.0 million in aggregate principal amount of Notes has been purchased pursuant to the Note Purchase Agreement following the Option Sale. The outstanding principal amount of the Notes, interest accrued thereon and any other amounts owing to the Note Purchase Agreement Purchasers under the Note Purchase Agreement will be due in two equal installments on (a)&#160;the sixth anniversary of the Note Purchase Agreement Closing Date, and (b)&#160;the Note Purchase Agreement Maturity Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">The Note Purchase Agreement contains no financial covenants. Our obligations under the Note Purchase Agreement are subject to customary covenants, including limitations on our ability to dispose of assets, undergo a change of control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of our capital stock, repurchase stock and make investments, in each case subject to certain exceptions. Our obligations under the Note Purchase Agreement are secured by a security interest on substantially all of our and our subsidiaries&#8217; assets, including our intellectual property related to avutometinib and defactinib, and a negative pledge on intellectual property related to the Company&#8217;s collaboration and option agreement with GenFleet, subject to certain exceptions relating to our development of our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">This indebtedness may create additional financing risk for us, particularly if our business or prevailing financial market conditions are not conducive to paying off or refinancing our outstanding debt obligations at maturity. This indebtedness could also have other important negative consequences, including we will need to repay our indebtedness by making payments of interest and principal, which will reduce the amount of money available to finance our operations, our research and development efforts and other general corporate activities. Further, our agreement to pay Oberland the Revenue Participation Percentage with respect to potential future sales of certain of our product candidates may limit future revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval, as well as our ability to generate revenues that are significant or large enough to achieve profitability. In addition, we may be delayed in satisfying the criteria required under the Note Purchase Agreement to exercise the Option Sale, or may never satisfy such criteria, which may require us to find other sources of funding to finance our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">To the extent additional debt is added to our current debt levels, the risks described above could increase.</p><a id="_Hlk221117458"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We may not have cash available in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">Failure to satisfy our current and future debt obligations under the Note Purchase Agreement or breaching any covenants under the Note Purchase Agreement, subject to specified cure periods with respect to certain breaches, could result in an event of default and, as a result, could accelerate all of the amounts due. In the event </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">of an acceleration of amounts due under the Note Purchase Agreement, we may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time of such acceleration. In that case, we may be required to delay, limit, reduce or terminate our product candidate development or grant to others the rights to develop and market our product candidates that we would otherwise prefer to develop and market internally. The Note Purchase Agreement Purchasers could also exercise their rights as collateral agent to take possession and dispose of the collateral securing the Notes for their benefit, which collateral includes substantially all of our property other than our intellectual property. Our business, financial condition and results of operations could be materially adversely affected as a result of any of these events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:5pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Dependence on Third Parties</b></p><div style="margin-top:0pt;"><a id="_Hlk221117450"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We rely in part on third parties to conduct our clinical trials and preclinical testing, and if they do not properly and successfully perform their obligations to us, we may not be able to obtain regulatory approvals for and commercialize any of our other product candidates.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">We rely on third parties, such as contract research organizations (&#8220;CROs&#8221;), clinical data management organizations, medical institutions, and clinical investigators, to conduct, provide monitors for, and manage data from all of our clinical trials. We compete with many other companies for the resources of these third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities and ultimately the commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:5pt 0pt 0pt 18pt;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and other regulatory agencies require us to comply with GCP for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators, and trial sites. If we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or other regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. We also are required to register ongoing clinical trials and post the results of completed clinical trials on government-sponsored databases, such as ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for some of our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</p><div style="margin-top:5pt;"><a id="_Hlk221117521"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We rely on third parties to conduct investigator-sponsored clinical trials of our product candidates. Any failure by a third party to meet its obligations with respect to the clinical development of our product candidates may delay or impair our ability to obtain regulatory approval for our product candidates.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">We rely on academic and private non-academic institutions to conduct and sponsor clinical trials relating to our product candidates. We will not control the design or conduct of the investigator sponsored trials, and it is possible that the FDA or non-U.S. regulatory authorities will not view these investigator-sponsored trials as providing adequate support for future clinical trials, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">Such arrangements will provide us certain information rights with respect to the investigator sponsored trials, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the investigator-sponsored trials. However, we do not have control over the timing and reporting of the data from investigator-sponsored trials, nor do we own the data from the investigator-sponsored trials. If we are unable to confirm or replicate the results from the investigator sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of our product candidates. Further, if investigators or institutions breach their obligations with respect to the clinical development of our product candidates, or if the data proves to be inadequate compared to the firsthand knowledge we might have gained had the investigator-sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Additionally, the FDA or non-U.S. regulatory authorities may disagree with the sufficiency of our right of reference to the preclinical, manufacturing, or clinical data generated by these investigator-sponsored trials, or our interpretation of preclinical, manufacturing, or clinical data from these investigator-sponsored trials. If so, the FDA or other non-U.S. regulatory authorities may require us to obtain and submit additional preclinical, manufacturing, or clinical data before we may initiate our planned trials and/or may not accept such additional data as adequate to initiate our planned trials.</p><div style="margin-top:5pt;"><a id="_Hlk221117529"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We contract with third parties for the manufacture of our products and product candidates and for compound formulation research, and these third parties may not perform satisfactorily.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:5pt 0pt 0pt 18pt;">We do not have any manufacturing facilities or personnel. We currently obtain all of our AVMAPKI FAKZYNJA CO-PACK commercial supply and supply of our product candidates for clinical development and commercial requirements from third-party manufacturers or third-party collaborators, and we expect to continue to rely on third parties for the manufacture of clinical and commercial quantities of our product candidates. In addition, we currently rely on third parties for the development of various formulations of our product candidates. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable cost or quality, which could delay, prevent, or impair our development or commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">We do not currently have arrangements in place for redundant supply for every commercial and clinical product candidate throughout our supply chain. Even though we have supply agreements in place with our third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reliance on the third party for regulatory compliance and quality assurance; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible breach of the manufacturing agreement by the third party, including the misappropriation of our proprietary information, trade secrets, and know-how; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruptions to the operations of our manufacturers or suppliers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier or a catastrophic event affecting our manufacturers or suppliers.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:12pt 0pt 0pt 18pt;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products and harm our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">Any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any interruption of the development or operation of the manufacturing facilities due to, among other reasons, events such as order delays for equipment or materials, equipment malfunction, quality control, and quality assurance issues, regulatory delays and possible negative </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">effects of such delays on supply chains and expected timelines for product availability, production yield issues, shortages of qualified personnel, discontinuation of a facility or business, failure, or damage to a facility by natural disasters or public health crises, such as the COVID-19 pandemic, could result in the cancellation of shipments, loss of product in the manufacturing process, or a shortfall in available product candidates or materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:5pt 0pt 0pt 18pt;">If our current contract manufacturers cannot perform as agreed or these parties cease to provide quality manufacturing and related services to us, we may be required to replace that manufacturer. If we are not able to engage appropriate replacements in a timely manner, our ability to manufacture our product candidates in sufficient quality and quantity required for planned preclinical testing, clinical trials and potential commercial use of our product candidates would be adversely affected. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement, as well as producing the drug product and obtaining regulatory approvals for the new manufacturer. In addition, we have to enter into technical transfer agreements and share our know-how with the third-party manufacturers, which can be time-consuming and may result in delays. In light of the lead time needed to manufacture our product candidates, and the availability of underlying materials, we may not be able to, in a timely manner or at all, establish or maintain sufficient commercial manufacturing arrangements on commercially reasonable terms necessary to provide adequate supply of our product candidates to meet demands that exceed our clinical assumptions. Furthermore, we may not be able to obtain the significant financial capital that may be required in connection with such arrangements. Even after successfully engaging third parties to execute the manufacturing process for our product candidates, such parties may not comply with the terms and timelines they have agreed to for various reasons, some of which may be out of their or our control, which could impact our ability to execute our business plans on expected or required timelines in connection with the commercialization of and the continued development of our product candidates. We may also be required to enter into long-term manufacturing agreements that contain exclusivity provisions and/or substantial termination penalties, which could have a material adverse effect on our business prior to and after commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Our current and anticipated future dependence upon others for the manufacture of our other product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">If we are not able to establish additional collaborations, we may have to alter our development and commercialization plans.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">Our drug development programs and the potential commercialization of our product candidates will require additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with biotechnology and pharmaceutical companies for the development and potential commercialization of those product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">We face significant competition in seeking appropriate collaborators. Whether we reach definitive agreements for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, and the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of certain product candidates, reduce or delay our </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">development programs, delay potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We may not realize the benefits of our current or future collaborations or licensing arrangements with third parties for the development and commercialization of our product candidates and may be unsuccessful in consummating future partnerships or capitalizing on the market potential of our product candidates.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">Our current or future collaborations or licensing arrangements may not be successful. Additionally, we have partnered, and intend to further partner, with third parties with respect to the clinical development and commercialization, if approved, of certain of our programs, and we may not be successful in identifying, negotiating and executing partnerships. Our likely future collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies, and biotechnology companies. Any such arrangements with any third parties may result in us having limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. For example, we have engaged in a strategic collaboration with IQVIA, pursuant to which we are leveraging IQVIA&#8217;s expertise and resources for the commercialization of the AVMAPKI FAKZYNJA CO-PACK for the treatment of KRAS mutated recurrent LGSOC, particularly marketing and commercial analytics support for AVMAPKI FAKZYNJA CO-PACK. Accordingly, we depend on IQVIA and their performance of these services under the strategic collaboration arrangements for the successful commercialization of AVMAPKI FAKZYNJA CO-PACK for the treatment of KRAS mutated recurrent LGSOC. If IQVIA does not successfully carry out their responsibilities under the collaboration agreements or does not perform the specific services we have engaged them to perform to the standard or level we anticipate, the benefits of the strategic collaboration with IQVIA may not be realized and our commercialization efforts will be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Collaborations involving our product candidates are subject to numerous risks, which may include that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator's strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agreements with collaborators may not provide exclusive rights to use their intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and product candidates in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing, manufacturing or distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or otherwise not perform satisfactorily in carrying out these activities; </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Our operations in foreign jurisdictions, and those of third parties for which we rely on, may be impacted by economic, political and social conditions in such jurisdictions. </i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Our business could be adversely affected by conditions the adverse geopolitical and macroeconomic developments, including the military conflict between Ukraine and Russia, the ongoing military conflict in the Middle East, U.S. foreign policy in Latin America, and any related sanctions. While we do not currently have clinical trials in Ukraine, Russia, Latin America or the Middle East, we have clinical trial sites in Europe. We also source clinical supply for our product candidates from third-party contract manufacturing organizations in Europe. Additionally, GenFleet is conducting a Phase 1/2 clinical trial evaluating GFH375/VS-7375 in China. For such activities conducted in China, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies of the U.S. or Chinese governments, political unrest or unstable economic conditions including sanctions on China or any of our China-based counterparties. Furthermore, the conflicts between Ukraine and Russia, the ongoing military conflict in the Middle East, and the associated measures taken or that may be taken by the U.S., North Atlantic Treaty Organization (&#8220;NATO&#8221;) and others create global security concerns, including the possibility of expanded regional or global conflict, and are likely to have short-term and likely longer-term negative impacts on regional and global economies, any or all of which could disrupt our supply chain, and adversely affect our ability to conduct ongoing and future clinical trials of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:5pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><div style="margin-top:0pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5pt 0pt 12pt 18pt;">We are a party to a number of intellectual property license agreements with third parties, including Pfizer and Chugai, and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose various diligence, milestone payment, royalty, insurance, and other obligations on us. For example, under our license agreements with Pfizer and Chugai, we are required to use diligent or commercially reasonable efforts to develop and commercialize licensed products under the agreement and to satisfy other specified obligations. If we fail to comply with our obligations under these licenses, our licensors may have the right to terminate these license agreements, in which event we might not be able to market any product that is covered by these agreements, or to convert the exclusive licenses to non-exclusive licenses, which could materially adversely affect the value of the product candidate being developed under these license agreements. Termination of these license agreements or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, which may not be possible. If Pfizer were to terminate its license agreement with us for any reason, we would lose our rights to defactinib. If Chugai were to terminate its license agreement with us for any reason, we could lose our rights to avutometinib.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 18pt;">In addition, we rely on certain of our licensors to prosecute patent applications and maintain patents and otherwise protect the intellectual property we license from them and may continue to do so in the future. We have limited control over these activities or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by these licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">and other intellectual property rights. We have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights or defend certain of the intellectual property that is licensed to us. It is possible that any licensors&#8217; infringement proceeding, or defense activities may be less vigorous than had we conducted them ourselves. </p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">If we are unable to obtain and maintain patent protection for our products, or if our licensors are unable to obtain and maintain patent protection for the products that we license from them, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">Our success depends in large part on our and our licensors&#8217; ability to obtain and maintain patent protection in the U.S. and other countries with respect to our products, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment and development that are important to our business. If we or our licensors do not adequately protect our or our licensors&#8217; intellectual property rights, competitors may be able to erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. We and our licensors seek to protect our proprietary position by filing patent applications in the U.S. and abroad related to our products that are important to our business. We may in the future also license or purchase patent applications filed by others. If we or our licensors are unable to secure or maintain patent protection with respect to our products and any proprietary products and technology we develop, our business, financial condition, results of operations, and prospects could be materially harmed. We also cannot be certain that any patents will issue with claims that cover our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 18pt;"><span style="white-space:pre-wrap;">If the scope of the patent protection we or our licensors obtain is not sufficiently broad, we may not be able to prevent others from developing and commercializing products and technology similar or identical to ours. The degree of patent protection we require to successfully compete in the marketplace may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our or our licensors&#8217; patents have, or that any of our or our licensors&#8217; pending patent applications that mature into issued patents will include, claims with a scope sufficient to protect our products or otherwise provide any competitive advantage. In addition, to the extent that we license intellectual property, we cannot make assurances that those licenses will remain in force. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. Furthermore, patents have a limited lifespan. In the U.S., the natural expiration of a patent is generally 20 years after it is filed (21 years if first filed as a provisional application). Various extensions may be available; however, the life of a patent, and the protection it affords, is limited.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 18pt;"><span style="white-space:pre-wrap;">Even if they are unchallenged, our or our licensors&#8217; patents and pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our or our licensors&#8217; patent claims to circumvent our patents by developing similar or alternative technologies or therapeutics in a non-infringing manner. For example, a third party may develop a competitive therapy that provides benefits similar to our products but that uses a formulation and/or a method that falls outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we hold, license, or pursue with respect to our products is not sufficiently broad to impede such competition, our ability to successfully commercialize our products could be negatively affected, which would harm our business. Similar risks would apply to any patents or patent applications that we may own or license.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">The patent prosecution process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering products that we license from third parties and are reliant on our licensors. Therefore, we cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. If such licensors fail to maintain such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability, and commercial value of our and our licensors&#8217; patent rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications may not result in patents being issued which protect our products or which effectively prevent others from commercializing competitive products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish our ability to protect our inventions, maintain and enforce our intellectual property rights, or narrow the scope of our patent protection, or affect the value of our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">The laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases, at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:5pt 0pt 0pt 18pt;">Assuming the other requirements for patentability are met, in the U.S., for patents that have an effective filing date prior to March 15, 2013, the first to make the claimed invention is entitled to the patent, while outside the U.S., the first to file a patent application is entitled to the patent. In March 2013, the U.S. transitioned to a first inventor to file system in which, assuming the other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent. We may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;), or become involved in opposition, derivation, reexamination, inter parties review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding, or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">Even if our owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. The scope of the invention claimed in a patent application can be significantly reduced before the patent is issued, and this scope can be reinterpreted after issuance. Even where patent applications we currently own, license, or that we may license in the future issue as patents, they may not issue in a form that will provide us with adequate protection to prevent competitors or other third parties from competing with us or otherwise provide us with a competitive advantage. Any patents that eventually issue may be challenged, narrowed or invalidated by third parties. Consequently, we do not know whether any of our products will be protectable or remain protected by valid and enforceable patent rights. Our competitors or other third parties may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. We may in the future, become subject to a third-party pre-issuance submission of prior art or opposition, derivation, revocation, re-examination, post-grant and <i style="font-style:italic;">inter partes</i> review, or interference proceeding and other similar proceedings challenging our patent rights or the patent rights of others in the USPTO or other foreign patent office. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the patent protection of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">In addition, given the amount of time required for the development, testing, and regulatory review of new products, patents protecting such products might expire before or shortly after such products are </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Moreover, some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we or our licensors may need the cooperation of any such co-owners of our owned and in-licensed patents in order to enforce such patents against third parties, and such cooperation may not be provided to us or our licensors. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">If our efforts to protect the proprietary nature of the intellectual property related to our products are not adequate, we may not be able to compete effectively in our market. </i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 18pt;">We rely upon a combination of patents, confidentiality agreements, trade secret protection and license agreements to protect the intellectual property related to our products. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. We, or any partners, collaborators, or licensors, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 18pt;">It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our partners, collaborators, or licensors fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, or licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 18pt;">We anticipate additional patent applications will be filed both in the U.S. and in other countries, as appropriate. However, we cannot predict: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if additional patent applications covering new technologies related to our products will be filed; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if and when patents will issue; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree and range of protection any issued patents will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether any of our intellectual property will provide any competitive advantage; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether any of our patents that may be issued may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether we will need to initiate or defend litigation or administrative proceedings which may be costly regardless of whether we win or lose. </span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 18pt;">Additionally, we cannot be certain that the claims in our pending patent applications covering our products and their methods of use will be considered patentable by the USPTO, or by patent offices in foreign countries, or </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">that the claims in any of our issued patents will be considered valid or patentable by courts in the U.S. or foreign countries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 18pt;"><span style="white-space:pre-wrap;">Method of use patents protect the use of a product for the specified method. These types of patents do not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may, but not necessarily, contribute to a finding of infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.  </span></p><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses. </i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">Presently we have rights to certain patents and applications through licenses from third parties and own patents and patent applications related to our products. Additional product candidates or therapies, including combination therapies, with avutometinib and/or defactinib, may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary or important to our business operations. If we fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, it would harm our business. We may need to cease use of the additional product candidates or methods covered by such third-party intellectual property rights, and/or may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if it is possible and we were able to develop such alternatives. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies that we have licensed. In that event, we may be required to expend significant time and resources to develop or license replacement technologies. Moreover, the specific product candidates or methods that may be used with our products may be covered by the intellectual property rights of others. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Additionally, we may seek to acquire new compounds and product candidates from other pharmaceutical and biotechnology companies, academic scientists and other researchers, such as our exclusive in-license from Pfizer, and Chugai to research, develop, commercialize, and manufacture products in oncology indications containing defactinib and avutometinib, respectively. The success of this strategy depends partly upon our ability to identify, select, discover and acquire promising pharmaceutical product candidates and products. The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:12pt 0pt 0pt 18pt;">Furthermore, we have and may continue to collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;"><span style="white-space:pre-wrap;">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our products. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.  Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We also may be unable to license or acquire the relevant compound or product candidate on terms that would allow us to make an appropriate return on our investment. Any product candidate that we acquire may require additional development efforts prior to commercial sale, including manufacturing, preclinical testing, extensive clinical testing and approval by the FDA and applicable </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;"><span style="white-space:pre-wrap;">foreign regulatory authorities. All product candidates are prone to risks of failure typical of pharmaceutical product development.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">In addition, future product or business acquisitions may entail numerous operational and financial risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exposure to unknown liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruption of our business and diversion of our management&#8217;s time and attention to develop acquired products, product candidates, or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">higher than expected acquisition and integration costs; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased amortization expenses; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incurrence of substantial debt, dilutive issuances of securities or depletion of cash to pay for acquisitions.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:12pt 0pt 12pt 18pt;">Future business acquisitions may also entail certain additional risks, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty in combining the operations and personnel of any acquired businesses with our operations and personnel; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to motivate key employees of any acquired businesses.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:0pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 12pt 18pt;">Some of our pending patent applications may not be allowed in the future. We cannot be certain that an allowed patent application will become an issued patent. There may be events that cause withdrawal of the allowance of a patent application. For example, after a patent application has been allowed, but prior to being issued, material that could be relevant to patentability may be identified. In such circumstances, the applicant may pull the application from allowance in order for the USPTO to review the application in view of the new material. We cannot be certain that the USPTO will issue the application in view of the new material. Further, periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign countries may require the payment of maintenance fees or patent annuities during the lifetime of a patent application and/or any subsequent patent that issues from the application. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application. Such noncompliance can result in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. Such an event could have a material adverse effect on our business. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Issued patents covering our products could be found invalid or unenforceable if challenged in court or the USPTO. </i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 18pt;">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering our products, the defendant could counterclaim that the patent covering our products, as applicable, is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are various grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, <i style="font-style:italic;">inter partes</i> review, post grant review and equivalent proceedings in foreign jurisdictions (such as opposition proceedings). </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our products. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our products. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and products. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Changes to patent law in the U.S. and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. </i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">As is the case with other drug and biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the drug and biopharmaceutical industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the U.S. has passed wide-ranging patent reform legislation under the America Invents Act. Moreover, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict how future decisions by the courts, Congress or the USPTO may impact the value of our patents. Similarly, any adverse changes in the patent laws of<b style="font-weight:bold;"> </b>other jurisdictions could have a material adverse effect on our business and financial condition. Changes in the laws and regulations governing patents in other jurisdictions could similarly have an adverse effect on our ability to obtain and effectively enforce our patent rights. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world. </i><span style="display:inline-block;width:36pt;"></span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 12pt 18pt;"><span style="white-space:pre-wrap;">We may not be able to pursue patent coverage of our products in certain countries outside of the U.S. Filing, prosecuting and defending patents on products in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. may be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. The breadth and strength of our patents issued in foreign jurisdictions or regions may not be the same as the corresponding patents issued in the U.S.  Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to certain territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span><span style="display:inline-block;width:6.79pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 18pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protections, particularly those relating to drug and biopharmaceutical products. This difficulty with enforcing patents could make it difficult for us to stop the infringement of our patents or marketing of competing products otherwise generally in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">If we do not obtain patent term extension and data exclusivity for any of our current products, our business may be materially harmed. </i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 12pt 18pt;">Depending upon the timing, duration and specifics of any FDA marketing approval of our current products, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply for a patent extension within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we believe we are entitled to, our competitors may obtain approval of competing products sooner than we would expect, and our business, financial condition, results of operations, and prospects could be materially harmed. </p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming, and unsuccessful.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">In addition, in an infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. Defense against these assertions, non-infringement, invalidity or unenforceability regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:12pt 0pt 0pt 18pt;">Post-grant proceedings provoked by third parties or brought by the USPTO may be brought to determine the validity or priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or post-grant proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as those within the United States. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, our licensors may have rights to file and prosecute such claims, and we are reliant on them.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5pt 0pt 12pt 18pt;">Our commercial success depends upon our ability and the ability of our collaborators to commercialize, develop, manufacture, market, and sell our products without infringing the proprietary rights of third parties. We have yet to conduct comprehensive freedom to operate searches to determine whether our use of certain of the patent rights owned by or licensed to us would infringe patents issued to third parties. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products, including interference proceedings before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing product. In addition, we could be found liable for monetary damages. A finding of infringement could prevent us from commercializing our products or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated confidential information or trade secrets of third parties could have a similar negative impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 18pt;">If a third party alleges that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:34pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">infringement and other intellectual property misappropriation which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:34pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial damages for infringement or misappropriation, which we may have to pay if a court decides that the product or technology at issue infringes on or violates the third-party&#8217;s rights, and, if the court finds we have willfully infringed intellectual property rights, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:34pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an injunction prohibiting us from manufacturing, marketing or selling our products, or from using our proprietary technologies, unless the third party agrees to license its patent rights to us; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:34pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">even if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights protecting our products; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:34pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be forced to try to redesign our products or processes so they do not infringe third-party intellectual property rights, an undertaking which may not be possible, or which may require substantial monetary expenditures and time. </span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Third parties may assert that we are employing their proprietary technology without authorization. Patents issued in the U.S. by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. There may be issued third-party patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our products. Patent applications can take many years to issue. There may be currently pending patent applications which may later result in issued patents that may be infringed by our products. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents, held now or obtained in the </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">future by a third party, were found by a court of competent jurisdiction to cover the manufacturing process of our products, constructs or molecules used in or formed during the manufacturing process, or any final product or methods use of the product, the holders of any such patents may be able to block our ability to commercialize the product unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover any aspect of our formulations, any combination therapies or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our products may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize our products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our products. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our products. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our products, which could harm our business significantly. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to us. Moreover, there may be some circumstances where we are unable to negotiate for such ownership rights. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such a dispute could be expensive and time-consuming. If we were unsuccessful, we could lose valuable rights in intellectual property that we regard as our own. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">In addition to seeking patents for some of our products, we also rely on trade secrets, including unpatented know-how, technology, and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. These parties may also be subject to cyberattacks that result in such information becoming available to competitors, including in jurisdictions where we or such parties may not be able to enforce our rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time consuming, and the outcome is unpredictable. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the U.S. and abroad. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our marks of interest, and our business may be adversely affected. </i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During the trademark registration process, we may receive Office Actions from the USPTO objecting to the registration of our trademark. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">recognition based on our trademarks and trade names, we may not be able to compete effectively, and our business may be adversely affected. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">European patents and patent applications could be challenged in the recently created Unified Patent Court for the European Union.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Our owned or our licensors&#8217; European patents and patent applications could be challenged in the recently created Unified Patent Court (&#8220;UPC&#8221;) for the European Union. We may decide to opt out our European patents and patent applications from the UPC. However, if certain formalities and requirements are not met, our European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. We cannot be certain that our or our licensors&#8217; European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC. Under the UPC, a granted European patent would be valid and enforceable in numerous European countries. A successful invalidity challenge to a European patent under the UPC would result in loss of patent protection in those European countries. Accordingly, a single proceeding under the UPC could result in the partial or complete loss of patent protection in numerous European countries, rather than in each validated European country separately as such patents always have been adjudicated. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and products and, resultantly, on our business, financial condition, prospects and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Achieving Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</b></p><div style="margin-top:0pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize such candidates, and our ability to generate revenue will be materially impaired.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">Obtaining approval of an NDA can be a lengthy, expensive, and uncertain process, and the FDA has substantial discretion in the review and approval process and may decide that our data is insufficient for approval and require additional preclinical, clinical, or other studies. There can be no assurance regarding the timing and outcome of the FDA review and approval of an NDA submission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">The activities associated with a product candidate&#8217;s development and commercialization, including its design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution are subject to comprehensive regulation by the FDA and other regulatory agencies in the U.S. and by comparable authorities in other countries. Failure to obtain marketing approval for product candidates will prevent us from commercializing such product candidates. We have not received approval to market any of our current product candidates from regulatory authorities in any jurisdiction in the U.S. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and have relied on and expect to rely on third-party contract research organizations to assist us in this process. Securing FDA approval requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing FDA approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the FDA. A product candidate may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">The process of obtaining marketing approvals, both in the U.S. and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Any marketing approval we ultimately obtain may be subject to more limited indications than those we propose or subject to restrictions or post approval commitments that render the approved product not commercially viable.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">If we experience delays in obtaining approval or if we fail to obtain approval of a product candidate, its commercial prospects may be harmed and our ability to generate revenues will be materially impaired.</p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We have received orphan drug designation for certain of our product candidates, but there can be no assurance that we will be able to prevent third parties from developing and commercializing products that are competitive to these product candidates.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5pt 0pt 12pt 18pt;">In March 2024, the FDA granted orphan drug designation to avutometinib in combination with defactinib for the treatment of patients with recurrent LGSOC. In July 2024, the FDA granted orphan drug designation to avutometinib in combination with defactinib for the treatment of pancreatic cancer. Defactinib has received orphan drug designation in the U.S., the European Union, and Australia for the treatment of patients with ovarian cancer. Orphan drug exclusivity grants seven years of marketing exclusivity under the FDCA, up to ten years of marketing exclusivity in the European Union, and five years of marketing exclusivity in Australia. Other companies have received orphan drug designations for compounds other than defactinib for the same indications for which we may have received orphan drug designation in corresponding territories. While orphan drug exclusivity for defactinib provides market exclusivity against the same active ingredient for the same indication, we would not be able to exclude other companies from manufacturing and/or selling drugs using the same active ingredient for the same indication beyond that timeframe on the basis of orphan drug exclusivity. Furthermore, the marketing exclusivity in the European Union can be reduced from ten years to six years if the orphan designation criteria are no longer met or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Even if we are the first to obtain marketing authorization for an orphan drug indication, there are circumstances under which the FDA may approve a competing product for the same indication during the seven-year period of marketing exclusivity, such as if the later product is the same compound as our product but is shown to be clinically superior to our product, or if the later product is a different drug than our product candidate. Further, the seven-year marketing exclusivity would not prevent competitors from obtaining approval of the same compound for other indications or of another compound for the same use as the orphan drug. A decision in 2021 by the U.S. Court of Appeals for the Eleventh Circuit in <i style="font-style:italic;">Catalyst Pharmaceuticals, Inc. vs. Becerra</i> (&#8220;<i style="font-style:italic;">Catalyst</i>&#8221;) regarding interpretation of the Orphan Drug Act&#8217;s exclusivity provisions as applied to drugs and biologics approved for orphan indications narrower than the product&#8217;s orphan designation has the potential to significantly broaden the scope of orphan exclusivity for such products. FDA announced on January 24, 2023, that despite the <i style="font-style:italic;">Catalyst</i> decision, it will continue to apply its longstanding regulations, which tie the scope of orphan exclusivity to the uses or indications for which the drug is approved, rather than to the designation. FDA&#8217;s application of its orphan drug regulations post-<i style="font-style:italic;">Catalyst</i> could be the subject of future legislation or to further challenges in court, which could impact our ability to obtain or seek to work around orphan exclusivity and might affect our ability to retain orphan exclusivity that the FDA previously has recognized for our products.</p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We have sought and obtained fast track designation from the FDA for one of our product candidates, and may seek such fast track designation for one more additional product candidates, but we might not receive such additional designation, and such designation may not actually lead to a faster development or regulatory review or approval process nor does it ensure that we will receive marketing approval.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">Any sponsor may seek fast track designation for a drug if it is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for this condition. In January 2024, the FDA granted fast track designation for combination of avutometinib and LUMAKRAS for the treatment of patients with KRAS G12C-mutant metastatic NSCLC who have received at least one prior systematic therapy and have not been previously treated with a KRAS G12C inhibitor. In April 2024, the FDA granted fast track designation for avutometinib, in combination with defactinib plus LUMAKRAS, for the treatment of patients with KRAS G12C-mutated metastatic NSCLC who received at least one prior systematic therapy. Additionally, in July 2025, the FDA granted fast track designation to VS-7375, for the first-line treatment of patients with KRAS G12D-mutated locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) and for the treatment of patients with KRAS G12D-mutated locally advanced or metastatic PDAC who have received at least one prior line of standard systemic therapy. We may also seek fast track designation for additional product candidates, which we may not receive from the FDA. However, fast track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe. We may not experience a faster development or regulatory review or approval process with fast </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">track designation compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We have obtained approval in the U.S. for the combination of avutometinib and defactinib under the FDA&#8217;s accelerated approval pathway, and we may seek accelerated approval for one more additional product candidates. The FDA has substantial discretion regarding approvals under the accelerated approval pathway, and we may not be able to obtain accelerated approval for any of our product candidates. </i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">In May 2025, the FDA approved our NDA under the accelerated approval pathway for avutometinib in combination with defactinib for the treatment of adult patients with recurrent LGSOC, who received at least one prior systemic therapy, and have a KRAS mutation. We may explore regulatory strategies for our other product candidates that involve use of the FDA&#8217;s accelerated approval pathway. Under the accelerated approval program, the FDA may grant accelerated approval to a drug designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the drug has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. As a condition of approval, the FDA requires that a sponsor of a drug receiving accelerated approval perform a post-marketing confirmatory clinical trial or trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">The FDA has broad discretion with regard to approval under the accelerated approval program, and the FDA&#8217;s interpretation of the criteria for accelerated approval, such as what it considers to be available therapies, is subject to change. No assurance can be given that other therapeutics will not receive full approval prior to our potential receipt of accelerated approval. If that were to occur, no assurance can be given that we would be successful in proving meaningful benefit over those later approved products. If we were unable to prove meaningful benefit over any available therapies, we would be effectively blocked from receiving accelerated approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">Even if we receive approval for any of our product candidates through the accelerated approval program, we will be subject to rigorous post-marketing requirements, including the completion of one or more post-market confirmatory studies, to verify the clinical benefit of our product candidate, and submission to the FDA of all promotional materials prior to their dissemination. The FDA could seek to withdraw the approval, if received, for multiple reasons, including if we fail to conduct any required post-market confirmatory trial with due diligence, our post-market confirmatory trial does not confirm the predicted clinical benefit, other evidence shows that our product candidate is not safe or effective under the conditions for use, or we disseminate promotional materials that are found by the FDA to be false or misleading. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Any delay in obtaining, or inability to obtain, approval through the accelerated approval pathway, or any issues in maintaining any such approvals that we receive, would delay or prevent commercialization of our product candidates, and would materially adversely affect our business, financial condition, results of operations, and cash flows. </p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Although we have received accelerated approval for the combination of AVMAPKI FAKZYNJA CO-PACK, it or any product candidate for which we obtain marketing approval are subject to ongoing regulatory obligations and could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products,</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">when and if any of them are approved.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">AVMAPKI FAKZYNJA CO-PACK and any other product candidate for which we obtain marketing approval, along with the manufacturing processes, post approval clinical data, labeling, advertising, and promotional activities for such product, is subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control, quality assurance, and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">approval or contain requirements for costly post marketing testing and surveillance to monitor the safety or efficacy of the product, including the imposition of a REMS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">The development of our marketing and sales capabilities will require significant financial and management resources. Our sales and marketing efforts may not be successful or may be limited by future government policies or initiatives. For example, the FDA stated in September 2025 that it intends to more aggressively enforce requirements related to direct-to-consumer drug advertising and sent a significant number of warning or untitled letters to pharmaceutical companies alleging deceptive prescription drug advertising, which represents a dramatic increase in FDA actions compared to prior years. The current administration&#8217;s focus on pharmaceutical advertising heightens the risk that we may, in the future, receive a warning or enforcement action related to our advertising and marketing practices, which could adversely affect our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">In addition, later discovery of previously unknown problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on such products, manufacturers, or manufacturing processes; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of a product; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product distribution or use; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post marketing clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning or untitled letters; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the products from the market; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution, or disgorgement of profits or revenue; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:12pt 0pt 12pt 18pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may fail to obtain any marketing approvals, lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Our business operations, including our relationships with healthcare providers, third-party payors, and patients, are subject to a broad range of healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings if our activities are challenged as non-compliant.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5pt 0pt 12pt 18pt;">Pharmaceutical manufacturers and their products are subject to extensive federal and state regulation, including laws intended to prevent fraud and abuse in the healthcare industry. These laws may constrain the business or financial arrangements and relationships through which we conduct business, including how we conduct research regarding, market, sell, and distribute our products. In the U.S., these laws include, but are not limited to the following, some of which are likely to apply only if or when we obtain marketing approval for a product candidate:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the anti-kickback statute or specific intent to violate it in order to have committed a violation; </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal False Claims Act (&#8220;FCA&#8221;), which imposes criminal and civil penalties on individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government and actions under the FCA may be brought by private whistleblowers as well as the government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the FCA; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also establishes requirements related to the privacy, security, and transmission of individually identifiable health information which apply to many healthcare providers, physicians, and third-party payors with whom we interact; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal false statements statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal anti-kickback prohibition known as Eliminating Kickbacks in Recovery Act, or EKRA, which prohibits certain payments related to referrals of patients to certain providers (recovery homes, clinical treatment facilities, and laboratories) and applies to services reimbursed by private health plans as well as government health care programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDCA, which, among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing such products for off-label use and regulates the distribution of samples; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal laws that require pharmaceutical manufacturers to calculate, report and certify certain complex product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under governmental healthcare programs, which data may be used in the calculation of reimbursement and/or discounts on approved products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal and state medical privacy and comprehensive privacy statutes, which regulate the privacy and security of personal information, and may vary significantly, complicating compliance efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the so-called federal &#8220;sunshine law&#8221; or Open Payments, which requires manufacturers of drugs, devices, biologics, and medical supplies to report to the Centers for Medicare &amp; Medicaid Services information related to payments and other transfers of value to teaching hospitals, physicians, and other healthcare practitioners, as well as ownership and investment interests held by physicians and their immediate family members; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non- governmental third-party payors, including private insurers, and state laws which regulate interactions between pharmaceutical companies and healthcare providers, require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, require pharmaceutical companies to report information on transfers of value to other healthcare providers, marketing expenditures or pricing information and/or require licensing of sales representatives. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">Similar healthcare and data privacy laws and regulations exist in the European Union and other foreign jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of certain protected information. For example, the General Data Protection Regulation (&#8220;GDPR&#8221;), impose obligations with respect to operations in the European Economic Area (&#8220;EEA&#8221;), and increasing the scrutiny applied to transfers of personal data from the EEA (including health data from our clinical sites in the EEA) to countries that are considered by the European Commission to lack an adequate level of data protection, such as the United States. The compliance obligations imposed by the GDPR </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">have required us to revise our operations and increased our cost of doing business. In addition, the GDPR provides for substantial fines for breaches of data protection requirements, and it confers a private right of action on data subjects for breaches of data protection requirements. In connection with the separation from the European Union, the United Kingdom adopted similar legislation, and many other countries and more than twelve U.S. states have adopted comprehensive data privacy laws that may increase the costs of compliance, inhibit the sharing of personal data across national boundaries, and impact operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">The number and complexity of both federal and state laws continue to increase; the laws contain ambiguous requirements or require administrative guidance for implementation; government interpretations of the laws continue to evolve; and additional governmental resources are being used to enforce these laws and to prosecute companies and individuals who are believed to be violating them. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations involves substantial costs. Governmental authorities may potentially conclude that our business practices, including arrangements we may have with physicians and other healthcare providers, or patient assistance programs, may not comply with applicable laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusions from government funded healthcare programs. Further, we are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in fraud or other misconduct, including actions resulting in non-compliance with legal requirements such as those described above and, if so, we could incur liability for their actions. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, or regulations. Defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The FDA and other comparable regulatory authorities could require clearance or approval of an in vitro diagnostic or companion diagnostic device as a condition of approval for any product candidates that require or would commercially benefit from such tests. If we are unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates, and our drug development strategy and operational results may be harmed.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">If safe and effective use of any of our product candidates depends on an in vitro diagnostic, then the FDA generally will require approval or clearance of that test, known as a companion diagnostic, at the same time that the FDA approves our product candidates. Companion diagnostics, which provide information that is essential for the safe and effective use of a corresponding therapeutic product, are subject to regulation by the FDA and other comparable regulatory authorities as medical devices and require separate regulatory authorization from therapeutic approval prior to commercialization. The development programs for some of our product candidates contemplate working with developers or obtaining access to marketed companion diagnostic tests, which are assays or tests to identify an appropriate patient population. For example, in connection with our NDA for the treatment of adult patients with recurrent LGSOC, who received at least one prior systemic therapy and have a KRAS mutation, we must satisfy a post-marketing commitment to conduct analytical and clinical validation to support development of a diagnostic device that is essential to the safe and effective use of the combination of avutometinib and defactinib in KRAS-mutated, recurrent low grade serous ovarian cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">If safe and effective use of any of our product candidates we may develop depends on a companion diagnostic, we may not receive marketing approval, or marketing approval may be delayed, if we are unable to or are </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">delayed in developing, identifying, or obtaining regulatory approval or clearance for the companion diagnostic product for use with our product candidate. In addition, the process of obtaining or creating such companion diagnostics is time consuming and costly and we, and/or future collaborators, may encounter difficulties in developing and obtaining regulatory clearance or approval for the companion diagnostics.</p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Current and future health care reforms may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:5pt 0pt 0pt 18pt;">In the U.S. and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post approval activities, and affect our ability to profitably sell any of our product candidates for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;"><span style="white-space:pre-wrap;">The U.S. healthcare industry generally and U.S. government healthcare programs in particular are highly regulated and subject to frequent and substantial changes. The U.S. government and individual states have been aggressively pursuing healthcare reform. For example, the ACA, enacted in 2010,  was intended to broaden access to health insurance through a Medicaid expansion and the implementation of the individual mandate for health insurance coverage, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health industry, and impose additional health policy reforms. The law, for example, increased drug rebates under state Medicaid programs for brand name prescription drugs and extended those rebates to Medicaid managed care and assessed a fee on manufacturers and importers of brand name prescription drugs reimbursed under certain government programs, including Medicare and Medicaid.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Beyond the ACA, there are ongoing and widespread healthcare reform efforts, a number of which have focused on regulation of prices or payment for drug products. Drug pricing and payment reform has been an ongoing focus. For example, the Inflation Reduction Act (&#8220;IRA&#8221;) of 2022 includes several changes intended to address rising prescription drug prices in Medicare Parts B and D, with varying implementation dates. These changes include caps on Medicare Part D out-of-pocket costs, Medicare Part B and Part D drug price inflation rebates, a new Medicare Part D manufacturer discount drug program (replacing the prior Medicare Part D coverage gap discount program) and a drug price negotiation program for certain high spend Medicare Part B and D drugs (with the first set of negotiated Medicare maximum fair prices going into effect in 2026). The IRA has had a significant impact on the pharmaceutical industry and that impact is anticipated to continue. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Beyond the IRA, changes to Medicaid effective in 2024 eliminated the Medicaid rebate cap and changes to certain Medicare price reporting requirements for drugs beginning in 2026 will likely increase the administrative and compliance burden for manufacturers. In addition, recent legislation expanded the orphan drug exclusion in the IRA Medicare drug price negotiation program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Under the current presidential administration there has been significant reform activity focused on drug pricing and reimbursement. For example, President Trump issued an Executive Order in April 2025 with multiple directives aimed at lowering drug prices, including refining the Medicare drug price negotiation program established by the IRA, accelerating competition for high-cost prescription drugs by accelerating approval of generics and biosimilars and facilitating the process for re-classifying prescription drugs as over-the-counter drugs, and increasing drug importation. In May 2025, President Trump issued another Executive Order that directed government agencies and officials to identify most-favored nation pricing targets for prescription drugs (and looked to pharmaceutical manufacturers to make significant progress towards delivering target prices to patients), prevent foreign countries from disproportionately shifting the cost of global pharmaceutical research and development to the U.S., and facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers to sell their products to patients at the most-favored-nation price. In the wake of the Executive Orders and related executive initiatives, a number of pharmaceutical manufacturers have announced direct-to-consumer offerings with discounted prices and/or reached agreement with the federal government regarding pricing for drugs, including prices for Medicaid drugs and newly launched products. A website sponsored by the federal government that offers pharmaceutical direct-to-consumer channels has been launched as of February 2026. Federal agencies are developing new drug pricing pilot programs, such as a Medicaid model </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">which would authorize the federal government to negotiate Medicaid supplemental rebates with participating manufacturers on behalf of state Medicaid programs, in exchange for standardized coverage criteria for participating manufacturer drugs, and proposed Medicare Part B and Part D pilot models that, if finalized as proposed, would replace existing inflation-based Medicare rebates with rebates determined on the basis of international prices, for drugs and patients subject to the model. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Other healthcare reform efforts or actions may affect access to healthcare coverage or the funding of health care benefits, although the full impact of such efforts or actions cannot be predicted. For example, the Congressional Budget Office has estimated that Medicaid provisions in the 2025 budget reconciliation legislation, including restrictions in eligibility and funding for Medicaid, as well as changes to the healthcare marketplace such as the elimination of certain subsidies, will increase the number of uninsured patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Individual states in the U.S. have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price and reimbursement constraints, restrictions on copayment assistance by pharmaceutical manufacturers, value-based pricing, marketing cost disclosure and other transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Healthcare reform efforts have been and may continue to be subject to scrutiny, legal challenge and subsequent amendment, creating further uncertainty. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Other government actions could have an adverse effect upon, and could prevent, our products&#8217; commercial success. For example, the Trump Administration&#8217;s announced tariff on branded or patented drugs may increase the cost of drug products that are imported from abroad or manufactured using products or materials imported from abroad. The timeline for implementation of this tariff has not yet been finalized. As another example, the Budget Control Act of 2011, as amended, resulted in the imposition of reductions in Medicare (but not Medicaid) payments to providers in 2013 and remains in effect through 2032 unless additional Congressional action is taken. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented and/or any significant taxes or fees that may be imposed on us could have an adverse impact on our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="white-space:pre-wrap;">We cannot be sure whether additional legislative changes will be enacted, or whether the regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post marketing testing and other requirements.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">The U.S. Supreme Court&#8217;s June 2024 decision in <i style="font-style:italic;">Loper Bright Enterprises v. Raimondo</i> overturned the longstanding <i style="font-style:italic;">Chevron</i> doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The <i style="font-style:italic;">Loper</i> decision could result in additional legal challenges to regulations and guidance issued by federal agencies, including the FDA, on which we rely. Any such legal challenges, if successful, could have a material impact on our business. Additionally, the <i style="font-style:italic;">Loper </i>decision may result in increased regulatory uncertainty, inconsistent judicial interpretations, and other impacts to the agency rulemaking process, any of which could adversely impact our business and operations. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action or as a result of legal challenges, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our business could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">We continue to evaluate federal and state health care reform efforts and the effect that such efforts may have on our business. Healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to successfully commercialize any product candidates, if and when approved.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">If we fail to comply with our obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to penalties and sanctions, which could have a material adverse effect on our business, financial condition, results of operations, and future prospects.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">We participate in the Medicaid Drug Rebate program, the Public Health Service's 340B program, the VA FSS program, and particular other federal and state government pricing programs. Such programs often require us to report pricing and other data to the government and, in turn, provide discounts and/or pay rebates to certain government payors and/or private purchasers that may be based on the reported data. Pricing and rebate calculations vary across programs, are complex, and are often subject to evolving interpretation by the governmental agencies, the courts, and us. Any price recalculations we determine are needed could result in a reassessment of liability for prior quarters. Any determination by governmental agencies that we have failed to comply with our reporting and payment obligations could subject us to civil monetary and other penalties and sanctions, including possible termination of our program participation agreements, which could have a material adverse effect on our business, financial condition, results of operations, and future prospects.</p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Disruptions at the FDA and other government agencies caused by funding shortages could prevent our product candidates from being developed, approved, or commercialized in a timely manner, or at all, which could negatively impact our business. </i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">The ability of the FDA and foreign regulatory authorities to review or approve new product candidates can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s or foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s or foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. For example, over the last several years, the U.S. federal government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown&#160;occurs, preventing the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We face uncertainty regarding potential regulatory developments that may adversely affect our business.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">We face uncertainty regarding the potential for changes in the regulatory environment. While many of the current administration&#8217;s proposed policies appear to be focused on deregulation, a new administration and federal government could adopt legislation, regulation, or policy that adversely affects our business or creates a more challenging and costly environment to pursue the development and commercialization of our current or future product candidates. For example, the federal government, including the FDA, may implement legislative, regulatory, or policy changes regarding the standards for approving drugs that we may be unable to satisfy or regarding the marketing of approved drugs that may limit or prohibit the advertising and promotion of our current or future product candidates, if approved. Additionally, because one objective of the current Trump administration appears to be to decrease spending in the federal government, the FDA could face staff reductions, which could impact the FDA&#8217;s ability to engage in routine regulatory and oversight activities and result in delays or limitations on our ability to proceed with clinical development programs and obtain regulatory approvals. It is difficult to predict how executive actions that may be taken under the current Trump administration may affect the FDA&#8217;s ability to exercise its regulatory authority. If such executive actions impose constraints on the FDA&#8217;s ability to engage in routine oversight and product review activities in the normal course, our business may be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:5pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Employee Matters and Managing Growth</b></p><div style="margin-top:0pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Our future success depends on our ability to retain our chief executive officer and other key executives and to attract, retain and motivate qualified personnel.</i></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">We are highly dependent on the efforts and abilities of the principal members of our senior management and other key personnel, including Daniel Paterson, our President and Chief Executive Officer, Daniel Calkins, our Chief Financial Officer and Michael Kauffman, our President of Development. Although we have formal employment agreements with Daniel Paterson, Daniel Calkins, Michael Kauffman and other members of our senior management and key personnel, these agreements do not prevent them from terminating their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Recruiting and retaining qualified scientific, clinical, manufacturing, and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous biotechnology and pharmaceutical companies, universities, and research institutions for similar personnel. Although we have implemented a retention plan for certain key employees, our retention plan may not be successful in incentivizing these employees to continue their employment with us. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors, including our scientific co-founders, may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We may expand our development, regulatory and future sales and marketing capabilities over time, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">We may experience significant growth over time in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs, and sales and marketing. To manage our anticipated future growth, we may continue to implement and improve our managerial, operational, and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel when we expand. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Our business and operations may be materially adversely affected in the event of computer system breaches or failures.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="white-space:pre-wrap;">There are growing risks related to the security, confidentiality, and integrity of personal and corporate information stored and transmitted electronically due to increasingly diverse and sophisticated threats to networks, systems, and data security. Despite our efforts to implement security measures, our information technology systems, and those of our contract research organizations and other third parties who process information on our behalf or have access to our systems, are vulnerable to damage from computer viruses, ransomware, unauthorized access, natural disasters, fire, terrorism, war, and telecommunication and electrical failures. Similarly, our information system providers and their software and hardware supply chains are vulnerable to attacks.  These attacks may not be identified or addressed quickly enough to avoid harm, particularly when threat actors use stealthy and persistent tactics. Cybersecurity&#160;breaches may be the result of negligent or unauthorized activity by our employees and contractors, as well as by third parties who use cyberattack techniques involving malware, ransomware, hacking and phishing, among others. Cyberattacks have increased in frequency and potential harm over time, and the methods used to gain unauthorized access constantly evolve, making it increasingly difficult to anticipate, prevent, and/or detect incidents successfully in every instance. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">We are required to expend significant resources in an effort to protect against security incidents and may be required or choose to spend additional resources or modify our business activities, particularly where required by applicable data privacy and security laws or regulations or industry standards. The SEC and other regulatory bodies are increasingly focusing on cybersecurity enforcement, and the costs of complying with these regulatory initiatives may be significant. If a security incident or data breach were to occur and cause interruptions in our operations, it could result in a material disruption of our key business processes and clinical </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">development programs. For example, the loss of clinical trial data from ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could be exposed to substantial remediation costs, claims or litigation, regulatory enforcement, liability including under laws that protect the privacy of personal information, and additional reporting requirements, any of which could have a material adverse effect on our operating results and financial condition, affect our reputation, undermine market and commercial confidence, erode goodwill, and possibly delay the further development and commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:5pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Capital Stock</b></p><div style="margin-top:0pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition, or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors are responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 3pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a classified board of directors such that not all members of the board are elected at one time; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:2pt 0pt 3pt 0pt;">&#9679;</td><td style="padding:2pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allow the authorized number of our directors to be changed only by resolution of our board of directors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:2pt 0pt 3pt 0pt;">&#9679;</td><td style="padding:2pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit the manner in which stockholders can remove directors from the board; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:2pt 0pt 3pt 0pt;">&#9679;</td><td style="padding:2pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:2pt 0pt 3pt 0pt;">&#9679;</td><td style="padding:2pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require that stockholder actions must be affected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:2pt 0pt 3pt 0pt;">&#9679;</td><td style="padding:2pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit who may call stockholder meetings; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:2pt 0pt 3pt 0pt;">&#9679;</td><td style="padding:2pt 0pt 3pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a "poison pill" that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:2pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:2pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 18pt;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The market price of our common stock has been, and may continue to be, highly volatile.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">Our stock price has been volatile. Since January 27, 2012, when we became a public company, the closing price for one share of our common stock has reached a high of $210.84 and a low of $2.20 through December 31, 2025, on a post reverse stock split basis. We cannot predict whether the price of our common stock will rise or fall. The market price for our common stock may be influenced by many factors, including:</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of competitive products or technologies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of clinical trials of our product candidates or those of our competitors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the recruitment or departure of key personnel; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of expenses related to any of our product candidates or clinical development programs; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our efforts to discover, develop, acquire, or in-license additional product candidates or products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by securities analysts; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments regarding the commercialization of AVMAPKI FAKZYNJA CO-PACK;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the pharmaceutical and biotechnology sectors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other factors described in this "Risk Factors" section.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">In addition, the stock market in general and the market for small pharmaceutical companies and biotechnology companies in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of particular companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the market, securities class action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management's attention and resources, which could materially and adversely affect our business and financial condition.</p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the source of gain for our stockholders.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings to finance the growth and development of our business. In addition, the terms of any current or future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.</p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">We can issue and have issued shares of preferred stock, which may adversely affect the rights of holders of our common stock.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 12pt 18pt;">We have in the past issued, and we may at any time in the future issue, shares of preferred stock. Our amended and restated certificate of incorporation authorizes us to issue up to 5,000,000 shares of preferred stock with designations, rights and preferences determined from time-to-time by our board of directors. Accordingly, our board of directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting or other rights superior to those of holders of our common stock. Should we issue preferred stock the terms thereof could make it more difficult to take certain corporate actions or make paying dividends and engaging in certain transactions more expensive or challenging. </p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Our stockholders will experience substantial dilution if outstanding warrants or pre-funded warrants are exercised for shares common stock.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">As of December 31, 2025, there were outstanding pre-funded warrants to purchase up to 13,656,048 shares of our common stock issued as part of the July 2024 Offering, 2025 Private Placement, and November 2025 Public Offering. The pre-funded warrants have an exercise price equal to either $0.001 or $0.0001 per underlying share of common stock and do not expire. Additionally, as part of the July 2024 Offering, warrants to purchase up to 8,429,166 shares of our common stock were outstanding as of December 31, 2025, of which 8,391,666 Warrants were exercised in January 2026 and the remaining 37,500 Warrants expired. The conversion of the </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 18pt;">outstanding pre-funded warrants into shares of common stock would be substantially dilutive to existing stockholders. Any dilution or potential dilution may cause our stockholders to sell their shares, which may contribute to a downward movement in the stock price of our common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:5pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Wingdings';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#216;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Raising additional capital or entering into certain licensing arrangements may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 18pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, grants and government funding, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or securities convertible into our common stock, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. To the extent that we enter into certain licensing arrangements, the ownership interest of our existing stockholders may be diluted if we elect to make certain payments in shares of our common stock. Additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish future revenue streams or valuable rights to product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_110177d5_1c40_4974_825d_b4b713a387d1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item1BUnresolvedStaffComments_621403"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1B.  Unresolved Staff Comments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_4e2b297a_80c1_433e_beca_a280b7b3a38e"></a><a id="Item1CCybersecurity_872844"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1C.  Cybersecurity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risk Management and Strategy</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="Tb_3hJp2G6BW0Ob2zTRkKcThA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In the ordinary course of our business, we and our third-party service providers, such as contract research organizations, contract manufacturing organizations, and managed service providers collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research and development data and personal information). The secure maintenance of this confidentiality, availability and integrity of this information is critical to our business and reputation.  In addition, we are heavily dependent on the functioning of our information technology applications and services to carry out our business processes. While we have adopted administrative, technical and physical safeguards to protect such systems and data, our systems and those of third-party service providers may be vulnerable to a cyber-attack. </span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="Tb_geEKSoFj60eWIsBRZik4cw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">We have adopted </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="Narr_WnYH_eH_W0aA-v33lnW53Q"><span style="font-size:10pt;">processes</span></ix:nonNumeric><span style="font-size:10pt;white-space:pre-wrap;"> designed to identify, assess and manage material risks from cybersecurity threats.  Those processes include assessment of, and response to internal and external threats to the security, confidentiality, integrity and availability of our data and information systems, along with other material risks to our operations, at least annually or whenever there are material changes to our systems or operations.</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="Tb_JlJ0qb8ggUCw_BCOr1VEUA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Our risk management team collaborates with our </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="Tb_fWUFsJWvb0uhbLSRTwplgQ" escape="true"><span style="font-size:10pt;">Chief Information Officer (&#8220;CIO&#8221;)</span></ix:nonNumeric><span style="font-size:10pt;white-space:pre-wrap;">, our internal information technology (&#8220;IT&#8221;) department, our Compliance team and our third-party IT managed service providers to evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.  We have established processes to detect potential vulnerabilities and anomalies through technical safeguards and have adopted policies and procedures around internal and external notification of cybersecurity incidents. Our CIO and IT Department implement processes around security monitoring and vulnerability testing.  We also have in place an incident response process for responding to and escalating cybersecurity events and incidents.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">As part of our risk management process, we </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="Narr_eL6Zii9EEE2oKoV1yLrdtQ"><span style="font-size:10pt;">engage outside providers</span></ix:nonNumeric><span style="font-size:10pt;"> to conduct periodic internal and external penetration testing of our systems, networks and web properties. We also employ internal security testing solutions and security awareness training for all employees. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We engage a security operations platform provider to assist us in monitoring, assessing and managing potential cyber events. We also perform periodic cyber maturity assessments to measure our cybersecurity profile against industry peers and standards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;white-space:pre-wrap;">We rely on third parties, including software-as-a-service and platform-as-a-services cloud vendors, for various business functions.  Our third-party services providers have access to our information systems and data, and we rely on such third parties for the continuous operation of our business.  </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="Narr_J4pzx0o7GUeXX2hxJDE6kA"><span style="font-size:10pt;">We oversee these third-party</span></ix:nonNumeric><span style="font-size:10pt;white-space:pre-wrap;"> service providers by conducting vendor diligence during contracting and onboarding and through ongoing monitoring.  Vendors are assessed for risk based on the nature of their service, access to data and systems, and the level to which those systems and data impact our business. Based on that assessment, we conduct diligence that may include completing security questionnaires, onsite audits, and other technical and data security evaluations.</span><span style="font-size:10pt;"> </span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Governance</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="Tb_K6VQyQ3xzUyzzqgRHjr_2w" continuedAt="Tb_K6VQyQ3xzUyzzqgRHjr_2w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="Tb_hgxF2-PzzUaAHyexU5l1tQ" escape="true"><span style="font-size:10pt;">Our Board of Directors provides oversight of the Company&#8217;s cybersecurity risk management program and integrates this oversight into its overall evaluation of enterprise risk. Our </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_WszhNT3VEkiJ-yUFuIbYng" escape="true"><span style="font-size:10pt;">Audit Committee</span></ix:nonNumeric><span style="font-size:10pt;"> has primary responsibility for oversight of cybersecurity and is briefed on cybersecurity risks at least once each year and following any material cybersecurity incidents.</span></ix:nonNumeric><span style="font-size:10pt;white-space:pre-wrap;">  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">At the management level, our cybersecurity program is managed by our </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="Narr_qMmwXg5RGEe9L28txtrmWw"><span style="font-size:10pt;">CIO</span></ix:nonNumeric><span style="font-size:10pt;">, reporting into the executive leadership team. </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="Tb_TdjtE6vAsUyCq8DpTCNa9g" escape="true"><span style="font-size:10pt;">Our CIO has over 30 years of experience managing IT operations and cybersecurity within the pharmaceutical, biotechnology and high-tech industries.</span></ix:nonNumeric><span style="font-size:10pt;"> </span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_K6VQyQ3xzUyzzqgRHjr_2w_cont1"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_tcS-QGtMh0eSiHcxwKPzyQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Our </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="Narr_oC0jAy0WCEW4bTIwJnnDFA"><span style="font-size:10pt;">CIO reports at least annually to the Audit Committee</span></ix:nonNumeric><span style="font-size:10pt;"> and such reporting includes an overall assessment of compliance with our cybersecurity policies and procedures as well as topics that may include risk assessments, risk management and control decisions, service provider arrangements, test results, security incidents and responses and recommendations for changes and updates to policies and procedures. In the event of a cybersecurity incident, the CIO reports the incident to the executive leadership team. If the cybersecurity incident is determined to be material, the executive leadership team will report the incident to the Audit Committee or Board of Directors as appropriate.</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">As of the date of this report, </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="Narr_LT4ELb8k30mKPowqfzl6dQ"><span style="font-size:10pt;">we have not experienced</span></ix:nonNumeric><span style="font-size:10pt;"> a cybersecurity incident that resulted in a material effect on our business strategy, results of operations, or financial condition. Despite our continuing efforts, we cannot guarantee that our cybersecurity safeguards will prevent breaches or breakdowns of our or our third-party service providers&#8217; information technology systems, particularly in the face of continually evolving cybersecurity threats and increasingly sophisticated threat actors. A cybersecurity incident may materially affect our business, results of operations or financial condition, including where such an incident results in reputational, competitive or business harm or damage to our brand, lost sales, reduced demand, loss of intellectual property rights, significant costs or government investigations, litigation, fines or damages. </span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For more information, see &#8220;Our business and operations may be materially adversely affected in the event of computer system breaches or failures&#8221; in Item 1A. Risk Factors in this Annual Report on Form 10-K. </p><a id="_793d0f78_f4c4_493f_aacf_852bd77e347f"></a><a id="Item2Properties_314266"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Properties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">We occupy approximately 27,810 square feet of office space in Needham, Massachusetts under a lease that expires in June 2026. We believe that our facility is sufficient to meet our current needs and that suitable additional space will be available as and when needed.</p><a id="_464d8525_3d7e_461f_8bee_920b9b13ab42"></a><a id="Item3LegalProceedings_948111"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">From time to time, we are subject to various legal proceedings and claims that arise in the ordinary course of our business activities. We do not believe we are currently party to any pending legal action, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business or operating results.</p><a id="_0a5c927f_e78f_403e_9b20_30b6c66ba173"></a><a id="Item4MineSafetyDisclosures_401479"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_0902663a_502a_4b1d_8168_9c077f48048b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTII_454447"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">PART II</b></p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuers Purchases of Equity Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">MARKET INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our common stock is publicly traded on The Nasdaq Global Market under the symbol &#8220;VSTM.&#8221; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">HOLDERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">As of February&#160;27, 2026, there were 5 holders of record of our common stock and the closing price of our common stock on The Nasdaq Capital Market as of that date was $5.72. The number of holders of record does not include beneficial owners whose shares are held by nominees in street name.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">DIVIDENDS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">We have never declared or paid cash dividends on our common stock, and we do not expect to pay any cash dividends on our common stock in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item 5 of Form 10-K regarding equity compensation plans will be included in our 2026 Proxy Statement and is incorporated herein by reference. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PERFORMANCE GRAPH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following performance graph and related information shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933, as amended, except to the extent that we specifically incorporate it by reference into such filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following graph compares the performance of our common stock to the Nasdaq Composite Index and to the Nasdaq Biotechnology Index from December 31, 2020 through December 31, 2025. The comparison assumes $100 was invested after the market closed on December&#160;31, 2020 in our common stock and in each of the foregoing indices, and it assumes reinvestment of dividends, if any.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:346.68pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="vstm-20251231x10k005.jpg" alt="Graphic" style="display:inline-block;height:346.68pt;width:417.1pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cumulative Total Return Comparison</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:34.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="12" style="vertical-align:bottom;white-space:nowrap;width:59.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:34.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:34.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Verastem,&#160;Inc</b>.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100.00</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 96.24</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18.90</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31.85</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20.23</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30.20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:34.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NASDAQ Composite</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100.00</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 122.18</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 82.43</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 119.22</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 154.48</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 187.14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:34.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NASDAQ Biotechnology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100.00</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100.02</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 89.90</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 94.02</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 93.49</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 124.74</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PURCHASE OF EQUITY SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We did not purchase any of our equity securities during the period covered by this Annual Report on Form&#160;10-K.</p><a id="_57ce5ef4_8747_49e0_83ad_36176ad2fd3c"></a><a id="Item6SelectedFinancialData_957616"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  </b><b style="font-weight:bold;">Reserved</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b8aef9ad_ed9a_4b02_a052_b9c1d3dfe7fa"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">7.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form&#160;10-K. The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those discussed below and as set forth under &#8220;Risk Factors.&#8221; Please also refer to the section under the heading &#8220;Forward-Looking Statements.&#8221;</i></p><a id="_Hlk125380904"></a><a id="_Hlk125381312"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">O</b><b style="font-weight:bold;">VERVIEW</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with challenging RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the U.S., the first treatment specifically FDA-approved for adults with KRAS mutated recurrent LGSOC who have received prior systemic therapy. AVMAPKI FAKZYNJA CO-PACK received accelerated approval in the U.S. on May 8, 2025. We are also conducting RAMP 301, a Phase 3 trial designed to evaluate avutometinib plus defactinib versus Investigator&#8217;s Choice of Treatment (&#8220;ICT&#8221;) in patients with recurrent LGSOC with and without a KRAS mutation. This trial will serve as a confirmatory study for the initial U.S. indication and has the potential to expand the indication regardless of KRAS mutation status. Results of the RAMP 301 trial may also support future regulatory filings in Europe and Japan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our pipeline includes clinical-stage programs, preclinical research programs and externally partnered early-stage programs. Our focus is on novel small molecule drugs developed both as monotherapy and in combination, which inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including targeting RAS directly with KRAS G12D inhibition, targeting the pathway downstream with RAF/MEK inhibition, and targeting the parallel pathway that drives resistance with FAK inhibition. Our focus is to expeditiously develop and deliver transformative therapies that truly change outcomes for people living with RAS/MAPK pathway-driven cancers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our operations to date have been focused on organizing and staffing our company, business planning, raising capital, identifying and acquiring potential product candidates, undertaking preclinical studies and clinical trials for our product candidates and initiating U.S. commercial operations following the approval of COPIKTRA through our ownership period ending in September 2020 and in anticipation of and following the approval of AVMAPKI FAKZYNJA CO-PACK in May 2025. </p><a id="_Hlk222323269"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have financed our operations to date primarily through public and private offerings of our common stock, pre-funded warrants and warrants, offerings of convertible notes, sales of common stock under our at-the-market equity offering program, our Note Purchase Agreement, former loan agreements, the upfront payments and milestone payments under our license and collaboration agreements with Sanofi, CSPC, and Yakult, the upfront payment and milestone payments received under the Secura APA, and sales of Series B Convertible Preferred Stock. Additionally, we have also financed a portion of our operations through product revenue, including from AVMAPKI FAKZYNJA CO-PACK, beginning with our U.S. commercial launch in May 2025 and from COPIKTRA, from its U.S. commercial launch in September 2018 through our sale of the COPIKTRA license in September 2020.</p><a id="_Hlk39483937"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2025, we had an accumulated deficit of $1,165.0 million. Our net loss was $209.5 million, $130.6 million, and $87.4 million, for the years ended December 31, 2025, 2024, and 2023, respectively. We anticipate to incur significant expenses and operating losses may continue for the foreseeable future as we continue to incur operating costs to execute our strategic plan, including costs related to research and development of our product candidates and commercial activities. As of December 31, 2025, we had cash, and cash equivalents of $205.0 million and received $29.4 million in January 2026 from exercises of warrants.&#160;We expect our existing cash resources including proceeds from exercise of warrants in January 2026, along with revenue we expect to generate from sales of AVMAPKI FAKZYNJA CO-PACK, will be sufficient to fund our&#160;planned operations through 12 months from the date of issuance of these consolidated financial statements.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our operations with our existing cash,&#160;cash equivalents and investments, through potential future milestones and royalties received pursuant to the Secura APA, through the Note Purchase Agreement, through future product revenues or through other strategic financing opportunities that could include, but are not limited to collaboration agreements, offerings of our equity, or the incurrence of debt. If we fail to obtain additional capital or generate sufficient revenue from our commercialization activities in the future, we may be unable to complete our planned preclinical studies and clinical trials and obtain approval of certain investigational product candidates from the FDA or foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FINANCIAL OPERATIONS OVERVIEW</b></p><a id="_Hlk531671639"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Product Revenue, net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Product revenue, net, is recognized when earned on gross sales of AVMAPKI FAKZYNJA CO-PACK in the U.S. less provisions for all variable consideration.&#160; These provisions include trade allowances, rebates, chargebacks and discounts, product returns and other incentives. We sell AVMAPKI FAKZYNJA CO-PACK to a limited number of specialty pharmacies and specialty distributors. Although we expect net product revenues to increase over time, the provisions for product sales allowances may fluctuate based on the mix of sales to either specialty pharmacy or specialty distributor customers.&#160; See &#8220;Critical Accounting Policies and Significant Judgements and Estimates&#8221; below for more information on the components of net U.S. product sales of AVMAPKI FAKZYNJA CO-PACK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sales of Intellectual Property</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Sales of intellectual property represents revenue generated from the sale of our COPIKTRA license and related assets to Secura. The sale included intellectual property related to duvelisib in oncology indications, certain existing duvelisib inventory, certain manufacturing equipment and, claims and rights under certain contracts pertaining to duvelisib, including net contract prepaid balances. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Costs of Sales - Product</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Cost of sales - product consists of costs of AVMAPKI FAKZYNJA CO-PACK on which product revenue was recognized, royalties owed on such sales, and certain period costs including inventory write downs. Prior to the FDA approval of AVMAPKI FAKZYNJA CO-PACK, expenses associated with the manufacturing of AVMAPKI FAKZYNJA CO-PACK were recorded as research and development expense. Certain of the product costs of <span style="white-space:pre-wrap;">AVMAPKI FAKZYNJA CO-PACK units sold during the year ended December 31, 2025, were expensed prior to obtaining regulatory approval and, therefore, are not included in cost of sales - product during this period.  We expect cost of sales </span>&#8211; product to increase in relation to product revenues as we deplete these inventories. There was no cost of sales &#8211; product recognized during the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cost of Sales - Intangible Amortization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cost of sales &#8211; intangible amortization represents amortization expense recognized on finite-lived AVMAPKI FAKZYNJA CO-PACK-related intangible assets, which we began amortizing during the second quarter of 2025. There was no cost of sales &#8211; intangible amortization recognized during the year ended December 31, 2024<b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research and Development Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses consist of costs associated with our research activities, including the development of our product candidates. Research and development expenses include product/ product candidate and/or project-specific costs, as well as unallocated costs. We allocate external research and development services, expenses incurred by third parties such as CROs, clinical sites, manufacturing organizations and consultants, by project and/or product candidate. We use our employee and infrastructure resources in a cross-functional manner </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">across multiple research and development projects. Our project costing methodology does not allocate personnel, infrastructure and other indirect costs to specific clinical programs or projects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Product/ product candidate/ project specific costs include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">direct third-party costs, which include expenses incurred under agreements with CROs, the cost of consultants who assist with the development of our product candidates on a program-specific basis, clinical site costs, and any other third-party expenses directly attributable to the development of the product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">direct costs related to avutometinib or defactinib that are not specific to a clinical trial such as the costs relating to contract manufacturing operations including manufacturing costs in connection with producing avutometinib and defactinib </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">are included within &#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Avutometinib and defactinib manufacturing and non-clinical trial specific&#8221; as the cost to manufacture avutometinib and defactinib is not allocated to specific clinical trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">license fees.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unallocated costs include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research and development employee-related expenses, including salaries, benefits, travel, and stock-based compensation expense;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cost of consultants, including our scientific advisory board, who assist with our research and development but are not allocated to a specific program; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities, depreciation, and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, and laboratory supplies.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The table below summarizes our direct research and development expenses for our product/ product candidates/ projects and our unallocated research and development costs for the years ended December&#160;31, 2025, 2024, and 2023:</p><a id="_Hlk531671719"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Product/ product candidate / project specific costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Avutometinib <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">+</span> defactinib - LGSOC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35,778</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,079</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,360</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Avutometinib <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">+</span> defactinib - NSCLC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,434</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,271</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,487</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Avutometinib + defactinib - pancreatic cancer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,854</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,966</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Avutometinib <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">+</span> defactinib - other indications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,431</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,282</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,225</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Avutometinib and defactinib manufacturing and non-clinical trial specific</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,273</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,462</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GenFleet / VS-7375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,490</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,939</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,177</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COPIKTRA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 93</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Unallocated costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel costs, excluding stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,799</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,657</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,299</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,527</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,134</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,987</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:63.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other unallocated expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,013</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,986</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,266</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total research and development expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 114,599</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 81,334</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 61,356</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 12pt 0pt;">Costs for certain development activities, such as clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks using patient enrollment, clinical site activations, and other information based on actual costs incurred or level of effort expended provided by our vendors. Payments for these activities are based on the terms of individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid expenses and other current assets or accrued expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our research and development expenses may increase significantly in future periods as we undertake costlier development activities for our existing and future product candidates, including larger and later-stage clinical trials.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete development of our product candidates or the period, if any, in which material net cash inflows from our product candidates may commence. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trial results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, rate of progress, and expense of our research and development activities, including preclinical research and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits of our product candidates over other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to market, commercialize, and achieve market acceptance of any of our product candidates for which we receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expense of filing, prosecuting, defending, and enforcing patent claims and other intellectual property rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in government regulation.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or other regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of clinical development of a product candidate or if we experience significant delays in enrollment in any clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selling, General, and Administrative Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Selling, general, and administrative expenses consist primarily of salaries and related costs for personnel, including stock-based compensation expense, in our executive, finance, legal, information technology, commercial, communication, human resources, and business development functions. Other selling, general, and administrative expenses include allocated facility costs, commercial costs, professional fees for legal, patent, investor and public relations, consulting, insurance premiums, audit, tax, and other public company costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other Income, Other Expense, Interest Income and Interest Expense</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other expense for each of the years ended December 31, 2025, 2024 and 2023 primarily represent transaction losses recognized due to changes in foreign currency exchange rates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest income reflects interest earned on our cash, cash equivalents and available-for-sale securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest expense reflects interest expense due on our Loan Agreement with Oxford and our convertible notes, interest expense related to vendor financing arrangements, as well as non-cash interest related to the amortization of debt discount and issuance costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Loss on Debt Extinguishment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The loss on<span style="color:#212529;"> debt extinguishment for the year ended December 31, 2025, represents the loss recognized on early extinguishment of our Loan Agreement with Oxford. On January 13, 2025, we repaid in full all principal, accrued and unpaid interest, fees, and expenses under the Loan Agreement in an aggregate amount. The amount of repayment, excluding accrued interest, which exceeded the carrying of the loan was recorded as loss on debt extinguishment. There was no loss on debt extinguishment for the year ended December 31, 2024 and 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Change in Fair Value of Preferred Stock Tranche Liability</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The change in fair value of preferred stock tranche liability for the years ended December 31, 2024 and December 31, 2023,&#160;represents the mark-to-market adjustment of the second tranche right issued as part of the <span style="background:#ffffff;">Securities </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Purchase Agreement (the &#8220;Series B Convertible Preferred Stock Securities Purchase Agreement&#8221;), dated January 24, 2023 with certain purchasers pursuant to which we agreed to sell and issue to the purchasers in a private placement up to 2,144,160 shares of its Series B Convertible Preferred Stock in two tranches. </span><span style="color:#212529;background:#ffffff;">The preferred stock tranche liability expired in July 2024 and is no longer outstanding.</span> There was no preferred stock tranche liability outstanding during the year ended December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Change in Fair Value of Common Stock Warrant Liability</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The change in fair value of warrant liability for the years ended December 31, 2025, and 2024 represents the mark-to-market adjustment of the liability classified warrants issued as part of the July 2024 Offering (defined herein). There were no warrants outstanding during the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Change in Fair Value of Notes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">We elected the fair value option to account for the Notes (defined herein) and therefore the changes in fair value, including interest, other than changes that are directly attributable to instrument specific credit risk, are recorded as change in fair value of Notes in the consolidated statements of operations and comprehensive loss. The Notes were not outstanding during the years ended December 31, 2024, and 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of certain assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued and prepaid research and development expenses, stock-based compensation, fair value of Notes and revenue recognition described in greater detail below. We base our estimates on our limited historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form&#160;10-K. However, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue Recognition </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606 <i style="font-style:italic;">Revenue from Contracts with Customers </i>(&#8220;ASC 606&#8221;).</p><a id="_Hlk221018065"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Product Revenue, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We sell AVMAPKI FAKZYNJA CO-PACK to a limited number of specialty pharmacies and specialty distributors in the U.S. The specialty pharmacies dispense AVMAPKI FAKZYNJA CO-PACK directly to patients while the specialty distributors resell AVMAPKI FAKZYNJA CO-PACK to healthcare entities who then resell AVMAPKI FAKZYNJA CO-PACK to patients. In addition to distribution agreements with specialty distributors, we also enter into arrangements with (1) certain government agencies and various private organizations (&#8220;Third-Party Purchasers&#8221;), which may provide for chargebacks or discounts with respect to the purchase of AVMAPKI FAKZYNJA CO-PACK, and (2) Medicare and Medicaid, which may provide for certain rebates with respect to their reimbursement of AVMAPKI FAKZYNJA CO-PACK.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize revenue on sales of AVMAPKI FAKZYNJA CO-PACK when a customer obtains control of the product, which occurs at a specific point in time (typically upon delivery). Product revenues are recorded at the wholesale acquisition costs, net of applicable reserves for variable consideration. Components of variable consideration include trade discounts and allowances, Third-Party Payer chargebacks and discounts, government rebates, product returns, other patient focused allowances, such as voluntary co-pay assistance, benefits verification, and other patient support programs that are offered within contracts between us and customers, payors, and other indirect customers relating to our sale of AVMAPKI FAKZYNJA CO-PACK. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable or a current liability. These estimates take into consideration a range of possible outcomes based upon relevant factors such as, customer contract terms, information received from third parties regarding the anticipated payor mix for AVMAPKI FAKZYNJA CO-PACK, known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled with respect to sales made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The amount of variable consideration included within a transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under contracts will not occur in a future period. Our analyses contemplate the application of the constraint in accordance with FASB ASC 606<span style="font-size:12pt;">. </span>For the year ended December 31, 2025, we determined a material reversal of revenue would not occur in a future period for the estimates detailed below and, therefore, transaction prices would not be reduced further. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Trade Discounts and Allowances: We generally provide customers with invoice discounts on sales of AVMAPKI FAKZYNJA CO-PACK for prompt payment and other discounts, which are explicitly stated in our contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we compensate the specialty pharmacy and specialty distributor customers for sales order management, data, distribution, and certain other services. We have determined such services are not distinct from our sale of AVMAPKI FAKZYNJA CO-PACK to the specialty pharmacy and specialty distributor customers and, therefore, these payments have also been recorded as a reduction of revenue within the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Third-Party Payer Chargebacks, Discounts and Fees: We execute contracts with Third-Party Purchasers that allow for eligible purchases of AVMAPKI FAKZYNJA CO-PACK at prices lower than the wholesale acquisition cost. In some cases, customers will charge us for the difference between what they pay for AVMAPKI FAKZYNJA CO-PACK and the ultimate selling price to the Third-Party Purchasers to whom they sell the product. Reserves will generally be established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable, net. Chargeback amounts will generally be determined at the time of resale to the qualified Third-Party Purchasers by customers, and we generally will issue credits for such amounts within a few weeks of the customer&#8217;s notification of the resale. The reserves for chargebacks are expected to consist of credits that we expect to issue for units that remain in customer inventories at the end of each reporting period that we expect will be sold to Third-Party Purchasers, and chargebacks that customers have claimed, but for which we have not yet issued a credit.</p><a id="_Hlk204947273"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Government Rebates: We are subject to discount and rebate payment obligations under various government programs including Federal and state Medicaid programs, Medicare, and others. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses on the consolidated balance sheets. Our liability for these rebates consist of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in customer inventories at the end of each reporting period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other Patient Support Initiatives: Other patient support initiatives that we offer include voluntary co-pay assistance programs, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payors. The calculation of the accrual for co-pay assistance is based on </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">an estimate of claims and the cost per claim that we expect to receive for product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Product Returns: Consistent with industry practice, we generally offer customers a limited right of return for product that has been purchased from us either directly or through one of its distribution channels. We estimate the amount of our product sales that may be returned by our customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. We estimate product return liabilities using available industry data and our own sales information, including our visibility into the inventory remaining in the distribution channel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our return policy generally allows for eligible returns of AVMAPKI FAKZYNJA CO-PACK for credit under the following circumstances:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Receipt of damaged product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shipment errors that were a result of an error by us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Expired product that is returned during the period beginning three months prior to the product&#8217;s expiration and ending six months after the expiration date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Quantities of product received by a customer in excess of quantity ordered;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product subject to a recall; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product that we at our sole discretion, has specified can be returned for credit. </span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, we have not received any product returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sales of Intellectual Property</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upon the sale of licenses or intellectual property that incorporate sale-based royalties, including milestone payments based on a level of sales, we evaluate whether the royalties and sales-based milestones are considered probable of being achieved and estimate the amount of royalties to include over the contractual term using the expected value method and estimate the sales-based milestones using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated royalty and milestone value is included in the transaction price. Royalties and sales-based milestones for territories for which there is not regulatory approval are not considered probable until such regulatory approval is achieved. We evaluate factors such as whether consideration is outside of our control, timeline for when the uncertainty will be resolved and historical sales of COPIKTRA if applicable. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, we reevaluate the probability of achievement of all milestones subject to constraint and amount of royalty revenue to be received and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. At December 31, 2025, we determined no future potential royalties pursuant to the Secura APA were constrained. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Refer to </span><i style="font-style:italic;background:#ffffff;">Note 2. Significant accounting policies</i><span style="background:#ffffff;"> and </span><i style="font-style:italic;background:#ffffff;">Note 16. License, collaboration and commercial agreements</i><span style="background:#ffffff;"> t</span>o our consolidated financial statements located in this Annual Report on Form&#160;10-K for further discussion of revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accrued and Prepaid Research and Development Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses. This process involves reviewing contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses include fees paid to CROs in connection with research and development activities for which we have not yet been invoiced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We base our research and development expenses on estimates of services received and efforts expended pursuant to quotes and contracts with CROs that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of research and development expenses. When recognizing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Refer to </span><i style="font-style:italic;background:#ffffff;">Note 2. Significant accounting policies</i><span style="background:#ffffff;">, and </span><i style="font-style:italic;background:#ffffff;">Note 7. Accrued expenses </i><span style="background:#ffffff;">t</span>o our consolidated financial statements located in this Annual Report on Form&#160;10-K for further discussion of accrued research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize stock-based compensation expense for service-based awards, such as stock options and restricted stock units (&#8220;RSUs&#8221;), issued to employees, directors and consultants based on the grant date fair value of the awards on a straight-line basis over the requisite service period. In addition, <span style="color:#212529;background:#ffffff;">we issue shares to employees under our employee stock purchase plan (&#8220;ESPP&#8221;).</span>&#160;The fair value of our stock options and ESPP grants is estimated at the date of grant using the Black-Scholes option pricing model. We are precluded from utilizing the simplified method as described in SEC SAB Topic 14.D.2 to calculate the expected term as a key assumption in the Black-Scholes pricing model when determining fair value of stock options not in the money because of a modification. Therefore, when valuing stock options that are not at the money, we utilize a binomial lattice model to calculate the fair value of the stock option. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have also granted performance-based RSUs and stock options with terms that allow the recipients to vest in a certain number of shares based upon the achievement of performance-based milestones as specified in the grants. Stock-based compensation expense associated with these performance-based RSUs and stock options is recognized if the performance condition is considered probable of achievement using management&#8217;s best estimates of the achievement of the performance-based milestones. If the actual achievement of the performance-based milestones varies from our estimates, stock-based compensation expense could be materially different than what is recorded in the period. The cumulative effect on current and prior periods of a change in estimate for performance-based RSUs and stock options will be recognized as compensation cost in the period of the revision and recorded as a change in estimate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While the assumptions used to calculate and account for stock-based compensation awards represent management&#8217;s best estimates, these estimates involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if revisions are made to our underlying assumptions and estimates, our stock-based compensation expense could vary significantly from period to period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the year ended December 31, 2025, we recorded $9.4 million of stock-based compensation expense. As of December 31, 2025, there was approximately $5.4 million of unrecognized stock-based compensation related to stock options, which is expected to be recognized over a weighted-average period of 2.2 years. As of December 31, 2025, there was approximately $4.6 million of unrecognized stock-based compensation related to RSUs, which is expected to be recognized over a weighted-average period of 1.9 years. See <i style="font-style:italic;">Note 2</i>. <i style="font-style:italic;">Significant accounting policies </i></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and <i style="font-style:italic;">Note 11. Stock-based compensation</i> to our consolidated financial statements located in this Annual Report on Form&#160;10-K for further discussion of stock-based compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Fair Value of Notes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The fair value of the Notes pursuant to the Note Purchase Agreement represents the present value of estimated future payments, including interest, principal, Repayment Amount, and Revenue Participation Payments (each as defined in the Note Purchase Agreement). The fair value measurement is based on significant Level 3 unobservable inputs such as the probability and timing of Revenue Participation Payments, Repayment Amount, and the discount rate. We determined the fair value of the Notes utilizing a discounted cash flow model of estimated future payments including interest, principal, Repayment Amount and Revenue Participation Payments utilizing a discount rate calculated as the term matched risk-free rate plus credit spread. At January 13, 2025, we utilized a discount rate between 11.9%-12.4% and at December 31, 2025, we utilized a discount rate between 12.6%-13.0%. The fair value of the Notes at December 31, 2025 was determined to be $76.3 million which differed from the contractual principal amount of $75.0 million by $1.3 million. Significant increases or decreases in any of these inputs in isolation could result in a significantly lower or higher fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While the assumptions used to calculate and account for the fair value of Notes represent management&#8217;s best estimates, these estimates involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if revisions are made to our underlying assumptions and estimates, the fair value of Notes and consequently the change in fair value of Notes could vary significantly from period to period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Refer to </span><i style="font-style:italic;background:#ffffff;">Note 2. Significant accounting policies</i><span style="background:#ffffff;">, and </span><i style="font-style:italic;background:#ffffff;">Note 8. Long-term debt </i><span style="background:#ffffff;">t</span>o our consolidated financial statements located in this Annual Report on Form&#160;10-K for further discussion of fair value of Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RESULTS OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">All financial information presented has been consolidated and includes the accounts of our wholly-owned subsidiaries, Verastem Securities Company and Verastem Europe GmbH. All intercompany balances and transactions have been eliminated in consolidation.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,914</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Sale of COPIKTRA license and related assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,914</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cost of sales - product</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,600</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cost of sales - intangible amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 698</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 114,599</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 81,334</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 61,356</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 81,146</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 43,622</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,728</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 201,043</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 124,956</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 92,084</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (170,129)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (114,956)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (92,084)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (203)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (123)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (109)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,068</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,149</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,214</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,138)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,562)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,139)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,826)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of preferred stock tranche liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,189</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,751</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27,492)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (19,149)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,751)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss before taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (209,471)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (130,452)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (87,367)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (185)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (209,471)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (130,452)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (87,367)</span></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Comparison of the Year Ended December 31, 2025 to the Year Ended December 31, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Product Revenue, Net. </i>We initiated commercial sales of AVMAPKI FAKZYNJA CO-PACK in the U.S. in May 2025, following receipt of FDA marketing approval on May 8, 2025. For the year ended December 31, 2025 (the &#8220;2025 Period&#8221;) we recognized approximately $30.9 million of net product revenue. We had no product revenue during the year ended December 31, 2024 (the &#8220;2024 Period&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Sale of COPIKTRA license and related assets revenue. </i>Sale of COPIKTRA license and related assets revenue for the 2025 Period was $0.0 million compared to $10.0 million for the 2024 Period.<span style="color:#212529;">&#160;Sale of COPIKTRA license and related assets revenue for the 2024 Period was comprised of one sales milestone of $10.0 million due upon Secura achieving cumulative worldwide net sales of COPIKTRA exceeding $100.0 million during the 2024 Period. The $10.0 million milestone payment was received by us in July 2024. There was no milestone achieved during the 2025 Period. Refer to&#160;</span><i style="color:#212529;font-style:italic;">Note 16. License, collaboration and commercial agreements </i><span style="color:#212529;">to our consolidated financial statements located in this Annual Report on Form 10-K for additional details on the Secura APA.</span></p><a id="_Hlk221018673"></a><a id="_Hlk221018733"></a><a id="_Hlk221018759"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Costs of Sales &#8211; Product. </i>Costs of sales &#8211; product of $4.6 million for the 2025 Period consisted of costs associated with the manufacturing of AVMAPKI FAKZYNJA CO-PACK, royalties owed on such sales, and certain period costs including inventory write downs. We began capitalizing inventory upon receiving FDA approval for AVMAPKI FAKZYNJA CO-PACK on May 8, 2025. Prior to the FDA approval of AVMAPKI FAKZYNJA CO-PACK, expenses associated with the manufacturing of AVMAPKI FAKZYNJA CO-PACK were recorded as research and development expense. Certain of the costs of AVMAPKI FAKZYNJA CO-PACK<span style="white-space:pre-wrap;"> units recognized as revenue during the 2025 Period, or approximately $0.2 million, were expensed prior to obtaining regulatory approval, therefore, are not included in cost of sales - product during this period.  We expect cost of sales - product to increase in relation to product revenues as we deplete these inventories. We had no cost of sales &#8211; product during the 2024 P</span>eriod.<i style="font-style:italic;"> </i></p><a id="_Hlk222351510"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Research and Development Expense.</i> Research and development expense was $114.6 million for the 2025 Period compared to $81.3 million for the 2024 Period. The increase of $33.3 million from the 2024 Period to the 2025 Period was primarily a result of the following incremental expenses incurred: $9.3 million in CRO costs, $7.1 million in investigator fees, $6.8 million in drug substance and drug product costs, $5.3 million in clinical supply costs, $4.6 million in personnel related costs, including non-cash stock-based compensation, <span style="background:#ffffff;">$0.7 million in preclinical costs, and $0.6 million in other costs</span><span style="white-space:pre-wrap;">  The increase was also attributable to a $6.0 million payment made to exercise the GenFleet Option with respect to VS-7375.  These increases were partially offset by a decrease of $4.1 million in consulting costs and the non-recurrence of a $3.0 million milestone payment made to GenFleet in the 2024 Period. </span>The increase in Research and Development costs was primarily driven by the RAMP 301 study, which began in the fourth quarter of 2023, and the VS-7375-101 study, which began in the second quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We anticipate an increase in research and development expenses in future periods as we continue development of VS-7375 for the treatment of patients with PDAC, NSCLC, CRC and other KRAS G12 cancers, complete the RAMP 301 clinical trial for the treatment of patients with recurrent LGSOC with and without KRAS mutation, and address post-marketing commitments for AVMAPKI FAKZYNJA CO-PACK as agreed upon with the FDA. This increase is expected to be partially offset by a reduction in costs incurred as a result of the discontinuation of the RAMP 203 clinical trial.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expense.</i> <span style="background:#ffffff;">Selling, general and administrative expense was $81.1 million for the 2025 Period compared to $43.6&#160;million for the 2024 Period. The increase of $37.5 million from the 2024 Period to the 2025 Period </span>was primarily a result of the following incremental expenses incurred: $28.2 million in consulting and professional fees related to the launch of AVMAPKI FAKZYNJA CO-PACK for the treatment of KRAS mutant recurrent LGSOC, $8.2 million in personnel costs including non-cash stock-based compensation, $1.1 million in commercial operations expense, and $2.3 million in travel related and other costs. These increases were partially offset by a decrease of $2.2 million in financing fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Expense.</i> Other expense was $0.2 million for the 2025 Period compared to $0.1 million for the 2024 Period. Other expense was comprised of transaction losses due to changes in foreign currency exchange rates in both periods.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest Income.</i> Interest income for the 2025 Period and the 2024 Period was $4.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><i style="font-style:italic;">Interest Expense.&#160;</i>Interest expense for the 2025 Period was $1.1 million compared to $4.6 million for the 2024 Period. The decrease of $3.5 million from the 2024 Period to the 2025 Period was primarily driven by the termination of the Loan Agreement with Oxford on January 13, 2025 resulting in a reduction of interest expense recorded in the 2025 Period. We have elected to present interest expense associated to the Notes within change in fair value of Notes within the consolidated statements of operations and comprehensive loss.</p><a id="_Hlk221022935"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Loss on Debt Extinguishment. </i>The loss on<span style="color:#212529;"> debt extinguishment for the 2025 Period of $1.8 million represents the loss recognized on early extinguishment of our Loan Agreement with Oxford. On January 13, 2025, we repaid in full all principal, accrued and unpaid interest, fees, and expenses under the Loan Agreement in an aggregate amount of $42.7 million (the &#8220;Payoff Amount&#8221;). The Payoff Amount, excluding accrued interest, exceeded the carrying amount of the Term Loans on January 13, 2025 by $1.8 million which was recorded as a loss on debt extinguishment. There was no loss on debt extinguishment in the 2024 Period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Change in Fair Value of Preferred Stock Tranche Liability. </i>The change in fair value of the preferred stock tranche liability was $4.2 million income for the 2024 Period.<span style="color:#212529;"> The change in fair value of preferred stock tranche liability was comprised of the mark-to-market adjustment related to the second tranche right issued as part of the Securities Purchase Agreement. The preferred stock tranche liability expired in July 2024 and therefore was not outstanding during the 2025 Period. The fair value of the preferred stock tranche liability decreased from $4.2 million at the beginning of the 2024 Period to $0.0 million at the end of the 2024 Period resulting in $4.2 million income in the 2024 Period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Change in Fair Value of Warrant Liability. </i>T<span style="color:#212529;">he change in fair value of the warrant liability was $27.5 million in expense for the 2025 Period compared to $19.1 million in expense for the 2024 Period. The change in fair value of warrant liability represents the mark-to-market adjustment for the liability classified warrants issued as part of the July 2024 Offering. The $27.5 million expense recognized in the 2025 Period was driven by an increase in fair value per Warrant from December 31, 2024 to the exercise date for 9.7 million Warrants exercised during the 2025 Period and an increase in fair value per Warrant for 8.4 million Warrants that remained outstanding at December 31, 2025 primarily driven by an increase in our stock price. The $19.1 million expense recognized in the 2024 Period was primarily driven an increase in fair value per Warrant from July 23, 2024, to the exercise date for 0.3 million Warrants exercised during the 2024 Period and an increase in fair value per Warrant for the 18.1 million Warrants that remained outstanding at December 31, 2024 primarily driven by an increase in our stock price.</span></p><a id="_Hlk221023059"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Change in Fair Value of Notes. </i><span style="color:#212529;">We elected the fair value option to account for the Notes and therefore the changes in fair value, including interest, other than changes that are directly attributable to instrument specific credit risk are recorded as change in fair of Notes in the consolidated statements of operations and comprehensive loss. The change in fair value of $12.8 million for the 2025 Period was primarily driven by interest on the Notes and a reduction in the risk-free rate during the 2025 Period. There were no Notes outstanding in the 2024 Period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><i style="color:#212529;font-style:italic;">Income Tax Expense.</i><span style="color:#212529;"> </span><span style="color:#212529;white-space:pre-wrap;">No income tax expense was recognized during the 2025 Period.  Income tax expense of $0.2 million for the 2024 Period was comprised of interest under IRC section 453A related to the $10.0 million milestone payment from Secura because it was an installment sale for tax purposes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LIQUIDITY AND CAPITAL RESOURCES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Sources of Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">We have financed our operations to date primarily through public and private offerings of our common stock, pre-funded warrants, and warrants, offerings of convertible notes, sales of common stock under our at-the-market equity offering program, our Note Purchase Agreement, former loan agreements, the upfront payments and milestone payments under our license and collaboration agreements with Sanofi, CSPC, and Yakult, the upfront payment and milestone payments received under the Secura APA, and sales of Series B Convertible Preferred Stock. Additionally, we have financed a portion of our operations through product revenue, including from AVMAPKI FAKZYNJA CO-PACK, beginning with our U.S. commercial launch in May 2025, and from COPIKTRA, from its </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">U.S. commercial launch in September 2018 through our sale of the COPIKTRA license in September 2020. We expect to finance a portion of our business through future potential milestones and royalties received pursuant to the Secura APA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, we had $205.0 million in cash, cash equivalents, and investments. We primarily invest our cash, cash equivalents and investments in U.S. Government money market funds, government bonds, corporate bonds and commercial paper of publicly traded companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Risks and uncertainties include those identified under Item 1A. <i style="font-style:italic;">Risk Factors,</i> in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Cash flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The following table sets forth the primary sources and uses of cash for each of the periods set forth below (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash (used in) provided by:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (137,509)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (104,771)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (86,460)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9,624)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 59,972</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (44,447)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 263,305</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 54,782</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 134,194</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Increase in cash, cash equivalents and restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 116,172</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,983</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,287</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Operating activities.</i> Cash used in operating activities was $137.5 million and $104.8 million for the 2025 Period and the 2024 Period, respectively. The use of cash in operating activities in the 2025 Period and 2024 Period resulted primarily from our net losses adjusted for non-cash adjustments and changes in the components of working capital. Our cash outflow from net losses adjusted for non-cash adjustments was $163.5 million and $108.5 million for the 2025 Period and 2024 Period, respectively. Non-cash charges and adjustments for the 2025 Period were primarily related to the change in fair value of warrant liability, non-cash changes in fair value of the Notes, loss on debt extinguishment and stock-based compensation expense. <span style="color:#212529;background:#ffffff;">Non-cash charges and adjustments for the 2024 Period were primarily related to the changes in fair value of the preferred stock tranche liability, the change in fair value of warrant liability and stock-based compensation expense.</span> Our cash inflow from operating activities due to changes in operating assets and liabilities was $26.0 million for the 2025 Period primarily driven by an increase of $30.8 million in accrued expenses and other liabilities and an increase of $8.4 million in accounts payable, partially offset by an increase of $8.8 million in accounts receivable, an increase of $2.6 million in prepaid expenses, other current assets and other assets, and an increase of $1.8 million in inventory. Our cash inflow from operating activities due to changes in operating assets and liabilities for the 2024 Period was $3.7 million primarily driven by an increase of $8.0 million in accrued expenses and other liabilities, partially offset by a decrease of $3.2 million in accounts payable, an increase of $0.6 million in prepaid expenses, other current assets and other assets, a decrease of $0.3 million in deferred liabilities and an increase of $0.2 million in grant receivable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing activities.</i><span style="color:#212529;background:#ffffff;"> Cash used in investing activities for the 2025 Period primarily represents milestone payments recorded as intangible assets in the amounts of $7.5 million under the Pfizer Agreement and $2.1 million under the License Agreement.</span><i style="font-style:italic;"> </i><span style="background:#ffffff;">Cash provided by investing activities for the 2024 Period primarily relates to net maturities of investments of $60.0 million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Financing activities.</i> Cash provided by financing activities for the 2025 Period includes $96.9 million of net proceeds from issuance of common stock and pre-funded warrants as part of the November 2025 Public Offering, $75.0 million of proceeds received pursuant to the Note Purchase Agreement, $69.9 million of net proceeds from issuance of common stock and pre-funded warrants as part of the 2025 Private Placement, $33.8 million of proceeds from the exercise of Warrants, $22.7 million of net proceeds received from issuance of common stock under the ATM Programs, $7.4 million of net proceeds received from issuance of common stock under the Stock Purchase Agreement, $1.2 million of proceeds received from insurance premium financing, and less than $0.1 million of proceeds received from exercise of stock options and employee stock purchase program, partially offset by the $42.6 million repayment of our Loan Agreement and $1.2 million of payments for insurance premium financing. <span style="color:#212529;background:#ffffff;">Cash provided by financing activities for the 2024 Period includes $53.8 million of net proceeds received from the </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;white-space:pre-wrap;background:#ffffff;">issuance of shares of common stock, pre-funded warrants, and warrants as part of the July 2024 Offering, $1.3 million of proceeds received from insurance premium financing, $0.9 million of proceeds received from exercise of Warrants and $0.2 million of proceeds received from exercise of stock options and our employee stock purchase plan, partially offset by $1.3 million of  payments on insurance premium financing and $0.2 million of fees paid to the Lenders to amend our Loan Agreement with Oxford. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">Refer to&#160;</span><i style="color:#212529;font-style:italic;background:#ffffff;">Note 10. Capital Stock</i><span style="color:#212529;background:#ffffff;">&#160;to our consolidated financial statements located in this Annual Report on Form 10-K for additional details on the November 2025 Public Offering, 2025 Private Placement, ATM Programs, the Stock Purchase Agreement, the July 2024 Offering and Warrants;&#160;</span><i style="color:#212529;font-style:italic;background:#ffffff;">Note 8 Long-Term Debt</i><span style="color:#212529;background:#ffffff;">&#160;</span><span style="color:#212529;white-space:pre-wrap;background:#ffffff;">to our consolidated financial statements located in this Annual Report on Form 10-K for additional details on the Note Purchase Agreement and  Loan Agreement; and&#160;</span><i style="color:#212529;font-style:italic;background:#ffffff;">Note 17. Notes Payable</i><span style="color:#212529;background:#ffffff;">&#160;to our consolidated financial statements located in this Annual Report on Form 10-K for additional details on the finance agreements related to insurance premium financing and the monthly payments of principal and interest related thereto.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Funding requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur significant expenses and may continue to incur operating losses. Refer to risk factor titled <i style="font-style:italic;">We have incurred significant losses since our inception. We may incur losses for the foreseeable future and may never achieve or maintain profitability</i> within section Item <i style="font-style:italic;">1A. Risk Factors</i> for detailed activities which may drive our continued operating losses and expenses in future periods. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, and the extent to which we may enter into collaborations with third parties for development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development of our current product candidates. Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">the costs and timing of activities of commercialization for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AVMAPKI FAKZYNJA CO-PACK</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> and product candidates for which we expect to receive marketing approval;&#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, and results of our ongoing and potential future clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we acquire or in-license other product candidates and technologies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing, and outcome of regulatory review of our product candidates (including our efforts to seek approval and fund the preparation and filing of regulatory submissions); </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">revenue received from commercial sales of AVMAPKI FAKZYNJA CO-PACK and our product candidates, should any of our product candidates also receive marketing approval; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending intellectual property related claims; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish collaborations or partnerships on favorable terms, if at all.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of milestone payments and royalties pursuant to the Secura APA including timing of such receipt. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements, and through future potential milestones and royalties received pursuant to the Secura APA. To the extent that we raise additional capital through the sale of equity, warrants or securities convertible into common stock, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. To the extent that we enter into certain licensing arrangements, the ownership interest of our existing stockholders may be diluted if we elect to make certain payments in shares of our common stock.  Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONTRACTUAL OBLIGATIONS AND COMMITMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On April 15, 2014, we entered into a lease agreement for approximately 15,197 square feet of office and laboratory space in Needham, Massachusetts. The lease term commenced on April 15, 2014 and was scheduled to expire on September 30, 2019. Effective February 15, 2018, we amended our lease agreement to relocate within the facility to another location consisting of 27,810 square feet of office space (the &#8220;February 2018 Amended Lease Agreement&#8221;). The February 2018 Amended Lease Agreement extended the expiration date of the lease from September 2019 through June 2025. Pursuant to the February 2018 Amended Lease Agreement, the initial annual base rent amount was approximately $0.7 million, which increased during the lease term to $1.1 million for the last 12-month period. Effective November 1, 2024, we amended the February 2018 Amended Lease Agreement to extend the expiration date from June 2025 to June 2026 (the &#8220;November 2024 Amended Lease Agreement&#8221;). The payment terms of the November 2024 Amended Lease Agreement are $1.1 million per annum through the expiration date in June 2026. As of December 31, 2025, the total future lease payments under the agreement are $0.5 million through June 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In the fourth quarter of 2024, we entered into a master services agreement with IQVIA (&#8220;IQVIA Master Services Agreement&#8221;) to leverage IQVIA&#8217;s infrastructure and established commercialization solutions to complement our </span><span style="white-space:pre-wrap;">AVMAPKI  FAKZYNJA CO-PACK </span><span style="background:#ffffff;">launch strategy. In signing the IQVIA Master Service Agreement we committed to spend $60.0 million, of which $48.1 million remains unpaid at December 31, 2025 and is expected to be spent in the next two to three years. As of December 31, 2025, </span>approximately $13.7&#160;million of this commitment is included within vendor financing arrangements, accrued expenses, and accounts payable on the consolidated balance sheets<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">As discussed in</span><i style="font-style:italic;background:#ffffff;"> Note 16. License, collaboration and commercial agreements&#160;</i><span style="background:#ffffff;">to the consolidated financial statements located in this Annual Report on Form 10-K, we are party to several agreements to license intellectual property. The license agreements may require us to pay upfront license fees, ongoing annual license maintenance fees, milestone payments, minimum royalty payments, as well as reimbursement of certain patent costs incurred by the licensors, as applicable. As of December 31, 2025, we do not have any minimum contractual obligations in relation to these agreements because: there were no upfront license fees payable in future periods; no annual license maintenance fees; we cannot estimate if milestone and/or royalty payments will occur in future periods; and patent cost reimbursement costs are perpetual and the agreements are cancelable by us at any time upon prior written notice to the licensor.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TAX LOSS CARRYFORWARDS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">As of December 31, 2025, we had federal and state NOL carryforwards of $460.5 million and $99.5 million, respectively, which are available to reduce future taxable income. We also had federal and state tax credits of $12.3 million and $0.7 million, respectively, which may be used to offset future tax liabilities. The NOL and tax credit carryforwards will expire at various dates through 2044, except for $423.3 million of federal NOL carryforwards which may be carried forward indefinitely. NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the IRC, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of our company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. At December 31, 2025 we recorded a 100% valuation allowance against our NOL and tax credit carryforwards, as we believe it is more likely than not that the tax benefits will not be fully realized. In the future, if we determine that a portion or all of the tax benefits associated with our tax carryforwards will be realized, net income would increase in the period of determination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Based on our analysis under Section 382 of the IRC and similar provisions under state law, we believe that our federal NOL carryforwards, our state NOL carryforwards, our research and development (&#8220;R&amp;D&#8221;) credits and our </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Orphan Drug (&#8220;OD&#8221;) credits will be limited as of December 31, 2025. The portion of federal NOL, state NOL, R&amp;D credits and OD credits that were determined to be limited by Section 382 have been written off as of December 31, 2025. The remaining unused carryforwards remain available for future periods. During 2024, we believe we triggered ownership changes under Section 382 of the IRC and similar provisions under state law. We have approximately $346.4 million of federal NOLs generated prior to such ownership changes inclusive of $309.3 million of federal NOLs <span style="color:#212529;background:#ffffff;">which may be carried forward indefinitely. Since the $309.3 million of federal NOLs may be carried forward indefinitely these have not been written off as of December 31, 2025, but due to the limitations under Section 382, generally we can only use $1.6 million per year against taxable income in the future. </span>Due to our full valuation allowance the write off of NOLs, R&amp;D credits, and OD credits did not have any impact to the statements of operation and comprehensive loss for the 2025 Period and 2024 Period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RECENTLY ADOPTED ACCOUNTING STANDARDS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Refer to<i style="font-style:italic;"> Note 2. Significant accounting policies</i> to our consolidated financial statements located in this Annual Report on Form&#160;10-K for recently adopted accounting standards. </p><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:11pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">7A.  Quantitative and Qualitative Disclosures About Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are exposed to market risk related to changes in interest rates. We had cash and cash equivalents investments of $205.0 million as of December 31, 2025, consisting of cash and U.S. Government money market funds. <span style="background:#ffffff;">Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because most of our investments are interest bearing. Our available for sale securities are subject to interest rate risk and will fall in value if market interest rates increase. Due to the short-term duration of most of our investment portfolio and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We enter into contracts with CROs and contract manufacturers globally that may be denominated in foreign currencies. We may be subject to fluctuations in foreign currency rates in connection with these agreements. Transactions denominated in currencies other than the functional currency are recorded based on exchange rates at the time such transactions arise. As of December 31, 2025, an immaterial amount of our total liabilities was denominated in currencies other than the functional currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">As of December 31, 2025, we have borrowed $75.0 million under the Note Purchase Agreement.&#160;The Notes under the Note Purchase Agreement&#160;<span style="background:#ffffff;">bear interest at a floating rate equal to the sum of (i)&#160;the greater of the Term SOFR (as defined in the Note Purchase Agreement) and 4.29%, and (ii)&#160;3.71%, which is subject to an overall floor and cap</span>. Changes in interest rates can cause interest charges to fluctuate under the Note Purchase Agreement. A 10% increase in current interest rates would have resulted in an immaterial increase in the amount of cash interest expense for the year ended December 31, 2025 due to the overall interest rate floor and cap.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><a id="_34b413f9_2675_4cfd_9aad_14a3166a35d3"></a><a id="Item8ConsolidatedFinancialStatementsandS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">8.  Consolidated Financial Statements and Supplementary Data</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our consolidated financial statements, together with the report of our independent registered public accounting firm (e.g., Report of Independent Registered Public Accounting Firm (PCAOB ID: <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:AuditorFirmId" id="Narr_VLVZYCM5jEOpph7iiGFkcA">42</ix:nonNumeric>)), appear on pages&#160;F-1 through F-49 of this Annual Report on Form&#160;10-K.</p><a id="_e7667792_79b7_4e16_9571_f5f01dc2917e"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">9.  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_e2edce38_6c56_466b_89ae_2d6a595c611f"></a><a id="Item9AControlsandProcedures_391706"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">9A.  Controls and Procedures</b></p><a id="_Hlk505875331"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Limitations on Effectiveness of Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In designing and evaluating our disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our Chief Executive Officer and our Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Management&#8217;s Report on Internal Control Over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules&#160;13a-15(f) and 15d-15(f) under the Exchange Act as the process designed by, or under the supervision of, our Chief Executive Officer and our Chief Financial Officer and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of our financial statements for external purposes in accordance with U.S. GAAP, and includes those policies and procedures that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures are being made only in accordance with the authorizations of management and directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework provided in <i style="font-style:italic;">Internal Control&#8212;Integrated Framework</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework). Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">This Annual Report on Form 10-K does not include an&#160;attestation&#160;report&#160;of our registered public accounting firm regarding internal control over financial reporting.&#160;Management&#8217;s report was not subject to attestation by the Company&#8217;s independent registered public accounting firm, as allowed by the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control Over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There has been no change in our internal control over financial reporting during the fiscal quarter ended December 31, 2025, that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</p><a id="_5e04f4db_dec1_40cc_a753_58abf99207fe"></a><a id="Item9BOtherInformation_30350"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">9B.  Other Information</b></p><a id="_Hlk158823052"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Trading Plans of Our Directors and Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"><span style="font-size:10pt;">During the fiscal quarter ended December 31, 2025, </span><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_9WuRZ5oiCEytQ-4llKR_8g" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_AVgM4ZKXFEWKph9EyYIMuQ"><span style="font-size:10pt;">n</span></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_9WuRZ5oiCEytQ-4llKR_8g" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_-DQSGDa_6EeuJQfpuyJPYA"><span style="font-size:10pt;">o</span></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_9WuRZ5oiCEytQ-4llKR_8g" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_bx2Q_gm7HUSCmYB5iVTJ3A"><span style="font-size:10pt;">n</span></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_9WuRZ5oiCEytQ-4llKR_8g" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_rgjSmPUeM0yx4NL5SftwJg"><span style="font-size:10pt;">e</span></ix:nonNumeric><span style="font-size:10pt;"> of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) entered into, modified (as to amount, price or timing of trades) or terminated (i) contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information or (ii) non-Rule 10b5-1 trading arrangements (as defined in Item 408(c) of Regulation S-K)</span><span style="font-size:10pt;">.</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">9B.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Trading Plans of Our Directors and Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the fiscal quarter ended December 31, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) entered into, modified (as to amount, price or timing of trades) or terminated (i) contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information or (ii) non-Rule 10b5-1 trading arrangements (as defined in Item 408(c) of Regulation S-K).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note Purchase Agreement Amendment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information set forth below is included for the purpose of providing disclosure under &#8220;Item 1.01 &#8212; Entry into a Material Definitive Agreement,&#8221; and &#8220;Item 2.03&#160;&#8212; Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant&#8221; of Form 8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On March 2, 2026, Verastem, Inc. (the &#8220;Company&#8221;) amended its Note Purchase Agreement, dated January 13, 2025 (as amended, the &#8220;Note Purchase Agreement&#8221;) with RGCM SA LLC, as Purchaser Agent, Oberland Capital Management LLC and certain funds managed by Oberland Capital Management LLC, as purchasers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The amendment extends the outside date for the period during which the Company may draw the Second Purchase (as defined in the Note Purchase Agreement) from December 31, 2025 to June 30, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A copy of the amendment is attached as Exhibit 10.50 to this Annual Report on Form 10-K and is incorporated herein by reference. The forgoing summary of the amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the amendment and the Note Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><a id="_788b9259_ec31_43b6_a78d_373fbf00777b"></a><a id="Item9CDisclosureREgardingForeignJurisdic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">9C.  Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><a id="_a9483033_6a18_4b9f_89e4_0fd91e1ac3e5"></a><a id="PARTIII_41607"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART III</b></p><a id="ITEM10DIRECTORSEXECUTIVEOFFICERS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">10.  DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Information regarding our directors, including the audit committee and audit committee financial experts, and executive officers, and compliance with Section 16(a) of the Exchange Act will be included in our 2026 Proxy Statement and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have adopted a Code of Business Conduct and Ethics for all of our directors, officers, and employees as required by Nasdaq governance rules and as defined by applicable SEC rules. Stockholders may locate a copy of our Code of Business Conduct and Ethics on our website at www.verastem.com or request a copy without charge from:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Verastem, Inc. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Attention: Investor Relations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">117 Kendrick St., Suite 500</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Needham, MA 02494</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We will post to our website any amendments to the Code of Business Conduct and Ethics and any waivers that are required to be disclosed by the rules of either the SEC or Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="Narr_7bmOI-zq8k6yFCWGM7R-0Q"><i style="font-style:italic;">Insider Trading Policies and Procedures</i></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">We have adopted an insider trading policy that governs the purchase, sale, and other dispositions of our securities by our directors, officers and employees, and other covered persons. The insider trading policy also applies to transactions by the Company in its securities. We believe that the insider trading policy is reasonably designed to promote compliance with insider trading laws, rules and regulations and the listing standards of Nasdaq. &#160;A copy of our Insider Trading Policy is filed with this Annual Report on Form 10-K as Exhibit 19.1.</p><a id="_53b4ff3d_ce83_4447_a471_09d97a5bde5f"></a><a id="ITEM11EXECUTIVECOMPENSATION_242284"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">11.  EXECUTIVE COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item 11 of Form 10-K regarding executive compensation will be included in our 2026 Proxy Statement and is incorporated herein by reference.</p><a id="_e1a73e78_2a75_441a_88eb_30ecd9058ef5"></a><a id="ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The information required by this Item 12 of Form 10-K regarding security ownership of certain beneficial owners and management will be included in our 2026 Proxy Statement and is incorporated herein by reference.</p><a id="_34c56b83_32d3_4e23_a4e1_d8988e5f2dec"></a><a id="ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item 13 of Form 10-K regarding certain relationships and related transactions and director independence will be included in our 2026 Proxy Statement and is incorporated herein by reference.</p><a id="_f56d6518_7681_4481_83c3_01743f9070fe"></a><a id="ITEM14PRINCIPALACCOUNTANTFEESANDSERVICES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item 14 of Form 10-K regarding principal accountant fees and services will be included in our 2026 Proxy Statement and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_292bc6fd_26c6_4f5f_b027_218936b58e4d"></a><a id="PARTIV_998053"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART IV</b></p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">15.  Exhibits and Financial Statement Schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(a) The following documents are filed as part of this Annual Report on Form 10-K:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Consolidated Financial Statements</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">See Part&#160;II, Item&#160;8 for the Financial Statements required to be included in this Annual Report on Form&#160;10-K.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Consolidated Financial Statement Schedules</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All financial statement schedules are omitted because they are not applicable or the required information is included in the consolidated financial statements or notes thereto.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Exhibits</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Those exhibits required to be filed by Item&#160;601 of Regulation&#160;S-K are listed in the Exhibit Index immediately preceding the exhibits hereto and such listing is incorporated herein by reference.</p><a id="_cp_text_1_613"></a><a id="_3d731359_ead5_493d_ae97_11b55ff7ba7e"></a><a id="Item16Form10KSummary"></a><a id="_cp_text_1_614"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">16.  Form 10-K Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d1241019_1ad8_4beb_b76f_fa7ef0d6c830"></a><a id="EXHIBITINDEX_345974"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT INDEX</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-3.3707275%;padding-left:3.6pt;padding-right:3.6pt;width:106.74%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:bottom;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:86.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:3.5pt;"><td colspan="2" style="vertical-align:bottom;width:9.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">number</b></p></td><td style="vertical-align:bottom;width:3.62%;background:#ffffff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:86.47%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Description&#160;of&#160;exhibit</b></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837019001852/vstm-20181231ex3015107bc.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Annual Report on Form 10-K filed by the Registrant on March 12, 2019)</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="white-space:pre-wrap;"> 3.2</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000155837019001852/vstm-20181231ex3023a9464.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Annual Report on Form 10-K filed by the Registrant on March 12, 2019)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000104746912000187/a2206820zex-3_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit&#160;3.4 to Amendment No.&#160;3 to the Registration Statement on Form&#160;S-1 (File No.&#160;333-177677) filed by the Registrant on January&#160;13, 2012)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465920064756/tm2020393d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Certificate of Amendment to the Restated Certificate of Incorporation of Verastem, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on May 21, 2020)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">3.5</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465922115103/tm2229823d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on November 7, 2022)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">3.6</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465923006382/tm234327d2_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on January 25, 2023)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">3.7</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465923066363/tm2317400d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Restated Certificate of Incorporation of Verastem, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on May 31, 2023)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000104746912000187/a2206820zex-4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen certificate evidencing shares of common stock (incorporated by reference to Exhibit&#160;4.1 to Amendment No.&#160;3 to the Registration Statement on Form&#160;S-1 (File No.&#160;333-177677) filed by the Registrant on January&#160;13, 2012)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">4.2*</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="vstm-20251231xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">D</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">escription of Securities</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465924082526/tm2413643d5_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant to Purchase Stock (incorporated by reference to Exhibit 4.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on July 25, 2024).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:2.6pt;"><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">4.4</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465924082526/tm2413643d5_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant to Purchase Stock (incorporated by reference to Exhibit 4.2 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on July 25, 2024).</span></a></p></td></tr><tr style="height:2.6pt;"><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:2.6pt;"><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465925039098/tm2513177d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated April 25, 2025, by and among Verastem, Inc. and the investors party thereto (incorporated by reference to Exhibit 10.2 to Form 8-K filed by the Registrant with the Securities and Exchange Commission on April 25, 2025)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465925039098/tm2513177d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 10.3 to Form 8-K filed by the Registrant with the Securities and Exchange Commission on April 25, 2025)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465925112946/tm2531440d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed by the Registrant with the Securities and Exchange Commission on November 17, 2025)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.1#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000104746912000187/a2206820zex-10_3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Incentive Stock Option Agreement under 2012 Incentive Plan (incorporated by reference to Exhibit&#160;10.3 to Amendment No.&#160;3 to the Registration Statement on Form&#160;S-1 (File No.&#160;333-177677) filed by the Registrant on January&#160;13, 2012)</span></a></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-3.3707275%;padding-left:3.6pt;padding-right:3.6pt;width:106.74%;"><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.2#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000155837018001953/vstm-20171231ex100432cd2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Incentive Stock Option Agreement under Amended and Restated 2012 Incentive Plan (incorporated by reference to Exhibit 10.4 of the Registrant&#8217;s Annual Report on Form 10-K filed by the Registrant on March 13, 2018)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.3#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000104746912000187/a2206820zex-10_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Nonstatutory Stock Option Agreement under 2012 Incentive Plan (incorporated by reference to Exhibit&#160;10.4 to Amendment No.&#160;3 to the Registration Statement on Form&#160;S-1 (File No.&#160;333-177677) filed by the Registrant on January&#160;13, 2012)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.4#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000155837018001953/vstm-20171231ex100666b20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Nonstatutory Stock Option Agreement under Amended and Restated 2012 Incentive Plan (incorporated by reference to Exhibit 10.6 of the Registrant&#8217;s Annual Report on Form 10-K filed by the Registrant on March 13, 2018)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.5#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000104746912000187/a2206820zex-10_16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Agreement under 2012 Incentive Plan (incorporated by reference to Exhibit&#160;10.16 to Amendment No.&#160;3 to the Registration Statement on Form&#160;S-1 (File No.&#160;333-177677) filed by the Registrant on January&#160;13, 2012)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.6#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000104746913003414/a2213456zex-10_25.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Form of Restricted Stock Unit Agreement under 2012 Incentive Plan (incorporated by reference to Exhibit&#160;10.25 to the Annual Report on Form&#160;10-K filed by the Registrant on March&#160;26, 2013)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.7#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000155837018001953/vstm-20171231ex1009fef29.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Agreement under Amended and Restated 2012 Incentive Plan </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(incorporated by reference to Exhibit 10.9 of the Registrant&#8217;s Annual Report on Form 10-K filed by the Registrant on March 13, 2018)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.8#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000155837018001953/vstm-20171231ex1011c401c.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Inducement Award Nonstatutory Stock Option Agreement (incorporated by reference to Exhibit 10.11 of the Registrant&#8217;s Annual Report on Form 10-K filed by the Registrant on March 13, 2018)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.9#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000155837018008809/vstm-20180930ex4347853a9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Inducement Award Restricted Stock Unit Agreement (incorporated by reference to Exhibit 4.3 of the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, filed by the Registrant with the Securities and Exchange Commission on November 7, 2018)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.10#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000155837017006281/vstm-20170630ex101d4f3ee.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement between the Registrant and each director and executive officer (incorporated by reference to Exhibit&#160;10.1 to the Quarterly Report on Form&#160;10-Q filed by the Registrant on August 8, 2017)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.11</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000110465914028573/a14-10672_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement, dated April&#160;15, 2014, between the Registrant and Intercontinental Fund&#160;III 117 Kendrick Street&#160;LLC (incorporated by reference to Exhibit&#160;10.1 to the Current Report on Form&#160;8-K filed by the Registrant on April&#160;18, 2014)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.12</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000155837018003896/vstm-20180331ex1015acc8d.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment of Lease Agreement, dated February 15, 2018, between the Registrant and 117 Kendrick DE, LLC, as successor-in-interest to Intercontinental Fund III 117 Kendrick Street, LLC (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by the Registrant on May 3, 2018)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.13</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837025003372/vstm-20241231xex10d13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment of Lease Agreement, dated November 1, 2024, between the Registrant and 117 Kendrick DE, LLC (incorporated by reference to Exhibit 10.13 to the Annual Report on Form 10-K filed by the Registrant on March 20, 2025)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.14#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465923087888/tm2322911d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Employment Agreement, dated August 2, 2023, by and between Verastem, Inc. and Daniel W. Paterson (incorporated by reference to Exhibit 10.14 on Form 10-K filed by the Registrant with the Securities and Exchange Commission on March 20, 2025).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.15&#8224;</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000104746912008189/a2210644zex-10_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated July&#160;11, 2012, by and between the Registrant and Pfizer&#160;Inc. (incorporated by reference to Exhibit&#160;10.2 to the Quarterly Report on Form&#160;10-Q filed by the Registrant on August&#160;13, 2012)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.16&#8224;</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1526119/000104746914001894/a2218355zex-10_31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Agreement, dated December&#160;7, 2012, by and between the Registrant and Pfizer&#160;Inc. (incorporated by reference to Exhibit&#160;10.31 to the Annual Report on Form&#160;10-K filed by the Registrant on March 6, 2014)</span></a></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-3.3707275%;padding-left:3.6pt;padding-right:3.6pt;width:106.74%;"><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.17&#8224;</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837020005727/vstm-20200331ex1013168a7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement for CKI27, dated January 7, 2020, between Verastem, Inc. and Chugai Pharmaceutical Co., Ltd. </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">(incorporated by reference to Exhibit 10.1 to the</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> Quarterly Report on Form 10-Q filed by the Registrant on May 7, 2020)</span></a><span style="color:#0000ff;text-decoration-line:none;"><br/></span><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.18&#8224;</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837025003372/vstm-20241231xex10d18.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to License Agreement for CKI27, dated April 19, 2020 between Verastem, Inc. and Chugai Pharmaceutical, Co. Ltd. (incorporated by reference to Exhibit 10.18 on Form 10-K filed by the Registrant with the Securities and Exchange Commission on March 20, 2025).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.19&#8224;</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837025003372/vstm-20241231xex10d19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to License Agreement for CKI27, dated August 12, 2021, between Verastem, Inc. and Chugai Pharmaceutical Co. Ltd. (incorporated by reference to Exhibit 10.19 on Form 10-K filed by the Registrant with the Securities and Exchange Commission on March 20, 2025).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.20&#8224;</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837025003372/vstm-20241231xex10d20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to License Agreement for CKI27, dated May 10, 2023, between Verastem, Inc. and Chugai Pharmaceutical Co. Ltd. (incorporated by reference to Exhibit 10.20 on Form 10-K filed by the Registrant with the Securities and Exchange Commission on March 20, 2025).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.21#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837020005727/vstm-20200331ex1022493f2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Agreement under the 2012 Incentive Plan </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">(incorporated by reference to Exhibit 10.2 to the</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> Quarterly Report on Form 10-Q filed by the Registrant on May 7, 2020)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.22#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837020005727/vstm-20200331ex103628cce.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Inducement Restricted Stock Unit Agreement </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">(incorporated by reference to Exhibit 10.3 to the</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> Quarterly Report on Form 10-Q filed by the Registrant on May 7, 2020)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.23#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837020005727/vstm-20200331ex104061e20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Incentive Stock Option Agreement under the 2012 Incentive Plan </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">(incorporated by reference to Exhibit 10.4 to the</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> Quarterly Report on Form 10-Q filed by the Registrant on May 7, 2020)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.24#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837020005727/vstm-20200331ex105d30e8f.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Nonstatutory Stock Option Agreement under the 2012 Incentive Plan </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">(incorporated by reference to Exhibit 10.5 to the</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> Quarterly Report on Form 10-Q filed by the Registrant on May 7, 2020)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.4pt;"><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.25#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837020005727/vstm-20200331ex1066b7869.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Inducement Nonstatutory Stock Option Agreement </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">(incorporated by reference to Exhibit 10.6 to the</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> Quarterly Report on Form 10-Q filed by the Registrant on May 7, 2020)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.26#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837021009812/vstm-20210630xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Incentive Stock Option Agreement under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q filed by the Registrant on August 2, 2021)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.27#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837021009812/vstm-20210630xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Form of Nonstatutory Stock Option Agreement (Employees) under the 2021 Equity Incentive Plan</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q filed by the Registrant on August 2, 2021)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.28#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837021009812/vstm-20210630xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Nonstatutory Stock Option Agreement (Non-Employees) under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q filed by the Registrant on August 2, 2021)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:6.75pt;"><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.29#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837021009812/vstm-20210630xex10d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Agreement under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Quarterly Report on Form 10-Q filed by the Registrant on August 2, 2021)</span></a></p></td></tr><tr style="height:6.75pt;"><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:6.75pt;"><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.30#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837021009812/vstm-20210630xex10d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Inducement Nonstatutory Stock Option Agreement (incorporated by reference to Exhibit 10.6 to the Quarterly Report on Form 10-Q filed by the Registrant on August 2, 2021)</span></a></p></td></tr><tr style="height:6.75pt;"><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:6.75pt;"><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.31#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837021009812/vstm-20210630xex10d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Form of Inducement Restricted Stock Unit Agreement</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> (incorporated by reference to Exhibit 10.7 to the Quarterly Report on Form 10-Q filed by the Registrant on August 2, 2021)</span></a></p></td></tr><tr style="height:6.75pt;"><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:6.75pt;"><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.32<span style="background:#ffffff;">&#8224;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837020013373/vstm-20200930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Asset Purchase Agreement by and between Secura Bio, Inc. and Verastem, Inc. </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">(incorporated by reference to Exhibit 10.1 to the</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> Quarterly Report on Form 10-Q filed by the Registrant on November 9, 2020)</span></a></p></td></tr><tr style="height:6.75pt;"><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-3.3707275%;padding-left:3.6pt;padding-right:3.6pt;width:106.74%;"><tr style="height:6.75pt;"><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.33</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837022004433/vstm-20220323xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Loan and Security Agreement, dated as of March 25, 2022, among Verastem, Inc., as borrower, Oxford Finance LLC, as collateral agent and a lender, and Oxford Finance Credit Fund III LP, as a lender (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K, filed by the Registrant with the Securities and Exchange Commission on March 27, 2022)</span></a></p></td></tr><tr style="height:6.75pt;"><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:6.75pt;"><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.34#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:'Times';" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465923112203/tm2329255d1_ex10-1.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Employment Agreement, dated October 24, 2023 by and between Verastem, Inc. and Daniel Calkins (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on October 27, 2023).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">10.35#</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465925004918/tm253996d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement dated January 14, 2025 by and between Verastem, Inc. and Matthew Ros. (incorporated by reference to Exhibit 10.1 to Form 8-K filed by the Registrant with the Securities and Exchange Commission on January 21, 2025)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.36</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465924002227/tm242257d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Loan and Security Agreement, dated as of January 4, 2024, among Verastem, Inc., as borrower, Oxford Finance LLC, as collateral agent and a lender, and the other lenders party thereto. (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on January 8, 2024)</span></a></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.37#</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837023013946/vstm-20230630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2018 Employee Stock Purchase Plan. (incorporated by reference to Exhibit 10.1 to Form 10-Q filed by the Registrant with the Securities and Exchange Commission on August 8, 2023)</span></a></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.38#</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837023013946/vstm-20230630xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated 2012 Incentive Plan</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">. (incorporated by reference to Exhibit 10.2 to Form 10-Q by the Registrant with the Securities and Exchange Commission on August 8, 2023)</span></a></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times';visibility:hidden;background:#ffffff;">&#8203;</span></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.39#</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837023013946/vstm-20230630xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2021 Equity Incentive Plan. (incorporated by reference to Exhibit 10.3 to Form 10-Q by the Registrant with the Securities and Exchange Commission on August 8, 2023)</span></a></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.40</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465922115103/tm2229823d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exchange Agreement, dated November 4, 2022, by and among Verastem, Inc. and B</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">iotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP and MSI BVF SPV, LLC (incorporated by reference to Exhibit 10.1 to for the form 8-K filed by the Registrant with the Securities and Exchange Commission on November 7, 2022)</span></a></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.41</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837024011599/vstm-20240630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2021 Equity Incentive Plan. (incorporated by reference to Exhibit 10.1 to Form 10-Q by the Registrant with the Securities and Exchange Commission on August 8, 2024)</span></a></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.42</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465925002859/tm253090d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Note Purchase Agreement, dated as of January 13 2025, by and among Verastem, Inc., RGCM SA LLC, Oberland Capital Management LLC and certain funds managed by Oberland Capital Management LLC. (incorporated by reference to Exhibit 10.1 to Form 8-K filed by the Registrant with the Securities and Exchange Commission on January 13, 2025)</span></a></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.43</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465925002859/tm253090d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Stock Purchase Agreement, dated as of January 13, 2025, among Verastem, Inc. and the investors party thereto. (incorporated by reference to Exhibit 10.2 to Form 8-K filed by the Registrant with the Securities and Exchange Commission on January 13, 2025)</span></a></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.44&#8224;</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837025003372/vstm-20241231xex10d44.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration and Option Agreement by and between Verastem, Inc. and GenFleet Therapeutics (Shanghai), Inc. dated as of August 24, 2023. (incorporated by reference to Exhibit 10.44 on Form 10-K filed by the Registrant with the Securities and Exchange Commission on March 20, 2025).</span></a></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.45#</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837025003372/vstm-20241231xex10d45.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Agreement under the Amended and Restated 2021 Equity Incentive Plan. (incorporated by reference to Exhibit 10.45 on Form 10-K filed by the Registrant with the Securities and Exchange Commission on March 20, 2025).</span></a></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.46&#8224;</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837025010757/vstm-20250630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to the License Agreement, dated April 3, 2025, by and between the Registrant and Pfizer Inc. (incorporated by reference to Exhibit 10.1 to Form 10-Q filed by the Registrant with the Securities and Exchange Commission on August 7, 2025)</span></a></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-3.3707275%;padding-left:3.6pt;padding-right:3.6pt;width:106.74%;"><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.47&#8224;</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465925039098/tm2513177d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Securities Purchase Agreement, dated April 25, 2025, by and among Verastem, Inc. and the investors party thereto (incorporated by reference to Exhibit 10.1 to Form 8-K filed by the Registrant with the Securities and Exchange Commission on April 25, 2025)</span></a></p></td></tr><tr style="height:2.6pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:2.6pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.48#</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000110465925123295/tm2533463d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Separation Agreement dated December 19, 2025 by and between Verastem, Inc. and Matthew Ros</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> (incorporated by reference to Exhibit 10.1 to Form 8-K filed by the Registrant with the Securities and Exchange Commission on December 19, 2025)</span></a></p></td></tr><tr style="height:2.6pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:2.6pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.49*</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="vstm-20251231xex10d49.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment Number One to Note Purchase Agreement, dated as of October 31, 2025 by and among Verastem, Inc., RGCM SA LLC, Oberland Capital Management LLC and certain funds managed by Oberland Capital Management LLC.</span></a></p></td></tr><tr style="height:2.6pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:2.6pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.50*</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="vstm-20251231xex10d50.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment Number Two to Note Purchase Agreement, dated as of March 2, 2026 by and among Verastem, Inc., RGCM SA LLC, Oberland Capital Management LLC and certain funds managed by Oberland Capital Management LLC.</span></a></p></td></tr><tr style="height:2.6pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:2.6pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">19.1</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837025003372/vstm-20241231xex19d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Insider Trading Policy (incorporated by reference to Exhibit 19.1 on Form 10-K filed by the Registrant with the Securities and Exchange Commission on March 20, 2025).</span></a> </p></td></tr><tr style="height:2.6pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:2.6pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21.1*</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="vstm-20251231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of the Registrant</span></a></p></td></tr><tr style="height:2.6pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">23.1*</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="vstm-20251231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Ernst&#160;&amp; Young&#160;LLP</span></a></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31.1*</p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="vstm-20251231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:9.79%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">31.2*</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="vstm-20251231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial and Accounting Officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">32.1*</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="vstm-20251231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">32.2*</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="vstm-20251231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section&#160;, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">97.1</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1526119/000155837024003250/vstm-20231231xex97d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Policy for Recoupment of Incentive Compensation (incorporated by reference to Exhibit 97.1 to Annual Report on Form 10-K filed by the Registrant with the Securities and Exchange Commission on March 14, 2024)</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">99.1*</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="vstm-20251231xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release issued by Verastem, Inc. on March 4, 2026</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">101.INS*</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document</p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">101.SCH*</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">101.CAL*</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">101.DEF*</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">101.LAB*</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">101.PRE*</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;">104*</p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-3.3707275%;padding-left:3.6pt;padding-right:3.6pt;width:106.74%;"><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:3.5pt;"><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-align:right;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.62%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Filed herewith.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Certain confidential information contained in this exhibit has been omitted because it (i) is not material and (ii) is of the type that the Company treats as private or confidential. Confidential materials omitted will be filed separately with the SEC upon request.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">#</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Management contract or compensatory plan, contract or agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk93332487"></a><a id="_ee33a51a_9216_4f5e_8882_68c69cfe3f1b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="SIGNATURES_102162"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 4th day of March 2026.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:16.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:39.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:43.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">VERASTEM,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:39.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/<span style="font-variant:small-caps;"> Daniel W. Paterson</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Daniel W. Paterson</p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">President and Chief Executive Officer</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:bottom;width:34.61%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:47.29%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:14.42%;margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:bottom;width:34.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:bottom;width:1.92%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:47.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;width:1.74%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">/s/<span style="font-variant:small-caps;"> Daniel W. Paterson</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:34.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">Daniel W. Paterson</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Director <br/>(Principal Executive Officer)</p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">March 4, 2026</p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">/s/ <span style="font-variant:small-caps;">Daniel Calkins</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:34.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">Daniel Calkins</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Chief Financial Officer<br/>(Principal Financial and Accounting officer)</p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">March 4, 2026</p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="font-size:10pt;">/s/ P</span>AUL<span style="font-size:10pt;font-variant:small-caps;"> B</span><span style="font-variant:small-caps;">UNN, </span><span style="font-size:10pt;font-variant:small-caps;">M.D.</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">Paul Bunn, M.D.</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">March 4, 2026</p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">/s/ <span style="font-variant:small-caps;">Robert Gagnon</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:3.3pt;"><td style="vertical-align:middle;width:34.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">Robert Gagnon</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">March 4, 2026</p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">/s/ <span style="font-variant:small-caps;">Anil Kapur</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:3.3pt;"><td style="vertical-align:middle;width:34.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">Anil Kapur</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">March 4, 2026</p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">/s/ <span style="font-variant:small-caps;">Michael Kauffman, M.D.,Ph.D.</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:3.3pt;"><td style="vertical-align:middle;width:34.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">Michael Kauffman, M.D., P<span style="font-variant:small-caps;">h</span>.D.</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">March 4, 2026</p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="font-size:10pt;">/s/ J</span>OHN <span style="font-size:10pt;">J</span>OHNSON</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">John Johnson</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">March 4, 2026</p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="font-size:10pt;">/s/ M</span>ICHELLE<span style="font-size:10pt;"> R</span>OBERTSON</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">Michelle Robertson</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">March 4, 2026</p></td></tr><tr style="height:7.9pt;"><td style="vertical-align:middle;width:34.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.9pt;"><td style="vertical-align:middle;width:34.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">/s/ <span style="font-variant:small-caps;">Eric Rowinsky, M.D.</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">Eric Rowinsky, M.D.</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">March 4, 2026</p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="font-size:10pt;">/s/ B</span>RIAN <span style="font-size:10pt;">S</span>TUGLIK</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">Brian Stuglik</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">March 4, 2026</p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">/s/ <span style="font-variant:small-caps;">Karin Tollefson</span></p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:34.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;">Karin Tollefson</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">March 4, 2026</p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:34.61%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:47.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a8875aa3_f7a8_47e6_b63f_f0087238d5cf"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Verastem,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:3.6pt;table-layout:auto;width:100%;"><tr style="height:0.6pt;"><td style="vertical-align:top;width:93.25%;margin:0pt;padding:0pt;"><div style="height:0.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.74%;margin:0pt;padding:0pt;"><div style="height:0.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:6.1pt;"><td style="vertical-align:top;width:93.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Report_of_Independent_Registered_Public"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:bottom;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr style="height:7.1pt;"><td style="vertical-align:top;width:93.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;">Consolidated Financial Statements</p></td><td style="vertical-align:bottom;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.1pt;"><td style="vertical-align:top;width:93.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_592599"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr style="height:7.1pt;"><td style="vertical-align:top;width:93.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOM"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:bottom;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr style="height:7.1pt;"><td style="vertical-align:top;width:93.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#STOCKHOLDERSDEFICITEQUITY_20715"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity</span></a></p></td><td style="vertical-align:bottom;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr style="height:7.1pt;"><td style="vertical-align:top;width:93.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#Cash_Flows"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr><tr style="height:7.1pt;"><td style="vertical-align:top;width:93.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-8</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5f168aa9_106d_4c28_9cbf_f6494902e149"></a><a id="Report_of_Independent_Registered_Public"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:4.44pt 0pt 0pt 86.3pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To the Stockholders and the Board of Directors of Verastem, Inc.</p><a id="_Hlk191477013"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Verastem, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; (deficit) equity and cash flows for each of the three years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis for Opinion </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Audit Matter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:15.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Verdana';font-size:11pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Verdana';font-size:11pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:81.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:top;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Verdana';font-size:11pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Verdana';font-size:11pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.98%;margin:0pt;padding:0pt;"><p style="font-family:'Verdana';font-size:11pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Accrued and Prepaid Clinical Trial Expense</span></p></td></tr><tr style=""><td style="vertical-align:top;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Verdana';font-size:11pt;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;">Description of the Matter</i></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Verdana';font-size:11pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.98%;margin:0pt;padding:0pt;"><p style="font-family:'Verdana';font-size:11pt;text-align:justify;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">As summarized in Note 7 to the consolidated financial statements, accrued clinical trial expenses were $14.3 million at December 31, 2025, which included the estimated obligation for clinical trial expenses related to contract research organizations, based upon estimates of costs incurred as of December 31, 2025, but not paid as of that date. In addition, total prepaid expenses and other current assets were $7.6 million at December 31, 2025, which included amounts that were paid in advance of services incurred pursuant to the agreements with contract research organizations. As discussed in Note 2 to the consolidated financial statements, the Company </span></p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:top;width:15.51%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:81.98%;margin:0pt;padding:0pt;"><p style="font-family:'Verdana';font-size:11pt;text-align:justify;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">records clinical trial expenses as incurred. The Company&#8217;s determination of costs incurred for certain development activities, such as clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendor on their actual costs incurred or level of effort expended. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid expenses and other current assets or accrued expenses. </span></p></td></tr><tr style=""><td style="vertical-align:top;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Verdana';font-size:11pt;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;">How We Addressed the Matter in Our Audit</i></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Verdana';font-size:11pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.98%;margin:0pt;padding:0pt;"><p style="font-family:'Verdana';font-size:11pt;text-align:justify;margin:0pt 3.5pt 18pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">To test the accrued and prepaid clinical trial expenses related to contract research organizations, our audit procedures included, among others, reviewing agreements with contract research organizations to corroborate key financial and contractual terms, and testing the accuracy and completeness of the underlying data used in the accrued and prepaid expense computations. We also evaluated management&#8217;s estimates of the progress of the clinical trials by making direct inquiries of the Company&#8217;s research and development personnel that oversee the clinical trial activities and confirming information directly with the contract research organizations. In addition, we performed analytical procedures over accrued and prepaid clinical trial expenses by clinical trial, throughout the period subject to audit, and compared subsequent invoices received from contract research organizations to amounts accrued.</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;">/s/ </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:AuditorName" id="Narr_7J1YrTvk3U29ZEv6NLGayg"><span style="color:#333333;">Ernst &amp; Young LLP</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have served as the Company&#8217;s auditor since 2011.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:4.19pt 0pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="dei:AuditorLocation" id="Narr__rcKIJ-UYk2s7pOF4Px-Lg">Boston, Massachusetts</ix:nonNumeric> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:4.34pt 0pt 0pt 0pt;">March 4, 2026</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:4.34pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:4.34pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_52945d9a_9f0d_4901_8609_6ca3f70fe2a0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Verastem,&#160;Inc.</b></p><a id="CONSOLIDATEDBALANCESHEETS_592599"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED BALANCE SHEETS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except per share amounts)</b></p><a id="_9fbc2505_0dc5_4d38_b410_6f70ff88beaf"></a><a id="Tc_86sOFEf0IUKJDw0FbAU_gw_2_2"></a><a id="Tc_rM4at3QdMU-3uFgHkrxk1w_3_2"></a><a id="Tc_wnbMz17RoUyYH_q3YCTRQA_3_5"></a><a id="Tc_XjMBwFEH7Ua8G_jwlkAznA_4_0"></a><a id="Tc_7jnV8J82f0eA47Kv8jZCsA_5_0"></a><a id="Tc_oR9ICIt80EGeQLXbWEzFew_6_0"></a><a id="Tc_UZEBOweocUSKaPF3S3V0Sg_6_2"></a><a id="Tc_Gb4IfxeFm0iy_P9HA6swkg_6_5"></a><a id="Tc_eIzIFdIpikCzGhFLK1X42g_7_0"></a><a id="Tc_pRTQN12EPUucLW15jF3zvw_7_6"></a><a id="Tc_iIyIjuoopEuITQiLXrIRPQ_8_0"></a><a id="Tc_iIgjihw1P0GP6YBpPkCYfQ_8_6"></a><a id="Tc_M81VlN7THUKWtHuQPsxqGg_9_0"></a><a id="Tc_3FOSGgeJek-glHtLO_xDGQ_10_0"></a><a id="Tc_t1KJOhHlhECPCUWDP-TGpg_11_0"></a><a id="Tc_J48O_8_0lkWegexb2U4XwA_12_0"></a><a id="Tc_B6IyO9VfQkCeQZRg9fXVDQ_12_3"></a><a id="Tc_R60srhn7n0iwUx1c5Nah_A_13_0"></a><a id="Tc_Nt1sBYJdCEyRCGw8NaTNsg_14_0"></a><a id="Tc_VQiocjqPV06YsVZ4PTIPsw_14_3"></a><a id="Tc_8NpHEb_gB0WW6IY1_zNyPQ_15_0"></a><a id="Tc_BXbPRTXs5E2tXNcYrVdEag_15_6"></a><a id="Tc_0enzcpT40kOO065CMhKBbg_16_0"></a><a id="Tc_YFTFBu8jdkyuBkoFbpTtpg_17_0"></a><a id="Tc_sSpDg99VKUi6R9e8fK-vnA_17_2"></a><a id="Tc_4KL6iVWbLEmF2_aIdsboRw_17_5"></a><a id="Tc_hlsjlB8dqEy4CxWXun1HYQ_18_0"></a><a id="Tc_Z-gL8QD1LECp1MkDkrY76w_19_0"></a><a id="Tc_F-66xsimjEOKNcYlE7c7fg_20_0"></a><a id="Tc_QRIz3yILW0eau4rUoxSKDQ_20_2"></a><a id="Tc_nv46XM3sc0uC3Z-GtJWg-g_20_5"></a><a id="Tc_jPrQZE-G70WJOnNCm2Y6LA_21_0"></a><a id="Tc_MEnyEP5HhUWRR4e7uf4yXQ_22_0"></a><a id="Tc__BEh-ImiY0iaNvdk7afFyw_22_6"></a><a id="Tc_4_KEqBDEUkm8AwhqnZ3GXQ_23_0"></a><a id="Tc_fvR0T-CQP0G_TgRRCjppNA_24_0"></a><a id="Tc_1ZRel8uQDEyddVXi1x8Hyw_25_0"></a><a id="Tc_BpcrLEP9p0mhIuODbQs_sw_26_0"></a><a id="Tc_oADKy8j1mEqC1xck0a96Sg_27_0"></a><a id="Tc_dNSVakqk5kmNNMmicZXaIA_27_6"></a><a id="Tc_VqyCmKZKCUi-G3cUfzPbEw_28_0"></a><a id="Tc_nMN0vcWe5E6zGCUbtq8t-w_28_3"></a><a id="Tc_n745t4VaEkW2ITVmcut4zw_29_0"></a><a id="Tc_JUvF0I4LQUyt5phXrJ_UKQ_30_0"></a><a id="Tc_ghDK11utnUSrxbWFYe9Yow_31_0"></a><a id="Tc_dlRjvNwyJEySqrQWaLao-w_32_0"></a><a id="Tc_m4RI_Avtnk-ceZgw5tEwDw_33_0"></a><a id="Tc_56QRtYpvu0WagYFEyUrBMg_34_0"></a><a id="Tc_8MIFL-VeVEuOgV6JzqBnVQ_35_0"></a><a id="Tc_WQrYiwSkgUaOA1RC_p6isw_36_0"></a><a id="Tc_SE1-p2ksFEKKJUrSgRxNRA_37_0"></a><a id="Tc_2KamsC4HmE2lbJNsWew1IA_38_0"></a><a id="Tc_wl4AaJHWDk6A9jM99lP5sQ_38_6"></a><a id="Tc_audkXFWDBUmfnLb1aVu4Zg_39_0"></a><a id="Tc_59x9MZbsYUOez1YEdf20Ag_40_0"></a><a id="Tc_hBicAOwmLEeV-E5zx-dbiw_41_0"></a><a id="Tc_SgaoYfrL2ECoc9CUYilzKw_41_2"></a><a id="Tc_6bwgDl-udkSf8ZQ8l3cUOw_41_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_BkuOBXgIKk-lwd-8UStJ-A_6_3">204,990</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_lFF6pNJQdUKUQAri1sGfew_6_6">88,818</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="3" id="Tc_drdGd5IhGkSAZClrwpppkw_7_3">8,813</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_Hcvw8XBzqEaIW_82cJU9ig_8_3">1,833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Grant receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:GrantsReceivableNet" scale="3" id="Tc_9LNC0aUIS0uiXKgzcTHU7w_9_3">200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:GrantsReceivableNet" scale="3" id="Tc_DVBFz1Bx5UWz_dk4fpnT4Q_9_6">200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_0jGb1DcGqUKcOlajNEInUg_10_3">7,577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_Nw9N93BBkkuuPW7tZffm4g_10_6">5,943</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_svwWKDFmn0yv23lBmq8oag_11_3">223,413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_l2AkSoKreE-81GdG10vNsA_11_6">94,961</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_dDPuckJ6PkawP8s3APXx6Q_12_6">32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Right-of-use asset, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_9OxMcI1wUEq6q4-pA0bLNQ_13_3">491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_3Bj25nz6k06tYoaYCk3xPg_13_6">1,405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="Tc_AQV_WPzmNUOi1m8T3PPfwg_14_6">241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_kWm3dXsFFEGQr5xp5IbUkQ_15_3">16,426</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_sGl21-3pCUqLVoyElTvlFA_16_3">6,112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_X0QICoi5-kSWE0n7iio8Pw_16_6">4,899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_N0eWcn-mGEm1V_xhIepSfg_17_3">246,442</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_5IYyhQo5WUSH99lcPbMEsw_17_6">101,538</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities, convertible preferred stock and stockholders&#8217; (deficit) equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_hdsRu5U_iUiqWawXzOABlA_20_3">12,448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_jf2RGVA8_0CiHaxv8bA_BA_20_6">4,026</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses, short-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_O2moTwH3gEKPOpQIPLjzSQ_21_3">53,981</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_Nt8aKqa8IEOHTjSLXZA6Og_21_6">25,952</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Vendor financing arrangement, short-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SupplierFinanceProgramObligationCurrent" scale="3" id="Tc_V0E30_AKAkq3hNRRgl3AmA_22_3">5,304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Lease liability, short-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_pBBraDUXjku-TJERlDfsJA_23_3">535</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_vjLBl1WO3U-eU77DZC4u8A_23_6">995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_MQQZVRgwJ0mYkU0j5ih6uA_24_3">72,268</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_PD7eFwGuSUaLoxoLhHlCYQ_24_6">30,973</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SecuredLongTermDebt" scale="3" id="Tc_vyGFRZ6UOkmuW1MJpW-XSQ_26_3">76,330</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SecuredLongTermDebt" scale="3" id="Tc_LI4gcbiat0qSb3Mwp_yyaA_26_6">40,724</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Vendor financing arrangement, long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SupplierFinanceProgramObligationNoncurrent" scale="3" id="Tc_GgvtH9960EKd8BaQi7bzTw_27_3">5,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Lease liability, long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_Ri2dI3V1P0GM-Ov5XxL1RQ_28_6">535</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="Tc_eQTa6-n_QUSWJwz4gubVVQ_29_3">35,647</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="Tc_ID4Yqv7YrEmQpaR7foHOaw_29_6">58,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_jMj8G9O-5kC51l4zk3gbLQ_30_3">189,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_xVBNLGvIT02fq3opyHNKAw_30_6">130,431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Convertible preferred stock:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8pt;">Series B Convertible Preferred Stock, </span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_seqv11hd7kGtRU21nUUodw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_7StbHx7kyE2UtWJwQkE8lw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_edm9qWQjT0uGo3Ul1o6KTA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_iBFGWlhA_0ioC7HBxtjcLA">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_edm9qWQjT0uGo3Ul1o6KTA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:PreferredStockSharesDesignated" scale="3" id="Narr_Ts9bGgaOWEy3xIu2Il6ICQ">944</ix:nonFraction></span><span style="font-size:8pt;"> shares designated at </span><span style="-sec-ix-hidden:Hidden_ysfm7Z_m_EuRZVq3lctHYw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">December 31, 2025</span></span><span style="font-size:8pt;"> and December 31, 2024, respectively; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_edm9qWQjT0uGo3Ul1o6KTA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="3" id="Narr_gkS04_bz30-LlkfquD8WRA">0</ix:nonFraction></span><span style="color:#ff0000;font-size:8pt;"> </span><span style="font-size:8pt;">shares issued and&#160;</span><span style="-sec-ix-hidden:Hidden_eYsU4ZNv00232JjNRkZteQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> at </span><span style="-sec-ix-hidden:Hidden_qHhHCzO2QUaDq3kIsGr8-A;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">December 31, 2025</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_VjEul_4ydEymIByn90mfmg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">December 31, 2024</span></span><span style="font-size:8pt;">, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_4fkcjdqq20K-eWbfNX-_fQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_sTNsB9LO6EuYGC4ZcgJfMw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_FENbJ6e8LUCyQO0RcrlfFw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_ASYqUqOIj0Sbuksd46TriA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_8jcz-NhL0EGmNv5s7ylAMg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_yeoXWcyuTUajPf_76GboXg">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_FENbJ6e8LUCyQO0RcrlfFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="Narr_M9g8S88UyUStP8iRv-2KsA"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_8jcz-NhL0EGmNv5s7ylAMg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="Narr_VD_j32MToEOwAIPyCr_G3w">5,000</ix:nonFraction></ix:nonFraction> shares authorized:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Series A Convertible Preferred Stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_1iNwjL1LvUC8CJz-JY9pGg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_2qB-kSZqmUu48zr4pwEZFQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_s_eRJ_IM-EC5I5guhHo3NA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_NF_6AovDFkaZLuTgHrWz7g">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_s_eRJ_IM-EC5I5guhHo3NA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_SJN-SONdx0KJpjyXttoLkw">0</ix:nonFraction> shares and <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_1iNwjL1LvUC8CJz-JY9pGg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_Mp-9XYds-UyUgW7aT2ezlQ">1,000</ix:nonFraction> shares designated at December 31, 2025 and December 31, 2024, respectively, <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_s_eRJ_IM-EC5I5guhHo3NA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_Z6iWZjBWg0-Uxh0ZYsDLlg"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_s_eRJ_IM-EC5I5guhHo3NA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_wtOHY_8Ji0m1I-CSjGilkg">0</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_1iNwjL1LvUC8CJz-JY9pGg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_ly308anebUGzAkOAEMAuVA"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_1iNwjL1LvUC8CJz-JY9pGg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_seRc-c_CPUG4GI91ah759w">1,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2025 and at December 31, 2024, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_QmHIF05vtkW-Lf37Rt1dAg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_YfginUZE2EOloL1Am_w-Fw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8pt;">Common stock, </span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_MQs_U7zWH0SPHc2ddF9u5A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_0iC9oiKnHEiidhctatDIuA">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="Narr_4oVthLFd6EGUV7B60uoRIg"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="Narr_tV8BpZRUs02HQ3SdJV8q8w">300,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> shares authorized, </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="Narr_4qVoqmVo60e0gztXQ4RNsA">77,740</ix:nonFraction></span><span style="font-size:8pt;"> and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="Narr_KWtryN6_VEOt9XfUbOxDMw">44,784</ix:nonFraction></span><span style="font-size:8pt;"> shares </span><span style="-sec-ix-hidden:Hidden_f0PNnUvzCUyNJXe3HQWfrg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;">&#160;and </span><span style="-sec-ix-hidden:Hidden_A0c_18zVRUq0bhgTAuwcJA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> at December 31, 2025 and December 31, 2024, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_QhpXh2jGC0K9bYjd3So1qA_36_3">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_BMh7B1A6TEa8_oqlDglLiw_36_6">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_iPx4944-7U2ocV2KStqzzA_37_3">1,216,958</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_eec50A0dBUyXpXc19bHGtA_37_6">926,630</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Accumulated other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_pblSO3hnWkCkIyk5VJm4lQ_38_3">5,229</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_cQoHA-KBH0uAZlCy0TMrvQ_39_3">1,164,998</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_hJPfC4o_sUSFKn91fQUg5w_39_6">955,527</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total stockholders&#8217; equity (deficit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2Or6VaKd_E6kv3JDY9dv_A_40_3">57,197</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_PyX1OIld9kyD8LOvmHO1-g_40_6">28,893</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total liabilities, convertible preferred stock and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_9kIzj_0rKkeSGAbgS4aXLQ_41_3">246,442</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_vhTRI6TAFUezdF2ehpi-lA_41_6">101,538</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 12pt 0pt;">See accompanying notes to the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_94303802_f403_44bb_99b7_5275fb1f2d42"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Verastem,&#160;Inc.</b></p><a id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOM"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except per share amounts)</b></p><a id="_361931ca_ec22_44e4_b4a9_a73e17cefc01"></a><a id="_239d107b_dd23_4700_b1c9_6b1d4fa9545a"></a><a id="Tc_adnmuyLhPEGjUMJCaKuogw_1_3"></a><a id="Tc_3goBvfmH3kWluKoWqVq8gg_2_3"></a><a id="Tc_31awb9nWjE6qSehz0rrj3w_2_6"></a><a id="Tc_L26KEufOYkyPEP_6zXm8bg_2_9"></a><a id="Tc_grGGOCe5tkiSV3BdClDqsw_3_0"></a><a id="Tc_2Nnalz6v4ECdISBgKjS12A_4_0"></a><a id="Tc_LVGjUNyDCEqGjcagvNDjdQ_4_3"></a><a id="Tc_HQTxRgjp60C3HFFJM9y6rw_4_6"></a><a id="Tc_XJnKYixFhUyoA-zIQJuVOg_4_7"></a><a id="Tc_CSJRrTbCiEygi2mmJPZStA_4_9"></a><a id="Tc_rgnV_4DKYUqEovF9KZOWeg_4_10"></a><a id="Tc_cIqNZjr7Ak69Q7_fvpRbrA_5_0"></a><a id="Tc_PY9Rpthf3kKkSU5TLoTalA_5_4"></a><a id="Tc_vXHHVubT5kC9Rg10ixFNZA_5_10"></a><a id="Tc_JCjmiJpQPEehvOaKqtr7YQ_6_0"></a><a id="Tc_a0mWSUtgl0OUw4erzlj87A_6_10"></a><a id="Tc_CnM7CsZG6U-WyRoO9BRx-Q_7_0"></a><a id="Tc_9lTLoYO-IkeCNhV8rF5hvA_8_0"></a><a id="Tc_Ne-rGmWjuEyTncQoBfVjww_8_7"></a><a id="Tc_hLmRrAwDhUiTYUsgbItA8Q_8_10"></a><a id="Tc_ytpLuQagyUKfg1rKnEhsYA_9_0"></a><a id="Tc_qrKpyay-d0aGjVHu-Yk_Zw_9_7"></a><a id="Tc_m5p6PjESGUCBBn6OfBz5Vg_9_10"></a><a id="Tc_2UPhj-A5H0ihyNxSDrac5A_10_0"></a><a id="Tc_wAuSwbaAF0KTLiLLd8PnVw_11_0"></a><a id="Tc_Lk7uASTNK0Wl_dSjYCDzNw_12_0"></a><a id="Tc_tmhNSg5uzUO2T1qE2qVGGg_13_0"></a><a id="Tc_klKGsZjmDUCEeWBkUW1tBQ_14_0"></a><a id="Tc_FHSxsGvFwECJou1ka14chA_15_0"></a><a id="Tc_i-loSDUNkUmyR3mD9GlzIA_16_0"></a><a id="Tc_2sLaVl5ao0qpzbtxRQ0UQg_17_0"></a><a id="Tc_KChh53fmvEayyvVHH7NDQw_17_7"></a><a id="Tc_-UtswwenBU65YHqFKkQ-bw_17_10"></a><a id="Tc_4olNRVFhJky_dJO83hIZfA_18_0"></a><a id="Tc_E2ynvGoN1EiGOEq4fed1aw_18_4"></a><a id="Tc_5cHY3Kuvc0e5x0iJKSFYHQ_19_0"></a><a id="Tc_EHC54s71sE2oqBjKMqwyEw_19_10"></a><a id="Tc_hrs__tJWI0q10hSCLutF5A_20_0"></a><a id="Tc_5cvv5KJA2U2BSmsNYNe8pQ_20_7"></a><a id="Tc_xVwtBAYMqkqiSWHrfHPImQ_20_10"></a><a id="Tc_AY1OeFXJi0GXIVO68X1sOQ_21_0"></a><a id="Tc_ga7hm3YsKEyJYnSlozVTJw_22_0"></a><a id="Tc_9yhku3pA802IE2GfCJRq3A_22_4"></a><a id="Tc_KlppdU5-oUK9i0s_CS9GEQ_22_10"></a><a id="Tc_t-MLofZEPkGsj5iWxgDJYg_23_0"></a><a id="Tc_MjOELxk1PEyP2tcwtmBJuw_23_3"></a><a id="Tc_lpqsnHWsLkOh_Hw7HMmMUQ_23_6"></a><a id="Tc_5vCJcjBKBkeRGZcgoLFgAA_23_9"></a><a id="Tc_reczQBf7NkuITkOSQn1ZRw_24_0"></a><a id="Tc_Y2TCWYMjRUWarKr1CWTq7A_24_3"></a><a id="Tc_0Uh1PAm7wEiPZO1WYk2zTw_24_6"></a><a id="Tc_aQrG5P6vkUuGAYKVphxprQ_24_9"></a><a id="Tc_gby6r980d0mG4muVPIv32Q_26_0"></a><a id="Tc_83gexJfVcE6SeKRDsqvkpA_28_0"></a><a id="Tc_THO2R87Kaky82w_vRVRZyg_28_3"></a><a id="Tc_CJTRRjhWG06Cm6ngrN4lMA_28_6"></a><a id="Tc_R0k9y0v7OUCbnB5DjOkQBQ_28_9"></a><a id="Tc_edDznaXHy0ivQDMM7JOmqg_29_0"></a><a id="Tc_3wBz2N5Gp0yr44gDjW-TAQ_29_4"></a><a id="Tc_NOB5hkPlU0m7VQSjow07oQ_30_0"></a><a id="Tc_n9lOW4MRdEePhqzQixE3Gg_30_7"></a><a id="Tc_shldaT4-C0mFtYkY8CyDkQ_30_10"></a><a id="Tc_L1AwKsfmckixPsWG3C97Jw_31_0"></a><a id="Tc_t5QdrH06QUan0zizv6TEbA_31_3"></a><a id="Tc_SkQXkZUNDUG45EbvHN9jSA_31_6"></a><a id="Tc_cx_ygaaS5EuHAkXMcx2zzw_31_9"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_LArOb7j6NEaAnMIYXIPzkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_FPZa2ZIXeEmLKBx-Zt4bhw_4_4">30,914</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Sale of COPIKTRA license and related assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_HA-hUtbuQkSrDIYOaGPRyw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_RoR3AhiUuUaeZbsrvDUXww_5_7">10,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_uNkt7ECQo0azu-N13Jcr3A_6_4">30,914</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_KfOX6GHV10aucbxeSjpQag_6_7">10,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cost of sales - product</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:CostOfGoodsSoldExcludingAmortization" scale="3" id="Tc_4ULroi5tAkK4B2hnLoeeww_8_4">4,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cost of sales - intangible amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="Tc_LddFVfspP0OIS_KcoN2dHA_9_4">698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_V9T1lu02CUWe_8OABJbadw_10_4">114,599</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_pm1kOU93vU2nSlhveVsi7g_10_7">81,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_H9azphMTcEGJRlwy4QpJfw_10_10">61,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_TSMumxh9gEW_8NvdOI7ZCA_11_4">81,146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_ASfUJzrEr0i0PbLUMqmcyA_11_7">43,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_PmrU3BxRDUyHgaYBVjemoA_11_10">30,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_gPrO0pIsYE6YbwBX-AOTQQ_12_4">201,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_05vluhis1UyaUcLexd7DTw_12_7">124,956</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_Xfso6RcCSUqFCfDrgqcQ2A_12_10">92,084</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_WApXnh0WQUafkB8DBSOQKA_13_4">170,129</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_tVVEy1KPmU60mBczTW-lZQ_13_7">114,956</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_IQ_K1nJhtUCfxmOkK08ogQ_13_10">92,084</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_1bDeAKAA20eGPjXXX7JILw_14_4">203</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_xnu2pF2w00W2MAw0Nqa6SA_14_7">123</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_35jhi3ghLUmNeKoX8fimcw_14_10">109</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_wbm5QtHwhkKTcIsjT8K4Ag_15_4">4,068</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_LjdYM1D0tECa3iFdDlbi1A_15_7">4,149</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_Sw2NYtksLUqqYP-ODyj8yQ_15_10">6,214</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="Tc_-xglPlUj-Eyu6zfZYytdiQ_16_4">1,138</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="Tc___Y3dh2mfkq1axLs-GleTQ_16_7">4,562</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="Tc_YfNcIjbqk06TeJrsn_vzCA_16_10">4,139</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_CC2Cr0Hx0UWhjZb8mVewbA_17_4">1,826</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of preferred stock tranche liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="vstm:IncomeLossFromPreferredStockTrancheLiability" scale="3" id="Tc_9Tn3DHBASEuAaQ7zkEYDYA_18_7">4,189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="vstm:IncomeLossFromPreferredStockTrancheLiability" scale="3" id="Tc_epZTKzTiw0Shw45v6csgzA_18_10">2,751</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_OoAp1reShkOxy-G9dn9wUw_19_4">27,492</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_Pd1qBM0SXE-Qqjo0Lhom6w_19_7">19,149</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:FairValueAdjustmentOfNotes" scale="3" id="Tc__9H1VnOiWkW98BA3_GSzYg_20_4">12,751</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss before taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_OeZPjaFGkUKrMUsS5_mm_w_21_4">209,471</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_BFObnxRZ-EWK2IkH4j6zUA_21_7">130,452</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_rXP3ehx-n0Kn_0xuYpLz_w_21_10">87,367</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_1Se-IVy-Y0qn_Sk4Gd0lew_22_7">185</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_zeLpv87N3EyG9n5CtJ1t9g_23_4">209,471</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1k-RD6M9AkGsSHI4NB5guA_23_7">130,637</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_99lji8rq8U6KtcUq45r_Ag_23_10">87,367</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_oEPzmFXkd0KU5fYbhbZ81w_24_4"><ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_oEPzmFXkd0KU5fYbhbZ81w_24_4_2">3.02</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_-l3WKQcGjEeINW-AlKuGJg_24_7"><ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_-l3WKQcGjEeINW-AlKuGJg_24_7_2">3.66</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_5587DH55s0KCIUcW__ypwA_24_10"><ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_5587DH55s0KCIUcW__ypwA_24_10_2">3.96</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common shares outstanding used in computing net loss per share&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_FokHkR7e_k6SVr_Sv9Trtw_26_4"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_FokHkR7e_k6SVr_Sv9Trtw_26_4_2">69,309</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_NeWFg4qI7UKfanuksqgB4w_26_7"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_NeWFg4qI7UKfanuksqgB4w_26_7_2">35,713</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_JH3lKKLVR0Ok7t_D3lJ_lw_26_10"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_JH3lKKLVR0Ok7t_D3lJ_lw_26_10_2">22,054</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_rwx1s5lcSk673BiYu4185Q_28_4">209,471</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_OExwCtJQp0K9M38RM5TDFw_28_7">130,637</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_s1Ancd16aE6iNJiIragENA_28_10">87,367</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unrealized gain (loss) on available-for-sale securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_r7sMrE4E70-xC7yv8q3Wyw_29_7">13</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_tt3C8VShV0Gxz0MTDhJ0kA_29_10">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of Notes attributable to instrument specific credit risk</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" sign="-" scale="3" id="Tc_FukEbAk7qEWDjqhL9u7-TA_30_4">5,229</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_uiBZuFAitUyW8ejU5eqOsQ_31_4">204,242</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_c_qxXKF9Qka5eyDxdSCpBA_31_7">130,650</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_TZqa-sDaMUe7O6RTVSQULw_31_10">87,354</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 12pt 0pt;">See accompanying notes to the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b3926c93_dbb7_4661_bb36_167c7206761c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Verastem,&#160;Inc.</b></p><a id="STOCKHOLDERSDEFICITEQUITY_20715"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF </b><b style="font-weight:bold;background:#ffffff;">CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p><a id="_49b6df0f_f3c3_45ce_a6e8_20621dfc4c7c"></a><a id="Tc_GHqsepnSBkGHtQ4up3a6Yg_2_21"></a><a id="Tc_AqEbh7l-B0-Hyo06rIQ-zw_2_27"></a><a id="Tc_VHgB8vfIgUyi7Hu_CMkgpA_3_18"></a><a id="Tc_brIKW_lufUalGeaYCi4KXQ_3_21"></a><a id="Tc_cb-B6DmS8EWJsHdo3M1VTQ_3_27"></a><a id="Tc_pH1qSr3HykOkcSSYx4CMEA_4_2"></a><a id="Tc_iAAGIDg_9EGywX4qhvr2lA_4_8"></a><a id="Tc_LCGg9YrzHUq1-CSBpj65nA_4_13"></a><a id="Tc_uu3daRY0Rkqs7yrrUInFxA_4_18"></a><a id="Tc_6zO8JzULk0yulsp8XLBiNw_4_21"></a><a id="Tc_UWoC0pfU902gmiFbZfoEHw_4_24"></a><a id="Tc_QD3b1xMrQ0ys1D25JmzhFg_4_27"></a><a id="Tc_W3pcUuEI3kClcUXvGzU0tw_5_2"></a><a id="Tc_JAdmqATiM02RyzVRdhC-rA_5_4"></a><a id="Tc_3VSlFbS98ESLnsjNzesKSQ_5_8"></a><a id="Tc_Dekq0lmN2Eu5JKG2llybeQ_5_10"></a><a id="Tc_C8Srvn0ma0WQHEkadiyT0g_5_13"></a><a id="Tc_BDzpIFEQTEyqQ83-jifNhg_5_15"></a><a id="Tc_Lc87w-Xpg0-HH9Ur3WhAFg_5_18"></a><a id="Tc_ggVj0_7abU-uBz6zAswizw_5_21"></a><a id="Tc_cZxPF4u9jk2-ScMDhN-nCg_5_24"></a><a id="Tc_CyA6EfwKJEqzAIk4bAGAYg_5_27"></a><a id="Tc_9BVK0zMR1U-r5PS4BCqAbQ_6_0"></a><a id="Tc_COUaW4pUqEmY0naYP_enYg_6_2"></a><a id="Tc_0O8jgxRCHE6qx2k05_X3Zg_6_4"></a><a id="Tc_herL7bxC3UyL9vCAKW2Xng_6_5"></a><a id="Tc_mkgnyn_qhEuGkgya8zRdpg_6_10"></a><a id="Tc_C5WafNBd7kqvoRExqZLkww_6_11"></a><a id="Tc_BBbFcIVHXkGjwnJ3hsIG-A_6_15"></a><a id="Tc_0gyhdF6UIE-R8GLKAD0rmQ_6_18"></a><a id="Tc_AajkMl0F80-qQzkWhdJliA_6_21"></a><a id="Tc_UKrk8odNkUi9bVQkIip50w_6_22"></a><a id="Tc_onsv9KRjf0GmD4tcJ01Ibw_6_24"></a><a id="Tc_3dQaKlvW4kuvMB5wcevw_Q_6_27"></a><a id="Tc_FDfDQOzsAkG6Xcwbk7quBQ_7_0"></a><a id="Tc_eOsQ1JBMA0WvmB_lEViYVw_7_2"></a><a id="Tc_IUHnAj050UixPmWMRa75FQ_7_5"></a><a id="Tc_CeR63y5Nf0agvNwVZblTsw_7_8"></a><a id="Tc_tng42HiEJkG70nRiSgzTQw_7_11"></a><a id="Tc_NEmu66VIrU-A8rJsNtAdgw_7_13"></a><a id="Tc_i3LcHcL1EEiKHHAoaOTVFA_7_16"></a><a id="Tc_s0fH1EC0-Eqa8YpTAi0JWw_7_19"></a><a id="Tc__3JWZrOfXE68_Exq0vrpUw_7_22"></a><a id="Tc_chcYpQ6_QkC5oaH_2Zn-bQ_8_0"></a><a id="Tc_BEuWbOSnK0CbDqMb0gTDYA_8_2"></a><a id="Tc_mL8avAzs4kGscqiKlfx01Q_8_5"></a><a id="Tc_l9yUb5cVxEGWU5Uu9jTUrQ_8_8"></a><a id="Tc_vAGgPHbsBUawGXliALokpw_8_11"></a><a id="Tc_RNCnOfP6NECc92yCT2OrIQ_8_13"></a><a id="Tc_1n6zsFA5iUKYH5mdsVdq4w_8_16"></a><a id="Tc_tGanM8hXGUSm3_Vi8-9QOA_8_19"></a><a id="Tc_d9Rebgpjh02qm57fXT18nQ_8_25"></a><a id="Tc_XXP_cabYSU6yk21dpDez-w_9_0"></a><a id="Tc_ngER0Zy0skefbbbELziyNw_9_8"></a><a id="Tc_Bc5yVNoVrUSRjcHOzM6pXw_9_11"></a><a id="Tc_iHpnSVyxdUuWNZH_vHZV3w_9_13"></a><a id="Tc_WhPZJgKBAEyPucwi7bL3UQ_9_16"></a><a id="Tc_9njf-Ezw40enBDruVbYezg_9_19"></a><a id="Tc_Ec7hPs2Ilk2r48qEJ3LroQ_9_22"></a><a id="Tc_mQKJ9N0Wm0CItB7Oz4B2iw_9_25"></a><a id="Tc_0uW3LKnU-Uy1tYjsNoD9DQ_9_28"></a><a id="Tc_rwUv2Msh_EeaDFZZIsRBPA_10_0"></a><a id="Tc_ZEv_J9r7JUqucaG1FKi-tg_10_2"></a><a id="Tc_QsXWbX-q1ku5Agkdisk2RQ_10_5"></a><a id="Tc_OG1eefuTY0C3yR5BSwwKYA_10_8"></a><a id="Tc_6QriolHdgkupOIB9AAeqgw_10_11"></a><a id="Tc_fpRIhCCYS0aB9sqBOkW0Hw_10_22"></a><a id="Tc_5wxMDEzNPkiCDbwYaaJkpw_10_25"></a><a id="Tc_lsF6Xt384kK7kY8bVSgr1Q_11_0"></a><a id="Tc_f8SEnFCj20iaDC4AUuzWEA_11_2"></a><a id="Tc_j9qoiHqkPkiEELac7Sfwug_11_5"></a><a id="Tc_iLUJulW0bka5HlMA7Zc8gQ_11_8"></a><a id="Tc_PDgVYNljLU2w32rb3vF2KA_11_11"></a><a id="Tc_yAalnIGPp0q_QRjl8vs2sw_11_16"></a><a id="Tc_FoQe4k_TNUaQfK_T2hBWMg_11_22"></a><a id="Tc_3oHPIKftbE2pvI2JElgoJQ_11_25"></a><a id="Tc_vLTrt_xHjkadtAtrT7FdBg_12_0"></a><a id="Tc_nog_-g0a8U2hgx8_qSD0LQ_12_2"></a><a id="Tc_AxCqFhiHwUKfhGZ4DO8h7g_12_5"></a><a id="Tc_1INrDQYNdkiFqHQldv-VBg_12_8"></a><a id="Tc_l5xkXfLFTEu3XXH5Voj7MA_12_11"></a><a id="Tc_mDKVSiOMhE2-GoK8bZKAsA_12_16"></a><a id="Tc_ZPMn8pLv7kmXl1iHDRKUgQ_12_19"></a><a id="Tc_hzY0W_2POk-lMmZcR8qP3A_12_22"></a><a id="Tc_JbraLMT26Ey1wbwjBWWEhA_12_25"></a><a id="Tc_bEUdYQGZO0e6IeiKut--BA_12_28"></a><a id="Tc_dLkYUpqSa0uagHc0PkPT-g_13_0"></a><a id="Tc_xwDVRC2SikuhDw_22G52Vg_13_2"></a><a id="Tc_T4Y4CDACukGrDEd8r5Lp9g_13_5"></a><a id="Tc_B7k-ca5mGECuYCPeE9g5jg_13_8"></a><a id="Tc_ePbfjMF5ykSjJpM2qaHotg_13_11"></a><a id="Tc_0fDqLjwz2k2CNqvebvBuag_13_22"></a><a id="Tc_a3ruDH6_4E2zFWAMjI2sTA_13_25"></a><a id="Tc_jxrJz45E20WEH4B9_5TfKw_14_0"></a><a id="Tc_POerPpuI7kapkT_VYZUM3w_14_4"></a><a id="Tc_6fMPwnMdbEWQsEh5eqkxYg_14_10"></a><a id="Tc_7_9Kn3QOSEKSGK_WADSB9Q_14_11"></a><a id="Tc_6jteh7JZ5EmZztQET7bOgg_14_15"></a><a id="Tc_3xVB8XaPVEy8B1Qnq1-Fxw_14_18"></a><a id="Tc_EvCTpZdmU0WwT5_s_d_88A_14_21"></a><a id="Tc_2i1lmQtaqk-QXiJ0ZfUgrA_14_24"></a><a id="Tc_4Ons5mO2IUuwFrJO5q7bng_14_27"></a><a id="Tc_HGkQUsM8wkmo6SGk9Vlg4g_15_0"></a><a id="Tc_503e5g2QmE-x4ZP1blBmow_15_2"></a><a id="Tc_kxTrpcXX5UmJ50q12lhavg_15_5"></a><a id="Tc_Jyll8mh-v0SoIBuGN6RqYQ_15_8"></a><a id="Tc_KlsNfgiVWEOfA736kHuoYw_15_11"></a><a id="Tc_VJaXW-21A0igHUB0Frz8aw_15_13"></a><a id="Tc_Eu9dJh1HB0-jkeeStqedrw_15_16"></a><a id="Tc_YyldfeR0MEaxQUZKcabsCA_15_19"></a><a id="Tc_yj_Bb-QT1USLcMjtDLkfkw_15_22"></a><a id="Tc_YuolxrNiqkO6MpmUeQH7mA_16_0"></a><a id="Tc_H6WoOFwt8Ui03JOUUyFVuA_16_2"></a><a id="Tc_BPvoazh2B0eUS0cEW7I_CQ_16_5"></a><a id="Tc_q6USMn6h1EOFusJjuS_qsw_16_8"></a><a id="Tc_6L3FfbF8JkSvHfgYu2kYag_16_11"></a><a id="Tc_KxnWmaah2UiQxc56V9iimQ_16_13"></a><a id="Tc__DNIAl47bkCoVkQ8ZmCxzg_16_16"></a><a id="Tc_MvXsmw184UqXsTyreMBLfg_16_19"></a><a id="Tc_WsoRvbJqgECoGEOgVUPcyw_16_25"></a><a id="Tc_5Nwy1PMBEUiRYt4V7e7IqQ_17_0"></a><a id="Tc_xWXfvHXD90-Ftc-vl2_W7A_17_2"></a><a id="Tc_9_kUjSCRHUeruMe9QAGrmQ_17_5"></a><a id="Tc_eSkBvoY6TE-uDa8ynDT65A_17_8"></a><a id="Tc_W3y4gS-my0aHAs0W1-Tsww_17_11"></a><a id="Tc_6fb5k5TvOkCu7Rr5AvAfkg_17_22"></a><a id="Tc_w2d2Qeiph0aeITn9VejyzA_17_25"></a><a id="Tc_vV3mZSDdrU6uySQQ0avquA_18_0"></a><a id="Tc_T5mzACMRtkufh7qCA219UA_18_8"></a><a id="Tc_-mJBHn7R_EidQB5ig9sRjw_18_11"></a><a id="Tc_yDy1pevuIUqKgkEhwOU7Tg_18_16"></a><a id="Tc_-07tMbzNlUGFc9DR96TcYQ_18_22"></a><a id="Tc_5kNCK4XvU06Ak402pBXEbg_18_25"></a><a id="Tc_KiLM7gyrIUqO8DRXjfEKwg_19_0"></a><a id="Tc_aRCzdJIW1UG8q7Ql_yRf1A_19_2"></a><a id="Tc_9XYfVS0b10yEMM7_stdIyA_19_5"></a><a id="Tc_HrVd45M-8k6HjSYEAWMbjQ_19_8"></a><a id="Tc_JP1DP_OJLEms9jNb-k4Xsg_19_11"></a><a id="Tc_hOnEX8sv90msLyDVGsnIRA_19_16"></a><a id="Tc_PSa6lMQJLkafqQPmeVfElg_19_19"></a><a id="Tc_UAlotFCeLE21-TMmjtMJEw_19_22"></a><a id="Tc_TEsfV8UuxUiF3atnDzbPlg_19_25"></a><a id="Tc_geI8iAMd6EaltrtLyVTX3Q_19_28"></a><a id="Tc_wdNayJVdXEmeZmToAdhuJw_20_0"></a><a id="Tc_AW7RSCtX60aed7C1hGg38w_20_2"></a><a id="Tc_IHlwCj_2A0qRoOse2HzNkw_20_5"></a><a id="Tc_9dmxEL4vg0qSG00g9rzaYg_20_8"></a><a id="Tc_mKVg4cLdXUq2cB1N736TxQ_20_11"></a><a id="Tc_GQaJG6P28k6lyB2DSKTy5A_20_16"></a><a id="Tc_I0Giay-f-EieYiyFflwdbA_20_22"></a><a id="Tc_UFkLs93goUGbqftmVDggXg_20_25"></a><a id="Tc_gxDLUIya7Uqxb5CS0jvpoA_21_0"></a><a id="Tc_jrk1N0t3SkiRMNGRxUY4DQ_21_2"></a><a id="Tc_rsSDz9pI2E6QInFHjwEa1A_21_5"></a><a id="Tc_lbTEtw2BK0eLo6Z9IRueWw_21_8"></a><a id="Tc_rB8uDfpoD0C22SoBMAr-Iw_21_11"></a><a id="Tc_VAekvmH0MEu4tAs33DwFQw_21_16"></a><a id="Tc_qGq8Cxlfv06Lf6oOis--Qg_21_22"></a><a id="Tc__-AbnpF2Z06NmHw7EBzKEQ_21_25"></a><a id="Tc_uYSCbiJbCky3cGa0effwig_22_0"></a><a id="Tc_z3TfrwnbyEiUFLHwWFTvLg_22_2"></a><a id="Tc_S6ot9_GvCUukLWpVRkwBbA_22_5"></a><a id="Tc_vXNpLHXPUk6nfp70zUfgUQ_22_8"></a><a id="Tc_XGf8YQ6tikiqtpOgcpxkJg_22_11"></a><a id="Tc_ahj0ciZQX02uyOE0OlFw5g_22_16"></a><a id="Tc_6er4Qu1bXEumkADDRGZ-jg_22_22"></a><a id="Tc_C2ZqOwg4jEuh80LejvRsYQ_22_25"></a><a id="Tc_JrGCkVOcxkudBD1PDUrpMA_23_0"></a><a id="Tc_nuM1NlDfQ0aQtzTTQOZIOA_23_2"></a><a id="Tc_W6I2MhWVn0i0MUkvkWvD_w_23_5"></a><a id="Tc_LLOxMZjqLU-SMEIP2eTbtg_23_8"></a><a id="Tc_jxIx47pvdkelzWGtClztZg_23_11"></a><a id="Tc_GQX7MujVg0a7lTj7yr9tCQ_23_16"></a><a id="Tc_uFyPk9M0mEyT1Rtkukka8g_23_19"></a><a id="Tc_nENZ0df360OdbpfG3YUyNA_23_22"></a><a id="Tc_A5iLI0rhmEy2FJQ7oT-i2A_23_25"></a><a id="Tc_HBEU-Dva2U6w0gR1zWbuvg_23_28"></a><a id="Tc_E5mSE_qImEWExy5O9n6Whg_24_0"></a><a id="Tc_pRESc88tjUOcg0nX7lbCwQ_24_2"></a><a id="Tc_1xpjx7WdbU2rCsk6koADqA_24_5"></a><a id="Tc_oUUo-in4j0eSt2j9eN6Y-A_24_8"></a><a id="Tc_eezUxAzSmk2JLKzFV7tRGA_24_11"></a><a id="Tc_ku5hlZzui0qTIrkd0AEQKQ_24_13"></a><a id="Tc_2bSskVTdxkyDalk_8kJPrw_24_16"></a><a id="Tc_PROurA-Rkkyrv03_OsEhCg_24_22"></a><a id="Tc_hOGbBBevLE2Ko91sUavAFA_24_25"></a><a id="Tc_6UAYLo527UC_CLwr0N-I0Q_25_0"></a><a id="Tc_e50-tFud8EuAtCq_pCUCGA_25_2"></a><a id="Tc_XkYPMA3LhU2rHOSjBW3FHw_25_4"></a><a id="Tc_I_ypiAW320CKpd6Ei1hWOw_25_5"></a><a id="Tc_3p98q6HekEez9orSPMpghA_25_10"></a><a id="Tc_RJuJtg3dqEuFZFGObdul4w_25_11"></a><a id="Tc_9U6fFpHjOEqXzwePuyxkyw_25_15"></a><a id="Tc_vjbBxNpSPk-QSRkDyDwsug_25_18"></a><a id="Tc_rXR1bwCFY0KSPqLhvHs6Eg_25_21"></a><a id="Tc_s_TRi5W6tkSbHp6WLirV5w_25_22"></a><a id="Tc_M3PcpCi_o0ufwTruO-hCsg_25_24"></a><a id="Tc_aaFF4KLSk02DoypGoPvZzA_25_27"></a><a id="Tc_ue0R10h9aE-8502Zt4fITg_26_0"></a><a id="Tc_w0vziGh6TE-y3zKNUZ-b6A_26_2"></a><a id="Tc_AhwxNHaPlka5wGlrwXMm9w_26_5"></a><a id="Tc_9nfJb0sp3E2XEDD1S9ODug_26_8"></a><a id="Tc_vpFe7Pncc0yYkuJkBDsKAw_26_11"></a><a id="Tc_teoM_t7gpUeNp-ec-qz46w_26_13"></a><a id="Tc_ktyppV77GkOUVB7WAqmL5Q_26_16"></a><a id="Tc_AP3t7FYPg0WyT5TEzZXcqA_26_19"></a><a id="Tc_W9NKkubw3U-tzGUevQbZDg_26_22"></a><a id="Tc_5zm9591vN0CsSVlHuZ4vVg_27_0"></a><a id="Tc_yhRFu_fkUUWvGZW4_oEO6A_27_2"></a><a id="Tc_m1zu2oud6UOtwC9tWFiHrg_27_5"></a><a id="Tc_nJa4llyrXkyOXxktZkI55w_27_8"></a><a id="Tc_wyLWqtb-4UOSnk7V0H2PEA_27_11"></a><a id="Tc_XlTCdKcH-028jGHLiDZd2g_27_13"></a><a id="Tc_KVq3BDXfmk23EywTKbrTkw_27_16"></a><a id="Tc_lbzqmJxbAU2Hm0DQxgvYHw_27_19"></a><a id="Tc_yLWdpeuYOUiFDBQAyrXNbg_27_25"></a><a id="Tc_w5goin3EjEC3dGbiBeXn0g_28_0"></a><a id="Tc_XEor6HKay0OKx4Wx07Tspg_28_2"></a><a id="Tc_UBHD10ujqUufgg599zd6Sw_28_5"></a><a id="Tc_iC8qaRBr8U-hmRkbkjyg9A_28_8"></a><a id="Tc_TM2lgDwe6Uy7r2zKpNrdBA_28_11"></a><a id="Tc_0Iny-Td05kSpgoz09SnpKQ_28_13"></a><a id="Tc_TKwqUP6HG06A9-1jeuzRhg_28_16"></a><a id="Tc_FyzS8VipzUSqrk7EIc4Hmg_28_22"></a><a id="Tc_dgceeSfc1kqjhp5OMHoTaA_28_25"></a><a id="Tc_rmJvSj93rUeN7KYleLY45g_29_0"></a><a id="Tc_YhQKQxhSW0yS9eHCTV3C0A_29_2"></a><a id="Tc_-jy-g_WWaUamnUsO5hBOJQ_29_5"></a><a id="Tc_nwERy5aBnk23f147eSQ0kA_29_8"></a><a id="Tc_QZhhMNLhX0WTWvvADddF6g_29_11"></a><a id="Tc_TMUHsvEqeE2WI7apIkEg1Q_29_16"></a><a id="Tc_buWssJVli0OhwjqUH2vLig_29_22"></a><a id="Tc_XOqSWlo4vEeFhXHY4HRaig_29_25"></a><a id="Tc_P-TLqtpyfEK2x9d-yKKsTQ_30_0"></a><a id="Tc_dbjB9ytbmEy4oci_4uxyDA_30_2"></a><a id="Tc_NKa2yTAh0EmsMtarY_s9iA_30_5"></a><a id="Tc_fEiKwgndM0qjfR3N5DIxSw_30_8"></a><a id="Tc_lCaCopAPAkO0NkjJ9mRuCw_30_11"></a><a id="Tc_VgyNztnmkECD-6-I5vqAVg_30_16"></a><a id="Tc_uZGIwe-ViUyPZK9QzRmC4w_30_19"></a><a id="Tc_cfAhz5VyBUeRGvUaA1QJOw_30_22"></a><a id="Tc_ipb0wt9pikCw8iaNS02mzQ_30_25"></a><a id="Tc_8zGjGh0O2UKcm3Yuj1oLRw_30_28"></a><a id="Tc_8TeBbxkuUk-TfnMQkgv55g_31_0"></a><a id="Tc_UkEcMl4FbESvk_A-A2s4ZA_31_2"></a><a id="Tc_rEXhh_ClMUawshYeEBHS9g_31_5"></a><a id="Tc_9XPFBp6BFUGV_L0bIBlwAg_31_8"></a><a id="Tc_L2UNvYptOUKZFeStjDCLWQ_31_11"></a><a id="Tc_7Y8bmWRiYkiV1eziv8vIRA_31_22"></a><a id="Tc_Lptf_c-Jd0qnnAzffzxebA_31_25"></a><a id="Tc_gucKNpDKgUWTTS_etgAWnw_32_0"></a><a id="Tc_eDn8GLdMAk6OYDgU3XYSZg_32_2"></a><a id="Tc_-YwRuUFx3027nMQkGq7q6Q_32_5"></a><a id="Tc_Av2aoCaZQU2sAC4NccHxLA_32_8"></a><a id="Tc_Hd3QoFbnM0S_CZmG25e3eA_32_11"></a><a id="Tc_NIiup2Jj-U29i9Fya5qZ8g_32_16"></a><a id="Tc_tjTzXkJly0u-ezHSWXHQGA_32_22"></a><a id="Tc_NH-9sCKR9UWgWn-vRUdcWQ_32_25"></a><a id="Tc_xFmlqPTsZEabqhLAL6bx5A_33_0"></a><a id="Tc_5mIdj696e0CQjRdCemQXkA_33_2"></a><a id="Tc_LsBlITB2REai0JcidaCKwg_33_5"></a><a id="Tc_MytrCd7B3EqWvXoNtFeA3A_33_11"></a><a id="Tc_Q9RTzArbLUGj04eBDbQrnw_33_16"></a><a id="Tc_NnHzrQ67JUWcvepYhlWmtw_33_19"></a><a id="Tc_uLhit2y4fkKjPPeKhYbphg_33_22"></a><a id="Tc_Sf-QZ7spL0qtP4qfHdDwXQ_33_25"></a><a id="Tc_tqb0uvmB3E6YJTtWUQ4MpQ_33_28"></a><a id="Tc_bPYIriXlpkOfQIwU5fbXWg_34_0"></a><a id="Tc_xymFCDB0EUe7a3YdGOADaw_34_2"></a><a id="Tc_JfJHoxDHl0e076m8sOpIEA_34_5"></a><a id="Tc_RVBM6bGTsEe5h2qbRbC6qQ_34_8"></a><a id="Tc_kPeIv2HhK0aU8xkeshyUZg_34_11"></a><a id="Tc_tGW1_H1fT02DXaW3x_YAxg_34_16"></a><a id="Tc_TDFkaAgKa0yAY1-yFdsdKA_34_19"></a><a id="Tc_dZHXCfHmHEKi4ysLUd1GrQ_34_22"></a><a id="Tc_DbGXZF-kH0iylpLxsICu0A_34_25"></a><a id="Tc_Mf93DO0SykyigZstj3AjTw_34_28"></a><a id="Tc_4jzUFkvPEUO60cUkjDvWdQ_35_0"></a><a id="Tc_9krOVBrA2EeTgf29qov2OQ_35_2"></a><a id="Tc_zB86NWMcmE29m-jKZFvSWg_35_5"></a><a id="Tc_G54stLpJl06z77S65zZuYQ_35_8"></a><a id="Tc_z8WpJD6rFE2AREs9mzrTYA_35_11"></a><a id="Tc_SZUKuzu35UW4vNfI8zEvZA_35_22"></a><a id="Tc_Ru71Dh_XmEiJANdCozO_-A_35_25"></a><a id="Tc_Zg68Fy0ouUG9yxEJQ5fIAg_36_0"></a><a id="Tc_jzKnMXadrUSvvFB1omCKtQ_36_2"></a><a id="Tc_g-DXCUnMnEG4SS8JqpSehg_36_5"></a><a id="Tc_BcUagjtFr0-rcpdnjGC55Q_36_8"></a><a id="Tc_mSYFQF7KQ0SL5XdxcKK4pA_36_11"></a><a id="Tc_HOWk0CqPSkO_lZgFwKufZA_36_16"></a><a id="Tc_Arm6_vRDOE2BkTD_9RcFgA_36_22"></a><a id="Tc_8Bqv-6ot8UafMdq22SJxvw_36_25"></a><a id="Tc_9w__7ugick-hYHQNJvRCzg_37_0"></a><a id="Tc_pz_SuEIdOU2XW17x5zXqtA_37_2"></a><a id="Tc_3EnAR58Huk251wa-WnuTsQ_37_5"></a><a id="Tc_Br1A0zOpfku1r-MfENUPrQ_37_8"></a><a id="Tc_VFRw4OKU-kyb_hKt4G5AyQ_37_11"></a><a id="Tc_qN6FiVbxo0az7PC7c0An6w_37_22"></a><a id="Tc_zO_eAFcyS0G_cND-nUoGFg_37_25"></a><a id="Tc_46XidV_yqUmLnh8OO_kyrg_38_0"></a><a id="Tc_hwyqOfZ3X0iHxK6eDBjNjQ_38_2"></a><a id="Tc_TEZfiYEcMEKKfwkcDGkhyg_38_5"></a><a id="Tc_WilMK1PGmkmhpsdTvLGrUw_38_8"></a><a id="Tc_IQ9SJzFjYUOsM_B03IF4pA_38_11"></a><a id="Tc_mtPZO9s7AkujFxzwzIeMUQ_38_22"></a><a id="Tc_sYpDPO3NUEaQm6O0d1xcbw_38_25"></a><a id="Tc_P3KtE2SzZUWox8gVd3KDgw_39_0"></a><a id="Tc_ZhbngDQqEkSFCY7Dp3wDBw_39_2"></a><a id="Tc_HVmJL3BzRkq8eUJ5ZQBiTw_39_4"></a><a id="Tc_Afd9Wr3vjkGaODFb9cxEkw_39_5"></a><a id="Tc_mrd4136Zn0uxrZ9YB7ycmQ_39_8"></a><a id="Tc_Nf95-OIqAEG4JEIsBzmebQ_39_10"></a><a id="Tc_Y31Px9tM9kqwUNNWugFVHg_39_11"></a><a id="Tc_Qsw4vy0v90OWpdgbuYyRPw_39_15"></a><a id="Tc__eJZvIXh90eHQO0RsENuWg_39_18"></a><a id="Tc_yoWxP_KY_EC5Ni8oawodrQ_39_21"></a><a id="Tc_5DbUcUdcpEW19gSsagFCKw_39_24"></a><a id="Tc_wJJ2bnygW0aCeKTIZ9elWA_39_27"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">stockholders'</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Series B Convertible Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Series A Convertible Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Common stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:5.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:5.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:5.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:5.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:5.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:5.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:5.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:5.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:5.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:5.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:5.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">(deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Balance at December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Y_mwN22A6kGbxpRR-EAdLw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_tWq-eW51bUKbWAfu-a4KAw_6_8">1,000,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_V_Epz3gmqU27y1VxbWmrEQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_XWCM9PpbKEOieGagFvFfAQ_6_13">16,711,761</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_V_Epz3gmqU27y1VxbWmrEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_QIGRV722bESvriY0wUFouA_6_16">2</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ASFttFVznUOS8yMRpJAbxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Zo8MkSXGl0yhFcGhyKaqAw_6_19">784,912</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lrgQGYbzQEm9cGGsaWCIRg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_DeSBPuSQkkC_Yh4rZR0yXg_6_25">737,523</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2022_z5GNzJxej0aeNGqmRjwWLg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_pi9y5KBIqk-Z0Y6LbpP1kQ_6_28">47,391</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yQk4kITunkGYKm5hIqAzWQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Xmu5rLHmQEmXDpE6G_7Thg_7_25">87,367</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_spT7QvgklUeOw_jk1byisw_7_28">87,367</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Unrealized gain on available-for-sale marketable securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_NfyaVSuOXEOBvk_0IuL8CA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_GUYb7yCsrUeLeS8UTqfJfQ_8_22">13</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_wPOs7h3WxEioa88LzGmhAw_8_28">13</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of Series B Convertible Preferred Stock, net of issuance costs of </span><span style="font-size:5.5pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_6SeiJlC4WkGCPvAYgU6Y5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_fH0HSJbpZ0GqrKbsiH9svw">1,901</ix:nonFraction></span><span style="font-size:5.5pt;"> and preferred stock tranche liability of </span><span style="font-size:5.5pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="vstm:IssuanceOfPreferredStockTrancheLiability" scale="3" id="Narr_RThfjA-XUke9xmfkFe7mcA">6,940</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_644V0cfv3U-29Mjt5jpGcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_s_4rJN7F3EmJN2X3DN4A6Q_9_2">1,200,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_644V0cfv3U-29Mjt5jpGcg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_vI9cJOawDkq6C-45GHe9qQ_9_5">21,159</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock, and pre-funded warrants, net of issuance cost of </span><span style="font-size:5.5pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_NWcBHi9lKUSfhsSxeHCddA">6,351</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4zRDVYOP-0K61PPNI3Uvhg" decimals="INF" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" scale="0" id="Tc_k7oYWN9jHEyNlQiTSNNWTQ_10_13">8,489,409</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4zRDVYOP-0K61PPNI3Uvhg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts" scale="3" id="Tc_Xtt1rF5S8kmHOUG7m5kjrg_10_16">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GZ0fEHkwU0OYcLlJwZ7pfQ" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts" scale="3" id="Tc_8sN-r_jZr06OaQ6FdUQL9A_10_19">91,419</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts" scale="3" id="Tc_va3K-xzzrU2bOLWVH-xVow_10_28">91,420</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock under Employee Stock Purchase Plan</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4zRDVYOP-0K61PPNI3Uvhg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_FKxIWK-7aE6440ahYTqpWw_11_13">14,270</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GZ0fEHkwU0OYcLlJwZ7pfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_kmOSulKHGEiTXvxV1DB3Aw_11_19">57</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_6EA2TPDQWUS1a9RuuVfOzw_11_28">57</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock resulting from vesting of restricted stock units</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4zRDVYOP-0K61PPNI3Uvhg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" scale="0" id="Tc_oMXVzuhPy0eMsWN4WrIgfQ_12_13">65,710</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Stock-based compensation expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GZ0fEHkwU0OYcLlJwZ7pfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_-kLp4by7AkCAL1fVAVXH7A_13_19">5,860</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_k9JyExpDHkGOdxvzYhZUZw_13_28">5,860</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Balance at December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ba-9SwGbmkucpagN-WsZYg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_GsZOhepio0Cv56vD90iS1w_14_2">1,200,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ba-9SwGbmkucpagN-WsZYg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_EtYPNUnay0eehaQcC-SyZw_14_5">21,159</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_rXXFIzj9hUybe-4ngReB2A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_OakRvXkkkkaUJJkqUlwCHA_14_8">1,000,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_W4v_8l5EHEOk8tW_t3-29w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_VQuLsAU6AU-hCAGsJ4OgEA_14_13">25,281,150</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_W4v_8l5EHEOk8tW_t3-29w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VWDQvJ7Pxk6vCjQX0agoig_14_16">3</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C6prOwECYEmM37Ntixav9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_gEH5XOg0kES7x09eTdBbOA_14_19">882,248</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8HWoELe-FUKs4q6zosK0_w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ZoZrg-g11E2n2f80GOCSdA_14_22">13</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_w551gdo2ok6ZEMwgbJunYg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_IdyHjCcIqkmQ6M0olVnevA_14_25">824,890</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2023_Uyhdm4_rYEOg-NEKFqTeBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_m6j9z8YebEm_AdEXYDvykA_14_28">57,374</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TtA8P5RxPEqhMQS4CQul_w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_pfpXm33lgESu06Ph3SYhJw_15_25">130,637</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_8CUzJkAcKEejgdc9hTUtyQ_15_28">130,637</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Unrealized loss on available-for-sale marketable securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_h5EVJwZSEkaojEFbMUpw3A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_9JgKhHEFl0e_lv6OMesfLg_16_22">13</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_M2dNgYrKxU-43JSF3QSpHw_16_28">13</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock and pre-funded warrants, net of issuance costs of </span><span style="font-size:5.5pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Nx7kZA6zXkqD1bBA5afBeQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_Ff-4_H1gckGJ-4CY7PUoTQ">1,179</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA" decimals="INF" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" scale="0" id="Tc_GIkw3O6QGUWe9nMcEXGSvQ_17_13">13,333,334</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts" scale="3" id="Tc_gfXqdkcKS0yEUZhJ9FubgQ_17_16">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_smxFsQJeIEe8LC1hRLDuYQ" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts" scale="3" id="Tc_4Ma4o9tPS0mwqFfEMtaryA_17_19">14,220</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts" scale="3" id="Tc_5QpuRHp-rUaYEF8NEkb2xg_17_28">14,221</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Conversion of Series B Convertible Preferred Stock to common stock</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_TAPCsw8lgkWIgfJ_mbgurQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" sign="-" scale="0" id="Tc_CQ0WL4DhtEyeKUyw_VVJfA_18_2">1,200,000</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_TAPCsw8lgkWIgfJ_mbgurQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" sign="-" scale="3" id="Tc_9klHhRg900qC_yOoWoNV8g_18_5">21,159</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_U1UChWSujE6ILbEbLqCdKA_18_13">4,236,568</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_smxFsQJeIEe8LC1hRLDuYQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_TByRptbo80OkZ83W1LN4RA_18_19">21,159</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_eb4a3mcbWE66diW2LjAgxg_18_28">21,159</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock upon exercise of pre-funded warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA" decimals="INF" format="ixt:num-dot-decimal" name="vstm:SharesIssuedFromPreFundedWarrantExercises" scale="0" id="Tc_nfaWqWU010WF5yvaUvf_2w_19_13">1,538,201</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock upon exercise of warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA" decimals="INF" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Tc_NcafDQeG0EyCU02FfEwmSQ_20_13">250,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_smxFsQJeIEe8LC1hRLDuYQ" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodValueExerciseOfWarrants" sign="-" scale="3" id="Tc_0psg2GeG9UGRozI873lPVA_20_19">1,420</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodValueExerciseOfWarrants" sign="-" scale="3" id="Tc_r7bU_vmQp0SjJXkVJk1wug_20_28">1,420</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock resulting from exercise of&#160;stock&#160;options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_bOmi8qx7sUW-pGyCotL2EQ_21_13">21,978</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_smxFsQJeIEe8LC1hRLDuYQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_pRR1rYuHekS9eOXYt6vxag_21_19">172</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_BHLUuJdWLUmnR6ro1nQdvQ_21_28">172</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock under Employee Stock Purchase Plan</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_TB3jtnX2sESijtU_gQiGhQ_22_13">15,231</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_smxFsQJeIEe8LC1hRLDuYQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_sEYPhAIZb0OPY6KPJAzUHw_22_19">69</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_OxjHb6Wpw0GsK6N5W8R9sQ_22_28">69</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock resulting from vesting of restricted stock units</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" scale="0" id="Tc_OSNmMdXMy0ySK3TNFF7MlQ_23_13">107,888</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Stock-based compensation expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_smxFsQJeIEe8LC1hRLDuYQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Xg3RLobkTUuIBp9Sxm0vjQ_24_19">7,342</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_w6w9qwj97EegXrHUMhE7ug_24_28">7,342</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Balance at December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_y9BYeLeimkGfbgD3G1n6_A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_FcsSWdJpX0ygBi16mKNqCg_25_8">1,000,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IVIVyZ8H2UGZjpXhTwRvWw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_5mwnpfx6pUeGdJM9pDXhzA_25_13">44,784,350</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IVIVyZ8H2UGZjpXhTwRvWw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_qojBVt3il0GiiZN-lInB2Q_25_16">4</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NDL3BYU3PUuJd3uSXk_5qA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_jSpkCLBqSU2BBPaq3pxaXg_25_19">926,630</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xiIip57Oi0ehdHOXQBNQkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_lnHbd9OHg0KkFqFdhnsSEQ_25_25">955,527</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_8M4cV9D5cUSCWUV0iFXmWg_25_28">28,893</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Net Loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-Ba5ewoa3EWicqSM_lHMtQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_fuOh_BtcZkW7PnEK5aY5_g_26_25">209,471</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_p305RP2C1EC13R7xZsj9tw_26_28">209,471</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Change in fair value of long-term debt attributable to instrument specific credit risk</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zCbuz_b2rkCKzl31gcidKg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" sign="-" scale="3" id="Tc_qzIYz66TtE6KMYST0QS4_A_27_22">5,229</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" sign="-" scale="3" id="Tc_Iqk-ukyu4U-9V0D9TcoqzQ_27_28">5,229</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Stock-based compensation expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H2d2wIpatEOMddtM_uXHjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_uVku1gc_g0ulnmla91jKpQ_28_19">9,404</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_w8TklVvuckixeWg0SF78qQ_28_28">9,404</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock under Employee Stock Purchase Plan</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_LHVlL6IXIEiHmgC5w1xZVQ_29_13">16,341</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H2d2wIpatEOMddtM_uXHjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_Ml1UYgeTJUu2aBA46dJMew_29_19">51</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_-5vv2tGKAkSSk_ZeITozBQ_29_28">51</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock resulting from vesting of restricted stock units</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_hSWVWtMPNUeZWvJlUIKEgw_30_13">687,093</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock upon exercise of warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw" decimals="INF" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Tc_WcepCGAP50yAzQmrUkAsOg_31_13">9,654,168</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodValueExerciseOfWarrants" sign="-" scale="3" id="Tc_fkDFfRXCfkWUcXEqrGS4tA_31_16">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H2d2wIpatEOMddtM_uXHjg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodValueExerciseOfWarrants" sign="-" scale="3" id="Tc_9M_ScUUXYUqYG9MMm38zwQ_31_19">83,835</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodValueExerciseOfWarrants" sign="-" scale="3" id="Tc_gO1u_t9Z-kOkX18lSzzCWA_31_28">83,836</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock upon exercise of options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_YM95tk-jZUSDopZ9uejaBA_32_13">12,674</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H2d2wIpatEOMddtM_uXHjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_I4COBgYwQ0SfQQqDs7cvBw_32_19">65</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Rhhx-snlJk6_3r8IMMPMDA_32_28">65</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock upon conversion of Series A Preferred Stock</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7MnmvaWWgEePqWQTjdY9HA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" sign="-" scale="0" id="Tc_hxpbt8K-t0-77QoKpvyp9Q_33_8">1,000,000</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_AJfBDGXcQ0WxwfWoBBzAZQ_33_13">833,332</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock upon exercise of pre-funded warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw" decimals="INF" format="ixt:num-dot-decimal" name="vstm:SharesIssuedFromPreFundedWarrantExercises" scale="0" id="Tc_KbY_UF-H3EW0N-LHAo9vfA_34_13">2,499,665</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock resulting from at-the-market transactions</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw" decimals="INF" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodSharesAtMarketTransactions" scale="0" id="Tc_N7yP7LsnO0e5fl4DtjKRaQ_35_13">4,000,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodValueAtMarketTransactions" scale="3" id="Tc_F2CQH6yojk-zX7xpajG24Q_35_16">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H2d2wIpatEOMddtM_uXHjg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodValueAtMarketTransactions" scale="3" id="Tc_svGuadgzTEWjnJnSeSDEug_35_19">22,736</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodValueAtMarketTransactions" scale="3" id="Tc_XkUr-Hr1K0OpSugA47_U3A_35_28">22,737</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">Issuance of common stock, net of issuance costs of </span><span style="font-size:5.5pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_1OWrT9Fu4UCQkj8KVirRIA">74</ix:nonFraction></span><span style="font-size:5.5pt;">K</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw" decimals="INF" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodSharesStockPurchaseAgreement" scale="0" id="Tc_i1vymRu-H0q9AxEdV08SQg_36_13">1,416,939</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H2d2wIpatEOMddtM_uXHjg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodValueStockPurchaseAgreement" scale="3" id="Tc_CXX1YDrSVk6muHkFK-8D4Q_36_19">7,426</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodValueStockPurchaseAgreement" scale="3" id="Tc_ZQo6AOIxUESVDxrPxGh62A_36_28">7,426</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">2025 Private Placement issuance of common stock, and pre-funded warrants, net of issuance cost of </span><span style="font-size:5.5pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_3L8cmMQep0K6q--7_1jqxA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_hbfVkkd0e0emxW072MVwgg">5,072</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_VeTMKHIwC0eLyAN6WUjVXA" decimals="INF" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" scale="0" id="Tc_isHfBfHiIkyx9AsO_awAkw_37_13">3,429,287</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_VeTMKHIwC0eLyAN6WUjVXA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts" scale="3" id="Tc_BrROHLVTLU2--m3RYawBbA_37_16">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_wgrwxnERa0qwi96U9x_blQ" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts" scale="3" id="Tc_H8K9YAUvs0ajrd-1YHc7Kw_37_19">69,932</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_3L8cmMQep0K6q--7_1jqxA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts" scale="3" id="Tc_oSHthQIjHkO3ScS7jlqL_w_37_28">69,933</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:5.5pt;">November 2025 Public Offering issuance of common stock, and pre-funded warrants, net of issuance cost of </span><span style="font-size:5.5pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_jUBqmRoabkGaS293dmEkgw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_Qnrmlfqco0SP_k38L9rNBg">6,617</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_SkzoBDCVyE253YNoI4hWww" decimals="INF" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" scale="0" id="Tc_TuuC8h7SM0uM_D1482Hc_w_38_13">10,405,863</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_SkzoBDCVyE253YNoI4hWww" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts" scale="3" id="Tc_QQ1VQhLPpECyb7wz2C1hFw_38_16">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_Pf0AlvNsAkKhEKrfCVhX9w" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts" scale="3" id="Tc_VdLaT6fDSUaCpnN5Ibg3MA_38_19">96,879</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><span style="font-size:5.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_jUBqmRoabkGaS293dmEkgw" decimals="-3" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts" scale="3" id="Tc_ZMx_3iEj90ifizxJ-zokDQ_38_28">96,880</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">Balance at December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MohRnXLqbEGEo5fjQezNRw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_iS3KjXRrxUu4mzG4bESIOg_39_13">77,739,712</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MohRnXLqbEGEo5fjQezNRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_kWXGdS2gh0635vU6dnrnCw_39_16">8</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fuhD4w1zHUO3JOvClD8XNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_qliHnNq1UUSQFNGeElaZrQ_39_19">1,216,958</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7Z9PHqH2q0S7RrWVtY151Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_57-dGx3Q_Uij5h3B8uDHIg_39_22">5,229</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dp0SN57cD0KXZDKWXesKDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ZEj422Jcvkq5pzKDVJe0HQ_39_25">1,164,998</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-size:5.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 1.5pt 0pt 0pt;"><b style="font-size:5.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_hTuCCvxfh0u1CrDnib6HyQ_39_28">57,197</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 12pt 0pt;">See accompanying notes to the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8fb2de4d_6828_4645_821f_5f04878821af"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Verastem,&#160;Inc.</b></p><a id="Cash_Flows"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><a id="_f7630c2d_04a8_43cb_9532_1b08b30ddeff"></a><a id="Tc_M1SBrqcew0KL57ZLQ19-9A_1_2"></a><a id="Tc_vGuDkFjjkEaEs5hPpLQLfQ_2_2"></a><a id="Tc_kdH4JvbXq0e-G53Is4ot8Q_2_5"></a><a id="Tc_hgFzIrYREUqA9aercgFmlw_2_8"></a><a id="Tc_SXuH7002dUO7o2FqUe24Xw_3_0"></a><a id="Tc_HW2YwvSwtUyw3Vnm1vEjTg_4_0"></a><a id="Tc_3q5CpctnfkSgKtM8nyoXWA_4_2"></a><a id="Tc_MfVVom8zmUqQWakUVtqrig_4_5"></a><a id="Tc_cS8NX3pNBUaXQk5YXRaFxg_4_8"></a><a id="Tc_MyCVZWK_RkWt-yg1ujx-Kg_5_0"></a><a id="Tc_bLg6QncxnECN-SdkBkMYhg_6_0"></a><a id="Tc_oYoFxSWWI0SMpp07g74vBw_7_0"></a><a id="Tc_iZXOfT3se0GLqrJZAX-pvw_7_6"></a><a id="Tc_y3AX0WggD0ufc0okv_rmjA_7_9"></a><a id="Tc_loyub3xg5EeIAOb2r5AjVQ_8_0"></a><a id="Tc_iqGg5LeFwEexZLWcpQH33Q_9_0"></a><a id="Tc_N21bQKTJ_U-1DVk8jl-hbw_10_0"></a><a id="Tc_plieGUMj8U-q0OBFjWv_0g_11_0"></a><a id="Tc_cdHIYwvh7EWHOp_ZEsNuww_11_3"></a><a id="Tc_hTTvilZOI0S2R03QfSgSFA_12_0"></a><a id="Tc_2sDYtbA2c0-f-stT1Xcfew_12_9"></a><a id="Tc_52RlAhM8lk6P9pvnxRusCg_13_0"></a><a id="Tc_92pvHg39A0KlX56jvxtrNw_13_6"></a><a id="Tc_PMlk0xUHJUSp2qareiah2g_13_9"></a><a id="Tc_-fFFufe-BUqk95rTgRKsBw_14_0"></a><a id="Tc_UvHUNWy_XkGNo3GjTy6gdw_14_6"></a><a id="Tc_cKq2T_-dJk-5c_5OOgJVXA_14_9"></a><a id="Tc_rPlE4-GHN0OIV9ksN1tMLA_15_0"></a><a id="Tc_cW5X2AeCIEmPvYZHFCwgGg_16_0"></a><a id="Tc_KtWbR3M2W0KTmy6zWvEhQw_16_6"></a><a id="Tc_kBa1PB9OtEWKWY9RndOWvQ_17_0"></a><a id="Tc_u8bLxGL--UWlMYnq18DxuQ_17_3"></a><a id="Tc_Vr80hdieYE-Diom_RcZgyw_17_9"></a><a id="Tc_Eab2Ciw1rE2kCZV1J71riw_18_0"></a><a id="Tc_uGjsnFV3ZE-s66TTbuo9XA_18_6"></a><a id="Tc_zNaR-OFdGkKUgS5PZtg-4A_18_9"></a><a id="Tc_jtgHxn7R-EyoZJcSWygByw_19_0"></a><a id="Tc_fen9jbQ8jk6dtpgNIqYycw_20_0"></a><a id="Tc_6edtp7XtYUW-3CwFxdkJmQ_21_0"></a><a id="Tc_fgE4dnst1U-_Oh4nLh1lNA_22_0"></a><a id="Tc_O6JveYtP7kaC2QSAVtx0gg_22_3"></a><a id="Tc_8NrYa4rBeEynl3FnXwxbWQ_23_0"></a><a id="Tc_0ffeWcg2JUmn-6krdRP5GQ_24_0"></a><a id="Tc_3AsD2Z5ilEOGeLzcEZoO0g_25_0"></a><a id="Tc_gCotJvDHCUycQh_SeEYUfA_25_3"></a><a id="Tc_rM6O6UR27E-Cod0JGqbN8Q_25_9"></a><a id="Tc_FX350p1rAEmqVNx38QOs0Q_26_0"></a><a id="Tc_qN7HgNZcyUyPO8Q0Nsmk1Q_26_6"></a><a id="Tc_Vl8KEvOPbEeNQC3Y6a_oMg_26_9"></a><a id="Tc_D1hKetjsT0qGM_9cZPfo1A_27_0"></a><a id="Tc_PbkY6ScgpkKMNVFeaSZqfQ_27_3"></a><a id="Tc_Q9fw-8gAXUyvaR01ZuAZWg_27_6"></a><a id="Tc_Ebb6K-k8uEyrvG-kwkS-kQ_28_0"></a><a id="Tc_n9K8_WOH4UWNCYlAfTYWcQ_28_3"></a><a id="Tc_4LEmLnv7VkqT0gAHyud6zw_29_0"></a><a id="Tc_9EOxmZTdk0-56aA4W6DK3w_30_0"></a><a id="Tc_dUNEcdb8ZEW5Zk1YdI1OsQ_31_0"></a><a id="Tc_rKMUtOYmwEWJ4yVBHNDD9Q_32_0"></a><a id="Tc_LnNZPlIRSkWZtSYbucJizA_32_3"></a><a id="Tc_yCaROmpZsUi1uvMinR-ACw_32_9"></a><a id="Tc_AVcSh5yrZUWEq9z8Lf-PYg_33_0"></a><a id="Tc_Le3S_wcRxUyO1kHvuiPoNQ_33_3"></a><a id="Tc_Pm--TD0UYkOa2A-jtNF4Jw_33_6"></a><a id="Tc_XXAi_cmqR0ye1szQGxMgRQ_34_0"></a><a id="Tc_E4_SqQEEx0uJ0uOgnCmElg_34_9"></a><a id="Tc_NUwkFy1Dl0ObCu_kMjblQA_35_0"></a><a id="Tc_ke6mVlG_SEyxKcCG-NzjKw_35_6"></a><a id="Tc_raLhza_Gv0eQdjqrsdDc1Q_36_0"></a><a id="Tc_tiKW1MpwA0uZNO9PyQuSEA_36_6"></a><a id="Tc_e9S_YU4mKEmJ_d499PvypA_36_9"></a><a id="Tc_7tgwKWWk-kKmSd5UWbW5FA_37_0"></a><a id="Tc_-QlCl1_BCkCHPtbW7F-IqA_37_3"></a><a id="Tc_Fer8bgS5E0-QtyC0HKSlSA_37_9"></a><a id="Tc_BDY7DCnPLkGyE_G56aa39Q_38_0"></a><a id="Tc_JQgCgf4RZE6Li1skMNKbXg_38_3"></a><a id="Tc_lEPYTolqgkKVA1PlUP4KKA_38_6"></a><a id="Tc_fiwjs7703Em7msceVNbZ_Q_39_0"></a><a id="Tc_FvoznEWXpke2aoTytJI_IQ_40_0"></a><a id="Tc_DCQ7cSV5rkOYXObReB-Vmg_41_0"></a><a id="Tc_pMKZxcDUX0OKZUvEw8Jdbg_42_0"></a><a id="Tc_SqCwOHPvuEeA09QA2LQO4A_43_0"></a><a id="Tc_V0Vr5Mvu4E6FyZl9qztSUw_44_0"></a><a id="Tc_TZnt9MXIxEivH1Hc3pDikg_45_0"></a><a id="Tc_fzm1YB70pUCxihsqwVWP-w_45_2"></a><a id="Tc_DSvrTYJ2Tk2DXlgS9ccYQA_45_5"></a><a id="Tc_9O1ZXHPzKkOGxeflswn8yQ_45_8"></a><a id="Tc_Ii38heGvhkm9Yz5-mPegYg_46_0"></a><a id="Tc_OlR7As9X7U2Be36T96DivA_47_0"></a><a id="Tc_mF5XqHVrOkiQIgt4elMVwA_47_2"></a><a id="Tc_S_fyRy010EySyrhS6xR8Ug_47_5"></a><a id="Tc_nKVdWWqa8kWz7_Hf12pMJA_47_8"></a><a id="Tc_jaYu_jxaKkKy-ru36RICOg_48_0"></a><a id="Tc_y_74eYVJR0aW_N97wodY_w_48_2"></a><a id="Tc_AjuYQR0RP0-PK63Ed7iMKg_48_5"></a><a id="Tc_uPztY0O7wEu9Ei7kszRvag_48_6"></a><a id="Tc_3CgX2HrHNE2ewFyIoALGHg_48_8"></a><a id="Tc_jPnzpDlxP0Cv-Vaa3m9rEw_48_9"></a><a id="Tc_oJALkH7NK06vtBTpN1wwVA_49_0"></a><a id="Tc_vEyzOwssMk-Lix6YVX8s6g_50_0"></a><a id="Tc_OvGybImQeEaXCWCXPXT1Og_50_2"></a><a id="Tc_xmN7A89diEOeqZPCDFxIsg_50_3"></a><a id="Tc_3OcOh4D2rkSEngUrcrZ0_w_50_5"></a><a id="Tc_qzh5gbHZLU-y0O-GDl9PAg_50_6"></a><a id="Tc_dDTzC5ZftEK2Fh3AvHJiNQ_50_8"></a><a id="Tc_y7oA7UO8DUKh34WxeJvhqw_51_0"></a><a id="Tc_nI0EqMOHPki5j6ID0Pm08g_51_2"></a><a id="Tc_yuJuk5yLm0eBhvgsd-c0Vw_51_3"></a><a id="Tc_RC0KnYdaaEWRWquUjeB3kw_51_5"></a><a id="Tc_RmbfXpA3QkGsj55-X5mjFQ_51_6"></a><a id="Tc_pAfzNZkJ906tLyWKcmWdqQ_51_8"></a><a id="Tc_6DA8VGY97UyrVVO7nujkHQ_52_0"></a><a id="Tc_U_RVb4hZYUKaUM6468T9hw_52_2"></a><a id="Tc_hlu8m63q80eMUYS0xSTlWw_52_3"></a><a id="Tc_sMjk431pa0mOsw1vJa4f1g_52_5"></a><a id="Tc_RHoyK2lF3EikTfaJ_8xc0Q_52_8"></a><a id="Tc_EYvnC3ZIVkqPkEyfOhcRAg_52_9"></a><a id="Tc_tO6Li9jRCEqkVozqSJZcSg_53_0"></a><a id="Tc_kcIayRiJS0KuGfDz-H4PEQ_53_2"></a><a id="Tc_txXA6zFfI0m4DQHnOKwZ6w_53_3"></a><a id="Tc_q8YFFZNuGU6idigIsoSVQg_53_5"></a><a id="Tc_oykzGjjck0-KnJQ2d1DNYQ_53_8"></a><a id="Tc_WkLjt8wAfUuxN9CXeMy2oA_53_9"></a><a id="Tc_q6zXhwiACUunW2b3vkZM1A_54_0"></a><a id="Tc_QZNTCTdTDkOaKgqCS6-AAg_54_2"></a><a id="Tc_JQGKsWQ2_kSXA9QjxeQpxA_54_5"></a><a id="Tc_UHcEqAtk7UW5jG03ikZTEA_54_8"></a><a id="Tc_bzUgglpY8U244__eqEo-NA_54_9"></a><a id="Tc_jv6foavdjUmINuu-EncqXA_55_0"></a><a id="Tc_Agtsua5XykOOg9zbfjtwKQ_55_2"></a><a id="Tc_fZVlOfwaf0W9sDvzW2-FxQ_55_3"></a><a id="Tc_VlPR3F8Rck2ArozGFDcyaw_55_5"></a><a id="Tc_m1AfVrOJpUCxirj9OxnnBQ_55_8"></a><a id="Tc_4677VGQlT0-7AnOqYhtCug_55_9"></a><a id="Tc_GbxyXLZod0CFL5y4R-0row_56_0"></a><a id="Tc_DWT-4pjWq0aGNgjrvFY4kw_56_2"></a><a id="Tc_pAnOZVSIs0aXFW9lDdX8EA_56_5"></a><a id="Tc_tSd5qKcgi02ndGjjCFb5tQ_56_6"></a><a id="Tc_pwVaMfsIO0CZHh4MpCBd-w_56_8"></a><a id="Tc_igc8kmiK-UKwKDOus2XzzQ_56_9"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_0SSzR22y0E2OZ1yMWKqdYQ_4_3">209,471</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_gIU1VK3xIEWstKMWNf22Jw_4_6">130,637</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_ZITObUFFrkmTFL5E-8H11A_4_9">87,367</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_qcqgXELq502-9yamdCV-cw_6_3">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_ByjUupzhU0SPZ9vlinyxZw_6_6">26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc__Z5w7iOxfUmhvnrhnnCR0g_6_9">62</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Amortization of acquired intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc__Unt3cXEHUG2fQNN4JGebA_7_3">698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Non-cash operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:OperatingLeaseNonCashCost" sign="-" scale="3" id="Tc__fmE771aSUarUSvA5fVUog_8_3">81</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="vstm:OperatingLeaseNonCashCost" sign="-" scale="3" id="Tc_fOG2ORt-wkCmhvGyHkh1fg_8_6">175</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="vstm:OperatingLeaseNonCashCost" sign="-" scale="3" id="Tc_HZ9WSXH0IUiGLQM3D3dHzQ_8_9">175</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_CWx3ZVq9iUCdmPd-JtjVDg_9_3">9,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_VEJD7x1kxkSWn8mdOnEedg_9_6">7,342</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_oUc4UoLIA0qM8r7W26savA_9_9">5,860</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Amortization of deferred financing costs, debt discounts and premiums and discounts on available-for-sale marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_XWg6ElZY40eRYRGZp7KMmg_10_3">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" sign="-" scale="3" id="Tc_vE-VA8qWhEefNEPJOsxibQ_10_6">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" sign="-" scale="3" id="Tc_czL8QIcEokKJDoeX8Lk_Qw_10_9">1,132</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of preferred stock tranche liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ChangeInFairValueOfOfPreferredStockTrancheLiability" sign="-" scale="3" id="Tc_0Aygby4rt0KbezifCqqIAQ_11_6">4,189</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ChangeInFairValueOfOfPreferredStockTrancheLiability" sign="-" scale="3" id="Tc_rGUNjO7spkevSBu0lq16oA_11_9">2,751</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_NccuQqC2JU6PwjMCg-T4Bw_12_3">27,492</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_Jh9TC0XiKkCtd1VzFiBv-w_12_6">19,149</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Non-cash change in fair value of Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:FairValueAdjustmentOfNotesNoncash" scale="3" id="Tc_hhviwa0CzUmJ_Sulae1fVg_13_3">6,560</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Loss on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_zUFr2EZ8WESteR8uvSkF4A_14_3">1,826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_lIf22UU3m0ys6NbaONzoYA_16_3">8,813</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_MoQoasyqOU28RyPQRibAHg_16_9">31</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Grant receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="vstm:IncreaseDecreaseInGrantsReceivableNet" sign="-" scale="3" id="Tc_vTHmpR2QnUWbcOO55pFuEg_17_6">200</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_RJ2T3AbMW02dq9R3G-ahWg_18_3">1,833</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses, other current assets and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_wShj8x_GmkuXleLyKWw1FQ_19_3">2,605</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_qOBklsmatkOTcPlThLqeYg_19_6">596</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_SxtGzRlimU-VQtWuHLX_Pg_19_9">5,826</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_OV2wSHebBku8tTwqHyh4HA_20_3">8,422</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_xqD3MKJvAU6uz9r_IUvVqA_20_6">3,158</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_7nvz1eYGbES6dOhnQCzVnA_20_9">2,283</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_YcK-fMWw4EiHG8pLi4HPIg_21_3">30,833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_TQqxHna3KkufZrdPk3eTuQ_21_6">7,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_R9aTG3PW2kmFlvxtgNiuTA_21_9">2,938</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Deferred liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" sign="-" scale="3" id="Tc_vQJMjH4cf0CL_kOki3SxnQ_22_6">327</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" sign="-" scale="3" id="Tc_lWMt_wsluUORD6GL9fbRxg_22_9">383</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_mCLytG3FUkGeWZIR5WU0og_23_3">137,509</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_tb_YI561SU-DBE1wguz5dg_23_6">104,771</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_oCn0jl7hMUK6598c4WPzVQ_23_9">86,460</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_8JSEJDEj60O_rXXuxwirdg_25_6">28</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Purchases of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_egLAM3383k-eMr5ObfPf-Q_26_3">9,624</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Purchases of investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="Tc_z3BKOazaskyX2S8dJ8rMjg_27_9">96,447</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Maturities of investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="Tc_tw7eykG0L0meVQZ_xqO0fA_28_6">60,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="Tc_5wDP5CtwaUKTcC4o4N2RBw_28_9">52,000</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net cash (used in) provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_mIbYla_iQ0eECLFEjPjUSQ_29_3">9,624</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_iaCvXd1dyE6Wa_JrZ2DR3w_29_6">59,972</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_bzAmD4deAkSF8Q0sAbOgAQ_29_9">44,447</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Proceeds from the issuance of common stock and pre-funded warrants, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_DUSkOs5TakOdsvi60RbPhA_31_3">196,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_WIzo0Hb1HUOVJweHV5RRXg_31_6">14,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_NT5iW9pkik2Kpzd-dZFERw_31_9">91,420</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Proceeds from the issuance of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="Tc_ydJ7bY4o5ky6c03ZifM8LA_32_6">39,595</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Proceeds from issuance of Series B Convertible Preferred Stock, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="3" id="Tc_q8et-cDcUE6kShq3CJ1zIA_33_9">28,099</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Proceeds from exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_9zZgfU0t0kmweHO7CXXreg_34_3">33,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_ekClTvBDH06U4kOAePA92w_34_6">875</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Proceeds from long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="3" id="Tc_L9i0JvIp2Uulmv93fMv-EA_35_3">75,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="3" id="Tc_7-BmDZRPhUGs_uK945NPDQ_35_9">14,918</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Repayment of long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Tc_JZM_F0HRNEWCaKndwTrIjw_36_3">42,579</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Payments for loan amendment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfLoanCosts" scale="3" id="Tc_uU27Efymo0CXOB10m-7-bw_37_6">150</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Repayment of 2018 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" sign="-" scale="3" id="Tc_Lix7f_muZU-J3jZH1tx1Rw_38_9">300</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Proceeds from insurance premium financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProceedsFromInsurancePremiumFinancing" scale="3" id="Tc_TOEpKLUB4E2u_TRR5rwFSw_39_3">1,180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProceedsFromInsurancePremiumFinancing" scale="3" id="Tc_pTDP15AQZkaLmCALxFgZkQ_39_6">1,298</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProceedsFromInsurancePremiumFinancing" scale="3" id="Tc_gQIecEZH5Euqb_hSrMlZuw_39_9">1,430</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Payments on insurance premium financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:PaymentsOnInsurancePremiumFinancing" scale="3" id="Tc_l0Sufz5DcUGW8BYEEwxSaQ_40_3">1,180</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="vstm:PaymentsOnInsurancePremiumFinancing" scale="3" id="Tc_xgkTlYGlxU2U6nBwimBMiA_40_6">1,298</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="vstm:PaymentsOnInsurancePremiumFinancing" scale="3" id="Tc_KdieBc_ujEKgC1VT-ZFyyw_40_9">1,430</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Proceeds from the exercise of stock options and employee stock purchase program</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_BGYT6B-yQkG2iqqe1QgRsQ_41_3">116</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_gHlDFLDMskyxHn1W_TFhJw_41_6">241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_3kzVg01cwE-17Pbu-xVYHg_41_9">57</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_5Ygco0InOE-cUDDwTVUYfQ_42_3">263,305</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_UdsJbS9b0ESFpAXuFpa2Ew_42_6">54,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_jAQ3xUsIJE6RuIeJrpyDFQ_42_9">134,194</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Increase in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_i9npdRxKvU6-QjhU1bc6_g_43_3">116,172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_4s0KjEMZOECgTsAfMLWpoQ_43_6">9,983</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_tj0rydcPekuhAxAhxpnkjg_43_9">3,287</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash, cash equivalents and restricted cash at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_aLI5p74MTk2BNKcLiRQFBQ_44_3">89,059</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2023_Uyhdm4_rYEOg-NEKFqTeBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_RxPyRjaXKEaW7lvLzdusXA_44_6">79,076</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2022_z5GNzJxej0aeNGqmRjwWLg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_3JbSZzSXGUGkUFekdq6UZw_44_9">75,789</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash, cash equivalents and restricted cash at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_cMBNSL73AkWvl9EDjFbEJw_45_3">205,231</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_I30byK9BBkSLmoxOwpBMVw_45_6">89,059</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2023_Uyhdm4_rYEOg-NEKFqTeBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_mb0tZGcnaU65vk_49qWFXg_45_9">79,076</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosure</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_uXb-DsDuiEeTwx84HrnOjA_47_3">6,364</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_o5SPG7cR3Uy-S47CvKp8Kg_47_6">3,774</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_z_HBuQ3xXkO1cWbKuYl4ig_47_9">3,361</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash paid for income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_heqHyCvMEUantsVzOyXTHw_48_3">185</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosure of non-cash investing and financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of preferred stock tranche liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="vstm:IssuanceOfPreferredStockTrancheLiability" scale="3" id="Tc_Ba8FqWDVNUKCa053DjxUWg_50_9">6,940</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Purchases of property and equipment included in accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_T5EBnN3IvEibTpOjCz9opw_51_9">7</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance costs included in accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="Tc_G2Oq6SjkJEeUFFkQFDoqXQ_52_6">32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Conversion of Series B Convertible Preferred Stock to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_bPhZieDPSEqAXRDTnngc_A_53_6">21,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Conversion of warrant liability into additional paid-in capital upon warrant exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:FairValueAdjustmentOfWarrantsExercised" scale="3" id="Tc_EmTK5_V6qkqkYpPFsl4Rew_54_3">50,044</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="vstm:FairValueAdjustmentOfWarrantsExercised" scale="3" id="Tc_myi5jYo6MUS9yK6PPG0l4g_54_6">545</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:68.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Right of use asset obtained in exchange for operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_CLmZubx_AEq2NVuYsLCsjQ_55_6">988</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:middle;width:68.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Purchases of intangible assets in accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="3" id="Tc_TvfDxgGB5UuLCZmeQculJQ_56_3">7,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS"></a><a id="_Hlk39483229"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:NatureOfOperations" id="Tb_5hdxbLf36k6bqkhfmJMERg" continuedAt="Tb_5hdxbLf36k6bqkhfmJMERg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Verastem, Inc. (the &#8220;Company&#8221;)<span style="background:#ffffff;"> is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with </span>challenging RAS/MAPK pathway-driven cancers. The Company markets AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the U.S., the first treatment specifically FDA-approved for adults with KRAS-mutated recurrent LGSOC who have received prior systemic therapy. AVMAPKI FAKZYNJA CO-PACK received accelerated approval in the U.S. on May 8, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s pipeline is focused on novel small molecule drugs developed both as monotherapy and in combination, which inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including targeting RAS directly with KRAS G12D inhibition, targeting the pathway downstream with RAF/MEK inhibition, and targeting the parallel pathway that drives resistance with FAK inhibition. The Company&#8217;s focus is to expeditiously develop and deliver transformative therapies that truly change outcomes for people living with RAS/MAPK pathway-driven cancers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of Verastem Securities Company and Verastem Europe GmbH, wholly-owned subsidiaries of the Company.&#160;All financial information presented has been consolidated and includes the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the risks associated with other life science companies, including, but not limited to, possible failure of preclinical testing or clinical trials, competitors developing new technological innovations, commercial success of the Company&#8217;s marketed product AVMAPKI FAKZYNJA CO-PACK, inability to obtain marketing approval of the Company&#8217;s product candidates, market acceptance and commercial success of the Company&#8217;s product candidates following receipt of regulatory approval, and, protection of proprietary technology and the continued ability to obtain adequate financing to fund the Company&#8217;s future operations. Until such time, if ever, that the Company can generate substantial product revenues or achieve profitability, it may need to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="Narr_s6erLGsY80GbHzVhGoRqmw">205.0</ix:nonFraction> million and an additional $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7S9Co7osyUKPh1S2Fr2wNQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_vcVDVSg3aE-Dk4erlVP0Gw">29.4</ix:nonFraction> million in proceeds in January 2026 from the exercise of Warrants (see <i style="font-style:italic;">Note 20. Subsequent Events</i>). <span style="background:#ffffff;">In accordance with applicable accounting standards, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within 12 months after the date of the issuance of these consolidated financial statements. </span>The Company expects its existing cash resources, including the proceeds from the exercise of Warrants in January 2026, along with revenue it expects to generate from sales of AVMAPKI FAKZYNJA CO-PACK and the availability to draw down $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_srt_StatementScenarioAxis_vstm_SecondSaleMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_1vwgf71uzE-hN_Nsosf5bQ" decimals="-5" format="ixt:num-dot-decimal" name="vstm:DebtInstrumentIssuanceOfAdditionalNotes" scale="6" id="Narr_ztsTd6dt1Eur941rvZ3eRA">25.0</ix:nonFraction> million under the Second Purchase (defined herein) pursuant to the Company&#8217;s Note Purchase Agreement (defined herein) (see <i style="font-style:italic;">Note 8. Long-term debt</i>) will be sufficient to fund its planned operations through 12 months from the date of issuance of these consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had concluded that there was substantial doubt about its ability to continue as a going concern primarily due to anticipated operating losses for the foreseeable future since the Company did not yet have regulatory approval to sell any of its product candidates, and the Company continued to incur operating costs to execute its strategic plan, including costs related to research and development of its product candidates and commercial readiness activities. The Company&#8217;s increased cash and cash equivalents position as of December 31, 2025, forecasted net product revenue following regulatory approval of AVMAPKI FAKZYNJA CO-PACK on May 8, 2025, and ability to draw down on the Second Purchase pursuant to the Note Purchase Agreement, alleviated the substantial doubt. </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_5hdxbLf36k6bqkhfmJMERg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company expects to finance its operations with its existing cash and&#160;cash equivalents, through revenue generated from sales of AVMAPKI FAKZYNJA CO-PACK, through potential future milestones and royalties received pursuant to the Company&#8217;s Asset Purchase Agreement (&#8220;Secura APA&#8221;) with Secura Bio, Inc. (&#8220;Secura&#8221;), note drawdowns pursuant to the Note Purchase Agreement, or through other strategic financing opportunities that could include, but are not limited to collaboration agreements, future offerings of its equity, or the incurrence of debt. However, there is no guarantee that any of these strategic or financing opportunities will be executed or executed on favorable terms, and some could be dilutive to existing stockholders. If the Company fails to obtain additional future capital or generate sufficient net product revenue, it may be unable to complete its planned preclinical studies and clinical trials and obtain approval of certain investigational product candidates from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:14pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><span style="font-size:10pt;">On May 30, 2023, the Company filed a Certificate of Amendment to the Company&#8217;s Restated Certificate of Incorporation, as amended to date, with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company&#8217;s issued and outstanding common stock, par value </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_5_30_2023_us-gaap_TypeOfArrangementAxis_vstm_CertificateOfAmendmentMember_Q_y7EUi3X0K_kq-y8s1gbw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_NcSiU9W8i02x7FSS8iTUiA">0.0001</ix:nonFraction></span><span style="font-size:10pt;">&#160;at a ratio of&#160;</span><span style="-sec-ix-hidden:Hidden_mxFYjHBtZEODqcY96vbZbg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-12</span></span><span style="font-size:10pt;">&#160;(the &#8220;Reverse Stock Split&#8221;), as authorized at the Company&#8217;s 2023 annual meeting of stockholders held on May 15, 2023. The Company effected the Reverse Stock Split on May 31, 2023. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise were entitled to a fractional share of common stock were entitled to receive a price equal to the closing price of the common stock on the Nasdaq Capital Market on the date immediately preceding the Reverse Stock Split, as adjusted by the ratio of&#160;</span><span style="-sec-ix-hidden:Hidden_UDYzqQ6S1E630AMzLLYW3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span><span style="font-size:10pt;">&#160;share of common stock for every 12 shares of common stock, multiplied by the applicable fraction of a share. The number of shares of common stock that the Company is authorized to issue remains at&#160;</span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_5_30_2023_us-gaap_TypeOfArrangementAxis_vstm_CertificateOfAmendmentMember_Q_y7EUi3X0K_kq-y8s1gbw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_mw0C8Odav02DyDt1Df5bTw">300,000,000</ix:nonFraction></span><span style="font-size:10pt;">&#160;shares and the par value of its common stock remains unchanged at </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_5_30_2023_us-gaap_TypeOfArrangementAxis_vstm_CertificateOfAmendmentMember_Q_y7EUi3X0K_kq-y8s1gbw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_G2U-4tOEYUOUFXjTznRIxg">0.0001</ix:nonFraction></span><span style="font-size:10pt;">&#160;per share.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">The Company has retroactively restated the share and per share amounts in the consolidated financial statements for the year ended December 31, 2023, to give retroactive effect to the Reverse Stock Split. The consolidated statements of convertible preferred stock and stockholders&#8217; equity reflect the impact of the Reverse Stock Split by reclassifying from &#8220;common stock&#8221; to &#8220;additional paid-in capital&#8221; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split the year ended December 31, 2023.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_vWyN4-5fukus7nNiyj-pYw" continuedAt="Tb_vWyN4-5fukus7nNiyj-pYw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. Significant accounting policies</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_6vUlRVoHPkOhpLP7yAY-0w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis of presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) under the assumption that the Company will continue as a going concern for the next 12 months. Accordingly, they do not include any adjustments that might result from the uncertainty related to the Company&#8217;s ability to continue as a going concern.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:UseOfEstimates" id="Tb_V1xph460H0qslkUP6Cx7ew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The preparation of the Company&#8217;s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including but not limited to estimates related to revenue recognition, accrued and prepaid clinical trial expense and other general accruals, stock-based compensation expense, long-term debt, and its warrant liability. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable. Actual results could differ from such estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_PTYBhBdm_kWeQq0Lp8dnRA" continuedAt="Tb_PTYBhBdm_kWeQq0Lp8dnRA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Segment and geographic information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available and regularly reviewed by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_2FKJs_GyQEmjdbqSsPiF6A_1_2"></a><a id="Tc_5sP2F7ZbzkqX5AY2y0poAQ_1_5"></a><a id="Tc_4ADxRpUhpEmQtfhSXuwBXA_2_0"></a><a id="Tc_6KJFacLGf0aiVKssGEELLQ_2_2"></a><a id="Tc_aQRLgwqcFka40gmcP2Ayuw_2_5"></a><a id="Tc_u66SK4dkW0u5OpU-j9H02g_3_0"></a><a id="Tc_O_9hMH51qk-XNuhjxZ-0_g_4_0"></a><a id="Tc_SC-2vqCwq0KQOb2VtC-oJA_4_2"></a><a id="Tc_vzLOswNeW02RiYk1k8TuPA_4_5"></a><ix:continuation id="Tb_vWyN4-5fukus7nNiyj-pYw_cont1" continuedAt="Tb_vWyN4-5fukus7nNiyj-pYw_cont2"><ix:continuation id="Tb_PTYBhBdm_kWeQq0Lp8dnRA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_item_5quK1hZThku2W0bLLpUodA" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_jTbTgmTMs0KhIoa5YQGTww">one</ix:nonFraction> operating segment, which is the business of researching, developing and commercializing drugs for the treatment of patients with cancer. All material long-lived assets of the Company reside in the U.S.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="vstm:ProceedsFromGrantsPolicyPolicyTextBlock" id="Tb_i4l6yR-JRU6wuSq4oHUFzA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Proceeds from grants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><span style="font-size:10pt;">In May 2022, the Company was awarded the &#8220;Therapeutic Accelerator Award&#8221; grant from Pancreatic Cancer Network (&#8220;PanCAN&#8221;) for up to </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_5_1_2022_To_5_31_2022_0S7CWDwAHkCwzDSQQTfHkw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GovernmentAssistanceAmount" scale="6" id="Narr_FUmzD7awh0SZxrZanPCWOQ">3.8</ix:nonFraction></span><span style="font-size:10pt;">&#160;million (the &#8220;</span><span style="-sec-ix-hidden:Hidden_q90ZIR8th0OGZ8dK-5vu4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PanCAN Grant</span></span><span style="font-size:10pt;">&#8221;). In August 2022, PanCAN agreed to provide the Company with an additional </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_GovernmentAssistanceTypeAxis_us-gaap_GovernmentAssistanceOtherMember_GBuPX_U0g0azpKLEVKIehg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GovernmentAssistanceAmount" scale="6" id="Narr_lfsO337R_kqJQ3_gezCSsQ">0.5</ix:nonFraction></span><span style="font-size:10pt;">&#160;million for the collection and analysis of patient samples. The grant is supporting a Phase 1b/2 clinical trial of GEMZAR (gemcitabine) and ABRAXANE (Nab-paclitaxel) in combination with avutometinib and defactinib entitled RAMP 205. The RAMP 205 trial is evaluating whether combining avutometinib (to target KRAS mutant, which is found in more than 90% of pancreatic adenocarcinomas), and defactinib (to reduce stromal density and adaptive resistance to avutometinib) to the standard GEMZAR/ABRAXANE regimen improves outcomes for patients with such pancreatic cancers. The Company recognizes grants as contra research and development expense in the consolidated statement of operations and comprehensive loss on a systematic basis over the periods in which the Company recognizes as expenses the related costs for which the grants are intended to compensate. Eligible expenses incurred in excess of grant payments received up to the total amount of the PanCAN Grant are recorded as a grant receivable. Through December 31, 2025, the Company has received </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GovernmentAssistanceAmount" scale="6" id="Narr_cfWSq9bxzkaQexDztsE4uQ">4.1</ix:nonFraction></span><span style="font-size:10pt;">&#160;million of cash proceeds that were initially recorded as deferred liabilities on the balance sheet. The Company recorded </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-5" format="ixt:num-dot-decimal" name="vstm:ReductionInResearchAndDevelopmentExpense" scale="6" id="Narr_8RuY6B-3O0-jmti92CPx9Q">0.0</ix:nonFraction></span><span style="font-size:10pt;"> million, </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-5" format="ixt:num-dot-decimal" name="vstm:ReductionInResearchAndDevelopmentExpense" scale="6" id="Narr_QnHNbUlPc0yxe_7y6u3TOg">2.0</ix:nonFraction></span><span style="font-size:10pt;"> million and </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:ReductionInResearchAndDevelopmentExpense" scale="6" id="Narr_jQZTnTMDjUiZ5aRTOXsyDw">2.0</ix:nonFraction></span><span style="font-size:10pt;white-space:pre-wrap;"> million of the proceeds as a reduction of research and development expense during the years ended December 31, 2025, 2024, and 2023, respectively.  As of December 31, 2025, the Company had </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GovernmentAssistanceAmountCumulativeCurrent" scale="6" id="Narr_J-YS-VIUekmJgpd9OdU_zg">0.2</ix:nonFraction></span><span style="font-size:10pt;"> million as a </span><span style="-sec-ix-hidden:Hidden_LYd0gLsYTUK5twLVxNTSUw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">grant receivable</span></span><span style="font-size:10pt;"> and </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:GovernmentAssistanceLiabilityCurrent" scale="6" id="Narr_C-u0OopesEmxEYN3cBzddA">no</ix:nonFraction></span><span style="font-size:10pt;"> deferred liabilities related to the PanCAN Grant recognized on the consolidated balance sheet.</span><span style="font-size:10pt;"> </span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_w-Hp0iEF902Q3VOTW6qcwA" continuedAt="Tb_w-Hp0iEF902Q3VOTW6qcwA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash, cash equivalents and restricted cash</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist of a U.S. Government money market funds and corporate bonds and commercial paper of publicly traded companies. Cash equivalents are reported at fair value. <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Group_fYOq2HoFf0mcEyrJJAQJHw" continuedAt="Group_fYOq2HoFf0mcEyrJJAQJHw_2" escape="true">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):</ix:nonNumeric></p><ix:continuation id="Group_fYOq2HoFf0mcEyrJJAQJHw_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:69.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_HpaPY8r520GCwrL5qOc_8g_2_3">204,990</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_CyangAmxL02iS49YHdg7jA_2_6">88,818</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="3" id="Tc_2Hup17hfEUmpISeX2UGBmw_3_3">241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashEquivalentsCurrent" scale="3" id="Tc_MmAyQgT8XUK9MflgCxnRWg_3_6">241</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total cash, cash equivalents and restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_OwOxeCY1Q0udWMpp9nClHw_4_3">205,231</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_e8hKDsF-ikaxDfWh9SPE7A_4_6">89,059</ix:nonFraction></b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Amounts included in restricted cash as of December 31, 2025 and December 31, 2024 represent cash held to collateralize outstanding letters of credit provided as a security deposit for the Company&#8217;s office space located in Needham, Massachusetts in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_BalanceSheetLocationAxis_vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_2wSiS_Brj0WdJYyQqH3Mow" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="6" id="Narr_ZpNCbGCFCESfQujDs9qzIQ"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_BalanceSheetLocationAxis_vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_2MkKTScWkE6izafnUVQf4g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="6" id="Narr__ruCEY-roEuZIZ7zj8VQ-Q">0.2</ix:nonFraction></ix:nonFraction>&#160;million. The letters of credit are included in<span style="color:#212529;">&#160;prepaid expenses and other current assets </span>on the consolidated balance sheet as of December 31, 2025, and in non-current restricted cash as of December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="6" id="Narr_c0P-5uJBeU68nJx0by4NOg"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="6" id="Narr_OqR9JdERVEqdl7Quuvj3Ow"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="6" id="Narr_DOt0Q7QgyEG4jJdibZAm7w">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> realized gains or losses on cash equivalents for the years ended December 31, 2025, 2024 or 2023. Accrued interest receivable is excluded from the amortized cost and estimated fair value of the Company&#8217;s cash equivalents. Accrued interest receivable of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivable" scale="6" id="Narr_l3jVtQna20KfYgIxrkV3Nw">0.2</ix:nonFraction> million is presented within prepaid expenses and other current assets on the consolidated balance sheets on December 31, 2025. There was <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:InterestReceivable" scale="6" id="Narr_AAoM4T8Gkkiq02xt1d1ttQ">no</ix:nonFraction> accrued interest receivable as of December </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_01442712_6c64_4248_b419_b14c29329ce1"></a><a id="Tc_ctEl9taha0-II7BxjeMcuw_1_2"></a><a id="Tc_k7JHZlorm06UWmWGFNB_Nw_2_5"></a><a id="Tc_1TlCUwSB-ki9Cb3a-thMqA_2_8"></a><a id="Tc_4Gn8U7OuL0-FdFkYPKVtig_3_2"></a><a id="Tc_JA6Kx92OrUm1LM6l4HpgGQ_3_5"></a><a id="Tc_TM8mZZG2bkWyTelY6y9Bsw_3_8"></a><a id="Tc_F8DO2HhdZEmdm42_wo0Q7g_3_11"></a><a id="Tc_phFaeMCDG0CFTmvEi6g_UA_4_2"></a><a id="Tc_ba66OFAw4kCf98ONNdpYHA_4_5"></a><a id="Tc_OpHddPNqYk62xMarwPHuUg_4_8"></a><a id="Tc_uFk1DKEiWkmsGaskNLZfOA_4_11"></a><a id="Tc_t1TkgV99eUieg-E3qZRg9Q_5_0"></a><a id="Tc_zlb4aeMv0UOzzpXw5FFlCA_6_0"></a><a id="Tc_Tu-q_5101EefCnf6iPv_bA_6_2"></a><a id="Tc_J53d19Vjy0O-3zMYdA4ykQ_6_5"></a><a id="Tc_yNi_9JNUUEmWQvIHQ2FJMQ_6_6"></a><a id="Tc_B2HDD4EsgU-wpZ25I9wqZw_6_8"></a><a id="Tc_xazEcnvR9EWvaN3moEvplQ_6_9"></a><a id="Tc_79TJe_zmm0OLAkQIX4zwVg_6_11"></a><a id="Tc_0DBTjVLOk0e9a3yUO5QNIg_7_0"></a><a id="Tc_bzOVf6FaqEiZTqO69bbKJw_7_2"></a><a id="Tc_wOpGb1VBrEmsM-w6xxt09A_7_5"></a><a id="Tc_nOWcejOPs029IQgmBdoGTQ_7_6"></a><a id="Tc_NHviwfiv6EOPxjAwKAS7Rg_7_8"></a><a id="Tc_jWk2GPYC8EitIfrTPPd1NQ_7_9"></a><a id="Tc_NcY3Z17RrEO2VpdAv7czTQ_7_11"></a><a id="_aefe3f1b_dfe8_47c6_8b8a_77324329c96d"></a><a id="Tc_s-il0es0ZEy2vZ4o6GmcOQ_1_2"></a><a id="Tc_U5c22CW6IECErRhu_JURRQ_2_5"></a><a id="Tc_mSN8ENESpk2gNC0GG56ovA_2_8"></a><a id="Tc_qu2p4QwSF06Vvdtztisr5w_3_2"></a><a id="Tc_o1x8_eXk60-DT5MKdKMHfQ_3_5"></a><a id="Tc_wd04R-tWaE23o9PJMqirOA_3_8"></a><a id="Tc_ACyftFosSUmhqqHcZ8-Zwg_3_11"></a><a id="Tc_G2TCpYId5Eyii7QhR5rLcQ_4_2"></a><a id="Tc_NL2HkfBtxkKv4fWaaaWyrg_4_5"></a><a id="Tc_oaQSxejhiEKQ0UDByGWisg_4_8"></a><a id="Tc_rxF3RBRhI0CKNtr-hyDQkQ_4_11"></a><a id="Tc_dgS9RpS4dEaAlIfk9IQFfA_5_0"></a><a id="Tc_hW73sUiAMEmNvVsbwc05qg_6_0"></a><a id="Tc_-bXJpD9yU0erWDHWEQx1TQ_6_2"></a><a id="Tc_nmd4gTwUg020n843ike--Q_6_5"></a><a id="Tc_05_tJ_rig0qo8zFA02ItgQ_6_6"></a><a id="Tc_OHbnSLXKjUmbY53sK6PPFA_6_8"></a><a id="Tc_NZyBqGFELUmnH7kzRAAHMw_6_9"></a><a id="Tc_ygN_vfqK5UOAUoSsO4FoUg_6_11"></a><a id="Tc_870AC3nik0i9rAnzrx8jHg_7_0"></a><a id="Tc_j-KLQ4lHIkSMBkOugj9B-w_7_2"></a><a id="Tc_ol4uNBQUDkeidyo9gRl9qA_7_5"></a><a id="Tc_DSyhL_g6-Eeb3frCLCGO1Q_7_6"></a><a id="Tc_cJyviUUp8UGbXWbCQlGJbg_7_8"></a><a id="Tc_44gGwmcmN06sYTqBsS4Niw_7_9"></a><a id="Tc_U3kyjDBYB0arpiLr06cy2Q_7_11"></a><a id="_cd7d3842_cdc7_4200_b1ff_0e3a69156176"></a><a id="Tc_2Dyi3aMyRES20vgpg0r-Bw_1_2"></a><a id="Tc_kdqHSFUDrUqyrKi-oCoNgw_2_0"></a><a id="Tc_ny2zyXdsuUq6GAtAyDFDZg_2_2"></a><a id="Tc_bGxbzE6-IE-mFw29Ws_Qvw_2_5"></a><a id="Tc_dWOOXZdrfUSpO60S3tTr7w_2_8"></a><a id="Tc_LoBK2vVV10uwbh0nhv5m5g_2_11"></a><a id="Tc_ZJS7ga-Uw0GNB1TOuxOLZg_3_0"></a><a id="Tc__hoX5XMPAEWc4QIXzCHdJA_4_0"></a><a id="Tc_Ni--h9tm-E27bEUqGh-oPA_4_2"></a><a id="Tc_7tpX16OCiUSbw-THTFbFkQ_4_5"></a><a id="Tc_tjw6jfUVrEWr56_0iLneig_4_8"></a><a id="Tc_53bfVwvbhEySHiNHE4CqTw_4_9"></a><a id="Tc_946l2LdNB0eiXmltBIj2bw_4_11"></a><a id="Tc_Q_CK7a2teUOZlIIwnMlgZg_4_12"></a><a id="Tc_BRnvp1fUw0qrhLLmuUvHKQ_5_0"></a><a id="Tc_PyyFwJKvy0aPhxVljblXqQ_5_2"></a><a id="Tc_rA30EiVVqEmxVV9ssmS0Kg_5_5"></a><a id="Tc_8oucK-B_rES8EdAaMvevUw_5_8"></a><a id="Tc_3hMXQoD3ckyWepEnaB5igQ_5_9"></a><a id="Tc_HYVK48-88kmqCl7mXS1jNw_5_11"></a><a id="Tc_zcEBovDkjkmKkn8hB7wZFg_5_12"></a><a id="Tc_cXRXigD2PUeywtGxar9a-Q_6_0"></a><a id="Tc_WVCQGOJ0uE-AAu90PT11vw_6_2"></a><a id="Tc_tsp352JqhEaCxGXdrn57eA_6_5"></a><a id="Tc_unN7sBmLAESMMzWPCGmwww_6_6"></a><a id="Tc_V-OWIA0acEu0xrSe8h0uAg_6_8"></a><a id="Tc_U8XPZCah3EeGYRPY7uOgNQ_6_9"></a><a id="Tc_HHBfSm6zrUiOP8a2R3Fh9g_6_11"></a><a id="Tc_JftXfs58j0GwxOZ05mhiKw_7_0"></a><a id="Tc_53wN3ulKn0uiAIhVm_pjVg_7_2"></a><a id="Tc__er8oAY6pUOYCG848-m_0g_7_5"></a><a id="Tc_JQlUahzlQkyAnRAMPJ--Mw_7_6"></a><a id="Tc_A3UQkXLmG0uedwWhf_U5LA_7_8"></a><a id="Tc_sxJx6PO0p0OEdApV1cXD6A_7_9"></a><a id="Tc_mw6E0CUNPkKiHpLNiTb62A_7_11"></a><a id="Tc_bGzcAs7_PUeA24YS4zWV9A_8_0"></a><a id="Tc_X4JtkSK_B0u1YTvfKeHZGQ_8_2"></a><a id="Tc_qQbAndFjkkSbjxUEDpgduw_8_5"></a><a id="Tc_eGyy_wOsfka59i_N-ipBbg_8_6"></a><a id="Tc_FBYhgtPrn0a4lbrhzW3_Zw_8_8"></a><a id="Tc__unTr71YvkarSVWfEsEFWA_8_9"></a><a id="Tc_SXtxZiiDpUu4Z5WQjhJ4BA_8_11"></a><ix:continuation id="Tb_vWyN4-5fukus7nNiyj-pYw_cont2" continuedAt="Tb_vWyN4-5fukus7nNiyj-pYw_cont3"><ix:continuation id="Tb_w-Hp0iEF902Q3VOTW6qcwA_cont1"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="Tb_g96AeisdXEGGzC4LMgflAw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">31, 2024. There were <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="6" id="Narr_FEmPyzgVCUexQ-V3MMn7zQ"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="6" id="Narr_O7QCbhYark2Q-smB-DSqzQ">no</ix:nonFraction></ix:nonFraction> debt securities in an unrealized loss position as of December 31, 2025, or December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Cash, cash equivalents &amp; restricted cash:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:9.5pt;">Cash and money market accounts</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_CashAndCashEquivalentsAxis_vstm_CashAndMoneyMarketAccountsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_vstm_CorporateBondsAndCommercialPaperMember_MWAiV7Cxnk2tfkH3USoRZg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_FlwakQom6EupBfx6mBGS1A_6_3">205,231</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_CashAndCashEquivalentsAxis_vstm_CashAndMoneyMarketAccountsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_vstm_CorporateBondsAndCommercialPaperMember_RPkjFi0xNEyDFZjufdCC-Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_ujA6IcaScEW8aS4tnX18QQ_6_12">205,231</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Total cash, cash equivalents &amp; restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_12Jwxj-GpUyMjUlJbpGHrw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_ZMLQ8anH4EuK31UVvX2Ldw_7_3">205,231</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7jjnAioBzkCDhttauz0FHg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_jc0CeL2pAEConfGHG5t8Yw_7_12">205,231</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Cash, cash equivalents &amp; restricted cash:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:9.5pt;">Cash and money market accounts</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_vstm_CashAndMoneyMarketAccountsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_2k6kDSuJ90Spe63C0ts7DA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_7EXDdBfje0-b7TJ87hyrzA_6_3">89,059</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_vstm_CashAndMoneyMarketAccountsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d4Dr_eG7_EGh26Hx67k-HQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_Ny9IKeAGLkOYMtd5lY0IPQ_6_12">89,059</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Total cash, cash equivalents &amp; restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_-gOCxHhMf0WnaIxAheCqPA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_GK1CXk0tTk-mtg7CgDin2g_7_3">89,059</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_eBqr6h4vlUOpwptV_czZMg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_78SNQ9-syUG5W68um_YroQ_7_12">89,059</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_P2ZpDJlLd0e0ISqwUFX6Fw" continuedAt="Tb_P2ZpDJlLd0e0ISqwUFX6Fw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Fair value of financial instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company determines the fair value of its financial instruments based upon the fair value hierarchy, which prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;">Level&#160;1 inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Quoted prices in active markets for identical assets or liabilities that the Company can access at the measurement date.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;">Level&#160;2 inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;">Level&#160;3 inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Items measured at fair value on a recurring basis</i></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="Tb_kvU0daP8_kuy5EyGVDlO7Q" continuedAt="Tb_kvU0daP8_kuy5EyGVDlO7Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The following table presents information about the Company&#8217;s financial instruments that are measured at fair value on a recurring basis (in thousands) </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AjLSxccsFEupWVwt4xkeYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_IRsYnCXrjUy4MMaSZ1IjNQ_4_3">106,830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0ZkUR0_jhUeO6Ak4kIOPSQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_j2EXmIeA-0G7matYdJcWGw_4_6">106,830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AjLSxccsFEupWVwt4xkeYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_z0DYXqyIDkCFnCLLd3RUgg_5_3">106,830</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0ZkUR0_jhUeO6Ak4kIOPSQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_sh7tGwZcWkm_8i9WyzCJBg_5_6">106,830</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AjLSxccsFEupWVwt4xkeYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="Tc_tCBBzXKRAESFDtGy-vynUg_6_3">35,647</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_olbo--1GgkW245MgvwjaNA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="Tc_D8Eyqp85b06V1i7Jyf72jw_6_12">35,647</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="3" id="Tc_pHPKgAvMQEWiqkJrPvsR8w_7_3">76,330</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_l6H3Xy5qKk-1R-nWGp4lrA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="3" id="Tc_UfIjsakQEEiL809O7d_aYw_7_12">76,330</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_spHgPYbpK0iKbmoGoGyL6Q_8_3">111,977</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_l6H3Xy5qKk-1R-nWGp4lrA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_tFZ84PZvCkmRikGqXpk2Jw_8_12">111,977</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_063db34f_2dd8_4454_9b6c_6baa4f6ebf57"></a><a id="Tc_4e4o-QP5S06Szl-x6rOKhg_1_2"></a><a id="Tc_l3ryIrnhFkS74AVQCGXKMQ_2_0"></a><a id="Tc_SzIroMFRnEuXjMYYNevjsw_2_2"></a><a id="Tc_F3ybCUzmaE-oDQuNRmCbmQ_2_5"></a><a id="Tc_uXtmG9eUSkOZwTEsKs1V2g_2_8"></a><a id="Tc_XVzfiB4fQ0SHYp1_8tp4EA_2_11"></a><a id="Tc_UU0tZrW2b0WLfMFYM3Y8Zw_3_0"></a><a id="Tc_yWTP_drpEUSymht3o05Bng_4_0"></a><a id="Tc_Nx_AzXlIZkqkb5Qb75n_lw_4_2"></a><a id="Tc_ULYAHLEUsEutG5hA_VLBUg_4_5"></a><a id="Tc_RzHO8qlFyUOQEa-OV46Zzg_4_8"></a><a id="Tc_-DcOYUCAqEyJIRC-XfNGhw_4_9"></a><a id="Tc_uKum9RTpPEiGDHwhPKZ30Q_4_11"></a><a id="Tc_jYnpqSGjXU2DMtA_z1SJXw_4_12"></a><a id="Tc_xH4TkDgAPUqNupEFSsWSEg_5_0"></a><a id="Tc_ia5SyAdCj02KciNRFcEK1A_5_2"></a><a id="Tc_ZqtQ7sWIcU6VysarOA92yQ_5_5"></a><a id="Tc_-C2xdoghREuNWlottP-TwA_5_8"></a><a id="Tc_xFtT19tyZkC-8eGh6ZC6Vg_5_9"></a><a id="Tc_Wa_WCFTa00y4KxZnqkssJA_5_11"></a><a id="Tc_BcEEg0Q3Xk6mxBKCtFIDNQ_5_12"></a><a id="Tc_YcJME4R_YUaF4zcAT_J0ZA_6_0"></a><a id="Tc_eNkCuPw1sUaab6H8XW320g_6_2"></a><a id="Tc_H6GK8XQCD0a3xb758TSP0g_6_5"></a><a id="Tc_qaXIJFOzt0SOQDc9MFp48Q_6_6"></a><a id="Tc_5zZl_Yz7jkO5WMF08wTvRA_6_8"></a><a id="Tc_AbVjarcMjkWDqcqieuRhtA_6_9"></a><a id="Tc_Hs1CcyRx1UmFs_QfHdTuoQ_6_11"></a><a id="Tc_y8DMfMgCLEeIqnXEJcnLwA_7_0"></a><a id="Tc_kV8ZsJoqf0CCD-JHE7QS8w_7_2"></a><a id="Tc_iOLtJIJIK0WV7Ep7wASNHw_7_5"></a><a id="Tc_gtyjuoYq9kicCtCBwSIGIA_7_6"></a><a id="Tc_R0bshbmXTkq8UUaNAgPfeA_7_8"></a><a id="Tc_JNK66XgdOUC8kOoGamcZdA_7_9"></a><a id="Tc_JLsjMZJXbUiKDgJbgHyo3Q_7_11"></a><a id="Tc_yLCSbvLVlUWJ37nIS80i7A_1_2"></a><a id="Tc_noBLHPF_PESIWaFwqkK_jQ_1_5"></a><a id="Tc_yl_P-aUJBEmuwOWpZvWNyg_2_0"></a><a id="Tc_iQj3EWqlf0mJpzrI9FY1hg_2_3"></a><a id="Tc_NljSlLmRmE-wC9Aq67f1hw_2_6"></a><a id="Tc_Noq0FeZ5MEqnqObuxyf0bQ_3_0"></a><a id="Tc_oO4ghsDr5kSRArRxy3MS6Q_3_3"></a><a id="Tc_i4ts-w3tX0ySUJUzQKS9oQ_3_6"></a><a id="Tc_pDypYOn4C0S_SaTZoVmj9A_4_0"></a><a id="Tc_UU852yApPkeRE8hNYz9VLA_4_2"></a><a id="Tc_Brjty-evxkqrXqaqQugxCA_4_5"></a><a id="Tc_dPVTq9cUFEOD-2l1xrfOtw_5_0"></a><a id="_ae2ff676_635e_4de9_a458_5e18e8e4d0f1"></a><a id="Tc_KUPqQ9zprE2RSUaeY80wPw_1_0"></a><a id="Tc_BH5wLKdUVkqb2s9dLhS9Gw_1_3"></a><a id="Tc_Qf1W6dWJ90O3eA1as2XnGg_2_0"></a><a id="Tc_r7iQ90Bj5ky_q2HTCIUsgQ_3_0"></a><a id="Tc_bihtWrFCHUqlv_VIjNMcsg_4_0"></a><a id="Tc_p918dKz010ypHqYYk4wN_Q_4_3"></a><ix:continuation id="Tb_vWyN4-5fukus7nNiyj-pYw_cont3" continuedAt="Tb_vWyN4-5fukus7nNiyj-pYw_cont4"><ix:continuation id="Tb_P2ZpDJlLd0e0ISqwUFX6Fw_cont1" continuedAt="Tb_P2ZpDJlLd0e0ISqwUFX6Fw_cont2"><ix:continuation id="Tb_kvU0daP8_kuy5EyGVDlO7Q_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5TQU9p2reEqK8sueEagIGw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_x6dekFqQDEKHqZD5q7Ruog_4_3">63,304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5WLmwNvOF0u7-gwsjUY1fw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_WzPfXgJhgkSoYmewHOZtDg_4_6">63,304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5TQU9p2reEqK8sueEagIGw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_AUrbpNv4uk-9j07BjEY2nQ_5_3">63,304</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5WLmwNvOF0u7-gwsjUY1fw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_CJBYADFy60WANNpi95ZRmw_5_6">63,304</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5TQU9p2reEqK8sueEagIGw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="Tc_dUySIErBdUeiu9isxg-UJA_6_3">58,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6mJXVPDki0CwWIMRXdTM3Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="Tc_eaF9TrQ3gEufPz4hvgDYZQ_6_12">58,199</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5TQU9p2reEqK8sueEagIGw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_FadcZCN0uEySCLSXhmuK6w_7_3">58,199</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6mJXVPDki0CwWIMRXdTM3Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_WUfuo9hGCkuJcKoRM1UsWg_7_12">58,199</ix:nonFraction></b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 12pt 0pt;">The investments and cash equivalents have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. The Company validates the prices provided by third party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active. After completing its validation procedures, the Company did not adjust or override any fair value measurements provided by the pricing services as of December 31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrant liability</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A warrant liability was recorded in connection with the July 2024 Offering (defined herein) (see&#160;<i style="font-style:italic;">Note 10. Capital Stock</i>). The fair value measurement of the warrant liability is classified as Level 3 under the fair value hierarchy. The fair value of the warrant liability at December 31, 2025 and December 31, 2024, was determined using the Black-Scholes valuation model. The inputs to the Black-Scholes valuation model include the risk-free rate, stock price volatility, expected dividends and remaining term. Significant increases or decreases in any of those inputs in isolation could result in a significantly lower or higher fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Below are the inputs used to value the warrant liability at December 31, 2025 and December 31, 2024:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_1Qz6cFAFeka5wxofCcaAqA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_12_31_2025_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_QfOCneyU3kuQfy4l3HkaFA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_YRv2Ng295kKuCP7Ci23L6g_2_2">3.74</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_0A2hZA9RokujrbpWC0nGmA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_2KZ9XbpknUmBH4nrdElEBw_2_5">4.17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_12_31_2025_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_r6xwMcGjUkmR3Dp9MxTNuA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_FRi20lcPSUGvAt3JOMSlug_3_2">53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_7rlVb8oVn0S0Tnw4gAwhJg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_vb-1aalOu0aVTB08sQd64g_3_5">137</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Remaining term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_QWKc7mjBxEydJx6eMjqhZA" contextRef="As_Of_12_31_2025_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_YFjHghTZW0Ch1fCZB71hlw" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_u8khxqE-tU2kk9T4zQYZoA_5_2">0.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_QWKc7mjBxEydJx6eMjqhZA" contextRef="As_Of_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_5LADYlfrGUudV0Z1BYW7WA" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_6ZcL8BAzI0Kzm_s3Cy48Yg_5_5">1.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="vstm:ReconciliationOfWarrantLiabilityTableTextBlock" id="Tb_04GyNOS9RUOJexwWhYL6ug" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table represents a reconciliation of the warrant liability (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_yUvfHNVxFkOmrE7fRHax3g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="Tc_4rMJYZuNDU6l0zAVxeynwQ_1_4">58,199</ix:nonFraction></b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Fair value of warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_FvCF6Wd2sUa1Ka_dpTtMeA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:FairValueAdjustmentOfWarrantsExercised" sign="-" scale="3" id="Tc_sa556__OkE-MoEqjaIkMew_2_4">50,044</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Fair value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_FvCF6Wd2sUa1Ka_dpTtMeA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_Paa9Xge5ok6-z6en7D82tw_3_4">27,492</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_l6H3Xy5qKk-1R-nWGp4lrA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="Tc_QWyfKzabT0-_rZTOh60S8Q_4_4">35,647</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Note Purchase Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">The fair value of the Notes pursuant to the Note Purchase Agreement represents the present value of estimated future payments, including interest, principal, Repayment Amount, and Revenue Participation Payments (each as defined in the Note Purchase Agreement) <span style="background:#ffffff;">(see </span><i style="font-style:italic;background:#ffffff;">Note 8. Long-term debt</i><span style="background:#ffffff;">)</span>. The fair value measurement is based on significant Level 3 unobservable inputs such as the probability and timing of Revenue Participation Payments, Repayment Amount, and the discount rate. The Company determined the fair value of the Notes utilizing a discounted cash flow model of estimated future payments including interest, principal, Repayment Amount and Revenue Participation Payments utilizing a discount rate calculated as the term matched risk-free rate plus credit spread. At January 13, 2025, the Company utilized a discount rate between <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_1_13_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_xbPXD0-44U2IqHm7qVghXg" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMeasurementInput" scale="0" id="Narr_cZFXCLTC50WxaL3zyJdC9A">11.9</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_1_13_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_OGwNsXA5AUWD7GEFLnYUtw" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMeasurementInput" scale="0" id="Narr_8LIAhSQlikWOyfJflZiZuQ">12.4</ix:nonFraction>% and at December 31, 2025, the Company utilized a discount rate between <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_MkLIiJaJsUiWkMQbaTnydg" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMeasurementInput" scale="0" id="Narr_d-lXxstKK0qrE7d8Hqi0sQ">12.6</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_fqBR8I39AkaH9nxabK_ZXg" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMeasurementInput" scale="0" id="Narr_W-rsrcchAE-YHLr7cGFbbg">13.0</ix:nonFraction>%. The fair value of the Notes at December 31, 2025 was determined to be $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_8S_QmEHi20-3Bt7pN3KrWg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="Narr_eATqRZvPG0e5e76cF6FTeA">76.3</ix:nonFraction> million which differed from the contractual principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_8S_QmEHi20-3Bt7pN3KrWg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_L-YPu64YZU-bYxeDyQmZ0w">75.0</ix:nonFraction> million by $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_8S_QmEHi20-3Bt7pN3KrWg" decimals="-5" format="ixt:num-dot-decimal" name="vstm:DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount" scale="6" id="Narr_kqb_o2cvJk68_Ed0zmOX-w">1.3</ix:nonFraction> </p></ix:continuation></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_Uyvrka3LmEOh6lduuIOZGA_1_0"></a><a id="Tc_G9QGRC-p5EySO9tuSBNXiQ_2_0"></a><a id="Tc_w7HeJ-BiqUiOcc_kaZl8YA_3_0"></a><a id="Tc_REFNy73Dl0yQUR36XD-img_4_0"></a><a id="Tc_6eV9WCfu1k-eXd35viS7Mw_4_2"></a><ix:continuation id="Tb_vWyN4-5fukus7nNiyj-pYw_cont4" continuedAt="Tb_vWyN4-5fukus7nNiyj-pYw_cont5"><ix:continuation id="Tb_P2ZpDJlLd0e0ISqwUFX6Fw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">million. Significant increases or decreases in any of these inputs in isolation could result in a significantly lower or higher fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Oxford Loan Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="background:#ffffff;">The fair value of the Company&#8217;s Term Loans (as defined herein) pursuant to the Loan Agreement (as defined herein) (see </span><i style="font-style:italic;background:#ffffff;">Note 10. Long-term debt</i><span style="background:#ffffff;">)</span><span style="background:#ffffff;"> was determined using a discounted cash flow analysis with current applicable rates for similar instruments as of the consolidated balance sheet dates. The Company estimated that the fair value of its Term Loans was approximately </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_yUvfHNVxFkOmrE7fRHax3g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtFairValue" scale="6" id="Narr_xMfxh41gwUCqojvKDlDydw">41.1</ix:nonFraction></span><span style="background:#ffffff;"> million at December 31, 2024 which differed from its carrying value of approximately </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_yUvfHNVxFkOmrE7fRHax3g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="Narr_NbMjLy0FLUiZJu9VQCjGnw">40.7</ix:nonFraction></span><span style="background:#ffffff;"> million. The fair value of the Company&#8217;s long-term debt was determined using Level&#160;3 inputs.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="vstm:ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" id="Tb_vnDembETl06N9caG_u73kQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentrations of credit risk and off-balance sheet risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Cash and cash equivalents and trade accounts receivable are financial instruments that potentially subject the Company to concentrations of credit risk. The Company mitigates this risk by maintaining its cash and cash equivalents with high quality, accredited financial institutions. The management of the Company&#8217;s investments is not discretionary on the part of these financial institutions. <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" id="Narr_a127Ugz1d0ybURrbCu9nJA">As of December 31, 2025, the Company&#8217;s cash, cash equivalents were deposited at four financial institutions and it has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:12pt 0pt 0pt 0pt;">As of December 31, 2025 there were <ix:nonFraction unitRef="Unit_Standard_customer_sDaO4Ago9kCUEtrMUagxqg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_6XXSqLAvakekgauvuyfFBQ" decimals="INF" format="ixt-sec:numwordsen" name="vstm:NumberOfCustomers" scale="0" id="Narr_OXQHfa1D10KkaUMZCYKZYA">five</ix:nonFraction> customers that cumulatively made up <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_6XXSqLAvakekgauvuyfFBQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_Uh1Foy87zUqmJQs-pzsTPw">100</ix:nonFraction>% of the Company&#8217;s trade accounts receivable balance and <ix:nonFraction unitRef="Unit_Standard_customer_sDaO4Ago9kCUEtrMUagxqg" contextRef="Duration_1_1_2025_To_12_31_2025_srt_MajorCustomersAxis_vstm_MajorCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_plJG3megQ0iGNmTnOb-Uvw" decimals="INF" format="ixt-sec:numwordsen" name="vstm:NumberOfCustomers" scale="0" id="Narr_sC6C_97VWUm22e17sgNT-g">two</ix:nonFraction> customers who cumulatively made up more than <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_srt_MajorCustomersAxis_vstm_MajorCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_plJG3megQ0iGNmTnOb-Uvw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_-uvmIXRaRk6f8n3vn64lTQ">60</ix:nonFraction>% of the Company&#8217;s trade accounts receivable balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2025, there were&#160;<ix:nonFraction unitRef="Unit_Standard_customer_sDaO4Ago9kCUEtrMUagxqg" contextRef="Duration_1_1_2025_To_12_31_2025_srt_MajorCustomersAxis_vstm_MajorCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_kdCTYwGzK0Wb4YPT-CMQMA" decimals="INF" format="ixt-sec:numwordsen" name="vstm:NumberOfCustomers" scale="0" id="Narr_8YLf3YDq4UydGrSygKE12A">two</ix:nonFraction>&#160;customers who each individually accounted for greater than&#160;10% of the Company&#8217;s total revenues, for a total of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_vstm_MajorCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_S7Vk9c7EfUOkiG3i3sRNMQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_pae14sMXnE-sjkRxFsr9NQ">27.4</ix:nonFraction> million. For the year ended December 31, 2024, there was&#160;<ix:nonFraction unitRef="Unit_Standard_customer_sDaO4Ago9kCUEtrMUagxqg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_vstm_MajorCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_S7Vk9c7EfUOkiG3i3sRNMQ" decimals="INF" format="ixt-sec:numwordsen" name="vstm:NumberOfCustomers" scale="0" id="Narr_9iQxMW4rDUSszvjzkVzAUA">one</ix:nonFraction>&#160;customer, Secura, who individually accounted for all of the Company&#8217;s revenue. Refer to&#160;<i style="font-style:italic;">Note 16. License, collaboration, and commercial agreements</i>&#160;for a detailed discussion of the Secura APA.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_VctoEM2zJkG_DjGybaYH6Q" continuedAt="Tb_VctoEM2zJkG_DjGybaYH6Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Property and equipment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consist of laboratory equipment, office furniture, computer equipment and leasehold improvements. Expenditures for repairs and maintenance are recorded to expense as incurred, whereas major betterments are capitalized as additions to property and equipment. Depreciation and amortization are calculated using the straight-line method over the following estimated useful lives of the assets:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="vstm:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" id="Tb_TC1QgEHlwEStnboBxD1qLQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_jTuekN8itU-PCSYuKMbIDQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_VF5Ih0-Q-kCTOBK947n8nQ_1_2">5&#160;years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_AXOj8gL7Jk6ZdhZ0AOwscw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_PJot5k4IikCSo1umIGq4PQ_2_2">5&#160;years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Gs8d_AaUlkS6G-nzgF-NEA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_zQJgdcp5kkCoUJZKKBPSvg_3_2">3&#160;years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lesser of useful life or life of lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying value of assets may not be recoverable. Recoverability is measured by comparison of the asset&#8217;s book value to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="Narr_hzp-B4zSu0yjGy4ncm3I1w">No</ix:nonFraction> impairment losses have been recorded through December 31, 2025.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_vWyN4-5fukus7nNiyj-pYw_cont5" continuedAt="Tb_vWyN4-5fukus7nNiyj-pYw_cont6"><ix:continuation id="Tb_VctoEM2zJkG_DjGybaYH6Q_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="vstm:CloudComputingImplementationCostsPolicyPolicyTextBlock" id="Tb_qhAxZuGQokSi9H_qFS1UnA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cloud Computing Implementation Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company incurs costs to implement cloud computing arrangements that are hosted by third-party vendors. In accordance with Accounting Standard Codification (&#8220;ASC&#8221;) 350-40,&#160;Goodwill and Other, Internal-Use Software, for cloud computing arrangements that meet the definition of a service contract, the Company capitalizes qualifying implementation costs incurred during the application development stage as a component of prepaid expenses and other current assets and other assets. Capitalization of these costs concludes once the project is substantially complete, and the software is ready for the Company's intended use. Once available for its intended use, the capitalized costs are amortized on a straight-line basis over the term of the associated hosting arrangement, and are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss. Costs related to data conversion, overhead, general and administrative activities, and training are expensed as incurred. Post-configuration training and maintenance costs will be expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, prepaid expenses and other current assets, and other long-term assets, included approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CapitalizedContractCostNetCurrent" scale="6" id="Narr_SbALcSbJb0ijljnsyQPk0Q">0.4</ix:nonFraction>&#160;million each of capitalized implementation costs on the consolidated balance sheet.&#160;For the year ended December 31, 2025, the Company recorded amortization expense associated with cloud computing implementation costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="Narr_i3x8pzUPrkm-idpCKW7ZQA">0.3</ix:nonFraction> million recorded within selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_t0jUeLOC0E6d_DVoQk5-fA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research and development costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company expenses research and development costs to operations as incurred. Research and development expenses consist of: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">external research and development expenses incurred under arrangements with third parties, such as contract research organizations, clinical trial sites, manufacturing organizations and consultants, including the scientific advisory board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">license fees; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, and laboratory supplies.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Costs for certain development activities, such as clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendor on their actual costs incurred or level of effort expended. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid expenses and other current assets or accrued expenses. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_65mHHqWvgE6c7UbYuINveA" continuedAt="Tb_65mHHqWvgE6c7UbYuINveA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For service-based equity awards, the Company recognizes stock-based compensation expense for stock options, and restricted stock units (&#8220;RSUs&#8221;) issued to employees, directors, and consultants based on the grant date fair value of the awards on a straight-line basis over the requisite service period, which typically is the vest period. The Company recognized stock-based compensation for shares issued to employees under the Company&#8217;s employee stock purchase plan (&#8220;ESPP&#8221;) plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company has granted performance-based RSUs and stock options with terms that allow the recipients to vest in a specific number of shares based upon the achievement of performance-based milestones as specified in the grants. Stock-based compensation expense associated with these performance-based RSUs and stock options is recognized if the performance condition is considered probable of achievement using the Company&#8217;s best estimates of the time to vesting for the achievement of the performance-based milestones. </span>Awards subject to performance-based vesting requirements are expensed utilizing an accelerated attribution model if achievement of the performance criteria is determined to be probable. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_vWyN4-5fukus7nNiyj-pYw_cont6" continuedAt="Tb_vWyN4-5fukus7nNiyj-pYw_cont7"><ix:continuation id="Tb_65mHHqWvgE6c7UbYuINveA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The grant date fair value of stock options is estimated using the Black-Scholes option pricing model that takes into account the fair value of its common stock, the exercise price, the expected life of the option, the expected volatility of its common stock, expected dividends on its common stock, and the risk-free interest rate over the expected life of the option. The Company applies the simplified method described in the Securities and Exchange Commission (&#8220;SEC&#8221;) Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 14.D.2 to calculate the expected term as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term for options granted to employees. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its population. The Company has not paid and do not anticipate paying cash dividends on the Company&#8217;s shares of common stock; therefore, the expected dividend yield is assumed to be zero. The computation of expected volatility is based on the historical volatility of the Company&#8217;s common stock. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options.<span style="background:#ffffff;"> The Company accounts for forfeitures as they occur.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">The Company issues shares under the Company&#8217;s ESPP to employees. Stock-based compensation expense for discounted purchases under the ESPP is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period</span>.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_Ze25__gBeEW--apWZbM5NA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Leases are accounted for in accordance with ASC Topic 842, Leases (&#8220;ASC 842&#8221;).&#160;This standard requires lessees to recognize in the statement of financial position a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term for both finance and operating leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances within the arrangement.&#160;A lease is identified where an arrangement conveys the right to control the use of identified property, plant, and equipment for a period of time in exchange for consideration.&#160;Leases which are identified within the scope of ASC 842 and which have a term greater than one year are recognized on the Company&#8217;s consolidated balance sheets as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize leases with terms of one year or less on its consolidated balance sheets. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates to calculate the present value of lease payments.&#160;Incremental borrowing rates are the rates the Company incurs to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 842, components of a lease are split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, maintenance, consumables, etc.), and non-components (e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on fair values to the lease components and non-lease components. Although separation of lease and non-lease components is required, certain practical expedients are available. Entities may elect the practical expedient to not separate lease and non-lease components. Rather, they would account for each lease component and the related non-lease component together as a single component. The Company has elected to account for the lease and non-lease components of each of its operating leases as a single lease component and allocate all of the contract consideration to the lease component only. The lease component results in an operating right-of-use asset being recorded on the consolidated balance sheets and amortized on a straight-line basis as lease expense.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_GSlJzIdN20mxmOiYnzlGKA" continuedAt="Tb_GSlJzIdN20mxmOiYnzlGKA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue recognition </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services in accordance with ASC Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;). To determine revenue recognition for contracts with its customers, the Company performs the following five step assessment: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk221043900"></a><ix:continuation id="Tb_vWyN4-5fukus7nNiyj-pYw_cont7" continuedAt="Tb_vWyN4-5fukus7nNiyj-pYw_cont8"><ix:continuation id="Tb_GSlJzIdN20mxmOiYnzlGKA_cont1" continuedAt="Tb_GSlJzIdN20mxmOiYnzlGKA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception and once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines which goods and services are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">P</i><i style="font-style:italic;">roduct Revenue, Net</i> - The Company sells AVMAPKI FAKZYNJA CO-PACK to a limited number of specialty pharmacies and specialty distributors in the United States. The specialty pharmacies dispense AVMAPKI FAKZYNJA CO-PACK directly to patients while the specialty distributors resell AVMAPKI FAKZYNJA CO-PACK to healthcare entities who then resell AVMAPKI FAKZYNJA CO-PACK to patients. In addition to distribution agreements with specialty distributors, the Company also enters into arrangements with (1) certain government agencies and various private organizations (&#8220;Third-Party Purchasers&#8221;), which may provide for chargebacks or discounts with respect to the purchase of AVMAPKI FAKZYNJA CO-PACK, and (2) Medicare and Medicaid, which may provide for certain rebates with respect to their reimbursement of AVMAPKI FAKZYNJA CO-PACK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue on sales of AVMAPKI FAKZYNJA CO-PACK when a customer obtains control of the product, which occurs at a specific point in time (typically upon delivery). Product revenues are recorded at the wholesale acquisition costs, net of applicable reserves for variable consideration. Components of variable consideration include trade discounts and allowances, Third-Party Payer chargebacks and discounts, government rebates, product returns, other patient focused allowances, such as voluntary co-pay assistance, benefits verification, and other patient support programs that are offered within contracts between the Company and customers, payors, and other indirect customers relating to the Company&#8217;s sale of AVMAPKI FAKZYNJA CO-PACK. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable or a current liability. These estimates take into consideration a range of possible outcomes based upon relevant factors such as, customer contract terms, information received from third parties regarding the anticipated payor mix for AVMAPKI FAKZYNJA CO-PACK, known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled with respect to sales made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The amount of variable consideration included within a transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under contracts will not occur in a future period. The Company&#8217;s analyses contemplate the application of the constraint in accordance with Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standard Codification (&#8220;ASC&#8221;) 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). For the twelve months ended December 31, 2025, the Company determined a material reversal of revenue would not occur in a future period for the estimates detailed below and, therefore, transaction prices would not be reduced further. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual results in the future vary from the Company&#8217;s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Trade Discounts and Allowances: The Company generally provides customers with invoice discounts on sales of AVMAPKI FAKZYNJA CO-PACK for prompt payment and other discounts, which are explicitly stated in the Company&#8217;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates its specialty pharmacy and specialty distributor customers for sales order management, data, distribution, and certain other services. The Company has determined such services are not distinct from the Company&#8217;s sale of AVMAPKI FAKZYNJA CO-PACK to the specialty pharmacy and specialty distributor customers and, therefore, these payments have also been recorded as a reduction of revenue within the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-Party Payer Chargebacks, Discounts and Fees: The Company executes contracts with Third-Party Purchasers which allow for eligible purchases of AVMAPKI FAKZYNJA CO-PACK at prices lower than the wholesale acquisition cost. In some cases, customers will charge the Company for the difference between what they pay for </p></ix:continuation></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_vWyN4-5fukus7nNiyj-pYw_cont8" continuedAt="Tb_vWyN4-5fukus7nNiyj-pYw_cont9"><ix:continuation id="Tb_GSlJzIdN20mxmOiYnzlGKA_cont2" continuedAt="Tb_GSlJzIdN20mxmOiYnzlGKA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">AVMAPKI FAKZYNJA CO-PACK and the ultimate selling price to the Third-Party Purchasers to whom they sell the product. Reserves will generally be established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable, net. Chargeback amounts will generally be determined at the time of resale to the qualified Third-Party Purchasers by customers, and the Company generally will issue credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. The reserves for chargebacks are expected to consist of credits that the Company expects to issue for units that remain in customer inventories at the end of each reporting period that the Company expects will be sold to Third-Party Purchasers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. <span style="color:#212529;background:#ffffff;">In addition, the Company compensated certain Third-Party Payers for administrative services, such as account management and data reporting. These administrative service fees have also been recorded as a reduction of net product revenue within the consolidated statements of operations and comprehensive loss.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Government Rebates: The Company is subject to discount and rebate payment obligations under various government programs including Federal and state Medicaid programs, Medicare, and others. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses on the consolidated balance sheets. The Company&#8217;s liability for these rebates consist of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in customer inventories at the end of each reporting period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other Patient Support Initiatives: Other patient support initiatives that the Company offers include voluntary co-pay assistance programs, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payors. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive for product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Product Returns: Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company either directly or through one of its distribution channels. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s return policy generally allows for eligible returns of AVMAPKI FAKZYNJA CO-PACK for credit under the following circumstances:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Receipt of damaged product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shipment errors that were a result of an error by the Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Expired product that is returned during the period beginning three months prior to the product&#8217;s expiration and ending six months after the expiration date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Quantities of product received by a customer in excess of quantity ordered;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product subject to a recall; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product that the Company, at its sole discretion, has specified can be returned for credit. </span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">As of December 31, 2025, the Company has not received any returns.</p></ix:continuation></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_vWyN4-5fukus7nNiyj-pYw_cont9" continuedAt="Tb_vWyN4-5fukus7nNiyj-pYw_cont10"><ix:continuation id="Tb_GSlJzIdN20mxmOiYnzlGKA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sales of intellectual property</i><span style="font-style:italic;font-weight:bold;"> - </span>For sales of license and intellectual property, that include sale-based royalties, including milestone payments based on a level of sales, the Company evaluates whether the royalties and sales-based milestones are considered probable of being achieved and estimates the amount of royalties to include over the contractual term using the expected value method and estimates the sales-based milestones using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated royalty and milestone value is included in the transaction price. Royalties and sales-based milestones for territories for which there is not regulatory approval are not considered probable until such regulatory approval is achieved. The Company evaluates factors such as whether consideration is outside of the Company&#8217;s control, timeline for when the uncertainty will be resolved and historical sales of COPIKTRA if applicable. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and amount of royalty revenue to be received and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_mBrqhsUKak2WtBXjp-2Rag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounts Receivable, Net </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Accounts receivable, net consists of amounts due from customers, net of applicable revenue reserves. Accounts receivable have standard payments that generally require payment within 30 to 90 days. Management determines the allowance for credit loss by regularly evaluating individual customer receivables and considering a customer&#8217;s financial condition, credit history and current economic conditions.  Based on the Company&#8217;s latest assessment of the collectability of its accounts receivable, an allowance for credit loss is not deemed necessary at December 31, 2025.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:InventoryPolicyTextBlock" id="Tb_eq0m3c2PIkyj-_CZdymIXg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inventory </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventories are stated at the lower of cost or estimated net realizable value. The Company determined the cost of inventories using the&#160;standard cost&#160;method, which approximates actual cost based on a first-in, first out basis. Inventories consist primarily of third-party manufacturing costs. The Company began capitalizing inventory upon receiving FDA approval for AVMAPKI FAKZYNJA CO-PACK on May 8, 2025. Prior to the FDA approval of AVMAPKI FAKZYNJA CO-PACK, expenses associated with the manufacturing of the Company's products were recorded as research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, are recorded within cost of sales &#8211; product within the consolidated statements of operations and net loss. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required which would be recorded as a cost of sales - product in the consolidated statements of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Shipping and handling costs for product shipments are recorded as incurred in cost of sales - product along with costs associated with manufacturing the product, and any inventory write-downs.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="Tb_tytIxV2M7UaWjmGnYtf0gg" continuedAt="Tb_tytIxV2M7UaWjmGnYtf0gg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span><i style="font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company records finite-lived intangible assets related to certain capitalized milestone payments at their fair value. These assets are amortized over their remaining useful lives, which are estimated based on the shorter of the remaining underlying patent life or the estimated useful life of the underlying product. Intangible assets are amortized using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when future revenues cannot be reasonably estimated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company assesses its finite-lived intangible assets for impairment if indicators are present or changes in circumstance suggest that impairment may exist. Events that could result in an impairment, or trigger an impairment assessment, include the receipt of additional clinical or nonclinical data regarding the Company&#8217;s drug products or a potentially competitive drug candidate, significant changes in the manner of our use of the acquired assets, or new </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_vWyN4-5fukus7nNiyj-pYw_cont10" continuedAt="Tb_vWyN4-5fukus7nNiyj-pYw_cont11"><ix:continuation id="Tb_tytIxV2M7UaWjmGnYtf0gg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">information regarding future projected sales for the product. If impairment indicators are present or changes in circumstance suggest that impairment may exist, the Company performs a recoverability test by comparing the sum of the estimated undiscounted cash flows of each finite-lived intangible asset to its carrying value on the consolidated balance sheets. If the undiscounted cash flows used in the recoverability test are less than the carrying value, the Company would determine the fair value of the finite-lived intangible asset and recognize an impairment loss if the carrying value of the finite-lived intangible asset exceeds its fair value.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="Tb_TH09AfVaA0eLP5DYa05I7g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Collaborative arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Contracts are considered to be collaborative arrangements when they satisfy the following criteria defined in ASC Topic 808, <i style="font-style:italic;">Collaborative Arrangements</i>: (i) the parties to the contract must actively participate in the joint operating activity and (ii) the joint operating activity must expose the parties to the possibility of significant risk and rewards, based on whether or not the activity is successful. Payments received from or made to a partner that are the result of a collaborative relationship with a partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction or increase to research and development expense, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:IncomeTaxPolicyTextBlock" id="Group_rqYokz2M102fXw0B4Hs4NQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes the tax effects of an uncertain tax position only if it is more likely than not that it will be sustained based solely on its technical merits as of the reporting date and only in an amount more likely than not that it will be sustained upon review by the tax authorities. The Company evaluates uncertain tax positions on a quarterly basis and adjust the liability for changes in facts and circumstances, such as new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, significant amendment to an existing tax law, or resolution of an examination. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the income tax provision in the period in which such determination is made. The resolution of its uncertain income tax positions is dependent on uncontrollable factors such as law changes, new case law, and the willingness of the income tax authorities to settle, including the timing thereof and other factors. Although the Company does not anticipate significant changes to its uncertain income tax positions in the next 12 months, items outside of its control could cause its uncertain income tax positions to change in the future, which would be recorded in its statements of operations. Interest and/or penalties related to income tax matters are recognized as a component of income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net operating loss (&#8220;NOL&#8221;) and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the Internal Revenue Code (&#8220;IRC&#8221;), as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company experienced a greater than <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="2" format="ixt:num-dot-decimal" name="vstm:ChangeInCompanyOwnershipPercent" scale="-2" id="Narr_b6OaBeYuGUSPhfmK5rBF8w">50</ix:nonFraction>% change in ownership as defined under Section 382 and 383 of the IRC as well as similar state provisions during the year ended December 31, 2024. For more details, please refer to <i style="font-style:italic;">Note 14. Income Taxes.</i></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_vWyN4-5fukus7nNiyj-pYw_cont11" continuedAt="Tb_vWyN4-5fukus7nNiyj-pYw_cont12"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_suCfi21Dj0GUU7bBW_rU6Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Net loss per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per common share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period. For purposes of calculating net loss per share, weighted-average number of common shares outstanding includes the weighted average effect of pre-funded warrants as the exercise of which requires little or no consideration for the delivery of shares of common stock. <span style="white-space:pre-wrap;">Diluted net loss per common share is calculated by increasing the denominator by the weighted-average number of additional shares that could have been outstanding from securities convertible into common stock, such as the warrants issued in July 2024, stock options, restricted stock units, and ESPP (using the &#8220;treasury stock&#8221; method), Series A Convertible Preferred Stock, and Series B Convertible Preferred Stock (using the &#8220;if-converted&#8221; method), unless their effect on net loss per share is antidilutive. Under the &#8220;if-converted&#8221; method, convertible instruments that are-in-the-money, are assumed to have been converted as of the beginning of the period or when issued, if later. Additionally, the effects of any interest expense and changes in fair value of any bifurcated derivatives shall be added back to the numerator of the diluted net loss per share calculation.  Refer to </span><i style="font-style:italic;">Note 13. Net Loss per share</i> for further details related to the calculation of net loss per share.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="vstm:NewAccountingStandardsAdoptedPolicyPolicyTextBlock" id="Tb_GrM6lTa05kCDgFyZbxj6VA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Adopted Accounting Standards Updates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;">In December 2023, the FASB issued ASU No. 2023-09,&#160;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#160;(&#8220;ASU 2023-09&#8221;). The guidance in ASU 2023-09 improves the transparency of income tax disclosures by greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The Company has adopted and applied the guidance under this ASU for the year ended December 31, 2025, using the prospective transition method. See&#160;<i style="font-style:italic;">Note 14. Income Taxes</i>&#160;in the accompanying notes to the consolidated financial statements for further detail.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_rpoLWqaQH0iLzKkv5zKCcA" continuedAt="Tb_rpoLWqaQH0iLzKkv5zKCcA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Recently issued accounting standards updates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">In November 2024, the FASB issued ASU No 2024-03&#8212;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). The guidance in ASU 2024-03 is intended to require more detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted.  The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to all prior periods presented in the financial statements. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;">In September 2025, the FASB issued ASU No. 2025-06,&#160;Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software&#160;(&#8220;ASU 2025-06&#8221;). This standard modernizes the accounting for internal-use software by removing references to prescriptive development stages and instead requiring capitalization of costs once (1) management has authorized and committed to funding the software project, and (2) it is probable the project will be completed and placed in service. Entities must evaluate whether there is &#8220;significant development uncertainty,&#8221; such as unresolved novel functionality or substantially revised performance requirements, before meeting this capitalization threshold. ASU 2025-06 is effective for annual reporting periods beginning after December 15, 2027, and interim periods within such annual reporting periods, with early adoption permitted. Entities may adopt the amendments prospectively, retrospectively, or under a modified transition approach. The Company is in the process of evaluating the impact that the adoption of this ASU may have on its consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;">Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_vWyN4-5fukus7nNiyj-pYw_cont12"><ix:continuation id="Tb_rpoLWqaQH0iLzKkv5zKCcA_cont1"></ix:continuation></ix:continuation><a id="_99f0de5a_32d8_424b_8eb6_450650648a45"></a><a id="Tc_6eaFQVSoCUqMb_hBMZN1Tg_1_2"></a><a id="Tc_y2vCNQOpNkeh26KGCmVPyQ_1_5"></a><a id="Tc_1F6NKMS_10eSEwJqo41tHQ_1_8"></a><a id="Tc_0ATLy37sB0ukO2ts_X61BA_2_2"></a><a id="Tc_OHJLQ3ouX0CJrYXTex3PFw_2_5"></a><a id="Tc_QmD-gOtuvU-SCVCVHgil8g_2_8"></a><a id="Tc_z9tR-c3R906dxbL7c7YSPg_3_2"></a><a id="Tc_Qj97H24fLk2VGelJUeXTZQ_3_5"></a><a id="Tc_qXK6zHR9TkWErq5KUCXKNQ_3_8"></a><a id="Tc__iPCVd52I0C1kv1-wwOBjQ_4_2"></a><a id="Tc_01TggP_n5EOxqbLnEiBx-Q_4_5"></a><a id="Tc_pMz-gho2iEC7V7CiZhA68w_4_8"></a><a id="Tc_FFoKzr10_0G_UDFM5iZkEQ_4_11"></a><a id="Tc_OE6ICpIp2ECXKLIuXOubWA_4_14"></a><a id="Tc_3yNAksqZ3UyznuFo9FH4fA_5_0"></a><a id="Tc_oHol72fA706u-5oP3scmhg_5_2"></a><a id="Tc_zNv1RCG7n0i7YybVbS-g_A_5_3"></a><a id="Tc_LZ1GPFg3wEGuRruL6K9llQ_5_5"></a><a id="Tc_xV_3MYN1c0K0mTvB_Dqj6w_5_6"></a><a id="Tc_eNhGTZZsnEq2fuFYjv_ZjQ_5_8"></a><a id="Tc_gHoejTJyW0qXXPtK0Z4L9g_5_9"></a><a id="Tc_679nABYFdkGevzz2Hsuv9A_5_11"></a><a id="Tc_Y3U0wVbu3kGCl78U8HQVIQ_5_12"></a><a id="Tc_eaYCPEGxCUGMzY0py1MWvg_5_14"></a><a id="Tc_w4WjYhuBjUClatdCN1uMVQ_5_15"></a><a id="Tc_o8NykVpntUCfx57MHYngcQ_6_0"></a><a id="Tc_ewwzrEbD606WXI1UY9B0XQ_7_0"></a><a id="Tc__cblG71JXk--92B0BSZy9w_7_3"></a><a id="Tc_-_-A3wni4k2PSJAj1ArrXA_7_6"></a><a id="Tc_gIHiO8dy00iHnhHB4WyFcQ_7_9"></a><a id="Tc_p54BymfvOUqxcG5ZpTl_Jg_7_12"></a><a id="Tc_a-3_eeLAT0STSYWU6l349Q_7_15"></a><a id="Tc_8b_116eFEUuLhG_7gDqbDA_8_0"></a><a id="Tc_q66z7XH5YE6qf_-L0yTEdg_8_12"></a><a id="Tc_rfJlOmpxFE2w5OcWMTmpBA_9_0"></a><a id="Tc_b4J4mqHJT0ONynRFzlMwMA_9_2"></a><a id="Tc_UPQKkkE5B02CoKhRm3yOJw_9_5"></a><a id="Tc_csOYq182QkSgtYbNkaxW9Q_9_8"></a><a id="Tc_BjQuRoANpECX63_35yb6xg_9_11"></a><a id="Tc_QkVB1f1baEu3gRWNVKyiRA_9_14"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="vstm:ProductRevenueReservesAndAllowancesDisclosureTextBlock" id="Tb_Vg_vCbv7X0uVF0Ogi7TQeg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Product revenue reserves and allowances</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="vstm:ProductRevenueReservesAndAllowancesTableTextBlock" id="Tb_tm7cnBLwGEimVls9WX_EbQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since 2025, the Company&#8217;s sole source of product revenue has been from sales of AVMAPKI FAKZYNJA CO-PACK in the United States. The following table summarizes activity in each of the product revenue allowance and reserve categories for the twelve months ended December 31, 2025 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trade</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Third Party Payer </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Government </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">chargebacks,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">rebates&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">allowances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and fees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">incentives</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision related to sales in the current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember_yE8fkK7qa06bC6iq6BUR2Q" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear" scale="3" id="Tc_zjOPH_WK60aNamauwWIELA_6_3">888</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember_OyYlxyJlr0W_orM9kelphA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear" scale="3" id="Tc_6sAS8gTctkij_qrsHZ1c_g_6_6">387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember_Uvl6OFaJ0Uq4ztzlNkkoEg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear" scale="3" id="Tc_SIPli-HpX0aXcHbH5gtgYg_6_9">4,392</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueAndAllowancesReturnsMember_FTUadeq3F0WCVMRH53KrHg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear" scale="3" id="Tc_G9_ZBxkaBkes0K5DWbXTMg_6_12">376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear" scale="3" id="Tc_hBIhaM-keUuZHOwmkPZ-Vw_6_15">6,043</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Adjustments related to prior period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credits and payments made</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember_yE8fkK7qa06bC6iq6BUR2Q" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProductRevenueReservesAndAllowancesDeductions" scale="3" id="Tc_hWu1AC7oLU6GcBbjRZ2COg_8_3">652</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember_OyYlxyJlr0W_orM9kelphA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProductRevenueReservesAndAllowancesDeductions" scale="3" id="Tc_xJOMd325nUaRIjgw8zguew_8_6">135</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember_Uvl6OFaJ0Uq4ztzlNkkoEg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProductRevenueReservesAndAllowancesDeductions" scale="3" id="Tc_r62CYVHSF0uQj3e5ODSrIw_8_9">1,367</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProductRevenueReservesAndAllowancesDeductions" scale="3" id="Tc_qIfRJeN_WkumkD5MqRKcLw_8_15">2,154</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Ending balance at December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember_168XNhm2-E2OU8g_oJr-ug" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProductRevenueReservesAndAllowances" scale="3" id="Tc_9qYtty9aH0-UAo_t324mjA_9_3">236</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember_RoPH4kuymE2ByqNH0aMdag" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProductRevenueReservesAndAllowances" scale="3" id="Tc_5eErAICICUSOyxoeWe2Dww_9_6">252</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember_sxwP1I5FCEKe9EEKt9_cgA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProductRevenueReservesAndAllowances" scale="3" id="Tc_ivDF3f1uxE6jBa6VZJON9Q_9_9">3,025</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueAndAllowancesReturnsMember_5FE7cQWXTUKpa-SgNguaWg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProductRevenueReservesAndAllowances" scale="3" id="Tc_snEX7c8IFkq1hNIDWaDggw_9_12">376</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ProductRevenueReservesAndAllowances" scale="3" id="Tc_iyUvzIrdfU-e_vFGf9y2bQ_9_15">3,889</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">Trade discounts and Payer chargebacks and discounts are recorded as a reduction to accounts receivable, net on the consolidated balance sheets. Trade allowances and Payer fees, government rebates, other incentives and returns are recorded as a component of accrued expenses on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><a id="_24fd46c1_e6bf_4b31_a707_bdae30c05cb0"></a><a id="Tc_4Lj8HNbEpkGmw9pzE56rLw_1_2"></a><a id="Tc_4UDFtK1BFUCYMIEI6D08Zg_1_5"></a><a id="Tc_JHWt1VDqj0WxN-zeDuuAUw_2_0"></a><a id="Tc_zyk5xg8kHkiMQuzmOPcqcg_2_2"></a><a id="Tc_EUlpa-IHok6GdPMfGsl0vw_2_3"></a><a id="Tc_kkZHin9FpEi15T8W8AOE5Q_2_5"></a><a id="Tc_0Zw2G7Lp0kW1cXnNDrjdBQ_2_6"></a><a id="Tc_C5rBAJT-Y0OKVfeKwM281g_3_0"></a><a id="Tc_GL9XrG5gpE-FjWUvB6yw8A_3_6"></a><a id="Tc_gQ0ssoKL8kyFUimeMBK9Pw_4_0"></a><a id="Tc_eq4VrV55eU6rtOXjyGlTiw_4_6"></a><a id="Tc_eVHzhOcSVEKjjYe__jwGYA_5_0"></a><a id="Tc_3S_U4Vj1uU2wTxuV0XI5-A_5_2"></a><a id="Tc_Cvf7i-A500qsZ0sWZUKy8g_5_5"></a><a id="Tc_pNU63sbUKUma1x8g4-mE0A_5_6"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_vQl1Xi9wT02k9YW_3Q-h-w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Inventory</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_RZe3IGPvpEWM8sx9g08ZCA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory consists of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:70.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:70.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:70.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_Cm5V02kbw02xghcdKsyJLA_3_3">1,797</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:70.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_yCO5mDfbB0SGbvzb_LyvEQ_4_3">36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:70.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total inventory</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc__A3HT8KPDUucISxrbeBRdg_5_3">1,833</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">At&#160;December&#160;31, 2025, all of the Company&#8217;s inventory was related to&#160;AVMAPKI and FAKZYNJA. In May 2025, the FDA approved AVMAPKI FAKZYNJA CO-PACK, at which time the Company began to capitalize costs to manufacture AVMAPKI FAKZYNJA CO-PACK. Prior to FDA approval of AVMAPKI FAKZYNJA CO-PACK, all costs related to the manufacturing of AVMAPKI and FAKZYNJA and related material were charged to research and development expense in the period incurred. At&#160;December&#160;31, 2025, the Company determined that a reserve related to inventory&#160;was&#160;not required.</p></ix:nonNumeric><a id="_78c1a876_2e64_4162_910e_bbc8359aa36b"></a><a id="Tc_SIuaRPBXo0-dVhFvMIChxQ_1_2"></a><a id="Tc_MhKoEzOdUkyuimaqOCt1zw_1_5"></a><a id="Tc_Gf0A3uvENUC3Orvc0oK8RA_2_0"></a><a id="Tc_SL0SWh8inkKUxde5poQYUw_2_2"></a><a id="Tc_-Q61tcHKi0SPUrrHFsVgZw_2_5"></a><a id="Tc_Sp11jid04EuquPne5vCT-g_3_0"></a><a id="Tc_HTqpWBCQqUWS-S0KVgNOug_4_0"></a><a id="Tc_9EKRnPPUdUCYUVfoWd6wQQ_4_2"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="Tb_X1TL9IrXyEmaAeSHkwRqLA" continuedAt="Tb_X1TL9IrXyEmaAeSHkwRqLA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5. Intangible Assets</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="Tb_i9Vay7YuD0iLKicwG6Y-Yg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s intangible assets consist of the following (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:15.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average Remaining Amortization Period (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired and in-licensed rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_UFLB7FQ-UkuBpVXhKscaVA_2_3">17,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="Narr_DmHEw5AL3U2VweIF-lb_Jw">14.8</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_WDaX-u8vlUeH69HUsl21fQ_3_3">698</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total intangible assets, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_64DRVe3Rokao5gKltc4UJg_4_3">16,426</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0c333df9_92d0_4912_a5d3_790ac1d0d32f"></a><a id="Tc_Z6_r2frD-027u-_uJ_Ympw_1_0"></a><a id="Tc_if5-pBT4fUSGwuC_ynmiXg_1_2"></a><a id="Tc_2IbRxKx35U63HyjNekm4BQ_2_0"></a><a id="Tc_7acDv3teskOrl1HRg0Ylwg_3_0"></a><a id="Tc_Fc0VTc1ouUCbIFZ-9p_qfw_4_0"></a><a id="Tc_AKtB_wLumU2m4SKWDVGX3Q_5_0"></a><a id="Tc_hoEpYFA6GESpldQ4VEqZ9g_6_0"></a><a id="Tc_lkr4V8AwL02_VjCUxCVqsQ_7_0"></a><a id="Tc_9eKkEecZ50igiFg1HjJQeg_8_0"></a><a id="Tc_6BIptUZ520OwTbQnbR1_oQ_8_2"></a><ix:continuation id="Tb_X1TL9IrXyEmaAeSHkwRqLA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company's finite-lived intangible assets are the result of milestone payments due under the Pfizer Agreement (defined herein) and the License Agreement (defined herein). Refer to <i style="font-style:italic;">Note 16. License, collaboration and commercial agreements</i> for further discussion of the Pfizer Agreement and License Agreement.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="Tb_K7BDoaujUUy026vMPGVMBA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The Company recorded approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="6" id="Narr_EwXj0Urs5EqqMQDWDFyP5g">0.7</ix:nonFraction> million in cost of sales &#8211; intangible amortization expense related to finite-lived intangible assets during the twelve months ended December 31, 2025 using straight-line methodology. Estimated future cost of sales- intangible amortization expense for finite-lived intangible assets as of December 31, 2025 is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:85.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year ending December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="Tc_XlqQlW1tzESg4KCaqHCHuw_2_3">1,117</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="Tc_LYTaxG-AokuCQGFv6tNj3Q_3_3">1,117</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="Tc_R0sfM6QMtkG1ZHbAfZjy-w_4_3">1,117</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="Tc_JMX6NXflxU-jPJN0CdnHgw_5_3">1,117</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="Tc_yZts8Zz-c0Scxgp7pTVPWg_6_3">1,117</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" id="Tc_6zd1ga_y70msyHSQxGPa0g_7_3">10,841</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total future amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_4-ecTO4TqUqZ6yUZ5nD8sg_8_3">16,426</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_e60760c2_c584_48a4_afc1_3f7321de4222"></a><a id="Tc_DA-MXh1Wh0GqQqLwiJ38sQ_1_2"></a><a id="Tc_HT35SkJtnkGCoomMyGy44A_1_5"></a><a id="Tc_yeUyfJbdxkur8wah6Owewg_2_2"></a><a id="Tc_XCdCXVIsMUa8e8Im_Hi64Q_2_5"></a><a id="Tc_edWZCXPVykeULYb918NXEA_3_0"></a><a id="Tc_yRwJj1rHQ0qjk_Q5xpq-Bw_3_2"></a><a id="Tc_fQa9UoDrU0WrfqPvP-tMpA_3_5"></a><a id="Tc_-SQxrsgkCEO203iPPa7B5w_4_0"></a><a id="Tc_e8IwDHiZAkKE1ML_98I_5g_5_0"></a><a id="Tc_ZE2FSbTKJkme3ScjQLK9Pg_6_0"></a><a id="Tc_uX6sgOm9XUqYJCk66tPwYQ_6_3"></a><a id="Tc_0_8VIIE840-SfTVJx9a9Vg_6_6"></a><a id="Tc_fzaajlhzwk2gR4wx3cM6cw_8_0"></a><a id="Tc_WZ3_acbh-Ui7z8vMExHAHw_9_0"></a><a id="Tc_8wg62CdrD0arqCuBuudiyg_9_2"></a><a id="Tc_RvxrS62V7E23JfceDAyoug_9_3"></a><a id="Tc_Fcad_rLtXUq0r1gm_4wj-g_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_qGPARtgD8kqfbZkYxl_Teg" continuedAt="Tb_qGPARtgD8kqfbZkYxl_Teg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6. Property and equipment, net</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb__8Z1QRyEWUybjXBKBBwU6w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Property and equipment and related accumulated depreciation are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:75.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_OkY1QtMdYk-oqCKMPg88RQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_qL28L4iIyU-1Z1yRlTjSsA_3_3">146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_YUbMCLNoMEiiVq3ezSlFGg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_BK02aro3mESghv0TYgbirA_3_6">146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_AXOj8gL7Jk6ZdhZ0AOwscw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Tvz3p8pRBU2BaxPeQbMuyg_4_3">811</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_Em0bxcv8gk6czzZLTd4Ywg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_SvD7ugqy5EGJhXxR9GRCJg_4_6">839</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Gs8d_AaUlkS6G-nzgF-NEA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_lG3SJwODJkewbj4Cfp6Skw_5_3">665</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_yve5Cj4_rU-htYKKwRh69g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Fil1PUY73UuZZQzVRAhGuA_5_6">665</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Assets not yet placed in service</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_1l5QGegeS02U-fJh6dqE6g_7_3">1,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_6Hemt8rZs0SDkR0Cvv2ojQ_7_6">1,650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_xLaeGW2Bbk6nmAY8FtP1xg_8_3">1,622</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_yDTUOtdPW02eFS1kfQUzqw_8_6">1,618</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total property and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_n6nvMWSWV0WEl7UFhmXdVg_9_6">32</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"><span style="font-size:10pt;">The Company recorded less than </span><span style="-sec-ix-hidden:Hidden_W4pGquiuLUKirJceSn_YoA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.1</span></span><span style="font-size:10pt;"> million, less than </span><span style="-sec-ix-hidden:Hidden_NwoIzrC_q02kziSjSvHlIw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.1</span></span><span style="font-size:10pt;"> million, and </span><span style="-sec-ix-hidden:Hidden_N2ulbwwA-UqvBSpy2gwqug;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.1</span></span><span style="font-size:10pt;"> million in depreciation expense for the years ended December 31, 2025, 2024, and 2023, respectively</span>.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qGPARtgD8kqfbZkYxl_Teg_cont1"></ix:continuation><a id="_07a37208_9231_431e_a979_b917c62dbb93"></a><a id="Tc_47QjYof2K0C5_foEQL1ZmA_1_2"></a><a id="Tc_0Dh0KRpHO0y8DcGO-6uWvA_1_5"></a><a id="Tc_-VCtS85ywEy-_pJXQDxcnw_3_0"></a><a id="Tc__TiTLVtmhUiwAm5abx4_qg_3_2"></a><a id="Tc__RIvxWgZIkeGm6O0YKunQw_3_5"></a><a id="Tc_ffSPDRHeVEiGG2cBOt36dA_4_0"></a><a id="Tc_mML2TUlWPUex4Dg9GTasJg_4_6"></a><a id="Tc_7Rnx2Ftuykm8U3fULDrtwg_5_0"></a><a id="Tc_V5PQoQZCDU-bzCpUVrFEZg_6_0"></a><a id="Tc_OR-B1Kx7nk2pMp6jfuE67w_7_0"></a><a id="Tc_jjbucjdmC0yt353M6x-v8g_8_0"></a><a id="Tc_nT9pSNm5JkWd-v5MzqD8tA_9_0"></a><a id="Tc_gx08NlrPM0-QFCxy3o1XqA_10_0"></a><a id="Tc_6MgMjHo6U06pWLX2zLtiYA_11_0"></a><a id="Tc_PmX3SseYOkiI716NHe-2gw_11_3"></a><a id="Tc_Su9jPkIjm0G2wWo7syPrGQ_12_0"></a><a id="Tc_Emxo2wzs7UaOrghnNqwHHA_13_0"></a><a id="Tc_Ckk_ZPDLIU2K-OR22YWktw_13_2"></a><a id="Tc_ZExdq_XXZE2Mtu7KtYOSTg_13_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_C_zVrKpgUkCMny13PluXwg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. Accrued expenses</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_NWvWyRHNpE-5rk2-fOhDfA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued clinical trial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:AccruedClinicalTrialExpensesCurrent" scale="3" id="Tc_gcUl8_F0FEqMxBqzBbDGMg_3_3">14,338</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:AccruedClinicalTrialExpensesCurrent" scale="3" id="Tc_S-2KVBV3d0-P4t7vTDlNhA_3_6">10,915</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued milestone payments &amp; royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:AccruedMilestonePaymentsCurrent" scale="3" id="Tc_wiziICe3h0mhk9WUIUAeRw_4_3">11,767</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued compensation and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_1F6TU5BGA0iaD3TQKRVZOw_5_3">10,860</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_31lTDo1g606zafXsRa_e4g_5_6">6,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued commercialization costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:AccruedCommercializationCostsCurrent" scale="3" id="Tc_T7muSmej0Uy48ySamyY1Ow_6_3">8,205</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:AccruedCommercializationCostsCurrent" scale="3" id="Tc_wrai1Hz7NUK6eu3tnJITVw_6_6">803</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued contract manufacturing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:AccruedContractManufacturingExpensesCurrent" scale="3" id="Tc_hbpKBCCRmkihj63WQ7laNQ_7_3">3,224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:AccruedContractManufacturingExpensesCurrent" scale="3" id="Tc_3Ib3KTrKZE-cklo4QacVMg_7_6">3,748</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued other research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:AccruedResearchAndDevelopmentExpensesCurrent" scale="3" id="Tc_vIbYFGmdKUir3M3Lki_nRQ_8_3">3,015</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:AccruedResearchAndDevelopmentExpensesCurrent" scale="3" id="Tc_Ph7fj6rOFkWVD0d819YJSw_8_6">1,359</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued consulting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:AccruedConsultingFeesCurrent" scale="3" id="Tc_9gsqEyaXIECSjYIofb4QGA_9_3">1,287</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:AccruedConsultingFeesCurrent" scale="3" id="Tc__uMWcssey02sPO_C7g3EmA_9_6">1,613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_xRhv8_Ys3kSeMsqPaUF55w_10_3">793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_B-mNYojIV0iYGyTGReP4jg_10_6">620</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_IFNq9PpyWEiKDX4X78rMhw_11_6">316</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_lUdhfzWjM0KCSg89l8RSdA_12_3">492</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_LkVo89_xyEC7gB9_HYCmDw_12_6">333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total accrued expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_ktQ2pivqUUaI70Skszdlpw_13_3">53,981</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_5w_0BaHtzkuqoxCwCznjxg_13_6">25,952</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk221209449"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:DebtDisclosureTextBlock" id="Tb_D4tklFxlIEKqbRToFcrtsQ" continuedAt="Tb_D4tklFxlIEKqbRToFcrtsQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Long-term debt</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Note Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On January&#160;13, 2025 (the &#8220;Note Purchase Agreement Closing Date&#8221;), the Company entered into the </span>Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;) with RGCM SA LLC, as purchaser agent, Oberland Capital Management LLC (&#8220;Oberland&#8221;) and certain funds managed by Oberland, as purchasers (together with the other purchasers party thereto referred as the &#8220;Note Purchase Agreement Purchasers&#8221;) <span style="background:#ffffff;">pursuant to which the Company may sell to the Purchasers, and the Purchasers may buy from the Company, notes (the &#8220;Notes&#8221;) in an aggregate principal amount not to exceed </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_1_13_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_kwGm2G1ANE6CxfNPRBiayA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_ZbP1wZN5ekGxshuyROwjmg">150.0</ix:nonFraction></span><span style="background:#ffffff;"> million. On the Note Purchase Agreement Closing Date, the Company issued and sold an initial Note in an aggregate principal amount </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_1_13_2025_srt_StatementScenarioAxis_vstm_InitialSaleMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_TGIhGhuPoUWERtDGZhnrlA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr__TX3RtjEXUCWJtRKUfgpZQ">75.0</ix:nonFraction></span><span style="background:#ffffff;"> million. In addition, the Company may issue and sell additional Notes with aggregate principal amount of up to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_Un8b41l_pEirHv8lmaIPmw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:DebtInstrumentIssuanceOfAdditionalNotes" scale="6" id="Narr_0_D4cc69AUqFHeFyPKgOGA">75.0</ix:nonFraction></span><span style="background:#ffffff;"> million as follows</span><span style="background:#ffffff;">:</span></p><div style="margin-top:14pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt 0pt 6pt 0pt;">iii.</td><td style="text-align:right;width:18pt;padding:0pt 0pt 6pt 0pt;"/><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at the option of the Company, the a second purchase (the &#8220;Second Purchase&#8221;) of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_1_13_2025_srt_StatementScenarioAxis_vstm_SecondSaleMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_kgBvIxdJtkiqAwZH4jNFMw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:DebtInstrumentIssuanceOfAdditionalNotes" scale="6" id="Narr_RuleXFH0-02UUdcZFrcEOg">25.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million principal amount of Notes, at any time prior to December 31, 2025, upon the FDA&#8217;s approval sufficient for the promotion and sale of avutometinib and defactinib for the treatment of LGSOC and subject to certain other customary conditions precedent. In March 2026, the Company amended the Note Purchase Agreement to extend the date by which it may draw down the Second Purchase from December 31, 2025 to June 30, 2026 (see </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Note 20. Subsequent Events</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">). and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt;">iv.</td><td style="text-align:right;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at the option of the Company, the, a third purchase (the &#8220;Third Purchase&#8221;) of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_1_13_2025_srt_StatementScenarioAxis_vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_FQVi45q7jkSuA4lClWDejQ" decimals="-5" format="ixt:num-dot-decimal" name="vstm:DebtInstrumentIssuanceOfAdditionalNotes" scale="6" id="Narr_HTkgKY4af0ifBVuIDXKhAQ">50.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million principal amount of Notes, at any time prior to December 31, 2026, provided that trailing six-month worldwide net sales of avutometinib and defactinib are at least </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_2MBviHog-02Q7tUt8Qeq9g" decimals="-5" format="ixt:num-dot-decimal" name="vstm:CovenantWorldwideNetSalesOfAvutometinibAndDefactinib" scale="6" id="Narr_eassn7D4n0SQASdqG4k-AQ">55.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million and subject to certain other customary conditions precedent.</span></td></tr></table><div style="margin-top:14pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:14pt;background:#ffffff;margin:14pt 0pt 0pt 0pt;"><span style="font-size:10pt;">The outstanding principal amount of the Notes bear interest at a rate per annum equal to the sum of (i)&#160;the greater of the Term </span><span style="-sec-ix-hidden:Hidden_Jq6EAhHjvU6lCRswi0Rx2Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SOFR</span></span><span style="font-size:10pt;"> (as defined in the Note Purchase Agreement) and </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_iZI7Ie7K00GLdoRZJcm5tA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_rsELOuPP102e7Nx_2yv6jQ">4.29</ix:nonFraction>%</span><span style="font-size:10pt;">, and (ii)&#160;</span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_Un8b41l_pEirHv8lmaIPmw" decimals="4" format="ixt:num-dot-decimal" name="vstm:DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate" scale="-2" id="Narr_n5pVhfZthUmhFQB5ZqL8mw">3.71</ix:nonFraction>%</span><span style="font-size:10pt;">, subject to adjustment in certain circumstances set forth in the Note Purchase Agreement and an overall cap of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_Un8b41l_pEirHv8lmaIPmw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_HlgWWbhw40ip1yzLixbrFw">9.75</ix:nonFraction>%</span><span style="font-size:10pt;">, payable quarterly in arrears until the seventh anniversary of the Note Purchase Agreement Closing Date or the date on which all amounts owing to the Note Purchase Agreement Purchasers under the Note Purchase Agreement have been paid in full (the &#8220;Note Purchase Agreement Maturity Date&#8221;). For the first eight quarters following the Note Purchase Agreement Closing Date, at the Company&#8217;s option, up to </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_13_2025_To_1_13_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_ZP6M46McoESK6chF5ck0mg" decimals="2" format="ixt:num-dot-decimal" name="vstm:InterestDuePaidInKindPercentage" scale="-2" id="Narr_6Cqp14-S9UuvwQmtuyIZNQ">50</ix:nonFraction>%</span><span style="font-size:10pt;"> of the interest due may be paid-in-kind and added to the then-outstanding principal balance of the Notes. Through December 31, 2025, the Company has not elected to defer any interest through its paid-in-kind option. Upon the occurrence and during the continuance of an Event of Default (as defined in the Note Purchase Agreement) under the Note Purchase Agreement, the then-applicable interest rate on all outstanding obligations may be increased by an additional </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_iZI7Ie7K00GLdoRZJcm5tA" decimals="4" format="ixt:num-dot-decimal" name="vstm:AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage" scale="-2" id="Narr_k9rROQLBgECPcP6t75ILaw">5.00</ix:nonFraction>%</span><span style="font-size:10pt;">.</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_D4tklFxlIEKqbRToFcrtsQ_cont1" continuedAt="Tb_D4tklFxlIEKqbRToFcrtsQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:0pt;">Beginning on January&#160;13, 2025 and continuing until the Note Purchase Agreement Maturity Date, the Note Purchase Agreement Purchasers will receive <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_First100MillionNetSalesOfEachIncludedProductMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_yDuuqaiCa0qAYyrozwvzzw" decimals="4" format="ixt:num-dot-decimal" name="vstm:ParticipationInNetSalesPercentage" scale="-2" id="Narr_nCdAVi1LZUac5EpJv6PF_g">1.00</ix:nonFraction>% (the &#8220;Revenue Participation Percentage&#8221;) of the first $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_First100MillionNetSalesOfEachIncludedProductMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_yDuuqaiCa0qAYyrozwvzzw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:ParticipationInNetSalesSalesAmount" scale="6" id="Narr_AboF4msjFkaVrb7TZNFAqg">100.0</ix:nonFraction> million of net sales of each Included Product (as defined in the Note Purchase Agreement) by the Company or its affiliates or licensees in each calendar year, payable quarterly. &#8220;Included Products&#8221; is defined in the Note Purchase Agreement to include (a)&#160;avutometinib and defactinib, including any product that contains either one of the foregoing in combination with any other active ingredient(s), and (b)&#160;all other compounds, chemical entities or pharmaceutical products being designed, developed, licensed, manufactured or commercialized by the Company or its subsidiaries from time to time. The Revenue Participation Percentage will increase&#160;pro rata&#160;immediately upon the occurrence of the Second Purchase and the Third Purchase, such that the Revenue Participation Percentage shall increase to a maximum of <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_pZ_a6EQacUaXNZDxp5JMNA" decimals="4" format="ixt:num-dot-decimal" name="vstm:ParticipationInNetSalesPercentage" scale="-2" id="Narr_EgTWiLBcMEe0-xJVS76zDQ">2.00</ix:nonFraction>% in the event that $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_1_13_2025_srt_StatementScenarioAxis_vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_L9jTrBAWiUuY_e_CNM8bCQ" decimals="-6" format="ixt:num-dot-decimal" name="vstm:ParticipationInNetSalesAggregatePrincipalAmountOfDebt" scale="6" id="Narr_3ep19niInEaIMfNvV8M2gg">150</ix:nonFraction> million in aggregate principal amount of Notes has been purchased pursuant to the Note Purchase Agreement following the Third Purchase. The outstanding principal amount of the Notes, interest accrued thereon and any other amounts owing to the Note Purchase Agreement Purchasers under the Note Purchase Agreement will be due in <ix:nonFraction unitRef="Unit_Standard_installment_8U3XYH-pF0m6Z5I545EDwQ" contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_iZI7Ie7K00GLdoRZJcm5tA" decimals="INF" format="ixt-sec:numwordsen" name="vstm:DebtInstrumentNumberOfEqualInstallments" scale="0" id="Narr_YQ8ZqAy7WEqEYAHEuZkyVQ">two</ix:nonFraction> equal instalments on (a)&#160;the sixth anniversary of the Note Purchase Agreement Closing Date, and (b)&#160;the Note Purchase Agreement Maturity Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">All of the Notes may be redeemed prior to the Note Purchase Agreement Maturity Date at the option of the Company, subject to payment of the Repayment Amount (as defined in the Note Purchase Agreement). The Note Purchase Agreement Purchasers may demand redemption of the Notes prior to the Note Purchase Agreement Maturity Date in the event of a Change of Control (as defined in the Note Purchase Agreement) of the Company or an Event of Default (as defined in the Note Purchase Agreement) under the Note Purchase Agreement, subject to payment of the Repayment Amount. The Repayment Amount is due at the earlier of the Maturity Date and when payment of all obligations under the Note Purchase Agreement are otherwise due. The Repayment Amount is: (a)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_RedemptionPriorToSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_YpTuBpiScUuxKI1zr7VhQg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="Narr_bn-xX6AkHk-pIJYm-VUPKQ">135</ix:nonFraction>% of the principal amount of the Notes if redemption occurs before the second anniversary of the Note Purchase Agreement Closing Date upon a Change of Control; (b)&#160;if the preceding clause (a)&#160;does not apply, <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_RedemptionPriorToThirdAnniversaryMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_E6tvvCsPZ0mBoCk6DsCySg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="Narr_A7B0jax8IE2-_GpLWoOgag">175</ix:nonFraction>% of the principal amount of the Notes if redemption occurs prior to the third anniversary the Note Purchase Agreement Closing date; and (c)&#160;thereafter, <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_RedemptionAfterYearThirdAnniversaryMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_E6iz-U49E0K1SJSRv0h8aQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="Narr_nG0votsf_kOFNvK1LXl5RA">195</ix:nonFraction>% of the principal amount of the Notes if redemption occurs after the third anniversary the Note Purchase Agreement Closing Date, minus, in each case, the sum of regularly scheduled interest paid in cash, payments of principal in cash, and payments of revenue participation in cash prior to such redemption date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_iZI7Ie7K00GLdoRZJcm5tA" name="us-gaap:DebtInstrumentCovenantDescription" id="Narr_BBWmYiAGCkarAuXCSmJlvw">The Note Purchase Agreement contains no financial covenants</ix:nonNumeric>. The Company&#8217;s obligations under the Note Purchase Agreement are subject to customary covenants, including limitations on the Company&#8217;s ability to dispose of assets, undergo a change of control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of its capital stock, repurchase stock and make investments, in each case subject to certain exceptions. The Company&#8217;s obligations under the Note Purchase Agreement are secured by a security interest on substantially all of the Company&#8217;s and its subsidiaries&#8217; assets, including its intellectual property related to avutometinib and defactinib, and a negative pledge on intellectual property related to the <span style="background:#ffffff;">Company&#8217;s collaboration and option agreement with GenFleet (the &#8220;GenFleet Agreement&#8221;), subject to certain exceptions relating to the Company&#8217;s development of its intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">A portion of the proceeds of the Note Purchase Agreement were used to repay the Company&#8217;s obligations under the Loan Agreement in full. The Loan Agreement was terminated concurrently with entry into the Note Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">The Company assessed the terms and features of the Note Purchase Agreement and determined that the Company is eligible to elect the fair value option under ASC 825, <i style="font-style:italic;">Financial Instruments</i>. The Note Purchase Agreement contains various embedded features and the election of the fair value option allows the Company to bypass analysis of potential embedded derivatives and further analysis of bifurcation of any recognized financial liabilities. Under the fair value option, the financial liability is initially measured at its fair value on the issuance date and subsequently remeasured at estimated fair value on a recurring basis at each reporting date. Changes in the fair value of the Note Purchase Agreement, which include accrued interest, if any, are recorded as a component of change in fair value of Notes in the consolidated statements of operations. The Company has not elected to present interest expense separately from changes in fair value and therefore will not separately present interest expense associated with the Note Purchase Agreement. Changes in fair value caused by instrument-specific credit risk are presented separately in other comprehensive income or loss within the consolidated statements of equity (deficit). The portion of total </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_YpAB5oF2ZkWmAGu8w7S0Iw_1_0"></a><a id="Tc_ioIZuf--qEWFwyaPYdKh4Q_1_2"></a><a id="Tc_rluCYwGJJkaVGwE2frBHaQ_4_0"></a><a id="Tc_0ywLJ9exeEC56E-Vlpx4hg_5_0"></a><a id="Tc_xdO0aAgK3EicEy8-ZQk1TQ_5_2"></a><a id="_7c28a16d_b106_4d66_9e5e_440172f07a99"></a><a id="Tc_-SurEKQWek6L2lRjkslrpg_1_0"></a><a id="Tc_hIzxxMfOOUKqAnA8zMOISw_1_3"></a><a id="Tc_C3iFEpoeVU6sCovhCoS6GA_2_0"></a><a id="Tc_e8AsIiTKtUqhsMOtwi0g3Q_2_3"></a><a id="Tc_YxuTd4nK2kmJlqsw5NTbXg_3_0"></a><a id="Tc_lxa4r3wRHkWnrqatBrd80g_3_3"></a><a id="Tc_h5Q8yZajskCGVUi-uQ4ptA_4_0"></a><a id="Tc_TO4HcQbStkOAWXa5X1EArg_4_3"></a><a id="Tc_hK5g5BOdZEOwEkySn0MoBQ_5_0"></a><a id="Tc_yp1-nN9uckqLpc57MSKSHw_5_3"></a><a id="Tc_rrQr2NU3IkOJNHTQg4GqHg_6_0"></a><a id="Tc_qULCT_gsGEWbhu9LhETotA_7_0"></a><a id="Tc_HCEVim9eCUSq57TH-a3p6A_8_0"></a><a id="Tc__GvEBbd6uk---f2L1E3Lmg_8_2"></a><ix:continuation id="Tb_D4tklFxlIEKqbRToFcrtsQ_cont2" continuedAt="Tb_D4tklFxlIEKqbRToFcrtsQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">changes in fair value of Notes attributable to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive loss. Under the fair value option, debt issuance costs are expensed as incurred. The Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_02A2El0zNE6rdIdZB1KSUg" decimals="-5" format="ixt:num-dot-decimal" name="vstm:DebtIssuanceCosts" scale="6" id="Narr_fIRKSHTPbEqj3gb5d9QEaQ">0.8</ix:nonFraction> million of debt issuance costs which were recorded within selling, general and administrative expense in the consolidated statements of operations for the year ended December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">The Company determined the fair value of the Notes on January 13, 2025 was </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_Un8b41l_pEirHv8lmaIPmw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="Narr_48s8YAAGrUub7cCghocKvw">75.0</ix:nonFraction></span><span style="font-size:10pt;">&#160;million. </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Group_zgaJxhLT3k6o8-qjLrTcCw" continuedAt="Group_zgaJxhLT3k6o8-qjLrTcCw_2" escape="true"><span style="font-size:10pt;">The following table reconciles the change in fair value of the Notes during the years ended December 31, 2025</span></ix:nonNumeric></p><ix:continuation id="Group_zgaJxhLT3k6o8-qjLrTcCw_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Beginning fair value balance at January 13, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_Un8b41l_pEirHv8lmaIPmw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_2z_VmJ9V70ygzG0ywIRbdg_1_3">75,000</ix:nonFraction></b></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden__aGtVmkn9kuWPabZ5DVUXg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value reported in statements of operations</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_14_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_0BoN3371-EmgElNU_GJ5pw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="3" id="Tc_T77DokhqhkGU0aBCsPcWGQ_2_3">12,751</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_-3F5ri1upkSXeC-rPJHM9A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value reported in comprehensive loss</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_14_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_0BoN3371-EmgElNU_GJ5pw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="3" id="Tc_S4NPfFsm5ky2nWRKUTts_w_3_3">5,229</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest and revenue participation payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_14_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_0BoN3371-EmgElNU_GJ5pw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="Tc_u_462H2p4kqWnFV73iTt6g_4_3">6,192</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Ending fair value at December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_8S_QmEHi20-3Bt7pN3KrWg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc__4VRWzQaAEKV0C_3NHrjkQ_5_3">76,330</ix:nonFraction></b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_-YdQ7h0dPUaScC-RCaPWDQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">As of December 31, 2025, future principal payments under the Note Purchase Agreement are due as follows (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:LongTermDebtMaturityYearSix" scale="3" id="Tc_yEjjVqDXqUGcQZm11rg45g_6_3">37,500</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:LongTermDebtMaturityYearSeven" scale="3" id="Tc_UyDN7Lf3dkm13i0_yhb_Yg_7_3">37,500</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total principal payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:LongTermDebtMaturitiesAggregatePrincipalDue" scale="3" id="Tc_xw7iDOrubEOJh6QKvWJQnA_8_3">75,000</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Loan Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On March 25, 2022 (the &#8220;Loan Agreement Closing Date&#8221;), the Company entered into a loan and security agreement (the &#8220;Original Loan Agreement&#8221;) with Oxford Finance, LLC (&#8220;Oxford&#8221;), as collateral agent and a lender, and Oxford Finance Credit Fund III LP, as a lender (&#8220;OFCF III&#8221; and together with Oxford, the &#8220;Lenders&#8221;), pursuant to which the Lenders agreed to lend the Company up to an aggregate principal amount of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_zrQB4qKfyEqQTrK2VnX_yg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_7r98nrI6Z0eDHR99ei-FNw">150.0</ix:nonFraction></span><span style="background:#ffffff;"> million in a series of term loans (the &#8220;Term Loans&#8221;). On January 4, 2024, the Company amended the Original Loan Agreement (as amended, the &#8220;Loan Agreement&#8221;) to extend the date by which it may draw down the Term C Loan from March 31, 2024, to March 31, 2025. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Pursuant to the Loan Agreement, the Company received an initial Term Loan of&#160;</span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_n_qBs1SNYkedi6TPK_3kgw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="Narr_d1cCuacnc0OX9RPXTLbIIA">25.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million on the Loan Agreement Closing Date, and drew down the second term loan of&#160;</span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_3_22_2023_To_3_22_2023_us-gaap_DebtInstrumentAxis_vstm_TermBLoanMember_Ko01k0D9G0CisdNqaY7CwQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="Narr_41PZAYhXOkyS8qR7VDbr9A">15.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million (the &#8220;Term B Loan&#8221;) on March 22, 2023, and could have borrowed an additional&#160;</span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_zrQB4qKfyEqQTrK2VnX_yg" decimals="-5" format="ixt:num-dot-decimal" name="vstm:DebtInstrumentCurrentBorrowingCapacity" scale="6" id="Narr_P-NPAqrIbk-Cuf-rOxyz8Q">110.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million of Term Loans at its option upon the satisfaction of certain conditions as follows:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">i.</td><td style="text-align:right;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermCLoanMember_LB9vQfFWtUOb5dJuYRvwQw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_dHnFqqSXy0mLiB6zNSAMJg">25.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million (the &#8220;Term C Loan&#8221;), when the Company has received accelerated or full approval from the FDA of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">avutometinib </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">for the treatment of LGSOC (the &#8220;Term C Milestone&#8221;). The Company could have drawn the Term C Loan within </span><ix:nonNumeric contextRef="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermCLoanMember_GwB-PS6Ju0-fUVSXWFqhUQ" format="ixt-sec:durwordsen" name="vstm:DebtInstrumentPeriodToDrawLoanMinimum" id="Narr_sOj1dxOnPEKTEFClbDjcOg"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">60 days</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> after the occurrence of the Term C Milestone, but no later than March 31, 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">ii.</td><td style="text-align:right;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermDLoanMember_w57GQ0GBSEaZmkdvKKZD1w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_q25n9EPBgU66XatzxtJ9cg">35.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million (the &#8220;Term D Loan&#8221;), when the Company has achieved at least </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermDLoanMember_0YiEHyy_qUmrRNBRC-bsYg" decimals="-5" format="ixt:num-dot-decimal" name="vstm:GrossProductRevenueToBeAchieved" scale="6" id="Narr_PwvO-v-6n0WKztgahFWSYw">50.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million in gross product revenue calculated on a trailing six-month basis (the &#8220;Term D Milestone&#8221;). The Company could have drawn the Term D Loan within </span><ix:nonNumeric contextRef="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermDLoanMember_0YiEHyy_qUmrRNBRC-bsYg" format="ixt-sec:durwordsen" name="vstm:DebtInstrumentPeriodToDrawLoanMinimum" id="Narr_DybtlcIVdU6ST2nb4KZbcg"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">30 days</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> after the occurrence of the Term D Milestone, but no later than March 31, 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">iii.</td><td style="text-align:right;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermELoanMember_oqIeKfAl3E-mBRkyj-y-iA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_nh8IkfLdX0C9y5Ezg9K-tA">50.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million (the &#8220;Term E Loan&#8221;), at the sole discretion of the Lenders.</span></td></tr></table></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_D4tklFxlIEKqbRToFcrtsQ_cont3" continuedAt="Tb_D4tklFxlIEKqbRToFcrtsQ_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Term Loans bore interest at a floating rate equal to (a) the greater of (i) the one-month </span><span style="-sec-ix-hidden:Hidden_YOPMCZqEsUS3-osVGkAxWQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">CME Secured Overnight Financing Rate</span></span><span style="background:#ffffff;"> and (ii) </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_3_22_2023_To_3_22_2023_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_5nolpa91pE-eWxvWNTzoIA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr__f1leL7SS0adoXBw2co-ow">0.13</ix:nonFraction>%</span><span style="background:#ffffff;"> plus (b) </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_3_22_2023_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_75mzb7bZKkioJTv-axGvyQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_6A27Rlw5LUuoYcKXw1ji6g">7.37</ix:nonFraction>%</span><span style="background:#ffffff;">, subject to an overall floor and cap. Interest was payable monthly in arrears on the first calendar day of each calendar month. As a result of the Term B Loan drawdown, beginning (i) April 1, 2025, or (ii) April 1, 2026, if either (A) </span>avutometinib h<span style="background:#ffffff;">as received FDA approval for the treatment of LGSOC or (B) COPIKTRA has received FDA approval for the treatment of peripheral T-cell lymphoma, the Company would have been required to repay the Term Loans in consecutive equal monthly payments of principal, together with applicable interest, in arrears. All unpaid principal and accrued and unpaid interest with respect to each Term Loan were due and payable in full on March 1, 2027.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company was required to make a final payment of&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_n_qBs1SNYkedi6TPK_3kgw" decimals="3" format="ixt:num-dot-decimal" name="vstm:DebtInstrumentFinalPaymentFeePercentage" scale="-2" id="Narr_Uri3-8L090WGTwmPcfK1YA">5.0</ix:nonFraction>%</span><span style="background:#ffffff;"> of the original principal amount of the Term Loans that are drawn, payable at maturity or upon any earlier acceleration or prepayment of the Term Loans (the &#8220;Final Payment Fee&#8221;). The Company could have prepaid all, but not less than all, of the Term Loans, subject to a prepayment fee equal to (i)&#160;3.0% of the principal amount of the applicable Term Loan if prepaid on or before the first anniversary date of the funding date of such Term Loan, (ii)&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_3_25_2022_To_3_25_2022_srt_StatementScenarioAxis_vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember_q8ti5S-pZU699rXFl4F2PQ" decimals="3" format="ixt:num-dot-decimal" name="vstm:DebtInstrumentFinalPaymentFeePercentage" scale="-2" id="Narr_HkvC5fnKDUOfu7ltK5xAYQ">2.0</ix:nonFraction>%</span><span style="background:#ffffff;"> of the principal amount of the applicable Term Loan if prepaid after the first anniversary and on or before the second anniversary of the funding date of such Term Loan, and (iii) </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_3_25_2022_To_3_25_2022_srt_StatementScenarioAxis_vstm_PrepaymentAfterSecondAnniversaryMember_1PALNeli40iSsLa7t8QfSA" decimals="3" format="ixt:num-dot-decimal" name="vstm:DebtInstrumentFinalPaymentFeePercentage" scale="-2" id="Narr_zUTTHgVPrkuU2fUgHyCh2A">1.0</ix:nonFraction>%</span><span style="background:#ffffff;"> of the principal amount of the applicable Term Loan if prepaid after the second anniversary of the applicable funding date of such Term Loan. All Term Loans were subject to a facility fee of&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_zrQB4qKfyEqQTrK2VnX_yg" decimals="3" format="ixt:num-dot-decimal" name="vstm:DebtInstrumentAdditionalInterestRateInEventOfDefault" scale="-2" id="Narr_lXC7al8q-0CqGQLF725yoQ">0.5</ix:nonFraction>%</span><span style="background:#ffffff;"> of the principal amount.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Loan Agreement contained </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_item_5quK1hZThku2W0bLLpUodA" contextRef="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember_hrCFuYf1CEmedfPlJxDI9w" decimals="INF" format="ixt-sec:numwordsen" name="vstm:NumberOfFinancialCovenants" scale="0" id="Narr_9aLgePVMWUWfpuB0PdmPPA">no</ix:nonFraction></span><span style="background:#ffffff;"> financial covenants. The Loan Agreement included customary events of default, including, among others, payment defaults, breach of representations and warrants, covenant defaults, judgment defaults, insolvency and bankruptcy defaults, and a material adverse change. The occurrence of an event of default could have resulted in the acceleration of the obligations under the Loan Agreement, termination of the Term Loan commitments and the right to foreclose on the collateral securing the obligations. During the existence of an event of default, the Term Loans would have accrued interest at a rate per annum equal to </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember_hJCM6F5LHUKiyc_uSMcFDQ" decimals="3" format="ixt:num-dot-decimal" name="vstm:DebtInstrumentAccruedInterestRate" scale="-2" id="Narr_wi8UJvY90EalNSs1oG8XJw">5.0</ix:nonFraction>%</span><span style="background:#ffffff;"> above the otherwise applicable interest rate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="background:#ffffff;">In connection with the Loan Agreement, the Company granted Oxford a security interest in all of the Company&#8217;s personal property now owned or hereafter acquired, excluding intellectual property (but including the right to payments and proceeds of intellectual property), and a negative pledge on intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="font-family:'Times';">The Company assessed all terms and features of the Loan Agreement in order to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the Loan Agreement, including put and call features. The Company determined that all features of the Loan Agreement were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's financial statements. The Company reassesses the features on a quarterly basis to determine if they require separate accounting. There have been no changes to the Company</span>&#8217;s <span style="font-family:'Times';">assessment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="font-family:'Times';">Concurrently with the closing of the Note Purchase Agreement, on January&#160;13, 2025, the Company terminated its Loan Agreement and repaid in full the balance of its obligations under the Loan Agreement of approximately </span><span style="font-family:'Times';">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember__WavrOlweUuRmxKfUY_vSg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="Narr_dCUplrOMGEKwhq2mqLiiVA">42.7</ix:nonFraction></span><span style="font-family:'Times';">&#160;million (the &#8220;Payoff Amount&#8221;). The Payoff Amount included the Final Payment Fee of </span><span style="font-family:'Times';">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember__WavrOlweUuRmxKfUY_vSg" decimals="-5" format="ixt:num-dot-decimal" name="vstm:RepaymentsOfLongTermDebtFinalPaymentFee" scale="6" id="Narr_MJFgj2oC90-OuuaMwlfDHQ">2.0</ix:nonFraction></span><span style="font-family:'Times';">&#160;million, which was due at the earlier of prepayment or loan maturity, and certain prepayment fees as set forth in the Loan Agreement, a prepayment penalty fee of </span><span style="font-family:'Times';">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember__WavrOlweUuRmxKfUY_vSg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="6" id="Narr_T1Pe00dMd0uUR31E4TAuRQ">0.6</ix:nonFraction></span><span style="font-family:'Times';">&#160;million, and unpaid interest of </span><span style="font-family:'Times';">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember__WavrOlweUuRmxKfUY_vSg" decimals="-5" format="ixt:num-dot-decimal" name="vstm:RepaymentsOfLongTermDebtUnpaidInterest" scale="6" id="Narr_TFlGjwjQ-0CsQtVteVXBHA">0.1</ix:nonFraction></span><span style="font-family:'Times';">&#160;million.&#160;Upon the Lender&#8217;s receipt of the Payoff Amount, the Loan Agreement was terminated along with the Lender&#8217;s commitment to provide funding under any future term loans.&#160; All liens on the Company&#8217;s assets to secure the loans under the Loan Agreement have been terminated and released. The Payoff Amount, excluding accrued interest, exceeded the carrying amount of the Term Loan on January 13, 2025 by&#160;</span><span style="font-family:'Times';">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember__WavrOlweUuRmxKfUY_vSg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="6" id="Narr_sY38XIi8UE6GUH2tnF-wTw">1.8</ix:nonFraction></span><span style="font-family:'Times';">&#160;million. As a result the Company recorded a loss on debt extinguishment of&#160;</span><span style="font-family:'Times';">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember_RAkPieYklE2it_DAfMg6bg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="6" id="Narr_x9nDOq1Df0SwMi3Fw3OLAw">1.8</ix:nonFraction></span><span style="font-family:'Times';">&#160;million included in the consolidated statements of operations and comprehensive loss for the twelve months ended December 31, 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="color:#212529;">The debt issuance costs and the Final Payment Fee were recorded as a debt discount which were accreted to interest expense through the maturity date of the Term Loan using the effective interest method.&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:ScheduleOfDebtTableTextBlock" id="Group_36ypkJHP3Uy9Q78n_xzZrg" continuedAt="Group_36ypkJHP3Uy9Q78n_xzZrg_2" escape="true"><span style="color:#212529;">The components of the carrying value of the Term Loan as of December 31, 2024, are detailed below (in thousands):</span></ix:nonNumeric></p><ix:continuation id="Group_36ypkJHP3Uy9Q78n_xzZrg_2" continuedAt="Group_36ypkJHP3Uy9Q78n_xzZrg_2_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_P3uRFK-WA0GCoMOCi2cYWA_1_1"></a><a id="Tc_2SCq0qC6AEaaEIw4N88K5w_2_0"></a><a id="Tc_mIlbZ5W6fUOLn5bDStcMYw_2_1"></a><a id="Tc_x1RjQOBUuUmmblImCa_aPA_3_0"></a><a id="Tc_1lCkVu7iYUeUHzdnUVXGxA_4_0"></a><a id="Tc_j4JjEzO_70OGzKKuNPWZ0w_5_0"></a><a id="_77be594f_ba56_457a_99d4_1ea117781f7c"></a><a id="Tc_mm3v0d9vkk2sD4DjmtS3vA_1_1"></a><a id="Tc_rfFwZMt7D0ejV1AIjSKfPw_2_1"></a><a id="Tc_4MsH1JeMckKr--R8BZeAjg_2_4"></a><a id="Tc_LNLx_o-clkaKn01YjsWnTA_2_7"></a><a id="Tc_-_78YEuNMUihz7EWEnHmWw_3_0"></a><a id="Tc_i63wAKZvwkmjAwYVEHl8RQ_3_1"></a><a id="Tc_lNI3zorxuUycoBFZkVdIWg_3_4"></a><a id="Tc_e9G_MKnAkE-pIHSwpY8NQQ_3_7"></a><a id="Tc_hd6REAMmnEuy5EAB30LHFg_4_0"></a><a id="Tc_gxtZFZtg0EWhwxZ0Kx0ZfA_5_0"></a><a id="Tc_WcCfk9-1kkOLdFi0rw-1BQ_6_0"></a><a id="Tc_2JQke1mKR0mh-G0gebUT5g_6_1"></a><a id="Tc_OcP06t174EmHx91CkJGapA_6_4"></a><a id="Tc_p482ScAvqUOJPZ1b_Qdo2A_6_7"></a><ix:continuation id="Tb_D4tklFxlIEKqbRToFcrtsQ_cont4"><ix:continuation id="Group_36ypkJHP3Uy9Q78n_xzZrg_2_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:33.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Principal loan balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_-4E3cJFf8kK0hmjS6Cdtzw_2_2">40,000</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Final Payment Fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:DebtInstrumentFinalPaymentFee" scale="3" id="Tc_5vhyVcHqKk6r3GVpqkO3zA_3_2">1,172</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Debt issuance costs, net of accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="3" id="Tc_G9szStQLZUCCbiCi0sw9hw_4_2">448</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Long-term debt, net of discount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_-jeF0e8-TU2oPGCFEoRPHg_5_2">40,724</ix:nonFraction></b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="Tb_zbMcuypbiUSIYEyMMNAB6A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The following table sets forth total interest expense for the years ended December 31, 2025, 2024, and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:52.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Contractual Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ContractualInterestExpense" scale="3" id="Tc_TD6s7rZdC0yU1KoVqt34QA_3_2">1,109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ContractualInterestExpense" scale="3" id="Tc_9mFPMP4ImE6uUcsjjs-DYg_3_5">3,774</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ContractualInterestExpense" scale="3" id="Tc_0pHm6ssqy0ehc2yDXVmU_w_3_8">3,472</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Amortization of debt discount and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="Tc_kuT2U_t8REmRTqNSwwxDiQ_4_2">11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="Tc_Xq3draT7NUScJNtizT5E-w_4_5">277</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="Tc_6w1yIaFpo0SLF1vgBo_DJg_4_8">230</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Amortization of Final Payment Fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:AmortizationOfFinalPaymentFee" scale="3" id="Tc_tnr3SV1g80iFkNz1XQ0NTQ_5_2">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="vstm:AmortizationOfFinalPaymentFee" scale="3" id="Tc_8Plr9_lg9Uqs0JADaRnQow_5_5">511</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="vstm:AmortizationOfFinalPaymentFee" scale="3" id="Tc_WB_Gat1yA0e8hUeOXvp8wQ_5_8">437</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="Tc_h0nrU6NJxkOJKTYrLdysow_6_2">1,138</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="Tc_1SSCqlFgIk-VjJrRUYv8Pw_6_5">4,562</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="Tc_gs9Elj_EcUaO_ZVlLxrvSg_6_8">4,139</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"><span style="font-size:1pt;font-style:italic;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"><span style="font-size:1pt;font-style:italic;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_g_lvTasI6U2EkV9g7vUTKA" continuedAt="Tb_g_lvTasI6U2EkV9g7vUTKA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9. Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On April 15, 2014, the Company entered into a lease agreement for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_FdbiNq8DNkeaOGqvsWqN6A" contextRef="As_Of_4_15_2014_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_xnA_Kvwj70evJoubr3vJJQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_Rm-pGXKFKkeqRvo26baZUA">15,197</ix:nonFraction> square feet of office and laboratory space in Needham, Massachusetts. The lease term commenced on April 15, 2014 and it was scheduled to expire on September 30, 2019. Effective February 15, 2018, the Company amended its lease agreement to relocate within the facility to another location consisting of <ix:nonFraction unitRef="Unit_Standard_sqft_FdbiNq8DNkeaOGqvsWqN6A" contextRef="As_Of_2_15_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_X8QqK4Hmd06KwW35Ix-WEQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_DX7r-rVtbUOS0aAqBJlPEg">27,810</ix:nonFraction> square feet of office space (the &#8220;February 2018 Amended Lease Agreement&#8221;). The February 2018 Amended Lease Agreement extended the expiration date of the lease from September 2019 through June 2025. Pursuant to the February 2018 Amended Lease Agreement, the initial annual base rent amount was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_2_15_2018_To_2_15_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_TZVH7IRG1kSvGhOZkG4XQA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_pOK9LKQI1U-VfBO_AJ-niw">0.7</ix:nonFraction> million, which increased during the lease term to $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_2_15_2018_To_2_15_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_PZfr7HL6HkyNjzMRM2PTpg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_C7-c2yaI_0OYRvt5WUeUvg">1.1</ix:nonFraction> million for the last 12-month period. Effective November 1, 2024, the Company amended the February 2018 Amended Lease Agreement to extend the expiration date from June 2025 to June 2026 (the &#8220;November 2024 Amended Lease Agreement&#8221;). The payment terms of the November 2024 Amended Lease Agreement are $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_nO8T_caZLkmO-wA1SFOP5w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_BG3N6jkKHkC4_tKhq_KPrw">1.1</ix:nonFraction> million per annum through the expiration date in June 2026. As a result of the November 2024 Amended Lease Agreement, the Company recorded an incremental $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_11_30_2024_UMnI-wXQ0USHesrFhwgQ9g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_dh02gn0gTUebMB1DeYXdlQ">1.0</ix:nonFraction> million right-of-use asset and corresponding lease liability during the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has accounted for its Needham, Massachusetts office space as an operating lease. The Company&#8217;s lease contains an option to renew and extend the lease terms and an option to terminate the lease prior to the expiration date. The Company has not included the lease extension or the termination options within the right-of-use asset and lease liability on the consolidated balance sheets as neither option is reasonably certain to be exercised. The Company&#8217;s lease includes variable non-lease components (e.g., common area maintenance, maintenance, consumables, etc.) that are not included in the right-of-use asset and lease liability and are reflected as an expense in the period incurred. The Company does not have any other operating or finance leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, a right-of-use asset of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_D_eiIEgAKEanzibepjmnhg">0.5</ix:nonFraction> million and lease liability of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_mWp8oh1MwEiHFFM2UJ3n7g">0.5</ix:nonFraction> million are reflected on the consolidated balance sheets. <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:LeaseCostTableTextBlock" id="Group_0ac6m0T6VUWty6P-ZVTmAQ" continuedAt="Group_0ac6m0T6VUWty6P-ZVTmAQ_2" escape="true">The elements of lease expense were as follows (dollar amounts in thousands):</ix:nonNumeric></p><ix:continuation id="Group_0ac6m0T6VUWty6P-ZVTmAQ_2" continuedAt="Group_0ac6m0T6VUWty6P-ZVTmAQ_2_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_29910bae_5415_48e4_82c7_47521d800b83"></a><a id="Tc_kXqF5s15DEGwZBFj_GQ_AA_1_3"></a><a id="Tc_xJGCRrK5ZUytOKa_vytcjg_2_3"></a><a id="Tc_nb06wOXpmEWRjA9B498RTw_2_6"></a><a id="Tc_fP79pdRBkE-X57KrnHx0qA_2_9"></a><a id="Tc_kO_KsM-0pEqna1OLsNgBEw_3_0"></a><a id="Tc_RBDa2teLQ0mnzC1AHg--vA_4_0"></a><a id="Tc_EJyQ7-fDXESPdGloGjbbBg_4_3"></a><a id="Tc_q82Y_C5gXke1b2n6wWZvXw_4_6"></a><a id="Tc_1NoslBnWvEWX0lV6I2xB5w_4_9"></a><a id="Tc_532rn3QHJEGrIWWuNLLtkw_5_0"></a><a id="Tc_c4kuZehZq0OKwdrleeag2Q_5_3"></a><a id="Tc_Xm8XIq1S6EW1SAt0F5PGPg_5_6"></a><a id="Tc_I06gCZ8ijEOtBPz6xebMhA_5_9"></a><a id="Tc_yvtnRKZt00W-o84sgVcNzA_6_0"></a><a id="Tc_RQQod5-CFk2fY9p66Qw1Pw_7_0"></a><a id="Tc_M08Xlz_h1UytPVC-8t4Skw_7_3"></a><a id="Tc_FK2g6NzNfEmV2x4oSihfyw_7_6"></a><a id="Tc_EEUXIidMS0S6y-3-4c_mpw_7_9"></a><a id="_3f0f1218_fc57_40fe_a367_319c40ae9258"></a><a id="Tc_fyadqStLl0mw9-f4VZzC3w_1_6"></a><a id="Tc_ekFKvxEPMk6dupQ5iZC-BQ_2_0"></a><a id="Tc_oBFvYQND-EiJP_fMJHSblA_3_0"></a><a id="Tc_q8L4-e0cc0yM9fjYmZO4xA_4_0"></a><a id="Tc_hNgTE4AZ40WkPvjQ4MYyKg_5_0"></a><a id="Tc_Ndcf9cnP6ESdBaDzOzDUHA_6_0"></a><a id="Tc_Il8N6FqZt0G2XHV7c2HCdQ_7_0"></a><a id="Tc_-VzGjdIO5E64Bc0BKhNwXw_7_5"></a><a id="Tc_6nmBHIh0TUSzVBRKIHHfWg_8_0"></a><a id="Tc_0ZcHAMNuOU6JH6rnwVE1ZQ_9_0"></a><a id="Tc_dv_Dt9YK_k-Fej8IYhdIwQ_9_5"></a><ix:continuation id="Tb_g_lvTasI6U2EkV9g7vUTKA_cont1"><ix:continuation id="Group_0ac6m0T6VUWty6P-ZVTmAQ_2_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:53.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Lease Expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_QNYh1lrqo0CBmRdh2mVqpA_4_4">1,011</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_gbhrokiKlkGFsLpEwZuxxg_4_7">906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_7seh7d2DMEiyKNwfLQGeEQ_4_10">885</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total Lease Expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="Tc_kwz8DxlpIkuNTSjxHrjAyA_5_4">1,011</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="Tc_Pju4MnW-DUWCpi7N1SPUrg_5_7">906</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="Tc_jQ08-duQMEmjqfyKEGh9fQ_5_10">885</ix:nonFraction></b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Information - Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating cash flows paid for amounts included in measurement of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_49hSRf4W90-YsL4TTftnSg_7_4">1,092</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_18DhkDvW3Emjspl8MzWhRw_7_7">1,081</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_RBuyXEgjA0S5vfrNiiBB-A_7_10">1,060</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Balance Sheet Information - Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_HGz4yfbBCEyTvKQT8f556g_3_6"> 0.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_5m5pmhC500O1xbsHKAhH1A_4_6">9.8</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Maturity Analysis</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_N4nQ0cGzUEis_5M9tcTViA_6_6">546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:48.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_hKiWZ0QNkkqaNs-5RXMf-A_7_6">546</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Less: Present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_6av96c3afkSwqL4KW-5wmg_8_6">11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:48.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Lease Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_26lGiZ3eyEmZdjeeoawq8Q_9_6">535</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e0ade1c2_0691_40e6_9cd7_9506a38d1747"></a><a id="Tc_VF8osqwgIEW4y0E8jSUKXg_1_2"></a><a id="Tc_qxy_SAFQdkqn-qhJTNDzfQ_2_2"></a><a id="Tc_gAFowNRfgUGaEX2LspZJGA_2_4"></a><a id="Tc_CjH9y_E6gE2kdbRaSBdOMw_3_0"></a><a id="Tc_va2y4YMUUUmUerhze5hxaA_4_0"></a><a id="Tc_xRMqhlrjlEmfLybwhr9EYQ_5_0"></a><a id="Tc_OHjIefKPjEWRvB1PeKo8RA_6_0"></a><a id="Tc_fJFNVVJZ20yUPTRHhMZN4g_6_2"></a><a id="Tc_zSvwkd0r70a50IlF35tBFg_7_0"></a><a id="Tc_Yabq9PQRCU6q6wL_J2NjNg_8_0"></a><a id="Tc_T71k8yOOvUuS8OtQqvQnXw_9_0"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_yszt-HnrEUq05F5ATMrHgw" continuedAt="Tb_yszt-HnrEUq05F5ATMrHgw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10. Capital Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Under the amended and restated certificate of incorporation, the Company&#8217;s board of directors has the authority, without further action by the stockholders, to issue up to&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_QHsY7To7NUyr8DsRNiGS2Q">5,000,000</ix:nonFraction>&#160;shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="vstm:ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock" id="Tb_0nf6NAqK4EWE1WyIBDr18w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the Company had reserved the following shares of common stock for the issuance of common stock for vested restricted stock units, the exercise of stock options, employee stock purchase plan, Series A Convertible Preferred Stock conversions to shares of common stock, and exercise of warrants and pre-funded warrants (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved under Equity Compensation Plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_jgUB4qLkMESjHNyit_jWJw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="Tc_Siw5l8K1WEi7akrGY0olGA_3_2">5,232</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_hNJYkO5IlkSxNYbhWOjEug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="Tc_HxNn5iEA-Eq5Q2EWfZSXLQ_3_4">5,925</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for Inducement Grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_v94nix69zkGeGJg-ULbs-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="Tc_Egz3mi-1E0WZHgg_gxHcUg_4_2">1,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_VwswXPy6N0iYiVDwlnG78g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="Tc_8hRqMOXqwEe9YCgKKdg0rQ_4_4">802</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_o3QykpaT9kO0MVdafyJpUg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="Tc_UTYQ2HBYIEOG3hzzyLw78w_5_2">43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_LdWz0v453kS4CX1tFFGG_Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="Tc_QlnzbqXkPUiVIofI4T8bTw_5_4">59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for Series A Convertible Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_vstm_SeriesaConvertiblePreferredStockMember_h2EwK_J3D0yrYJTXRulnyg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="Tc_2oCjhxE3LkutLwpgasQcYQ_6_4">833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_WarrantMember_wbTMM7gk_U6IJSEizGwY4w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="Tc_of7HL8lbEUqoHt3fTNivzA_7_2">8,429</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_WarrantMember_3vY0IAdGpE23ucHgSc6EPA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="Tc_qhvnZEh9JUykBLKhwAHqeQ_7_4">18,083</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for pre-funded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_PreFundedWarrantMember_KnGNGKDd4UaRuVatC6F9Bg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="Tc_1ThEsF6Xm0qN3TY6joCrZA_8_2">13,656</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_vstm_PreFundedWarrantMember_Fay4PRvQWEyTg9vyJimtfA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="Tc_Q9M7KrfKg0alHay9pj_TPA_8_4">5,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total shares reserved</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="Tc_pm7R8nOdR0aON7NKkhelPw_9_2">28,555</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="Tc_egP815A2wEqrbbKbjtvFpA_9_4">30,702</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:12pt 0pt 0pt 0pt;">Each share of common stock is entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_tReSOj-zJkipnhJ_-h7uBA" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="INF" format="ixt-sec:numwordsen" name="vstm:NumberOfVotesPerEachShareOfCommonStock" scale="0" id="Narr_dUl7CoYWq0mvaRAMKdAagQ">one</ix:nonFraction> vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">November 2025 Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 13, 2025, the Company entered into an Underwriting Agreement (the &#8220;November 2025 Public Offering&#8221;) with several Underwriters to sell in a public offering <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_11_13_2025_To_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_8KWsZFM4mEuCXxQ0JyrXPg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_DP6sHyPkrEOWK09m8-xy8g">8,543,794</ix:nonFraction> shares of the Company&#8217;s common stock, at a price to the public of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_n96ND7-6FkaDWs_KK9qUrw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Narr_oU4Jjp27nUq-GqYKyvR_nA">7.25</ix:nonFraction> per share, less the underwriting discounts and commissions, and, in lieu of shares of common stock to certain investors, pre-funded warrants (the &#8220;November 2025 Pre-Funded Warrants&#8221;) to purchase up to an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_n96ND7-6FkaDWs_KK9qUrw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_5s5UxHTe60KU3HzGsXO7ow">3,870,000</ix:nonFraction> shares of common stock at a price to the public of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_n96ND7-6FkaDWs_KK9qUrw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_E5FMx6azo0yXEbf7SYoE8A">7.2499</ix:nonFraction> per share of common stock underlying a pre-funded warrant, which represents the per share public offering price for the shares of common stock </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yszt-HnrEUq05F5ATMrHgw_cont1" continuedAt="Tb_yszt-HnrEUq05F5ATMrHgw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">less the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_n96ND7-6FkaDWs_KK9qUrw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Zdo7g-_YzEescFo34Lz4Hw">0.001</ix:nonFraction> per share exercise price for each such share of common stock underlying a November 2025 Pre-Funded Warrant. Furthermore, as part of the Underwriting Agreement, Greenshoe Options (&#8220;November 2025 Overallotment Options&#8221;) were granted to the Underwriters to purchase up to an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_KS1tXWlGL0mDHAAYpEFAqQ" decimals="INF" format="ixt:num-dot-decimal" name="vstm:SaleOfStockOptionToPurchaseMaximumNumberOfShares" scale="0" id="Narr_wx76mietGUqlqjz1DYWQ_g">1,862,069</ix:nonFraction> shares of the Company&#8217;s Common Stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_KS1tXWlGL0mDHAAYpEFAqQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_QwAT3ZRLjkac_67Jq9_T5g">0.0001</ix:nonFraction> per share, at a price to the Underwriters of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_KS1tXWlGL0mDHAAYpEFAqQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Narr_-e9kBHQHaUy6eusIflINAg">7.25</ix:nonFraction> per share, less the underwriting discounts and commissions. On November 14, 2025, the underwriters exercised their Overallotment Options in full and the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_11_14_2025_To_11_14_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_WUufEo4u2kmXKrrBjVvTxA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_JkxYpGi9SkyE_KVmYXAyew">1,862,069</ix:nonFraction> additional shares of common stock at the price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_11_14_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_u5xj-WOakUigG8lS-TAocg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_2v0az4jhI0O-jKh8y-Jd3A">7.25</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">The exercise price of each November 2025 Pre-Funded Warrant equals&#160;$<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_KS1tXWlGL0mDHAAYpEFAqQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_p4ISp3QyWUqvdGdWHf3hGQ">0.0001</ix:nonFraction>&#160;per underlying share of common stock.&#160;The exercise price and the number of shares of common stock issuable upon exercise of each November 2025 Pre-Funded Warrant is subject to appropriate adjustment in the event of certain stock dividends, stock splits, stock combinations, or similar events affecting the Company&#8217;s common stock. The November 2025 Pre-Funded Warrants are exercisable in cash or by means of a cashless exercise and will not expire until the date the November 2025 Pre-Funded Warrants are fully exercised.&#160;The November 2025 Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof (together with its affiliates) immediately following such exercise would exceed a specified beneficial ownership limitation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The November 2025 Pre-Funded Warrants cannot require cash settlement, are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its common stock shares and permit the holders to receive a fixed number of shares of common stock upon exercise. Additionally, the November 2025 Pre-Funded Warrants do not provide any guarantee of value or return. Accordingly, the November 2025 Pre-Funded Warrants are classified as a component of permanent equity. The net proceeds of the 2025 Public Offering were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_11_13_2025_To_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_8KWsZFM4mEuCXxQ0JyrXPg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_jyxICwk4qkWpAlUKDZfD-A">96.9</ix:nonFraction>&#160;million, after deducting underwriting fees and other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">April 2025 PIPE Transaction</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">On April 25, 2025, the Company entered into a securities purchase agreement with certain institutional accredited investors (the &#8220;PIPE Investors&#8221;), pursuant to which the Company sold to the PIPE Investors, in a private placement (the &#8220;2025 Private Placement&#8221;), an aggregate of&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_4_25_2025_To_4_25_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_w6Qgr7wiUECKdrz2j0wQgw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_jWv6cyo9H0mnh1JwE1GSsQ">3,429,287</ix:nonFraction>&#160;shares of the Company&#8217;s common stock at an offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_4_25_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_RmWH6lNih0uXM3yO2Zl1qQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_QrzIijEtBEywTyhuecoplw">7.00</ix:nonFraction>&#160;per share and,&#160;in lieu of common stock to certain PIPE Investors, pre-funded warrants to purchase an aggregate of&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_4_25_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_ehT0HA0cvUW9AwZHGjQ9nw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_v75MpIYoBkyfZOUHrwOWhQ">7,285,713</ix:nonFraction>&#160;shares of common stock (the &#8220;April 2025 Pre-Funded Warrants,&#8221;) at an offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_4_25_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_ehT0HA0cvUW9AwZHGjQ9nw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_qcTF4oM6hUKCuEFsJutFOA">6.9999</ix:nonFraction>&#160;per April 2025 Pre-Funded Warrant. The 2025 Private Placement closed on April 28, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">The exercise price of each April 2025 Pre-Funded Warrant equals&#160;</span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_4_25_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_ehT0HA0cvUW9AwZHGjQ9nw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_CncMOKVb50yjPfuZXsSVGQ">0.0001</ix:nonFraction></span><span style="font-size:10pt;">&#160;per underlying share of common stock.&#160;The exercise price and the number of shares of common stock issuable upon exercise of each April 2025 Pre-Funded Warrant is subject to appropriate adjustment in the event of certain stock dividends, stock splits, stock combinations, or similar events affecting the Company&#8217;s common stock. The April 2025 Pre-Funded Warrants are exercisable in cash or by means of a cashless exercise and will not expire until the date the April 2025 Pre-Funded Warrants are fully exercised.&#160;The April 2025 Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof (together with its affiliates) immediately following such exercise would exceed a specified beneficial ownership limitation; provided, however, that a holder may increase or decrease the beneficial ownership limitation by giving&#160;</span><ix:nonNumeric contextRef="Duration_4_25_2025_To_4_25_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_t2jNkx3weEK3-E4-F4tIgA" format="ixt-sec:durwordsen" name="vstm:WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod" id="Narr_7nw1yNddyk-DwsarU0suTg"><span style="font-size:10pt;">61 days</span></ix:nonNumeric><span style="font-size:10pt;">&#8217; notice to the Company, but not to any percentage in excess of&#160;</span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_4_25_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_ehT0HA0cvUW9AwZHGjQ9nw" decimals="4" format="ixt:num-dot-decimal" name="vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" scale="-2" id="Narr_CGRLTInQ8kiit7xs-_AY3A">19.99</ix:nonFraction>%</span><span style="font-size:10pt;">. I</span><span style="color:#212529;font-size:10pt;">n addition, upon the occurrence of a fundamental transaction (as described in the April 2025 Pre-Funded Warrant), each April 2025 Pre-Funded Warrant will have the right to receive, upon exercise of such April 2025 Pre-Funded Warrant, the kind and amount of securities, cash or other property that such holders would have received had they exercised such April 2025 Pre-Funded Warrant immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the April 2025 Pre-Funded Warrants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The April 2025 Pre-Funded Warrants cannot require cash settlement, are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its common stock shares and permit the holders to receive a fixed number of shares of common stock upon exercise. Additionally, the April 2025 Pre-Funded Warrants do not provide any guarantee of value or return. Accordingly, the April 2025 Pre-Funded Warrants are classified as a component of permanent equity. The net proceeds of the 2025 Private Placement were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_4_25_2025_To_4_25_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_t2jNkx3weEK3-E4-F4tIgA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_UrykjkY3J0e4XZd0SdlqoA">69.9</ix:nonFraction>&#160;million, after deducting placement agent fees and other expenses.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yszt-HnrEUq05F5ATMrHgw_cont2" continuedAt="Tb_yszt-HnrEUq05F5ATMrHgw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><span style="font-size:10pt;">In connection with the Note Purchase Agreement, on January&#160;13, 2025, the Company entered into a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with the certain funds managed by Oberland and affiliates thereof (the &#8220;SPA Investors&#8221;), pursuant to which the SPA Investors purchased an aggregate of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_76lNElnqP0Ge645AbtZsrA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_XjTOTh6aaUqgey66w0sR1Q">1,416,939</ix:nonFraction></span><span style="font-size:10pt;"> shares of the Company&#8217;s common stock, at a price of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_UBix19n6xEadDF59Ya6BCw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_A-jHTFdOQ0m1ZjYFYAoITg">5.2931</ix:nonFraction></span><span style="font-size:10pt;"> per share, based on the trailing 30-trading day volume-weighted average price of the Company&#8217;s common stock, as of the date of the Stock Purchase Agreement. The Company received net proceeds of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_x-U4MebMkEusy4zb3w2UTg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_C7hcEbe9bUyD8qZTCdwk7g">7.4</ix:nonFraction></span><span style="font-size:10pt;"> million after deducting for offering costs which was recorded as component of permanent equity during the year ended December 31, 2025. In addition, pursuant to the Stock Purchase Agreement, the Company granted the SPA Investors, for a period of </span><ix:nonNumeric contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_76lNElnqP0Ge645AbtZsrA" format="ixt-sec:durwordsen" name="vstm:StockPurchaseRightPeriod" id="Narr_0ITESEsRmkSC6qdpnmuTnA"><span style="font-size:10pt;">three years</span></ix:nonNumeric><span style="font-size:10pt;"> following the closing on January 13, 2025, a right to participate in any equity offerings consummated by the Company in an amount up to </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_UBix19n6xEadDF59Ya6BCw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:StockPurchaseRightMaximumAmount" scale="6" id="Narr_Bk0u8tftd0e_YieMn2IhNg">2.5</ix:nonFraction></span><span style="font-size:10pt;"> million, subject to certain limitations and exclusions set out in the Stock Purchase Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">July 2024 Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On July&#160;23, 2024, the Company entered into an underwriting agreement with Guggenheim Securities, LLC and Cantor Fitzgerald&#160;&amp; Co. (&#8220;Cantor&#8221;), as representatives of the several underwriters relating to the underwritten offering, issuance and sale by the Company of: (i)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_xgsOVZqDvUy1HFomyzF7Hg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_xR8bqa4TpUGXi2LVx-pGWA">13,333,334</ix:nonFraction>&#160;shares of the Company&#8217;s common stock, and accompanying warrants (the &#8220;Warrants&#8221;) to purchase up to&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_qoqGwn8YFkepdjxAScNrxA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_UFVycn5_IkKq00vMDPHrCA">13,333,334</ix:nonFraction>&#160;shares of common stock; and (ii)&#160;to certain investors, pre-funded warrants (the &#8220;July 2024 Pre-Funded Warrants&#8221;) to purchase up to&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_9uZ0RStEKUaT5_5fRWamIg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_TbyPQ3V5T0uCSKSCv1wuQQ">5,000,000</ix:nonFraction>&#160;shares of common stock and accompanying Warrants to purchase&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_9uZ0RStEKUaT5_5fRWamIg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_HuPbCkgEUkKHmV8d1N_Saw">5,000,000</ix:nonFraction>&#160;shares of common stock (collectively, the &#8220;July 2024 Offering&#8221;). Each share of common stock was sold with an accompanying Warrant at a combined price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_qoqGwn8YFkepdjxAScNrxA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_1DvAeJnX5kCqa6vKFthzyw">3.00</ix:nonFraction>, and each July 2024 Pre-Funded Warrant was sold together with an accompanying Warrant at a combined price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_9uZ0RStEKUaT5_5fRWamIg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_fg6Z8-O-wUqKx1iAAWRNWg">2.999</ix:nonFraction>, which is equal to the combined offering price per share of common stock and accompanying Warrant less the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_9uZ0RStEKUaT5_5fRWamIg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_wbDbvPC9lECZ4anKftrcEw">0.001</ix:nonFraction>&#160;exercise price of each July 2024 Pre-Funded Warrant. The July 2024 Offering closed on July 25, 2024. The Company received approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_7_23_2024_To_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_semVXOzt7UuTbjL3iSPnbw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_XpzCZFmRsEiBncptZr58fA">50.8</ix:nonFraction>&#160;million in net proceeds, after deducting underwriting discounts and commissions and offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Each July 2024 Pre-Funded Warrant has an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_9uZ0RStEKUaT5_5fRWamIg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_GFZk9ZVR4kKE5DDpcOKzow">0.001</ix:nonFraction>&#160;per underlying share of common stock. The July 2024 Pre-Funded Warrants are exercisable as of July 25, 2024, do not expire and are exercisable in cash or by means of cashless exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">Each Warrant has an exercise price equal to&#160;</span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_qoqGwn8YFkepdjxAScNrxA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_8RqACoxj40KZiRjrOGa7MQ">3.50</ix:nonFraction></span><span style="color:#212529;">. Each Warrant is exercisable for&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_qoqGwn8YFkepdjxAScNrxA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_VIsn8K0ymkCf9vf19FQQzQ">one</ix:nonFraction></span><span style="color:#212529;">&#160;share of the Company&#8217;s common stock (or, in certain limited circumstances in lieu of a share of common stock, a pre-funded warrant for&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_9uZ0RStEKUaT5_5fRWamIg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_co24gIPEbkuFBhFogRQTDA">one</ix:nonFraction></span><span style="color:#212529;">&#160;share of the Company&#8217;s common stock at the warrant exercise price less the exercise price of the pre-funded warrant purchased). The Warrants are exercisable as of July 25, 2024 until their expiration on January 25, 2026. The Warrants are exercisable in cash or, in certain limited circumstances only, by means of a cashless exercise.</span><span style="white-space:pre-wrap;">  </span><span style="color:#212529;">The exercise price and the number of shares of common stock issuable upon exercise of each Warrant or July 2024 Pre-Funded Warrant, as applicable, is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Company&#8217;s common stock as well as upon any distribution of assets, including cash, stock or other property, to the Company&#8217;s stockholders.</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yszt-HnrEUq05F5ATMrHgw_cont3" continuedAt="Tb_yszt-HnrEUq05F5ATMrHgw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:0pt;"><span style="color:#212529;font-size:10pt;">The Company may not effect the exercise of any Warrant or July 2024 Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Warrant or July 2024 Pre-Funded Warrant if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) would exceed&#160;</span><span style="color:#212529;font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_xgsOVZqDvUy1HFomyzF7Hg" decimals="4" format="ixt:num-dot-decimal" name="vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants" scale="-2" id="Narr_5TiNUwW7F0arTNZDh3VDOA">4.99</ix:nonFraction>%</span><span style="color:#212529;font-size:10pt;">&#160;(or such higher percentage up to&#160;</span><span style="color:#212529;font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_xgsOVZqDvUy1HFomyzF7Hg" decimals="4" format="ixt:num-dot-decimal" name="vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" scale="-2" id="Narr_qhz2p27GZ06akRzJxFggrg">19.99</ix:nonFraction>%</span><span style="color:#212529;font-size:10pt;">, at the election of the holder) of the number of shares of the Company&#8217;s common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder&#8217;s election upon&#160;</span><ix:nonNumeric contextRef="Duration_7_23_2024_To_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_semVXOzt7UuTbjL3iSPnbw" format="ixt-sec:durwordsen" name="vstm:WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod" id="Narr_HB7Sa1Xdh0OpRCEQobMJow"><span style="color:#212529;font-size:10pt;">61 days</span></ix:nonNumeric><span style="color:#212529;font-size:10pt;">&#8217; notice to the Company subject to the terms of such Warrants or July 2024 Pre-Funded Warrants, as applicable, provided that such percentage may in no event exceed&#160;</span><span style="color:#212529;font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_xgsOVZqDvUy1HFomyzF7Hg" decimals="4" format="ixt:num-dot-decimal" name="vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" scale="-2" id="Narr_RykXjZMeOEGKW9n9pgrDdw">19.99</ix:nonFraction>%</span><span style="color:#212529;font-size:10pt;">. In the event that the exercise of a Warrant would cause the holder to beneficially own in excess of&#160;</span><span style="color:#212529;font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_xgsOVZqDvUy1HFomyzF7Hg" decimals="4" format="ixt:num-dot-decimal" name="vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants" scale="-2" id="Narr_Z1Oxx5tgWk28jrFjaNuR-Q">4.99</ix:nonFraction>%</span><span style="color:#212529;font-size:10pt;">&#160;(or such higher percentage up to&#160;</span><span style="color:#212529;font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_xgsOVZqDvUy1HFomyzF7Hg" decimals="4" format="ixt:num-dot-decimal" name="vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" scale="-2" id="Narr_YTbINblqikuEP9lDpheBWA">19.99</ix:nonFraction>%</span><span style="color:#212529;font-size:10pt;">, at the election of the holder) of the total number shares of the Company&#8217;s common stock outstanding immediately after giving effect to such exercise, the holder of a Warrant may elect to purchase a pre-funded warrant for&#160;</span><span style="color:#212529;font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_9uZ0RStEKUaT5_5fRWamIg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_wEh8GtMuVUyEHoteiiHY7A">one</ix:nonFraction></span><span style="color:#212529;font-size:10pt;">&#160;share of the Company&#8217;s common Stock, rather than a share of common stock, at the Warrant exercise price less the exercise price of the pre-funded warrant purchased.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">In addition, upon the consummation of an acquisition (as described in the Warrants agreements and July 2024 Pre-Funded Warrants agreements, as applicable), each Warrant and July 2024 Pre-Funded Warrant will automatically be converted into the right of the holder of such Warrant or July 2024 Pre-Funded Warrant, as applicable, to receive the kind and amount of securities, cash or other property that such holders would have received had they exercised such Warrant or July 2024 Pre-Funded Warrant, as applicable, immediately prior to such acquisition, without regard to any limitations on exercise contained in the Warrant agreements or July 2024 Pre-Funded Warrant agreements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">The Warrants meet the definition of a derivative pursuant to FASB Accounting Standard Codification 815,&#160;<i style="font-style:italic;">Derivatives and Hedging</i>, and do not meet the derivative scope exception given the Warrants do not qualify under the indexation guidance. As a result, the Warrants were initially recognized as liabilities and measured at fair value using the Black-Scholes valuation model with subsequent changes in fair value recorded in earnings. The warrants were recorded at a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_xgsOVZqDvUy1HFomyzF7Hg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="Narr_bDnVG0OnKkGP_uDR27p2DA">39.6</ix:nonFraction>&#160;million upon issuance and the Company allocated $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_7_23_2024_To_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_semVXOzt7UuTbjL3iSPnbw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="Narr_mCk_CMqYKk6g0c0E24Gq_w">39.6</ix:nonFraction>&#160;million of the proceeds to this liability and recorded this amount as warrant liability. During the year ended December 31, 2025 and 2024, <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_fGAFkO2I5k6tbgjWbUyMMg" decimals="INF" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Narr_f1PUiRM5iUCKPe1ET5d2Jg">9,654,168</ix:nonFraction> Warrants and <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_M3ZzNPTGjEyOJy5c4k1gkw" decimals="INF" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Narr_FpWxBFZmmky_eFZw4JUHcQ">250</ix:nonFraction> Warrants, respectively, were exercised for shares of common stock and the fair value of the Warrants on the respective exercise dates was $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_fGAFkO2I5k6tbgjWbUyMMg" decimals="-5" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="6" id="Narr_p3vMWw9RU0mx2pxAHy1UFA">50.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_M3ZzNPTGjEyOJy5c4k1gkw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="6" id="Narr_q9rCw9a_ZUOZlXHlJSj5hg">0.5</ix:nonFraction> million, respectively, which was reclassified from warrant liability to additional paid in capital. On December 31, 2025 and 2024, the fair value of the outstanding <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_W-OWHjTX20eGOqczNgrSyQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_Q1BJ_KeK-k6T6iTAQM4FKQ">8,429,166</ix:nonFraction> Warrants and <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_XleLLeLgMUaEtBjxP-2klw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_Y_1UNMvGm0eAjSrZ0RfSFQ">18,083,334</ix:nonFraction> Warrants, respectively, was determined to be $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_W-OWHjTX20eGOqczNgrSyQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="Narr_AI9B3Dg70kmwG-b0hYrz2w">35.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_XleLLeLgMUaEtBjxP-2klw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="Narr_b0JULhJny0aq88GpcLxEkA">58.2</ix:nonFraction> million, respectively and the Company recorded this amount as warrant liability on the consolidated balance sheets. During the year ended December 31, 2025 and 2024, the Company recorded the mark-to-market adjustment of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_fGAFkO2I5k6tbgjWbUyMMg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" id="Narr_zCASMGfxqEaa5qFencbBCg">27.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_M3ZzNPTGjEyOJy5c4k1gkw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" id="Narr_ic8VmWkcZUKwIes0lr1bvg">19.1</ix:nonFraction> million, respectively, under change in fair value of warrant liability within the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">The July 2024 Pre-Funded Warrants cannot require cash settlement, are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock and Warrants with which they were issued, are immediately exercisable, and do not embody an obligation for the Company to repurchase its common stock shares and permit the holders to receive a fixed number of shares of common stock upon exercise. Additionally, the July 2024 Pre-Funded Warrants do not provide any guarantee of value or return. Accordingly, the July 2024 Pre-Funded Warrants are classified as a component of permanent equity. The Company allocated&#160;</span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_7_23_2024_To_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_semVXOzt7UuTbjL3iSPnbw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:ProceedsFromIssuanceOfWarrantsAndCommonStock" scale="6" id="Narr_ccCdG8BDwk650x7MUR5W4g">15.4</ix:nonFraction></span><span style="color:#212529;">&#160;million of the proceeds to the July 2024 Pre-Funded Warrants and shares of common stock issued. During the second quarter of 2025, the holders exercised </span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_NZvKvAzq-k2_cBvWayCtvA" decimals="INF" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Narr_BB1KvsIgKEiyP6C_w8pagQ">2,500,000</ix:nonFraction></span><span style="color:#212529;"> July 2024 Pre-Funded Warrants, exercise price </span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_NVq59xSXbE6uvQXjAgxbQg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_WcC2KW1X_kSKi68x4QLdXw">0.001</ix:nonFraction></span><span style="color:#212529;"> per share, via cashless exercise resulting in the issuance of </span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_NZvKvAzq-k2_cBvWayCtvA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_H-_OclWg5ky7PZE5cNUIzg">2,499,665</ix:nonFraction></span><span style="color:#212529;"> shares of common stock. During the third quarter of 2025, </span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_-TqHBbCtZkCiLS7Kdk667Q" decimals="INF" format="ixt-sec:numwordsen" name="vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Narr_np4BPLqJkku7zGYuAIWZMw">no</ix:nonFraction></span><span style="color:#212529;"> July 2024 Pre-Funded Warrants were exercised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="color:#212529;font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">The Company incurred a total of&#160;</span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_7_23_2024_To_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_semVXOzt7UuTbjL3iSPnbw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_YcUzs2jk6kKLbsjL0kYphw">4.2</ix:nonFraction></span><span style="color:#212529;">&#160;million in issuance costs, which the Company allocated to the Warrants, and 2024 Pre-Funded Warrants and shares of common stock consistent with the allocation of proceeds.&#160;</span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_7_23_2024_To_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_oG3TWOGlW0SJkm54UqDFTQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_d2mBhE6Kd0yIzZ27ac8f5g">3.0</ix:nonFraction></span><span style="color:#212529;">&#160;million of issuance costs were allocated to the Warrants and expensed within selling, general and administrative expenses in the statements of operations and comprehensive loss for the year ended December 31, 2024.&#160;</span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_7_23_2024_To_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_hbgxBNPYbUyJb5vXdalJvg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="Narr_OtfIV8kp2kSjhAEAI8SEYQ">1.2</ix:nonFraction></span><span style="color:#212529;">&#160;million of the issuance costs were allocated to the July 2024 Pre-Funded Warrants and shares of common stock and applied against additional paid-in capital.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yszt-HnrEUq05F5ATMrHgw_cont4" continuedAt="Tb_yszt-HnrEUq05F5ATMrHgw_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">June 2023 Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">In June 2023, in an underwritten offering, the Company offered <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_vstm_PublicMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_Jr05H4l9L0uUqAYKxs4qxw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="Narr_GqEmFH6kJ0iJXhnSNVMErQ">8,489,409</ix:nonFraction> shares of the Company&#8217;s common stock, at a price to the public of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_vstm_PublicMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_y99DVEYGyUKxX-8hVBLWvQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Narr_OhY9ChI3MkCxEzO3EhRrPQ">9.75</ix:nonFraction> per share, less the underwriting discounts and commissions, and, in lieu of shares of common stock to certain investors, pre-funded warrants (the &#8220;June 2023 Pre-Funded Warrants&#8221;) to purchase up to an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_9JY_1UA-ZEecEwccCTRt3w" decimals="INF" format="ixt:num-dot-decimal" name="vstm:CommonStockSharesOffered" scale="0" id="Narr_mPcZk0-r00eSc3YaqaBzHw">1,538,591</ix:nonFraction> shares of common stock at a price to the public of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_9JY_1UA-ZEecEwccCTRt3w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Narr_rkPtSekkOEqBlFeyX45R6g">9.749</ix:nonFraction> per share of common stock underlying a pre-funded warrant, which represents the per share public offering price for the shares of common stock less the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_9JY_1UA-ZEecEwccCTRt3w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_l3tk1bQl2k6J5upCBrLU-Q">0.001</ix:nonFraction> per share exercise price for each such share of common stock underlying a June 2023 Pre-Funded Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:14pt;padding-top:2pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">The Company could not have effected the exercise of any June 2023 Pre-Funded Warrant, and a holder was not entitled to exercise any portion of any June 2023 Pre-Funded Warrant if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) would have exceeded </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_O0Rufo-BykGzNlAstqrYkQ" decimals="4" format="ixt:num-dot-decimal" name="vstm:MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage" scale="-2" id="Narr_NRqacBzvwkW3W_kgJ54h1Q">9.99</ix:nonFraction>%</span><span style="font-size:10pt;"> of the number of shares of common stock outstanding immediately after giving effect to the exercise, which percentage could have been increased or decreased at the holder&#8217;s election upon </span><ix:nonNumeric contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_O0Rufo-BykGzNlAstqrYkQ" format="ixt-sec:durwordsen" name="vstm:PreFundedWarrantElectionToExerciseNoticePeriod" id="Narr_J4a0F-fj7UO9lC64A95-gQ"><span style="font-size:10pt;">61 days</span></ix:nonNumeric><span style="font-size:10pt;">&#8217; notice to the Company subject to the terms of such June 2023 Pre-Funded Warrant, provided that such percentage in no event exceeded </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_O0Rufo-BykGzNlAstqrYkQ" decimals="4" format="ixt:num-dot-decimal" name="vstm:MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage" scale="-2" id="Narr_u7-8EVJQRUCkcJ__40_HEA">19.99</ix:nonFraction>%</span><span style="font-size:10pt;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Each June 2023 Pre-Funded Warrant had an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_ewMMPiBO5k-cPP2IurkzMA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_iaQkN9iNw0ShvRie1cKa4w">0.001</ix:nonFraction> per share of common stock. The exercise price and the number of shares of common stock issuable upon exercise of each June 2023 Pre-Funded Warrant was subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Company&#8217;s common stock as well as upon any distribution of assets, including cash, stock or other property, to the Company&#8217;s stockholders. The June 2023 Pre-Funded Warrants were exercisable as of June 21, 2023, did not expire and were exercisable in cash or by means of a cashless exercise. In addition, upon the consummation of an acquisition (as described in the June 2023 Pre-Funded Warrant agreements), each June 2023 Pre-Funded Warrant would have automatically been converted into the right of the holder of such June 2023 Pre-Funded Warrant to receive the kind and amount of securities, cash or other property that such holders would have received had they exercised such June 2023 Pre-Funded Warrant immediately prior to such acquisition, without regard to any limitations on exercise contained in the June 2023 Pre-Funded Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The June 2023 Pre-Funded Warrants could not have required cash settlement, were freestanding financial instruments that were legally detachable and separately exercisable from the shares of common stock with which they were issued, were immediately exercisable, and did not embody an obligation for the Company to repurchase its common stock shares and permitted the holders to receive a fixed number of shares of common stock upon exercise. Additionally, the June 2023 Pre-Funded Warrants did not provide any guarantee of value or return. Accordingly, the June 2023 Pre-Funded Warrants were classified as a component of permanent equity. After deducting for commissions and other offering expenses, the Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_9kM5FIopg02NBn8H3CtCvw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts" scale="6" id="Narr_yVV42_KraEqa6FxfLbZ33A">91.4</ix:nonFraction> million from the sale of <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_mUhVWV8WMkScZAT8JeG4VQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_rc6bx5RwAUC5WGEQz7JCjQ">8,489,409</ix:nonFraction> shares of common stock and June 2023 Pre-Funded Warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_UQMJ9oLa3kmJvYGMn38KsQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_aDgV5lxMDEKUI0vInFETOA">1,538,591</ix:nonFraction> shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">During the year ended December 31, 2024, the holders exercised all of the June 2023 Pre-Funded Warrants representing <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_T__SJ-zwq0yVJL4kvpsp4w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr__zuca05QF0arvkinYBDEzg">1,538,591</ix:nonFraction> underlying shares of common stock, at an exercise price $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_eegaa3ABKkqBRahdn4RezA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_UTaiGrHljEuAdXQZeB7nsQ">0.0001</ix:nonFraction> per share, via cashless exercise resulting in the issuance of <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_T__SJ-zwq0yVJL4kvpsp4w" decimals="INF" format="ixt:num-dot-decimal" name="vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" scale="0" id="Narr_updBQOvxRkOHF2oyVTbxWg">1,538,201</ix:nonFraction> shares of common stock. As of December 31, 2024 there were <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="INF" format="ixt-sec:numwordsen" name="vstm:PreFundedWarrantsWarrantsOutstanding" scale="0" id="Narr_ZNPxViH-lEmvtNBaY6sExQ">no</ix:nonFraction> June 2023 Pre-Funded Warrants outstanding. </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yszt-HnrEUq05F5ATMrHgw_cont5" continuedAt="Tb_yszt-HnrEUq05F5ATMrHgw_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Series B Convertible Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">On January 24, 2023, the Company entered into a Securities Purchase Agreement (the &#8220;Series B Convertible Preferred Stock Securities Purchase Agreement&#8221;) with certain purchasers pursuant to which the Company agreed to sell and issue to the purchasers in a private placement (the &#8220;Private Placement&#8221;) up to <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_24_2023_To_1_24_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_vGMn7XIAIUSBLUxCpfC0tQ" decimals="INF" format="ixt:num-dot-decimal" name="vstm:PreferredStockConvertibleAggregateSharesToBeSold" scale="0" id="Narr_YQJksgAk_0mQcZvIIsj4jw">2,144,160</ix:nonFraction> shares of its Series B convertible preferred stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_1_24_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_FQWIrrRmRkCSrnKhzFgoaQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_7rYvfuETb0CXWnljIPVUjg">0.0001</ix:nonFraction> per share (the &#8220;Series B Convertible Preferred Stock&#8221;), in <ix:nonFraction unitRef="Unit_Standard_tranche_AR7EJ57OqEq8JqHSzH8_Aw" contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Lb8_EogSb0aV0xpnEYsScg" decimals="INF" format="ixt-sec:numwordsen" name="vstm:PreferredStockIssueNumberOfTranches" scale="0" id="Narr_EtmWxKi7yUamp9qCMBiq8A">two</ix:nonFraction> tranches. On January 24, 2023, the Company filed the Certificate of Designation of the Preferences, Rights and Limitations of the Series B Convertible Preferred Stock (the &#8220;Series B Convertible Preferred Stock Certificate of Designation&#8221;) setting forth the preferences, rights and limitations of the Series B Convertible Preferred Stock with the Secretary of State of the State of Delaware. The Series B Convertible Preferred Stock Certificate of Designation became effective upon filing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Each share of the Series B Convertible Preferred Shares is convertible into </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_S54_9duti0-qFLlDHg8uag" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_Ifs0OjJIHEqDXy6EDfcfZg">3.5305</ix:nonFraction></span><span style="font-size:10pt;"> shares of the Company&#8217;s common stock, such conversion rate reflects an adjustment to account for the Reverse Stock Split, at the option of the holders at any time, subject to certain limitations, including that the holder will be prohibited from converting Series B Convertible Preferred Stock into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares of common stock above a conversion blocker, which is initially set at </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Lb8_EogSb0aV0xpnEYsScg" decimals="4" format="ixt:num-dot-decimal" name="vstm:ConversionOfPreferredStockConversionBlockerPercent" scale="-2" id="Narr_nowSATg5MEyvb1bWgD0WSA">9.99</ix:nonFraction>%</span><span style="font-size:10pt;"> (the &#8220;Conversion Blocker&#8221;) of the total common stock then issued and outstanding immediately following the conversion of such shares of Series B Convertible Preferred Stock. Holders of the Series B Convertible Preferred Stock are permitted to increase the Conversion Blocker to an amount not to exceed </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Lb8_EogSb0aV0xpnEYsScg" decimals="4" format="ixt:num-dot-decimal" name="vstm:ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice" scale="-2" id="Narr_rNQ17J5fdEe1poed9a0Dcg">19.99</ix:nonFraction>%</span><span style="font-size:10pt;"> upon</span><ix:nonNumeric contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Lb8_EogSb0aV0xpnEYsScg" format="ixt-sec:durwordsen" name="vstm:ConversionOfPreferredStockConversionBlockerNoticePeriod" id="Narr_bMFjKUk0FE-1T-38ir34SA"><span style="font-size:10pt;"> 60 days</span></ix:nonNumeric><span style="font-size:10pt;">&#8217; notice.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The Company agreed to sell and issue in the first tranche of the Private Placement <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_24_2023_To_1_24_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_vGMn7XIAIUSBLUxCpfC0tQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_6oqX6ftoRkuD37hJj_RjUg">1,200,000</ix:nonFraction> shares of Series B Convertible Preferred Stock at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_1_24_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_FQWIrrRmRkCSrnKhzFgoaQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_NLCP4Nb4N0ug1ozfaspGzg">25.00</ix:nonFraction> per share of Series B Convertible Preferred Stock (equivalent to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_EgpHd6yzBUuaIpY-YY3qXw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_xLyFcIaU60q59WvrjRQ5dA">7.0812</ix:nonFraction> per share of common stock). The first tranche of the Private Placement closed on January 27, 2023. The Company received gross proceeds from the first tranche of the Private Placement of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Btgqk5RY306LVDoxcjygVA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="Narr_vrDjzPynXEK5Syb5JL_ILg">30.0</ix:nonFraction> million, before deducting fees to the placement agent and other offering expenses payable by the Company (&#8220;Series B Convertible Preferred Stock Proceeds&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">In addition, the Company agreed to sell and issue in the second tranche of the Private Placement </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Btgqk5RY306LVDoxcjygVA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_hBjbr2cMq0ixirutx34H6Q">944,160</ix:nonFraction></span><span style="font-size:10pt;"> shares of Series B Convertible Preferred Stock at a purchase price of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Lb8_EogSb0aV0xpnEYsScg" decimals="2" format="ixt:num-dot-decimal" name="vstm:PreferredStockIssuanceThresholdSharePrice" scale="0" id="Narr_Vf96i-LWVkOuKRaJ7UX4Pw">31.77</ix:nonFraction></span><span style="font-size:10pt;"> per share of Series B Convertible Preferred Stock (equivalent to </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_EgpHd6yzBUuaIpY-YY3qXw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_qBJdf8m1pUKlRMEqg6BF7w">9.00</ix:nonFraction></span><span style="font-size:10pt;"> per share of common stock) if at any time within 18 months following the closing of the first tranche the </span><ix:nonNumeric contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Lb8_EogSb0aV0xpnEYsScg" format="ixt-sec:durwordsen" name="vstm:PreferredStockIssuanceExpectedClosingPeriod" id="Narr_MGSbYKMiDkuvY0r7qXNtjA"><span style="font-size:10pt;">10-day</span></ix:nonNumeric><span style="font-size:10pt;"> volume weighted average price of the Company&#8217;s common stock (as quoted on Nasdaq and as calculated by Bloomberg) should reach at least </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Btgqk5RY306LVDoxcjygVA" decimals="2" format="ixt:num-dot-decimal" name="vstm:PreferredStockIssuanceThresholdSharePrice" scale="0" id="Narr_5MCj-bCWtUyDN8gneW03LA">13.50</ix:nonFraction></span><span style="font-size:10pt;"> per share, such threshold reflects an adjustment to account for the Reverse Stock Split (which may be further adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction as needed) with aggregate trading volume during the same </span><ix:nonNumeric contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Btgqk5RY306LVDoxcjygVA" format="ixt-sec:durwordsen" name="vstm:PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche" id="Narr_Z3Rk1-cVskiKgM4G7VAxvw"><span style="font-size:10pt;">10-day</span></ix:nonNumeric><span style="font-size:10pt;"> period of at least </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Btgqk5RY306LVDoxcjygVA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:PreferredStockIssuanceThresholdAggregateTradingVolume" scale="6" id="Narr_X9E3GNLx0UKZveKHGLDyhA">25</ix:nonFraction></span><span style="font-size:10pt;"> million (the &#8220;Second Tranche Right&#8221;). The second tranche of the Private Placement is expected to close within </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Btgqk5RY306LVDoxcjygVA" decimals="INF" format="ixt-sec:numwordsen" name="vstm:PreferredStockIssuanceThresholdTradingDays" scale="0" id="Narr_DIZKeg95wk23fp00TM0P-Q">seven</ix:nonFraction></span><span style="font-size:10pt;"> trading days of meeting the second tranche conditions and will be subject to additional, customary closing conditions. If the Second Tranche Right conditions are satisfied, the Company anticipates receiving gross proceeds from the second tranche of the Private Placement of approximately </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Btgqk5RY306LVDoxcjygVA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="Narr_K5UcepJsOE2Nly2DyPyl6g">30.0</ix:nonFraction></span><span style="font-size:10pt;"> million, before deducting fees to the placement agent and other offering expenses payable by the Company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The Series B Convertible Preferred Stock ranks (i) senior to the common stock; (ii) senior to all other classes and series of equity securities of the Company that by their terms do not rank senior to the Series B Convertible Preferred Stock; (iii) senior to all shares of the Company&#8217;s Series A Convertible Preferred Stock the equity securities described in (i)-(iii), the &#8220;Junior Stock&#8221;); (iv) on parity with any class or series of capital stock of the Company hereafter created specifically ranking by its terms on parity with the Series B Convertible Preferred Stock (the &#8220;Parity Stock&#8221;); (v) junior to any class or series of capital stock of the Company hereafter created specifically ranking by its terms senior to any Series B Convertible Preferred Stock (&#8220;Senior Stock&#8221;); and (vi) junior to all of the Company&#8217;s existing and future debt obligations, including convertible or exchangeable debt securities, in each case, as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily and as to the right to receive dividends.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yszt-HnrEUq05F5ATMrHgw_cont6" continuedAt="Tb_yszt-HnrEUq05F5ATMrHgw_cont7"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">In the event of the liquidation, dissolution or winding up of the affairs of the Company, whether voluntary or involuntary, after payment or provision for payment of the debts and other liabilities of the Company, and subject to the prior and superior rights of any Senior Stock, each holder of shares of Series B Convertible Preferred Stock will be entitled to receive, in preference to any distributions of any of the assets or surplus funds of the Company to the holders of the common stock and any of the Company&#8217;s securities that are Junior Stock and pari passu with any distribution to the holders of any Parity Stock, an amount equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_S54_9duti0-qFLlDHg8uag" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_qnklZDWkWE62GQLjlsL28w">1.00</ix:nonFraction> per share of Series B Convertible Preferred Stock, plus an additional amount equal to any dividends declared but unpaid on such shares, before any payments shall be made or any assets distributed to holders of the common stock or any of the Company&#8217;s securities that are Junior Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">So long as any shares of the Series B Convertible Preferred Stock remain outstanding, the Company cannot without the affirmative vote or consent of the holders of majority of the shares of the Series B Convertible Preferred Stock then-outstanding, in which the holders of the Series B Convertible Preferred Stock vote separately as a class: (a) amend, alter, modify or repeal (whether by merger, consolidation or otherwise) the Series B Convertible Preferred Stock Certificate of Designation, the Company&#8217;s certificate of incorporation, or the Company&#8217;s bylaws in any manner that adversely affects the rights, preferences, privileges or the restrictions provided for the benefit of, the Series B Convertible Preferred Stock; (b) issue further shares of Series B Convertible Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series B Convertible Preferred Stock; (c) authorize or issue any Senior Stock; or (d) enter into any agreement to do any of the foregoing that is not expressly made conditional on obtaining the affirmative vote or written consent of the majority of then-outstanding Series B Convertible Preferred Stock. Holders of Series B Convertible Preferred Stock are entitled to receive when, as and if dividends are declared and paid on the common stock, an equivalent dividend, calculated on an as-converted basis. Shares of Series B Convertible Preferred Stock are otherwise not entitled to dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The Company initially classified the first tranche of the Series B Convertible Preferred Stock as temporary equity in the consolidated balance sheets as the Company could have been required to redeem the Series B Convertible Preferred Stock if the Company could not convert the Series B Convertible Preferred Stock into shares of common stock for any reason including due to any applicable laws or by the rules or regulations of any stock exchange, interdealer quotation system, or other self-regulatory organization with jurisdiction over the Company which is not solely in the control of the Company. If the Company was required to redeem the Series B Convertible Preferred Stock, it would have been based upon the volume-weighted-average price of common stock on an as converted basis on the date the holders provided a conversion notice to the Company. <span style="color:#212529;">On October 18, 2024, holders of the Series B Convertible Preferred Stock elected to convert&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_10_18_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_ACFKxOC2mUGBN1ufbr5J8w" decimals="INF" format="ixt:num-dot-decimal" name="vstm:NumberOfPreferredStockConvertibleIntoCommonStock" scale="0" id="Narr_HgHMmi0Hy0SsV9vAhdx12Q">1,200,000</ix:nonFraction></span><span style="color:#212529;">&#160;shares of Series B Convertible Preferred Stock for&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_10_18_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_ACFKxOC2mUGBN1ufbr5J8w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" id="Narr_VTxpHDGR7ECilOqSI3py_A">4,236,568</ix:nonFraction></span><span style="color:#212529;">&#160;shares of the Company&#8217;s common stock and consequently, the Company issued&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_10_18_2024_To_10_18_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Kvj5joERQU2FBgyJpIJZgQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_JsXKzWExQUarWm-f4YPHbw">4,236,568</ix:nonFraction></span><span style="color:#212529;">&#160;shares of its common stock to holders of the Series B Convertible Preferred Stock. During the year ended December 31, 2024, the&#160;Company did not adjust the carrying value of the Series B Convertible Preferred Stock since it was not probable the holders would be unable to convert the Series B Convertible Preferred Stock into shares of common stock due to any reason including due to any applicable laws or by the rules or regulations of any stock exchange, interdealer quotation system, or other self-regulatory organization with jurisdiction over the Company. Upon conversion, the Company reclassified </span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_10_18_2024_To_10_18_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fM5yxfUyOk2FmCtStYKMUQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="Narr_fA0d3FTWjk2O-gRbm8WadA">21.2</ix:nonFraction></span><span style="color:#212529;"> million from Series B Convertible Preferred Stock to common stock and additional paid in capital on the consolidated balance sheet. As of December 31, 2025 and 2024, there are&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_edm9qWQjT0uGo3Ul1o6KTA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_04olCHd8akCEAz6c4dx-6g">0</ix:nonFraction></span><span style="color:#212529;">&#160;shares of Series B Convertible Preferred Stock outstanding.</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yszt-HnrEUq05F5ATMrHgw_cont7" continuedAt="Tb_yszt-HnrEUq05F5ATMrHgw_cont8"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The Company evaluated the Second Tranche Right under ASC 480, <i style="font-style:italic;">Distinguishing Liabilities from Equity</i> (&#8220;ASC 480&#8221;) and determined that it met the requirements for separate accounting from the initial issuance of Series B Convertible Preferred Stock as a freestanding financial instrument. The Company then determined the Second Tranche Right should be liability classified pursuant to ASC 480. As a result, the Company classified the Second Tranche Right as a non-current liability within the consolidated balance sheets and the Second Tranche Right was initially recorded at fair value and is subsequently re-measured at fair value at the end of each reporting period. The fair value of the Second Tranche Right on the date of issuance was determined to be $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_S54_9duti0-qFLlDHg8uag" decimals="-5" format="ixt:num-dot-decimal" name="vstm:SecondTrancheRightLiabilityNonCurrentFairValue" scale="6" id="Narr_5d6KjbathECA4S3eVn1BJQ">6.9</ix:nonFraction> million based on a Monte-Carlo valuation and the Company allocated $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_S54_9duti0-qFLlDHg8uag" decimals="-5" format="ixt:num-dot-decimal" name="vstm:PreferredStockTrancheLiability" scale="6" id="Narr_flixRbg8lEyYz_2HCEi0Cg">6.9</ix:nonFraction> million of the Series B Convertible Preferred Stock Proceeds to this liability and recorded this amount as preferred stock tranche liability. On December 31, 2023, the fair value of the Second Tranche Right was determined to be $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_a-kauTSQJEW4yLfm5-WSHA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:SecondTrancheRightLiabilityNonCurrentFairValue" scale="6" id="Narr_iQtx0kvl9kuw4jMjOk1K4w">4.2</ix:nonFraction> million and the Company recorded this amount as preferred stock tranche liability on the consolidated balance sheets. The Second Tranche Right expired in July 2024 and is no longer outstanding. The Company recorded the mark-to-market adjustment of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_mTaWPJHmCU-O7Tpo-6Loaw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:MarketToMarketAdjustmentOfPreferredStockTrancheLiability" scale="6" id="Narr_MTGDTTmed0imwrmCk0CswA">4.2</ix:nonFraction> million for the year ended December 31, 2024, under change in fair value of preferred stock tranche liability within the consolidated statements of operations and loss. The Company recorded the mark-to-market adjustment of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_usrikRrbhk2qFlA8-ytCWA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:MarketToMarketAdjustmentOfPreferredStockTrancheLiability" scale="6" id="Narr_4sWFfM6DtkeyLOC7HnepEA">2.8</ix:nonFraction> million for the year ended December 31, 2023, under change in fair value of preferred stock tranche liability within the consolidated statements of operations and loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;padding-top:2pt;background:#ffffff;margin:0pt;">The Company determined that all other features of the securities offered pursuant to the Series B Convertible Preferred Stock Securities Purchase Agreement were clearly and closely associated with the equity host and did not require bifurcation or the fair value of the feature was immaterial to the Company's consolidated financial statements. The Company reassesses the features on a quarterly basis to determine if they require separate accounting. There were no changes to the Company&#8217;s original assessment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Series A Convertible Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:12pt 0pt 0pt 0pt;">On November 4, 2022, the Company e<span style="background:#ffffff;">ntered into an exchange agreement (the &#8220;Exchange Agreement&#8221;) with Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP and MSI BVF SPV, LLC (collectively referred to as &#8220;BVF&#8221;), pursuant to which BVF exchanged </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_11_4_2022_To_11_4_2022_srt_CounterpartyNameAxis_vstm_BiotechnologyValueFundMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fvPNrQJtrkWkJoV_MdT_gw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_gXMK5gkcG02f2R2bmI8O_A">833,333</ix:nonFraction></span><span style="background:#ffffff;"> shares of the Company&#8217;s common stock for </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_11_4_2022_To_11_4_2022_srt_CounterpartyNameAxis_vstm_BiotechnologyValueFundMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_tMPnHLFbrkuMv8YVveCukQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_4ABkSYzv7023xezLZHkrig">1,000,000</ix:nonFraction></span><span style="background:#ffffff;"> shares of newly designated Series A convertible preferred stock, par value </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_11_4_2022_srt_CounterpartyNameAxis_vstm_BiotechnologyValueFundMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_ZbyWkvA4UE-y5mQ7pRm7Mw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_BG2bUdPzwkyGX8mig5nemA">0.0001</ix:nonFraction></span><span style="background:#ffffff;"> per share (the &#8220;Series A Convertible Preferred Stock&#8221;) (the &#8220;Exchange&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Each share of the Series A Convertible Preferred Stock was convertible into </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_11_4_2022_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_zoyOL8-GYk65yM8gGKkE-g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_T0MkWC0KvkCkWHwikpsmKA">0.833</ix:nonFraction></span><span style="font-size:10pt;"> shares of the Company&#8217;s common stock at the option of the holder at any time, subject to certain limitations, including that the holder was prohibited from converting the Series A Convertible Preferred Stock into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares of common stock above the Conversion Blocker, initially set at </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_11_4_2022_To_11_4_2022_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_gfizhfrkqE64g9G7nBHm7w" decimals="4" format="ixt:num-dot-decimal" name="vstm:ConversionOfPreferredStockConversionBlockerPercent" scale="-2" id="Narr__EzJZfHZ9Uu5PFbBdW1GmA">9.99</ix:nonFraction>%</span><span style="font-size:10pt;">, of the total common stock then issued and outstanding immediately following the conversion of such shares of the Series A Convertible Preferred Stock. Holders of the Series A Convertible Preferred Stock were permitted to increase the Conversion Blocker to an amount not to exceed </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_11_4_2022_To_11_4_2022_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_gfizhfrkqE64g9G7nBHm7w" decimals="4" format="ixt:num-dot-decimal" name="vstm:ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice" scale="-2" id="Narr_DiqQ4JI7pke9fdKCEneGZg">19.99</ix:nonFraction>%</span><span style="font-size:10pt;"> upon </span><ix:nonNumeric contextRef="Duration_11_4_2022_To_11_4_2022_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_gfizhfrkqE64g9G7nBHm7w" format="ixt-sec:durwordsen" name="vstm:ConversionOfPreferredStockConversionBlockerNoticePeriod" id="Narr_8n1W8tQVOk-2gAJZk0dz9w"><span style="font-size:10pt;">60 days</span></ix:nonNumeric><span style="font-size:10pt;">&#8217; notice.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">Shares of Series A Convertible Preferred Stock generally had no voting rights, except as required by law and except that the consent of a majority of the holders of the outstanding Series A Convertible Preferred Stock was required to amend the terms of the Series A Convertible Preferred Stock. In the event of the Company&#8217;s liquidation, dissolution or winding up, holders of Series A Convertible Preferred Stock would have participated pari passu with any distribution of proceeds to holders of common stock. Holders of Series A Convertible Preferred Stock were entitled to receive when, as and if dividends were declared and paid on the common stock, an equivalent dividend, calculated on an as-converted basis. Shares of Series A Convertible Preferred Stock were otherwise not entitled to dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">The Series A Convertible Preferred Stock were (i) senior to any class or series of capital stock of the Company hereafter created specifically ranking by its terms junior to the Series A Convertible Preferred Stock; (ii) on parity with the common stock and any class or series of capital stock of the Company created specifically ranking by its terms on parity with the Series A Convertible Preferred Stock; and (iii) junior to the Series B Convertible Preferred Stock and to any class or series of capital stock of the Company created specifically ranking by its terms senior to any Series A Convertible Preferred Stock, in each case, as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yszt-HnrEUq05F5ATMrHgw_cont8"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:0pt;">The Company evaluated the Series A Convertible Preferred Stock for liability or equity classification under ASC 480 and determined that equity treatment was appropriate because the Series A Convertible Preferred Stock did not meet the definition of the liability under ASC 480. Additionally, the Series A Convertible Preferred Stock were not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, or (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Company recorded the Series A Convertible Preferred Stock as permanent equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">In June 2025, holders of the Series A Convertible Preferred Stock elected to convert all&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_6_30_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_-48AVsFUBEugaVAWJ90CjA" decimals="INF" format="ixt:num-dot-decimal" name="vstm:NumberOfPreferredStockConvertibleIntoCommonStock" scale="0" id="Narr_NLpmmbzs3ESz2TICgAlBHg">1,000,000</ix:nonFraction></span><span style="color:#212529;">&#160;shares of Series A Convertible Preferred Stock for&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ykjfpsDf9EClxEq1QlGEFQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" id="Narr_uaSbiq7vfUWjTmDPH8FTSw">833,332</ix:nonFraction></span><span style="color:#212529;">&#160;shares of the Company&#8217;s common stock and consequently, the Company issued&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ykjfpsDf9EClxEq1QlGEFQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" id="Narr_4iWMe6FREEqXggyp36JFwA">833,332</ix:nonFraction></span><span style="color:#212529;"> shares of its common stock to holders of the Series A Convertible Preferred Stock. As of December 31, 2025, there were </span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_s_eRJ_IM-EC5I5guhHo3NA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr__MVRpDDhQUKOU3BQ5RhF5Q">no</ix:nonFraction></span><span style="color:#212529;">&#160;shares of Series A Convertible Preferred Stock outstanding.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">At-the-market equity offering programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In August 2021, the Company entered into a sales agreement with Cantor pursuant to which the Company can offer and sell up to&#160;</span><span style="background:#ffffff;">$</span><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_gb-CSVl9SE2eIj1tdK0XYA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram" scale="6" id="Narr_WYdvg7O9oE-HI3Elyf9Fqg">100.0</ix:nonFraction><span style="background:#ffffff;">&#160;million of its common stock at the current market prices from time to time through Cantor as sales agent (the &#8220;August 2021 ATM&#8221;). In August 2025, the Company entered into a separate sales agreement with Cantor pursuant to which the Company can offer and sell up to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_8_1_2025_To_8_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_9R4yRxA400KtN3lsZ5eH2A" decimals="-5" format="ixt:num-dot-decimal" name="vstm:MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram" scale="6" id="Narr_mlVRvOOh0USbDSICFFyscQ">100.0</ix:nonFraction></span><span style="background:#ffffff;"> million of its common stock at the current market prices from time to time through Cantor as sales agent (the &#8220;August 2025 ATM&#8221; and together with the August 2021 ATM, the &#8220;ATM Programs&#8221;). During the years ended December 31, 2025, 2024, and 2023, the Company sold </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_L9scB89F9EeAgUmzCCgzrA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_LfBUiuuuTUmS4hHGT4gj4Q">4,000,000</ix:nonFraction></span><span style="background:#ffffff;"> shares,&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_tpO1jPCeLkKmH0m8Lyeh1A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_vc_QRfyztEGNCWRVvAVcpw">0</ix:nonFraction></span><span style="background:#ffffff;"> shares, and </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_2UfHf6a-7UekKeqNumvvTw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_pVncBMs810W4pqR3RbyIJg">0</ix:nonFraction></span><span style="background:#ffffff;"> shares, respectively, under the ATM Programs for net proceeds of approximately </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_L9scB89F9EeAgUmzCCgzrA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:ProceedsFromIssuanceOfCommonStockNet" scale="6" id="Narr_hcN7XxI93UKa1_IB3hxfoA">22.7</ix:nonFraction></span><span style="background:#ffffff;"> million, </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_tpO1jPCeLkKmH0m8Lyeh1A" decimals="-5" format="ixt:num-dot-decimal" name="vstm:ProceedsFromIssuanceOfCommonStockNet" scale="6" id="Narr_jUguNPEbDUGrvoO3kzFChQ">0.0</ix:nonFraction></span><span style="background:#ffffff;"> million, and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_2UfHf6a-7UekKeqNumvvTw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:ProceedsFromIssuanceOfCommonStockNet" scale="6" id="Narr_PYnz8_dCRUqCuyVWRBDWvw">0.0</ix:nonFraction></span><span style="background:#ffffff;"> million, respectively, (after deducting commissions and other offering expenses)</span>.</p></ix:continuation><a id="_7a531be4_e45f_404c_85a4_5c8b1e15f505"></a><a id="Tc_HrP4dwMjN0WiWxEU5sabKA_1_2"></a><a id="Tc_O6IaeQ0wME-pXVfTkF5HHg_2_2"></a><a id="Tc_N4d_vV7PpEu1oH-82TeqVw_2_5"></a><a id="Tc_5YC_VYJGY0aIBIq7SWm-mg_2_8"></a><a id="Tc_qoWvvk_zXE64uQw-8V1Lcw_3_0"></a><a id="Tc_0IAjml6VT0O_qimPqz4NMg_3_2"></a><a id="Tc_LC_Qd6zV90yS2XeMbo6n8w_3_5"></a><a id="Tc_GildXMcBKEikrQETigv6sg_3_8"></a><a id="Tc_YYw25sXovE6EnHX_Idf2Jw_4_0"></a><a id="Tc_xgqfoTZHUk6X7MLmkoM32w_5_0"></a><a id="Tc_ws5009PGnUywU5llInr3rg_5_2"></a><a id="Tc_qb7GbpsUV0e5xyboDMlpqQ_5_5"></a><a id="Tc_-AcoaJU660y6zZ8TN3kQ0g_5_8"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_0T3fJyZ5j0S72HD7DP8uwA" continuedAt="Tb_0T3fJyZ5j0S72HD7DP8uwA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11. Stock-based compensation</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_LrDYNpo9nEWzGpBGuJxQfQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense as reflected in the Company&#8217;s consolidated statements of operations and comprehensive loss was as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_81vFum6e40qPRWAKzAeYEA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_A86HJSzzVk6cr368gDfprA_3_3">2,527</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2rH54lHkjUGemFEv-HKuhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Tp72rHsB1E-LvorS9TIerA_3_6">2,134</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_M0_H0x6EIkiEVk025KKwUw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_7EfyvuGP-kWMwSjlGhdhQA_3_9">1,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_vstm_SellingGeneralAndAdministrativeExpenseMember_GF1wQLe1cEepBDtan8hiOg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_XmTjsHyboUyy0xfaR7yhdA_4_3">6,878</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_vstm_SellingGeneralAndAdministrativeExpenseMember_sCAZBIHJT0aFnxlMm6H5GQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_IGdQfXNrCEedkRDDWi4MaA_4_6">5,208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_vstm_SellingGeneralAndAdministrativeExpenseMember_F3TTaRhxYEqLX5MuwsstiQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_JrsX3odlcUOnhpWSts2BGQ_4_9">3,873</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total stock-based compensation expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Ui3OVlHj5Uu63w2AELuqsw_5_3">9,405</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_aqsfIL-GnEO0F6Q-SDCmBw_5_6">7,342</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_FobVnM48aESwcFFc8ylgMg_5_9">5,860</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:192.9pt;"></span><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">All of the $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_h2eMDvl7M0SOOHK4BLmy8A">9.4</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_YhKFNgnZM026IqmONOUirQ">7.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_fbPalMgOYUOMI7NKZ87WrQ">5.9</ix:nonFraction> million of stock-based compensation expense recorded during the years ended December 31, 2025, 2024 and 2023, respectively, was recorded to additional paid-in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has awards outstanding under <ix:nonFraction unitRef="Unit_Standard_item_5quK1hZThku2W0bLLpUodA" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="INF" format="ixt-sec:numwordsen" name="vstm:NumberOfEquityCompensationPlans" scale="0" id="Narr_hLW7ZSl7zEGsXqEz0_-c5g">two</ix:nonFraction> equity compensation plans, the Amended and Restated 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;), and the Amended and Restated 2012 Incentive Plan (the &#8220;2012 Plan&#8221;), as well as the inducement award program. Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the individual plans. </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-36</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_0T3fJyZ5j0S72HD7DP8uwA_cont1" continuedAt="Tb_0T3fJyZ5j0S72HD7DP8uwA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2021 Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During 2021, the Company&#8217;s stockholders approved the 2021 Equity Incentive Plan (the &#8220;Original 2021 Plan&#8221;). Upon effectiveness of the Original 2021 Plan, the Company ceased making awards under the 2012 Plan. At the Company&#8217;s 2024 Annual General Meeting of Shareholders in May 2024, the Company&#8217;s shareholders approved the Amended 2021 Plan. The Amended 2021 Plan together with the Original 2021 Plan is referred to as the 2021 Plan. The 2021 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs and other stock-based awards. The number of shares of common stock initially reserved for issuance under the Original 2021 Plan was (i) <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_9MQgPcH2EUCI7sWeUwpq2w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_0DcmMWwnHES-CwFQy3OD_A">1,991,666</ix:nonFraction> plus (ii) the number of shares of the Company&#8217;s common stock underlying awards under the 2012 Plan and the <span style="background:#ffffff;">2010 Equity Incentive Plan (the &#8220;</span>2010 Plan&#8221;) that expire, terminate or are surrendered without delivery of shares, are forfeited to or repurchased by the Company, or otherwise become available again for grant under the terms of the 2012 Plan or the 2010 Plan, as applicable. The Amended 2021 Plan increased the maximum number of shares available for issuance by <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_kF5MtIMMKk-IM7zcfxe9ng" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_wfQlLhkBvkGPng4Q7qdvDg">3,200,000</ix:nonFraction> shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, under the 2021 Plan, the Company has granted stock options for <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_vVu2uuQvG06s9WNMj9GHKQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_S88e4j0uPEWKKdOG66XVQA">2,590,423</ix:nonFraction> shares of common stock, of which <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_vVu2uuQvG06s9WNMj9GHKQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Narr_7vV_ZesYFkaKyhNKlgabqA">418,541</ix:nonFraction> have been forfeited and <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_vVu2uuQvG06s9WNMj9GHKQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr__LDdOY2a2E-iOpXtCWxaUg">34,402</ix:nonFraction> have been exercised, and granted RSUs for <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member__JkWWHFFE02LfRdH8KCQ3w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Bey8n5TnsUKh0zq9RzgqVw">2,268,761</ix:nonFraction> shares of common stock, of which <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member__JkWWHFFE02LfRdH8KCQ3w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Narr_Bj8X20pS6EyRbIUQyoe8YQ">105,361</ix:nonFraction> have been forfeited and <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member__JkWWHFFE02LfRdH8KCQ3w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Narr_ENx3occDb0elJ75DV3-ZDw">852,679</ix:nonFraction> have vested. As of December 31, 2025, <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_oquxji7W7kORBWim9QZqHQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_UGumss9mPEKR-mTxQfYQ9Q">1,567,799</ix:nonFraction> shares remain available for future issuance under the 2021 Plan. The exercise price of each option has been equal to the closing price of a share of the Company&#8217;s common stock on the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2012 Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The 2012 Plan became effective immediately upon the closing of the Company&#8217;s initial public offering in February 2012. Upon effectiveness of the 2012 Plan, the Company ceased making awards under the 2010 Plan. The 2012 Plan initially allowed the Company to grant awards for up to <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_2_29_2012_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member__U1eFLyyYUinIuRMK__m6g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_i4X32TXhGkSVrjXlu4fk8Q">285,714</ix:nonFraction> shares of common stock, plus the number of shares of common stock available for grant under the 2010 Plan as of the effectiveness of the 2012 Plan (which was an additional <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_2_29_2012_To_2_29_2012_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_I4P8dDbjHU-7QChhWz3WUw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_WtlPLEp9WkSv2FyuEAqvAA">2,508</ix:nonFraction> shares), plus that number of shares of common stock related to awards outstanding under the 2010 Plan which terminate by expiration, forfeiture, cancellation or otherwise. The 2012 Plan included an &#8220;evergreen provision&#8221; that allowed for an annual increase in the number of shares of common stock available for issuance under the 2012 Plan. The annual increase was added on the first day of each year from 2013 through 2018 and was equal to the lesser of <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2013_To_12_31_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_InUwV157EEmuIs833j_9kA" decimals="INF" format="ixt:num-dot-decimal" name="vstm:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" scale="0" id="Narr_VMij6G1pYECyyXkkXZt68g">107,412</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2013_To_12_31_2018_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_6UYIohPWOE6apXvvQXRZUg" decimals="INF" format="ixt:num-dot-decimal" name="vstm:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved" scale="-2" id="Narr_gVoLgUrydkOy1ffUwz5pBg">4.0</ix:nonFraction>% of the number of shares of common stock outstanding, or a lesser amount as determined by the board of directors. On each of January 1, 2018, January 1, 2017 and January 1, 2016, the number of shares available for issuance under the 2012 Plan increased by <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2016_To_12_31_2018_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_3QOHsDLjBU6VMM7clr-E_Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_8DUilHNr_EKrdak-2u-PXA">107,412</ix:nonFraction> under this provision. On December 18, 2018, the shareholders of the Company approved the Amended and Restated 2012 Incentive Plan which increased the maximum number of shares available for issuance under the 2012 Plan to <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_18_2018_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_VfDIZ_ny_0SEOGbgvYKH1A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_xlauqyC4oUmxlt_TyB3msQ">1,385,702</ix:nonFraction> and eliminated the evergreen provision. On May 19, 2020, the shareholders of the Company approved the Amended and Restated 2012 Incentive Plan which increased the maximum number of shares available for issuance by <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_5_19_2020_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_7ogkiNGxH0Cudi_sLSt8Sg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_u2nVw3bqnk6yFmwYm0AmTg">1,083,333</ix:nonFraction> shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Awards under the 2012 Plan may include the following award types: incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, RSUs, other stock-based or cash-based awards and any combination of the foregoing. As of December 31, 2025, under the 2012 Plan, the Company has granted stock options for <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_XEXyJOXQwU6kwc_ldYtXQA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_bqkgfj3XgkWhVy6KfmeL0A">1,841,188</ix:nonFraction> shares of common stock, of which <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_XEXyJOXQwU6kwc_ldYtXQA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Narr_i9QjoLV7fE-h0Dc1xTFKgQ">1,201,898</ix:nonFraction> have been forfeited, <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_XEXyJOXQwU6kwc_ldYtXQA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Narr_dJi3TJ0dGUiXwLApMCPELA">238,203</ix:nonFraction> have expired, and <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_XEXyJOXQwU6kwc_ldYtXQA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_dxr3a0gCn0-ETqK5UVlGdg">191,342</ix:nonFraction> have been exercised, and granted RSUs for <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_PLQMRuTiiE6wbLtAwlEjMw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_NHbpYSQuXkO0d3Wkh48pSg">556,432</ix:nonFraction> shares of common stock, of which <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_PLQMRuTiiE6wbLtAwlEjMw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Narr_mKhQAIkRnE-CAo9zevgjMQ">87,547</ix:nonFraction> have been forfeited and <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_PLQMRuTiiE6wbLtAwlEjMw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Narr_ty9h3eJZTk-Zc8mBeVZoIw">468,885</ix:nonFraction> have vested. The exercise price of each stock option has been equal to the closing price of a share of the Company&#8217;s common stock on the grant date. Upon adoption of the Original 2021 Plan, the Company ceased issuing awards from the 2012 Plan.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-37</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk191483982"></a><ix:continuation id="Tb_0T3fJyZ5j0S72HD7DP8uwA_cont2" continuedAt="Tb_0T3fJyZ5j0S72HD7DP8uwA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:10pt;font-weight:bold;">Inducement Award Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December&#160;2014, the Company established an inducement award program (in accordance with Nasdaq Listing Rule&#160;5635(c)(4)) under which it may grant non-statutory stock options to purchase, and RSUs in respect of up to an aggregate of<span style="letter-spacing:-0.3pt;"> </span><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2014_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_HTpasKVhbEijVBMXmoAR3g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_oobw3oADkEqQ0LHc-BJgJA">62,500</ix:nonFraction> shares of common stock to new or prospective employees as inducement to enter into employment with the Company. In December 2016, the Board of Directors authorized and reserved <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_hb0DPVUMikKyDJikKyOjUQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_gTT2jM95REKFJMws-5merg">48,333</ix:nonFraction> additional shares of common stock under this program. In December 2017, the Board of Directors authorized and reserved <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_sFo85W5EcE2hWIXSctPLDg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_2RwFaXUX9U-Os5p9qJRDJg">208,333</ix:nonFraction> additional shares of common stock under this program. In June and December 2018, the Board of Directors authorized and reserved <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_6dsoZ6DBIU6g6FY7wcduKw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_Sw32TGkJ-kejl6hd1xJzVA">141,666</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_12_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_ZKoZ1HtmKEOVJFeHyY-zGQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_iWMCY-gz_k6B_gNh97pkFw">104,166</ix:nonFraction> additional shares of common stock under this program, respectively. In February 2020, the Board of Directors authorized the reduction of <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_2_1_2020_To_2_29_2020_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_KH8OwIiqFUWzZ49IgN-PQQ" decimals="INF" format="ixt:num-dot-decimal" name="vstm:ReductionOfSharesAvailableForIssuance" scale="0" id="Narr_JdbhxoCxsUesKlZt2XjL9g">169,447</ix:nonFraction> shares available for issuance under this program. In September 2023, the Board of Directors authorized and reserved <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_9_1_2023_To_9_30_2023_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_D0hnNXSwOkqr4_93nEPQFw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_jleSOILf8kKbZtRrh6TLZg">500,000</ix:nonFraction> additional shares of common stock under this program. In September 2025, the Board of Directors authorized and reserved <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_9_1_2025_To_9_30_2025_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_cywh5amltUm6Kt3zBqYeYw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_1UsQhW6xa06PuNWbGXBVEA">400,000</ix:nonFraction> additional shares of common stock under this program. The program is governed by the terms of the 2021 Plan, but shares issued pursuant to the program are not issued under the 2021 Plan. As of December 31, 2025, the Company had granted options for <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Qle4ZI3AIEyBN5JnaC-kDw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_a5exA9ABWkmITLXi81OmZg">1,459,605</ix:nonFraction> shares of common stock under the program, of which <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Qle4ZI3AIEyBN5JnaC-kDw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Narr_wRQouAHYi0S4aYkQraGOJQ">725,488</ix:nonFraction> have been forfeited, <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Qle4ZI3AIEyBN5JnaC-kDw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Narr_Sz8zkmkbxkCsKc5Sfgot0g">1,997</ix:nonFraction> have expired and <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Qle4ZI3AIEyBN5JnaC-kDw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_whjVv2mCwU21kZhzIAZw_A">48,913</ix:nonFraction> have been exercised, and granted RSUs for <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Thu2JVJXHE-NAiF2FbkbWQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_wRYayRigIUG4JRB6SyRlCQ">164,137</ix:nonFraction> shares, of which <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Thu2JVJXHE-NAiF2FbkbWQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Narr_sQLBvPbZ9kelORZmE2TZ0A">45,658</ix:nonFraction> have been forfeited and <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Thu2JVJXHE-NAiF2FbkbWQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Narr_XTUU_1vLL0WndGtfFLRBeQ">115,302</ix:nonFraction> have vested. As of December 31, 2025, <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_v94nix69zkGeGJg-ULbs-w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_smZLPT2W6EOtbYo8vjv9Dw">508,330</ix:nonFraction> shares remain available for future issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Stock Options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Most options granted by the Company vest twenty-five percent (<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_SRNGIXeB20ejdnPS4J6CHA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_YaLyH8LlGkK7iR78DTvDnQ">25</ix:nonFraction>%) <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_SRNGIXeB20ejdnPS4J6CHA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Iyp7OpVLFE-eO27vV20A6g">one year</ix:nonNumeric> from vesting start date and six and a quarter percent (<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_AH-XF6rwGUWP_UuR-y8kTA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_VNjyHbyr7k-znwmnYZLafw">6.25</ix:nonFraction>%) for each successive <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_AH-XF6rwGUWP_UuR-y8kTA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_nag1e6fgHESNGzw7xO6olA">three-month</ix:nonNumeric> period, thereafter (subject to acceleration of vesting in the event of certain change of control transactions) subject to the employee&#8217;s continued employment with, or service to, the Company on such vesting date and are exercisable for a period of <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_SC2H8g5dvk6Zm5BthjLl9g">ten years</ix:nonNumeric> from the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Option Exchange Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 17, 2024, the Company&#8217;s stockholders, upon recommendation of the board of directors, approved a one-time stock option exchange program (the &#8220;Option Exchange Program&#8221;) for certain employees, executive officers and non-employee directors of the Company who held certain underwater options and remained employed or otherwise engaged by the Company through the completion of the Exchange Offer. The Company&#8217;s offer to participate in the Option Exchange Program commenced on February 8, 2024, and expired on March 8, 2024 (the &#8220;Exchange Offer&#8221;). Pursuant to the Exchange Offer,&#160;<ix:nonFraction unitRef="Unit_Standard_item_5quK1hZThku2W0bLLpUodA" contextRef="Duration_1_17_2024_To_1_17_2024_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_9tsdrgQO-UKXsRxV5I_Sjg" decimals="INF" format="ixt:num-dot-decimal" name="vstm:NumberOfEligibleStockholders" scale="0" id="Narr_BCZDQI21qUu4ZooI-hn8Tw">42</ix:nonFraction>&#160;eligible holders elected to exchange, and the Company accepted for cancellation, eligible options to purchase an aggregate of&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_1_17_2024_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_6mVNyROOJkSrg0yW3Dje3g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_u2uc7-_C9ka0ujwdKOKQ-w">603,330</ix:nonFraction>&#160;shares of the Company&#8217;s common stock (the &#8220;Exchanged Options&#8221;). On March 11, 2024, promptly following the expiration of the Exchange Offer, the Company granted new options to purchase&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_3_11_2024_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_-AttFnMCSU6nI2v6Vkvu9A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_obEIqggHjECi40kRmuqDPA">603,330</ix:nonFraction>&#160;shares of common stock (the &#8220;New Options&#8221;), pursuant to the terms of the Exchange Offer and the Amended 2021 Plan. The exercise price of the New Options granted was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_3_11_2024_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_-AttFnMCSU6nI2v6Vkvu9A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Narr_z3WOhGGj5UKXl41jInQHcA">11.44</ix:nonFraction>&#160;per share, which was the closing price of the Company&#8217;s common stock on the Nasdaq Capital Market on the grant date of the New Options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The exchange of stock options was treated as a modification for accounting purposes. As a result of the Option Exchange Program, the Company will recognize incremental stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_P0DHBOoSh0iaybDJceiPYw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_5E-xTVFTFUevk3G-2f5R_A">1.7</ix:nonFraction> million over the requisite service period of the New Options, which is two or four years depending on whether the Exchanged Options were vested at the time of exchange. Since the Exchanged Options were not at-the-money on the modification date, the Company was precluded from utilizing the simplified method as described in SEC Staff Accounting Bulletin Topic 14.D.2 to calculate the expected term as a key assumption in the Black-Scholes pricing model. Therefore, the Company utilized the binomial lattice model to calculate the fair value of the Exchanged Options immediately prior to the exchange. The Company utilized the Black-Scholes option-pricing model to calculate the fair value of the New Options on the modification date. The Company is recognizing the remaining unamortized stock compensation expense for the Exchanged Options on the modification date over the original requisite service period of the Exchanged Options. At December 31, 2025, there was <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_7P_amzQ5tEm7vf5xPezzyQ" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_gpSVD_SlvU6o8QFjQG4iEw">no</ix:nonFraction> unrecognized compensation cost related to Exchanged Options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-38</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_aCisY-VCtE6JzRDUd_gmlg_1_2"></a><a id="Tc_aVaMQ3HIiEuZhJUT57sEaQ_1_4"></a><a id="Tc_TGe2_94lzE6KC8hDUYK4AQ_1_7"></a><a id="Tc_ppY0o2HYCUuVbSMa8TL92A_1_9"></a><a id="Tc_UVvBg_T8eUOinxcCxrWkoQ_2_0"></a><a id="Tc_fxVKeqQaYE2i7tkk3VK2mA_2_4"></a><a id="Tc_wZgY5iNhskivMOZvpdWI2Q_2_9"></a><a id="Tc_GrBuH_6eU0qkVqg1HWW0tA_3_0"></a><a id="Tc_f-Nl4HymS0q96XtjNDcNVA_4_0"></a><a id="Tc_DI3BEW2yykKERX_bRQ1qug_5_0"></a><a id="Tc_fCVUsFKgO02-fRCNRMrpww_6_0"></a><a id="Tc_k36-gkgGpUy_meE_tEtx9g_7_0"></a><a id="Tc_2X6gJlSqFkq39UExh9NW8g_7_4"></a><a id="Tc_2RNEU3IUyEOX6jLHzSmzgg_7_9"></a><a id="Tc_HWBB_KT8aEyF8l9O7Pp5jg_8_0"></a><a id="Tc_k-gA_MaBYEyybe9Gpvy9Pw_8_4"></a><a id="Tc_VsBj79bF0kqOoI7uCF5OUQ_8_9"></a><a id="Tc_dGOR_boQ5ESwooia5MuIog_1_2"></a><a id="Tc_8xclnQ6-80q3sj7Hv6CFxw_2_2"></a><a id="Tc_9cZ9GLmvKEWeYwMT0d89Ig_2_5"></a><a id="Tc_L5xHMjFeEUaBjbm51j3THg_2_8"></a><a id="Tc_V7rki83omkWixkVMiyXQww_3_0"></a><a id="Tc_kQdfyDAAcU-EOTvitL7MpQ_3_3"></a><a id="Tc_1LQ_pANqXk-7TNXN5B6FXQ_3_6"></a><a id="Tc_HQhwlHAPM0aCLBMdWB97yA_3_9"></a><a id="Tc_4mMKqYSv3U2ni2u43LHWNQ_4_0"></a><a id="Tc_fhYRPw0-10GjyKzQrzeV0A_4_3"></a><a id="Tc_pdULhHX330ymIWAjkkV2Sg_4_6"></a><a id="Tc_aTHUH3OVk0CjaqYHRo5p6g_4_9"></a><a id="Tc_QZ4dnutoVE--rkjSvlb5yw_5_0"></a><a id="Tc_-WMrMEDiKkae56neNWkjsg_6_0"></a><ix:continuation id="Tb_0T3fJyZ5j0S72HD7DP8uwA_cont3" continuedAt="Tb_0T3fJyZ5j0S72HD7DP8uwA_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A summary of the Company&#8217;s stock option activity and related information for the year ended December 31, 2025, is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_8eduIiBirUG8jgOiv2oi-A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.58760834%;padding-left:0pt;padding-right:0pt;width:101.17%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-average exercise&#160;price&#160;per share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-average remaining contractual term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate intrinsic value (in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_KXGM5R7Mj0CV9njTnuX__g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_sCd87jmMe0CQFLmuWlUglA_2_2">2,479,037</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_KXGM5R7Mj0CV9njTnuX__g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_VTHm0Ltupk-DEnUDeTHAFA_2_5">11.43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_x_gHbIld7ECveTO6q1Q1Cg_2_7"> 8.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_KXGM5R7Mj0CV9njTnuX__g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_HgXZ1Xa6bkm_NmiBx3SBIA_2_10">843</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_s5eAt_CqH0Gyzu16FD5YVg_3_2">754,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_CCGGBRzAKEq3wDfhe68r9w_3_5">6.63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised/Released</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_EhzdhGXcoEGHxIt2rwd5WA_4_2">12,674</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_aK8EK_GJQUql15HQaWDqBg_4_5">5.13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_uwGP1nUaJ0qpuAWjIsQwLg_5_2">189,306</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_WApZGijrr0uyjWun1apKuQ_5_5">6.83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_TLHe8liR0U-AB1fA4-RiTA_6_2">625</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_Il_416xKO06EkC7A9fz4Ww_6_5">95.88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_QxkWpkXINU6ewZdwyiOEzg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_qLatyEc58UajsH4z6cGZ3w_7_2">3,030,432</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_QxkWpkXINU6ewZdwyiOEzg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_ulfFfnoC5USk5YuCq1vEpw_7_5">10.53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_KQ7i4uhZzEqxqLSSW9kddg_7_7"> 7.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_QxkWpkXINU6ewZdwyiOEzg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_fawlB7h030KpWSDV3dLnvg_7_10">2,731</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested at December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Tc_YXnPFqZKaUuEuZOgDMZhNw_8_2">1,568,702</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_QxkWpkXINU6ewZdwyiOEzg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_ybKjb3qTzUa39c5khqGpcw_8_5">12.78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_TscwwyIyoU6BmG5ypMiIsg_8_7"> 7.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_QxkWpkXINU6ewZdwyiOEzg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_o_p3kA21ekGOe3eG-x9Udg_8_10">1,248</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 12pt 0pt;">The fair value of each stock option was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_32AhqiqjJkK1JcaMiqiK9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_trKe_V2rzEWLi5J3ff8xYQ_3_2">3.93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_zWgMuTXhaE-mDqW8gQ7mBw_3_5">4.07</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_tIdJE1g98kGmGUc-bA-rnA_3_8">3.77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_cVMnVJM4rku45Nqx7Ywnhg_4_2">107</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_W9d7WUc1JE6YZ-KG0ilV2w_4_5">99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_pnQ2rj6YAEGroAO2ttU2EA_4_8">92</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_YOcQjIuCj0K0LDx9cQZm0w_5_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_SEeHbylm4UCRxdoDsvt_VQ_5_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_EjdGnCetQUK7N8VrG8Lzjw_5_8">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_L6VzEcv0K0OuhU_j4j_wyQ_6_2"> 5.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_k7GHJx5hcEe3er5z5_TjyA_6_5"> 5.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_fjDaMKja9ECiGswqkWQhXA_6_8"> 6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The Company recorded stock-based compensation expense associated with employee and non-employee stock options of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_F2jyYTL6xUmfGY5yS3wmpA">4.5</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_Hs9xpSGPqkiugApncoIT8g">4.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_6s8HY_iFxk-tkBR0w-_KAw">4.2</ix:nonFraction> million, for the years ended December 31, 2025, 2024, and 2023, respectively. The weighted-average grant date fair value of stock options granted in the years ended December 31, 2025, 2024, and 2023 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_8V62Vm6_-UOksAZNxME_rQ">5.48</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_sdAMnqRe-UCxn-Uocp8v_w">3.35</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_tkmR2VII2UyqfImYmZbTbg">6.16</ix:nonFraction> per stock option, respectively. The fair value of stock options that vested during the years ended December 31, 2025, 2024, and 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_uC8-frVkN0KsHtbb6NDi5w">3.7</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_ahgKbxxbaE-TnF2w7o2EEg">3.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_hSteCa7QZ0aFCrSCAuJoQw">3.1</ix:nonFraction> million, respectively. The aggregate intrinsic value of options exercised (i.e.,&#160;the difference between the market price at exercise and the price paid by employees to exercise the option) during the years ended December&#160;31, 2025, 2024, and 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_luB0Uf5h_kCMI46FvH4t4g">0.1</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_e_D1aSA070qozLYXNtzyOg">0.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_9UwJdzBpyk-iRfIGwY2lsA">0.0</ix:nonFraction> million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2025 there was $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_QxkWpkXINU6ewZdwyiOEzg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_Z5GmvrOiYk-__VIKj0IDew">5.4</ix:nonFraction> million of total unrecognized compensation cost related to unvested stock options and the Company expects to recognize this cost over a remaining weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_8RS5wTEoV0SkaOhxOuBT3Q">2.2</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Restricted Stock Units (&#8220;RSUs&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Each RSU entitles the holder to receive <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw" decimals="INF" format="ixt-sec:numwordsen" name="vstm:NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" scale="0" id="Narr_vwMYrea6kkWSAZOVrbfGDw">one</ix:nonFraction> share of the Company&#8217;s common stock when the RSU vests. The RSUs generally vest (i) twenty-five percent (<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DIZOBohzgUCmiDTqRAMCOA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_cdb7HtW42kSLqkksj4oJWw">25</ix:nonFraction>%) <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DIZOBohzgUCmiDTqRAMCOA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_w4Za5Wh8C0GcyS0mOW7CZg">one year</ix:nonNumeric> from vesting start date and six and a quarter percent (<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8LF9tFy9yEe9w7E5AvqW_g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_hFBWEqZn9k2Pg2RvNIt8Pw">6.25</ix:nonFraction>%) for each successive <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8LF9tFy9yEe9w7E5AvqW_g" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_RXnR-SPfN0-BSs8mDAMO6w">three-month</ix:nonNumeric> period, thereafter, (ii) <ix:nonFraction unitRef="Unit_Standard_tranche_AR7EJ57OqEq8JqHSzH8_Aw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_mUQePIf6k0Ox3rRBC0Wpxg" decimals="INF" format="ixt-sec:numwordsen" name="vstm:NumberOfInstallmentsForVestingOfRestrictedStockUnits" scale="0" id="Narr_i_e-G3TqfU-pSrz7xG6-_Q">two</ix:nonFraction> tranches for <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_mUQePIf6k0Ox3rRBC0Wpxg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_aOm4hCWXcUiGrmW05iwUXA">50</ix:nonFraction>% of the award with the second and final vesting date on the <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_mUQePIf6k0Ox3rRBC0Wpxg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_xOKVN1n_BUmzF-H_8qOY2w"><ix:nonFraction unitRef="Unit_Standard_item_5quK1hZThku2W0bLLpUodA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DIZOBohzgUCmiDTqRAMCOA" decimals="INF" format="ixt-sec:numwordsen" name="vstm:NumberOfAnniversariesForVestingRestrictedStockUnits" scale="0" id="Narr_FPzPoLBJUkSPAk_ZMNbnRA">one</ix:nonFraction> year</ix:nonNumeric> anniversary of the vesting commencement date, (iii) <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_vstm_ShareBasedCompensationAwardTrancheFourMember_NWg1r4cHA0-EOBRAYidUbA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_4Wts0-mPd0O7ZAst5koZlw">100</ix:nonFraction> percent within <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_vstm_ShareBasedCompensationAwardTrancheFourMember_NWg1r4cHA0-EOBRAYidUbA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ozER2tR300CQtwPNQbU73w">two years</ix:nonNumeric> of the vesting commencement date and (iv) <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_vstm_ShareBasedPaymentArrangementTrancheFiveMember_9vzgnyw0KEW9zorH509q7Q" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_7W0sdDhcYUGtal3fvQpq-g">33.3</ix:nonFraction>% of the RSUs on the first <span style="-sec-ix-hidden:Hidden_Y9Qm4X9j2kKBLrWQXymdSw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> anniversaries of the grant date. The RSUs are subject to acceleration of vesting in the event of certain change of control transactions and subject to the employee&#8217;s continued employment with, or service to, the Company on such vesting date. Compensation expense is recognized on a straight-line basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A summary of RSU activity during the year ended December 31, 2025, is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_OJ9bWqw9mEugtR27RQRPhA" continuedAt="Tb_OJ9bWqw9mEugtR27RQRPhA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-39</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_CWGdCi6AL0qlc8WSNCgiJQ_1_3"></a><a id="Tc_1XI22UuCcUC7WNfkZ5vTTA_1_5"></a><a id="Tc_jaJ7g2BtTUuPml_iT9ZEgQ_2_0"></a><a id="Tc_2jrZNZOwX0atfnCco9SmYg_2_5"></a><a id="Tc_lFLcMpTPK0iutjMP_NVUpw_3_0"></a><a id="Tc_pjYJyvdkWk6cj9E444wboQ_3_5"></a><a id="Tc_XxbXmnt6OEi0qtBQlo5MgA_4_0"></a><a id="Tc_91x3L97ezkehemm1LDNqzA_4_5"></a><a id="Tc_CuGY0w9twU27cUqTT0nDig_5_0"></a><a id="Tc_cQ04HENqA0Syn0UYwt6Qng_5_5"></a><a id="Tc_QQBhUDxaP0OoPaLI-e2XUQ_6_0"></a><a id="Tc_Ojc7OXh9qEGaTOmRo7Q-sw_6_5"></a><a id="Tc_D8L_nnEaiESonB_MDx1Lig_1_2"></a><a id="Tc_J1LzGZqLuUG-IFpkmS6ewA_2_2"></a><a id="Tc_8CU_JH_gq0azMryjDgdinA_2_5"></a><a id="Tc_CNljU-eyS0G1aPh-f_KHUg_2_8"></a><a id="Tc_Qg0fkAD54kiE3e90kUnXsQ_3_0"></a><a id="Tc_h6uzLoqMk0CXFWArUV418A_3_3"></a><a id="Tc_GHNGSYAyqEiBvMzhi4WFiA_3_6"></a><a id="Tc_o3XCcRapPUOB9hmIv7sokg_3_9"></a><a id="Tc_nyNjCbYxbEuw8S340fVCDw_4_0"></a><a id="Tc_7WIvkBmwIE6rUmHAz00Imw_4_3"></a><a id="Tc_zcczdrpoFU6FTHlSMotxhA_4_6"></a><a id="Tc_FlhnavgXdk-tvUewcfNOVg_4_9"></a><a id="Tc_KHFdH1vCcUuYbTn8MNk3hg_5_0"></a><a id="Tc_yTfhKGPKf0ebfpd8UqnasA_5_2"></a><a id="Tc_-kTX6Ob_PEWaABn_ScQj1A_5_5"></a><a id="Tc__yEjlehwKEi-99FCHyF_0A_5_8"></a><a id="Tc_waPacd5PukaGA2mPHwR_4A_6_0"></a><ix:continuation id="Tb_0T3fJyZ5j0S72HD7DP8uwA_cont4" continuedAt="Tb_0T3fJyZ5j0S72HD7DP8uwA_cont5"><ix:continuation id="Tb_OJ9bWqw9mEugtR27RQRPhA_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:73.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-average grant date fair value per&#160;share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_H7UvvfgjnUqqlhC1ni7-Kw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_i3gPxHSZC0Sgmu_ASNLoww_2_3">1,010,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_H7UvvfgjnUqqlhC1ni7-Kw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_ZD27IqbRI0iXNHObDceyfg_2_6">6.29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_Nbmigkqc-EWV5fh6jhi3Hw_3_3">1,132,374</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_Utd89yxhcUOJcNbfifvuQA_3_6">5.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_B5Ddc2czW0-ODM_az5tYvg_4_3">687,067</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_HCvGBDgDEUuGWFC44_A1cw_4_6">6.37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/cancelled</p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_Hq01PArQg0OuGko9lFzrKg_5_3">141,642</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_QkK4Vft_ME6dWh3UnxeyRQ_5_6">6.61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aS2tcr5syUKqamx-hjW3Pw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_sUXcYA55I0-cdNnuW7-ntg_6_3">1,313,898</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aS2tcr5syUKqamx-hjW3Pw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_kiBaNzpon0SDV5xcCBvfqw_6_6">5.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 6pt 0pt;">The Company recorded stock-based compensation expense associated with employee and non-employee RSUs of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr__pAxjdeG40CExkf6j4vQZg">4.9</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_S_kTXh7xV0m8qg0cNUl6aw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_dMMh7j9FLUSoJb2dYsea5g">2.7</ix:nonFraction> million, and $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_o06JHclHKkuBTNuWXs-wzg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_m2vtPKlIU0mOpkZS1NGySA">1.6</ix:nonFraction> million, for the years ended December 31, 2025, 2024, and 2023, respectively. The total fair value of restricted stock units that vested during the years ended December 31, 2025, 2024, and 2023 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_6j8UAnadBEahjzUwFQw7Ig">4.4</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_S_kTXh7xV0m8qg0cNUl6aw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_cERYGY0Qek-tosGt9zjFVQ">1.7</ix:nonFraction> million, and $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_o06JHclHKkuBTNuWXs-wzg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_kwX8dpE6-0OLVen_6RCAsg">1.7</ix:nonFraction> million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2025, there was $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aS2tcr5syUKqamx-hjW3Pw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="Narr_yqfj6pXwGUW21iwl2QMTXg">4.6</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs and the Company expects to recognize this cost over a remaining weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_XAf2syPMG02GVbOMxhELjg">1.9</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Employee stock purchase plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">At the special meeting of stockholders, held on December 18, 2018, the stockholders approved the 2018 Employee Stock Purchase Plan (&#8220;2018 ESPP&#8221;). On June 21, 2019, the board of directors of the Company amended and restated the 2018 ESPP, to account for certain non-material changes to the plan&#8217;s administration (the &#8220;Amended and Restated 2018 ESPP&#8221;). The Amended and Restated 2018 ESPP provides eligible employees with the opportunity, through regular payroll deductions, to purchase shares of the Company&#8217;s common stock at </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_6_21_2019_To_6_21_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_m3em9BxJfkWCCgCqGcDWTw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_WPOwIS_6yEeHVH-uQW8nkQ">85</ix:nonFraction>%</span><span style="font-size:10pt;"> of the lesser of the fair market value of the common stock (a) on the date the option is granted, which is the first day of the purchase period, and (b) on the exercise date, which is the last business day of the purchase period. The Amended and Restated 2018 ESPP generally allows for </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_item_5quK1hZThku2W0bLLpUodA" contextRef="Duration_6_21_2019_To_6_21_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_m3em9BxJfkWCCgCqGcDWTw" decimals="INF" format="ixt-sec:numwordsen" name="vstm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods" scale="0" id="Narr_RQ6kg7NdUk2Ig5HTVzPBqA">two</ix:nonFraction></span><span style="font-size:10pt;">&#160;</span><ix:nonNumeric contextRef="Duration_6_21_2019_To_6_21_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_m3em9BxJfkWCCgCqGcDWTw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_IiU-AWgtfki9g2aCL7dw6A"><span style="font-size:10pt;">six-month</span></ix:nonNumeric><span style="font-size:10pt;"> purchase periods per year beginning in January and July, or such other periods as determined by the compensation committee of the Company&#8217;s board of directors. The Company has reserved </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="As_Of_6_21_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_kZlm7MS8p0C-2514CTT6lg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_vJujti0k_USRxXAXhLG7IA">166,666</ix:nonFraction></span><span style="font-size:10pt;"> shares of common stock for the administration of the Amended and Restated 2018 ESPP. The fair value of shares expected to be purchased under the Amended and Restated 2018 ESPP was calculated using the Black-Scholes model with the following weighted-average assumptions:</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="Group_C3VJP-IxkEyurc5Yc8fccA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_HI4Ao1b7KUaKAhD6JIXWwA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_9f2jiuN6NUalveVZ4ELGmA_3_2">4.27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_oOgDU519zEqo7xvys1DGvA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_XGMsQVIqxUyhA8baA-jx4Q_3_5">5.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_vKi2RrPfkku5amSLSGzqiw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_tMh6TAU5T0Cwt5TmKh22Aw_3_8">5.16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_HI4Ao1b7KUaKAhD6JIXWwA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_sbLsp7KKoUCCpsNq-ZIExA_4_2">96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_oOgDU519zEqo7xvys1DGvA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_w7kM7L-fVU-frsjXY5MEqg_4_5">115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_vKi2RrPfkku5amSLSGzqiw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_s90OEMrg8E2Tt6KMm9LvBw_4_8">126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_HI4Ao1b7KUaKAhD6JIXWwA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_AHqbWeaz00S8CXEMRmyGmA_6_2"> 0.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_oOgDU519zEqo7xvys1DGvA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_UsS4-g1eIkWNz5F45r9Arg_6_5"> 0.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_vKi2RrPfkku5amSLSGzqiw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_O-1GcKVUyEiP1m5xy1ZcPw_6_8"> 0.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">For the years ended December 31, 2025, 2024, and 2023, the Company has recognized less than $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_vKi2RrPfkku5amSLSGzqiw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr__L0nfl8tLkSWjFXvJE52fA"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_oOgDU519zEqo7xvys1DGvA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_xXYBwhYnyE-_IN2KTTVUPw"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_HI4Ao1b7KUaKAhD6JIXWwA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_ykzaRNQ_l0miM2Ch84T0Gg">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction> million of stock-based compensation expense each year under the Amended and Restated 2018 ESPP. During the years ended December 31, 2025, 2024, and 2023, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_HI4Ao1b7KUaKAhD6JIXWwA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Narr_bCXAY9DDEEO7CFnBKRrvQw">16,341</ix:nonFraction> shares, <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_oOgDU519zEqo7xvys1DGvA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Narr_PZelasnb206AqoX7KVVOxg">15,231</ix:nonFraction> shares and <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_vKi2RrPfkku5amSLSGzqiw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Narr_CNgduFK7YUqCDbLfD-PHIw">14,270</ix:nonFraction> shares, respectively, of common stock for proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_vKi2RrPfkku5amSLSGzqiw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="Narr_mSjZ0m4WkkybAxJ8D40tvg"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_oOgDU519zEqo7xvys1DGvA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="Narr_W2kWOjeaikK1R_tSV_qXMg"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_HI4Ao1b7KUaKAhD6JIXWwA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="Narr_oG_LYB9jIka7zgqdGMBGlQ">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction> million in each year under the Amended and Restated 2018 ESPP.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-40</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_0T3fJyZ5j0S72HD7DP8uwA_cont5"></ix:continuation><a id="_a0a7797e_7a7a_4b60_9666_a87ee7e72a2f"></a><a id="Tc_PoGV2yAZpEClaGHQNqSHjg_1_2"></a><a id="Tc_FLrRTIW-oUiakEc6n72FkQ_2_2"></a><a id="Tc_CFmp8jIVPUGiNtk5-ve8bg_2_5"></a><a id="Tc_kFhmgRgRBUul9oBtt0e7Fw_2_8"></a><a id="Tc_LBCFP-MXWEKlyBGFNXH_TQ_3_0"></a><a id="Tc_z31-zopYZ0uLti4FV7dApg_4_0"></a><a id="Tc_9rkqdit5aEGMcuDU1F2YmA_4_2"></a><a id="Tc_Z8sDrQyQaEmRuKDZopT_EA_4_5"></a><a id="Tc_CahlCAQA50y26_NEDTLEsQ_4_6"></a><a id="Tc_ZodyF_fwwEyTfyZYOnNYYA_4_9"></a><a id="Tc_Bg1sk0p8CkyN4S_Lv5SGKg_5_0"></a><a id="Tc_DCz3EMUCx06ugnWfGHkoFA_5_3"></a><a id="Tc_XXZBRnwjyk2om446BM_jCg_5_8"></a><a id="Tc_4vAtg4_QEku1o9WQJ-veMw_5_9"></a><a id="Tc_dr1PIVMQ90aFMuvCEpBGpw_6_0"></a><a id="Tc_m6S4GGpo1Ee7-K2zr7OsyA_7_0"></a><a id="Tc_BW39h5MyPEuA3hs7rLQ6wA_7_6"></a><a id="Tc_LPSWQrsUPkaVpLWQvFtDCw_7_9"></a><a id="Tc_HiDTSCIeNku3QzLeSAm3fg_8_0"></a><a id="Tc_Ej6-MKgkj0Kjw1z6SNTPww_8_6"></a><a id="Tc_lZ_Mt1MEq0ytgPMmZfd0cw_8_9"></a><a id="Tc_Br7RKzgKqUWSs2ghghCflg_9_0"></a><a id="Tc_8Qs5MfoQ3EypLArzYStbNA_10_0"></a><a id="Tc_DgyGUI3dWke00fovb9hQ4Q_11_0"></a><a id="Tc_JLzLTvklzUaF_IpG66rVvw_12_0"></a><a id="Tc_l1h_PtgbRkeBt17GdgowdQ_13_0"></a><a id="Tc_yX821Ys_lUmPvJ7X7Pigiw_14_0"></a><a id="Tc_2t7B17HWn0uvJ81UKTqk9Q_15_0"></a><a id="Tc_ptr-0QfEgkyFvJWYjsC1zA_16_0"></a><a id="Tc_8RavS9PNjkqaPd-C0e5MAg_17_0"></a><a id="Tc_AuQCWda6-EeyF9WPO-cy5Q_17_6"></a><a id="Tc_orxBX1KOiEqhSeOzSqINBw_17_9"></a><a id="Tc_XDf7i-OmEUqGCJJlq4xm0A_18_0"></a><a id="Tc_Jl7YZCuN8k2dzjHOySU1sw_18_3"></a><a id="Tc_3n0IwtLgnk2CUobTDeqRIQ_19_0"></a><a id="Tc_S-8mChOLK0uFHo5qUqx5Sg_19_9"></a><a id="Tc_XSYHNViCV0-3JL8g2Tb6nQ_20_0"></a><a id="Tc_FdqXe_GT10G8cRLpk39WgQ_20_6"></a><a id="Tc_gFmDWKqyJU-lbbXOt25_gw_20_9"></a><a id="Tc_dhYViKsKrEmCslnYGWcxmw_21_0"></a><a id="Tc_lpwoVSHbG0WLMG8eA7J_Ug_22_0"></a><a id="Tc_igynpd7EZ0mVho6HrpzNfg_22_3"></a><a id="Tc_XMgInQ27HEyCBw91ZYrM7w_22_9"></a><a id="Tc_OgMGLkFUXUayGuZ5egZu4A_23_0"></a><a id="Tc_oId78qgSQ0CIQcCzDkwldw_23_2"></a><a id="Tc_8Q1Jvddffk2YpH9Yn7_Huw_23_5"></a><a id="Tc_t8ftHsn7IUmVZMcFQT9jIA_23_8"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_axZHcbOlgkSwmoorxCroZw" continuedAt="Tb_axZHcbOlgkSwmoorxCroZw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">12. Segment Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has&#160;<ix:nonFraction unitRef="Unit_Standard_segment_zofEUC3Xr0eG4_rh7aLMNg" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_u2Abk89eZkSQNdSi7Y6Cqg"><ix:nonFraction unitRef="Unit_Standard_segment_zofEUC3Xr0eG4_rh7aLMNg" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_W_mwjeGCgkeoyH2r4NxgxA">one</ix:nonFraction></ix:nonFraction>&#160;operating segment which is the business of researching, developing and commercializing drugs for the treatment of patients with cancer. While the Company group consists of entities incorporated in both the U.S. and Germany, the Company manages all business activities on a consolidated basis for the purposes of assessing performance, making operating decisions, and allocating Company resources. The Company&#8217;s Chief Operating Decision Maker (the &#8220;CODM&#8221;) is its President and Chief Executive Officer. The measure of segment assets is the same as reported on the consolidated balance sheets as total assets. The CODM assesses performance based on consolidated net loss that is also reported on the statements of operations and comprehensive loss. The CODM uses net loss to monitor budget versus actual results and to determine how to allocate resources and capital in line with the Company&#8217;s overall strategy and goals. The accounting policies of the Company's segment are the same as those described in <i style="font-style:italic;">Note 2. Significant accounting policies</i>.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Tb_YiH62p3iCkWn9fd-jHp4DA" continuedAt="Tb_YiH62p3iCkWn9fd-jHp4DA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The table below is a summary of segment net loss including significant segment expenses for the years ended December 31, 2025, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenue:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_zBiJ6bOlu0qlmuRS_OwhWQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc__1O2uhj6RkeMTVjCyCSlbQ_4_3">30,914</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Sale of COPIKTRA license and related assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_ycCXXJQjykqCsZOvjuthHg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_rNk346YeHESQ16LGyuc5nA_5_6">10,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of sales - product</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:CostOfGoodsSoldExcludingAmortization" scale="3" id="Tc_MtYWEA5ZMUK-2a-w2T8yzg_7_3">4,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of sales - intangible amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="Tc_nsrInbpXJkqx8bsitzONvQ_8_3">698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development expenses<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense" scale="3" id="Tc_GMqUV3gAmEe7LjHEOc4-Sw_9_3">112,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense" scale="3" id="Tc_p0VERsawskqmCaGd9L4FdQ_9_6">78,648</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q" decimals="-3" format="ixt:num-dot-decimal" name="vstm:ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense" scale="3" id="Tc_lXT_8t3j-UaYRKHtWj-EzQ_9_9">59,137</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Commercial expenses<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:CommercialExpenditure" scale="3" id="Tc_HrRLAfFsSk6BWYM-A261gw_10_3">34,316</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:CommercialExpenditure" scale="3" id="Tc_Pwe3LTZueUiJ3UdfHdGSOQ_10_6">10,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q" decimals="-3" format="ixt:num-dot-decimal" name="vstm:CommercialExpenditure" scale="3" id="Tc_hPNOtgTRzUSdEw6owja-fQ_10_9">4,164</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Medical affairs expenses<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:MedicalAffairExpenditure" scale="3" id="Tc_ORU9MWVyhEeoRFXUNldJug_11_3">11,046</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:MedicalAffairExpenditure" scale="3" id="Tc_iLoZhsahZ0aFwNHaLtpQYw_11_6">5,231</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q" decimals="-3" format="ixt:num-dot-decimal" name="vstm:MedicalAffairExpenditure" scale="3" id="Tc_UjPL9jh7GUOddiJ4FoS2Ug_11_9">2,907</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative expenses<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_EGTVfrgL0EaRqrLJNJhvnA_12_3">28,512</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc__bJ44L0Z-0qUFsgybHfZMw_12_6">21,785</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_loR9D8iDs0SRMJQ_feBBZA_12_9">19,755</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_SEFVKiXiS0KlsNTHlmd0VQ_13_3">9,405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_CciP6t9B4EOuzli0dPqvrw_13_6">7,342</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_vEns4urpgki0kB7LsgJZig_13_9">5,860</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_D-E3LlnB70m27qTREBkqjw_14_3">32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_7CcnGyidM06ZvaVorJIdWw_14_6">26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_b3c1qW6mD0ixFRfaBnGnag_14_9">62</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_13Y8A-61OUam9NPuPkfw_Q_15_3">4,068</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_Ymdw5TlXDEK0StltKofdFQ_15_6">4,149</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_gY-YKFQ_v0uqnASCicyDrQ_15_9">6,214</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="Tc_zDEcHcBIEk2YVlHjwLmM4g_16_3">1,138</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="Tc_q3G-zoxKvUSKPc8NJOhKsA_16_6">4,562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="Tc_b8TrASQKg0u3sqkIJ_SqjQ_16_9">4,139</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_DSBFpvSQRUO6-YEL3U5akA_17_3">1,826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of preferred stock tranche liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:IncomeLossFromPreferredStockTrancheLiability" scale="3" id="Tc_kvjvBjhg-keGcDjc17ZLvw_18_6">4,189</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q" decimals="-3" format="ixt:num-dot-decimal" name="vstm:IncomeLossFromPreferredStockTrancheLiability" scale="3" id="Tc_ala7IRR3o0621qZvJY_M4w_18_9">2,751</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_1hg1P4gE_UaNwbjEHNB6-w_19_3">27,492</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_NBiTQoB1zkGO5szeAysNWA_19_6">19,149</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:FairValueAdjustmentOfNotes" scale="3" id="Tc_WJePc459bUynUF8LB4UQog_20_3">12,751</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_lV6OThNLUka459E0K8DJEw_21_3">572</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_TE31y9lh4U-Lstzyx_ntDQ_21_6">1,113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_jy6N9rS1pU-JdkZRPkdmsQ_21_9">308</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_DnzqTHDYG0Sen1T6WSM9lw_22_6">185</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_vtObeuLDIEGkFesDmzVmiA_23_3">209,471</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_r_19QD-kWk6dO-oqFBk4kg_23_6">130,637</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_JP9lBpLjyUSByY3Yiuu24w_23_9">87,367</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This category is exclusive of non-cash stock-based compensation and severance expense.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_FbFXiW040kaEn2tmYpAOeA"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_-EqtGj3DqUG7IaaT7xzGBw"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_Z4S1r6lINUORzcvYub4qwA"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other segment items primarily include severance expense and transactions losses and gains due to foreign currency fluctuations.</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-41</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_axZHcbOlgkSwmoorxCroZw_cont1"><ix:continuation id="Tb_YiH62p3iCkWn9fd-jHp4DA_cont1"></ix:continuation></ix:continuation><a id="Tc_qA_KJe_0Q0eBytZlZ1o6bw_1_2"></a><a id="Tc_pLG-hppM_0ejw0R3V3-ajQ_2_2"></a><a id="Tc_wApSssUGqk2HDC_EqxR7aw_2_4"></a><a id="Tc_YipxGwKk3UCAQnKV_hjUFw_2_6"></a><a id="Tc__na5b8tnlUm1q5F2YLWfCQ_3_0"></a><a id="Tc_m4sWLppmdEGyrdxwGlPvWA_4_0"></a><a id="Tc_HYprTgRJGU6RrmrxRvLNhg_5_0"></a><a id="Tc_CgSNsEoqF0ezEPOd6GfmVA_5_6"></a><a id="Tc_jTc12acIL0iEORGKLAkizg_6_0"></a><a id="Tc_GyMcgekjrkq762UM9PJ8Hw_7_0"></a><a id="Tc_BEaBeYV0CUmajvLtx7Hs3A_7_2"></a><a id="Tc_MH49BdMYLU2PQOyHh6xRsw_8_0"></a><a id="Tc_MIZTS4H1c0mxH46LokqXng_8_2"></a><a id="Tc_Uh_-Qc3orU-1ll74qNMmEg_8_4"></a><a id="Tc_DHqxMWpgxk6hAma2uhGuZQ_9_0"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:EarningsPerShareTextBlock" id="Tb_4ucU2zRLhkagdEOsOg_bjg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">13. Net Loss per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ASC Topic 260, <i style="font-style:italic;">Earnings Per Share,</i> requires the Company to calculate its net loss per share based on basic and diluted net loss per share, as defined. Basic EPS excludes dilution and is computed by dividing net loss by the weighted average number of shares outstanding for the period. For the years ended December 31, 2025, 2024, and 2023 net loss, basic and diluted EPS are the same as the assumed exercise of stock options, RSUs, ESPP, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Warrants are anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_HnXq2GXmlk6seKtHHwQddA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:50.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_YnZ3x6uu-0Wme4Fzg28ezw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_sbalBEZVSU6qfXydAiXmRw_3_2">3,030,432</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_NV4P7J5B-UKwUVnwqEP6NQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_cTSfVlQNJEuzS6WN_rrJKw_3_4">2,479,037</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_xY-UvU2IMkukHRCrwlS71A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_fgp-C1K1GEef0uKCOlOZdw_3_6">2,270,359</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_2Bs0lZ91y0Cmf6Th8FtUgg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_lTUhwSMHRkK-BL-yyBdVKQ_4_2">1,313,898</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_YJkjgHtK7UWwDuHpo_dJVg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_keyBdZNHZ0aeyYEDli7Jxw_4_4">1,010,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Q-P8zB2YJ0Gd2Zv66vU9Sw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_eo1A8eienU-Q8w4ws5xO2Q_4_6">209,289</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_haNRViJSzEOTdDWixSwWZQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_32NyF2Z9a0a_P2iHwVohCQ_5_2">8,429,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_nET5C9dUgUCwg9L0-kWvkg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_PQ6EHYQJlkqhUPQ2Q8ncXQ_5_4">18,083,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_GHWd8K1WG0u-Q7uzXgEt8A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Vh_nwz_liEeNP4tg_dB_0Q_6_2">10,240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_Z7vMySuKckCsJVbZ8qZDQg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_G7_gBsdnqEee2VhZvXaujQ_6_4">8,033</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_-x24TYsG3USzRfi7iWlv3A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ySlHuF5WPkSRPUX5FES0Mw_6_6">7,475</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A Convertible Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_V8o_TMafXU69pWaNyC7oHA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_-gPa2DrPkEWb39t0uwuzEw_7_4">833,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_eu_9_6CHf0y-Lj52IH4byw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_VqivyjaYvkCz3d8RQa4biA_7_6">833,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B Convertible Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_UVwviP4qFk2O79hJ4CkV4Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_4GM7yK7V5UuB1JyzqmSn7A_8_6">4,236,570</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total potentially dilutive securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_qQwQPxSrNUW7hV-5oOAa1A_9_2">12,783,736</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_tJ1oyf8rfUCkLR45vQ-Saw_9_4">22,413,970</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_sM7aXEdHPEq2KgY-y0prpQ_9_6">7,557,026</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_3ce0d9c7_601f_4ead_89ab_60ddd3009547"></a><a id="Tc_lTsX6lmg4EakLjhj4J7iaQ_1_2"></a><a id="Tc_rR0Z2MpFbkCmCTd2U7vswQ_2_2"></a><a id="Tc_Ghb8MJyPx0iIRILCs3Cbpg_2_5"></a><a id="Tc_W0sRfgBu_0am3N60YPMI_A_2_8"></a><a id="Tc_Vvj-XVIEWEywfWfxlvB5Xw_3_0"></a><a id="Tc_bES2N5lw3E6fNCE6bw3jXQ_4_0"></a><a id="Tc_mcaNBMcGBkiOgEbv5yNmzw_4_2"></a><a id="Tc_xrqp4476qUW4DQuECq-c3g_4_3"></a><a id="Tc_fORCvZFelEy_6cM89GDeGw_4_5"></a><a id="Tc_F5Kpj1VOtUK1c4OrtXeisQ_4_8"></a><a id="Tc_En6LFKC1S0ysq0IETBS_zg_4_9"></a><a id="Tc_nVWzly2GaUmmfsYWN1KDzw_5_0"></a><a id="Tc_b2vAP5k3Q06_HJ2fh77WbA_5_3"></a><a id="Tc_26QKYiZLdEGcWFBITjhjdA_5_6"></a><a id="Tc_isJpC94SCk2JKJRHIa2QpQ_5_9"></a><a id="Tc_ajPYakqEYUut4SDy6uI0NA_6_0"></a><a id="Tc_FCLCrt1E_0OXLDd_SbPnfw_6_3"></a><a id="Tc_5iCYKb24pEGyro8heSpmNQ_6_9"></a><a id="Tc_bevXQsEfdUCbI0U9BXTO4g_7_0"></a><a id="Tc_qWTzbB_ARUKrISMXT5x1ng_8_0"></a><a id="Tc_a1TSpPdzAESHEn07ScuSQA_8_3"></a><a id="Tc_LLpB3ZSmj0CL5hqkJuMohQ_8_6"></a><a id="Tc_KjG0DnvywEGvf1iQVp3UgQ_8_9"></a><a id="Tc_OjTpIpcKnEeg3Zd20osdgQ_9_0"></a><a id="Tc_MEN9s_0BrkCV8NMqBHFZUQ_9_3"></a><a id="Tc_oMFlYcId30mDco19byZKxg_9_6"></a><a id="Tc_6TGCgCCQvU6FmruRQGj_RQ_9_9"></a><a id="Tc_qikoKrYL7UKxX3OWLAgvUg_10_0"></a><a id="Tc_RUbr3IpliE-UR0HM9Krovw_10_3"></a><a id="Tc_Thw_lEip5ECMMVXgZxqHKw_10_6"></a><a id="Tc_9Vh_a4qgBUmowPmMMwUE7g_10_9"></a><a id="Tc_mf7XfJf4AU-lhZWtJzMd_w_11_0"></a><a id="Tc_6XINDiGSK0ikzlWqXhd0wA_11_2"></a><a id="Tc_c7t-vJghRE67g3y23GYP9Q_11_3"></a><a id="Tc_H3_9lbIB6kSj7Kd7uqftdA_11_5"></a><a id="Tc_zD3RUx_X8ES34gNxCWNDvg_11_8"></a><a id="Tc_TOkORFFT8U6srPnEO5B9Bw_11_9"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_Xkma-fCafUWRkdh6gcPUyg" continuedAt="Tb_Xkma-fCafUWRkdh6gcPUyg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">14. Income Taxes </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">There was no income tax expense for the years ended December 31, 2025 and 2023. The Company recorded income tax expense of </span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_X9s9h67n2Umyci3F1L5Mdw">0.2</ix:nonFraction></span><span style="color:#212529;"> million for the year ended December 31, 2024 comprised of a federal income tax payment due to interest under IRC section 453A related to the </span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_5ZISHrVDkE2EvnOvhrL_rA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra" scale="6" id="Narr_b_N1ThXiN0yBSbc0VJI0Ag">10.0</ix:nonFraction></span><span style="color:#212529;"> million milestone payment from Secura because it was an installment sale. This payment was made in 2025. Refer to </span><i style="color:#212529;font-style:italic;">Note. 16. License collaboration and commercial agreements</i><span style="color:#212529;"> for further discussion of the Secura APA</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_lqIBBuCLSUu8tYEvgf__VA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">For the years ended December 31, 2025, 2024, and 2023 income tax expense consisted of the following (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:45.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current income tax expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="Tc_PMOCTKftCUiVmMl8pTLFpg_4_6">185</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_qIP_xcdoAEqogIDXHBR6hw_6_6">185</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total income tax expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_JtJaDQay4k2pJ3Wad0fMgA_11_6">185</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">As further described in&#160;<a style="-sec-extract:exhibit;color:#000000;font-family:&quot;&quot;'Times New Roman','Times','serif'&quot;&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Note&#160;</i></a><a style="-sec-extract:exhibit;color:#000000;font-family:&quot;&quot;'Times New Roman','Times','serif'&quot;&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">2,</i></a><a style="-sec-extract:exhibit;color:#000000;font-family:&quot;&quot;'Times New Roman','Times','serif'&quot;&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">&#160;Summary of Significant Accounting Policies</i></a>, the Company elected to prospectively adopt the guidance in ASU 2023-09.&#160;The following table is a reconciliation of our effective income tax&#160;rate to the statutory federal income tax&#160;rate for the year ended December&#160;31, 2025 in accordance with the guidance in ASU 2023-09:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Group_ALVbksKW-UCZgvbAvdz9-w" continuedAt="Group_ALVbksKW-UCZgvbAvdz9-w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-42</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_FmTksXmHrEmqXM4ckSzvHA_2_2"></a><a id="Tc_CCCE150ogEOXl27Mb2TpvA_3_3"></a><a id="Tc__4kbon-cfEWlKgYT691vYA_3_5"></a><a id="Tc_Sg_Ii0_OXUyPEmE4iMj8gQ_5_0"></a><a id="Tc_Gi2kf_UNoUqb2iutajfdyg_5_2"></a><a id="Tc_BBkEbyxsXUG-O4AqvzNOZg_7_0"></a><a id="Tc_uiM_APAosUWAD6r59c2y-w_7_6"></a><a id="Tc_J_CPwNcXu0y4pJPSsmuBHQ_8_0"></a><a id="Tc_F12pgQSdlU6fLodK4bW1Tg_8_3"></a><a id="Tc_Cqc5jh6Nk0Sz_9ZkNJa4Ow_8_5"></a><a id="Tc_J1cei0vjfkGzzTm_euXRjQ_8_6"></a><a id="Tc_OqmrGsDM-ka1hHpngrvQ1Q_9_0"></a><a id="Tc_ytXLXES5p0-k8vuTb--suQ_10_0"></a><a id="Tc_ojkh4SW-M0Coo2rEFTULMQ_10_6"></a><a id="Tc_7qbvEiGLzEqvIJHEgUX_Og_11_0"></a><a id="Tc_fCZKLEZUN02Y-7UeyMNYXA_11_6"></a><a id="Tc_QDNGiOaWEUClgO6Kt-AcvA_12_0"></a><a id="Tc_0dt5olc2okqrHT0pqdS2gg_13_0"></a><a id="Tc_pH0CqE0_wEyefillBu-8IQ_13_6"></a><a id="Tc_tp5LPOPaAUSZrIxzlN30BQ_14_0"></a><a id="Tc_Szv5W7EeYU27Z3cFnogaWA_14_6"></a><a id="Tc_Puws5RAaUE-5tpsVXfBP1Q_15_0"></a><a id="Tc_LJRmsk72R0iTb2_x2XlNoA_15_6"></a><a id="Tc_jpLpj8-qgE2FBb6B5-G-Gw_16_2"></a><a id="Tc_PYDTWCwDwECO10ADvXORhQ_16_3"></a><a id="Tc_03KzFnmKEEGAE1Bm83Dg4g_16_5"></a><a id="Tc_dV-oPi-OpE2TQOg8xLOc-w_16_6"></a><a id="Tc_Db0y5Rwm9kSGmo0_D1k4yA_1_3"></a><a id="Tc_PAUJfNsdS0ulkvIqFhAX6w_2_0"></a><a id="Tc_Oc3QVMN-8kKDDuOOzj_bAw_2_4"></a><a id="Tc_4deun8dPz0mzqauV-SCzww_3_0"></a><a id="Tc_XjcfHKq1lEqrDyIcyimfIA_3_4"></a><a id="Tc_r7o-ZM3Q2kCihUUcrd8y6w_4_0"></a><a id="Tc_Ai2k7eIN0kqSG9Z_55N0nQ_4_4"></a><a id="Tc_wSyY1G0eKEKoi5VKMRh31g_5_0"></a><a id="Tc_ox6exvnh4k6s6SPWAQFrSQ_5_4"></a><a id="Tc_L3tyzczXf0eTZcOVwtIrkQ_6_0"></a><a id="Tc_nnwip_WxI0e4r9pbb1-4pw_6_4"></a><a id="Tc_2_amEvPX4EiPmFHZJuQwmg_7_0"></a><a id="Tc_Ew-mSolnZEyq1OB7hdNcYA_7_4"></a><a id="Tc_P-437RVANEuBLOoHue_RaQ_8_0"></a><a id="Tc_teHmpx5Y5kuL2-uL7HHmFQ_8_4"></a><a id="Tc_cYfzA65kM0u6CEbmnEv3kA_9_0"></a><a id="Tc_khrK3C2m30G_m7H_82CNeQ_9_4"></a><a id="Tc_CkgXCNd2WUmI0vGzx0610g_10_0"></a><a id="Tc_iRVqnntlwEebvbG-JWdJhA_10_4"></a><a id="Tc_nvkeQqql6EO2j2znb4rpWQ_11_0"></a><a id="Tc_u0wQzYc9AUGS3YqFedfoig_11_4"></a><a id="_c3e821ad_e801_4bf5_b50a_e76f90495e38"></a><a id="Tc_t1IqpRFhiUiir_BdbrdwWQ_1_2"></a><a id="Tc_94OchFrFOE2rri-DzKkjyA_2_2"></a><a id="Tc_mJHYD3gyfkS_sNoLwQj8eg_2_5"></a><a id="Tc_v1Lapw75m0udVEqbqRcpMA_3_0"></a><a id="Tc_6FLqb9DmFECLOd0fb-WrCg_4_0"></a><a id="Tc_o_8UhSliiUaicaL4kDW7og_4_2"></a><a id="Tc_-E_BEqtUOUK3IKXY_pUfyQ_4_5"></a><a id="Tc_nM6NXbnpb0uXtlQ-PLYLUQ_5_0"></a><a id="Tc_JJe-S7V0d0anBW3p_NadCg_6_0"></a><a id="Tc_y-bzpWWJNE2eUD7VQzH9FA_7_0"></a><a id="Tc_e7uPCErDnU2KuM9VN7UA9g_8_0"></a><a id="Tc_h_QbgsPOJk2h5MbUOu-LMA_9_0"></a><a id="Tc_KfIZcFQ3lEqwAYOrT6rJDA_10_0"></a><a id="Tc_z9rbCJctLESMmSGOXxPRSg_11_0"></a><a id="Tc_vQ2ISvFhR0WvvvF9P6k8Jw_12_0"></a><a id="Tc_hogVrmrEmUm6Kg00KP0TVg_13_0"></a><a id="Tc_L4uwfRYi50qnmRWXUSVGHw_14_0"></a><a id="Tc_YlJvO5t_sku7YsCbXoJTJg_15_0"></a><a id="Tc_Ku_FhWCqo0qEiQ2i22zxMQ_16_0"></a><a id="Tc_4IKiKAxS7EmnRdqstSpUKQ_17_0"></a><a id="Tc_ds5_c6C3sEWDDG1GkBKwzg_17_2"></a><a id="Tc_9fJI2XYsAEWCKHYRz8ZazA_17_3"></a><a id="Tc_KPGPkPB_m0ClLs0JtOT_Hw_17_5"></a><a id="Tc_oW_wNuTaBUODY8qc-EjpcA_17_6"></a><ix:continuation id="Tb_Xkma-fCafUWRkdh6gcPUyg_cont1" continuedAt="Tb_Xkma-fCafUWRkdh6gcPUyg_cont2"><ix:continuation id="Group_ALVbksKW-UCZgvbAvdz9-w_cont1" continuedAt="Group_ALVbksKW-UCZgvbAvdz9-w_2"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, 2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pretax loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_yDvz-B7Zsk-DjvRs7g5_Yg_5_3">209,471</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="3" id="Tc_T_SlRC1Oy0mjuDOzRWVHCg_7_3">43,989</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_7rab0HbaG0-ojjX1JkLz4w_7_5">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local income tax benefit, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="Tc_MZ9yOG-NeUuhmo38S090yw_10_3">9,710</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" sign="-" scale="-2" id="Tc_voIN49gRnkmN9mWOTikIIg_10_5">4.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in the valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="Tc_OcsX9iUIDEmHls1racs4tQ_11_3">45,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_4vMwqHf-jU6R4LOAJAXCkg_11_5">21.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nontaxable or nondeductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="vstm:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount" scale="3" id="Tc_LM1pVITVr0CTSf9jmPVCEA_13_3">5,773</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="3" format="ixt:num-dot-decimal" name="vstm:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent" sign="-" scale="-2" id="Tc_gDW4dQZznk6qHu1hqjAgiQ_13_5">2.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="Tc_0ID9cQGUkUeeAD9LDKfFvg_14_3">698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" sign="-" scale="-2" id="Tc_2KNiTIgVC0uNFqOm3GsVsw_14_5">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="Tc_nRiqIIz41E6z9EgfOva9dQ_15_3">1,828</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" sign="-" scale="-2" id="Tc_Ozhrkyiqo0mZ-bm0x-puIQ_15_5">0.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_0gfH3kQvRkeG5SIGukyrFQ;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Effective income tax rate</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table is a reconciliation of the Company&#8217;s effective&#160;income tax&#160;rate to the statutory federal&#160;income tax&#160;rate for the year ended December&#160;31, 2024 in accordance with the guidance prior to the adoption of&#160;ASU 2023-09:</p><ix:continuation id="Group_ALVbksKW-UCZgvbAvdz9-w_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax benefit using U.S. federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_qC8lJzlemkOnwQYvklmHoQ_2_3">21.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State tax benefit, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_LhSF8zbXYE2lhb4N9dolQQ_3_3">2.92</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" sign="-" scale="-2" id="Tc_VLxbOLstmEexvcdGm2EMvA_4_3">4.56</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" sign="-" scale="-2" id="Tc_F_DXnNnQ4E2UBQ2uxSjZ9w_5_3">1.91</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_J4tmjwdAbEmXc0hXGge-pg_6_3">2.88</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in the valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_8ljs_cAQj0qRrfGS-kD2Sw_7_3">14.59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax law change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="Tc_tYLkxIsFZUGKKL-TXR_n1w_8_3">6.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NOL and tax credit expiration under Section 382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="4" format="ixt:num-dot-decimal" name="vstm:EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent" sign="-" scale="-2" id="Tc_GXljHGvg2kiZycWZF4QutA_9_3">44.44</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" sign="-" scale="-2" id="Tc_eloNALWgMkqW-Avuq9DW7Q_10_3">0.18</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Effective income tax rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_JEgnAd0zUUiwsnVo3FwMcw_11_3">0.14</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_S8ml_et65ESBt073FgcCZQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The principal components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_4QPGauZQLkeqL5csqLmy_w_4_3">101,083</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_Pz5u2nYbu0ugUm1maN3sqA_4_6">81,151</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="3" id="Tc_Xxs3U30TPkKBs_I4CJ_YWA_5_3">52,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="3" id="Tc_eTqku-iSg0m-Tow70sKIag_5_6">38,478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_9YVwLhwLgEe74f3SrZBwWA_6_3">12,850</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_01GIOnYMVECcr_9KLtc1LA_6_6">2,786</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_rmRKyMfQnUyDBIK-E_3TXQ_7_3">2,902</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_msW5NFgQlkuPbPekFzb2Tw_7_6">2,762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Installment sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:DeferredTaxAssetsInstallmentSale" scale="3" id="Tc_-SWX9U2iSUWW8G9M7rvPSA_8_3">7,187</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:DeferredTaxAssetsInstallmentSale" scale="3" id="Tc_p8BKvKKl9UWNHDYuWgVQHg_8_6">7,652</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:DeferredTaxAssetsLeaseLiability" scale="3" id="Tc_JUu6k2HKrkeE7iX9tJbHUA_9_3">130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:DeferredTaxAssetsLeaseLiability" scale="3" id="Tc_rHCsUet8gkSm9veOzhIs7A_9_6">395</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_lPVJWqx76UuITXY8LUMgyA_10_3">2,408</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_UW_IJeOma0OA2yGUbs9CQQ_10_6">462</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_1Or8C6DjC0-eo7yRNvefag_11_3">179,447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_mjTgerJywECYYYS2SOpsrw_11_6">133,686</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="Tc_KkhqT60Bdk6vFMKyGyE1rA_13_3">119</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="Tc_VZN4WvpQA0OYxiB3Uoe9Sg_13_6">362</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_cqpSVs6QNEGRLE1JofQUYA_14_3">119</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_UVSAKUYJ6Em6FAvNSqCx1g_14_6">362</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax asset prior to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance" scale="3" id="Tc_EApijdg5hkWvySOyOHwUzw_15_3">179,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="vstm:DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance" scale="3" id="Tc_L0dX8_50LUOf7J572tZWTA_15_6">133,324</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_yyahlFJ1Q0G6J7Vbxmyi7A_16_3">179,328</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_W_DCXFAx2kuxYzv7wqwQnw_16_6">133,324</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net deferred tax asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-43</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Xkma-fCafUWRkdh6gcPUyg_cont2" continuedAt="Tb_Xkma-fCafUWRkdh6gcPUyg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has recorded a valuation allowance against its deferred tax assets at December 31, 2025 and 2024 because the Company&#8217;s management believes that it is more likely than not that these assets will not be fully realized. The increase in the valuation allowance of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_BEM8HDjGpE2WvgsZNetx2Q">46.0</ix:nonFraction> million in the year ended December 31, 2025, primarily relates to federal and state NOLs and credits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, the Company had federal and state NOL carryforwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_M65DxSkBeUWXwkv5yp4KTw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_5bOFCCgFEku18e2fCmOcvQ">460.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_EMxewkfryEW0MgeN6Ed9RQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_tRqw2re8dkC_X0z1UgKN6Q">99.5</ix:nonFraction> million, respectively, which are available to reduce future taxable income. The Company also had federal and state tax credits of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_M65DxSkBeUWXwkv5yp4KTw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_z-2GNnnfnUKwvY0loOOZ3g">12.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_EMxewkfryEW0MgeN6Ed9RQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_A3aVj0SMjEW7g2xuLNHqwg">0.7</ix:nonFraction> million, respectively, which may be used to offset future tax liabilities. The NOL and tax credit carryforwards will expire at various dates through 2045, except for $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_M65DxSkBeUWXwkv5yp4KTw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:OperatingLossCarryforwardsIndefinitePeriod" scale="6" id="Narr_n_CjYcCqekakmBMo3WpPwQ">423.3</ix:nonFraction> million of federal <span style="color:#212529;background:#ffffff;">NOL carryforwards which may be carried forward indefinitely. </span>Section 382 and 383 of the IRC and similar provisions under state law limit the utilization of U.S. NOL carryforwards, state NOL carryforwards, R&amp;D credits, and OD credits following certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%. During 2024, the Company believes it triggered ownership changes under Section 382 of the IRC and similar provisions under state law. Based on the Company&#8217;s analysis under Section 382, the Company believes that its federal NOL carryforwards, its state NOL carryforwards, R&amp;D credits, and OD credits are limited by Section 382 and similar provisions under state law as of December 31, 2025. The portion of federal NOL carryforwards, state NOL carryforwards, R&amp;D credits, and OD credits that were determined to be limited have been written off as of December 31, 2025. The remaining unused carryforwards and credits remain available for future periods. The Company has approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:OperatingLossCarryforwardsPriorToOwnershipChanges" scale="6" id="Narr_Fz_f-rsGAkGeKkL-6p_Kcg">346.4</ix:nonFraction> million of federal NOLs generated prior to such ownership changes inclusive of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:OperatingLossCarryforwardsInclusiveOfOwnershipChanges" scale="6" id="Narr_x1KjSe7cjken655z8Qmsgg">309.3</ix:nonFraction> million of federal NOLs <span style="color:#212529;background:#ffffff;">which may be carried forward indefinitely. Since the </span><span style="color:#212529;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:OperatingLossCarryforwardsInclusiveOfOwnershipChanges" scale="6" id="Narr_4YbLVzHN60uS7Lwzwxrk2g">309.3</ix:nonFraction></span><span style="color:#212529;background:#ffffff;"> million of federal NOLs may be carried forward indefinitely, these have not been written off as of December 31, 2025, but due to the limitations under Section 382 generally the Company can only use </span><span style="color:#212529;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:OperatingLossCarryforwardsSection382Limitation" scale="6" id="Narr_QnnDUpFdbEOw190IRYE4fQ">1.6</ix:nonFraction></span><span style="color:#212529;background:#ffffff;"> million per year against taxable income in the future. </span>Due to the Company&#8217;s full valuation allowance the write off of certain NOL carryforwards and R&amp;D and OD credits did not have any impact to the statements of operation and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) requires taxpayers to capitalize and amortize research and development (&#8220;R&amp;D&#8221;) expenditures under section 174 for tax years beginning after December 31, 2021. This rule became effective for the Company during 2022. The Company is amortizing these costs for tax purposes over <span style="-sec-ix-hidden:Hidden_UdxKXO7ke0C6w3GjR8sZiQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span> years for R&amp;D performed in the U.S. and over <span style="-sec-ix-hidden:Hidden_gx1jXOcOUEaYyXuc-ygToQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15</span></span> years for R&amp;D performed outside the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">The One Big Beautiful Bill Act ("OBBBA") was passed and became effective for the Company during 2025. The legislation includes, among other provisions, permanent full expensing for certain business assets, changes to the interest deduction limitation under Section 163(j), amendments to international tax provisions including the global intangible low-taxed income (&#8220;GILTI&#8221;) and foreign-derived intangible income (&#8220;FDII&#8221;) regimes, the permanent extension of the controlled foreign corporation (&#8220;CFC&#8221;) look-through rule, as well as modifications to the treatment of research and development expenditures mentioned above.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">Congress modified the treatment for research and development expenditures by adding new Section 174A, which applies for tax years beginning after December 31, 2024. Section 174A permits the immediate deduction of domestic R&amp;D expenditures or, at the taxpayer&#8217;s election, capitalization and amortization over a period of at least five years beginning when the related benefits are first realized. Foreign R&amp;D expenditures continue to be capitalized and amortized over 15 years. Transition provisions allow taxpayers either to continue amortizing amounts capitalized under the TCJA rules or to deduct remaining unamortized domestic R&amp;D expenditures in the first tax year beginning after December 31, 2024. The Company has elected to continue amortizing previously capitalized domestic R&amp;D expenditures over the remaining amortization period permitted under OBBBA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">On October 4, 2023, Massachusetts enacted tax law changes which included the adoption of a single sales apportionment factor effective on January 1, 2025. On December 4, 2024, Massachusetts subsequently enacted supplemental legislation modifying Massachusetts' single sales apportionment factor in certain circumstances. As required under ASC 740, the Company has accounted for the deferred tax impacts of this tax law change in the period the tax law was enacted. The impact of the tax law change is offset by a change in valuation allowance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s reserves related to taxes are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. From inception and through December 31, 2025, the </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-44</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Xkma-fCafUWRkdh6gcPUyg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Company had <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_W3yA4h-JD0OOfQcFGujI8Q">no</ix:nonFraction> unrecognized tax benefits or related <span style="-sec-ix-hidden:Hidden_7alXqiLFbU--YfYHWYlRNA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interest</span></span>, and penalties accrued. The Company has not conducted a study of R&amp;D credit and OD credit carryforwards. A future study may result in an adjustment to the Company&#8217;s R&amp;D credit carryforwards; however, until a study is completed and any adjustment is known, <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" scale="3" id="Narr_c6kUPEA-XEOaZrRzwcWkqQ">no</ix:nonFraction> amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s R&amp;D credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or statement of operations if an adjustment were required. The Company would recognize both accrued interest and penalties related to unrecognized benefits in income tax expense. The Company&#8217;s uncertain tax positions are related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_qSvFppiGn0aQmts7oYl7KA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15. Commitments and contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a lease agreement for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_FdbiNq8DNkeaOGqvsWqN6A" contextRef="As_Of_2_15_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_xJV-v7FV5UyE4Ztk9gpPcA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_pZuwAYzNgUSmBa03KzrK3A">27,810</ix:nonFraction> square feet of office space in Needham, Massachusetts.&#160;Please refer to <i style="font-style:italic;">Note 9. Leases </i>for further details regarding the minimum aggregate future lease commitments as of December 31, 2025. In&#160;conjunction with the execution of the February 2018 Amended Lease Agreement and November 2024 Amended Lease Agreement, the Company has provided a security deposit in the form of a letter of credit in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_us-gaap_BalanceSheetLocationAxis_vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_10pAZepk4k-KD0pKIdmI3Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="6" id="Narr_j4Nt916JV0Op6w0ow7MTGg"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_BalanceSheetLocationAxis_vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_ursq9MeRN0yWn5gbwLYHOg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="6" id="Narr_IC3-28NonEupuQYupgoxQg">0.2</ix:nonFraction></ix:nonFraction> million as of December 31, 2025, and 2024.&#160;The amount is included in non-current restricted cash on the consolidated balance sheets as of December 31, 2025, and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">As of December 31, 2025, the Company has committed to spend approximately </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_vstm_IqviaIncMember_sAB2nn3xb06KIRwK0qRhxA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherCommitment" scale="6" id="Narr_UqB8p4xzDECPbK61XWyt6A">48.1</ix:nonFraction></span><span style="background:#ffffff;"> million under the IQVIA Master Services Agreement which the Company expects to spend in the next two to three years. As of December 31, 2025, </span>approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_vstm_IqviaIncMember_us-gaap_BalanceSheetLocationAxis_vstm_AccountsPayableCurrentMember_EPTDxkm6dUGE_Y2j9gCeGg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherCommitment" scale="6" id="Narr_AIwKFm7hS0ONUTfsTOWTlg">13.7</ix:nonFraction>&#160;million of this commitment is included within vendor financing arrangements, accrued expenses, and accounts payable on the consolidated balance sheets.&#160;Pursuant to the terms of various other agreements, the Company may be required to pay various development, regulatory and commercial milestones. In addition, if any products related to these agreements are approved for sale, the Company may be required to pay significant royalties on future sales. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurring.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="vstm:LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock" id="Tb_uqNYEUMhiEWaquKFPBo2kA" continuedAt="Tb_uqNYEUMhiEWaquKFPBo2kA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">16. License, collaboration and commercial agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pfizer, Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On July&#160;11, 2012, the Company entered into a license agreement (the &#8220;Pfizer Agreement&#8221;) with Pfizer (&#8220;Pfizer&#8221;) under which Pfizer granted the Company worldwide, exclusive rights to research, develop, manufacture and commercialize products containing certain of Pfizer&#8217;s inhibitors of FAK, including defactinib, for all therapeutic, diagnostic and prophylactic uses in humans. The Company has the right to grant sublicenses under the foregoing licensed rights, subject to certain restrictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Upon entering into the Pfizer Agreement, the Company made a one-time cash payment to Pfizer in the amount of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_7_11_2012_To_7_11_2012_srt_CounterpartyNameAxis_vstm_PfizerIncMember_BItiDfIFn0WcHJLqHz3mqw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:CollaborativeArrangementsOneTimeCashPayment" scale="6" id="Narr_ZzKe_pPeE0ee_y71j0pv7A">1.5</ix:nonFraction></span><span style="background:#ffffff;">&#160;million and issued </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_7_11_2012_To_7_11_2012_srt_CounterpartyNameAxis_vstm_PfizerIncMember_BItiDfIFn0WcHJLqHz3mqw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_PLU6nhbT3kenrl1t8x7tNA">16,001</ix:nonFraction></span><span style="background:#ffffff;"> shares of its common stock. In April 2025, the Company entered into an amendment to the Pfizer Agreement such that a </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_srt_StatementScenarioAxis_vstm_AchievementOfFdaApprovalMember_tZQwQiMhYEqbPdhEQQ5HEg" decimals="-5" format="ixt:num-dot-decimal" name="vstm:PotentialMilestonePayments" scale="6" id="Narr_YZ0jjP1-1Eus1JCP0Yv5zg">7.5</ix:nonFraction></span><span style="background:#ffffff;"> million milestone became payable upon FDA approval of AVMAPKI FAKZYNJA CO-PACK on May 8, 2025 (the &#8220;First Pfizer Milestone&#8221;), and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_srt_StatementScenarioAxis_vstm_AchievementOfFdaApprovalAnniversaryMember_xTJSoxkVBEah1aNhnYblRg" decimals="-5" format="ixt:num-dot-decimal" name="vstm:PotentialMilestonePayments" scale="6" id="Narr_Ou3APzVRxkeHI-fE4E--kA">8.0</ix:nonFraction></span><span style="background:#ffffff;"> million milestone (the &#8220;Second Pfizer Milestone&#8221;) is payable upon the one-year anniversary of the FDA approval of AVMAPKI FAKZYNJA CO-PACK. The Company recorded a </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_6KQR_VTJyEGtpgOTeeNfig" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="Narr_XIn-mKgYYUC0lzF4XPb6_w">15.0</ix:nonFraction></span><span style="background:#ffffff;"> million intangible asset related to these payments on the consolidated balance sheets and will record </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_4_1_2025_To_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_QSij2lq4ik6s4CjD_2yz9A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="6" id="Narr_rUjGt1UzuU67XfjUj2A-lA">0.5</ix:nonFraction></span><span style="background:#ffffff;"> million of interest expense related to the Second Pfizer Milestone. </span>Pfizer is also eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_srt_StatementScenarioAxis_vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_o3q236vw0keqOsqNBTnifA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:PotentialMilestonePayments" scale="6" id="Narr__9CtRLmHFEWuhUQ9N7EM2g">2.0</ix:nonFraction>&#160;million in developmental milestones and up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_srt_StatementScenarioAxis_vstm_AchievementOfCertainSalesMilestonesMember_31ejtZ8BeEqgLwzBvmRC6g" decimals="-5" format="ixt:num-dot-decimal" name="vstm:PotentialMilestonePayments" scale="6" id="Narr_ub-U_3HMuUesuNF6q3Q8mw">110.0</ix:nonFraction>&#160;million based on the successful attainment of regulatory and commercial sales milestones. <span style="color:#212529;background:#ffffff;">The future milestone payments are contingent in nature and will be recognized if and when the respective contingencies are resolved. </span>Pfizer is also eligible to receive high single to mid-double-digit royalties on future net sales of the products. The Company&#8217;s </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-45</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk192847511"></a><ix:continuation id="Tb_uqNYEUMhiEWaquKFPBo2kA_cont1" continuedAt="Tb_uqNYEUMhiEWaquKFPBo2kA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">royalty obligations with respect to each product in each country begin on the date of first commercial sale of the product in that country, and end on the later of <ix:nonNumeric contextRef="Duration_4_1_2025_To_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_QSij2lq4ik6s4CjD_2yz9A" format="ixt-sec:durwordsen" name="vstm:CollaborativeArrangementsRoyaltyObligationsTerm" id="Narr__1n89cEUfEGU6nOQKs3Vpw">10 years</ix:nonNumeric> after the date of first commercial sale of the product in that country or the date of expiration or abandonment of the last claim contained in any issued patent or patent application licensed by Pfizer to the Company that covers the product in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the second quarter of 2025, the Company entered into an agreement with a third party to obtain an exclusive license for certain patents and intellectual property related to avutometinib and defactinib (the &#8220;License Agreement&#8221;). This agreement covers <ix:nonFraction unitRef="Unit_Standard_item_5quK1hZThku2W0bLLpUodA" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_ouTeCHDu4Ey5RJk0ycXIKQ" decimals="INF" format="ixt-sec:numwordsen" name="vstm:NumberOfPatents" scale="0" id="Narr_nH9fU2iWSUCY3yJFtMupyQ">one</ix:nonFraction> of the four patent families that the Company has exclusively licensed and are owned by either Chugai or the third party. Pursuant to the License Agreement, the Company became obligated to pay $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_srt_StatementScenarioAxis_vstm_PursuantToLicenseAgreementMember_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_VDan3WYf1EevGGqNXzZ9hw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:CollaborativeArrangementsOneTimeCashPayment" scale="6" id="Narr_G2SJlGQ4SkaxzMo176C02g">2.1</ix:nonFraction> million in the year ended December 31, 2025 and is further obligated to pay up to $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_srt_StatementScenarioAxis_vstm_AchievementOfCertainSalesMilestonesMember_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_zzkKq8OR_UOKfHUpO3ZAdw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:PotentialMilestonePayments" scale="6" id="Narr_D7P71K3VUE2knSI4meYg0Q">2.3</ix:nonFraction> million upon achievement of certain milestones. <span style="background:#ffffff;">The Company recorded </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_Uj6ZHm1iCka91Tq8-q7rTA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="Narr_8CwrDyWre0uOwGtQEzcChA">2.1</ix:nonFraction></span><span style="background:#ffffff;"> million within intangible assets related to these payments on the consolidated balance sheets. </span>The future milestone payments are contingent in nature and will be recognized if and when the respective contingencies are resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GenFleet Therapeutics (Shanghai), Inc. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">On August 24, 2023, the Company entered into the GenFleet Agreement, pursuant to which GenFleet granted the Company the option to obtain exclusive development and commercialization rights worldwide outside of mainland China, Hong Kong, Macau, and Taiwan (the &#8220;Territory&#8221;) for up to three oncology programs targeting RAS pathway driven cancers (the &#8220;GenFleet Options&#8221;). The Company may exercise its GenFleet Options on a program-by-program basis.</span> In January 2025, the Company exercised its GenFleet Option with respect to VS-7375 and made a $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_1_31_2025_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_lGAzc-lkAkKmcWT8YEBiIg" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsDevelopmentMilestonePayments" scale="6" id="Narr_i4eOvFsclkKiR1sqOuQmEQ">6.0</ix:nonFraction> million payment to GenFleet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company made an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_8_24_2023_To_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_dsxUwW56ZECoNMCxu8ilPA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementUpfrontPayment" scale="6" id="Narr_bzOWYvAawEyFoeMOd_OWsw">2.0</ix:nonFraction> million to GenFleet in September 2023 and will provide $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_8_24_2023_To_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_us-gaap_ResearchAndDevelopmentArrangementMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_tYSyxNxH1Uuvalr8k9zyHg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="6" id="Narr_A6tbtSTC30qgC7poTyxQkA">1.5</ix:nonFraction> million of research support over the first three years of the GenFleet Agreement. In addition, pursuant to the GenFleet Agreement, upon achievement of certain milestones, and upon the Company exercising its GenFleet Options, GenFleet will be entitled to receive payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_E2vhbuJLHEynsOukxWJq3A" decimals="-5" format="ixt:num-dot-decimal" name="vstm:PotentialMilestonePayments" scale="6" id="Narr_I42TUiXmVUOpoNT6fW3xJQ">622.0</ix:nonFraction> million, inclusive of (i) up to $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_39lEE9M2vkGrczaWHlXE3Q" decimals="-5" format="ixt:num-dot-decimal" name="vstm:PotentialMilestonePayments" scale="6" id="Narr_lLVuopybTUOytKReUaOe_Q">154.0</ix:nonFraction> million upon achievement of certain development and commercialization milestones, (ii) up to $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_vstm_AchievementOfCertainSalesMilestonesMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_njuY9ME3DkeF5IZXfRJNAw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:PotentialMilestonePayments" scale="6" id="Narr_3MbZifsPyUqFTFOst0QyPQ">450.0</ix:nonFraction> million upon achievement of certain sales milestones, and (iii) up to $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_vstm_ExerciseOfAllThreeGenFleetOptionsMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_o_C5UTUcQ0-Z9MtY_JiXjQ" decimals="-5" format="ixt:num-dot-decimal" name="vstm:PotentialMilestonePayments" scale="6" id="Narr_1LYqd2Z1okmjST72I88ILA">18.0</ix:nonFraction> million upon exercise of all three GenFleet Options. The Company paid GenFleet a $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_DF8qnE1w-kGq9_Ct4jgrAw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsDevelopmentMilestonePayments" scale="6" id="Narr_pHaDAEy95UCHLcjk7wgUIw">3.0</ix:nonFraction> million milestone in the year ended December 31, 2024, upon GenFleet achieving a development milestone. The Company has also agreed to pay GenFleet royalties on net sales of licensed products in the Territory ranging from the mid to high single digits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company may terminate the GenFleet Agreement in its entirety or on a program-by-program basis by providing <span style="-sec-ix-hidden:Hidden_JU_oIydDdkuR8-FICIEckw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">90 days</span></span> written notice to GenFleet. Either party may terminate the GenFleet Agreement in its entirety or on a program-by-program and country-by-country basis, with <span style="-sec-ix-hidden:Hidden_AfA5SF6tv0-rw53ZSmEEFw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">60 days</span></span>&#8217; written notice for the other party&#8217;s material breach if such party fails to cure the breach. Either party may also terminate the GenFleet Agreement in its entirety upon certain insolvency events involving the other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company expensed $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_1_31_2025_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_lGAzc-lkAkKmcWT8YEBiIg" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementUpfrontPayment" scale="6" id="Narr_V5LivzhygEuiMIKbBcZcQQ">6.0</ix:nonFraction> million in January 2025, related to the GenFleet Option payment within</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">research and development expense in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2025. The other future milestone payments are contingent in nature and will be recognized if and when the respective contingencies are resolved. If the Company elects to exercise further GenFleet Options, the related payment will be recognized if and when each respective GenFleet Option is elected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Secura Bio, Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">On August 10, 2020, the Company and Secura signed the Secura APA and on September 30, 2020, the transaction closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Pursuant to the Secura APA, the Company sold to Secura its exclusive worldwide license, including related assets, for the research, development, commercialization, and manufacture in oncology indications of products containing duvelisib. The sale included certain intellectual property related to duvelisib in oncology indications, certain existing duvelisib inventory, claims and rights under certain contracts pertaining to duvelisib. Pursuant to the Secura APA, </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-46</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_uqNYEUMhiEWaquKFPBo2kA_cont2" continuedAt="Tb_uqNYEUMhiEWaquKFPBo2kA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Secura assumed all operational and financial responsibility for activities that were part of the Company&#8217;s duvelisib oncology program, including all commercialization efforts related to duvelisib in the United States and Europe, as well as the Company&#8217;s ongoing duvelisib clinical trials. Further, Secura assumed all obligations with existing collaboration partners developing and commercializing duvelisib, which include Yakult, Honsha Co., Ltd. (&#8220;Yakult&#8221;), CSPC Pharmaceutical Group Limited (&#8220;CSPC&#8221;) and Sanofi. Additionally, Secura assumed all royalty payment obligations due under the amended and restated license agreement with Infinity Pharmaceuticals, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Pursuant to the terms of the Secura APA, Secura has paid the Company an up-front payment of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_9WaY4ozWNUCB3Lci8zTJtg" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementUpfrontPayment" scale="6" id="Narr_65u5y9BM7UmPEpH8WOD1CA">70.0</ix:nonFraction> million in September 2020 and has agreed to pay the Company (i) regulatory milestone payments up to $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_besuRyf8Y0a58JN5tevWUA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable" scale="6" id="Narr_kYmAE6QIUEGwIl3DY4woaA">45.0</ix:nonFraction> million, consisting of a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_K33i8h8swEuknRDePz8siA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra" scale="6" id="Narr_xHlCCe7Zok-7rQnvoIMqVA">35.0</ix:nonFraction> million upon receipt of regulatory approval of COPIKTRA in the United States for the treatment of peripheral T-cell lymphoma and a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_K33i8h8swEuknRDePz8siA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale" scale="6" id="Narr_ArzA6gUC7UGBtOYPEWWrhg">10.0</ix:nonFraction> million upon receipt of the first regulatory approval for the commercial sale of COPIKTRA in the European Union for the treatment of peripheral T-cell lymphoma, (ii)&#160;sales milestone payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_besuRyf8Y0a58JN5tevWUA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceivable" scale="6" id="Narr_rjU_onl1y0qC1jog8NM6Cg">50.0</ix:nonFraction> million, consisting of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_m7dZCqcrSkuva19JwTUE4A" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceivable" scale="6" id="Narr_kk3DiRmR70WZNF38pp9i_A">10.0</ix:nonFraction> million when total worldwide net sales of COPIKTRA exceed $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_4eTmUVOzd0mGjZsxlu90SQ" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" scale="6" id="Narr_z45xOCDmEk2_9_AB70pRBA">100.0</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_5YDVN68wcUm0VSa7Wv493Q" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceivable" scale="6" id="Narr_aan3tHkYlUyGhT-t6716gw">15.0</ix:nonFraction> million when total worldwide net sales of COPIKTRA exceed $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_8uqSrXDV0EmTZ1ByOF2jBA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" scale="6" id="Narr_aVjlPO5q1kWa0T1iFn13vA">200.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_MdVGT0IgvUmbjCVDMtrXUg" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceivable" scale="6" id="Narr_5AMju06YAkG6hW2BrqXoCw">25.0</ix:nonFraction> million when total worldwide net sales of COPIKTRA exceed $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_e8TDv-L8LUauwZTI1obpiw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" scale="6" id="Narr_zIrxnzpG5E2V1pbpYuJ2IQ">300.0</ix:nonFraction> million, (iii)&#160;low double-digit royalties on the annual aggregate net sales above $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_9WaY4ozWNUCB3Lci8zTJtg" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments" scale="6" id="Narr_rx1-rz4oh0Ky1rgHmsLanA">100.0</ix:nonFraction> million in the United States, European Union, and the United Kingdom of Great Britain and Northern Ireland and (iv)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_9WaY4ozWNUCB3Lci8zTJtg" decimals="2" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements" scale="-2" id="Narr_fu3zGolnDEqxuhEXDKuwiQ">50</ix:nonFraction>% of all royalty, milestone and sublicense revenue payments payable to Secura under the Company&#8217;s existing license agreements with Sanofi, Yakult, and CSPC, and <ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_9WaY4ozWNUCB3Lci8zTJtg" decimals="2" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions" scale="-2" id="Narr_-cJtIjIFYEuMfDJRK8VKDw">50</ix:nonFraction>% of all royalty and milestone payments payable to Secura under any license or sublicense agreement entered into by Secura in certain jurisdictions.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The Company evaluated the Secura APA in accordance with ASC 606 as the Company concluded that the counterparty, Secura, is a customer. The Company identified a bundled performance obligation consisting of delivery of the duvelisib global license and intellectual property, certain existing duvelisib inventory, certain duvelisib contracts and clinical trials, certain regulatory approvals, and certain regulatory documentation and books and records (the &#8220;Bundled Secura Performance Obligation&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The Company concluded that the duvelisib global license and intellectual property were not distinct within the context of the contract (i.e. separately identifiable) because the other assets including certain existing duvelisib inventory, certain duvelisib contracts and clinical trials, certain regulatory approval, and certain regulatory documentation and books and records do not have stand-alone value from other duvelisib global license and intellectual property and Secura could not benefit from them without the duvelisib global license and intellectual property. Consistent with the guidance under ASC 606-10-25-16A, the Company disregarded immaterial promised goods and services when determining performance obligations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The Company determined that the upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_9WaY4ozWNUCB3Lci8zTJtg" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementUpfrontPayment" scale="6" id="Narr_oM0ljkvrmkCpuHQhARTX8A">70.0</ix:nonFraction> million, future potential milestone payments and royalties including from Secura&#8217;s sublicensees should be allocated to the delivery of the Bundled Secura Performance Obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:2pt;background:#ffffff;margin:0pt;">During the years ended December 31, 2025 and 2023, the Company has <ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_C_jlzU3foUSnLHdbsgYZFQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_UHLrNE9FL0Of3kuI8YTcqQ"><ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_VByLpZd3oUumXTdQ76R5ZA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_3qs7hlQl80mWqkv3AXhwOA">no</ix:nonFraction></ix:nonFraction>t recognized any revenue associated with the Secura APA. During the year end ended December 31, 2024, Secura achieved $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_pEx0srU5Ak2GiczyEYhqRA" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" scale="6" id="Narr__RKHjmk9U0a4gnN6SUPcJQ">100.0</ix:nonFraction> million of total worldwide net sales of COPIKTRA which triggered a $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_s7JVz9MorkeAVWRt5OMAbQ" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceivable" scale="6" id="Narr_HfRulA2hOEGfp3m6N7hKLQ">10.0</ix:nonFraction> million sales milestone payment to the Company under the Secura APA. The Company received the $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_7_31_2024_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_ipNYPIX9lkyb7J4LRrkchw" decimals="-5" format="ixt:num-dot-decimal" name="vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceived" scale="6" id="Narr_BelGm00V8UiElbcg5CRptA">10.0</ix:nonFraction> million milestone payment in July 2024. The Company determined all future potential milestones and royalties were excluded from the transaction price, as all other milestone amounts were fully constrained under the guidance as of December 31, 2025. As part of the Company&#8217;s evaluation of the constraint, the Company considered several factors in determining whether there is significant uncertainty associated with the future events that would result in the milestone payments. Those factors included: the likelihood and magnitude of revenue reversals related to future milestones, the amount of variable consideration that is highly susceptible to factors outside of the Company&#8217;s influence and the uncertainty about the consideration is not expected to be resolved for an extended period of time. All future potential milestone payments were fully constrained as the risk of significant revenue reversal related to these amounts has not yet been resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-47</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:21.6pt;min-height:50.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_uqNYEUMhiEWaquKFPBo2kA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:LongTermDebtTextBlock" id="Tb_NJxOhUJO1EmeGUIZ3kLQFQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">17. Notes Payable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In January 2025, the&#160;Company entered into a finance agreement with FIRST Insurance Funding (&#8220;First Insurance&#8221;). Pursuant to the terms of the agreement, First Insurance loaned the Company the principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_1_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_UhCOi_V-Yk--a9CzLZu_Og" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_eSvBjsigkkqMMNMOz8CBVA">1.2</ix:nonFraction>&#160;million, which accrued interest at&#160;<ix:nonFraction unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA" contextRef="As_Of_1_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_UhCOi_V-Yk--a9CzLZu_Og" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_j3O5WTG_3kKYoAOn8n99Zw">6.9</ix:nonFraction>% per annum, to fund a portion of the Company&#8217;s insurance policies. Pursuant to the agreement with First Insurance, the Company made an initial payment of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_1_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_cQjwjoVWG0yneJwH7D4Q0A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="Narr_5uvVG5paxUe11kMirM4Btg">0.3</ix:nonFraction>&#160;million and made monthly payments of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_1_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_cQjwjoVWG0yneJwH7D4Q0A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="6" id="Narr_ivLEuVvX6ESBRh6zmLU0Xg">0.1</ix:nonFraction>&#160;million through November 2025 including principal and interest. The agreement assigned First Insurance a first priority lien and security interest in the financed insurance policies. The outstanding balance at December 31, 2025 was $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_SnnAtXkpqkWQ3yAjnYmU6A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="6" id="Narr_BE3jKUEIUk6CPYLR7LprJw">0.0</ix:nonFraction> million.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_Y5Qe83xppUWu55zjh9d0nQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">18. Employee benefit Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June 2011, the Company adopted a 401(k) retirement and savings plan (the 401(k) Plan) covering all employees. The 401(k) Plan allows employees to make pre-tax or post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. Under the 401(k) Plan, the Company may make discretionary contributions as approved by the board of directors. The Company made contributions to the 401(k) Plan of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_vkGRqBYgT0ucgR3_P4wMhA">1.3</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_b3vC4Rx4g0aqYLsThWiVMg">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_l1fXgCptBka33IQJbCNMpA">0.8</ix:nonFraction> million in each of the years ended December 31, 2025, 2024, and 2023.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:SupplierFinanceProgramTextBlock" id="Tb_9vvzqG6QEEKSb1jacUaQnQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">19. Vendor Financing Arrangement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the IQVIA Master Services Agreement, the Company has extended payment terms with respect to a portion of the services provided and has recorded a vendor financing arrangement liability of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SupplierFinanceProgramObligation" scale="6" id="Narr_teAUrGtRdEmmKG_LInDAQw">10.3</ix:nonFraction> million as of December 31, 2025. The Company expects to pay the amounts recorded as <span style="-sec-ix-hidden:Hidden_gxfwXUi5dECGg1py2bW53w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">vendor financing arrangement</span></span> liabilities during 2026 and 2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_-K8JldTAMU2fTRCmVk-xKg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">20. Subsequent events </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">The Company reviews all activity subsequent to year end but prior to the issuance of the consolidated financial statements for events that could require disclosure or that could impact the carrying value of assets or liabilities as of the consolidated balance sheet date. The Company is not aware of any material subsequent events other than the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Warrants exercise</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:0pt;">In January 2026, <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7S9Co7osyUKPh1S2Fr2wNQ" decimals="INF" format="ixt:num-dot-decimal" name="vstm:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="0" id="Narr_AhFzGskOdkWVFeV8CyXZ_A">8,391,666</ix:nonFraction> Warrants were exercised. As a result, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw" contextRef="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7S9Co7osyUKPh1S2Fr2wNQ" decimals="INF" format="ixt:num-dot-decimal" name="vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Narr_BlOYbgwzkk6PQkVV5uIfWQ">8,391,666</ix:nonFraction> shares of common stock and received net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w" contextRef="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7S9Co7osyUKPh1S2Fr2wNQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_WTJKQbbpZk6M4Lo_HMR-mA">29.4</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note Purchase Agreement amendment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">In March 2026, the Company amended the Note Purchase Agreement to extend the date the Company may draw the Second Purchase from December 31, 2025 to June 30, 2026. Refer to&#160;<i style="font-style:italic;">Note 8. Long-term debt</i>&#160;for additional details on the Note Purchase Agreement.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:50.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-48</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>vstm-20251231xex4d2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/4/2026 08:56:06 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:12.1%;padding-right:12.1%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:0.07;margin:0pt;"><font style="font-size:16pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:right;margin:4.34pt 0.6pt 0pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Exhibit 4.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:4.34pt 0.6pt 0pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">DESCRIPTION</b><b style="font-weight:bold;letter-spacing:-0.45pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">OF</b><b style="font-weight:bold;letter-spacing:-0.4pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">THE</b><b style="font-weight:bold;letter-spacing:-0.4pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">REGISTRANT&#8217;S</b><b style="font-weight:bold;letter-spacing:-0.4pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:2.25pt 0pt 0pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 0pt 24.1pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">DESCRIPTION</b><b style="font-weight:bold;letter-spacing:-0.5pt;"> </b><b style="font-weight:bold;letter-spacing:-0.2pt;">OF</b><b style="font-weight:bold;letter-spacing:-0.55pt;"> </b><b style="font-weight:bold;letter-spacing:-0.2pt;">CAPITAL</b><b style="font-weight:bold;letter-spacing:-0.55pt;"> </b><b style="font-weight:bold;letter-spacing:-0.2pt;">STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;margin:11.19pt 0pt 0pt 24.1pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:1.14pt 0pt 0pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.22;margin:0.05pt 26.3pt 0pt 24.1pt;">The following is a summary of information concerning the capital stock of Verastem, Inc. (&#8220;Verastem&#8221; or &#8220;the<font style="letter-spacing:2pt;"> </font>Company&#8221;).<font style="letter-spacing:1.35pt;"> </font>The<font style="letter-spacing:1.3pt;"> </font>summaries<font style="letter-spacing:1.35pt;"> </font>and<font style="letter-spacing:1.3pt;"> </font>descriptions<font style="letter-spacing:1.35pt;"> </font>below<font style="letter-spacing:1.3pt;"> </font>do<font style="letter-spacing:1.35pt;"> </font>not<font style="letter-spacing:1.3pt;"> </font>purport<font style="letter-spacing:1.35pt;"> </font>to<font style="letter-spacing:1.3pt;"> </font>be<font style="letter-spacing:1.35pt;"> </font>complete<font style="letter-spacing:1.3pt;"> </font>and<font style="letter-spacing:1.35pt;"> </font>are<font style="letter-spacing:1.3pt;"> </font>subject<font style="letter-spacing:1.35pt;"> </font>to<font style="letter-spacing:1.3pt;"> </font>and<font style="letter-spacing:2pt;"> </font>qualified in their entirety by reference to the Delaware General Corporation Law, the Company&#8217;s Restated<font style="letter-spacing:4pt;"> </font>Certificate<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:1pt;"> </font>Incorporation,<font style="letter-spacing:1pt;"> </font>as<font style="letter-spacing:1pt;"> </font>amended<font style="letter-spacing:1pt;"> </font>(the<font style="letter-spacing:1pt;"> </font>&#8220;Certificate<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:1pt;"> </font>Incorporation&#8221;),<font style="letter-spacing:1pt;"> </font>and<font style="letter-spacing:1pt;"> </font>Amended<font style="letter-spacing:1pt;"> </font>and<font style="letter-spacing:1pt;"> </font>Restated<font style="letter-spacing:1pt;"> </font>Bylaws<font style="letter-spacing:2pt;"> </font>(the &#8220;Bylaws&#8221;) each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of<font style="letter-spacing:2pt;"> </font>which this exhibit is a part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.85pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;margin:0pt 0pt 0pt 24.1pt;">Common<b style="font-weight:bold;letter-spacing:-0.4pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:1.14pt 0pt 0pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.22;margin:0pt 26.3pt 0pt 24.1pt;">Under<font style="letter-spacing:1.05pt;"> </font>the<font style="letter-spacing:1.05pt;"> </font>Certificate<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:1.05pt;"> </font>Incorporation,<font style="letter-spacing:1.05pt;"> </font>Verastem<font style="letter-spacing:1.05pt;"> </font>has<font style="letter-spacing:1.05pt;"> </font>authority<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:1.05pt;"> </font>issue<font style="letter-spacing:1.05pt;"> </font>up<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:1.05pt;"> </font>300,000,000<font style="letter-spacing:1.05pt;"> </font>shares<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:1.05pt;"> </font>common<font style="letter-spacing:2pt;"> </font>stock, par value $0.0001 per share. As of February 23, 2026, 87,835,106 shares of common stock were issued and<font style="letter-spacing:2pt;"> </font><font style="letter-spacing:-0.1pt;">outstanding.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.89pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.22;margin:0pt 26.3pt 0pt 24.1pt;">Holders<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:1.05pt;"> </font>common<font style="letter-spacing:1.05pt;"> </font>stock<font style="letter-spacing:1.05pt;"> </font>are<font style="letter-spacing:1.05pt;"> </font>entitled<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:1.05pt;"> </font>one<font style="letter-spacing:1.05pt;"> </font>vote<font style="letter-spacing:1.05pt;"> </font>for<font style="letter-spacing:1.05pt;"> </font>each<font style="letter-spacing:1.05pt;"> </font>share<font style="letter-spacing:1.05pt;"> </font>held<font style="letter-spacing:1.05pt;"> </font>on<font style="letter-spacing:1.05pt;"> </font>all<font style="letter-spacing:1.05pt;"> </font>matters<font style="letter-spacing:1.05pt;"> </font>submitted<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:1.05pt;"> </font>a<font style="letter-spacing:1.05pt;"> </font>vote<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:2pt;"> </font>stockholders<font style="letter-spacing:1.2pt;"> </font>and<font style="letter-spacing:1.2pt;"> </font>do<font style="letter-spacing:1.2pt;"> </font>not<font style="letter-spacing:1.15pt;"> </font>have<font style="letter-spacing:1.15pt;"> </font>cumulative<font style="letter-spacing:1.15pt;"> </font>voting<font style="letter-spacing:1.2pt;"> </font>rights.<font style="letter-spacing:1.2pt;"> </font>An<font style="letter-spacing:1.2pt;"> </font>election<font style="letter-spacing:1.2pt;"> </font>of<font style="letter-spacing:1.2pt;"> </font>directors<font style="letter-spacing:1.2pt;"> </font>by<font style="letter-spacing:1.2pt;"> </font>the<font style="letter-spacing:1.15pt;"> </font>Company&#8217;s<font style="letter-spacing:1.2pt;"> </font>stockholders<font style="letter-spacing:2pt;"> </font>shall<font style="letter-spacing:1.05pt;"> </font>be<font style="letter-spacing:1.05pt;"> </font>determined<font style="letter-spacing:1.05pt;"> </font>by<font style="letter-spacing:1.05pt;"> </font>a<font style="letter-spacing:1.05pt;"> </font>plurality<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:1.05pt;"> </font>the<font style="letter-spacing:1.05pt;"> </font>votes<font style="letter-spacing:1.05pt;"> </font>cast<font style="letter-spacing:1.05pt;"> </font>by<font style="letter-spacing:1.05pt;"> </font>the<font style="letter-spacing:1.05pt;"> </font>stockholders<font style="letter-spacing:1.05pt;"> </font>entitled<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:1.05pt;"> </font>vote<font style="letter-spacing:1.05pt;"> </font>on<font style="letter-spacing:1.05pt;"> </font>the<font style="letter-spacing:1.05pt;"> </font>election.<font style="letter-spacing:1.05pt;"> </font>Holders<font style="letter-spacing:2pt;"> </font>of<font style="letter-spacing:1.3pt;"> </font>common<font style="letter-spacing:1.3pt;"> </font>stock<font style="letter-spacing:1.3pt;"> </font>are<font style="letter-spacing:1.3pt;"> </font>entitled<font style="letter-spacing:1.3pt;"> </font>to<font style="letter-spacing:1.3pt;"> </font>receive<font style="letter-spacing:1.3pt;"> </font>proportionately<font style="letter-spacing:1.3pt;"> </font>any<font style="letter-spacing:1.3pt;"> </font>dividends<font style="letter-spacing:1.3pt;"> </font>as<font style="letter-spacing:1.3pt;"> </font>may<font style="letter-spacing:1.3pt;"> </font>be<font style="letter-spacing:1.3pt;"> </font>declared<font style="letter-spacing:1.3pt;"> </font>by<font style="letter-spacing:1.3pt;"> </font>the<font style="letter-spacing:1.3pt;"> </font>Company&#8217;s<font style="letter-spacing:2pt;"> </font>board<font style="letter-spacing:1.65pt;"> </font>of<font style="letter-spacing:1.65pt;"> </font>directors,<font style="letter-spacing:1.65pt;"> </font>subject<font style="letter-spacing:1.65pt;"> </font>to<font style="letter-spacing:1.65pt;"> </font>any<font style="letter-spacing:1.65pt;"> </font>preferential<font style="letter-spacing:1.65pt;"> </font>dividend<font style="letter-spacing:1.65pt;"> </font>rights<font style="letter-spacing:1.65pt;"> </font>of<font style="letter-spacing:1.65pt;"> </font>outstanding<font style="letter-spacing:1.65pt;"> </font>preferred<font style="letter-spacing:1.65pt;"> </font>stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.85pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.22;margin:0pt 29.1pt 0pt 24.1pt;">In<font style="letter-spacing:1.25pt;"> </font>the<font style="letter-spacing:1.25pt;"> </font>event<font style="letter-spacing:1.25pt;"> </font>of<font style="letter-spacing:1.25pt;"> </font>the<font style="letter-spacing:1.25pt;"> </font>Company&#8217;s<font style="letter-spacing:1.25pt;"> </font>liquidation<font style="letter-spacing:1.25pt;"> </font>or<font style="letter-spacing:1.25pt;"> </font>dissolution,<font style="letter-spacing:1.25pt;"> </font>the<font style="letter-spacing:1.25pt;"> </font>holders<font style="letter-spacing:1.25pt;"> </font>of<font style="letter-spacing:1.25pt;"> </font>common<font style="letter-spacing:1.25pt;"> </font>stock<font style="letter-spacing:1.25pt;"> </font>are<font style="letter-spacing:1.25pt;"> </font>entitled<font style="letter-spacing:1.25pt;"> </font>to<font style="letter-spacing:1.25pt;"> </font>receive<font style="letter-spacing:2pt;"> </font>proportionately<font style="letter-spacing:1.45pt;"> </font>all<font style="letter-spacing:1.45pt;"> </font>assets<font style="letter-spacing:1.45pt;"> </font>available<font style="letter-spacing:1.45pt;"> </font>for<font style="letter-spacing:1.45pt;"> </font>distribution<font style="letter-spacing:1.45pt;"> </font>to<font style="letter-spacing:1.45pt;"> </font>stockholders<font style="letter-spacing:1.45pt;"> </font>after<font style="letter-spacing:1.45pt;"> </font>the<font style="letter-spacing:1.45pt;"> </font>payment<font style="letter-spacing:1.45pt;"> </font>of<font style="letter-spacing:1.45pt;"> </font>all<font style="letter-spacing:1.45pt;"> </font>debts<font style="letter-spacing:1.45pt;"> </font>and<font style="letter-spacing:1.45pt;"> </font>other<font style="letter-spacing:2pt;"> </font>liabilities<font style="letter-spacing:1.05pt;"> </font>and<font style="letter-spacing:1.05pt;"> </font>subject<font style="letter-spacing:1pt;"> </font>to<font style="letter-spacing:1.05pt;"> </font>the<font style="letter-spacing:1pt;"> </font>prior<font style="letter-spacing:1.05pt;"> </font>rights<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:1.05pt;"> </font>any<font style="letter-spacing:1.05pt;"> </font>outstanding<font style="letter-spacing:1.05pt;"> </font>preferred<font style="letter-spacing:1.05pt;"> </font>stock.<font style="letter-spacing:1.05pt;"> </font>Holders<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:1.05pt;"> </font>common<font style="letter-spacing:1.05pt;"> </font>stock<font style="letter-spacing:1.05pt;"> </font>have<font style="letter-spacing:1pt;"> </font>no<font style="letter-spacing:2pt;"> </font>preemptive,<font style="letter-spacing:1.25pt;"> </font>subscription,<font style="letter-spacing:1.25pt;"> </font>redemption<font style="letter-spacing:1.25pt;"> </font>or<font style="letter-spacing:1.25pt;"> </font>conversion<font style="letter-spacing:1.25pt;"> </font>rights.<font style="letter-spacing:1.25pt;"> </font>The<font style="letter-spacing:1.25pt;"> </font>rights,<font style="letter-spacing:1.25pt;"> </font>preferences<font style="letter-spacing:1.25pt;"> </font>and<font style="letter-spacing:1.25pt;"> </font>privileges<font style="letter-spacing:1.25pt;"> </font>of<font style="letter-spacing:1.25pt;"> </font>holders<font style="letter-spacing:1.25pt;"> </font>of<font style="letter-spacing:2pt;"> </font>common<font style="letter-spacing:0.85pt;"> </font>stock<font style="letter-spacing:0.85pt;"> </font>are<font style="letter-spacing:0.85pt;"> </font>subject<font style="letter-spacing:0.85pt;"> </font>to<font style="letter-spacing:0.85pt;"> </font>and<font style="letter-spacing:0.85pt;"> </font>may<font style="letter-spacing:0.85pt;"> </font>be<font style="letter-spacing:0.85pt;"> </font>adversely<font style="letter-spacing:0.85pt;"> </font>affected<font style="letter-spacing:0.85pt;"> </font>by<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.85pt;"> </font>rights<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.85pt;"> </font>holders<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.85pt;"> </font>shares<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.85pt;"> </font>any<font style="letter-spacing:0.85pt;"> </font>series<font style="letter-spacing:2pt;"> </font>of<font style="letter-spacing:1.45pt;"> </font>preferred<font style="letter-spacing:1.45pt;"> </font>stock<font style="letter-spacing:1.45pt;"> </font>that<font style="letter-spacing:1.45pt;"> </font>the<font style="letter-spacing:1.45pt;"> </font>Company<font style="letter-spacing:1.45pt;"> </font>may<font style="letter-spacing:1.45pt;"> </font>designate<font style="letter-spacing:1.45pt;"> </font>and<font style="letter-spacing:1.45pt;"> </font>issue<font style="letter-spacing:1.45pt;"> </font>in<font style="letter-spacing:1.45pt;"> </font>the<font style="letter-spacing:1.45pt;"> </font>future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.22;margin:0pt 29.1pt 0pt 24.1pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.22;margin:0pt 29.1pt 0pt 24.1pt;">On May 30, 2023, the Company filed a Certificate of Amendment to the Company&#8217;s Restated Certificate of Incorporation, as amended to date, with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company&#8217;s issued and outstanding common stock at a ratio of 1-for-12 (the &#8220;Reverse Stock Split&#8221;), as authorized at the Company&#8217;s 2023 annual meeting of stockholders held on May 15, 2023. The Company effected the Reverse Stock Split on May 31, 2023. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise were entitled to a fractional share of common stock were entitled to receive a price equal to the closing price of the common stock on the Nasdaq Capital Market on the date immediately preceding the Reverse Stock Split, as adjusted by the ratio of one share of common stock for every 12 shares of common stock, multiplied by the applicable fraction of a share. The number of shares of common stock that the Company is authorized to issue remains at 300,000,000 shares and the par value of its common stock remains unchanged at $0.0001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.85pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;margin:0pt 0pt 0pt 24.1pt;">Preferred<b style="font-weight:bold;letter-spacing:0.75pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:1.2pt 0pt 0pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24.1pt;">Under<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.5pt;"> </font>Certificate<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.5pt;"> </font>Incorporation,<font style="letter-spacing:0.45pt;"> </font>Verastem<font style="letter-spacing:0.5pt;"> </font>has<font style="letter-spacing:0.5pt;"> </font>authority<font style="letter-spacing:0.5pt;"> </font>to<font style="letter-spacing:0.45pt;"> </font>issue<font style="letter-spacing:0.5pt;"> </font>up<font style="letter-spacing:0.5pt;"> </font>to<font style="letter-spacing:0.5pt;"> </font>5,000,000<font style="letter-spacing:0.45pt;"> </font>shares<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.5pt;"> </font>preferred<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">stock,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.22;margin:0.25pt 23.75pt 0pt 24.1pt;">$0.0001 par value per share and the Company&#8217;s board of directors is authorized to establish, from the authorized<font style="letter-spacing:2pt;"> </font>shares<font style="letter-spacing:1.4pt;"> </font>of<font style="letter-spacing:1.4pt;"> </font>preferred<font style="letter-spacing:1.4pt;"> </font>stock,<font style="letter-spacing:1.4pt;"> </font>one<font style="letter-spacing:1.4pt;"> </font>or<font style="letter-spacing:1.4pt;"> </font>more<font style="letter-spacing:1.4pt;"> </font>classes<font style="letter-spacing:1.4pt;"> </font>or<font style="letter-spacing:1.4pt;"> </font>series<font style="letter-spacing:1.4pt;"> </font>of<font style="letter-spacing:1.4pt;"> </font>shares,<font style="letter-spacing:1.4pt;"> </font>to<font style="letter-spacing:1.4pt;"> </font>designate<font style="letter-spacing:1.4pt;"> </font>each<font style="letter-spacing:1.4pt;"> </font>such<font style="letter-spacing:1.4pt;"> </font>class<font style="letter-spacing:1.4pt;"> </font>and<font style="letter-spacing:1.4pt;"> </font>series,<font style="letter-spacing:1.4pt;"> </font>and<font style="letter-spacing:2pt;"> </font>fix<font style="letter-spacing:0.95pt;"> </font>the<font style="letter-spacing:0.85pt;"> </font>rights<font style="letter-spacing:0.95pt;"> </font>and<font style="letter-spacing:0.95pt;"> </font>preferences<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.95pt;"> </font>each<font style="letter-spacing:0.95pt;"> </font>such<font style="letter-spacing:0.95pt;"> </font>class<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.95pt;"> </font>preferred<font style="letter-spacing:0.95pt;"> </font>stock,<font style="letter-spacing:0.95pt;"> </font>which<font style="letter-spacing:0.95pt;"> </font>shall<font style="letter-spacing:0.85pt;"> </font>have<font style="letter-spacing:0.85pt;"> </font>voting<font style="letter-spacing:0.95pt;"> </font>powers,<font style="letter-spacing:0.95pt;"> </font>preferences,<font style="letter-spacing:2pt;"> </font>participating,<font style="letter-spacing:1.6pt;"> </font>optional<font style="letter-spacing:1.5pt;"> </font>or<font style="letter-spacing:1.6pt;"> </font>other<font style="letter-spacing:1.6pt;"> </font>special<font style="letter-spacing:1.5pt;"> </font>rights,<font style="letter-spacing:1.6pt;"> </font>qualifications<font style="letter-spacing:1.6pt;"> </font>and<font style="letter-spacing:1.6pt;"> </font>limitations<font style="letter-spacing:1.6pt;"> </font>or<font style="letter-spacing:1.6pt;"> </font>restrictions<font style="letter-spacing:1.6pt;"> </font>as<font style="letter-spacing:1.6pt;"> </font>adopted<font style="letter-spacing:1.6pt;"> </font>by<font style="letter-spacing:1.6pt;"> </font>the<font style="letter-spacing:2pt;"> </font>board<font style="letter-spacing:1.3pt;"> </font>of<font style="letter-spacing:1.3pt;"> </font>directors<font style="letter-spacing:1.3pt;"> </font>prior<font style="letter-spacing:1.3pt;"> </font>to<font style="letter-spacing:1.3pt;"> </font>the<font style="letter-spacing:1.3pt;"> </font>issuance<font style="letter-spacing:1.3pt;"> </font>of<font style="letter-spacing:1.3pt;"> </font>any<font style="letter-spacing:1.3pt;"> </font>such<font style="letter-spacing:1.3pt;"> </font>preferred<font style="letter-spacing:1.3pt;"> </font>shares.<font style="letter-spacing:1.3pt;"> </font>As of December 31, 2025, there were no shares of Series A convertible preferred stock, par value $0.0001 per share (the &#8220;Series A Preferred Stock&#8221;) and 944,160 shares of Series B convertible preferred stock, par value $0.0001 per share (the<font style="letter-spacing:2pt;"> </font>&#8220;Series B Preferred Stock&#8221;) designated, respectively. As of December 31, 2025, there were no shares of either Series A Preferred Stock or Series B Preferred Stock issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.85pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24.1pt;"><i style="font-style:italic;">Series</i><i style="font-style:italic;letter-spacing:0.7pt;"> </i><i style="font-style:italic;">A</i><i style="font-style:italic;letter-spacing:0.75pt;"> </i><i style="font-style:italic;">Preferred</i><i style="font-style:italic;letter-spacing:0.75pt;"> </i><i style="font-style:italic;letter-spacing:-0.1pt;">Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:1.14pt 0pt 0pt 0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24.1pt;">The<font style="letter-spacing:0.4pt;"> </font>Series<font style="letter-spacing:0.45pt;"> </font>A<font style="letter-spacing:0.45pt;"> </font>Preferred<font style="letter-spacing:0.45pt;"> </font>Stock<font style="letter-spacing:0.45pt;"> </font>have<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>following<font style="letter-spacing:0.4pt;"> </font>rights<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.45pt;"> </font><font style="letter-spacing:-0.1pt;">preferences:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:1.2pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Each</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">share</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Series</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">A</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Preferred</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">is</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">convertible</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">into</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.45pt;"> 0.833 </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">shares</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">common</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">stock (as adjusted to account for the Reverse Stock Split). No fractional shares of common stock shall be issued upon conversion of the Series A Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, Verastem, at its option, shall yentas (A) pay cash equal to the product of such fraction multiplied by the average of the closing bid prices of the common stock for the five (5) consecutive trading immediately preceding the applicable conversion date, or (B) issue one whole share of common stock to the holder.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;margin-bottom:0pt;margin-top:5.3pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">The</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Series</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">A</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Preferred</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">generally</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">has</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">no</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">voting</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">rights,</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">except</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">as</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">required</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">by</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">law</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">except</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">the consent of a majority of the holders of the outstanding Series A Preferred Stock will be required to</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">amend the terms of the Series A Preferred Stock.</font></td><td style="width:24.4pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;margin-bottom:0pt;margin-top:5.3pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">In</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">event</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Company&#8217;s</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">liquidation,</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">dissolution</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">winding</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">up,</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">holders</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Series</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">A</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Preferred</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">will</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">participate</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">pari</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">passu</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">with</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">distribution</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">proceeds</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">holders</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">common</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">stock.</font></td><td style="width:24.4pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;margin-bottom:0pt;margin-top:5pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Holders</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Series</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">A</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Preferred</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">are</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">entitled</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">receive</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">when,</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">as</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">if</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">dividends</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">are</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">declared</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">paid</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">on</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font></td><td style="width:24.2pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;margin-bottom:0pt;margin-top:5pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">common</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">stock,</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">an</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">equivalent</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">dividend,</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">calculated</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">on</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">an</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">as-converted</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">basis.</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Shares</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Series A Preferred </font></td><td style="width:24.2pt;"></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.1%;margin-right:12.1%;margin-top:30pt;page-break-after:always;width:75.8%;border-width:0;"><div style="max-width:100%;padding-left:12.1%;padding-right:12.1%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:0.07;margin:0pt;"><font style="font-size:16pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;margin-bottom:0pt;margin-top:5pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Stock are otherwise not entitled to dividends.</font></td><td style="width:24.2pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:5.05pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">The</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Series</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">A</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Preferred</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">ranks:</font></td></tr></table><div style="margin-top:5.3pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;padding-left:15.15pt;text-align:justify;text-indent:-15.15pt;margin:0pt 24.15pt 0pt 70.8pt;"><font style="display:inline-block;font-size:8pt;min-width:15.05pt;text-indent:0pt;white-space:nowrap;">a.</font><font style="font-size:8pt;">senior</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">to</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">any</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">class</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">or</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">series</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">of</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">capital</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">stock</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">of</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">the</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">Company</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">hereafter</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">created</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">specifically</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">ranking by its terms junior to the Series A Preferred Stock&#894;</font></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;margin-bottom:0pt;margin-top:5.05pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:70.8pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">on</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">parity</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">with</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">common</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">class</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">series</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">capital</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Company</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">created specifically ranking by its terms on parity with the Series A Preferred Stock&#894; and</font></td><td style="width:24.2pt;"></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;padding-left:15.15pt;text-align:justify;text-indent:-15.15pt;margin:5.05pt 24.25pt 0pt 70.8pt;"><font style="display:inline-block;font-size:8pt;min-width:15.05pt;text-indent:0pt;white-space:nowrap;">c.</font><font style="font-size:8pt;">junior to any class or series of capital stock of the Company created specifically ranking by its</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">terms senior to any Series A Preferred Stock, in each case, as to distributions of assets upon</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.85pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24.1pt;"><i style="font-style:italic;">Series</i><i style="font-style:italic;letter-spacing:0.7pt;"> </i><i style="font-style:italic;">B</i><i style="font-style:italic;letter-spacing:0.75pt;"> </i><i style="font-style:italic;">Preferred</i><i style="font-style:italic;letter-spacing:0.75pt;"> </i><i style="font-style:italic;letter-spacing:-0.1pt;">Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:1.2pt 0pt 0pt 0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24.1pt;">The<font style="letter-spacing:0.4pt;"> </font>Series<font style="letter-spacing:0.45pt;"> </font>B<font style="letter-spacing:0.45pt;"> </font>Preferred<font style="letter-spacing:0.45pt;"> </font>Stock<font style="letter-spacing:0.45pt;"> </font>have<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.4pt;"> </font>following<font style="letter-spacing:0.45pt;"> </font>rights<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.45pt;"> </font><font style="letter-spacing:-0.1pt;">preferences:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:1.14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Each</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">share</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Series</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">B</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Preferred</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">is</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">convertible</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">into</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">3.5305</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">shares</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">common</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">stock (as adjusted to account for the Reverse Stock Split). No fractional shares of common stock shall be issued upon conversion of the Series B Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, Verastem, at its option, shall yentas (A) pay cash equal to the product of such fraction multiplied by the average of the closing bid prices of the common stock for the five (5) consecutive trading immediately preceding the applicable conversion date, or (B) issue one whole share of common stock to the holder.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;margin-bottom:0pt;margin-top:5.34pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">The Series B Preferred Stock generally has no voting rights. The Company shall not, without the</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">affirmative vote or consent of the holders of majority of the shares of the Series B Preferred Stock then-</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding, given in person or by proxy, either in writing or at a meeting, in which the holders of the</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Series B Preferred Stock vote separately as a class:</font></td><td style="width:24.25pt;"></td></tr></table><div style="margin-top:5pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;padding-left:15.15pt;text-align:justify;text-indent:-15.15pt;margin:0pt 24.3pt 0pt 70.8pt;"><font style="display:inline-block;font-size:8pt;min-width:15.05pt;text-indent:0pt;white-space:nowrap;">a.</font><font style="font-size:8pt;">amend, alter, modify or repeal (whether by merger, consolidation or otherwise) the certificate of</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">designation</font><font style="font-size:8pt;letter-spacing:0.8pt;"> </font><font style="font-size:8pt;">of</font><font style="font-size:8pt;letter-spacing:0.8pt;"> </font><font style="font-size:8pt;">the</font><font style="font-size:8pt;letter-spacing:0.8pt;"> </font><font style="font-size:8pt;">preference</font><font style="font-size:8pt;letter-spacing:0.8pt;"> </font><font style="font-size:8pt;">rights,</font><font style="font-size:8pt;letter-spacing:0.8pt;"> </font><font style="font-size:8pt;">and</font><font style="font-size:8pt;letter-spacing:0.8pt;"> </font><font style="font-size:8pt;">limitations</font><font style="font-size:8pt;letter-spacing:0.8pt;"> </font><font style="font-size:8pt;">of</font><font style="font-size:8pt;letter-spacing:0.8pt;"> </font><font style="font-size:8pt;">Series</font><font style="font-size:8pt;letter-spacing:0.8pt;"> </font><font style="font-size:8pt;">B</font><font style="font-size:8pt;letter-spacing:0.8pt;"> </font><font style="font-size:8pt;">Preferred</font><font style="font-size:8pt;letter-spacing:0.8pt;"> </font><font style="font-size:8pt;">Stock,</font><font style="font-size:8pt;letter-spacing:0.8pt;"> </font><font style="font-size:8pt;">the</font><font style="font-size:8pt;letter-spacing:0.8pt;"> </font><font style="font-size:8pt;">Certificate</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">of Incorporation, or the Bylaws in any manner that adversely affects the rights, preferences,</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">privileges or the restrictions provided for the benefit of, the Series B Preferred Stock&#894;</font></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;margin-bottom:0pt;margin-top:5.05pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:70.8pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issue</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">further</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">shares</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Series</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">B</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Preferred</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">increase</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">decrease</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">(other</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">than</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">by</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">conversion) the number of authorized shares of Preferred Stock&#894;</font></td><td style="width:24.15pt;"></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;padding-left:15.15pt;text-align:justify;text-indent:-15.15pt;margin:5pt 24.4pt 0pt 70.8pt;"><font style="display:inline-block;font-size:8pt;min-width:15.05pt;text-indent:0pt;white-space:nowrap;">c.</font><font style="font-size:8pt;">authorize</font><font style="font-size:8pt;letter-spacing:0.95pt;"> </font><font style="font-size:8pt;">or</font><font style="font-size:8pt;letter-spacing:0.95pt;"> </font><font style="font-size:8pt;">issue</font><font style="font-size:8pt;letter-spacing:0.95pt;"> </font><font style="font-size:8pt;">any</font><font style="font-size:8pt;letter-spacing:0.95pt;"> </font><font style="font-size:8pt;">class</font><font style="font-size:8pt;letter-spacing:0.95pt;"> </font><font style="font-size:8pt;">or</font><font style="font-size:8pt;letter-spacing:0.95pt;"> </font><font style="font-size:8pt;">series</font><font style="font-size:8pt;letter-spacing:0.95pt;"> </font><font style="font-size:8pt;">of</font><font style="font-size:8pt;letter-spacing:0.95pt;"> </font><font style="font-size:8pt;">capital</font><font style="font-size:8pt;letter-spacing:0.95pt;"> </font><font style="font-size:8pt;">stock</font><font style="font-size:8pt;letter-spacing:0.95pt;"> </font><font style="font-size:8pt;">hereafter</font><font style="font-size:8pt;letter-spacing:0.95pt;"> </font><font style="font-size:8pt;">creating</font><font style="font-size:8pt;letter-spacing:0.95pt;"> </font><font style="font-size:8pt;">specifically</font><font style="font-size:8pt;letter-spacing:0.95pt;"> </font><font style="font-size:8pt;">ranking</font><font style="font-size:8pt;letter-spacing:0.95pt;"> </font><font style="font-size:8pt;">by</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">its terms senior to the Series B Preferred Stock (&#8220;Senior Stock&#8221;) or&#894;</font></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;margin-bottom:0pt;margin-top:5.05pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:70.8pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">enter into any agreement to do any of the foregoing that is not expressly made conditional on</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">obtaining the affirmative vote or written consent of the majority of then-outstanding Series B</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Preferred</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Stock.</font></td><td style="width:24.5pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;margin-bottom:0pt;margin-top:5.05pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:41.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">In</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">event</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Company&#8217;s</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">liquidation,</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">dissolution</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">winding</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">up,</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">holders</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Series</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">B</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Preferred</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">will</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">be</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">entitled</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">an</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">amount</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">equal</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$1.00</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">per</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">share</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Series</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">B</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Preferred</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Stock,</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">plus</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">an</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">additional</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">amount</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">equal</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">dividends</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">declared</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">but</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">unpaid</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">on</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">such</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">shares,</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">before</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">distributions</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">payments</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">are</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">made</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">holders</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">common</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">other</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">classes</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">ranking</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">junior</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Series</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">B</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Preferred</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Stock.</font></td><td style="width:24.25pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;margin-bottom:0pt;margin-top:5pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Holders</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Series</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">B</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Preferred</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">are</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">entitled</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">receive</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">when,</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">as</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">if</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">dividends</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">are</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">declared</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">paid</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">on</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">common</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">stock,</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">an</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">equivalent</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">dividend,</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">calculated</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">on</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">an</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">as-converted</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">basis.</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Shares</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Series B Preferred Stock are otherwise not entitled to dividends.</font></td><td style="width:24.2pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:5.05pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">The</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Series</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">B</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Preferred</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">rank:</font></td></tr></table><div style="margin-top:5.3pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:70.8pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.05pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">senior</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.75pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">common</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.75pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">stock&#894;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;margin-bottom:0pt;margin-top:5.3pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:70.8pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">senior</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">all</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">other</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">classes</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">series</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">equity</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">securities</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Company</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">by</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">their</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">terms</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">do not rank senior to the Series B Preferred Stock&#894;</font></td><td style="width:24.25pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;margin-bottom:0pt;margin-top:4.34pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:70.8pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">senior</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">all</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">shares</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Series</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">A</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Preferred</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">Stock&#894;</font></td><td style="width:23.9pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;margin-bottom:0pt;margin-top:4.34pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:70.8pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:15.15pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">on</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">parity</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">with</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">class</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">series</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">capital</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Company</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">hereafter</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;letter-spacing:0.5pt;">created </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">specifically ranking by its terms on parity with the Series B Preferred Stock&#894;</font></td><td style="width:23.9pt;"></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;padding-left:15.15pt;text-align:justify;text-indent:-15.15pt;margin:5pt 24.15pt 0pt 70.8pt;"><font style="display:inline-block;font-size:8pt;min-width:15.05pt;text-indent:0pt;white-space:nowrap;">e.</font><font style="font-size:8pt;">junior</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">to</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">any</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">class</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">or</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">series</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">of</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">capital</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">stock</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">of</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">the</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">Company</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">hereafter</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">created</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">specifically</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">ranking by its terms senior to the Series B Preferred Stock&#894; and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.22;padding-left:15.15pt;text-align:justify;text-indent:-15.15pt;margin:5.05pt 24.2pt 0pt 70.8pt;"><font style="display:inline-block;font-size:8pt;min-width:15.05pt;text-indent:0pt;white-space:nowrap;">f.</font><font style="font-size:8pt;">junior to all of the Company&#8217;s existing and future debt obligations, including convertible or</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">exchangeable debt securities, in each case, as to distributions of assets upon liquidation,</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">dissolution</font><font style="font-size:8pt;letter-spacing:1.7pt;"> </font><font style="font-size:8pt;">or</font><font style="font-size:8pt;letter-spacing:1.7pt;"> </font><font style="font-size:8pt;">winding</font><font style="font-size:8pt;letter-spacing:1.7pt;"> </font><font style="font-size:8pt;">up</font><font style="font-size:8pt;letter-spacing:1.7pt;"> </font><font style="font-size:8pt;">of</font><font style="font-size:8pt;letter-spacing:1.7pt;"> </font><font style="font-size:8pt;">the</font><font style="font-size:8pt;letter-spacing:1.7pt;"> </font><font style="font-size:8pt;">Corporation,</font><font style="font-size:8pt;letter-spacing:1.7pt;"> </font><font style="font-size:8pt;">whether</font><font style="font-size:8pt;letter-spacing:1.7pt;"> </font><font style="font-size:8pt;">voluntarily</font><font style="font-size:8pt;letter-spacing:1.7pt;"> </font><font style="font-size:8pt;">or</font><font style="font-size:8pt;letter-spacing:1.7pt;"> </font><font style="font-size:8pt;">involuntarily</font><font style="font-size:8pt;letter-spacing:1.7pt;"> </font><font style="font-size:8pt;">and</font><font style="font-size:8pt;letter-spacing:1.7pt;"> </font><font style="font-size:8pt;">as</font><font style="font-size:8pt;letter-spacing:1.7pt;"> </font><font style="font-size:8pt;">to</font><font style="font-size:8pt;letter-spacing:2pt;"> </font><font style="font-size:8pt;">the right to receive dividends.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.85pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;margin:0.05pt 0pt 0pt 24.1pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Delaware</b><b style="font-weight:bold;letter-spacing:-0.25pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">Anti-Takeover</b><b style="font-weight:bold;letter-spacing:-0.2pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">Law</b><b style="font-weight:bold;letter-spacing:-0.2pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">and</b><b style="font-weight:bold;letter-spacing:-0.25pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">Certain</b><b style="font-weight:bold;letter-spacing:-0.2pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">Charter</b><b style="font-weight:bold;letter-spacing:-0.2pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">and</b><b style="font-weight:bold;letter-spacing:-0.25pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">Bylaw</b><b style="font-weight:bold;letter-spacing:-0.2pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">Provisions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;font-weight:bold;margin:0pt 0pt 0pt 24.1pt;">Delaware<font style="letter-spacing:2pt;"> </font><font style="letter-spacing:-0.25pt;">law</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:1.79pt 0pt 0pt 0pt;"><font style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.22;margin:0pt 23.75pt 0pt 24.1pt;">Verastem<font style="letter-spacing:0.75pt;"> </font>is<font style="letter-spacing:0.75pt;"> </font>subject<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.75pt;"> </font>Section<font style="letter-spacing:0.75pt;"> </font>203<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.75pt;"> </font>Delaware<font style="letter-spacing:0.75pt;"> </font>General<font style="letter-spacing:0.75pt;"> </font>Corporation<font style="letter-spacing:0.75pt;"> </font>Law.<font style="letter-spacing:0.75pt;"> </font>Subject<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.75pt;"> </font>certain<font style="letter-spacing:0.75pt;"> </font>exceptions,<font style="letter-spacing:2pt;"> </font>Section<font style="letter-spacing:1.55pt;"> </font>203<font style="letter-spacing:1.55pt;"> </font>prevents<font style="letter-spacing:1.55pt;"> </font>a<font style="letter-spacing:1.55pt;"> </font>publicly-traded<font style="letter-spacing:1.55pt;"> </font>Delaware<font style="letter-spacing:1.55pt;"> </font>corporation<font style="letter-spacing:1.55pt;"> </font>from<font style="letter-spacing:1.55pt;"> </font>engaging<font style="letter-spacing:1.55pt;"> </font>in<font style="letter-spacing:1.55pt;"> </font>a<font style="letter-spacing:1.55pt;"> </font>&#8220;business<font style="letter-spacing:1.55pt;"> </font>combination&#8221;<font style="letter-spacing:1.55pt;"> </font>with<font style="letter-spacing:2pt;"> </font>any<font style="letter-spacing:1.7pt;"> </font>&#8220;interested<font style="letter-spacing:1.7pt;"> </font>stockholder&#8221;<font style="letter-spacing:1.7pt;"> </font>for<font style="letter-spacing:1.7pt;"> </font>three<font style="letter-spacing:1.7pt;"> </font>years<font style="letter-spacing:1.7pt;"> </font>following<font style="letter-spacing:1.7pt;"> </font>the<font style="letter-spacing:1.7pt;"> </font>date<font style="letter-spacing:1.7pt;"> </font>that<font style="letter-spacing:1.7pt;"> </font>the<font style="letter-spacing:1.7pt;"> </font>person<font style="letter-spacing:1.7pt;"> </font>became<font style="letter-spacing:1.7pt;"> </font>an<font style="letter-spacing:1.7pt;"> </font>interested<font style="letter-spacing:2pt;"> </font>stockholder,<font style="letter-spacing:1.9pt;"> </font>unless<font style="letter-spacing:1.9pt;"> </font>either<font style="letter-spacing:1.9pt;"> </font>the<font style="letter-spacing:1.9pt;"> </font>interested<font style="letter-spacing:1.9pt;"> </font>stockholder<font style="letter-spacing:1.9pt;"> </font>attained<font style="letter-spacing:1.9pt;"> </font>such<font style="letter-spacing:1.9pt;"> </font>status<font style="letter-spacing:1.9pt;"> </font>with<font style="letter-spacing:1.9pt;"> </font>the<font style="letter-spacing:1.9pt;"> </font>approval<font style="letter-spacing:1.9pt;"> </font>of<font style="letter-spacing:1.9pt;"> </font>a<font style="letter-spacing:1.9pt;"> </font>corporation&#8217;s<font style="letter-spacing:2pt;"> </font>board<font style="letter-spacing:1.3pt;"> </font>of<font style="letter-spacing:1.3pt;"> </font>directors,<font style="letter-spacing:1.3pt;"> </font>the<font style="letter-spacing:1.3pt;"> </font>business<font style="letter-spacing:1.3pt;"> </font>combination<font style="letter-spacing:1.3pt;"> </font>is<font style="letter-spacing:1.3pt;"> </font>approved<font style="letter-spacing:1.3pt;"> </font>by<font style="letter-spacing:1.3pt;"> </font>a<font style="letter-spacing:1.3pt;"> </font>corporation&#8217;s<font style="letter-spacing:1.3pt;"> </font>board<font style="letter-spacing:1.3pt;"> </font>of<font style="letter-spacing:1.3pt;"> </font>directors<font style="letter-spacing:1.3pt;"> </font>and<font style="letter-spacing:1.3pt;"> </font>stockholders<font style="letter-spacing:2pt;"> </font>in<font style="letter-spacing:0.95pt;"> </font>a<font style="letter-spacing:0.95pt;"> </font>prescribed<font style="letter-spacing:0.95pt;"> </font>manner<font style="letter-spacing:0.95pt;"> </font>or<font style="letter-spacing:0.95pt;"> </font>the<font style="letter-spacing:0.95pt;"> </font>interested<font style="letter-spacing:0.95pt;"> </font>stockholder<font style="letter-spacing:0.95pt;"> </font>acquired<font style="letter-spacing:0.95pt;"> </font>at<font style="letter-spacing:0.95pt;"> </font>least<font style="letter-spacing:0.95pt;"> </font>85%<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.95pt;"> </font>the<font style="letter-spacing:0.95pt;"> </font>outstanding<font style="letter-spacing:0.95pt;"> </font>voting<font style="letter-spacing:0.95pt;"> </font>stock<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.95pt;"> </font>the<font style="letter-spacing:2pt;"> </font>corporation<font style="letter-spacing:1.3pt;"> </font>in<font style="letter-spacing:1.3pt;"> </font>the<font style="letter-spacing:1.3pt;"> </font>transaction<font style="letter-spacing:1.3pt;"> </font>in<font style="letter-spacing:1.3pt;"> </font>which<font style="letter-spacing:1.3pt;"> </font>it<font style="letter-spacing:1.3pt;"> </font>became<font style="letter-spacing:1.3pt;"> </font>an<font style="letter-spacing:1.3pt;"> </font>interested<font style="letter-spacing:1.3pt;"> </font>stockholder.<font style="letter-spacing:1.3pt;"> </font>A<font style="letter-spacing:1.3pt;"> </font>&#8220;business<font style="letter-spacing:1.3pt;"> </font>combination&#8221;<font style="letter-spacing:1.3pt;"> </font>includes,<font style="letter-spacing:2pt;"> </font>among<font style="letter-spacing:1.45pt;"> </font>other<font style="letter-spacing:1.45pt;"> </font>things,<font style="letter-spacing:1.45pt;"> </font>a<font style="letter-spacing:1.45pt;"> </font>merger<font style="letter-spacing:1.45pt;"> </font>or<font style="letter-spacing:1.45pt;"> </font>consolidation<font style="letter-spacing:1.45pt;"> </font>involving<font style="letter-spacing:1.45pt;"> </font>the<font style="letter-spacing:1.45pt;"> </font>Company<font style="letter-spacing:1.45pt;"> </font>and<font style="letter-spacing:1.45pt;"> </font>an<font style="letter-spacing:1.45pt;"> </font>&#8220;interested<font style="letter-spacing:1.45pt;"> </font>stockholder&#8221;<font style="letter-spacing:1.45pt;"> </font>and<font style="letter-spacing:1.45pt;"> </font>the<font style="letter-spacing:2pt;"> </font>sale<font style="letter-spacing:1.25pt;"> </font>of<font style="letter-spacing:1.25pt;"> </font>more<font style="letter-spacing:1.25pt;"> </font>than<font style="letter-spacing:1.25pt;"> </font>10%<font style="letter-spacing:1.25pt;"> </font>of<font style="letter-spacing:1.25pt;"> </font>the<font style="letter-spacing:1.25pt;"> </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.1%;margin-right:12.1%;margin-top:30pt;page-break-after:always;width:75.8%;border-width:0;"><div style="max-width:100%;padding-left:12.1%;padding-right:12.1%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:0.07;margin:0pt;"><font style="font-size:16pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.22;margin:0pt 23.75pt 0pt 24.1pt;">Company&#8217;s<font style="letter-spacing:1.25pt;"> </font>assets.<font style="letter-spacing:1.25pt;"> </font>In<font style="letter-spacing:1.25pt;"> </font>general,<font style="letter-spacing:1.25pt;"> </font>an<font style="letter-spacing:1.25pt;"> </font>&#8220;interested<font style="letter-spacing:1.25pt;"> </font>stockholder&#8221;<font style="letter-spacing:1.25pt;"> </font>is<font style="letter-spacing:1.25pt;"> </font>any<font style="letter-spacing:1.25pt;"> </font>entity<font style="letter-spacing:1.25pt;"> </font>or<font style="letter-spacing:1.25pt;"> </font>person<font style="letter-spacing:2pt;"> </font>beneficially<font style="letter-spacing:1.1pt;"> </font>owning<font style="letter-spacing:1.1pt;"> </font>15%<font style="letter-spacing:1.1pt;"> </font>or<font style="letter-spacing:1.1pt;"> </font>more<font style="letter-spacing:1.1pt;"> </font>of<font style="letter-spacing:1.1pt;"> </font>the<font style="letter-spacing:1.1pt;"> </font>Company&#8217;s<font style="letter-spacing:1.1pt;"> </font>outstanding<font style="letter-spacing:1.1pt;"> </font>voting<font style="letter-spacing:1.1pt;"> </font>stock<font style="letter-spacing:1.1pt;"> </font>and<font style="letter-spacing:1.1pt;"> </font>any<font style="letter-spacing:1.1pt;"> </font>entity<font style="letter-spacing:1.1pt;"> </font>or<font style="letter-spacing:1.1pt;"> </font>person<font style="letter-spacing:1.1pt;"> </font>affiliated<font style="letter-spacing:2pt;"> </font>with or controlling or controlled by such entity or person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.2pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;font-weight:bold;margin:0pt 0pt 0pt 24.1pt;">Staggered<font style="letter-spacing:2.25pt;"> </font><font style="letter-spacing:-0.1pt;">board</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:1.79pt 0pt 0pt 0pt;"><font style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.22;margin:0pt 26.35pt 0pt 24.1pt;">Verastem&#8217;s Certificate of Incorporation and Bylaws divide its board of directors into three classes with staggered<font style="letter-spacing:2pt;"> </font>three-year terms. In addition, the Certificate of Incorporation and Bylaws provide that directors may be removed<font style="letter-spacing:4pt;"> </font>only<font style="letter-spacing:1pt;"> </font>for<font style="letter-spacing:1pt;"> </font>cause<font style="letter-spacing:1pt;"> </font>and<font style="letter-spacing:1pt;"> </font>only<font style="letter-spacing:1pt;"> </font>by<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:1pt;"> </font>affirmative<font style="letter-spacing:1pt;"> </font>vote<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:1pt;"> </font>holders<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:1pt;"> </font>75%<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:1pt;"> </font>shares<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:1pt;"> </font>capital<font style="letter-spacing:1pt;"> </font>stock<font style="letter-spacing:1pt;"> </font>present<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:2pt;"> </font>person<font style="letter-spacing:1.05pt;"> </font>or<font style="letter-spacing:1.05pt;"> </font>by<font style="letter-spacing:1.05pt;"> </font>proxy<font style="letter-spacing:1.05pt;"> </font>and<font style="letter-spacing:1.05pt;"> </font>entitled<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:1.05pt;"> </font>vote.<font style="letter-spacing:1.05pt;"> </font>Under<font style="letter-spacing:1.05pt;"> </font>the<font style="letter-spacing:1.05pt;"> </font>Certificate<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:1.05pt;"> </font>Incorporation<font style="letter-spacing:1.05pt;"> </font>and<font style="letter-spacing:1.05pt;"> </font>Bylaws,<font style="letter-spacing:1.05pt;"> </font>any<font style="letter-spacing:1.05pt;"> </font>vacancy<font style="letter-spacing:1.05pt;"> </font>on<font style="letter-spacing:1.05pt;"> </font>the<font style="letter-spacing:2pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>board<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.9pt;"> </font>directors,<font style="letter-spacing:0.9pt;"> </font>including<font style="letter-spacing:0.9pt;"> </font>a<font style="letter-spacing:0.9pt;"> </font>vacancy<font style="letter-spacing:0.9pt;"> </font>resulting<font style="letter-spacing:0.9pt;"> </font>from<font style="letter-spacing:0.9pt;"> </font>an<font style="letter-spacing:0.9pt;"> </font>enlargement<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.9pt;"> </font>the<font style="letter-spacing:0.9pt;"> </font>board<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.9pt;"> </font>directors,<font style="letter-spacing:0.9pt;"> </font>may<font style="letter-spacing:2pt;"> </font>be filled only by vote of a majority of the directors then in office. Furthermore, the Certificate of Incorporation<font style="letter-spacing:2pt;"> </font>provides<font style="letter-spacing:1.25pt;"> </font>that<font style="letter-spacing:1.25pt;"> </font>the<font style="letter-spacing:1.25pt;"> </font>authorized<font style="letter-spacing:1.25pt;"> </font>number<font style="letter-spacing:1.25pt;"> </font>of<font style="letter-spacing:1.25pt;"> </font>directors<font style="letter-spacing:1.25pt;"> </font>may<font style="letter-spacing:1.25pt;"> </font>be<font style="letter-spacing:1.25pt;"> </font>changed<font style="letter-spacing:1.25pt;"> </font>only<font style="letter-spacing:1.25pt;"> </font>by<font style="letter-spacing:1.25pt;"> </font>the<font style="letter-spacing:1.25pt;"> </font>resolution<font style="letter-spacing:1.25pt;"> </font>of<font style="letter-spacing:1.25pt;"> </font>the<font style="letter-spacing:1.25pt;"> </font>board<font style="letter-spacing:1.25pt;"> </font>of<font style="letter-spacing:2pt;"> </font>directors.<font style="letter-spacing:1.25pt;"> </font>The<font style="letter-spacing:1.25pt;"> </font>classification<font style="letter-spacing:1.25pt;"> </font>of<font style="letter-spacing:1.25pt;"> </font>the<font style="letter-spacing:1.25pt;"> </font>board<font style="letter-spacing:1.25pt;"> </font>of<font style="letter-spacing:1.25pt;"> </font>directors<font style="letter-spacing:1.25pt;"> </font>and<font style="letter-spacing:1.25pt;"> </font>the<font style="letter-spacing:1.25pt;"> </font>limitations<font style="letter-spacing:1.25pt;"> </font>on<font style="letter-spacing:1.25pt;"> </font>the<font style="letter-spacing:1.25pt;"> </font>ability<font style="letter-spacing:1.25pt;"> </font>of<font style="letter-spacing:1.25pt;"> </font>the<font style="letter-spacing:1.25pt;"> </font>Company&#8217;s<font style="letter-spacing:2pt;"> </font>stockholders<font style="letter-spacing:1.4pt;"> </font>to<font style="letter-spacing:1.4pt;"> </font>remove<font style="letter-spacing:1.4pt;"> </font>directors,<font style="letter-spacing:1.4pt;"> </font>change<font style="letter-spacing:1.4pt;"> </font>the<font style="letter-spacing:1.4pt;"> </font>authorized<font style="letter-spacing:1.4pt;"> </font>number<font style="letter-spacing:1.4pt;"> </font>of<font style="letter-spacing:1.4pt;"> </font>directors<font style="letter-spacing:1.4pt;"> </font>and<font style="letter-spacing:1.4pt;"> </font>fill<font style="letter-spacing:1.4pt;"> </font>vacancies<font style="letter-spacing:1.4pt;"> </font>could<font style="letter-spacing:1.4pt;"> </font>make<font style="letter-spacing:1.4pt;"> </font>it<font style="letter-spacing:2pt;"> </font>more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of the<font style="letter-spacing:2pt;"> </font><font style="letter-spacing:-0.1pt;">Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.2pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;font-weight:bold;line-height:1.22;margin:0pt 26.3pt 0pt 24.1pt;">Stockholder<font style="letter-spacing:1.7pt;"> </font>action&#894;<font style="letter-spacing:1.7pt;"> </font>special<font style="letter-spacing:1.7pt;"> </font>meeting<font style="letter-spacing:1.7pt;"> </font>of<font style="letter-spacing:1.7pt;"> </font>stockholders&#894;<font style="letter-spacing:1.7pt;"> </font>advance<font style="letter-spacing:1.7pt;"> </font>notice<font style="letter-spacing:1.7pt;"> </font>requirements<font style="letter-spacing:1.7pt;"> </font>for<font style="letter-spacing:1.7pt;"> </font>stockholder<font style="letter-spacing:1.7pt;"> </font>proposals<font style="letter-spacing:2pt;"> </font>and director nominations</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:1.54pt 0pt 0pt 0pt;"><font style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.22;margin:0pt 23.75pt 0pt 24.1pt;">Verastem&#8217;s<font style="letter-spacing:1.05pt;"> </font>Certificate<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:1.05pt;"> </font>Incorporation<font style="letter-spacing:1.05pt;"> </font>and<font style="letter-spacing:1.05pt;"> </font>Bylaws<font style="letter-spacing:1.05pt;"> </font>provide<font style="letter-spacing:1.05pt;"> </font>that<font style="letter-spacing:1.05pt;"> </font>any<font style="letter-spacing:1.05pt;"> </font>action<font style="letter-spacing:1.05pt;"> </font>required<font style="letter-spacing:1.05pt;"> </font>or<font style="letter-spacing:1.05pt;"> </font>permitted<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:1.05pt;"> </font>be<font style="letter-spacing:1.05pt;"> </font>taken<font style="letter-spacing:1.05pt;"> </font>by<font style="letter-spacing:2pt;"> </font>its<font style="letter-spacing:1.15pt;"> </font>stockholders<font style="letter-spacing:1.15pt;"> </font>at<font style="letter-spacing:1.15pt;"> </font>an<font style="letter-spacing:1.15pt;"> </font>annual<font style="letter-spacing:1.15pt;"> </font>meeting<font style="letter-spacing:1.15pt;"> </font>or<font style="letter-spacing:1.15pt;"> </font>special<font style="letter-spacing:1.15pt;"> </font>meeting<font style="letter-spacing:1.15pt;"> </font>of<font style="letter-spacing:1.15pt;"> </font>stockholders<font style="letter-spacing:1.15pt;"> </font>may<font style="letter-spacing:1.15pt;"> </font>only<font style="letter-spacing:1.15pt;"> </font>be<font style="letter-spacing:1.15pt;"> </font>taken<font style="letter-spacing:1.15pt;"> </font>if<font style="letter-spacing:1.15pt;"> </font>it<font style="letter-spacing:1.15pt;"> </font>is<font style="letter-spacing:1.15pt;"> </font>properly<font style="letter-spacing:2pt;"> </font>brought before such meeting and may not be taken by written action in lieu of a meeting. The Certificate of<font style="letter-spacing:2pt;"> </font>Incorporation<font style="letter-spacing:1.4pt;"> </font>and<font style="letter-spacing:1.4pt;"> </font>Bylaws<font style="letter-spacing:1.35pt;"> </font>also<font style="letter-spacing:1.4pt;"> </font>provide<font style="letter-spacing:1.4pt;"> </font>that,<font style="letter-spacing:1.35pt;"> </font>except<font style="letter-spacing:1.4pt;"> </font>as<font style="letter-spacing:1.4pt;"> </font>otherwise<font style="letter-spacing:1.35pt;"> </font>required<font style="letter-spacing:1.4pt;"> </font>by<font style="letter-spacing:1.4pt;"> </font>law,<font style="letter-spacing:1.35pt;"> </font>special<font style="letter-spacing:1.4pt;"> </font>meetings<font style="letter-spacing:1.4pt;"> </font>of<font style="letter-spacing:1.35pt;"> </font>the<font style="letter-spacing:2pt;"> </font>stockholders<font style="letter-spacing:1pt;"> </font>can<font style="letter-spacing:1.05pt;"> </font>be<font style="letter-spacing:1pt;"> </font>called<font style="letter-spacing:1.05pt;"> </font>only<font style="letter-spacing:1.05pt;"> </font>by<font style="letter-spacing:1.05pt;"> </font>the<font style="letter-spacing:1pt;"> </font>Company&#8217;s<font style="letter-spacing:1pt;"> </font>chairman<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:1.05pt;"> </font>the<font style="letter-spacing:1pt;"> </font>board,<font style="letter-spacing:1.05pt;"> </font>president<font style="letter-spacing:1pt;"> </font>or<font style="letter-spacing:1.05pt;"> </font>chief<font style="letter-spacing:1.05pt;"> </font>executive<font style="letter-spacing:1pt;"> </font>officer<font style="letter-spacing:1.05pt;"> </font>or<font style="letter-spacing:2pt;"> </font>the<font style="letter-spacing:1.05pt;"> </font>board<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:1.05pt;"> </font>directors.<font style="letter-spacing:1.05pt;"> </font>In<font style="letter-spacing:1.05pt;"> </font>addition,<font style="letter-spacing:1.05pt;"> </font>the<font style="letter-spacing:1.05pt;"> </font>Company&#8217;s<font style="letter-spacing:1.05pt;"> </font>Bylaws<font style="letter-spacing:1.05pt;"> </font>establish<font style="letter-spacing:1.05pt;"> </font>an<font style="letter-spacing:1.05pt;"> </font>advance<font style="letter-spacing:1.05pt;"> </font>notice<font style="letter-spacing:1.05pt;"> </font>procedure<font style="letter-spacing:1.05pt;"> </font>for<font style="letter-spacing:1.05pt;"> </font>stockholder<font style="letter-spacing:2pt;"> </font>proposals<font style="letter-spacing:1.95pt;"> </font>to<font style="letter-spacing:1.95pt;"> </font>be<font style="letter-spacing:1.95pt;"> </font>brought<font style="letter-spacing:1.95pt;"> </font>before<font style="letter-spacing:1.95pt;"> </font>an<font style="letter-spacing:1.95pt;"> </font>annual<font style="letter-spacing:1.95pt;"> </font>meeting<font style="letter-spacing:1.95pt;"> </font>of<font style="letter-spacing:1.95pt;"> </font>stockholders,<font style="letter-spacing:1.95pt;"> </font>including<font style="letter-spacing:1.95pt;"> </font>proposed<font style="letter-spacing:1.95pt;"> </font>nominations<font style="letter-spacing:1.95pt;"> </font>of<font style="letter-spacing:2pt;"> </font>candidates<font style="letter-spacing:1.05pt;"> </font>for<font style="letter-spacing:1.05pt;"> </font>election<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:1.05pt;"> </font>the<font style="letter-spacing:1.05pt;"> </font>board<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:1.05pt;"> </font>directors.<font style="letter-spacing:1.05pt;"> </font>Stockholders<font style="letter-spacing:1.05pt;"> </font>at<font style="letter-spacing:1.05pt;"> </font>an<font style="letter-spacing:1.05pt;"> </font>annual<font style="letter-spacing:1.05pt;"> </font>meeting<font style="letter-spacing:1.05pt;"> </font>may<font style="letter-spacing:1.05pt;"> </font>consider<font style="letter-spacing:1.05pt;"> </font>only<font style="letter-spacing:1.05pt;"> </font>proposals<font style="letter-spacing:2pt;"> </font>or<font style="letter-spacing:1.1pt;"> </font>nominations<font style="letter-spacing:1.1pt;"> </font>specified<font style="letter-spacing:1.1pt;"> </font>in<font style="letter-spacing:1.1pt;"> </font>the<font style="letter-spacing:1.1pt;"> </font>notice<font style="letter-spacing:1.1pt;"> </font>of<font style="letter-spacing:1.1pt;"> </font>meeting<font style="letter-spacing:1.1pt;"> </font>or<font style="letter-spacing:1.1pt;"> </font>brought<font style="letter-spacing:1.1pt;"> </font>before<font style="letter-spacing:1.1pt;"> </font>the<font style="letter-spacing:1.1pt;"> </font>meeting<font style="letter-spacing:1.1pt;"> </font>by<font style="letter-spacing:1.1pt;"> </font>or<font style="letter-spacing:1.1pt;"> </font>at<font style="letter-spacing:1.1pt;"> </font>the<font style="letter-spacing:1.1pt;"> </font>direction<font style="letter-spacing:1.1pt;"> </font>of<font style="letter-spacing:1.1pt;"> </font>the board<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.7pt;"> </font>directors,<font style="letter-spacing:1.85pt;"> </font>or<font style="letter-spacing:0.7pt;"> </font>by<font style="letter-spacing:0.7pt;"> </font>a<font style="letter-spacing:0.7pt;"> </font>stockholder<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.7pt;"> </font>record<font style="letter-spacing:0.7pt;"> </font>on<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.7pt;"> </font>record<font style="letter-spacing:0.7pt;"> </font>date<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.7pt;"> </font>meeting<font style="letter-spacing:0.7pt;"> </font>who<font style="letter-spacing:0.7pt;"> </font>is<font style="letter-spacing:0.7pt;"> </font>entitled<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.7pt;"> </font>vote<font style="letter-spacing:0.7pt;"> </font>at<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:2pt;"> </font>meeting<font style="letter-spacing:1pt;"> </font>and<font style="letter-spacing:1pt;"> </font>who<font style="letter-spacing:1pt;"> </font>has<font style="letter-spacing:1pt;"> </font>delivered<font style="letter-spacing:1pt;"> </font>timely<font style="letter-spacing:1pt;"> </font>written<font style="letter-spacing:1pt;"> </font>notice<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:1pt;"> </font>proper<font style="letter-spacing:1pt;"> </font>form<font style="letter-spacing:1pt;"> </font>to<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:1pt;"> </font>Company&#8217;s<font style="letter-spacing:1pt;"> </font>secretary<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:2pt;"> </font>stockholder&#8217;s<font style="letter-spacing:1.75pt;"> </font>intention<font style="letter-spacing:1.75pt;"> </font>to<font style="letter-spacing:1.75pt;"> </font>bring<font style="letter-spacing:1.75pt;"> </font>such<font style="letter-spacing:1.75pt;"> </font>business<font style="letter-spacing:1.75pt;"> </font>before<font style="letter-spacing:1.75pt;"> </font>the<font style="letter-spacing:1.75pt;"> </font>meeting.<font style="letter-spacing:1.75pt;"> </font>These<font style="letter-spacing:1.75pt;"> </font>provisions<font style="letter-spacing:1.75pt;"> </font>could<font style="letter-spacing:1.75pt;"> </font>have<font style="letter-spacing:1.75pt;"> </font>the<font style="letter-spacing:1.75pt;"> </font>effect<font style="letter-spacing:1.75pt;"> </font>of<font style="letter-spacing:2pt;"> </font>delaying<font style="letter-spacing:1.15pt;"> </font>until<font style="letter-spacing:1.15pt;"> </font>the<font style="letter-spacing:1.15pt;"> </font>next<font style="letter-spacing:1.15pt;"> </font>stockholder<font style="letter-spacing:1.15pt;"> </font>meeting<font style="letter-spacing:1.15pt;"> </font>stockholder<font style="letter-spacing:1.15pt;"> </font>actions<font style="letter-spacing:1.15pt;"> </font>that<font style="letter-spacing:1.15pt;"> </font>are<font style="letter-spacing:1.15pt;"> </font>favored<font style="letter-spacing:1.15pt;"> </font>by<font style="letter-spacing:1.15pt;"> </font>the<font style="letter-spacing:1.15pt;"> </font>holders<font style="letter-spacing:1.15pt;"> </font>of<font style="letter-spacing:1.15pt;"> </font>a<font style="letter-spacing:1.15pt;"> </font>majority<font style="letter-spacing:1.15pt;"> </font>of the<font style="letter-spacing:0.9pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>outstanding<font style="letter-spacing:0.9pt;"> </font>voting<font style="letter-spacing:0.9pt;"> </font>securities.<font style="letter-spacing:0.9pt;"> </font>These<font style="letter-spacing:0.9pt;"> </font>provisions<font style="letter-spacing:0.9pt;"> </font>also<font style="letter-spacing:0.9pt;"> </font>could<font style="letter-spacing:0.9pt;"> </font>discourage<font style="letter-spacing:0.9pt;"> </font>a<font style="letter-spacing:0.9pt;"> </font>third<font style="letter-spacing:0.9pt;"> </font>party<font style="letter-spacing:0.9pt;"> </font>from<font style="letter-spacing:0.95pt;"> </font><font style="letter-spacing:-0.1pt;">making </font>a<font style="letter-spacing:0.4pt;"> </font>tender<font style="letter-spacing:0.45pt;"> </font>offer<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>Company&#8217;s<font style="letter-spacing:0.45pt;"> </font>common<font style="letter-spacing:0.45pt;"> </font>stock,<font style="letter-spacing:0.4pt;"> </font>because<font style="letter-spacing:0.45pt;"> </font>even<font style="letter-spacing:0.45pt;"> </font>if<font style="letter-spacing:0.45pt;"> </font>it<font style="letter-spacing:0.4pt;"> </font>acquired<font style="letter-spacing:0.45pt;"> </font><font style="letter-spacing:-0.5pt;">a </font>majority<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.85pt;"> </font>outstanding<font style="letter-spacing:0.85pt;"> </font>voting<font style="letter-spacing:0.85pt;"> </font>stock,<font style="letter-spacing:0.85pt;"> </font>it<font style="letter-spacing:0.85pt;"> </font>would<font style="letter-spacing:0.85pt;"> </font>be<font style="letter-spacing:0.85pt;"> </font>able<font style="letter-spacing:0.85pt;"> </font>to<font style="letter-spacing:0.85pt;"> </font>take<font style="letter-spacing:0.85pt;"> </font>action<font style="letter-spacing:0.85pt;"> </font>as<font style="letter-spacing:0.85pt;"> </font>a<font style="letter-spacing:0.85pt;"> </font>stockholder,<font style="letter-spacing:0.85pt;"> </font>such<font style="letter-spacing:0.85pt;"> </font>as<font style="letter-spacing:0.85pt;"> </font>electing<font style="letter-spacing:0.85pt;"> </font>new<font style="letter-spacing:2pt;"> </font>directors<font style="letter-spacing:1.3pt;"> </font>or<font style="letter-spacing:1.3pt;"> </font>approving<font style="letter-spacing:1.3pt;"> </font>a<font style="letter-spacing:1.3pt;"> </font>merger,<font style="letter-spacing:1.3pt;"> </font>only<font style="letter-spacing:1.3pt;"> </font>at<font style="letter-spacing:1.3pt;"> </font>a<font style="letter-spacing:1.3pt;"> </font>duly<font style="letter-spacing:1.3pt;"> </font>called<font style="letter-spacing:1.3pt;"> </font>stockholders<font style="letter-spacing:1.3pt;"> </font>meeting<font style="letter-spacing:1.3pt;"> </font>and<font style="letter-spacing:1.3pt;"> </font>not<font style="letter-spacing:1.3pt;"> </font>by<font style="letter-spacing:1.3pt;"> </font>written<font style="letter-spacing:1.3pt;"> </font>consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.25pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;font-weight:bold;margin:0pt 0pt 0pt 24.1pt;"><font style="letter-spacing:0.1pt;">Super-majority</font><font style="letter-spacing:1.1pt;"> </font><font style="letter-spacing:-0.1pt;">voting</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:1.79pt 0pt 0pt 0pt;"><font style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.22;margin:0pt 29.1pt 0pt 24.1pt;">The Delaware General Corporation Law provides generally that the affirmative vote of a majority of the shares<font style="letter-spacing:2pt;"> </font>entitled<font style="letter-spacing:0.85pt;"> </font>to<font style="letter-spacing:0.85pt;"> </font>vote<font style="letter-spacing:0.85pt;"> </font>on<font style="letter-spacing:0.85pt;"> </font>any<font style="letter-spacing:0.85pt;"> </font>matter<font style="letter-spacing:0.85pt;"> </font>is<font style="letter-spacing:0.85pt;"> </font>required<font style="letter-spacing:0.85pt;"> </font>to<font style="letter-spacing:0.85pt;"> </font>amend<font style="letter-spacing:0.85pt;"> </font>a<font style="letter-spacing:0.85pt;"> </font>corporation&#8217;s<font style="letter-spacing:0.85pt;"> </font>certificate<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.85pt;"> </font>incorporation<font style="letter-spacing:0.85pt;"> </font>or<font style="letter-spacing:0.85pt;"> </font>bylaws,<font style="letter-spacing:0.85pt;"> </font>unless<font style="letter-spacing:2pt;"> </font>a<font style="letter-spacing:1.4pt;"> </font>corporation&#8217;s<font style="letter-spacing:1.4pt;"> </font>certificate<font style="letter-spacing:1.4pt;"> </font>of<font style="letter-spacing:1.35pt;"> </font>incorporation<font style="letter-spacing:1.4pt;"> </font>or<font style="letter-spacing:1.4pt;"> </font>bylaws,<font style="letter-spacing:1.4pt;"> </font>as<font style="letter-spacing:1.35pt;"> </font>the<font style="letter-spacing:1.4pt;"> </font>case<font style="letter-spacing:1.4pt;"> </font>may<font style="letter-spacing:1.4pt;"> </font>be,<font style="letter-spacing:1.35pt;"> </font>requires<font style="letter-spacing:1.4pt;"> </font>a<font style="letter-spacing:1.4pt;"> </font>greater<font style="letter-spacing:1.4pt;"> </font>percentage. Verastem&#8217;s bylaws may be amended or repealed by a majority vote of the Company&#8217;s board of directors or the<font style="letter-spacing:2pt;"> </font>affirmative<font style="letter-spacing:0.9pt;"> </font>vote<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.9pt;"> </font>the<font style="letter-spacing:0.9pt;"> </font>holders<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.9pt;"> </font>at<font style="letter-spacing:0.9pt;"> </font>least<font style="letter-spacing:0.9pt;"> </font>75%<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.9pt;"> </font>the<font style="letter-spacing:0.9pt;"> </font>votes<font style="letter-spacing:0.9pt;"> </font>that<font style="letter-spacing:0.9pt;"> </font>the<font style="letter-spacing:0.9pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>stockholders<font style="letter-spacing:0.9pt;"> </font>would<font style="letter-spacing:0.9pt;"> </font>be<font style="letter-spacing:0.9pt;"> </font>entitled<font style="letter-spacing:0.9pt;"> </font>to<font style="letter-spacing:2pt;"> </font>cast<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:1pt;"> </font>any<font style="letter-spacing:1pt;"> </font>annual<font style="letter-spacing:1pt;"> </font>election<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:1pt;"> </font>directors.<font style="letter-spacing:1pt;"> </font>In<font style="letter-spacing:1pt;"> </font>addition,<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:1pt;"> </font>affirmative<font style="letter-spacing:1pt;"> </font>vote<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:1pt;"> </font>holders<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:1pt;"> </font>at<font style="letter-spacing:1pt;"> </font>least<font style="letter-spacing:1pt;"> </font>75%<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:2pt;"> </font>votes<font style="letter-spacing:0.9pt;"> </font>that<font style="letter-spacing:0.9pt;"> </font>the<font style="letter-spacing:0.9pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>stockholders<font style="letter-spacing:0.9pt;"> </font>would<font style="letter-spacing:0.9pt;"> </font>be<font style="letter-spacing:0.9pt;"> </font>entitled<font style="letter-spacing:0.9pt;"> </font>to<font style="letter-spacing:0.9pt;"> </font>cast<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.9pt;"> </font>any<font style="letter-spacing:0.9pt;"> </font>election<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.9pt;"> </font>directors<font style="letter-spacing:0.9pt;"> </font>is<font style="letter-spacing:0.9pt;"> </font>required<font style="letter-spacing:0.9pt;"> </font>to<font style="letter-spacing:0.9pt;"> </font>amend<font style="letter-spacing:2pt;"> </font>or<font style="letter-spacing:1.3pt;"> </font>repeal<font style="letter-spacing:1.3pt;"> </font>or<font style="letter-spacing:1.3pt;"> </font>to<font style="letter-spacing:1.3pt;"> </font>adopt<font style="letter-spacing:1.3pt;"> </font>any<font style="letter-spacing:1.3pt;"> </font>provisions<font style="letter-spacing:1.3pt;"> </font>inconsistent<font style="letter-spacing:1.3pt;"> </font>with<font style="letter-spacing:1.3pt;"> </font>any<font style="letter-spacing:1.3pt;"> </font>of<font style="letter-spacing:1.3pt;"> </font>the<font style="letter-spacing:1.3pt;"> </font>provisions<font style="letter-spacing:1.3pt;"> </font>of<font style="letter-spacing:1.3pt;"> </font>Verastem&#8217;s<font style="letter-spacing:1.3pt;"> </font>Certificate<font style="letter-spacing:1.3pt;"> </font>of<font style="letter-spacing:2pt;"> </font>Incorporation described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.8pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;margin:0.05pt 0pt 0pt 24.1pt;">Transfer<b style="font-weight:bold;letter-spacing:-0.15pt;"> </b>Agent<b style="font-weight:bold;letter-spacing:-0.1pt;"> </b>and<b style="font-weight:bold;letter-spacing:-0.1pt;"> Registrar</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:1.14pt 0pt 0pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24.1pt;">The<font style="letter-spacing:0.5pt;"> </font>transfer<font style="letter-spacing:0.5pt;"> </font>agent<font style="letter-spacing:0.5pt;"> </font>and<font style="letter-spacing:0.5pt;"> </font>registrar<font style="letter-spacing:0.5pt;"> </font>for<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.5pt;"> </font>common<font style="letter-spacing:0.5pt;"> </font>stock<font style="letter-spacing:0.5pt;"> </font>is<font style="letter-spacing:0.5pt;"> </font>Computershare<font style="letter-spacing:0.5pt;"> </font>Trust<font style="letter-spacing:0.5pt;"> </font>Company,<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.2pt;">N.A.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:1.14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;margin:0pt 0pt 0pt 24.1pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Listing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:1.2pt 0pt 0pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24.1pt;">The<font style="letter-spacing:0.45pt;"> </font>Company&#8217;s<font style="letter-spacing:0.45pt;"> </font>common<font style="letter-spacing:0.5pt;"> </font>stock<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.45pt;"> </font>listed<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.45pt;"> </font>The<font style="letter-spacing:0.45pt;"> </font>Nasdaq<font style="letter-spacing:0.5pt;"> </font>Capital<font style="letter-spacing:0.45pt;"> </font>Market<font style="letter-spacing:0.5pt;"> </font>under<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>symbol<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">&#8220;VSTM.&#8221;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:12.1%;margin-right:12.1%;margin-top:30pt;page-break-after:avoid;width:75.8%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.49
<SEQUENCE>3
<FILENAME>vstm-20251231xex10d49.htm
<DESCRIPTION>EX-10.49
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/4/2026 08:56:06 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:8.82%;position:relative;"><div style="min-height:69pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:48.15%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.49</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:center;margin:3.04pt 0pt 0pt 48.5pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AMENDMENT</b><b style="font-weight:bold;letter-spacing:-0.3pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NO.</b><b style="font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1</b><b style="font-weight:bold;letter-spacing:-0.45pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TO</b><b style="font-weight:bold;letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE</b><b style="font-weight:bold;letter-spacing:-0.35pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PURCHASE</b><b style="font-weight:bold;letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AGREEMENT</b><b style="font-weight:bold;letter-spacing:-0.35pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AND</b><b style="font-weight:bold;letter-spacing:0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">WAIVER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:12.55pt 17.65pt 0pt 0pt;">October<font style="letter-spacing:-0.15pt;"> </font>31,<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.2pt;">2025</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:12.1pt 17.55pt 0pt 0pt;">This<font style="letter-spacing:-0.25pt;"> </font>Amendment<font style="letter-spacing:-0.25pt;"> </font>No.<font style="letter-spacing:-0.2pt;"> </font>1<font style="letter-spacing:-0.3pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>Note<font style="letter-spacing:-0.4pt;"> </font>Purchase<font style="letter-spacing:-0.35pt;"> </font>Agreement<font style="letter-spacing:-0.25pt;"> </font>and<font style="letter-spacing:-0.1pt;"> </font>Waiver<font style="letter-spacing:-0.35pt;"> </font>(this<font style="letter-spacing:-0.25pt;"> </font>&#8220;<font style="font-style:italic;font-weight:bold;">Amendment</font>&#8221;),<font style="letter-spacing:-0.4pt;"> </font>dated<font style="letter-spacing:-0.3pt;"> </font>as<font style="letter-spacing:-0.25pt;"> </font>of the date first set forth above, is entered into by and among Verastem, Inc., a Delaware corporation (&#8220;<font style="font-style:italic;font-weight:bold;">Issuer</font>&#8221;), the Persons listed on the signature pages hereof under the heading &#8220;<b style="font-weight:bold;">PURCHASERS</b>&#8221; (each a &#8220;<font style="font-style:italic;font-weight:bold;">Purchaser</font>&#8221; and, collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Purchasers</font>&#8221;), and RGCM SA LLC, a Delaware limited liability company (&#8220;<font style="font-style:italic;font-weight:bold;">Purchaser Agent</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:11.89pt 17.45pt 0pt 0pt;">Reference is hereby made to the Note Purchase Agreement, dated as of January 13, 2025 (as amended, restated,<font style="letter-spacing:-0.2pt;"> </font>amended<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>restated,<font style="letter-spacing:-0.2pt;"> </font>supplemented<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.35pt;"> </font>otherwise<font style="letter-spacing:-0.35pt;"> </font>modified<font style="letter-spacing:-0.3pt;"> </font>prior<font style="letter-spacing:-0.35pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>date<font style="letter-spacing:-0.15pt;"> </font>hereof,<font style="letter-spacing:-0.2pt;"> </font>the &#8220;<font style="font-style:italic;font-weight:bold;">Purchase Agreement</font>&#8221;), among Issuer, the Purchasers party thereto from time to time and Purchaser Agent.<font style="letter-spacing:2pt;"> </font>Capitalized<font style="letter-spacing:-0.3pt;"> </font>terms<font style="letter-spacing:-0.45pt;"> </font>not<font style="letter-spacing:-0.45pt;"> </font>otherwise<font style="letter-spacing:-0.35pt;"> </font>defined<font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.5pt;"> </font>this<font style="letter-spacing:-0.25pt;"> </font>Amendment<font style="letter-spacing:-0.2pt;"> </font>shall<font style="letter-spacing:-0.25pt;"> </font>have<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>meanings<font style="letter-spacing:-0.45pt;"> </font>set<font style="letter-spacing:-0.25pt;"> </font>forth<font style="letter-spacing:-0.5pt;"> </font>in<font style="letter-spacing:-0.5pt;"> </font>the Purchase Agreement.<font style="letter-spacing:2pt;"> </font>Issuer, the Purchasers and Purchaser Agent are sometimes referred to herein individually as a &#8220;<font style="font-style:italic;font-weight:bold;">Party</font>&#8221; and collectively as the &#8220;<font style="font-style:italic;font-weight:bold;">Parties</font>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:12.19pt 17.55pt 0pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Issuer acknowledges<font style="letter-spacing:-0.05pt;"> </font>that<font style="letter-spacing:-0.05pt;"> </font>Events<font style="letter-spacing:-0.05pt;"> </font>of Default have<font style="letter-spacing:-0.2pt;"> </font>occurred and are continuing under Section 8.2 of the Purchase Agreement for (a) failure to satisfy the post-closing requirement set forth in Section 3.6(d) of the<font style="letter-spacing:-0.05pt;"> </font>Purchase Agreement within<font style="letter-spacing:-0.05pt;"> </font>the timeframe specified therein, (b) failure to satisfy the reporting requirements set forth in Sections 6.2(a)(i) and 6.2(a)(iii) of the Purchase Agreement for the quarter<font style="letter-spacing:-0.35pt;"> </font>ended<font style="letter-spacing:-0.3pt;"> </font>June<font style="letter-spacing:-0.6pt;"> </font>30,<font style="letter-spacing:-0.4pt;"> </font>2025,<font style="letter-spacing:-0.4pt;"> </font>and<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.65pt;"> </font>requirement<font style="letter-spacing:-0.45pt;"> </font>set<font style="letter-spacing:-0.45pt;"> </font>forth<font style="letter-spacing:-0.55pt;"> </font>in<font style="letter-spacing:-0.55pt;"> </font>Section<font style="letter-spacing:-0.55pt;"> </font>6.2(a)(vi)<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.65pt;"> </font>Purchase<font style="letter-spacing:-0.35pt;"> </font>Agreement, in<font style="letter-spacing:-0.05pt;"> </font>each<font style="letter-spacing:-0.05pt;"> </font>case<font style="letter-spacing:-0.15pt;"> </font>within<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>timeframes<font style="letter-spacing:-0.05pt;"> </font>specified<font style="letter-spacing:-0.05pt;"> </font>therein,<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>(c)<font style="letter-spacing:-0.15pt;"> </font>any<font style="letter-spacing:-0.05pt;"> </font>other<font style="letter-spacing:-0.15pt;"> </font>Default or<font style="letter-spacing:-0.35pt;"> </font>Event<font style="letter-spacing:-0.25pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>Default<font style="letter-spacing:-0.25pt;"> </font>that<font style="letter-spacing:-0.25pt;"> </font>has occurred as a direct result or natural consequence of the Events of Default specified in<font style="letter-spacing:-0.05pt;"> </font>clauses (a) and (b) above (collectively, the Events of Defaults described in clauses (a) through (c), the &#8220;<font style="font-style:italic;font-weight:bold;">Specified Events of </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Default</font><font style="letter-spacing:-0.1pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:11.94pt 17.7pt 0pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Issuer has requested that Purchaser Agent and the Purchasers waive the Specified Events of Default, and, without waiving<font style="letter-spacing:-0.05pt;"> </font>or altering any<font style="letter-spacing:-0.05pt;"> </font>other previously agreed conditions, requirements, or representations made in any prior agreement between the Parties, Purchaser Agent and the Purchasers have agreed to grant such waiver on the terms set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:12.05pt 17.5pt 0pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, for good<font style="letter-spacing:-0.05pt;"> </font>and valuable consideration, the sufficiency and receipt of<font style="letter-spacing:-0.15pt;"> </font>which are hereby acknowledged, the Parties intending to be legally bound do hereby agree as follows:</p><div style="margin-top:11.94pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:18.05pt;text-indent:-18.05pt;margin:0pt 17.9pt 0pt 18pt;"><font style="display:inline-block;font-weight:bold;min-width:17.95pt;text-indent:0pt;white-space:nowrap;">1.</font><b style="font-weight:bold;">Waiver.</b><b style="font-weight:bold;letter-spacing:1.45pt;"> </b>Subject<font style="letter-spacing:1.4pt;"> </font>to<font style="letter-spacing:1.2pt;"> </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section</u><u style="letter-spacing:1.4pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3</u><font style="letter-spacing:1.1pt;"> </font>of<font style="letter-spacing:1.25pt;"> </font>this<font style="letter-spacing:1.4pt;"> </font>Amendment,<font style="letter-spacing:1.25pt;"> </font>Purchaser<font style="letter-spacing:1.25pt;"> </font>Agent<font style="letter-spacing:1.5pt;"> </font>and<font style="letter-spacing:1.35pt;"> </font>the<font style="letter-spacing:1.25pt;"> </font>Purchasers<font style="letter-spacing:1.45pt;"> </font>hereby waive the Specified Events of Default.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:18.05pt;text-indent:-18.05pt;margin:12.14pt 17.4pt 0pt 18pt;"><font style="display:inline-block;font-weight:bold;min-width:17.95pt;text-indent:0pt;white-space:nowrap;">2.</font><b style="font-weight:bold;">Amendment. </b>Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</u> of this Amendment, clause (c) of the definition of &#8220;Change of Control&#8221; in the Purchase Agreement is hereby amended and restated in its entirety as follows:</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:11.89pt 17.5pt 0pt 36.05pt;"><font style="display:inline-block;text-indent:0pt;width:35.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">&#8220;(c)</font></font>the<font style="letter-spacing:-0.4pt;"> </font>Transfer<font style="letter-spacing:-0.35pt;"> </font>in<font style="letter-spacing:-0.55pt;"> </font>one<font style="letter-spacing:-0.4pt;"> </font>or<font style="letter-spacing:-0.6pt;"> </font>a<font style="letter-spacing:-0.4pt;"> </font>series<font style="letter-spacing:-0.5pt;"> </font>of<font style="letter-spacing:-0.35pt;"> </font>transactions<font style="letter-spacing:-0.5pt;"> </font>(whether<font style="letter-spacing:-0.35pt;"> </font>or<font style="letter-spacing:-0.35pt;"> </font>not<font style="letter-spacing:-0.45pt;"> </font>related)<font style="letter-spacing:-0.35pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>all<font style="letter-spacing:-0.45pt;"> </font>or<font style="letter-spacing:-0.6pt;"> </font>substantially all of the consolidated assets of Issuers and its Subsidiaries; or&#8221;.</p><div style="margin-top:11.89pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:18.05pt;text-indent:-18.05pt;margin:0pt 17.75pt 0pt 18pt;"><font style="display:inline-block;font-weight:bold;min-width:17.95pt;text-indent:0pt;white-space:nowrap;">3.</font><b style="font-weight:bold;">Conditions</b><b style="font-weight:bold;letter-spacing:-0.3pt;"> </b><b style="font-weight:bold;">Precedent</b><b style="font-weight:bold;letter-spacing:-0.2pt;"> </b><b style="font-weight:bold;">to</b><b style="font-weight:bold;letter-spacing:-0.1pt;"> </b><b style="font-weight:bold;">Effectiveness</b>.<font style="letter-spacing:2pt;"> </font>The<font style="letter-spacing:-0.25pt;"> </font>effectiveness<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>this Amendment shall<font style="letter-spacing:-0.05pt;"> </font>be<font style="letter-spacing:-0.4pt;"> </font>subject<font style="letter-spacing:-0.3pt;"> </font>to the following conditions precedent:</div><div style="margin-top:12.14pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Purchaser Agent shall</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">have received this Amendment,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">duly executed</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">by</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Issuer,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Purchaser Agent and the Purchasers as required by Section 13.6(a) of the Purchase Agreement;</font></td><td style="width:17.65pt;"></td></tr></table><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36.05pt;"><font style="font-size:0pt;margin-left:0pt;margin-top:11.9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.15pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">1</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:8.82%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-top:3.04pt;"></div><div style="margin-top:3.04pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">No Event of Default, other than the Specified Events of Default, shall have occurred and not been waived as of the effective date of this Amendment; and</font></td><td style="width:17.8pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.2;margin-bottom:0pt;margin-top:11.89pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Issuer</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">shall</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">have</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">paid</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">all</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Reimbursable</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Expenses</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">all</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">other</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">amounts</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">then</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">due</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">owing pursuant to the Purchase Agreement.</font></td><td style="width:17.75pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:11.94pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:17.95pt;padding:0pt;">4.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Representations</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.3pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">and</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.35pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.1pt;">Warranties</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">.</font></td></tr></table><div style="margin-top:11.8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">The execution, delivery and performance by Issuer of this Amendment have been duly authorized</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">by</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">all</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">necessary</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">corporate</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">other</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">organizational</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">action.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">This</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Amendment</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Purchase</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">constitute</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Issuer&#8217;s</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">legal,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">valid</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">binding</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">obligation,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">enforceable against it in accordance with its terms.</font></td><td style="width:17.45pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.15pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">All written certificates and written statements heretofore furnished to Purchaser Agent or any Purchaser by or on behalf of Issuer for purposes of or in connection with this Amendment or any Note Document contemplated hereby are, taken as a whole, true, complete and correct in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">all material respects and Issuer</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">has not omitted</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">state a</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">material fact</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">necessary</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">order</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">make</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">such</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">information,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">taken</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">as</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">a</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">whole,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">not</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">misleading</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">light of the circumstances under which they were furnished.</font></td><td style="width:17.7pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Each</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">representations</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">warranties</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Article</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">V</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Purchase</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">are</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">true, accurate</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">complete</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">all</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">material</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">respects</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">as</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">date</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">hereof;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">that such</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">materiality</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">qualifier</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">shall</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">not</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">be</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">applicable</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">representations</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">warranties</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">that already are qualified or modified by materiality in the text thereof; </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date.</font></td><td style="width:17.5pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Other than the Specified Events of Default, no Event of Default has occurred and is continuing</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">no</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">event</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">has</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">occurred</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">is</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">continuing</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">which,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">with</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">giving</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">notice</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">or passage</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">time, or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">both, would constitute</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">an Event of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Default, on or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">prior</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">to the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">effective date of this Amendment.</font></td><td style="width:17.7pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:17.95pt;padding:0pt;">5.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Release</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">of</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.1pt;">Claims</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">.</font></td></tr></table><div style="margin-top:12.1pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Issuer hereby absolutely and unconditionally releases and forever discharges Purchaser Agent and each Purchaser, and any and all parent corporations, subsidiary corporations, affiliated</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">corporations, successors</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">assigns</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">thereof, together</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">with</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">all of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">present and former directors, officers, agents, attorneys and employees of any of the foregoing (each, a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">Releasee</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; and collectively, the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">Releasees</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), from any and all claims, demands or causes</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">action</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">kind,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">nature</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">description,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">whether</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">arising</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">law</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">equity</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">upon contract or tort or under any state or federal law or otherwise (each, a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">Claim</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; and collectively, the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">Claims</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), which Issuer has had, now has or has made claim to have against any such person for or by reason of any act, omission, matter, cause or thing whatsoever arising from the beginning of time to and including the date of this Amendment,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">whether</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">such</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">claims,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">demands</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">causes</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">action</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">are</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">matured</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">unmatured or known or unknown.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Issuer understands, acknowledges and agrees that the release set forth above</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">may</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">be pleaded as a full and complete</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">defense to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Claim and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">may</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">be</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Issuer agrees that no</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">fact, event, circumstance, evidence or Note Document which</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">could</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">now</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">be</font></td><td style="width:17.45pt;"></td></tr></table><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 36.05pt;"><font style="font-size:0pt;margin-left:0pt;margin-top:11.9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.95pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">2</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:8.82%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:3.04pt 17.5pt 0pt 72.05pt;">asserted<font style="letter-spacing:-0.35pt;"> </font>or<font style="letter-spacing:-0.4pt;"> </font>which<font style="letter-spacing:-0.35pt;"> </font>may<font style="letter-spacing:-0.35pt;"> </font>hereafter<font style="letter-spacing:-0.4pt;"> </font>be<font style="letter-spacing:-0.45pt;"> </font>discovered<font style="letter-spacing:-0.35pt;"> </font>will<font style="letter-spacing:-0.3pt;"> </font>affect<font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.35pt;"> </font>any<font style="letter-spacing:-0.35pt;"> </font>manner<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.45pt;"> </font>final,<font style="letter-spacing:-0.25pt;"> </font>absolute and unconditional nature of the release set forth above.</p><div style="margin-top:11.89pt;"></div><div style="margin-top:11.89pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Issuer hereby absolutely, unconditionally and irrevocably covenants and agrees with and in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">favor</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">each</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Releasee</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">it</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">will</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">not</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">sue</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(at</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">law,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">equity,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">regulatory</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">proceeding or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">otherwise)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Releasee</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">on</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">basis</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Claim</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">released, remised</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">discharged</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">by Issuer pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">above.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">If Issuer violates the foregoing covenant, Issuer for itself and its successors and assigns, agrees to pay, in addition to such other damages as any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Releasee</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">may</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">sustain</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">as</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">a</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">result</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">such</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">violation,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">all</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Reimbursable</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Expenses</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">incurred by any Releasee as a result of such violation.</font></td><td style="width:17.6pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:12.1pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:17.95pt;padding:0pt;">6.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.1pt;">General</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">.</font></td></tr></table><div style="margin-top:12.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Issuer hereby (i) acknowledges and agrees that all of its obligations under the Purchase Agreement and each other Note Document and under any other document or instrument executed and delivered or furnished in connection with such Note Documents are reaffirmed and remain in full force and effect on a continuous basis, including, for the avoidance of doubt, after giving effect to this Amendment, (ii) acknowledges, agrees and reaffirms that each Lien granted by it to Purchaser Agent under the Note Documents for the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">ratable</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">benefit</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Purchasers</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">is</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">shall</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">remain</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">full</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">force</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">effect</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">after</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">giving effect to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">this Amendment, (iii)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">agrees that</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the Obligations secured by</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the Note Document to which it is a party shall include all Obligations arising after giving effect to this Amendment and (iv) agrees that the Guaranteed Obligations guaranteed by the Guaranty to which it is a party shall include all Obligations arising after giving effect to this </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">Amendment.</font></td><td style="width:17.5pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:11.94pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i) Except as expressly set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> above, the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any rights, power or remedy of the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Purchasers or Purchaser Agent under the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Purchase Agreement or any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">other documents executed</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">connection with</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Purchase Agreement or constitute</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">a waiver</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of any provision of the Purchase Agreement or any other document executed in connection therewith</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">including,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">without</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">limitation,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Event</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Default</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(ii)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">this</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Amendment</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">shall not</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">by</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">implication,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">course</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">dealing</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">otherwise</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">limit,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">modify,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">amend</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">way</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">affect any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">terms,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">conditions,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">obligations,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">covenants</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">agreements</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Note</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Documents, in each case, except to the extent limited, modified, amended or affected by this </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">Amendment.</font></td><td style="width:17.5pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:12.05pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Except</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">as</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">expressly</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">modified</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">by</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">this</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Amendment,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">terms</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">provisions</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Purchase Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">shall</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">remain</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">unchanged</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">full</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">force</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">effect</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">accordance</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">with</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">its</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">terms. In the event of any inconsistencies between the provisions of this Amendment and the provisions of Purchase Agreement or any other Note Document, the provisions of this Amendment shall govern and prevail.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">This Amendment is a Note Document.</font></td><td style="width:17.6pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:12.1pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">This Amendment shall be governed by, and construed, interpreted and enforced in accordance</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">with,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">laws</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">state</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">New</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">York, without</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">giving</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">effect</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">principles of conflicts of law thereof.</font></td><td style="width:17.9pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">The provisions of Article X (Notices; Service of Process), Section 13.6 (Amendments in Writing;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">No</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Integration),</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Section</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">13.7</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(Counterparts;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Effectiveness;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Electronic</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Signature), Section 13.4 (Severability of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Provisions) and Article XI (Choice of Law, Venue and Jury</font></td><td style="width:17.45pt;"></td></tr></table><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 36.05pt;"><font style="font-size:0pt;margin-left:0pt;margin-top:11.9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.95pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">3</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:8.82%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:3.04pt 0pt 0pt 72.05pt;">Trial Waiver) of the Purchase Agreement are hereby incorporated by reference into this Amendment, <i style="font-style:italic;">mutatis mutandis</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:11.89pt 17.7pt 0pt 0pt;">[SIGNATURE<font style="letter-spacing:-0.3pt;"> </font>PAGE<font style="letter-spacing:-0.25pt;"> </font><font style="letter-spacing:-0.1pt;">FOLLOWS]</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.95pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">4</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:8.82%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.17;text-indent:36pt;margin:3.15pt 0pt 0pt 0pt;"><b style="font-weight:bold;">IN</b><b style="font-weight:bold;letter-spacing:-0.25pt;"> </b><b style="font-weight:bold;">WITNESS</b><b style="font-weight:bold;letter-spacing:-0.35pt;"> </b><b style="font-weight:bold;">WHEREOF</b>,<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.6pt;"> </font>Parties<font style="letter-spacing:-0.2pt;"> </font>have<font style="letter-spacing:-0.35pt;"> </font>caused<font style="letter-spacing:-0.25pt;"> </font>this<font style="letter-spacing:-0.1pt;"> </font>Amendment<font style="letter-spacing:-0.4pt;"> </font>to<font style="letter-spacing:-0.25pt;"> </font>be<font style="letter-spacing:-0.35pt;"> </font>duly<font style="letter-spacing:-0.25pt;"> </font>executed<font style="letter-spacing:-0.25pt;"> </font>by<font style="letter-spacing:-0.25pt;"> </font>their respective duly authorized officers as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:2.4pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:none;">ISSUER:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:12.55pt 0pt 0pt 0pt;">VERASTEM,<font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.2pt;">INC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:12.6pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 270.4pt 0pt 0pt;"><font style="letter-spacing:-0.2pt;">By:</font><u style="letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Daniel Calkins</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 270.4pt 0pt 0pt;"><font style="white-space:pre-wrap;">Name:   Daniel Calkins</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.2pt 0pt 0pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Title:</font></font>Chief<font style="letter-spacing:-0.1pt;"> </font>Financial<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.1pt;">Officer</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.64pt 0pt 0pt 1pt;">[Signature<font style="letter-spacing:-0.45pt;"> </font>Page<font style="letter-spacing:-0.35pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>Amendment<font style="letter-spacing:-0.15pt;"> </font>No.<font style="letter-spacing:-0.25pt;"> </font>1<font style="letter-spacing:-0.45pt;"> </font>to<font style="letter-spacing:-0.4pt;"> </font>Note<font style="letter-spacing:-0.1pt;"> </font>Purchase<font style="letter-spacing:-0.1pt;"> </font>Agreement<font style="letter-spacing:-0.35pt;"> </font>and<font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.1pt;">Waiver]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:8.82%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:3.04pt 0pt 0pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">PURCHASER</b><b style="font-weight:bold;letter-spacing:-0.25pt;text-decoration-color:#000000;text-decoration-line:none;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:none;">AGENT:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:12.55pt 0pt 0pt 0pt;">RGCM<font style="letter-spacing:-0.15pt;"> </font>SA<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.25pt;">LLC</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 270.4pt 0pt 0pt;"><font style="letter-spacing:-0.2pt;">By: </font><u style="letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ David Dubinsky</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 270.4pt 0pt 0pt;">Name: David Dubinsky</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.55pt;margin:0pt;">Title:<font style="letter-spacing:3.75pt;"> </font>Authorized <font style="letter-spacing:-0.1pt;">Signatory</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:12.6pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:none;">PURCHASERS:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">TPC<font style="letter-spacing:-0.25pt;"> </font>INVESTMENTS<font style="letter-spacing:-0.3pt;"> </font>SOLUTIONS<font style="letter-spacing:-0.35pt;"> </font><font style="letter-spacing:-0.25pt;">LP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:12.55pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 270.4pt 0pt 0pt;"><font style="letter-spacing:-0.2pt;">By:</font><u style="letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> /s/ David Dubinsky</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 270.4pt 0pt 0pt;">Name: David Dubinsky</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.15pt 0pt 0pt 0pt;">Title:<font style="letter-spacing:3.75pt;"> </font>Authorized<font style="letter-spacing:-0.1pt;"> Signatory</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:9.85pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">TPC<font style="letter-spacing:-0.3pt;"> </font>INVESTMENTS<font style="letter-spacing:-0.4pt;"> </font>SOLUTIONS<font style="letter-spacing:-0.3pt;"> </font>CO-<font style="letter-spacing:-0.1pt;">INVEST</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:12.5pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 270.4pt 0pt 0pt;"><font style="letter-spacing:-0.2pt;">By:</font><u style="letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> /s/ David Dubinsky</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 270.4pt 0pt 0pt;">Name: David Dubinsky</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.55pt;margin:0pt;">Title:<font style="letter-spacing:3.75pt;"> </font>Authorized <font style="letter-spacing:-0.1pt;">Signatory</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.64pt 0pt 0pt 1pt;">[Signature<font style="letter-spacing:-0.45pt;"> </font>Page<font style="letter-spacing:-0.35pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>Amendment<font style="letter-spacing:-0.15pt;"> </font>No.<font style="letter-spacing:-0.25pt;"> </font>1<font style="letter-spacing:-0.45pt;"> </font>to<font style="letter-spacing:-0.4pt;"> </font>Note<font style="letter-spacing:-0.1pt;"> </font>Purchase<font style="letter-spacing:-0.1pt;"> </font>Agreement<font style="letter-spacing:-0.35pt;"> </font>and<font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.1pt;">Waiver]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.50
<SEQUENCE>4
<FILENAME>vstm-20251231xex10d50.htm
<DESCRIPTION>EX-10.50
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/4/2026 08:56:06 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 10.50</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:12pt;"><a name="_Hlk55201239"></a><a name="_Hlk54889592"></a><a name="_Hlk93608908"></a></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AMENDMENT NO. 2 TO NOTE PURCHASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;">March 2, 2026</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Amendment No. 2 to Note Purchase Agreement (this &#8220;<font style="font-style:italic;font-weight:bold;">Amendment</font>&#8221;), dated as of the date first set forth above, is entered into by and among Verastem, Inc., a Delaware corporation (&#8220;<font style="font-style:italic;font-weight:bold;">Issuer</font>&#8221;), the Persons listed on the signature pages hereof under the heading &#8220;<b style="font-weight:bold;">PURCHASERS</b>&#8221; (each a &#8220;<font style="font-style:italic;font-weight:bold;">Purchaser</font>&#8221; and, collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Purchasers</font>&#8221;), and RGCM SA LLC, a Delaware limited liability company (&#8220;<font style="font-style:italic;font-weight:bold;">Purchaser Agent</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Reference is hereby made to the Note Purchase Agreement, dated as of January 13, 2025 (as amended by the Amendment No. 1 to Note Purchase Agreement and Waiver, dated as of October 31, 2025, and as further amended, restated, amended and restated, supplemented or otherwise modified prior to the date hereof, the &#8220;<font style="font-style:italic;font-weight:bold;">Purchase Agreement</font>&#8221;), among Issuer, the Purchasers party thereto from time to time and Purchaser Agent. &#160;Capitalized terms not otherwise defined in this Amendment shall have the meanings set forth in the Purchase Agreement. &#160;Issuer, the Purchasers and Purchaser Agent are sometimes referred to herein individually as a &#8220;<font style="font-style:italic;font-weight:bold;">Party</font>&#8221; and collectively as the &#8220;<font style="font-style:italic;font-weight:bold;">Parties</font>.&#8221; </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;"><a name="_cp_change_36"></a></font><b style="font-weight:bold;">WHEREAS</b>, <font style="text-decoration-color:#ff0000;background:#ffffff;">without waiving or altering any other previously agreed conditions, requirements, or representations made in any prior agreement between the Parties,</font> the Parties<font style="text-decoration-color:#ff0000;background:#ffffff;"> wish to amend the Purchase Agreement on the terms set forth herein</font>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, for good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the Parties intending to be legally bound do hereby agree as follows:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Amendment.</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> Subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of this Amendment, clause (i)(b) of the definition of &#8220;Commitment Termination Date&#8221; in the Purchase Agreement is hereby amended and restated in its entirety as follows:</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">&#8220;(i)(b)with respect to the Second Purchase, June 30, 2026,&#8221;.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Conditions Precedent to Effectiveness</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. The effectiveness of this Amendment shall be subject to the following conditions precedent:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Purchaser Agent shall have received this Amendment, duly executed by Issuer, Purchaser Agent and the Purchasers as required by Section 13.6(a) of the Purchase Agreement;</font><sup style="font-family:'Times New Roman','Times','serif';font-size:8.25pt;font-style:normal;font-weight:normal;vertical-align:top;"> </sup></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">No Event of Default shall have occurred and not been waived as of the effective date of this Amendment; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Issuer shall have paid all Reimbursable Expenses and all other amounts then due and owing pursuant to the Purchase Agreement.</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Representations and Warranties</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">The execution, delivery and performance by Issuer of this Amendment have been duly authorized by all necessary corporate or other organizational action. &#160;This Amendment and the Purchase Agreement constitute Issuer&#8217;s legal, valid and binding obligation, enforceable against it in accordance with its terms.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">All written certificates and written statements heretofore furnished to Purchaser Agent or any Purchaser by or on behalf of Issuer for purposes of or in connection with this Amendment or any Note Document contemplated hereby are, taken as a whole, true, complete and correct in all material respects and Issuer has not omitted to state a material fact necessary in order to make such information, taken as a whole, not misleading in light of the circumstances under which they were furnished.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Each of the representations and warranties in Article V of the Purchase Agreement are true, accurate and complete in all material respects as of the date hereof; </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">No Event of Default has occurred and is continuing and no event has occurred and is continuing which, with the giving of notice or passage of time, or both, would constitute an Event of Default, on or prior to the effective date of this Amendment.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Release of Claims</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Issuer hereby absolutely and unconditionally releases and forever discharges Purchaser Agent and each Purchaser, and any and all parent corporations, subsidiary corporations, affiliated corporations, successors and assigns thereof, together with all of the present and former directors, officers, agents, attorneys and employees of any of the foregoing (each, a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">Releasee</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; and collectively, the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">Releasees</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), from any and all claims, demands or causes of action of any kind, nature or description, whether arising in law or equity or upon contract or tort or under any state or federal law or otherwise (each, a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">Claim</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; and collectively, the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;">Claims</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), which Issuer has had, now has or has made claim to have against any such person for or by reason of any act, omission, matter, cause or thing whatsoever arising from the beginning of time to and including the date of this Amendment, whether such claims, demands and causes of action are matured or unmatured or known or unknown. &#160;Issuer understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense to any Claim and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release. &#160;Issuer agrees that no fact, event, circumstance, evidence or Note Document which could now be asserted or which may hereafter be discovered will affect in any manner the final, absolute and unconditional nature of the release set forth above.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Issuer hereby absolutely, unconditionally and irrevocably covenants and agrees with and in favor of each Releasee that it will not sue (at law, in equity, in any regulatory proceeding or otherwise) any Releasee on the basis of any Claim released, remised and discharged by Issuer pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> above. &#160;If Issuer violates the foregoing covenant, Issuer for itself and its successors and assigns, agrees to pay, in addition to such other damages as any Releasee may sustain as a result of such violation, all Reimbursable Expenses incurred by any Releasee as a result of such violation.</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">General</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Issuer hereby (i) acknowledges and agrees that all of its obligations under the Purchase Agreement and each other Note Document and under any other document or instrument </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">2</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">executed and delivered or furnished in connection with such Note Documents are reaffirmed and remain in full force and effect on a continuous basis, including, for the avoidance of doubt, after giving effect to this Amendment, (ii) acknowledges, agrees and reaffirms that each Lien granted by it to Purchaser Agent under the Note Documents for the ratable benefit of </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> Purchasers is and shall remain in full force and effect after giving effect to this Amendment, (iii) agrees that the Obligations secured by the Note Document to which it is a party shall include all Obligations arising after giving effect to this Amendment and (iv) agrees that the Guaranteed Obligations guaranteed by the Guaranty to which it is a party shall include all Obligations arising after giving effect to this Amendment.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i) Except as expressly set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> above, the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any rights, power or remedy of the Purchasers or Purchaser Agent under the Purchase Agreement or any other documents executed in connection with the Purchase Agreement or constitute a waiver of any provision of the Purchase Agreement or any other document executed in connection therewith including, without limitation, any Event of Default and (ii) this Amendment shall not by implication, course of dealing or otherwise limit, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements in the Note Documents, in each case, except to the extent limited, modified, amended or affected by this Amendment. &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Except as expressly modified by this Amendment, the terms and provisions of the Purchase Agreement shall remain unchanged and in full force and effect in accordance with its terms. &#160;In the event of any inconsistencies between the provisions of this Amendment and the provisions of Purchase Agreement or any other Note Document, the provisions of this Amendment shall govern and prevail. &#160;This Amendment is a Note Document.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">This Amendment shall be governed by, and construed, interpreted and enforced in accordance with, the laws of the state of New York, without giving effect to the principles of conflicts of law thereof.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">The provisions of Article X (Notices; Service of Process), Section 13.6 (Amendments in Writing; No Integration), &#160;Section 13.7 (Counterparts; Effectiveness; Electronic Signature), Section 13.4 (Severability of Provisions) and Article XI (Choice of Law, Venue and Jury Trial Waiver) of the Purchase Agreement are hereby incorporated by reference into this Amendment, </font><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;">mutatis mutandis</i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:12pt;"><a name="_Hlk89033928"></a></font>[SIGNATURE PAGE FOLLOWS]</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">3</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the Parties have caused this Amendment to be duly executed by their respective duly authorized officers as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:5.75pt;padding-right:5.75pt;table-layout:auto;width:100%;"><tr style="height:14.85pt;"><td style="vertical-align:top;width:50.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">ISSUER:</b></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">VERASTEM, INC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">By:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> /s/ Daniel Calkins</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:115.38pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Name: Daniel Calkins</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="white-space:pre-wrap;">Title:   Chief Financial Officer </font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a name="_Hlk81185971"></a><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Signature Page to Amendment No. 2 to Note Purchase Agreement]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:5.75pt;padding-right:5.75pt;table-layout:auto;width:105.76%;"><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">PURCHASER AGENT:</b></p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">RGCM SA LLC</p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">By:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> /s/ David Dubinsky</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:108.65pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Name: David Dubinsky</p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="white-space:pre-wrap;">Title:   Authorized Signatory</font></p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">PURCHASERS:</b></p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">TPC INVESTMENTS SOLUTIONS LP</p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:top;width:43.63%;" rowspan="4"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">By:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> /s/ David Dubinsky</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:108.65pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="display:none;vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Name: David Dubinsky</p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="display:none;vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:47.7pt;"><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="white-space:pre-wrap;">Title:   Authorized Signatory</font></p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="display:none;vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">TPC INVESTMENTS SOLUTIONS CO-INVEST</p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">By: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ David Dubinsky</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:108.65pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:3.15pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Name: David Dubinsky</p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="white-space:pre-wrap;">Title:   Authorized Signatory</font></p></td><td style="vertical-align:top;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Signature Page to Amendment No. 2 to Note Purchase Agreement]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>vstm-20251231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/4/2026 08:56:06 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">List of Registrant&#8217;s Subsidiaries</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Verastem Securities Company, incorporated in Massachusetts, a wholly owned subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Verastem Europe GmbH, incorporated in Germany, a wholly owned subsidiary.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>vstm-20251231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/4/2026 08:56:16 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;">We consent to the incorporation by reference in the following Registration Statements:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;">&#160;&#160;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Hlk128988080"></a></font><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-180475) pertaining to the 2010 Equity Incentive Plan and the 2012 Incentive Plan of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-190578) pertaining to the 2012 Incentive Plan of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(3)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-201075) pertaining to the 2014 Inducement Award Program of Verastem, Inc., </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(4)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-201076) pertaining to the 2012 Incentive Plan of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(5)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-211235) pertaining to the 2012 Incentive Plan of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(6)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-218768) pertaining to the 2014 Inducement Award Program of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(7)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-218769) pertaining to the 2012 Incentive Plan of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(8)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No.333-223616) pertaining to the 2014 Inducement Award Program of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(9)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No.333-228309) pertaining to the 2014 Inducement Award Program of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(10)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No.333-229430) pertaining to the 2018 Employee Stock Purchase Plan, 2012 Amended and Restated Incentive Plan, and 2014 Inducement Award Program of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(11)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-238877) pertaining to the Amended and Restated 2012 Incentive Plan of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(12)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-3 No. 333-237332) of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(13)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-257111) pertaining to the 2021 Equity Incentive Plan of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(14)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-3 No. 333-270794) of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(15)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-3 No. 333-275408) of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(16)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-277948) pertaining to the 2014 Inducement Award Program of Verastem, Inc., </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(17)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-279826) pertaining to the Amended and Restated 2021 Equity Incentive Plan of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(18)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-3 No. 333-285972) of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(19)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-3 No. 333-287235) of Verastem, Inc.,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(20)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-3 No. 333-289399) of Verastem, Inc., and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(21)</td><td style="padding:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-291253) pertaining to the 2014 Inducement Award Program of Verastem, Inc.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;">of our report dated March 4, 2026 with respect to the consolidated financial statements of Verastem, Inc. included in this Annual Report (Form 10-K) of Verastem, Inc. for the year ended December 31, 2025.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;">/s/ Ernst &amp; Young LLP</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;">Boston, Massachusetts</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10.5pt;">March 4, 2026</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>vstm-20251231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/4/2026 08:56:16 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">I, Daniel W. Paterson certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>I have reviewed this Annual Report on Form&#160;10-K of Verastem,&#160;Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a)</font></font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b)</font></font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c)</font></font>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">d)</font></font>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a)</font></font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b)</font></font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:3.6pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50.61%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49.38%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><i style="font-style:italic;">Chief Executive Officer</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50.61%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 1pt 0pt;"><font style="margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.38%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt 0pt 1pt 0pt;">/s/ <font style="font-variant:small-caps;">Daniel W. Paterson</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;">Daniel W. Paterson<br><i style="font-style:italic;">President and Chief Executive Officer</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;">Date: March 4, 2026</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>vstm-20251231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/4/2026 08:56:16 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">I, Daniel Calkins, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>I have reviewed this Annual Report on Form&#160;10-K of Verastem,&#160;Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a)</font></font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b)</font></font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c)</font></font>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">d)</font></font>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a)</font></font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b)</font></font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 1.45pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ <font style="font-variant:small-caps;">DANIEL CALKINS</font></p></td></tr><tr style=""><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.98%;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 1.45pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Daniel Calkins</p></td></tr><tr style=""><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt 0pt 0pt 1.45pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Chief Financial Officer</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;">Date: March 4, 2026</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>vstm-20251231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/4/2026 08:56:16 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report on Form&#160;10-K of Verastem,&#160;Inc. (the &#8220;Company&#8221;) for the period ended December&#160;31, 2025 as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on the date hereof (the &#8220;Report&#8221;), the undersigned, Daniel W. Paterson, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</font></font>the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</font></font>the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ DANIEL W. PATERSON</p></td></tr><tr style=""><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Daniel W. Paterson</p></td></tr><tr style=""><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">President and Chief Executive Officer</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;">Date: March&#160;4, 2026</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the SEC or its staff upon request.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>vstm-20251231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/4/2026 08:56:25 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report on Form&#160;10-K of Verastem,&#160;Inc. (the &#8220;Company&#8221;) for the period ended December&#160;31, 2025 as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on the date hereof (the &#8220;Report&#8221;), the undersigned, Daniel Calkins, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</font></font>the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</font></font>the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ DANIEL CALKINS</p></td></tr><tr style=""><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Daniel Calkins</p></td></tr><tr style=""><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Chief Financial Officer</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;">Date: March&#160;4, 2026</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the SEC or its staff upon request.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>11
<FILENAME>vstm-20251231xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/4/2026 08:56:25 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">AVMAPKI&#8482; FAKZYNJA&#8482; CO-PACK net product revenues of $17.5 million</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">&#160;</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">for the fourth quarter of 2025 and $30.9 million</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">&#160;</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">for the full year 2025, following</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">&#160;accelerated </i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">U.S.</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">&#160;</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">FDA approval in</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">&#160;</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">May 2025</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">Based on FDA guidance, Company to develop Phase 2 registration-directed protocols to evaluate VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in 2L PDAC, 2L/3L NSCLC and 2L+ CRC in combination with cetuximab</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">Cleared multiple dose levels of VS-7375 with no DLTs, continuing dose escalation to 1200 mg QD; cleared 600 mg QD dose level of VS-7375 in combination with cetuximab with no DLTs; continuing higher dose evaluations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">Company cash, cash equivalents, and investments of</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">&#160;</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">$205 million</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">&#160;</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">as of</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">&#160;</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">December 31, 2025; pro-forma year-end cash, cash equivalents and investments of</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">&#160;</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">$234 million</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">&#160;</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">inclusive of net proceeds from exercise of expiring cash warrants; expected cash runway into first half of 2027</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';background:#ffffff;">BOSTON--(BUSINESS WIRE) -- Mar. 4, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the three months and full year ended&#160;December 31, 2025, and highlighted recent progress.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;2025 was a transformative year for us, highlighted by the landmark FDA approval of AVMAPKI FAKZYNJA CO-PACK, the only medicine approved to specifically treat KRAS-mutated recurrent LGSOC. The launch is off to a strong start, and this novel-novel combination therapy is gaining positive response across the LGSOC community with gynecologic and medical oncologists in both academic and community settings increasingly turning to it when patients experience a first or subsequent recurrence. We also made considerable progress with VS-7375, our oral, KRAS G12D (ON/OFF) inhibitor with best-in-class potential for solid tumor cancers, clearing multiple dose levels across both monotherapy and cetuximab combination cohorts with no DLTs or major toxicities. Building on the insights from the China data, the tolerability profile that is emerging with VS-7375 in the U.S. has shown meaningful improvement and supports continued dose escalation,&#8221; said Dan Paterson, president and chief executive officer at Verastem Oncology. &#8220;In 2026, our priorities are to continue driving a strong launch of AVMAPKI FAKZYNJA CO-PACK to fuel sustainable growth, while we continue to accelerate the clinical development of VS-7375 and breakout Phase 2 registration-directed clinical trials in pancreatic, lung, and colorectal cancers.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;background:#ffffff;">Fourth Quarter 2025 and</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"> Recent</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;background:#ffffff;"> Highlights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;background:#ffffff;">AVMAPKI&#8482; FAKZYNJA&#8482; CO-PACK (avutometinib capsules; defactinib tablets)&#160;U.S.&#160;Launch</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">AVMAPKI FAKZYNJA CO-PACK generated net product revenues of $17.5 million&#160;for the fourth quarter of 2025 and $30.9 million&#160;for the full year 2025, following&#160;accelerated U.S.&#160;Food and Drug Administration (FDA) approval in&#160;May 2025, approximately two months ahead of its Prescription Drug User Fee Act (PDUFA) action date of&#160;June 30, 2025.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">On February 4, 2026, the Company </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">announced</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> updated data for RAMP 201J in Japan with a data cutoff of January 30, 2026. Of the 16 patients enrolled with a median follow-up of 10 months, a </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">confirmed overall response rate (ORR) of 38% (6/16) was achieved by investigator assessment. Among patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), the confirmed ORR was 57% (4/7) and the disease control rate (DCR) was 100% (7/7). Among patients with KRAS wild-type recurrent LGSOC, the confirmed ORR was 22% (2/9) and the DCR was 89% (8/9). Of the 16 patients enrolled, 11 patients remain on treatment. No patients discontinued due to an adverse event. The safety profile was similar to previously reported data outside of Japan. Steady-state exposures of avutometinib and defactinib in the RAMP 201J study were comparable to those seen in RAMP 201.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">On February 25, 2026, the annual update of the National Comprehensive Cancer Network&#174;&#160;(NCCN&#174;) Clinical Practice Guidelines in Oncology (NCCN Guidelines&#174;) for Ovarian Cancer was released. The Guidelines did not expand the recommendation for avutometinib plus defactinib to include patients with recurrent LGSOC without a KRAS mutation. The Guidelines retained the category 2A recommendation for avutometinib plus defactinib for patients with KRAS-mutated recurrent LGSOC. </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><br><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8220;We are disappointed for the patients with KRAS wild-type recurrent LGSOC, who currently have no targeted, FDA-approved treatment options specifically for their disease and face a particularly poor prognosis. Across three separate clinical trials (the FRAME study, RAMP 201, and RAMP 201J) we have observed what we believe are robust objective responses rates for patients with recurrent LGSOC with and without KRAS mutations. We remain committed to advancing the clinical evidence through longer term follow-up analyses from the RAMP 201 study planned for the SGO annual meeting, and completing our ongoing confirmatory RAMP 301 Phase 3 clinical trial, which includes patients with and without KRAS mutations, and look forward to sharing these data  with the NCCN and the medical community to support future guideline consideration,&#8221; said John Hayslip, chief medical officer at Verastem Oncology.  </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">Expected Key Milestones:</i></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Maximize adoption of AVMAPKI FAKZYNJA CO-PACK in the&#160;U.S.&#160;as the treatment of choice at the earliest recurrence, leveraging its robust clinical data.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Report a topline readout of the primary endpoint in the RAMP 301 trial in mid-2027.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Continue to pursue regulatory paths for potential expansion into&#160;Europe&#160;and&#160;Japan.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor in Advanced Solid Tumors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">The Company today announced an update on its progress with the VS-7375-101 Phase 1/2 study:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">After clearing the 900 mg daily (QD) dose level with no dose-limiting toxicities (DLTs), the dose escalation phase will continue to 1200 mg QD </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">to further interrogate the dose range and characterize the safety, tolerability, and efficacy profile of VS-7375.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">The 600 mg QD dose level of VS-7375 in combination with cetuximab was cleared with no DLTs and higher doses are now being evaluated. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In a pharmacokinetics (PK) analysis, doses of VS-7375 at 600 mg QD and above, with feeding and anti-emetic prophylaxis, yielded similar exposures to fasted patients in China. The exposures achieved cover the exposures in preclinical models necessary for maximal anti-tumor efficacy.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">As of the January 30, 2026 data cutoff, VS-7375 demonstrated an encouraging safety profile and was generally well-tolerated across all monotherapy dose levels evaluated to date. Patients (n=23) receiving VS-7375 at either 400 mg QD, 600 mg QD or 900 mg QD with a mean duration of therapy of 1.6 months (0.7-5.6), </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">reported no drug related liver function test abnormalities. There was no drug-related neutropenia greater than Grade 2 and rates </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">of nausea, vomiting and diarrhea remained lower than those reported by the Company&#8217;s partner in China.</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> No DLTs have been reported to date, and the maximum tolerated dose has not been reached.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Following recent feedback from the FDA, the Company is amending the VS-7375-101 Phase 1/2 protocol to separate out disease-specific Phase 2 registration-directed trials for KRAS G12D mutated 2L pancreatic ductal adenocarcinoma (PDAC) and 2L/3L non-small cell lung cancer (NSCLC) (monotherapy) and 2L+ colorectal cancer (CRC) in combination with cetuximab.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In January 2026, the </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Company reported</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> updates on its VS-7375-101 trial including that it had </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;background:#ffffff;">cleared the 400 mg QD, 600 mg QD and 900 mg QD dose levels with no DLTs and no major toxicities.  The VS-7375 monotherapy expansion cohorts were initiated, and the cohort sizes were expanded in 2L PDAC, 2L/3L NSCLC, and 2L+ </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">other KRAS G12D-mutated</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;"> solid tumors. In the VS-7375 dose-escalation combination cohort, the 400 mg QD dose was</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> cleared in combination with cetuximab with no DLTs. The combination dose escalation cohorts were initiated in 1L NSCLC and 2L PDAC at the end of 2025.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In October 2025, the Company </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">announced</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;a preliminary update on the Phase 1/2 monotherapy dose escalation trial of VS-7375 in patients with previously treated advanced KRAS G12D mutant solid tumors. In the study, VS-7375 cleared both the 400 mg QD and the 600 mg QD monotherapy doses with no DLTs observed. At the two dose levels evaluated in the&#160;U.S.&#160;cohort, no nausea, vomiting, or diarrhea greater than Grade 1 were reported. In addition, no new safety signals have been observed relative to earlier data presentations in both </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">PDAC</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> and </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">NSCLC</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;by GenFleet Therapeutics, the Company&#8217;s partner in China. Of the five efficacy evaluable patients in the VS-7375-101 study with at least one scan, four out of five patients have had a tumor reduction and were still on treatment.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">The Company shared multiple updates from GenFleet and its ongoing evaluation of VS-7375, known as GFH375, in</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">China:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">On March 2, 2026, GenFleet announced that GFH375 was granted its first Breakthrough Therapy Designation in China for patients with KRAS G12D-mutated NSCLC who have received prior systemic therapy.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In December 2025, GenFleet announced the initiation of a registrational Phase 3 study for GFH375 in patients with pretreated KRAS G12D-mutated metastatic pancreatic cancer in China.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In October 2025, the Company </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">announced</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> updated data for GFH375 in PDAC featured in a late-breaking oral presentation at the</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">European Society for Medical Oncology (ESMO) Congress. GenFleet shared additional analyses of this data set on</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">October 27, 2025:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In a subgroup analysis, 12 patients with 2L PDAC at 600 mg QD achieved an ORR of 58.3% and a DCR of 100%. In the 3L+ setting, 47 PDAC patients receiving 600 mg QD achieved an ORR of 36.2% and a DCR of 95.7%. In the 2L subgroup, the median progression free survival (mPFS) and median overall survival (mOS) have not been reached. An additional analysis of gastrointestinal disorders, hematological toxicities, and liver enzyme abnormalities in 2L+ patients with PDAC (n=66) at 600 mg QD showed no adverse events Grade &#8805;3 occurred at rates above 8.0%.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In an analysis of pre-treated patients with NSCLC at 600 mg QD, the four-month PFS rate was greater than 75% and the mPFS has not been reached. The median follow-up time was 4.2 months.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In October 2025, GenFleet announced</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">that the first patient has been dosed in a Phase 1b/2 study of GFH375 combined with cetuximab or chemotherapy for advanced solid tumors, including 1L PDAC, in China.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In August 2025, the Company </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">announced </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">data of GFH375 would be featured in a mini oral presentation at the IASLC 2025</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">World Conference on Lung Cancer (WCLC)</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">on</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">September 8, 2025. At the recommended Phase 2 dose (RP2D) of 600 mg QD, the ORR was 68.8% (11/16) (both confirmed and unconfirmed) and the DCR was 93.8% (15/16). Among the 26 evaluable patients with NSCLC treated across all dose levels, the ORR was 57.7% (15/26) (both confirmed and unconfirmed) and the DCR was 88.5% (23/26).</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">Expected Key Milestones:</i></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Report early data from the VS-7375-101 trial in 1H 2026. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Select the RP2D with cetuximab and initiate the CRC combination expansion cohort in 1H 2026.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Complete enrollment in combination dose-escalation cohorts in mid-2026.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Complete enrollment in monotherapy expansion cohorts in 2H 2026.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Select the RP2D and plan to initiate the PDAC and NSCLC combination expansion cohorts in 2H 2026.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">RAMP 205: Avutometinib Plus Defactinib in Combination with Chemotherapy in 1L Metastatic Pancreatic Cancer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In November 2025, the Company </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">announced</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> that enrollment was completed in the expansion cohort in Q3 2025.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">Expected Key Milestone:</i></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Report an update on the safety and efficacy of the RAMP 205 expansion cohort with at least six months of follow-up on all patients in Q2 2026.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Upcoming Presentations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Multiple abstracts were selected for oral and poster presentations at the&#160;Society of Gynecologic Oncology&#160;(SGO) 2026 Annual Meeting on Women&#8217;s Cancer on&#160;April 10-13&#160;in&#160;Puerto Rico. These presentations will include a late-breaking oral presentation on the long-term analysis of the Phase 2 RAMP 201 trial of avutometinib and defactinib combination in recurrent LGSOC.&#160;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Corporate Updates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In December 2025, the Company </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">announced</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> John Johnson, current board member, was appointed to chairman of Verastem&#8217;s Board of Directors, and Michael Kauffman, M.D., Ph.D., lead director since 2016, was appointed to president of development of Verastem. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In November 2025, the Company </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">announced</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> it had completed a public offering of over $96.9 million of common stock and pre-funded warrants.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Fourth Quarter 2025 Financial Results</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Verastem Oncology ended the fourth quarter of 2025 with cash, cash equivalents, and investments of</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$205 million. On a pro forma basis, taking into account the net proceeds from the exercise of warrants in</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">January 2026</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">of</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$29.4 million, cash, cash equivalents, and investments were</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$234.4 million</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">as of</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">December 31, 2025. These additional sources of capital along with the existing cash, cash equivalents, and investments and ongoing product revenue provide an expected cash runway into first half of 2027.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Net product revenue for the three months ended December 31, 2025 (the &#8220;2025 Quarter&#8221;) was $17.5 million, compared to no revenue recognized for the three months ended December 31, 2024 (the &#8220;2024 Quarter&#8221;). The Company began commercial sales of the AVMAPKI FAKZYNJA CO-PACK within the U.S. following receipt of FDA approval in May 2025.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Total operating expenses for the 2025 Quarter were $59.0 million, compared to $31.6 million for the 2024 Quarter. Cost of sales associated with product revenue was $2.9 million for the 2025 Quarter, compared to no cost of sales recognized for the 2024 Quarter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Research &amp; development expenses for the 2025 Quarter were $31.7 million, compared to $20.8 million for the 2024 Quarter. The increase of $10.9 million, or 52.4%, was primarily due to higher costs incurred for drug substance and drug product manufacturing, contract research organizations, and investigator fees.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Selling, general &amp; administrative expenses for the 2025 Quarter were $24.4 million, compared to $10.8 million for the 2024 Quarter. The increase of $13.6 million, or 125.9%, was primarily due to commercialization costs, including consulting, personnel costs, and professional fees, incurred in connection with the launch of AVMAPKI FAKZYNJA CO-PACK in KRAS-mutated recurrent LGSOC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Net loss (GAAP basis) for the 2025 Quarter was $32.9 million, or $0.39 per share (basic), compared to $64.6 million, or $1.33 per share (basic and diluted) for the 2024 Quarter.</font><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">For the 2025 Quarter, non-GAAP adjusted net loss was $39.8 million, or $0.48 per share (basic) compared to non-GAAP adjusted net loss of $29.3 million, or $0.60 per share (basic), for the 2024 Quarter. Please refer to the GAAP to non-GAAP Reconciliation attached to this press release.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Full-Year 2025 Financial Results</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"><br></b><font style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;">Net product revenue for the year ended December 31, 2025 (the &#8220;2025 Period&#8221;) was $30.9 million, compared to no product revenue recognized for the year ended December 31, 2024 (the &#8220;2024 Period&#8221;).  Sale of COPIKTRA license and related assets revenue was $0.0 million for the 2025 Period, compared to $10.0 million for the 2024 Period. Revenue for the 2024 Period was comprised of one sales milestone payment of $10.0 million due upon Secura Bio achieving cumulative worldwide net sales of COPIKTRA exceeding $100.0 million.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Total operating expenses for the 2025 Period were</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$201.0 million, compared to</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$125.0 million</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;">for the  2024 Period. Cost of sales associated with product revenue was $5.3 million for the 2025 period, compared to no cost of sales recognized for the 2024 Period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Research &amp; development expenses for the 2025 Period were</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$114.6 million, compared to</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$81.3 million</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">for the 2024 Period. The increase of</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$33.3 million, or 41.0%, was primarily due to higher costs incurred for contract research organizations, investigator fees, and drug substance and drug product manufacturing. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Selling, general &amp; administrative expenses for the 2025 Period were</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$81.1 million, compared to</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$43.6 million</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">for the 2024 Period. The increase of</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$37.5 million, or 86.0%, was primarily due to </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">commercialization costs, including consulting, personnel costs, and professional fees, incurred in connection with the launch of AVMAPKI FAKZYNJA CO-PACK in KRAS-mutated recurrent LGSOC. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Net loss for the 2025 Period was</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$209.5 million, or</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$3.02</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">per share (basic and diluted), compared to</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$130.6 million, or</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$3.66</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">per share (basic and diluted) for the 2024 period. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">For the 2025 Period, non-GAAP adjusted net loss was</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$163.1 million, or</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$2.35</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">per share (basic) compared to non-GAAP adjusted net loss of</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$107.4 million, or</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$3.01</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">per share (basic), for the 2024 Period. Please refer to the GAAP to non-GAAP Reconciliation attached to this press release.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Conference Call and Webcast</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Verastem</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">will host a conference call and webcast today at</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;4:30</font><font style="font-family:'Calibri','Helvetica','sans-serif';"> p.m. ET</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">to review the fourth quarter and full year 2025 financial results and recent business updates. </font><font style="font-family:'Calibri','Helvetica','sans-serif';">To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">7321921</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under &quot;Events &amp; Presentations&quot; in the Investor section of the Company&#39;s website, </font><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-line:underline;text-decoration-style:solid;">https://investor.verastem.com/events</u><font style="font-family:'Calibri','Helvetica','sans-serif';">. A replay of the webcast will be archived and available following the event.</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Use of Non-GAAP Financial Measures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">To supplement Verastem Oncology&#8217;s condensed consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles in</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">the United States</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">(GAAP), the Company uses the following non-GAAP financial measures in this press release: non-GAAP adjusted net loss and non-GAAP net loss per share. These non-GAAP financial measures exclude certain amounts or expenses from the corresponding financial measures determined in accordance with GAAP. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Management believes this non-GAAP information is useful for investors, taken in conjunction with the Company&#8217;s GAAP financial statements, because it provides greater transparency and period-over- period comparability with respect to the Company&#8217;s operating performance and can enhance investors&#8217; ability to identify operating trends in the Company&#8217;s business. Management uses these measures, among other factors, to assess and analyze operational results and trends and to make financial and operational decisions. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company&#8217;s operating results as reported under GAAP, not in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. In addition, these non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. The determination of the amounts that are excluded from non-GAAP financial measures is a matter of management judgment and depends upon, among other factors, the nature of the underlying expense or income amounts. Reconciliations between these non-GAAP financial measures and the most comparable GAAP financial measures for the three months and year ended</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">December 31, 2025,</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">and 2024 are included in the tables accompanying this press release after the unaudited condensed consolidated financial statements.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About AVMAPKI and FAKZYNJA Combination Therapy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">AVMAPKI (avutometinib) inhibits MEK kinase activity while also blocking the compensatory reactivation of MEK by upstream RAF. RAF and MEK proteins are regulators of the RAS/RAF/MEK/ERK (MAPK) </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">pathway. Blocking RAF and/or MEK activates FAK, a key mediator of drug resistance. FAKZYNJA (defactinib) is a FAK inhibitor and together, the avutometinib and defactinib combination was designed to provide a more complete blockade of the signaling that drives the growth and drug resistance of RAS/MAPK pathway-dependent tumors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">The</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">U.S. Food and Drug Administration</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">(FDA) approved AVMAPKI&#8482; FAKZYNJA&#8482; CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent LGSOC who have received prior systemic therapy on</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">May 8, 2025. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">Verastem</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">is conducting RAMP 301 (GOG-3097/ENGOT-ov81/GTG-UK) (NCT06072781), an international Phase 3 confirmatory trial evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the treatment of recurrent low-grade serous ovarian cancer (LGSOC) with and without a KRAS mutation.</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">Verastem</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">is also evaluating avutometinib plus defactinib with standard-of-care chemotherapy as a potential treatment in the first-line for patients with advanced pancreatic cancer (RAMP 205; NCT05669482). Avutometinib and defactinib are not approved by the FDA or any other regulatory authority, either in combination or with other therapies, for any of these investigative uses. Neither avutometinib nor defactinib are approved by the FDA or any other regulatory authority on a stand-alone basis for any use.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">AVMAPKI FAKZYNJA CO-PACK</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">U.S.</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Indication</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indication</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">AVMAPKI FAKZYNJA CO-PACK is indicated for the treatment of adult patients with</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">KRAS</i><font style="font-family:'Calibri','Helvetica','sans-serif';">-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">This indication is approved under accelerated approval based on tumor response rate and duration of response</font><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">.</i><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Important Safety Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Warnings and Precautions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Ocular Toxicities:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Ocular toxicities, including visual impairment and vitreoretinal disorders, occurred. Perform comprehensive ophthalmic evaluation at baseline, prior to cycle 2, every three cycles thereafter, and as clinically indicated. Withhold AVMAPKI FAKZYNJA CO-PACK for ocular toxicities until improvement at the same or reduced dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for any grade 4 toxicity.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Serious Skin Toxicities:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Skin toxicities, including photosensitivity and severe cutaneous adverse reactions (SCARSs) occurred. Adhere to concomitant medications. Monitor for skin toxicities and interrupt, reduce or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity, tolerability and duration.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Hepatotoxicity:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Monitor liver function tests prior to each cycle, on day 15 of the first 4 cycles, and as clinically indicated. Withhold, reduce or discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and persistence of abnormality.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Rhabdomyolysis:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Monitor creatine phosphokinase prior to the start of each cycle, on day 15 of the first four cycles, and as clinically indicated. If increased CPK occurs, evaluate patients for </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">rhabdomyolysis or other causes. Withhold, reduce or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and duration of the adverse reaction.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Embryo-Fetal Toxicity:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">AVMAPKI FAKZYNJA CO-PACK can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Adverse Reactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">The most common (&#8805; 25%) adverse reactions, including laboratory abnormalities, were increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase, rash, diarrhea, musculoskeletal pain, edema, decreased hemoglobin, increased alanine aminotransferase, vomiting, increased blood bilirubin, increased triglycerides, decreased lymphocyte count, abdominal pain, dyspepsia, dermatitis acneiform, vitreoretinal disorders, increased alkaline phosphatase, stomatitis, pruritus, visual impairment, decreased platelet count, constipation, dry skin, dyspnea, cough, urinary tract infection, and decreased neutrophil count.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Drug Interactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Strong and moderate CYP3A4 inhibitors</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">: Avoid concomitant use with AVMAPKI FAKZYNJA CO-PACK.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Strong and moderate CYP3A4 inducers</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">: Avoid concomitant use with AVMAPKI FAKZYNJA CO-PACK.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Warfarin:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with warfarin and use an alternative to warfarin.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Gastric acid reducing agents</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">: Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with proton pump inhibitors (PPIs) or H2 receptor antagonists. If use of an acid-reducing agent cannot be avoided, administer FAKZYNJA 2 hours before or 2 hours after the administration of a locally acting antacid.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Use in Specific Populations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Lactation</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">: Advise not to breastfeed.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Fertility:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">May impair fertility in males and females.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Click here for full</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-line:none;">Prescribing Information</font><font style="font-family:'Calibri','Helvetica','sans-serif';">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">VS-7375 is a potential best-in-class, potent, and selective oral KRAS G12D dual ON/OFF inhibitor. VS-7375 is the lead program from the Verastem Oncology discovery and development collaboration with GenFleet Therapeutics.</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">Verastem</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">initiated VS-7375-101, an international Phase 1/2 clinical trial, in June of 2025 in the</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">U.S., that is evaluating the safety and efficacy of VS-7375 in patients with advanced KRAS G12D mutant solid tumors.</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';"> In July 2025, </font><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;">U.S. Food and Drug Administration (FDA) granted Fast Track Designation (FTD) to VS-7375 for the first-line treatment of patients with KRAS G12D-mutated locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) and for the treatment of patients with KRAS G12D-mutated locally advanced or metastatic PDAC who have received at least one prior line of standard systemic therapy.  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About the GenFleet Therapeutics Collaboration</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">The collaboration with GenFleet Therapeutics aims to advance three oncology discovery programs related to RAS/MAPK pathway-driven cancers. The collaboration provides</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">Verastem</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">with an exclusive option to obtain a license for each of the three compounds in the collaboration after the successful completion of pre-determined milestones in a Phase 1 trial.</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">Verastem</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">selected VS-7375 (also known as GFH375), an oral KRAS G12D (ON/OFF) inhibitor, as its lead program in</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">December 2023</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">and the license for VS-7375 that was exercised in</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">January 2025</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">is the first one from this collaboration. The licenses would give</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">Verastem</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">development and commercialization rights outside the GenFleet markets of mainland</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">China,</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">Hong Kong,</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">Macau, and</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">Taiwan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About Verastem Oncology</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers.</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">Verastem</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">markets AVMAPKI&#8482; FAKZYNJA&#8482; CO-PACK in the</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">U.S.</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-line:none;">www.verastem.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">and follow us on</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-line:none;">LinkedIn</font><font style="font-family:'Calibri','Helvetica','sans-serif';">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;project,&#8221; and other words of similar meaning. Such forward-looking statements address various matters about, among other things, Verastem Oncology&#8217;s programs and product candidates, strategy, future plans and prospects, including statements related to the potential for and timing of commercialization of product candidates, the anticipated timing for the IND application for VS-7375/GFH375, the expected outcome and benefits of the Company&#8217;s collaboration with</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">GenFleet Therapeutics (Shanghai), Inc., the timing of commencing and completing trials and compiling data, the expected timing of the presentation of data by the Company and the potential clinical value of various of the Company&#8217;s clinical trials. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: the uncertainties inherent in research and development, such as the possibility of negative or unexpected results of clinical trials; that we may not see a return on investment on the payments we have and may continue to make pursuant to the collaboration and option agreement with GenFleet, or that GenFleet may fail to fully perform under the agreement; that we may not be successful in our continued commercialization of AVMAPKI FAKZYNJA CO-PACK; that the development and commercialization of our product candidates may take longer or cost more than planned, including as a result of conducting additional studies or our decisions regarding execution of such commercialization; that data may not be available when expected; risks associated with preliminary and interim data, which may not be representative of more mature data; risks associated with the recent changes in administration policy or actions that may create regulatory uncertainty that may adversely affect our business; risks associated with the current administration&#8217;s reductions to the FDA&#8217;s owrkforce and any subsequent reductions that may lead to disruptions and delays in the FDA&#8217;s review and oversight of our product candidates and impact the FDA&#8217;s ability to provide timely feedback on our development programs; that our product candidates may not receive regulatory approval, become commercially successful products, or result in new treatment options being offered to patients; and the risks </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">identified under the heading &quot;Risk Factors&quot; as detailed in the Company&#8217;s Annual Report on Form 10-K for the year ended</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">December 31, 2025, as filed with the</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">Securities and Exchange Commission</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">(SEC) on</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">March 4, 2026, as well as the other information we file with the</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">SEC, are possibly realized. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">SEC, available at</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-line:none;">www.sec.gov</font><font style="font-family:'Calibri','Helvetica','sans-serif';">, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this press release, and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">For Investor and Media Inquiries:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Julissa Viana</font><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">Vice President, Corporate Communications,</font><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">Investor Relations &amp; Patient Advocacy</font><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">investors@verastem.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;or</font><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">media@verastem.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Verastem Oncology</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Condensed Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">(in thousands)</font></p><div style="left:0%;position:relative;top:23.3pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr style="height:15.1pt;"><td style="vertical-align:top;width:55.73%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:20.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">December 31, 2024</b></p></td></tr><tr style="height:15.1pt;"><td style="vertical-align:top;width:55.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:19.59%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:6.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:13.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr style="height:15.1pt;"><td style="vertical-align:bottom;width:55.73%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Cash,&#160;cash&#160;equivalents,&#160;&amp;&#160;investments</font></p></td><td style="vertical-align:bottom;width:2.07%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:19.59%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">204,990</font></p></td><td style="vertical-align:bottom;width:1.97%;background:#ccedff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.67%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:13.94%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">88,818</font></p></td></tr><tr style="height:15.1pt;"><td style="vertical-align:bottom;width:55.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Accounts receivable, net</font></p></td><td style="vertical-align:bottom;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">8,813</font></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td></tr><tr style="height:15.1pt;"><td style="vertical-align:bottom;width:55.73%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Inventory</font></p></td><td style="vertical-align:bottom;width:2.07%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:19.59%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">1,833</font></p></td><td style="vertical-align:bottom;width:1.97%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.67%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.94%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td></tr><tr style="height:15.15pt;"><td style="vertical-align:bottom;width:55.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Grants receivable</font></p></td><td style="vertical-align:bottom;width:2.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">200</font></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:13.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">200</font></p></td></tr><tr style="height:15.1pt;"><td style="vertical-align:bottom;width:55.73%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Prepaid&#160;expenses&#160;and&#160;other&#160;current&#160;assets</font></p></td><td style="vertical-align:bottom;width:2.07%;background:#ccedff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:19.59%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">7,577</font></p></td><td style="vertical-align:bottom;width:1.97%;background:#ccedff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.67%;background:#ccedff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:13.94%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">5,943</font></p></td></tr><tr style="height:14.95pt;"><td style="vertical-align:bottom;width:55.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Property&#160;and&#160;equipment,&#160;net</font></p></td><td style="vertical-align:bottom;width:2.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:13.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">32</font></p></td></tr><tr style="height:15.1pt;"><td style="vertical-align:bottom;width:55.73%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Right-of-use&#160;asset,&#160;net</font></p></td><td style="vertical-align:bottom;width:2.07%;background:#ccedff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:19.59%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">491</font></p></td><td style="vertical-align:bottom;width:1.97%;background:#ccedff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.67%;background:#ccedff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:13.94%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">1,405</font></p></td></tr><tr style="height:15.1pt;"><td style="vertical-align:bottom;width:55.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Intangible assets, net</font></p></td><td style="vertical-align:bottom;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">16,426</font></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td></tr><tr style="height:15.1pt;"><td style="vertical-align:bottom;width:55.73%;background:#caeefb;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Restricted&#160;cash&#160;and&#160;other&#160;assets</font></p></td><td style="vertical-align:bottom;width:2.07%;background:#caeefb;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:19.59%;background:#caeefb;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">6,112</font></p></td><td style="vertical-align:bottom;width:1.97%;background:#caeefb;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.67%;background:#caeefb;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:13.94%;background:#caeefb;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">5,140</font></p></td></tr><tr style="height:15.05pt;"><td style="vertical-align:bottom;width:55.73%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Total&#160;assets</b></p></td><td style="vertical-align:bottom;width:2.07%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:19.59%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">246,442</b></p></td><td style="vertical-align:bottom;width:1.97%;background:#ffffff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.67%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:13.94%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">101,538</b></p></td></tr><tr style="height:15.05pt;"><td style="vertical-align:bottom;width:55.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.07%;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:19.59%;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.67%;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:13.94%;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"></td></tr><tr style="height:15.1pt;"><td style="vertical-align:bottom;width:55.73%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Current&#160;Liabilities</font></p></td><td style="vertical-align:bottom;width:2.07%;background:#ccedff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:19.59%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">72,268</font></p></td><td style="vertical-align:bottom;width:1.97%;background:#ccedff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.67%;background:#ccedff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:13.94%;background:#ccedff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">30,973</font></p></td></tr><tr style="height:15.6pt;"><td style="vertical-align:bottom;width:55.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Long&#160;term&#160;debt</font></p></td><td style="vertical-align:bottom;width:2.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">76,330</font></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:13.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">40,724</font></p></td></tr><tr style="height:15.6pt;"><td style="vertical-align:bottom;width:55.73%;background:#caeefb;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Vendor financing arrangement, long-term</font></p></td><td style="vertical-align:bottom;width:2.07%;background:#caeefb;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:19.59%;background:#caeefb;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">5,000</font></p></td><td style="vertical-align:bottom;width:1.97%;background:#caeefb;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.67%;background:#caeefb;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.94%;background:#caeefb;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td></tr><tr style="height:15.6pt;"><td style="vertical-align:bottom;width:55.73%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Lease liability, long-term</font></p></td><td style="vertical-align:bottom;width:2.07%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:19.59%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:1.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.67%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.94%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">535</font></p></td></tr><tr style="height:15.1pt;"><td style="vertical-align:bottom;width:55.73%;background:#caeefb;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Warrant Liability</font></p></td><td style="vertical-align:bottom;width:2.07%;background:#caeefb;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:19.59%;background:#caeefb;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">35,647</font></p></td><td style="vertical-align:bottom;width:1.97%;background:#caeefb;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.67%;background:#caeefb;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:13.94%;background:#caeefb;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">58,199</font></p></td></tr><tr style="height:15.1pt;"><td style="vertical-align:bottom;width:55.73%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Stockholders&#8217;&#160;equity</font></p></td><td style="vertical-align:bottom;width:2.07%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:19.59%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">57,197</font></p></td><td style="vertical-align:bottom;width:1.97%;background:#ffffff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.67%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:13.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">(28,893)</font></p></td></tr><tr style="height:15.1pt;"><td style="vertical-align:bottom;width:55.73%;background:#caeefb;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Total&#160;liabilities, convertible preferred stock&#160;and&#160;stockholders&#8217;&#160;equity</b></p></td><td style="vertical-align:bottom;width:2.07%;background:#caeefb;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:19.59%;background:#caeefb;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">246,442</b></p></td><td style="vertical-align:bottom;width:1.97%;background:#caeefb;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.67%;background:#caeefb;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:13.94%;background:#caeefb;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">101,538</b></p></td></tr></table></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Verastem Oncology</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Verastem Oncology</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Condensed Consolidated Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">(in thousands, except per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">(unaudited)</b></p><div style="margin-left:-40.5pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:120.51%;padding:0.75pt 0pt 0.75pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.37%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.76%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;width:10.61%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.7%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.25%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;width:11.33%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.04%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:0.95pt;"><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.76%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0pt;"></td><td colspan="11" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:14.45pt;"><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.76%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0pt;"></td><td colspan="11" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:14.45pt;"><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.76%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0pt;"></td><td colspan="11" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:14.45pt;"><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"></td><td colspan="6" style="vertical-align:bottom;width:27.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Three months ended December 31,</b></p></td><td style="vertical-align:bottom;width:0.7%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></td><td colspan="6" style="vertical-align:bottom;width:25.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Year ended December 31,</b></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:0.45%;margin:0pt;padding:0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:14.45pt;"><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="3" style="vertical-align:bottom;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:0.7%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;width:0.8%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="3" style="vertical-align:bottom;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">2024</b></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:0.04%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:14.45pt;"><td style="vertical-align:bottom;width:35.12%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Revenue:</font></p></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.37%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.61%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.7%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.25%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.33%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:14.45pt;"><td style="vertical-align:bottom;width:35.12%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Product Revenue, net</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.75%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:10.37%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">17,535</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.76%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:10.25%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">30,914</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:top;width:0.17%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.04%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.2pt;"><td style="vertical-align:bottom;width:35.12%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Sale of COPIKTRA license and related assets</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.37%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.25%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ffffff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="border-bottom-color:#000000;border-bottom-style:solid;border-bottom-width:1px;color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0.75pt;padding-left:0pt;padding-right:0pt;padding-top:0.75pt;text-align:left;vertical-align:bottom;width:1.74%;background:#ffffff;"></td><td colspan="2" style="border-bottom-color:#000000;border-bottom-style:solid;border-bottom-width:1px;color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0.75pt;padding-left:0pt;padding-right:0pt;padding-top:0.75pt;text-align:left;vertical-align:bottom;width:11.33%;background:#ffffff;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">10,000</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:14.45pt;"><td style="vertical-align:bottom;width:35.12%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Total revenue</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ccedff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.37%;background:#ccedff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">17,535</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ccedff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ccedff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ccedff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.25%;background:#ccedff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">30,914</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ccedff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ccedff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">10,000</font></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.2pt;"><td style="vertical-align:bottom;width:35.12%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Operating expenses:</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.37%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.72%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.25%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.8%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.2pt;"><td style="vertical-align:bottom;width:35.12%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Cost of sales &#8211; product</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.75%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.37%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">2,611</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.76%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.25%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">4,600</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.04%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.2pt;"><td style="vertical-align:bottom;width:35.12%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Cost of sales &#8211; intangible amortization </font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.75%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.37%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">280</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.76%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.25%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">698</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.04%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:14.45pt;"><td style="vertical-align:bottom;width:35.12%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Research and development</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.37%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">31,675</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">20,811</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.25%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">114,599 </font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">81,334 </font></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.2pt;"><td style="vertical-align:bottom;width:35.12%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Selling, general and administrative</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.37%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">24,443</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ffffff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">10,779</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.25%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">81,146</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ffffff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">43,622 </font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.95pt;"><td style="vertical-align:bottom;width:35.12%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Total operating expenses</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ccedff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.37%;background:#ccedff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">59,009</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ccedff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ccedff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ccedff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">31,590</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.25%;background:#ccedff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">201,043</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ccedff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ccedff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">124,956</font></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:15pt;"><td style="vertical-align:bottom;width:35.12%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Loss from operations</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.37%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(41,474)</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(31,590)</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.25%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(170,129)</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(114,956)</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.95pt;"><td style="vertical-align:bottom;width:35.12%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Other income (expense)</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.37%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(18)</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">9</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.25%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(203)</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(123)</font></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.2pt;"><td style="vertical-align:bottom;width:35.12%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Interest income</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.37%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">1,103</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">968</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.25%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">4,068</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">4,149</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:5.2pt;"><td style="vertical-align:bottom;width:35.12%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Interest expense</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.37%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(415)</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(1,146)</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.25%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(1,138)</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(4,562)</font></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:5.2pt;"><td style="vertical-align:bottom;width:35.12%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Loss on debt extinguishment</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.75%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.37%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.76%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.25%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(1,826)</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.04%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:5.2pt;"><td style="vertical-align:bottom;width:35.12%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Change in fair value of preferred stock tranche liability</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.37%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.25%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">4,189</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:5.2pt;"><td style="vertical-align:bottom;width:35.12%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Change in fair value of warrant liability</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.37%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">10,485</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(32,606)</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.25%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(27,492)</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(19,149)</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:5.2pt;"><td style="vertical-align:bottom;width:35.12%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Change in fair value of Notes</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.75%;background:#ccedff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.37%;background:#ccedff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(2,597)</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ccedff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.76%;background:#ccedff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ccedff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.25%;background:#ccedff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(12,751)</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ccedff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ccedff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.04%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:8.6pt;"><td style="vertical-align:bottom;width:35.12%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Net loss before taxes</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.37%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(32,916)</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ffffff;border-bottom:2.25pt double transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(64,365)</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;border-bottom:2.25pt double transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.25%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(209,471)</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ffffff;border-bottom:2.25pt double transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(130,452)</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:8.6pt;"><td style="vertical-align:bottom;width:35.12%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Income tax expense</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ccedff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.37%;background:#ccedff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ccedff;border-bottom:2.25pt double transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ccedff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ccedff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(185)</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;border-bottom:2.25pt double transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.25%;background:#ccedff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ccedff;border-bottom:2.25pt double transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ccedff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(185)</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:8.6pt;"><td style="vertical-align:bottom;width:35.12%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Net Loss</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:10.37%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(32,916)</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ffffff;border-bottom:2.25pt double transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(64,550)</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;border-bottom:2.25pt double transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:10.25%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(209,471)</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ffffff;border-bottom:2.25pt double transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ffffff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(130,637)</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.95pt;"><td style="vertical-align:bottom;width:35.12%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Net loss per share&#8212;basic</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:10.37%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(0.39)</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(1.33)</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:10.25%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(3.02)</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;border-top:2.25pt double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ccedff;border-top:2.25pt double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(3.66)</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.95pt;"><td style="vertical-align:bottom;width:35.12%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Net loss per share&#8212;diluted</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:10.37%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(0.50)</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(1.33)</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:10.25%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(3.02)</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(3.66)</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="11" style="vertical-align:middle;width:9.91%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td></tr><tr style="height:25.25pt;"><td style="vertical-align:bottom;width:35.12%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Weighted average common shares outstanding used in computing:</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.37%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.25%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:2.85pt;"><td style="vertical-align:bottom;width:35.12%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Net loss per share &#8211; basic</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.75%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.37%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">83,400</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.76%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">48,709</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.25%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">69,309</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">35,713</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.04%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:2.85pt;"><td style="vertical-align:bottom;width:35.12%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Net loss per share &#8211; diluted</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.75%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.37%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">86,710</font></p></td><td style="vertical-align:bottom;width:1.72%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.76%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.61%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">48,709</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.25%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">69,309</font></p></td><td style="vertical-align:bottom;width:0.8%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.33%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">35,713</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.04%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:0.9pt;"><td colspan="6" style="vertical-align:bottom;width:52.41%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.72%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.59%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;width:19.94%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;width:6.45%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"></td></tr><tr style="height:0.85pt;"><td colspan="6" style="vertical-align:bottom;width:52.41%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.72%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.59%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;width:19.94%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;width:6.45%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:14pt 0pt 0pt 0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Verastem Oncology</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Reconciliation of GAAP to Non-GAAP Financial Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">(in thousands, except per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><div style="margin-left:-40.5pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:120.51%;padding:0.75pt 0pt 0.75pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.18%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.38%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.62%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.7%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.26%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.57%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;width:11.34%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.16%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:0.95pt;"><td style="vertical-align:bottom;width:35.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.62%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.26%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0pt;"></td><td colspan="11" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:14.45pt;"><td style="vertical-align:bottom;width:35.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.62%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.26%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0pt;"></td><td colspan="11" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:14.45pt;"><td style="vertical-align:bottom;width:35.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.62%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.26%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0pt;"></td><td colspan="11" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:14.45pt;"><td style="vertical-align:bottom;width:35.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"></td><td colspan="6" style="vertical-align:bottom;width:27.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Three months ended December 31,</b></p></td><td style="vertical-align:bottom;width:0.7%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></td><td colspan="7" style="vertical-align:bottom;width:25.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Year ended December 31,</b></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:0.57%;margin:0pt;padding:0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:14.45pt;"><td style="vertical-align:bottom;width:35.18%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;width:1.88%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="3" style="vertical-align:bottom;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:0.7%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">2025</b></p></td><td colspan="2" style="vertical-align:bottom;width:0.8%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="3" style="vertical-align:bottom;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">2024</b></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:0.16%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:14.45pt;"><td style="vertical-align:bottom;width:35.18%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Net loss reconciliation:</b></p></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.38%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.62%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.7%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.26%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.57%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.34%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:14.45pt;"><td style="vertical-align:bottom;width:35.18%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Net loss (GAAP basis)</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(32,916)</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(64,550)</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(209,471)</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(130,637)</font></p></td><td style="vertical-align:top;width:0.17%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.16%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.2pt;"><td style="vertical-align:bottom;width:35.18%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Adjust:</b></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.88%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:top;width:10.26%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.57%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:top;width:11.34%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:14.45pt;"><td style="vertical-align:bottom;width:35.18%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Stock-based compensation expense</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">2,025</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">2,019</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">9,404</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">7,342</font></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.2pt;"><td style="vertical-align:bottom;width:35.18%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Amortization of acquired intangible assets</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">280</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.26%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">698</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.2pt;"><td style="vertical-align:bottom;width:35.18%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Non-cash interest, net</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">207</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">29</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(5)</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.16%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.2pt;"><td style="vertical-align:bottom;width:35.18%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Change in fair value of preferred stock tranche liability</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(4,189)</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.16%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:14.45pt;"><td style="vertical-align:bottom;width:35.18%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Change in fair value of warrant liability</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(10,485)</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">32,606</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:10.26%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">27,492</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">19,149</font></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.2pt;"><td style="vertical-align:bottom;width:35.18%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Non-cash change in fair value of Notes</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">890</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">6,560</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.95pt;"><td style="vertical-align:bottom;width:35.18%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Loss on debt extinguishment</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">1,826</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:15pt;"><td style="vertical-align:bottom;width:35.18%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Severance and other</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">392</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ffffff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">371</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">392</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ffffff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">990</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.95pt;"><td style="vertical-align:bottom;width:35.18%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Adjusted net loss (non-GAAP basis)</b></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ccedff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(39,814)</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ccedff;border-bottom:3px double transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:2.62%;background:#ccedff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ccedff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(29,347)</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;border-bottom:3px double transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ccedff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(163,070)</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ccedff;border-bottom:3px double transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ccedff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ccedff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(107,350)</font></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.2pt;"><td style="vertical-align:bottom;width:35.18%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;border-top:3px double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ffffff;border-top:3px double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ffffff;border-top:3px double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ffffff;border-top:3px double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;border-top:3px double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ffffff;border-top:3px double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ffffff;border-top:3px double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ffffff;border-top:3px double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:5.2pt;"><td style="vertical-align:bottom;width:35.18%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Reconciliation of net loss per share</b></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:5.2pt;"><td style="vertical-align:bottom;width:35.18%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Net loss per share &#8211; basic (GAAP basis)</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(0.39) </font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(1.33) </font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(3.02)</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(3.66)</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.16%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:5.2pt;"><td style="vertical-align:bottom;width:35.18%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Adjust per basic share</b></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:5.2pt;"><td style="vertical-align:bottom;width:35.18%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Stock-based compensation expense</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">0.02</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">0.04</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">0.14</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">0.21</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:5.2pt;"><td style="vertical-align:bottom;width:35.18%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Amortization of acquired intangible assets</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">0.01</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.16%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:8.6pt;"><td style="vertical-align:bottom;width:35.18%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Non-cash interest, net</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">0.01</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:8.6pt;"><td style="vertical-align:bottom;width:35.18%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Change in fair value of preferred stock tranche liability</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(0.12)</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:8.6pt;"><td style="vertical-align:bottom;width:35.18%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Change in fair value of warrant liability</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(0.12)</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">0.67</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">0.39</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">0.53</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.95pt;"><td style="vertical-align:bottom;width:35.18%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Non-cash change in fair value of Notes</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">0.01</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">0.09</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:12.95pt;"><td style="vertical-align:bottom;width:35.18%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Loss on debt extinguishment</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">0.03</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="11" style="vertical-align:middle;width:10.05%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td></tr><tr style="height:2.55pt;"><td style="vertical-align:bottom;width:35.18%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Severance and other</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ccedff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">&#8212;</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ccedff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ccedff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ccedff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">0.01</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ccedff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">0.01</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ccedff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ccedff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ccedff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">0.03</font></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:2.85pt;"><td style="vertical-align:bottom;width:35.18%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Adjusted net loss per share &#8211; basic (non-GAAP basis)</b></p></td><td style="vertical-align:bottom;width:0.66%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:1.74%;background:#ffffff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ffffff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(0.48)</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ffffff;border-bottom:3px double transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ffffff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ffffff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(0.60)</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ffffff;border-bottom:3px double transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ffffff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ffffff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(2.35)</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ffffff;border-bottom:3px double transparent;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ffffff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ffffff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">(3.01)</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td style="vertical-align:middle;width:0.16%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:2.85pt;"><td style="vertical-align:bottom;width:35.18%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">Weighted average common shares outstanding used in computing net loss per share&#8212;basic</font></p></td><td style="vertical-align:bottom;width:0.66%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.74%;background:#ccedff;border-top:3px double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#ccedff;border-top:3px double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">83,400</font></p></td><td style="vertical-align:bottom;width:1.88%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.62%;background:#ccedff;border-top:3px double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;background:#ccedff;border-top:3px double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">48,709</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.63%;background:#ccedff;border-top:3px double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.26%;background:#ccedff;border-top:3px double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">69,309</font></p></td><td style="vertical-align:bottom;width:0.57%;background:#ccedff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:1.74%;background:#ccedff;border-top:3px double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:11.34%;background:#ccedff;border-top:3px double #000000;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';">35,713</font></p></td><td style="vertical-align:top;width:0.17%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.4%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.16%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#003349;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="10" style="margin:0pt;padding:0pt;"></td></tr><tr style="height:0.9pt;"><td colspan="6" style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.72%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.59%;margin:0pt;padding:0pt;"></td><td colspan="6" style="vertical-align:bottom;width:19.95%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"></td></tr><tr style="height:0.85pt;"><td colspan="6" style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.72%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:10.59%;margin:0pt;padding:0pt;"></td><td colspan="6" style="vertical-align:bottom;width:19.95%;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>vstm-20251231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vstm-20251231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &$ [X# 2(  A$! Q$!_\0
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MZEJ?PUT6R2Q*+<GS[99FW3'@DD8''3BJ/_"!Z3_<G_[_ !I1R+%R5TX_>_\
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M][_R#^U</V?W?\$\[WT;Z]2A^&NBR:+=796Y\R*>*, 3'!#*Y/;_ &15'_A
M])_N3_\ ?XU*R+%NZ3CIYO\ R*>:8=6T>OE_P3SO?1OKT3_A ])_N3_]_C1_
MP@>D_P!R?_O\:K^P<9WC][_R)_M7#]G]W_!/.]]&^O1/^$#TG^Y/_P!_C1_P
M@>D_W)_^_P :/[!QG>/WO_(/[5P_9_=_P3SO?1OKT3_A ])_N3_]_C1_P@>D
M_P!R?_O\:/[!QG>/WO\ R#^U</V?W?\ !/.]]&^O1/\ A ])_N3_ /?XT?\
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MD#C(I/'?[+_Q"^'/A>ZU_6=+M5L+-HTO1:7T5Q+9%^$\Y$)*9) ^IKNKO]L
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MO'_Z.2LFM;2/^03KO_7O'_Z.2LFLH?%/U_1&L]H^GZL****U,@HHHH ****
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M;_,6BBBNPY0HHHH X?XC?\?&G_[DG\UKDEKK?B-_Q\:?_N2?S6N26OS#-_\
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M!9=:[K_:M\KK_@Z^1\W> O@+XY^(]SH2Z1H-R;+6;EK6UU*9"MKN0D2%G )
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M 1(AW*"<<J>]>G@\3C*M>4*]+ECK9Z]&OOO=_<>?BL/A:=%2HU+RTO\ -/\
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MPQ&#^!JC7;@,OP^!YO8-ZV6KOMLOD<F,QM;%\OMEM=[6WW84445ZIYH4444
M</\ $;_CXT__ ')/YK7)+76_$;_CXT__ ')/YK7)+7YAF_\ OU3Y?DC[?+_]
MTA\_S8U^E>LZ'_R!=/\ ^O=/_017DS]*]9T/_D"Z?_U[I_Z"*]3AW^-4]/U.
M'./X</4O4445]V?+!1110 4444 %%%% !1110 4#K10.M &KKW^JTG_KPC_]
M":LJM77O]5I/_7A'_P"A-656-+X$:5/B"BBBMC,*EM;6:^N8;:WC::XF=8XX
MT&6=B< #W)(%15Z_^RO>^#="^+NG^(?'&K0Z;I&AHVH112JS-=7*_P"JC4*#
MR&._G ^4#O7-B:SH49U5%R:6RW?D=&'I*M5C3;LF]WT&_'?]FCQ)\ H-#GUB
M[LM2@U3>@EL"Q6"9 I:%\@?-AL\=<'TK@4O/%&BZ+<Z,DVKV.D:C*GGV ,L<
M%S(,%=R<*[# QD$\<5]8^+/CS\*OC)\)?&N@RW&I>&=8.I_\)%ILGB&43^;=
ML^YXXFC!V*5!3:>!O'I70:U^USX7N_VGM&N=1\0#5_AS8V"?8IHH"T5EJ#1%
M&N""F]F 9ESSM#9%?+4<QQZI<E?#N4X\S>EKVLXVLFKN]M^CZZ'T53 X-U.>
ME648OE2UOO=.^J=E:^W5'PQ<Z;=VEREO/:SP7#XVQ2Q,KMGIA2,FFWFGW6G2
M".[MIK60C<$GC9"1ZX(%?=OQ&^/?PO\ $OQ-^%YD\6![71[JZNY_$FGF>2XM
M<H1'$TDL9)1W.3P=NWC&<UP7[9/Q8\%?$WX>>#HM'\0V6N^(]-OIUG-J\\I2
M!U.,R3(K.,A?H<X&*Z\/FV)K5:5.>&E%3O=ZZ;VZ>7EOZ7Y:^6T*5.K.-=-Q
MV6FNWGY_A]WR11117TY\^%%%% %W0_\ D-:?_P!?,7_H8J+4O^0E=_\ 79__
M $(U+H?_ "&M/_Z^8O\ T,5%J7_(2N_^NS_^A&L?^7OR-?\ EW\RO1116QD%
M%%% !3HI7@E22)VCD0AE="0RD="".AIM% '1>(/B-XL\66$5CK?B?6=8LHB&
MCMK^_EGC0CH0K,0#7.T45$(1IJT%9>14IRF[R=V%%%%62%%%% !1110 5K^$
M/^1JTG_KY3^=9%:_A#_D:M)_Z^4_G6-;^%+T9K2_B1]48Z_=7Z"EI%^ZOT%+
M6QD%%%% !1110 4444 %%%% &MI'_()UW_KWC_\ 1R5DUK:1_P @G7?^O>/_
M -')6364/BGZ_HC6>T?3]6%%%%:F04444 %%%% !1110 4444 %%%% &K;?\
MBMJ'_7W;_P#H,M95:MM_R*VH?]?=O_Z#+656,/BGZ_HC2>T?3]6%%%%;&844
M44 %%%% !1110 4444 %%%% &M+_ ,BI:_\ 7[-_Z+CK)K6E_P"14M?^OV;_
M -%QUDUC2V?J_P S2INO1 HRP&0,]ST'UK[IT/\ :;^$7PD_X5EX=TE=4\0V
MWAFW)?6=-F:WM//N 4N7DA=5:7&6?[O&[CFOA:BN''9=2S%1C6;LKZ)VW5M?
ME?[V=N#QU3 MNDE=VU:OL[_G;[C]!_AYJWA/PW\-/C7?^#OB&?"OA>X\06\U
MCXDL[&27[%YRQDQ>4RAL!B8\@< @CI6E\,_BQX:^('[1VHZCH&LRWJZ3X!>S
MU#Q1]D\I[Z:.16-QY1 SM'/(Y/'0"O@?3_B#XATOP5JGA*UU)X?#NJ3QW-Y8
MB-")9$(*,6*[A@JO0@<4O@KXA^(?AU>7UUX=U)],N+ZT>QN'2-'\R%\;D^=3
MC.!R,'WKYZIP\YQK-SO*6BO;:T5>3Y;MZ/35=;7/;AG:BZ2Y+16KM?>[>FMK
M:^OF?8EY^T1X&L]8^$=MJ?Q"D\?:AHNNRZE?>+9]-DMOLUJT4BB':%W-DLG
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M5LT@E5;D)YCS,H*_+\S*,MMR%%:6K_M'?#R[\=ZO?Q^*8FM9_AFV@13>1/\
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M# ?_ !-?J711_KAF?]W[O^"'^K& _O??_P  _+3_ (=V?%W_ )XZ+_X,!_\
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M_GCHO_@P'_Q-?J715?ZX9G_=^[_@B_U8P'][[_\ @'Y:?\.[/B[_ ,\=%_\
M!@/_ (FC_AW9\7?^>.B_^# ?_$U^I=%'^N&9_P!W[O\ @A_JQ@/[WW_\ _+3
M_AW9\7?^>.B_^# ?_$T?\.[/B[_SQT7_ ,& _P#B:_4NBC_7#,_[OW?\$/\
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M?IRFI0O,\2RJTT85G0'E0V=I/UP?RJY%*&I+C+,I*\7%_+_@C?"^!6_-]_\
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M_P"# ?\ Q-?J5FC(KH_UPS/^[]W_  0_U8P'][[_ /@'YAWW_!/GXLW&FZ;
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MYXZ+_P"# ?\ Q-?J711_KAF?]W[O^"'^K& _O??_ , _+3_AW9\7?^>.B_\
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M'_Y$/]:\;_)'[G_\D?K7_P -V?!'_H<C_P""R[_^-4?\-V?!'_H<C_X++O\
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MPW9\$?\ H<C_ ."R[_\ C5?DI11_J7E_\\_OC_\ (A_K7C?Y(_<__DC]:_\
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M>)N[3T_X/IV_KJ<WJ/QHBL--M;K^S1))/J]_I1A%R,K]FAN92_3G<+8#';S
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MLTEZ$%]_QY7'_7-OY4ZV_P"/:+_<'\J;??\ 'E<?]<V_E3K;_CVB_P!P?RK
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M?_@T;6X\&6IM88X95E>*[*#YI'!RK,>I^4C Z<&MC2/ CC2KW3M9CM]0MII
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M/%_N#^54[W3+86<Y\L\1M_&WI]:=;Z7;&WB/EG[H_C;T^M B]FC-5?[+MO\
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M 'VW^-']EVW_ #S/_?;?XT 6LBC-5?[+MO\ GF?^^V_QH_LNV_YYG_OMO\:
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MO^?O1?\ P6__ &='_#PKXO?\_>B_^"W_ .SH_P!3LR[Q^]_Y!_K/@/[WW?\
M!/U'NO\ C[LO]]O_ $!JMU^5;_\ !0;XNNR,;O1<H<C_ (EGMC^_[T[_ (>%
M?%[_ )^]%_\ !;_]G1_J=F7>/WO_ "#_ %GP'][[O^"?JE17Y6_\/"OB]_S]
MZ+_X+?\ [.C_ (>%?%[_ )^]%_\ !;_]G1_J=F7>/WO_ "#_ %GP'][[O^"?
MJE17Y6_\/"OB]_S]Z+_X+?\ [.C_ (>%?%[_ )^]%_\ !;_]G1_J=F7>/WO_
M "#_ %GP'][[O^"?JE17Y6_\/"OB]_S]Z+_X+?\ [.C_ (>%?%[_ )^]%_\
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MRM]4TX["E^+7'EM(.JD@!6Q]Y0H/05WOBU=2;PKK T<@:N;.869/3SMA\O\
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M^0JW52P^]=?]=F_D*M&@#F]/U+0;K5=<G6S@MKG1KDK=7DL*)AV@C=G#]?\
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MA'_(/[!RW_GU^+_S/AS_ (=>:3_T/]]_X+(__CE'_#KS2?\ H?[[_P %D?\
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M]'_XJKE% %/RKW_GO!_WZ/\ \51Y5[_SW@_[]'_XJKE% %/RKW_GO!_WZ/\
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M"GY5[_SW@_[]'_XJCRKW_GO!_P!^C_\ %5<HH S;R.]^QSYFA(\MO^69]/\
M>IUO'>_9XL30XVC_ )9GT_WJLWW_ !Y7'_7-OY4ZV_X]HO\ <'\J!$'EWO\
MSW@_[]'_ .*H$=Z?^6\'_?L__%5!XFGDMO#NJ2Q.8I$M965UZJ0A((KY[\#^
M.]2\,Z%J^KRG58#8^'[,-INJ7S7TM]?7 4V\\(#.0C$LA /)R-HV<]^'PDL1
M"4HO567WG)6Q,:,U&2WO^!]%^7>_\]X/^_9_^*H\N]_Y[P?]^S_\57SU'XPO
MY?!MSX;6_P!9U>]L-<TY1.7EL;N]M;B525#OL(^<31YR!M51FNTO[R^M['3=
M!L8=3T:X1;C5[Y+O4?M4Z6\0.Q3+YC\22E!C=]U7Z5K/ 2@[.77\+7OWV\C*
M.,4M4O\ A[VMV_$]1\N]Q_KX/^_9_P#BJ-E[_P ]X/\ OV?_ (JOEW5?B#XB
M'P3_ .$=CUN]7Q'IVGQZK<ZJ)2+B2R$<4T3ENN9'E6(GOY<M=UHDFH7>K^+K
M^:UUR3[-J6I)#J8UDBUA5%<(OV;S>0, #]V>>?>M9Y;*G%RE);NWG:UGK;>_
MKY$0Q\9R48QZ+]=.NUO3S/:/+O?^>\'_ '[/_P 51Y=[_P ]X/\ OV?_ (JO
M*_@5K][XM@CO=<U*YCUNTL8(?[&>0A8X612ERW_/9I<;O,Z#E1@ALV_"5C_P
MG+:MK6K:YJ5IJ-MJMS;)96E\T$=@D$[*B-&#M<LBJY+AL^9Q@8KFGA'2E*,Y
M?#;IWV^7GMVOI?>&)52,916_Z?KY??U/2?+O?^>\'_?H_P#Q5'E7O_/>#_OT
M?_BJ\0T?XUW'@_P9:S7J?VS,+C49[HRW+&X2!=0EB7:H1N HP"Y1?EQNS701
M_&76[_Q#%IUAX9MI(KK6;W1;6>XU'R]TELKL\CJ(SM0B-P,9.0.,'-7++Z\6
M]-%?6Z6V^Y,<;1DEKJ[:6;WV/3_*O?\ GO!_WZ/_ ,51Y5[_ ,]X/^_1_P#B
MJ\KM/CGJ6K0W5SI_AR%[6QT:#6+O[3J*Q2*':97B1=A#%?(?!)53QR*Z'X@?
M%!O"WP\7Q+IVE7FIB>U%U"D<#$(I56!EQRHPU9/!5XS5-K5NVZW_ $-%BJ+B
MYIZ+79G9^5>_\]X/^_1_^*H\J]_Y[P?]^C_\53=$U0ZSID-X;2YL3)N_<7D?
MERK@D<KVSC/T(J]7$TXNS.I--713\J]_Y[P?]^C_ /%57U*.[%A<%Y8F38<A
M8R"1^=:E5-6_Y!EU_P!<S_*D!-B7^\OY4;9?[R_E4@I:!D6V7^\OY4;9?[R_
ME4M% $6V7^\OY4;9?[R_E4M% $6V7^\OY4;9?[R_E4M% $6V7^\OY4;9?[R_
ME4M% %*Y#_:;3)!.]L$#_9-6-LO]Y?RJ&Z_X^[+_ 'V_] :K= $6V7^\OY4;
M9?[R_E4M% $6V7^\OY4;9?[R_E4M% $6V7^\OY4;9?[R_E4M% $6V7^\OY4;
M9?[R_E4M% $6V7^\OY4;9?[R_E4M% $6V7^\OY4;9?[R_E4M% %*0/\ VA#R
M-WEO@XXZK5C;+_>7\JAD_P"0G!_UR?\ FM6Z (MLO]Y?RHVR_P!Y?RJ6B@"+
M;+_>7\J-LO\ >7\JEHH BVR_WE_*C;+_ 'E_*I:* (MLO]Y?RHVR_P!Y?RJ6
MB@"+;+_>7\J-LO\ >7\JEHH BVR_WE_*C;+_ 'E_*I:* *2A_P"T9.1N\I><
M<8RU6-LO]Y?RJ%?^0I)_UQ3_ -":K= B+;+_ 'E_*C;+_>7\JEHH&1;9?[R_
ME1ME_O+^52T4 1;9?[R_E1ME_O+^52T4 1;9?[R_E1ME_O+^52T4 1;9?[R_
ME1ME_O+^52T4 1;9?[R_E1ME_O+^52T4 9L:7#7MUY4D:\KNW(3D[1[BIO*O
M?^>\'_?H_P#Q5+:_\?M[_O+_ .@BK= %/RKW_GO!_P!^C_\ %4>5>_\ />#_
M +]'_P"*IT^IVEK,(IKJ&*4XPCR $_A5JG9H5T4_*O?^>\'_ 'Z/_P 51Y5[
M_P ]X/\ OT?_ (JKE%(93\J]_P">\'_?H_\ Q5'E7O\ SW@_[]'_ .*JWFEH
M I^5>_\ />#_ +]'_P"*H\J]_P">\'_?H_\ Q57** *?E7O_ #W@_P"_1_\
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M'[P_UFR_N_N/TXHK\Q_^'E7Q2_Z!?AG_ ,!)O_CU'_#RKXI?] OPS_X"3?\
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MX3/'J,AGDCV18D !"(C%06.95QD#)]!3X@Z%/XCBT2VGM+F$V=S=SS13(T<
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M_E3J:G^K3_='\J=7]2'\^/<****!!1110 4444 %%%% !1110 4444 %%%%
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M8)/S<G.#=? G5;K2Y-&-UI:6=O\ VC);ZBL+_;+A[F.9 LYQC://RQ!._8O
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M\*/^'9'@_P#Z&W6_^_4/^%?9U%'^L6:_\_W^'^0?V+E__/E?B?&/_#LCP?\
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M+_WZ_P#KT %A]ZZ_Z[-_(5;K+L8+DM<XN5'[YO\ EG[#WJUY%U_S]+_WZ_\
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MI?\ OU_]>CR+K_GZ7_OU_P#7H LX'I1BJWD77_/TO_?K_P"O1Y%U_P _2_\
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M[M17DL/C_7%^%?CG6+:X@U6XTA;G^R]32W*Q7H2%75]F?F <LA*G#;,BN?\
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M**2[):;3XY3(9B-Z@RL#&I5F&1$<GG!R]/\ @[XJO].F&K";S[?0+VUT]5U
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M4KW:MIY^OH_N[V,$?"CQ+!>2Z+:3"+36UI=5?7[N074]Q#&H>""5';<VR4@
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MXC]PO[7Q_P#S^E]Y]1?\/&?BS_<\/_\ @ __ ,=H_P"'C/Q9_N>'_P#P ?\
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M'_\ P ?_ ..U\NT4?V'EG_/B/W!_:^/_ .?TOO/J+_AXS\6?[GA__P  '_\
MCM?=O[+7Q-UGXO\ P4T3Q3KPMAJEY+<I(+2,QQXCG>-<*2>RCO7XX5^L7[ _
M_)K_ (7_ .N]]_Z5RU\9Q7EN#P>!C4P])1?,E=+I9GU/#F/Q6)Q<H5JCDN5O
M7U1]#4445^3'Z0%%%% !1110!4D_Y"<'_7)_YK5NJDG_ "$X/^N3_P UJW0
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MG_?A/\*/]>%_T#_^3?\ VH?ZI?\ 3[\/^"?A;]CG_P">,G_?)K]7OV"D:/\
M9A\+JP*L)[[@C'_+W+7NG_"/:9_T#K3_ +\)_A5NWMHK2(101)#&.B1J% _
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MR>?81/#;/DYB1@H8#GN$7KZ5#Q-)QLX:VM_Y+;\]?^"4J%1.ZEI>_P#Y-?\
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M.?FJ25NR_P"&+U%%%<!VGYA?\%B_^1I^%O\ UY:E_P"C+:OSO6OT0_X+%_\
M(T_"W_KRU+_T9;5^=ZU]CE_^[Q^?YGQ^8?QY?(8_2OZ!/V8O^3;OA5_V*NE_
M^DD=?S]OTK^@3]F+_DV[X5?]BKI?_I)'7%FOPQ]3MRKXY>AZ91117S9]&%%%
M% !1110 4444 %%%% !2'I2TAZ4 5;#[UU_UV;^0JW52P^]=?]=F_D*MT <K
MKWQ"L- \7:/X?GBF>;40<W" >7;DDB(2'.1YC*RKZE36^^J6<5U]G>ZA6XX_
M=-( W/3BO,O$'P;U+Q/-XJO[CQ%=V.HZE-&]G%:.GV>%;?!M-^Z,OD."[;6'
M+$#UKS[5M&D?Q5;:68]$U76YO%-MJ,\Z,[7\'SJ\B!2F?+C 8!RVW8!QFO9I
MX2A624)ZI:_YZVVV^1Y<\35I-N4=&]/\OU^9]'0:I97)E\JZAD\H9DVR [![
M\\4T:Q8?9?M(O(/L^[;YOF#;GTSGK7BUG^SS=V'A/2]-M)M/L[N+16L;YX0P
M2]F^T0S*), %HV$<BL3\P$AQU-3:Q\&-8U:UU"X2PT6PGN;J&:+3+:8BV@,<
M,L9E^:$HSMYN"#'C:B\[AFH^K89O2KI?M_P>N_D5[>O;6G_7W?(].'B'1-5U
M<PP-#?W^FW@MGV89K61XMV>>F48#(_O8]:VK:_MKR21(+B.9XCAU1P2I]\=*
M\>7X+:N-9AGW:3"HU:RU66\M4,4C&.S-O(H3:<?/\ZY8_>.>>3TWPI\"7_@F
MUCM+W3M'@-O:):_VA8%C/>E3_K)<J,$]3DL<L>:SK4:"AS0J7:2T_,NE5K.5
MIPLG?_@'H6*,4M%>:=XF*6BB@ HHHH @OO\ CRN/^N;?RIUM_P >T7^X/Y4V
M^_X\KC_KFW\J=;?\>T7^X/Y4"):3%+10,*3%+10 F*,4M% "8HQFEHH 3%90
M\,62^*9/$ $G]H2626!._P"7RED9QQZY8\UK452DXWL]R7%/<QM/\+VMAXAU
M+6O,FN+Z]2.(M.P811IDB.,8&U<LS'J23UX&-FBBB4G)W8**CH@HHHJ2@JIJ
MW_(,NO\ KF?Y5;JIJW_(,NO^N9_E0!:%+2"EH **** "BBB@ HHHH **** *
MEU_Q]V7^^W_H#5;JI=?\?=E_OM_Z U6Z "BBB@ HHHH **** "BBB@ HHHH
M**** *DG_(3@_P"N3_S6K=5)/^0G!_UR?^:U;H **** "BBB@ HHHH ****
M"BBB@ HHHH J+_R%)/\ KBG_ *$U6ZJ+_P A23_KBG_H35;H **** "BBB@
MHHHH **** "BBB@ HHHH J6O_'[>_P"\O_H(JW52U_X_;W_>7_T$5;H \;\5
MZ)XRNOB9)+#/>KISW%FVGSVFXQ01*5,ZRKYBKDD/G<K$JPV\BL.Y\&>.K+PG
M<7%E/K#:[?6NO17"O>E]F[SC8[ 6VH01%M*X///M[_BC%>I''SBHQ45I;IV5
MO^#ZZGGRP<9-MR>O^=_^!Z:'A'B'PGXKT[[9:6::[>3OI\":'=6^H-Y=K=X9
MI6N2S?-^\*L=P9=GRJ!C%9>L_#[Q?'J/BR\TRRNK>ZGB\0&RN()55Q).UD8&
M4YX+>5(1Z;>:^B\48%5',JD+/E7]?U]]WU)E@82O[S_K^ONL>*P^ /$FF>(]
M8NK*ZU@PVVI:2VFB?4'EC: F,7NY6;YA@R$[N1CY<5S,7A;XCR^&-;A:?5X]
M=;3C#/)'(52>Z,T9\R%VE(7"B0C8JC#8(SBOI#%&!Z41S&I'>*>VZ[?Y[OSU
M"6!@]I-;_C_EMZ:'BFK^ ]3L_%=A(;;5]2T73/$$-S:8O9))(X9+*1)6R7W,
MHF*DY)(!;'RDBM'XA^'O%>L>)]133Y-0BTJ=M#16M+GR\*E[(UYMYR/W)7<1
MU&,=*]:Q167UZ=XR:3:5OQ3^^ZU]33ZI"S2;U=_PM_PQYG'IGB71_AYXML((
M+R_NH[RY32XY;LB9K9BI7$I)8E0SXR=QV@9SS7FFJ^ _&FO>')89M/O+@Q2Z
MTEHMQ(=ZPS:88XA\[LP#3,X 9B1GL*^EZ,#TJZ6/G2;:BKMW_"W]>I-3!1J)
M)R=E_G<\R\<:7K(LO"86UU.[T>VB=-2LM)G,5PTGE*(CE6#%5;?D*>I4G(!K
MG8=%\7#7X]]OKG]H-J5G+9W;7@-I!IZB+S8IE#;6?:)PWRDLS J<8Q[?BC K
M.&,E"/+RK^G?_@>:T+EA5*5^9_TK?UV>I\]Z-\//&GAKPE#'H1O[/5+NWUE;
MB*:[W1QN]R9+8JI)5&VE@I _B^;-6Y/"WB?6+^TBTZ'Q%I7AN34;#[1!>W[?
M:=JB?[2P?>7$9!A! /)&5QUKWG%&!Z5L\QJ-MN*N[_B[_AT[(R6!@DDI.RM^
M5OQZ]SYWO_ ^OZ!I^L6FDV&O"1=<N[N-8+MVBNTD1C#E_-#@9(RW.&'SAA7T
M%8F4V4'GIY<WEKO7=NPV!D9[\]ZFP/2EKEQ&*EB$E);'11P\:#?*]PHHHKC.
MH_,+_@L7_P C3\+?^O+4O_1EM7YWK7Z(?\%B_P#D:?A;_P!>6I?^C+:OSO6O
ML<O_ -WC\_S/C\P_CR^0Q^E?OU^S+;3-^SA\+"+IU!\+:9P%''^BQU^ K]*_
MH$_9B_Y-N^%7_8JZ7_Z21UQ9K\,?4[<J^.1Z#]DG_P"?Q_\ OD4?9)_^?Q_^
M^15NBOFSZ,J?9)_^?Q_^^11]DG_Y_'_[Y%6Z* *GV2?_ )_'_P"^11]DG_Y_
M'_[Y%6Z* *GV2?\ Y_'_ .^11]DG_P"?Q_\ OD5;HH J?9)_^?Q_^^11]DG_
M .?Q_P#OD5;HH J?9)_^?Q_^^11]DG_Y_'_[Y%6Z0]* ,NRM9BUSB[<?OF_A
M'H*M?9)_^?Q_^^118?>NO^NS?R%6Z!&?@[)'_M'Y8SAV^7"GW]*8BJ\X5=15
MIB.@V[L=?RKXW^+_ (?U?1OBYXI^%NF1W":7\4K_ $_4HIXR=MLJN?[1Y[96
M,-^/O5'P&VF^!_VD)+;1;>'X@WUQ?7_V:6&>X@U#2Q'"P6"56(B:'Y1&K' R
M<]J^HCDT94G4C4O>/,E;I9/5WLM;K_MUVN>"\SDJB@X=>5N_6_16N]+/YZGV
MO.ZVKA)M46)B,A7*@X_&ER/,2/\ M(;W&57Y<L/85\J_M-^&;+XG:?X*TS4/
M"1TKXG>++A=,A$MUYLFFV<<A>:8F)RAPF2/]_P!JYCX^Z=X6T+XJ^$K?PU=S
M_P#"1:3J>EV=Q8QBY.HO%'L5!;,3Y7E^6/GP.?7/7/#Y3"NH+G:E)2^RFE;2
M]U+X6[J_D76S&=)R]Q6376SUUM9K=+6WF?9XE1IO*&JJ9<[=@*9SZ8I876XD
M,<6J+(XY*H5)_*OEQOAIX7\2?M=27'A_2?L5MX0CEUK7-0A>1C=:E/N:*+&2
M/E^:0@#KQ7!?LQ7$?@KX@75EX9TBP\?ZB-'NKEM5T_[1:W*2>>/]'G^T,(P6
MSP<+PE/^R(2I2J0J.ZBI6:2WON^:RT2?FGL+^T9JHH2@K-M73;VMLK7>MU\C
M[C>-XY$1M0*N_"J0H+?2DVGS_)_M']]C/E_+NQ]*^;OBMX;GD^.GP,\6WB:E
M8ZOJ6IF"ZTJ:\$L%D%M)&*JJ?+G<>6!.<"O)Q]I/QP9B^I?\+6'Q(50I:39_
M8/E\@#[OD[/UQ4T<HC6@I*I]F^VS3:[[*VLOP*K9C*C+E<.MM^ED^V^NWXGW
M4L;O(T:Z@6D7[R@+D?45)]DG_P"?Q_\ OD5\Z?!#PA%X(_:C^*FG6UYJ%_"^
MF:=<FXU*X,TCO(TC-\Q[#(  Z "OI:O)Q>'CAJBA&7,FHN]K;I/]3T<-6=>#
ME)6:;7?9V*GV2?\ Y_'_ .^11]DG_P"?Q_\ OD5;HKB.HSKRTG%G.3=N1Y;<
M;1Z4ZWM)S;Q?Z6X^4?PCTJQ??\>5Q_US;^5.MO\ CVB_W!_*@1#]DG_Y_'_[
MY%'V2?\ Y_'_ .^14]Q<1VD$D\SB.*-2[NQP% &23^%8-_\ $/PWIEN)[G6+
M2*(V8U#<9!C[.2H$G^Z2RX/?-7&$Y_"KDRG&/Q.QK_9)_P#G\?\ [Y%'V2?_
M )_'_P"^163IOC_P]JVC7^JVNJVTEAIX9KN;?@0!5W'?G[OR\\]J?JOCK0=%
MTFSU.\U.WALKP!K>8OD2@KN!7UXYX[57LJE^7E=_0GVD+7YE;U-/[)/_ ,_C
M_P#?(H^R3_\ /X__ 'R*KW?B72['0QK-Q?P0Z68UE%V[@1E&QM.??(Q]:S[#
MXB^'-2TF_P!2@U>V-E8#==3,^T0C&<MGH, T*E4:NHNVPW4@G9LV/LD__/X_
M_?(H^R3_ //X_P#WR*QM4^(WAK1M/TZ^O=9M+>TU&,36LK2#$L> =X_V<,#G
MIR*AU#XH^%=*U=M,N];M(+Q-F]'? 7>H9,GH,@@CZBJ5"J]HO[B76IK>2^\W
M_LD__/X__?(H^R3_ //X_P#WR*M A@"#D'D$4M8&Q4^R3_\ /X__ 'R*/LD_
M_/X__?(JW10!4^R3_P#/X_\ WR*/LD__ #^/_P!\BK=% %3[)/\ \_C_ /?(
MJMJ5M,EA<,UR[J$)*E1S6I535O\ D&77_7,_RH$3^6__ #T/Y"CRW_YZ'\A3
MQ2T#(_+?_GH?R%'EO_ST/Y"I** (_+?_ )Z'\A1Y;_\ /0_D*DHH C\M_P#G
MH?R%'EO_ ,]#^0J2B@"/RW_YZ'\A1Y;_ //0_D*DHH I7*L+FT!<DEVP<=/E
M-6?+?_GH?R%077_'W9?[[?\ H#5;H C\M_\ GH?R%'EO_P ]#^0J2B@"/RW_
M .>A_(4>6_\ ST/Y"I** (_+?_GH?R%'EO\ \]#^0J2B@"/RW_YZ'\A1Y;_\
M]#^0J2B@"/RW_P">A_(4>6__ #T/Y"I** (_+?\ YZ'\A1Y;_P#/0_D*DHH
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MHHHKR#TR"^_X\KC_ *YM_*G6W_'M%_N#^5-OO^/*X_ZYM_*G6W_'M%_N#^5
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M(_\ V+U__P"B'K2A356K"F^K2^]D5ING3E-=$V0?\--?"C_HH7A[_P &$?\
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MG-N%</E^"J8J%1MQMH[=6E^IZ>6\0UL;BH8><$D[]^US]!****_-#[P****
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M-4F:-95:1DV1X!R1L)8]MR>M<C=_''5K316ULV-@]G<KJ*VUB)V^U0-;0SR
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M]":K=5%_Y"DG_7%/_0FJW0 4444 %%%% !1110 4444 %%%% !1110!4M?\
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M /#U#X+?\]=9_P# !J/^'J'P6_YZZS_X -1[#$O[+'[?#?S(^Q54(H50%4#
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MX+YO_B:/JU;^1_<'UBC_ #K[SZIHKY6_X>8? ?\ Z&6Z_P#!?-_\31_P\P^
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MG_P :CZK7_D8?6J'\Z/L:BOCG_AZA\%O^>NL_P#@ U'_  ]0^"W_ #UUG_P
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0/<T8]Z** % S3J**HEG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>vstm-20251231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vstm-20251231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (/ Z@# 2(  A$! Q$!_\0
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M@:A"L&GQ17,D:SS"11A0J#)&23GCG%9RQE.*3?6WX_\ #&L<%4DVETO^%O\
M,^ **]U?X >'U_:X;X3MXI">'AK0T_\ MHE-P0J&VYSMW@GR\]-PZ=J]9^+O
M[(OA.U^)/AGX>>$O#'CWPOX@U7638)JWBAX9M,N;8 EIXGC'S' +!,@X'(K1
MXFFFD^JO\C*.%J23:Z.Q\8T5]7_%_P  ?LS?#6[U[P7:7GQ U;QKI7^B_P!I
M1FW6RENP1E2I'" GD@=C@FO6[+]A?X;'XO:KX>-EXHU6PL_!4'B&.QT_4%^U
MW%TT@4QHQ0#!' 4]^]0\7"*NTT:+!S;LFC\]:*^Y/AS^RC\-_'?QR_X135_!
MWC_X>:3%H$^IRP^)K^%;EG61%612BD; "V0>^*Q;K]C[PI\-?#/Q9U;QPFL:
ME!X2U"PET^32;M(1?Z=.6.]=RE2Q48!S@$&CZW3O;KI^(W@JB]-?P/C6BOL_
MXF?!KX >%?A/X&\4:=H?CH77C99$TQ)]7@9;5U8KF8;>1Q_#FN^7]AGX:VWQ
M,^(&C+I7B[Q!9^']!L]4M-,TG4$^VW4TA;<BED ).T8!Q]:3QE-*[3_X;0%@
MIMV37_#GYY45]IZ7^ROX#\22?% MX2\<>"Y_#/AY-2M-+\27L?VIIV+8=MBD
M-&<<#/8U2UWX!_ 7X ^&/"EO\6M4\8ZQXOU^PCU)[;PP(HX;&)U!4$.,L>>Y
MY(/ IK%0>B3N2\)-:MJQ\<T5[E^SC\&_!_QU_: 3PH^KW^D^%Y3/-:_:&B6^
MN40$I"#]P2-T_P :]+\8_"CX(^ ?BEH_AK7_  #\6-%^WM]E^SZE>6T/[PRA
M4ECEP1)&1DG:>.*N6(C&7)9WM<B&&E*//=6O8^0J*_0#_AE+X&:C^TM-\)=/
MTKQJ;S3K66[O+E]6B*7"B(LB183<&SCJ *\Z_:8_92\+_#_X7>'O%7AS2?%7
MA'6-1U4Z9_PC/BVX@FN9P3A94\OD#Z]O2LXXNG*2CKJ:2P=2,7+>Q\B45]I_
M&7]CSP+\*OA=HOB2"]U76M3T&XM4\;:=:W:>9"DR;L1 KB-ATR21Q4?Q'^#?
MP \,_"3P/XKT[1/'0N/&;&+3HY]7@86S!@,S#;R.OW<TUBH2M9-WT!X2:O=K
M34^,**^Z?C]^R'X(^&>AW\.@?#;XEZI=+8PS0^)DO89-)BEDV\R# ?:"<' [
MU+'^R!\)_!-U8>#]=T_XD?$'X@2:;'J6H1^"H8O)L$D'R J^,\\<D^^*2QE-
MJZ&\%43LV?"-%?9_@;]CCPC\:?#5O_PB;:QX;\2Z#K)LO%FF^(;R,RVUGR?/
M"A0%.T<@9 )KQKXW?!NTTU=5\8?#W1-3;X5V=]_94.N:A>QS-<W"\,VT88*2
M#CY<>]:1Q$)RY5O_ %^?0RGAIPCS=/Z_(\5HHHKJ.0**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#HK'
MXA^(M-T=M*MM5FBL&&#$,=/K7.DDDDG)/<T45$81@VXJURY3E-)2=[!1115D
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'MW[-/[2*? U_$FC:YX=
MB\8>!O%%L+36-$DE,32 9"O&_9@&8<]0>H(!KL?''[6'A+1OA1?_  _^#G@*
M?P-I>KW4=UJVH:E??:[JXV,"D8.3A> .3TR,<DUQW[+'[+>I_M3>)=:T?3->
ML] DTRT6[>6\MWF$@+A, *1@\U[WK'_!)SQI'I=[-H7CWPWK]_;*3]A2*2$L
MP_@W[F"DX(^8#GTKS:LL-&K^\=GIWMY>1ZE*.)E2]Q:?*Y4D_;_\%?\ "0O\
M1H_A7.OQADTG^S&U=M3_ - W;-AE\KKTSQC..,]ZY'X=_MRR_#SPE\+M,M=+
MU">Z\,ZI>7>L%KA%@U."Y,GF1A1T;]YD%A@$9KY=US1+_P -:S?:1JEI+8ZG
M8S/;W-K,,/%(IPRD>H(JCUK582C:UM/7^NYB\763OU]/ZUT/2;WQ9\.Y?C9<
M^(?^$1U.]\!3WK71\.RWZV\X5N6C$T8/RAB2,8.,#(ZU[;XL_;ALM%\)^$O#
MOPQ\/ZQI%KH.MKK:77BG53J4P=?NP1DD[8L9!&>F1CDFODFBM94(3MS:V,HX
MB<;\NESZO^(W[3?P2^($>N^()?@?-'X_UF'$]Z^L-]CBG.,W$: Y#\9^Z,]^
MYKLH?V_?"D_Q+U3Q!>^%/$0TW4/",7AF2&ROH8;I65]S2I("-O'3'(-?/G[,
M'PS\!?%7XC_V-\0_&:^"=$^RO*EXTL4/G2#&(Q+*"B<9.6'.,#DUQ'Q-T#1/
M"OC_ %_2/#FM#Q%H5E=O#9ZHH %Q&.C<<'N,C@XR.#7/["BY>SUT7F=/UBLH
MJIIKZ'T1X8_:G^'7@#QO>:YX>\.^-[J.]T&ZTB<>(=>2_FWR%#&R,Y.U5PV1
MGDD5#>?ML_\ "0_LFWGPGU[1+J^U\PI9VVO))'M-NC!HTD!^8E>0,9XQ7S5X
M7T^PU;Q'IEEJFH#2M-N+F.*YOBNX6\98!GQWP,FO7?VK?A)\-OA'XHT6Q^&W
MCU?'5C=V9FNY%N(9_LSY 4;X0%^8$G;U&.>M-T:*G&+3OOUZ>8E7K2A*::MM
M]X[Q[^T+IOC#X6?"/PI#I%Y;W'@IW:XN))4*7.YRWR <CK_%7K'C3]O'2?$&
MJ_$R_P!,\/ZWI=SXJ\/6^C6<R7D:26DL>[]Z60@X^88V\\5\:45J\-3>Z_IN
MYBL546W]65CWSX(_M.?\*W\,?$FP\00:MXCU#Q5I7]G0WKWGF- 1G!=I"6(&
M>@KO+;]KSX9^/O"WA:#XO?"67QAXD\-VJ65IJ=AJ/V=+F%  JSID9' S][\*
M^1ZM:58'5-4L[)9%B:YF2$.PR%W,!D_G1+#TY-R>_K8(XFHDH[^IW_@WQI\/
M['XHWVN>)/ MW>>%9Y)7M]#TK5WMI+,L?D*38RVWL,C^E>F_&C]K#2?B%_PK
MG2=#T#5K/PYX.N5N4DUO4?MVHW)W9(:4]!C@<GMZ5[+:_P#!(SQ->1J\7Q,T
M"3*AL)I\S8!^DE>5_M(?L$ZO^SE\/F\57WC72=>B%S';?8[.U>.3+G&<LY''
MTKE5;"U9JTKOIN=;HXJE3=UIN]B:W_;)T6#]JKQ#\6!X=U,6&I:;+91Z>L\0
MGC9HM@8M]W //'-3:1^U[X,UVV^&][X_\):SK_B3P3=R207UK=0[;R L6CCE
M\PYRI(Y]A7R9172\+3[>1S+%U5^9]EQ_\%$;OQ9-XYTOQUX1TZ^\+>)+:6$0
M:+9Q6UZC'/E-+,S?O"HQDGGCBO*/'?[0>E>*OA1\*O"%KI%]!-X,G:2:YFEC
M*W*EL@(!R#CUKPNBG'#4H.\5;^K$RQ56:M)GV!\:/VM?AI\78[N_?P_\0[#7
M6LX[>!(?$JQZ<LD8&QFME.UAD9(QS6KX=_;K\"ZAJGAWQ9XT^'&K7/Q!T:WC
MM?[7\/ZTUI#>I&,()HL@,/8AA7Q51VS4?5*5N77[S3Z[5OS:?<?17@G]J>P\
M.^-/B]X@N]!O"?'-G/;0V]K<(?LC2$D%V8#<!GL*\U_X33PI_P *5'AC_A']
M2_X2T:A]I_MC^U9/LGE8QL^RYV;O]K&??M6C\2/V:?'_ ,)_!.B^+?$NE6UG
MH>L;?L<\5]%,TFY=PRBDD<'O79_%;X*?"?PC\!?"_BOPU\3H_$/C+4"GVW0@
M\3>7D?/^[4>9%M/'SDY[4+V*:<>KZ>0/VS34NBZ^9\]T445VG %%%% !111U
MH **^H/V,/V.[/\ :47Q!K7B+7Y_#_A30\+<2V:H9I'V[SAG!5%5>22#7E'[
M0/A3P!X,^)%WI?PV\2W'BSPQ'%&4U&Y*EVE(^=<JB#@Y'W:P5:$JCIK='0Z$
MXTU5>S/-J*^N?@1_P3OUOXY_"K3O'5OXYTC0K&\,@\B]LY&,>UROS.' YQ^M
M5?CM_P $Z?'?P8\#7'B^TUK2?&.AVB^9=OIBO'+"F<;]C9#*,\D-D>F.:S^M
M4>?DYM=C3ZI6Y.?ET/E"BO1?@#\$=8_:#^)FG^#M%GBLI[A))I;V>-GCMXD&
M2[!>3R0/JPKJ_P!J7]E'Q!^RUK^D6&KZG;:W::I;M-;W]G"\2;E;#1D,3\PX
M/7HPK5U8*:IMZF*HS=-U$M#P^BOH3]FC]B?QQ^TS8W>K:5<V.@^';60PMJNI
M;BLD@ZK&B\MC/)R /7.:Z/\ :%_X)^>+/@%X#;QC)XI\/^(=#B=8Y6MI#;RA
MF.%V(Y(DY[*V>"<8!J'B:2G[-RU-%AJKA[11T/EBBO=/V0_V<8?VD/B'J&EZ
MGJ,^C>'=+T^2^U#4K<+NA XC&6!7DY)SV1OK7H7P%_X)^W_[17AG5?$?AOQQ
M8V.CVNJW&GV_V_3Y&EF2-AMD(1\+N!!QSCUHGB*5-M3=K?J%/#5:B3BMSY)H
MKOM8^"WB#1_C7+\,'C63Q"NKC1U*J0CN9 JR#OL((;/I7O?[07_!.SQ!^S[\
M+-1\;:AXRTS5K>RD@C:SMK&6-V,DBH,,S$<%L].U.5>G%QBWJ]A1P]62DTMM
MSY&HKUG]FK]G37/VF?B"_A?1;N'3%@M'O+K4+F)I(H$!"KE5()+,P &?4]J?
M^TS^S?KO[,?CZ#PUK-[!JJ7-HEY:ZC:Q-'',A)5@%8D@JRD$9/8]ZKVL.?V=
M_>(]C/V?M;:'D=%?6G[/W_!/;6OC[\*++QW:^-])T&QN99XS;WMG(YC\N0H2
MSAP.<9_&F?'7_@G/X[^#/@*Y\96>MZ3XRT*S3S;Q],5XY8(N,R[&R'0=RK9
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MM=.I]8_'?]E+2/''[.?BWQ+K7PGT#X2>-O#T$U[:'PW=Q30W$4:[R'\I$!R
M5PRY! (/:L&P^&_P8_8S_9J\)^-O&W@&W^(GB?Q)' =E[#'./,EC\T1KYH*1
MHB \A221[\?/OQX_:,^!_B?X:S^&/AM\)+O0K^XE$O\ :^IW966V/0[-DKE\
MC(VLP7V-=E\*/V^_!US\'-/^''QI^'TGC;2=,C2&TN;58I&:-.(PZ2,NUE'
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M]X/6O,O@=X>A\6_M7>-H-1^%][\6+2'4+QET]+H1PVLGFMMDE\QA&5SQAS]
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M24^[UYS6&O[6?@G4/V,]"^"NHZ1KZW]O<VYO+ZWC@,!A6]\Z3R\R!BWED@9
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M<D ' Z]J^%OBQ^T5\./$WQ3\$:UX(^'DW@_0?#UU!-/MN-US>HC@@&/>8P0
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M7&-&%12E5O\ UYW/4_VP_P!G+PE??LP:GXY;X9:1\,/&.CN)#::'-#)&T>X
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MB_&[X7^#M*_X)L>!O%%CX4T6S\37,&E&?6(-/B2[E+GYRTH7<=W?)YI_Q_\
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M2RMU/LE/V2-#^"OASP]H?@_X&>&_BI=.BG6M:\2W\$4Q88#&,2QN<G+8"A5
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M %*O)I*?'UKDQ7\&1U8;^+$<!3@,4H&*<!7SECW[B!:=124""EHHH)N%%%%
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M444""BBB@ HHHH **** "BBB@ H'6B@=::W$5#UHH/6BOK#YL****8@HHHH
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MC(K0R'YHS3<TF10 _- ;D4S<* W(IH1 >M%!ZT5]8?,!1113$%%%% !1110
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M%%%,04444 %%%% !4L'4U%4D'4_2N3%?P9'3AOXL2>BBBOG#W0HHHH ****
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MG<7?B^\34-<A>WL"D-E&R;X 0P*D\^IZU3/B.XOM=T.TN;+3[Z'^SEN5BN8
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ML6^'=ITI\\%=Q9,#YN.>,C%9J5*5US)WU_KY%.G6AJXM.]OZ^9Q(LA<".2(
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MMJ&IV_DA)[+3$\WRT8'?+C"+^ _4UF-H5Q9">2[5\1JUS,5'WVP=JCURQS]
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MIZ5[_P#L_?&K0/A;^P]XO%Q;>$O$FOCQ1'/!X9\2[)Q.F(1YOV?>'8*02&'
M(]J^*:,#.<<U^A8'+I87!4\)6K2JN&\I:REK?7\O0^/Q..5;%3Q-*FJ:E]F.
MRTMH?H3\._VCO#+?##QI\4?BGXNGM?&GC>YAT2UM/!!MO[3TK3[?)3RX7?\
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M/ 7VKOM ^.'PPOOC%JOPDO/$VCQ?#'0M(L;C3+U[^W%I->P3^>VV7.TEMP&
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M?C3\4M%^+#V%U!I4VE:NJ^6Y,JR),G48(P<C^5,T3,OP%\3+&50KK-L& )/
M0G&>M?J%7%9C5R*A#'0=*O4E3IU+-7UFHR<7%M:J[33NKJVJ/SFGA\#3S>M+
M"252E",YPT=M(MQ332V>Z:UMKN9GB/XS^-==ND":W<:?:JV4L],F:TCA0=%
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M2GS*5[?UKJS*O6<H<KC:_?\ 0@HHHKO/-"BBB@ HHHH **** "BBB@ HHHH
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MO-1=GW5^UK?8O@K3_#_A_6=0LM(\>:BWABX/FS:.L^5,AY)8Y^8>WYUJ>)?
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M53X7X3XC^&V"D9U& #@Y'SBD^*,C)\2/%#=O[2N-Q5<G[YQ7BJI;/;_].?\
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MA G"YW1MV<$=*I>$_AGXP\??O= \/:AJL&[:;B)"L*L.Q<G&>?6O4=%_9/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#AH;4^G_")^"\YV\Z G_Q5*/VAM4SSX4\%MDXXT%/_ (JH689K_P! :_\
M!J_^0)>"P'_02_\ P!__ "1YB9U/R>>K#!!Z9SU%.,RDJ=ZG##J?4<UZ6?VB
M-5 _Y%/P6#QUT%.?_'J!^T/JI(5/"?@LNQVJ!H*$D]@/FY^E']HYK_T!K_P:
MO_D!_4L!_P!!#_\  /\ [8\R\Y2S?O1AB#PXR:LV4$VI3B&TC:XDQG:G( !Z
ML>  /4D"O7O^%V7VDC?K/ACP;!+C*Z?!H49N&[C=EL1C_>RW^S64_P"TEJZB
M:*'PKX.@M9SEH!HJE3Z _,-V/<5;QV:P?OX-?^#5?_TC0%@\ ]L0_P#P!_\
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MD3W7A\1&ZBNI9X@Z1CIO 8'<!U&*XU',T4<C1KYR\?+D')^GIUK=^(7P\O\
MX8^)9]'U )&''G)]CF+QR1GD$X/Z$5S4;M)$A9I(CT3CG'O_ )%?6Y+B<1B<
M.J]6M&K"23@XIK3^\W)W=^JMZ'SF:4,/2KRA0IR@TW=2?Y62TMZEG<[Y>.59
M-K<$XSM[\CC.>Y%/EFWK,P9F"\+C(QZC(].Y%5DD::8L0<("J2+Z]VQZ?G2^
M<@61D4N ,;4''T;T]:^C4SPG#4RZ***9J%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4^)PFX$Y##!3^\/;WIE&XJ05^^.5!Z&LZCM%LT@KR2)7W1;21YA
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MT<HP,GRJ=7_P?7_^6'GRQV+BN9PI_P#@JE_\@=+_ ,+)^&7_ $21/_"BN?\
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MI^[ R&/S'/RGK7Z50C"A3C2IJT8I)>BT/CZKG6J2JU'>4G=_,F!5&6-,*R#
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MW+P5\9O#WC+P#XGU[QEXQ\-VVBWUW?:M8_8-6DL->T2Z *01QHK;I=R\#
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M^+/B[\&M8\#_ !%LX_%M_<7"7.GZ[F*TDL67MY44(5P?J#7#?'#XZ-\9]/\
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M-)@TSV!**7!HQ0(ZWX1_\E2\)?\ 84M__1BTGQ=_Y*KXP_["US_Z,-+\(_\
MDJ7A+_L*6_\ Z,6D^+O_ "57QA_V%KG_ -&&O _YG'_<+_V\]3_F7_\ ;_\
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MZIIFD,S36UBF76(XX57)R :0S(US3I](UB\L[I42XAE9'6(@J#GMCM5*N_\
MA#\%/$WQSUC5;#PY]E:XT^R>_GDOYC&I1?X0V#EVZ =S6Y:?LR>+)? =IXSO
M;S1]%\,W%L;DZCJ5R\:1'S?*$380GS"V3M7/ )-;W.>QY(!2XKT/XP_!*_\
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MBON#XEA1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOG"BCVTNR^X?U>/=_>?2^G?MZ>/;&^N))M/\/ZC8SZ9::4^F7VFB6T,5JY>
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MY-&367]FXG_H.J_=1_\ E1?URA_T#0^^I_\ +#U[_A7_ ,)?^BMWG_A,3_\
MQ5=MHFC_  QT+25BG^)\ES#/:/"I7P],DAMV^^CX8G8<#.<5\UYKT_X)_"[Q
MU\1(?%TG@W1KS58[?1KB"\:UM#<9611B'@_*[A3M;_9-<M?)J]=)2QU6R\J2
M?R:I)H]O*^(%E4JDZ&&AS25M>9QW3]Z,I2C)::)VL[.^AU'BKP/\,KR^AFO/
MBS*@>(&%+?PU*R+'DX (<UB_\*_^$G_16[S_ ,)B?_XJO))D:*5XW!#HQ5E/
M8@X(_.F?A6E'*<12IJ"QU33LJ*_]Q'+F&;TL?BIXJ>&BW-W?-*I)_-\R^6BL
MK(]>_P"$ ^$G_16[O_PF)_\ XJC_ (0#X2?]%;O/_"8G_P#BJ\AS1NK7^S<3
M_P!!U7[J/_RHX/KE'_H&A]]3_P"6'KW_  @'PD_Z*W>?^$Q/_P#%4^$?!CP<
M_P!I^TZ_\0+M.8[5[<:?:$_[9)+D>PKQ[=2;J3RNK/2KC*LEVO"/XPA&2^30
MUCH1UIX>"??WG^$I27WH[#XB_$_5_B1>V[7HAL=-LT\NQTJR79;6B>B+Z^K'
MDUR&:;17KT*%'"TE1H148K9+^OO?4X*M2=>;J5'=OJ+DT?C24PSQ*2#+&".H
M+BM[F=A]%=G)\%OB#%HMGK#^!_$*Z3>&,6U\=-E\F<R'$>QL8;<2 ,=<U,GP
M*^)$FOW.AIX"\1OK5M"MQ-IZZ;*9XXB<!RH'W2>,^O%(=CAJ*GOK&YTR\GM+
MRWEM+N!S'+!.A22-P<%64\@CT-5]PSC(R.U :"UZ-\#](\0^,O&VE>%O"MMI
MLVMZA<KY0U&X6!)L<^5O;@9].I[5YS_^OFM3PTNM1:Q:7FA)>#4K6998)K-&
M+12 Y5@PZ'/K652E"M'EJ*Z.W!X[$9?5]MA)N$[-76CL]'9]-.JU.Q^..DZ]
MX/\ '&K^%_%%IID&N6%TQE_LRX6=(0Q)$6]>#@$<=1QFO.%.1D'(KZ3\-?!:
MWUK[3KOBL7UWK4TXN;@W\FSSW8[G8?WB/QS65\8_A3:36%[KFD26KFWS+(\;
MB-7B'&%7'S,/:BE3A1CR4U9!C,9B<PJ^WQ<W.=DKO=VT5WU?F]3P/%'2O=/A
M9\+_  ]9:58>(M>N+36IIQN_L&12&1.SGYANX_ 5C_&KX8V7AVVM=>T.PGT_
M3;IB9+2683>2"?E8%>%4],9XK:ZV.!K2YY)F@&DHID#LTM,I<FJ =1FF@TH.
M:8K'JO[,&AZ1XD^/'A'3]?TR'6=&DN)&NK"X3=',BQ.Y4CN/EKZQ^(?PI^%G
MPH\+:;J#>#-*UE;GQ5!).SQ;V73KS>(H0<\;%*L!ZJ*^ K'4[K2+I+RSNI;*
MXBR5G@D,;ID8.&'(X)'XUN^(-1\1V*V]GJ6M7-PLD4-RL U$SA !^[W ,0K*
M.@ZK[4FBEH?9M_\ #;P3X>\2^.-/\(_#'3/&U[X7U+2O#D.G:G;%GO%FWF>=
MR#A'9L*)3P@ KXH\66)TOQ1J]F;(:88+N6,V2S"8088CR]XX;;TSWQ4VF^/_
M !/H^J7FI6'B35['4;U2ES>6U]+'-.IZAW#98?4UB,Q=BS,69CDLQR2:6P!U
MIP)IHQZ4ZF(5F+8R2<# R<X%*@^8?6FBGI]X?6DMQ,TJ***^\/AGN%%%%,04
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'Z%_L/_ /)"8O\ L,77\HZ^G-+_ -7^5?$?[*/[27P_^&'P
MI3P_XBOI[/5?[1GN"19/+&$<)M.Y<_W3QBOL/0O'5IJ5G:WEE.+BQNHUFAFC
M4;71AE6''0BOB<;3E&M*4E9-GV^#G&=&,8N[2.^MCPM;=D>E<M8^+[90-[_H
M*Z/3O%-I+C!R?H*X;H[;'16G05Q/QS&-!TC_ *^C_P"@&MCQ;\3O#_PZ\+7W
MB+Q#>+I^D62;YIRF['(   &222  .I->93_&CPQ^T#X1L=3\)W%W+IT%VZ-+
M<VC0DLJ@$ 'GN*TY)<O-;0CFCS<M]2'1?X*ZNUY0?2N9TPV]NRJTDA(]$'^-
M=78+!*HQ(XSZJ/\ &LRV:]B?E%;=J>!6=8VD> !*W_?/_P!>MF"V10/G)_X#
M_P#7IB/GK_@H&V/V6O$GO/:C_P C+7Y$'K7Z[?\ !0M3'^R[X@&UQFYM>63
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M!N$/F#Y<'L<UR08,,@@CU!K]"]/\3V/Q'8P2:F;"&WLDDDDO'$UO<DGC<G
MW!>,'UKQ#]HSX*ZCJ[#QIIUO80S2VAFO[*U(C$NSCS84"@,=O+#CID9YIIB<
M;'S)10#D9'(HJB0HHHI6 ****0 >AK[S\!?'CX4Z+X5\(:9=7OA=%MK?18[P
M3Z+%)(IW3K?[G,)8G88PQR3@C%?!F*7GWI6'<^M?AK\=/"?A73?A-!>:^5@T
M;Q=JEU>0*9&%I:2!5@E*X^Z.H R1CI7<6'Q[^'W@3PJ="O/$.E>.;[3]"2U>
M:&YNTM[R5M4$^R.90DA*1_,>@SQS7PES72?#G2K?6O'.BV=[ UU9R7"^?$HS
MN0=<\CC'6BP7.@^/^LV7C#XZ>,]5TC4_[<T_4M4>>VOD7'G(^,8&!T^[T[5]
M,?#'P9I]IH$$$>A6Y>S(>WFNK*)Y(IB@WR,F0WXL>?:J.D_!GP'/KUQ=V.G6
ML-Z' 2UANRT:!6#":/&2A8<?GTJ35(@_Q(O)KW0X+33V7S7U&:X*2M@;=F5)
M##/\(YYYI%)!\7/AEI7BS3TBU294O(H0+*ZLH!YCNW 4*H_U8)Y7)QUS7DWA
M;P?JWP>O+F#5KZ-9;V0QI96\C%9%3D2/CC!Z!3S7K>L?%^*;P\=/T'2+]'3=
M"URJ^5:0MGYMK' ;Z<=:K6_@:V\5>'[S^UX8XM^V6=[:X*FW?.5P6 \GOT)S
MF@=B[X;^(6IZ]?F2'<TLL;QIIYG*6^T+]U0GSY]S@4EAI+:QH%QI?BO2!9Z;
M/%_&Z))ACP>I=FST[UX]\+-<_L3QAK&G:]!=2Q6BM)%*S%)(H]W#G^_D=/6O
M;O"MUI6NW,\NG7\%IID&V[*SS+.\AR0&<,,QD?W<T@6IQ?A[PAXK\)7&IVF@
M/)]DC02A;V..2<Q_\\T8@YP.W%4_&FI:7JGA75K9M,4VPMRPQ"]HKR@=9,,0
M2IZ&O0-5^)&D27Q73M2$]T%*W*NKI;1J.#*YQ^6*Y7XX^)K"3P#=6MCJBW"?
M9MC!9LPR]QM"_P 0]Z?4.A\B#H****T, HHHI@%36EM/?74-M;0R7%Q,XCCA
MB0L[L3@  <DDU$B-(ZHBEG8X"CJ:ZF\>U\&17%A;M9:GK3F*1=9L;F0BRXRT
M<1& 7R<&09'8>M,"S#<K\-WBE@>1?&43S07-K>64;Q:>"-HVEB=TW7Y@,+GU
MKD"Q+%CR222?4TQF+,6))8G)).230#0,>#FG#K3!UIV:0A].%1BGB@!XIR_>
M'UI@IZ_>'UIK<3V-*BBBONSX9[A1113$%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]7?L3?L^>%_B8
MFJ>)?%\#:E96=RMI:Z<25B>3:&9Y,<L "H"],DYK]'?#W@KPM;V=O;16@BMH
M(UBBAB4(D: 8"@#H *^-_P!@V!XOA#,Y7:)M6G92>-P"(,CUY&*^S=!@G*J0
MA(]C7QF.J2G7DF]$?:8&G&%"+2U9U5EX,\+@#_B7HY_VB36W:>%_#T>-FGPK
M_P  K+LHI@!\C5LP))_=->>=Y!XA^'_A7Q?H=UH^LZ+9ZII=RNV:TNHM\;C.
M>1]0#7YN_M6?LC>)_A?\0M(C^"_]O)X?UA9)I-*LK^1(K"92N<,7 VL"" 22
M,$=,5^FJR"-?G8+]2!7D7QMUAK'4-"EMI$9O,D#8(..!730Q$Z#O';MT.>M0
MA65GOWZGGOA/P/XMCTJQ\[2[B6X6"-9#D$EPHSD]^<\UV-MX4\7#&-&N%'J6
M4?UKHO"WCB]^SH"PZ>E=G:>+[F0#)%<SU.C8X2T\)^*L#?8RI_VT'^-/UCPA
MXLFT:]CM;>;[4\+K%ME"G<5..<\<UZ;!XCF<<XJR-:D;TI6 _#;XV?"_XU_#
MJ!O^%C6'B:WTZ>7 GO[R2ZM'?.0-X=DSZ \UX[7[_P#Q8TJR\;_#?Q'HFJVD
M5[8WEC-&\,J@@G8<'Z@X(/:OP#FB,,SQGJC%3^!Q7V.!Q/UB+NK-'R&.PWU>
M2:=T^XRMCP?XIO?!'BK2O$&G"%K_ $VY2Z@$Z%XRZG(W $9'XBO>/#/[-?A9
M?@/I'CKQ%J?BFYU+7I)XM.MO#>F1W%I:F,XS>2M_JP3R<8P*[[QA^POX8T+P
M_K26?B;Q'_;_ (>AL[C4KC4=+2#2KQ9BN5LYNKL-W&<YQ6\L32OROT,(X6K;
MF7J>!>'/VB_%7A?XM:W\1;*#2_\ A(-86X2Y62U8P8F38^U X(X/'S''O5[3
M/VG?%&G>*O#7B"32?#NI7?A_3%TFRBU#3FEB$0)(8CS ?,&?O*5KZ3UO]AWX
M/:%>:M!<>-/&^[2M9M=$N EC9MOGN%4QE#Q\HW#<3^ KJ=#^ WAC4OV=[?X=
M:_>>)YK:S\?7>GVU_P"&]+2YE,@551YP<B./GD_E7-*O0:NH^7R.N-#$7LY?
M\.?*7BG]K_QYXVT[QG8:[#H>IV?BIXI+F*XT[(MGC7:CVYW91@.YW51\!?M2
M^,OASX>\*Z+I4.DO9^&]3EU6R-S:L[M-(FQA(0XW+CL /K7TUI'[)</B'PSX
M5\#:_P".]2FT*S\0:O;I%IMK:;8C#%O\Q&*;RS  %68@<XQ7*6G[$/@_5M?\
M+W^F:]XGN? NK:3<:C<7DT5E;W-D8I?*S*SL(U1FZ8W-TX--5</;E:T_I?D2
MZ6(OS*7];_F>7Z9^V[\2-,T"3353P_<3K]H%GJUSI*2W^GI,29([>8G*+EC@
M$''K7,']I_QX?@W!\,_MUN/#T-V+M9O)/VO<'WA?,W?=W<XV_C7T_P"(/V0/
MAE\+_ WQ$:_E\1:UKFC75A-INKV2QEX8I\&/]V#Y;#(.\LIP,;<4>/?V4=*\
M6^./$7B'QOXL\7Z\D5QI^F1MX=T2WGNS++$,/*D:*BQ+P,A<^II*MA[W4=/3
MT_S*='$VMS:_U_D>#^)/VV_B'XKBT,ZC:^'I+S2KJ"\&H)II2XNI(ON><X?Y
MAZA0N:Y7QQ^T3K_CB3PU)-8Z?8-HM_+JH2U#^7<W<D@D:5U9CCH!@'I7OOAW
M]A_P/:ZSJ>C^*O&&OB]3Q0/#=E-HUI T4C-&'1Y1)RN,_-@GV%<K^S9\"/ .
MO?&'XC^$/'$&JZZF@V5XUF=,_=ES"3F3 8$O@95>5)Z\5:J8>*<HK8S=/$R:
MC*6YQUS^VA\2)+S4[RWETS3[S4-<3Q!)<6MFRLERJ[0%W.1Y9'!4@Y]:K^,O
MVP?'OC'4?#UTL6A^'HM$O_[4M[/P_IHLH);K/S32JK$NQ[\CJ:^HO&/P5\$_
M&#X'_##2#K6NZ/K6G^%M0U#2$DM(3')#"[,1='JKXP,+^=><^-/V%/#7@WX4
MV^N7/CB?_A(?L5I?R0L(?LLZS,H,42C]X& ;AF.TD=*B-7#Z7C9[;?(N5+$_
M9E=;_J>8']MKXEO\5-0\=O-I4M_J%DNGW6FR61:PE@7HABWY'/.0P.:P_%?[
M4GC#QAHWB[2KNUT6WL?$\D#W<5G9&(1>4,((1O.T>N=Q/K7N]E^Q?\-M0^*&
MK>&8/$/C)M-T.&(:MJLT6GP007$N/+C5Y&&X8/922>@HL?V'/!.EWGB"#7]>
M\9WWV'Q*- MG\-:3%=%@R@I+,I!V 9^8]/04U5PRU2[=/N%[+%/3F[GQ117V
MEIO[!_AN\N-6'_"7:A);>%=4O+/Q3.BP*+:"./S(I8MPZN,##9YZ5\A^)-!N
M-"OR'L;^SLI\RV3:A T3S09.QQE0&!'<<5VTZT*KM$X:E"=)7D9-4]1^XGUJ
MY5/4?N)]:Y\=_N\_ZZFV!_WB']=#/)Q24XFFU\:?8B&DR:=13 ;@T8-.I,>]
M AM%+MI=M.PKC:*=MHVTPN-HIVVDVT!<2C%+CWHP: N)1@4NVC!H"XF!2\4;
M:-IH$'%:FA^)+WP_Y_V.=[<3;-[1G!!5MRD>X-9>#6YX'LM)O_%^CVVO7'V3
M1I;E%NILX"Q]\D=!T!/H: 5SZ:L/AOXS\=>#K#4(K:_TG6'C+&:YD6-;A<98
MQ<GJ,'VKL?#'A'P!XE\/:EI+VJ:+J5K;A'>"8^;YBGYO,))W9.3SP:SO&?CN
MQ\ C3T74#KVF7%L]OIUO;M^\MR!A3UP?E&0PZ<=:^>=7DU#Q-J$_B'0[9GNH
MP?M:LQ1!C^#/<UD;GT38:9X(\(W.LZ9<7?\ ;=[J%NJVGFQ[/(<X VLO 7^1
M'I6#\2?B+XN^$-U:MJ.BK<6DUK'LF2?S(488^ZWJ>,CWKD/@]\1=9N6O%3PL
MLVJWEGY-N\Z!HH85.6=G/W.3R<'BN"^+_CG4]3BM_#UYJ4UZED^]U*A%#8Z<
M=?\ "FE<3=D>?:YJG]N:U?ZB8(K4W<[SF&%<(FYB=JCT&:I<>M?3WA[X)> 7
M^ /P^\1W\%I)XC\37MQ;2-=^)GM+C;'>1PC[+9B,B<[7.[YEQP>:]BO_ -A[
MX;ZWX^&@:<\NAK*OB"V2Z&O_ &^SA>R\L033R[1Y4@WDR0$G '45=S*S/S^X
M]:,BNU^.'AO2O!?Q9\3^'=%TV_TO3](NVL$AU27S+ES& K2N>@\PY<*. K*!
M7#;J8A^11FF;J0M0!)GWHSGO46ZC=[T6 DR*W?!GC._\#:[%JFGE#*@VO'(N
M5D4]5/L:YW>/6C>*+#N?1=E\2;B71[6^TY+'2]0U*1XUNK6[Q-D<MYD1/RH.
MQ&.E<KXVEAG73D3Q8^NN TL@MICLAESCY>!SCJ>]>:VND3S:;%<6T;/</)\J
MD#&!W'KSVK;M+(Z+<6,]^@\N4Y><*Q2//0G;T/M6;-4]#T1?B/I>G:)=Z7H^
MF7)%U B'[?<;Q#(#EBC?Q!NXP*U#\2-:\7V\.FV]EY=[+(LEP(E!20(,( ,=
M@#G)KSO0?#'_  FVK7)AO!8644B*UQ#&6CR3VSSFOJ_PE\/-,\(:9%919<';
M/-/.B9!Q_>(S@^E(9P;Z5>2Z(FI,]AJ-L^!<7-J3(RYZJZ$9;:.P.!7.2^ A
MI%A)KNA>(HO*+D8G;R)=P/RCR1DN/K7M-Y8P:/<MXC246-E:Q,BVT9 $@/8%
M?Z UQ?B?2M*U70UU.6RA2_G0QQ3F8O))GJQ52"I X&10!Y-XA^,>HZ<NF+?:
M=9BXMF+R1(VXW9)Y\\ X '85Y+XB\17'B+49KJ54@C>1G6WB&U(\GH!5#5(S
M:ZG=PD[C'*RY+;B<'U[U6WY%:)6,F[DFZG9S4(>G@TR1X&3@<FK^B:#J'B/5
M[;2]-M9+N_N'V1P+@$GJ<YP  .23P .:W? FDV&I7UNRW-Q_:,+>:85MBZ;!
MU)(S@>YP!6OXOLFT[2;Z&QMM-E@ENO/GU/.+P<8$/)^51SPO+=Z\YXZFL1]7
MEH_.ZN[[*^Y]FN%L;4RC^UJ-JB3U4'&3C'EO>7*VU;JFE;=F*^M1^$+8VVAW
M-W#J\T$EKJMT3$8\%L&. KDA<#!<-EO85RU'2BO1/C IP%)MIU !0#BBE"TP
M'#FG#(IH&:>*!"@YIZ'YA]:93TQN7ZU2W$]C3HHHK[H^&>X4444Q!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?H!^R';S77P"L(;>Z:RG>\N@EPBAC&=XY /!KZK\*Z%KGV&)5\372
MNL94R"UB^9L\-C'N!CIQ7RY^QI_R0_2?^OZZ_P#0Q77ZQX!\1ZAX^UCQ%I/C
M?2K"YGD6VCM)FG5K6,)Y*YQD,3')<'A0 VSD]1\56C&>(FI2MJS[C#MJA"RO
MHCZ@TWPOXS&M/<MXV+:<>5L#HT0V#;C[^[)^;G]*[_0+'4+/3DAU"[;4KM<E
MK@0>7N!Z?*.G%?&VD_"[7/#_ (JAN]%\<Z7+HMEK/]M6&GW.ISY+*#"BRG:?
ME,03Y>07+'WK8\/_  /U6ZL-&M/$7Q$LI?#EK<7%\=1M)IDNC-/#&)5192VP
MB8%U?/R^8=JCI3^KTM_:K[C7GE_*?1_CS2=4U%+4Z;K<FBF)V:4"UCG$X(P%
M(?I@\Y'>O&]>LWTRRA/B#6&U5K65WDOV@6 E<=T3@8]JR/ GPQETCQ%:QZMX
METSQ2EM)<7C!II9+@(Z2B. 9 5HXRRNK'!RSYR<&NOUH[[NVW<DR'.?I7-4A
M&#M&5RDV]U8G\-^)O##VD4T>H*8GR%?Y\'&,_P /N*ZJT\=^"8IX8)/$^G0S
M2[=D;W(#-N)"\8[E6_(UP\_C=/#=S?P?V9!)#:PQ.IY02R2$A4SMVKT[G/MQ
M73Z-XUTC6=4N(8-$T^9K6T6]^U7>Q$$90.,'83D%L<=.36?*]S!XNC&7*Y:_
M\/\ Y'I&BMI>L0R2Z=?QWL<<AB=X7#!7'53[U)KFH:;X8TR;4=3O8[&QAQYE
MQ.VU%R<#)^I%<O:_$&73;2W63PP]C+=6K7Z11R*$,:@ERQVC#8VG!&3O'H:I
MW'Q8LM6\/FY?3MD3.(I8IW4['$1D96&,9!&W\<T^21#QM!:.7X/_ "+,GCW1
MO$4-_8Z=?V=_(D3"9+:<.R C&3CZU^%/BBV2R\3:O;QDF.*]GC4MU($C 9K]
MQ[6>"_T47\5I;VWG0DCR0N0,<@D ="/TK\.O%9W>*=9/K?3G_P B-7O95HYK
MT/*S.2G"$EU-CPY\6_&_@_P_>:%H?B[6M(T6\S]IT^SO7C@ER,'<@..1P:EU
M'XS>/M8\/V&A7WC37KS1;!D>UT^?4)'AA*?<*J3@;>WI7&T5[_)&]['A^TG:
MUSL[SXT^/M0ENI+GQEK<\EW=1WT[27CDRW$>/+E;U=<#![8K4TO]H7XK^'K6
MX33_ !_XHTVWO9Y+F40:A+&D\KXWN<<,QP,GVKSBOOOP7XN\%_$GX)?!31=7
MUCX;:9:Z5>2PZK!KEO$US"5):,")G0A9. [DA23R>M<U9QII>Y='314JC?OV
M9\;Z7\9O'NB06\.G^,=;LXK>66>)(;UP$DE!$KCG[S@D$]\U8TGX[?$?0&L&
MTWQSX@L#80O;VGV>_D3R(G;<Z+@\ MR1ZU]O>.W^!/AGQ+<^(=+TGX;ZC=)X
M/O)FT@R6,]F^H1S*(E\N%S'YC*3PAR1W-;WP+\)?##XA>&] N=,\)?"^]TR[
MT2\O=8BO+0'6H-0"LV(HVR%A7MV  P<US/$P4>9T]#J6&GS<JJ:GP'-\=_B1
M<W^H7TOCKQ#+>:C MM>3MJ$A>YB7[J.<_,!V!KJ/!'C'XTZO<>*_$GA_Q?KU
MM=Z?IZ7&KWAUG[+,ULIVIP[J9,9P H)KZBOY/V>="^ $&I:9I_A#4[ZWL5E\
MN:>U75A?K)DY1OW[C/\ !]PK6_\ $WQ=\,OB1K?B+6M:N?AKJ-K)X,M6TB>%
MK7[8EV'021N&.Y749"KU"Y[4.NGHJ?X>@*@UJZG]:GP)I_Q4\9:4J"S\4ZO;
M!+[^TU\N[<8NO^>^<_ZS_:ZU7T?XA^*?#WBJ3Q-I?B'4M.\12,[OJMM<M'<,
MS?>)<<G/>ONGXA2? #7;;7M-DTSP%I^GZ3>Z1):7N@>3%>74;@?:ANC8F4 \
M,%''/>HOVG/ GA&#]FGQEKFF^&OAI:M;Z[:6^CZGX)A!G%HV?EGD(R)".H!S
MZU<<3%M)PM?0B6&FDVIWMJ?*?@7Q/\7_ (H^+]&T+0?$NN7VM7,,]E8K-J)B
M'E29,T:R.0H5N=PSSFL+6/BE\1M)TB3P1?>,-=71]-F\DZ/_ &B[6T3QMT"@
M[2 PX[5]L_ +XQ>&KGP7\"I;W4O &C)HFI3PZFDLD%I?6ORG8ZAF!57_ (VZ
M&HK/4_@!X[\9^#O$7BFQ\"Z3?7,VJ0W%M8O'':22JY^S272;F7YNN^3Y6)YX
MJ/;VDTZ>B_X)?L+Q7+4U?_ /B?2?CE\1- U[4-:TWQOK^GZOJ*JMY?6U_(DM
MP%^Z'8'YL=LUW%A^U[X_TGX>7>@V.O:S9Z]>ZJVIW?B6#59$NK@%-OE. .1Q
MU+?A6A^V;%X!@^(VGQ^!;71K<+8K_:#^'[FWELI9L\,@MQY:-CJ%XKY_KLC"
MG5BI.)QRG4HR<5(]ET7]HV7PW\&O$?@W3= \K7O$TN=;\43ZE++->Q!MPC\D
MC:ONV237"_$?XFZY\5-:MM3UV2W,UM:16,$5I"(8HH8UVHJH.G Y]37*45I&
MG"+YDM3*56<ERMZ!5/4?N)]:N54U#[B?6N;&_P"[R_KJ=&"_WB/]=#/Q2;:<
M10JEC@#)KX^Q]>VEJQI'I28-3&"3^[2>1(?X#3LS+VL/YE]Y%14GD2'^ BC[
M/)_<-%F'M8?S+[R.BI/L\G]TT?9Y/[IIV8O:0_F7WD=%2?9Y/[IH^SR?W319
MA[2'\R^\CHJ3[/)_=-'V>3^Z:+![2'\R^\CHH((.",&BEH:!1113T ****-
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M:!IVDI8P6$%H#O: 8:<GNY[URI:J2[B;[%V^U"34;V>ZFVB6:0R/L7:N2<G
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MBFGJ)[&K1117W1\,PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _0G]C3_ )(?I/\ U_77_H8K
MU:VM?&,7B+7YH/!-GJ]D@N9K1RHC-RW[@0@R*^[O<$\=A7E/[&G_ "0_2?\
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M@@N'\N&((3<.V]T($(^?AHW!XXQ[UA7OAO6--M#=WFD:A:6HE: SW%I)'&)
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M^$[CPQ;W$Y\3V&L7\!4>2NCWD5LZMGDL9(W!'L *Z;^T?A)_T+OC?_P>6?\
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M1S37.F:W';++M[2I)$X/H"N"!P*S]GB:<;1?]?-?UV-/:8:I*\E_7WG;2?\
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MV?+D4<J,_P +#)%4WN5O"D:[HDNB51R<>7,O0'TY[^C5[U&A3H+W=^_7^O\
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M<N;R75;AGN76&2YD66=%XCMXLY6-<G@>U7[O6&>\_=7#PV\2;Y"K?=B7H/\
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M"00<@@\BOCD['UM2"G%Q9UO_  K[Q+_T [W_ +]__7H_X5]XE_Z =[_W[_\
MKUSXU[4P,#4KS'_7P_\ C2_V_JG_ $$KS_P(?_&KYV<7U*'=F_\ \*^\2_\
M0#O?^_?_ ->C_A7OB;_H!WO_ '[_ /KU@?V_JG_02O/_  (?_&D_M[4_^@E>
M?^!#_P"-'.Q_48=V=!_PKWQ-_P! *]_[]_\ UZ/^%>^)O^@'>_\ ?O\ ^O7/
M_P!O:G_T$KS_ ,"'_P :/[>U/_H)7G_@0_\ C3YV+ZE#NSH/^%?>)?\ H!WO
M_?O_ .O1_P *^\2_] .]_P"_?_UZY_\ M[4_^@E>?^!#_P"-']O:G_T$KS_P
M(?\ QHYV'U*'=G0?\*^\2_\ 0#O?^_?_ ->C_A7OB7_H!WO_ '[_ /KUS_\
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MZ89#ZUFYL[(T$CZ _9FTKX1^*KK7]-^*GB&ZT7-L9M(6,-'$]RN3AIP2(]P
M4@I\P/WEP*\,-V2!SC'8&NEL?A#XMU7X?R^-K338KCPY'="R:XCO83+YYZ1B
M /YI8]0 O(!/0&N;MM!U:\95M]+OIR5\P"*UD?*Y(##"],@C/M4W9:IQ&&XW
M$G^=(;G(Z\9IZ:%JCW4=LNF7K7,D?G)"+:3>R8SO"[<E< \CCBH)-/O([1;M
MK2X%HQPLYA81D],!L8/YT797LXDHNB%ZGZ4Y;L]2:ZKQ-\$O''@_0-'UC5=
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MVGO9WN'BM]PC0LV2%W$G&3W)JN=F3P\6]C6CU>1W+LQ))RW8'_/M6C:ZW(H
M:3@= #C\ZY!)_0XJ:.?8<#\?6J51HYYX*$EJCO[7Q$T:C<V6'\*UT=GXWG.1
M-,9@P$;[SSM_N@]J\FBNP@!^ZOM5Z#4F'.3CUKHAB)1V9XF)R:E56L3VF'48
MO$$\LT$@BN,")8Q]V&+N0?6K/V^.\5+8,8K1!A(PV%"+U9O7->06.L21R [M
MI/7!(_\ UUTEGXC-_"+2XN!%#*0KR(HR%';->I2Q=]&?&8O(Y4G[NR_#_/\
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M7WQ\ ]PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNTGY4?V1>_\ /M)^5+V%;^1_<S3ZQ0_G7WHJ$TA-6CI%[G_CUD_*C^R+[/\
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M;DYJZTMM;?MU*I8:M5K8F@HV>'4G4OHH\F^_X6WZ'@]%>V:?\$O"^J_M _\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG+ZWI>H,F4BMHF42Q8DX;DQD9->/>$_$^DVG[+'CS0I]1MHM9O-=TR>WL6D
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M2FWL:.-.VCU,F7P_>0:='?2B"."1=Z![J(2.N<9$>[<?RJBD9D1V!3"#)W.
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M]U(%#%OWJKD^G6N%HINFF[MB56RLD>G1Z["NKS7-SK5K<>'W5!!8K-DH<KM
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MYL7M>Z.^\GPK.\JQ0V,4T6%@$ES((ISY8.9&+<#=GD8]*D6P\("Q@,[6PE+
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M^)X["+5W73@BP!$R(Y Z;]OS;2&;C/;<<>IK*HHK=*RL8MW=PHHHIDA1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>vstm-20251231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vstm-20251231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *W T0# 2(  A$! Q$!_\0
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M8S_=!#$88LN/H(_L=_&;7/V=?@5X+UI-'?7/ /BZ&^N'74-T;:;$^Y-K;>6
M)7;_ +(YKT_]J']EKQIJOQX\#?'#X//80>.-(E6UUG3[ZX-M#JEF!C#2 'G;
MF,Y!R&4_P8(!PGPSMM4O?^"AW[4EOH<ZVNM2^&K-+*=^D<YMH1&Q^C8-?'OA
MO0/AUX4L[O0/VB?#/Q$^&OQ<EO7V?%DW-W=1I)ORIV+)M*[0%RBOD'.Y1@C]
M!O"W[,7C+_AJ+XY>.+^]_L#0/'&A6VG:=?Z5?,M_:3+!&C.-N"C*RDA@W8=*
M\TU'X,_MDR_##4OA'?ZQ\/\ QEX8OK:;3I/%VOO<SZDUO)D%GWDAG /!96(X
MY. : *?[5_B[7/&<?[./P1\._$.\NM%\=;/[5\7Z:_E3ZG:QHJY##(&\%F(R
M<MMSQD' _:Z_9Q\-_L*^#_#7Q>^"=UJ?@[5M*UBVMM3LCJ=Q<P:Q%(<$3)*[
M G@Y P,,W&0"/5_'W_!/_4IO@1\(]$\&>+4TSXC_  Q*SZ5K=W&6M[B0MOEC
M=>2J%\%3@X"X(()Q@^*_V<OVCOVKM3\-:'\<+_P9X9^'^C:A'J%W9^$Q-)<:
MHR?=5C(S!<\C(( W$[20* /G_P#;3\9^,?#?[=WA_P")'@>V$^H^&O!EGXCN
MK,LP\ZR5V^T1G'4%)#GI@9/:O;_@M\3-&^,?_!2BT\9Z!-YVE:S\*HKJ+)RT
M9-S'NC;_ &E8%3[@U['-^SCXAD_;K@^)YMM/?P&O@UO#[1/-NE,A;[IB(Y3;
MQG->7?LK?L&>(OV:_P!L;Q=XPLGLY/AI<Z9<VFD*+HM<0"6:&41&,CA5*R#.
M>< ]Z /9_P!O[XQZW\#OV6_%GB+PY.UIKLHBT^TO%&6MFF<(95]&52Q!['!K
MY\N?^"=7@FR_9FE\:)K.NK\8(]$.NGQRVLW(G^T^5YY7;OV>7_!]W=CG=GFO
ML;]H7X)Z5^T1\(/$7@+6)Y+.VU6#;'=Q#<UM,I#12@<;MK $KD9&1D9S7R1)
M\%_VR;CX7'X.2:]\/_\ A$VLO[);Q?B?^T39[=FW9G;G9\N=F<?Q9YH ^?/V
MBOB]<_'+]A_]G'Q/XYMKKQ!,_BH6>K16BG[1J"0[XWVA2I,DB+C@C+'J*^EO
MV(/"_P"SY>_%2^U/X9_ [Q[\-O$>FZ<[?VIXMCNXH)(G94:-!)=S*SG(."O0
M$YK2^+/[#>JVWPE^ W@/X?26UY9^!/$EKJFH76HS>0\Z*VZ:4  _,S%B%[9
MS7VQ0!X5^W!;^*M2_9;\>Z5X*T2]\0>)-5LQIUO96"%I2LKJDK ?[,9<_A7Q
MM^R%X/\ "'P&_:2\#^%?'7[/LWPN^(&JZ;*=!\1KXFGU)+YUB*S>9&LSPH[J
M&)4#Y20,#(K[M_:4^&GBCXL?"+5]!\%>,-0\#>*F*3Z?J^GW+P$2(<^7(R?-
MY;C*G'J#SC!^?OAQ^SQ\<OB7\?/ OQ%^.]]X7M[;P%:SQ:1IWALRL;NXD4*U
MQ*6) ) !."!E5PHYH ]%_;@_9LG^/_PPBO?#DCZ?\1O"LW]K^&]1@8)(MPGS
M&'/H^!UZ,%/0'/RY\'?%7B/_ (*7?%KPA/XST";1OA]\,X([C6]/E4HFIZ_T
M*$?W%*AMAY W!OOC'Z85\X?L7? ?Q1\"K/XIQ>)ULU;Q'XSOM=L?LD_FYMI0
MFS=P-K?*<B@#X9^/=M\)W_X*#_&5/BI\+_%OQ-TU;'2A8V?A&&9Y+23[';Y>
M017$)"E>!DD9[5]<_L6/\%/"'@?Q[XH^&_PP\6_"K3;,*^K)XN2XCDN5BC>0
M/&);B;Y5!8$@KR>]<KXT^#?[1_@#]KKXE_%'X4:-X)U;2_%=I8V87Q-=S!E6
M&WB4D)&R$'>C=2>,5J>/M _:V^+WP)^(?A#Q+H'P_P!)U;6;6&QTZ?0;Z>,+
M&\G^DF1I'?\ Y9@J  .6]J /DSX7ZQK?@/QU\/OVNM6ED6Q\>>-]1TO6XG)V
M6^G7#+%;D?[,?ER\]]J"O4O^"FX\)3?M2? [_A-_#&K^-?"C:?>F]T305=[R
M[7=\HC"21L2&VGAQP#75^.O^"0WPX/P6O+7PG#>P_$F+34-I?W6J2&VDO552
MQ9#\H5V##IQNSVKNHOV</BIXD^,?[-7CCQ%'I@N/!&CRV7B-TO=[-.8V0/%\
MOSAN&/3&?:@#YQ_9%T[PQXT_;#\+>(/V;/!/BWP%\.-&M[FV\9PZ_>,T$DIC
MD$:&-IYFWDE0 7ZJ"%7:Q/Z(_M*_$J]^#OP#\>>,],C274M&TF>YM%E&Y!-M
MQ&6'<!B"1W KPG6?V7/&_P ,OVT++XO_  L^P2>&/$J?9_&6@W5T;?<2<-<1
M<$,W(D ./F1N<2<?4/Q!\#:5\3? VO>$M<B:;1]:LI;"Z1#M;RY%*DJ>S#.0
M>Q - 'P7\!_V!O"?[0/[.>E?$+QOKFOZO\6O%5F=5@\72:M.)=+E<DQ+#&C"
M/8N!D,K'+-@K\H67]MWP7KOP[^!G[.GAOQ+XGF\9:QIWCS389M:N(O+DN<>9
MM+#)R0,+DG)QD\U>T?\ 9]_:W^%WPWN/@WX/\1^"-3\!,DME8^)]16:/4[&S
MD+?(%4[<@,1]UL9X/ QZ!\5OV&=9\4?LG>#/AMHWC:>Z\9>$+NWU6QU_66>1
M9[N/<2#DLT:?.0H!.T!1SR: ,;_@IC_Q\_L\?]E'T_\ K7R9^T]=:CX-_P""
MC7C3XDZ<\B'P+-HFK703HUJYMK>8'CH5F(/3@FOJ&Z_9_P#VD/VB_B+\.;CX
MU2^"=!\)>#-6CUKR?#1F>XOYX_N;MS, 21S@J ">#P*WO$O['7B3QE^T/\?/
M$VIQV)\+>.O"0T/3G%SF43^3&N73'R@,F0>>@H ^0OV]-6/Q4_:>TWQG9W9F
MT'PSXHT/PE9E#E)97C>[N"/=&V*??/7M]7?![_E*K\=_^Q7TW_T5:5YMI7_!
M/CXD:=^RYX!\(R2:9<^-;+X@Q^*M:DDO2R- H=,B4KEWV[#@C^(\\5[)\;/V
M>/B_X4_:5N?C;\#;SPY>:KK.DQZ3K>@^)PZP3!,!95="#]U(AC((*'DAL  Y
M#P-_RDS^//\ V(\/\K>NH_X),_\ )G.D?]AC4?\ T>:U/V;?V:?B+HOQ&^)'
MQ:^*^H:++X]\76":9#IF@!Q9V4"KTW-DL25C ZX"DDG=QY!^SS\+/VROV:/A
MM!X'\,>&/AAJ&DP74]TD^K7MR\Y:5]S F.1%QGI\M 'H7_!1Z>?XDO\ "?X$
MZ?.Z7'C_ ,0QF_6$_.MA;D22N0.PR&_[9^U<]^Q#X+T?Q]\%_B=^S7\2K ZO
M:^!/$$VFRV,EQ+ TUF\S36[AXW5PI978$$<$=J?XE_8>\4?M1?M!GQA\?+&Q
M7PU9^&K6PLM/\/:I(@2]&'G('W@GF/-C+$D;<YQ6Y\&/V(=2_9?_ &L+;Q)\
M,D6+X5ZIHK6.M6=]J+27"S@ED=0P)8!E3OP&8=Z / /@O^Q)\%O%O[<OQR^'
MVJ^#/M7A#PU96$NE:=_:MZGV9I(8F<^8LPD?)=C\['&>,5K>#O@1IOQ:^)_[
M;_PXM;98XVM]+ATI&8MY$\$,S6WS$DG#(@))R1GUKZE^$/P \5^"OVS_ (S_
M !-U);,>&/%=G8PZ<T4^Z8M%%$K[TQ\O*-CDU)^SY\ _%7PV_:;^/GCK65LQ
MH7C2ZL9M*,$^^4K$L@?S%Q\OWQCDT ?*6H_M67^L?\$P=,T2'S)?B)J-TOPY
M%D#^^:X!V$X]3;@9_P!IL5@?MG_"3PA\$?\ ADGP+XI\.ZAXP\,:1;W\&K:1
MH"R-=:@^VW:7R0KQL2TA+<,IQ7K7AG_@GAXET/\ ;FD\>->VC?"6WU>;Q+9:
M?YY,BWTD:Y7R<8&)?XL_=1:]._;1^!WQ6\?_ !5^#OCSX56>@7^J>"9[VY>#
MQ!<O% SRB(("$PS#"OG##M0!YG^QUH?[.%U\;K";X>? 'XC?#_Q1:VL\T&M^
M)X;N.T1=NUTS)>RJ68,0 4/X5]Q?$+X?Z!\5/!FK>$_%%A_:GA_58?(O+/SI
M(?-3(.-\;*R\@<@@UX-\*?$7[6U[X^TF'XB>%OAG8>#F=OM]QH<]TUXB[3M\
ML/,RYW;>H/&:^FZ /RM\"?L2?!;6?^"@GQ!^&MYX,\[P5I7ANWO[/2_[5O5\
MJ=C#N?S1,)&SO;@L1STKL?"/PET?]L3]K#XC>#/%L^H+\(_A-#;:#I/@VVOY
MX(9W56C\R5U8.V#$YSNW'Y.< [OHGP5\ /%>@_MU^._BO=+9CPGK/A^#3;5D
MGS.9D\K.Y,<#Y&YS7'?$_P#9E^+7PX_:%UWXQ? /5/#[W?B:V2'7_#/B<2"U
MN94P%F5D((/&>JD'=R0Q  .%^&GAEOV2OV]]+^#?AO5;ZZ^%_CSP_/?V_A^^
MO)+@:7+&LQQ&SDL%/D.!SDA^22H->:_M+_L4?!CP5^UM^SUX2T7P;]B\/^+[
MS4%UNS_M2]D^UB,1%/G:8NF"[?<*]>:^E?V?_P!F/XC7/Q_OOCG\;M6T:[\9
MC3O[+TC1O#X?[)ID!W;\,_).&< 9/WV))SQT7[0?P"\5?$G]I[X">.]&6S.@
M^"[F^EU4SS[)0LJQ!/+7'S?<.>10!\R_M.?LW>%_%7Q.^&'[*_PUL6\/>&+6
MUU'QAJ=O'=SW @D,;QP,[RN[#=(-O)P/,XZUZ!\!OB9>_$'_ ()B^/=.UC<G
MB#PCX8UKPSJ$,O\ K(WMK214#@\Y\LH#[@T'_@G;%\=OC_\ %+Q]\<;4W5IJ
M=Y$GAVWTK5G1HK6-=@\S:!@[5CX]2U-\ ?L/>,?@GJ/Q_P#"/@G[*WPN\<>%
MY[31K>]U O/;ZBULT:[\@D*3(X+9/&WTH ]N_P""??\ R9E\*/\ L$#_ -&O
M7T$_W&^E? _P;\+_ +:WP2^&7AWP+HOA/X4W>DZ);_9;>>_O+MIW7<6RY255
M)^8]%%?>D'FM:Q^>%6<H-X3[H;'./;- 'X3_  @UO]FWPWX5\6WOQF^$?C3Q
M?JY\07<4&OZ*TT=E&A/R0EUO(4W@[C@J3@CKTKZ"O?!_C_P9_P $EOBE;^.8
M]1M;:YU2VNO#]EJ]P)KJWTUKVS\M7(Z L'(''7. "*^E/V</V*KS2/V;/B)\
M+?BE:V<EOXGUF\O$.GSB4Q1R!?*E5BHVR*RAAQU'<5Q%K^RI\=+W]ACQY\"/
M$$^CZOJ$-Q;0^%]4-^<2V27<4ICFRN4VB-MO7A@O110!X1\-=&_9,U*W\*VM
MS^R]\6Y=8N%M(I=3^S7PM6G8*#-N&H8$>XELA<8[=J^D?^"E'[+GPQU?X(>/
M?BG=^&?-\>:;I<$5KJWV^Z7RU1T1!Y0E$1PI(Y0^]7?#6H?MQ>&=!TK1X/!W
MPBDM-/MHK2-Y+J\+E(U"@G$X&<#L!7MO[5/PO\3?&S]F'Q7X,TJ.S'BC6-/B
MB5))3';B8.C.-QSA>&QU[4 ?$GQ5_9?^&7PK_P"":&M^//"WAK^R_%>O^%M%
M.I:A]ONIO/,EW9R/^[DE9%RXS\JC'0<5[1^VG_RC%_[@&B_^V]>PZ[^S?/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^&7_  N#X*V7A[P#XB\.^+S!?VWBJ[UK3;JW,MP=/D$L=S-* EU,S[V#IO&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 5M1TZVU?3[JQO(5N+.ZB:&:%QE71@0RGV()%>6?#S]EWP5\-
M-;@U33)=?O;FSMI+/34UC7;J^BTN%P T=HDLC+ "%4?(!PH':O7** .4^&OP
MRT/X4>'7T?0ENVAEN9;RXN=0NY+NZN9Y#EY99I"7=C@#)/0 =JZNBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M);<!V/%?2M '.^ _^0'<_P#84U+_ -+9ZZ*N=\!_\@.Y_P"PIJ7_ *6SUT5
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MVN;6&&RTU$8M'Y$$8'S [<LS$MM&36A<_!'6I? Y\(V_B;2]-T!85A@M-/\
M#L<"VVTAHVB"RX1D8*RL!PR@]10!Z_14=NCQ01I)(9I%4!I" -QQR<#IFI*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK)M_%NAW>O3:)!K6GS:U N^73H[J-KB-?5HP=P'N10!K4444 %%%% !1110
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M -+9ZZ*N9^'B/'X=F220S.NI:B&D( +'[;-DX' S734 %%%% !1110 4444
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M?1K!M0 6_-O&;@#H)-HW?KFKM%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %13VL-UY?G0QR^6XD3S%#;6'1AGH1ZU+1
M0 4444 %%%% '.^ _P#D!W/_ &%-2_\ 2V>NBKG? ?\ R [G_L*:E_Z6SUT5
M !117#?$_P"-/A+X0^&7USQ%J+K:BY6Q2&PMY+RXEN65F2%(HE9BY"L<8Z D
MXH [FJ6L:SI_A[39]0U2^MM-L(%WRW5W*L44:^K,Q  ^M>;'QI\2?%?B?PRW
MAKPG8:3X)NX8+W4=6\23R1:@L;@EK>.R5<QS+QEI&P#QM/6HM$_9UTRXTW6+
M3Q]KNJ_%2/5I8I;BT\5&.:PB,;L\8AM%011@$\G!+8&2<   ?K_[0ED'\++X
M,\-:U\2(?$#GR=1\.)&^GV\*R>7)+-<NZHH4AOE!+$KTJ:3P;\1_%>O>)[?Q
M'XKT_2?!UY!/9:=9>&()(M1C1R EP]W(3ME"YX1 H)ZM@&O2K"PM=*LH+.RM
MHK.T@01Q6\"!(XU' 55'  ]!5B@#@/!7P*\%^!=#L=,M-).IK9W#WD5WKD[Z
MC<BX< /+YLY=@S;1]T@<< "N_HHH **** "BBB@ HHHH **** /,/%7P+T][
M7Q+?^ [J/X<>,];6+S_$FD64+R.T;[U,D3J4D!)(;(R0QYJA%\7M2^'6O>#_
M  ?\0-.O;W4]7MDB/BW1M,?^QY;TR,@MV 9W@=@%;+C9\V W8>O4C*'4JP!4
MC!![T (DBRH'1@ZGD,IR#3J\0A^%&J?L\^%=7?X.:3_;45Q?1W?_  A^K:JT
M5G!%ES.E@S ^0[ELX8F/('"Y.?2?"WQ!TGQ/=OI8NK>S\36MM!<:CX>DNHGO
M=/\ -0.JS(C''!ZC@]B: .FHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %?./[17[6NH?!WXF>&/ 7ACP+<^./$NJP#4);5;Z*TQ:^88\0E_];,2#A
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;\/#1/V:/$&NZ1X6^%7Q$\9ZOJ,L=UJ?B=(DO)-2D()4O=W$R;MF\C:,!<G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 45X3XM_;$\&^$_CC:?##^SM=U75-T<6HZCINGO-9Z7+((S$D[C^\)8R2
MH(7>N>IQU^K?'[PCI'QOT/X3O=37'C#5;";4E@MU5H[:",9S,VX%2_S;0 <[
M3G QD ]'HKQ'X<?M@> /BC\39_!.C_VO%>L;I=/U*]T]H;#5C;/LN1:3$_O#
M&W#9 Z$C(YKVZ@#G? ?_ " [G_L*:E_Z6SUT5<[X#_Y =S_V%-2_]+9ZZ*@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'X=F220S.NI:B&D( +'[;-DX''/M735SO@/_ ) =S_V%-2_]+9ZZ*@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &30QW,+
MQ2QK+$ZE71QE6!Z@@]17RV6F_8C\22L4:3X ZO<;\H"[>$KR5^>.3]BD9NW^
MK8]E-?4]5=3TRTUK3KJPO[:*]L;J-H9[>= \<J,,,K*>""#C% $MM<Q7EO%/
M!*D\$JAXY8V#*ZD9!!'4$=ZEKY6L+[5?V)];73-2:\UGX#W]P?L>J.QEF\(R
M.>()N[698_*_)CSAN,&OJ.SO+?4;2&ZM9X[FUG02130N'21",AE8<$$'((H
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M&C*K.&+GRU?G."/;+CXS?&OPD!_PD7P+?78$_P!9>>#/$-M=#CNL-QY,ASZ
M&OH&B@#YU3]M*P@ _M/X1?%O2&!(?[3X2D<*!U;,;ME>O(].E))^VQI$O_(-
M^%?Q8UK^[]B\(2C=ZX\QDZ5]%T4 ?/5K^T7\3?$V#X<_9X\6"%NEQXDU*PTL
M+[M&TK2?DIJ:]L?VE/&B&--2\!_#.UD'+VD%QK=[&/9I/)BS[%&'N:]_HH ^
M>[7]CC2?$2%_B9XY\7_%*:0?O;75M2-IIQ/<"TMO+0K_ ++[QS7L'@;X;>%/
MAGI8T[PGX<TSP[9<9ATVU2$-CH6V@%C[G-=)10 4444 %%%% !1110 4444
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M_P )^_\ _C%'_"Q=*_Y]-=_\)^__ /C% '3T5S'_  L72O\ GTUW_P )^_\
M_C%'_"Q=*_Y]-=_\)^__ /C% '3T5S'_  L72O\ GTUW_P )^_\ _C%'_"Q=
M*_Y]-=_\)^__ /C% '3T5QFG_$>U9[S[59:XJB<B#'A^_P"8]JX)Q#Z[JN?\
M+%TK_GTUW_PG[_\ ^,4 =/17,?\ "Q=*_P"?37?_  G[_P#^,4?\+%TK_GTU
MW_PG[_\ ^,4 =/17,?\ "Q=*_P"?37?_  G[_P#^,4?\+%TK_GTUW_PG[_\
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MSZ:[_P"$_?\ _P 8H Z>BN8_X6+I7_/IKO\ X3]__P#&*/\ A8NE?\^FN_\
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M>&O#_@OPQ>S6]QKE_! D$:PM$ZNNRY,[''RD#+9  H ^]:*^(OBCIWQ=\$^
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M 9?A;PQIG@OPYIF@Z-;?8])TVW2UM;?S&?RXD&%7<Q+' '4DFM2BB@ HHHH
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M !6A10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(X4R-Z+GJ?84 3T444 %%0W=[;Z?;O/=3Q6T"8W2S.$49.!DGCK4U !1110
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M#7Q)^/&L_$GX<>$)_B\$7QM\/U\537T7ANQWZ=.J!ML"E,,&R-WF!A][:%R
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MV[C/"D8(YJWHGCBY^('PVUS4[OPGK_@V58;B'^SO$<4$=R0(L^8!#+*NP[L
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M'7 U/#?Q^U/Q)XC\)+#X7MU\+^)M4O\ 3++5/[2;[0GV:.=_,DMS"  YMV
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M(T'E7!#Y5D64."&RH&W< ?2U%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>vstm-20251231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/4/2026 8:56:24 PM-->
<!--Modified on: 3/4/2026 8:56:24 PM-->
<xsd:schema xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:attributeFormDefault="unqualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" targetNamespace="http://www.verastem.com/20251231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:vstm="http://www.verastem.com/20251231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2025" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>99940203 - Disclosure - Significant accounting policies - Reconciliation of cash, cash equivalents and restricted cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>99940205 - Disclosure - Significant accounting policies - Items Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureInventoryScheduleOfInventoryDetails" id="DisclosureInventoryScheduleOfInventoryDetails">
        <link:definition>99940401 - Disclosure - Inventory - Schedule of inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" id="DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails">
        <link:definition>99940502 - Disclosure - Intangible Assets - Schedule of intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails" id="DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails">
        <link:definition>99940503 - Disclosure - Intangible Assets - Schedule of future amortization expense of finite-lived intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>99940601 - Disclosure - Property and equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>99940701 - Disclosure - Accrued expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails" id="DisclosureLongTermDebtFuturePrincipalPaymentsDetails">
        <link:definition>99940803 - Disclosure - Long-term debt - Future principal payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails" id="DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails">
        <link:definition>99940805 - Disclosure - Long-term debt - Components of carrying value of the Term Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLongTermDebtScheduleOfInterestExpensesDetails" id="DisclosureLongTermDebtScheduleOfInterestExpensesDetails">
        <link:definition>99940806 - Disclosure - Long-term debt - Schedule of interest expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails" id="DisclosureLeasesBalanceSheetAndOtherInformationDetails">
        <link:definition>99940902 - Disclosure - Leases - Balance sheet and other information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails" id="DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails">
        <link:definition>99941202 - Disclosure - Segment Reporting - Segment net loss including segment expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" id="DisclosureIncomeTaxesIncomeTaxExpenseDetails">
        <link:definition>99941401 - Disclosure - Income Taxes - Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails">
        <link:definition>99941402 - Disclosure - Income Taxes - Reconciliation of Income Taxes and Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity">
        <link:definition>995200300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical">
        <link:definition>995200305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>995210101 - Disclosure - Nature of business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>995210201 - Disclosure - Significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>995210601 - Disclosure - Property and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>995210701 - Disclosure - Accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLongTermDebt" id="DisclosureLongTermDebt">
        <link:definition>995210801 - Disclosure - Long-term debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureCapitalStock" id="DisclosureCapitalStock">
        <link:definition>995211001 - Disclosure - Capital Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>995211101 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995211301 - Disclosure - Net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995211401 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995211501 - Disclosure - Commitments and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureEmployeeBenefitPlan" id="DisclosureEmployeeBenefitPlan">
        <link:definition>995211801 - Disclosure - Employee benefit plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995212001 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>99920202 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesTables" id="DisclosureSignificantAccountingPoliciesTables">
        <link:definition>99930203 - Disclosure - Significant accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>99930603 - Disclosure - Property and equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>99930703 - Disclosure - Accrued expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureCapitalStockTables" id="DisclosureCapitalStockTables">
        <link:definition>99931003 - Disclosure - Capital Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>99931103 - Disclosure - Stock-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>99931303 - Disclosure - Net loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>99931403 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureNatureOfBusinessDetails" id="DisclosureNatureOfBusinessDetails">
        <link:definition>99940101 - Disclosure - Nature of business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureNatureOfBusinessReverseStockSplitDetails" id="DisclosureNatureOfBusinessReverseStockSplitDetails">
        <link:definition>99940102 - Disclosure - Nature of business - Reverse Stock Split (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentAndGeographicInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSegmentAndGeographicInformationDetails">
        <link:definition>99940201 - Disclosure - Summary of significant accounting policies - Segment and geographic information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails" id="DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails">
        <link:definition>99940202 - Disclosure - Significant accounting policies - Proceeds from Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" id="DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails">
        <link:definition>99940204 - Disclosure - Significant accounting policies - Cash, cash equivalents, restricted cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails" id="DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails">
        <link:definition>99940206 - Disclosure - Significant accounting policies - Inputs used to value the warrant liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails" id="DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails">
        <link:definition>99940207 - Disclosure - Significant accounting policies - Reconciliation of the warrant liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails" id="DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails">
        <link:definition>99940208 - Disclosure - Significant accounting policies - Note Purchase Agreement and Oxford Loan Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails" id="DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails">
        <link:definition>99940209 - Disclosure - Significant accounting policies - Concentrations of credit risk and off-balance sheet risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>99940210 - Disclosure - Significant accounting policies - Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails" id="DisclosureProductRevenueReservesAndAllowancesDetails">
        <link:definition>99940301 - Disclosure - Product revenue reserves and allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureIntangibleAssetsDetails" id="DisclosureIntangibleAssetsDetails">
        <link:definition>99940501 - Disclosure - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails" id="DisclosureLongTermDebtNotePurchaseAgreementDetails">
        <link:definition>99940801 - Disclosure - Long-term debt - Note Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails" id="DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails">
        <link:definition>99940802 - Disclosure - Long-term debt - Reconciliation of changes in the fair value of the Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails" id="DisclosureLongTermDebtLoanAgreementDetails">
        <link:definition>99940804 - Disclosure - Long-term debt - Loan Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
        <link:definition>99940901 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureCapitalStockDetails" id="DisclosureCapitalStockDetails">
        <link:definition>99941001 - Disclosure - Capital Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails" id="DisclosureCapitalStockNovember2025PublicOfferingDetails">
        <link:definition>99941002 - Disclosure - Capital stock - November 2025 Public Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails" id="DisclosureCapitalStockApril2025PrivatePlacementDetails">
        <link:definition>99941003 - Disclosure - Capital stock - April 2025 Private Placement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails" id="DisclosureCapitalStockStockPurchaseAgreementDetails">
        <link:definition>99941004 - Disclosure - Capital stock - Stock Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails" id="DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails">
        <link:definition>99941005 - Disclosure - Capital stock - July 2024 and June 2023 Public Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails" id="DisclosureCapitalStockConvertiblePreferredStockDetails">
        <link:definition>99941006 - Disclosure - Capital stock - Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails" id="DisclosureCapitalStockAtMarketEquityOfferingProgramDetails">
        <link:definition>99941007 - Disclosure - Capital stock - At-the market equity offering program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" id="DisclosureStockBasedCompensationStockBasedCompensationDetails">
        <link:definition>99941101 - Disclosure - Stock-based compensation - Stock-based compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails" id="DisclosureStockBasedCompensationStockOptionsDetails">
        <link:definition>99941102 - Disclosure - Stock-based compensation - Stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails" id="DisclosureStockBasedCompensationOptionExchangeProgramDetails">
        <link:definition>99941103 - Disclosure - Stock-based compensation - Option Exchange Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" id="DisclosureStockBasedCompensationRestrictedStockUnitsDetails">
        <link:definition>99941104 - Disclosure - Stock-based compensation - Restricted stock units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" id="DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails">
        <link:definition>99941105 - Disclosure - Stock-based compensation - Employee stock purchase plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails" id="DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails">
        <link:definition>99941301 - Disclosure - Net loss per share - Potentially dilutive shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" id="DisclosureIncomeTaxesOperatingLossCarryforwardsDetails">
        <link:definition>99941403 - Disclosure - Income Taxes - Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureIncomeTaxesTaxCreditsDetails" id="DisclosureIncomeTaxesTaxCreditsDetails">
        <link:definition>99941404 - Disclosure - Income Taxes - Tax Credits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>99941501 - Disclosure - Commitments and contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails" id="DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails">
        <link:definition>99941601 - Disclosure - License, collaboration and commercial agreements - Pfizer, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails" id="DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails">
        <link:definition>99941602 - Disclosure - License, collaboration and commercial agreements - License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails" id="DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails">
        <link:definition>99941603 - Disclosure - License, collaboration and commercial agreements - Genfleet Therapeutics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails" id="DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails">
        <link:definition>99941604 - Disclosure - License, collaboration and commercial agreements - Secura (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureNotesPayableDetails" id="DisclosureNotesPayableDetails">
        <link:definition>99941701 - Disclosure - Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureEmployeeBenefitPlanDetails" id="DisclosureEmployeeBenefitPlanDetails">
        <link:definition>99941801 - Disclosure - Employee benefit plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>99942001 - Disclosure - Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowances" id="DisclosureProductRevenueReservesAndAllowances">
        <link:definition>995210301 - Disclosure - Product revenue reserves and allowances</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureInventory" id="DisclosureInventory">
        <link:definition>995210401 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureIntangibleAssets" id="DisclosureIntangibleAssets">
        <link:definition>995210501 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995210901 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSegmentReporting" id="DisclosureSegmentReporting">
        <link:definition>995211201 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreements" id="DisclosureLicenseCollaborationAndCommercialAgreements">
        <link:definition>995211601 - Disclosure - License, collaboration and commercial agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureNotesPayable" id="DisclosureNotesPayable">
        <link:definition>995211701 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureVendorFinancingArrangement" id="DisclosureVendorFinancingArrangement">
        <link:definition>995211901 - Disclosure - Vendor Financing Arrangement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesTables" id="DisclosureProductRevenueReservesAndAllowancesTables">
        <link:definition>99930303 - Disclosure - Product revenue reserves and allowances (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureInventoryTables" id="DisclosureInventoryTables">
        <link:definition>99930403 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureIntangibleAssetsTables" id="DisclosureIntangibleAssetsTables">
        <link:definition>99930503 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLongTermDebtTables" id="DisclosureLongTermDebtTables">
        <link:definition>99930803 - Disclosure - Long-term debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>99930903 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSegmentReportingTables" id="DisclosureSegmentReportingTables">
        <link:definition>99931203 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCloudComputingImplementationCostsDetails" id="DisclosureSignificantAccountingPoliciesCloudComputingImplementationCostsDetails">
        <link:definition>99940211 - Disclosure - Significant accounting policies - Cloud Computing Implementation Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetails" id="DisclosureSignificantAccountingPoliciesIncomeTaxesDetails">
        <link:definition>99940212 - Disclosure - Significant accounting policies - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureSegmentReportingDetails" id="DisclosureSegmentReportingDetails">
        <link:definition>99941201 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.verastem.com/role/DisclosureVendorFinancingArrangementRollForwardDetails" id="DisclosureVendorFinancingArrangementRollForwardDetails">
        <link:definition>99941901 - Disclosure - Vendor Financing Arrangement - Roll forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="vstm-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="vstm-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="vstm-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="vstm-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd" />
  <xsd:element name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" id="vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract" id="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" id="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" id="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PfizerIncMember" id="vstm_PfizerIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_CollaborativeArrangementsOneTimeCashPayment" name="CollaborativeArrangementsOneTimeCashPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="CollaborativeArrangementsRoyaltyObligationsTerm" id="vstm_CollaborativeArrangementsRoyaltyObligationsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SegmentAndGeographicInformationAbstract" id="vstm_SegmentAndGeographicInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock" id="vstm_ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExclusiveLicenseAgreementMember" id="vstm_ExclusiveLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfEquityCompensationPlans" id="vstm_NumberOfEquityCompensationPlans" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncentivePlan2012Member" id="vstm_IncentivePlan2012Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeAndNonEmployeesStockOptionMember" id="vstm_EmployeeAndNonEmployeesStockOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" id="vstm_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" id="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_InducementAwardProgramMember" name="InducementAwardProgramMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_StockIssuedDuringPeriodValueAtMarketTransactions" name="StockIssuedDuringPeriodValueAtMarketTransactions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="vstm_StockIssuedDuringPeriodSharesAtMarketTransactions" name="StockIssuedDuringPeriodSharesAtMarketTransactions" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_WarrantAbstract" name="WarrantAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram" name="MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="vstm_NumberOfVotesPerEachShareOfCommonStock" name="NumberOfVotesPerEachShareOfCommonStock" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_AtMarketEquityOfferingProgramMember" name="AtMarketEquityOfferingProgramMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_ShareBasedCompensationAwardTrancheFourMember" name="ShareBasedCompensationAwardTrancheFourMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_TermLoanFacilityMember" name="TermLoanFacilityMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault" name="DebtInstrumentAdditionalInterestRateInEventOfDefault" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="vstm_AccruedConsultingFeesCurrent" name="AccruedConsultingFeesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="vstm_CorporateBondsAndCommercialPaperMember" name="CorporateBondsAndCommercialPaperMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_ProceedsFromIssuanceOfCommonStockNet" name="ProceedsFromIssuanceOfCommonStockNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" abstract="false" />
  <xsd:element id="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" name="ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" name="NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits" name="NumberOfInstallmentsForVestingOfRestrictedStockUnits" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_NumberOfAnniversariesForVestingRestrictedStockUnits" name="NumberOfAnniversariesForVestingRestrictedStockUnits" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_UnderwritingAgreementMember" name="UnderwritingAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_CantorFitzgeraldCo.Member" name="CantorFitzgeraldCo.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_LicenseAndCollaborationAgreementAbstract" name="LicenseAndCollaborationAgreementAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_LicenseAndCollaborationAgreementMember" name="LicenseAndCollaborationAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement." name="NumberOfDaysOfPriorNoticeToTerminateAgreement." nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach" name="NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_NatureOfBusinessTable" name="NatureOfBusinessTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_NatureOfBusinessLineItems" name="NatureOfBusinessLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract" name="ProductRevenueReservesAndAllowancesDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_ProductRevenueReservesAndAllowancesDisclosureTextBlock" name="ProductRevenueReservesAndAllowancesDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_ProductRevenueReservesAndAllowancesTableTextBlock" name="ProductRevenueReservesAndAllowancesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_ProductRevenueReservesAndAllowancesDisclosureTable" name="ProductRevenueReservesAndAllowancesDisclosureTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems" name="ProductRevenueReservesAndAllowanceDisclosureLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_ProductRevenueAllowancesAndReservesTypeAxis" name="ProductRevenueAllowancesAndReservesTypeAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_ProductRevenueReservesAndAllowances" name="ProductRevenueReservesAndAllowances" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="vstm_ProductRevenueReservesAndAllowancesDeductions" name="ProductRevenueReservesAndAllowancesDeductions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="vstm_ProductRevenueReservesAndAllowancesDomain" name="ProductRevenueReservesAndAllowancesDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember" name="ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember" name="ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_ProductRevenueAndAllowancesReturnsMember" name="ProductRevenueAndAllowancesReturnsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear" name="ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="vstm_AccruedCommercializationCostsCurrent" name="AccruedCommercializationCostsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember" name="ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_NumberOfCustomers" name="NumberOfCustomers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance" name="DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="vstm_CashAndMoneyMarketAccountsMember" name="CashAndMoneyMarketAccountsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_LongTermDebtMaturitiesAggregatePrincipalDue" name="LongTermDebtMaturitiesAggregatePrincipalDue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="vstm_OfficeAndLaboratorySpaceLeaseArrangementMember" name="OfficeAndLaboratorySpaceLeaseArrangementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_CostOfGoodsSoldExcludingAmortization" name="CostOfGoodsSoldExcludingAmortization" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="vstm_TermELoanMember" name="TermELoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_OperatingLossCarryforwardsIndefinitePeriod" name="OperatingLossCarryforwardsIndefinitePeriod" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="vstm_LicenseAndCollaborationAgreementUpfrontPayment" name="LicenseAndCollaborationAgreementUpfrontPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="vstm_AccountsPayableCurrentMember" name="AccountsPayableCurrentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_SecuraBioInc.Member" name="SecuraBioInc.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable" name="LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra" name="LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale" name="LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable" name="LicenseAndCollaborationAgreementsSalesMilestoneReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember" name="LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember" name="LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember" name="LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" name="LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments" name="LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements" name="LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions" name="LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_CopiktraLicenseAndRelatedAssetsMember" name="CopiktraLicenseAndRelatedAssetsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_SellingGeneralAndAdministrativeExpenseMember" name="SellingGeneralAndAdministrativeExpenseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_ReductionOfSharesAvailableForIssuance" name="ReductionOfSharesAvailableForIssuance" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock" name="LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent" name="EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="vstm_DeferredTaxAssetsInstallmentSale" name="DeferredTaxAssetsInstallmentSale" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="vstm_RestrictedCashAndCashEquivalentsNoncurrentMember" name="RestrictedCashAndCashEquivalentsNoncurrentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember" name="OfficeAndLaboratorySpaceInNeedhamMassachusettsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="EquityIncentivePlan2021Member" id="vstm_EquityIncentivePlan2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsLeaseLiability" id="vstm_DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxLiabilitiesRightOfUseAsset" id="vstm_DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentFinalPaymentFeePercentage" id="vstm_DebtInstrumentFinalPaymentFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember" id="vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrepaymentAfterSecondAnniversaryMember" id="vstm_PrepaymentAfterSecondAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentCurrentBorrowingCapacity" id="vstm_DebtInstrumentCurrentBorrowingCapacity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="TermBLoanMember" id="vstm_TermBLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TermCLoanMember" id="vstm_TermCLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TermDLoanMember" id="vstm_TermDLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentPeriodToDrawLoanMinimum" id="vstm_DebtInstrumentPeriodToDrawLoanMinimum" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GrossProductRevenueToBeAchieved" id="vstm_GrossProductRevenueToBeAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DebtInstrumentFinalPaymentFee" id="vstm_DebtInstrumentFinalPaymentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentAccruedInterestRate" id="vstm_DebtInstrumentAccruedInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromGrantsPolicyPolicyTextBlock" id="vstm_ProceedsFromGrantsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ReductionInResearchAndDevelopmentExpense" id="vstm_ReductionInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SeriesBConvertiblePreferredStockMember" id="vstm_SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BiotechnologyValueFundMember" id="vstm_BiotechnologyValueFundMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PreferredStockConvertibleAggregateSharesToBeSold" id="vstm_PreferredStockConvertibleAggregateSharesToBeSold" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PreferredStockIssueNumberOfTranches" id="vstm_PreferredStockIssueNumberOfTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeriesaConvertiblePreferredStockMember" id="vstm_SeriesaConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ConversionOfPreferredStockConversionBlockerPercent" id="vstm_ConversionOfPreferredStockConversionBlockerPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice" id="vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ConversionOfPreferredStockConversionBlockerNoticePeriod" id="vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche" id="vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PreferredStockIssuanceThresholdTradingDays" id="vstm_PreferredStockIssuanceThresholdTradingDays" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PreferredStockIssuanceThresholdSharePrice" id="vstm_PreferredStockIssuanceThresholdSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PreferredStockIssuanceThresholdAggregateTradingVolume" id="vstm_PreferredStockIssuanceThresholdAggregateTradingVolume" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PreferredStockIssuanceExpectedClosingPeriod" id="vstm_PreferredStockIssuanceExpectedClosingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod" id="vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PreferredStockTrancheLiability" id="vstm_PreferredStockTrancheLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncomeLossFromPreferredStockTrancheLiability" id="vstm_IncomeLossFromPreferredStockTrancheLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PaymentsOnInsurancePremiumFinancing" id="vstm_PaymentsOnInsurancePremiumFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IssuanceOfPreferredStockTrancheLiability" id="vstm_IssuanceOfPreferredStockTrancheLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AmortizationOfFinalPaymentFee" id="vstm_AmortizationOfFinalPaymentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ContractualInterestExpense" id="vstm_ContractualInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SecondTrancheRightLiabilityNonCurrentFairValue" id="vstm_SecondTrancheRightLiabilityNonCurrentFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MarketToMarketAdjustmentOfPreferredStockTrancheLiability" id="vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ChangeInFairValueOfOfPreferredStockTrancheLiability" id="vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ProceedsFromInsurancePremiumFinancing" id="vstm_ProceedsFromInsurancePremiumFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConvertiblePreferredStockAbstract" id="vstm_ConvertiblePreferredStockAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockholdersEquityReverseStockSplitConversionRatio" id="vstm_StockholdersEquityReverseStockSplitConversionRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedPreFundedWarrantsNetOfIssuanceCosts" id="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CertificateOfAmendmentMember" id="vstm_CertificateOfAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PublicMember" id="vstm_PublicMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage" id="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage" id="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PreFundedWarrantElectionToExerciseNoticePeriod" id="vstm_PreFundedWarrantElectionToExerciseNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommonStockSharesOffered" id="vstm_CommonStockSharesOffered" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="GenfleetTherapeuticsShanghaiIncMember" id="vstm_GenfleetTherapeuticsShanghaiIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PotentialMilestonePayments" id="vstm_PotentialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="StockOptionExchangeProgramMember" id="vstm_StockOptionExchangeProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfEligibleStockholders" id="vstm_NumberOfEligibleStockholders" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccruedClinicalTrialExpensesCurrent" id="vstm_AccruedClinicalTrialExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedContractManufacturingExpensesCurrent" id="vstm_AccruedContractManufacturingExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="GrantsReceivableNet" id="vstm_GrantsReceivableNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IncreaseDecreaseInGrantsReceivableNet" id="vstm_IncreaseDecreaseInGrantsReceivableNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfFinancialCovenants" id="vstm_NumberOfFinancialCovenants" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PreFundedWarrantMember" id="vstm_PreFundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PreFundedWarrantsWarrantsOutstanding" id="vstm_PreFundedWarrantsWarrantsOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LicenseAndCollaborationAgreementsSalesMilestoneReceived" id="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLeaseNonCashCost" id="vstm_OperatingLeaseNonCashCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfPreferredStockConvertibleIntoCommonStock" id="vstm_NumberOfPreferredStockConvertibleIntoCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LicenseAndCollaborationAgreementsDevelopmentMilestonePayments" id="vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PreferredStockSharesDesignated" id="vstm_PreferredStockSharesDesignated" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="July2024PublicOfferingMember" id="vstm_July2024PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants" id="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" id="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod" id="vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromIssuanceOfWarrantsAndCommonStock" id="vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ReconciliationOfWarrantLiabilityTableTextBlock" id="vstm_ReconciliationOfWarrantLiabilityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromPreFundedWarrantExercises" id="vstm_ProceedsFromPreFundedWarrantExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SharesIssuedFromPreFundedWarrantExercises" id="vstm_SharesIssuedFromPreFundedWarrantExercises" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodValueExerciseOfWarrants" id="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="StockIssuedDuringPeriodSharesExerciseOfWarrants" id="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FairValueAdjustmentOfWarrantsExercised" id="vstm_FairValueAdjustmentOfWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NewAccountingStandardsAdoptedPolicyPolicyTextBlock" id="vstm_NewAccountingStandardsAdoptedPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ChangeInCompanyOwnershipPercent" id="vstm_ChangeInCompanyOwnershipPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="OperatingLossCarryforwardsPriorToOwnershipChanges" id="vstm_OperatingLossCarryforwardsPriorToOwnershipChanges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLossCarryforwardsInclusiveOfOwnershipChanges" id="vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLossCarryforwardsSection382Limitation" id="vstm_OperatingLossCarryforwardsSection382Limitation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IqviaIncMember" id="vstm_IqviaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ResearchDevelopingAndCommercializationDrugsSegmentMember" id="vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense" id="vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CommercialExpenditure" id="vstm_CommercialExpenditure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MedicalAffairExpenditure" id="vstm_MedicalAffairExpenditure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedPaymentArrangementTrancheFiveMember" id="vstm_ShareBasedPaymentArrangementTrancheFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NotePurchaseAgreementMember" id="vstm_NotePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InitialSaleMember" id="vstm_InitialSaleMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SecondSaleMember" id="vstm_SecondSaleMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember" id="vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="First8QuartersFollowingNotePurchaseAgreementClosingDateMember" id="vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="First100MillionNetSalesOfEachIncludedProductMember" id="vstm_First100MillionNetSalesOfEachIncludedProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember" id="vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RedemptionPriorToSecondAnniversaryMember" id="vstm_RedemptionPriorToSecondAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RedemptionPriorToThirdAnniversaryMember" id="vstm_RedemptionPriorToThirdAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RedemptionAfterYearThirdAnniversaryMember" id="vstm_RedemptionAfterYearThirdAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentIssuanceOfAdditionalNotes" id="vstm_DebtInstrumentIssuanceOfAdditionalNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CovenantWorldwideNetSalesOfAvutometinibAndDefactinib" id="vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate" id="vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="InterestDuePaidInKindPercentage" id="vstm_InterestDuePaidInKindPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage" id="vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ParticipationInNetSalesPercentage" id="vstm_ParticipationInNetSalesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ParticipationInNetSalesSalesAmount" id="vstm_ParticipationInNetSalesSalesAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ParticipationInNetSalesAggregatePrincipalAmountOfDebt" id="vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentNumberOfEqualInstallments" id="vstm_DebtInstrumentNumberOfEqualInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockPurchaseRightPeriod" id="vstm_StockPurchaseRightPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockPurchaseRightMaximumAmount" id="vstm_StockPurchaseRightMaximumAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockPurchaseAgreementMember" id="vstm_StockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" id="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AchievementOfCertainSalesMilestonesMember" id="vstm_AchievementOfCertainSalesMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExerciseOfAllThreeGenFleetOptionsMember" id="vstm_ExerciseOfAllThreeGenFleetOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FirstInsuranceFundingMember" id="vstm_FirstInsuranceFundingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FairValueAdjustmentOfNotes" id="vstm_FairValueAdjustmentOfNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" id="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="FairValueAdjustmentOfNotesNoncash" id="vstm_FairValueAdjustmentOfNotesNoncash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="StockIssuedDuringPeriodValueStockPurchaseAgreement" id="vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesStockPurchaseAgreement" id="vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtIssuanceCosts" id="vstm_DebtIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LongTermDebtMaturityYearSix" id="vstm_LongTermDebtMaturityYearSix" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LongTermDebtMaturityYearSeven" id="vstm_LongTermDebtMaturityYearSeven" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PrivatePlacement2025Member" id="vstm_PrivatePlacement2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RepaymentsOfLongTermDebtFinalPaymentFee" id="vstm_RepaymentsOfLongTermDebtFinalPaymentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RepaymentsOfLongTermDebtUnpaidInterest" id="vstm_RepaymentsOfLongTermDebtUnpaidInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="VendorFinancingAgreementAbstract" id="vstm_VendorFinancingAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" id="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount" id="vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AchievementOfFdaApprovalMember" id="vstm_AchievementOfFdaApprovalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AchievementOfFdaApprovalAnniversaryMember" id="vstm_AchievementOfFdaApprovalAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AccruedMilestonePaymentsCurrent" id="vstm_AccruedMilestonePaymentsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PursuantToLicenseAgreementMember" id="vstm_PursuantToLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PaulBunnMember" id="vstm_PaulBunnMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MichaelKauffmanMember" id="vstm_MichaelKauffmanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DanielPatersonMember" id="vstm_DanielPatersonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfPatents" id="vstm_NumberOfPatents" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MajorCustomerMember" id="vstm_MajorCustomerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="November2025PublicOfferingMember" id="vstm_November2025PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassOfWarrantOrRightNumberOfWarrantsExercised" id="vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount" id="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent" id="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SaleOfStockOptionToPurchaseMaximumNumberOfShares" id="vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="CloudComputingImplementationCostsPolicyPolicyTextBlock" id="vstm_CloudComputingImplementationCostsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>vstm-20251231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/4/2026 8:56:24 PM-->
<!--Modified on: 3/4/2026 8:56:24 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.verastem.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureInventoryScheduleOfInventoryDetails" roleURI="http://www.verastem.com/role/DisclosureInventoryScheduleOfInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" roleURI="http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails" roleURI="http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.verastem.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLongTermDebtFuturePrincipalPaymentsDetails" roleURI="http://www.verastem.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails" roleURI="http://www.verastem.com/role/DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLongTermDebtScheduleOfInterestExpensesDetails" roleURI="http://www.verastem.com/role/DisclosureLongTermDebtScheduleOfInterestExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLeasesBalanceSheetAndOtherInformationDetails" roleURI="http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails" roleURI="http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIncomeTaxesIncomeTaxExpenseDetails" roleURI="http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails" roleURI="http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <calculationLink xlink:role="http://www.verastem.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_639082545813847854" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639082545813847854" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639082545813847854" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_GrantsReceivableNet" xlink:label="vstm_GrantsReceivableNet_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639082545813847854" xlink:to="vstm_GrantsReceivableNet_639082545813847854" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639082545813847854" xlink:to="us-gaap_AccountsReceivableNet_639082545813847854" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639082545813847854" xlink:to="us-gaap_InventoryNet_639082545813847854" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639082545813847854" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639082545813847854" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_639082545813847854" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_639082545813847854" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_639082545813847854" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_639082545813847854" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_639082545813847854" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_639082545813847854" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_639082545813847854" xlink:to="us-gaap_LiabilitiesCurrent_639082545813847854" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639082545813847854" xlink:to="us-gaap_AccountsPayableCurrent_639082545813847854" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639082545813847854" xlink:to="us-gaap_AccruedLiabilitiesCurrent_639082545813847854" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationCurrent" xlink:label="us-gaap_SupplierFinanceProgramObligationCurrent_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639082545813847854" xlink:to="us-gaap_SupplierFinanceProgramObligationCurrent_639082545813847854" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639082545813847854" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_639082545813847854" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_639082545813847854" xlink:to="us-gaap_SecuredLongTermDebt_639082545813847854" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_639082545813847854" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_639082545813847854" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationNoncurrent" xlink:label="us-gaap_SupplierFinanceProgramObligationNoncurrent_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_639082545813847854" xlink:to="us-gaap_SupplierFinanceProgramObligationNoncurrent_639082545813847854" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_639082545813847854" xlink:to="us-gaap_WarrantsAndRightsOutstanding_639082545813847854" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:label="us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_639082545813847854" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_639082545813847854" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_639082545813847854" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639082545813847854" xlink:to="us-gaap_PreferredStockValue_639082545813847854" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639082545813847854" xlink:to="us-gaap_CommonStockValue_639082545813898066" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639082545813847854" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_639082545813898066" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639082545813847854" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_639082545813898066" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639082545813847854" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639082545813898066" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" xlink:label="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_639082545813898066" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_639082545813898066" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_639082545813898066" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_639082545813898066" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639082545813898066" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_639082545813898066" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639082545813898066" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639082545813898066" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_639082545813898066" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639082545813898066" xlink:to="us-gaap_InvestmentIncomeInterest_639082545813898066" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639082545813898066" xlink:to="us-gaap_InterestExpense_639082545813898066" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639082545813898066" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_639082545813898066" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IncomeLossFromPreferredStockTrancheLiability" xlink:label="vstm_IncomeLossFromPreferredStockTrancheLiability_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639082545813898066" xlink:to="vstm_IncomeLossFromPreferredStockTrancheLiability_639082545813898066" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotes" xlink:label="vstm_FairValueAdjustmentOfNotes_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639082545813898066" xlink:to="vstm_FairValueAdjustmentOfNotes_639082545813898066" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639082545813898066" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639082545813898066" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639082545813898066" xlink:to="us-gaap_OperatingIncomeLoss_639082545813898066" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_639082545813898066" xlink:to="us-gaap_CostsAndExpenses_639082545813898066" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_639082545813898066" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_639082545813898066" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_639082545813898066" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639082545813898066" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_639082545813898066" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_639082545813898066" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CostOfGoodsSoldExcludingAmortization" xlink:label="vstm_CostOfGoodsSoldExcludingAmortization_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_639082545813898066" xlink:to="vstm_CostOfGoodsSoldExcludingAmortization_639082545813898066" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_639082545813898066" xlink:to="us-gaap_Revenues_639082545813898066" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Revenues_639082545813898066" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_639082545813898066" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="us-gaap_ProfitLoss_639082545813898066" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="us-gaap_Depreciation_639082545813898066" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="us-gaap_AmortizationOfIntangibleAssets_639082545813898066" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OperatingLeaseNonCashCost" xlink:label="vstm_OperatingLeaseNonCashCost_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="vstm_OperatingLeaseNonCashCost_639082545813898066" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="us-gaap_ShareBasedCompensation_639082545813898066" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_639082545813898066" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_639082545813898066" order="7" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639082545813898066" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotesNoncash" xlink:label="vstm_FairValueAdjustmentOfNotesNoncash_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="vstm_FairValueAdjustmentOfNotesNoncash_639082545813898066" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability" xlink:label="vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability_639082545813898066" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_639082545813898066" order="11" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IncreaseDecreaseInGrantsReceivableNet" xlink:label="vstm_IncreaseDecreaseInGrantsReceivableNet_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="vstm_IncreaseDecreaseInGrantsReceivableNet_639082545813898066" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="us-gaap_IncreaseDecreaseInInventories_639082545813898066" order="13" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639082545813898066" order="14" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_639082545813898066" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_639082545813898066" order="16" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545813898066" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_639082545813898066" order="17" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_639082545813898066" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_639082545813898066" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639082545813898066" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_639082545813898066" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_639082545813898066" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_639082545813898066" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_639082545813898066" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_639082545813898066" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_639082545813898066" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_639082545813898066" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639082545813898066" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_639082545813898066" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639082545813898066" xlink:to="us-gaap_RepaymentsOfLongTermDebt_639082545813898066" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfLoanCosts" xlink:label="us-gaap_PaymentsOfLoanCosts_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639082545813898066" xlink:to="us-gaap_PaymentsOfLoanCosts_639082545813898066" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639082545813898066" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_639082545813898066" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProceedsFromInsurancePremiumFinancing" xlink:label="vstm_ProceedsFromInsurancePremiumFinancing_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639082545813898066" xlink:to="vstm_ProceedsFromInsurancePremiumFinancing_639082545813898066" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PaymentsOnInsurancePremiumFinancing" xlink:label="vstm_PaymentsOnInsurancePremiumFinancing_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639082545813898066" xlink:to="vstm_PaymentsOnInsurancePremiumFinancing_639082545813898066" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639082545813898066" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_639082545813898066" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639082545813898066" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_639082545813898066" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639082545813898066" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_639082545813898066" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639082545813898066" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639082545813898066" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639082545813898066" xlink:to="us-gaap_ProceedsFromWarrantExercises_639082545813898066" order="11" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="99940203 - Disclosure - Significant accounting policies - Reconciliation of cash, cash equivalents and restricted cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639082545813898066" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xlink:to="us-gaap_SecurityDeposit_639082545813898066" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashEquivalentsCurrent" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xlink:to="us-gaap_RestrictedCashEquivalentsCurrent_639082545813898066" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="99940205 - Disclosure - Significant accounting policies - Items Measured at Fair Value on a Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_639082545813898066" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure_1" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_639082545813898066" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_639082545814008743" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_WarrantsAndRightsOutstanding_639082545814008743" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure_639082545814008743" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_639082545814008743" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.verastem.com/role/DisclosureInventoryScheduleOfInventoryDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Inventory - Schedule of inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess_639082545814010602" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods_639082545814010602" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="extended" xlink:title="99940502 - Disclosure - Intangible Assets - Schedule of intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_639082545814010602" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_639082545814010602" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails" xlink:type="extended" xlink:title="99940503 - Disclosure - Intangible Assets - Schedule of future amortization expense of finite-lived intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_639082545814010602" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_639082545814010602" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_639082545814010602" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_639082545814010602" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_639082545814010602" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_639082545814010602" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Property and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_635447473484835973" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_635447473484835973" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_639082545814010602" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_635447473484835973" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_639082545814010602" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.verastem.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Accrued expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_639082545814010602" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent_639082545814010602" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedConsultingFeesCurrent" xlink:label="vstm_AccruedConsultingFeesCurrent_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="vstm_AccruedConsultingFeesCurrent_639082545814010602" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_639082545814010602" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="vstm_AccruedResearchAndDevelopmentExpensesCurrent_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="vstm_AccruedResearchAndDevelopmentExpensesCurrent_639082545814010602" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedContractManufacturingExpensesCurrent" xlink:label="vstm_AccruedContractManufacturingExpensesCurrent_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="vstm_AccruedContractManufacturingExpensesCurrent_639082545814010602" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedClinicalTrialExpensesCurrent" xlink:label="vstm_AccruedClinicalTrialExpensesCurrent_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="vstm_AccruedClinicalTrialExpensesCurrent_639082545814010602" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_639082545814010602" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedMilestonePaymentsCurrent" xlink:label="vstm_AccruedMilestonePaymentsCurrent_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="vstm_AccruedMilestonePaymentsCurrent_639082545814010602" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedCommercializationCostsCurrent" xlink:label="vstm_AccruedCommercializationCostsCurrent_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="vstm_AccruedCommercializationCostsCurrent_639082545814010602" order="10" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.verastem.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - Long-term debt - Future principal payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LongTermDebtMaturitiesAggregatePrincipalDue" xlink:label="vstm_LongTermDebtMaturitiesAggregatePrincipalDue" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LongTermDebtMaturityYearSix" xlink:label="vstm_LongTermDebtMaturityYearSix_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="vstm_LongTermDebtMaturitiesAggregatePrincipalDue" xlink:to="vstm_LongTermDebtMaturityYearSix_639082545814010602" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LongTermDebtMaturityYearSeven" xlink:label="vstm_LongTermDebtMaturityYearSeven_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="vstm_LongTermDebtMaturitiesAggregatePrincipalDue" xlink:to="vstm_LongTermDebtMaturityYearSeven_639082545814010602" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.verastem.com/role/DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails" xlink:type="extended" xlink:title="99940805 - Disclosure - Long-term debt - Components of carrying value of the Term Loan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentCarryingAmount_639082545814010602" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentFinalPaymentFee" xlink:label="vstm_DebtInstrumentFinalPaymentFee_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="vstm_DebtInstrumentFinalPaymentFee_639082545814010602" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_639082545814010602" order="3" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.verastem.com/role/DisclosureLongTermDebtScheduleOfInterestExpensesDetails" xlink:type="extended" xlink:title="99940806 - Disclosure - Long-term debt - Schedule of interest expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ContractualInterestExpense" xlink:label="vstm_ContractualInterestExpense_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InterestExpense_1" xlink:to="vstm_ContractualInterestExpense_639082545814010602" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InterestExpense_1" xlink:to="us-gaap_AmortizationOfFinancingCosts_639082545814010602" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AmortizationOfFinalPaymentFee" xlink:label="vstm_AmortizationOfFinalPaymentFee_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InterestExpense_1" xlink:to="vstm_AmortizationOfFinalPaymentFee_639082545814010602" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Leases - Balance sheet and other information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_639082545814010602" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_639082545814010602" order="1" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - Segment Reporting - Segment net loss including segment expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_639082545814010602" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CostOfGoodsSoldExcludingAmortization" xlink:label="vstm_CostOfGoodsSoldExcludingAmortization_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="vstm_CostOfGoodsSoldExcludingAmortization_639082545814010602" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_639082545814010602" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense" xlink:label="vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense_639082545814010602" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CommercialExpenditure" xlink:label="vstm_CommercialExpenditure_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="vstm_CommercialExpenditure_639082545814010602" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MedicalAffairExpenditure" xlink:label="vstm_MedicalAffairExpenditure_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="vstm_MedicalAffairExpenditure_639082545814010602" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense_639082545814010602" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_639082545814010602" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_Depreciation_639082545814010602" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest_639082545814010602" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense_639082545814010602" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_639082545814010602" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IncomeLossFromPreferredStockTrancheLiability" xlink:label="vstm_IncomeLossFromPreferredStockTrancheLiability_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="vstm_IncomeLossFromPreferredStockTrancheLiability_639082545814010602" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639082545814010602" order="14" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotes" xlink:label="vstm_FairValueAdjustmentOfNotes_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="vstm_FairValueAdjustmentOfNotes_639082545814010602" order="15" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_SegmentReportingOtherItemAmount_639082545814010602" order="16" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639082545814010602" order="17" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - Income Taxes - Income Tax Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_639082545814010602" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_639082545814010602" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_639082545814010602" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="99941402 - Disclosure - Income Taxes - Reconciliation of Income Taxes and Deferred Tax Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_639082545814010602" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance" xlink:label="vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance_639082545814010602" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance_639082545814010602" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_639082545814010602" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="vstm_DeferredTaxLiabilitiesRightOfUseAsset_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_639082545814010602" xlink:to="vstm_DeferredTaxLiabilitiesRightOfUseAsset_639082545814010602" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance_639082545814010602" xlink:to="us-gaap_DeferredTaxAssetsGross_639082545814010602" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639082545814010602" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639082545814010602" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxAssetsInstallmentSale" xlink:label="vstm_DeferredTaxAssetsInstallmentSale_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639082545814010602" xlink:to="vstm_DeferredTaxAssetsInstallmentSale_639082545814010602" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxAssetsLeaseLiability" xlink:label="vstm_DeferredTaxAssetsLeaseLiability_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639082545814010602" xlink:to="vstm_DeferredTaxAssetsLeaseLiability_639082545814010602" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639082545814010602" xlink:to="vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment_639082545814010602" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639082545814010602" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_639082545814010602" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639082545814010602" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_639082545814010602" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639082545814010602" xlink:to="us-gaap_DeferredTaxAssetsOther_639082545814010602" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639082545814010602" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_639082545814010602" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_639082545814010602" order="3" use="optional" weight="-1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639082545814010602" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent_639082545814010602" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_639082545814010602" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_639082545814010602" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_639082545814010602" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent_639082545814010602" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_639082545814010602" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_3" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639082545814010602" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_3" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_639082545814010602" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_3" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639082545814010602" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_3" xlink:to="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount_639082545814010602" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_639082545814010602" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_3" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_639082545814010602" order="5" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>vstm-20251231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/4/2026 8:56:24 PM-->
<!--Modified on: 3/4/2026 8:56:24 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.verastem.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" roleURI="http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" roleURI="http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureNatureOfBusinessDetails" roleURI="http://www.verastem.com/role/DisclosureNatureOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureNatureOfBusinessReverseStockSplitDetails" roleURI="http://www.verastem.com/role/DisclosureNatureOfBusinessReverseStockSplitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureProductRevenueReservesAndAllowancesDetails" roleURI="http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLongTermDebtNotePurchaseAgreementDetails" roleURI="http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails" roleURI="http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLongTermDebtLoanAgreementDetails" roleURI="http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLeasesDetails" roleURI="http://www.verastem.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCapitalStockDetails" roleURI="http://www.verastem.com/role/DisclosureCapitalStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCapitalStockNovember2025PublicOfferingDetails" roleURI="http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCapitalStockApril2025PrivatePlacementDetails" roleURI="http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCapitalStockStockPurchaseAgreementDetails" roleURI="http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails" roleURI="http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCapitalStockConvertiblePreferredStockDetails" roleURI="http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCapitalStockAtMarketEquityOfferingProgramDetails" roleURI="http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureStockBasedCompensationStockBasedCompensationDetails" roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureStockBasedCompensationStockOptionsDetails" roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureStockBasedCompensationOptionExchangeProgramDetails" roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureStockBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails" roleURI="http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails" roleURI="http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIncomeTaxesIncomeTaxExpenseDetails" roleURI="http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails" roleURI="http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" roleURI="http://www.verastem.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIncomeTaxesTaxCreditsDetails" roleURI="http://www.verastem.com/role/DisclosureIncomeTaxesTaxCreditsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails" roleURI="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails" roleURI="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails" roleURI="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails" roleURI="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureNotesPayableDetails" roleURI="http://www.verastem.com/role/DisclosureNotesPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.verastem.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.verastem.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="vstm-20251231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2" xlink:title="us-gaap_ResearchAndDevelopmentExpense_2" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To us-gaap_ResearchAndDevelopmentExpense_2" order="1" priority="0" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_1" xlink:title="us-gaap_LiabilitiesCurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_1" xlink:title="us-gaap_DeferredRevenueCurrent_1" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1" xlink:to="us-gaap_DeferredRevenueCurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesCurrentAbstract_1 To us-gaap_DeferredRevenueCurrent_1" order="1" priority="0" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_1" xlink:title="us-gaap_AssetsCurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_GrantsReceivableNet" xlink:label="vstm_GrantsReceivableNet_2" xlink:title="vstm_GrantsReceivableNet_2" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_AssetsCurrentAbstract_1" xlink:to="vstm_GrantsReceivableNet_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_AssetsCurrentAbstract_1 To vstm_GrantsReceivableNet_2" order="1" priority="0" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" xlink:label="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_2" xlink:title="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_2" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_2" order="2" priority="0" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotes" xlink:label="vstm_FairValueAdjustmentOfNotes_1" xlink:title="vstm_FairValueAdjustmentOfNotes_1" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="vstm_FairValueAdjustmentOfNotes_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To vstm_FairValueAdjustmentOfNotes_1" order="3" priority="0" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:title="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" xlink:label="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_3" xlink:title="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_3" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_3" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_StatementOfOtherComprehensiveIncomeAbstract To vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_3" order="1" priority="0" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xlink:title="us-gaap_LiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationCurrent" xlink:label="us-gaap_SupplierFinanceProgramObligationCurrent_1" xlink:title="us-gaap_SupplierFinanceProgramObligationCurrent_1" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_SupplierFinanceProgramObligationCurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_SupplierFinanceProgramObligationCurrent_1" order="4" priority="0" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationNoncurrent" xlink:label="us-gaap_SupplierFinanceProgramObligationNoncurrent_1" xlink:title="us-gaap_SupplierFinanceProgramObligationNoncurrent_1" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_SupplierFinanceProgramObligationNoncurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_SupplierFinanceProgramObligationNoncurrent_1" order="5" priority="0" />
  </definitionLink>
  <link:definitionLink xlink:role="http://www.verastem.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_1" xlink:title="us-gaap_CreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_1" xlink:title="us-gaap_CreditFacilityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CreditFacilityAxis_1" xlink:to="us-gaap_CreditFacilityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CreditFacilityAxis_1 To us-gaap_CreditFacilityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:title="us-gaap_FairValueByMeasurementBasisAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" xlink:title="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementBasisAxis_1 To us-gaap_PortionAtFairValueFairValueDisclosureMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueAllowancesAndReservesTypeAxis" xlink:label="vstm_ProductRevenueAllowancesAndReservesTypeAxis_1" xlink:title="vstm_ProductRevenueAllowancesAndReservesTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesDomain" xlink:label="vstm_ProductRevenueReservesAndAllowancesDomain_1" xlink:title="vstm_ProductRevenueReservesAndAllowancesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="vstm_ProductRevenueAllowancesAndReservesTypeAxis_1" xlink:to="vstm_ProductRevenueReservesAndAllowancesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:vstm_ProductRevenueAllowancesAndReservesTypeAxis_1 To vstm_ProductRevenueReservesAndAllowancesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" xlink:title="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" xlink:title="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1 To us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis_1" xlink:title="us-gaap_DisposalGroupClassificationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_1" xlink:title="us-gaap_DisposalGroupClassificationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DisposalGroupClassificationAxis_1" xlink:to="us-gaap_DisposalGroupClassificationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DisposalGroupClassificationAxis_1 To us-gaap_DisposalGroupClassificationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis_1" xlink:title="us-gaap_RestructuringPlanAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_1" xlink:title="us-gaap_RestructuringPlanDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestructuringPlanAxis_1" xlink:to="us-gaap_RestructuringPlanDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestructuringPlanAxis_1 To us-gaap_RestructuringPlanDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_1" xlink:title="us-gaap_RestructuringCostAndReserveAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_1" xlink:title="us-gaap_TypeOfRestructuringDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestructuringCostAndReserveAxis_1" xlink:to="us-gaap_TypeOfRestructuringDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestructuringCostAndReserveAxis_1 To us-gaap_TypeOfRestructuringDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_1" xlink:title="us-gaap_LineOfCreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_1" xlink:title="us-gaap_LineOfCreditFacilityLenderDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LineOfCreditFacilityAxis_1" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LineOfCreditFacilityAxis_1 To us-gaap_LineOfCreditFacilityLenderDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" xlink:title="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:title="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1 To us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis" xlink:label="us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_1" xlink:title="us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain" xlink:label="us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_1" xlink:title="us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_1" xlink:to="us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_1 To us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis_1" xlink:title="us-gaap_GovernmentAssistanceTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain_1" xlink:title="us-gaap_GovernmentAssistanceTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GovernmentAssistanceTypeAxis_1" xlink:to="us-gaap_GovernmentAssistanceTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GovernmentAssistanceTypeAxis_1 To us-gaap_GovernmentAssistanceTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended" xlink:title="Individuals">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember" xlink:title="ecd_AllIndividualsMember" />
    <link:loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PaulBunnMember" xlink:label="vstm_PaulBunnMember" xlink:title="vstm_PaulBunnMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="vstm_PaulBunnMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To vstm_PaulBunnMember" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MichaelKauffmanMember" xlink:label="vstm_MichaelKauffmanMember" xlink:title="vstm_MichaelKauffmanMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="vstm_MichaelKauffmanMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To vstm_MichaelKauffmanMember" order="2" priority="0" />
    <link:loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DanielPatersonMember" xlink:label="vstm_DanielPatersonMember" xlink:title="vstm_DanielPatersonMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="vstm_DanielPatersonMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To vstm_DanielPatersonMember" order="3" priority="0" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesBConvertiblePreferredStockMember" xlink:label="vstm_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vstm_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_GrantsReceivableNet" xlink:label="vstm_GrantsReceivableNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="vstm_GrantsReceivableNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationCurrent" xlink:label="us-gaap_SupplierFinanceProgramObligationCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_SupplierFinanceProgramObligationCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_SecuredLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationNoncurrent" xlink:label="us-gaap_SupplierFinanceProgramObligationNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_SupplierFinanceProgramObligationNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConvertiblePreferredStockAbstract" xlink:label="vstm_ConvertiblePreferredStockAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="vstm_ConvertiblePreferredStockAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:label="us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="vstm_ConvertiblePreferredStockAbstract" xlink:to="us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesaConvertiblePreferredStockMember" xlink:label="vstm_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vstm_SeriesaConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesBConvertiblePreferredStockMember" xlink:label="vstm_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vstm_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockSharesDesignated" xlink:label="vstm_PreferredStockSharesDesignated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="vstm_PreferredStockSharesDesignated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CopiktraLicenseAndRelatedAssetsMember" xlink:label="vstm_CopiktraLicenseAndRelatedAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vstm_CopiktraLicenseAndRelatedAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CostOfGoodsSoldExcludingAmortization" xlink:label="vstm_CostOfGoodsSoldExcludingAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="vstm_CostOfGoodsSoldExcludingAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IncomeLossFromPreferredStockTrancheLiability" xlink:label="vstm_IncomeLossFromPreferredStockTrancheLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="vstm_IncomeLossFromPreferredStockTrancheLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotes" xlink:label="vstm_FairValueAdjustmentOfNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="vstm_FairValueAdjustmentOfNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" xlink:label="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesBConvertiblePreferredStockMember" xlink:label="vstm_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vstm_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesaConvertiblePreferredStockMember" xlink:label="vstm_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vstm_SeriesaConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_November2025PublicOfferingMember" xlink:label="vstm_November2025PublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vstm_November2025PublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PrivatePlacement2025Member" xlink:label="vstm_PrivatePlacement2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vstm_PrivatePlacement2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" xlink:label="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodValueAtMarketTransactions" xlink:label="vstm_StockIssuedDuringPeriodValueAtMarketTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="vstm_StockIssuedDuringPeriodValueAtMarketTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodSharesAtMarketTransactions" xlink:label="vstm_StockIssuedDuringPeriodSharesAtMarketTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="vstm_StockIssuedDuringPeriodValueAtMarketTransactions" xlink:to="vstm_StockIssuedDuringPeriodSharesAtMarketTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:label="vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:label="vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:to="vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProceedsFromPreFundedWarrantExercises" xlink:label="vstm_ProceedsFromPreFundedWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="vstm_ProceedsFromPreFundedWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SharesIssuedFromPreFundedWarrantExercises" xlink:label="vstm_SharesIssuedFromPreFundedWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="vstm_ProceedsFromPreFundedWarrantExercises" xlink:to="vstm_SharesIssuedFromPreFundedWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts" xlink:label="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" xlink:label="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts" xlink:to="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xlink:type="extended" xlink:title="995200305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesBConvertiblePreferredStockMember" xlink:label="vstm_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vstm_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PrivatePlacement2025Member" xlink:label="vstm_PrivatePlacement2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vstm_PrivatePlacement2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_November2025PublicOfferingMember" xlink:label="vstm_November2025PublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vstm_November2025PublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IssuanceOfPreferredStockTrancheLiability" xlink:label="vstm_IssuanceOfPreferredStockTrancheLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="vstm_IssuanceOfPreferredStockTrancheLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockholdersEquityReverseStockSplitConversionRatio" xlink:label="vstm_StockholdersEquityReverseStockSplitConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="vstm_StockholdersEquityReverseStockSplitConversionRatio" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureNatureOfBusinessDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Nature of business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NatureOfBusinessTable" xlink:label="vstm_NatureOfBusinessTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="vstm_NatureOfBusinessTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NotePurchaseAgreementMember" xlink:label="vstm_NotePurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vstm_NotePurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="vstm_NatureOfBusinessTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SecondSaleMember" xlink:label="vstm_SecondSaleMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_SecondSaleMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="vstm_NatureOfBusinessTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NatureOfBusinessLineItems" xlink:label="vstm_NatureOfBusinessLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="vstm_NatureOfBusinessLineItems" xlink:to="vstm_NatureOfBusinessTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="vstm_NatureOfBusinessLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="vstm_NatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentIssuanceOfAdditionalNotes" xlink:label="vstm_DebtInstrumentIssuanceOfAdditionalNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="vstm_NatureOfBusinessLineItems" xlink:to="vstm_DebtInstrumentIssuanceOfAdditionalNotes" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureNatureOfBusinessReverseStockSplitDetails" xlink:type="extended" xlink:title="99940102 - Disclosure - Nature of business - Reverse Stock Split (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NatureOfBusinessTable" xlink:label="vstm_NatureOfBusinessTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="vstm_NatureOfBusinessTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CertificateOfAmendmentMember" xlink:label="vstm_CertificateOfAmendmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vstm_CertificateOfAmendmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NatureOfBusinessLineItems" xlink:label="vstm_NatureOfBusinessLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="vstm_NatureOfBusinessLineItems" xlink:to="vstm_NatureOfBusinessTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="vstm_NatureOfBusinessLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockholdersEquityReverseStockSplitConversionRatio" xlink:label="vstm_StockholdersEquityReverseStockSplitConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="vstm_NatureOfBusinessLineItems" xlink:to="vstm_StockholdersEquityReverseStockSplitConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="vstm_NatureOfBusinessLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails" xlink:type="extended" xlink:title="99940202 - Disclosure - Significant accounting policies - Proceeds from Grants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTable" xlink:label="us-gaap_GovernmentAssistanceTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_GovernmentAssistanceTable" xlink:to="us-gaap_GovernmentAssistanceTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceOtherMember" xlink:label="us-gaap_GovernmentAssistanceOtherMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="us-gaap_GovernmentAssistanceOtherMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceLineItems" xlink:label="us-gaap_GovernmentAssistanceLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="us-gaap_GovernmentAssistanceTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="us-gaap_GovernmentAssistanceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ReductionInResearchAndDevelopmentExpense" xlink:label="vstm_ReductionInResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="vstm_ReductionInResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceAmountCumulativeCurrent" xlink:label="us-gaap_GovernmentAssistanceAmountCumulativeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="us-gaap_GovernmentAssistanceAmountCumulativeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceLiabilityCurrent" xlink:label="us-gaap_GovernmentAssistanceLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="us-gaap_GovernmentAssistanceLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="us-gaap_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="99940203 - Disclosure - Significant accounting policies - Reconciliation of cash, cash equivalents and restricted cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember" xlink:label="vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RestrictedCashAndCashEquivalentsNoncurrentMember" xlink:label="vstm_RestrictedCashAndCashEquivalentsNoncurrentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="vstm_RestrictedCashAndCashEquivalentsNoncurrentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashEquivalentsCurrent" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_RestrictedCashEquivalentsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_InterestReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" xlink:type="extended" xlink:title="99940204 - Disclosure - Significant accounting policies - Cash, cash equivalents, restricted cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CashAndMoneyMarketAccountsMember" xlink:label="vstm_CashAndMoneyMarketAccountsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="vstm_CashAndMoneyMarketAccountsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CorporateBondsAndCommercialPaperMember" xlink:label="vstm_CorporateBondsAndCommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="vstm_CorporateBondsAndCommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfInvestmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="99940205 - Disclosure - Significant accounting policies - Items Measured at Fair Value on a Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_NotesPayableFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails" xlink:type="extended" xlink:title="99940206 - Disclosure - Significant accounting policies - Inputs used to value the warrant liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails" xlink:type="extended" xlink:title="99940207 - Disclosure - Significant accounting policies - Reconciliation of the warrant liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfWarrantsExercised" xlink:label="vstm_FairValueAdjustmentOfWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vstm_FairValueAdjustmentOfWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails" xlink:type="extended" xlink:title="99940208 - Disclosure - Significant accounting policies - Note Purchase Agreement and Oxford Loan Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NotePurchaseAgreementMember" xlink:label="vstm_NotePurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vstm_NotePurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMeasurementInput" xlink:label="us-gaap_LongTermDebtMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount" xlink:label="vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LongTermDebtFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails" xlink:type="extended" xlink:title="99940209 - Disclosure - Significant accounting policies - Concentrations of credit risk and off-balance sheet risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SecuraBioInc.Member" xlink:label="vstm_SecuraBioInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vstm_SecuraBioInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MajorCustomerMember" xlink:label="vstm_MajorCustomerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="vstm_MajorCustomerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract" xlink:label="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfCustomers" xlink:label="vstm_NumberOfCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract" xlink:to="vstm_NumberOfCustomers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940210 - Disclosure - Significant accounting policies - Property and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Product revenue reserves and allowances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesDisclosureTable" xlink:label="vstm_ProductRevenueReservesAndAllowancesDisclosureTable" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueAllowancesAndReservesTypeAxis" xlink:label="vstm_ProductRevenueAllowancesAndReservesTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="vstm_ProductRevenueReservesAndAllowancesDisclosureTable" xlink:to="vstm_ProductRevenueAllowancesAndReservesTypeAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesDomain" xlink:label="vstm_ProductRevenueReservesAndAllowancesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="vstm_ProductRevenueAllowancesAndReservesTypeAxis" xlink:to="vstm_ProductRevenueReservesAndAllowancesDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember" xlink:label="vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="vstm_ProductRevenueReservesAndAllowancesDomain" xlink:to="vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember" xlink:label="vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="vstm_ProductRevenueReservesAndAllowancesDomain" xlink:to="vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember" xlink:label="vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="vstm_ProductRevenueReservesAndAllowancesDomain" xlink:to="vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueAndAllowancesReturnsMember" xlink:label="vstm_ProductRevenueAndAllowancesReturnsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="vstm_ProductRevenueReservesAndAllowancesDomain" xlink:to="vstm_ProductRevenueAndAllowancesReturnsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems" xlink:label="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems" xlink:to="vstm_ProductRevenueReservesAndAllowancesDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowances" xlink:label="vstm_ProductRevenueReservesAndAllowances" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems" xlink:to="vstm_ProductRevenueReservesAndAllowances" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear" xlink:label="vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems" xlink:to="vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesDeductions" xlink:label="vstm_ProductRevenueReservesAndAllowancesDeductions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems" xlink:to="vstm_ProductRevenueReservesAndAllowancesDeductions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Property and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Long-term debt - Note Purchase Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NotePurchaseAgreementMember" xlink:label="vstm_NotePurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vstm_NotePurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_InitialSaleMember" xlink:label="vstm_InitialSaleMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_InitialSaleMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SecondSaleMember" xlink:label="vstm_SecondSaleMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_SecondSaleMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember" xlink:label="vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember" xlink:label="vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_First100MillionNetSalesOfEachIncludedProductMember" xlink:label="vstm_First100MillionNetSalesOfEachIncludedProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_First100MillionNetSalesOfEachIncludedProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember" xlink:label="vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RedemptionPriorToSecondAnniversaryMember" xlink:label="vstm_RedemptionPriorToSecondAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_RedemptionPriorToSecondAnniversaryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RedemptionPriorToThirdAnniversaryMember" xlink:label="vstm_RedemptionPriorToThirdAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_RedemptionPriorToThirdAnniversaryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RedemptionAfterYearThirdAnniversaryMember" xlink:label="vstm_RedemptionAfterYearThirdAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_RedemptionAfterYearThirdAnniversaryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentIssuanceOfAdditionalNotes" xlink:label="vstm_DebtInstrumentIssuanceOfAdditionalNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_DebtInstrumentIssuanceOfAdditionalNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib" xlink:label="vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate" xlink:label="vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_InterestDuePaidInKindPercentage" xlink:label="vstm_InterestDuePaidInKindPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_InterestDuePaidInKindPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage" xlink:label="vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ParticipationInNetSalesPercentage" xlink:label="vstm_ParticipationInNetSalesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_ParticipationInNetSalesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ParticipationInNetSalesSalesAmount" xlink:label="vstm_ParticipationInNetSalesSalesAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_ParticipationInNetSalesSalesAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt" xlink:label="vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentNumberOfEqualInstallments" xlink:label="vstm_DebtInstrumentNumberOfEqualInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_DebtInstrumentNumberOfEqualInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="us-gaap_DebtInstrumentCovenantDescription" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantDescription" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtIssuanceCosts" xlink:label="vstm_DebtIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_DebtIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Long-term debt - Reconciliation of changes in the fair value of the Notes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NotePurchaseAgreementMember" xlink:label="vstm_NotePurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vstm_NotePurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - Long-term debt - Loan Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LoanAndSecurityAgreementMember" xlink:label="vstm_LoanAndSecurityAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vstm_LoanAndSecurityAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_TermLoanFacilityMember" xlink:label="vstm_TermLoanFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vstm_TermLoanFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_TermELoanMember" xlink:label="vstm_TermELoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="vstm_TermLoanFacilityMember" xlink:to="vstm_TermELoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_TermBLoanMember" xlink:label="vstm_TermBLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="vstm_TermLoanFacilityMember" xlink:to="vstm_TermBLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_TermCLoanMember" xlink:label="vstm_TermCLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="vstm_TermLoanFacilityMember" xlink:to="vstm_TermCLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_TermDLoanMember" xlink:label="vstm_TermDLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="vstm_TermLoanFacilityMember" xlink:to="vstm_TermDLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember" xlink:label="vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PrepaymentAfterSecondAnniversaryMember" xlink:label="vstm_PrepaymentAfterSecondAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_PrepaymentAfterSecondAnniversaryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentCurrentBorrowingCapacity" xlink:label="vstm_DebtInstrumentCurrentBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_DebtInstrumentCurrentBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentPeriodToDrawLoanMinimum" xlink:label="vstm_DebtInstrumentPeriodToDrawLoanMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_DebtInstrumentPeriodToDrawLoanMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_GrossProductRevenueToBeAchieved" xlink:label="vstm_GrossProductRevenueToBeAchieved" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_GrossProductRevenueToBeAchieved" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentFinalPaymentFeePercentage" xlink:label="vstm_DebtInstrumentFinalPaymentFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_DebtInstrumentFinalPaymentFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault" xlink:label="vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="us-gaap_DebtInstrumentCovenantDescription" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantDescription" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfFinancialCovenants" xlink:label="vstm_NumberOfFinancialCovenants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_NumberOfFinancialCovenants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentAccruedInterestRate" xlink:label="vstm_DebtInstrumentAccruedInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_DebtInstrumentAccruedInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RepaymentsOfLongTermDebtFinalPaymentFee" xlink:label="vstm_RepaymentsOfLongTermDebtFinalPaymentFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_RepaymentsOfLongTermDebtFinalPaymentFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RepaymentsOfLongTermDebtUnpaidInterest" xlink:label="vstm_RepaymentsOfLongTermDebtUnpaidInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vstm_RepaymentsOfLongTermDebtUnpaidInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember" xlink:label="vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureCapitalStockDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Capital Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesaConvertiblePreferredStockMember" xlink:label="vstm_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="vstm_SeriesaConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantMember" xlink:label="vstm_PreFundedWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="vstm_PreFundedWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_InducementAwardProgramMember" xlink:label="vstm_InducementAwardProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="vstm_InducementAwardProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="vstm_PreFundedWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AtMarketEquityOfferingProgramMember" xlink:label="vstm_AtMarketEquityOfferingProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vstm_AtMarketEquityOfferingProgramMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_BiotechnologyValueFundMember" xlink:label="vstm_BiotechnologyValueFundMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vstm_BiotechnologyValueFundMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfVotesPerEachShareOfCommonStock" xlink:label="vstm_NumberOfVotesPerEachShareOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="vstm_NumberOfVotesPerEachShareOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram" xlink:label="vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProceedsFromIssuanceOfCommonStockNet" xlink:label="vstm_ProceedsFromIssuanceOfCommonStockNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="vstm_ProceedsFromIssuanceOfCommonStockNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConversionOfPreferredStockConversionBlockerPercent" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="vstm_ConversionOfPreferredStockConversionBlockerPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_WarrantAbstract" xlink:label="vstm_WarrantAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="vstm_WarrantAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="vstm_WarrantAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="vstm_WarrantAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - Capital stock - November 2025 Public Offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_November2025PublicOfferingMember" xlink:label="vstm_November2025PublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vstm_November2025PublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="vstm_November2025PublicOfferingMember" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares" xlink:label="vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails" xlink:type="extended" xlink:title="99941003 - Disclosure - Capital stock - April 2025 Private Placement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PrivatePlacement2025Member" xlink:label="vstm_PrivatePlacement2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vstm_PrivatePlacement2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantMember" xlink:label="vstm_PreFundedWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="vstm_PreFundedWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod" xlink:label="vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" xlink:label="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails" xlink:type="extended" xlink:title="99941004 - Disclosure - Capital stock - Stock Purchase Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NotePurchaseAgreementMember" xlink:label="vstm_NotePurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vstm_NotePurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockPurchaseAgreementMember" xlink:label="vstm_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vstm_StockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockPurchaseRightPeriod" xlink:label="vstm_StockPurchaseRightPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_StockPurchaseRightPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockPurchaseRightMaximumAmount" xlink:label="vstm_StockPurchaseRightMaximumAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_StockPurchaseRightMaximumAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails" xlink:type="extended" xlink:title="99941005 - Disclosure - Capital stock - July 2024 and June 2023 Public Offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantMember" xlink:label="vstm_PreFundedWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="vstm_PreFundedWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="vstm_PreFundedWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_July2024PublicOfferingMember" xlink:label="vstm_July2024PublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vstm_July2024PublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_UnderwritingAgreementMember" xlink:label="vstm_UnderwritingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vstm_UnderwritingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PublicMember" xlink:label="vstm_PublicMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vstm_PublicMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants" xlink:label="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" xlink:label="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod" xlink:label="vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock" xlink:label="vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CommonStockSharesOffered" xlink:label="vstm_CommonStockSharesOffered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_CommonStockSharesOffered" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage" xlink:label="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantElectionToExerciseNoticePeriod" xlink:label="vstm_PreFundedWarrantElectionToExerciseNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_PreFundedWarrantElectionToExerciseNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage" xlink:label="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts" xlink:label="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" xlink:label="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantsWarrantsOutstanding" xlink:label="vstm_PreFundedWarrantsWarrantsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_PreFundedWarrantsWarrantsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="99941006 - Disclosure - Capital stock - Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesaConvertiblePreferredStockMember" xlink:label="vstm_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vstm_SeriesaConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesBConvertiblePreferredStockMember" xlink:label="vstm_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vstm_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_BiotechnologyValueFundMember" xlink:label="vstm_BiotechnologyValueFundMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vstm_BiotechnologyValueFundMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockConvertibleAggregateSharesToBeSold" xlink:label="vstm_PreferredStockConvertibleAggregateSharesToBeSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_PreferredStockConvertibleAggregateSharesToBeSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockIssueNumberOfTranches" xlink:label="vstm_PreferredStockIssueNumberOfTranches" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_PreferredStockIssueNumberOfTranches" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConversionOfPreferredStockConversionBlockerPercent" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_ConversionOfPreferredStockConversionBlockerPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockIssuanceThresholdSharePrice" xlink:label="vstm_PreferredStockIssuanceThresholdSharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_PreferredStockIssuanceThresholdSharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockIssuanceExpectedClosingPeriod" xlink:label="vstm_PreferredStockIssuanceExpectedClosingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_PreferredStockIssuanceExpectedClosingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche" xlink:label="vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockIssuanceThresholdAggregateTradingVolume" xlink:label="vstm_PreferredStockIssuanceThresholdAggregateTradingVolume" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_PreferredStockIssuanceThresholdAggregateTradingVolume" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockIssuanceThresholdTradingDays" xlink:label="vstm_PreferredStockIssuanceThresholdTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_PreferredStockIssuanceThresholdTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfPreferredStockConvertibleIntoCommonStock" xlink:label="vstm_NumberOfPreferredStockConvertibleIntoCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_NumberOfPreferredStockConvertibleIntoCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SecondTrancheRightLiabilityNonCurrentFairValue" xlink:label="vstm_SecondTrancheRightLiabilityNonCurrentFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_SecondTrancheRightLiabilityNonCurrentFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockTrancheLiability" xlink:label="vstm_PreferredStockTrancheLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_PreferredStockTrancheLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability" xlink:label="vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails" xlink:type="extended" xlink:title="99941007 - Disclosure - Capital stock - At-the market equity offering program (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CantorFitzgeraldCo.Member" xlink:label="vstm_CantorFitzgeraldCo.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vstm_CantorFitzgeraldCo.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AtMarketEquityOfferingProgramMember" xlink:label="vstm_AtMarketEquityOfferingProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vstm_AtMarketEquityOfferingProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram" xlink:label="vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProceedsFromIssuanceOfCommonStockNet" xlink:label="vstm_ProceedsFromIssuanceOfCommonStockNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vstm_ProceedsFromIssuanceOfCommonStockNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Stock-based compensation - Stock-based compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SellingGeneralAndAdministrativeExpenseMember" xlink:label="vstm_SellingGeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="vstm_SellingGeneralAndAdministrativeExpenseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EquityIncentivePlan2021Member" xlink:label="vstm_EquityIncentivePlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="vstm_EquityIncentivePlan2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IncentivePlan2012Member" xlink:label="vstm_IncentivePlan2012Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="vstm_IncentivePlan2012Member" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_InducementAwardProgramMember" xlink:label="vstm_InducementAwardProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="vstm_InducementAwardProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EmployeeAndNonEmployeesStockOptionMember" xlink:label="vstm_EmployeeAndNonEmployeesStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="vstm_EmployeeAndNonEmployeesStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfEquityCompensationPlans" xlink:label="vstm_NumberOfEquityCompensationPlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="vstm_NumberOfEquityCompensationPlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ReductionOfSharesAvailableForIssuance" xlink:label="vstm_ReductionOfSharesAvailableForIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="vstm_ReductionOfSharesAvailableForIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - Stock-based compensation - Stock options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockOptionExchangeProgramMember" xlink:label="vstm_StockOptionExchangeProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="vstm_StockOptionExchangeProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EmployeeAndNonEmployeesStockOptionMember" xlink:label="vstm_EmployeeAndNonEmployeesStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="vstm_EmployeeAndNonEmployeesStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails" xlink:type="extended" xlink:title="99941103 - Disclosure - Stock-based compensation - Option Exchange Program (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockOptionExchangeProgramMember" xlink:label="vstm_StockOptionExchangeProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="vstm_StockOptionExchangeProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfEligibleStockholders" xlink:label="vstm_NumberOfEligibleStockholders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vstm_NumberOfEligibleStockholders" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="99941104 - Disclosure - Stock-based compensation - Restricted stock units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationAwardTrancheFourMember" xlink:label="vstm_ShareBasedCompensationAwardTrancheFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_VestingDomain" xlink:to="vstm_ShareBasedCompensationAwardTrancheFourMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedPaymentArrangementTrancheFiveMember" xlink:label="vstm_ShareBasedPaymentArrangementTrancheFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_VestingDomain" xlink:to="vstm_ShareBasedPaymentArrangementTrancheFiveMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" xlink:label="vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits" xlink:label="vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfAnniversariesForVestingRestrictedStockUnits" xlink:label="vstm_NumberOfAnniversariesForVestingRestrictedStockUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vstm_NumberOfAnniversariesForVestingRestrictedStockUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended" xlink:title="99941105 - Disclosure - Stock-based compensation - Employee stock purchase plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - Segment Reporting - Segment net loss including segment expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember" xlink:label="vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CopiktraLicenseAndRelatedAssetsMember" xlink:label="vstm_CopiktraLicenseAndRelatedAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vstm_CopiktraLicenseAndRelatedAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CostOfGoodsSoldExcludingAmortization" xlink:label="vstm_CostOfGoodsSoldExcludingAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="vstm_CostOfGoodsSoldExcludingAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense" xlink:label="vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CommercialExpenditure" xlink:label="vstm_CommercialExpenditure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="vstm_CommercialExpenditure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MedicalAffairExpenditure" xlink:label="vstm_MedicalAffairExpenditure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="vstm_MedicalAffairExpenditure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IncomeLossFromPreferredStockTrancheLiability" xlink:label="vstm_IncomeLossFromPreferredStockTrancheLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="vstm_IncomeLossFromPreferredStockTrancheLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotes" xlink:label="vstm_FairValueAdjustmentOfNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="vstm_FairValueAdjustmentOfNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Net loss per share - Potentially dilutive shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesaConvertiblePreferredStockMember" xlink:label="vstm_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vstm_SeriesaConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesBConvertiblePreferredStockMember" xlink:label="vstm_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vstm_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - Income Taxes - Income Tax Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CopiktraLicenseAndRelatedAssetsMember" xlink:label="vstm_CopiktraLicenseAndRelatedAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vstm_CopiktraLicenseAndRelatedAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SecuraBioInc.Member" xlink:label="vstm_SecuraBioInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vstm_SecuraBioInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="99941402 - Disclosure - Income Taxes - Reconciliation of Income Taxes and Deferred Tax Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xlink:label="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxAssetsInstallmentSale" xlink:label="vstm_DeferredTaxAssetsInstallmentSale" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="vstm_DeferredTaxAssetsInstallmentSale" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxAssetsLeaseLiability" xlink:label="vstm_DeferredTaxAssetsLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="vstm_DeferredTaxAssetsLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="vstm_DeferredTaxLiabilitiesRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="vstm_DeferredTaxLiabilitiesRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance" xlink:label="vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod" xlink:label="vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OperatingLossCarryforwardsPriorToOwnershipChanges" xlink:label="vstm_OperatingLossCarryforwardsPriorToOwnershipChanges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="vstm_OperatingLossCarryforwardsPriorToOwnershipChanges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges" xlink:label="vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OperatingLossCarryforwardsSection382Limitation" xlink:label="vstm_OperatingLossCarryforwardsSection382Limitation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="vstm_OperatingLossCarryforwardsSection382Limitation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xlink:type="extended" xlink:title="99941403 - Disclosure - Income Taxes - Operating Loss Carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OperatingLossCarryforwardsIndefinitePeriod" xlink:label="vstm_OperatingLossCarryforwardsIndefinitePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="vstm_OperatingLossCarryforwardsIndefinitePeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureIncomeTaxesTaxCreditsDetails" xlink:type="extended" xlink:title="99941404 - Disclosure - Income Taxes - Tax Credits (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99941501 - Disclosure - Commitments and contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OfficeAndLaboratorySpaceLeaseArrangementMember" xlink:label="vstm_OfficeAndLaboratorySpaceLeaseArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="vstm_OfficeAndLaboratorySpaceLeaseArrangementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RestrictedCashAndCashEquivalentsNoncurrentMember" xlink:label="vstm_RestrictedCashAndCashEquivalentsNoncurrentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="vstm_RestrictedCashAndCashEquivalentsNoncurrentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccountsPayableCurrentMember" xlink:label="vstm_AccountsPayableCurrentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="vstm_AccountsPayableCurrentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IqviaIncMember" xlink:label="vstm_IqviaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vstm_IqviaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OtherCommitment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails" xlink:type="extended" xlink:title="99941601 - Disclosure - License, collaboration and commercial agreements - Pfizer, Inc. (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PfizerIncMember" xlink:label="vstm_PfizerIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vstm_PfizerIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfFdaApprovalMember" xlink:label="vstm_AchievementOfFdaApprovalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_AchievementOfFdaApprovalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfFdaApprovalAnniversaryMember" xlink:label="vstm_AchievementOfFdaApprovalAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_AchievementOfFdaApprovalAnniversaryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" xlink:label="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfCertainSalesMilestonesMember" xlink:label="vstm_AchievementOfCertainSalesMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_AchievementOfCertainSalesMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CollaborativeArrangementsOneTimeCashPayment" xlink:label="vstm_CollaborativeArrangementsOneTimeCashPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_CollaborativeArrangementsOneTimeCashPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PotentialMilestonePayments" xlink:label="vstm_PotentialMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_PotentialMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_InterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CollaborativeArrangementsRoyaltyObligationsTerm" xlink:label="vstm_CollaborativeArrangementsRoyaltyObligationsTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_CollaborativeArrangementsRoyaltyObligationsTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails" xlink:type="extended" xlink:title="99941602 - Disclosure - License, collaboration and commercial agreements - License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ExclusiveLicenseAgreementMember" xlink:label="vstm_ExclusiveLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vstm_ExclusiveLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfFdaApprovalMember" xlink:label="vstm_AchievementOfFdaApprovalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_AchievementOfFdaApprovalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfFdaApprovalAnniversaryMember" xlink:label="vstm_AchievementOfFdaApprovalAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_AchievementOfFdaApprovalAnniversaryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PursuantToLicenseAgreementMember" xlink:label="vstm_PursuantToLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_PursuantToLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" xlink:label="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfCertainSalesMilestonesMember" xlink:label="vstm_AchievementOfCertainSalesMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_AchievementOfCertainSalesMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfPatents" xlink:label="vstm_NumberOfPatents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_NumberOfPatents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CollaborativeArrangementsOneTimeCashPayment" xlink:label="vstm_CollaborativeArrangementsOneTimeCashPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_CollaborativeArrangementsOneTimeCashPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PotentialMilestonePayments" xlink:label="vstm_PotentialMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_PotentialMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CollaborativeArrangementsRoyaltyObligationsTerm" xlink:label="vstm_CollaborativeArrangementsRoyaltyObligationsTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_CollaborativeArrangementsRoyaltyObligationsTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails" xlink:type="extended" xlink:title="99941603 - Disclosure - License, collaboration and commercial agreements - Genfleet Therapeutics (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementMember" xlink:label="vstm_LicenseAndCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vstm_LicenseAndCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_GenfleetTherapeuticsShanghaiIncMember" xlink:label="vstm_GenfleetTherapeuticsShanghaiIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vstm_GenfleetTherapeuticsShanghaiIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" xlink:label="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfCertainSalesMilestonesMember" xlink:label="vstm_AchievementOfCertainSalesMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_AchievementOfCertainSalesMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ExerciseOfAllThreeGenFleetOptionsMember" xlink:label="vstm_ExerciseOfAllThreeGenFleetOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_ExerciseOfAllThreeGenFleetOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementUpfrontPayment" xlink:label="vstm_LicenseAndCollaborationAgreementUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PotentialMilestonePayments" xlink:label="vstm_PotentialMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_PotentialMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments" xlink:label="vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable" xlink:label="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" xlink:label="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments" xlink:label="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements" xlink:label="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions" xlink:label="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement." xlink:label="vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement." />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement." priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach" xlink:label="vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails" xlink:type="extended" xlink:title="99941604 - Disclosure - License, collaboration and commercial agreements - Secura (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementMember" xlink:label="vstm_LicenseAndCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vstm_LicenseAndCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SecuraBioInc.Member" xlink:label="vstm_SecuraBioInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vstm_SecuraBioInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember" xlink:label="vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember" xlink:label="vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember" xlink:label="vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CopiktraLicenseAndRelatedAssetsMember" xlink:label="vstm_CopiktraLicenseAndRelatedAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vstm_CopiktraLicenseAndRelatedAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementUpfrontPayment" xlink:label="vstm_LicenseAndCollaborationAgreementUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable" xlink:label="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" xlink:label="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments" xlink:label="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements" xlink:label="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions" xlink:label="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement." xlink:label="vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement." />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement." priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived" xlink:label="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureNotesPayableDetails" xlink:type="extended" xlink:title="99941701 - Disclosure - Notes Payable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FirstInsuranceFundingMember" xlink:label="vstm_FirstInsuranceFundingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vstm_FirstInsuranceFundingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_RepaymentsOfShortTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_NotesPayable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.verastem.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99942001 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantMember" xlink:label="vstm_PreFundedWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="vstm_PreFundedWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:label="vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>vstm-20251231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/4/2026 8:56:24 PM-->
<!--Modified on: 3/4/2026 8:56:24 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Documents Incorporated by Reference [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Documents Incorporated by Reference</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesBConvertiblePreferredStockMember" xlink:label="vstm_SeriesBConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_SeriesBConvertiblePreferredStockMember" xlink:to="vstm_SeriesBConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Series B convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents &amp; restricted cash, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total inventory</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_GrantsReceivableNet" xlink:label="vstm_GrantsReceivableNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_GrantsReceivableNet" xlink:to="vstm_GrantsReceivableNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_GrantsReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of eligible expenses incurred in excess of grant payments received up to the total amount of grants, which are recorded as a receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_GrantsReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Receivable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_GrantsReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents, Noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, convertible preferred stock and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses, short-term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationCurrent" xlink:label="us-gaap_SupplierFinanceProgramObligationCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierFinanceProgramObligationCurrent" xlink:to="us-gaap_SupplierFinanceProgramObligationCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierFinanceProgramObligationCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplier Finance Program, Obligation, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplierFinanceProgramObligationCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vendor financing arrangement, short-term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability, short-term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredLongTermDebt" xlink:to="us-gaap_SecuredLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Long-term Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationNoncurrent" xlink:label="us-gaap_SupplierFinanceProgramObligationNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierFinanceProgramObligationNoncurrent" xlink:to="us-gaap_SupplierFinanceProgramObligationNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierFinanceProgramObligationNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplier Finance Program, Obligation, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplierFinanceProgramObligationNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vendor financing arrangement, long-term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability, long-term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConvertiblePreferredStockAbstract" xlink:label="vstm_ConvertiblePreferredStockAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ConvertiblePreferredStockAbstract" xlink:to="vstm_ConvertiblePreferredStockAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ConvertiblePreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ConvertiblePreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ConvertiblePreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:label="us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:to="us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Convertible Preferred Stock, $0.0001 par value; 944 shares designated at December 31, 2025 and December 31, 2024, respectively; 0 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.0001 par value; 5,000 shares authorized: Series A Convertible Preferred Stock, $0.0001 par value; 0 shares and 1,000 shares designated at December 31, 2025 and December 31, 2024, respectively, 0 shares and 1,000 shares issued and outstanding at December 31, 2025 and at December 31, 2024, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.0001 par value; 300,000 shares authorized, 77,740 and 44,784 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities, convertible preferred stock and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesaConvertiblePreferredStockMember" xlink:label="vstm_SeriesaConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_SeriesaConvertiblePreferredStockMember" xlink:to="vstm_SeriesaConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_SeriesaConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Series A convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_SeriesaConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_SeriesaConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockSharesDesignated" xlink:label="vstm_PreferredStockSharesDesignated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PreferredStockSharesDesignated" xlink:to="vstm_PreferredStockSharesDesignated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PreferredStockSharesDesignated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of preferred shares designated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PreferredStockSharesDesignated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Designated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PreferredStockSharesDesignated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares designated</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product revenue, net</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CopiktraLicenseAndRelatedAssetsMember" xlink:label="vstm_CopiktraLicenseAndRelatedAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_CopiktraLicenseAndRelatedAssetsMember" xlink:to="vstm_CopiktraLicenseAndRelatedAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_CopiktraLicenseAndRelatedAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Copiktra license and other revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_CopiktraLicenseAndRelatedAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of COPIKTRA license and related assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CostOfGoodsSoldExcludingAmortization" xlink:label="vstm_CostOfGoodsSoldExcludingAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_CostOfGoodsSoldExcludingAmortization" xlink:to="vstm_CostOfGoodsSoldExcludingAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_CostOfGoodsSoldExcludingAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate costs related to goods produced and sold by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities and intangible amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_CostOfGoodsSoldExcludingAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods Sold Excluding Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_CostOfGoodsSoldExcludingAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales - product</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales - intangible amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expenses)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on debt extinguishment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on debt extinguishment</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IncomeLossFromPreferredStockTrancheLiability" xlink:label="vstm_IncomeLossFromPreferredStockTrancheLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_IncomeLossFromPreferredStockTrancheLiability" xlink:to="vstm_IncomeLossFromPreferredStockTrancheLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_IncomeLossFromPreferredStockTrancheLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of income (loss) from change in value of preferred stock tranche liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_IncomeLossFromPreferredStockTrancheLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from preferred stock tranche liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="vstm_IncomeLossFromPreferredStockTrancheLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of preferred stock tranche liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_IncomeLossFromPreferredStockTrancheLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of preferred stock tranche liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value adjustment</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotes" xlink:label="vstm_FairValueAdjustmentOfNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_FairValueAdjustmentOfNotes" xlink:to="vstm_FairValueAdjustmentOfNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_FairValueAdjustmentOfNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense (income) related to adjustment to fair value of notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_FairValueAdjustmentOfNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="vstm_FairValueAdjustmentOfNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_FairValueAdjustmentOfNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pretax loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss before taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share-basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share-diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding used in computing net loss per share - basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding used in computing net loss per share - diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on available-for-sale securities</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" xlink:label="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" xlink:to="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense (income) related to adjustment to fair value of notes attributable to instrument specific credit risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Notes, Instrument Specific Credit Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of Notes attributable to instrument specific credit risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income/ (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_November2025PublicOfferingMember" xlink:label="vstm_November2025PublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_November2025PublicOfferingMember" xlink:to="vstm_November2025PublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_November2025PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the November 2025 public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_November2025PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2025 Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_November2025PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2025 Public Offering</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PrivatePlacement2025Member" xlink:label="vstm_PrivatePlacement2025Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PrivatePlacement2025Member" xlink:to="vstm_PrivatePlacement2025Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PrivatePlacement2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to 2025 Private Placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PrivatePlacement2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PrivatePlacement2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement 2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodValueAtMarketTransactions" xlink:label="vstm_StockIssuedDuringPeriodValueAtMarketTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_StockIssuedDuringPeriodValueAtMarketTransactions" xlink:to="vstm_StockIssuedDuringPeriodValueAtMarketTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_StockIssuedDuringPeriodValueAtMarketTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued during the period from at the market transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_StockIssuedDuringPeriodValueAtMarketTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value at the Market Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_StockIssuedDuringPeriodValueAtMarketTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock resulting from at-the-market transactions</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodSharesAtMarketTransactions" xlink:label="vstm_StockIssuedDuringPeriodSharesAtMarketTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_StockIssuedDuringPeriodSharesAtMarketTransactions" xlink:to="vstm_StockIssuedDuringPeriodSharesAtMarketTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_StockIssuedDuringPeriodSharesAtMarketTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents number of shares issued during the period from at the market transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_StockIssuedDuringPeriodSharesAtMarketTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares at the Market Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_StockIssuedDuringPeriodSharesAtMarketTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock resulting from at-the-market transactions (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock resulting from vesting of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock resulting from vesting of restricted stock units (in shares)</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:label="vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:to="vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued as a result of the stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:label="vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:to="vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options (or share units) issued during the period from a stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Stock Purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProceedsFromPreFundedWarrantExercises" xlink:label="vstm_ProceedsFromPreFundedWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProceedsFromPreFundedWarrantExercises" xlink:to="vstm_ProceedsFromPreFundedWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProceedsFromPreFundedWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow associated with the amount received from holders exercising their pre-funded stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProceedsFromPreFundedWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Pre-Funded Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ProceedsFromPreFundedWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SharesIssuedFromPreFundedWarrantExercises" xlink:label="vstm_SharesIssuedFromPreFundedWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_SharesIssuedFromPreFundedWarrantExercises" xlink:to="vstm_SharesIssuedFromPreFundedWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_SharesIssuedFromPreFundedWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The shares issued from holders exercising their pre-funded stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_SharesIssuedFromPreFundedWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued From Pre-Funded Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_SharesIssuedFromPreFundedWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of pre-funded warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts" xlink:label="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts" xlink:to="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate change in value for stock issued during the period as a result of an underwriting agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued, Pre Funded Warrants, Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, and pre-funded warrants, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" xlink:label="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" xlink:to="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued during the period related to an underwriting agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued, Pre Funded Warrants, Net of Issuance Costs in Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, and pre-funded warrants, net of issuance cost (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock resulting from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised/Released (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock resulting from exercise of stock options (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares exercised</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate change in value during the period related to the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Exercise of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of warrants on issuance date</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares issued during the period related to exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of warrants (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under Employee Stock Purchase Plan (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon conversion of preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series B Convertible Preferred Stock to common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon conversion of preferred stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Convertible Preferred Stock, net of issuance costs and preferred stock tranche liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Convertible Preferred Stock, net of issuance costs and preferred stock tranche liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock resulting from vesting of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock resulting from vesting of restricted stock units (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of preferred stock, issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock costs</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IssuanceOfPreferredStockTrancheLiability" xlink:label="vstm_IssuanceOfPreferredStockTrancheLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_IssuanceOfPreferredStockTrancheLiability" xlink:to="vstm_IssuanceOfPreferredStockTrancheLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_IssuanceOfPreferredStockTrancheLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of preferred stock tranche liability that were incurred during a noncash or partial noncash transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_IssuanceOfPreferredStockTrancheLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of preferred stock tranche liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_IssuanceOfPreferredStockTrancheLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock tranche liability</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockholdersEquityReverseStockSplitConversionRatio" xlink:label="vstm_StockholdersEquityReverseStockSplitConversionRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_StockholdersEquityReverseStockSplitConversionRatio" xlink:to="vstm_StockholdersEquityReverseStockSplitConversionRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_StockholdersEquityReverseStockSplitConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ratio applied to the conversion of the reverse stock split, for example but not limited to, one share converted to two or two shares converted to one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_StockholdersEquityReverseStockSplitConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity, Reverse Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_StockholdersEquityReverseStockSplitConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of acquired intangible assets</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OperatingLeaseNonCashCost" xlink:label="vstm_OperatingLeaseNonCashCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_OperatingLeaseNonCashCost" xlink:to="vstm_OperatingLeaseNonCashCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_OperatingLeaseNonCashCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of single lease cost, noncash, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_OperatingLeaseNonCashCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Non-Cash Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_OperatingLeaseNonCashCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of deferred financing costs, debt discounts and premiums and discounts on available-for-sale marketable securities</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability" xlink:label="vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability" xlink:to="vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of unrealized gain (loss) on the preferred stock tranche liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Fair Value of of Preferred Stock Tranche Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of preferred stock tranche liability</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotesNoncash" xlink:label="vstm_FairValueAdjustmentOfNotesNoncash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_FairValueAdjustmentOfNotesNoncash" xlink:to="vstm_FairValueAdjustmentOfNotesNoncash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_FairValueAdjustmentOfNotesNoncash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense (income) related to adjustment to fair value of notes, noncash portion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_FairValueAdjustmentOfNotesNoncash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Notes, Noncash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_FairValueAdjustmentOfNotesNoncash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash change in fair value of Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IncreaseDecreaseInGrantsReceivableNet" xlink:label="vstm_IncreaseDecreaseInGrantsReceivableNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_IncreaseDecreaseInGrantsReceivableNet" xlink:to="vstm_IncreaseDecreaseInGrantsReceivableNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_IncreaseDecreaseInGrantsReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in eligible expenses incurred in excess of grant payments received up to the total amount of grants, which are recorded as a receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_IncreaseDecreaseInGrantsReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Grants Receivable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_IncreaseDecreaseInGrantsReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses, other current assets and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deferred Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Debt Securities, Available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used in) provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of common stock and pre-funded warrants, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of Series B Convertible Preferred Stock, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Secured Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of long-term, debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfLoanCosts" xlink:label="us-gaap_PaymentsOfLoanCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfLoanCosts" xlink:to="us-gaap_PaymentsOfLoanCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfLoanCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Loan Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfLoanCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for loan amendment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from (Repayments of) Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of 2018 Notes</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProceedsFromInsurancePremiumFinancing" xlink:label="vstm_ProceedsFromInsurancePremiumFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProceedsFromInsurancePremiumFinancing" xlink:to="vstm_ProceedsFromInsurancePremiumFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProceedsFromInsurancePremiumFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash received as payments from insurance premium financing during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProceedsFromInsurancePremiumFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Insurance Premium Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ProceedsFromInsurancePremiumFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from insurance premium financing</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PaymentsOnInsurancePremiumFinancing" xlink:label="vstm_PaymentsOnInsurancePremiumFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PaymentsOnInsurancePremiumFinancing" xlink:to="vstm_PaymentsOnInsurancePremiumFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PaymentsOnInsurancePremiumFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for payments on insurance premium financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PaymentsOnInsurancePremiumFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments on insurance premium financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="vstm_PaymentsOnInsurancePremiumFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments on insurance premium financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the exercise of stock options and employee stock purchase program</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of non-cash investing and financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment in accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment included in accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs included in accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfWarrantsExercised" xlink:label="vstm_FairValueAdjustmentOfWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_FairValueAdjustmentOfWarrantsExercised" xlink:to="vstm_FairValueAdjustmentOfWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_FairValueAdjustmentOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense (income) related to adjustment to fair value of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_FairValueAdjustmentOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_FairValueAdjustmentOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of warrant liability into additional paid-in capital upon warrant exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vstm_FairValueAdjustmentOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of warrants exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right of use asset obtained in exchange for operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of intangible asset in accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract" xlink:label="vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract" xlink:to="vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product revenue reserves and allowances</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesDisclosureTextBlock" xlink:label="vstm_ProductRevenueReservesAndAllowancesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProductRevenueReservesAndAllowancesDisclosureTextBlock" xlink:to="vstm_ProductRevenueReservesAndAllowancesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProductRevenueReservesAndAllowancesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for product revenue reserves and allowances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProductRevenueReservesAndAllowancesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Revenue Reserves And Allowances Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ProductRevenueReservesAndAllowancesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product revenue reserves and allowances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementAbstract" xlink:label="vstm_LicenseAndCollaborationAgreementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseAndCollaborationAgreementAbstract" xlink:to="vstm_LicenseAndCollaborationAgreementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseAndCollaborationAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseAndCollaborationAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License, collaboration and commercial agreements</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock" xlink:label="vstm_LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock" xlink:to="vstm_LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for license, collaboration and commercial agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License, Collaboration And Commercial Agreements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vstm_LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License, collaboration and commercial agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee benefit plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee benefit plan</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_VendorFinancingAgreementAbstract" xlink:label="vstm_VendorFinancingAgreementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_VendorFinancingAgreementAbstract" xlink:to="vstm_VendorFinancingAgreementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_VendorFinancingAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_VendorFinancingAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vendor Financing Arrangement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTextBlock" xlink:label="us-gaap_SupplierFinanceProgramTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierFinanceProgramTextBlock" xlink:to="us-gaap_SupplierFinanceProgramTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierFinanceProgramTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplier Finance Program [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplierFinanceProgramTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vendor Financing Arrangement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment and geographic information</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProceedsFromGrantsPolicyPolicyTextBlock" xlink:label="vstm_ProceedsFromGrantsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProceedsFromGrantsPolicyPolicyTextBlock" xlink:to="vstm_ProceedsFromGrantsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProceedsFromGrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for proceeds from grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProceedsFromGrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Grants Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ProceedsFromGrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial instruments</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" xlink:label="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" xlink:to="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for credit risk and description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations Of Credit Risk And Off Balance Sheet Risk [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of credit risk and off-balance sheet risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CloudComputingImplementationCostsPolicyPolicyTextBlock" xlink:label="vstm_CloudComputingImplementationCostsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_CloudComputingImplementationCostsPolicyPolicyTextBlock" xlink:to="vstm_CloudComputingImplementationCostsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_CloudComputingImplementationCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy pertaining to cloud computing implementation costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_CloudComputingImplementationCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cloud Computing Implementation Costs Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_CloudComputingImplementationCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cloud Computing Implementation Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and Other Accounts Receivable, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Accounting Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative arrangements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NewAccountingStandardsAdoptedPolicyPolicyTextBlock" xlink:label="vstm_NewAccountingStandardsAdoptedPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_NewAccountingStandardsAdoptedPolicyPolicyTextBlock" xlink:to="vstm_NewAccountingStandardsAdoptedPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_NewAccountingStandardsAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy pertaining to new accounting standards adopted that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_NewAccountingStandardsAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Standards Adopted Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_NewAccountingStandardsAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Adopted Accounting Standards Updates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently issued accounting standards updates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Marketable Securities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cash, cash equivalents and investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of financial instruments measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of inputs used to value the preferred stock tranche liability and warrant liability</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ReconciliationOfWarrantLiabilityTableTextBlock" xlink:label="vstm_ReconciliationOfWarrantLiabilityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ReconciliationOfWarrantLiabilityTableTextBlock" xlink:to="vstm_ReconciliationOfWarrantLiabilityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ReconciliationOfWarrantLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure for reconciliation of warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ReconciliationOfWarrantLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation Of Warrant Liability [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ReconciliationOfWarrantLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of warrant liability</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="vstm_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="vstm_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the estimated useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant and Equipment Estimated Useful Lives [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of estimated useful lives of the assets</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesTableTextBlock" xlink:label="vstm_ProductRevenueReservesAndAllowancesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProductRevenueReservesAndAllowancesTableTextBlock" xlink:to="vstm_ProductRevenueReservesAndAllowancesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProductRevenueReservesAndAllowancesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of product revenue reserves and allowances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProductRevenueReservesAndAllowancesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Revenue Reserves And Allowances [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ProductRevenueReservesAndAllowancesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of product revenue allowance and reserve categories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future amortization expense for finite-lived intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property equipment and related accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of changes in the fair value of the Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Maturities of Long-Term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future principal payments under the Notes Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of carrying value of the Term Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income and Interest Expense Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of interest expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of elements of lease expenses</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock" xlink:label="vstm_ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock" xlink:to="vstm_ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the shares of common stock reserved for the potential conversion of outstanding preferred stock and the exercise of stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Shares of Common Stock Reserved for Potential Conversion [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of shares of common stock reserved for the issuance of common stock for vested restricted stock units and the exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense as reflected in the Company's consolidated statements of operations and comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity and related information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions used to estimate fair value of each stock option on grant date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions used to estimate fair value of each employee stock purchase plan on grant date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of segment net loss including significant segment expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potentially dilutive securities were excluded from the calculation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of Income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of effective income tax rate to the statutory federal income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of principal components of deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NatureOfBusinessTable" xlink:label="vstm_NatureOfBusinessTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_NatureOfBusinessTable" xlink:to="vstm_NatureOfBusinessTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_NatureOfBusinessTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A table disclosing information relating to nature of business.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_NatureOfBusinessTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature Of Business [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NotePurchaseAgreementMember" xlink:label="vstm_NotePurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_NotePurchaseAgreementMember" xlink:to="vstm_NotePurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_NotePurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Note Purchase Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_NotePurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Note Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_NotePurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SecondSaleMember" xlink:label="vstm_SecondSaleMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_SecondSaleMember" xlink:to="vstm_SecondSaleMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_SecondSaleMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to second sale, at the option of the Company, at any time prior to December 31, 2025, upon the FDA's approval sufficient for the promotion and sale of avutometinib and defactinib for the treatment of LGSOC and subject to certain other customary conditions precedent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_SecondSaleMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Sale [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_SecondSaleMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second sale, any time prior to December 31, 2025</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NatureOfBusinessLineItems" xlink:label="vstm_NatureOfBusinessLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_NatureOfBusinessLineItems" xlink:to="vstm_NatureOfBusinessLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_NatureOfBusinessLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_NatureOfBusinessLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature Of Business [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_NatureOfBusinessLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents, and investments</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentIssuanceOfAdditionalNotes" xlink:label="vstm_DebtInstrumentIssuanceOfAdditionalNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_DebtInstrumentIssuanceOfAdditionalNotes" xlink:to="vstm_DebtInstrumentIssuanceOfAdditionalNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_DebtInstrumentIssuanceOfAdditionalNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of an additional issue of notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_DebtInstrumentIssuanceOfAdditionalNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Issuance of Additional Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_DebtInstrumentIssuanceOfAdditionalNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional issue of principal amount of notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CertificateOfAmendmentMember" xlink:label="vstm_CertificateOfAmendmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_CertificateOfAmendmentMember" xlink:to="vstm_CertificateOfAmendmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_CertificateOfAmendmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the certificate of amendment to the Company's Restated Certificate of Incorporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_CertificateOfAmendmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certificate of Amendment</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SegmentAndGeographicInformationAbstract" xlink:label="vstm_SegmentAndGeographicInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_SegmentAndGeographicInformationAbstract" xlink:to="vstm_SegmentAndGeographicInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_SegmentAndGeographicInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment and Geographic Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_SegmentAndGeographicInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment and geographic information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTable" xlink:label="us-gaap_GovernmentAssistanceTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceTable" xlink:to="us-gaap_GovernmentAssistanceTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="us-gaap_GovernmentAssistanceTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceOtherMember" xlink:label="us-gaap_GovernmentAssistanceOtherMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceOtherMember" xlink:to="us-gaap_GovernmentAssistanceOtherMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceOtherMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Other [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GovernmentAssistanceOtherMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional funding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceLineItems" xlink:label="us-gaap_GovernmentAssistanceLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="us-gaap_GovernmentAssistanceLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceAmount" xlink:to="us-gaap_GovernmentAssistanceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Income, Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GovernmentAssistanceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant awarded, amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ReductionInResearchAndDevelopmentExpense" xlink:label="vstm_ReductionInResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ReductionInResearchAndDevelopmentExpense" xlink:to="vstm_ReductionInResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ReductionInResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The proceeds recorded as a reduction of research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ReductionInResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ReductionInResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction of research and development expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceAmountCumulativeCurrent" xlink:label="us-gaap_GovernmentAssistanceAmountCumulativeCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceAmountCumulativeCurrent" xlink:to="us-gaap_GovernmentAssistanceAmountCumulativeCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceAmountCumulativeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Asset, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GovernmentAssistanceAmountCumulativeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant, grants receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceLiabilityCurrent" xlink:label="us-gaap_GovernmentAssistanceLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceLiabilityCurrent" xlink:to="us-gaap_GovernmentAssistanceLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GovernmentAssistanceLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants, deferred liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:to="us-gaap_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Asset, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LetterOfCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Letter of credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember" xlink:label="vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember" xlink:to="vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to a lease agreement for office and laboratory space in Needham, Massachusetts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and Laboratory Space in Needham, Massachusetts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and Laboratory Space in Needham, Massachusetts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RestrictedCashAndCashEquivalentsNoncurrentMember" xlink:label="vstm_RestrictedCashAndCashEquivalentsNoncurrentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_RestrictedCashAndCashEquivalentsNoncurrentMember" xlink:to="vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents, Noncurrent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents, Noncurrent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashEquivalentsCurrent" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashEquivalentsCurrent" xlink:to="us-gaap_RestrictedCashEquivalentsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash Equivalent, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Realized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realized gains or losses on investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of investments in unrealized loss position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="us-gaap_ScheduleOfInvestmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_ScheduleOfInvestmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInvestmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Investments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CashAndMoneyMarketAccountsMember" xlink:label="vstm_CashAndMoneyMarketAccountsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_CashAndMoneyMarketAccountsMember" xlink:to="vstm_CashAndMoneyMarketAccountsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_CashAndMoneyMarketAccountsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents cash and money market accounts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_CashAndMoneyMarketAccountsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and money market accounts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_CashAndMoneyMarketAccountsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and money market accounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CorporateBondsAndCommercialPaperMember" xlink:label="vstm_CorporateBondsAndCommercialPaperMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_CorporateBondsAndCommercialPaperMember" xlink:to="vstm_CorporateBondsAndCommercialPaperMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_CorporateBondsAndCommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt security, in which the authorized issuer owes the holder a debt and is obliged to repay the principal and interest (the coupon) and unsecured promissory note (generally negotiable) that provides institutions with short-term funds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_CorporateBondsAndCommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate bonds and commercial paper</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Basis [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Portion at Fair Value Measurement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Investments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents &amp; restricted cash, Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate, cash flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate, notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMeasurementInput" xlink:label="us-gaap_LongTermDebtMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMeasurementInput" xlink:to="us-gaap_LongTermDebtMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, fair value</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount" xlink:label="vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount" xlink:to="vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Difference in the fair value between the face (par) amount of debt instrument at time of issuance and the current fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Difference in Fair Value to Carrying Value, Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Difference in fair value and principle amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Long-term debt, net of discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SecuraBioInc.Member" xlink:label="vstm_SecuraBioInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_SecuraBioInc.Member" xlink:to="vstm_SecuraBioInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_SecuraBioInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent the information pertaining to Secura Bio, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_SecuraBioInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secura</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Domain]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MajorCustomerMember" xlink:label="vstm_MajorCustomerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_MajorCustomerMember" xlink:to="vstm_MajorCustomerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_MajorCustomerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to major customer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_MajorCustomerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Customer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_MajorCustomerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major customer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract" xlink:label="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract" xlink:to="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of Credit Risk and Off Balance Sheet Risk [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of credit risk and off-balance sheet risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Financial Instruments, Off-balance Sheet Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Off-balance sheet concentrations of credit risk description</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfCustomers" xlink:label="vstm_NumberOfCustomers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_NumberOfCustomers" xlink:to="vstm_NumberOfCustomers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_NumberOfCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_NumberOfCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_NumberOfCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of customer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of trade accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets Held-for-use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment losses on long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostNetCurrent" xlink:label="us-gaap_CapitalizedContractCostNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNetCurrent" xlink:to="us-gaap_CapitalizedContractCostNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Contract Cost, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedContractCostNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized implementation costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAmortization" xlink:to="us-gaap_CapitalizedContractCostAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Contract Cost, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ChangeInCompanyOwnershipPercent" xlink:label="vstm_ChangeInCompanyOwnershipPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ChangeInCompanyOwnershipPercent" xlink:to="vstm_ChangeInCompanyOwnershipPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ChangeInCompanyOwnershipPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The change in the Company's ownership as a percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ChangeInCompanyOwnershipPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Company Ownership, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ChangeInCompanyOwnershipPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in ownership, percent</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesDisclosureTable" xlink:label="vstm_ProductRevenueReservesAndAllowancesDisclosureTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProductRevenueReservesAndAllowancesDisclosureTable" xlink:to="vstm_ProductRevenueReservesAndAllowancesDisclosureTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProductRevenueReservesAndAllowancesDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of product revenue reserves and allowances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProductRevenueReservesAndAllowancesDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Revenue Reserves And Allowances Disclosure [Table]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueAllowancesAndReservesTypeAxis" xlink:label="vstm_ProductRevenueAllowancesAndReservesTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProductRevenueAllowancesAndReservesTypeAxis" xlink:to="vstm_ProductRevenueAllowancesAndReservesTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProductRevenueAllowancesAndReservesTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information of product revenue reserves and allowances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProductRevenueAllowancesAndReservesTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Revenue Allowances And Reserves Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesDomain" xlink:label="vstm_ProductRevenueReservesAndAllowancesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProductRevenueReservesAndAllowancesDomain" xlink:to="vstm_ProductRevenueReservesAndAllowancesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProductRevenueReservesAndAllowancesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation and qualifying accounts and reserves.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProductRevenueReservesAndAllowancesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Revenue Reserves and Allowances [Domain]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember" xlink:label="vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember" xlink:to="vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for trade discounts and allowances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade discounts and allowances</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember" xlink:label="vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember" xlink:to="vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for third-party payer chargebacks, discounts and fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Party Payer chargebacks, discounts and fees</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember" xlink:label="vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember" xlink:to="vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for government rebates and other incentives.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government rebates and other incentives</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueAndAllowancesReturnsMember" xlink:label="vstm_ProductRevenueAndAllowancesReturnsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProductRevenueAndAllowancesReturnsMember" xlink:to="vstm_ProductRevenueAndAllowancesReturnsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProductRevenueAndAllowancesReturnsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for returns.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProductRevenueAndAllowancesReturnsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Returns</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems" xlink:label="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems" xlink:to="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Revenue Reserves And Allowance Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product revenue reserves and allowances</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowances" xlink:label="vstm_ProductRevenueReservesAndAllowances" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProductRevenueReservesAndAllowances" xlink:to="vstm_ProductRevenueReservesAndAllowances_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProductRevenueReservesAndAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of product revenue reserves and allowances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProductRevenueReservesAndAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Revenue Reserves and Allowances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="vstm_ProductRevenueReservesAndAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product revenue reserves and allowances at ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="vstm_ProductRevenueReservesAndAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product revenue reserves and allowances at beginning</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear" xlink:label="vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear" xlink:to="vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in product revenue reserves and allowances for provision related to sales in the current year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Revenue Reserves And Allowances Provision Related To Sales In Current Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision related to sales in the current year</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesDeductions" xlink:label="vstm_ProductRevenueReservesAndAllowancesDeductions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProductRevenueReservesAndAllowancesDeductions" xlink:to="vstm_ProductRevenueReservesAndAllowancesDeductions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProductRevenueReservesAndAllowancesDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of decrease in product revenue reserves and allowances for credits and payments made.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProductRevenueReservesAndAllowancesDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Revenue Reserves and Allowances, Deductions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="vstm_ProductRevenueReservesAndAllowancesDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credits and payments made</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryCurrentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Current [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Work in Process, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Work in process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Finished Goods, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired and in-licensed rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Remaining Amortization Period (Years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2029</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2030</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedClinicalTrialExpensesCurrent" xlink:label="vstm_AccruedClinicalTrialExpensesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_AccruedClinicalTrialExpensesCurrent" xlink:to="vstm_AccruedClinicalTrialExpensesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_AccruedClinicalTrialExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_AccruedClinicalTrialExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued clinical trial expenses, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_AccruedClinicalTrialExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued clinical trial expenses</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedMilestonePaymentsCurrent" xlink:label="vstm_AccruedMilestonePaymentsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_AccruedMilestonePaymentsCurrent" xlink:to="vstm_AccruedMilestonePaymentsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_AccruedMilestonePaymentsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for milestone payments. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_AccruedMilestonePaymentsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Milestone Payments, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_AccruedMilestonePaymentsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued milestone payments &amp; royalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation and related benefits</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedCommercializationCostsCurrent" xlink:label="vstm_AccruedCommercializationCostsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_AccruedCommercializationCostsCurrent" xlink:to="vstm_AccruedCommercializationCostsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_AccruedCommercializationCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for commercialization costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_AccruedCommercializationCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Commercialization Costs Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_AccruedCommercializationCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued commercialization costs</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedContractManufacturingExpensesCurrent" xlink:label="vstm_AccruedContractManufacturingExpensesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_AccruedContractManufacturingExpensesCurrent" xlink:to="vstm_AccruedContractManufacturingExpensesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_AccruedContractManufacturingExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for contract manufacturing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_AccruedContractManufacturingExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Contract Manufacturing Expenses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_AccruedContractManufacturingExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued contract manufacturing expenses</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="vstm_AccruedResearchAndDevelopmentExpensesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="vstm_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research And Development Expenses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued other research and development expenses</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedConsultingFeesCurrent" xlink:label="vstm_AccruedConsultingFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_AccruedConsultingFeesCurrent" xlink:to="vstm_AccruedConsultingFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_AccruedConsultingFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_AccruedConsultingFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Consulting Fees Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_AccruedConsultingFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued consulting fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_InitialSaleMember" xlink:label="vstm_InitialSaleMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_InitialSaleMember" xlink:to="vstm_InitialSaleMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_InitialSaleMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to initial sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_InitialSaleMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Sale [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_InitialSaleMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial sale</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember" xlink:label="vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember" xlink:to="vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to third sale, at the option of the Company, at any time prior to December 31, 2026, provided that trailing six-month worldwide net sales of avutometinib and defactinib are at least $55.0 million and subject to certain other customary conditions precedent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trailing 6 Months Worldwide Net Sales of Avutometinib And Defactinib, At Least $55 Million [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third sale, any time prior to December 31, 2026 (trailing six-month worldwide net sales of avutometinib and defactinib are at least $55.0 million)</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember" xlink:label="vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember" xlink:to="vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to first 8 quarters following the Note Purchase Agreement closing date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First 8 Quarters Following The Note Purchase Agreement Closing Date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First 8 Quarters following the Note Purchase Agreement Closing Date</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_First100MillionNetSalesOfEachIncludedProductMember" xlink:label="vstm_First100MillionNetSalesOfEachIncludedProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_First100MillionNetSalesOfEachIncludedProductMember" xlink:to="vstm_First100MillionNetSalesOfEachIncludedProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_First100MillionNetSalesOfEachIncludedProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to first $100 million net sales of each included product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_First100MillionNetSalesOfEachIncludedProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First $100 Million Net Sales Of Each Included Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_First100MillionNetSalesOfEachIncludedProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First $100 million net sales of each included product</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember" xlink:label="vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember" xlink:to="vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to purchased of full $150 million principal amount of Notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Of Full $150 Million Aggregate Principal Amount Of Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased of full $150 million aggregate principal amount of Notes</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RedemptionPriorToSecondAnniversaryMember" xlink:label="vstm_RedemptionPriorToSecondAnniversaryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_RedemptionPriorToSecondAnniversaryMember" xlink:to="vstm_RedemptionPriorToSecondAnniversaryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_RedemptionPriorToSecondAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to redemption prior to second anniversary of the Note Purchase Agreement Closing Date upon a Change of Control.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_RedemptionPriorToSecondAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption Prior To Second Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_RedemptionPriorToSecondAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption prior to second anniversary</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RedemptionPriorToThirdAnniversaryMember" xlink:label="vstm_RedemptionPriorToThirdAnniversaryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_RedemptionPriorToThirdAnniversaryMember" xlink:to="vstm_RedemptionPriorToThirdAnniversaryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_RedemptionPriorToThirdAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to redemption prior to third anniversary of the Note Purchase Agreement Closing Date upon a Change of Control.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_RedemptionPriorToThirdAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption Prior To Third Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_RedemptionPriorToThirdAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption prior to third anniversary</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RedemptionAfterYearThirdAnniversaryMember" xlink:label="vstm_RedemptionAfterYearThirdAnniversaryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_RedemptionAfterYearThirdAnniversaryMember" xlink:to="vstm_RedemptionAfterYearThirdAnniversaryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_RedemptionAfterYearThirdAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to redemption occurs after the third anniversary the Note Purchase Agreement Closing Date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_RedemptionAfterYearThirdAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption After Year Third Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_RedemptionAfterYearThirdAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption after third anniversary</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate principal amount of notes</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib" xlink:label="vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib" xlink:to="vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of worldwide net sales of Avutometinib and Defactinib.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Covenant, Worldwide Net Sales Of Avutometinib And Defactinib</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Worldwide net sales of avutobetinib and defactinib during trailing 6-months</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount drawn</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable rate (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis spread</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate" xlink:label="vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate" xlink:to="vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of additional interest rate for notes issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Interest Rate Stated, Percentage, Additional Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional interest rate (%)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_InterestDuePaidInKindPercentage" xlink:label="vstm_InterestDuePaidInKindPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_InterestDuePaidInKindPercentage" xlink:to="vstm_InterestDuePaidInKindPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_InterestDuePaidInKindPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of interest due paid-in-kind.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_InterestDuePaidInKindPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Due, Paid-In-Kind, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_InterestDuePaidInKindPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest due paid-in-kind (%)</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage" xlink:label="vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage" xlink:to="vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of additional interest rate at the event of default.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Increase In Interest Rate At The Event Of Default, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional increase in interest rate at event of default</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ParticipationInNetSalesPercentage" xlink:label="vstm_ParticipationInNetSalesPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ParticipationInNetSalesPercentage" xlink:to="vstm_ParticipationInNetSalesPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ParticipationInNetSalesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of participation in net sales of the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ParticipationInNetSalesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Participation In Net Sales, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ParticipationInNetSalesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Participation Percentage</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ParticipationInNetSalesSalesAmount" xlink:label="vstm_ParticipationInNetSalesSalesAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ParticipationInNetSalesSalesAmount" xlink:to="vstm_ParticipationInNetSalesSalesAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ParticipationInNetSalesSalesAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of sales to achieve in order to participate in participation percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ParticipationInNetSalesSalesAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Participation In Net Sales, Sales Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ParticipationInNetSalesSalesAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales amount</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt" xlink:label="vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt" xlink:to="vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate principal amount of debt to achieve in order to participate in participation percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Participation In Net Sales, Aggregate Principal Amount of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate principal amount of notes</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentNumberOfEqualInstallments" xlink:label="vstm_DebtInstrumentNumberOfEqualInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_DebtInstrumentNumberOfEqualInstallments" xlink:to="vstm_DebtInstrumentNumberOfEqualInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_DebtInstrumentNumberOfEqualInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equal installments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_DebtInstrumentNumberOfEqualInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Number Of Equal Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_DebtInstrumentNumberOfEqualInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equal installments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Redemption Price, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt redemption, percentage of principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="us-gaap_DebtInstrumentCovenantDescription" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCovenantDescription" xlink:to="us-gaap_DebtInstrumentCovenantDescription_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCovenantDescription_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Covenant Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCovenantDescription_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial covenants</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtIssuanceCosts" xlink:label="vstm_DebtIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_DebtIssuanceCosts" xlink:to="vstm_DebtIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_DebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of debt issuance costs incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_DebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_DebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of changes in the fair value of the Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning fair value balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value reported in statements of operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value reported in comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and revenue participation payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future principal payments</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LongTermDebtMaturityYearSix" xlink:label="vstm_LongTermDebtMaturityYearSix" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LongTermDebtMaturityYearSix" xlink:to="vstm_LongTermDebtMaturityYearSix_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LongTermDebtMaturityYearSix_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LongTermDebtMaturityYearSix_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Six</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_LongTermDebtMaturityYearSix_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2031</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LongTermDebtMaturityYearSeven" xlink:label="vstm_LongTermDebtMaturityYearSeven" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LongTermDebtMaturityYearSeven" xlink:to="vstm_LongTermDebtMaturityYearSeven_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LongTermDebtMaturityYearSeven_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in seventh fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LongTermDebtMaturityYearSeven_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Seven</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_LongTermDebtMaturityYearSeven_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2032</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LongTermDebtMaturitiesAggregatePrincipalDue" xlink:label="vstm_LongTermDebtMaturitiesAggregatePrincipalDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LongTermDebtMaturitiesAggregatePrincipalDue" xlink:to="vstm_LongTermDebtMaturitiesAggregatePrincipalDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LongTermDebtMaturitiesAggregatePrincipalDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate amount of principal debt due.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LongTermDebtMaturitiesAggregatePrincipalDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt Maturities Aggregate Principal Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="vstm_LongTermDebtMaturitiesAggregatePrincipalDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total principal payments</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LoanAndSecurityAgreementMember" xlink:label="vstm_LoanAndSecurityAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LoanAndSecurityAgreementMember" xlink:to="vstm_LoanAndSecurityAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for loan and security agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Agreement</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_TermLoanFacilityMember" xlink:label="vstm_TermLoanFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_TermLoanFacilityMember" xlink:to="vstm_TermLoanFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_TermLoanFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to term loan facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_TermLoanFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term loan</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_TermBLoanMember" xlink:label="vstm_TermBLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_TermBLoanMember" xlink:to="vstm_TermBLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_TermBLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Term B.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_TermBLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term B Loan</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_TermCLoanMember" xlink:label="vstm_TermCLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_TermCLoanMember" xlink:to="vstm_TermCLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_TermCLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Term C.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_TermCLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term C Loan</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_TermDLoanMember" xlink:label="vstm_TermDLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_TermDLoanMember" xlink:to="vstm_TermDLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_TermDLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Term D.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_TermDLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term D Loan</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_TermELoanMember" xlink:label="vstm_TermELoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_TermELoanMember" xlink:to="vstm_TermELoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_TermELoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Term E.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_TermELoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term E Loan</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember" xlink:label="vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember" xlink:to="vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to prepayments after the first anniversary and on or before the second anniversary date of loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">If prepaid after the first anniversary and on or before the second anniversary</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PrepaymentAfterSecondAnniversaryMember" xlink:label="vstm_PrepaymentAfterSecondAnniversaryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PrepaymentAfterSecondAnniversaryMember" xlink:to="vstm_PrepaymentAfterSecondAnniversaryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PrepaymentAfterSecondAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to prepayments after the second anniversary date of loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PrepaymentAfterSecondAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">If prepaid after the second anniversary</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentCurrentBorrowingCapacity" xlink:label="vstm_DebtInstrumentCurrentBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_DebtInstrumentCurrentBorrowingCapacity" xlink:to="vstm_DebtInstrumentCurrentBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_DebtInstrumentCurrentBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of current borrowing capacity under the debt facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_DebtInstrumentCurrentBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Current Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_DebtInstrumentCurrentBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable" xlink:to="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of regulatory milestone payments receivable under the License and collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License And Collaboration Agreements, Regulatory Milestone Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory milestone payments</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentPeriodToDrawLoanMinimum" xlink:label="vstm_DebtInstrumentPeriodToDrawLoanMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_DebtInstrumentPeriodToDrawLoanMinimum" xlink:to="vstm_DebtInstrumentPeriodToDrawLoanMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_DebtInstrumentPeriodToDrawLoanMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent the information pertaining to Debt Instrument Period to Draw Loan, Minimum.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_DebtInstrumentPeriodToDrawLoanMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Period to Draw Loan, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_DebtInstrumentPeriodToDrawLoanMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument period to draw loan, Minimum</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_GrossProductRevenueToBeAchieved" xlink:label="vstm_GrossProductRevenueToBeAchieved" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_GrossProductRevenueToBeAchieved" xlink:to="vstm_GrossProductRevenueToBeAchieved_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_GrossProductRevenueToBeAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of gross product revenue to be achieved to draw the loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_GrossProductRevenueToBeAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Product Revenue to be Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_GrossProductRevenueToBeAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross product revenue to be achieved</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentFinalPaymentFeePercentage" xlink:label="vstm_DebtInstrumentFinalPaymentFeePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_DebtInstrumentFinalPaymentFeePercentage" xlink:to="vstm_DebtInstrumentFinalPaymentFeePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_DebtInstrumentFinalPaymentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of final payment fee on original principal amount of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_DebtInstrumentFinalPaymentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Final Payment Fee, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_DebtInstrumentFinalPaymentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of final prepayment fee</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault" xlink:label="vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault" xlink:to="vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the additional interest rate in event of default.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Additional Interest Rate In Event Of Default</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional interest rate in an event of default</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfFinancialCovenants" xlink:label="vstm_NumberOfFinancialCovenants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_NumberOfFinancialCovenants" xlink:to="vstm_NumberOfFinancialCovenants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_NumberOfFinancialCovenants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of financial covenants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_NumberOfFinancialCovenants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Financial Covenants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_NumberOfFinancialCovenants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of financial covenants</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentAccruedInterestRate" xlink:label="vstm_DebtInstrumentAccruedInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_DebtInstrumentAccruedInterestRate" xlink:to="vstm_DebtInstrumentAccruedInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_DebtInstrumentAccruedInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of term Loans will accrue interest at a rate per annum during the existence of an event of default.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_DebtInstrumentAccruedInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Accrued Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_DebtInstrumentAccruedInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest rate</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RepaymentsOfLongTermDebtFinalPaymentFee" xlink:label="vstm_RepaymentsOfLongTermDebtFinalPaymentFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_RepaymentsOfLongTermDebtFinalPaymentFee" xlink:to="vstm_RepaymentsOfLongTermDebtFinalPaymentFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_RepaymentsOfLongTermDebtFinalPaymentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for final payment fee included in debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_RepaymentsOfLongTermDebtFinalPaymentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-Term Debt, Final Payment Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_RepaymentsOfLongTermDebtFinalPaymentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final payment fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for Debt Extinguishment or Debt Prepayment Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayment penalty fee</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RepaymentsOfLongTermDebtUnpaidInterest" xlink:label="vstm_RepaymentsOfLongTermDebtUnpaidInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_RepaymentsOfLongTermDebtUnpaidInterest" xlink:to="vstm_RepaymentsOfLongTermDebtUnpaidInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_RepaymentsOfLongTermDebtUnpaidInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for unpaid interest included in debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_RepaymentsOfLongTermDebtUnpaidInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-Term Debt, Unpaid Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_RepaymentsOfLongTermDebtUnpaidInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unpaid interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal loan balance</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentFinalPaymentFee" xlink:label="vstm_DebtInstrumentFinalPaymentFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_DebtInstrumentFinalPaymentFee" xlink:to="vstm_DebtInstrumentFinalPaymentFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_DebtInstrumentFinalPaymentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of final payment fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_DebtInstrumentFinalPaymentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Final Payment Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vstm_DebtInstrumentFinalPaymentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final Payment Fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount (Premium), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance costs, net of accretion</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ContractualInterestExpense" xlink:label="vstm_ContractualInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ContractualInterestExpense" xlink:to="vstm_ContractualInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ContractualInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the cost of borrowed funds accounted for as contractual interest expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ContractualInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ContractualInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of debt discount and issuance costs</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AmortizationOfFinalPaymentFee" xlink:label="vstm_AmortizationOfFinalPaymentFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_AmortizationOfFinalPaymentFee" xlink:to="vstm_AmortizationOfFinalPaymentFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_AmortizationOfFinalPaymentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of amortization expense attributable to Final Payment Fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_AmortizationOfFinalPaymentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Final Payment Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_AmortizationOfFinalPaymentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Final Payment Fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of Real Estate Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of space</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Lease Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Information - Operating Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash flows paid for amounts included in measurement of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining lease term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity Analysis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Present value discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity compensation plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantMember" xlink:label="vstm_PreFundedWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PreFundedWarrantMember" xlink:to="vstm_PreFundedWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PreFundedWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PreFundedWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-Funded Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PreFundedWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_InducementAwardProgramMember" xlink:label="vstm_InducementAwardProgramMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_InducementAwardProgramMember" xlink:to="vstm_InducementAwardProgramMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_InducementAwardProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents about inducement award program established in accordance with NASDAQ Listing Rule 5635(c)(4).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_InducementAwardProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inducement Award Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_InducementAwardProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inducement Award Program</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AtMarketEquityOfferingProgramMember" xlink:label="vstm_AtMarketEquityOfferingProgramMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_AtMarketEquityOfferingProgramMember" xlink:to="vstm_AtMarketEquityOfferingProgramMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_AtMarketEquityOfferingProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the at-the-market equity offering program of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_AtMarketEquityOfferingProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At-the-market equity offering program</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_BiotechnologyValueFundMember" xlink:label="vstm_BiotechnologyValueFundMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_BiotechnologyValueFundMember" xlink:to="vstm_BiotechnologyValueFundMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_BiotechnologyValueFundMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Biotechnology Value Fund.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_BiotechnologyValueFundMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Biotechnology Value Fund [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_BiotechnologyValueFundMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BVF</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfVotesPerEachShareOfCommonStock" xlink:label="vstm_NumberOfVotesPerEachShareOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_NumberOfVotesPerEachShareOfCommonStock" xlink:to="vstm_NumberOfVotesPerEachShareOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_NumberOfVotesPerEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of votes entitled per each share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_NumberOfVotesPerEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Votes Per Each Share of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_NumberOfVotesPerEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes entitled for each share of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram" xlink:label="vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram" xlink:to="vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum value of common stock able to be offered and sold through the market equity offering program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Value Of Common Stock Offered Through Market Equity Offering Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum value of common stock allowed to be sold</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProceedsFromIssuanceOfCommonStockNet" xlink:label="vstm_ProceedsFromIssuanceOfCommonStockNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProceedsFromIssuanceOfCommonStockNet" xlink:to="vstm_ProceedsFromIssuanceOfCommonStockNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProceedsFromIssuanceOfCommonStockNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate cash inflow from the additional capital contribution to the entity, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProceedsFromIssuanceOfCommonStockNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Common Stock, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ProceedsFromIssuanceOfCommonStockNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuance of stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of stock, shares converted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued on conversion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares issued upon conversion</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConversionOfPreferredStockConversionBlockerPercent" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ConversionOfPreferredStockConversionBlockerPercent" xlink:to="vstm_ConversionOfPreferredStockConversionBlockerPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percent of conversion blocker for conversion of shares into common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Preferred Stock, Conversion Blocker, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock, conversion blocker, percent</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice" xlink:to="vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percent of conversion blocker for conversion of shares into common stock, upon giving notice.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Preferred Stock, Conversion Blocker, Percent, Upon Giving Notice</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Conversion Blocker for conversion of shares into common stock, upon giving notice</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod" xlink:to="vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of notice to be given for increase in conversion blocker amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Preferred Stock, Conversion Blocker, Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion Blocker notice period for conversion of shares</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_WarrantAbstract" xlink:label="vstm_WarrantAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_WarrantAbstract" xlink:to="vstm_WarrantAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_WarrantAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_WarrantAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_WarrantAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock warrants can purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of common stock in the warrant issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of shares of common stock in the warrant issued (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Overallotment Option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital stock</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares" xlink:label="vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares" xlink:to="vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum number of share that can be purchased pursuant to the option under the stock transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock, Option To Purchase, Maximum Number Of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option to purchase, maximum number of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale price of the Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling price per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod" xlink:label="vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod" xlink:to="vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of notice to be given for increase/decrease in the maximum percentage of shares owned by any holder to exercise warrants or pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Or Pre-Funded Warrant Election To Exercise Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of notice for ownership limitation</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" xlink:label="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" xlink:to="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage held to the total shares outstanding to exercise warrants or pre-funded warrants at election of the holder.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Percentage Held To The Shares Outstanding To Exercise Warrants Or Pre-funded Warrants At Election Of The Holder</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold percentage held to the shares outstanding at election of the holder</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockPurchaseAgreementMember" xlink:label="vstm_StockPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_StockPurchaseAgreementMember" xlink:to="vstm_StockPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_StockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Stock Purchase Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_StockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_StockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock purchase agreement</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockPurchaseRightPeriod" xlink:label="vstm_StockPurchaseRightPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_StockPurchaseRightPeriod" xlink:to="vstm_StockPurchaseRightPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_StockPurchaseRightPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period up to which investors can exercise the stock purchase right.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_StockPurchaseRightPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Right, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_StockPurchaseRightPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock purchase period</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockPurchaseRightMaximumAmount" xlink:label="vstm_StockPurchaseRightMaximumAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_StockPurchaseRightMaximumAmount" xlink:to="vstm_StockPurchaseRightMaximumAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_StockPurchaseRightMaximumAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount under the stock purchase agreement purchased by investors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_StockPurchaseRightMaximumAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Right, Maximum Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_StockPurchaseRightMaximumAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock purchase, maximum amount</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_July2024PublicOfferingMember" xlink:label="vstm_July2024PublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_July2024PublicOfferingMember" xlink:to="vstm_July2024PublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_July2024PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 2024 public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_July2024PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 2024 Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_July2024PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 2024 Public Offering</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_UnderwritingAgreementMember" xlink:label="vstm_UnderwritingAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_UnderwritingAgreementMember" xlink:to="vstm_UnderwritingAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_UnderwritingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for underwriting agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_UnderwritingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting Agreement</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PublicMember" xlink:label="vstm_PublicMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PublicMember" xlink:to="vstm_PublicMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PublicMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent the information pertaining to general members of the public.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PublicMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share of exercisable warrant</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants" xlink:label="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants" xlink:to="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold percentage held to the total shares outstanding to exercise warrants or pre-funded warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Percentage Held To The Shares Outstanding To Exercise Warrants Or Pre-funded Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold percentage held to the shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant outstanding</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock" xlink:label="vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock" xlink:to="vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash inflow from  issuance of rights to purchase common shares and additional capital contribution to the entity from issuances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Warrants And Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of warrants and common stock</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CommonStockSharesOffered" xlink:label="vstm_CommonStockSharesOffered" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_CommonStockSharesOffered" xlink:to="vstm_CommonStockSharesOffered_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_CommonStockSharesOffered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of common shares offered by the Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_CommonStockSharesOffered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Offered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_CommonStockSharesOffered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares, offered</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage" xlink:label="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage" xlink:to="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum amount of common shares that can be owned by any holder as a percentage that would prevent the exercise of any warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Amount of Common Stock Owned by Holder, Exercise of Pre Funded Warrants, as a Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of common stock owned, as a percentage, that would prevent exercise</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantElectionToExerciseNoticePeriod" xlink:label="vstm_PreFundedWarrantElectionToExerciseNoticePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PreFundedWarrantElectionToExerciseNoticePeriod" xlink:to="vstm_PreFundedWarrantElectionToExerciseNoticePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PreFundedWarrantElectionToExerciseNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of notice to be given for increase/decrease in the maximum amount of shares owned by any holder.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PreFundedWarrantElectionToExerciseNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre Funded Warrant, Election to Exercise, Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PreFundedWarrantElectionToExerciseNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Days of notice for increase/decrease to maximum percentage owned</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage" xlink:label="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage" xlink:to="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum amount of common shares that can be owned by any holder as a percentage that would prevent the exercise of any warrants. By the holder's election, this amount can be increased or decrease but cannot exceed 19.99%.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Amount of Common Stock Owned by Holder, Exercise of Pre Funded Warrants, Maximum Allowable Increase, as a Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upper limit of maximum amount of common stock owned by a holder, as a percentage</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantsWarrantsOutstanding" xlink:label="vstm_PreFundedWarrantsWarrantsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PreFundedWarrantsWarrantsOutstanding" xlink:to="vstm_PreFundedWarrantsWarrantsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PreFundedWarrantsWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of pre-funded warrants outstanding. Warrants represent the right to buy a stock at a specific price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PreFundedWarrantsWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-Funded Warrants, Warrants Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PreFundedWarrantsWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private placement</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockConvertibleAggregateSharesToBeSold" xlink:label="vstm_PreferredStockConvertibleAggregateSharesToBeSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PreferredStockConvertibleAggregateSharesToBeSold" xlink:to="vstm_PreferredStockConvertibleAggregateSharesToBeSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PreferredStockConvertibleAggregateSharesToBeSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate number of convertible preferred shares to be sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PreferredStockConvertibleAggregateSharesToBeSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Aggregate Shares To Be Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PreferredStockConvertibleAggregateSharesToBeSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate shares to be sold</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockIssueNumberOfTranches" xlink:label="vstm_PreferredStockIssueNumberOfTranches" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PreferredStockIssueNumberOfTranches" xlink:to="vstm_PreferredStockIssueNumberOfTranches_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PreferredStockIssueNumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of tranches in which the preferred shares are sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PreferredStockIssueNumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Issue, Number of Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PreferredStockIssueNumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of tranches</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockIssuanceThresholdSharePrice" xlink:label="vstm_PreferredStockIssuanceThresholdSharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PreferredStockIssuanceThresholdSharePrice" xlink:to="vstm_PreferredStockIssuanceThresholdSharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PreferredStockIssuanceThresholdSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price of the entity's common stock which would be required to be attained for issuance of preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PreferredStockIssuanceThresholdSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Issuance, Threshold Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PreferredStockIssuanceThresholdSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold share price</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockIssuanceExpectedClosingPeriod" xlink:label="vstm_PreferredStockIssuanceExpectedClosingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PreferredStockIssuanceExpectedClosingPeriod" xlink:to="vstm_PreferredStockIssuanceExpectedClosingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PreferredStockIssuanceExpectedClosingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The expected closing period of second tranche of issuance of preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PreferredStockIssuanceExpectedClosingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Issuance, Expected Closing Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PreferredStockIssuanceExpectedClosingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected closing period of issuance</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche" xlink:label="vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche" xlink:to="vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of issuance of shares in second tranche, after closing first tranche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of Stock Issuance In Second Tranche After Closing First Tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issue period</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockIssuanceThresholdAggregateTradingVolume" xlink:label="vstm_PreferredStockIssuanceThresholdAggregateTradingVolume" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PreferredStockIssuanceThresholdAggregateTradingVolume" xlink:to="vstm_PreferredStockIssuanceThresholdAggregateTradingVolume_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PreferredStockIssuanceThresholdAggregateTradingVolume_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold trading volume of stock for preferred stock issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PreferredStockIssuanceThresholdAggregateTradingVolume_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Issuance, Threshold Aggregate Trading Volume</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PreferredStockIssuanceThresholdAggregateTradingVolume_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold trading volume</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockIssuanceThresholdTradingDays" xlink:label="vstm_PreferredStockIssuanceThresholdTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PreferredStockIssuanceThresholdTradingDays" xlink:to="vstm_PreferredStockIssuanceThresholdTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PreferredStockIssuanceThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold number of specified trading days that common stock price to conversion price of convertible preferred stock must exceed threshold percentage within a specified consecutive trading period for issuance of preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PreferredStockIssuanceThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Issuance, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PreferredStockIssuanceThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading days</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Liquidation Preference Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidation preference per share</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfPreferredStockConvertibleIntoCommonStock" xlink:label="vstm_NumberOfPreferredStockConvertibleIntoCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_NumberOfPreferredStockConvertibleIntoCommonStock" xlink:to="vstm_NumberOfPreferredStockConvertibleIntoCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_NumberOfPreferredStockConvertibleIntoCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of preferred stock that are convertible into common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_NumberOfPreferredStockConvertibleIntoCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Preferred Stock, Convertible into Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_NumberOfPreferredStockConvertibleIntoCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of preferred stock converted into common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Shares Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable upon conversion</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SecondTrancheRightLiabilityNonCurrentFairValue" xlink:label="vstm_SecondTrancheRightLiabilityNonCurrentFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_SecondTrancheRightLiabilityNonCurrentFairValue" xlink:to="vstm_SecondTrancheRightLiabilityNonCurrentFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_SecondTrancheRightLiabilityNonCurrentFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of fair value of non current portion of second tranche right classified as liability as at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_SecondTrancheRightLiabilityNonCurrentFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Tranche Right Liability, Non Current, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_SecondTrancheRightLiabilityNonCurrentFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of the Second Tranche Right</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockTrancheLiability" xlink:label="vstm_PreferredStockTrancheLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PreferredStockTrancheLiability" xlink:to="vstm_PreferredStockTrancheLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PreferredStockTrancheLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of liabilities classified as preferred stock tranche liability, due after one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PreferredStockTrancheLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock tranche liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PreferredStockTrancheLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock tranche liability</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability" xlink:label="vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability" xlink:to="vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of market to market adjustment under change in fair value of preferred stock tranche liability as during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Market to Market Adjustment of Preferred Stock Tranche Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mark-to-market adjustment under change in fair value of preferred stock tranche liability</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CantorFitzgeraldCo.Member" xlink:label="vstm_CantorFitzgeraldCo.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_CantorFitzgeraldCo.Member" xlink:to="vstm_CantorFitzgeraldCo.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_CantorFitzgeraldCo.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Cantor Fitzgerald &amp; Co. which entity has entered into an underwriting agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_CantorFitzgeraldCo.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cantor</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SellingGeneralAndAdministrativeExpenseMember" xlink:label="vstm_SellingGeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_SellingGeneralAndAdministrativeExpenseMember" xlink:to="vstm_SellingGeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_SellingGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption encompassing selling and general and administrative expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_SellingGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_SellingGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EquityIncentivePlan2021Member" xlink:label="vstm_EquityIncentivePlan2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_EquityIncentivePlan2021Member" xlink:to="vstm_EquityIncentivePlan2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_EquityIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to 2021 equity incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_EquityIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_EquityIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Plan</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IncentivePlan2012Member" xlink:label="vstm_IncentivePlan2012Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_IncentivePlan2012Member" xlink:to="vstm_IncentivePlan2012Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_IncentivePlan2012Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the 2012 Incentive Plan of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_IncentivePlan2012Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incentive Plan 2012 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_IncentivePlan2012Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2012 Plan</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EmployeeAndNonEmployeesStockOptionMember" xlink:label="vstm_EmployeeAndNonEmployeesStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_EmployeeAndNonEmployeesStockOptionMember" xlink:to="vstm_EmployeeAndNonEmployeesStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_EmployeeAndNonEmployeesStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_EmployeeAndNonEmployeesStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfEquityCompensationPlans" xlink:label="vstm_NumberOfEquityCompensationPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_NumberOfEquityCompensationPlans" xlink:to="vstm_NumberOfEquityCompensationPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_NumberOfEquityCompensationPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of equity compensation plans of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_NumberOfEquityCompensationPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Equity Compensation Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_NumberOfEquityCompensationPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equity compensation plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares reserved</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional number of shares reserved</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/cancelled (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/cancelled (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for future issuance</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" xlink:to="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the annual increase in the maximum number of shares (or other type of equity) that was initially approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation, Arrangement by Share Based Payment Award, Annual Increase in Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual increase in number of shares reserved</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved" xlink:to="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of the number of shares of outstanding stock relating to determining the annual increase in the maximum number of shares available for issuance under the plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation, Arrangement by Share Based Payment Award, Percentage of Outstanding Common Stock for Computation of Annual Increase in Number of Shares Reserved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of outstanding shares of common stock used to compute annual increase in number of shares reserved</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expired (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares expired</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ReductionOfSharesAvailableForIssuance" xlink:label="vstm_ReductionOfSharesAvailableForIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ReductionOfSharesAvailableForIssuance" xlink:to="vstm_ReductionOfSharesAvailableForIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ReductionOfSharesAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction of shares available for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ReductionOfSharesAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction of Shares Available For Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ReductionOfSharesAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction of shares available for issuance</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockOptionExchangeProgramMember" xlink:label="vstm_StockOptionExchangeProgramMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_StockOptionExchangeProgramMember" xlink:to="vstm_StockOptionExchangeProgramMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_StockOptionExchangeProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the stock option exchange program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_StockOptionExchangeProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Exchange Program</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One Year From Vesting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One year from vesting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Successive Three-Month Periods After One Year From Vesting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Successive three-month periods after one year from vesting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested at the end of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average exercise price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised/Released (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/cancelled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expired (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested at the end of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award, Options Weighted Average Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining contractual term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested at the end of the period</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award Options Aggregate Intrinsic Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period (in dollars)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested at the end of the period (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumptions used to estimate fair value of each stock-based award on the grant date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend yield (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional disclosures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant date fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of vested stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options exercised (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total unrecognized stock-based compensation expense (in dollars)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average recognition period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfEligibleStockholders" xlink:label="vstm_NumberOfEligibleStockholders" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_NumberOfEligibleStockholders" xlink:to="vstm_NumberOfEligibleStockholders_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_NumberOfEligibleStockholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of eligible stockholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_NumberOfEligibleStockholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Eligible Stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_NumberOfEligibleStockholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of eligible stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of new options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One Year Anniversary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One year anniversary</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationAwardTrancheFourMember" xlink:label="vstm_ShareBasedCompensationAwardTrancheFourMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ShareBasedCompensationAwardTrancheFourMember" xlink:to="vstm_ShareBasedCompensationAwardTrancheFourMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ShareBasedCompensationAwardTrancheFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fourth portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ShareBasedCompensationAwardTrancheFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Within Two Years of Vesting Commencement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ShareBasedCompensationAwardTrancheFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Within two years for vesting commencement</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedPaymentArrangementTrancheFiveMember" xlink:label="vstm_ShareBasedPaymentArrangementTrancheFiveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ShareBasedPaymentArrangementTrancheFiveMember" xlink:to="vstm_ShareBasedPaymentArrangementTrancheFiveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ShareBasedPaymentArrangementTrancheFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fifth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ShareBasedPaymentArrangementTrancheFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ShareBasedPaymentArrangementTrancheFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First three anniversaries of grant date</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" xlink:label="vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" xlink:to="vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares of entity's common stock the holder to receive when the restricted stock unit vests.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Shares Common Stock Holder To Receive When Restricted Stock Unit Vests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares holder to receive when RSU vests</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits" xlink:label="vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits" xlink:to="vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of installments for vesting of restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Installments For Vesting Of Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of installments</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfAnniversariesForVestingRestrictedStockUnits" xlink:label="vstm_NumberOfAnniversariesForVestingRestrictedStockUnits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_NumberOfAnniversariesForVestingRestrictedStockUnits" xlink:to="vstm_NumberOfAnniversariesForVestingRestrictedStockUnits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_NumberOfAnniversariesForVestingRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of anniversaries for vesting for restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_NumberOfAnniversariesForVestingRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Anniversaries For Vesting Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_NumberOfAnniversariesForVestingRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of anniversaries</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of shares vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant date fair value per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/cancelled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of common stock at market price to be purchased</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods" xlink:to="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of vesting periods which employees have right to exercise an award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Award Vesting Periods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of vesting periods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reportable segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Domain]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember" xlink:label="vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember" xlink:to="vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Research, developing and commercialization drugs segment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research, Developing And Commercialization Drugs Segment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research, developing and commercialization drugs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense" xlink:label="vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense" xlink:to="vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenditure incurred towards research and development expense excluding non-cash stock-based compensation and severance expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense, Excluding Non-Cash Stock-Based Compensation And Severance Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CommercialExpenditure" xlink:label="vstm_CommercialExpenditure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_CommercialExpenditure" xlink:to="vstm_CommercialExpenditure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_CommercialExpenditure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenditure incurred towards commercial expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_CommercialExpenditure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Expenditure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_CommercialExpenditure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial expenses</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MedicalAffairExpenditure" xlink:label="vstm_MedicalAffairExpenditure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_MedicalAffairExpenditure" xlink:to="vstm_MedicalAffairExpenditure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_MedicalAffairExpenditure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenditure incurred towards medical affairs expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_MedicalAffairExpenditure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medical Affair Expenditure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_MedicalAffairExpenditure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medical affairs expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Other Segment Item, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other segment items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Other Segment Item, Composition, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment reporting, other segment items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total potentially dilutive securities (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and collaboration agreements</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra" xlink:to="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of regulatory milestone payments receivable up on approval received from the approval of COPIKTRA in the United States for the treatment of peripheral T-cell lymphoma under the License and collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License And Collaboration Agreements, Regulatory Milestone Payments Receivable Upon Approval Of COPIKTRA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments receivable upon approval of COPIKTRA</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current income tax expense:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Federal Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of effective income tax rate to the statutory federal income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in the valuation allowance</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount" xlink:to="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in fair value of warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Fair Value Of Warrant Liability, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xlink:label="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xlink:to="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Jurisdiction of Domicile [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of effective income tax rate to the statutory federal income tax rate (in percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US federal statutory rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and local income tax benefit, net of federal benefit (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development tax credits (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in the valuation allowance (as a percent)</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent" xlink:to="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in fair value of warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Fair Value Of Warrant Liability, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liability (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent items (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax law change (as a percent)</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent" xlink:to="vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to net operating loss and tax credit carryforwards expiration under section 382.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Operating Loss Tax Credit Carryforwards Expiration, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL and tax credit expiration under Section 382 (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Capitalized Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxAssetsInstallmentSale" xlink:label="vstm_DeferredTaxAssetsInstallmentSale" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_DeferredTaxAssetsInstallmentSale" xlink:to="vstm_DeferredTaxAssetsInstallmentSale_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_DeferredTaxAssetsInstallmentSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from installment sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_DeferredTaxAssetsInstallmentSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Installment Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_DeferredTaxAssetsInstallmentSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Installment sale</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxAssetsLeaseLiability" xlink:label="vstm_DeferredTaxAssetsLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_DeferredTaxAssetsLeaseLiability" xlink:to="vstm_DeferredTaxAssetsLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="vstm_DeferredTaxLiabilitiesRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="vstm_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Right of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="vstm_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance" xlink:label="vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance" xlink:to="vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax assets net of deferred tax liabilities before valuation allowance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Net Of Deferred Tax Liabilities Before Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax asset prior to valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional disclosures</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod" xlink:label="vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod" xlink:to="vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period over which the entity will amortize the capitalized research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Research and Development Expenses, Amortization Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Change in Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OperatingLossCarryforwardsPriorToOwnershipChanges" xlink:label="vstm_OperatingLossCarryforwardsPriorToOwnershipChanges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_OperatingLossCarryforwardsPriorToOwnershipChanges" xlink:to="vstm_OperatingLossCarryforwardsPriorToOwnershipChanges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_OperatingLossCarryforwardsPriorToOwnershipChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws, generated before ownership changes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_OperatingLossCarryforwardsPriorToOwnershipChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Prior to Ownership Changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_OperatingLossCarryforwardsPriorToOwnershipChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL carryforward prior to ownership changes</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges" xlink:label="vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges" xlink:to="vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws, inclusive of ownership changes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Inclusive of Ownership Changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL carryforward inclusive of ownership changes</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OperatingLossCarryforwardsSection382Limitation" xlink:label="vstm_OperatingLossCarryforwardsSection382Limitation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_OperatingLossCarryforwardsSection382Limitation" xlink:to="vstm_OperatingLossCarryforwardsSection382Limitation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_OperatingLossCarryforwardsSection382Limitation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under Section 382.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_OperatingLossCarryforwardsSection382Limitation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Section 382 Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_OperatingLossCarryforwardsSection382Limitation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL carryforwards Section 382 limitations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and penalties accrued related to unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability for Uncertainty in Income Taxes, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability for uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL carryforwards</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OperatingLossCarryforwardsIndefinitePeriod" xlink:label="vstm_OperatingLossCarryforwardsIndefinitePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_OperatingLossCarryforwardsIndefinitePeriod" xlink:to="vstm_OperatingLossCarryforwardsIndefinitePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_OperatingLossCarryforwardsIndefinitePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws, which may be carried forward indefinitely.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_OperatingLossCarryforwardsIndefinitePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Indefinite Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_OperatingLossCarryforwardsIndefinitePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards, indefinite period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credits</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OfficeAndLaboratorySpaceLeaseArrangementMember" xlink:label="vstm_OfficeAndLaboratorySpaceLeaseArrangementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_OfficeAndLaboratorySpaceLeaseArrangementMember" xlink:to="vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the office and laboratory space lease arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and Laboratory Space in Needham, Massachusetts.</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccountsPayableCurrentMember" xlink:label="vstm_AccountsPayableCurrentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_AccountsPayableCurrentMember" xlink:to="vstm_AccountsPayableCurrentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_AccountsPayableCurrentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption encompassing accounts payable current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_AccountsPayableCurrentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IqviaIncMember" xlink:label="vstm_IqviaIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_IqviaIncMember" xlink:to="vstm_IqviaIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_IqviaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent the information pertaining to IQVIA, Inc. (IQVIA)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_IqviaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IQVIA Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_IqviaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IQVIA</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other commitments</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PfizerIncMember" xlink:label="vstm_PfizerIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PfizerIncMember" xlink:to="vstm_PfizerIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PfizerIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Pfizer Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PfizerIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PFIZER</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PfizerIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pfizer</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfFdaApprovalMember" xlink:label="vstm_AchievementOfFdaApprovalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_AchievementOfFdaApprovalMember" xlink:to="vstm_AchievementOfFdaApprovalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_AchievementOfFdaApprovalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to achievement of FDA approval milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_AchievementOfFdaApprovalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement Of FDA Approval [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_AchievementOfFdaApprovalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement of FDA approval</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfFdaApprovalAnniversaryMember" xlink:label="vstm_AchievementOfFdaApprovalAnniversaryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_AchievementOfFdaApprovalAnniversaryMember" xlink:to="vstm_AchievementOfFdaApprovalAnniversaryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_AchievementOfFdaApprovalAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to achievement of FDA approval anniversary milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_AchievementOfFdaApprovalAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement Of FDA Approval Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_AchievementOfFdaApprovalAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement of FDA approval anniversary</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" xlink:label="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" xlink:to="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to achievement of development and commercialization milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement Of Certain Development And Commercialization Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement of certain development and commercialization milestones</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfCertainSalesMilestonesMember" xlink:label="vstm_AchievementOfCertainSalesMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_AchievementOfCertainSalesMilestonesMember" xlink:to="vstm_AchievementOfCertainSalesMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_AchievementOfCertainSalesMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to achievement of sales milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_AchievementOfCertainSalesMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement Of Certain Sales Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_AchievementOfCertainSalesMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement of certain sales milestones</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CollaborativeArrangementsOneTimeCashPayment" xlink:label="vstm_CollaborativeArrangementsOneTimeCashPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_CollaborativeArrangementsOneTimeCashPayment" xlink:to="vstm_CollaborativeArrangementsOneTimeCashPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_CollaborativeArrangementsOneTimeCashPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the one-time cash payment made under the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_CollaborativeArrangementsOneTimeCashPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements One Time Cash Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_CollaborativeArrangementsOneTimeCashPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One-time cash payment</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PotentialMilestonePayments" xlink:label="vstm_PotentialMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PotentialMilestonePayments" xlink:to="vstm_PotentialMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PotentialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of milestone payments the Company may make.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PotentialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PotentialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential milestone payments</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CollaborativeArrangementsRoyaltyObligationsTerm" xlink:label="vstm_CollaborativeArrangementsRoyaltyObligationsTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_CollaborativeArrangementsRoyaltyObligationsTerm" xlink:to="vstm_CollaborativeArrangementsRoyaltyObligationsTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_CollaborativeArrangementsRoyaltyObligationsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the product's royalty obligations term that begin on the date of first commercial sale of the product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_CollaborativeArrangementsRoyaltyObligationsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements Royalty Obligations Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_CollaborativeArrangementsRoyaltyObligationsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty obligations term</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ExclusiveLicenseAgreementMember" xlink:label="vstm_ExclusiveLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ExclusiveLicenseAgreementMember" xlink:to="vstm_ExclusiveLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ExclusiveLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the exclusive license agreement entered into by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ExclusiveLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exclusive license agreement</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PursuantToLicenseAgreementMember" xlink:label="vstm_PursuantToLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_PursuantToLicenseAgreementMember" xlink:to="vstm_PursuantToLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_PursuantToLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to information pursuant to the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_PursuantToLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pursuant to License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_PursuantToLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pursuant to license agreement</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfPatents" xlink:label="vstm_NumberOfPatents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_NumberOfPatents" xlink:to="vstm_NumberOfPatents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_NumberOfPatents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of patents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_NumberOfPatents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Patents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_NumberOfPatents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementMember" xlink:label="vstm_LicenseAndCollaborationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseAndCollaborationAgreementMember" xlink:to="vstm_LicenseAndCollaborationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseAndCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for license and collaboration agreement for exclusive rights to develop and commercialize products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseAndCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_GenfleetTherapeuticsShanghaiIncMember" xlink:label="vstm_GenfleetTherapeuticsShanghaiIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_GenfleetTherapeuticsShanghaiIncMember" xlink:to="vstm_GenfleetTherapeuticsShanghaiIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_GenfleetTherapeuticsShanghaiIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent the information pertaining to Genfleet Therapeutics (Shanghai), Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_GenfleetTherapeuticsShanghaiIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genfleet</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Category of Item Purchased [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ExerciseOfAllThreeGenFleetOptionsMember" xlink:label="vstm_ExerciseOfAllThreeGenFleetOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ExerciseOfAllThreeGenFleetOptionsMember" xlink:to="vstm_ExerciseOfAllThreeGenFleetOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ExerciseOfAllThreeGenFleetOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to exercise of all 3 GenFleet options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ExerciseOfAllThreeGenFleetOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of All Three Gen Fleet Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ExerciseOfAllThreeGenFleetOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of All Three Gen Fleet Options</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementUpfrontPayment" xlink:label="vstm_LicenseAndCollaborationAgreementUpfrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseAndCollaborationAgreementUpfrontPayment" xlink:to="vstm_LicenseAndCollaborationAgreementUpfrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseAndCollaborationAgreementUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenses for non refundable up front payment for license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseAndCollaborationAgreementUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License And Collaboration Agreement Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_LicenseAndCollaborationAgreementUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments" xlink:label="vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments" xlink:to="vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount paid upon achievement of development milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License And Collaboration Agreements, Development Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for development milestone</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Purchase Commitment, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genfleet R&amp;D Support Fee</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable" xlink:label="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable" xlink:to="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of sales milestone receivable under the License and collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License And Collaboration Agreements, Sales Milestone Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestone receivable</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" xlink:label="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" xlink:to="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of threshold sale revenue to be achieved in order for the company to receive the sales milestone payments under the License and collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License And Collaboration Agreements, Threshold Sales To Trigger Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold sales to trigger milestone payments</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments" xlink:label="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments" xlink:to="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of threshold sale revenue to be achieved in order for the company to receive the royalty payments under the License and collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License And Collaboration Agreements, Threshold Sales To Trigger Royalty Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold sales to trigger royalty payments</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements" xlink:label="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements" xlink:to="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of royalty, milestone and sublicense revenue payments entitled to the company under the existing license and collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License And Collaboration Agreements, Percentage Of Royalty, Milestone And Sub Licensing Revenue Payments Entitled Under Existing License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of all royalty, milestone and sublicense revenue payments payable</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions" xlink:label="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions" xlink:to="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of royalties and milestone payments entitled under any license or sublicense agreements in certain jurisdictions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License And Collaboration Agreements, Percentage Of Royalty And Milestone Payments Entitled Under Certain Jurisdictions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of all royalty and milestone payments payable under certain jurisdictions</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement." xlink:label="vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement." xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement." xlink:to="vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement._lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement._lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number days of prior written notice to terminate the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement._lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Days of Prior Notice to Terminate Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement._lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days written prior notice required for other party to terminate agreement</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach" xlink:label="vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach" xlink:to="vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number days of written notice from either party to the agreement to terminate agreement for the other party's material breach if such party fails to cure the breach.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Days of Prior Notice, Termination, Fails to Cure Breach</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days written notice required to terminate agreement if fails to cure breach</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember" xlink:label="vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember" xlink:to="vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the scenario if sales exceeds $100 million.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Exceeds $100 Million</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember" xlink:label="vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember" xlink:to="vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the scenario if sales exceeds $200 million.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Exceeds $200 Million</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember" xlink:label="vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember" xlink:to="vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the scenario if sales exceeds $300 million.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Exceeds $300 Million</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale" xlink:to="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of regulatory milestone payments receivable up on approval received from the approval for commercial sale under the License and collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License And Collaboration Agreements, Regulatory Milestone Payments Receivable Upon Approval For Commercial Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments receivable upon approval for commercial sale</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived" xlink:label="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived" xlink:to="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of sales milestone received under the License and collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License And Collaboration Agreements, Sales Milestone Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestone received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Short-Term Debt [Table]</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FirstInsuranceFundingMember" xlink:label="vstm_FirstInsuranceFundingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_FirstInsuranceFundingMember" xlink:to="vstm_FirstInsuranceFundingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_FirstInsuranceFundingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to First Insurance Funding ("First Insurance").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_FirstInsuranceFundingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Insurance Funding [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_FirstInsuranceFundingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Insurance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Debt [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Short-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Periodic Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Monthly payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Note Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Cost Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contributions made under 401(k) plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationRollForward" xlink:label="us-gaap_SupplierFinanceProgramObligationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierFinanceProgramObligationRollForward" xlink:to="us-gaap_SupplierFinanceProgramObligationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierFinanceProgramObligationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplier Finance Program, Obligation [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligation" xlink:label="us-gaap_SupplierFinanceProgramObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierFinanceProgramObligation" xlink:to="us-gaap_SupplierFinanceProgramObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierFinanceProgramObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplier Finance Program, Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SupplierFinanceProgramObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplierFinanceProgramObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vendor financing arrangement liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" xlink:to="us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:label="vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:to="vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exercised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>vstm-20251231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/4/2026 8:56:24 PM-->
<!--Modified on: 3/4/2026 8:56:24 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.verastem.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.verastem.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" roleURI="http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" roleURI="http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureNatureOfBusiness" roleURI="http://www.verastem.com/role/DisclosureNatureOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureProductRevenueReservesAndAllowances" roleURI="http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowances" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureInventory" roleURI="http://www.verastem.com/role/DisclosureInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIntangibleAssets" roleURI="http://www.verastem.com/role/DisclosureIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.verastem.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureAccruedExpenses" roleURI="http://www.verastem.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLongTermDebt" roleURI="http://www.verastem.com/role/DisclosureLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLeases" roleURI="http://www.verastem.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCapitalStock" roleURI="http://www.verastem.com/role/DisclosureCapitalStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSegmentReporting" roleURI="http://www.verastem.com/role/DisclosureSegmentReporting" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureNetLossPerShare" roleURI="http://www.verastem.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIncomeTaxes" roleURI="http://www.verastem.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.verastem.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLicenseCollaborationAndCommercialAgreements" roleURI="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureNotesPayable" roleURI="http://www.verastem.com/role/DisclosureNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureEmployeeBenefitPlan" roleURI="http://www.verastem.com/role/DisclosureEmployeeBenefitPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureVendorFinancingArrangement" roleURI="http://www.verastem.com/role/DisclosureVendorFinancingArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSubsequentEvents" roleURI="http://www.verastem.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesTables" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureProductRevenueReservesAndAllowancesTables" roleURI="http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureInventoryTables" roleURI="http://www.verastem.com/role/DisclosureInventoryTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIntangibleAssetsTables" roleURI="http://www.verastem.com/role/DisclosureIntangibleAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.verastem.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLongTermDebtTables" roleURI="http://www.verastem.com/role/DisclosureLongTermDebtTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLeasesTables" roleURI="http://www.verastem.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCapitalStockTables" roleURI="http://www.verastem.com/role/DisclosureCapitalStockTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSegmentReportingTables" roleURI="http://www.verastem.com/role/DisclosureSegmentReportingTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.verastem.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.verastem.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureNatureOfBusinessDetails" roleURI="http://www.verastem.com/role/DisclosureNatureOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureNatureOfBusinessReverseStockSplitDetails" roleURI="http://www.verastem.com/role/DisclosureNatureOfBusinessReverseStockSplitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSegmentAndGeographicInformationDetails" roleURI="http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentAndGeographicInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesCloudComputingImplementationCostsDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCloudComputingImplementationCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSignificantAccountingPoliciesIncomeTaxesDetails" roleURI="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureProductRevenueReservesAndAllowancesDetails" roleURI="http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureInventoryScheduleOfInventoryDetails" roleURI="http://www.verastem.com/role/DisclosureInventoryScheduleOfInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIntangibleAssetsDetails" roleURI="http://www.verastem.com/role/DisclosureIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" roleURI="http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails" roleURI="http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.verastem.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLongTermDebtNotePurchaseAgreementDetails" roleURI="http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails" roleURI="http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLongTermDebtFuturePrincipalPaymentsDetails" roleURI="http://www.verastem.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLongTermDebtLoanAgreementDetails" roleURI="http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails" roleURI="http://www.verastem.com/role/DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLongTermDebtScheduleOfInterestExpensesDetails" roleURI="http://www.verastem.com/role/DisclosureLongTermDebtScheduleOfInterestExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLeasesDetails" roleURI="http://www.verastem.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLeasesBalanceSheetAndOtherInformationDetails" roleURI="http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCapitalStockDetails" roleURI="http://www.verastem.com/role/DisclosureCapitalStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCapitalStockNovember2025PublicOfferingDetails" roleURI="http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCapitalStockApril2025PrivatePlacementDetails" roleURI="http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCapitalStockStockPurchaseAgreementDetails" roleURI="http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails" roleURI="http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCapitalStockConvertiblePreferredStockDetails" roleURI="http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCapitalStockAtMarketEquityOfferingProgramDetails" roleURI="http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureStockBasedCompensationStockBasedCompensationDetails" roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureStockBasedCompensationStockOptionsDetails" roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureStockBasedCompensationOptionExchangeProgramDetails" roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureStockBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" roleURI="http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSegmentReportingDetails" roleURI="http://www.verastem.com/role/DisclosureSegmentReportingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails" roleURI="http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails" roleURI="http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIncomeTaxesIncomeTaxExpenseDetails" roleURI="http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails" roleURI="http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" roleURI="http://www.verastem.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureIncomeTaxesTaxCreditsDetails" roleURI="http://www.verastem.com/role/DisclosureIncomeTaxesTaxCreditsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails" roleURI="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails" roleURI="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails" roleURI="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails" roleURI="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureNotesPayableDetails" roleURI="http://www.verastem.com/role/DisclosureNotesPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureEmployeeBenefitPlanDetails" roleURI="http://www.verastem.com/role/DisclosureEmployeeBenefitPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureVendorFinancingArrangementRollForwardDetails" roleURI="http://www.verastem.com/role/DisclosureVendorFinancingArrangementRollForwardDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vstm-20251231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.verastem.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.verastem.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_639082545815422528" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_639082545815422528" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_639082545815422528" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_639082545815422528" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_639082545815422528" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_639082545815422528" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_639082545815422528" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_639082545815422528" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_639082545815422528" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_639082545815422528" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_639082545815422528" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_639082545815422528" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_639082545815422528" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_639082545815422528" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_639082545815422528" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_639082545815422528" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_639082545815422528" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_639082545815422528" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_639082545815422528" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_639082545815422528" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_639082545815422528" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_639082545815422528" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_639082545815422528" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_639082545815422528" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_639082545815422528" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_639082545815422528" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_639082545815422528" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_639082545815422528" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_639082545815422528" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_639082545815422528" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_639082545815422528" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_639082545815422528" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_639082545815422528" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_639082545815422528" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_639082545815422528" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_639082545815422528" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_639082545815422528" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_639082545815422528" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_639082545815422528" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639082545815422528" xlink:to="us-gaap_StatementClassOfStockAxis_639082545815422528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639082545815422528" xlink:to="us-gaap_ClassOfStockDomain_639082545815422528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesBConvertiblePreferredStockMember" xlink:label="vstm_SeriesBConvertiblePreferredStockMember_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639082545815422528" xlink:to="vstm_SeriesBConvertiblePreferredStockMember_639082545815422528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639082545815422528" xlink:to="us-gaap_StatementLineItems_639082545815422528" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815422528" xlink:to="us-gaap_AssetsAbstract_639082545815422528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639082545815422528" xlink:to="us-gaap_AssetsCurrentAbstract_639082545815422528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639082545815422528" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639082545815422528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639082545815422528" xlink:to="us-gaap_AccountsReceivableNet_639082545815422528" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639082545815422528" xlink:to="us-gaap_InventoryNet_639082545815422528" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_GrantsReceivableNet" xlink:label="vstm_GrantsReceivableNet_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639082545815422528" xlink:to="vstm_GrantsReceivableNet_639082545815422528" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639082545815422528" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639082545815422528" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639082545815422528" xlink:to="us-gaap_AssetsCurrent_639082545815422528" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639082545815422528" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_639082545815422528" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639082545815422528" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_639082545815422528" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639082545815422528" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_639082545815422528" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639082545815422528" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_639082545815422528" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639082545815422528" xlink:to="us-gaap_OtherAssetsNoncurrent_639082545815422528" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639082545815422528" xlink:to="us-gaap_Assets_639082545815422528" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815422528" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639082545815422528" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639082545815422528" xlink:to="us-gaap_LiabilitiesCurrentAbstract_639082545815422528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639082545815422528" xlink:to="us-gaap_AccountsPayableCurrent_639082545815422528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639082545815422528" xlink:to="us-gaap_AccruedLiabilitiesCurrent_639082545815422528" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationCurrent" xlink:label="us-gaap_SupplierFinanceProgramObligationCurrent_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639082545815422528" xlink:to="us-gaap_SupplierFinanceProgramObligationCurrent_639082545815422528" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639082545815422528" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_639082545815422528" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639082545815422528" xlink:to="us-gaap_LiabilitiesCurrent_639082545815422528" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639082545815422528" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_639082545815422528" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_639082545815422528" xlink:to="us-gaap_SecuredLongTermDebt_639082545815422528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationNoncurrent" xlink:label="us-gaap_SupplierFinanceProgramObligationNoncurrent_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_639082545815422528" xlink:to="us-gaap_SupplierFinanceProgramObligationNoncurrent_639082545815422528" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_639082545815422528" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_639082545815422528" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_639082545815422528" xlink:to="us-gaap_WarrantsAndRightsOutstanding_639082545815422528" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_639082545815422528" xlink:to="us-gaap_Liabilities_639082545815422528" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConvertiblePreferredStockAbstract" xlink:label="vstm_ConvertiblePreferredStockAbstract_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639082545815422528" xlink:to="vstm_ConvertiblePreferredStockAbstract_639082545815422528" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:label="us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ConvertiblePreferredStockAbstract_639082545815422528" xlink:to="us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_639082545815422528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639082545815422528" xlink:to="us-gaap_StockholdersEquityAbstract_639082545815422528" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639082545815422528" xlink:to="us-gaap_PreferredStockValue_639082545815422528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639082545815422528" xlink:to="us-gaap_CommonStockValue_639082545815422528" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639082545815422528" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_639082545815422528" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639082545815422528" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_639082545815422528" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639082545815422528" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639082545815422528" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639082545815422528" xlink:to="us-gaap_StockholdersEquity_639082545815422528" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639082545815422528" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_639082545815422528" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_639082545815422528" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639082545815422528" xlink:to="us-gaap_StatementClassOfStockAxis_639082545815422528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639082545815422528" xlink:to="us-gaap_ClassOfStockDomain_639082545815422528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesaConvertiblePreferredStockMember" xlink:label="vstm_SeriesaConvertiblePreferredStockMember_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639082545815422528" xlink:to="vstm_SeriesaConvertiblePreferredStockMember_639082545815422528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesBConvertiblePreferredStockMember" xlink:label="vstm_SeriesBConvertiblePreferredStockMember_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639082545815422528" xlink:to="vstm_SeriesBConvertiblePreferredStockMember_639082545815422528" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639082545815422528" xlink:to="us-gaap_PreferredStockMember_639082545815422528" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639082545815422528" xlink:to="us-gaap_StatementLineItems_639082545815422528" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815422528" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_639082545815422528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815422528" xlink:to="us-gaap_PreferredStockSharesAuthorized_639082545815422528" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockSharesDesignated" xlink:label="vstm_PreferredStockSharesDesignated_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815422528" xlink:to="vstm_PreferredStockSharesDesignated_639082545815422528" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_639082545815422528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815422528" xlink:to="us-gaap_PreferredStockSharesIssued_639082545815422528" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815422528" xlink:to="us-gaap_PreferredStockSharesOutstanding_639082545815578159" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815422528" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639082545815578159" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815422528" xlink:to="us-gaap_CommonStockSharesAuthorized_639082545815578159" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815422528" xlink:to="us-gaap_CommonStockSharesIssued_639082545815578159" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815422528" xlink:to="us-gaap_CommonStockSharesOutstanding_639082545815578159" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable_639082545815578159" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639082545815578159" xlink:to="srt_ProductOrServiceAxis_639082545815578159" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_639082545815578159" xlink:to="srt_ProductsAndServicesDomain_639082545815578159" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639082545815578159" xlink:to="us-gaap_ProductMember_639082545815578159" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CopiktraLicenseAndRelatedAssetsMember" xlink:label="vstm_CopiktraLicenseAndRelatedAssetsMember_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639082545815578159" xlink:to="vstm_CopiktraLicenseAndRelatedAssetsMember_639082545815578159" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639082545815578159" xlink:to="us-gaap_StatementLineItems_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_RevenuesAbstract_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_639082545815578159" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_639082545815578159" xlink:to="us-gaap_Revenues_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_CostsAndExpensesAbstract_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CostOfGoodsSoldExcludingAmortization" xlink:label="vstm_CostOfGoodsSoldExcludingAmortization_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545815578159" xlink:to="vstm_CostOfGoodsSoldExcludingAmortization_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545815578159" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545815578159" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639082545815578159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545815578159" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_639082545815578159" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_CostsAndExpenses_639082545815578159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_OperatingIncomeLoss_639082545815578159" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_639082545815578159" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_InvestmentIncomeInterest_639082545815578159" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_InterestExpense_639082545815578159" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_639082545815578159" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IncomeLossFromPreferredStockTrancheLiability" xlink:label="vstm_IncomeLossFromPreferredStockTrancheLiability_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="vstm_IncomeLossFromPreferredStockTrancheLiability_639082545815578159" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639082545815578159" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotes" xlink:label="vstm_FairValueAdjustmentOfNotes_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="vstm_FairValueAdjustmentOfNotes_639082545815578159" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639082545815578159" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639082545815578159" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_NetIncomeLoss_639082545815578159" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_EarningsPerShareBasic_639082545815578159" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_EarningsPerShareDiluted_639082545815578159" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639082545815578159" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639082545815578159" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_6390825458155781591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_NetIncomeLoss_6390825458155781591" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_639082545815578159" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" xlink:label="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_639082545815578159" order="21" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_639082545815578159" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_639082545815578159" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639082545815578159" xlink:to="us-gaap_StatementEquityComponentsAxis_639082545815578159" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639082545815578159" xlink:to="us-gaap_PreferredStockMember_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639082545815578159" xlink:to="us-gaap_CommonStockMember_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639082545815578159" xlink:to="us-gaap_AdditionalPaidInCapitalMember_639082545815578159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639082545815578159" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_639082545815578159" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639082545815578159" xlink:to="us-gaap_RetainedEarningsMember_639082545815578159" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639082545815578159" xlink:to="us-gaap_EquityComponentDomain_639082545815578159" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639082545815578159" xlink:to="us-gaap_StatementClassOfStockAxis_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesBConvertiblePreferredStockMember" xlink:label="vstm_SeriesBConvertiblePreferredStockMember_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639082545815578159" xlink:to="vstm_SeriesBConvertiblePreferredStockMember_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesaConvertiblePreferredStockMember" xlink:label="vstm_SeriesaConvertiblePreferredStockMember_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639082545815578159" xlink:to="vstm_SeriesaConvertiblePreferredStockMember_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639082545815578159" xlink:to="us-gaap_ClassOfStockDomain_639082545815578159" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639082545815578159" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639082545815578159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_November2025PublicOfferingMember" xlink:label="vstm_November2025PublicOfferingMember_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639082545815578159" xlink:to="vstm_November2025PublicOfferingMember_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PrivatePlacement2025Member" xlink:label="vstm_PrivatePlacement2025Member_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639082545815578159" xlink:to="vstm_PrivatePlacement2025Member_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639082545815578159" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639082545815578159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639082545815578159" xlink:to="us-gaap_StatementLineItems_639082545815578159" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="us-gaap_StockholdersEquity_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="us-gaap_SharesOutstanding_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="us-gaap_NetIncomeLoss_639082545815578159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_639082545815578159" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk" xlink:label="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk_639082545815578159" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_639082545815578159" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodValueAtMarketTransactions" xlink:label="vstm_StockIssuedDuringPeriodValueAtMarketTransactions_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="vstm_StockIssuedDuringPeriodValueAtMarketTransactions_639082545815578159" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodSharesAtMarketTransactions" xlink:label="vstm_StockIssuedDuringPeriodSharesAtMarketTransactions_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_StockIssuedDuringPeriodValueAtMarketTransactions_639082545815578159" xlink:to="vstm_StockIssuedDuringPeriodSharesAtMarketTransactions_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_639082545815578159" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_639082545815578159" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:label="vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement_639082545815578159" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:label="vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement_639082545815578159" xlink:to="vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProceedsFromPreFundedWarrantExercises" xlink:label="vstm_ProceedsFromPreFundedWarrantExercises_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="vstm_ProceedsFromPreFundedWarrantExercises_639082545815578159" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SharesIssuedFromPreFundedWarrantExercises" xlink:label="vstm_SharesIssuedFromPreFundedWarrantExercises_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ProceedsFromPreFundedWarrantExercises_639082545815578159" xlink:to="vstm_SharesIssuedFromPreFundedWarrantExercises_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts" xlink:label="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts_639082545815578159" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" xlink:label="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts_639082545815578159" xlink:to="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_639082545815578159" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_639082545815578159" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants_639082545815578159" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants_639082545815578159" xlink:to="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_639082545815578159" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_639082545815578159" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_639082545815578159" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_639082545815578159" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_639082545815578159" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_639082545815578159" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_639082545815578159" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_639082545815578159" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6390825458155781591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="us-gaap_StockholdersEquity_6390825458155781591" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_6390825458155781591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639082545815578159" xlink:to="us-gaap_SharesOutstanding_6390825458155781591" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xlink:type="extended" xlink:title="995200305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_639082545815578159" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639082545815578159" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639082545815578159" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639082545815578159" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639082545815578159" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesBConvertiblePreferredStockMember" xlink:label="vstm_SeriesBConvertiblePreferredStockMember_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639082545815578159" xlink:to="vstm_SeriesBConvertiblePreferredStockMember_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PrivatePlacement2025Member" xlink:label="vstm_PrivatePlacement2025Member_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639082545815578159" xlink:to="vstm_PrivatePlacement2025Member_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_November2025PublicOfferingMember" xlink:label="vstm_November2025PublicOfferingMember_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639082545815578159" xlink:to="vstm_November2025PublicOfferingMember_639082545815578159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639082545815578159" xlink:to="us-gaap_StatementLineItems_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IssuanceOfPreferredStockTrancheLiability" xlink:label="vstm_IssuanceOfPreferredStockTrancheLiability_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="vstm_IssuanceOfPreferredStockTrancheLiability_639082545815578159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockholdersEquityReverseStockSplitConversionRatio" xlink:label="vstm_StockholdersEquityReverseStockSplitConversionRatio_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639082545815578159" xlink:to="vstm_StockholdersEquityReverseStockSplitConversionRatio_639082545815578159" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_ProfitLoss_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_Depreciation_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_AmortizationOfIntangibleAssets_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OperatingLeaseNonCashCost" xlink:label="vstm_OperatingLeaseNonCashCost_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" xlink:to="vstm_OperatingLeaseNonCashCost_639082545815578159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_ShareBasedCompensation_639082545815578159" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_639082545815578159" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability" xlink:label="vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" xlink:to="vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability_639082545815578159" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639082545815578159" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotesNoncash" xlink:label="vstm_FairValueAdjustmentOfNotesNoncash_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" xlink:to="vstm_FairValueAdjustmentOfNotesNoncash_639082545815578159" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_639082545815578159" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639082545815578159" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639082545815578159" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IncreaseDecreaseInGrantsReceivableNet" xlink:label="vstm_IncreaseDecreaseInGrantsReceivableNet_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639082545815578159" xlink:to="vstm_IncreaseDecreaseInGrantsReceivableNet_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639082545815578159" xlink:to="us-gaap_IncreaseDecreaseInInventories_639082545815578159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639082545815578159" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639082545815578159" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639082545815578159" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_639082545815578159" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639082545815578159" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_639082545815578159" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639082545815578159" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_639082545815578159" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639082545815578159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_639082545815578159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_639082545815578159" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_639082545815578159" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639082545815578159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_639082545815578159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_ProceedsFromWarrantExercises_639082545815578159" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_639082545815578159" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_RepaymentsOfLongTermDebt_639082545815578159" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfLoanCosts" xlink:label="us-gaap_PaymentsOfLoanCosts_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_PaymentsOfLoanCosts_639082545815578159" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_639082545815578159" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProceedsFromInsurancePremiumFinancing" xlink:label="vstm_ProceedsFromInsurancePremiumFinancing_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639082545815578159" xlink:to="vstm_ProceedsFromInsurancePremiumFinancing_639082545815578159" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PaymentsOnInsurancePremiumFinancing" xlink:label="vstm_PaymentsOnInsurancePremiumFinancing_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639082545815578159" xlink:to="vstm_PaymentsOnInsurancePremiumFinancing_639082545815578159" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_639082545815578159" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639082545815578159" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_639082545815578159" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_639082545815578159" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639082545815578159" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6390825458155781591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6390825458155781591" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_639082545815578159" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_639082545815578159" xlink:to="us-gaap_InterestPaidNet_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_639082545815578159" xlink:to="us-gaap_IncomeTaxesPaidNet_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639082545815578159" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IssuanceOfPreferredStockTrancheLiability" xlink:label="vstm_IssuanceOfPreferredStockTrancheLiability_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639082545815578159" xlink:to="vstm_IssuanceOfPreferredStockTrancheLiability_639082545815578159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639082545815578159" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_639082545815578159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639082545815578159" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_639082545815578159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639082545815578159" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_639082545815578159" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfWarrantsExercised" xlink:label="vstm_FairValueAdjustmentOfWarrantsExercised_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639082545815578159" xlink:to="vstm_FairValueAdjustmentOfWarrantsExercised_639082545815578159" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639082545815578159" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_639082545815578159" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_639082545815578159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_639082545815578159" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_639082545815578159" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureNatureOfBusiness" xlink:type="extended" xlink:title="995210101 - Disclosure - Nature of business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210201 - Disclosure - Significant accounting policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowances" xlink:type="extended" xlink:title="995210301 - Disclosure - Product revenue reserves and allowances" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract" xlink:label="vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesDisclosureTextBlock" xlink:label="vstm_ProductRevenueReservesAndAllowancesDisclosureTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract" xlink:to="vstm_ProductRevenueReservesAndAllowancesDisclosureTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureInventory" xlink:type="extended" xlink:title="995210401 - Disclosure - Inventory" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureIntangibleAssets" xlink:type="extended" xlink:title="995210501 - Disclosure - Intangible Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="995210601 - Disclosure - Property and equipment, net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="995210701 - Disclosure - Accrued expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLongTermDebt" xlink:type="extended" xlink:title="995210801 - Disclosure - Long-term debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLeases" xlink:type="extended" xlink:title="995210901 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureCapitalStock" xlink:type="extended" xlink:title="995211001 - Disclosure - Capital Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="995211101 - Disclosure - Stock-based compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSegmentReporting" xlink:type="extended" xlink:title="995211201 - Disclosure - Segment Reporting" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="995211301 - Disclosure - Net loss per share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="995211401 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="995211501 - Disclosure - Commitments and contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreements" xlink:type="extended" xlink:title="995211601 - Disclosure - License, collaboration and commercial agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementAbstract" xlink:label="vstm_LicenseAndCollaborationAgreementAbstract" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock" xlink:label="vstm_LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_LicenseAndCollaborationAgreementAbstract" xlink:to="vstm_LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureNotesPayable" xlink:type="extended" xlink:title="995211701 - Disclosure - Notes Payable" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_LongTermDebtTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureEmployeeBenefitPlan" xlink:type="extended" xlink:title="995211801 - Disclosure - Employee benefit plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureVendorFinancingArrangement" xlink:type="extended" xlink:title="995211901 - Disclosure - Vendor Financing Arrangement" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_VendorFinancingAgreementAbstract" xlink:label="vstm_VendorFinancingAgreementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTextBlock" xlink:label="us-gaap_SupplierFinanceProgramTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_VendorFinancingAgreementAbstract" xlink:to="us-gaap_SupplierFinanceProgramTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995212001 - Disclosure - Subsequent events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_635481906593668475" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_635481906593668475" xlink:to="us-gaap_SubsequentEventsTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920202 - Disclosure - Summary of significant accounting policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_639082545815734214" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_639082545815734214" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProceedsFromGrantsPolicyPolicyTextBlock" xlink:label="vstm_ProceedsFromGrantsPolicyPolicyTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vstm_ProceedsFromGrantsPolicyPolicyTextBlock_639082545815734214" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_639082545815734214" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_639082545815734214" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" xlink:label="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_639082545815734214" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_639082545815734214" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CloudComputingImplementationCostsPolicyPolicyTextBlock" xlink:label="vstm_CloudComputingImplementationCostsPolicyPolicyTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vstm_CloudComputingImplementationCostsPolicyPolicyTextBlock_639082545815734214" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_639082545815734214" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_639082545815734214" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_639082545815734214" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_639082545815734214" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_639082545815734214" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_639082545815734214" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_639082545815734214" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_639082545815734214" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_639082545815734214" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_639082545815734214" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NewAccountingStandardsAdoptedPolicyPolicyTextBlock" xlink:label="vstm_NewAccountingStandardsAdoptedPolicyPolicyTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vstm_NewAccountingStandardsAdoptedPolicyPolicyTextBlock_639082545815734214" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_639082545815734214" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="99930203 - Disclosure - Significant accounting policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_639082545815734214" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_639082545815734214" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_639082545815734214" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ReconciliationOfWarrantLiabilityTableTextBlock" xlink:label="vstm_ReconciliationOfWarrantLiabilityTableTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="vstm_ReconciliationOfWarrantLiabilityTableTextBlock_639082545815734214" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="vstm_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="vstm_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_639082545815734214" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesTables" xlink:type="extended" xlink:title="99930303 - Disclosure - Product revenue reserves and allowances (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract" xlink:label="vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract_636743339198728095" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesTableTextBlock" xlink:label="vstm_ProductRevenueReservesAndAllowancesTableTextBlock_639082545815734214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract_636743339198728095" xlink:to="vstm_ProductRevenueReservesAndAllowancesTableTextBlock_639082545815734214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureInventoryTables" xlink:type="extended" xlink:title="99930403 - Disclosure - Inventory (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureIntangibleAssetsTables" xlink:type="extended" xlink:title="99930503 - Disclosure - Intangible Assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_639082545815799465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="99930603 - Disclosure - Property and equipment, net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="99930703 - Disclosure - Accrued expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLongTermDebtTables" xlink:type="extended" xlink:title="99930803 - Disclosure - Long-term debt (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_639082545815799465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_639082545815799465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_639082545815799465" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="99930903 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureCapitalStockTables" xlink:type="extended" xlink:title="99931003 - Disclosure - Capital Stock (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock" xlink:label="vstm_ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="vstm_ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="99931103 - Disclosure - Stock-based compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_639082545815799465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_639082545815799465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_639082545815799465" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_639082545815799465" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSegmentReportingTables" xlink:type="extended" xlink:title="99931203 - Disclosure - Segment Reporting (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="99931303 - Disclosure - Net loss per share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="99931403 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_639082545815799465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_639082545815799465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureNatureOfBusinessDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Nature of business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NatureOfBusinessTable" xlink:label="vstm_NatureOfBusinessTable_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="vstm_NatureOfBusinessTable_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_NatureOfBusinessTable_639082545815799465" xlink:to="us-gaap_SubsequentEventTypeAxis_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_639082545815799465" xlink:to="us-gaap_SubsequentEventTypeDomain_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_639082545815799465" xlink:to="us-gaap_SubsequentEventMember_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_NatureOfBusinessTable_639082545815799465" xlink:to="us-gaap_DebtInstrumentAxis_639082545815799465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639082545815799465" xlink:to="us-gaap_DebtInstrumentNameDomain_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NotePurchaseAgreementMember" xlink:label="vstm_NotePurchaseAgreementMember_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639082545815799465" xlink:to="vstm_NotePurchaseAgreementMember_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_NatureOfBusinessTable_639082545815799465" xlink:to="srt_StatementScenarioAxis_639082545815799465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_639082545815799465" xlink:to="srt_ScenarioUnspecifiedDomain_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SecondSaleMember" xlink:label="vstm_SecondSaleMember_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545815799465" xlink:to="vstm_SecondSaleMember_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NatureOfBusinessLineItems" xlink:label="vstm_NatureOfBusinessLineItems_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_NatureOfBusinessTable_639082545815799465" xlink:to="vstm_NatureOfBusinessLineItems_639082545815799465" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_NatureOfBusinessLineItems_639082545815799465" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_NatureOfBusinessLineItems_639082545815799465" xlink:to="us-gaap_ProceedsFromWarrantExercises_639082545815799465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentIssuanceOfAdditionalNotes" xlink:label="vstm_DebtInstrumentIssuanceOfAdditionalNotes_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_NatureOfBusinessLineItems_639082545815799465" xlink:to="vstm_DebtInstrumentIssuanceOfAdditionalNotes_639082545815799465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureNatureOfBusinessReverseStockSplitDetails" xlink:type="extended" xlink:title="99940102 - Disclosure - Nature of business - Reverse Stock Split (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NatureOfBusinessTable" xlink:label="vstm_NatureOfBusinessTable_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xlink:to="vstm_NatureOfBusinessTable_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_NatureOfBusinessTable_639082545815799465" xlink:to="us-gaap_TypeOfArrangementAxis_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_639082545815799465" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639082545815799465" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CertificateOfAmendmentMember" xlink:label="vstm_CertificateOfAmendmentMember_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639082545815799465" xlink:to="vstm_CertificateOfAmendmentMember_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NatureOfBusinessLineItems" xlink:label="vstm_NatureOfBusinessLineItems_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_NatureOfBusinessTable_639082545815799465" xlink:to="vstm_NatureOfBusinessLineItems_639082545815799465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_NatureOfBusinessLineItems_639082545815799465" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockholdersEquityReverseStockSplitConversionRatio" xlink:label="vstm_StockholdersEquityReverseStockSplitConversionRatio_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_NatureOfBusinessLineItems_639082545815799465" xlink:to="vstm_StockholdersEquityReverseStockSplitConversionRatio_639082545815799465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_NatureOfBusinessLineItems_639082545815799465" xlink:to="us-gaap_CommonStockSharesAuthorized_639082545815799465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentAndGeographicInformationDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Summary of significant accounting policies - Segment and geographic information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_636809964620468459" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SegmentAndGeographicInformationAbstract" xlink:label="vstm_SegmentAndGeographicInformationAbstract_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_636809964620468459" xlink:to="vstm_SegmentAndGeographicInformationAbstract_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_SegmentAndGeographicInformationAbstract_639082545815799465" xlink:to="us-gaap_NumberOfOperatingSegments_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails" xlink:type="extended" xlink:title="99940202 - Disclosure - Significant accounting policies - Proceeds from Grants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTable" xlink:label="us-gaap_GovernmentAssistanceTable_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_GovernmentAssistanceTable_639082545815799465" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTable_639082545815799465" xlink:to="us-gaap_GovernmentAssistanceTypeAxis_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeAxis_639082545815799465" xlink:to="us-gaap_GovernmentAssistanceTypeDomain_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceOtherMember" xlink:label="us-gaap_GovernmentAssistanceOtherMember_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeDomain_639082545815799465" xlink:to="us-gaap_GovernmentAssistanceOtherMember_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceLineItems" xlink:label="us-gaap_GovernmentAssistanceLineItems_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTable_639082545815799465" xlink:to="us-gaap_GovernmentAssistanceLineItems_639082545815799465" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_639082545815799465" xlink:to="us-gaap_GovernmentAssistanceAmount_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_639082545815799465" xlink:to="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_639082545815799465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ReductionInResearchAndDevelopmentExpense" xlink:label="vstm_ReductionInResearchAndDevelopmentExpense_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_639082545815799465" xlink:to="vstm_ReductionInResearchAndDevelopmentExpense_639082545815799465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceAmountCumulativeCurrent" xlink:label="us-gaap_GovernmentAssistanceAmountCumulativeCurrent_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_639082545815799465" xlink:to="us-gaap_GovernmentAssistanceAmountCumulativeCurrent_639082545815799465" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceLiabilityCurrent" xlink:label="us-gaap_GovernmentAssistanceLiabilityCurrent_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_639082545815799465" xlink:to="us-gaap_GovernmentAssistanceLiabilityCurrent_639082545815799465" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_639082545815799465" xlink:to="us-gaap_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration_639082545815799465" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="99940203 - Disclosure - Significant accounting policies - Reconciliation of cash, cash equivalents and restricted cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545815799465" xlink:to="us-gaap_CreditFacilityAxis_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_639082545815799465" xlink:to="us-gaap_CreditFacilityDomain_639082545815799465" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_639082545815799465" xlink:to="us-gaap_LetterOfCreditMember_639082545815799465" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545815799465" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639082545815799465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639082545815799465" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545815799465" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember" xlink:label="vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545815799465" xlink:to="vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545815799465" xlink:to="us-gaap_BalanceSheetLocationAxis_639082545815799465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_639082545815799465" xlink:to="us-gaap_BalanceSheetLocationDomain_639082545815799465" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RestrictedCashAndCashEquivalentsNoncurrentMember" xlink:label="vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_639082545815799465" xlink:to="vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545815799465" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815799465" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815799465" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815799465" xlink:to="us-gaap_SecurityDeposit_639082545815799465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashEquivalentsCurrent" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815799465" xlink:to="us-gaap_RestrictedCashEquivalentsCurrent_639082545815799465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815799465" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639082545815799465" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_6390825458157994651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815799465" xlink:to="us-gaap_SecurityDeposit_6390825458157994651" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815799465" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_639082545815799465" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815799465" xlink:to="us-gaap_InterestReceivable_639082545815799465" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815799465" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_639082545815799465" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" xlink:type="extended" xlink:title="99940204 - Disclosure - Significant accounting policies - Cash, cash equivalents, restricted cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="us-gaap_ScheduleOfInvestmentsTable_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_6" xlink:to="us-gaap_ScheduleOfInvestmentsTable_639082545815799465" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable_639082545815799465" xlink:to="us-gaap_CashAndCashEquivalentsAxis_639082545815799465" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_639082545815799465" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_639082545815799465" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CashAndMoneyMarketAccountsMember" xlink:label="vstm_CashAndMoneyMarketAccountsMember_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_639082545815799465" xlink:to="vstm_CashAndMoneyMarketAccountsMember_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable_639082545815799465" xlink:to="us-gaap_FinancialInstrumentAxis_639082545815799465" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_639082545815799465" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639082545815799465" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CorporateBondsAndCommercialPaperMember" xlink:label="vstm_CorporateBondsAndCommercialPaperMember_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639082545815799465" xlink:to="vstm_CorporateBondsAndCommercialPaperMember_639082545815799465" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable_639082545815799465" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_639082545815799465" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_639082545815799465" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_639082545815799465" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_639082545815799465" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_639082545815799465" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_639082545815799465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable_639082545815799465" xlink:to="us-gaap_ScheduleOfInvestmentsLineItems_639082545815799465" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems_639082545815799465" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems_639082545815799465" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_639082545815799465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems_639082545815799465" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_639082545815799465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="99940205 - Disclosure - Significant accounting policies - Items Measured at Fair Value on a Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_3" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815799465" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_639082545815799465" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_639082545815799465" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_639082545815799465" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_639082545815799465" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815799465" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_639082545815799465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_639082545815799465" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639082545815799465" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639082545815799465" xlink:to="us-gaap_FairValueInputsLevel1Member_639082545815799465" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639082545815799465" xlink:to="us-gaap_FairValueInputsLevel3Member_639082545815799465" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815799465" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639082545815799465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639082545815799465" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_639082545815799465" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_639082545815799465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_639082545815799465" xlink:to="us-gaap_AssetsFairValueDisclosure_639082545815799465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_639082545815799465" xlink:to="us-gaap_WarrantsAndRightsOutstanding_639082545815799465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure_639082545815799465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_639082545815799465" xlink:to="us-gaap_NotesPayableFairValueDisclosure_639082545815799465" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_639082545815894733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_639082545815799465" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_639082545815894733" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails" xlink:type="extended" xlink:title="99940206 - Disclosure - Significant accounting policies - Inputs used to value the warrant liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815895392" xlink:to="us-gaap_MeasurementInputTypeAxis_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_639082545815895392" xlink:to="us-gaap_MeasurementInputTypeDomain_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639082545815895392" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639082545815895392" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_639082545815895392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639082545815895392" xlink:to="us-gaap_MeasurementInputExpectedTermMember_639082545815895392" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815895392" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639082545815895392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639082545815895392" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails" xlink:type="extended" xlink:title="99940207 - Disclosure - Significant accounting policies - Reconciliation of the warrant liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_7" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815895392" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_639082545815895392" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639082545815895392" xlink:to="us-gaap_FairValueInputsLevel3Member_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815895392" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639082545815895392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639082545815895392" xlink:to="us-gaap_WarrantsAndRightsOutstanding_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfWarrantsExercised" xlink:label="vstm_FairValueAdjustmentOfWarrantsExercised_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639082545815895392" xlink:to="vstm_FairValueAdjustmentOfWarrantsExercised_639082545815895392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639082545815895392" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639082545815895392" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_6390825458158953921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639082545815895392" xlink:to="us-gaap_WarrantsAndRightsOutstanding_6390825458158953921" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails" xlink:type="extended" xlink:title="99940208 - Disclosure - Significant accounting policies - Note Purchase Agreement and Oxford Loan Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_8" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815895392" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815895392" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_639082545815895392" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_639082545815895392" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639082545815895392" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639082545815895392" xlink:to="us-gaap_FairValueInputsLevel3Member_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815895392" xlink:to="us-gaap_MeasurementInputTypeAxis_639082545815895392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_639082545815895392" xlink:to="us-gaap_MeasurementInputTypeDomain_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_639082545815895392" xlink:to="us-gaap_MeasurementInputDiscountRateMember_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815895392" xlink:to="us-gaap_DebtInstrumentAxis_639082545815895392" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639082545815895392" xlink:to="us-gaap_DebtInstrumentNameDomain_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NotePurchaseAgreementMember" xlink:label="vstm_NotePurchaseAgreementMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639082545815895392" xlink:to="vstm_NotePurchaseAgreementMember_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815895392" xlink:to="srt_RangeAxis_639082545815895392" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639082545815895392" xlink:to="srt_RangeMember_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639082545815895392" xlink:to="srt_MaximumMember_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639082545815895392" xlink:to="srt_MinimumMember_639082545815895392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639082545815895392" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639082545815895392" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639082545815895392" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMeasurementInput" xlink:label="us-gaap_LongTermDebtMeasurementInput_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_639082545815895392" xlink:to="us-gaap_LongTermDebtMeasurementInput_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_639082545815895392" xlink:to="us-gaap_DebtInstrumentFaceAmount_639082545815895392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_639082545815895392" xlink:to="us-gaap_DebtInstrumentFairValue_639082545815895392" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount" xlink:label="vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_639082545815895392" xlink:to="vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount_639082545815895392" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_639082545815895392" xlink:to="us-gaap_LongTermDebtFairValue_639082545815895392" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_639082545815895392" xlink:to="us-gaap_LongTermDebt_639082545815895392" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails" xlink:type="extended" xlink:title="99940209 - Disclosure - Significant accounting policies - Concentrations of credit risk and off-balance sheet risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskTable_639082545815895392" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_639082545815895392" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_639082545815895392" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_639082545815895392" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_639082545815895392" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_639082545815895392" xlink:to="us-gaap_AccountsReceivableMember_639082545815895392" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_639082545815895392" xlink:to="us-gaap_SalesRevenueNetMember_639082545815895392" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_639082545815895392" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_639082545815895392" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_639082545815895392" xlink:to="us-gaap_ConcentrationRiskTypeDomain_639082545815895392" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_639082545815895392" xlink:to="us-gaap_CreditConcentrationRiskMember_639082545815895392" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_639082545815895392" xlink:to="us-gaap_CustomerConcentrationRiskMember_639082545815895392" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_639082545815895392" xlink:to="srt_CounterpartyNameAxis_639082545815895392" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639082545815895392" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639082545815895392" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SecuraBioInc.Member" xlink:label="vstm_SecuraBioInc.Member_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639082545815895392" xlink:to="vstm_SecuraBioInc.Member_639082545815895392" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_639082545815895392" xlink:to="srt_MajorCustomersAxis_639082545815895392" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_639082545815895392" xlink:to="srt_NameOfMajorCustomerDomain_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MajorCustomerMember" xlink:label="vstm_MajorCustomerMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_639082545815895392" xlink:to="vstm_MajorCustomerMember_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_639082545815895392" xlink:to="us-gaap_ConcentrationRiskLineItems_639082545815895392" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract" xlink:label="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_639082545815895392" xlink:to="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract_639082545815895392" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfCustomers" xlink:label="vstm_NumberOfCustomers_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract_639082545815895392" xlink:to="vstm_NumberOfCustomers_639082545815895392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract_639082545815895392" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_639082545815895392" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract_639082545815895392" xlink:to="us-gaap_ConcentrationRiskPercentage1_639082545815895392" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940210 - Disclosure - Significant accounting policies - Property and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545815895392" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545815895392" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639082545815895392" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639082545815895392" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545815895392" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545815895392" xlink:to="us-gaap_EquipmentMember_639082545815895392" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545815895392" xlink:to="us-gaap_FurnitureAndFixturesMember_639082545815895392" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545815895392" xlink:to="us-gaap_ComputerEquipmentMember_639082545815895392" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545815895392" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815895392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815895392" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_639082545815895392" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_639082545815895392" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_639082545815895392" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_639082545815895392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCloudComputingImplementationCostsDetails" xlink:type="extended" xlink:title="99940211 - Disclosure - Significant accounting policies - Cloud Computing Implementation Costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostNetCurrent" xlink:label="us-gaap_CapitalizedContractCostNetCurrent_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_5" xlink:to="us-gaap_CapitalizedContractCostNetCurrent_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_5" xlink:to="us-gaap_CapitalizedContractCostAmortization_639082545815895392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="extended" xlink:title="99940212 - Disclosure - Significant accounting policies - Income taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_11" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ChangeInCompanyOwnershipPercent" xlink:label="vstm_ChangeInCompanyOwnershipPercent_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_11" xlink:to="vstm_ChangeInCompanyOwnershipPercent_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Product revenue reserves and allowances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract" xlink:label="vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesDisclosureTable" xlink:label="vstm_ProductRevenueReservesAndAllowancesDisclosureTable_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract" xlink:to="vstm_ProductRevenueReservesAndAllowancesDisclosureTable_639082545815895392" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueAllowancesAndReservesTypeAxis" xlink:label="vstm_ProductRevenueAllowancesAndReservesTypeAxis_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ProductRevenueReservesAndAllowancesDisclosureTable_639082545815895392" xlink:to="vstm_ProductRevenueAllowancesAndReservesTypeAxis_639082545815895392" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesDomain" xlink:label="vstm_ProductRevenueReservesAndAllowancesDomain_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ProductRevenueAllowancesAndReservesTypeAxis_639082545815895392" xlink:to="vstm_ProductRevenueReservesAndAllowancesDomain_639082545815895392" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember" xlink:label="vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ProductRevenueReservesAndAllowancesDomain_639082545815895392" xlink:to="vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember_639082545815895392" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember" xlink:label="vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ProductRevenueReservesAndAllowancesDomain_639082545815895392" xlink:to="vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember_639082545815895392" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember" xlink:label="vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ProductRevenueReservesAndAllowancesDomain_639082545815895392" xlink:to="vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember_639082545815895392" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueAndAllowancesReturnsMember" xlink:label="vstm_ProductRevenueAndAllowancesReturnsMember_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ProductRevenueReservesAndAllowancesDomain_639082545815895392" xlink:to="vstm_ProductRevenueAndAllowancesReturnsMember_639082545815895392" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems" xlink:label="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ProductRevenueReservesAndAllowancesDisclosureTable_639082545815895392" xlink:to="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems_639082545815895392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowances" xlink:label="vstm_ProductRevenueReservesAndAllowances_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems_639082545815895392" xlink:to="vstm_ProductRevenueReservesAndAllowances_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear" xlink:label="vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems_639082545815895392" xlink:to="vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear_639082545815895392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowancesDeductions" xlink:label="vstm_ProductRevenueReservesAndAllowancesDeductions_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems_639082545815895392" xlink:to="vstm_ProductRevenueReservesAndAllowancesDeductions_639082545815895392" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProductRevenueReservesAndAllowances" xlink:label="vstm_ProductRevenueReservesAndAllowances_6390825458158953921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems_639082545815895392" xlink:to="vstm_ProductRevenueReservesAndAllowances_6390825458158953921" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureInventoryScheduleOfInventoryDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Inventory - Schedule of inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_2" xlink:to="us-gaap_InventoryWorkInProcess_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_2" xlink:to="us-gaap_InventoryFinishedGoods_639082545815895392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_2" xlink:to="us-gaap_InventoryNet_639082545815895392" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureIntangibleAssetsDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="extended" xlink:title="99940502 - Disclosure - Intangible Assets - Schedule of intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_639082545815895392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_639082545815895392" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_639082545815895392" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails" xlink:type="extended" xlink:title="99940503 - Disclosure - Intangible Assets - Schedule of future amortization expense of finite-lived intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_639082545815895392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_639082545815895392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_639082545815895392" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_639082545815895392" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_639082545815895392" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_639082545815895392" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_639082545815895392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_639082545815895392" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Property and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_635447473120107973" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_635447473120107973" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545815997453" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545815997453" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639082545815997453" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639082545815997453" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545815997453" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545815997453" xlink:to="us-gaap_LeaseholdImprovementsMember_639082545815997453" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545815997453" xlink:to="us-gaap_FurnitureAndFixturesMember_639082545815997453" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545815997453" xlink:to="us-gaap_ComputerEquipmentMember_639082545815997453" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545815997453" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815997453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815997453" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_639082545815997453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815997453" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_639082545815997453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815997453" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_639082545815997453" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639082545815997453" xlink:to="us-gaap_Depreciation_639082545815997453" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Accrued expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedClinicalTrialExpensesCurrent" xlink:label="vstm_AccruedClinicalTrialExpensesCurrent_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="vstm_AccruedClinicalTrialExpensesCurrent_639082545815997453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedMilestonePaymentsCurrent" xlink:label="vstm_AccruedMilestonePaymentsCurrent_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="vstm_AccruedMilestonePaymentsCurrent_639082545815997453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_639082545815997453" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedCommercializationCostsCurrent" xlink:label="vstm_AccruedCommercializationCostsCurrent_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="vstm_AccruedCommercializationCostsCurrent_639082545815997453" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedContractManufacturingExpensesCurrent" xlink:label="vstm_AccruedContractManufacturingExpensesCurrent_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="vstm_AccruedContractManufacturingExpensesCurrent_639082545815997453" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="vstm_AccruedResearchAndDevelopmentExpensesCurrent_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="vstm_AccruedResearchAndDevelopmentExpensesCurrent_639082545815997453" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccruedConsultingFeesCurrent" xlink:label="vstm_AccruedConsultingFeesCurrent_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="vstm_AccruedConsultingFeesCurrent_639082545815997453" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_639082545815997453" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_InterestPayableCurrent_639082545815997453" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_639082545815997453" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_639082545815997453" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Long-term debt - Note Purchase Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_6" xlink:to="us-gaap_DebtInstrumentTable_639082545815997453" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_639082545815997453" xlink:to="us-gaap_IncomeStatementLocationAxis_639082545815997453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_639082545815997453" xlink:to="us-gaap_IncomeStatementLocationDomain_639082545815997453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_639082545815997453" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_639082545815997453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_639082545815997453" xlink:to="us-gaap_DebtInstrumentAxis_639082545815997453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639082545815997453" xlink:to="us-gaap_DebtInstrumentNameDomain_639082545815997453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NotePurchaseAgreementMember" xlink:label="vstm_NotePurchaseAgreementMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639082545815997453" xlink:to="vstm_NotePurchaseAgreementMember_639082545815997453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_639082545815997453" xlink:to="srt_StatementScenarioAxis_639082545815997453" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_639082545815997453" xlink:to="srt_ScenarioUnspecifiedDomain_639082545815997453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_InitialSaleMember" xlink:label="vstm_InitialSaleMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545815997453" xlink:to="vstm_InitialSaleMember_639082545815997453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SecondSaleMember" xlink:label="vstm_SecondSaleMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545815997453" xlink:to="vstm_SecondSaleMember_639082545815997453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember" xlink:label="vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545815997453" xlink:to="vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember_639082545815997453" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember" xlink:label="vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545815997453" xlink:to="vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember_639082545815997453" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_First100MillionNetSalesOfEachIncludedProductMember" xlink:label="vstm_First100MillionNetSalesOfEachIncludedProductMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545815997453" xlink:to="vstm_First100MillionNetSalesOfEachIncludedProductMember_639082545815997453" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember" xlink:label="vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545815997453" xlink:to="vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember_639082545815997453" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RedemptionPriorToSecondAnniversaryMember" xlink:label="vstm_RedemptionPriorToSecondAnniversaryMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545815997453" xlink:to="vstm_RedemptionPriorToSecondAnniversaryMember_639082545815997453" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RedemptionPriorToThirdAnniversaryMember" xlink:label="vstm_RedemptionPriorToThirdAnniversaryMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545815997453" xlink:to="vstm_RedemptionPriorToThirdAnniversaryMember_639082545815997453" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RedemptionAfterYearThirdAnniversaryMember" xlink:label="vstm_RedemptionAfterYearThirdAnniversaryMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545815997453" xlink:to="vstm_RedemptionAfterYearThirdAnniversaryMember_639082545815997453" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_639082545815997453" xlink:to="srt_RangeAxis_639082545815997453" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639082545815997453" xlink:to="srt_RangeMember_639082545815997453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639082545815997453" xlink:to="srt_MaximumMember_639082545815997453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_639082545815997453" xlink:to="us-gaap_DebtInstrumentLineItems_639082545815997453" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_639082545815997453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="us-gaap_DebtInstrumentFaceAmount_639082545815997453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentIssuanceOfAdditionalNotes" xlink:label="vstm_DebtInstrumentIssuanceOfAdditionalNotes_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="vstm_DebtInstrumentIssuanceOfAdditionalNotes_639082545815997453" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib" xlink:label="vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib_639082545815997453" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_639082545815997453" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_639082545815997453" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_639082545815997453" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate" xlink:label="vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate_639082545815997453" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_639082545815997453" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_InterestDuePaidInKindPercentage" xlink:label="vstm_InterestDuePaidInKindPercentage_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="vstm_InterestDuePaidInKindPercentage_639082545815997453" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage" xlink:label="vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage_639082545815997453" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ParticipationInNetSalesPercentage" xlink:label="vstm_ParticipationInNetSalesPercentage_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="vstm_ParticipationInNetSalesPercentage_639082545815997453" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ParticipationInNetSalesSalesAmount" xlink:label="vstm_ParticipationInNetSalesSalesAmount_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="vstm_ParticipationInNetSalesSalesAmount_639082545815997453" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt" xlink:label="vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt_639082545815997453" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentNumberOfEqualInstallments" xlink:label="vstm_DebtInstrumentNumberOfEqualInstallments_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="vstm_DebtInstrumentNumberOfEqualInstallments_639082545815997453" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_639082545815997453" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="us-gaap_DebtInstrumentCovenantDescription_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="us-gaap_DebtInstrumentCovenantDescription_639082545815997453" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtIssuanceCosts" xlink:label="vstm_DebtIssuanceCosts_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="vstm_DebtIssuanceCosts_639082545815997453" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="us-gaap_NotesPayableFairValueDisclosure_639082545815997453" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Long-term debt - Reconciliation of changes in the fair value of the Notes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_5" xlink:to="us-gaap_DebtInstrumentTable_639082545815997453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_639082545815997453" xlink:to="us-gaap_DebtInstrumentAxis_639082545815997453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639082545815997453" xlink:to="us-gaap_DebtInstrumentNameDomain_639082545815997453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NotePurchaseAgreementMember" xlink:label="vstm_NotePurchaseAgreementMember_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639082545815997453" xlink:to="vstm_NotePurchaseAgreementMember_639082545815997453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_639082545815997453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_639082545815997453" xlink:to="us-gaap_DebtInstrumentLineItems_639082545815997453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545815997453" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639082545816052753" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639082545816052753" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639082545816052753" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_639082545816052753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639082545816052753" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_639082545816052753" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639082545816052753" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList_639082545816052753" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639082545816052753" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_639082545816052753" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6390825458160527531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_639082545816052753" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6390825458160527531" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - Long-term debt - Future principal payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_3" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LongTermDebtMaturityYearSix" xlink:label="vstm_LongTermDebtMaturityYearSix_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_639082545816052753" xlink:to="vstm_LongTermDebtMaturityYearSix_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LongTermDebtMaturityYearSeven" xlink:label="vstm_LongTermDebtMaturityYearSeven_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_639082545816052753" xlink:to="vstm_LongTermDebtMaturityYearSeven_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LongTermDebtMaturitiesAggregatePrincipalDue" xlink:label="vstm_LongTermDebtMaturitiesAggregatePrincipalDue_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_639082545816052753" xlink:to="vstm_LongTermDebtMaturitiesAggregatePrincipalDue_639082545816052753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - Long-term debt - Loan Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_636276767519014083" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_636276767519014083" xlink:to="us-gaap_DebtInstrumentTable_639082545816052753" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_639082545816052753" xlink:to="us-gaap_DebtInstrumentAxis_639082545816052753" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639082545816052753" xlink:to="us-gaap_DebtInstrumentNameDomain_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LoanAndSecurityAgreementMember" xlink:label="vstm_LoanAndSecurityAgreementMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639082545816052753" xlink:to="vstm_LoanAndSecurityAgreementMember_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_TermLoanFacilityMember" xlink:label="vstm_TermLoanFacilityMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639082545816052753" xlink:to="vstm_TermLoanFacilityMember_639082545816052753" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_TermBLoanMember" xlink:label="vstm_TermBLoanMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_TermLoanFacilityMember_639082545816052753" xlink:to="vstm_TermBLoanMember_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_TermCLoanMember" xlink:label="vstm_TermCLoanMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_TermLoanFacilityMember_639082545816052753" xlink:to="vstm_TermCLoanMember_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_TermDLoanMember" xlink:label="vstm_TermDLoanMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_TermLoanFacilityMember_639082545816052753" xlink:to="vstm_TermDLoanMember_639082545816052753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_TermELoanMember" xlink:label="vstm_TermELoanMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_TermLoanFacilityMember_639082545816052753" xlink:to="vstm_TermELoanMember_639082545816052753" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_639082545816052753" xlink:to="srt_StatementScenarioAxis_639082545816052753" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_639082545816052753" xlink:to="srt_ScenarioUnspecifiedDomain_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember" xlink:label="vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816052753" xlink:to="vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PrepaymentAfterSecondAnniversaryMember" xlink:label="vstm_PrepaymentAfterSecondAnniversaryMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816052753" xlink:to="vstm_PrepaymentAfterSecondAnniversaryMember_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_639082545816052753" xlink:to="srt_RangeAxis_639082545816052753" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639082545816052753" xlink:to="srt_RangeMember_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639082545816052753" xlink:to="srt_MaximumMember_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_639082545816052753" xlink:to="us-gaap_DebtInstrumentLineItems_639082545816052753" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="us-gaap_DebtInstrumentFaceAmount_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentCurrentBorrowingCapacity" xlink:label="vstm_DebtInstrumentCurrentBorrowingCapacity_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="vstm_DebtInstrumentCurrentBorrowingCapacity_639082545816052753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable_639082545816052753" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentPeriodToDrawLoanMinimum" xlink:label="vstm_DebtInstrumentPeriodToDrawLoanMinimum_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="vstm_DebtInstrumentPeriodToDrawLoanMinimum_639082545816052753" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_GrossProductRevenueToBeAchieved" xlink:label="vstm_GrossProductRevenueToBeAchieved_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="vstm_GrossProductRevenueToBeAchieved_639082545816052753" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_639082545816052753" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_639082545816052753" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_639082545816052753" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentFinalPaymentFeePercentage" xlink:label="vstm_DebtInstrumentFinalPaymentFeePercentage_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="vstm_DebtInstrumentFinalPaymentFeePercentage_639082545816052753" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault" xlink:label="vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault_639082545816052753" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="us-gaap_DebtInstrumentCovenantDescription_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="us-gaap_DebtInstrumentCovenantDescription_639082545816052753" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfFinancialCovenants" xlink:label="vstm_NumberOfFinancialCovenants_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="vstm_NumberOfFinancialCovenants_639082545816052753" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentAccruedInterestRate" xlink:label="vstm_DebtInstrumentAccruedInterestRate_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="vstm_DebtInstrumentAccruedInterestRate_639082545816052753" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="us-gaap_RepaymentsOfLongTermDebt_639082545816052753" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RepaymentsOfLongTermDebtFinalPaymentFee" xlink:label="vstm_RepaymentsOfLongTermDebtFinalPaymentFee_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="vstm_RepaymentsOfLongTermDebtFinalPaymentFee_639082545816052753" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_639082545816052753" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RepaymentsOfLongTermDebtUnpaidInterest" xlink:label="vstm_RepaymentsOfLongTermDebtUnpaidInterest_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="vstm_RepaymentsOfLongTermDebtUnpaidInterest_639082545816052753" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_639082545816052753" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_639082545816052753" order="19" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails" xlink:type="extended" xlink:title="99940805 - Disclosure - Long-term debt - Components of carrying value of the Term Loan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_2" xlink:to="us-gaap_DebtInstrumentCarryingAmount_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DebtInstrumentFinalPaymentFee" xlink:label="vstm_DebtInstrumentFinalPaymentFee_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_2" xlink:to="vstm_DebtInstrumentFinalPaymentFee_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_2" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_639082545816052753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_2" xlink:to="us-gaap_LongTermDebt_639082545816052753" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLongTermDebtScheduleOfInterestExpensesDetails" xlink:type="extended" xlink:title="99940806 - Disclosure - Long-term debt - Schedule of interest expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ContractualInterestExpense" xlink:label="vstm_ContractualInterestExpense_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="vstm_ContractualInterestExpense_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_AmortizationOfFinancingCosts_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AmortizationOfFinalPaymentFee" xlink:label="vstm_AmortizationOfFinalPaymentFee_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="vstm_AmortizationOfFinalPaymentFee_639082545816052753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_InterestExpense_639082545816052753" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_639082545816052753" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_639082545816052753" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639082545816052753" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639082545816052753" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember" xlink:label="vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545816052753" xlink:to="vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_639082545816052753" xlink:to="srt_RangeAxis_639082545816052753" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639082545816052753" xlink:to="srt_RangeMember_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639082545816052753" xlink:to="srt_MinimumMember_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639082545816052753" xlink:to="srt_MaximumMember_639082545816052753" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_639082545816052753" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_639082545816052753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_639082545816052753" xlink:to="us-gaap_AreaOfRealEstateProperty_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_639082545816052753" xlink:to="us-gaap_OperatingLeaseExpense_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Leases - Balance sheet and other information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract_639082545816052753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_639082545816052753" xlink:to="us-gaap_OperatingLeaseCost_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_639082545816052753" xlink:to="us-gaap_LeaseCost_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_639082545816052753" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_639082545816052753" xlink:to="us-gaap_OperatingLeasePayments_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_639082545816052753" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_639082545816052753" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_639082545816052753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_639082545816052753" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_639082545816052753" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639082545816052753" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639082545816052753" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639082545816052753" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639082545816052753" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_639082545816052753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_6390825458160527531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639082545816052753" xlink:to="us-gaap_OperatingLeaseLiability_6390825458160527531" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureCapitalStockDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Capital Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639082545816052753" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639082545816052753" xlink:to="us-gaap_AwardTypeAxis_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_639082545816052753" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816052753" xlink:to="us-gaap_StockCompensationPlanMember_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816052753" xlink:to="us-gaap_EmployeeStockMember_639082545816052753" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesaConvertiblePreferredStockMember" xlink:label="vstm_SeriesaConvertiblePreferredStockMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816052753" xlink:to="vstm_SeriesaConvertiblePreferredStockMember_639082545816052753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816052753" xlink:to="us-gaap_WarrantMember_639082545816052753" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantMember" xlink:label="vstm_PreFundedWarrantMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816052753" xlink:to="vstm_PreFundedWarrantMember_639082545816052753" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639082545816052753" xlink:to="us-gaap_PlanNameAxis_639082545816052753" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_639082545816052753" xlink:to="us-gaap_PlanNameDomain_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_InducementAwardProgramMember" xlink:label="vstm_InducementAwardProgramMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639082545816052753" xlink:to="vstm_InducementAwardProgramMember_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639082545816052753" xlink:to="us-gaap_StatementEquityComponentsAxis_639082545816052753" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639082545816052753" xlink:to="us-gaap_EquityComponentDomain_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantMember" xlink:label="vstm_PreFundedWarrantMember_6390825458160527531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_639082545816052753" xlink:to="vstm_PreFundedWarrantMember_6390825458160527531" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_639082545816052753" xlink:to="us-gaap_CommonStockMember_639082545816052753" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639082545816052753" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639082545816052753" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639082545816052753" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AtMarketEquityOfferingProgramMember" xlink:label="vstm_AtMarketEquityOfferingProgramMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816052753" xlink:to="vstm_AtMarketEquityOfferingProgramMember_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639082545816052753" xlink:to="srt_CounterpartyNameAxis_639082545816052753" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639082545816052753" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_BiotechnologyValueFundMember" xlink:label="vstm_BiotechnologyValueFundMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816052753" xlink:to="vstm_BiotechnologyValueFundMember_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639082545816052753" xlink:to="srt_RangeAxis_639082545816052753" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639082545816052753" xlink:to="srt_RangeMember_639082545816052753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639082545816052753" xlink:to="srt_MaximumMember_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639082545816052753" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_639082545816052753" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639082545816052753" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfVotesPerEachShareOfCommonStock" xlink:label="vstm_NumberOfVotesPerEachShareOfCommonStock_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639082545816052753" xlink:to="vstm_NumberOfVotesPerEachShareOfCommonStock_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639082545816052753" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_639082545816052753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram" xlink:label="vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_639082545816052753" xlink:to="vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_639082545816052753" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_639082545816052753" xlink:to="us-gaap_SharesOutstanding_639082545816052753" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProceedsFromIssuanceOfCommonStockNet" xlink:label="vstm_ProceedsFromIssuanceOfCommonStockNet_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_639082545816052753" xlink:to="vstm_ProceedsFromIssuanceOfCommonStockNet_639082545816052753" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_639082545816052753" xlink:to="us-gaap_SharesIssuedPricePerShare_639082545816052753" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_639082545816052753" xlink:to="us-gaap_PreferredStockSharesAuthorized_639082545816052753" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_639082545816052753" xlink:to="us-gaap_ConversionOfStockSharesConverted1_639082545816052753" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_639082545816052753" xlink:to="us-gaap_ConversionOfStockSharesIssued1_639082545816052753" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_639082545816052753" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_639082545816052753" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_639082545816052753" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_639082545816052753" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConversionOfPreferredStockConversionBlockerPercent" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerPercent_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_639082545816052753" xlink:to="vstm_ConversionOfPreferredStockConversionBlockerPercent_639082545816052753" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_639082545816052753" xlink:to="vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice_639082545816052753" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_639082545816052753" xlink:to="vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod_639082545816052753" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_WarrantAbstract" xlink:label="vstm_WarrantAbstract_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639082545816052753" xlink:to="vstm_WarrantAbstract_639082545816052753" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_WarrantAbstract_639082545816052753" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_WarrantAbstract_639082545816052753" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - Capital stock - November 2025 Public Offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="us-gaap_ScheduleOfStockByClassTable_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816052753" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639082545816052753" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_November2025PublicOfferingMember" xlink:label="vstm_November2025PublicOfferingMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816052753" xlink:to="vstm_November2025PublicOfferingMember_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_November2025PublicOfferingMember_639082545816052753" xlink:to="us-gaap_OverAllotmentOptionMember_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816052753" xlink:to="us-gaap_ClassOfStockLineItems_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares" xlink:label="vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816052753" xlink:to="vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares_639082545816052753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816052753" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639082545816052753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816052753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816052753" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816052753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_639082545816210104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816052753" xlink:to="us-gaap_SharePrice_639082545816210104" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639082545816210104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816052753" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639082545816210104" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639082545816210104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816052753" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639082545816210104" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639082545816210104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816052753" xlink:to="us-gaap_SharesIssuedPricePerShare_639082545816210104" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639082545816213755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816052753" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639082545816213755" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails" xlink:type="extended" xlink:title="99941003 - Disclosure - Capital stock - April 2025 Private Placement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_639082545816213755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_5" xlink:to="us-gaap_ScheduleOfStockByClassTable_639082545816213755" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639082545816213755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816213755" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639082545816213755" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816213755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639082545816213755" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816213755" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PrivatePlacement2025Member" xlink:label="vstm_PrivatePlacement2025Member_639082545816213755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816213755" xlink:to="vstm_PrivatePlacement2025Member_639082545816213755" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816213755" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639082545816219021" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantMember" xlink:label="vstm_PreFundedWarrantMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639082545816219021" xlink:to="vstm_PreFundedWarrantMember_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816213755" xlink:to="us-gaap_ClassOfStockLineItems_639082545816219021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_SharesIssuedPricePerShare_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639082545816219021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639082545816219021" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod" xlink:label="vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod_639082545816219021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" xlink:label="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder_639082545816219021" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_639082545816219021" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails" xlink:type="extended" xlink:title="99941004 - Disclosure - Capital stock - Stock Purchase Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_4" xlink:to="us-gaap_ScheduleOfStockByClassTable_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="us-gaap_DebtInstrumentAxis_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639082545816219021" xlink:to="us-gaap_DebtInstrumentNameDomain_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NotePurchaseAgreementMember" xlink:label="vstm_NotePurchaseAgreementMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639082545816219021" xlink:to="vstm_NotePurchaseAgreementMember_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639082545816219021" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockPurchaseAgreementMember" xlink:label="vstm_StockPurchaseAgreementMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816219021" xlink:to="vstm_StockPurchaseAgreementMember_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="us-gaap_ClassOfStockLineItems_639082545816219021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_SharesIssuedPricePerShare_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639082545816219021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_639082545816219021" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockPurchaseRightPeriod" xlink:label="vstm_StockPurchaseRightPeriod_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_StockPurchaseRightPeriod_639082545816219021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockPurchaseRightMaximumAmount" xlink:label="vstm_StockPurchaseRightMaximumAmount_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_StockPurchaseRightMaximumAmount_639082545816219021" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails" xlink:type="extended" xlink:title="99941005 - Disclosure - Capital stock - July 2024 and June 2023 Public Offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_2" xlink:to="us-gaap_ScheduleOfStockByClassTable_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639082545816219021" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_July2024PublicOfferingMember" xlink:label="vstm_July2024PublicOfferingMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816219021" xlink:to="vstm_July2024PublicOfferingMember_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_UnderwritingAgreementMember" xlink:label="vstm_UnderwritingAgreementMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816219021" xlink:to="vstm_UnderwritingAgreementMember_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639082545816219021" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639082545816219021" xlink:to="us-gaap_WarrantMember_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantMember" xlink:label="vstm_PreFundedWarrantMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639082545816219021" xlink:to="vstm_PreFundedWarrantMember_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="us-gaap_StatementEquityComponentsAxis_639082545816219021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639082545816219021" xlink:to="us-gaap_EquityComponentDomain_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantMember" xlink:label="vstm_PreFundedWarrantMember_6390825458162190211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_639082545816219021" xlink:to="vstm_PreFundedWarrantMember_6390825458162190211" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_639082545816219021" xlink:to="us-gaap_CommonStockMember_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="srt_CounterpartyNameAxis_639082545816219021" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639082545816219021" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PublicMember" xlink:label="vstm_PublicMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816219021" xlink:to="vstm_PublicMember_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="us-gaap_ClassOfStockLineItems_639082545816219021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_SharesIssuedPricePerShare_639082545816219021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639082545816219021" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639082545816219021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_639082545816219021" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants" xlink:label="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants_639082545816219021" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder" xlink:label="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder_639082545816219021" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod" xlink:label="vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod_639082545816219021" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_WarrantsAndRightsOutstanding_639082545816219021" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_639082545816219021" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants_639082545816219021" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_StockIssuedDuringPeriodValueExerciseOfWarrants_639082545816219021" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_639082545816219021" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639082545816219021" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock" xlink:label="vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock_639082545816219021" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_639082545816219021" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816219021" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_SharePrice_639082545816219021" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CommonStockSharesOffered" xlink:label="vstm_CommonStockSharesOffered_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_CommonStockSharesOffered_639082545816219021" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage" xlink:label="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage_639082545816219021" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantElectionToExerciseNoticePeriod" xlink:label="vstm_PreFundedWarrantElectionToExerciseNoticePeriod_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_PreFundedWarrantElectionToExerciseNoticePeriod_639082545816219021" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage" xlink:label="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage_639082545816219021" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts" xlink:label="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts_639082545816219021" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639082545816219021" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares" xlink:label="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares_639082545816219021" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantsWarrantsOutstanding" xlink:label="vstm_PreFundedWarrantsWarrantsOutstanding_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_PreFundedWarrantsWarrantsOutstanding_639082545816219021" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_639082545816219021" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="99941006 - Disclosure - Capital stock - Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_1" xlink:to="us-gaap_ScheduleOfStockByClassTable_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="us-gaap_StatementClassOfStockAxis_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639082545816219021" xlink:to="us-gaap_ClassOfStockDomain_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesBConvertiblePreferredStockMember" xlink:label="vstm_SeriesBConvertiblePreferredStockMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639082545816219021" xlink:to="vstm_SeriesBConvertiblePreferredStockMember_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesaConvertiblePreferredStockMember" xlink:label="vstm_SeriesaConvertiblePreferredStockMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639082545816219021" xlink:to="vstm_SeriesaConvertiblePreferredStockMember_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="srt_RangeAxis_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639082545816219021" xlink:to="srt_RangeMember_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639082545816219021" xlink:to="srt_MaximumMember_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639082545816219021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639082545816219021" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816219021" xlink:to="us-gaap_PrivatePlacementMember_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="us-gaap_StatementEquityComponentsAxis_639082545816219021" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639082545816219021" xlink:to="us-gaap_EquityComponentDomain_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_639082545816219021" xlink:to="us-gaap_AdditionalPaidInCapitalMember_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_639082545816219021" xlink:to="us-gaap_CommonStockMember_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="srt_CounterpartyNameAxis_639082545816219021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639082545816219021" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_BiotechnologyValueFundMember" xlink:label="vstm_BiotechnologyValueFundMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816219021" xlink:to="vstm_BiotechnologyValueFundMember_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="us-gaap_ClassOfStockLineItems_639082545816219021" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockConvertibleAggregateSharesToBeSold" xlink:label="vstm_PreferredStockConvertibleAggregateSharesToBeSold_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_PreferredStockConvertibleAggregateSharesToBeSold_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockIssueNumberOfTranches" xlink:label="vstm_PreferredStockIssueNumberOfTranches_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_PreferredStockIssueNumberOfTranches_639082545816219021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_639082545816219021" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConversionOfPreferredStockConversionBlockerPercent" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerPercent_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_ConversionOfPreferredStockConversionBlockerPercent_639082545816219021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice_639082545816219021" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod" xlink:label="vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod_639082545816219021" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816219021" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_SharesIssuedPricePerShare_639082545816219021" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_639082545816219021" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_639082545816219021" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockIssuanceThresholdSharePrice" xlink:label="vstm_PreferredStockIssuanceThresholdSharePrice_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_PreferredStockIssuanceThresholdSharePrice_639082545816219021" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockIssuanceExpectedClosingPeriod" xlink:label="vstm_PreferredStockIssuanceExpectedClosingPeriod_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_PreferredStockIssuanceExpectedClosingPeriod_639082545816219021" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche" xlink:label="vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche_639082545816219021" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockIssuanceThresholdAggregateTradingVolume" xlink:label="vstm_PreferredStockIssuanceThresholdAggregateTradingVolume_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_PreferredStockIssuanceThresholdAggregateTradingVolume_639082545816219021" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockIssuanceThresholdTradingDays" xlink:label="vstm_PreferredStockIssuanceThresholdTradingDays_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_PreferredStockIssuanceThresholdTradingDays_639082545816219021" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_PreferredStockLiquidationPreference_639082545816219021" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfPreferredStockConvertibleIntoCommonStock" xlink:label="vstm_NumberOfPreferredStockConvertibleIntoCommonStock_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_NumberOfPreferredStockConvertibleIntoCommonStock_639082545816219021" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_639082545816219021" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_639082545816219021" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_PreferredStockSharesOutstanding_639082545816219021" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SecondTrancheRightLiabilityNonCurrentFairValue" xlink:label="vstm_SecondTrancheRightLiabilityNonCurrentFairValue_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_SecondTrancheRightLiabilityNonCurrentFairValue_639082545816219021" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreferredStockTrancheLiability" xlink:label="vstm_PreferredStockTrancheLiability_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_PreferredStockTrancheLiability_639082545816219021" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability" xlink:label="vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability_639082545816219021" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_ConversionOfStockSharesConverted1_639082545816219021" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_ConversionOfStockSharesIssued1_639082545816219021" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails" xlink:type="extended" xlink:title="99941007 - Disclosure - Capital stock - At-the market equity offering program (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_3" xlink:to="us-gaap_ScheduleOfStockByClassTable_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="srt_CounterpartyNameAxis_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639082545816219021" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CantorFitzgeraldCo.Member" xlink:label="vstm_CantorFitzgeraldCo.Member_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816219021" xlink:to="vstm_CantorFitzgeraldCo.Member_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639082545816219021" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AtMarketEquityOfferingProgramMember" xlink:label="vstm_AtMarketEquityOfferingProgramMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639082545816219021" xlink:to="vstm_AtMarketEquityOfferingProgramMember_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="us-gaap_StatementEquityComponentsAxis_639082545816219021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639082545816219021" xlink:to="us-gaap_EquityComponentDomain_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_639082545816219021" xlink:to="us-gaap_CommonStockMember_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639082545816219021" xlink:to="us-gaap_ClassOfStockLineItems_639082545816219021" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram" xlink:label="vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ProceedsFromIssuanceOfCommonStockNet" xlink:label="vstm_ProceedsFromIssuanceOfCommonStockNet_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639082545816219021" xlink:to="vstm_ProceedsFromIssuanceOfCommonStockNet_639082545816219021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Stock-based compensation - Stock-based compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_639082545816219021" xlink:to="us-gaap_IncomeStatementLocationAxis_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_639082545816219021" xlink:to="us-gaap_IncomeStatementLocationDomain_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_639082545816219021" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SellingGeneralAndAdministrativeExpenseMember" xlink:label="vstm_SellingGeneralAndAdministrativeExpenseMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_639082545816219021" xlink:to="vstm_SellingGeneralAndAdministrativeExpenseMember_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_639082545816219021" xlink:to="us-gaap_PlanNameAxis_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_639082545816219021" xlink:to="us-gaap_PlanNameDomain_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EquityIncentivePlan2021Member" xlink:label="vstm_EquityIncentivePlan2021Member_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639082545816219021" xlink:to="vstm_EquityIncentivePlan2021Member_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IncentivePlan2012Member" xlink:label="vstm_IncentivePlan2012Member_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639082545816219021" xlink:to="vstm_IncentivePlan2012Member_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_InducementAwardProgramMember" xlink:label="vstm_InducementAwardProgramMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639082545816219021" xlink:to="vstm_InducementAwardProgramMember_639082545816219021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_639082545816219021" xlink:to="us-gaap_AwardTypeAxis_639082545816219021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EmployeeAndNonEmployeesStockOptionMember" xlink:label="vstm_EmployeeAndNonEmployeesStockOptionMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816219021" xlink:to="vstm_EmployeeAndNonEmployeesStockOptionMember_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816219021" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_639082545816219021" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_639082545816219021" xlink:to="srt_RangeAxis_639082545816219021" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639082545816219021" xlink:to="srt_RangeMember_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639082545816219021" xlink:to="srt_MaximumMember_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_639082545816219021" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfEquityCompensationPlans" xlink:label="vstm_NumberOfEquityCompensationPlans_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" xlink:to="vstm_NumberOfEquityCompensationPlans_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_639082545816219021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_639082545816219021" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639082545816219021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639082545816219021" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_639082545816219021" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_639082545816219021" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_639082545816219021" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_639082545816219021" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_639082545816219021" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" xlink:to="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized_639082545816219021" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" xlink:to="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved_639082545816219021" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_639082545816219021" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ReductionOfSharesAvailableForIssuance" xlink:label="vstm_ReductionOfSharesAvailableForIssuance_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639082545816219021" xlink:to="vstm_ReductionOfSharesAvailableForIssuance_639082545816219021" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - Stock-based compensation - Stock options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635419805721461597" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635419805721461597" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816219021" xlink:to="us-gaap_PlanNameAxis_639082545816219021" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_639082545816219021" xlink:to="us-gaap_PlanNameDomain_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockOptionExchangeProgramMember" xlink:label="vstm_StockOptionExchangeProgramMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639082545816219021" xlink:to="vstm_StockOptionExchangeProgramMember_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816219021" xlink:to="us-gaap_AwardTypeAxis_639082545816219021" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EmployeeAndNonEmployeesStockOptionMember" xlink:label="vstm_EmployeeAndNonEmployeesStockOptionMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816219021" xlink:to="vstm_EmployeeAndNonEmployeesStockOptionMember_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816219021" xlink:to="us-gaap_VestingAxis_639082545816219021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_639082545816219021" xlink:to="us-gaap_VestingDomain_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_639082545816219021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_639082545816219021" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816219021" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816219021" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_639082545816219021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_639082545816219021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816219021" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_639082545816219021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639082545816369517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639082545816369517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639082545816369517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639082545816369517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639082545816369517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639082545816369517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639082545816369517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639082545816369517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639082545816369517" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639082545816369517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_639082545816372541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639082545816369517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_639082545816372541" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639082545816369517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639082545816372541" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639082545816369517" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_639082545816372541" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639082545816372541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_639082545816372541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_639082545816372541" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6390825458163725411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6390825458163725411" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_639082545816372541" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816219021" xlink:to="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_639082545816372541" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_639082545816372541" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_639082545816372541" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816219021" xlink:to="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_639082545816372541" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6390825458163725411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6390825458163725411" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_639082545816372541" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_639082545816372541" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_639082545816372541" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_639082545816372541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816219021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639082545816372541" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639082545816372541" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639082545816372541" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_639082545816372541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639082545816372541" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_639082545816372541" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639082545816372541" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_639082545816372541" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_639082545816372541" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails" xlink:type="extended" xlink:title="99941103 - Disclosure - Stock-based compensation - Option Exchange Program (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635419797923686597" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635419797923686597" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816372541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816372541" xlink:to="us-gaap_PlanNameAxis_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_639082545816372541" xlink:to="us-gaap_PlanNameDomain_639082545816372541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockOptionExchangeProgramMember" xlink:label="vstm_StockOptionExchangeProgramMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639082545816372541" xlink:to="vstm_StockOptionExchangeProgramMember_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfEligibleStockholders" xlink:label="vstm_NumberOfEligibleStockholders_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="vstm_NumberOfEligibleStockholders_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_639082545816372541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_639082545816372541" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_639082545816372541" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="99941104 - Disclosure - Stock-based compensation - Restricted stock units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635956228828974449" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635956228828974449" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816372541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816372541" xlink:to="us-gaap_AwardTypeAxis_639082545816372541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816372541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816372541" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_639082545816372541" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816372541" xlink:to="us-gaap_VestingAxis_639082545816372541" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_639082545816372541" xlink:to="us-gaap_VestingDomain_639082545816372541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationAwardTrancheFourMember" xlink:label="vstm_ShareBasedCompensationAwardTrancheFourMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_639082545816372541" xlink:to="vstm_ShareBasedCompensationAwardTrancheFourMember_639082545816372541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedPaymentArrangementTrancheFiveMember" xlink:label="vstm_ShareBasedPaymentArrangementTrancheFiveMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_639082545816372541" xlink:to="vstm_ShareBasedPaymentArrangementTrancheFiveMember_639082545816372541" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" xlink:label="vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits" xlink:label="vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits_639082545816372541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfAnniversariesForVestingRestrictedStockUnits" xlink:label="vstm_NumberOfAnniversariesForVestingRestrictedStockUnits_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="vstm_NumberOfAnniversariesForVestingRestrictedStockUnits_639082545816372541" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_639082545816372541" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_639082545816372541" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_639082545816372541" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_639082545816372541" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_639082545816372541" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_639082545816372541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6390825458163725411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6390825458163725411" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_639082545816372541" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_639082545816372541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6390825458163725411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6390825458163725411" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended" xlink:title="99941105 - Disclosure - Stock-based compensation - Employee stock purchase plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816372541" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816372541" xlink:to="us-gaap_AwardTypeAxis_639082545816372541" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816372541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639082545816372541" xlink:to="us-gaap_EmployeeStockMember_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods" xlink:label="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_639082545816372541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_639082545816372541" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_639082545816372541" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_639082545816372541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_639082545816372541" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_639082545816372541" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639082545816372541" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_639082545816372541" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSegmentReportingDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Segment Reporting (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_NumberOfOperatingSegments_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_NumberOfReportableSegments_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - Segment Reporting - Segment net loss including segment expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_3" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_639082545816372541" xlink:to="us-gaap_StatementBusinessSegmentsAxis_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_639082545816372541" xlink:to="us-gaap_SegmentDomain_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember" xlink:label="vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_639082545816372541" xlink:to="vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_639082545816372541" xlink:to="srt_ProductOrServiceAxis_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_639082545816372541" xlink:to="srt_ProductsAndServicesDomain_639082545816372541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639082545816372541" xlink:to="us-gaap_ProductMember_639082545816372541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CopiktraLicenseAndRelatedAssetsMember" xlink:label="vstm_CopiktraLicenseAndRelatedAssetsMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639082545816372541" xlink:to="vstm_CopiktraLicenseAndRelatedAssetsMember_639082545816372541" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_639082545816372541" xlink:to="us-gaap_SegmentReportingInformationLineItems_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_639082545816372541" xlink:to="us-gaap_RevenuesAbstract_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_639082545816372541" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_639082545816372541" xlink:to="us-gaap_CostsAndExpensesAbstract_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CostOfGoodsSoldExcludingAmortization" xlink:label="vstm_CostOfGoodsSoldExcludingAmortization_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545816372541" xlink:to="vstm_CostOfGoodsSoldExcludingAmortization_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545816372541" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense" xlink:label="vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545816372541" xlink:to="vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CommercialExpenditure" xlink:label="vstm_CommercialExpenditure_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545816372541" xlink:to="vstm_CommercialExpenditure_639082545816372541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_MedicalAffairExpenditure" xlink:label="vstm_MedicalAffairExpenditure_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545816372541" xlink:to="vstm_MedicalAffairExpenditure_639082545816372541" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545816372541" xlink:to="us-gaap_GeneralAndAdministrativeExpense_639082545816372541" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545816372541" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_639082545816372541" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545816372541" xlink:to="us-gaap_Depreciation_639082545816372541" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545816372541" xlink:to="us-gaap_InvestmentIncomeInterest_639082545816372541" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545816372541" xlink:to="us-gaap_InterestExpense_639082545816372541" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545816372541" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_639082545816372541" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IncomeLossFromPreferredStockTrancheLiability" xlink:label="vstm_IncomeLossFromPreferredStockTrancheLiability_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545816372541" xlink:to="vstm_IncomeLossFromPreferredStockTrancheLiability_639082545816372541" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545816372541" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639082545816372541" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FairValueAdjustmentOfNotes" xlink:label="vstm_FairValueAdjustmentOfNotes_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545816372541" xlink:to="vstm_FairValueAdjustmentOfNotes_639082545816372541" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545816372541" xlink:to="us-gaap_SegmentReportingOtherItemAmount_639082545816372541" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639082545816372541" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639082545816372541" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_639082545816372541" xlink:to="us-gaap_NetIncomeLoss_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_639082545816372541" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription_639082545816372541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Net loss per share - Potentially dilutive shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639082545816372541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639082545816372541" xlink:to="us-gaap_StatementClassOfStockAxis_639082545816372541" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639082545816372541" xlink:to="us-gaap_ClassOfStockDomain_639082545816372541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesaConvertiblePreferredStockMember" xlink:label="vstm_SeriesaConvertiblePreferredStockMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639082545816372541" xlink:to="vstm_SeriesaConvertiblePreferredStockMember_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SeriesBConvertiblePreferredStockMember" xlink:label="vstm_SeriesBConvertiblePreferredStockMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639082545816372541" xlink:to="vstm_SeriesBConvertiblePreferredStockMember_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639082545816372541" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639082545816372541" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639082545816372541" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_639082545816372541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639082545816372541" xlink:to="us-gaap_EmployeeStockOptionMember_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639082545816372541" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639082545816372541" xlink:to="us-gaap_WarrantMember_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639082545816372541" xlink:to="us-gaap_EmployeeStockMember_639082545816372541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639082545816372541" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_639082545816372541" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - Income Taxes - Income Tax Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816372541" xlink:to="srt_ProductOrServiceAxis_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_639082545816372541" xlink:to="srt_ProductsAndServicesDomain_639082545816372541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CopiktraLicenseAndRelatedAssetsMember" xlink:label="vstm_CopiktraLicenseAndRelatedAssetsMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639082545816372541" xlink:to="vstm_CopiktraLicenseAndRelatedAssetsMember_639082545816372541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816372541" xlink:to="srt_CounterpartyNameAxis_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639082545816372541" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SecuraBioInc.Member" xlink:label="vstm_SecuraBioInc.Member_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816372541" xlink:to="vstm_SecuraBioInc.Member_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816372541" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816372541" xlink:to="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816372541" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816372541" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816372541" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816372541" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816372541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816372541" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="99941402 - Disclosure - Income Taxes - Reconciliation of Income Taxes and Deferred Tax Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_639082545816372541" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable_639082545816372541" xlink:to="us-gaap_IncomeTaxAuthorityAxis_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_639082545816372541" xlink:to="us-gaap_IncomeTaxAuthorityDomain_639082545816372541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639082545816372541" xlink:to="us-gaap_InternalRevenueServiceIRSMember_639082545816372541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639082545816372541" xlink:to="us-gaap_ForeignCountryMember_639082545816372541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable_639082545816372541" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_639082545816372541" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639082545816372541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_639082545816372541" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639082545816372541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639082545816372541" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639082545816372541" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639082545816372541" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_639082545816528390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639082545816372541" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639082545816528390" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639082545816372541" xlink:to="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount_639082545816528390" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639082545816372541" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_639082545816528390" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639082545816372541" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_639082545816528390" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639082545816372541" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639082545816528390" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xlink:label="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefit_639082545816528390" xlink:to="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_639082545816372541" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639082545816528390" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639082545816528390" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639082545816528390" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_639082545816528390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639082545816528390" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639082545816528390" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639082545816528390" xlink:to="vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent_639082545816528390" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639082545816528390" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_639082545816528390" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639082545816528390" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_639082545816528390" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639082545816528390" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_639082545816528390" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent" xlink:label="vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639082545816528390" xlink:to="vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent_639082545816528390" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639082545816528390" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_639082545816528390" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639082545816528390" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_639082545816528390" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_639082545816372541" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639082545816528390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639082545816528390" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639082545816528390" xlink:to="vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639082545816528390" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_639082545816528390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639082545816528390" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_639082545816528390" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxAssetsInstallmentSale" xlink:label="vstm_DeferredTaxAssetsInstallmentSale_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639082545816528390" xlink:to="vstm_DeferredTaxAssetsInstallmentSale_639082545816528390" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxAssetsLeaseLiability" xlink:label="vstm_DeferredTaxAssetsLeaseLiability_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639082545816528390" xlink:to="vstm_DeferredTaxAssetsLeaseLiability_639082545816528390" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639082545816528390" xlink:to="us-gaap_DeferredTaxAssetsOther_639082545816528390" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639082545816528390" xlink:to="us-gaap_DeferredTaxAssetsGross_639082545816528390" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_639082545816372541" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_639082545816528390" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="vstm_DeferredTaxLiabilitiesRightOfUseAsset_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_639082545816528390" xlink:to="vstm_DeferredTaxLiabilitiesRightOfUseAsset_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_639082545816372541" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_639082545816528390" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance" xlink:label="vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_639082545816372541" xlink:to="vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance_639082545816528390" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_639082545816372541" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_639082545816528390" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_639082545816372541" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_639082545816528390" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_639082545816372541" xlink:to="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816528390" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod" xlink:label="vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816528390" xlink:to="vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816528390" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OperatingLossCarryforwardsPriorToOwnershipChanges" xlink:label="vstm_OperatingLossCarryforwardsPriorToOwnershipChanges_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816528390" xlink:to="vstm_OperatingLossCarryforwardsPriorToOwnershipChanges_639082545816528390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges" xlink:label="vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816528390" xlink:to="vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges_639082545816528390" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OperatingLossCarryforwardsSection382Limitation" xlink:label="vstm_OperatingLossCarryforwardsSection382Limitation_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816528390" xlink:to="vstm_OperatingLossCarryforwardsSection382Limitation_639082545816528390" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816528390" xlink:to="us-gaap_UnrecognizedTaxBenefits_639082545816528390" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816528390" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_639082545816528390" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract_639082545816528390" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_639082545816528390" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xlink:type="extended" xlink:title="99941403 - Disclosure - Income Taxes - Operating Loss Carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_639082545816528390" xlink:to="us-gaap_IncomeTaxAuthorityAxis_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_639082545816528390" xlink:to="us-gaap_IncomeTaxAuthorityDomain_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639082545816528390" xlink:to="us-gaap_InternalRevenueServiceIRSMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639082545816528390" xlink:to="us-gaap_StateAndLocalJurisdictionMember_639082545816528390" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_639082545816528390" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_639082545816528390" xlink:to="us-gaap_OperatingLossCarryforwards_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OperatingLossCarryforwardsIndefinitePeriod" xlink:label="vstm_OperatingLossCarryforwardsIndefinitePeriod_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_639082545816528390" xlink:to="vstm_OperatingLossCarryforwardsIndefinitePeriod_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureIncomeTaxesTaxCreditsDetails" xlink:type="extended" xlink:title="99941404 - Disclosure - Income Taxes - Tax Credits (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardTable_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_639082545816528390" xlink:to="us-gaap_IncomeTaxAuthorityAxis_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_639082545816528390" xlink:to="us-gaap_IncomeTaxAuthorityDomain_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639082545816528390" xlink:to="us-gaap_InternalRevenueServiceIRSMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639082545816528390" xlink:to="us-gaap_StateAndLocalJurisdictionMember_639082545816528390" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_639082545816528390" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_639082545816528390" xlink:to="us-gaap_TaxCreditCarryforwardAmount_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99941501 - Disclosure - Commitments and contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_635587317778956428" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_635587317778956428" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545816528390" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545816528390" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639082545816528390" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639082545816528390" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_OfficeAndLaboratorySpaceLeaseArrangementMember" xlink:label="vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639082545816528390" xlink:to="vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545816528390" xlink:to="us-gaap_CreditFacilityAxis_639082545816528390" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_639082545816528390" xlink:to="us-gaap_CreditFacilityDomain_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_639082545816528390" xlink:to="us-gaap_LetterOfCreditMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545816528390" xlink:to="us-gaap_BalanceSheetLocationAxis_639082545816528390" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_639082545816528390" xlink:to="us-gaap_BalanceSheetLocationDomain_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_RestrictedCashAndCashEquivalentsNoncurrentMember" xlink:label="vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_639082545816528390" xlink:to="vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AccountsPayableCurrentMember" xlink:label="vstm_AccountsPayableCurrentMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_639082545816528390" xlink:to="vstm_AccountsPayableCurrentMember_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545816528390" xlink:to="srt_CounterpartyNameAxis_639082545816528390" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639082545816528390" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_IqviaIncMember" xlink:label="vstm_IqviaIncMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816528390" xlink:to="vstm_IqviaIncMember_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639082545816528390" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_639082545816528390" order="5" use="optional" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639082545816528390" xlink:to="us-gaap_AreaOfRealEstateProperty_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639082545816528390" xlink:to="us-gaap_SecurityDeposit_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639082545816528390" xlink:to="us-gaap_OtherCommitment_639082545816528390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails" xlink:type="extended" xlink:title="99941601 - Disclosure - License, collaboration and commercial agreements - Pfizer, Inc. (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementAbstract" xlink:label="vstm_LicenseAndCollaborationAgreementAbstract_636814137101229079" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_LicenseAndCollaborationAgreementAbstract_636814137101229079" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="srt_CounterpartyNameAxis_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639082545816528390" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PfizerIncMember" xlink:label="vstm_PfizerIncMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816528390" xlink:to="vstm_PfizerIncMember_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="srt_StatementScenarioAxis_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_639082545816528390" xlink:to="srt_ScenarioUnspecifiedDomain_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfFdaApprovalMember" xlink:label="vstm_AchievementOfFdaApprovalMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816528390" xlink:to="vstm_AchievementOfFdaApprovalMember_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfFdaApprovalAnniversaryMember" xlink:label="vstm_AchievementOfFdaApprovalAnniversaryMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816528390" xlink:to="vstm_AchievementOfFdaApprovalAnniversaryMember_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" xlink:label="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816528390" xlink:to="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_639082545816528390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfCertainSalesMilestonesMember" xlink:label="vstm_AchievementOfCertainSalesMilestonesMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816528390" xlink:to="vstm_AchievementOfCertainSalesMilestonesMember_639082545816528390" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="srt_RangeAxis_639082545816528390" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639082545816528390" xlink:to="srt_RangeMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639082545816528390" xlink:to="srt_MaximumMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CollaborativeArrangementsOneTimeCashPayment" xlink:label="vstm_CollaborativeArrangementsOneTimeCashPayment_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_CollaborativeArrangementsOneTimeCashPayment_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PotentialMilestonePayments" xlink:label="vstm_PotentialMilestonePayments_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_PotentialMilestonePayments_639082545816528390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_639082545816528390" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="us-gaap_InterestExpense_639082545816528390" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CollaborativeArrangementsRoyaltyObligationsTerm" xlink:label="vstm_CollaborativeArrangementsRoyaltyObligationsTerm_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_CollaborativeArrangementsRoyaltyObligationsTerm_639082545816528390" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails" xlink:type="extended" xlink:title="99941602 - Disclosure - License, collaboration and commercial agreements - License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementAbstract" xlink:label="vstm_LicenseAndCollaborationAgreementAbstract_636814137101229079_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_LicenseAndCollaborationAgreementAbstract_636814137101229079_1" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="us-gaap_TypeOfArrangementAxis_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_639082545816528390" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ExclusiveLicenseAgreementMember" xlink:label="vstm_ExclusiveLicenseAgreementMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639082545816528390" xlink:to="vstm_ExclusiveLicenseAgreementMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="srt_StatementScenarioAxis_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_639082545816528390" xlink:to="srt_ScenarioUnspecifiedDomain_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfFdaApprovalMember" xlink:label="vstm_AchievementOfFdaApprovalMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816528390" xlink:to="vstm_AchievementOfFdaApprovalMember_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfFdaApprovalAnniversaryMember" xlink:label="vstm_AchievementOfFdaApprovalAnniversaryMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816528390" xlink:to="vstm_AchievementOfFdaApprovalAnniversaryMember_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PursuantToLicenseAgreementMember" xlink:label="vstm_PursuantToLicenseAgreementMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816528390" xlink:to="vstm_PursuantToLicenseAgreementMember_639082545816528390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" xlink:label="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816528390" xlink:to="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_639082545816528390" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfCertainSalesMilestonesMember" xlink:label="vstm_AchievementOfCertainSalesMilestonesMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816528390" xlink:to="vstm_AchievementOfCertainSalesMilestonesMember_639082545816528390" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfPatents" xlink:label="vstm_NumberOfPatents_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_NumberOfPatents_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CollaborativeArrangementsOneTimeCashPayment" xlink:label="vstm_CollaborativeArrangementsOneTimeCashPayment_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_CollaborativeArrangementsOneTimeCashPayment_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639082545816528390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PotentialMilestonePayments" xlink:label="vstm_PotentialMilestonePayments_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_PotentialMilestonePayments_639082545816528390" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CollaborativeArrangementsRoyaltyObligationsTerm" xlink:label="vstm_CollaborativeArrangementsRoyaltyObligationsTerm_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_CollaborativeArrangementsRoyaltyObligationsTerm_639082545816528390" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_639082545816528390" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails" xlink:type="extended" xlink:title="99941603 - Disclosure - License, collaboration and commercial agreements - Genfleet Therapeutics (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementAbstract" xlink:label="vstm_LicenseAndCollaborationAgreementAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_LicenseAndCollaborationAgreementAbstract_1" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="us-gaap_TypeOfArrangementAxis_639082545816528390" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_639082545816528390" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementMember" xlink:label="vstm_LicenseAndCollaborationAgreementMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="srt_CounterpartyNameAxis_639082545816528390" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639082545816528390" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_GenfleetTherapeuticsShanghaiIncMember" xlink:label="vstm_GenfleetTherapeuticsShanghaiIncMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816528390" xlink:to="vstm_GenfleetTherapeuticsShanghaiIncMember_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_639082545816528390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_639082545816528390" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_639082545816528390" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="srt_RangeAxis_639082545816528390" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639082545816528390" xlink:to="srt_RangeMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639082545816528390" xlink:to="srt_MaximumMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="srt_StatementScenarioAxis_639082545816528390" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_639082545816528390" xlink:to="srt_ScenarioUnspecifiedDomain_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember" xlink:label="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816528390" xlink:to="vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_AchievementOfCertainSalesMilestonesMember" xlink:label="vstm_AchievementOfCertainSalesMilestonesMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816528390" xlink:to="vstm_AchievementOfCertainSalesMilestonesMember_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ExerciseOfAllThreeGenFleetOptionsMember" xlink:label="vstm_ExerciseOfAllThreeGenFleetOptionsMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816528390" xlink:to="vstm_ExerciseOfAllThreeGenFleetOptionsMember_639082545816528390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementUpfrontPayment" xlink:label="vstm_LicenseAndCollaborationAgreementUpfrontPayment_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementUpfrontPayment_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PotentialMilestonePayments" xlink:label="vstm_PotentialMilestonePayments_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_PotentialMilestonePayments_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments" xlink:label="vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments_639082545816528390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_639082545816528390" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable" xlink:label="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable_639082545816528390" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" xlink:label="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments_639082545816528390" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments" xlink:label="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments_639082545816528390" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements" xlink:label="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements_639082545816528390" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions" xlink:label="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions_639082545816528390" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement." xlink:label="vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement._639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement._639082545816528390" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach" xlink:label="vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach_639082545816528390" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails" xlink:type="extended" xlink:title="99941604 - Disclosure - License, collaboration and commercial agreements - Secura (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementAbstract" xlink:label="vstm_LicenseAndCollaborationAgreementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_LicenseAndCollaborationAgreementAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="us-gaap_TypeOfArrangementAxis_639082545816528390" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_639082545816528390" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementMember" xlink:label="vstm_LicenseAndCollaborationAgreementMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="srt_CounterpartyNameAxis_639082545816528390" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639082545816528390" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_SecuraBioInc.Member" xlink:label="vstm_SecuraBioInc.Member_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639082545816528390" xlink:to="vstm_SecuraBioInc.Member_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="srt_RangeAxis_639082545816528390" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639082545816528390" xlink:to="srt_RangeMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639082545816528390" xlink:to="srt_MaximumMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="srt_StatementScenarioAxis_639082545816528390" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_639082545816528390" xlink:to="srt_ScenarioUnspecifiedDomain_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember" xlink:label="vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember" xlink:label="vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember_639082545816528390" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember" xlink:label="vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember_639082545816528390" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="srt_ProductOrServiceAxis_639082545816528390" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_639082545816528390" xlink:to="srt_ProductsAndServicesDomain_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_CopiktraLicenseAndRelatedAssetsMember" xlink:label="vstm_CopiktraLicenseAndRelatedAssetsMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639082545816528390" xlink:to="vstm_CopiktraLicenseAndRelatedAssetsMember_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639082545816528390" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementUpfrontPayment" xlink:label="vstm_LicenseAndCollaborationAgreementUpfrontPayment_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementUpfrontPayment_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra_639082545816528390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale" xlink:label="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale_639082545816528390" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable" xlink:label="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable_639082545816528390" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments" xlink:label="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments_639082545816528390" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments" xlink:label="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments_639082545816528390" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements" xlink:label="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements_639082545816528390" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions" xlink:label="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions_639082545816528390" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement." xlink:label="vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement._639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement._639082545816528390" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_639082545816528390" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived" xlink:label="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639082545816528390" xlink:to="vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived_639082545816528390" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureNotesPayableDetails" xlink:type="extended" xlink:title="99941701 - Disclosure - Notes Payable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_639082545816528390" xlink:to="us-gaap_DebtInstrumentAxis_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_639082545816528390" xlink:to="us-gaap_DebtInstrumentNameDomain_639082545816528390" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_FirstInsuranceFundingMember" xlink:label="vstm_FirstInsuranceFundingMember_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_639082545816528390" xlink:to="vstm_FirstInsuranceFundingMember_639082545816528390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems_639082545816528390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_639082545816528390" xlink:to="us-gaap_ShortTermDebtLineItems_639082545816528390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_639082545816528390" xlink:to="us-gaap_DebtInstrumentFaceAmount_639082545816685599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_639082545816528390" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_639082545816685599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_639082545816528390" xlink:to="us-gaap_RepaymentsOfShortTermDebt_639082545816685599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_639082545816528390" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_639082545816685599" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_639082545816528390" xlink:to="us-gaap_NotesPayable_639082545816685599" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureEmployeeBenefitPlanDetails" xlink:type="extended" xlink:title="99941801 - Disclosure - Employee benefit plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_639082545816685599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureVendorFinancingArrangementRollForwardDetails" xlink:type="extended" xlink:title="99941901 - Disclosure - Vendor Financing Arrangement - Roll forward (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_VendorFinancingAgreementAbstract" xlink:label="vstm_VendorFinancingAgreementAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationRollForward" xlink:label="us-gaap_SupplierFinanceProgramObligationRollForward_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vstm_VendorFinancingAgreementAbstract_3" xlink:to="us-gaap_SupplierFinanceProgramObligationRollForward_639082545816685599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligation" xlink:label="us-gaap_SupplierFinanceProgramObligation_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramObligationRollForward_639082545816685599" xlink:to="us-gaap_SupplierFinanceProgramObligation_639082545816685599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligation" xlink:label="us-gaap_SupplierFinanceProgramObligation_6390825458166855991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramObligationRollForward_639082545816685599" xlink:to="us-gaap_SupplierFinanceProgramObligation_6390825458166855991" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramObligationRollForward_639082545816685599" xlink:to="us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration_639082545816685599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.verastem.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99942001 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_639082545816685599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639082545816685599" xlink:to="us-gaap_SubsequentEventTypeAxis_639082545816685599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_639082545816685599" xlink:to="us-gaap_SubsequentEventTypeDomain_639082545816685599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_639082545816685599" xlink:to="us-gaap_SubsequentEventMember_639082545816685599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639082545816685599" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639082545816685599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639082545816685599" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639082545816685599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_PreFundedWarrantMember" xlink:label="vstm_PreFundedWarrantMember_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639082545816685599" xlink:to="vstm_PreFundedWarrantMember_639082545816685599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639082545816685599" xlink:to="us-gaap_SubsequentEventLineItems_639082545816685599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:label="vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639082545816685599" xlink:to="vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised_639082545816685599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vstm-20251231.xsd#vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639082545816685599" xlink:to="vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants_639082545816685599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639082545816685599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639082545816685599" xlink:to="us-gaap_ProceedsFromWarrantExercises_639082545816685599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended" xlink:title="995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 27, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Verastem,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3269467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">117 Kendrick Street, Suite&#160;500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Needham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">292-4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VSTM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,804,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,835,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001526119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">Portions of the definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A relating to the Registrant&#8217;s Annual General Meeting of Shareholders, to be held on May 21, 2026 will be incorporated by reference in this Form 10-K in response to Items 10, 11, 12, 13 and 14 of Part III. The definitive proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December&#160;31, 2025.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 204,990<span></span>
</td>
<td class="nump">$ 88,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">8,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_GrantsReceivableNet', window );">Grant receivable</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,577<span></span>
</td>
<td class="nump">5,943<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">223,413<span></span>
</td>
<td class="nump">94,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">16,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,112<span></span>
</td>
<td class="nump">4,899<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">246,442<span></span>
</td>
<td class="nump">101,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,448<span></span>
</td>
<td class="nump">4,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses, short-term</a></td>
<td class="nump">53,981<span></span>
</td>
<td class="nump">25,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationCurrent', window );">Vendor financing arrangement, short-term</a></td>
<td class="nump">5,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, short-term</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">995<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">72,268<span></span>
</td>
<td class="nump">30,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Long-term debt</a></td>
<td class="nump">76,330<span></span>
</td>
<td class="nump">40,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationNoncurrent', window );">Vendor financing arrangement, long-term</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">35,647<span></span>
</td>
<td class="nump">58,199<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">189,245<span></span>
</td>
<td class="nump">130,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ConvertiblePreferredStockAbstract', window );"><strong>Convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue', window );">Series B Convertible Preferred Stock, $0.0001 par value; 944 shares designated at December 31, 2025 and December 31, 2024, respectively; 0 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 5,000 shares authorized: Series A Convertible Preferred Stock, $0.0001 par value; 0 shares and 1,000 shares designated at December 31, 2025 and December 31, 2024, respectively, 0 shares and 1,000 shares issued and outstanding at December 31, 2025 and at December 31, 2024, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000 shares authorized, 77,740 and 44,784 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,216,958<span></span>
</td>
<td class="nump">926,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">5,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,164,998)<span></span>
</td>
<td class="num">(955,527)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">57,197<span></span>
</td>
<td class="num">(28,893)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' equity</a></td>
<td class="nump">$ 246,442<span></span>
</td>
<td class="nump">$ 101,538<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding nonredeemable convertible preferred stock or outstanding convertible preferred stock that is redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation for supplier finance program, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation for supplier finance program, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_GrantsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of eligible expenses incurred in excess of grant payments received up to the total amount of grants, which are recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_GrantsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">77,740,000<span></span>
</td>
<td class="nump">44,784,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">77,740,000<span></span>
</td>
<td class="nump">44,784,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vstm_SeriesaConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vstm_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PreferredStockSharesDesignated', window );">Preferred stock, shares designated</a></td>
<td class="nump">944,000<span></span>
</td>
<td class="nump">944,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_PreferredStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of preferred shares designated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_PreferredStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vstm_SeriesaConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vstm_SeriesaConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vstm_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vstm_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 30,914<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_CostOfGoodsSoldExcludingAmortization', window );">Cost of sales - product</a></td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Cost of sales - intangible amortization</a></td>
<td class="nump">698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">114,599<span></span>
</td>
<td class="nump">81,334<span></span>
</td>
<td class="nump">$ 61,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">81,146<span></span>
</td>
<td class="nump">43,622<span></span>
</td>
<td class="nump">30,728<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">201,043<span></span>
</td>
<td class="nump">124,956<span></span>
</td>
<td class="nump">92,084<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(170,129)<span></span>
</td>
<td class="num">(114,956)<span></span>
</td>
<td class="num">(92,084)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(203)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">4,068<span></span>
</td>
<td class="nump">4,149<span></span>
</td>
<td class="nump">6,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,138)<span></span>
</td>
<td class="num">(4,562)<span></span>
</td>
<td class="num">(4,139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="num">(1,826)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_IncomeLossFromPreferredStockTrancheLiability', window );">Change in fair value of preferred stock tranche liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,189<span></span>
</td>
<td class="nump">2,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(27,492)<span></span>
</td>
<td class="num">(19,149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_FairValueAdjustmentOfNotes', window );">Change in fair value of Notes</a></td>
<td class="num">(12,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before taxes</a></td>
<td class="num">(209,471)<span></span>
</td>
<td class="num">(130,452)<span></span>
</td>
<td class="num">(87,367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (209,471)<span></span>
</td>
<td class="num">$ (130,637)<span></span>
</td>
<td class="num">$ (87,367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share-basic</a></td>
<td class="num">$ (3.02)<span></span>
</td>
<td class="num">$ (3.66)<span></span>
</td>
<td class="num">$ (3.96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share-diluted</a></td>
<td class="num">$ (3.02)<span></span>
</td>
<td class="num">$ (3.66)<span></span>
</td>
<td class="num">$ (3.96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding used in computing net loss per share - basic</a></td>
<td class="nump">69,309<span></span>
</td>
<td class="nump">35,713<span></span>
</td>
<td class="nump">22,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding used in computing net loss per share - diluted</a></td>
<td class="nump">69,309<span></span>
</td>
<td class="nump">35,713<span></span>
</td>
<td class="nump">22,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (209,471)<span></span>
</td>
<td class="num">$ (130,637)<span></span>
</td>
<td class="num">$ (87,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk', window );">Change in fair value of Notes attributable to instrument specific credit risk</a></td>
<td class="nump">5,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(204,242)<span></span>
</td>
<td class="num">(130,650)<span></span>
</td>
<td class="num">$ (87,354)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 30,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vstm_CopiktraLicenseAndRelatedAssetsMember', window );">Sale of COPIKTRA license and related assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_CostOfGoodsSoldExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities and intangible amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_CostOfGoodsSoldExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_FairValueAdjustmentOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_FairValueAdjustmentOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of notes attributable to instrument specific credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_IncomeLossFromPreferredStockTrancheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from change in value of preferred stock tranche liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_IncomeLossFromPreferredStockTrancheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vstm_CopiktraLicenseAndRelatedAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vstm_CopiktraLicenseAndRelatedAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Preferred stock </div>
<div>Series B Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Preferred stock </div>
<div>Series A Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Common stock </div>
<div>November 2025 Public Offering</div>
</th>
<th class="th">
<div>Common stock </div>
<div>Private Placement 2025</div>
</th>
<th class="th"><div>Common stock</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>November 2025 Public Offering</div>
</th>
<th class="th">
<div>Additional paid-in capital </div>
<div>Private Placement 2025</div>
</th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>November 2025 Public Offering</div></th>
<th class="th"><div>Private Placement 2025</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 784,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (737,523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,391<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,711,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87,367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts', window );">Issuance of common stock, and pre-funded warrants, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares', window );">Issuance of common stock, and pre-funded warrants, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,489,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Convertible Preferred Stock, net of issuance costs and preferred stock tranche liability</a></td>
<td class="nump">$ 21,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Convertible Preferred Stock, net of issuance costs and preferred stock tranche liability</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Issuance of common stock resulting from vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 21,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882,248<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="num">(824,890)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,374<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,281,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(130,637)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(130,637)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_SharesIssuedFromPreFundedWarrantExercises', window );">Issuance of common stock upon exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,538,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts', window );">Issuance of common stock, and pre-funded warrants, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares', window );">Issuance of common stock, and pre-funded warrants, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock resulting from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock resulting from exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of preferred stock</a></td>
<td class="num">$ (21,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of preferred stock (in shares)</a></td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,236,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Issuance of common stock resulting from vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">926,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(955,527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,893)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,784,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(209,471)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(209,471)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk', window );">Change in fair value of Notes attributable to instrument specific credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedDuringPeriodValueAtMarketTransactions', window );">Issuance of common stock resulting from at-the-market transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedDuringPeriodSharesAtMarketTransactions', window );">Issuance of common stock resulting from at-the-market transactions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock resulting from vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,416,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_SharesIssuedFromPreFundedWarrantExercises', window );">Issuance of common stock upon exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,499,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts', window );">Issuance of common stock, and pre-funded warrants, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,879<span></span>
</td>
<td class="nump">$ 69,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,880<span></span>
</td>
<td class="nump">$ 69,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares', window );">Issuance of common stock, and pre-funded warrants, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,405,863<span></span>
</td>
<td class="nump">3,429,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock resulting from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock resulting from exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,654,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,216,958<span></span>
</td>
<td class="nump">$ 5,229<span></span>
</td>
<td class="num">$ (1,164,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,197<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,739,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of notes attributable to instrument specific credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_SharesIssuedFromPreFundedWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares issued from holders exercising their pre-funded stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_SharesIssuedFromPreFundedWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_StockIssuedDuringPeriodSharesAtMarketTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of shares issued during the period from at the market transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_StockIssuedDuringPeriodSharesAtMarketTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period related to exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) issued during the period from a stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_StockIssuedDuringPeriodValueAtMarketTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period from at the market transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_StockIssuedDuringPeriodValueAtMarketTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate change in value during the period related to the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of an underwriting agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to an underwriting agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance of stock costs</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_IssuanceOfPreferredStockTrancheLiability', window );">Preferred stock tranche liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of preferred stock, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,179<span></span>
</td>
<td class="nump">$ 1,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_PrivatePlacement2025Member', window );">Private Placement 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance of stock costs</a></td>
<td class="nump">5,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_November2025PublicOfferingMember', window );">November 2025 Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance of stock costs</a></td>
<td class="nump">$ 6,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_IssuanceOfPreferredStockTrancheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock tranche liability that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_IssuanceOfPreferredStockTrancheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vstm_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_PrivatePlacement2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vstm_PrivatePlacement2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_November2025PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vstm_November2025PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (209,471)<span></span>
</td>
<td class="num">$ (130,637)<span></span>
</td>
<td class="num">$ (87,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_OperatingLeaseNonCashCost', window );">Non-cash operating lease cost</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,404<span></span>
</td>
<td class="nump">7,342<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred financing costs, debt discounts and premiums and discounts on available-for-sale marketable securities</a></td>
<td class="nump">29<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(1,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability', window );">Change in fair value of preferred stock tranche liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,189)<span></span>
</td>
<td class="num">(2,751)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">27,492<span></span>
</td>
<td class="nump">19,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_FairValueAdjustmentOfNotesNoncash', window );">Non-cash change in fair value of Notes</a></td>
<td class="nump">6,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">1,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(8,813)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_IncreaseDecreaseInGrantsReceivableNet', window );">Grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(1,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets and other assets</a></td>
<td class="num">(2,605)<span></span>
</td>
<td class="num">(596)<span></span>
</td>
<td class="num">(5,826)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">8,422<span></span>
</td>
<td class="num">(3,158)<span></span>
</td>
<td class="nump">2,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">30,833<span></span>
</td>
<td class="nump">7,999<span></span>
</td>
<td class="nump">2,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="num">(383)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(137,509)<span></span>
</td>
<td class="num">(104,771)<span></span>
</td>
<td class="num">(86,460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="num">(9,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,447)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(9,624)<span></span>
</td>
<td class="nump">59,972<span></span>
</td>
<td class="num">(44,447)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and pre-funded warrants, net</a></td>
<td class="nump">196,976<span></span>
</td>
<td class="nump">14,221<span></span>
</td>
<td class="nump">91,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from the issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Series B Convertible Preferred Stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">33,792<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from long-term debt</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(42,579)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfLoanCosts', window );">Payments for loan amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Repayment of 2018 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProceedsFromInsurancePremiumFinancing', window );">Proceeds from insurance premium financing</a></td>
<td class="nump">1,180<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PaymentsOnInsurancePremiumFinancing', window );">Payments on insurance premium financing</a></td>
<td class="num">(1,180)<span></span>
</td>
<td class="num">(1,298)<span></span>
</td>
<td class="num">(1,430)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options and employee stock purchase program</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">263,305<span></span>
</td>
<td class="nump">54,782<span></span>
</td>
<td class="nump">134,194<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">116,172<span></span>
</td>
<td class="nump">9,983<span></span>
</td>
<td class="nump">3,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">89,059<span></span>
</td>
<td class="nump">79,076<span></span>
</td>
<td class="nump">75,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">205,231<span></span>
</td>
<td class="nump">89,059<span></span>
</td>
<td class="nump">79,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">6,364<span></span>
</td>
<td class="nump">3,774<span></span>
</td>
<td class="nump">3,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income tax expense</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_IssuanceOfPreferredStockTrancheLiability', window );">Issuance of preferred stock tranche liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Issuance costs included in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series B Convertible Preferred Stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_FairValueAdjustmentOfWarrantsExercised', window );">Conversion of warrant liability into additional paid-in capital upon warrant exercise</a></td>
<td class="nump">50,044<span></span>
</td>
<td class="nump">545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use asset obtained in exchange for operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Purchases of intangible asset in accounts payable and accrued expenses</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfLoanCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan origination associated cost which is usually collected through escrow.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfLoanCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unrealized gain (loss) on the preferred stock tranche liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_FairValueAdjustmentOfNotesNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of notes, noncash portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_FairValueAdjustmentOfNotesNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_FairValueAdjustmentOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_FairValueAdjustmentOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_IncreaseDecreaseInGrantsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in eligible expenses incurred in excess of grant payments received up to the total amount of grants, which are recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_IncreaseDecreaseInGrantsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_IssuanceOfPreferredStockTrancheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock tranche liability that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_IssuanceOfPreferredStockTrancheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_OperatingLeaseNonCashCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, noncash, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_OperatingLeaseNonCashCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_PaymentsOnInsurancePremiumFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payments on insurance premium financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_PaymentsOnInsurancePremiumFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ProceedsFromInsurancePremiumFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received as payments from insurance premium financing during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ProceedsFromInsurancePremiumFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Verastem, Inc. (the &#8220;Company&#8221;)<span style="background:#ffffff;"> is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with </span>challenging RAS/MAPK pathway-driven cancers. The Company markets AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the U.S., the first treatment specifically FDA-approved for adults with KRAS-mutated recurrent LGSOC who have received prior systemic therapy. AVMAPKI FAKZYNJA CO-PACK received accelerated approval in the U.S. on May 8, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s pipeline is focused on novel small molecule drugs developed both as monotherapy and in combination, which inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including targeting RAS directly with KRAS G12D inhibition, targeting the pathway downstream with RAF/MEK inhibition, and targeting the parallel pathway that drives resistance with FAK inhibition. The Company&#8217;s focus is to expeditiously develop and deliver transformative therapies that truly change outcomes for people living with RAS/MAPK pathway-driven cancers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of Verastem Securities Company and Verastem Europe GmbH, wholly-owned subsidiaries of the Company.&#160;All financial information presented has been consolidated and includes the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the risks associated with other life science companies, including, but not limited to, possible failure of preclinical testing or clinical trials, competitors developing new technological innovations, commercial success of the Company&#8217;s marketed product AVMAPKI FAKZYNJA CO-PACK, inability to obtain marketing approval of the Company&#8217;s product candidates, market acceptance and commercial success of the Company&#8217;s product candidates following receipt of regulatory approval, and, protection of proprietary technology and the continued ability to obtain adequate financing to fund the Company&#8217;s future operations. Until such time, if ever, that the Company can generate substantial product revenues or achieve profitability, it may need to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, the Company had cash and cash equivalents of $205.0 million and an additional $29.4 million in proceeds in January 2026 from the exercise of Warrants (see <i style="font-style:italic;">Note 20. Subsequent Events</i>). <span style="background:#ffffff;">In accordance with applicable accounting standards, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within 12 months after the date of the issuance of these consolidated financial statements. </span>The Company expects its existing cash resources, including the proceeds from the exercise of Warrants in January 2026, along with revenue it expects to generate from sales of AVMAPKI FAKZYNJA CO-PACK and the availability to draw down $25.0 million under the Second Purchase (defined herein) pursuant to the Company&#8217;s Note Purchase Agreement (defined herein) (see <i style="font-style:italic;">Note 8. Long-term debt</i>) will be sufficient to fund its planned operations through 12 months from the date of issuance of these consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had concluded that there was substantial doubt about its ability to continue as a going concern primarily due to anticipated operating losses for the foreseeable future since the Company did not yet have regulatory approval to sell any of its product candidates, and the Company continued to incur operating costs to execute its strategic plan, including costs related to research and development of its product candidates and commercial readiness activities. The Company&#8217;s increased cash and cash equivalents position as of December 31, 2025, forecasted net product revenue following regulatory approval of AVMAPKI FAKZYNJA CO-PACK on May 8, 2025, and ability to draw down on the Second Purchase pursuant to the Note Purchase Agreement, alleviated the substantial doubt. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company expects to finance its operations with its existing cash and&#160;cash equivalents, through revenue generated from sales of AVMAPKI FAKZYNJA CO-PACK, through potential future milestones and royalties received pursuant to the Company&#8217;s Asset Purchase Agreement (&#8220;Secura APA&#8221;) with Secura Bio, Inc. (&#8220;Secura&#8221;), note drawdowns pursuant to the Note Purchase Agreement, or through other strategic financing opportunities that could include, but are not limited to collaboration agreements, future offerings of its equity, or the incurrence of debt. However, there is no guarantee that any of these strategic or financing opportunities will be executed or executed on favorable terms, and some could be dilutive to existing stockholders. If the Company fails to obtain additional future capital or generate sufficient net product revenue, it may be unable to complete its planned preclinical studies and clinical trials and obtain approval of certain investigational product candidates from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:14pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><span style="font-size:10pt;">On May 30, 2023, the Company filed a Certificate of Amendment to the Company&#8217;s Restated Certificate of Incorporation, as amended to date, with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company&#8217;s issued and outstanding common stock, par value </span><span style="font-size:10pt;">$0.0001</span><span style="font-size:10pt;">&#160;at a ratio of&#160;</span><span style="-sec-ix-hidden:Hidden_mxFYjHBtZEODqcY96vbZbg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-12</span></span><span style="font-size:10pt;">&#160;(the &#8220;Reverse Stock Split&#8221;), as authorized at the Company&#8217;s 2023 annual meeting of stockholders held on May 15, 2023. The Company effected the Reverse Stock Split on May 31, 2023. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise were entitled to a fractional share of common stock were entitled to receive a price equal to the closing price of the common stock on the Nasdaq Capital Market on the date immediately preceding the Reverse Stock Split, as adjusted by the ratio of&#160;</span><span style="-sec-ix-hidden:Hidden_UDYzqQ6S1E630AMzLLYW3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span><span style="font-size:10pt;">&#160;share of common stock for every 12 shares of common stock, multiplied by the applicable fraction of a share. The number of shares of common stock that the Company is authorized to issue remains at&#160;</span><span style="font-size:10pt;">300,000,000</span><span style="font-size:10pt;">&#160;shares and the par value of its common stock remains unchanged at </span><span style="font-size:10pt;">$0.0001</span><span style="font-size:10pt;">&#160;per share.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">The Company has retroactively restated the share and per share amounts in the consolidated financial statements for the year ended December 31, 2023, to give retroactive effect to the Reverse Stock Split. The consolidated statements of convertible preferred stock and stockholders&#8217; equity reflect the impact of the Reverse Stock Split by reclassifying from &#8220;common stock&#8221; to &#8220;additional paid-in capital&#8221; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split the year ended December 31, 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Significant accounting policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. Significant accounting policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis of presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) under the assumption that the Company will continue as a going concern for the next 12 months. Accordingly, they do not include any adjustments that might result from the uncertainty related to the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The preparation of the Company&#8217;s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including but not limited to estimates related to revenue recognition, accrued and prepaid clinical trial expense and other general accruals, stock-based compensation expense, long-term debt, and its warrant liability. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable. Actual results could differ from such estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Segment and geographic information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available and regularly reviewed by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">one operating segment, which is the business of researching, developing and commercializing drugs for the treatment of patients with cancer. All material long-lived assets of the Company reside in the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Proceeds from grants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><span style="font-size:10pt;">In May 2022, the Company was awarded the &#8220;Therapeutic Accelerator Award&#8221; grant from Pancreatic Cancer Network (&#8220;PanCAN&#8221;) for up to </span><span style="font-size:10pt;">$3.8</span><span style="font-size:10pt;">&#160;million (the &#8220;</span><span style="-sec-ix-hidden:Hidden_q90ZIR8th0OGZ8dK-5vu4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PanCAN Grant</span></span><span style="font-size:10pt;">&#8221;). In August 2022, PanCAN agreed to provide the Company with an additional </span><span style="font-size:10pt;">$0.5</span><span style="font-size:10pt;">&#160;million for the collection and analysis of patient samples. The grant is supporting a Phase 1b/2 clinical trial of GEMZAR (gemcitabine) and ABRAXANE (Nab-paclitaxel) in combination with avutometinib and defactinib entitled RAMP 205. The RAMP 205 trial is evaluating whether combining avutometinib (to target KRAS mutant, which is found in more than 90% of pancreatic adenocarcinomas), and defactinib (to reduce stromal density and adaptive resistance to avutometinib) to the standard GEMZAR/ABRAXANE regimen improves outcomes for patients with such pancreatic cancers. The Company recognizes grants as contra research and development expense in the consolidated statement of operations and comprehensive loss on a systematic basis over the periods in which the Company recognizes as expenses the related costs for which the grants are intended to compensate. Eligible expenses incurred in excess of grant payments received up to the total amount of the PanCAN Grant are recorded as a grant receivable. Through December 31, 2025, the Company has received </span><span style="font-size:10pt;">$4.1</span><span style="font-size:10pt;">&#160;million of cash proceeds that were initially recorded as deferred liabilities on the balance sheet. The Company recorded </span><span style="font-size:10pt;">$0.0</span><span style="font-size:10pt;"> million, </span><span style="font-size:10pt;">$2.0</span><span style="font-size:10pt;"> million and </span><span style="font-size:10pt;">$2.0</span><span style="font-size:10pt;white-space:pre-wrap;"> million of the proceeds as a reduction of research and development expense during the years ended December 31, 2025, 2024, and 2023, respectively.  As of December 31, 2025, the Company had </span><span style="font-size:10pt;">$0.2</span><span style="font-size:10pt;"> million as a </span><span style="-sec-ix-hidden:Hidden_LYd0gLsYTUK5twLVxNTSUw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">grant receivable</span></span><span style="font-size:10pt;"> and </span><span style="font-size:10pt;">no</span><span style="font-size:10pt;"> deferred liabilities related to the PanCAN Grant recognized on the consolidated balance sheet.</span><span style="font-size:10pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash, cash equivalents and restricted cash</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist of a U.S. Government money market funds and corporate bonds and commercial paper of publicly traded companies. Cash equivalents are reported at fair value. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:69.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 204,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88,818</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 241</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total cash, cash equivalents and restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 205,231</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 89,059</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Amounts included in restricted cash as of December 31, 2025 and December 31, 2024 represent cash held to collateralize outstanding letters of credit provided as a security deposit for the Company&#8217;s office space located in Needham, Massachusetts in the amount of $0.2&#160;million. The letters of credit are included in<span style="color:#212529;">&#160;prepaid expenses and other current assets </span>on the consolidated balance sheet as of December 31, 2025, and in non-current restricted cash as of December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were no realized gains or losses on cash equivalents for the years ended December 31, 2025, 2024 or 2023. Accrued interest receivable is excluded from the amortized cost and estimated fair value of the Company&#8217;s cash equivalents. Accrued interest receivable of $0.2 million is presented within prepaid expenses and other current assets on the consolidated balance sheets on December 31, 2025. There was no accrued interest receivable as of December </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">31, 2024. There were no debt securities in an unrealized loss position as of December 31, 2025, or December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Cash, cash equivalents &amp; restricted cash:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:9.5pt;">Cash and money market accounts</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 205,231</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 205,231</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Total cash, cash equivalents &amp; restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> 205,231</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> 205,231</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Cash, cash equivalents &amp; restricted cash:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:9.5pt;">Cash and money market accounts</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 89,059</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 89,059</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Total cash, cash equivalents &amp; restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> 89,059</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> 89,059</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Fair value of financial instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company determines the fair value of its financial instruments based upon the fair value hierarchy, which prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;">Level&#160;1 inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Quoted prices in active markets for identical assets or liabilities that the Company can access at the measurement date.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;">Level&#160;2 inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;">Level&#160;3 inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Items measured at fair value on a recurring basis</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The following table presents information about the Company&#8217;s financial instruments that are measured at fair value on a recurring basis (in thousands) </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 106,830</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 106,830</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,647</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,330</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 111,977</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 111,977</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 63,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 63,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 63,304</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 63,304</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,199</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 58,199</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 58,199</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 12pt 0pt;">The investments and cash equivalents have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. The Company validates the prices provided by third party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active. After completing its validation procedures, the Company did not adjust or override any fair value measurements provided by the pricing services as of December 31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrant liability</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A warrant liability was recorded in connection with the July 2024 Offering (defined herein) (see&#160;<i style="font-style:italic;">Note 10. Capital Stock</i>). The fair value measurement of the warrant liability is classified as Level 3 under the fair value hierarchy. The fair value of the warrant liability at December 31, 2025 and December 31, 2024, was determined using the Black-Scholes valuation model. The inputs to the Black-Scholes valuation model include the risk-free rate, stock price volatility, expected dividends and remaining term. Significant increases or decreases in any of those inputs in isolation could result in a significantly lower or higher fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Below are the inputs used to value the warrant liability at December 31, 2025 and December 31, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Remaining term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">1.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table represents a reconciliation of the warrant liability (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 58,199</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Fair value of warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (50,044)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Fair value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 27,492</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 35,647</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Note Purchase Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">The fair value of the Notes pursuant to the Note Purchase Agreement represents the present value of estimated future payments, including interest, principal, Repayment Amount, and Revenue Participation Payments (each as defined in the Note Purchase Agreement) <span style="background:#ffffff;">(see </span><i style="font-style:italic;background:#ffffff;">Note 8. Long-term debt</i><span style="background:#ffffff;">)</span>. The fair value measurement is based on significant Level 3 unobservable inputs such as the probability and timing of Revenue Participation Payments, Repayment Amount, and the discount rate. The Company determined the fair value of the Notes utilizing a discounted cash flow model of estimated future payments including interest, principal, Repayment Amount and Revenue Participation Payments utilizing a discount rate calculated as the term matched risk-free rate plus credit spread. At January 13, 2025, the Company utilized a discount rate between 11.9%-12.4% and at December 31, 2025, the Company utilized a discount rate between 12.6%-13.0%. The fair value of the Notes at December 31, 2025 was determined to be $76.3 million which differed from the contractual principal amount of $75.0 million by $1.3 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">million. Significant increases or decreases in any of these inputs in isolation could result in a significantly lower or higher fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Oxford Loan Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="background:#ffffff;">The fair value of the Company&#8217;s Term Loans (as defined herein) pursuant to the Loan Agreement (as defined herein) (see </span><i style="font-style:italic;background:#ffffff;">Note 10. Long-term debt</i><span style="background:#ffffff;">)</span><span style="background:#ffffff;"> was determined using a discounted cash flow analysis with current applicable rates for similar instruments as of the consolidated balance sheet dates. The Company estimated that the fair value of its Term Loans was approximately </span><span style="background:#ffffff;">$41.1</span><span style="background:#ffffff;"> million at December 31, 2024 which differed from its carrying value of approximately </span><span style="background:#ffffff;">$40.7</span><span style="background:#ffffff;"> million. The fair value of the Company&#8217;s long-term debt was determined using Level&#160;3 inputs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentrations of credit risk and off-balance sheet risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Cash and cash equivalents and trade accounts receivable are financial instruments that potentially subject the Company to concentrations of credit risk. The Company mitigates this risk by maintaining its cash and cash equivalents with high quality, accredited financial institutions. The management of the Company&#8217;s investments is not discretionary on the part of these financial institutions. As of December 31, 2025, the Company&#8217;s cash, cash equivalents were deposited at four financial institutions and it has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:12pt 0pt 0pt 0pt;">As of December 31, 2025 there were five customers that cumulatively made up 100% of the Company&#8217;s trade accounts receivable balance and two customers who cumulatively made up more than 60% of the Company&#8217;s trade accounts receivable balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2025, there were&#160;two&#160;customers who each individually accounted for greater than&#160;10% of the Company&#8217;s total revenues, for a total of $27.4 million. For the year ended December 31, 2024, there was&#160;one&#160;customer, Secura, who individually accounted for all of the Company&#8217;s revenue. Refer to&#160;<i style="font-style:italic;">Note 16. License, collaboration, and commercial agreements</i>&#160;for a detailed discussion of the Secura APA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Property and equipment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consist of laboratory equipment, office furniture, computer equipment and leasehold improvements. Expenditures for repairs and maintenance are recorded to expense as incurred, whereas major betterments are capitalized as additions to property and equipment. Depreciation and amortization are calculated using the straight-line method over the following estimated useful lives of the assets:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5&#160;years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5&#160;years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3&#160;years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lesser of useful life or life of lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying value of assets may not be recoverable. Recoverability is measured by comparison of the asset&#8217;s book value to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. No impairment losses have been recorded through December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cloud Computing Implementation Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company incurs costs to implement cloud computing arrangements that are hosted by third-party vendors. In accordance with Accounting Standard Codification (&#8220;ASC&#8221;) 350-40,&#160;Goodwill and Other, Internal-Use Software, for cloud computing arrangements that meet the definition of a service contract, the Company capitalizes qualifying implementation costs incurred during the application development stage as a component of prepaid expenses and other current assets and other assets. Capitalization of these costs concludes once the project is substantially complete, and the software is ready for the Company's intended use. Once available for its intended use, the capitalized costs are amortized on a straight-line basis over the term of the associated hosting arrangement, and are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss. Costs related to data conversion, overhead, general and administrative activities, and training are expensed as incurred. Post-configuration training and maintenance costs will be expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, prepaid expenses and other current assets, and other long-term assets, included approximately $0.4&#160;million each of capitalized implementation costs on the consolidated balance sheet.&#160;For the year ended December 31, 2025, the Company recorded amortization expense associated with cloud computing implementation costs of approximately $0.3 million recorded within selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research and development costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company expenses research and development costs to operations as incurred. Research and development expenses consist of: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">external research and development expenses incurred under arrangements with third parties, such as contract research organizations, clinical trial sites, manufacturing organizations and consultants, including the scientific advisory board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">license fees; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, and laboratory supplies.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Costs for certain development activities, such as clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendor on their actual costs incurred or level of effort expended. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid expenses and other current assets or accrued expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For service-based equity awards, the Company recognizes stock-based compensation expense for stock options, and restricted stock units (&#8220;RSUs&#8221;) issued to employees, directors, and consultants based on the grant date fair value of the awards on a straight-line basis over the requisite service period, which typically is the vest period. The Company recognized stock-based compensation for shares issued to employees under the Company&#8217;s employee stock purchase plan (&#8220;ESPP&#8221;) plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company has granted performance-based RSUs and stock options with terms that allow the recipients to vest in a specific number of shares based upon the achievement of performance-based milestones as specified in the grants. Stock-based compensation expense associated with these performance-based RSUs and stock options is recognized if the performance condition is considered probable of achievement using the Company&#8217;s best estimates of the time to vesting for the achievement of the performance-based milestones. </span>Awards subject to performance-based vesting requirements are expensed utilizing an accelerated attribution model if achievement of the performance criteria is determined to be probable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The grant date fair value of stock options is estimated using the Black-Scholes option pricing model that takes into account the fair value of its common stock, the exercise price, the expected life of the option, the expected volatility of its common stock, expected dividends on its common stock, and the risk-free interest rate over the expected life of the option. The Company applies the simplified method described in the Securities and Exchange Commission (&#8220;SEC&#8221;) Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 14.D.2 to calculate the expected term as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term for options granted to employees. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its population. The Company has not paid and do not anticipate paying cash dividends on the Company&#8217;s shares of common stock; therefore, the expected dividend yield is assumed to be zero. The computation of expected volatility is based on the historical volatility of the Company&#8217;s common stock. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options.<span style="background:#ffffff;"> The Company accounts for forfeitures as they occur.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">The Company issues shares under the Company&#8217;s ESPP to employees. Stock-based compensation expense for discounted purchases under the ESPP is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Leases are accounted for in accordance with ASC Topic 842, Leases (&#8220;ASC 842&#8221;).&#160;This standard requires lessees to recognize in the statement of financial position a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term for both finance and operating leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances within the arrangement.&#160;A lease is identified where an arrangement conveys the right to control the use of identified property, plant, and equipment for a period of time in exchange for consideration.&#160;Leases which are identified within the scope of ASC 842 and which have a term greater than one year are recognized on the Company&#8217;s consolidated balance sheets as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize leases with terms of one year or less on its consolidated balance sheets. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates to calculate the present value of lease payments.&#160;Incremental borrowing rates are the rates the Company incurs to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 842, components of a lease are split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, maintenance, consumables, etc.), and non-components (e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on fair values to the lease components and non-lease components. Although separation of lease and non-lease components is required, certain practical expedients are available. Entities may elect the practical expedient to not separate lease and non-lease components. Rather, they would account for each lease component and the related non-lease component together as a single component. The Company has elected to account for the lease and non-lease components of each of its operating leases as a single lease component and allocate all of the contract consideration to the lease component only. The lease component results in an operating right-of-use asset being recorded on the consolidated balance sheets and amortized on a straight-line basis as lease expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue recognition </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services in accordance with ASC Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;). To determine revenue recognition for contracts with its customers, the Company performs the following five step assessment: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception and once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines which goods and services are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">P</i><i style="font-style:italic;">roduct Revenue, Net</i> - The Company sells AVMAPKI FAKZYNJA CO-PACK to a limited number of specialty pharmacies and specialty distributors in the United States. The specialty pharmacies dispense AVMAPKI FAKZYNJA CO-PACK directly to patients while the specialty distributors resell AVMAPKI FAKZYNJA CO-PACK to healthcare entities who then resell AVMAPKI FAKZYNJA CO-PACK to patients. In addition to distribution agreements with specialty distributors, the Company also enters into arrangements with (1) certain government agencies and various private organizations (&#8220;Third-Party Purchasers&#8221;), which may provide for chargebacks or discounts with respect to the purchase of AVMAPKI FAKZYNJA CO-PACK, and (2) Medicare and Medicaid, which may provide for certain rebates with respect to their reimbursement of AVMAPKI FAKZYNJA CO-PACK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue on sales of AVMAPKI FAKZYNJA CO-PACK when a customer obtains control of the product, which occurs at a specific point in time (typically upon delivery). Product revenues are recorded at the wholesale acquisition costs, net of applicable reserves for variable consideration. Components of variable consideration include trade discounts and allowances, Third-Party Payer chargebacks and discounts, government rebates, product returns, other patient focused allowances, such as voluntary co-pay assistance, benefits verification, and other patient support programs that are offered within contracts between the Company and customers, payors, and other indirect customers relating to the Company&#8217;s sale of AVMAPKI FAKZYNJA CO-PACK. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable or a current liability. These estimates take into consideration a range of possible outcomes based upon relevant factors such as, customer contract terms, information received from third parties regarding the anticipated payor mix for AVMAPKI FAKZYNJA CO-PACK, known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled with respect to sales made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The amount of variable consideration included within a transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under contracts will not occur in a future period. The Company&#8217;s analyses contemplate the application of the constraint in accordance with Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standard Codification (&#8220;ASC&#8221;) 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). For the twelve months ended December 31, 2025, the Company determined a material reversal of revenue would not occur in a future period for the estimates detailed below and, therefore, transaction prices would not be reduced further. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual results in the future vary from the Company&#8217;s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Trade Discounts and Allowances: The Company generally provides customers with invoice discounts on sales of AVMAPKI FAKZYNJA CO-PACK for prompt payment and other discounts, which are explicitly stated in the Company&#8217;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates its specialty pharmacy and specialty distributor customers for sales order management, data, distribution, and certain other services. The Company has determined such services are not distinct from the Company&#8217;s sale of AVMAPKI FAKZYNJA CO-PACK to the specialty pharmacy and specialty distributor customers and, therefore, these payments have also been recorded as a reduction of revenue within the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-Party Payer Chargebacks, Discounts and Fees: The Company executes contracts with Third-Party Purchasers which allow for eligible purchases of AVMAPKI FAKZYNJA CO-PACK at prices lower than the wholesale acquisition cost. In some cases, customers will charge the Company for the difference between what they pay for </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">AVMAPKI FAKZYNJA CO-PACK and the ultimate selling price to the Third-Party Purchasers to whom they sell the product. Reserves will generally be established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable, net. Chargeback amounts will generally be determined at the time of resale to the qualified Third-Party Purchasers by customers, and the Company generally will issue credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. The reserves for chargebacks are expected to consist of credits that the Company expects to issue for units that remain in customer inventories at the end of each reporting period that the Company expects will be sold to Third-Party Purchasers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. <span style="color:#212529;background:#ffffff;">In addition, the Company compensated certain Third-Party Payers for administrative services, such as account management and data reporting. These administrative service fees have also been recorded as a reduction of net product revenue within the consolidated statements of operations and comprehensive loss.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Government Rebates: The Company is subject to discount and rebate payment obligations under various government programs including Federal and state Medicaid programs, Medicare, and others. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses on the consolidated balance sheets. The Company&#8217;s liability for these rebates consist of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in customer inventories at the end of each reporting period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other Patient Support Initiatives: Other patient support initiatives that the Company offers include voluntary co-pay assistance programs, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payors. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive for product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Product Returns: Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company either directly or through one of its distribution channels. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s return policy generally allows for eligible returns of AVMAPKI FAKZYNJA CO-PACK for credit under the following circumstances:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Receipt of damaged product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shipment errors that were a result of an error by the Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Expired product that is returned during the period beginning three months prior to the product&#8217;s expiration and ending six months after the expiration date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Quantities of product received by a customer in excess of quantity ordered;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product subject to a recall; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product that the Company, at its sole discretion, has specified can be returned for credit. </span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">As of December 31, 2025, the Company has not received any returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sales of intellectual property</i><span style="font-style:italic;font-weight:bold;"> - </span>For sales of license and intellectual property, that include sale-based royalties, including milestone payments based on a level of sales, the Company evaluates whether the royalties and sales-based milestones are considered probable of being achieved and estimates the amount of royalties to include over the contractual term using the expected value method and estimates the sales-based milestones using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated royalty and milestone value is included in the transaction price. Royalties and sales-based milestones for territories for which there is not regulatory approval are not considered probable until such regulatory approval is achieved. The Company evaluates factors such as whether consideration is outside of the Company&#8217;s control, timeline for when the uncertainty will be resolved and historical sales of COPIKTRA if applicable. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and amount of royalty revenue to be received and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounts Receivable, Net </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Accounts receivable, net consists of amounts due from customers, net of applicable revenue reserves. Accounts receivable have standard payments that generally require payment within 30 to 90 days. Management determines the allowance for credit loss by regularly evaluating individual customer receivables and considering a customer&#8217;s financial condition, credit history and current economic conditions.  Based on the Company&#8217;s latest assessment of the collectability of its accounts receivable, an allowance for credit loss is not deemed necessary at December 31, 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inventory </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventories are stated at the lower of cost or estimated net realizable value. The Company determined the cost of inventories using the&#160;standard cost&#160;method, which approximates actual cost based on a first-in, first out basis. Inventories consist primarily of third-party manufacturing costs. The Company began capitalizing inventory upon receiving FDA approval for AVMAPKI FAKZYNJA CO-PACK on May 8, 2025. Prior to the FDA approval of AVMAPKI FAKZYNJA CO-PACK, expenses associated with the manufacturing of the Company's products were recorded as research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, are recorded within cost of sales &#8211; product within the consolidated statements of operations and net loss. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required which would be recorded as a cost of sales - product in the consolidated statements of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Shipping and handling costs for product shipments are recorded as incurred in cost of sales - product along with costs associated with manufacturing the product, and any inventory write-downs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span><i style="font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company records finite-lived intangible assets related to certain capitalized milestone payments at their fair value. These assets are amortized over their remaining useful lives, which are estimated based on the shorter of the remaining underlying patent life or the estimated useful life of the underlying product. Intangible assets are amortized using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when future revenues cannot be reasonably estimated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company assesses its finite-lived intangible assets for impairment if indicators are present or changes in circumstance suggest that impairment may exist. Events that could result in an impairment, or trigger an impairment assessment, include the receipt of additional clinical or nonclinical data regarding the Company&#8217;s drug products or a potentially competitive drug candidate, significant changes in the manner of our use of the acquired assets, or new </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">information regarding future projected sales for the product. If impairment indicators are present or changes in circumstance suggest that impairment may exist, the Company performs a recoverability test by comparing the sum of the estimated undiscounted cash flows of each finite-lived intangible asset to its carrying value on the consolidated balance sheets. If the undiscounted cash flows used in the recoverability test are less than the carrying value, the Company would determine the fair value of the finite-lived intangible asset and recognize an impairment loss if the carrying value of the finite-lived intangible asset exceeds its fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Collaborative arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Contracts are considered to be collaborative arrangements when they satisfy the following criteria defined in ASC Topic 808, <i style="font-style:italic;">Collaborative Arrangements</i>: (i) the parties to the contract must actively participate in the joint operating activity and (ii) the joint operating activity must expose the parties to the possibility of significant risk and rewards, based on whether or not the activity is successful. Payments received from or made to a partner that are the result of a collaborative relationship with a partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction or increase to research and development expense, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes the tax effects of an uncertain tax position only if it is more likely than not that it will be sustained based solely on its technical merits as of the reporting date and only in an amount more likely than not that it will be sustained upon review by the tax authorities. The Company evaluates uncertain tax positions on a quarterly basis and adjust the liability for changes in facts and circumstances, such as new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, significant amendment to an existing tax law, or resolution of an examination. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the income tax provision in the period in which such determination is made. The resolution of its uncertain income tax positions is dependent on uncontrollable factors such as law changes, new case law, and the willingness of the income tax authorities to settle, including the timing thereof and other factors. Although the Company does not anticipate significant changes to its uncertain income tax positions in the next 12 months, items outside of its control could cause its uncertain income tax positions to change in the future, which would be recorded in its statements of operations. Interest and/or penalties related to income tax matters are recognized as a component of income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net operating loss (&#8220;NOL&#8221;) and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the Internal Revenue Code (&#8220;IRC&#8221;), as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company experienced a greater than 50% change in ownership as defined under Section 382 and 383 of the IRC as well as similar state provisions during the year ended December 31, 2024. For more details, please refer to <i style="font-style:italic;">Note 14. Income Taxes.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Net loss per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per common share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period. For purposes of calculating net loss per share, weighted-average number of common shares outstanding includes the weighted average effect of pre-funded warrants as the exercise of which requires little or no consideration for the delivery of shares of common stock. <span style="white-space:pre-wrap;">Diluted net loss per common share is calculated by increasing the denominator by the weighted-average number of additional shares that could have been outstanding from securities convertible into common stock, such as the warrants issued in July 2024, stock options, restricted stock units, and ESPP (using the &#8220;treasury stock&#8221; method), Series A Convertible Preferred Stock, and Series B Convertible Preferred Stock (using the &#8220;if-converted&#8221; method), unless their effect on net loss per share is antidilutive. Under the &#8220;if-converted&#8221; method, convertible instruments that are-in-the-money, are assumed to have been converted as of the beginning of the period or when issued, if later. Additionally, the effects of any interest expense and changes in fair value of any bifurcated derivatives shall be added back to the numerator of the diluted net loss per share calculation.  Refer to </span><i style="font-style:italic;">Note 13. Net Loss per share</i> for further details related to the calculation of net loss per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Adopted Accounting Standards Updates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;">In December 2023, the FASB issued ASU No. 2023-09,&#160;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#160;(&#8220;ASU 2023-09&#8221;). The guidance in ASU 2023-09 improves the transparency of income tax disclosures by greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The Company has adopted and applied the guidance under this ASU for the year ended December 31, 2025, using the prospective transition method. See&#160;<i style="font-style:italic;">Note 14. Income Taxes</i>&#160;in the accompanying notes to the consolidated financial statements for further detail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Recently issued accounting standards updates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">In November 2024, the FASB issued ASU No 2024-03&#8212;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). The guidance in ASU 2024-03 is intended to require more detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted.  The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to all prior periods presented in the financial statements. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;">In September 2025, the FASB issued ASU No. 2025-06,&#160;Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software&#160;(&#8220;ASU 2025-06&#8221;). This standard modernizes the accounting for internal-use software by removing references to prescriptive development stages and instead requiring capitalization of costs once (1) management has authorized and committed to funding the software project, and (2) it is probable the project will be completed and placed in service. Entities must evaluate whether there is &#8220;significant development uncertainty,&#8221; such as unresolved novel functionality or substantially revised performance requirements, before meeting this capitalization threshold. ASU 2025-06 is effective for annual reporting periods beginning after December 15, 2027, and interim periods within such annual reporting periods, with early adoption permitted. Entities may adopt the amendments prospectively, retrospectively, or under a modified transition approach. The Company is in the process of evaluating the impact that the adoption of this ASU may have on its consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;">Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product revenue reserves and allowances<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract', window );"><strong>Product revenue reserves and allowances</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowancesDisclosureTextBlock', window );">Product revenue reserves and allowances</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Product revenue reserves and allowances</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since 2025, the Company&#8217;s sole source of product revenue has been from sales of AVMAPKI FAKZYNJA CO-PACK in the United States. The following table summarizes activity in each of the product revenue allowance and reserve categories for the twelve months ended December 31, 2025 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trade</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Third Party Payer </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Government </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">chargebacks,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">rebates&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">allowances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and fees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">incentives</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision related to sales in the current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 888</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,392</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,043</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Adjustments related to prior period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credits and payments made</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (652)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (135)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,367)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,154)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Ending balance at December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 236</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 252</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 3,025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 376</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 3,889</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">Trade discounts and Payer chargebacks and discounts are recorded as a reduction to accounts receivable, net on the consolidated balance sheets. Trade allowances and Payer fees, government rebates, other incentives and returns are recorded as a component of accrued expenses on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ProductRevenueReservesAndAllowancesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for product revenue reserves and allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ProductRevenueReservesAndAllowancesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Inventory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory consists of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:70.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:70.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:70.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:70.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:70.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total inventory</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 1,833</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">At&#160;December&#160;31, 2025, all of the Company&#8217;s inventory was related to&#160;AVMAPKI and FAKZYNJA. In May 2025, the FDA approved AVMAPKI FAKZYNJA CO-PACK, at which time the Company began to capitalize costs to manufacture AVMAPKI FAKZYNJA CO-PACK. Prior to FDA approval of AVMAPKI FAKZYNJA CO-PACK, all costs related to the manufacturing of AVMAPKI and FAKZYNJA and related material were charged to research and development expense in the period incurred. At&#160;December&#160;31, 2025, the Company determined that a reserve related to inventory&#160;was&#160;not required.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5. Intangible Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s intangible assets consist of the following (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:15.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average Remaining Amortization Period (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired and in-licensed rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14.8 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (698)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total intangible assets, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 16,426</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company's finite-lived intangible assets are the result of milestone payments due under the Pfizer Agreement (defined herein) and the License Agreement (defined herein). Refer to <i style="font-style:italic;">Note 16. License, collaboration and commercial agreements</i> for further discussion of the Pfizer Agreement and License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The Company recorded approximately $0.7 million in cost of sales &#8211; intangible amortization expense related to finite-lived intangible assets during the twelve months ended December 31, 2025 using straight-line methodology. Estimated future cost of sales- intangible amortization expense for finite-lived intangible assets as of December 31, 2025 is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:85.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year ending December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,117</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,117</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,117</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,117</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,117</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,841</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total future amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 16,426</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6. Property and equipment, net</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Property and equipment and related accumulated depreciation are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:75.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 811</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Assets not yet placed in service</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 1,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 1,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,622)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,618)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total property and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 32</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"><span style="font-size:10pt;">The Company recorded less than </span><span style="-sec-ix-hidden:Hidden_W4pGquiuLUKirJceSn_YoA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.1</span></span><span style="font-size:10pt;"> million, less than </span><span style="-sec-ix-hidden:Hidden_NwoIzrC_q02kziSjSvHlIw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.1</span></span><span style="font-size:10pt;"> million, and </span><span style="-sec-ix-hidden:Hidden_N2ulbwwA-UqvBSpy2gwqug;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.1</span></span><span style="font-size:10pt;"> million in depreciation expense for the years ended December 31, 2025, 2024, and 2023, respectively</span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. Accrued expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued clinical trial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,915</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued milestone payments &amp; royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued compensation and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,860</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued commercialization costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 803</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued contract manufacturing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued other research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued consulting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,287</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total accrued expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 53,981</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Long-term debt</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Note Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On January&#160;13, 2025 (the &#8220;Note Purchase Agreement Closing Date&#8221;), the Company entered into the </span>Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;) with RGCM SA LLC, as purchaser agent, Oberland Capital Management LLC (&#8220;Oberland&#8221;) and certain funds managed by Oberland, as purchasers (together with the other purchasers party thereto referred as the &#8220;Note Purchase Agreement Purchasers&#8221;) <span style="background:#ffffff;">pursuant to which the Company may sell to the Purchasers, and the Purchasers may buy from the Company, notes (the &#8220;Notes&#8221;) in an aggregate principal amount not to exceed </span><span style="background:#ffffff;">$150.0</span><span style="background:#ffffff;"> million. On the Note Purchase Agreement Closing Date, the Company issued and sold an initial Note in an aggregate principal amount </span><span style="background:#ffffff;">$75.0</span><span style="background:#ffffff;"> million. In addition, the Company may issue and sell additional Notes with aggregate principal amount of up to </span><span style="background:#ffffff;">$75.0</span><span style="background:#ffffff;"> million as follows</span><span style="background:#ffffff;">:</span></p><div style="margin-top:14pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt 0pt 6pt 0pt;">iii.</td><td style="text-align:right;width:18pt;padding:0pt 0pt 6pt 0pt;"></td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at the option of the Company, the a second purchase (the &#8220;Second Purchase&#8221;) of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$25.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million principal amount of Notes, at any time prior to December 31, 2025, upon the FDA&#8217;s approval sufficient for the promotion and sale of avutometinib and defactinib for the treatment of LGSOC and subject to certain other customary conditions precedent. In March 2026, the Company amended the Note Purchase Agreement to extend the date by which it may draw down the Second Purchase from December 31, 2025 to June 30, 2026 (see </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Note 20. Subsequent Events</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">). and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt;">iv.</td><td style="text-align:right;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at the option of the Company, the, a third purchase (the &#8220;Third Purchase&#8221;) of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$50.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million principal amount of Notes, at any time prior to December 31, 2026, provided that trailing six-month worldwide net sales of avutometinib and defactinib are at least </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$55.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million and subject to certain other customary conditions precedent.</span></td></tr></table><div style="margin-top:14pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:14pt;background:#ffffff;margin:14pt 0pt 0pt 0pt;"><span style="font-size:10pt;">The outstanding principal amount of the Notes bear interest at a rate per annum equal to the sum of (i)&#160;the greater of the Term </span><span style="-sec-ix-hidden:Hidden_Jq6EAhHjvU6lCRswi0Rx2Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SOFR</span></span><span style="font-size:10pt;"> (as defined in the Note Purchase Agreement) and </span><span style="font-size:10pt;">4.29%</span><span style="font-size:10pt;">, and (ii)&#160;</span><span style="font-size:10pt;">3.71%</span><span style="font-size:10pt;">, subject to adjustment in certain circumstances set forth in the Note Purchase Agreement and an overall cap of </span><span style="font-size:10pt;">9.75%</span><span style="font-size:10pt;">, payable quarterly in arrears until the seventh anniversary of the Note Purchase Agreement Closing Date or the date on which all amounts owing to the Note Purchase Agreement Purchasers under the Note Purchase Agreement have been paid in full (the &#8220;Note Purchase Agreement Maturity Date&#8221;). For the first eight quarters following the Note Purchase Agreement Closing Date, at the Company&#8217;s option, up to </span><span style="font-size:10pt;">50%</span><span style="font-size:10pt;"> of the interest due may be paid-in-kind and added to the then-outstanding principal balance of the Notes. Through December 31, 2025, the Company has not elected to defer any interest through its paid-in-kind option. Upon the occurrence and during the continuance of an Event of Default (as defined in the Note Purchase Agreement) under the Note Purchase Agreement, the then-applicable interest rate on all outstanding obligations may be increased by an additional </span><span style="font-size:10pt;">5.00%</span><span style="font-size:10pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:0pt;">Beginning on January&#160;13, 2025 and continuing until the Note Purchase Agreement Maturity Date, the Note Purchase Agreement Purchasers will receive 1.00% (the &#8220;Revenue Participation Percentage&#8221;) of the first $100.0 million of net sales of each Included Product (as defined in the Note Purchase Agreement) by the Company or its affiliates or licensees in each calendar year, payable quarterly. &#8220;Included Products&#8221; is defined in the Note Purchase Agreement to include (a)&#160;avutometinib and defactinib, including any product that contains either one of the foregoing in combination with any other active ingredient(s), and (b)&#160;all other compounds, chemical entities or pharmaceutical products being designed, developed, licensed, manufactured or commercialized by the Company or its subsidiaries from time to time. The Revenue Participation Percentage will increase&#160;pro rata&#160;immediately upon the occurrence of the Second Purchase and the Third Purchase, such that the Revenue Participation Percentage shall increase to a maximum of 2.00% in the event that $150 million in aggregate principal amount of Notes has been purchased pursuant to the Note Purchase Agreement following the Third Purchase. The outstanding principal amount of the Notes, interest accrued thereon and any other amounts owing to the Note Purchase Agreement Purchasers under the Note Purchase Agreement will be due in two equal instalments on (a)&#160;the sixth anniversary of the Note Purchase Agreement Closing Date, and (b)&#160;the Note Purchase Agreement Maturity Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">All of the Notes may be redeemed prior to the Note Purchase Agreement Maturity Date at the option of the Company, subject to payment of the Repayment Amount (as defined in the Note Purchase Agreement). The Note Purchase Agreement Purchasers may demand redemption of the Notes prior to the Note Purchase Agreement Maturity Date in the event of a Change of Control (as defined in the Note Purchase Agreement) of the Company or an Event of Default (as defined in the Note Purchase Agreement) under the Note Purchase Agreement, subject to payment of the Repayment Amount. The Repayment Amount is due at the earlier of the Maturity Date and when payment of all obligations under the Note Purchase Agreement are otherwise due. The Repayment Amount is: (a)&#160;135% of the principal amount of the Notes if redemption occurs before the second anniversary of the Note Purchase Agreement Closing Date upon a Change of Control; (b)&#160;if the preceding clause (a)&#160;does not apply, 175% of the principal amount of the Notes if redemption occurs prior to the third anniversary the Note Purchase Agreement Closing date; and (c)&#160;thereafter, 195% of the principal amount of the Notes if redemption occurs after the third anniversary the Note Purchase Agreement Closing Date, minus, in each case, the sum of regularly scheduled interest paid in cash, payments of principal in cash, and payments of revenue participation in cash prior to such redemption date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 10pt 0pt;">The Note Purchase Agreement contains no financial covenants. The Company&#8217;s obligations under the Note Purchase Agreement are subject to customary covenants, including limitations on the Company&#8217;s ability to dispose of assets, undergo a change of control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of its capital stock, repurchase stock and make investments, in each case subject to certain exceptions. The Company&#8217;s obligations under the Note Purchase Agreement are secured by a security interest on substantially all of the Company&#8217;s and its subsidiaries&#8217; assets, including its intellectual property related to avutometinib and defactinib, and a negative pledge on intellectual property related to the <span style="background:#ffffff;">Company&#8217;s collaboration and option agreement with GenFleet (the &#8220;GenFleet Agreement&#8221;), subject to certain exceptions relating to the Company&#8217;s development of its intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">A portion of the proceeds of the Note Purchase Agreement were used to repay the Company&#8217;s obligations under the Loan Agreement in full. The Loan Agreement was terminated concurrently with entry into the Note Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">The Company assessed the terms and features of the Note Purchase Agreement and determined that the Company is eligible to elect the fair value option under ASC 825, <i style="font-style:italic;">Financial Instruments</i>. The Note Purchase Agreement contains various embedded features and the election of the fair value option allows the Company to bypass analysis of potential embedded derivatives and further analysis of bifurcation of any recognized financial liabilities. Under the fair value option, the financial liability is initially measured at its fair value on the issuance date and subsequently remeasured at estimated fair value on a recurring basis at each reporting date. Changes in the fair value of the Note Purchase Agreement, which include accrued interest, if any, are recorded as a component of change in fair value of Notes in the consolidated statements of operations. The Company has not elected to present interest expense separately from changes in fair value and therefore will not separately present interest expense associated with the Note Purchase Agreement. Changes in fair value caused by instrument-specific credit risk are presented separately in other comprehensive income or loss within the consolidated statements of equity (deficit). The portion of total </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">changes in fair value of Notes attributable to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive loss. Under the fair value option, debt issuance costs are expensed as incurred. The Company incurred $0.8 million of debt issuance costs which were recorded within selling, general and administrative expense in the consolidated statements of operations for the year ended December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">The Company determined the fair value of the Notes on January 13, 2025 was </span><span style="font-size:10pt;">$75.0</span><span style="font-size:10pt;">&#160;million. </span><span style="font-size:10pt;">The following table reconciles the change in fair value of the Notes during the years ended December 31, 2025</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Beginning fair value balance at January 13, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">75,000</b></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden__aGtVmkn9kuWPabZ5DVUXg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value reported in statements of operations</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,751</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_-3F5ri1upkSXeC-rPJHM9A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value reported in comprehensive loss</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,229)</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest and revenue participation payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,192)</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Ending fair value at December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">76,330</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">As of December 31, 2025, future principal payments under the Note Purchase Agreement are due as follows (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,500</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,500</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total principal payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 75,000</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Loan Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On March 25, 2022 (the &#8220;Loan Agreement Closing Date&#8221;), the Company entered into a loan and security agreement (the &#8220;Original Loan Agreement&#8221;) with Oxford Finance, LLC (&#8220;Oxford&#8221;), as collateral agent and a lender, and Oxford Finance Credit Fund III LP, as a lender (&#8220;OFCF III&#8221; and together with Oxford, the &#8220;Lenders&#8221;), pursuant to which the Lenders agreed to lend the Company up to an aggregate principal amount of </span><span style="background:#ffffff;">$150.0</span><span style="background:#ffffff;"> million in a series of term loans (the &#8220;Term Loans&#8221;). On January 4, 2024, the Company amended the Original Loan Agreement (as amended, the &#8220;Loan Agreement&#8221;) to extend the date by which it may draw down the Term C Loan from March 31, 2024, to March 31, 2025. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Pursuant to the Loan Agreement, the Company received an initial Term Loan of&#160;</span><span style="background:#ffffff;">$25.0</span><span style="background:#ffffff;">&#160;million on the Loan Agreement Closing Date, and drew down the second term loan of&#160;</span><span style="background:#ffffff;">$15.0</span><span style="background:#ffffff;">&#160;million (the &#8220;Term B Loan&#8221;) on March 22, 2023, and could have borrowed an additional&#160;</span><span style="background:#ffffff;">$110.0</span><span style="background:#ffffff;">&#160;million of Term Loans at its option upon the satisfaction of certain conditions as follows:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">i.</td><td style="text-align:right;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$25.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million (the &#8220;Term C Loan&#8221;), when the Company has received accelerated or full approval from the FDA of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">avutometinib </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">for the treatment of LGSOC (the &#8220;Term C Milestone&#8221;). The Company could have drawn the Term C Loan within </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">60 days</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> after the occurrence of the Term C Milestone, but no later than March 31, 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">ii.</td><td style="text-align:right;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$35.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million (the &#8220;Term D Loan&#8221;), when the Company has achieved at least </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$50.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million in gross product revenue calculated on a trailing six-month basis (the &#8220;Term D Milestone&#8221;). The Company could have drawn the Term D Loan within </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">30 days</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> after the occurrence of the Term D Milestone, but no later than March 31, 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">iii.</td><td style="text-align:right;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$50.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million (the &#8220;Term E Loan&#8221;), at the sole discretion of the Lenders.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Term Loans bore interest at a floating rate equal to (a) the greater of (i) the one-month </span><span style="-sec-ix-hidden:Hidden_YOPMCZqEsUS3-osVGkAxWQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">CME Secured Overnight Financing Rate</span></span><span style="background:#ffffff;"> and (ii) </span><span style="background:#ffffff;">0.13%</span><span style="background:#ffffff;"> plus (b) </span><span style="background:#ffffff;">7.37%</span><span style="background:#ffffff;">, subject to an overall floor and cap. Interest was payable monthly in arrears on the first calendar day of each calendar month. As a result of the Term B Loan drawdown, beginning (i) April 1, 2025, or (ii) April 1, 2026, if either (A) </span>avutometinib h<span style="background:#ffffff;">as received FDA approval for the treatment of LGSOC or (B) COPIKTRA has received FDA approval for the treatment of peripheral T-cell lymphoma, the Company would have been required to repay the Term Loans in consecutive equal monthly payments of principal, together with applicable interest, in arrears. All unpaid principal and accrued and unpaid interest with respect to each Term Loan were due and payable in full on March 1, 2027.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company was required to make a final payment of&#160;</span><span style="background:#ffffff;">5.0%</span><span style="background:#ffffff;"> of the original principal amount of the Term Loans that are drawn, payable at maturity or upon any earlier acceleration or prepayment of the Term Loans (the &#8220;Final Payment Fee&#8221;). The Company could have prepaid all, but not less than all, of the Term Loans, subject to a prepayment fee equal to (i)&#160;3.0% of the principal amount of the applicable Term Loan if prepaid on or before the first anniversary date of the funding date of such Term Loan, (ii)&#160;</span><span style="background:#ffffff;">2.0%</span><span style="background:#ffffff;"> of the principal amount of the applicable Term Loan if prepaid after the first anniversary and on or before the second anniversary of the funding date of such Term Loan, and (iii) </span><span style="background:#ffffff;">1.0%</span><span style="background:#ffffff;"> of the principal amount of the applicable Term Loan if prepaid after the second anniversary of the applicable funding date of such Term Loan. All Term Loans were subject to a facility fee of&#160;</span><span style="background:#ffffff;">0.5%</span><span style="background:#ffffff;"> of the principal amount.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Loan Agreement contained </span><span style="background:#ffffff;">no</span><span style="background:#ffffff;"> financial covenants. The Loan Agreement included customary events of default, including, among others, payment defaults, breach of representations and warrants, covenant defaults, judgment defaults, insolvency and bankruptcy defaults, and a material adverse change. The occurrence of an event of default could have resulted in the acceleration of the obligations under the Loan Agreement, termination of the Term Loan commitments and the right to foreclose on the collateral securing the obligations. During the existence of an event of default, the Term Loans would have accrued interest at a rate per annum equal to </span><span style="background:#ffffff;">5.0%</span><span style="background:#ffffff;"> above the otherwise applicable interest rate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="background:#ffffff;">In connection with the Loan Agreement, the Company granted Oxford a security interest in all of the Company&#8217;s personal property now owned or hereafter acquired, excluding intellectual property (but including the right to payments and proceeds of intellectual property), and a negative pledge on intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="font-family:'Times';">The Company assessed all terms and features of the Loan Agreement in order to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the Loan Agreement, including put and call features. The Company determined that all features of the Loan Agreement were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's financial statements. The Company reassesses the features on a quarterly basis to determine if they require separate accounting. There have been no changes to the Company</span>&#8217;s <span style="font-family:'Times';">assessment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="font-family:'Times';">Concurrently with the closing of the Note Purchase Agreement, on January&#160;13, 2025, the Company terminated its Loan Agreement and repaid in full the balance of its obligations under the Loan Agreement of approximately </span><span style="font-family:'Times';">$42.7</span><span style="font-family:'Times';">&#160;million (the &#8220;Payoff Amount&#8221;). The Payoff Amount included the Final Payment Fee of </span><span style="font-family:'Times';">$2.0</span><span style="font-family:'Times';">&#160;million, which was due at the earlier of prepayment or loan maturity, and certain prepayment fees as set forth in the Loan Agreement, a prepayment penalty fee of </span><span style="font-family:'Times';">$0.6</span><span style="font-family:'Times';">&#160;million, and unpaid interest of </span><span style="font-family:'Times';">$0.1</span><span style="font-family:'Times';">&#160;million.&#160;Upon the Lender&#8217;s receipt of the Payoff Amount, the Loan Agreement was terminated along with the Lender&#8217;s commitment to provide funding under any future term loans.&#160; All liens on the Company&#8217;s assets to secure the loans under the Loan Agreement have been terminated and released. The Payoff Amount, excluding accrued interest, exceeded the carrying amount of the Term Loan on January 13, 2025 by&#160;</span><span style="font-family:'Times';">$1.8</span><span style="font-family:'Times';">&#160;million. As a result the Company recorded a loss on debt extinguishment of&#160;</span><span style="font-family:'Times';">$1.8</span><span style="font-family:'Times';">&#160;million included in the consolidated statements of operations and comprehensive loss for the twelve months ended December 31, 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="color:#212529;">The debt issuance costs and the Final Payment Fee were recorded as a debt discount which were accreted to interest expense through the maturity date of the Term Loan using the effective interest method.&#160;</span><span style="color:#212529;">The components of the carrying value of the Term Loan as of December 31, 2024, are detailed below (in thousands):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:33.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Principal loan balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,000</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Final Payment Fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,172</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Debt issuance costs, net of accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (448)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Long-term debt, net of discount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 40,724</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The following table sets forth total interest expense for the years ended December 31, 2025, 2024, and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:52.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Contractual Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3,472</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Amortization of debt discount and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 230</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Amortization of Final Payment Fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 437</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,138</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4,562</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4,139</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"><span style="font-size:1pt;font-style:italic;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9. Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On April 15, 2014, the Company entered into a lease agreement for approximately 15,197 square feet of office and laboratory space in Needham, Massachusetts. The lease term commenced on April 15, 2014 and it was scheduled to expire on September 30, 2019. Effective February 15, 2018, the Company amended its lease agreement to relocate within the facility to another location consisting of 27,810 square feet of office space (the &#8220;February 2018 Amended Lease Agreement&#8221;). The February 2018 Amended Lease Agreement extended the expiration date of the lease from September 2019 through June 2025. Pursuant to the February 2018 Amended Lease Agreement, the initial annual base rent amount was approximately $0.7 million, which increased during the lease term to $1.1 million for the last 12-month period. Effective November 1, 2024, the Company amended the February 2018 Amended Lease Agreement to extend the expiration date from June 2025 to June 2026 (the &#8220;November 2024 Amended Lease Agreement&#8221;). The payment terms of the November 2024 Amended Lease Agreement are $1.1 million per annum through the expiration date in June 2026. As a result of the November 2024 Amended Lease Agreement, the Company recorded an incremental $1.0 million right-of-use asset and corresponding lease liability during the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has accounted for its Needham, Massachusetts office space as an operating lease. The Company&#8217;s lease contains an option to renew and extend the lease terms and an option to terminate the lease prior to the expiration date. The Company has not included the lease extension or the termination options within the right-of-use asset and lease liability on the consolidated balance sheets as neither option is reasonably certain to be exercised. The Company&#8217;s lease includes variable non-lease components (e.g., common area maintenance, maintenance, consumables, etc.) that are not included in the right-of-use asset and lease liability and are reflected as an expense in the period incurred. The Company does not have any other operating or finance leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, a right-of-use asset of $0.5 million and lease liability of $0.5 million are reflected on the consolidated balance sheets. The elements of lease expense were as follows (dollar amounts in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:53.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Lease Expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 885</p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total Lease Expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 1,011</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 906</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 885</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Information - Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating cash flows paid for amounts included in measurement of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,092</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,060</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Balance Sheet Information - Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.8%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Maturity Analysis</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:48.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 546</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Less: Present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:48.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Lease Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 535</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10. Capital Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Under the amended and restated certificate of incorporation, the Company&#8217;s board of directors has the authority, without further action by the stockholders, to issue up to&#160;5,000,000&#160;shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the Company had reserved the following shares of common stock for the issuance of common stock for vested restricted stock units, the exercise of stock options, employee stock purchase plan, Series A Convertible Preferred Stock conversions to shares of common stock, and exercise of warrants and pre-funded warrants (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved under Equity Compensation Plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for Inducement Grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for Series A Convertible Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for pre-funded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,656</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total shares reserved</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 28,555</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 30,702</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:12pt 0pt 0pt 0pt;">Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">November 2025 Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 13, 2025, the Company entered into an Underwriting Agreement (the &#8220;November 2025 Public Offering&#8221;) with several Underwriters to sell in a public offering 8,543,794 shares of the Company&#8217;s common stock, at a price to the public of $7.25 per share, less the underwriting discounts and commissions, and, in lieu of shares of common stock to certain investors, pre-funded warrants (the &#8220;November 2025 Pre-Funded Warrants&#8221;) to purchase up to an aggregate of 3,870,000 shares of common stock at a price to the public of $7.2499 per share of common stock underlying a pre-funded warrant, which represents the per share public offering price for the shares of common stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">less the $0.001 per share exercise price for each such share of common stock underlying a November 2025 Pre-Funded Warrant. Furthermore, as part of the Underwriting Agreement, Greenshoe Options (&#8220;November 2025 Overallotment Options&#8221;) were granted to the Underwriters to purchase up to an aggregate of 1,862,069 shares of the Company&#8217;s Common Stock, par value $0.0001 per share, at a price to the Underwriters of $7.25 per share, less the underwriting discounts and commissions. On November 14, 2025, the underwriters exercised their Overallotment Options in full and the Company issued 1,862,069 additional shares of common stock at the price of $7.25 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">The exercise price of each November 2025 Pre-Funded Warrant equals&#160;$0.0001&#160;per underlying share of common stock.&#160;The exercise price and the number of shares of common stock issuable upon exercise of each November 2025 Pre-Funded Warrant is subject to appropriate adjustment in the event of certain stock dividends, stock splits, stock combinations, or similar events affecting the Company&#8217;s common stock. The November 2025 Pre-Funded Warrants are exercisable in cash or by means of a cashless exercise and will not expire until the date the November 2025 Pre-Funded Warrants are fully exercised.&#160;The November 2025 Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof (together with its affiliates) immediately following such exercise would exceed a specified beneficial ownership limitation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The November 2025 Pre-Funded Warrants cannot require cash settlement, are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its common stock shares and permit the holders to receive a fixed number of shares of common stock upon exercise. Additionally, the November 2025 Pre-Funded Warrants do not provide any guarantee of value or return. Accordingly, the November 2025 Pre-Funded Warrants are classified as a component of permanent equity. The net proceeds of the 2025 Public Offering were approximately $96.9&#160;million, after deducting underwriting fees and other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">April 2025 PIPE Transaction</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">On April 25, 2025, the Company entered into a securities purchase agreement with certain institutional accredited investors (the &#8220;PIPE Investors&#8221;), pursuant to which the Company sold to the PIPE Investors, in a private placement (the &#8220;2025 Private Placement&#8221;), an aggregate of&#160;3,429,287&#160;shares of the Company&#8217;s common stock at an offering price of $7.00&#160;per share and,&#160;in lieu of common stock to certain PIPE Investors, pre-funded warrants to purchase an aggregate of&#160;7,285,713&#160;shares of common stock (the &#8220;April 2025 Pre-Funded Warrants,&#8221;) at an offering price of $6.9999&#160;per April 2025 Pre-Funded Warrant. The 2025 Private Placement closed on April 28, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">The exercise price of each April 2025 Pre-Funded Warrant equals&#160;</span><span style="font-size:10pt;">$0.0001</span><span style="font-size:10pt;">&#160;per underlying share of common stock.&#160;The exercise price and the number of shares of common stock issuable upon exercise of each April 2025 Pre-Funded Warrant is subject to appropriate adjustment in the event of certain stock dividends, stock splits, stock combinations, or similar events affecting the Company&#8217;s common stock. The April 2025 Pre-Funded Warrants are exercisable in cash or by means of a cashless exercise and will not expire until the date the April 2025 Pre-Funded Warrants are fully exercised.&#160;The April 2025 Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof (together with its affiliates) immediately following such exercise would exceed a specified beneficial ownership limitation; provided, however, that a holder may increase or decrease the beneficial ownership limitation by giving&#160;</span><span style="font-size:10pt;">61 days</span><span style="font-size:10pt;">&#8217; notice to the Company, but not to any percentage in excess of&#160;</span><span style="font-size:10pt;">19.99%</span><span style="font-size:10pt;">. I</span><span style="color:#212529;font-size:10pt;">n addition, upon the occurrence of a fundamental transaction (as described in the April 2025 Pre-Funded Warrant), each April 2025 Pre-Funded Warrant will have the right to receive, upon exercise of such April 2025 Pre-Funded Warrant, the kind and amount of securities, cash or other property that such holders would have received had they exercised such April 2025 Pre-Funded Warrant immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the April 2025 Pre-Funded Warrants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The April 2025 Pre-Funded Warrants cannot require cash settlement, are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its common stock shares and permit the holders to receive a fixed number of shares of common stock upon exercise. Additionally, the April 2025 Pre-Funded Warrants do not provide any guarantee of value or return. Accordingly, the April 2025 Pre-Funded Warrants are classified as a component of permanent equity. The net proceeds of the 2025 Private Placement were approximately $69.9&#160;million, after deducting placement agent fees and other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><span style="font-size:10pt;">In connection with the Note Purchase Agreement, on January&#160;13, 2025, the Company entered into a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with the certain funds managed by Oberland and affiliates thereof (the &#8220;SPA Investors&#8221;), pursuant to which the SPA Investors purchased an aggregate of </span><span style="font-size:10pt;">1,416,939</span><span style="font-size:10pt;"> shares of the Company&#8217;s common stock, at a price of </span><span style="font-size:10pt;">$5.2931</span><span style="font-size:10pt;"> per share, based on the trailing 30-trading day volume-weighted average price of the Company&#8217;s common stock, as of the date of the Stock Purchase Agreement. The Company received net proceeds of </span><span style="font-size:10pt;">$7.4</span><span style="font-size:10pt;"> million after deducting for offering costs which was recorded as component of permanent equity during the year ended December 31, 2025. In addition, pursuant to the Stock Purchase Agreement, the Company granted the SPA Investors, for a period of </span><span style="font-size:10pt;">three years</span><span style="font-size:10pt;"> following the closing on January 13, 2025, a right to participate in any equity offerings consummated by the Company in an amount up to </span><span style="font-size:10pt;">$2.5</span><span style="font-size:10pt;"> million, subject to certain limitations and exclusions set out in the Stock Purchase Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">July 2024 Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On July&#160;23, 2024, the Company entered into an underwriting agreement with Guggenheim Securities, LLC and Cantor Fitzgerald&#160;&amp; Co. (&#8220;Cantor&#8221;), as representatives of the several underwriters relating to the underwritten offering, issuance and sale by the Company of: (i)&#160;13,333,334&#160;shares of the Company&#8217;s common stock, and accompanying warrants (the &#8220;Warrants&#8221;) to purchase up to&#160;13,333,334&#160;shares of common stock; and (ii)&#160;to certain investors, pre-funded warrants (the &#8220;July 2024 Pre-Funded Warrants&#8221;) to purchase up to&#160;5,000,000&#160;shares of common stock and accompanying Warrants to purchase&#160;5,000,000&#160;shares of common stock (collectively, the &#8220;July 2024 Offering&#8221;). Each share of common stock was sold with an accompanying Warrant at a combined price of $3.00, and each July 2024 Pre-Funded Warrant was sold together with an accompanying Warrant at a combined price of $2.999, which is equal to the combined offering price per share of common stock and accompanying Warrant less the $0.001&#160;exercise price of each July 2024 Pre-Funded Warrant. The July 2024 Offering closed on July 25, 2024. The Company received approximately $50.8&#160;million in net proceeds, after deducting underwriting discounts and commissions and offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Each July 2024 Pre-Funded Warrant has an exercise price equal to $0.001&#160;per underlying share of common stock. The July 2024 Pre-Funded Warrants are exercisable as of July 25, 2024, do not expire and are exercisable in cash or by means of cashless exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">Each Warrant has an exercise price equal to&#160;</span><span style="color:#212529;">$3.50</span><span style="color:#212529;">. Each Warrant is exercisable for&#160;</span><span style="color:#212529;">one</span><span style="color:#212529;">&#160;share of the Company&#8217;s common stock (or, in certain limited circumstances in lieu of a share of common stock, a pre-funded warrant for&#160;</span><span style="color:#212529;">one</span><span style="color:#212529;">&#160;share of the Company&#8217;s common stock at the warrant exercise price less the exercise price of the pre-funded warrant purchased). The Warrants are exercisable as of July 25, 2024 until their expiration on January 25, 2026. The Warrants are exercisable in cash or, in certain limited circumstances only, by means of a cashless exercise.</span><span style="white-space:pre-wrap;">  </span><span style="color:#212529;">The exercise price and the number of shares of common stock issuable upon exercise of each Warrant or July 2024 Pre-Funded Warrant, as applicable, is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Company&#8217;s common stock as well as upon any distribution of assets, including cash, stock or other property, to the Company&#8217;s stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:0pt;"><span style="color:#212529;font-size:10pt;">The Company may not effect the exercise of any Warrant or July 2024 Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Warrant or July 2024 Pre-Funded Warrant if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) would exceed&#160;</span><span style="color:#212529;font-size:10pt;">4.99%</span><span style="color:#212529;font-size:10pt;">&#160;(or such higher percentage up to&#160;</span><span style="color:#212529;font-size:10pt;">19.99%</span><span style="color:#212529;font-size:10pt;">, at the election of the holder) of the number of shares of the Company&#8217;s common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder&#8217;s election upon&#160;</span><span style="color:#212529;font-size:10pt;">61 days</span><span style="color:#212529;font-size:10pt;">&#8217; notice to the Company subject to the terms of such Warrants or July 2024 Pre-Funded Warrants, as applicable, provided that such percentage may in no event exceed&#160;</span><span style="color:#212529;font-size:10pt;">19.99%</span><span style="color:#212529;font-size:10pt;">. In the event that the exercise of a Warrant would cause the holder to beneficially own in excess of&#160;</span><span style="color:#212529;font-size:10pt;">4.99%</span><span style="color:#212529;font-size:10pt;">&#160;(or such higher percentage up to&#160;</span><span style="color:#212529;font-size:10pt;">19.99%</span><span style="color:#212529;font-size:10pt;">, at the election of the holder) of the total number shares of the Company&#8217;s common stock outstanding immediately after giving effect to such exercise, the holder of a Warrant may elect to purchase a pre-funded warrant for&#160;</span><span style="color:#212529;font-size:10pt;">one</span><span style="color:#212529;font-size:10pt;">&#160;share of the Company&#8217;s common Stock, rather than a share of common stock, at the Warrant exercise price less the exercise price of the pre-funded warrant purchased.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">In addition, upon the consummation of an acquisition (as described in the Warrants agreements and July 2024 Pre-Funded Warrants agreements, as applicable), each Warrant and July 2024 Pre-Funded Warrant will automatically be converted into the right of the holder of such Warrant or July 2024 Pre-Funded Warrant, as applicable, to receive the kind and amount of securities, cash or other property that such holders would have received had they exercised such Warrant or July 2024 Pre-Funded Warrant, as applicable, immediately prior to such acquisition, without regard to any limitations on exercise contained in the Warrant agreements or July 2024 Pre-Funded Warrant agreements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">The Warrants meet the definition of a derivative pursuant to FASB Accounting Standard Codification 815,&#160;<i style="font-style:italic;">Derivatives and Hedging</i>, and do not meet the derivative scope exception given the Warrants do not qualify under the indexation guidance. As a result, the Warrants were initially recognized as liabilities and measured at fair value using the Black-Scholes valuation model with subsequent changes in fair value recorded in earnings. The warrants were recorded at a fair value of $39.6&#160;million upon issuance and the Company allocated $39.6&#160;million of the proceeds to this liability and recorded this amount as warrant liability. During the year ended December 31, 2025 and 2024, 9,654,168 Warrants and 250 Warrants, respectively, were exercised for shares of common stock and the fair value of the Warrants on the respective exercise dates was $50.0 million and $0.5 million, respectively, which was reclassified from warrant liability to additional paid in capital. On December 31, 2025 and 2024, the fair value of the outstanding 8,429,166 Warrants and 18,083,334 Warrants, respectively, was determined to be $35.6&#160;million and $58.2 million, respectively and the Company recorded this amount as warrant liability on the consolidated balance sheets. During the year ended December 31, 2025 and 2024, the Company recorded the mark-to-market adjustment of $27.5&#160;million and $19.1 million, respectively, under change in fair value of warrant liability within the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">The July 2024 Pre-Funded Warrants cannot require cash settlement, are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock and Warrants with which they were issued, are immediately exercisable, and do not embody an obligation for the Company to repurchase its common stock shares and permit the holders to receive a fixed number of shares of common stock upon exercise. Additionally, the July 2024 Pre-Funded Warrants do not provide any guarantee of value or return. Accordingly, the July 2024 Pre-Funded Warrants are classified as a component of permanent equity. The Company allocated&#160;</span><span style="color:#212529;">$15.4</span><span style="color:#212529;">&#160;million of the proceeds to the July 2024 Pre-Funded Warrants and shares of common stock issued. During the second quarter of 2025, the holders exercised </span><span style="color:#212529;">2,500,000</span><span style="color:#212529;"> July 2024 Pre-Funded Warrants, exercise price </span><span style="color:#212529;">$0.001</span><span style="color:#212529;"> per share, via cashless exercise resulting in the issuance of </span><span style="color:#212529;">2,499,665</span><span style="color:#212529;"> shares of common stock. During the third quarter of 2025, </span><span style="color:#212529;">no</span><span style="color:#212529;"> July 2024 Pre-Funded Warrants were exercised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="color:#212529;font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">The Company incurred a total of&#160;</span><span style="color:#212529;">$4.2</span><span style="color:#212529;">&#160;million in issuance costs, which the Company allocated to the Warrants, and 2024 Pre-Funded Warrants and shares of common stock consistent with the allocation of proceeds.&#160;</span><span style="color:#212529;">$3.0</span><span style="color:#212529;">&#160;million of issuance costs were allocated to the Warrants and expensed within selling, general and administrative expenses in the statements of operations and comprehensive loss for the year ended December 31, 2024.&#160;</span><span style="color:#212529;">$1.2</span><span style="color:#212529;">&#160;million of the issuance costs were allocated to the July 2024 Pre-Funded Warrants and shares of common stock and applied against additional paid-in capital.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">June 2023 Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">In June 2023, in an underwritten offering, the Company offered 8,489,409 shares of the Company&#8217;s common stock, at a price to the public of $9.75 per share, less the underwriting discounts and commissions, and, in lieu of shares of common stock to certain investors, pre-funded warrants (the &#8220;June 2023 Pre-Funded Warrants&#8221;) to purchase up to an aggregate of 1,538,591 shares of common stock at a price to the public of $9.749 per share of common stock underlying a pre-funded warrant, which represents the per share public offering price for the shares of common stock less the $0.001 per share exercise price for each such share of common stock underlying a June 2023 Pre-Funded Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:14pt;padding-top:2pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">The Company could not have effected the exercise of any June 2023 Pre-Funded Warrant, and a holder was not entitled to exercise any portion of any June 2023 Pre-Funded Warrant if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) would have exceeded </span><span style="font-size:10pt;">9.99%</span><span style="font-size:10pt;"> of the number of shares of common stock outstanding immediately after giving effect to the exercise, which percentage could have been increased or decreased at the holder&#8217;s election upon </span><span style="font-size:10pt;">61 days</span><span style="font-size:10pt;">&#8217; notice to the Company subject to the terms of such June 2023 Pre-Funded Warrant, provided that such percentage in no event exceeded </span><span style="font-size:10pt;">19.99%</span><span style="font-size:10pt;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Each June 2023 Pre-Funded Warrant had an exercise price equal to $0.001 per share of common stock. The exercise price and the number of shares of common stock issuable upon exercise of each June 2023 Pre-Funded Warrant was subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Company&#8217;s common stock as well as upon any distribution of assets, including cash, stock or other property, to the Company&#8217;s stockholders. The June 2023 Pre-Funded Warrants were exercisable as of June 21, 2023, did not expire and were exercisable in cash or by means of a cashless exercise. In addition, upon the consummation of an acquisition (as described in the June 2023 Pre-Funded Warrant agreements), each June 2023 Pre-Funded Warrant would have automatically been converted into the right of the holder of such June 2023 Pre-Funded Warrant to receive the kind and amount of securities, cash or other property that such holders would have received had they exercised such June 2023 Pre-Funded Warrant immediately prior to such acquisition, without regard to any limitations on exercise contained in the June 2023 Pre-Funded Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The June 2023 Pre-Funded Warrants could not have required cash settlement, were freestanding financial instruments that were legally detachable and separately exercisable from the shares of common stock with which they were issued, were immediately exercisable, and did not embody an obligation for the Company to repurchase its common stock shares and permitted the holders to receive a fixed number of shares of common stock upon exercise. Additionally, the June 2023 Pre-Funded Warrants did not provide any guarantee of value or return. Accordingly, the June 2023 Pre-Funded Warrants were classified as a component of permanent equity. After deducting for commissions and other offering expenses, the Company received net proceeds of approximately $91.4 million from the sale of 8,489,409 shares of common stock and June 2023 Pre-Funded Warrants to purchase up to 1,538,591 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">During the year ended December 31, 2024, the holders exercised all of the June 2023 Pre-Funded Warrants representing 1,538,591 underlying shares of common stock, at an exercise price $0.0001 per share, via cashless exercise resulting in the issuance of 1,538,201 shares of common stock. As of December 31, 2024 there were no June 2023 Pre-Funded Warrants outstanding. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Series B Convertible Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">On January 24, 2023, the Company entered into a Securities Purchase Agreement (the &#8220;Series B Convertible Preferred Stock Securities Purchase Agreement&#8221;) with certain purchasers pursuant to which the Company agreed to sell and issue to the purchasers in a private placement (the &#8220;Private Placement&#8221;) up to 2,144,160 shares of its Series B convertible preferred stock, par value $0.0001 per share (the &#8220;Series B Convertible Preferred Stock&#8221;), in two tranches. On January 24, 2023, the Company filed the Certificate of Designation of the Preferences, Rights and Limitations of the Series B Convertible Preferred Stock (the &#8220;Series B Convertible Preferred Stock Certificate of Designation&#8221;) setting forth the preferences, rights and limitations of the Series B Convertible Preferred Stock with the Secretary of State of the State of Delaware. The Series B Convertible Preferred Stock Certificate of Designation became effective upon filing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Each share of the Series B Convertible Preferred Shares is convertible into </span><span style="font-size:10pt;">3.5305</span><span style="font-size:10pt;"> shares of the Company&#8217;s common stock, such conversion rate reflects an adjustment to account for the Reverse Stock Split, at the option of the holders at any time, subject to certain limitations, including that the holder will be prohibited from converting Series B Convertible Preferred Stock into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares of common stock above a conversion blocker, which is initially set at </span><span style="font-size:10pt;">9.99%</span><span style="font-size:10pt;"> (the &#8220;Conversion Blocker&#8221;) of the total common stock then issued and outstanding immediately following the conversion of such shares of Series B Convertible Preferred Stock. Holders of the Series B Convertible Preferred Stock are permitted to increase the Conversion Blocker to an amount not to exceed </span><span style="font-size:10pt;">19.99%</span><span style="font-size:10pt;"> upon</span><span style="font-size:10pt;"> 60 days</span><span style="font-size:10pt;">&#8217; notice.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The Company agreed to sell and issue in the first tranche of the Private Placement 1,200,000 shares of Series B Convertible Preferred Stock at a purchase price of $25.00 per share of Series B Convertible Preferred Stock (equivalent to $7.0812 per share of common stock). The first tranche of the Private Placement closed on January 27, 2023. The Company received gross proceeds from the first tranche of the Private Placement of approximately $30.0 million, before deducting fees to the placement agent and other offering expenses payable by the Company (&#8220;Series B Convertible Preferred Stock Proceeds&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">In addition, the Company agreed to sell and issue in the second tranche of the Private Placement </span><span style="font-size:10pt;">944,160</span><span style="font-size:10pt;"> shares of Series B Convertible Preferred Stock at a purchase price of </span><span style="font-size:10pt;">$31.77</span><span style="font-size:10pt;"> per share of Series B Convertible Preferred Stock (equivalent to </span><span style="font-size:10pt;">$9.00</span><span style="font-size:10pt;"> per share of common stock) if at any time within 18 months following the closing of the first tranche the </span><span style="font-size:10pt;">10-day</span><span style="font-size:10pt;"> volume weighted average price of the Company&#8217;s common stock (as quoted on Nasdaq and as calculated by Bloomberg) should reach at least </span><span style="font-size:10pt;">$13.50</span><span style="font-size:10pt;"> per share, such threshold reflects an adjustment to account for the Reverse Stock Split (which may be further adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction as needed) with aggregate trading volume during the same </span><span style="font-size:10pt;">10-day</span><span style="font-size:10pt;"> period of at least </span><span style="font-size:10pt;">$25</span><span style="font-size:10pt;"> million (the &#8220;Second Tranche Right&#8221;). The second tranche of the Private Placement is expected to close within </span><span style="font-size:10pt;">seven</span><span style="font-size:10pt;"> trading days of meeting the second tranche conditions and will be subject to additional, customary closing conditions. If the Second Tranche Right conditions are satisfied, the Company anticipates receiving gross proceeds from the second tranche of the Private Placement of approximately </span><span style="font-size:10pt;">$30.0</span><span style="font-size:10pt;"> million, before deducting fees to the placement agent and other offering expenses payable by the Company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The Series B Convertible Preferred Stock ranks (i) senior to the common stock; (ii) senior to all other classes and series of equity securities of the Company that by their terms do not rank senior to the Series B Convertible Preferred Stock; (iii) senior to all shares of the Company&#8217;s Series A Convertible Preferred Stock the equity securities described in (i)-(iii), the &#8220;Junior Stock&#8221;); (iv) on parity with any class or series of capital stock of the Company hereafter created specifically ranking by its terms on parity with the Series B Convertible Preferred Stock (the &#8220;Parity Stock&#8221;); (v) junior to any class or series of capital stock of the Company hereafter created specifically ranking by its terms senior to any Series B Convertible Preferred Stock (&#8220;Senior Stock&#8221;); and (vi) junior to all of the Company&#8217;s existing and future debt obligations, including convertible or exchangeable debt securities, in each case, as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily and as to the right to receive dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">In the event of the liquidation, dissolution or winding up of the affairs of the Company, whether voluntary or involuntary, after payment or provision for payment of the debts and other liabilities of the Company, and subject to the prior and superior rights of any Senior Stock, each holder of shares of Series B Convertible Preferred Stock will be entitled to receive, in preference to any distributions of any of the assets or surplus funds of the Company to the holders of the common stock and any of the Company&#8217;s securities that are Junior Stock and pari passu with any distribution to the holders of any Parity Stock, an amount equal to $1.00 per share of Series B Convertible Preferred Stock, plus an additional amount equal to any dividends declared but unpaid on such shares, before any payments shall be made or any assets distributed to holders of the common stock or any of the Company&#8217;s securities that are Junior Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">So long as any shares of the Series B Convertible Preferred Stock remain outstanding, the Company cannot without the affirmative vote or consent of the holders of majority of the shares of the Series B Convertible Preferred Stock then-outstanding, in which the holders of the Series B Convertible Preferred Stock vote separately as a class: (a) amend, alter, modify or repeal (whether by merger, consolidation or otherwise) the Series B Convertible Preferred Stock Certificate of Designation, the Company&#8217;s certificate of incorporation, or the Company&#8217;s bylaws in any manner that adversely affects the rights, preferences, privileges or the restrictions provided for the benefit of, the Series B Convertible Preferred Stock; (b) issue further shares of Series B Convertible Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series B Convertible Preferred Stock; (c) authorize or issue any Senior Stock; or (d) enter into any agreement to do any of the foregoing that is not expressly made conditional on obtaining the affirmative vote or written consent of the majority of then-outstanding Series B Convertible Preferred Stock. Holders of Series B Convertible Preferred Stock are entitled to receive when, as and if dividends are declared and paid on the common stock, an equivalent dividend, calculated on an as-converted basis. Shares of Series B Convertible Preferred Stock are otherwise not entitled to dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The Company initially classified the first tranche of the Series B Convertible Preferred Stock as temporary equity in the consolidated balance sheets as the Company could have been required to redeem the Series B Convertible Preferred Stock if the Company could not convert the Series B Convertible Preferred Stock into shares of common stock for any reason including due to any applicable laws or by the rules or regulations of any stock exchange, interdealer quotation system, or other self-regulatory organization with jurisdiction over the Company which is not solely in the control of the Company. If the Company was required to redeem the Series B Convertible Preferred Stock, it would have been based upon the volume-weighted-average price of common stock on an as converted basis on the date the holders provided a conversion notice to the Company. <span style="color:#212529;">On October 18, 2024, holders of the Series B Convertible Preferred Stock elected to convert&#160;</span><span style="color:#212529;">1,200,000</span><span style="color:#212529;">&#160;shares of Series B Convertible Preferred Stock for&#160;</span><span style="color:#212529;">4,236,568</span><span style="color:#212529;">&#160;shares of the Company&#8217;s common stock and consequently, the Company issued&#160;</span><span style="color:#212529;">4,236,568</span><span style="color:#212529;">&#160;shares of its common stock to holders of the Series B Convertible Preferred Stock. During the year ended December 31, 2024, the&#160;Company did not adjust the carrying value of the Series B Convertible Preferred Stock since it was not probable the holders would be unable to convert the Series B Convertible Preferred Stock into shares of common stock due to any reason including due to any applicable laws or by the rules or regulations of any stock exchange, interdealer quotation system, or other self-regulatory organization with jurisdiction over the Company. Upon conversion, the Company reclassified </span><span style="color:#212529;">$21.2</span><span style="color:#212529;"> million from Series B Convertible Preferred Stock to common stock and additional paid in capital on the consolidated balance sheet. As of December 31, 2025 and 2024, there are&#160;</span><span style="color:#212529;">0</span><span style="color:#212529;">&#160;shares of Series B Convertible Preferred Stock outstanding.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The Company evaluated the Second Tranche Right under ASC 480, <i style="font-style:italic;">Distinguishing Liabilities from Equity</i> (&#8220;ASC 480&#8221;) and determined that it met the requirements for separate accounting from the initial issuance of Series B Convertible Preferred Stock as a freestanding financial instrument. The Company then determined the Second Tranche Right should be liability classified pursuant to ASC 480. As a result, the Company classified the Second Tranche Right as a non-current liability within the consolidated balance sheets and the Second Tranche Right was initially recorded at fair value and is subsequently re-measured at fair value at the end of each reporting period. The fair value of the Second Tranche Right on the date of issuance was determined to be $6.9 million based on a Monte-Carlo valuation and the Company allocated $6.9 million of the Series B Convertible Preferred Stock Proceeds to this liability and recorded this amount as preferred stock tranche liability. On December 31, 2023, the fair value of the Second Tranche Right was determined to be $4.2 million and the Company recorded this amount as preferred stock tranche liability on the consolidated balance sheets. The Second Tranche Right expired in July 2024 and is no longer outstanding. The Company recorded the mark-to-market adjustment of $4.2 million for the year ended December 31, 2024, under change in fair value of preferred stock tranche liability within the consolidated statements of operations and loss. The Company recorded the mark-to-market adjustment of $2.8 million for the year ended December 31, 2023, under change in fair value of preferred stock tranche liability within the consolidated statements of operations and loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;padding-top:2pt;background:#ffffff;margin:0pt;">The Company determined that all other features of the securities offered pursuant to the Series B Convertible Preferred Stock Securities Purchase Agreement were clearly and closely associated with the equity host and did not require bifurcation or the fair value of the feature was immaterial to the Company's consolidated financial statements. The Company reassesses the features on a quarterly basis to determine if they require separate accounting. There were no changes to the Company&#8217;s original assessment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Series A Convertible Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:12pt 0pt 0pt 0pt;">On November 4, 2022, the Company e<span style="background:#ffffff;">ntered into an exchange agreement (the &#8220;Exchange Agreement&#8221;) with Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP and MSI BVF SPV, LLC (collectively referred to as &#8220;BVF&#8221;), pursuant to which BVF exchanged </span><span style="background:#ffffff;">833,333</span><span style="background:#ffffff;"> shares of the Company&#8217;s common stock for </span><span style="background:#ffffff;">1,000,000</span><span style="background:#ffffff;"> shares of newly designated Series A convertible preferred stock, par value </span><span style="background:#ffffff;">$0.0001</span><span style="background:#ffffff;"> per share (the &#8220;Series A Convertible Preferred Stock&#8221;) (the &#8220;Exchange&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Each share of the Series A Convertible Preferred Stock was convertible into </span><span style="font-size:10pt;">0.833</span><span style="font-size:10pt;"> shares of the Company&#8217;s common stock at the option of the holder at any time, subject to certain limitations, including that the holder was prohibited from converting the Series A Convertible Preferred Stock into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares of common stock above the Conversion Blocker, initially set at </span><span style="font-size:10pt;">9.99%</span><span style="font-size:10pt;">, of the total common stock then issued and outstanding immediately following the conversion of such shares of the Series A Convertible Preferred Stock. Holders of the Series A Convertible Preferred Stock were permitted to increase the Conversion Blocker to an amount not to exceed </span><span style="font-size:10pt;">19.99%</span><span style="font-size:10pt;"> upon </span><span style="font-size:10pt;">60 days</span><span style="font-size:10pt;">&#8217; notice.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">Shares of Series A Convertible Preferred Stock generally had no voting rights, except as required by law and except that the consent of a majority of the holders of the outstanding Series A Convertible Preferred Stock was required to amend the terms of the Series A Convertible Preferred Stock. In the event of the Company&#8217;s liquidation, dissolution or winding up, holders of Series A Convertible Preferred Stock would have participated pari passu with any distribution of proceeds to holders of common stock. Holders of Series A Convertible Preferred Stock were entitled to receive when, as and if dividends were declared and paid on the common stock, an equivalent dividend, calculated on an as-converted basis. Shares of Series A Convertible Preferred Stock were otherwise not entitled to dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">The Series A Convertible Preferred Stock were (i) senior to any class or series of capital stock of the Company hereafter created specifically ranking by its terms junior to the Series A Convertible Preferred Stock; (ii) on parity with the common stock and any class or series of capital stock of the Company created specifically ranking by its terms on parity with the Series A Convertible Preferred Stock; and (iii) junior to the Series B Convertible Preferred Stock and to any class or series of capital stock of the Company created specifically ranking by its terms senior to any Series A Convertible Preferred Stock, in each case, as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:0pt;">The Company evaluated the Series A Convertible Preferred Stock for liability or equity classification under ASC 480 and determined that equity treatment was appropriate because the Series A Convertible Preferred Stock did not meet the definition of the liability under ASC 480. Additionally, the Series A Convertible Preferred Stock were not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, or (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Company recorded the Series A Convertible Preferred Stock as permanent equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">In June 2025, holders of the Series A Convertible Preferred Stock elected to convert all&#160;</span><span style="color:#212529;">1,000,000</span><span style="color:#212529;">&#160;shares of Series A Convertible Preferred Stock for&#160;</span><span style="color:#212529;">833,332</span><span style="color:#212529;">&#160;shares of the Company&#8217;s common stock and consequently, the Company issued&#160;</span><span style="color:#212529;">833,332</span><span style="color:#212529;"> shares of its common stock to holders of the Series A Convertible Preferred Stock. As of December 31, 2025, there were </span><span style="color:#212529;">no</span><span style="color:#212529;">&#160;shares of Series A Convertible Preferred Stock outstanding.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">At-the-market equity offering programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In August 2021, the Company entered into a sales agreement with Cantor pursuant to which the Company can offer and sell up to&#160;</span><span style="background:#ffffff;">$</span>100.0<span style="background:#ffffff;">&#160;million of its common stock at the current market prices from time to time through Cantor as sales agent (the &#8220;August 2021 ATM&#8221;). In August 2025, the Company entered into a separate sales agreement with Cantor pursuant to which the Company can offer and sell up to </span><span style="background:#ffffff;">$100.0</span><span style="background:#ffffff;"> million of its common stock at the current market prices from time to time through Cantor as sales agent (the &#8220;August 2025 ATM&#8221; and together with the August 2021 ATM, the &#8220;ATM Programs&#8221;). During the years ended December 31, 2025, 2024, and 2023, the Company sold </span><span style="background:#ffffff;">4,000,000</span><span style="background:#ffffff;"> shares,&#160;</span><span style="background:#ffffff;">0</span><span style="background:#ffffff;"> shares, and </span><span style="background:#ffffff;">0</span><span style="background:#ffffff;"> shares, respectively, under the ATM Programs for net proceeds of approximately </span><span style="background:#ffffff;">$22.7</span><span style="background:#ffffff;"> million, </span><span style="background:#ffffff;">$0.0</span><span style="background:#ffffff;"> million, and </span><span style="background:#ffffff;">$0.0</span><span style="background:#ffffff;"> million, respectively, (after deducting commissions and other offering expenses)</span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11. Stock-based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense as reflected in the Company&#8217;s consolidated statements of operations and comprehensive loss was as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,134</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total stock-based compensation expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 9,405</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 7,342</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 5,860</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:192.9pt;"></span><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">All of the $9.4 million, $7.3 million, and $5.9 million of stock-based compensation expense recorded during the years ended December 31, 2025, 2024 and 2023, respectively, was recorded to additional paid-in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has awards outstanding under two equity compensation plans, the Amended and Restated 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;), and the Amended and Restated 2012 Incentive Plan (the &#8220;2012 Plan&#8221;), as well as the inducement award program. Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the individual plans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2021 Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During 2021, the Company&#8217;s stockholders approved the 2021 Equity Incentive Plan (the &#8220;Original 2021 Plan&#8221;). Upon effectiveness of the Original 2021 Plan, the Company ceased making awards under the 2012 Plan. At the Company&#8217;s 2024 Annual General Meeting of Shareholders in May 2024, the Company&#8217;s shareholders approved the Amended 2021 Plan. The Amended 2021 Plan together with the Original 2021 Plan is referred to as the 2021 Plan. The 2021 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs and other stock-based awards. The number of shares of common stock initially reserved for issuance under the Original 2021 Plan was (i) 1,991,666 plus (ii) the number of shares of the Company&#8217;s common stock underlying awards under the 2012 Plan and the <span style="background:#ffffff;">2010 Equity Incentive Plan (the &#8220;</span>2010 Plan&#8221;) that expire, terminate or are surrendered without delivery of shares, are forfeited to or repurchased by the Company, or otherwise become available again for grant under the terms of the 2012 Plan or the 2010 Plan, as applicable. The Amended 2021 Plan increased the maximum number of shares available for issuance by 3,200,000 shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, under the 2021 Plan, the Company has granted stock options for 2,590,423 shares of common stock, of which 418,541 have been forfeited and 34,402 have been exercised, and granted RSUs for 2,268,761 shares of common stock, of which 105,361 have been forfeited and 852,679 have vested. As of December 31, 2025, 1,567,799 shares remain available for future issuance under the 2021 Plan. The exercise price of each option has been equal to the closing price of a share of the Company&#8217;s common stock on the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2012 Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The 2012 Plan became effective immediately upon the closing of the Company&#8217;s initial public offering in February 2012. Upon effectiveness of the 2012 Plan, the Company ceased making awards under the 2010 Plan. The 2012 Plan initially allowed the Company to grant awards for up to 285,714 shares of common stock, plus the number of shares of common stock available for grant under the 2010 Plan as of the effectiveness of the 2012 Plan (which was an additional 2,508 shares), plus that number of shares of common stock related to awards outstanding under the 2010 Plan which terminate by expiration, forfeiture, cancellation or otherwise. The 2012 Plan included an &#8220;evergreen provision&#8221; that allowed for an annual increase in the number of shares of common stock available for issuance under the 2012 Plan. The annual increase was added on the first day of each year from 2013 through 2018 and was equal to the lesser of 107,412 shares of common stock and 4.0% of the number of shares of common stock outstanding, or a lesser amount as determined by the board of directors. On each of January 1, 2018, January 1, 2017 and January 1, 2016, the number of shares available for issuance under the 2012 Plan increased by 107,412 under this provision. On December 18, 2018, the shareholders of the Company approved the Amended and Restated 2012 Incentive Plan which increased the maximum number of shares available for issuance under the 2012 Plan to 1,385,702 and eliminated the evergreen provision. On May 19, 2020, the shareholders of the Company approved the Amended and Restated 2012 Incentive Plan which increased the maximum number of shares available for issuance by 1,083,333 shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Awards under the 2012 Plan may include the following award types: incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, RSUs, other stock-based or cash-based awards and any combination of the foregoing. As of December 31, 2025, under the 2012 Plan, the Company has granted stock options for 1,841,188 shares of common stock, of which 1,201,898 have been forfeited, 238,203 have expired, and 191,342 have been exercised, and granted RSUs for 556,432 shares of common stock, of which 87,547 have been forfeited and 468,885 have vested. The exercise price of each stock option has been equal to the closing price of a share of the Company&#8217;s common stock on the grant date. Upon adoption of the Original 2021 Plan, the Company ceased issuing awards from the 2012 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:10pt;font-weight:bold;">Inducement Award Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December&#160;2014, the Company established an inducement award program (in accordance with Nasdaq Listing Rule&#160;5635(c)(4)) under which it may grant non-statutory stock options to purchase, and RSUs in respect of up to an aggregate of<span style="letter-spacing:-0.3pt;"> </span>62,500 shares of common stock to new or prospective employees as inducement to enter into employment with the Company. In December 2016, the Board of Directors authorized and reserved 48,333 additional shares of common stock under this program. In December 2017, the Board of Directors authorized and reserved 208,333 additional shares of common stock under this program. In June and December 2018, the Board of Directors authorized and reserved 141,666 and 104,166 additional shares of common stock under this program, respectively. In February 2020, the Board of Directors authorized the reduction of 169,447 shares available for issuance under this program. In September 2023, the Board of Directors authorized and reserved 500,000 additional shares of common stock under this program. In September 2025, the Board of Directors authorized and reserved 400,000 additional shares of common stock under this program. The program is governed by the terms of the 2021 Plan, but shares issued pursuant to the program are not issued under the 2021 Plan. As of December 31, 2025, the Company had granted options for 1,459,605 shares of common stock under the program, of which 725,488 have been forfeited, 1,997 have expired and 48,913 have been exercised, and granted RSUs for 164,137 shares, of which 45,658 have been forfeited and 115,302 have vested. As of December 31, 2025, 508,330 shares remain available for future issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Stock Options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Most options granted by the Company vest twenty-five percent (25%) one year from vesting start date and six and a quarter percent (6.25%) for each successive three-month period, thereafter (subject to acceleration of vesting in the event of certain change of control transactions) subject to the employee&#8217;s continued employment with, or service to, the Company on such vesting date and are exercisable for a period of ten years from the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Option Exchange Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 17, 2024, the Company&#8217;s stockholders, upon recommendation of the board of directors, approved a one-time stock option exchange program (the &#8220;Option Exchange Program&#8221;) for certain employees, executive officers and non-employee directors of the Company who held certain underwater options and remained employed or otherwise engaged by the Company through the completion of the Exchange Offer. The Company&#8217;s offer to participate in the Option Exchange Program commenced on February 8, 2024, and expired on March 8, 2024 (the &#8220;Exchange Offer&#8221;). Pursuant to the Exchange Offer,&#160;42&#160;eligible holders elected to exchange, and the Company accepted for cancellation, eligible options to purchase an aggregate of&#160;603,330&#160;shares of the Company&#8217;s common stock (the &#8220;Exchanged Options&#8221;). On March 11, 2024, promptly following the expiration of the Exchange Offer, the Company granted new options to purchase&#160;603,330&#160;shares of common stock (the &#8220;New Options&#8221;), pursuant to the terms of the Exchange Offer and the Amended 2021 Plan. The exercise price of the New Options granted was $11.44&#160;per share, which was the closing price of the Company&#8217;s common stock on the Nasdaq Capital Market on the grant date of the New Options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The exchange of stock options was treated as a modification for accounting purposes. As a result of the Option Exchange Program, the Company will recognize incremental stock-based compensation expense of $1.7 million over the requisite service period of the New Options, which is two or four years depending on whether the Exchanged Options were vested at the time of exchange. Since the Exchanged Options were not at-the-money on the modification date, the Company was precluded from utilizing the simplified method as described in SEC Staff Accounting Bulletin Topic 14.D.2 to calculate the expected term as a key assumption in the Black-Scholes pricing model. Therefore, the Company utilized the binomial lattice model to calculate the fair value of the Exchanged Options immediately prior to the exchange. The Company utilized the Black-Scholes option-pricing model to calculate the fair value of the New Options on the modification date. The Company is recognizing the remaining unamortized stock compensation expense for the Exchanged Options on the modification date over the original requisite service period of the Exchanged Options. At December 31, 2025, there was no unrecognized compensation cost related to Exchanged Options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A summary of the Company&#8217;s stock option activity and related information for the year ended December 31, 2025, is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.58760834%;padding-left:0pt;padding-right:0pt;width:101.17%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-average exercise&#160;price&#160;per share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-average remaining contractual term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate intrinsic value (in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,479,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 754,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised/Released</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,674)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (189,306)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (625)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 95.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,030,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested at December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,568,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 12pt 0pt;">The fair value of each stock option was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The Company recorded stock-based compensation expense associated with employee and non-employee stock options of $4.5 million, $4.6 million, and $4.2 million, for the years ended December 31, 2025, 2024, and 2023, respectively. The weighted-average grant date fair value of stock options granted in the years ended December 31, 2025, 2024, and 2023 was $5.48, $3.35 and $6.16 per stock option, respectively. The fair value of stock options that vested during the years ended December 31, 2025, 2024, and 2023 was $3.7 million, $3.5 million, and $3.1 million, respectively. The aggregate intrinsic value of options exercised (i.e.,&#160;the difference between the market price at exercise and the price paid by employees to exercise the option) during the years ended December&#160;31, 2025, 2024, and 2023 was $0.1 million, $0.1 million, and $0.0 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2025 there was $5.4 million of total unrecognized compensation cost related to unvested stock options and the Company expects to recognize this cost over a remaining weighted-average period of 2.2 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Restricted Stock Units (&#8220;RSUs&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Each RSU entitles the holder to receive one share of the Company&#8217;s common stock when the RSU vests. The RSUs generally vest (i) twenty-five percent (25%) one year from vesting start date and six and a quarter percent (6.25%) for each successive three-month period, thereafter, (ii) two tranches for 50% of the award with the second and final vesting date on the one year anniversary of the vesting commencement date, (iii) 100 percent within two years of the vesting commencement date and (iv) 33.3% of the RSUs on the first <span style="-sec-ix-hidden:Hidden_Y9Qm4X9j2kKBLrWQXymdSw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> anniversaries of the grant date. The RSUs are subject to acceleration of vesting in the event of certain change of control transactions and subject to the employee&#8217;s continued employment with, or service to, the Company on such vesting date. Compensation expense is recognized on a straight-line basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A summary of RSU activity during the year ended December 31, 2025, is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:73.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-average grant date fair value per&#160;share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,010,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,132,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (687,067)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/cancelled</p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (141,642)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,313,898</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 6pt 0pt;">The Company recorded stock-based compensation expense associated with employee and non-employee RSUs of $4.9 million, $2.7 million, and $1.6 million, for the years ended December 31, 2025, 2024, and 2023, respectively. The total fair value of restricted stock units that vested during the years ended December 31, 2025, 2024, and 2023 was approximately $4.4 million, $1.7 million, and $1.7 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2025, there was $4.6 million of total unrecognized compensation cost related to unvested RSUs and the Company expects to recognize this cost over a remaining weighted-average period of 1.9 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Employee stock purchase plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">At the special meeting of stockholders, held on December 18, 2018, the stockholders approved the 2018 Employee Stock Purchase Plan (&#8220;2018 ESPP&#8221;). On June 21, 2019, the board of directors of the Company amended and restated the 2018 ESPP, to account for certain non-material changes to the plan&#8217;s administration (the &#8220;Amended and Restated 2018 ESPP&#8221;). The Amended and Restated 2018 ESPP provides eligible employees with the opportunity, through regular payroll deductions, to purchase shares of the Company&#8217;s common stock at </span><span style="font-size:10pt;">85%</span><span style="font-size:10pt;"> of the lesser of the fair market value of the common stock (a) on the date the option is granted, which is the first day of the purchase period, and (b) on the exercise date, which is the last business day of the purchase period. The Amended and Restated 2018 ESPP generally allows for </span><span style="font-size:10pt;">two</span><span style="font-size:10pt;">&#160;</span><span style="font-size:10pt;">six-month</span><span style="font-size:10pt;"> purchase periods per year beginning in January and July, or such other periods as determined by the compensation committee of the Company&#8217;s board of directors. The Company has reserved </span><span style="font-size:10pt;">166,666</span><span style="font-size:10pt;"> shares of common stock for the administration of the Amended and Restated 2018 ESPP. The fair value of shares expected to be purchased under the Amended and Restated 2018 ESPP was calculated using the Black-Scholes model with the following weighted-average assumptions:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">For the years ended December 31, 2025, 2024, and 2023, the Company has recognized less than $0.1 million of stock-based compensation expense each year under the Amended and Restated 2018 ESPP. During the years ended December 31, 2025, 2024, and 2023, the Company issued 16,341 shares, 15,231 shares and 14,270 shares, respectively, of common stock for proceeds of $0.1 million in each year under the Amended and Restated 2018 ESPP.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">12. Segment Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has&#160;one&#160;operating segment which is the business of researching, developing and commercializing drugs for the treatment of patients with cancer. While the Company group consists of entities incorporated in both the U.S. and Germany, the Company manages all business activities on a consolidated basis for the purposes of assessing performance, making operating decisions, and allocating Company resources. The Company&#8217;s Chief Operating Decision Maker (the &#8220;CODM&#8221;) is its President and Chief Executive Officer. The measure of segment assets is the same as reported on the consolidated balance sheets as total assets. The CODM assesses performance based on consolidated net loss that is also reported on the statements of operations and comprehensive loss. The CODM uses net loss to monitor budget versus actual results and to determine how to allocate resources and capital in line with the Company&#8217;s overall strategy and goals. The accounting policies of the Company's segment are the same as those described in <i style="font-style:italic;">Note 2. Significant accounting policies</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The table below is a summary of segment net loss including significant segment expenses for the years ended December 31, 2025, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenue:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,914</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Sale of COPIKTRA license and related assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of sales - product</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of sales - intangible amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development expenses<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 112,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,137</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Commercial expenses<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,164</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Medical affairs expenses<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,907</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative expenses<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,512</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,755</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,860</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,068)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,149)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,214)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,139</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of preferred stock tranche liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,189)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,751)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (209,471)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (130,637)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (87,367)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This category is exclusive of non-cash stock-based compensation and severance expense.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other segment items primarily include severance expense and transactions losses and gains due to foreign currency fluctuations.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">13. Net Loss per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ASC Topic 260, <i style="font-style:italic;">Earnings Per Share,</i> requires the Company to calculate its net loss per share based on basic and diluted net loss per share, as defined. Basic EPS excludes dilution and is computed by dividing net loss by the weighted average number of shares outstanding for the period. For the years ended December 31, 2025, 2024, and 2023 net loss, basic and diluted EPS are the same as the assumed exercise of stock options, RSUs, ESPP, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Warrants are anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:50.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,030,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,479,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,270,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,313,898</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,010,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 209,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,429,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,083,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A Convertible Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 833,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 833,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B Convertible Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,236,570</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total potentially dilutive securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,783,736</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 22,413,970</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,557,026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">14. Income Taxes </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">There was no income tax expense for the years ended December 31, 2025 and 2023. The Company recorded income tax expense of </span><span style="color:#212529;">$0.2</span><span style="color:#212529;"> million for the year ended December 31, 2024 comprised of a federal income tax payment due to interest under IRC section 453A related to the </span><span style="color:#212529;">$10.0</span><span style="color:#212529;"> million milestone payment from Secura because it was an installment sale. This payment was made in 2025. Refer to </span><i style="color:#212529;font-style:italic;">Note. 16. License collaboration and commercial agreements</i><span style="color:#212529;"> for further discussion of the Secura APA</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">For the years ended December 31, 2025, 2024, and 2023 income tax expense consisted of the following (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:45.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current income tax expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total income tax expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 185</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">As further described in&#160;<a href="https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm" style="-sec-extract:exhibit;color:#000000;font-family:&quot;&quot;'Times New Roman','Times','serif'&quot;&quot;;font-size:10pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Note&#160;</i></a><a href="https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm" style="-sec-extract:exhibit;color:#000000;font-family:&quot;&quot;'Times New Roman','Times','serif'&quot;&quot;;font-size:10pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">2,</i></a><a href="https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm" style="-sec-extract:exhibit;color:#000000;font-family:&quot;&quot;'Times New Roman','Times','serif'&quot;&quot;;font-size:10pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">&#160;Summary of Significant Accounting Policies</i></a>, the Company elected to prospectively adopt the guidance in ASU 2023-09.&#160;The following table is a reconciliation of our effective income tax&#160;rate to the statutory federal income tax&#160;rate for the year ended December&#160;31, 2025 in accordance with the guidance in ASU 2023-09:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, 2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pretax loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (209,471)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,989)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local income tax benefit, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,710)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in the valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nontaxable or nondeductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,773</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,828</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_0gfH3kQvRkeG5SIGukyrFQ;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Effective income tax rate</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table is a reconciliation of the Company&#8217;s effective&#160;income tax&#160;rate to the statutory federal&#160;income tax&#160;rate for the year ended December&#160;31, 2024 in accordance with the guidance prior to the adoption of&#160;ASU 2023-09:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax benefit using U.S. federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State tax benefit, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.91)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in the valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax law change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NOL and tax credit expiration under Section 382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (44.44)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Effective income tax rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (0.14)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The principal components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,786</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,902</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Installment sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 462</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 179,447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,686</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (119)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (362)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (119)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (362)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax asset prior to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 179,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (179,328)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133,324)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net deferred tax asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has recorded a valuation allowance against its deferred tax assets at December 31, 2025 and 2024 because the Company&#8217;s management believes that it is more likely than not that these assets will not be fully realized. The increase in the valuation allowance of approximately $46.0 million in the year ended December 31, 2025, primarily relates to federal and state NOLs and credits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, the Company had federal and state NOL carryforwards of approximately $460.5 million and $99.5 million, respectively, which are available to reduce future taxable income. The Company also had federal and state tax credits of $12.3 million and $0.7 million, respectively, which may be used to offset future tax liabilities. The NOL and tax credit carryforwards will expire at various dates through 2045, except for $423.3 million of federal <span style="color:#212529;background:#ffffff;">NOL carryforwards which may be carried forward indefinitely. </span>Section 382 and 383 of the IRC and similar provisions under state law limit the utilization of U.S. NOL carryforwards, state NOL carryforwards, R&amp;D credits, and OD credits following certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%. During 2024, the Company believes it triggered ownership changes under Section 382 of the IRC and similar provisions under state law. Based on the Company&#8217;s analysis under Section 382, the Company believes that its federal NOL carryforwards, its state NOL carryforwards, R&amp;D credits, and OD credits are limited by Section 382 and similar provisions under state law as of December 31, 2025. The portion of federal NOL carryforwards, state NOL carryforwards, R&amp;D credits, and OD credits that were determined to be limited have been written off as of December 31, 2025. The remaining unused carryforwards and credits remain available for future periods. The Company has approximately $346.4 million of federal NOLs generated prior to such ownership changes inclusive of $309.3 million of federal NOLs <span style="color:#212529;background:#ffffff;">which may be carried forward indefinitely. Since the </span><span style="color:#212529;background:#ffffff;">$309.3</span><span style="color:#212529;background:#ffffff;"> million of federal NOLs may be carried forward indefinitely, these have not been written off as of December 31, 2025, but due to the limitations under Section 382 generally the Company can only use </span><span style="color:#212529;background:#ffffff;">$1.6</span><span style="color:#212529;background:#ffffff;"> million per year against taxable income in the future. </span>Due to the Company&#8217;s full valuation allowance the write off of certain NOL carryforwards and R&amp;D and OD credits did not have any impact to the statements of operation and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) requires taxpayers to capitalize and amortize research and development (&#8220;R&amp;D&#8221;) expenditures under section 174 for tax years beginning after December 31, 2021. This rule became effective for the Company during 2022. The Company is amortizing these costs for tax purposes over <span style="-sec-ix-hidden:Hidden_UdxKXO7ke0C6w3GjR8sZiQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span> years for R&amp;D performed in the U.S. and over <span style="-sec-ix-hidden:Hidden_gx1jXOcOUEaYyXuc-ygToQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15</span></span> years for R&amp;D performed outside the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">The One Big Beautiful Bill Act ("OBBBA") was passed and became effective for the Company during 2025. The legislation includes, among other provisions, permanent full expensing for certain business assets, changes to the interest deduction limitation under Section 163(j), amendments to international tax provisions including the global intangible low-taxed income (&#8220;GILTI&#8221;) and foreign-derived intangible income (&#8220;FDII&#8221;) regimes, the permanent extension of the controlled foreign corporation (&#8220;CFC&#8221;) look-through rule, as well as modifications to the treatment of research and development expenditures mentioned above.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">Congress modified the treatment for research and development expenditures by adding new Section 174A, which applies for tax years beginning after December 31, 2024. Section 174A permits the immediate deduction of domestic R&amp;D expenditures or, at the taxpayer&#8217;s election, capitalization and amortization over a period of at least five years beginning when the related benefits are first realized. Foreign R&amp;D expenditures continue to be capitalized and amortized over 15 years. Transition provisions allow taxpayers either to continue amortizing amounts capitalized under the TCJA rules or to deduct remaining unamortized domestic R&amp;D expenditures in the first tax year beginning after December 31, 2024. The Company has elected to continue amortizing previously capitalized domestic R&amp;D expenditures over the remaining amortization period permitted under OBBBA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">On October 4, 2023, Massachusetts enacted tax law changes which included the adoption of a single sales apportionment factor effective on January 1, 2025. On December 4, 2024, Massachusetts subsequently enacted supplemental legislation modifying Massachusetts' single sales apportionment factor in certain circumstances. As required under ASC 740, the Company has accounted for the deferred tax impacts of this tax law change in the period the tax law was enacted. The impact of the tax law change is offset by a change in valuation allowance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s reserves related to taxes are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. From inception and through December 31, 2025, the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Company had no unrecognized tax benefits or related <span style="-sec-ix-hidden:Hidden_7alXqiLFbU--YfYHWYlRNA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interest</span></span>, and penalties accrued. The Company has not conducted a study of R&amp;D credit and OD credit carryforwards. A future study may result in an adjustment to the Company&#8217;s R&amp;D credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s R&amp;D credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or statement of operations if an adjustment were required. The Company would recognize both accrued interest and penalties related to unrecognized benefits in income tax expense. The Company&#8217;s uncertain tax positions are related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15. Commitments and contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a lease agreement for approximately 27,810 square feet of office space in Needham, Massachusetts.&#160;Please refer to <i style="font-style:italic;">Note 9. Leases </i>for further details regarding the minimum aggregate future lease commitments as of December 31, 2025. In&#160;conjunction with the execution of the February 2018 Amended Lease Agreement and November 2024 Amended Lease Agreement, the Company has provided a security deposit in the form of a letter of credit in the amount of $0.2 million as of December 31, 2025, and 2024.&#160;The amount is included in non-current restricted cash on the consolidated balance sheets as of December 31, 2025, and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">As of December 31, 2025, the Company has committed to spend approximately </span><span style="background:#ffffff;">$48.1</span><span style="background:#ffffff;"> million under the IQVIA Master Services Agreement which the Company expects to spend in the next two to three years. As of December 31, 2025, </span>approximately $13.7&#160;million of this commitment is included within vendor financing arrangements, accrued expenses, and accounts payable on the consolidated balance sheets.&#160;Pursuant to the terms of various other agreements, the Company may be required to pay various development, regulatory and commercial milestones. In addition, if any products related to these agreements are approved for sale, the Company may be required to pay significant royalties on future sales. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurring.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, collaboration and commercial agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementAbstract', window );"><strong>License, collaboration and commercial agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock', window );">License, collaboration and commercial agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">16. License, collaboration and commercial agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pfizer, Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On July&#160;11, 2012, the Company entered into a license agreement (the &#8220;Pfizer Agreement&#8221;) with Pfizer (&#8220;Pfizer&#8221;) under which Pfizer granted the Company worldwide, exclusive rights to research, develop, manufacture and commercialize products containing certain of Pfizer&#8217;s inhibitors of FAK, including defactinib, for all therapeutic, diagnostic and prophylactic uses in humans. The Company has the right to grant sublicenses under the foregoing licensed rights, subject to certain restrictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Upon entering into the Pfizer Agreement, the Company made a one-time cash payment to Pfizer in the amount of </span><span style="background:#ffffff;">$1.5</span><span style="background:#ffffff;">&#160;million and issued </span><span style="background:#ffffff;">16,001</span><span style="background:#ffffff;"> shares of its common stock. In April 2025, the Company entered into an amendment to the Pfizer Agreement such that a </span><span style="background:#ffffff;">$7.5</span><span style="background:#ffffff;"> million milestone became payable upon FDA approval of AVMAPKI FAKZYNJA CO-PACK on May 8, 2025 (the &#8220;First Pfizer Milestone&#8221;), and </span><span style="background:#ffffff;">$8.0</span><span style="background:#ffffff;"> million milestone (the &#8220;Second Pfizer Milestone&#8221;) is payable upon the one-year anniversary of the FDA approval of AVMAPKI FAKZYNJA CO-PACK. The Company recorded a </span><span style="background:#ffffff;">$15.0</span><span style="background:#ffffff;"> million intangible asset related to these payments on the consolidated balance sheets and will record </span><span style="background:#ffffff;">$0.5</span><span style="background:#ffffff;"> million of interest expense related to the Second Pfizer Milestone. </span>Pfizer is also eligible to receive up to $2.0&#160;million in developmental milestones and up to an additional $110.0&#160;million based on the successful attainment of regulatory and commercial sales milestones. <span style="color:#212529;background:#ffffff;">The future milestone payments are contingent in nature and will be recognized if and when the respective contingencies are resolved. </span>Pfizer is also eligible to receive high single to mid-double-digit royalties on future net sales of the products. The Company&#8217;s </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">royalty obligations with respect to each product in each country begin on the date of first commercial sale of the product in that country, and end on the later of 10 years after the date of first commercial sale of the product in that country or the date of expiration or abandonment of the last claim contained in any issued patent or patent application licensed by Pfizer to the Company that covers the product in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the second quarter of 2025, the Company entered into an agreement with a third party to obtain an exclusive license for certain patents and intellectual property related to avutometinib and defactinib (the &#8220;License Agreement&#8221;). This agreement covers one of the four patent families that the Company has exclusively licensed and are owned by either Chugai or the third party. Pursuant to the License Agreement, the Company became obligated to pay $2.1 million in the year ended December 31, 2025 and is further obligated to pay up to $2.3 million upon achievement of certain milestones. <span style="background:#ffffff;">The Company recorded </span><span style="background:#ffffff;">$2.1</span><span style="background:#ffffff;"> million within intangible assets related to these payments on the consolidated balance sheets. </span>The future milestone payments are contingent in nature and will be recognized if and when the respective contingencies are resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GenFleet Therapeutics (Shanghai), Inc. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">On August 24, 2023, the Company entered into the GenFleet Agreement, pursuant to which GenFleet granted the Company the option to obtain exclusive development and commercialization rights worldwide outside of mainland China, Hong Kong, Macau, and Taiwan (the &#8220;Territory&#8221;) for up to three oncology programs targeting RAS pathway driven cancers (the &#8220;GenFleet Options&#8221;). The Company may exercise its GenFleet Options on a program-by-program basis.</span> In January 2025, the Company exercised its GenFleet Option with respect to VS-7375 and made a $6.0 million payment to GenFleet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company made an upfront payment of $2.0 million to GenFleet in September 2023 and will provide $1.5 million of research support over the first three years of the GenFleet Agreement. In addition, pursuant to the GenFleet Agreement, upon achievement of certain milestones, and upon the Company exercising its GenFleet Options, GenFleet will be entitled to receive payments of up to $622.0 million, inclusive of (i) up to $154.0 million upon achievement of certain development and commercialization milestones, (ii) up to $450.0 million upon achievement of certain sales milestones, and (iii) up to $18.0 million upon exercise of all three GenFleet Options. The Company paid GenFleet a $3.0 million milestone in the year ended December 31, 2024, upon GenFleet achieving a development milestone. The Company has also agreed to pay GenFleet royalties on net sales of licensed products in the Territory ranging from the mid to high single digits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company may terminate the GenFleet Agreement in its entirety or on a program-by-program basis by providing <span style="-sec-ix-hidden:Hidden_JU_oIydDdkuR8-FICIEckw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">90 days</span></span> written notice to GenFleet. Either party may terminate the GenFleet Agreement in its entirety or on a program-by-program and country-by-country basis, with <span style="-sec-ix-hidden:Hidden_AfA5SF6tv0-rw53ZSmEEFw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">60 days</span></span>&#8217; written notice for the other party&#8217;s material breach if such party fails to cure the breach. Either party may also terminate the GenFleet Agreement in its entirety upon certain insolvency events involving the other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company expensed $6.0 million in January 2025, related to the GenFleet Option payment within</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">research and development expense in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2025. The other future milestone payments are contingent in nature and will be recognized if and when the respective contingencies are resolved. If the Company elects to exercise further GenFleet Options, the related payment will be recognized if and when each respective GenFleet Option is elected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Secura Bio, Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">On August 10, 2020, the Company and Secura signed the Secura APA and on September 30, 2020, the transaction closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Pursuant to the Secura APA, the Company sold to Secura its exclusive worldwide license, including related assets, for the research, development, commercialization, and manufacture in oncology indications of products containing duvelisib. The sale included certain intellectual property related to duvelisib in oncology indications, certain existing duvelisib inventory, claims and rights under certain contracts pertaining to duvelisib. Pursuant to the Secura APA, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Secura assumed all operational and financial responsibility for activities that were part of the Company&#8217;s duvelisib oncology program, including all commercialization efforts related to duvelisib in the United States and Europe, as well as the Company&#8217;s ongoing duvelisib clinical trials. Further, Secura assumed all obligations with existing collaboration partners developing and commercializing duvelisib, which include Yakult, Honsha Co., Ltd. (&#8220;Yakult&#8221;), CSPC Pharmaceutical Group Limited (&#8220;CSPC&#8221;) and Sanofi. Additionally, Secura assumed all royalty payment obligations due under the amended and restated license agreement with Infinity Pharmaceuticals, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Pursuant to the terms of the Secura APA, Secura has paid the Company an up-front payment of $70.0 million in September 2020 and has agreed to pay the Company (i) regulatory milestone payments up to $45.0 million, consisting of a payment of $35.0 million upon receipt of regulatory approval of COPIKTRA in the United States for the treatment of peripheral T-cell lymphoma and a payment of $10.0 million upon receipt of the first regulatory approval for the commercial sale of COPIKTRA in the European Union for the treatment of peripheral T-cell lymphoma, (ii)&#160;sales milestone payments of up to $50.0 million, consisting of $10.0 million when total worldwide net sales of COPIKTRA exceed $100.0 million, $15.0 million when total worldwide net sales of COPIKTRA exceed $200.0 million and $25.0 million when total worldwide net sales of COPIKTRA exceed $300.0 million, (iii)&#160;low double-digit royalties on the annual aggregate net sales above $100.0 million in the United States, European Union, and the United Kingdom of Great Britain and Northern Ireland and (iv)&#160;50% of all royalty, milestone and sublicense revenue payments payable to Secura under the Company&#8217;s existing license agreements with Sanofi, Yakult, and CSPC, and 50% of all royalty and milestone payments payable to Secura under any license or sublicense agreement entered into by Secura in certain jurisdictions.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The Company evaluated the Secura APA in accordance with ASC 606 as the Company concluded that the counterparty, Secura, is a customer. The Company identified a bundled performance obligation consisting of delivery of the duvelisib global license and intellectual property, certain existing duvelisib inventory, certain duvelisib contracts and clinical trials, certain regulatory approvals, and certain regulatory documentation and books and records (the &#8220;Bundled Secura Performance Obligation&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The Company concluded that the duvelisib global license and intellectual property were not distinct within the context of the contract (i.e. separately identifiable) because the other assets including certain existing duvelisib inventory, certain duvelisib contracts and clinical trials, certain regulatory approval, and certain regulatory documentation and books and records do not have stand-alone value from other duvelisib global license and intellectual property and Secura could not benefit from them without the duvelisib global license and intellectual property. Consistent with the guidance under ASC 606-10-25-16A, the Company disregarded immaterial promised goods and services when determining performance obligations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The Company determined that the upfront payment of $70.0 million, future potential milestone payments and royalties including from Secura&#8217;s sublicensees should be allocated to the delivery of the Bundled Secura Performance Obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:2pt;background:#ffffff;margin:0pt;">During the years ended December 31, 2025 and 2023, the Company has not recognized any revenue associated with the Secura APA. During the year end ended December 31, 2024, Secura achieved $100.0 million of total worldwide net sales of COPIKTRA which triggered a $10.0 million sales milestone payment to the Company under the Secura APA. The Company received the $10.0 million milestone payment in July 2024. The Company determined all future potential milestones and royalties were excluded from the transaction price, as all other milestone amounts were fully constrained under the guidance as of December 31, 2025. As part of the Company&#8217;s evaluation of the constraint, the Company considered several factors in determining whether there is significant uncertainty associated with the future events that would result in the milestone payments. Those factors included: the likelihood and magnitude of revenue reversals related to future milestones, the amount of variable consideration that is highly susceptible to factors outside of the Company&#8217;s influence and the uncertainty about the consideration is not expected to be resolved for an extended period of time. All future potential milestone payments were fully constrained as the risk of significant revenue reversal related to these amounts has not yet been resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LicenseAndCollaborationAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LicenseAndCollaborationAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for license, collaboration and commercial agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Notes Payable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">17. Notes Payable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In January 2025, the&#160;Company entered into a finance agreement with FIRST Insurance Funding (&#8220;First Insurance&#8221;). Pursuant to the terms of the agreement, First Insurance loaned the Company the principal amount of $1.2&#160;million, which accrued interest at&#160;6.9% per annum, to fund a portion of the Company&#8217;s insurance policies. Pursuant to the agreement with First Insurance, the Company made an initial payment of $0.3&#160;million and made monthly payments of $0.1&#160;million through November 2025 including principal and interest. The agreement assigned First Insurance a first priority lien and security interest in the financed insurance policies. The outstanding balance at December 31, 2025 was $0.0 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee benefit plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee benefit plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee benefit plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">18. Employee benefit Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June 2011, the Company adopted a 401(k) retirement and savings plan (the 401(k) Plan) covering all employees. The 401(k) Plan allows employees to make pre-tax or post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. Under the 401(k) Plan, the Company may make discretionary contributions as approved by the board of directors. The Company made contributions to the 401(k) Plan of approximately $1.3 million, $1.0 million and $0.8 million in each of the years ended December 31, 2025, 2024, and 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Vendor Financing Arrangement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_VendorFinancingAgreementAbstract', window );"><strong>Vendor Financing Arrangement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramTextBlock', window );">Vendor Financing Arrangement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">19. Vendor Financing Arrangement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the IQVIA Master Services Agreement, the Company has extended payment terms with respect to a portion of the services provided and has recorded a vendor financing arrangement liability of $10.3 million as of December 31, 2025. The Company expects to pay the amounts recorded as <span style="-sec-ix-hidden:Hidden_gxfwXUi5dECGg1py2bW53w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">vendor financing arrangement</span></span> liabilities during 2026 and 2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplier finance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-50/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477128/405-50-55-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_VendorFinancingAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_VendorFinancingAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent events.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">20. Subsequent events </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">The Company reviews all activity subsequent to year end but prior to the issuance of the consolidated financial statements for events that could require disclosure or that could impact the carrying value of assets or liabilities as of the consolidated balance sheet date. The Company is not aware of any material subsequent events other than the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Warrants exercise</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:0pt;">In January 2026, 8,391,666 Warrants were exercised. As a result, the Company issued 8,391,666 shares of common stock and received net proceeds of $29.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note Purchase Agreement amendment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">In March 2026, the Company amended the Note Purchase Agreement to extend the date the Company may draw the Second Purchase from December 31, 2025 to June 30, 2026. Refer to&#160;<i style="font-style:italic;">Note 8. Long-term debt</i>&#160;for additional details on the Note Purchase Agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (209,471)<span></span>
</td>
<td class="num">$ (130,637)<span></span>
</td>
<td class="num">$ (87,367)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In the ordinary course of our business, we and our third-party service providers, such as contract research organizations, contract manufacturing organizations, and managed service providers collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research and development data and personal information). The secure maintenance of this confidentiality, availability and integrity of this information is critical to our business and reputation.  In addition, we are heavily dependent on the functioning of our information technology applications and services to carry out our business processes. While we have adopted administrative, technical and physical safeguards to protect such systems and data, our systems and those of third-party service providers may be vulnerable to a cyber-attack. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">We have adopted </span><span style="font-size:10pt;">processes</span><span style="font-size:10pt;white-space:pre-wrap;"> designed to identify, assess and manage material risks from cybersecurity threats.  Those processes include assessment of, and response to internal and external threats to the security, confidentiality, integrity and availability of our data and information systems, along with other material risks to our operations, at least annually or whenever there are material changes to our systems or operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Our risk management team collaborates with our </span><span style="font-size:10pt;">Chief Information Officer (&#8220;CIO&#8221;)</span><span style="font-size:10pt;white-space:pre-wrap;">, our internal information technology (&#8220;IT&#8221;) department, our Compliance team and our third-party IT managed service providers to evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.  We have established processes to detect potential vulnerabilities and anomalies through technical safeguards and have adopted policies and procedures around internal and external notification of cybersecurity incidents. Our CIO and IT Department implement processes around security monitoring and vulnerability testing.  We also have in place an incident response process for responding to and escalating cybersecurity events and incidents.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">As part of our risk management process, we </span><span style="font-size:10pt;">engage outside providers</span><span style="font-size:10pt;"> to conduct periodic internal and external penetration testing of our systems, networks and web properties. We also employ internal security testing solutions and security awareness training for all employees. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We engage a security operations platform provider to assist us in monitoring, assessing and managing potential cyber events. We also perform periodic cyber maturity assessments to measure our cybersecurity profile against industry peers and standards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;white-space:pre-wrap;">We rely on third parties, including software-as-a-service and platform-as-a-services cloud vendors, for various business functions.  Our third-party services providers have access to our information systems and data, and we rely on such third parties for the continuous operation of our business.  </span><span style="font-size:10pt;">We oversee these third-party</span><span style="font-size:10pt;white-space:pre-wrap;"> service providers by conducting vendor diligence during contracting and onboarding and through ongoing monitoring.  Vendors are assessed for risk based on the nature of their service, access to data and systems, and the level to which those systems and data impact our business. Based on that assessment, we conduct diligence that may include completing security questionnaires, onsite audits, and other technical and data security evaluations.</span><span style="font-size:10pt;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">We have adopted </span><span style="font-size:10pt;">processes</span><span style="font-size:10pt;white-space:pre-wrap;"> designed to identify, assess and manage material risks from cybersecurity threats.  Those processes include assessment of, and response to internal and external threats to the security, confidentiality, integrity and availability of our data and information systems, along with other material risks to our operations, at least annually or whenever there are material changes to our systems or operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Our risk management team collaborates with our </span><span style="font-size:10pt;">Chief Information Officer (&#8220;CIO&#8221;)</span><span style="font-size:10pt;white-space:pre-wrap;">, our internal information technology (&#8220;IT&#8221;) department, our Compliance team and our third-party IT managed service providers to evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.  We have established processes to detect potential vulnerabilities and anomalies through technical safeguards and have adopted policies and procedures around internal and external notification of cybersecurity incidents. Our CIO and IT Department implement processes around security monitoring and vulnerability testing.  We also have in place an incident response process for responding to and escalating cybersecurity events and incidents.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">As part of our risk management process, we </span><span style="font-size:10pt;">engage outside providers</span><span style="font-size:10pt;"> to conduct periodic internal and external penetration testing of our systems, networks and web properties. We also employ internal security testing solutions and security awareness training for all employees. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We engage a security operations platform provider to assist us in monitoring, assessing and managing potential cyber events. We also perform periodic cyber maturity assessments to measure our cybersecurity profile against industry peers and standards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;white-space:pre-wrap;">We rely on third parties, including software-as-a-service and platform-as-a-services cloud vendors, for various business functions.  Our third-party services providers have access to our information systems and data, and we rely on such third parties for the continuous operation of our business.  </span><span style="font-size:10pt;">We oversee these third-party</span><span style="font-size:10pt;white-space:pre-wrap;"> service providers by conducting vendor diligence during contracting and onboarding and through ongoing monitoring.  Vendors are assessed for risk based on the nature of their service, access to data and systems, and the level to which those systems and data impact our business. Based on that assessment, we conduct diligence that may include completing security questionnaires, onsite audits, and other technical and data security evaluations.</span><span style="font-size:10pt;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;">Our Board of Directors provides oversight of the Company&#8217;s cybersecurity risk management program and integrates this oversight into its overall evaluation of enterprise risk. Our </span><span style="font-size:10pt;">Audit Committee</span><span style="font-size:10pt;"> has primary responsibility for oversight of cybersecurity and is briefed on cybersecurity risks at least once each year and following any material cybersecurity incidents.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;">Audit Committee</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Our </span><span style="font-size:10pt;">CIO reports at least annually to the Audit Committee</span><span style="font-size:10pt;"> and such reporting includes an overall assessment of compliance with our cybersecurity policies and procedures as well as topics that may include risk assessments, risk management and control decisions, service provider arrangements, test results, security incidents and responses and recommendations for changes and updates to policies and procedures. In the event of a cybersecurity incident, the CIO reports the incident to the executive leadership team. If the cybersecurity incident is determined to be material, the executive leadership team will report the incident to the Audit Committee or Board of Directors as appropriate.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Our Board of Directors provides oversight of the Company&#8217;s cybersecurity risk management program and integrates this oversight into its overall evaluation of enterprise risk. Our </span><span style="font-size:10pt;">Audit Committee</span><span style="font-size:10pt;"> has primary responsibility for oversight of cybersecurity and is briefed on cybersecurity risks at least once each year and following any material cybersecurity incidents.</span><span style="font-size:10pt;white-space:pre-wrap;">  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">At the management level, our cybersecurity program is managed by our </span><span style="font-size:10pt;">CIO</span><span style="font-size:10pt;">, reporting into the executive leadership team. </span><span style="font-size:10pt;">Our CIO has over 30 years of experience managing IT operations and cybersecurity within the pharmaceutical, biotechnology and high-tech industries.</span><span style="font-size:10pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Our </span><span style="font-size:10pt;">CIO reports at least annually to the Audit Committee</span><span style="font-size:10pt;"> and such reporting includes an overall assessment of compliance with our cybersecurity policies and procedures as well as topics that may include risk assessments, risk management and control decisions, service provider arrangements, test results, security incidents and responses and recommendations for changes and updates to policies and procedures. In the event of a cybersecurity incident, the CIO reports the incident to the executive leadership team. If the cybersecurity incident is determined to be material, the executive leadership team will report the incident to the Audit Committee or Board of Directors as appropriate.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;">Chief Information Officer (&#8220;CIO&#8221;)</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;">Our CIO has over 30 years of experience managing IT operations and cybersecurity within the pharmaceutical, biotechnology and high-tech industries.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Our risk management team collaborates with our </span><span style="font-size:10pt;">Chief Information Officer (&#8220;CIO&#8221;)</span><span style="font-size:10pt;white-space:pre-wrap;">, our internal information technology (&#8220;IT&#8221;) department, our Compliance team and our third-party IT managed service providers to evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.  We have established processes to detect potential vulnerabilities and anomalies through technical safeguards and have adopted policies and procedures around internal and external notification of cybersecurity incidents. Our CIO and IT Department implement processes around security monitoring and vulnerability testing.  We also have in place an incident response process for responding to and escalating cybersecurity events and incidents.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis of presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) under the assumption that the Company will continue as a going concern for the next 12 months. Accordingly, they do not include any adjustments that might result from the uncertainty related to the Company&#8217;s ability to continue as a going concern.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The preparation of the Company&#8217;s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including but not limited to estimates related to revenue recognition, accrued and prepaid clinical trial expense and other general accruals, stock-based compensation expense, long-term debt, and its warrant liability. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable. Actual results could differ from such estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and geographic information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Segment and geographic information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available and regularly reviewed by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">one operating segment, which is the business of researching, developing and commercializing drugs for the treatment of patients with cancer. All material long-lived assets of the Company reside in the U.S.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProceedsFromGrantsPolicyPolicyTextBlock', window );">Proceeds from Grants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Proceeds from grants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><span style="font-size:10pt;">In May 2022, the Company was awarded the &#8220;Therapeutic Accelerator Award&#8221; grant from Pancreatic Cancer Network (&#8220;PanCAN&#8221;) for up to </span><span style="font-size:10pt;">$3.8</span><span style="font-size:10pt;">&#160;million (the &#8220;</span><span style="-sec-ix-hidden:Hidden_q90ZIR8th0OGZ8dK-5vu4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PanCAN Grant</span></span><span style="font-size:10pt;">&#8221;). In August 2022, PanCAN agreed to provide the Company with an additional </span><span style="font-size:10pt;">$0.5</span><span style="font-size:10pt;">&#160;million for the collection and analysis of patient samples. The grant is supporting a Phase 1b/2 clinical trial of GEMZAR (gemcitabine) and ABRAXANE (Nab-paclitaxel) in combination with avutometinib and defactinib entitled RAMP 205. The RAMP 205 trial is evaluating whether combining avutometinib (to target KRAS mutant, which is found in more than 90% of pancreatic adenocarcinomas), and defactinib (to reduce stromal density and adaptive resistance to avutometinib) to the standard GEMZAR/ABRAXANE regimen improves outcomes for patients with such pancreatic cancers. The Company recognizes grants as contra research and development expense in the consolidated statement of operations and comprehensive loss on a systematic basis over the periods in which the Company recognizes as expenses the related costs for which the grants are intended to compensate. Eligible expenses incurred in excess of grant payments received up to the total amount of the PanCAN Grant are recorded as a grant receivable. Through December 31, 2025, the Company has received </span><span style="font-size:10pt;">$4.1</span><span style="font-size:10pt;">&#160;million of cash proceeds that were initially recorded as deferred liabilities on the balance sheet. The Company recorded </span><span style="font-size:10pt;">$0.0</span><span style="font-size:10pt;"> million, </span><span style="font-size:10pt;">$2.0</span><span style="font-size:10pt;"> million and </span><span style="font-size:10pt;">$2.0</span><span style="font-size:10pt;white-space:pre-wrap;"> million of the proceeds as a reduction of research and development expense during the years ended December 31, 2025, 2024, and 2023, respectively.  As of December 31, 2025, the Company had </span><span style="font-size:10pt;">$0.2</span><span style="font-size:10pt;"> million as a </span><span style="-sec-ix-hidden:Hidden_LYd0gLsYTUK5twLVxNTSUw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">grant receivable</span></span><span style="font-size:10pt;"> and </span><span style="font-size:10pt;">no</span><span style="font-size:10pt;"> deferred liabilities related to the PanCAN Grant recognized on the consolidated balance sheet.</span><span style="font-size:10pt;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash, cash equivalents and restricted cash</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist of a U.S. Government money market funds and corporate bonds and commercial paper of publicly traded companies. Cash equivalents are reported at fair value. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:69.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 204,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88,818</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 241</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total cash, cash equivalents and restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 205,231</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 89,059</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Amounts included in restricted cash as of December 31, 2025 and December 31, 2024 represent cash held to collateralize outstanding letters of credit provided as a security deposit for the Company&#8217;s office space located in Needham, Massachusetts in the amount of $0.2&#160;million. The letters of credit are included in<span style="color:#212529;">&#160;prepaid expenses and other current assets </span>on the consolidated balance sheet as of December 31, 2025, and in non-current restricted cash as of December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were no realized gains or losses on cash equivalents for the years ended December 31, 2025, 2024 or 2023. Accrued interest receivable is excluded from the amortized cost and estimated fair value of the Company&#8217;s cash equivalents. Accrued interest receivable of $0.2 million is presented within prepaid expenses and other current assets on the consolidated balance sheets on December 31, 2025. There was no accrued interest receivable as of December </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">31, 2024. There were no debt securities in an unrealized loss position as of December 31, 2025, or December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Cash, cash equivalents &amp; restricted cash:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:9.5pt;">Cash and money market accounts</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 205,231</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 205,231</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Total cash, cash equivalents &amp; restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> 205,231</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> 205,231</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Cash, cash equivalents &amp; restricted cash:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:9.5pt;">Cash and money market accounts</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 89,059</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 89,059</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Total cash, cash equivalents &amp; restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> 89,059</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> 89,059</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Fair value of financial instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company determines the fair value of its financial instruments based upon the fair value hierarchy, which prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;">Level&#160;1 inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Quoted prices in active markets for identical assets or liabilities that the Company can access at the measurement date.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;">Level&#160;2 inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;">Level&#160;3 inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Items measured at fair value on a recurring basis</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The following table presents information about the Company&#8217;s financial instruments that are measured at fair value on a recurring basis (in thousands) </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 106,830</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 106,830</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,647</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,330</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 111,977</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 111,977</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 63,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 63,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 63,304</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 63,304</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,199</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 58,199</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 58,199</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 12pt 0pt;">The investments and cash equivalents have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. The Company validates the prices provided by third party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active. After completing its validation procedures, the Company did not adjust or override any fair value measurements provided by the pricing services as of December 31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrant liability</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A warrant liability was recorded in connection with the July 2024 Offering (defined herein) (see&#160;<i style="font-style:italic;">Note 10. Capital Stock</i>). The fair value measurement of the warrant liability is classified as Level 3 under the fair value hierarchy. The fair value of the warrant liability at December 31, 2025 and December 31, 2024, was determined using the Black-Scholes valuation model. The inputs to the Black-Scholes valuation model include the risk-free rate, stock price volatility, expected dividends and remaining term. Significant increases or decreases in any of those inputs in isolation could result in a significantly lower or higher fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Below are the inputs used to value the warrant liability at December 31, 2025 and December 31, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Remaining term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">1.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table represents a reconciliation of the warrant liability (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 58,199</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Fair value of warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (50,044)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Fair value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 27,492</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 35,647</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Note Purchase Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">The fair value of the Notes pursuant to the Note Purchase Agreement represents the present value of estimated future payments, including interest, principal, Repayment Amount, and Revenue Participation Payments (each as defined in the Note Purchase Agreement) <span style="background:#ffffff;">(see </span><i style="font-style:italic;background:#ffffff;">Note 8. Long-term debt</i><span style="background:#ffffff;">)</span>. The fair value measurement is based on significant Level 3 unobservable inputs such as the probability and timing of Revenue Participation Payments, Repayment Amount, and the discount rate. The Company determined the fair value of the Notes utilizing a discounted cash flow model of estimated future payments including interest, principal, Repayment Amount and Revenue Participation Payments utilizing a discount rate calculated as the term matched risk-free rate plus credit spread. At January 13, 2025, the Company utilized a discount rate between 11.9%-12.4% and at December 31, 2025, the Company utilized a discount rate between 12.6%-13.0%. The fair value of the Notes at December 31, 2025 was determined to be $76.3 million which differed from the contractual principal amount of $75.0 million by $1.3 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">million. Significant increases or decreases in any of these inputs in isolation could result in a significantly lower or higher fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Oxford Loan Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="background:#ffffff;">The fair value of the Company&#8217;s Term Loans (as defined herein) pursuant to the Loan Agreement (as defined herein) (see </span><i style="font-style:italic;background:#ffffff;">Note 10. Long-term debt</i><span style="background:#ffffff;">)</span><span style="background:#ffffff;"> was determined using a discounted cash flow analysis with current applicable rates for similar instruments as of the consolidated balance sheet dates. The Company estimated that the fair value of its Term Loans was approximately </span><span style="background:#ffffff;">$41.1</span><span style="background:#ffffff;"> million at December 31, 2024 which differed from its carrying value of approximately </span><span style="background:#ffffff;">$40.7</span><span style="background:#ffffff;"> million. The fair value of the Company&#8217;s long-term debt was determined using Level&#160;3 inputs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock', window );">Concentrations of credit risk and off-balance sheet risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentrations of credit risk and off-balance sheet risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Cash and cash equivalents and trade accounts receivable are financial instruments that potentially subject the Company to concentrations of credit risk. The Company mitigates this risk by maintaining its cash and cash equivalents with high quality, accredited financial institutions. The management of the Company&#8217;s investments is not discretionary on the part of these financial institutions. As of December 31, 2025, the Company&#8217;s cash, cash equivalents were deposited at four financial institutions and it has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:12pt 0pt 0pt 0pt;">As of December 31, 2025 there were five customers that cumulatively made up 100% of the Company&#8217;s trade accounts receivable balance and two customers who cumulatively made up more than 60% of the Company&#8217;s trade accounts receivable balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2025, there were&#160;two&#160;customers who each individually accounted for greater than&#160;10% of the Company&#8217;s total revenues, for a total of $27.4 million. For the year ended December 31, 2024, there was&#160;one&#160;customer, Secura, who individually accounted for all of the Company&#8217;s revenue. Refer to&#160;<i style="font-style:italic;">Note 16. License, collaboration, and commercial agreements</i>&#160;for a detailed discussion of the Secura APA.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Property and equipment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consist of laboratory equipment, office furniture, computer equipment and leasehold improvements. Expenditures for repairs and maintenance are recorded to expense as incurred, whereas major betterments are capitalized as additions to property and equipment. Depreciation and amortization are calculated using the straight-line method over the following estimated useful lives of the assets:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5&#160;years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5&#160;years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3&#160;years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lesser of useful life or life of lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying value of assets may not be recoverable. Recoverability is measured by comparison of the asset&#8217;s book value to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. No impairment losses have been recorded through December 31, 2025.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_CloudComputingImplementationCostsPolicyPolicyTextBlock', window );">Cloud Computing Implementation Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cloud Computing Implementation Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company incurs costs to implement cloud computing arrangements that are hosted by third-party vendors. In accordance with Accounting Standard Codification (&#8220;ASC&#8221;) 350-40,&#160;Goodwill and Other, Internal-Use Software, for cloud computing arrangements that meet the definition of a service contract, the Company capitalizes qualifying implementation costs incurred during the application development stage as a component of prepaid expenses and other current assets and other assets. Capitalization of these costs concludes once the project is substantially complete, and the software is ready for the Company's intended use. Once available for its intended use, the capitalized costs are amortized on a straight-line basis over the term of the associated hosting arrangement, and are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss. Costs related to data conversion, overhead, general and administrative activities, and training are expensed as incurred. Post-configuration training and maintenance costs will be expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, prepaid expenses and other current assets, and other long-term assets, included approximately $0.4&#160;million each of capitalized implementation costs on the consolidated balance sheet.&#160;For the year ended December 31, 2025, the Company recorded amortization expense associated with cloud computing implementation costs of approximately $0.3 million recorded within selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research and development costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company expenses research and development costs to operations as incurred. Research and development expenses consist of: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">external research and development expenses incurred under arrangements with third parties, such as contract research organizations, clinical trial sites, manufacturing organizations and consultants, including the scientific advisory board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">license fees; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, and laboratory supplies.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Costs for certain development activities, such as clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendor on their actual costs incurred or level of effort expended. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid expenses and other current assets or accrued expenses. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For service-based equity awards, the Company recognizes stock-based compensation expense for stock options, and restricted stock units (&#8220;RSUs&#8221;) issued to employees, directors, and consultants based on the grant date fair value of the awards on a straight-line basis over the requisite service period, which typically is the vest period. The Company recognized stock-based compensation for shares issued to employees under the Company&#8217;s employee stock purchase plan (&#8220;ESPP&#8221;) plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company has granted performance-based RSUs and stock options with terms that allow the recipients to vest in a specific number of shares based upon the achievement of performance-based milestones as specified in the grants. Stock-based compensation expense associated with these performance-based RSUs and stock options is recognized if the performance condition is considered probable of achievement using the Company&#8217;s best estimates of the time to vesting for the achievement of the performance-based milestones. </span>Awards subject to performance-based vesting requirements are expensed utilizing an accelerated attribution model if achievement of the performance criteria is determined to be probable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The grant date fair value of stock options is estimated using the Black-Scholes option pricing model that takes into account the fair value of its common stock, the exercise price, the expected life of the option, the expected volatility of its common stock, expected dividends on its common stock, and the risk-free interest rate over the expected life of the option. The Company applies the simplified method described in the Securities and Exchange Commission (&#8220;SEC&#8221;) Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 14.D.2 to calculate the expected term as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term for options granted to employees. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its population. The Company has not paid and do not anticipate paying cash dividends on the Company&#8217;s shares of common stock; therefore, the expected dividend yield is assumed to be zero. The computation of expected volatility is based on the historical volatility of the Company&#8217;s common stock. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options.<span style="background:#ffffff;"> The Company accounts for forfeitures as they occur.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">The Company issues shares under the Company&#8217;s ESPP to employees. Stock-based compensation expense for discounted purchases under the ESPP is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period</span>.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Leases are accounted for in accordance with ASC Topic 842, Leases (&#8220;ASC 842&#8221;).&#160;This standard requires lessees to recognize in the statement of financial position a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term for both finance and operating leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances within the arrangement.&#160;A lease is identified where an arrangement conveys the right to control the use of identified property, plant, and equipment for a period of time in exchange for consideration.&#160;Leases which are identified within the scope of ASC 842 and which have a term greater than one year are recognized on the Company&#8217;s consolidated balance sheets as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize leases with terms of one year or less on its consolidated balance sheets. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates to calculate the present value of lease payments.&#160;Incremental borrowing rates are the rates the Company incurs to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 842, components of a lease are split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, maintenance, consumables, etc.), and non-components (e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on fair values to the lease components and non-lease components. Although separation of lease and non-lease components is required, certain practical expedients are available. Entities may elect the practical expedient to not separate lease and non-lease components. Rather, they would account for each lease component and the related non-lease component together as a single component. The Company has elected to account for the lease and non-lease components of each of its operating leases as a single lease component and allocate all of the contract consideration to the lease component only. The lease component results in an operating right-of-use asset being recorded on the consolidated balance sheets and amortized on a straight-line basis as lease expense.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue recognition </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services in accordance with ASC Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;). To determine revenue recognition for contracts with its customers, the Company performs the following five step assessment: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception and once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines which goods and services are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">P</i><i style="font-style:italic;">roduct Revenue, Net</i> - The Company sells AVMAPKI FAKZYNJA CO-PACK to a limited number of specialty pharmacies and specialty distributors in the United States. The specialty pharmacies dispense AVMAPKI FAKZYNJA CO-PACK directly to patients while the specialty distributors resell AVMAPKI FAKZYNJA CO-PACK to healthcare entities who then resell AVMAPKI FAKZYNJA CO-PACK to patients. In addition to distribution agreements with specialty distributors, the Company also enters into arrangements with (1) certain government agencies and various private organizations (&#8220;Third-Party Purchasers&#8221;), which may provide for chargebacks or discounts with respect to the purchase of AVMAPKI FAKZYNJA CO-PACK, and (2) Medicare and Medicaid, which may provide for certain rebates with respect to their reimbursement of AVMAPKI FAKZYNJA CO-PACK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue on sales of AVMAPKI FAKZYNJA CO-PACK when a customer obtains control of the product, which occurs at a specific point in time (typically upon delivery). Product revenues are recorded at the wholesale acquisition costs, net of applicable reserves for variable consideration. Components of variable consideration include trade discounts and allowances, Third-Party Payer chargebacks and discounts, government rebates, product returns, other patient focused allowances, such as voluntary co-pay assistance, benefits verification, and other patient support programs that are offered within contracts between the Company and customers, payors, and other indirect customers relating to the Company&#8217;s sale of AVMAPKI FAKZYNJA CO-PACK. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable or a current liability. These estimates take into consideration a range of possible outcomes based upon relevant factors such as, customer contract terms, information received from third parties regarding the anticipated payor mix for AVMAPKI FAKZYNJA CO-PACK, known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled with respect to sales made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The amount of variable consideration included within a transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under contracts will not occur in a future period. The Company&#8217;s analyses contemplate the application of the constraint in accordance with Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standard Codification (&#8220;ASC&#8221;) 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). For the twelve months ended December 31, 2025, the Company determined a material reversal of revenue would not occur in a future period for the estimates detailed below and, therefore, transaction prices would not be reduced further. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual results in the future vary from the Company&#8217;s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Trade Discounts and Allowances: The Company generally provides customers with invoice discounts on sales of AVMAPKI FAKZYNJA CO-PACK for prompt payment and other discounts, which are explicitly stated in the Company&#8217;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates its specialty pharmacy and specialty distributor customers for sales order management, data, distribution, and certain other services. The Company has determined such services are not distinct from the Company&#8217;s sale of AVMAPKI FAKZYNJA CO-PACK to the specialty pharmacy and specialty distributor customers and, therefore, these payments have also been recorded as a reduction of revenue within the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-Party Payer Chargebacks, Discounts and Fees: The Company executes contracts with Third-Party Purchasers which allow for eligible purchases of AVMAPKI FAKZYNJA CO-PACK at prices lower than the wholesale acquisition cost. In some cases, customers will charge the Company for the difference between what they pay for </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">AVMAPKI FAKZYNJA CO-PACK and the ultimate selling price to the Third-Party Purchasers to whom they sell the product. Reserves will generally be established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable, net. Chargeback amounts will generally be determined at the time of resale to the qualified Third-Party Purchasers by customers, and the Company generally will issue credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. The reserves for chargebacks are expected to consist of credits that the Company expects to issue for units that remain in customer inventories at the end of each reporting period that the Company expects will be sold to Third-Party Purchasers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. <span style="color:#212529;background:#ffffff;">In addition, the Company compensated certain Third-Party Payers for administrative services, such as account management and data reporting. These administrative service fees have also been recorded as a reduction of net product revenue within the consolidated statements of operations and comprehensive loss.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Government Rebates: The Company is subject to discount and rebate payment obligations under various government programs including Federal and state Medicaid programs, Medicare, and others. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses on the consolidated balance sheets. The Company&#8217;s liability for these rebates consist of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in customer inventories at the end of each reporting period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other Patient Support Initiatives: Other patient support initiatives that the Company offers include voluntary co-pay assistance programs, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payors. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive for product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Product Returns: Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company either directly or through one of its distribution channels. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s return policy generally allows for eligible returns of AVMAPKI FAKZYNJA CO-PACK for credit under the following circumstances:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Receipt of damaged product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shipment errors that were a result of an error by the Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Expired product that is returned during the period beginning three months prior to the product&#8217;s expiration and ending six months after the expiration date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Quantities of product received by a customer in excess of quantity ordered;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product subject to a recall; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product that the Company, at its sole discretion, has specified can be returned for credit. </span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">As of December 31, 2025, the Company has not received any returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sales of intellectual property</i><span style="font-style:italic;font-weight:bold;"> - </span>For sales of license and intellectual property, that include sale-based royalties, including milestone payments based on a level of sales, the Company evaluates whether the royalties and sales-based milestones are considered probable of being achieved and estimates the amount of royalties to include over the contractual term using the expected value method and estimates the sales-based milestones using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated royalty and milestone value is included in the transaction price. Royalties and sales-based milestones for territories for which there is not regulatory approval are not considered probable until such regulatory approval is achieved. The Company evaluates factors such as whether consideration is outside of the Company&#8217;s control, timeline for when the uncertainty will be resolved and historical sales of COPIKTRA if applicable. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and amount of royalty revenue to be received and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, Net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounts Receivable, Net </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Accounts receivable, net consists of amounts due from customers, net of applicable revenue reserves. Accounts receivable have standard payments that generally require payment within 30 to 90 days. Management determines the allowance for credit loss by regularly evaluating individual customer receivables and considering a customer&#8217;s financial condition, credit history and current economic conditions.  Based on the Company&#8217;s latest assessment of the collectability of its accounts receivable, an allowance for credit loss is not deemed necessary at December 31, 2025.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inventory </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventories are stated at the lower of cost or estimated net realizable value. The Company determined the cost of inventories using the&#160;standard cost&#160;method, which approximates actual cost based on a first-in, first out basis. Inventories consist primarily of third-party manufacturing costs. The Company began capitalizing inventory upon receiving FDA approval for AVMAPKI FAKZYNJA CO-PACK on May 8, 2025. Prior to the FDA approval of AVMAPKI FAKZYNJA CO-PACK, expenses associated with the manufacturing of the Company's products were recorded as research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, are recorded within cost of sales &#8211; product within the consolidated statements of operations and net loss. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required which would be recorded as a cost of sales - product in the consolidated statements of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Shipping and handling costs for product shipments are recorded as incurred in cost of sales - product along with costs associated with manufacturing the product, and any inventory write-downs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span><i style="font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company records finite-lived intangible assets related to certain capitalized milestone payments at their fair value. These assets are amortized over their remaining useful lives, which are estimated based on the shorter of the remaining underlying patent life or the estimated useful life of the underlying product. Intangible assets are amortized using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when future revenues cannot be reasonably estimated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company assesses its finite-lived intangible assets for impairment if indicators are present or changes in circumstance suggest that impairment may exist. Events that could result in an impairment, or trigger an impairment assessment, include the receipt of additional clinical or nonclinical data regarding the Company&#8217;s drug products or a potentially competitive drug candidate, significant changes in the manner of our use of the acquired assets, or new </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">information regarding future projected sales for the product. If impairment indicators are present or changes in circumstance suggest that impairment may exist, the Company performs a recoverability test by comparing the sum of the estimated undiscounted cash flows of each finite-lived intangible asset to its carrying value on the consolidated balance sheets. If the undiscounted cash flows used in the recoverability test are less than the carrying value, the Company would determine the fair value of the finite-lived intangible asset and recognize an impairment loss if the carrying value of the finite-lived intangible asset exceeds its fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative arrangements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Collaborative arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Contracts are considered to be collaborative arrangements when they satisfy the following criteria defined in ASC Topic 808, <i style="font-style:italic;">Collaborative Arrangements</i>: (i) the parties to the contract must actively participate in the joint operating activity and (ii) the joint operating activity must expose the parties to the possibility of significant risk and rewards, based on whether or not the activity is successful. Payments received from or made to a partner that are the result of a collaborative relationship with a partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction or increase to research and development expense, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes the tax effects of an uncertain tax position only if it is more likely than not that it will be sustained based solely on its technical merits as of the reporting date and only in an amount more likely than not that it will be sustained upon review by the tax authorities. The Company evaluates uncertain tax positions on a quarterly basis and adjust the liability for changes in facts and circumstances, such as new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, significant amendment to an existing tax law, or resolution of an examination. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the income tax provision in the period in which such determination is made. The resolution of its uncertain income tax positions is dependent on uncontrollable factors such as law changes, new case law, and the willingness of the income tax authorities to settle, including the timing thereof and other factors. Although the Company does not anticipate significant changes to its uncertain income tax positions in the next 12 months, items outside of its control could cause its uncertain income tax positions to change in the future, which would be recorded in its statements of operations. Interest and/or penalties related to income tax matters are recognized as a component of income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net operating loss (&#8220;NOL&#8221;) and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the Internal Revenue Code (&#8220;IRC&#8221;), as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Net loss per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per common share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period. For purposes of calculating net loss per share, weighted-average number of common shares outstanding includes the weighted average effect of pre-funded warrants as the exercise of which requires little or no consideration for the delivery of shares of common stock. <span style="white-space:pre-wrap;">Diluted net loss per common share is calculated by increasing the denominator by the weighted-average number of additional shares that could have been outstanding from securities convertible into common stock, such as the warrants issued in July 2024, stock options, restricted stock units, and ESPP (using the &#8220;treasury stock&#8221; method), Series A Convertible Preferred Stock, and Series B Convertible Preferred Stock (using the &#8220;if-converted&#8221; method), unless their effect on net loss per share is antidilutive. Under the &#8220;if-converted&#8221; method, convertible instruments that are-in-the-money, are assumed to have been converted as of the beginning of the period or when issued, if later. Additionally, the effects of any interest expense and changes in fair value of any bifurcated derivatives shall be added back to the numerator of the diluted net loss per share calculation.  Refer to </span><i style="font-style:italic;">Note 13. Net Loss per share</i> for further details related to the calculation of net loss per share.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NewAccountingStandardsAdoptedPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards Updates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Adopted Accounting Standards Updates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;">In December 2023, the FASB issued ASU No. 2023-09,&#160;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#160;(&#8220;ASU 2023-09&#8221;). The guidance in ASU 2023-09 improves the transparency of income tax disclosures by greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The Company has adopted and applied the guidance under this ASU for the year ended December 31, 2025, using the prospective transition method. See&#160;<i style="font-style:italic;">Note 14. Income Taxes</i>&#160;in the accompanying notes to the consolidated financial statements for further detail.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting standards updates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Recently issued accounting standards updates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">In November 2024, the FASB issued ASU No 2024-03&#8212;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). The guidance in ASU 2024-03 is intended to require more detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted.  The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to all prior periods presented in the financial statements. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;">In September 2025, the FASB issued ASU No. 2025-06,&#160;Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software&#160;(&#8220;ASU 2025-06&#8221;). This standard modernizes the accounting for internal-use software by removing references to prescriptive development stages and instead requiring capitalization of costs once (1) management has authorized and committed to funding the software project, and (2) it is probable the project will be completed and placed in service. Entities must evaluate whether there is &#8220;significant development uncertainty,&#8221; such as unresolved novel functionality or substantially revised performance requirements, before meeting this capitalization threshold. ASU 2025-06 is effective for annual reporting periods beginning after December 15, 2027, and interim periods within such annual reporting periods, with early adoption permitted. Entities may adopt the amendments prospectively, retrospectively, or under a modified transition approach. The Company is in the process of evaluating the impact that the adoption of this ASU may have on its consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;">Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_CloudComputingImplementationCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to cloud computing implementation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_CloudComputingImplementationCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk and description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_NewAccountingStandardsAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting standards adopted that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_NewAccountingStandardsAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ProceedsFromGrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for proceeds from grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ProceedsFromGrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of reconciliation of cash, cash equivalents and restricted cash</a></td>
<td class="text">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:69.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 204,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88,818</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 241</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total cash, cash equivalents and restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 205,231</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 89,059</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Schedule of cash, cash equivalents and investments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">31, 2024. There were no debt securities in an unrealized loss position as of December 31, 2025, or December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Cash, cash equivalents &amp; restricted cash:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:9.5pt;">Cash and money market accounts</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 205,231</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 205,231</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Total cash, cash equivalents &amp; restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> 205,231</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> 205,231</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Cash, cash equivalents &amp; restricted cash:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:9.5pt;">Cash and money market accounts</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 89,059</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> 89,059</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Total cash, cash equivalents &amp; restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> 89,059</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;"> 89,059</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of financial instruments measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The following table presents information about the Company&#8217;s financial instruments that are measured at fair value on a recurring basis (in thousands) </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 106,830</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 106,830</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,647</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,330</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 111,977</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 111,977</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 63,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 63,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 63,304</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 63,304</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,199</p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 58,199</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 58,199</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of inputs used to value the preferred stock tranche liability and warrant liability</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Remaining term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">1.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ReconciliationOfWarrantLiabilityTableTextBlock', window );">Schedule of reconciliation of warrant liability</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table represents a reconciliation of the warrant liability (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 58,199</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Fair value of warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (50,044)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Fair value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 27,492</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 35,647</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Schedule of estimated useful lives of the assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5&#160;years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5&#160;years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3&#160;years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lesser of useful life or life of lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the estimated useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ReconciliationOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for reconciliation of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ReconciliationOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product revenue reserves and allowances (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract', window );"><strong>Product revenue reserves and allowances</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowancesTableTextBlock', window );">Schedule of product revenue allowance and reserve categories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since 2025, the Company&#8217;s sole source of product revenue has been from sales of AVMAPKI FAKZYNJA CO-PACK in the United States. The following table summarizes activity in each of the product revenue allowance and reserve categories for the twelve months ended December 31, 2025 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trade</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Third Party Payer </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Government </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">chargebacks,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">rebates&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">allowances</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and fees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">incentives</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision related to sales in the current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 888</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,392</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,043</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Adjustments related to prior period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credits and payments made</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (652)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (135)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,367)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,154)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:38.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Ending balance at December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 236</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 252</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 3,025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 376</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 3,889</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ProductRevenueReservesAndAllowancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of product revenue reserves and allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ProductRevenueReservesAndAllowancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory consists of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:70.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:70.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:70.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:70.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:70.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total inventory</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 1,833</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s intangible assets consist of the following (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:15.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average Remaining Amortization Period (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired and in-licensed rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14.8 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (698)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total intangible assets, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 16,426</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future amortization expense for finite-lived intangible assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The Company recorded approximately $0.7 million in cost of sales &#8211; intangible amortization expense related to finite-lived intangible assets during the twelve months ended December 31, 2025 using straight-line methodology. Estimated future cost of sales- intangible amortization expense for finite-lived intangible assets as of December 31, 2025 is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:85.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year ending December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,117</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,117</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,117</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,117</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,117</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,841</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total future amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 16,426</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property equipment and related accumulated depreciation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Property and equipment and related accumulated depreciation are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:75.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 811</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Assets not yet placed in service</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 1,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 1,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,622)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,618)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total property and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 32</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued clinical trial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,915</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued milestone payments &amp; royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued compensation and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,860</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued commercialization costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 803</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued contract manufacturing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued other research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued consulting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,287</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total accrued expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 53,981</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of reconciliation of changes in the fair value of the Notes</a></td>
<td class="text"><span style="font-size:10pt;">The following table reconciles the change in fair value of the Notes during the years ended December 31, 2025</span><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Beginning fair value balance at January 13, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">75,000</b></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden__aGtVmkn9kuWPabZ5DVUXg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value reported in statements of operations</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,751</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_-3F5ri1upkSXeC-rPJHM9A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value reported in comprehensive loss</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,229)</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest and revenue participation payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,192)</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Ending fair value at December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">76,330</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of future principal payments under the Notes Purchase Agreement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">As of December 31, 2025, future principal payments under the Note Purchase Agreement are due as follows (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,500</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,500</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total principal payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 75,000</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of carrying value of the Term Loan</a></td>
<td class="text"><span style="color:#212529;">The components of the carrying value of the Term Loan as of December 31, 2024, are detailed below (in thousands):</span><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:33.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Principal loan balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,000</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Final Payment Fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,172</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Debt issuance costs, net of accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (448)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Long-term debt, net of discount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 40,724</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of interest expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The following table sets forth total interest expense for the years ended December 31, 2025, 2024, and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:52.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Contractual Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3,472</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Amortization of debt discount and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 230</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Amortization of Final Payment Fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 437</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,138</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4,562</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4,139</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"><span style="font-size:1pt;font-style:italic;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of elements of lease expenses</a></td>
<td class="text">The elements of lease expense were as follows (dollar amounts in thousands):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:53.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Lease Expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 885</p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total Lease Expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 1,011</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 906</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 885</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Information - Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:43.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating cash flows paid for amounts included in measurement of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,092</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,060</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Balance Sheet Information - Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.8%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Maturity Analysis</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:48.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 546</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Less: Present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:48.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Lease Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 535</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock', window );">Schedule of shares of common stock reserved for the issuance of common stock for vested restricted stock units and the exercise of stock options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, the Company had reserved the following shares of common stock for the issuance of common stock for vested restricted stock units, the exercise of stock options, employee stock purchase plan, Series A Convertible Preferred Stock conversions to shares of common stock, and exercise of warrants and pre-funded warrants (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved under Equity Compensation Plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for Inducement Grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for Series A Convertible Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares reserved for pre-funded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,656</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total shares reserved</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 28,555</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 30,702</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the shares of common stock reserved for the potential conversion of outstanding preferred stock and the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense as reflected in the Company's consolidated statements of operations and comprehensive loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense as reflected in the Company&#8217;s consolidated statements of operations and comprehensive loss was as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,134</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total stock-based compensation expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 9,405</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 7,342</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 5,860</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity and related information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.58760834%;padding-left:0pt;padding-right:0pt;width:101.17%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-average exercise&#160;price&#160;per share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-average remaining contractual term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate intrinsic value (in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,479,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 754,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised/Released</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,674)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (189,306)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (625)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 95.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,030,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested at December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,568,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to estimate fair value of each stock option on grant date</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock units</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:73.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-average grant date fair value per&#160;share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,010,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,132,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (687,067)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/cancelled</p></td><td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (141,642)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,313,898</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to estimate fair value of each employee stock purchase plan on grant date</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718-50/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summary of segment net loss including significant segment expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The table below is a summary of segment net loss including significant segment expenses for the years ended December 31, 2025, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenue:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,914</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Sale of COPIKTRA license and related assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of sales - product</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of sales - intangible amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development expenses<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 112,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,137</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Commercial expenses<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,164</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Medical affairs expenses<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,907</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative expenses<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,512</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,755</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,860</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,068)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,149)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,214)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,139</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of preferred stock tranche liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,189)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,751)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (209,471)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (130,637)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (87,367)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This category is exclusive of non-cash stock-based compensation and severance expense.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other segment items primarily include severance expense and transactions losses and gains due to foreign currency fluctuations.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities were excluded from the calculation of diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:50.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,030,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,479,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,270,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,313,898</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,010,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 209,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,429,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,083,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A Convertible Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 833,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 833,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series B Convertible Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,236,570</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total potentially dilutive securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 12,783,736</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 22,413,970</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,557,026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of Income tax expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">For the years ended December 31, 2025, 2024, and 2023 income tax expense consisted of the following (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:45.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current income tax expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total income tax expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 185</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of effective income tax rate to the statutory federal income tax rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, 2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pretax loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (209,471)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,989)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local income tax benefit, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,710)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in the valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nontaxable or nondeductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,773</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,828</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_0gfH3kQvRkeG5SIGukyrFQ;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Effective income tax rate</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, 2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax benefit using U.S. federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State tax benefit, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.91)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in the valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax law change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NOL and tax credit expiration under Section 382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (44.44)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Effective income tax rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (0.14)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of principal components of deferred tax assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The principal components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,786</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,902</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Installment sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 462</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 179,447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,686</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (119)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (362)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (119)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (362)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax asset prior to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 179,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (179,328)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (133,324)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net deferred tax asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 13, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NatureOfBusinessLineItems', window );"><strong>Nature of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,792<span></span>
</td>
<td class="nump">$ 875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember', window );">Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NatureOfBusinessLineItems', window );"><strong>Nature of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtInstrumentIssuanceOfAdditionalNotes', window );">Additional issue of principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember', window );">Notes | Second sale, any time prior to December 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NatureOfBusinessLineItems', window );"><strong>Nature of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtInstrumentIssuanceOfAdditionalNotes', window );">Additional issue of principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NatureOfBusinessLineItems', window );"><strong>Nature of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">$ 29,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DebtInstrumentIssuanceOfAdditionalNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of an additional issue of notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DebtInstrumentIssuanceOfAdditionalNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_NatureOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_NatureOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_SecondSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_SecondSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of business - Reverse Stock Split (Details)<br></strong></div></th>
<th class="th">
<div>May 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NatureOfBusinessLineItems', window );"><strong>Nature of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockholdersEquityReverseStockSplitConversionRatio', window );">Reverse stock split ratio</a></td>
<td class="nump">0.0833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vstm_CertificateOfAmendmentMember', window );">Certificate of Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NatureOfBusinessLineItems', window );"><strong>Nature of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockholdersEquityReverseStockSplitConversionRatio', window );">Reverse stock split ratio</a></td>
<td class="nump">0.0833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_NatureOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_NatureOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_StockholdersEquityReverseStockSplitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of the reverse stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_StockholdersEquityReverseStockSplitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vstm_CertificateOfAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vstm_CertificateOfAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies - Segment and geographic information (Details) - 12 months ended Dec. 31, 2025<br></strong></div></th>
<th class="th"><div>item</div></th>
<th class="th"><div>segment</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_SegmentAndGeographicInformationAbstract', window );"><strong>Segment and geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_SegmentAndGeographicInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_SegmentAndGeographicInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies - Proceeds from Grants (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Grant awarded, amount</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Research and Development Expense<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ReductionInResearchAndDevelopmentExpense', window );">Reduction of research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmountCumulativeCurrent', window );">Grant, grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLiabilityCurrent', window );">Grants, deferred liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration', window );">Government Assistance, Asset, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Grants Receivable, Net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=us-gaap_GovernmentAssistanceOtherMember', window );">Additional funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Grant awarded, amount</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in income from government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmountCumulativeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset from government assistance, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmountCumulativeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes asset from government assistance, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability from government assistance, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes increase (decrease) in income from government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ReductionInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proceeds recorded as a reduction of research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ReductionInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=us-gaap_GovernmentAssistanceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=us-gaap_GovernmentAssistanceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies - Reconciliation of cash, cash equivalents and restricted cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 204,990<span></span>
</td>
<td class="nump">$ 88,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Restricted cash</a></td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">205,231<span></span>
</td>
<td class="nump">89,059<span></span>
</td>
<td class="nump">$ 79,076<span></span>
</td>
<td class="nump">$ 75,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gains or losses on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued interest receivable</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in unrealized loss position</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of credit | Office and Laboratory Space in Needham, Massachusetts | Non-current restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Restricted cash</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalent restricted as to withdrawal or usage, classified as current. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=vstm_RestrictedCashAndCashEquivalentsNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=vstm_RestrictedCashAndCashEquivalentsNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant accounting policies - Cash, cash equivalents, restricted cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, cash equivalents &amp; restricted cash, Amortized Cost</a></td>
<td class="nump">$ 204,990<span></span>
</td>
<td class="nump">$ 88,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and investments</a></td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, cash equivalents &amp; restricted cash, Amortized Cost</a></td>
<td class="nump">205,231<span></span>
</td>
<td class="nump">89,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash, cash equivalents &amp; restricted cash, Fair Value</a></td>
<td class="nump">205,231<span></span>
</td>
<td class="nump">89,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=vstm_CashAndMoneyMarketAccountsMember', window );">Cash and money market accounts | Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, cash equivalents &amp; restricted cash, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=vstm_CashAndMoneyMarketAccountsMember', window );">Cash and money market accounts | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash, cash equivalents &amp; restricted cash, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=vstm_CashAndMoneyMarketAccountsMember', window );">Cash and money market accounts | Corporate bonds and commercial paper | Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, cash equivalents &amp; restricted cash, Amortized Cost</a></td>
<td class="nump">205,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=vstm_CashAndMoneyMarketAccountsMember', window );">Cash and money market accounts | Corporate bonds and commercial paper | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash, cash equivalents &amp; restricted cash, Fair Value</a></td>
<td class="nump">$ 205,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=vstm_CashAndMoneyMarketAccountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=vstm_CashAndMoneyMarketAccountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=vstm_CorporateBondsAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=vstm_CorporateBondsAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant accounting policies - Items Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">$ 35,647<span></span>
</td>
<td class="nump">$ 58,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes</a></td>
<td class="nump">76,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">111,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">35,647<span></span>
</td>
<td class="nump">58,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes</a></td>
<td class="nump">76,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">111,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">106,830<span></span>
</td>
<td class="nump">63,304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">106,830<span></span>
</td>
<td class="nump">63,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">35,647<span></span>
</td>
<td class="nump">58,199<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">106,830<span></span>
</td>
<td class="nump">63,304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">106,830<span></span>
</td>
<td class="nump">63,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">$ 35,647<span></span>
</td>
<td class="nump">58,199<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant accounting policies - Inputs used to value the warrant liability (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>Y</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>Y</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant liability</a></td>
<td class="nump">3.74<span></span>
</td>
<td class="nump">4.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant liability</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant liability</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies - Reconciliation of the warrant liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Beginning balance</a></td>
<td class="nump">$ 58,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_FairValueAdjustmentOfWarrantsExercised', window );">Fair value of warrants exercised</a></td>
<td class="nump">50,044<span></span>
</td>
<td class="nump">$ 545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment</a></td>
<td class="nump">27,492<span></span>
</td>
<td class="nump">19,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Ending balance</a></td>
<td class="nump">35,647<span></span>
</td>
<td class="nump">58,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Beginning balance</a></td>
<td class="nump">58,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_FairValueAdjustmentOfWarrantsExercised', window );">Fair value of warrants exercised</a></td>
<td class="num">(50,044)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment</a></td>
<td class="nump">27,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Ending balance</a></td>
<td class="nump">$ 35,647<span></span>
</td>
<td class="nump">$ 58,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_FairValueAdjustmentOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_FairValueAdjustmentOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant accounting policies - Note Purchase Agreement and Oxford Loan Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 13, 2025</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember', window );">Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt, fair value</a></td>
<td class="nump">76,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount', window );">Difference in fair value and principle amount</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Discount rate, notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMeasurementInput', window );">Discount rate</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Discount rate, notes | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMeasurementInput', window );">Discount rate</a></td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference in the fair value between the face (par) amount of debt instrument at time of issuance and the current fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies - Concentrations of credit risk and off-balance sheet risk (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract', window );"><strong>Concentrations of credit risk and off-balance sheet risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk', window );">Off-balance sheet concentrations of credit risk description</a></td>
<td class="text">As of December 31, 2025, the Company&#8217;s cash, cash equivalents were deposited at four financial institutions and it has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Trade accounts receivable | Credit Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract', window );"><strong>Concentrations of credit risk and off-balance sheet risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NumberOfCustomers', window );">Number of customer</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of trade accounts receivable</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Trade accounts receivable | Credit Concentration Risk | Major customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract', window );"><strong>Concentrations of credit risk and off-balance sheet risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NumberOfCustomers', window );">Number of customer</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of trade accounts receivable</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Customer Concentration Risk | Major customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract', window );"><strong>Concentrations of credit risk and off-balance sheet risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NumberOfCustomers', window );">Number of customer</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of financial instruments, excluding certain derivatives, with off-balance sheet credit risk (for example, standby letters of credit or financial guarantees), including (1) information about the (shared) activity, region or economic characteristic that identifies the concentration, (2) the face or contract amount of the instrument, (3) the nature and terms of the instrument, including the market risk, cash requirements and accounting policies for it, (4) the maximum amount of loss due to credit risk that would be incurred if the counterparties failed completely to perform according to the terms of the contracts, and any security or collateral that proved to be of no value, (5) the entity's policy of requiring collateral or other security to support financial instruments subject to credit risk, information about access to collateral or other security, and a brief description of the security supporting those financial instruments, and (6) the policy of entering into and a brief description of master netting arrangements to mitigate the credit risk, and the extent to which such arrangements would reduce the maximum amount of loss due to credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vstm_MajorCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vstm_MajorCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies - Property and equipment (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses on long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies - Cloud Computing Implementation Costs (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetCurrent', window );">Capitalized implementation costs</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization expense</a></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant accounting policies - Income taxes (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ChangeInCompanyOwnershipPercent', window );">Change in ownership, percent</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ChangeInCompanyOwnershipPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in the Company's ownership as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ChangeInCompanyOwnershipPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product revenue reserves and allowances (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems', window );"><strong>Product revenue reserves and allowances</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear', window );">Provision related to sales in the current year</a></td>
<td class="nump">$ 6,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowancesDeductions', window );">Credits and payments made</a></td>
<td class="num">(2,154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowances', window );">Product revenue reserves and allowances at ending</a></td>
<td class="nump">3,889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueAllowancesAndReservesTypeAxis=vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember', window );">Trade discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems', window );"><strong>Product revenue reserves and allowances</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear', window );">Provision related to sales in the current year</a></td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowancesDeductions', window );">Credits and payments made</a></td>
<td class="num">(652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowances', window );">Product revenue reserves and allowances at ending</a></td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueAllowancesAndReservesTypeAxis=vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember', window );">Third Party Payer chargebacks, discounts and fees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems', window );"><strong>Product revenue reserves and allowances</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear', window );">Provision related to sales in the current year</a></td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowancesDeductions', window );">Credits and payments made</a></td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowances', window );">Product revenue reserves and allowances at ending</a></td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueAllowancesAndReservesTypeAxis=vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember', window );">Government rebates and other incentives</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems', window );"><strong>Product revenue reserves and allowances</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear', window );">Provision related to sales in the current year</a></td>
<td class="nump">4,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowancesDeductions', window );">Credits and payments made</a></td>
<td class="num">(1,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowances', window );">Product revenue reserves and allowances at ending</a></td>
<td class="nump">3,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueAllowancesAndReservesTypeAxis=vstm_ProductRevenueAndAllowancesReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems', window );"><strong>Product revenue reserves and allowances</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear', window );">Provision related to sales in the current year</a></td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProductRevenueReservesAndAllowances', window );">Product revenue reserves and allowances at ending</a></td>
<td class="nump">$ 376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ProductRevenueReservesAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of product revenue reserves and allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ProductRevenueReservesAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ProductRevenueReservesAndAllowancesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in product revenue reserves and allowances for credits and payments made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ProductRevenueReservesAndAllowancesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in product revenue reserves and allowances for provision related to sales in the current year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ProductRevenueAllowancesAndReservesTypeAxis=vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ProductRevenueAllowancesAndReservesTypeAxis=vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ProductRevenueAllowancesAndReservesTypeAxis=vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ProductRevenueAllowancesAndReservesTypeAxis=vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ProductRevenueAllowancesAndReservesTypeAxis=vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ProductRevenueAllowancesAndReservesTypeAxis=vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ProductRevenueAllowancesAndReservesTypeAxis=vstm_ProductRevenueAndAllowancesReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ProductRevenueAllowancesAndReservesTypeAxis=vstm_ProductRevenueAndAllowancesReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of inventory (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">$ 1,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 1,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Cost of sales - intangible amortization</a></td>
<td class="nump">$ 698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Schedule of intangible assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Acquired and in-licensed rights</a></td>
<td class="nump">$ 17,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(698)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total intangible assets, net</a></td>
<td class="nump">$ 16,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-Average Remaining Amortization Period (Years)</a></td>
<td class="text">14 years 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule of future amortization expense of finite-lived intangible assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 1,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">1,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">1,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">1,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2030</a></td>
<td class="nump">1,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">10,841<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total intangible assets, net</a></td>
<td class="nump">$ 16,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,622<span></span>
</td>
<td class="nump">$ 1,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,622)<span></span>
</td>
<td class="num">(1,618)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">811<span></span>
</td>
<td class="nump">839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 665<span></span>
</td>
<td class="nump">$ 665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_AccruedClinicalTrialExpensesCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">$ 14,338<span></span>
</td>
<td class="nump">$ 10,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_AccruedMilestonePaymentsCurrent', window );">Accrued milestone payments &amp; royalties</a></td>
<td class="nump">11,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related benefits</a></td>
<td class="nump">10,860<span></span>
</td>
<td class="nump">6,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_AccruedCommercializationCostsCurrent', window );">Accrued commercialization costs</a></td>
<td class="nump">8,205<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_AccruedContractManufacturingExpensesCurrent', window );">Accrued contract manufacturing expenses</a></td>
<td class="nump">3,224<span></span>
</td>
<td class="nump">3,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued other research and development expenses</a></td>
<td class="nump">3,015<span></span>
</td>
<td class="nump">1,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_AccruedConsultingFeesCurrent', window );">Accrued consulting fees</a></td>
<td class="nump">1,287<span></span>
</td>
<td class="nump">1,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">793<span></span>
</td>
<td class="nump">620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 53,981<span></span>
</td>
<td class="nump">$ 25,952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_AccruedClinicalTrialExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_AccruedClinicalTrialExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_AccruedCommercializationCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for commercialization costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_AccruedCommercializationCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_AccruedConsultingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_AccruedConsultingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_AccruedContractManufacturingExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contract manufacturing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_AccruedContractManufacturingExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_AccruedMilestonePaymentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for milestone payments. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_AccruedMilestonePaymentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term debt - Note Purchase Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 13, 2025 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th"><div>Mar. 22, 2023</div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration', window );">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:SecuredOvernightFinancingRateSofrMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair value of Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember', window );">Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtInstrumentIssuanceOfAdditionalNotes', window );">Additional issue of principal amount of notes</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration', window );">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</a></td>
<td class="text">us-gaap:SecuredOvernightFinancingRateSofrMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">4.29%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate', window );">Additional interest rate (%)</a></td>
<td class="nump">3.71%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">9.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage', window );">Additional increase in interest rate at event of default</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtInstrumentNumberOfEqualInstallments', window );">Number of equal installments | installment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantDescription', window );">Financial covenants</a></td>
<td class="text">The Note Purchase Agreement contains no financial covenants<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair value of Notes</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember', window );">Notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principal amount of notes</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember', window );">Notes | Initial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember', window );">Notes | Second sale, any time prior to December 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtInstrumentIssuanceOfAdditionalNotes', window );">Additional issue of principal amount of notes</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember', window );">Notes | Third sale, any time prior to December 31, 2026 (trailing six-month worldwide net sales of avutometinib and defactinib are at least $55.0 million)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtInstrumentIssuanceOfAdditionalNotes', window );">Additional issue of principal amount of notes</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib', window );">Worldwide net sales of avutobetinib and defactinib during trailing 6-months</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember', window );">Notes | First 8 Quarters following the Note Purchase Agreement Closing Date | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_InterestDuePaidInKindPercentage', window );">Interest due paid-in-kind (%)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember', window );">Notes | First $100 million net sales of each included product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ParticipationInNetSalesPercentage', window );">Participation Percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ParticipationInNetSalesSalesAmount', window );">Sales amount</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember', window );">Notes | Purchased of full $150 million aggregate principal amount of Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ParticipationInNetSalesPercentage', window );">Participation Percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt', window );">Aggregate principal amount of notes</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember', window );">Notes | Redemption prior to second anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt redemption, percentage of principal amount</a></td>
<td class="nump">135.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember', window );">Notes | Redemption prior to third anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt redemption, percentage of principal amount</a></td>
<td class="nump">175.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember', window );">Notes | Redemption after third anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt redemption, percentage of principal amount</a></td>
<td class="nump">195.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member] | Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of variable interest rate on debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of additional interest rate at the event of default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of worldwide net sales of Avutometinib and Defactinib.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of additional interest rate for notes issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DebtInstrumentIssuanceOfAdditionalNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of an additional issue of notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DebtInstrumentIssuanceOfAdditionalNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DebtInstrumentNumberOfEqualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equal installments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DebtInstrumentNumberOfEqualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_InterestDuePaidInKindPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of interest due paid-in-kind.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_InterestDuePaidInKindPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate principal amount of debt to achieve in order to participate in participation percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ParticipationInNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of participation in net sales of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ParticipationInNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ParticipationInNetSalesSalesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sales to achieve in order to participate in participation percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ParticipationInNetSalesSalesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_InitialSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_InitialSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_SecondSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_SecondSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_First100MillionNetSalesOfEachIncludedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_First100MillionNetSalesOfEachIncludedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_RedemptionPriorToSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_RedemptionPriorToSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_RedemptionPriorToThirdAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_RedemptionPriorToThirdAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_RedemptionAfterYearThirdAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_RedemptionAfterYearThirdAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term debt - Reconciliation of changes in the fair value of the Notes (Details) - Notes<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Reconciliation of changes in the fair value of the Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning fair value balance</a></td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value reported in statements of operations</a></td>
<td class="nump">$ 12,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Fair Value Adjustment of Notes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Change in fair value reported in comprehensive loss</a></td>
<td class="num">$ (5,229)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Fair Value Adjustment of Notes, Instrument Specific Credit Risk<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Interest and revenue participation payments</a></td>
<td class="num">$ (6,192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending fair value</a></td>
<td class="nump">$ 76,330<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which other comprehensive income (OCI) is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term debt - Future principal payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Future principal payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LongTermDebtMaturityYearSix', window );">2031</a></td>
<td class="nump">$ 37,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LongTermDebtMaturityYearSeven', window );">2032</a></td>
<td class="nump">37,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LongTermDebtMaturitiesAggregatePrincipalDue', window );">Total principal payments</a></td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LongTermDebtMaturitiesAggregatePrincipalDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of principal debt due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LongTermDebtMaturitiesAggregatePrincipalDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LongTermDebtMaturityYearSeven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in seventh fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LongTermDebtMaturityYearSeven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LongTermDebtMaturityYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LongTermDebtMaturityYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term debt - Loan Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 13, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 22, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 25, 2022 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration', window );">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:SecuredOvernightFinancingRateSofrMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember', window );">If prepaid after the first anniversary and on or before the second anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtInstrumentFinalPaymentFeePercentage', window );">Percentage of final prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=vstm_PrepaymentAfterSecondAnniversaryMember', window );">If prepaid after the second anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtInstrumentFinalPaymentFeePercentage', window );">Percentage of final prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_LoanAndSecurityAgreementMember', window );">Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NumberOfFinancialCovenants', window );">Number of financial covenants | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtInstrumentAccruedInterestRate', window );">Accrued interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term, debt</a></td>
<td class="nump">$ 42,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_RepaymentsOfLongTermDebtFinalPaymentFee', window );">Final payment fee</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Prepayment penalty fee</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_RepaymentsOfLongTermDebtUnpaidInterest', window );">Unpaid interest</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_TermLoanFacilityMember', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtInstrumentCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtInstrumentFinalPaymentFeePercentage', window );">Percentage of final prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault', window );">Additional interest rate in an event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_TermBLoanMember', window );">Term B Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_TermCLoanMember', window );">Term C Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtInstrumentPeriodToDrawLoanMinimum', window );">Debt instrument period to draw loan, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_TermDLoanMember', window );">Term D Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtInstrumentPeriodToDrawLoanMinimum', window );">Debt instrument period to draw loan, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_GrossProductRevenueToBeAchieved', window );">Gross product revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vstm_TermELoanMember', window );">Term E Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of variable interest rate on debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DebtInstrumentAccruedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of term Loans will accrue interest at a rate per annum during the existence of an event of default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DebtInstrumentAccruedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the additional interest rate in event of default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DebtInstrumentCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the debt facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DebtInstrumentCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DebtInstrumentFinalPaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of final payment fee on original principal amount of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DebtInstrumentFinalPaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DebtInstrumentPeriodToDrawLoanMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the information pertaining to Debt Instrument Period to Draw Loan, Minimum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DebtInstrumentPeriodToDrawLoanMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_GrossProductRevenueToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gross product revenue to be achieved to draw the loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_GrossProductRevenueToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_NumberOfFinancialCovenants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of financial covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_NumberOfFinancialCovenants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_RepaymentsOfLongTermDebtFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for final payment fee included in debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_RepaymentsOfLongTermDebtFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_RepaymentsOfLongTermDebtUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for unpaid interest included in debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_RepaymentsOfLongTermDebtUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_PrepaymentAfterSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_PrepaymentAfterSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vstm_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vstm_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vstm_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vstm_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vstm_TermBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vstm_TermBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vstm_TermCLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vstm_TermCLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vstm_TermDLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vstm_TermDLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vstm_TermELoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vstm_TermELoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term debt - Components of carrying value of the Term Loan (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal loan balance</a></td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DebtInstrumentFinalPaymentFee', window );">Final Payment Fee</a></td>
<td class="nump">1,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Debt issuance costs, net of accretion</a></td>
<td class="num">(448)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total Long-term debt, net of discount</a></td>
<td class="nump">$ 40,724<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DebtInstrumentFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of final payment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DebtInstrumentFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term debt - Schedule of interest expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ContractualInterestExpense', window );">Contractual Interest</a></td>
<td class="nump">$ 1,109<span></span>
</td>
<td class="nump">$ 3,774<span></span>
</td>
<td class="nump">$ 3,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_AmortizationOfFinalPaymentFee', window );">Amortization of Final Payment Fee</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total</a></td>
<td class="nump">$ 1,138<span></span>
</td>
<td class="nump">$ 4,562<span></span>
</td>
<td class="nump">$ 4,139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_AmortizationOfFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to Final Payment Fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_AmortizationOfFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ContractualInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as contractual interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ContractualInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Office and Laboratory Space in Needham, Massachusetts<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 15, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 15, 2014 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of space | ft&#178;</a></td>
<td class="nump">27,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Balance sheet and other information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of use asset</a></td>
<td class="nump">$ 491<span></span>
</td>
<td class="nump">$ 1,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">906<span></span>
</td>
<td class="nump">$ 885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total Lease Expense</a></td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">906<span></span>
</td>
<td class="nump">885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Other Information - Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows paid for amounts included in measurement of lease liabilities</a></td>
<td class="nump">$ 1,092<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">$ 1,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use asset obtained in exchange for operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity Analysis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value discount</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease Liability</a></td>
<td class="nump">$ 535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 04, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>Vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 21, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,555,000<span></span>
</td>
<td class="nump">30,702,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NumberOfVotesPerEachShareOfCommonStock', window );">Number of votes entitled for each share of common stock | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,739,712<span></span>
</td>
<td class="nump">44,784,350<span></span>
</td>
<td class="nump">25,281,150<span></span>
</td>
<td class="nump">16,711,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Biotechnology Value Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted</a></td>
<td class="nump">833,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | At-the-market equity offering program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram', window );">Maximum value of common stock allowed to be sold | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vstm_InducementAwardProgramMember', window );">Inducement Award Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,195,000<span></span>
</td>
<td class="nump">802,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Equity compensation plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,232,000<span></span>
</td>
<td class="nump">5,925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vstm_SeriesaConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,429,000<span></span>
</td>
<td class="nump">18,083,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vstm_PreFundedWarrantMember', window );">Pre-Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,656,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum value of common stock able to be offered and sold through the market equity offering program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_NumberOfVotesPerEachShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes entitled per each share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_NumberOfVotesPerEachShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vstm_BiotechnologyValueFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vstm_BiotechnologyValueFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_AtMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vstm_AtMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vstm_InducementAwardProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vstm_InducementAwardProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vstm_SeriesaConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vstm_SeriesaConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vstm_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vstm_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital stock - November 2025 Public Offering (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Nov. 14, 2025</div></th>
<th class="th"><div>Nov. 13, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_November2025PublicOfferingMember', window );">November 2025 Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,543,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Selling price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock in the warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of shares of common stock in the warrant issued (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.2499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Overallotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares', window );">Option to purchase, maximum number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,862,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">1,862,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Selling price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 7.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of share that can be purchased pursuant to the option under the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_November2025PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vstm_November2025PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital stock - April 2025 Private Placement (Details) - Private Placement 2025<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 25, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="nump">3,429,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_PrivatePlacement2025Member', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 6.9999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock warrants can purchase | shares</a></td>
<td class="nump">7,285,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of shares of common stock in the warrant issued (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod', window );">Period of notice for ownership limitation</a></td>
<td class="text">61 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder', window );">Threshold percentage held to the shares outstanding at election of the holder</a></td>
<td class="nump">19.99%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds | $</a></td>
<td class="nump">$ 69.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage held to the total shares outstanding to exercise warrants or pre-funded warrants at election of the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of notice to be given for increase/decrease in the maximum percentage of shares owned by any holder to exercise warrants or pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_PrivatePlacement2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vstm_PrivatePlacement2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vstm_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vstm_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital stock - Stock Purchase Agreement (Details) - Notes - Stock purchase agreement - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 13, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Convertible Preferred Stock, net of issuance costs and preferred stock tranche liability</a></td>
<td class="nump">1,416,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 5.2931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockPurchaseRightPeriod', window );">Stock purchase period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockPurchaseRightMaximumAmount', window );">Stock purchase, maximum amount</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_StockPurchaseRightMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount under the stock purchase agreement purchased by investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_StockPurchaseRightMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_StockPurchaseRightPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period up to which investors can exercise the stock purchase right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_StockPurchaseRightPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vstm_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vstm_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital stock - July 2024 and June 2023 Public Offering (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 23, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,555,000<span></span>
</td>
<td class="nump">30,702,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,647,000<span></span>
</td>
<td class="nump">$ 58,199,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from the issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,595,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Value of warrants on issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83,836,000)<span></span>
</td>
<td class="num">(1,420,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,492,000<span></span>
</td>
<td class="nump">19,149,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance of stock costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,351,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts', window );">Issuance of common stock, and pre-funded warrants, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,221,000<span></span>
</td>
<td class="nump">91,420,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PreFundedWarrantsWarrantsOutstanding', window );">Pre-funded warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,654,168<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Value of warrants on issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts', window );">Issuance of common stock, and pre-funded warrants, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,674<span></span>
</td>
<td class="nump">21,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares', window );">Issuance of common stock, and pre-funded warrants, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,333,334<span></span>
</td>
<td class="nump">8,489,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_July2024PublicOfferingMember', window );">July 2024 Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="nump">13,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds</a></td>
<td class="nump">$ 50,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants', window );">Threshold percentage held to the shares outstanding</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder', window );">Threshold percentage held to the shares outstanding at election of the holder</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod', window );">Period of notice for ownership limitation</a></td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">$ 39,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,600,000<span></span>
</td>
<td class="nump">$ 58,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from the issuance of warrants</a></td>
<td class="nump">39,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,654,168<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Value of warrants on issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,429,166<span></span>
</td>
<td class="nump">18,083,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="nump">$ 19,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock', window );">Proceeds from issuance of warrants and common stock</a></td>
<td class="nump">15,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance of stock costs</a></td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_July2024PublicOfferingMember', window );">July 2024 Public Offering | Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock in the warrant issued</a></td>
<td class="nump">13,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of shares of common stock in the warrant issued (in dollars per share)</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Share of exercisable warrant</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance of stock costs</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_July2024PublicOfferingMember', window );">July 2024 Public Offering | Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock in the warrant issued</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 2.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of shares of common stock in the warrant issued (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Share of exercisable warrant</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,499,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of preferred stock, issuance costs</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_UnderwritingAgreementMember', window );">Underwriting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts', window );">Issuance of common stock, and pre-funded warrants, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_UnderwritingAgreementMember', window );">Underwriting Agreement | Public</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,489,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Sale price of the Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_UnderwritingAgreementMember', window );">Underwriting Agreement | Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of shares of common stock in the warrant issued (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,538,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage', window );">Maximum amount of common stock owned, as a percentage, that would prevent exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PreFundedWarrantElectionToExerciseNoticePeriod', window );">Days of notice for increase/decrease to maximum percentage owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage', window );">Upper limit of maximum amount of common stock owned by a holder, as a percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,538,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares', window );">Issuance of common stock, and pre-funded warrants, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,538,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_UnderwritingAgreementMember', window );">Underwriting Agreement | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,489,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_UnderwritingAgreementMember', window );">Underwriting Agreement | Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of shares of common stock in the warrant issued (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Sale price of the Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_CommonStockSharesOffered', window );">Common shares, offered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,538,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_CommonStockSharesOffered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of common shares offered by the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_CommonStockSharesOffered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of common shares that can be owned by any holder as a percentage that would prevent the exercise of any warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of common shares that can be owned by any holder as a percentage that would prevent the exercise of any warrants. By the holder's election, this amount can be increased or decrease but cannot exceed 19.99%.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_PreFundedWarrantElectionToExerciseNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of notice to be given for increase/decrease in the maximum amount of shares owned by any holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_PreFundedWarrantElectionToExerciseNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_PreFundedWarrantsWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pre-funded warrants outstanding. Warrants represent the right to buy a stock at a specific price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_PreFundedWarrantsWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow from  issuance of rights to purchase common shares and additional capital contribution to the entity from issuances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period related to exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate change in value during the period related to the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of an underwriting agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to an underwriting agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold percentage held to the total shares outstanding to exercise warrants or pre-funded warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage held to the total shares outstanding to exercise warrants or pre-funded warrants at election of the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of notice to be given for increase/decrease in the maximum percentage of shares owned by any holder to exercise warrants or pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_July2024PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vstm_July2024PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vstm_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vstm_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vstm_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vstm_PublicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vstm_PublicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=vstm_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=vstm_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital stock - Convertible Preferred Stock (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 18, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 24, 2023 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 04, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series B Convertible Preferred Stock to common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series B Convertible Preferred Stock to common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Shares issuable upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | BVF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vstm_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PreferredStockIssueNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ConversionOfPreferredStockConversionBlockerPercent', window );">Conversion of preferred stock, conversion blocker, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice', window );">Percentage of Conversion Blocker for conversion of shares into common stock, upon giving notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod', window );">Conversion Blocker notice period for conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">4,236,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PreferredStockIssuanceThresholdSharePrice', window );">Threshold share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PreferredStockIssuanceExpectedClosingPeriod', window );">Expected closing period of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NumberOfPreferredStockConvertibleIntoCommonStock', window );">Number of preferred stock converted into common stock</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Shares issuable upon conversion</a></td>
<td class="nump">4,236,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_SecondTrancheRightLiabilityNonCurrentFairValue', window );">Fair value of the Second Tranche Right | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PreferredStockTrancheLiability', window );">Preferred stock tranche liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability', window );">Mark-to-market adjustment under change in fair value of preferred stock tranche liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vstm_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series B Convertible Preferred Stock to common stock | $</a></td>
<td class="nump">$ 21,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vstm_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">944,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PreferredStockIssuanceThresholdSharePrice', window );">Threshold share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche', window );">Share issue period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PreferredStockIssuanceThresholdAggregateTradingVolume', window );">Threshold trading volume | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PreferredStockIssuanceThresholdTradingDays', window );">Trading days | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vstm_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PreferredStockConvertibleAggregateSharesToBeSold', window );">Aggregate shares to be sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,144,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vstm_SeriesaConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ConversionOfPreferredStockConversionBlockerPercent', window );">Conversion of preferred stock, conversion blocker, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice', window );">Percentage of Conversion Blocker for conversion of shares into common stock, upon giving notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod', window );">Conversion Blocker notice period for conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NumberOfPreferredStockConvertibleIntoCommonStock', window );">Number of preferred stock converted into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vstm_SeriesaConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | BVF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued on conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of notice to be given for increase in conversion blocker amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ConversionOfPreferredStockConversionBlockerPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent of conversion blocker for conversion of shares into common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ConversionOfPreferredStockConversionBlockerPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent of conversion blocker for conversion of shares into common stock, upon giving notice.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of market to market adjustment under change in fair value of preferred stock tranche liability as during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_NumberOfPreferredStockConvertibleIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of preferred stock that are convertible into common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_NumberOfPreferredStockConvertibleIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of issuance of shares in second tranche, after closing first tranche.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_PreferredStockConvertibleAggregateSharesToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate number of convertible preferred shares to be sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_PreferredStockConvertibleAggregateSharesToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_PreferredStockIssuanceExpectedClosingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected closing period of second tranche of issuance of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_PreferredStockIssuanceExpectedClosingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_PreferredStockIssuanceThresholdAggregateTradingVolume">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold trading volume of stock for preferred stock issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_PreferredStockIssuanceThresholdAggregateTradingVolume</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_PreferredStockIssuanceThresholdSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of the entity's common stock which would be required to be attained for issuance of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_PreferredStockIssuanceThresholdSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_PreferredStockIssuanceThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible preferred stock must exceed threshold percentage within a specified consecutive trading period for issuance of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_PreferredStockIssuanceThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_PreferredStockIssueNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of tranches in which the preferred shares are sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_PreferredStockIssueNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_PreferredStockTrancheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as preferred stock tranche liability, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_PreferredStockTrancheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_SecondTrancheRightLiabilityNonCurrentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fair value of non current portion of second tranche right classified as liability as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_SecondTrancheRightLiabilityNonCurrentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vstm_BiotechnologyValueFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vstm_BiotechnologyValueFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vstm_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vstm_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vstm_SeriesaConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vstm_SeriesaConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital stock - At-the market equity offering program (Details) - At-the-market equity offering program - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2025</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_AtMarketEquityOfferingProgramMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram', window );">Maximum value of common stock allowed to be sold</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vstm_CantorFitzgeraldCo.Member', window );">Cantor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Capital stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ProceedsFromIssuanceOfCommonStockNet', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum value of common stock able to be offered and sold through the market equity offering program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ProceedsFromIssuanceOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash inflow from the additional capital contribution to the entity, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ProceedsFromIssuanceOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vstm_AtMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vstm_AtMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vstm_CantorFitzgeraldCo.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vstm_CantorFitzgeraldCo.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Stock-based compensation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
<th class="th" colspan="1">72 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>item </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 19, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 18, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,405<span></span>
</td>
<td class="nump">$ 7,342<span></span>
</td>
<td class="nump">$ 5,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NumberOfEquityCompensationPlans', window );">Number of equity compensation plans | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vstm_EmployeeAndNonEmployeesStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">754,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Shares expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,132,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vstm_EquityIncentivePlan2021Member', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,991,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional number of shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,567,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vstm_EquityIncentivePlan2021Member', window );">2021 Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,590,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vstm_EquityIncentivePlan2021Member', window );">2021 Plan | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,268,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vstm_IncentivePlan2012Member', window );">2012 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved</a></td>
<td class="nump">285,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,083,333<span></span>
</td>
<td class="nump">1,385,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional number of shares reserved</a></td>
<td class="nump">2,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved', window );">Percentage of outstanding shares of common stock used to compute annual increase in number of shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vstm_IncentivePlan2012Member', window );">2012 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized', window );">Annual increase in number of shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vstm_IncentivePlan2012Member', window );">2012 Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,841,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,201,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Shares expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vstm_IncentivePlan2012Member', window );">2012 Plan | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vstm_InducementAwardProgramMember', window );">Inducement Award Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional number of shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,166<span></span>
</td>
<td class="nump">141,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,333<span></span>
</td>
<td class="nump">48,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ReductionOfSharesAvailableForIssuance', window );">Reduction of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vstm_InducementAwardProgramMember', window );">Inducement Award Program | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,459,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Shares expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vstm_InducementAwardProgramMember', window );">Inducement Award Program | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,527<span></span>
</td>
<td class="nump">2,134<span></span>
</td>
<td class="nump">1,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=vstm_SellingGeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,878<span></span>
</td>
<td class="nump">$ 5,208<span></span>
</td>
<td class="nump">$ 3,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_NumberOfEquityCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of equity compensation plans of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_NumberOfEquityCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ReductionOfSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction of shares available for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ReductionOfSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the annual increase in the maximum number of shares (or other type of equity) that was initially approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of the number of shares of outstanding stock relating to determining the annual increase in the maximum number of shares available for issuance under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vstm_EmployeeAndNonEmployeesStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vstm_EmployeeAndNonEmployeesStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vstm_EquityIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vstm_EquityIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vstm_IncentivePlan2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vstm_IncentivePlan2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vstm_InducementAwardProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vstm_InducementAwardProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=vstm_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=vstm_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Stock options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 9,405<span></span>
</td>
<td class="nump">$ 7,342<span></span>
</td>
<td class="nump">$ 5,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vstm_EmployeeAndNonEmployeesStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">2,479,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">754,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised/Released (in shares)</a></td>
<td class="num">(12,674)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/cancelled (in shares)</a></td>
<td class="num">(189,306)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">3,030,432<span></span>
</td>
<td class="nump">2,479,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested at the end of the period (in shares)</a></td>
<td class="nump">1,568,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 11.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">6.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised/Released (in dollars per share)</a></td>
<td class="nump">5.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/cancelled (in dollars per share)</a></td>
<td class="nump">6.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">95.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">10.53<span></span>
</td>
<td class="nump">$ 11.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Vested at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 12.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted-average remaining contractual term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the end of the period</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested at the end of the period</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the beginning of the period (in dollars)</a></td>
<td class="nump">$ 843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end of the period (in dollars)</a></td>
<td class="nump">2,731<span></span>
</td>
<td class="nump">$ 843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested at the end of the period (in dollars)</a></td>
<td class="nump">$ 1,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to estimate fair value of each stock-based award on the grant date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">3.93%<span></span>
</td>
<td class="nump">4.07%<span></span>
</td>
<td class="nump">3.77%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">107.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 5.48<span></span>
</td>
<td class="nump">$ 3.35<span></span>
</td>
<td class="nump">$ 6.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of vested stock options</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised (in dollars)</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized stock-based compensation expense (in dollars)</a></td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average recognition period</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vstm_EmployeeAndNonEmployeesStockOptionMember', window );">Stock options | One Year From Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vstm_EmployeeAndNonEmployeesStockOptionMember', window );">Stock options | Successive Three-Month Periods After One Year From Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vstm_StockOptionExchangeProgramMember', window );">Option Exchange Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized stock-based compensation expense (in dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vstm_EmployeeAndNonEmployeesStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vstm_EmployeeAndNonEmployeesStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vstm_StockOptionExchangeProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vstm_StockOptionExchangeProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Option Exchange Program (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 17, 2024 </div>
<div>item </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 11, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,405<span></span>
</td>
<td class="nump">$ 7,342<span></span>
</td>
<td class="nump">$ 5,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vstm_StockOptionExchangeProgramMember', window );">Option Exchange Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NumberOfEligibleStockholders', window );">Number of eligible stockholders | item</a></td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved | shares</a></td>
<td class="nump">603,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price of new options | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_NumberOfEligibleStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of eligible stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_NumberOfEligibleStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vstm_StockOptionExchangeProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vstm_StockOptionExchangeProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Restricted stock units (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="nump">$ 9,405<span></span>
</td>
<td class="nump">$ 7,342<span></span>
</td>
<td class="nump">$ 5,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests', window );">Number of shares holder to receive when RSU vests</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of shares vested | $</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average recognition period</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">1,010,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,132,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(687,067)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/cancelled (in shares)</a></td>
<td class="num">(141,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">1,313,898<span></span>
</td>
<td class="nump">1,010,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average grant date fair value per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the beginning of the period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">6.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited/cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">6.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the end of the period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="nump">$ 6.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | One year from vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NumberOfAnniversariesForVestingRestrictedStockUnits', window );">Number of anniversaries | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Successive three-month periods after one year from vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | One year anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits', window );">Number of installments | tranche</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Within two years for vesting commencement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | First three anniversaries of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_NumberOfAnniversariesForVestingRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of anniversaries for vesting for restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_NumberOfAnniversariesForVestingRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of installments for vesting of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares of entity's common stock the holder to receive when the restricted stock unit vests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=vstm_ShareBasedCompensationAwardTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=vstm_ShareBasedCompensationAwardTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=vstm_ShareBasedPaymentArrangementTrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=vstm_ShareBasedPaymentArrangementTrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Employee stock purchase plan (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 21, 2019 </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to estimate fair value of each stock-based award on the grant date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,405<span></span>
</td>
<td class="nump">$ 7,342<span></span>
</td>
<td class="nump">$ 5,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options and employee stock purchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of common stock at market price to be purchased</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods', window );">Number of vesting periods | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to estimate fair value of each stock-based award on the grant date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.27%<span></span>
</td>
<td class="nump">5.31%<span></span>
</td>
<td class="nump">5.16%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="nump">126.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,341<span></span>
</td>
<td class="nump">15,231<span></span>
</td>
<td class="nump">14,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options and employee stock purchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of vesting periods which employees have right to exercise an award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Reporting (Details) - 12 months ended Dec. 31, 2025<br></strong></div></th>
<th class="th"><div>item</div></th>
<th class="th"><div>segment</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Segment net loss including segment expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_CostOfGoodsSoldExcludingAmortization', window );">Cost of sales - product</a></td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Cost of sales - intangible amortization</a></td>
<td class="nump">698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">9,405<span></span>
</td>
<td class="nump">$ 7,342<span></span>
</td>
<td class="nump">$ 5,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(4,068)<span></span>
</td>
<td class="num">(4,149)<span></span>
</td>
<td class="num">(6,214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">4,562<span></span>
</td>
<td class="nump">4,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">1,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_IncomeLossFromPreferredStockTrancheLiability', window );">Change in fair value of preferred stock tranche liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,189)<span></span>
</td>
<td class="num">(2,751)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">27,492<span></span>
</td>
<td class="nump">19,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_FairValueAdjustmentOfNotes', window );">Change in fair value of Notes</a></td>
<td class="nump">12,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(209,471)<span></span>
</td>
<td class="num">(130,637)<span></span>
</td>
<td class="num">(87,367)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">30,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vstm_CopiktraLicenseAndRelatedAssetsMember', window );">Sale of COPIKTRA license and related assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember', window );">Research, developing and commercialization drugs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_CostOfGoodsSoldExcludingAmortization', window );">Cost of sales - product</a></td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Cost of sales - intangible amortization</a></td>
<td class="nump">698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense', window );">Research and development expenses</a></td>
<td class="nump">112,065<span></span>
</td>
<td class="nump">78,648<span></span>
</td>
<td class="nump">59,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_CommercialExpenditure', window );">Commercial expenses</a></td>
<td class="nump">34,316<span></span>
</td>
<td class="nump">10,934<span></span>
</td>
<td class="nump">4,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_MedicalAffairExpenditure', window );">Medical affairs expenses</a></td>
<td class="nump">11,046<span></span>
</td>
<td class="nump">5,231<span></span>
</td>
<td class="nump">2,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">28,512<span></span>
</td>
<td class="nump">21,785<span></span>
</td>
<td class="nump">19,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">9,405<span></span>
</td>
<td class="nump">7,342<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(4,068)<span></span>
</td>
<td class="num">(4,149)<span></span>
</td>
<td class="num">(6,214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">4,562<span></span>
</td>
<td class="nump">4,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">1,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_IncomeLossFromPreferredStockTrancheLiability', window );">Change in fair value of preferred stock tranche liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,189)<span></span>
</td>
<td class="num">(2,751)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">27,492<span></span>
</td>
<td class="nump">19,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_FairValueAdjustmentOfNotes', window );">Change in fair value of Notes</a></td>
<td class="nump">12,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="nump">572<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (209,471)<span></span>
</td>
<td class="num">$ (130,637)<span></span>
</td>
<td class="num">$ (87,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemCompositionDescription', window );">Segment reporting, other segment items</a></td>
<td class="text">Other segment items primarily include severance expense and transactions losses and gains due to foreign currency fluctuations.<span></span>
</td>
<td class="text">Other segment items primarily include severance expense and transactions losses and gains due to foreign currency fluctuations.<span></span>
</td>
<td class="text">Other segment items primarily include severance expense and transactions losses and gains due to foreign currency fluctuations.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember', window );">Research, developing and commercialization drugs | Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 30,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember', window );">Research, developing and commercialization drugs | Sale of COPIKTRA license and related assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemCompositionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of composition of other segment item not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemCompositionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_CommercialExpenditure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenditure incurred towards commercial expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_CommercialExpenditure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_CostOfGoodsSoldExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities and intangible amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_CostOfGoodsSoldExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_FairValueAdjustmentOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_FairValueAdjustmentOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_IncomeLossFromPreferredStockTrancheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from change in value of preferred stock tranche liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_IncomeLossFromPreferredStockTrancheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_MedicalAffairExpenditure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenditure incurred towards medical affairs expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_MedicalAffairExpenditure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenditure incurred towards research and development expense excluding non-cash stock-based compensation and severance expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vstm_CopiktraLicenseAndRelatedAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vstm_CopiktraLicenseAndRelatedAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share - Potentially dilutive shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities (in shares)</a></td>
<td class="nump">12,783,736<span></span>
</td>
<td class="nump">22,413,970<span></span>
</td>
<td class="nump">7,557,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities (in shares)</a></td>
<td class="nump">3,030,432<span></span>
</td>
<td class="nump">2,479,037<span></span>
</td>
<td class="nump">2,270,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities (in shares)</a></td>
<td class="nump">1,313,898<span></span>
</td>
<td class="nump">1,010,233<span></span>
</td>
<td class="nump">209,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities (in shares)</a></td>
<td class="nump">8,429,166<span></span>
</td>
<td class="nump">18,083,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities (in shares)</a></td>
<td class="nump">10,240<span></span>
</td>
<td class="nump">8,033<span></span>
</td>
<td class="nump">7,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vstm_SeriesaConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,333<span></span>
</td>
<td class="nump">833,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vstm_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,236,570<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vstm_SeriesaConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vstm_SeriesaConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vstm_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vstm_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax expense</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vstm_CopiktraLicenseAndRelatedAssetsMember', window );">Sale of COPIKTRA license and related assets | Secura</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra', window );">Milestone payments receivable upon approval of COPIKTRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of regulatory milestone payments receivable up on approval received from the approval of COPIKTRA in the United States for the treatment of peripheral T-cell lymphoma under the License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vstm_CopiktraLicenseAndRelatedAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vstm_CopiktraLicenseAndRelatedAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vstm_SecuraBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vstm_SecuraBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Taxes and Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Reconciliation of effective income tax rate to the statutory federal income tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pretax loss</a></td>
<td class="num">$ (209,471)<span></span>
</td>
<td class="num">$ (130,452)<span></span>
</td>
<td class="num">$ (87,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">US federal statutory rate</a></td>
<td class="num">(43,989)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="num">(9,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in the valuation allowance</a></td>
<td class="nump">45,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount', window );">Change in fair value of warrant liability</a></td>
<td class="nump">5,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">$ 1,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration', window );">Tax Jurisdiction of Domicile [Extensible Enumeration]</a></td>
<td class="text">country:US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of effective income tax rate to the statutory federal income tax rate (in percentage)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">US federal statutory rate (as a percent)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local income tax benefit, net of federal benefit (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits (as a percent)</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in the valuation allowance (as a percent)</a></td>
<td class="num">(21.70%)<span></span>
</td>
<td class="nump">14.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent', window );">Change in fair value of warrant liability (as a percent)</a></td>
<td class="num">(2.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation (as a percent)</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(1.91%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent items (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.88%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax law change (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent', window );">NOL and tax credit expiration under Section 382 (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44.44%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other (as a percent)</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(0.18%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.14%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 101,083<span></span>
</td>
<td class="nump">$ 81,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">52,887<span></span>
</td>
<td class="nump">38,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">12,850<span></span>
</td>
<td class="nump">2,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,902<span></span>
</td>
<td class="nump">2,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DeferredTaxAssetsInstallmentSale', window );">Installment sale</a></td>
<td class="nump">7,187<span></span>
</td>
<td class="nump">7,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other deferred tax assets</a></td>
<td class="nump">2,408<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">179,447<span></span>
</td>
<td class="nump">133,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance', window );">Net deferred tax asset prior to valuation allowance</a></td>
<td class="nump">179,328<span></span>
</td>
<td class="nump">133,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(179,328)<span></span>
</td>
<td class="num">$ (133,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_OperatingLossCarryforwardsPriorToOwnershipChanges', window );">NOL carryforward prior to ownership changes</a></td>
<td class="nump">346,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges', window );">NOL carryforward inclusive of ownership changes</a></td>
<td class="nump">309,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_OperatingLossCarryforwardsSection382Limitation', window );">NOL carryforwards Section 382 limitations</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest and penalties accrued related to unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Liability for uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod', window );">Capitalized Research and Development Expenses, Amortization Period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod', window );">Capitalized Research and Development Expenses, Amortization Period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates tax jurisdiction of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which the entity will amortize the capitalized research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DeferredTaxAssetsInstallmentSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from installment sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DeferredTaxAssetsInstallmentSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets net of deferred tax liabilities before valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to net operating loss and tax credit carryforwards expiration under section 382.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws, inclusive of ownership changes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_OperatingLossCarryforwardsPriorToOwnershipChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws, generated before ownership changes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_OperatingLossCarryforwardsPriorToOwnershipChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_OperatingLossCarryforwardsSection382Limitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under Section 382.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_OperatingLossCarryforwardsSection382Limitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Operating Loss Carryforwards (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 460.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_OperatingLossCarryforwardsIndefinitePeriod', window );">Operating loss carryforwards, indefinite period</a></td>
<td class="nump">423.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 99.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_OperatingLossCarryforwardsIndefinitePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws, which may be carried forward indefinitely.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_OperatingLossCarryforwardsIndefinitePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Tax Credits (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 12.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 15, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vstm_IqviaIncMember', window );">IQVIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitments</a></td>
<td class="nump">48,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=vstm_AccountsPayableCurrentMember', window );">Accounts Payable | IQVIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitments</a></td>
<td class="nump">13,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vstm_OfficeAndLaboratorySpaceLeaseArrangementMember', window );">Office and Laboratory Space in Needham, Massachusetts.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vstm_OfficeAndLaboratorySpaceLeaseArrangementMember', window );">Office and Laboratory Space in Needham, Massachusetts. | Letter of credit | Non-current restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vstm_IqviaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vstm_IqviaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=vstm_AccountsPayableCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=vstm_AccountsPayableCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vstm_OfficeAndLaboratorySpaceLeaseArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=vstm_OfficeAndLaboratorySpaceLeaseArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=vstm_RestrictedCashAndCashEquivalentsNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=vstm_RestrictedCashAndCashEquivalentsNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, collaboration and commercial agreements - Pfizer, Inc. (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 11, 2012</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,138<span></span>
</td>
<td class="nump">$ 4,562<span></span>
</td>
<td class="nump">$ 4,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vstm_PfizerIncMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_CollaborativeArrangementsOneTimeCashPayment', window );">One-time cash payment</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">16,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_CollaborativeArrangementsRoyaltyObligationsTerm', window );">Royalty obligations term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vstm_PfizerIncMember', window );">Pfizer | Achievement of FDA approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vstm_PfizerIncMember', window );">Pfizer | Achievement of FDA approval anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vstm_PfizerIncMember', window );">Pfizer | Achievement of certain development and commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vstm_PfizerIncMember', window );">Pfizer | Achievement of certain sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_CollaborativeArrangementsOneTimeCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the one-time cash payment made under the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_CollaborativeArrangementsOneTimeCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_CollaborativeArrangementsRoyaltyObligationsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the product's royalty obligations term that begin on the date of first commercial sale of the product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_CollaborativeArrangementsRoyaltyObligationsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_PotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments the Company may make.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_PotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vstm_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vstm_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_AchievementOfFdaApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_AchievementOfFdaApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_AchievementOfFdaApprovalAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_AchievementOfFdaApprovalAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_AchievementOfCertainSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_AchievementOfCertainSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, collaboration and commercial agreements - License Agreement (Details) - Exclusive license agreement<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NumberOfPatents', window );">Number of patents | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vstm_ExclusiveLicenseAgreementMember', window );">Pursuant to license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_CollaborativeArrangementsOneTimeCashPayment', window );">One-time cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vstm_ExclusiveLicenseAgreementMember', window );">Achievement of certain sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_CollaborativeArrangementsOneTimeCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the one-time cash payment made under the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_CollaborativeArrangementsOneTimeCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_NumberOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of patents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_NumberOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_PotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments the Company may make.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_PotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vstm_ExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vstm_ExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_PursuantToLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_PursuantToLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_AchievementOfCertainSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_AchievementOfCertainSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, collaboration and commercial agreements - Genfleet Therapeutics (Details) - License and Collaboration Agreement - Genfleet - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 24, 2023</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementUpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">$ 622.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments', window );">Payment for development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement.', window );">Number of days written prior notice required for other party to terminate agreement</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach', window );">Number of days written notice required to terminate agreement if fails to cure breach</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vstm_LicenseAndCollaborationAgreementMember', window );">Maximum | Achievement of certain development and commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">$ 154.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vstm_LicenseAndCollaborationAgreementMember', window );">Maximum | Achievement of certain sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vstm_LicenseAndCollaborationAgreementMember', window );">Maximum | Exercise of All Three Gen Fleet Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vstm_LicenseAndCollaborationAgreementMember', window );">Research and Development Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Genfleet R&amp;D Support Fee</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LicenseAndCollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for non refundable up front payment for license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LicenseAndCollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid upon achievement of development milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number days of written notice from either party to the agreement to terminate agreement for the other party's material breach if such party fails to cure the breach.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement.">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number days of prior written notice to terminate the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement.</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_PotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments the Company may make.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_PotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vstm_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vstm_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vstm_GenfleetTherapeuticsShanghaiIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vstm_GenfleetTherapeuticsShanghaiIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_AchievementOfCertainSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_AchievementOfCertainSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_ExerciseOfAllThreeGenFleetOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_ExerciseOfAllThreeGenFleetOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, collaboration and commercial agreements - Secura (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vstm_CopiktraLicenseAndRelatedAssetsMember', window );">Sale of COPIKTRA license and related assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vstm_SecuraBioInc.Member', window );">Secura | Sale of COPIKTRA license and related assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra', window );">Milestone payments receivable upon approval of COPIKTRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vstm_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Secura</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementUpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra', window );">Milestone payments receivable upon approval of COPIKTRA</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale', window );">Milestone payments receivable upon approval for commercial sale</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments', window );">Threshold sales to trigger royalty payments</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements', window );">Percentage of all royalty, milestone and sublicense revenue payments payable</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions', window );">Percentage of all royalty and milestone payments payable under certain jurisdictions</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vstm_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Secura | Sales Exceeds $100 Million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable', window );">Sales milestone receivable</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments', window );">Threshold sales to trigger milestone payments</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived', window );">Sales milestone received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vstm_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Secura | Sales Exceeds $200 Million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable', window );">Sales milestone receivable</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments', window );">Threshold sales to trigger milestone payments</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vstm_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Secura | Sales Exceeds $300 Million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable', window );">Sales milestone receivable</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments', window );">Threshold sales to trigger milestone payments</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vstm_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Secura | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable', window );">Regulatory milestone payments</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable', window );">Sales milestone receivable</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LicenseAndCollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for non refundable up front payment for license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LicenseAndCollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of royalties and milestone payments entitled under any license or sublicense agreements in certain jurisdictions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of royalty, milestone and sublicense revenue payments entitled to the company under the existing license and collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of regulatory milestone payments receivable under the License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of regulatory milestone payments receivable up on approval received from the approval for commercial sale under the License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of regulatory milestone payments receivable up on approval received from the approval of COPIKTRA in the United States for the treatment of peripheral T-cell lymphoma under the License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sales milestone receivable under the License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sales milestone received under the License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of threshold sale revenue to be achieved in order for the company to receive the sales milestone payments under the License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of threshold sale revenue to be achieved in order for the company to receive the royalty payments under the License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vstm_CopiktraLicenseAndRelatedAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vstm_CopiktraLicenseAndRelatedAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vstm_SecuraBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vstm_SecuraBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vstm_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vstm_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details) - First Insurance - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Initial payment</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Monthly payments</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Note Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vstm_FirstInsuranceFundingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vstm_FirstInsuranceFundingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee benefit plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee benefit plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contributions made under 401(k) plan</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Vendor Financing Arrangement - Roll forward (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationRollForward', window );"><strong>Supplier Finance Program, Obligation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligation', window );">Vendor financing arrangement liability</a></td>
<td class="nump">$ 10.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration', window );">Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Supplier Finance Program, Obligation, Current, Supplier Finance Program, Obligation, Noncurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation for supplier finance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477128/405-50-55-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes obligation for supplier finance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,792<span></span>
</td>
<td class="nump">$ 875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">8,391,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="nump">8,391,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">$ 29,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period related to exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vstm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>346</ContextCount>
  <ElementCount>544</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>121</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - Nature of business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - Significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - Product revenue reserves and allowances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowances</Role>
      <ShortName>Product revenue reserves and allowances</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureInventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - Accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - Long-term debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLongTermDebt</Role>
      <ShortName>Long-term debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureCapitalStock</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - Stock-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995211201 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995211301 - Disclosure - Net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995211401 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995211501 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995211601 - Disclosure - License, collaboration and commercial agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreements</Role>
      <ShortName>License, collaboration and commercial agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995211701 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.verastem.com/role/DisclosureNotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995211801 - Disclosure - Employee benefit plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee benefit plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995211901 - Disclosure - Vendor Financing Arrangement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureVendorFinancingArrangement</Role>
      <ShortName>Vendor Financing Arrangement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995212001 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99920202 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99930203 - Disclosure - Significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99930303 - Disclosure - Product revenue reserves and allowances (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesTables</Role>
      <ShortName>Product revenue reserves and allowances (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowances</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureInventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureInventory</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureIntangibleAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - Property and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99930703 - Disclosure - Accrued expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - Long-term debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLongTermDebtTables</Role>
      <ShortName>Long-term debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureLongTermDebt</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureLeases</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99931003 - Disclosure - Capital Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureCapitalStockTables</Role>
      <ShortName>Capital Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureCapitalStock</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99931103 - Disclosure - Stock-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99931203 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureSegmentReporting</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99931303 - Disclosure - Net loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99931403 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - Nature of business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureNatureOfBusinessDetails</Role>
      <ShortName>Nature of business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureNatureOfBusiness</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>99940102 - Disclosure - Nature of business - Reverse Stock Split (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureNatureOfBusinessReverseStockSplitDetails</Role>
      <ShortName>Nature of business - Reverse Stock Split (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - Summary of significant accounting policies - Segment and geographic information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentAndGeographicInformationDetails</Role>
      <ShortName>Summary of significant accounting policies - Segment and geographic information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>99940202 - Disclosure - Significant accounting policies - Proceeds from Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails</Role>
      <ShortName>Significant accounting policies - Proceeds from Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>99940203 - Disclosure - Significant accounting policies - Reconciliation of cash, cash equivalents and restricted cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Significant accounting policies - Reconciliation of cash, cash equivalents and restricted cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>99940204 - Disclosure - Significant accounting policies - Cash, cash equivalents, restricted cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails</Role>
      <ShortName>Significant accounting policies - Cash, cash equivalents, restricted cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>99940205 - Disclosure - Significant accounting policies - Items Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Significant accounting policies - Items Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>99940206 - Disclosure - Significant accounting policies - Inputs used to value the warrant liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails</Role>
      <ShortName>Significant accounting policies - Inputs used to value the warrant liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>99940207 - Disclosure - Significant accounting policies - Reconciliation of the warrant liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails</Role>
      <ShortName>Significant accounting policies - Reconciliation of the warrant liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>99940208 - Disclosure - Significant accounting policies - Note Purchase Agreement and Oxford Loan Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails</Role>
      <ShortName>Significant accounting policies - Note Purchase Agreement and Oxford Loan Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>99940209 - Disclosure - Significant accounting policies - Concentrations of credit risk and off-balance sheet risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails</Role>
      <ShortName>Significant accounting policies - Concentrations of credit risk and off-balance sheet risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>99940210 - Disclosure - Significant accounting policies - Property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Significant accounting policies - Property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>99940211 - Disclosure - Significant accounting policies - Cloud Computing Implementation Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCloudComputingImplementationCostsDetails</Role>
      <ShortName>Significant accounting policies - Cloud Computing Implementation Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>99940212 - Disclosure - Significant accounting policies - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetails</Role>
      <ShortName>Significant accounting policies - Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - Product revenue reserves and allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails</Role>
      <ShortName>Product revenue reserves and allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - Inventory - Schedule of inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureInventoryScheduleOfInventoryDetails</Role>
      <ShortName>Inventory - Schedule of inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>99940502 - Disclosure - Intangible Assets - Schedule of intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>99940503 - Disclosure - Intangible Assets - Schedule of future amortization expense of finite-lived intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of future amortization expense of finite-lived intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - Property and equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - Accrued expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - Long-term debt - Note Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails</Role>
      <ShortName>Long-term debt - Note Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>99940802 - Disclosure - Long-term debt - Reconciliation of changes in the fair value of the Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails</Role>
      <ShortName>Long-term debt - Reconciliation of changes in the fair value of the Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>99940803 - Disclosure - Long-term debt - Future principal payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails</Role>
      <ShortName>Long-term debt - Future principal payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>99940804 - Disclosure - Long-term debt - Loan Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails</Role>
      <ShortName>Long-term debt - Loan Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>99940805 - Disclosure - Long-term debt - Components of carrying value of the Term Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails</Role>
      <ShortName>Long-term debt - Components of carrying value of the Term Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>99940806 - Disclosure - Long-term debt - Schedule of interest expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLongTermDebtScheduleOfInterestExpensesDetails</Role>
      <ShortName>Long-term debt - Schedule of interest expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureLeasesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>99940902 - Disclosure - Leases - Balance sheet and other information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails</Role>
      <ShortName>Leases - Balance sheet and other information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - Capital Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureCapitalStockDetails</Role>
      <ShortName>Capital Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureCapitalStockTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>99941002 - Disclosure - Capital stock - November 2025 Public Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails</Role>
      <ShortName>Capital stock - November 2025 Public Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>99941003 - Disclosure - Capital stock - April 2025 Private Placement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails</Role>
      <ShortName>Capital stock - April 2025 Private Placement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>99941004 - Disclosure - Capital stock - Stock Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails</Role>
      <ShortName>Capital stock - Stock Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>99941005 - Disclosure - Capital stock - July 2024 and June 2023 Public Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails</Role>
      <ShortName>Capital stock - July 2024 and June 2023 Public Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>99941006 - Disclosure - Capital stock - Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails</Role>
      <ShortName>Capital stock - Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>99941007 - Disclosure - Capital stock - At-the market equity offering program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails</Role>
      <ShortName>Capital stock - At-the market equity offering program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - Stock-based compensation - Stock-based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails</Role>
      <ShortName>Stock-based compensation - Stock-based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>99941102 - Disclosure - Stock-based compensation - Stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails</Role>
      <ShortName>Stock-based compensation - Stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>99941103 - Disclosure - Stock-based compensation - Option Exchange Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails</Role>
      <ShortName>Stock-based compensation - Option Exchange Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>99941104 - Disclosure - Stock-based compensation - Restricted stock units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-based compensation - Restricted stock units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>99941105 - Disclosure - Stock-based compensation - Employee stock purchase plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock-based compensation - Employee stock purchase plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>99941201 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureSegmentReportingTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>99941202 - Disclosure - Segment Reporting - Segment net loss including segment expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails</Role>
      <ShortName>Segment Reporting - Segment net loss including segment expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>99941301 - Disclosure - Net loss per share - Potentially dilutive shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails</Role>
      <ShortName>Net loss per share - Potentially dilutive shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>99941401 - Disclosure - Income Taxes - Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>99941402 - Disclosure - Income Taxes - Reconciliation of Income Taxes and Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Income Taxes and Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>99941403 - Disclosure - Income Taxes - Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>99941404 - Disclosure - Income Taxes - Tax Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureIncomeTaxesTaxCreditsDetails</Role>
      <ShortName>Income Taxes - Tax Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>99941501 - Disclosure - Commitments and contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>99941601 - Disclosure - License, collaboration and commercial agreements - Pfizer, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails</Role>
      <ShortName>License, collaboration and commercial agreements - Pfizer, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>99941602 - Disclosure - License, collaboration and commercial agreements - License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails</Role>
      <ShortName>License, collaboration and commercial agreements - License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>99941603 - Disclosure - License, collaboration and commercial agreements - Genfleet Therapeutics (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails</Role>
      <ShortName>License, collaboration and commercial agreements - Genfleet Therapeutics (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>99941604 - Disclosure - License, collaboration and commercial agreements - Secura (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails</Role>
      <ShortName>License, collaboration and commercial agreements - Secura (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreements</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>99941701 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.verastem.com/role/DisclosureNotesPayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureNotesPayable</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>99941801 - Disclosure - Employee benefit plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureEmployeeBenefitPlanDetails</Role>
      <ShortName>Employee benefit plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureEmployeeBenefitPlan</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>99941901 - Disclosure - Vendor Financing Arrangement - Roll forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureVendorFinancingArrangementRollForwardDetails</Role>
      <ShortName>Vendor Financing Arrangement - Roll forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="vstm-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>99942001 - Disclosure - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.verastem.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.verastem.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>102</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>vstm-20251231.xsd</File>
    <File>vstm-20251231_cal.xml</File>
    <File>vstm-20251231_def.xml</File>
    <File>vstm-20251231_lab.xml</File>
    <File>vstm-20251231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="vstm-20251231x10k.htm">vstm-20251231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vstm-20251231x10k003.jpg</File>
    <File>vstm-20251231x10k004.jpg</File>
    <File>vstm-20251231x10k005.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="890">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>129
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "vstm-20251231x10k.htm": {
   "nsprefix": "vstm",
   "nsuri": "http://www.verastem.com/20251231",
   "dts": {
    "schema": {
     "local": [
      "vstm-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "vstm-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vstm-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "vstm-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vstm-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "vstm-20251231x10k.htm"
     ]
    }
   },
   "keyStandard": 400,
   "keyCustom": 144,
   "axisStandard": 32,
   "axisCustom": 1,
   "memberStandard": 44,
   "memberCustom": 68,
   "hidden": {
    "total": 33,
    "http://fasb.org/us-gaap/2025": 22,
    "http://xbrl.sec.gov/dei/2025": 4,
    "http://www.verastem.com/20251231": 7
   },
   "contextCount": 346,
   "entityCount": 1,
   "segmentCount": 121,
   "elementCount": 944,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 890,
    "http://xbrl.sec.gov/dei/2025": 38,
    "http://xbrl.sec.gov/cyd/2025": 15,
    "http://xbrl.sec.gov/ecd/2025": 5
   },
   "report": {
    "R1": {
     "role": "http://www.verastem.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.verastem.com/role/StatementConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
     "longName": "995200300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_V_Epz3gmqU27y1VxbWmrEQ",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_V_Epz3gmqU27y1VxbWmrEQ",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical",
     "longName": "995200305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Nx7kZA6zXkqD1bBA5afBeQ",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.verastem.com/role/DisclosureNatureOfBusiness",
     "longName": "995210101 - Disclosure - Nature of business",
     "shortName": "Nature of business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.verastem.com/role/DisclosureSignificantAccountingPolicies",
     "longName": "995210201 - Disclosure - Significant accounting policies",
     "shortName": "Significant accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowances",
     "longName": "995210301 - Disclosure - Product revenue reserves and allowances",
     "shortName": "Product revenue reserves and allowances",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "vstm:ProductRevenueReservesAndAllowancesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "vstm:ProductRevenueReservesAndAllowancesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.verastem.com/role/DisclosureInventory",
     "longName": "995210401 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.verastem.com/role/DisclosureIntangibleAssets",
     "longName": "995210501 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNet",
     "longName": "995210601 - Disclosure - Property and equipment, net",
     "shortName": "Property and equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.verastem.com/role/DisclosureAccruedExpenses",
     "longName": "995210701 - Disclosure - Accrued expenses",
     "shortName": "Accrued expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.verastem.com/role/DisclosureLongTermDebt",
     "longName": "995210801 - Disclosure - Long-term debt",
     "shortName": "Long-term debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.verastem.com/role/DisclosureLeases",
     "longName": "995210901 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.verastem.com/role/DisclosureCapitalStock",
     "longName": "995211001 - Disclosure - Capital Stock",
     "shortName": "Capital Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.verastem.com/role/DisclosureStockBasedCompensation",
     "longName": "995211101 - Disclosure - Stock-based compensation",
     "shortName": "Stock-based compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.verastem.com/role/DisclosureSegmentReporting",
     "longName": "995211201 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.verastem.com/role/DisclosureNetLossPerShare",
     "longName": "995211301 - Disclosure - Net loss per share",
     "shortName": "Net loss per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.verastem.com/role/DisclosureIncomeTaxes",
     "longName": "995211401 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.verastem.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "995211501 - Disclosure - Commitments and contingencies",
     "shortName": "Commitments and contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreements",
     "longName": "995211601 - Disclosure - License, collaboration and commercial agreements",
     "shortName": "License, collaboration and commercial agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "vstm:LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "vstm:LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.verastem.com/role/DisclosureNotesPayable",
     "longName": "995211701 - Disclosure - Notes Payable",
     "shortName": "Notes Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.verastem.com/role/DisclosureEmployeeBenefitPlan",
     "longName": "995211801 - Disclosure - Employee benefit plan",
     "shortName": "Employee benefit plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.verastem.com/role/DisclosureVendorFinancingArrangement",
     "longName": "995211901 - Disclosure - Vendor Financing Arrangement",
     "shortName": "Vendor Financing Arrangement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:SupplierFinanceProgramTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:SupplierFinanceProgramTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.verastem.com/role/DisclosureSubsequentEvents",
     "longName": "995212001 - Disclosure - Subsequent events",
     "shortName": "Subsequent events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2025_To_12_31_2025_9WuRZ5oiCEytQ-4llKR_8g",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2025_To_12_31_2025_9WuRZ5oiCEytQ-4llKR_8g",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "99920202 - Disclosure - Summary of significant accounting policies (Policies)",
     "shortName": "Summary of significant accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesTables",
     "longName": "99930203 - Disclosure - Significant accounting policies (Tables)",
     "shortName": "Significant accounting policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesTables",
     "longName": "99930303 - Disclosure - Product revenue reserves and allowances (Tables)",
     "shortName": "Product revenue reserves and allowances (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "vstm:ProductRevenueReservesAndAllowancesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "vstm:ProductRevenueReservesAndAllowancesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "vstm:ProductRevenueReservesAndAllowancesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "vstm:ProductRevenueReservesAndAllowancesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.verastem.com/role/DisclosureInventoryTables",
     "longName": "99930403 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.verastem.com/role/DisclosureIntangibleAssetsTables",
     "longName": "99930503 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetTables",
     "longName": "99930603 - Disclosure - Property and equipment, net (Tables)",
     "shortName": "Property and equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.verastem.com/role/DisclosureAccruedExpensesTables",
     "longName": "99930703 - Disclosure - Accrued expenses (Tables)",
     "shortName": "Accrued expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.verastem.com/role/DisclosureLongTermDebtTables",
     "longName": "99930803 - Disclosure - Long-term debt (Tables)",
     "shortName": "Long-term debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.verastem.com/role/DisclosureLeasesTables",
     "longName": "99930903 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.verastem.com/role/DisclosureCapitalStockTables",
     "longName": "99931003 - Disclosure - Capital Stock (Tables)",
     "shortName": "Capital Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "vstm:ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "vstm:ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.verastem.com/role/DisclosureStockBasedCompensationTables",
     "longName": "99931103 - Disclosure - Stock-based compensation (Tables)",
     "shortName": "Stock-based compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.verastem.com/role/DisclosureSegmentReportingTables",
     "longName": "99931203 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.verastem.com/role/DisclosureNetLossPerShareTables",
     "longName": "99931303 - Disclosure - Net loss per share (Tables)",
     "shortName": "Net loss per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.verastem.com/role/DisclosureIncomeTaxesTables",
     "longName": "99931403 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.verastem.com/role/DisclosureNatureOfBusinessDetails",
     "longName": "99940101 - Disclosure - Nature of business (Details)",
     "shortName": "Nature of business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://www.verastem.com/role/DisclosureNatureOfBusinessReverseStockSplitDetails",
     "longName": "99940102 - Disclosure - Nature of business - Reverse Stock Split (Details)",
     "shortName": "Nature of business - Reverse Stock Split (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_5_30_2023_us-gaap_TypeOfArrangementAxis_vstm_CertificateOfAmendmentMember_Q_y7EUi3X0K_kq-y8s1gbw",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentAndGeographicInformationDetails",
     "longName": "99940201 - Disclosure - Summary of significant accounting policies - Segment and geographic information (Details)",
     "shortName": "Summary of significant accounting policies - Segment and geographic information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_item_5quK1hZThku2W0bLLpUodA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails",
     "longName": "99940202 - Disclosure - Significant accounting policies - Proceeds from Grants (Details)",
     "shortName": "Significant accounting policies - Proceeds from Grants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_5_1_2022_To_5_31_2022_0S7CWDwAHkCwzDSQQTfHkw",
      "name": "us-gaap:GovernmentAssistanceAmount",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "vstm:ProceedsFromGrantsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_5_1_2022_To_5_31_2022_0S7CWDwAHkCwzDSQQTfHkw",
      "name": "us-gaap:GovernmentAssistanceAmount",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "vstm:ProceedsFromGrantsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
     "longName": "99940203 - Disclosure - Significant accounting policies - Reconciliation of cash, cash equivalents and restricted cash (Details)",
     "shortName": "Significant accounting policies - Reconciliation of cash, cash equivalents and restricted cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA",
      "name": "us-gaap:RestrictedCashEquivalentsCurrent",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails",
     "longName": "99940204 - Disclosure - Significant accounting policies - Cash, cash equivalents, restricted cash (Details)",
     "shortName": "Significant accounting policies - Cash, cash equivalents, restricted cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_12Jwxj-GpUyMjUlJbpGHrw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "99940205 - Disclosure - Significant accounting policies - Items Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Significant accounting policies - Items Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails",
     "longName": "99940206 - Disclosure - Significant accounting policies - Inputs used to value the warrant liability (Details)",
     "shortName": "Significant accounting policies - Inputs used to value the warrant liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_QfOCneyU3kuQfy4l3HkaFA",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_QfOCneyU3kuQfy4l3HkaFA",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails",
     "longName": "99940207 - Disclosure - Significant accounting policies - Reconciliation of the warrant liability (Details)",
     "shortName": "Significant accounting policies - Reconciliation of the warrant liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_FvCF6Wd2sUa1Ka_dpTtMeA",
      "name": "vstm:FairValueAdjustmentOfWarrantsExercised",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "vstm:ReconciliationOfWarrantLiabilityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails",
     "longName": "99940208 - Disclosure - Significant accounting policies - Note Purchase Agreement and Oxford Loan Agreement (Details)",
     "shortName": "Significant accounting policies - Note Purchase Agreement and Oxford Loan Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_8S_QmEHi20-3Bt7pN3KrWg",
      "name": "us-gaap:DebtInstrumentFairValue",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails",
     "longName": "99940209 - Disclosure - Significant accounting policies - Concentrations of credit risk and off-balance sheet risk (Details)",
     "shortName": "Significant accounting policies - Concentrations of credit risk and off-balance sheet risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "vstm:ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "vstm:ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "longName": "99940210 - Disclosure - Significant accounting policies - Property and equipment (Details)",
     "shortName": "Significant accounting policies - Property and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCloudComputingImplementationCostsDetails",
     "longName": "99940211 - Disclosure - Significant accounting policies - Cloud Computing Implementation Costs (Details)",
     "shortName": "Significant accounting policies - Cloud Computing Implementation Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:CapitalizedContractCostNetCurrent",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "vstm:CloudComputingImplementationCostsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:CapitalizedContractCostNetCurrent",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "vstm:CloudComputingImplementationCostsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetails",
     "longName": "99940212 - Disclosure - Significant accounting policies - Income taxes (Details)",
     "shortName": "Significant accounting policies - Income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "vstm:ChangeInCompanyOwnershipPercent",
      "unitRef": "Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "vstm:ChangeInCompanyOwnershipPercent",
      "unitRef": "Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails",
     "longName": "99940301 - Disclosure - Product revenue reserves and allowances (Details)",
     "shortName": "Product revenue reserves and allowances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "vstm:ProductRevenueReservesAndAllowancesTableTextBlock",
       "vstm:ProductRevenueReservesAndAllowancesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "vstm:ProductRevenueReservesAndAllowancesTableTextBlock",
       "vstm:ProductRevenueReservesAndAllowancesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.verastem.com/role/DisclosureInventoryScheduleOfInventoryDetails",
     "longName": "99940401 - Disclosure - Inventory - Schedule of inventory (Details)",
     "shortName": "Inventory - Schedule of inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:InventoryWorkInProcess",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:InventoryWorkInProcess",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.verastem.com/role/DisclosureIntangibleAssetsDetails",
     "longName": "99940501 - Disclosure - Intangible Assets (Details)",
     "shortName": "Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:CostOfGoodsAndServicesSoldAmortization",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails",
     "longName": "99940502 - Disclosure - Intangible Assets - Schedule of intangible assets (Details)",
     "shortName": "Intangible Assets - Schedule of intangible assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails",
     "longName": "99940503 - Disclosure - Intangible Assets - Schedule of future amortization expense of finite-lived intangible assets (Details)",
     "shortName": "Intangible Assets - Schedule of future amortization expense of finite-lived intangible assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "longName": "99940601 - Disclosure - Property and equipment, net (Details)",
     "shortName": "Property and equipment, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.verastem.com/role/DisclosureAccruedExpensesDetails",
     "longName": "99940701 - Disclosure - Accrued expenses (Details)",
     "shortName": "Accrued expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "vstm:AccruedClinicalTrialExpensesCurrent",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "vstm:AccruedClinicalTrialExpensesCurrent",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
     "longName": "99940801 - Disclosure - Long-term debt - Note Purchase Agreement (Details)",
     "shortName": "Long-term debt - Note Purchase Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_iZI7Ie7K00GLdoRZJcm5tA",
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "unitRef": "Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails",
     "longName": "99940802 - Disclosure - Long-term debt - Reconciliation of changes in the fair value of the Notes (Details)",
     "shortName": "Long-term debt - Reconciliation of changes in the fair value of the Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_Un8b41l_pEirHv8lmaIPmw",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_Un8b41l_pEirHv8lmaIPmw",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.verastem.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails",
     "longName": "99940803 - Disclosure - Long-term debt - Future principal payments (Details)",
     "shortName": "Long-term debt - Future principal payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "vstm:LongTermDebtMaturityYearSix",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "vstm:LongTermDebtMaturityYearSix",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
     "longName": "99940804 - Disclosure - Long-term debt - Loan Agreement (Details)",
     "shortName": "Long-term debt - Loan Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_25_2022_To_3_25_2022_srt_StatementScenarioAxis_vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember_q8ti5S-pZU699rXFl4F2PQ",
      "name": "vstm:DebtInstrumentFinalPaymentFeePercentage",
      "unitRef": "Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.verastem.com/role/DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails",
     "longName": "99940805 - Disclosure - Long-term debt - Components of carrying value of the Term Loan (Details)",
     "shortName": "Long-term debt - Components of carrying value of the Term Loan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.verastem.com/role/DisclosureLongTermDebtScheduleOfInterestExpensesDetails",
     "longName": "99940806 - Disclosure - Long-term debt - Schedule of interest expenses (Details)",
     "shortName": "Long-term debt - Schedule of interest expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "vstm:ContractualInterestExpense",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "vstm:ContractualInterestExpense",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.verastem.com/role/DisclosureLeasesDetails",
     "longName": "99940901 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "As_Of_2_15_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_X8QqK4Hmd06KwW35Ix-WEQ",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "Unit_Standard_sqft_FdbiNq8DNkeaOGqvsWqN6A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_2_15_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_X8QqK4Hmd06KwW35Ix-WEQ",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "Unit_Standard_sqft_FdbiNq8DNkeaOGqvsWqN6A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails",
     "longName": "99940902 - Disclosure - Leases - Balance sheet and other information (Details)",
     "shortName": "Leases - Balance sheet and other information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_11_30_2024_UMnI-wXQ0USHesrFhwgQ9g",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.verastem.com/role/DisclosureCapitalStockDetails",
     "longName": "99941001 - Disclosure - Capital Stock (Details)",
     "shortName": "Capital Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "vstm:ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "vstm:NumberOfVotesPerEachShareOfCommonStock",
      "unitRef": "Unit_Standard_Vote_tReSOj-zJkipnhJ_-h7uBA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails",
     "longName": "99941002 - Disclosure - Capital stock - November 2025 Public Offering (Details)",
     "shortName": "Capital stock - November 2025 Public Offering (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_13_2025_To_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_8KWsZFM4mEuCXxQ0JyrXPg",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails",
     "longName": "99941003 - Disclosure - Capital stock - April 2025 Private Placement (Details)",
     "shortName": "Capital stock - April 2025 Private Placement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "Duration_4_25_2025_To_4_25_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_w6Qgr7wiUECKdrz2j0wQgw",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_25_2025_To_4_25_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_w6Qgr7wiUECKdrz2j0wQgw",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails",
     "longName": "99941004 - Disclosure - Capital stock - Stock Purchase Agreement (Details)",
     "shortName": "Capital stock - Stock Purchase Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_76lNElnqP0Ge645AbtZsrA",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_76lNElnqP0Ge645AbtZsrA",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
     "longName": "99941005 - Disclosure - Capital stock - July 2024 and June 2023 Public Offering (Details)",
     "shortName": "Capital stock - July 2024 and June 2023 Public Offering (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "vstm:ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA",
      "name": "vstm:PreFundedWarrantsWarrantsOutstanding",
      "unitRef": "Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
     "longName": "99941006 - Disclosure - Capital stock - Convertible Preferred Stock (Details)",
     "shortName": "Capital stock - Convertible Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g",
      "name": "us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ykjfpsDf9EClxEq1QlGEFQ",
      "name": "us-gaap:PreferredStockConvertibleSharesIssuable",
      "unitRef": "Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails",
     "longName": "99941007 - Disclosure - Capital stock - At-the market equity offering program (Details)",
     "shortName": "Capital stock - At-the market equity offering program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "Duration_8_1_2025_To_8_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_9R4yRxA400KtN3lsZ5eH2A",
      "name": "vstm:MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_L9scB89F9EeAgUmzCCgzrA",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails",
     "longName": "99941101 - Disclosure - Stock-based compensation - Stock-based compensation (Details)",
     "shortName": "Stock-based compensation - Stock-based compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "vstm:NumberOfEquityCompensationPlans",
      "unitRef": "Unit_Standard_item_5quK1hZThku2W0bLLpUodA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
     "longName": "99941102 - Disclosure - Stock-based compensation - Stock options (Details)",
     "shortName": "Stock-based compensation - Stock options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails",
     "longName": "99941103 - Disclosure - Stock-based compensation - Option Exchange Program (Details)",
     "shortName": "Stock-based compensation - Option Exchange Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_17_2024_To_1_17_2024_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_9tsdrgQO-UKXsRxV5I_Sjg",
      "name": "vstm:NumberOfEligibleStockholders",
      "unitRef": "Unit_Standard_item_5quK1hZThku2W0bLLpUodA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
     "longName": "99941104 - Disclosure - Stock-based compensation - Restricted stock units (Details)",
     "shortName": "Stock-based compensation - Restricted stock units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw",
      "name": "vstm:NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests",
      "unitRef": "Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
     "longName": "99941105 - Disclosure - Stock-based compensation - Employee stock purchase plan (Details)",
     "shortName": "Stock-based compensation - Employee stock purchase plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_6_21_2019_To_6_21_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_m3em9BxJfkWCCgCqGcDWTw",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "unitRef": "Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.verastem.com/role/DisclosureSegmentReportingDetails",
     "longName": "99941201 - Disclosure - Segment Reporting (Details)",
     "shortName": "Segment Reporting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_item_5quK1hZThku2W0bLLpUodA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Unit_Standard_segment_zofEUC3Xr0eG4_rh7aLMNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
     "longName": "99941202 - Disclosure - Segment Reporting - Segment net loss including segment expenses (Details)",
     "shortName": "Segment Reporting - Segment net loss including segment expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "vstm:CostOfGoodsSoldExcludingAmortization",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg",
      "name": "vstm:CostOfGoodsSoldExcludingAmortization",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails",
     "longName": "99941301 - Disclosure - Net loss per share - Potentially dilutive shares (Details)",
     "shortName": "Net loss per share - Potentially dilutive shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
     "longName": "99941401 - Disclosure - Income Taxes - Income Tax Expense (Details)",
     "shortName": "Income Taxes - Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails",
     "longName": "99941402 - Disclosure - Income Taxes - Reconciliation of Income Taxes and Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Reconciliation of Income Taxes and Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.verastem.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails",
     "longName": "99941403 - Disclosure - Income Taxes - Operating Loss Carryforwards (Details)",
     "shortName": "Income Taxes - Operating Loss Carryforwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_M65DxSkBeUWXwkv5yp4KTw",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_M65DxSkBeUWXwkv5yp4KTw",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.verastem.com/role/DisclosureIncomeTaxesTaxCreditsDetails",
     "longName": "99941404 - Disclosure - Income Taxes - Tax Credits (Details)",
     "shortName": "Income Taxes - Tax Credits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_M65DxSkBeUWXwkv5yp4KTw",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_M65DxSkBeUWXwkv5yp4KTw",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "99941501 - Disclosure - Commitments and contingencies (Details)",
     "shortName": "Commitments and contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:SecurityDeposit",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_srt_CounterpartyNameAxis_vstm_IqviaIncMember_sAB2nn3xb06KIRwK0qRhxA",
      "name": "us-gaap:OtherCommitment",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails",
     "longName": "99941601 - Disclosure - License, collaboration and commercial agreements - Pfizer, Inc. (Details)",
     "shortName": "License, collaboration and commercial agreements - Pfizer, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_11_2012_To_7_11_2012_srt_CounterpartyNameAxis_vstm_PfizerIncMember_BItiDfIFn0WcHJLqHz3mqw",
      "name": "vstm:CollaborativeArrangementsOneTimeCashPayment",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "vstm:LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails",
     "longName": "99941602 - Disclosure - License, collaboration and commercial agreements - License Agreement (Details)",
     "shortName": "License, collaboration and commercial agreements - License Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2025_To_6_30_2025_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_ouTeCHDu4Ey5RJk0ycXIKQ",
      "name": "vstm:NumberOfPatents",
      "unitRef": "Unit_Standard_item_5quK1hZThku2W0bLLpUodA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2025_To_6_30_2025_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_ouTeCHDu4Ey5RJk0ycXIKQ",
      "name": "vstm:NumberOfPatents",
      "unitRef": "Unit_Standard_item_5quK1hZThku2W0bLLpUodA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
     "longName": "99941603 - Disclosure - License, collaboration and commercial agreements - Genfleet Therapeutics (Details)",
     "shortName": "License, collaboration and commercial agreements - Genfleet Therapeutics (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "Duration_8_24_2023_To_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_dsxUwW56ZECoNMCxu8ilPA",
      "name": "vstm:LicenseAndCollaborationAgreementUpfrontPayment",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_24_2023_To_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_dsxUwW56ZECoNMCxu8ilPA",
      "name": "vstm:LicenseAndCollaborationAgreementUpfrontPayment",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails",
     "longName": "99941604 - Disclosure - License, collaboration and commercial agreements - Secura (Details)",
     "shortName": "License, collaboration and commercial agreements - Secura (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_HA-hUtbuQkSrDIYOaGPRyw",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_VByLpZd3oUumXTdQ76R5ZA",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.verastem.com/role/DisclosureNotesPayableDetails",
     "longName": "99941701 - Disclosure - Notes Payable (Details)",
     "shortName": "Notes Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "As_Of_1_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_UhCOi_V-Yk--a9CzLZu_Og",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_1_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_UhCOi_V-Yk--a9CzLZu_Og",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.verastem.com/role/DisclosureEmployeeBenefitPlanDetails",
     "longName": "99941801 - Disclosure - Employee benefit plan (Details)",
     "shortName": "Employee benefit plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.verastem.com/role/DisclosureVendorFinancingArrangementRollForwardDetails",
     "longName": "99941901 - Disclosure - Vendor Financing Arrangement - Roll forward (Details)",
     "shortName": "Vendor Financing Arrangement - Roll forward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:SupplierFinanceProgramObligation",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SupplierFinanceProgramTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA",
      "name": "us-gaap:SupplierFinanceProgramObligation",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SupplierFinanceProgramTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.verastem.com/role/DisclosureSubsequentEventsDetails",
     "longName": "99942001 - Disclosure - Subsequent events (Details)",
     "shortName": "Subsequent events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7S9Co7osyUKPh1S2Fr2wNQ",
      "name": "vstm:ClassOfWarrantOrRightNumberOfWarrantsExercised",
      "unitRef": "Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vstm-20251231x10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant accounting policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r53",
      "r58",
      "r1330"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r1025"
     ]
    },
    "vstm_AccountsPayableCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "AccountsPayableCurrentMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts payable current.",
        "label": "Accounts Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade accounts receivable",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r1260"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net",
        "terseLabel": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r818",
      "r932",
      "r1040",
      "r1380",
      "r1381"
     ]
    },
    "vstm_AccruedClinicalTrialExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "AccruedClinicalTrialExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued clinical trial expenses, current",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_AccruedCommercializationCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "AccruedCommercializationCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for commercialization costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Commercialization Costs Current",
        "terseLabel": "Accrued commercialization costs"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_AccruedConsultingFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "AccruedConsultingFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Consulting Fees Current",
        "terseLabel": "Accrued consulting fees"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_AccruedContractManufacturingExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "AccruedContractManufacturingExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contract manufacturing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Contract Manufacturing Expenses, Current",
        "terseLabel": "Accrued contract manufacturing expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses, short-term",
        "totalLabel": "Total accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "vstm_AccruedMilestonePaymentsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "AccruedMilestonePaymentsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for milestone payments. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Milestone Payments, Current",
        "terseLabel": "Accrued milestone payments &amp; royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "vstm_AccruedResearchAndDevelopmentExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research And Development Expenses, Current",
        "terseLabel": "Accrued other research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r140",
      "r736"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r73",
      "r147",
      "r732",
      "r773",
      "r774",
      "r1344"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income/ (loss)",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r10",
      "r18",
      "r601",
      "r604",
      "r669",
      "r769",
      "r770",
      "r1189",
      "r1190",
      "r1191",
      "r1252",
      "r1253",
      "r1254",
      "r1255"
     ]
    },
    "vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "AchievementOfCertainDevelopmentAndCommercializationMilestonesMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to achievement of development and commercialization milestones.",
        "label": "Achievement Of Certain Development And Commercialization Milestones [Member]",
        "terseLabel": "Achievement of certain development and commercialization milestones"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_AchievementOfCertainSalesMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "AchievementOfCertainSalesMilestonesMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to achievement of sales milestones.",
        "label": "Achievement Of Certain Sales Milestones [Member]",
        "terseLabel": "Achievement of certain sales milestones"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_AchievementOfFdaApprovalAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "AchievementOfFdaApprovalAnniversaryMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to achievement of FDA approval anniversary milestones.",
        "label": "Achievement Of FDA Approval Anniversary [Member]",
        "terseLabel": "Achievement of FDA approval anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_AchievementOfFdaApprovalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "AchievementOfFdaApprovalMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to achievement of FDA approval milestones.",
        "label": "Achievement Of FDA Approval [Member]",
        "terseLabel": "Achievement of FDA approval"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted-Average Remaining Amortization Period (Years)",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r938"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "vstm_AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of additional interest rate at the event of default.",
        "label": "Additional Increase In Interest Rate At The Event Of Default, Percentage",
        "terseLabel": "Additional increase in interest rate at event of default"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1345",
      "r1416"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance of preferred stock, issuance costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r95"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1080",
      "r1090",
      "r1123"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r1072",
      "r1083",
      "r1093",
      "r1126"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1118",
      "r1127",
      "r1131",
      "r1139"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r513",
      "r522"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "vstm_AmortizationOfFinalPaymentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "AmortizationOfFinalPaymentFee",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureLongTermDebtScheduleOfInterestExpensesDetails": {
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtScheduleOfInterestExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to Final Payment Fee.",
        "label": "Amortization of Final Payment Fee",
        "terseLabel": "Amortization of Final Payment Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureLongTermDebtScheduleOfInterestExpensesDetails": {
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtScheduleOfInterestExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt discount and issuance costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r400",
      "r1239",
      "r1364"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of deferred financing costs, debt discounts and premiums and discounts on available-for-sale marketable securities",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r983",
      "r984",
      "r1239",
      "r1364"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of acquired intangible assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r166",
      "r332",
      "r335",
      "r942",
      "r948",
      "r949",
      "r951",
      "r953"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Total potentially dilutive securities (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net loss per share",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.verastem.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of space",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails",
      "http://www.verastem.com/role/DisclosureNatureOfBusinessReverseStockSplitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r113",
      "r143",
      "r176",
      "r179",
      "r180",
      "r218",
      "r233",
      "r259",
      "r263",
      "r303",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r577",
      "r581",
      "r637",
      "r716",
      "r717",
      "r729",
      "r823",
      "r969",
      "r970",
      "r985",
      "r1025",
      "r1034",
      "r1035",
      "r1047",
      "r1293",
      "r1294",
      "r1368"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r150",
      "r176",
      "r179",
      "r180",
      "r303",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r577",
      "r581",
      "r637",
      "r1025",
      "r1293",
      "r1294",
      "r1368"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r617",
      "r1011"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_AtMarketEquityOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "AtMarketEquityOfferingProgramMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the at-the-market equity offering program of the entity.",
        "label": "At-the-market equity offering program"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1076"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1076"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1076"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r636",
      "r1008",
      "r1009",
      "r1165",
      "r1383"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r636",
      "r1008",
      "r1009",
      "r1165",
      "r1383"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1242"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant accounting policies",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1241"
     ]
    },
    "vstm_BiotechnologyValueFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "BiotechnologyValueFundMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Biotechnology Value Fund.",
        "label": "Biotechnology Value Fund [Member]",
        "terseLabel": "BVF"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_CantorFitzgeraldCo.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "CantorFitzgeraldCo.Member",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Cantor Fitzgerald &amp; Co. which entity has entered into an underwriting agreement.",
        "label": "Cantor"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchases of property and equipment in accounts payable",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCloudComputingImplementationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Amortization expense",
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r319"
     ]
    },
    "us-gaap_CapitalizedContractCostNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCloudComputingImplementationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost, Net, Current",
        "terseLabel": "Capitalized implementation costs",
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "vstm_CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which the entity will amortize the capitalized research and development expenses.",
        "label": "Capitalized Research and Development Expenses, Amortization Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortized Cost",
        "terseLabel": "Amortized Cost",
        "documentation": "Measured as reported on the statement of financial position (balance sheet)."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r634",
      "r635",
      "r940",
      "r1358"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash, cash equivalents &amp; restricted cash, Amortized Cost",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r138",
      "r943"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "verboseLabel": "Cash, cash equivalents &amp; restricted cash, Fair Value",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r633",
      "r634",
      "r1347",
      "r1348"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r101"
     ]
    },
    "vstm_CashAndMoneyMarketAccountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "CashAndMoneyMarketAccountsMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents cash and money market accounts.",
        "label": "Cash and money market accounts.",
        "terseLabel": "Cash and money market accounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Schedule of cash, cash equivalents and investments",
        "documentation": "The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "verboseLabel": "Cash, cash equivalents, and investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r1179"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r82",
      "r175"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r82"
     ]
    },
    "vstm_CertificateOfAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "CertificateOfAmendmentMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNatureOfBusinessReverseStockSplitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the certificate of amendment to the Company's Restated Certificate of Incorporation.",
        "label": "Certificate of Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ChangeInCompanyOwnershipPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ChangeInCompanyOwnershipPercent",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the Company's ownership as a percentage.",
        "label": "Change in Company Ownership, Percent",
        "terseLabel": "Change in ownership, percent"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ChangeInFairValueOfOfPreferredStockTrancheLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ChangeInFairValueOfOfPreferredStockTrancheLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unrealized gain (loss) on the preferred stock tranche liability.",
        "label": "Change in Fair Value of of Preferred Stock Tranche Liability",
        "terseLabel": "Change in fair value of preferred stock tranche liability"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r144",
      "r145",
      "r146",
      "r176",
      "r180",
      "r207",
      "r208",
      "r210",
      "r212",
      "r220",
      "r221",
      "r303",
      "r369",
      "r371",
      "r372",
      "r373",
      "r376",
      "r377",
      "r409",
      "r410",
      "r412",
      "r413",
      "r415",
      "r418",
      "r421",
      "r422",
      "r426",
      "r429",
      "r437",
      "r637",
      "r781",
      "r782",
      "r783",
      "r784",
      "r788",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r810",
      "r831",
      "r849",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r1161",
      "r1245",
      "r1247",
      "r1256"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Capital stock",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r220",
      "r412",
      "r421",
      "r422",
      "r424",
      "r426",
      "r429",
      "r435",
      "r437",
      "r599",
      "r781",
      "r782",
      "r783",
      "r784",
      "r986",
      "r1161",
      "r1243",
      "r1245"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price of shares of common stock in the warrant issued (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r182",
      "r438"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Share of exercisable warrant",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of common stock warrants can purchase",
        "verboseLabel": "Number of shares of common stock in the warrant issued",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "vstm_ClassOfWarrantOrRightNumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised during the period.",
        "label": "Class of Warrant or Right, Number Of Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrant outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "vstm_CloudComputingImplementationCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "CloudComputingImplementationCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to cloud computing implementation costs.",
        "label": "Cloud Computing Implementation Costs Policy [Policy Text Block]",
        "terseLabel": "Cloud Computing Implementation Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative arrangements",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "verboseLabel": "License and collaboration agreements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "vstm_CollaborativeArrangementsOneTimeCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "CollaborativeArrangementsOneTimeCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the one-time cash payment made under the agreement.",
        "label": "Collaborative Arrangements One Time Cash Payment",
        "terseLabel": "One-time cash payment"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_CollaborativeArrangementsRoyaltyObligationsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "CollaborativeArrangementsRoyaltyObligationsTerm",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the product's royalty obligations term that begin on the date of first commercial sale of the product.",
        "label": "Collaborative Arrangements Royalty Obligations Term",
        "terseLabel": "Royalty obligations term"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_CommercialExpenditure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "CommercialExpenditure",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenditure incurred towards commercial expenses.",
        "label": "Commercial Expenditure",
        "terseLabel": "Commercial expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r361",
      "r362",
      "r934",
      "r1284",
      "r1289"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1038",
      "r1039",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1252",
      "r1253",
      "r1255",
      "r1345",
      "r1413",
      "r1416"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureNatureOfBusinessReverseStockSplitDetails",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNatureOfBusinessReverseStockSplitDetails",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r810"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "vstm_CommonStockSharesOffered": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "CommonStockSharesOffered",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of common shares offered by the Company.",
        "label": "Common Stock, Shares Offered",
        "terseLabel": "Common shares, offered"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r64",
      "r810",
      "r829",
      "r1416",
      "r1417"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.0001 par value; 300,000 shares authorized, 77,740 and 44,784 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r410",
      "r417",
      "r731",
      "r1025"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee benefit plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r152",
      "r154",
      "r160",
      "r714",
      "r743",
      "r744"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r270",
      "r777",
      "r778",
      "r933",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r270",
      "r777",
      "r778",
      "r933",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r270",
      "r777",
      "r778",
      "r933",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Financial Instruments, Off-balance Sheet Risk",
        "verboseLabel": "Off-balance sheet concentrations of credit risk description",
        "documentation": "Description of financial instruments, excluding certain derivatives, with off-balance sheet credit risk (for example, standby letters of credit or financial guarantees), including (1) information about the (shared) activity, region or economic characteristic that identifies the concentration, (2) the face or contract amount of the instrument, (3) the nature and terms of the instrument, including the market risk, cash requirements and accounting policies for it, (4) the maximum amount of loss due to credit risk that would be incurred if the counterparties failed completely to perform according to the terms of the contracts, and any security or collateral that proved to be of no value, (5) the entity's policy of requiring collateral or other security to support financial instruments subject to credit risk, information about access to collateral or other security, and a brief description of the security supporting those financial instruments, and (6) the policy of entering into and a brief description of master netting arrangements to mitigate the credit risk, and the extent to which such arrangements would reduce the maximum amount of loss due to credit risk."
       }
      }
     },
     "auth_ref": [
      "r724",
      "r725",
      "r726",
      "r727"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r933",
      "r958",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of trade accounts receivable",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r270",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r933",
      "r958",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r270",
      "r777",
      "r778",
      "r933",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263"
     ]
    },
    "vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ConcentrationsOfCreditRiskAndOffBalanceSheetRiskAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations of Credit Risk and Off Balance Sheet Risk [Abstract]",
        "terseLabel": "Concentrations of credit risk and off-balance sheet risk"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk and description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.",
        "label": "Concentrations Of Credit Risk And Off Balance Sheet Risk [Policy Text Block]",
        "terseLabel": "Concentrations of credit risk and off-balance sheet risk"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ContractualInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ContractualInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureLongTermDebtScheduleOfInterestExpensesDetails": {
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtScheduleOfInterestExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as contractual interest expense.",
        "label": "Contractual Interest Expense",
        "terseLabel": "Contractual Interest"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ConversionOfPreferredStockConversionBlockerNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ConversionOfPreferredStockConversionBlockerNoticePeriod",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of notice to be given for increase in conversion blocker amount.",
        "label": "Conversion of Preferred Stock, Conversion Blocker, Notice Period",
        "terseLabel": "Conversion Blocker notice period for conversion of shares"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ConversionOfPreferredStockConversionBlockerPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ConversionOfPreferredStockConversionBlockerPercent",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent of conversion blocker for conversion of shares into common stock.",
        "label": "Conversion of Preferred Stock, Conversion Blocker, Percent",
        "terseLabel": "Conversion of preferred stock, conversion blocker, percent"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent of conversion blocker for conversion of shares into common stock, upon giving notice.",
        "label": "Conversion of Preferred Stock, Conversion Blocker, Percent, Upon Giving Notice",
        "terseLabel": "Percentage of Conversion Blocker for conversion of shares into common stock, upon giving notice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of stock, shares converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Shares issued on conversion",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "vstm_ConvertiblePreferredStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ConvertiblePreferredStockAbstract",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Convertible Preferred Stock:",
        "terseLabel": "Convertible preferred stock:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value",
        "verboseLabel": "Series B Convertible Preferred Stock, $0.0001 par value; 944 shares designated at December 31, 2025 and December 31, 2024, respectively; 0 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively",
        "documentation": "Value of outstanding nonredeemable convertible preferred stock or outstanding convertible preferred stock that is redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r63"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Convertible preferred stock, shares issued upon conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r41",
      "r63",
      "r93",
      "r432"
     ]
    },
    "vstm_CopiktraLicenseAndRelatedAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "CopiktraLicenseAndRelatedAssetsMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails",
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Copiktra license and other revenue.",
        "label": "Sale of COPIKTRA license and related assets"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_CorporateBondsAndCommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "CorporateBondsAndCommercialPaperMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security, in which the authorized issuer owes the holder a debt and is obliged to repay the principal and interest (the coupon) and unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Corporate bonds and commercial paper"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIntangibleAssetsDetails",
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost, Amortization",
        "terseLabel": "Cost of sales - intangible amortization",
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r1192"
     ]
    },
    "vstm_CostOfGoodsSoldExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "CostOfGoodsSoldExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities and intangible amortization.",
        "label": "Cost of Goods Sold Excluding Amortization",
        "terseLabel": "Cost of sales - product"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:",
        "verboseLabel": "Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r184",
      "r185",
      "r382",
      "r424",
      "r670",
      "r690",
      "r728",
      "r945",
      "r946",
      "r947",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1340",
      "r1341",
      "r1342",
      "r1343"
     ]
    },
    "vstm_CovenantWorldwideNetSalesOfAvutometinibAndDefactinib": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "CovenantWorldwideNetSalesOfAvutometinibAndDefactinib",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of worldwide net sales of Avutometinib and Defactinib.",
        "label": "Covenant, Worldwide Net Sales Of Avutometinib And Defactinib",
        "terseLabel": "Worldwide net sales of avutobetinib and defactinib during trailing 6-months"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditConcentrationRiskMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Concentration Risk",
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r1292"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r1292"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1166",
      "r1243",
      "r1249",
      "r1337"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current income tax expense",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r1243",
      "r1249"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current income tax expense:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r1260"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1150"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1150"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1152"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1152"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1154"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1152"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1056",
      "r1145"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1146"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1146"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1144"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1144"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1144"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1147"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1149"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1149"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1150"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1153"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1151"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1148"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-term debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r176",
      "r178",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r367",
      "r368",
      "r378",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r394",
      "r401",
      "r402",
      "r404",
      "r599",
      "r650"
     ]
    },
    "vstm_DebtInstrumentAccruedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "DebtInstrumentAccruedInterestRate",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of term Loans will accrue interest at a rate per annum during the existence of an event of default.",
        "label": "Debt Instrument, Accrued Interest Rate",
        "terseLabel": "Accrued interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_DebtInstrumentAdditionalInterestRateInEventOfDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "DebtInstrumentAdditionalInterestRateInEventOfDefault",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the additional interest rate in event of default.",
        "label": "Debt Instrument Additional Interest Rate In Event Of Default",
        "terseLabel": "Additional interest rate in an event of default"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails",
      "http://www.verastem.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.verastem.com/role/DisclosureNotesPayableDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r52",
      "r53",
      "r103",
      "r105",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r1023",
      "r1243",
      "r1244",
      "r1246",
      "r1251",
      "r1285",
      "r1286",
      "r1287",
      "r1363",
      "r1365",
      "r1377"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate (as a percent)",
        "verboseLabel": "Basis spread",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal loan balance",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r105",
      "r405"
     ]
    },
    "us-gaap_DebtInstrumentCovenantDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCovenantDescription",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Covenant Description",
        "terseLabel": "Financial covenants",
        "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r49"
     ]
    },
    "vstm_DebtInstrumentCurrentBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "DebtInstrumentCurrentBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the debt facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets).",
        "label": "Debt Instrument, Current Borrowing Capacity",
        "terseLabel": "Current borrowing capacity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureNotesPayableDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r650",
      "r651",
      "r981",
      "r982",
      "r1023"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt, fair value",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r632",
      "r633",
      "r634",
      "r635",
      "r981",
      "r982",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352"
     ]
    },
    "vstm_DebtInstrumentFinalPaymentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "DebtInstrumentFinalPaymentFee",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of final payment fee.",
        "label": "Debt Instrument, Final Payment Fee",
        "verboseLabel": "Final Payment Fee"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_DebtInstrumentFinalPaymentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "DebtInstrumentFinalPaymentFeePercentage",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of final payment fee on original principal amount of debt.",
        "label": "Debt Instrument, Final Payment Fee, Percentage",
        "terseLabel": "Percentage of final prepayment fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)",
        "verboseLabel": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r380"
     ]
    },
    "vstm_DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of additional interest rate for notes issued.",
        "label": "Debt Instrument Interest Rate Stated, Percentage, Additional Interest Rate",
        "terseLabel": "Additional interest rate (%)"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_DebtInstrumentIssuanceOfAdditionalNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "DebtInstrumentIssuanceOfAdditionalNotes",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of an additional issue of notes.",
        "label": "Debt Instrument, Issuance of Additional Notes",
        "terseLabel": "Additional issue of principal amount of notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r599",
      "r719",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r1023",
      "r1243",
      "r1244",
      "r1246",
      "r1251",
      "r1363",
      "r1365"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails",
      "http://www.verastem.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.verastem.com/role/DisclosureNotesPayableDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r1023",
      "r1243",
      "r1244",
      "r1246",
      "r1251",
      "r1285",
      "r1286",
      "r1287",
      "r1363",
      "r1365",
      "r1377"
     ]
    },
    "vstm_DebtInstrumentNumberOfEqualInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "DebtInstrumentNumberOfEqualInstallments",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equal installments.",
        "label": "Debt Instrument, Number Of Equal Installments",
        "terseLabel": "Number of equal installments"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_DebtInstrumentPeriodToDrawLoanMinimum": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "DebtInstrumentPeriodToDrawLoanMinimum",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information pertaining to Debt Instrument Period to Draw Loan, Minimum.",
        "label": "Debt Instrument Period to Draw Loan, Minimum",
        "terseLabel": "Debt instrument period to draw loan, Minimum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Monthly payments",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r48"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt redemption, percentage of principal amount",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r41",
      "r44",
      "r47",
      "r92",
      "r94",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r599",
      "r719",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r1023",
      "r1243",
      "r1244",
      "r1246",
      "r1251",
      "r1363",
      "r1365"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "negatedLabel": "Debt issuance costs, net of accretion",
        "documentation": "Amount, after accumulated amortization, of debt discount (premium)."
       }
      }
     },
     "auth_ref": [
      "r1296",
      "r1362",
      "r1363",
      "r1365"
     ]
    },
    "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]",
        "terseLabel": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]",
        "documentation": "Indicates type of variable interest rate on debt instrument."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "vstm_DebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "DebtIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs incurred.",
        "label": "Debt Issuance Costs",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "verboseLabel": "Issuance costs included in accounts payable and accrued expenses",
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)",
        "terseLabel": "Realized gains or losses on investments",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1274"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in unrealized loss position",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r312"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r104",
      "r548"
     ]
    },
    "vstm_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development.",
        "label": "Deferred Tax Assets Capitalized Research and Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "vstm_DeferredTaxAssetsInstallmentSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "DeferredTaxAssetsInstallmentSale",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from installment sale.",
        "label": "Deferred Tax Assets, Installment Sale",
        "terseLabel": "Installment sale"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liability.",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1333"
     ]
    },
    "vstm_DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets net of deferred tax liabilities before valuation allowance.",
        "label": "Deferred Tax Assets Net Of Deferred Tax Liabilities Before Valuation Allowance",
        "totalLabel": "Net deferred tax asset prior to valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1335"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other deferred tax assets",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1335"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1335"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1335"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "vstm_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right of use asset.",
        "label": "Deferred Tax Liabilities, Right of Use Asset",
        "negatedLabel": "Right-of-use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost Recognized",
        "terseLabel": "Contributions made under 401(k) plan",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "verboseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r35",
      "r165",
      "r948",
      "r949",
      "r951",
      "r953"
     ]
    },
    "vstm_DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference in the fair value between the face (par) amount of debt instrument at time of issuance and the current fair value.",
        "label": "Difference in Fair Value to Carrying Value, Debt Instrument, Face Amount",
        "terseLabel": "Difference in fair value and principle amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-based compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r477",
      "r508",
      "r509",
      "r511",
      "r996"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1076"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1076",
      "r1119"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1108"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share-basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r161",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r205",
      "r207",
      "r210",
      "r211",
      "r212",
      "r217",
      "r408",
      "r512",
      "r569",
      "r574",
      "r613",
      "r614",
      "r715",
      "r745",
      "r957"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share-diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r161",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r207",
      "r210",
      "r211",
      "r212",
      "r217",
      "r408",
      "r512",
      "r569",
      "r574",
      "r613",
      "r614",
      "r715",
      "r745",
      "r957"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r214"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net loss per share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r213",
      "r215",
      "r216"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate (as a percent)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r1000"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation of effective income tax rate to the statutory federal income tax rate (in percentage)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "US federal statutory rate (as a percent)",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r181",
      "r531",
      "r560",
      "r1000"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in the valuation allowance (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r1000",
      "r1243",
      "r1250",
      "r1331"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Tax law change (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r1000",
      "r1243",
      "r1250",
      "r1331"
     ]
    },
    "vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in fair value of warrant liability.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Fair Value Of Warrant Liability, Amount",
        "terseLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in fair value of warrant liability.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Fair Value Of Warrant Liability, Percent",
        "terseLabel": "Change in fair value of warrant liability (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532",
      "r1000"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Permanent items (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538",
      "r1243",
      "r1250",
      "r1331"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Other (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1243",
      "r1250",
      "r1331",
      "r1332"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation (as a percent)",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1243",
      "r1250",
      "r1331",
      "r1332"
     ]
    },
    "vstm_EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to net operating loss and tax credit carryforwards expiration under section 382.",
        "label": "Effective Income Tax Rate Reconciliation, Operating Loss Tax Credit Carryforwards Expiration, Percent",
        "terseLabel": "NOL and tax credit expiration under Section 382 (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and local income tax benefit, net of federal benefit (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r1000",
      "r1243",
      "r1250",
      "r1331"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532",
      "r1000"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Research and development tax credits (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1243",
      "r1250",
      "r1331",
      "r1332"
     ]
    },
    "vstm_EmployeeAndNonEmployeesStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "EmployeeAndNonEmployeesStockOptionMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.",
        "label": "Stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and related benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]",
        "terseLabel": "Stock-based compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1326"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Weighted-average recognition period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1327"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Total unrecognized stock-based compensation expense (in dollars)",
        "verboseLabel": "Unrecognized compensation cost",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1327"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1159"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r128",
      "r129",
      "r130",
      "r156",
      "r157",
      "r158",
      "r187",
      "r188",
      "r189",
      "r191",
      "r198",
      "r200",
      "r202",
      "r219",
      "r304",
      "r305",
      "r340",
      "r407",
      "r439",
      "r512",
      "r558",
      "r559",
      "r566",
      "r567",
      "r568",
      "r570",
      "r573",
      "r574",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r612",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r652",
      "r654",
      "r669",
      "r741",
      "r769",
      "r770",
      "r771",
      "r788",
      "r849"
     ]
    },
    "vstm_EquityIncentivePlan2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "EquityIncentivePlan2021Member",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to 2021 equity incentive plan.",
        "label": "Equity Incentive Plan 2021 [Member]",
        "terseLabel": "2021 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1080",
      "r1090",
      "r1123"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r1066",
      "r1077",
      "r1087",
      "r1120"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "terseLabel": "Fair Value",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r632",
      "r633",
      "r635",
      "r940",
      "r981",
      "r982"
     ]
    },
    "vstm_ExclusiveLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ExclusiveLicenseAgreementMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exclusive license agreement entered into by the entity.",
        "label": "Exclusive license agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "vstm_ExerciseOfAllThreeGenFleetOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ExerciseOfAllThreeGenFleetOptionsMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to exercise of all 3 GenFleet options.",
        "label": "Exercise of All Three Gen Fleet Options [Member]",
        "terseLabel": "Exercise of All Three Gen Fleet Options"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_FairValueAdjustmentOfNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "FairValueAdjustmentOfNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 6.0
      },
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of notes.",
        "label": "Fair Value Adjustment of Notes",
        "negatedLabel": "Change in fair value of Notes",
        "terseLabel": "Change in fair value of Notes"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of notes attributable to instrument specific credit risk.",
        "label": "Fair Value Adjustment of Notes, Instrument Specific Credit Risk",
        "negatedLabel": "Change in fair value of Notes attributable to instrument specific credit risk"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_FairValueAdjustmentOfNotesNoncash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "FairValueAdjustmentOfNotesNoncash",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of notes, noncash portion.",
        "label": "Fair Value Adjustment of Notes, Noncash",
        "terseLabel": "Non-cash change in fair value of Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 7.0
      },
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      },
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in fair value of warrant liability",
        "terseLabel": "Change in fair value of warrant liability",
        "verboseLabel": "Fair value adjustment",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "vstm_FairValueAdjustmentOfWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "FairValueAdjustmentOfWarrantsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrants exercised.",
        "label": "Fair Value Adjustment of Warrants Exercised",
        "terseLabel": "Conversion of warrant liability into additional paid-in capital upon warrant exercise",
        "verboseLabel": "Fair value of warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value of financial instruments",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r617",
      "r627",
      "r1011"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r617",
      "r627",
      "r1011"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of inputs used to value the preferred stock tranche liability and warrant liability",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r1015"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial instruments measured at fair value on a recurring basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1347",
      "r1348"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Hierarchy [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r466",
      "r467",
      "r615",
      "r617",
      "r618",
      "r619",
      "r620",
      "r626",
      "r627",
      "r629",
      "r632",
      "r677",
      "r678",
      "r679",
      "r940",
      "r981",
      "r982",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r1011",
      "r1015",
      "r1022"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r632",
      "r633",
      "r634",
      "r635",
      "r637",
      "r638",
      "r940",
      "r981",
      "r982",
      "r1358"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r617",
      "r618",
      "r620",
      "r1011",
      "r1350",
      "r1353"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of financial instruments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r454",
      "r459",
      "r466",
      "r617",
      "r627",
      "r632",
      "r677",
      "r940",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r1011",
      "r1022"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 3",
        "verboseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r466",
      "r467",
      "r617",
      "r618",
      "r619",
      "r620",
      "r627",
      "r632",
      "r679",
      "r940",
      "r981",
      "r982",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r1011",
      "r1015",
      "r1022"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Reconciliation of changes in the fair value of the Notes",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule of reconciliation of changes in the fair value of the Notes",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r625",
      "r628"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r617",
      "r618",
      "r620",
      "r1011",
      "r1350",
      "r1353"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Change in fair value reported in statements of operations",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r628"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "negatedLabel": "Change in fair value reported in comprehensive loss",
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r628"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Interest and revenue participation payments",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r628"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending fair value",
        "periodStartLabel": "Beginning fair value balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r628"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r466",
      "r467",
      "r615",
      "r617",
      "r618",
      "r619",
      "r620",
      "r626",
      "r627",
      "r629",
      "r632",
      "r677",
      "r678",
      "r679",
      "r940",
      "r981",
      "r982",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r1011",
      "r1015",
      "r1022"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recurring basis",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r1011",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1353"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1354"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r628"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement in which other comprehensive income (OCI) is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r628"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r403",
      "r435",
      "r599",
      "r610",
      "r630",
      "r636",
      "r639",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r723",
      "r742",
      "r976",
      "r1011",
      "r1013",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1026",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1346",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1355",
      "r1356"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Total financial liabilities",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r1347",
      "r1348",
      "r1352",
      "r1355",
      "r1356",
      "r1357",
      "r1359"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less: accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r320",
      "r334",
      "r942"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1282",
      "r1419"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r938",
      "r942"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2030",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r938",
      "r942"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r938",
      "r942"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r938",
      "r942"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r938",
      "r942"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Acquired and in-licensed rights",
        "verboseLabel": "Intangible asset",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r334",
      "r713",
      "r942"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationExpenseOfFiniteLivedIntangibleAssetsDetails",
      "http://www.verastem.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Total intangible assets, net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r712",
      "r1281"
     ]
    },
    "vstm_First100MillionNetSalesOfEachIncludedProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "First100MillionNetSalesOfEachIncludedProductMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to first $100 million net sales of each included product.",
        "label": "First $100 Million Net Sales Of Each Included Product [Member]",
        "terseLabel": "First $100 million net sales of each included product"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "First8QuartersFollowingNotePurchaseAgreementClosingDateMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to first 8 quarters following the Note Purchase Agreement closing date.",
        "label": "First 8 Quarters Following The Note Purchase Agreement Closing Date [Member]",
        "terseLabel": "First 8 Quarters following the Note Purchase Agreement Closing Date"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_FirstInsuranceFundingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "FirstInsuranceFundingMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to First Insurance Funding (\"First Insurance\").",
        "label": "First Insurance Funding [Member]",
        "terseLabel": "First Insurance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1127"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1127"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1127"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1127"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1127"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      },
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on debt extinguishment",
        "terseLabel": "Loss on debt extinguishment",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r37",
      "r38"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r833"
     ]
    },
    "vstm_GenfleetTherapeuticsShanghaiIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "GenfleetTherapeuticsShanghaiIncMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information pertaining to Genfleet Therapeutics (Shanghai), Inc.",
        "label": "Genfleet"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentAssistanceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Income, Increase (Decrease)",
        "terseLabel": "Grant awarded, amount",
        "documentation": "Amount of increase (decrease) in income from government assistance."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_GovernmentAssistanceAmountCumulativeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceAmountCumulativeCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Asset, Current",
        "terseLabel": "Grant, grants receivable",
        "documentation": "Amount of asset from government assistance, classified as current."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Asset, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes asset from government assistance, classified as current."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_GovernmentAssistanceLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Liability, Current",
        "terseLabel": "Grants, deferred liability",
        "documentation": "Amount of liability from government assistance, classified as current."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_GovernmentAssistanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_GovernmentAssistanceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceOtherMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Other [Member]",
        "terseLabel": "Additional funding",
        "documentation": "Government assistance classified as other."
       }
      }
     },
     "auth_ref": [
      "r1361"
     ]
    },
    "us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes increase (decrease) in income from government assistance."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_GovernmentAssistanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance [Table]",
        "documentation": "Disclosure of information about government assistance."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_GovernmentAssistanceTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceTypeAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Type [Axis]",
        "documentation": "Information by type of government assistance."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_GovernmentAssistanceTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceTypeDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Type [Domain]",
        "documentation": "Type of government assistance."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "vstm_GrantsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "GrantsReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of eligible expenses incurred in excess of grant payments received up to the total amount of grants, which are recorded as a receivable.",
        "label": "Grants Receivable, Net",
        "terseLabel": "Grant receivable"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_GrossProductRevenueToBeAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "GrossProductRevenueToBeAchieved",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gross product revenue to be achieved to draw the loan.",
        "label": "Gross Product Revenue to be Achieved",
        "terseLabel": "Gross product revenue to be achieved"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1076"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairment losses on long-lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r34",
      "r88",
      "r162",
      "r949",
      "r1012"
     ]
    },
    "vstm_IncentivePlan2012Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "IncentivePlan2012Member",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2012 Incentive Plan of the entity.",
        "label": "Incentive Plan 2012 [Member]",
        "terseLabel": "2012 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Pretax loss",
        "totalLabel": "Net loss before taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r107",
      "r112",
      "r716",
      "r718",
      "r738",
      "r950",
      "r952",
      "r954",
      "r963",
      "r969",
      "r1258",
      "r1265",
      "r1266",
      "r1267",
      "r1268"
     ]
    },
    "vstm_IncomeLossFromPreferredStockTrancheLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "IncomeLossFromPreferredStockTrancheLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from change in value of preferred stock tranche liability.",
        "label": "Income (Loss) from preferred stock tranche liability",
        "negatedLabel": "Change in fair value of preferred stock tranche liability",
        "terseLabel": "Change in fair value of preferred stock tranche liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r348",
      "r358",
      "r584",
      "r589",
      "r590",
      "r598",
      "r622",
      "r625",
      "r628",
      "r638",
      "r639",
      "r640",
      "r766",
      "r768",
      "r834",
      "r938",
      "r940",
      "r1001",
      "r1002",
      "r1009",
      "r1010",
      "r1014",
      "r1022",
      "r1338",
      "r1339",
      "r1384"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r358",
      "r584",
      "r589",
      "r590",
      "r598",
      "r622",
      "r625",
      "r628",
      "r638",
      "r639",
      "r640",
      "r766",
      "r768",
      "r834",
      "r938",
      "r940",
      "r1001",
      "r1002",
      "r1009",
      "r1010",
      "r1014",
      "r1022",
      "r1338",
      "r1339",
      "r1384"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails",
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails",
      "http://www.verastem.com/role/DisclosureIncomeTaxesTaxCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r531",
      "r532",
      "r543",
      "r554",
      "r1000",
      "r1334"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails",
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails",
      "http://www.verastem.com/role/DisclosureIncomeTaxesTaxCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r531",
      "r532",
      "r543",
      "r554",
      "r1000",
      "r1334"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r181",
      "r526",
      "r531",
      "r539",
      "r540",
      "r541",
      "r545",
      "r552",
      "r561",
      "r563",
      "r564",
      "r565",
      "r722",
      "r776",
      "r786",
      "r1000"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 17.0
      },
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails",
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "terseLabel": "Income tax expense",
        "totalLabel": "Total income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r125",
      "r176",
      "r201",
      "r202",
      "r218",
      "r241",
      "r263",
      "r530",
      "r531",
      "r562",
      "r746",
      "r950",
      "r952",
      "r954",
      "r1000"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Reconciliation of effective income tax rate to the statutory federal income tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r528",
      "r529",
      "r545",
      "r546",
      "r551",
      "r556",
      "r780"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in the valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r1000",
      "r1331"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "US federal statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r1000"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "terseLabel": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1331",
      "r1332"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1331",
      "r1332"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development tax credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1331",
      "r1332"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income tax expense",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r174",
      "r553",
      "r554"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1238"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDeferredLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Liabilities",
        "terseLabel": "Deferred liabilities",
        "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "vstm_IncreaseDecreaseInGrantsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "IncreaseDecreaseInGrantsReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in eligible expenses incurred in excess of grant payments received up to the total amount of grants, which are recorded as a receivable.",
        "label": "Increase (Decrease) in Grants Receivable, Net",
        "terseLabel": "Grant receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses, other current assets and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1118",
      "r1127",
      "r1131",
      "r1139"
     ]
    },
    "vstm_InducementAwardProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "InducementAwardProgramMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about inducement award program established in accordance with NASDAQ Listing Rule 5635(c)(4).",
        "label": "Inducement Award Program [Member]",
        "terseLabel": "Inducement Award Program"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_InitialSaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "InitialSaleMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to initial sale.",
        "label": "Initial Sale [Member]",
        "terseLabel": "Initial sale"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r1054",
      "r1143"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r1054",
      "r1143"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r1054",
      "r1143"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r337",
      "r339",
      "r937",
      "r938"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r709",
      "r710",
      "r712",
      "r955",
      "r1279"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r1281",
      "r1283"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_InterestDuePaidInKindPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "InterestDuePaidInKindPercentage",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of interest due paid-in-kind.",
        "label": "Interest Due, Paid-In-Kind, Percentage",
        "terseLabel": "Interest due paid-in-kind (%)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 11.0
      },
      "http://www.verastem.com/role/DisclosureLongTermDebtScheduleOfInterestExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtScheduleOfInterestExpensesDetails",
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Total",
        "verboseLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r233",
      "r237",
      "r243",
      "r263",
      "r649",
      "r969",
      "r970",
      "r1415"
     ]
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Schedule of interest expenses",
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Net",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r172",
      "r173"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable",
        "terseLabel": "Accrued interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r1176",
      "r1418"
     ]
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails",
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails",
      "http://www.verastem.com/role/DisclosureIncomeTaxesTaxCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureInventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureInventoryScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureInventoryScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1177"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.verastem.com/role/DisclosureInventoryScheduleOfInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureInventoryScheduleOfInventoryDetails",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r944",
      "r1025"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r137",
      "r148",
      "r315",
      "r316",
      "r317",
      "r707",
      "r956"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureInventoryScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureInventoryScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1178"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r236",
      "r263",
      "r969",
      "r1193"
     ]
    },
    "vstm_IqviaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "IqviaIncMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information pertaining to IQVIA, Inc. (IQVIA)",
        "label": "IQVIA Inc [Member]",
        "terseLabel": "IQVIA"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_IssuanceOfPreferredStockTrancheLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "IssuanceOfPreferredStockTrancheLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of preferred stock tranche liability that were incurred during a noncash or partial noncash transaction.",
        "label": "Issuance of preferred stock tranche liability",
        "terseLabel": "Preferred stock tranche liability"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_July2024PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "July2024PublicOfferingMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 2024 public offering.",
        "label": "July 2024 Public Offering [Member]",
        "terseLabel": "July 2024 Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total Lease Expense",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r1024"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of elements of lease expenses",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1367"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r667"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeDisclosureAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Information - Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r668"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r668"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r1244",
      "r1251",
      "r1377"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r1244",
      "r1251",
      "r1377"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Present value discount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter of credit",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r52",
      "r53",
      "r54",
      "r57",
      "r58",
      "r59",
      "r62",
      "r176",
      "r179",
      "r180",
      "r303",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r578",
      "r581",
      "r582",
      "r637",
      "r809",
      "r962",
      "r985",
      "r1047",
      "r1293",
      "r1368",
      "r1369"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r106",
      "r734",
      "r1025",
      "r1034",
      "r1035",
      "r1243",
      "r1248",
      "r1278",
      "r1360"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, convertible preferred stock and stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r136",
      "r176",
      "r179",
      "r180",
      "r303",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r578",
      "r581",
      "r582",
      "r637",
      "r1025",
      "r1293",
      "r1368",
      "r1369"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Uncertainty in Income Taxes, Noncurrent",
        "terseLabel": "Liability for uncertain tax positions",
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "vstm_LicenseAndCollaborationAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseAndCollaborationAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "License, collaboration and commercial agreements"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the scenario if sales exceeds $100 million.",
        "label": "Sales Exceeds $100 Million"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the scenario if sales exceeds $200 million.",
        "label": "Sales Exceeds $200 Million"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the scenario if sales exceeds $300 million.",
        "label": "Sales Exceeds $300 Million"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LicenseAndCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseAndCollaborationAgreementMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for license and collaboration agreement for exclusive rights to develop and commercialize products.",
        "label": "License and Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LicenseAndCollaborationAgreementUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseAndCollaborationAgreementUpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for non refundable up front payment for license agreement.",
        "label": "License And Collaboration Agreement Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LicenseAndCollaborationAgreementsDevelopmentMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseAndCollaborationAgreementsDevelopmentMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid upon achievement of development milestones.",
        "label": "License And Collaboration Agreements, Development Milestone Payments",
        "terseLabel": "Payment for development milestone"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of royalties and milestone payments entitled under any license or sublicense agreements in certain jurisdictions",
        "label": "License And Collaboration Agreements, Percentage Of Royalty And Milestone Payments Entitled Under Certain Jurisdictions",
        "terseLabel": "Percentage of all royalty and milestone payments payable under certain jurisdictions"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of royalty, milestone and sublicense revenue payments entitled to the company under the existing license and collaboration agreement.",
        "label": "License And Collaboration Agreements, Percentage Of Royalty, Milestone And Sub Licensing Revenue Payments Entitled Under Existing License Agreements",
        "terseLabel": "Percentage of all royalty, milestone and sublicense revenue payments payable"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of regulatory milestone payments receivable under the License and collaboration agreements.",
        "label": "License And Collaboration Agreements, Regulatory Milestone Payments Receivable",
        "terseLabel": "Regulatory milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of regulatory milestone payments receivable up on approval received from the approval for commercial sale under the License and collaboration agreements.",
        "label": "License And Collaboration Agreements, Regulatory Milestone Payments Receivable Upon Approval For Commercial Sale",
        "terseLabel": "Milestone payments receivable upon approval for commercial sale"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of regulatory milestone payments receivable up on approval received from the approval of COPIKTRA in the United States for the treatment of peripheral T-cell lymphoma under the License and collaboration agreements.",
        "label": "License And Collaboration Agreements, Regulatory Milestone Payments Receivable Upon Approval Of COPIKTRA",
        "terseLabel": "Milestone payments receivable upon approval of COPIKTRA"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseAndCollaborationAgreementsSalesMilestoneReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of sales milestone receivable under the License and collaboration agreements.",
        "label": "License And Collaboration Agreements, Sales Milestone Receivable",
        "terseLabel": "Sales milestone receivable"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LicenseAndCollaborationAgreementsSalesMilestoneReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseAndCollaborationAgreementsSalesMilestoneReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of sales milestone received under the License and collaboration agreements.",
        "label": "License And Collaboration Agreements, Sales Milestone Received",
        "terseLabel": "Sales milestone received"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of threshold sale revenue to be achieved in order for the company to receive the sales milestone payments under the License and collaboration agreements.",
        "label": "License And Collaboration Agreements, Threshold Sales To Trigger Milestone Payments",
        "terseLabel": "Threshold sales to trigger milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of threshold sale revenue to be achieved in order for the company to receive the royalty payments under the License and collaboration agreements.",
        "label": "License And Collaboration Agreements, Threshold Sales To Trigger Royalty Payments",
        "terseLabel": "Threshold sales to trigger royalty payments"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for license, collaboration and commercial agreements.",
        "label": "License, Collaboration And Commercial Agreements Disclosure [Text Block]",
        "verboseLabel": "License, collaboration and commercial agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Aggregate principal amount of notes",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r56"
     ]
    },
    "vstm_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for loan and security agreement.",
        "label": "Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtComponentsOfCarryingValueOfTermLoanDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt.",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total Long-term debt, net of discount",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r105",
      "r177",
      "r186",
      "r391",
      "r406",
      "r719",
      "r981",
      "r982",
      "r1023",
      "r1378"
     ]
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtByMaturityAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Future principal payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Fair value of long-term debt",
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission."
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1022",
      "r1347",
      "r1349",
      "r1350",
      "r1351",
      "r1355",
      "r1356",
      "r1357",
      "r1359"
     ]
    },
    "vstm_LongTermDebtMaturitiesAggregatePrincipalDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LongTermDebtMaturitiesAggregatePrincipalDue",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of principal debt due.",
        "label": "Long Term Debt Maturities Aggregate Principal Due",
        "totalLabel": "Total principal payments"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LongTermDebtMaturityYearSeven": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LongTermDebtMaturityYearSeven",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails": {
       "parentTag": "vstm_LongTermDebtMaturitiesAggregatePrincipalDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in seventh fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Seven",
        "terseLabel": "2032"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_LongTermDebtMaturityYearSix": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "LongTermDebtMaturityYearSix",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails": {
       "parentTag": "vstm_LongTermDebtMaturitiesAggregatePrincipalDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Six",
        "terseLabel": "2031"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMeasurementInput",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Measurement Input",
        "terseLabel": "Discount rate",
        "documentation": "Value of input used to measure long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1349",
      "r1350",
      "r1351"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt [Text Block]",
        "terseLabel": "Notes Payable",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Amount",
        "terseLabel": "Genfleet R&amp;D Support Fee",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category of Item Purchased [Axis]",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "vstm_MajorCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "MajorCustomerMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to major customer.",
        "label": "Major Customer [Member]",
        "terseLabel": "Major customer"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r987",
      "r989",
      "r1028",
      "r1032",
      "r1382",
      "r1385",
      "r1386",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412"
     ]
    },
    "vstm_MarketToMarketAdjustmentOfPreferredStockTrancheLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "MarketToMarketAdjustmentOfPreferredStockTrancheLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of market to market adjustment under change in fair value of preferred stock tranche liability as during the reporting period.",
        "label": "Market to Market Adjustment of Preferred Stock Tranche Liability",
        "terseLabel": "Mark-to-market adjustment under change in fair value of preferred stock tranche liability"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount of common shares that can be owned by any holder as a percentage that would prevent the exercise of any warrants.",
        "label": "Maximum Amount of Common Stock Owned by Holder, Exercise of Pre Funded Warrants, as a Percentage",
        "terseLabel": "Maximum amount of common stock owned, as a percentage, that would prevent exercise"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount of common shares that can be owned by any holder as a percentage that would prevent the exercise of any warrants. By the holder's election, this amount can be increased or decrease but cannot exceed 19.99%.",
        "label": "Maximum Amount of Common Stock Owned by Holder, Exercise of Pre Funded Warrants, Maximum Allowable Increase, as a Percentage",
        "terseLabel": "Upper limit of maximum amount of common stock owned by a holder, as a percentage"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureLeasesDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r363",
      "r364",
      "r365",
      "r366",
      "r471",
      "r503",
      "r504",
      "r505",
      "r523",
      "r620",
      "r706",
      "r765",
      "r767",
      "r775",
      "r801",
      "r802",
      "r857",
      "r876",
      "r880",
      "r881",
      "r910",
      "r926",
      "r927",
      "r928",
      "r929",
      "r935",
      "r936",
      "r975",
      "r986",
      "r995",
      "r1001",
      "r1003",
      "r1004",
      "r1015",
      "r1016",
      "r1020",
      "r1021",
      "r1029",
      "r1295",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375"
     ]
    },
    "vstm_MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum value of common stock able to be offered and sold through the market equity offering program.",
        "label": "Maximum Value Of Common Stock Offered Through Market Equity Offering Program",
        "terseLabel": "Maximum value of common stock allowed to be sold"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount rate, cash flows",
        "terseLabel": "Discount rate, notes",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1003",
      "r1004",
      "r1349",
      "r1350",
      "r1351"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining term",
        "terseLabel": "Remaining term",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r1349",
      "r1350",
      "r1351"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Volatility",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r1015",
      "r1349",
      "r1350",
      "r1351"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r1349",
      "r1350",
      "r1351"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r618",
      "r619",
      "r620",
      "r1001",
      "r1003",
      "r1004",
      "r1015"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r620",
      "r1001",
      "r1003",
      "r1004",
      "r1015"
     ]
    },
    "vstm_MedicalAffairExpenditure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "MedicalAffairExpenditure",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenditure incurred towards medical affairs expenses.",
        "label": "Medical Affair Expenditure",
        "terseLabel": "Medical affairs expenses"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r363",
      "r364",
      "r365",
      "r366",
      "r471",
      "r503",
      "r504",
      "r505",
      "r523",
      "r620",
      "r706",
      "r765",
      "r767",
      "r775",
      "r801",
      "r802",
      "r857",
      "r876",
      "r880",
      "r881",
      "r910",
      "r926",
      "r927",
      "r928",
      "r929",
      "r935",
      "r936",
      "r975",
      "r986",
      "r995",
      "r1001",
      "r1003",
      "r1004",
      "r1015",
      "r1016",
      "r1020",
      "r1029",
      "r1295",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r987",
      "r989",
      "r1028",
      "r1032",
      "r1382",
      "r1385",
      "r1386",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "vstm_NatureOfBusinessLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "NatureOfBusinessLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.verastem.com/role/DisclosureNatureOfBusinessReverseStockSplitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Nature Of Business [Line Items]",
        "terseLabel": "Nature of business"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_NatureOfBusinessTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "NatureOfBusinessTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.verastem.com/role/DisclosureNatureOfBusinessReverseStockSplitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing information relating to nature of business.",
        "label": "Nature Of Business [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r223",
      "r959",
      "r960"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r84"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r84",
      "r108",
      "r130",
      "r134",
      "r151",
      "r153",
      "r158",
      "r176",
      "r179",
      "r180",
      "r183",
      "r190",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r209",
      "r303",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r408",
      "r411",
      "r414",
      "r419",
      "r512",
      "r569",
      "r574",
      "r614",
      "r637",
      "r740",
      "r830",
      "r847",
      "r848",
      "r950",
      "r952",
      "r954",
      "r1045",
      "r1293"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting standards updates",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "vstm_NewAccountingStandardsAdoptedPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "NewAccountingStandardsAdoptedPolicyPolicyTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting standards adopted that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Standards Adopted Policy Policy [Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards Updates"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1084",
      "r1094",
      "r1118",
      "r1127"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired",
        "terseLabel": "Purchases of intangible asset in accounts payable and accrued expenses",
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "vstm_NotePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "NotePurchaseAgreementMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtReconciliationOfChangesInFairValueOfNotesDetails",
      "http://www.verastem.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Note Purchase Agreement.",
        "label": "Note Purchase Agreement [Member]",
        "terseLabel": "Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable",
        "terseLabel": "Note Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r105",
      "r1378",
      "r1379"
     ]
    },
    "us-gaap_NotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayableFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Fair Value Disclosure",
        "terseLabel": "Fair value of Notes",
        "verboseLabel": "Notes",
        "documentation": "Fair value portion of notes payable."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r52",
      "r53",
      "r1348",
      "r1352",
      "r1355",
      "r1356",
      "r1357",
      "r1359"
     ]
    },
    "vstm_November2025PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "November2025PublicOfferingMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the November 2025 public offering.",
        "label": "November 2025 Public Offering [Member]",
        "terseLabel": "November 2025 Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_NumberOfAnniversariesForVestingRestrictedStockUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "NumberOfAnniversariesForVestingRestrictedStockUnits",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of anniversaries for vesting for restricted stock units.",
        "label": "Number Of Anniversaries For Vesting Restricted Stock Units",
        "terseLabel": "Number of anniversaries"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_NumberOfCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "NumberOfCustomers",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of customers.",
        "label": "Number of Customers",
        "terseLabel": "Number of customer"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number days of written notice from either party to the agreement to terminate agreement for the other party's material breach if such party fails to cure the breach.",
        "label": "Number of Days of Prior Notice, Termination, Fails to Cure Breach",
        "terseLabel": "Number of days written notice required to terminate agreement if fails to cure breach"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_NumberOfDaysOfPriorNoticeToTerminateAgreement.": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "NumberOfDaysOfPriorNoticeToTerminateAgreement.",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number days of prior written notice to terminate the agreement.",
        "label": "Number of Days of Prior Notice to Terminate Agreement",
        "terseLabel": "Number of days written prior notice required for other party to terminate agreement"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_NumberOfEligibleStockholders": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "NumberOfEligibleStockholders",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of eligible stockholders.",
        "label": "Number Of Eligible Stockholders",
        "terseLabel": "Number of eligible stockholders"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_NumberOfEquityCompensationPlans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "NumberOfEquityCompensationPlans",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of equity compensation plans of the entity.",
        "label": "Number of Equity Compensation Plans",
        "terseLabel": "Number of equity compensation plans"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_NumberOfFinancialCovenants": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "NumberOfFinancialCovenants",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of financial covenants.",
        "label": "Number of Financial Covenants",
        "terseLabel": "Number of financial covenants"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_NumberOfInstallmentsForVestingOfRestrictedStockUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "NumberOfInstallmentsForVestingOfRestrictedStockUnits",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of installments for vesting of restricted stock units.",
        "label": "Number Of Installments For Vesting Of Restricted Stock Units",
        "terseLabel": "Number of installments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingDetails",
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentAndGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r970",
      "r1264"
     ]
    },
    "vstm_NumberOfPatents": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "NumberOfPatents",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of patents.",
        "label": "Number of Patents",
        "terseLabel": "Number of patents"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_NumberOfPreferredStockConvertibleIntoCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "NumberOfPreferredStockConvertibleIntoCommonStock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of preferred stock that are convertible into common stock.",
        "label": "Number of Preferred Stock, Convertible into Common Stock",
        "terseLabel": "Number of preferred stock converted into common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r974",
      "r1264"
     ]
    },
    "vstm_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares of entity's common stock the holder to receive when the restricted stock unit vests.",
        "label": "Number Of Shares Common Stock Holder To Receive When Restricted Stock Unit Vests",
        "terseLabel": "Number of shares holder to receive when RSU vests"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_NumberOfVotesPerEachShareOfCommonStock": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "NumberOfVotesPerEachShareOfCommonStock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of votes entitled per each share of common stock.",
        "label": "Number of Votes Per Each Share of Common Stock",
        "terseLabel": "Number of votes entitled for each share of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "OfficeAndLaboratorySpaceInNeedhamMassachusettsMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to a lease agreement for office and laboratory space in Needham, Massachusetts.",
        "label": "Office and Laboratory Space in Needham, Massachusetts",
        "terseLabel": "Office and Laboratory Space in Needham, Massachusetts"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_OfficeAndLaboratorySpaceLeaseArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "OfficeAndLaboratorySpaceLeaseArrangementMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the office and laboratory space lease arrangement.",
        "label": "Office and Laboratory Space in Needham, Massachusetts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r950",
      "r954",
      "r963",
      "r1258",
      "r1265",
      "r1266",
      "r1267",
      "r1268"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r1024"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1366"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity Analysis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liability",
        "verboseLabel": "Lease Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability, short-term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, long-term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "vstm_OperatingLeaseNonCashCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "OperatingLeaseNonCashCost",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, noncash, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Non-Cash Cost",
        "terseLabel": "Non-cash operating lease cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows paid for amounts included in measurement of lease liabilities",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r662"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of use asset",
        "verboseLabel": "Right-of-use asset, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r1024"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r1024"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "NOL carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "vstm_OperatingLossCarryforwardsInclusiveOfOwnershipChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "OperatingLossCarryforwardsInclusiveOfOwnershipChanges",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws, inclusive of ownership changes.",
        "label": "Operating Loss Carryforwards, Inclusive of Ownership Changes",
        "terseLabel": "NOL carryforward inclusive of ownership changes"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_OperatingLossCarryforwardsIndefinitePeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "OperatingLossCarryforwardsIndefinitePeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws, which may be carried forward indefinitely.",
        "label": "Operating Loss Carryforwards, Indefinite Period",
        "terseLabel": "Operating loss carryforwards, indefinite period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating loss carryforwards",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "vstm_OperatingLossCarryforwardsPriorToOwnershipChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "OperatingLossCarryforwardsPriorToOwnershipChanges",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws, generated before ownership changes.",
        "label": "Operating Loss Carryforwards, Prior to Ownership Changes",
        "terseLabel": "NOL carryforward prior to ownership changes"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_OperatingLossCarryforwardsSection382Limitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "OperatingLossCarryforwardsSection382Limitation",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under Section 382.",
        "label": "Operating Loss Carryforwards, Section 382 Limitation",
        "terseLabel": "NOL carryforwards Section 382 limitations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment",
        "terseLabel": "Other commitments",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": [
      "r1244",
      "r1251",
      "r1377"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r10",
      "r100"
     ]
    },
    "us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Additional disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expenses)",
        "terseLabel": "Other expense",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r1007"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1082",
      "r1092",
      "r1125"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1085",
      "r1095",
      "r1128"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1085",
      "r1095",
      "r1128"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Overallotment Option",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ParticipationInNetSalesAggregatePrincipalAmountOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ParticipationInNetSalesAggregatePrincipalAmountOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate principal amount of debt to achieve in order to participate in participation percentage.",
        "label": "Participation In Net Sales, Aggregate Principal Amount of Debt",
        "terseLabel": "Aggregate principal amount of notes"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ParticipationInNetSalesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ParticipationInNetSalesPercentage",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of participation in net sales of the company.",
        "label": "Participation In Net Sales, Percentage",
        "terseLabel": "Participation Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ParticipationInNetSalesSalesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ParticipationInNetSalesSalesAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sales to achieve in order to participate in participation percentage.",
        "label": "Participation In Net Sales, Sales Amount",
        "terseLabel": "Sales amount"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "terseLabel": "Prepayment penalty fee",
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsOfLoanCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfLoanCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Loan Costs",
        "negatedLabel": "Payments for loan amendment",
        "documentation": "The cash outflow for loan origination associated cost which is usually collected through escrow."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Financing Costs",
        "verboseLabel": "Issuance of stock costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "vstm_PaymentsOnInsurancePremiumFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PaymentsOnInsurancePremiumFinancing",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for payments on insurance premium financing.",
        "label": "Payments on insurance premium financing",
        "negatedLabel": "Payments on insurance premium financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of investments",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r167",
      "r272"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Purchases of intangible assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureEmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Employee benefit plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r468",
      "r469",
      "r470",
      "r994"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "vstm_PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of issuance of shares in second tranche, after closing first tranche.",
        "label": "Period of Stock Issuance In Second Tranche After Closing First Tranche",
        "verboseLabel": "Share issue period"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_PfizerIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PfizerIncMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Pfizer Inc.",
        "label": "PFIZER",
        "terseLabel": "Pfizer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1158"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r637",
      "r638",
      "r940",
      "r1358"
     ]
    },
    "vstm_PotentialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PotentialMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payments the Company may make.",
        "label": "Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_PreFundedWarrantElectionToExerciseNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PreFundedWarrantElectionToExerciseNoticePeriod",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of notice to be given for increase/decrease in the maximum amount of shares owned by any holder.",
        "label": "Pre Funded Warrant, Election to Exercise, Notice Period",
        "terseLabel": "Days of notice for increase/decrease to maximum percentage owned"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Pre-Funded Warrant [Member]",
        "terseLabel": "Pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_PreFundedWarrantsWarrantsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PreFundedWarrantsWarrantsOutstanding",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pre-funded warrants outstanding. Warrants represent the right to buy a stock at a specific price.",
        "label": "Pre-Funded Warrants, Warrants Outstanding",
        "terseLabel": "Pre-funded warrants outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_PreferredStockConvertibleAggregateSharesToBeSold": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PreferredStockConvertibleAggregateSharesToBeSold",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate number of convertible preferred shares to be sold.",
        "label": "Preferred Stock, Convertible, Aggregate Shares To Be Sold",
        "terseLabel": "Aggregate shares to be sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Conversion Price",
        "terseLabel": "Conversion price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "terseLabel": "Shares issuable upon conversion",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "vstm_PreferredStockIssuanceExpectedClosingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PreferredStockIssuanceExpectedClosingPeriod",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected closing period of second tranche of issuance of preferred stock.",
        "label": "Preferred Stock Issuance, Expected Closing Period",
        "terseLabel": "Expected closing period of issuance"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_PreferredStockIssuanceThresholdAggregateTradingVolume": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PreferredStockIssuanceThresholdAggregateTradingVolume",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold trading volume of stock for preferred stock issuance.",
        "label": "Preferred Stock Issuance, Threshold Aggregate Trading Volume",
        "terseLabel": "Threshold trading volume"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_PreferredStockIssuanceThresholdSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PreferredStockIssuanceThresholdSharePrice",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of the entity's common stock which would be required to be attained for issuance of preferred stock.",
        "label": "Preferred Stock Issuance, Threshold Share Price",
        "terseLabel": "Threshold share price"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_PreferredStockIssuanceThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PreferredStockIssuanceThresholdTradingDays",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible preferred stock must exceed threshold percentage within a specified consecutive trading period for issuance of preferred stock.",
        "label": "Preferred Stock Issuance, Threshold Trading Days",
        "terseLabel": "Trading days"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_PreferredStockIssueNumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PreferredStockIssueNumberOfTranches",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of tranches in which the preferred shares are sold.",
        "label": "Preferred Stock Issue, Number of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Liquidation Preference Per Share",
        "terseLabel": "Liquidation preference per share",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r63",
      "r1243",
      "r1245",
      "r1297"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1038",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1413",
      "r1416"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r421"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r810"
     ]
    },
    "vstm_PreferredStockSharesDesignated": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PreferredStockSharesDesignated",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of preferred shares designated.",
        "label": "Preferred Stock, Shares Designated",
        "terseLabel": "Preferred stock, shares designated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r421"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r810",
      "r829",
      "r1416",
      "r1417"
     ]
    },
    "vstm_PreferredStockTrancheLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PreferredStockTrancheLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as preferred stock tranche liability, due after one year or the normal operating cycle, if longer.",
        "label": "Preferred stock tranche liability",
        "terseLabel": "Preferred stock tranche liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.0001 par value; 5,000 shares authorized: Series A Convertible Preferred Stock, $0.0001 par value; 0 shares and 1,000 shares designated at December 31, 2025 and December 31, 2024, respectively, 0 shares and 1,000 shares issued and outstanding at December 31, 2025 and at December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r410",
      "r416",
      "r730",
      "r1025"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1179"
     ]
    },
    "vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to prepayments after the first anniversary and on or before the second anniversary date of loan.",
        "label": "If prepaid after the first anniversary and on or before the second anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_PrepaymentAfterSecondAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PrepaymentAfterSecondAnniversaryMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to prepayments after the second anniversary date of loan.",
        "label": "If prepaid after the second anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_PrivatePlacement2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PrivatePlacement2025Member",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to 2025 Private Placement.",
        "label": "Private Placement 2025 [Member]",
        "terseLabel": "Private Placement 2025"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ProceedsFromGrantsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProceedsFromGrantsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for proceeds from grants.",
        "label": "Proceeds from Grants Policy [Policy Text Block]",
        "terseLabel": "Proceeds from Grants"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ProceedsFromInsurancePremiumFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProceedsFromInsurancePremiumFinancing",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received as payments from insurance premium financing during the current period.",
        "label": "Proceeds from Insurance Premium Financing",
        "terseLabel": "Proceeds from insurance premium financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from the issuance of common stock and pre-funded warrants, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "vstm_ProceedsFromIssuanceOfCommonStockNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProceedsFromIssuanceOfCommonStockNet",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cash inflow from the additional capital contribution to the entity, net of issuance costs.",
        "label": "Proceeds From Issuance Of Common Stock, Net",
        "terseLabel": "Net proceeds from issuance of stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Gross proceeds",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Amount drawn",
        "verboseLabel": "Issuance of debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1237"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of Series B Convertible Preferred Stock, net",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Gross proceeds",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from long-term debt",
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from the issuance of warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "vstm_ProceedsFromIssuanceOfWarrantsAndCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProceedsFromIssuanceOfWarrantsAndCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash inflow from  issuance of rights to purchase common shares and additional capital contribution to the entity from issuances.",
        "label": "Proceeds From Issuance Of Warrants And Common Stock",
        "terseLabel": "Proceeds from issuance of warrants and common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquityAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity [Abstract]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of investments",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r1273"
     ]
    },
    "vstm_ProceedsFromPreFundedWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProceedsFromPreFundedWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their pre-funded stock warrants.",
        "label": "Proceeds from Pre-Funded Warrant Exercises",
        "terseLabel": "Issuance of common stock upon exercise of pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromRepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRepaymentsOfNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from (Repayments of) Notes Payable",
        "terseLabel": "Repayment of 2018 Notes",
        "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options and employee stock purchase program",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.verastem.com/role/DisclosureSubsequentEventsDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1236"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product revenue, net",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r949",
      "r954",
      "r987",
      "r988"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails",
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r267",
      "r711",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r941",
      "r949",
      "r952",
      "r954",
      "r987",
      "r988",
      "r1027",
      "r1029",
      "r1030",
      "r1033",
      "r1036",
      "r1164",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1290",
      "r1291",
      "r1382",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412"
     ]
    },
    "vstm_ProductRevenueAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProductRevenueAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information of product revenue reserves and allowances.",
        "label": "Product Revenue Allowances And Reserves Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ProductRevenueAndAllowancesReturnsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProductRevenueAndAllowancesReturnsMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for returns.",
        "label": "Returns"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ProductRevenueReservesAndAllowanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProductRevenueReservesAndAllowanceDisclosureLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Revenue Reserves And Allowance Disclosure [Line Items]",
        "terseLabel": "Product revenue reserves and allowances"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ProductRevenueReservesAndAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProductRevenueReservesAndAllowances",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of product revenue reserves and allowances.",
        "label": "Product Revenue Reserves and Allowances.",
        "periodEndLabel": "Product revenue reserves and allowances at ending",
        "periodStartLabel": "Product revenue reserves and allowances at beginning"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ProductRevenueReservesAndAllowancesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProductRevenueReservesAndAllowancesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in product revenue reserves and allowances for credits and payments made.",
        "label": "Product Revenue Reserves and Allowances, Deductions",
        "negatedLabel": "Credits and payments made"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ProductRevenueReservesAndAllowancesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProductRevenueReservesAndAllowancesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Product revenue reserves and allowances"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ProductRevenueReservesAndAllowancesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProductRevenueReservesAndAllowancesDisclosureTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of product revenue reserves and allowances.",
        "label": "Product Revenue Reserves And Allowances Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ProductRevenueReservesAndAllowancesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProductRevenueReservesAndAllowancesDisclosureTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowances"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for product revenue reserves and allowances.",
        "label": "Product Revenue Reserves And Allowances Disclosure [Text Block]",
        "terseLabel": "Product revenue reserves and allowances"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ProductRevenueReservesAndAllowancesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProductRevenueReservesAndAllowancesDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "Product Revenue Reserves and Allowances [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for government rebates and other incentives.",
        "label": "Government rebates and other incentives"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in product revenue reserves and allowances for provision related to sales in the current year.",
        "label": "Product Revenue Reserves And Allowances Provision Related To Sales In Current Year",
        "terseLabel": "Provision related to sales in the current year"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ProductRevenueReservesAndAllowancesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProductRevenueReservesAndAllowancesTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of product revenue reserves and allowances.",
        "label": "Product Revenue Reserves And Allowances [Table Text Block]",
        "terseLabel": "Schedule of product revenue allowance and reserve categories"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for third-party payer chargebacks, discounts and fees.",
        "label": "Third Party Payer chargebacks, discounts and fees"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureProductRevenueReservesAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for trade discounts and allowances.",
        "label": "Trade discounts and allowances"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails",
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r267",
      "r711",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r941",
      "r949",
      "r952",
      "r954",
      "r987",
      "r988",
      "r1027",
      "r1029",
      "r1030",
      "r1033",
      "r1036",
      "r1164",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1290",
      "r1291",
      "r1382",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r134",
      "r151",
      "r153",
      "r170",
      "r176",
      "r179",
      "r180",
      "r183",
      "r190",
      "r198",
      "r201",
      "r202",
      "r303",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r408",
      "r512",
      "r569",
      "r574",
      "r576",
      "r579",
      "r580",
      "r614",
      "r637",
      "r716",
      "r718",
      "r739",
      "r787",
      "r830",
      "r847",
      "r848",
      "r1005",
      "r1006",
      "r1046",
      "r1191",
      "r1293"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.verastem.com/role/DisclosureLeasesDetails",
      "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r667"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and equipment, net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r122",
      "r123",
      "r124"
     ]
    },
    "vstm_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the estimated useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant and Equipment Estimated Useful Lives [Table Text Block]",
        "terseLabel": "Schedule of estimated useful lives of the assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r139",
      "r737"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and equipment",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r667",
      "r720",
      "r737",
      "r1025"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r122",
      "r123",
      "r735"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property equipment and related accumulated depreciation",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.verastem.com/role/DisclosureLeasesDetails",
      "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r667"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "vstm_PublicMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PublicMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information pertaining to general members of the public.",
        "label": "Public"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to purchased of full $150 million principal amount of Notes.",
        "label": "Purchase Of Full $150 Million Aggregate Principal Amount Of Note [Member]",
        "terseLabel": "Purchased of full $150 million aggregate principal amount of Notes"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_PursuantToLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "PursuantToLicenseAgreementMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to information pursuant to the license agreement.",
        "label": "Pursuant to License Agreement [Member]",
        "terseLabel": "Pursuant to license agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureLeasesDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r363",
      "r364",
      "r365",
      "r366",
      "r452",
      "r471",
      "r503",
      "r504",
      "r505",
      "r511",
      "r523",
      "r620",
      "r680",
      "r689",
      "r706",
      "r765",
      "r767",
      "r775",
      "r801",
      "r802",
      "r857",
      "r876",
      "r880",
      "r881",
      "r910",
      "r926",
      "r927",
      "r928",
      "r929",
      "r935",
      "r936",
      "r975",
      "r986",
      "r995",
      "r1001",
      "r1003",
      "r1004",
      "r1015",
      "r1016",
      "r1020",
      "r1021",
      "r1029",
      "r1039",
      "r1288",
      "r1295",
      "r1350",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureLeasesDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesNotePurchaseAgreementAndOxfordLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r363",
      "r364",
      "r365",
      "r366",
      "r452",
      "r471",
      "r503",
      "r504",
      "r505",
      "r511",
      "r523",
      "r620",
      "r680",
      "r689",
      "r706",
      "r765",
      "r767",
      "r775",
      "r801",
      "r802",
      "r857",
      "r876",
      "r880",
      "r881",
      "r910",
      "r926",
      "r927",
      "r928",
      "r929",
      "r935",
      "r936",
      "r975",
      "r986",
      "r995",
      "r1001",
      "r1003",
      "r1004",
      "r1015",
      "r1016",
      "r1020",
      "r1021",
      "r1029",
      "r1039",
      "r1288",
      "r1295",
      "r1350",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375"
     ]
    },
    "vstm_ReconciliationOfWarrantLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ReconciliationOfWarrantLiabilityTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for reconciliation of warrant liability.",
        "label": "Reconciliation Of Warrant Liability [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1066",
      "r1077",
      "r1087",
      "r1120"
     ]
    },
    "vstm_RedemptionAfterYearThirdAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "RedemptionAfterYearThirdAnniversaryMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to redemption occurs after the third anniversary the Note Purchase Agreement Closing Date.",
        "label": "Redemption After Year Third Anniversary [Member]",
        "terseLabel": "Redemption after third anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_RedemptionPriorToSecondAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "RedemptionPriorToSecondAnniversaryMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to redemption prior to second anniversary of the Note Purchase Agreement Closing Date upon a Change of Control.",
        "label": "Redemption Prior To Second Anniversary [Member]",
        "terseLabel": "Redemption prior to second anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_RedemptionPriorToThirdAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "RedemptionPriorToThirdAnniversaryMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to redemption prior to third anniversary of the Note Purchase Agreement Closing Date upon a Change of Control.",
        "label": "Redemption Prior To Third Anniversary [Member]",
        "terseLabel": "Redemption prior to third anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ReductionInResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ReductionInResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesProceedsFromGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The proceeds recorded as a reduction of research and development expenses.",
        "label": "Reduction in Research and Development Expense",
        "terseLabel": "Reduction of research and development expense"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ReductionOfSharesAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ReductionOfSharesAvailableForIssuance",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction of shares available for issuance.",
        "label": "Reduction of Shares Available For Issuance",
        "terseLabel": "Reduction of shares available for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of long-term debt",
        "terseLabel": "Repayment of long-term, debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r784"
     ]
    },
    "vstm_RepaymentsOfLongTermDebtFinalPaymentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "RepaymentsOfLongTermDebtFinalPaymentFee",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for final payment fee included in debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt, Final Payment Fee",
        "terseLabel": "Final payment fee"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_RepaymentsOfLongTermDebtUnpaidInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "RepaymentsOfLongTermDebtUnpaidInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for unpaid interest included in debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt, Unpaid Interest",
        "terseLabel": "Unpaid interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Short-Term Debt",
        "terseLabel": "Initial payment",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r184",
      "r185",
      "r382",
      "r424",
      "r670",
      "r690",
      "r728",
      "r945",
      "r946",
      "r947",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1340",
      "r1341",
      "r1342",
      "r1343"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement",
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r938",
      "r950",
      "r951",
      "r969",
      "r1376"
     ]
    },
    "vstm_ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenditure incurred towards research and development expense excluding non-cash stock-based compensation and severance expense.",
        "label": "Research And Development Expense, Excluding Non-Cash Stock-Based Compensation And Severance Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ResearchDevelopingAndCommercializationDrugsSegmentMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Research, developing and commercialization drugs segment.",
        "label": "Research, Developing And Commercialization Drugs Segment [Member]",
        "terseLabel": "Research, developing and commercialization drugs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1078",
      "r1088",
      "r1121"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1079",
      "r1089",
      "r1122"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r1075",
      "r1086",
      "r1096",
      "r1129"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents, Noncurrent.",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r116",
      "r175"
     ]
    },
    "vstm_RestrictedCashAndCashEquivalentsNoncurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrentMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash and Cash Equivalents, Noncurrent [Member]",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent [Member]",
        "terseLabel": "Non-current restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashEquivalentsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashEquivalentsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash Equivalent, Current",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash equivalent restricted as to withdrawal or usage, classified as current. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r930",
      "r931",
      "r1174",
      "r1240"
     ]
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "Issuance of common stock resulting from vesting of restricted stock units (in shares)",
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": [
      "r1298",
      "r1328"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock units",
        "verboseLabel": "Outstanding restricted stock units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325"
     ]
    },
    "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings",
        "terseLabel": "Issuance of common stock resulting from vesting of restricted stock units",
        "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": [
      "r1298",
      "r1328"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r95",
      "r733",
      "r772",
      "r774",
      "r785",
      "r811",
      "r1025"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r187",
      "r188",
      "r189",
      "r191",
      "r198",
      "r200",
      "r202",
      "r304",
      "r305",
      "r340",
      "r407",
      "r512",
      "r558",
      "r559",
      "r566",
      "r567",
      "r568",
      "r570",
      "r573",
      "r574",
      "r600",
      "r602",
      "r603",
      "r605",
      "r612",
      "r652",
      "r654",
      "r769",
      "r771",
      "r788",
      "r1416"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails",
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue recognized",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r218",
      "r234",
      "r235",
      "r257",
      "r263",
      "r267",
      "r269",
      "r270",
      "r448",
      "r449",
      "r450",
      "r711",
      "r950",
      "r954"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r939"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "totalLabel": "Total revenue",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r159",
      "r176",
      "r179",
      "r180",
      "r218",
      "r234",
      "r235",
      "r257",
      "r263",
      "r267",
      "r269",
      "r270",
      "r303",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r637",
      "r716",
      "r718",
      "r969",
      "r1007",
      "r1034",
      "r1035",
      "r1293"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLeasesBalanceSheetAndOtherInformationDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use asset obtained in exchange for operating lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r1024"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Gross proceeds",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "vstm_SaleOfStockOptionToPurchaseMaximumNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "SaleOfStockOptionToPurchaseMaximumNumberOfShares",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of share that can be purchased pursuant to the option under the stock transaction.",
        "label": "Sale Of Stock, Option To Purchase, Maximum Number Of Shares",
        "terseLabel": "Option to purchase, maximum number of shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r1260",
      "r1261"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r203",
      "r472",
      "r1162"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities were excluded from the calculation of diluted net loss per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of cash, cash equivalents and restricted cash",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of Income tax expense",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1336"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of carrying value of the Term Loan",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of principal components of deferred tax assets and liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1333"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of effective income tax rate to the statutory federal income tax rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r1000",
      "r1331"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense as reflected in the Company's consolidated statements of operations and comprehensive loss",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r942",
      "r1280"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureInventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r70",
      "r71",
      "r72"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInvestmentsLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Investments",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of future principal payments under the Notes Purchase Agreement",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.verastem.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r667"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Summary of segment net loss including significant segment expenses",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r476",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r511"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock units",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity and related information",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r96"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used to estimate fair value of each employee stock purchase plan on grant date",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r1329"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used to estimate fair value of each stock option on grant date",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "vstm_ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the shares of common stock reserved for the potential conversion of outstanding preferred stock and the exercise of stock options.",
        "label": "Schedule of Shares of Common Stock Reserved for Potential Conversion [Table Text Block]",
        "terseLabel": "Schedule of shares of common stock reserved for the issuance of common stock for vested restricted stock units and the exercise of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r92",
      "r94",
      "r95",
      "r144",
      "r145",
      "r146",
      "r220",
      "r421",
      "r422",
      "r424",
      "r426",
      "r429",
      "r435",
      "r437",
      "r599",
      "r781",
      "r782",
      "r783",
      "r784",
      "r986",
      "r1161",
      "r1243",
      "r1245"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of future amortization expense for finite-lived intangible assets",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r942",
      "r1282"
     ]
    },
    "vstm_SecondSaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "SecondSaleMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to second sale, at the option of the Company, at any time prior to December 31, 2025, upon the FDA's approval sufficient for the promotion and sale of avutometinib and defactinib for the treatment of LGSOC and subject to certain other customary conditions precedent.",
        "label": "Second Sale [Member]",
        "terseLabel": "Second sale, any time prior to December 31, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_SecondTrancheRightLiabilityNonCurrentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "SecondTrancheRightLiabilityNonCurrentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of fair value of non current portion of second tranche right classified as liability as at the end of the reporting period.",
        "label": "Second Tranche Right Liability, Non Current, Fair Value",
        "terseLabel": "Fair value of the Second Tranche Right"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_SecuraBioInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "SecuraBioInc.Member",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOffBalanceSheetRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information pertaining to Secura Bio, Inc.",
        "label": "Secura"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuredLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Long-term Debt, Noncurrent",
        "terseLabel": "Long-term debt",
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Deposit",
        "terseLabel": "Security deposit",
        "verboseLabel": "Restricted cash",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r1175"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "vstm_SegmentAndGeographicInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "SegmentAndGeographicInformationAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentAndGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment and Geographic Information [Abstract]",
        "terseLabel": "Segment and geographic information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r113",
      "r218",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r270",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r338",
      "r359",
      "r360",
      "r571",
      "r572",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r966",
      "r969",
      "r970",
      "r977",
      "r1031",
      "r1382",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r218",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r246",
      "r248",
      "r249",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r270",
      "r964",
      "r967",
      "r968",
      "r969",
      "r971",
      "r973",
      "r974"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other segment items",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r248",
      "r249",
      "r263",
      "r969"
     ]
    },
    "us-gaap_SegmentReportingOtherItemCompositionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemCompositionDescription",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Composition, Description",
        "terseLabel": "Segment reporting, other segment items",
        "documentation": "Description of composition of other segment item not separately disclosed."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r248",
      "r249",
      "r263",
      "r969"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and geographic information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r266",
      "r269",
      "r965",
      "r966",
      "r972"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r949",
      "r950",
      "r951",
      "r954",
      "r1231"
     ]
    },
    "vstm_SellingGeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "SellingGeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and general and administrative expense.",
        "label": "Selling, General And Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1002"
     ]
    },
    "vstm_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Series B convertible preferred stock.",
        "label": "Series B Convertible Preferred Stock",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_SeriesaConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "SeriesaConvertiblePreferredStockMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Series A convertible preferred stock.",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the annual increase in the maximum number of shares (or other type of equity) that was initially approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan.",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Annual Increase in Number of Shares Authorized",
        "terseLabel": "Annual increase in number of shares reserved"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited/cancelled (in shares)",
        "terseLabel": "Shares forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited/cancelled (in dollars per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares granted",
        "verboseLabel": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r491"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r491"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "verboseLabel": "Weighted-average grant date fair value per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)",
        "verboseLabel": "Shares vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Assumptions used to estimate fair value of each stock-based award on the grant date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield (as a percent)",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility (as a percent)",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (as a percent)",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock-based compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r476",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r511"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional number of shares reserved",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1328"
     ]
    },
    "vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of vesting periods which employees have right to exercise an award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Award Vesting Periods",
        "terseLabel": "Number of vesting periods"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Number of shares reserved",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Vested at the end of the period (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value of options exercised (in dollars)",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)",
        "verboseLabel": "Shares expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited/cancelled (in shares)",
        "verboseLabel": "Shares forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Shares granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Outstanding at the end of the period (in dollars)",
        "periodStartLabel": "Outstanding at the beginning of the period (in dollars)",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r483"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r483"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-average exercise price per share"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted-average remaining contractual term (years)"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of the number of shares of outstanding stock relating to determining the annual increase in the maximum number of shares available for issuance under the plan.",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Percentage of Outstanding Common Stock for Computation of Annual Increase in Number of Shares Reserved",
        "terseLabel": "Percentage of outstanding shares of common stock used to compute annual increase in number of shares reserved"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised/Released (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited/cancelled (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "vstm_ShareBasedCompensationAwardTrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ShareBasedCompensationAwardTrancheFourMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Within Two Years of Vesting Commencement",
        "terseLabel": "Within two years for vesting commencement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Year From Vesting",
        "terseLabel": "One year from vesting",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Year Anniversary",
        "terseLabel": "One year anniversary",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Successive Three-Month Periods After One Year From Vesting",
        "terseLabel": "Successive three-month periods after one year from vesting",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r481",
      "r500",
      "r501",
      "r502",
      "r503",
      "r506",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ]
    },
    "vstm_ShareBasedPaymentArrangementTrancheFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ShareBasedPaymentArrangementTrancheFiveMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fifth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Five [Member]",
        "terseLabel": "First three anniversaries of grant date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Sale price of the Common Stock",
        "verboseLabel": "Selling price per share (in dollars per share)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1300"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration term",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Vested at the end of the period (in dollars)",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Vested at the end of the period",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding at the end of the period",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of vested stock options",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "verboseLabel": "Vested at the end of the period (in shares)",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r1328"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percent of common stock at market price to be purchased",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": [
      "r1328"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercise price of new options",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "vstm_SharesIssuedFromPreFundedWarrantExercises": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "SharesIssuedFromPreFundedWarrantExercises",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The shares issued from holders exercising their pre-funded stock warrants.",
        "label": "Shares Issued From Pre-Funded Warrant Exercises",
        "terseLabel": "Issuance of common stock upon exercise of pre-funded warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share price (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "terseLabel": "Notes Payable",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails",
      "http://www.verastem.com/role/DisclosureIncomeTaxesTaxCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSegmentReportingSegmentNetLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r113",
      "r133",
      "r218",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r270",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r338",
      "r342",
      "r359",
      "r360",
      "r571",
      "r572",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r966",
      "r969",
      "r970",
      "r977",
      "r1031",
      "r1382",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r144",
      "r145",
      "r146",
      "r176",
      "r180",
      "r207",
      "r208",
      "r210",
      "r212",
      "r220",
      "r221",
      "r303",
      "r369",
      "r371",
      "r372",
      "r373",
      "r376",
      "r377",
      "r409",
      "r410",
      "r412",
      "r413",
      "r415",
      "r418",
      "r421",
      "r422",
      "r426",
      "r429",
      "r437",
      "r637",
      "r781",
      "r782",
      "r783",
      "r784",
      "r788",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r810",
      "r831",
      "r849",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r1161",
      "r1245",
      "r1247",
      "r1256"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r64",
      "r67",
      "r68",
      "r128",
      "r129",
      "r130",
      "r156",
      "r157",
      "r158",
      "r187",
      "r188",
      "r189",
      "r191",
      "r198",
      "r200",
      "r202",
      "r219",
      "r304",
      "r305",
      "r340",
      "r407",
      "r439",
      "r512",
      "r558",
      "r559",
      "r566",
      "r567",
      "r568",
      "r570",
      "r573",
      "r574",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r612",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r652",
      "r654",
      "r669",
      "r741",
      "r769",
      "r770",
      "r771",
      "r788",
      "r849"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r219",
      "r409",
      "r410",
      "r412",
      "r415",
      "r654",
      "r711",
      "r779",
      "r789",
      "r800",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r810",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r819",
      "r820",
      "r821",
      "r822",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r832",
      "r833",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r849",
      "r952",
      "r954",
      "r1040",
      "r1414"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails",
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r203",
      "r472",
      "r1162",
      "r1163"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r219",
      "r271",
      "r409",
      "r410",
      "r412",
      "r415",
      "r654",
      "r711",
      "r779",
      "r789",
      "r800",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r810",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r819",
      "r820",
      "r821",
      "r822",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r832",
      "r833",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r849",
      "r952",
      "r954",
      "r1040",
      "r1414"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r1070",
      "r1081",
      "r1091",
      "r1124"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325"
     ]
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity compensation plans",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r1257"
     ]
    },
    "vstm_StockIssuedDuringPeriodSharesAtMarketTransactions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesAtMarketTransactions",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of shares issued during the period from at the market transactions.",
        "label": "Stock Issued During Period Shares at the Market Transactions",
        "terseLabel": "Issuance of common stock resulting from at-the-market transactions (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion of preferred stock (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r41",
      "r64",
      "r67",
      "r95",
      "r395"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan (in shares)",
        "verboseLabel": "Issuance of common stock under ESPP",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r63",
      "r64",
      "r95"
     ]
    },
    "vstm_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureSubsequentEventsDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period related to exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Exercise Of Warrants",
        "terseLabel": "Issuance of common stock upon exercise of warrants (in shares)",
        "verboseLabel": "Exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsPfizerIncDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Convertible Preferred Stock, net of issuance costs and preferred stock tranche liability",
        "verboseLabel": "Shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r63",
      "r64",
      "r95",
      "r781",
      "r849",
      "r921"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock resulting from vesting of restricted stock units (in shares)",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r63",
      "r64",
      "r95"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised/Released (in shares)",
        "terseLabel": "Issuance of common stock resulting from exercise of stock options (in shares)",
        "verboseLabel": "Shares exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r63",
      "r64",
      "r95",
      "r487"
     ]
    },
    "vstm_StockIssuedDuringPeriodSharesStockPurchaseAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesStockPurchaseAgreement",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) issued during the period from a stock purchase agreement.",
        "label": "Stock Issued During Period, Shares, Stock Purchase Agreement",
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_StockIssuedDuringPeriodValueAtMarketTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "StockIssuedDuringPeriodValueAtMarketTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during the period from at the market transactions.",
        "label": "Stock Issued During Period Value at the Market Transactions",
        "terseLabel": "Issuance of common stock resulting from at-the-market transactions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion of preferred stock",
        "verboseLabel": "Conversion of Series B Convertible Preferred Stock to common stock",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r64",
      "r67",
      "r68",
      "r95"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r63",
      "r64",
      "r95"
     ]
    },
    "vstm_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate change in value during the period related to the exercise of warrants.",
        "label": "Stock Issued During Period, Value, Exercise of Warrants",
        "negatedLabel": "Issuance of common stock upon exercise of warrants",
        "terseLabel": "Value of warrants on issuance date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Convertible Preferred Stock, net of issuance costs and preferred stock tranche liability",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r63",
      "r64",
      "r95",
      "r788",
      "r849",
      "r921",
      "r1046"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock resulting from vesting of restricted stock units",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r95"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock resulting from exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r64",
      "r67",
      "r68",
      "r95"
     ]
    },
    "vstm_StockIssuedDuringPeriodValueStockPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "StockIssuedDuringPeriodValueStockPurchaseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the stock purchase agreement.",
        "label": "Stock Issued During Period, Value, Stock Purchase Agreement",
        "terseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "StockIssuedPreFundedWarrantsNetOfIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of an underwriting agreement.",
        "label": "Stock Issued, Pre Funded Warrants, Net of Issuance Costs",
        "terseLabel": "Issuance of common stock, and pre-funded warrants, net of issuance cost"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to an underwriting agreement.",
        "label": "Stock Issued, Pre Funded Warrants, Net of Issuance Costs in Shares",
        "terseLabel": "Issuance of common stock, and pre-funded warrants, net of issuance cost (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_StockOptionExchangeProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "StockOptionExchangeProgramMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationOptionExchangeProgramDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the stock option exchange program.",
        "label": "Option Exchange Program"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_StockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "StockPurchaseAgreementMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Stock Purchase Agreement.",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_StockPurchaseRightMaximumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "StockPurchaseRightMaximumAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount under the stock purchase agreement purchased by investors.",
        "label": "Stock Purchase Right, Maximum Amount",
        "terseLabel": "Stock purchase, maximum amount"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_StockPurchaseRightPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "StockPurchaseRightPeriod",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period up to which investors can exercise the stock purchase right.",
        "label": "Stock Purchase Right, Period",
        "terseLabel": "Stock purchase period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity (deficit)",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r67",
      "r68",
      "r85",
      "r812",
      "r829",
      "r850",
      "r851",
      "r1025",
      "r1047",
      "r1243",
      "r1247",
      "r1248",
      "r1278",
      "r1360",
      "r1416"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Capital stock",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r420",
      "r422",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r436",
      "r439",
      "r599",
      "r611",
      "r852",
      "r853",
      "r925"
     ]
    },
    "vstm_StockholdersEquityReverseStockSplitConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "StockholdersEquityReverseStockSplitConversionRatio",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNatureOfBusinessReverseStockSplitDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of the reverse stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity, Reverse Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent events",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r672"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.verastem.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent events",
        "terseLabel": "Subsequent events",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r672"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r672"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.verastem.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r672"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.verastem.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r672"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent events."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r673"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockAtMarketEquityOfferingProgramDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockConvertiblePreferredStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockNovember2025PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockStockPurchaseAgreementDetails",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Common stock",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierFinanceProgramObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureVendorFinancingArrangementRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier Finance Program, Obligation",
        "periodEndLabel": "Ending balance",
        "terseLabel": "Vendor financing arrangement liability",
        "documentation": "Amount of obligation for supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r979"
     ]
    },
    "us-gaap_SupplierFinanceProgramObligationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramObligationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier Finance Program, Obligation, Current",
        "terseLabel": "Vendor financing arrangement, short-term",
        "documentation": "Amount of obligation for supplier finance program, classified as current."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r357"
     ]
    },
    "us-gaap_SupplierFinanceProgramObligationNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramObligationNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier Finance Program, Obligation, Noncurrent",
        "terseLabel": "Vendor financing arrangement, long-term",
        "documentation": "Amount of obligation for supplier finance program, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r357"
     ]
    },
    "us-gaap_SupplierFinanceProgramObligationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramObligationRollForward",
     "presentation": [
      "http://www.verastem.com/role/DisclosureVendorFinancingArrangementRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier Finance Program, Obligation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.verastem.com/role/DisclosureVendorFinancingArrangementRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes obligation for supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_SupplierFinanceProgramTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramTextBlock",
     "presentation": [
      "http://www.verastem.com/role/DisclosureVendorFinancingArrangement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier Finance Program [Text Block]",
        "terseLabel": "Vendor Financing Arrangement",
        "documentation": "The entire disclosure for supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r352",
      "r978"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesTaxCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credits",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesTaxCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesTaxCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxJurisdictionOfDomicileExtensibleEnumeration",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Jurisdiction of Domicile [Extensible Enumeration]",
        "documentation": "Indicates tax jurisdiction of domicile."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r1000"
     ]
    },
    "vstm_TermBLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "TermBLoanMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Term B.",
        "label": "Term B Loan"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_TermCLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "TermCLoanMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Term C.",
        "label": "Term C Loan"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_TermDLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "TermDLoanMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Term D.",
        "label": "Term D Loan"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_TermELoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "TermELoanMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Term E.",
        "label": "Term E Loan"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_TermLoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "TermLoanFacilityMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to term loan facility.",
        "label": "Term loan"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold percentage held to the total shares outstanding to exercise warrants or pre-funded warrants",
        "label": "Threshold Percentage Held To The Shares Outstanding To Exercise Warrants Or Pre-funded Warrants",
        "terseLabel": "Threshold percentage held to the shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "vstm_ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage held to the total shares outstanding to exercise warrants or pre-funded warrants at election of the holder.",
        "label": "Threshold Percentage Held To The Shares Outstanding To Exercise Warrants Or Pre-funded Warrants At Election Of The Holder",
        "terseLabel": "Threshold percentage held to the shares outstanding at election of the holder"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and Other Accounts Receivable, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable, Net",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1269",
      "r1270",
      "r1271"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.verastem.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLongTermDebtNotePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to third sale, at the option of the Company, at any time prior to December 31, 2026, provided that trailing six-month worldwide net sales of avutometinib and defactinib are at least $55.0 million and subject to certain other customary conditions precedent.",
        "label": "Trailing 6 Months Worldwide Net Sales of Avutometinib And Defactinib, At Least $55 Million [Member]",
        "terseLabel": "Third sale, any time prior to December 31, 2026 (trailing six-month worldwide net sales of avutometinib and defactinib are at least $55.0 million)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r403",
      "r435",
      "r599",
      "r610",
      "r630",
      "r636",
      "r639",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r723",
      "r742",
      "r1011",
      "r1013",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1026",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1346",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1355",
      "r1356"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1140"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1142"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1140"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsGenfleetTherapeuticsDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsLicenseAgreementDetails",
      "http://www.verastem.com/role/DisclosureLicenseCollaborationAndCommercialAgreementsSecuraDetails",
      "http://www.verastem.com/role/DisclosureNatureOfBusinessReverseStockSplitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "vstm_UnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "UnderwritingAgreementMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for underwriting agreement.",
        "label": "Underwriting Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r544",
      "r999"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest and penalties accrued related to unrecognized tax benefits",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r999"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r222",
      "r226",
      "r227",
      "r228",
      "r716",
      "r718",
      "r961"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.verastem.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Change in Amount",
        "terseLabel": "Increase (decrease) in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "vstm_VendorFinancingAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "VendorFinancingAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Vendor Financing Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.verastem.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.verastem.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "vstm_WarrantAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "WarrantAbstract",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Warrant Abstract",
        "terseLabel": "Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants",
        "verboseLabel": "Warrant liability",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1038",
      "r1041",
      "r1042",
      "r1043",
      "r1044"
     ]
    },
    "vstm_WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.verastem.com/20251231",
     "localname": "WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod",
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockApril2025PrivatePlacementDetails",
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of notice to be given for increase/decrease in the maximum percentage of shares owned by any holder to exercise warrants or pre-funded warrants.",
        "label": "Warrant Or Pre-Funded Warrant Election To Exercise Notice Period",
        "verboseLabel": "Period of notice for ownership limitation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.verastem.com/role/DisclosureCapitalStockJuly2024AndJune2023PublicOfferingDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesItemsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfWarrantLiabilityDetails",
      "http://www.verastem.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Warrant liability",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1349",
      "r1350",
      "r1351"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.verastem.com/role/DisclosureSignificantAccountingPoliciesInputsUsedToValueWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrant liability",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1349",
      "r1350",
      "r1351"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding used in computing net loss per share - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r212"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.verastem.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding used in computing net loss per share - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r212"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-50/tableOfContent"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-4"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477128/405-50-55-3"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477128/405-50-55-5"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "SubTopic": "310",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718-50/tableOfContent"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>130
<FILENAME>0001104659-26-023444-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-023444-xbrl.zip
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M5A0Y9MSN?DJWO*&7MH3^%1M6Z7(!)ZR\#OE*"SL?:U;&] _](M(T3K]0-E_
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M$CR+.EFNQ%L!+)JNLN/M?1E4->&//^+^_3%V1V0OZ)+\^']02P,$%     @
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M@\U@5/&([;!;]3&P_0?@!G/Z;X!YPDM58E6J]YS7RA"5_58-,4E+(JK.9XR
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M[ROLFW]D>7L+Y"+_F=WA[]$IT*)FE6U UK"!6*N(A>4S]RK+ EB9&,M@;$.
M!?P]Q/-.O7_2JRC;6/+(WMN0@I=6]GC8(I<E QQS(W@B4&\DOI34'ZO;(T1#
MX* <+!JBD8OCQU[%T4SD*LI2H[U5T>E]6ZTO'H4M]9/5+?4 _&PYB]>(E&I\
M9/@I-MH:(YQLOD8CG(7"_M2BPO[4:-75X5Y#)?ZIYU5J@&)3Q?X)R$&Y<-[7
MOT J5BFW9<_**MEN Q^1&S]D28-Y>.;L*?!7J4%,?G_4["V\(QCT;^>&*3/
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M+2(=-E03<470]%^>6@P^)R-7!#:,0^]%$ODABJ('M%(%.DK[J ]<HEXVL,]
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M$1ELTD-:OZ3^CV;V+DBTO?.=)U:$PT_?CD[] FL<4"PCID/CG<+XJ-\=P#E
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M_BT?MRN;C^@(?((=SZ C:]CO+L/>CS]69Y!8<W@-K9MQU 0O[BL\%*QN\66
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MP/=<C^^:^,&Q@N<OQ^RNT);97D7&LM-6 'S!-1?F*29P6%%6]P7QD7N4U-T
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M1BJ/&B^[93#I_C8- ARG+V.D0$BS227M;1\H=:6N5 Q3C Z$XZ)6I+&@K;4
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MK\,F?X*T_3MD+?2.6(2>EFF_FZE@. BXLMY.,4\9\E9%A[='+!Z^<MT1FGT
MN".Z7!!%@5!0PBIG\W@!B=XNM>A?:XN,SUUJ[1+*$-@C5;8G;6!H28Y<<2@,
M0KD)!"B5$"I$5-!F(9*J.J,1 "@^KE1I;&%\A( S[_$[;LB\P@@ W&XM,*^
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M) ]6XIY9K2,_3%BP)CU0I110U@YJ,"  #T;7&JX)><!)S0WR6':];I: LA<
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M&(BJ%O>*&'9ALUHNZ3F7':J<)TQ8M]W#UG%1FK,^98615^GNS#UHUAH!P,7
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M,(8&C*$!IU0X*I9/8YS &">@=0K<F]K9/E#<%]2>!]V>9Q UH(OJ6%45:.@
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M6F=M=<3!Y+$T1;3C(%;%5C@GV$O<>$8>$'FFF C.+OQFKR@5ED\ 6^QBV.2
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M94YP6I^"!:SD\.T!%BE&>1<(]DH#-2E'IH95YB_O,IKE9HS__/\!4$L#!!0
M   ( ," 9%R6=:H(U]D  (*Y#0 5    =G-T;2TR,#(U,3(S,5]L86(N>&UL
MY+UK<^PVDBCX_4;L?\#VW9BV(TJV3[M[9MKSN*&CAT<Q.I)6DMMWUG&C R)1
M51RSR#+(TI'ZUR\2X+.*($'P@>3I"'<?207DJS(3"2"1^:__ZVT7DE?&DR".
M_NUW'[[Y[G>$15[L!]'FWWYW2-=G__R[__7O_]?_^-?_^^SL?W]\O"5^[!UV
M+$J)QQE-F4\^!^F6/,?[/8W()\9Y$(;D(P_\#2/DPX=O_O#-=]_\B9R=_;L$
M\9$F8DH<$0GK#]]\R#^XR*#%T0_D^V__^.T?OOO#/Y)__N%/__C#'_Y('C[E
MPSX)PM9!Q[@PB'[] ?[O16 C@K\H^>$M"?[M=]LTW?_P[;>?/W_^YO/WW\1\
M(Z9_]^';__WI]LG;LAT]"Z(DI9''?I?- B"U:6\O/,PG?O]MCB,?_G8R/D/S
MX<]__O.W\E,Q- E^2"2ZV]BCJ11[)P:B'0&_G>7#SN!/9Q_^</;]AV_>$K^@
M2XSQTP)-%<"?OE4?_N[?_P<A_\KCD#VR-9&D_I"^[]F__2X)=OL06)1_VW*V
M;J8WY/Q;F/]MQ#;P50(M?P9:/OPCT/(_LS_?TA<6_H[ R)\>;[2L_[D&*YLD
MN3'Z/KZ=BYUG83G,BJ?J3(R,Q2D-[1BKS.S+F#)=F'LK?JKQQ]Y2%OG,SSD$
ME"V0)472X@ P@(Z]&KP0K"_FIP)+<A-)F/?-)G[]UF<!^)D_P0]G\(.4D_CE
MKQ>Q\)SG+TG*J9?FD"3Y__:[IL_[20.(!ECGO$XYY5Z.2_S8(8=LQ+=>+/S:
M/CT+LR]&3E_S>-=,J4(7-WSXU_"E_Q>;LU+C@[,D/G"/]?I&J^3K)%V0*$;
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MS\!KZX9TCY:N5V!P:]@3LRVA%GOY=]<F;+R?6.!&PFP'L:2MPP31Y6Q[A:X
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M(&5/C+\&'GN0,GUD7KR))!3YR$>;6S Y6MS^;BZYUY-NIL6)UQO/QKFU<X<
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M<9-?<NS_Q\DIK0,IE6*@!7 GA[ \7@?I;9QHCURK W";_RDOM>/4XE.\YMI
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M+'$ ^W>*_0S/_/YO>M:+4R1/X_8D-A<[V)O(XW">=<G4OY7,A>R!?4>J5"\
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M28X2C3MP)!K.O'BCRH6X<!?/G/HL+^23O1=+'IG'@E>H6]*Z2S"=B]LY]))
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M\5$(QA??!RRNTD=5VC4E']_+,0_J'.[\,^6^_%HZ3Q&&P\>Y\$TFR>9SLX'
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M<ZTC2+5/D-D3Q;*<ZQB,3AM^EE1E?E;2E9V/+BT8=2GBYHM@+*ZRN@859R)
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M( ').LOA.\E48L+3P-4JVT,BE48DIZ-PFZV&JUIZ47T(7H/4$6I?9%+!(QE
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MM$]>B(8;R4 3M+3,7("6F]$_/'Y?D0(\LM E.15 [R"F#<9"3*"/1#J]O0[
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M1KL=5K X]V1L RW36/ *BTCK$YB6X;CUN8O/6K5<S5B\^MM)L75@S*G/",W
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M[B'WD1NWY5ABPC_\(WXW!-_0\^=X%!&6L+XDIW,D(7M?DP'Z4ES,,3L./(M
MOP#/,I:@A*7_TT(<BL"LVX;90_OBG$I52@/="H#ZHAQ+C2$7K@4(6(IS&458
MPN[_>1GNY5H(?33A9<"^-.=2E=$PWP*0OB374N/'@6<!_ MQ+*.(2AC\GQ?B
M5\38\62G@'UQ?J4BHX%^18S]HOQ*E1\7?D7,68I?&4-4?_CN^^_P^Y7SM9#?
MJ,[E&.*7Y&$:I67O9FK@OA1?T\S4O Z' @V+<COC2NUYRSB30G#A@6[AK=PV
M#OV;';Q7EJTJF^OIF<W [4$,N*UZB);A>#V "='VR1T9;.AK6@!WH;?:YNQM
M2:Z=DW!KKQG/505NGX%7APWI'O#L58)?$8E )GH6*%SFML[$MV28E0QO&AB>
M*36K2!.[A#)\4!I/K+/BYY#!#_#$M[+^:L6C3389#3QNSS"V'.OI6^/ QNMM
M1N?0/JVKS)JL4@+O[S-:U,O\6@!]Y,U6=7?F*/,4C4Q/\U']"CWC54$1#/,#
M\R_$R,"CX3,/:)CM%Y+LI?:1J'I,P^E]^O)=U#DQF(.\NDD?#JSK4%#.98^R
M5QH>X%$&E#>!,CXO-)2E3Y,M8RGQA5+#)_%+&&PDP;)L+1#AB^$\/FRVXE^:
MC<RJ6LC*M++N2<8"28&'Y!O($)65@X2RAV*_7BL<!#5ML_Z)\.<PH"]!&*0!
M2\A7OJ 1:MIFM6NAQA 4L,W^!,,C*(,;$K!T0:=@S'OWH#[NFH1QM&'\ZWE+
MK<SQ'68XCJ2<MXI/5KEDYZ]:A8#[T9WOIR!D22JT[R$KV]+M>%NFX'>Z7?P>
M.US=^&4XVT[J<3O:74Y^453H[\_73O85YIZF0$!R#$6='&<N=G*F3S6+_ /=
M[?^%\/B=AJ Q+O;V5[M]&+\SEI4\O"WUM]DK]YF'TS7WYKRZS>Z<A'?_;$ZZ
MK:;G&,[RRI85'&X,?#[>BR JWD'85'8QSF7QPB*V#JR.X3OVLO%NQS@TQ,AV
MZ1=Q8A)3=<W#:;V].3_9SK9-6D:(9<8"[CC+.^9!_"7Y>PRVIOTR<[=T@H5(
M-,ZCKGFXURC;!*XX2CGUTD\T.JS%OP<NU*S'\:+9]"4X9G,YG/KG[KE+<=,]
M.,'NK14KT.BJY.7OT5G/\)66/CL3>@T;N2I.)=T[[QFET:R"TYU20OUJX?:V
MYY%_R5Y9&,N++G-G;CH?OS?O)8EC=VXT>1G^O!\KN!TZSWB1'_@E-W]_+GV>
M;S7W8CDVV3FE@@^15Y]7(*HAM4X=IW/O8NU*#B&HX34SC,T;Q^-WWZV<-D3?
MIX.7X9[;2<?MCKV"=K(6Q/_]>>%IOKQ*))V+%\ [=['3<GND3(XR1H&4!QZO
M60+-KFBH=[/&DW#ZVGX\'^5LMLS >Y-D2/=0/:["EW;K]@YI)J[W5:Y=V>]-
M),3!DO1!K5'M=JL=C-M>VWFL=PAH&HG7/COH'5!Z6H(E&5RWYC@1D[D9!AEX
M%]9W#WNBC!#CA(S.2;BMT8SGJE6VS\!KG89TVRJP!$]R-4:3@3$QU[7C!!<V
M>\E>TILH2;G<J[;U_VL>B=LZ6[BKFF3#,+QVV$:LK1H^>5OF'T)Y%' KMM-G
MPBYV!#"1$E7BMA>@%^_84TI3^2KX%I# 0Y^W0-\ JFT&;KTUX+8>Z&F'X]5C
M$Z+M0SZ 30K@)(=.?@'XF#3X,H8BX?UD5,Q9I!;7.3;08S5A<9I\1/8$NJPP
M.-'F)Q8*<)L?6<0X#>&]I;^#[F0IG,Z^LOS:I;761U\8N+7=2B)5[>\% *\U
MV+%A';DH;"N2X5,OF&L8BSM*\HM":F,PFENYFTAL!VCX1$/6J.K:03AUN9VG
MXM+M9 3RFS8]O;9J]PBOO!,9% ?1&JZFI$>&5^99RX\T)H%"2Q*!=][;J?$9
MSB 2 *FSHQDNHJ9C#+ZD\?S",Z<!^*5_5"T:?HYYZ'\.?';'4J ]N5^?OQY2
ML:ZG0DE>9,H"Y(;)7U*H@Y3^Z4^? N':XDCO5Z9 @M@O32;3PJ^-C@&Y7YR.
MWTG]:KH-N"\-=D6HRC&(]]74@HMXMZ?1N_Q4_$O20 30>Q[$'*9?,D\22[[_
ML"+0^V0%EU>O@F]?I3JDF5A($KR=[4 TY',N&A*Q5**6"16T(IXL!R@7T/_?
MWKLVR8U;:<+?WU^!V)A=JR-2MML>3XQG-S:B5*KJ*:^DK*DJM6-6\7Y@D<A*
M3C/);))94O:O7QP O&42O.)RF/(76UT)G!N!YQP !P?$2RGPC\!,Y)_^\I??
M_Q&N4D;%_:KL\/Q?/$,B(;[03N84^8>,T?32(QR(!Z'(R8":(C2 1#>K?@3?
M "DD(O]"A$RD%(HPJ;A_XI^F+IC,6BM$6Y$KMHHJO@N1 CKT:@C-7)]B_3.(
MO#$]9Z:\DZ;PS;=AFN7_^A\'+X6O<IM$4?*52?XIR>D]^ZY;9H"KEY3RQ?9U
ME&3LM_=L[:WVPW,)(O:Y6FQ5^M=9U)#[4CVZ:?";X #5OG,#8I)_);]*0<FF
MD)1W!'%)(2\I!2:^D)AG =IU06[M>BO-5? GI0#DJ<-<4A "DCCT*\AL-VRH
MU6VG&?1__.,?I9NL/.N-YV_O8C\Z!#Q'*CCX>0_2CZ6"'=XG6:6)Z:-(+ '(
MIRED";W_B4E7KB4:L15E(D+^-I<15C4@I .\MFN^V\HJ12Q?+076&P*<2<&:
M2-ZN8=F9B88/''WH6\#\>G-[B*(?_U*H?O7"8!^J?=ZGC'FX]Z*K77*(\_4&
MO(,:AV?20XS(.BQ58O,<8LA16HMJQO%Z+Z4,8(YMF*!L"OZEFH+[0D;B<2&A
M%8B9V85LI[8L(T &U+>EA0H<+T4@I0Q$" 'M>0CI#L=1V$TQM+S2<,I!I@_>
M'VA =WM1:3E,TJ?DD<+>Y54<AZ_,@EYZ5$/YB+Z(87NL!4J('MH1.1R/5L/H
M 4%:2E/M669<(.)5$A6G!8,6\8<]3"IRO65B\S1)7D0BB>PBM44SEQ;DG,A3
M0@0O4F/F$'M=6*)C+!G$4KX5/PU*E5V7A*3=^JN!M+W?TG"T1POK,"K.7B\,
M18T9^1Q$Q<$:4@PU;P?U.#*!H.53>E,PM+_S(E!TH U:<+2GYV*0=*@>MK T
M\?U#FLF7*0$ZSS%U**"ZPDWS)BVM=54]X(D3.RW:HA@R\Z%3\[W!#V%,[W*Z
M4]W%4K?&B:$#M53?(2R;XLW3[Q-XZG@]N35(O@!IPFG;G:<V%'7RJ"[38+VY
M9AXES&\]'VXD'S]ZW\+=8?<N25-^PG[M[=DO^5%ADI$D<$_2*?9HO,,[HC_>
MZ3Q)BZE#GT]I6+YQ=J3@MR*2(RE9DH*GDZEOU2A7G5ONL=XM]^ODE<9>G(_)
M%6V+8R;2P8D(LRU3KH*F$$&^()JETN0Y48Y_13;PU6DV<,7<[N+&B7D*IJO6
M+/9U9Q:[_36/$Q/]O2.+_+D]BSP0);;+E/1_$0GIKEZ2]RD-LEL&4'=9=H#:
MF^L-A(X*E]79 2?L#M?UY/5X16N\0=8 F2>?YTO2!&Q*"N(PU%O6&7:B)X/:
M2K\0I-[7TU>2M>CV2M/GQ)EV]:\7.%HE-E>]/WMI"+5[BNIS#RQ,?6+<;[[E
M-,Y"]LM-S!JF;=&#'HJXH4N#M=2;0:/(X04_'4IIVE1:D8(]*:L[@@ K B*0
M+Y40I"8%ANVG"S"; _AZYV5A]KA/J1>LXT('D/S'04;O[+XD8.JW@QJ%U'V7
M CD#-- V43@O(IB1)*XFSL/YM207.&+0%J6J*>QEO?$RXL%AIL^XGM["M16K
M6=-=?/:,T]:W6=<4OP[]O*I7<"^LZ[W0JT#<^/>B>JNVQ;@&FCB13ZO%R@V]
MN021;^YI4V_R\K5DP'=G2B9E06J!)O!H"-\))R%;(]' [AZ?<RN=GHTVHC!1
MXB]8D4J,%:D$:3:VO_OGW'A7JD'UYK]/J0ZA.43M,L@@K]9# "=83[>%.E#M
MZKV44'60#MJ"U9/%G&!8@Q$$\:I1@]PUX0!?Q&I/>YVE+079]P=Z[X7!7?Q_
MPEB-:0.[X$2Q,?K6BF!VMD<>, Z57D\\6/IK>.=MS_B]#>.WOS".MLMBFE6Z
MG(F, 0OC0,^[^"TP6;E"8[MZGW[>B:&9Z@G,6ESILQ5Z1N_B.K)>Y3>O%*[9
MPO'S(<J[P6H6-<0X-M]*U>.:DTDA1S\-BAE>*,NZEA3$$,>(7!#+CURZ,U-C
MW2MXLW^<+)BO<EZ%BPL!V3)2#+=@B\-H86&T,#X?6:>C2F.A%R_-0TA]!#'N
MRM(VW4@\I!-BP!VL<U67I:\'<O@<+K\>E-S7^<&(;J2"\3>&1<5?RW53S)NA
MH?A=K:Z56XRSK;E25_U0Q?]'I">-T+S9:WE@U:)U'UK5NBP3KMH4F)_G+& I
M3XCG;T/F: &NDC2@_-9S!63\[TU<VY>#' 6,Z31/%XZ)7&?!" V2Z51>*.BU
M*:@?OM2UIUIRCF<16A[(#;--'^YU4UDF% [4R<S-*,B0O03 -&S$+@SM*)/G
M(H$<[5#3? FO><CSZ0#W_=>;FU\/L/;/<B^*^+NI_:?I75T1X^Q(_17).,I^
MR+%TK!93A[2@S*OT FV&@Q5QE_DSYC0^.^"6)H!:SMP$=6ZN,V'<?'CW"2^-
MZE$^'9GMTM4;)^)-M((ZST79=2E)+OT*: . 9BDUGSK;_G)BB:IXU*H6]/*=
MT9,@QSTL%)>$W]/,3\/]X/MD[?V6! 4=FJM!H*734J9_E^C:)G[!A-2X()CP
M)G2_#1E%']XB]25UW4L5>2WU.LDZ%B4GC7#.P&Z=F@N->HLE+"E:Y9TZJ.!\
M_&2K)2QN)_O  4Z*#VGJ)!5?JZ8".@K=.$U'2P/]:C4_F0LG?^N%Z<]>=* ?
M0N\9ZBB%\(2[EQW8R%G'#Q3&4!B_\/M3G^/D.:/IJ[CGNC^P\ BF,NO%!_ZU
M%_F'B/_S(8FBVR3]ZJ6! G9M\,4)<=8M7P]2C#/%&^384WURH, D)%S$%:D)
M20HIX;YJ*:>XR;HB=5$)EY4TA66Q5B4N^0("$RFQFXOS^#]$DPDX6)]7-@>G
MRM-2-O"E7D&'>IETMP N30AQR-_#?'MFN:RI5=8T=/$MCIQ6WY?3S&LA0&W"
MPJW@K)/1 @#9B+HZ0+@F&/G*)&L!V^P,;<\0NA10D#6!N7N:ADEP$P>#<!>5
MO9G08*L*4<W9YS'WTGQY%GI'7\(X;AJ)/'L1+!R6Y'$41OK)"^,/2985#V3>
MQ3=>"NJJBH[;Y'^9GFGRE]#AK48SOSP/-MT$"+W:BH#<Y U(_D/U'"_[4R&]
M5D3_J_@L,4\&,>+O['\=^6X2,UD-X5.Z3])<6#*#N\7\?!C6&\E>5O!RN^ 8
MM5([,^-CH=)ZPRR:[&J5TCZ$F:J*JC7F"P%^*]^@%?6-<EX Y-O17^=6TK$%
MQ0?L'M7079:@V,E;9D)RDJ3D.MGM4[H%#5YI\7=,90>-^X)UOJ5IPPS""JY\
M4X<\"X$V5U_*:HRK$F8! .C,)(N*@;DV[?@H6E]J<&SL,_8&RW[#V!&3ZC+"
M9)5%'07.@\59B+]Q])W,!M?#9%F MW%E$00!>+N7.8G%._S,=QB?/](\CVC;
M)1TK#!>">,9L;3"$KG%; &J9TQEE$%P3]#+"6IV6+TL<P:M6*93JX475&A=?
MO:.S2T ?DOCEB:8[R$M\=_SHY8>4&>#J.<M3SU=%E;V=<"/A,)T;;XIV]L"+
M2 /EGCJV@?Q;-KQW_$[RBMR&F>]%XG7O@AGY4K!SDW9FV 2W!T:P?CMYQF16
MY/K7-2CD!Q,_AM_:<I:[F^.<F4/U+&\"=+1%?B=@B.3SR]9$Y<SD=P38H 07
MN"(9:\M32@[<&_UZ"(6S7''WE/#51 9.4:2@BJK^)-]ZS'^EE-]<HSL>)SP?
MR3:)H*X#^VT3?H,\U91Q Z9AS)OLX?*<>,V1%[+><749=SC:#+^QR&,C .,(
M@+%)HDB\,<PO,,1Y_=??DYMO?(LI$^7OPAVGZ\4QW*05>3X9^<J6.N7OQ1^%
MW'*?B+_&5]#/ZBNI37E=9Y]DO.P>EYJ\89\U JF\_3Y-/'_[@]V;%2;'"\?O
MIPJ_"_HK >&,A?TK%R;U_=,?__RC!5R&(&^4:K+#$K&YKFL_.D/KI>)S0_;O
M :%Y6=%_8/0<C-8R9OI0&I@@PFDM.C.D_I-1I [;2A>]/[L",:'[LE"\SPY=
MF*[JNSR$[]5DUGW=LH95=7.W6B]R] \.EFN>V;0!\"(E?I&*76N=L_=FK@+D
M2>Y%8\#,W)  20QO&'CQ51P\BBCA>,6TX"[T(X4"1.WZ]_1 #6I#M*WA6%=S
M]- U2/CI:!5F9,=I0> 5P_/U+&2,&%<>RLFX\\@@33*VC5I&U0?RI"2J;SX"
ML@#M6\_GQPOJ>:ALB7C^=6M7SKOV9LCG6X_0TR\:[YFX/*\_C-D,VY4%4',O
MY%>^\H3PM2&?>AO)W>YD,Z3[4Z&6WOGU#D3MGEC-)LAG5(L^C:E4^WT!<ZA-
M6J.3AX^R=_8GC$Y%A0[D@_:Y<MT_5ZZ7-%=:]&G,E>M%S94V:<W/E6O[<T6G
MHD(' W/E??]<>;^DN=*B3V.NO%_47&F3UOQ<>6]_KNA45.A@8*[<],^5FR7-
ME19]&G/E9E%SI4U:\W/EQOY<T:FHT$'S7+E/J=STN]JP5=YMF&;Y51R'KS3-
MO/1X%0?K>)V^H\RP]!'R%8/:K^KYI8<LXCFIT6[5JS#S:2*?^SHU-(H7^U+0
MC'@@JJBY!O+"(7(ADC@'AT=ER#,7FC?+N.2-=OQHF)^T>['E%V40F/QN(PP:
M!CJ,:0S\IN/;)4#81)2Z""!"B#680<0J3I@$@)/*ZR+/YUV2ICRQZ-K;>WZ8
M']LL,K@G8@ 8I[WBB255-^0 ,%*)^3EV11+9<\&#^)().<2!'.L\ :,X8B'L
M^V4A^XEGD\7'D@1<X4E#GY=? H>95X78>>Z=GQRB@/E0R8L&Y T<G=)OWFX/
M:7VE"!G9>4=H&(6[$-+=GH]U8C6IO2RC>68YE<W2-SI_&$(J7;(B!2_7#T(9
ML\&U<G1J3 4)?1IGE$6<UTG$B";BLF]YR)T]T!>HI)PP?Q)&;(PG,;V7CO&!
M^C3D5^=:S^)U448,UGJM5Z6@:"&+'.PU*ZGGP8RTY$EV!=,R 8O]6K"MN0>I
M!U\H^75-JB08R\_V(;%L81@F!VD(4J709'!ON+1X*0PII"&5. X2F'&8\:%K
M2)J*NN]YWOU3\C[UOO+=4K8PVAUV_<Y0W1$QC(_271%R*WHA!^%Q.LQ><7/
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MY*O(Y.75C8M47IZDD]5+-Y6%D86K8W.#>$$0@F8L>O-EU3SVX?,T?#X4A9_
M.3(#A/E1,"EX6#YMMVKG,D'ZMI$@O:Z5W68<C=?QZ0ZQW%BD,09@G%4WAIA%
MZJ6W=3ZC5RHBPT<X@J.*=_*4;1&C:9^&M9?NVALB1\E>L><@8GSV:$=1"I[S
M@!TV675K[\5'VV_2&5*\CCVK<GDHB+MX4,ZLFN*+KHI/J@]:&LE+ZTU-CS5<
MV']W%!?3BB4J?R[OY!9;5BUQVTRCG0-B&#-CS1+\]))'#IF&E-51:K86@C8
MMUYRMJW>A<>"A/K^"V__-3G KDQ*7XL#VG+'D#& WFYJ8""S?S/O4[Q[7'D
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M@^-T5S06_41S$B59YO8UI9GFZ#P$T$7[H@%.?:"@A?#%0INFK7E-N&;R^&+
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M;%.7IPX55B?0G2M1G=H3OVY]T$2:7[XKGU%QH>;/__HG?%N]3L;3<'=:BD=
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MS[)039NVVJ&O_*$\(ZOSYFA0B%?<<1 Y^XUF(",:F'1N;(V5UH>NE^_BC,6
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M6'2^4CL-"8OZZ&)#4('R$\C@A*RY=JF'/V-IX U[)FLR?[5?>Q7V?.54?WE
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M"F%GNT?N'<.8A98[40AD+Y+98"KE";G[CY_OKGA:\>_)&_X?/UB=1YK5YAJ
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M<(L#MN#XQOD4GI U4.U9* <UU+\@2[/ T+WZ&F3IJPU@@M]!GICF<0SR0;3
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M8IY2TRKXE>.$KFJ&]?TZ5+O1W6ZG$(OF6>RN8 L41*3- K?XXG%B6B?S=#V
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M0U8I;H&>=D"@+<%#J*U[Y\-C70+@F?PR"J"@H[S0XO9V-7D 2_3B(8)G-#\
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M*,!T;@>8B"_DJUKU?1.%.[6CFB6AD:R'F2J>E#Z\]T: CG!"KQKF?6IW?[F
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MVN($:BTUJTVZ1?JXZ3K*FDM>,;I8+&LVG9W$"'1TU_L?6? & ?-Q&GK_D84
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M@:KT'PDN]-!=XJ.Q^1/:/K*OR>#])\UWT]GB=R?*GN/DJ!)AGY' I3FM)41
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M;Y!K$5FDV,=%Y,K!G[+'!W)RR,^Y6Z)!=,>[FNB.XR^8A(OC!D[@3<K/R$)
M\@^Q$2!FPVH7"^12E;W[ID<G0<>B$@5V2/>'IF@4XS7:T2F1_OVNM^WC.DU6
MV4<($@+9C:')M)V0!%M%/=5#-O)7R12FX_&:0T.#@O1D1 \_<RZK^$SF+=Y*
M+$(5[AZ?A.D2-;W@2U4I9:()M4#$>QM&""^#S&$9;84R934=F2"E20078:'Y
M=%;G7U4: QI(=._H[9DA@%/_1[GZR_*>[B.:92\LK2<8(L!4S5:&N34N7^5Q
MT7D6C[Z@17ADRKCY19A#N( #)]IF@LGLCV0?"'T_JS)9\P",L1F/Y'7Y[C/Y
M"<8>:P:)/.AWQ]LQKH6*##A2O"[]?;3Z64IC(8YT6)TJUS&'Q;MQ;H[+W<_A
M%_G%E%!"2U84#^*JH;?:WR*S%:?:>LJ@/>3"X<9T1=V4=T'%_4%?NLBY[OOA
M3_JTLAH@%0:V2#7#PB&\BRQS^RCYL'N 9??"SNXQ)F95 /T3G"U2.V+EN!YZ
MYK"<'.X]1+/I: W/0G#L!VOINR-J6E=M[+.%LWDN:GJ,>GA(SEZE: _:;!B+
M3QT,T_2T-30H:HOY.FM@2?!%TUO9?N_0(>3^.XUP[&$WCP#[&JXQX2!90@EA
M0K:8@G1=<)J#*+5!!@(TYF=64:.!=KU1(CV"B7T89JU8YCFYQMVD:71H\#/A
M:S+)JG&9'F6XW\RDKF'D84!5#ZR:>>5;V,Z'6_Q:AC'9VS?7@7=/OL _\*NU
M "MO2(M2K9P;_,,D<M$YDJZ=9H-92&KBF6&/3^>Y?"KFVN;N'\VS6#2;9F;?
MI=#-.H+F*'*144]0,<-Y K4K1H[+$23#,"U>(?T3G2?,.^;GN)Q%39FF&=,6
MN=JX9M2#!/I<?!,X]$&I]M8O]H 6HQKYILE/I0>E+4ZY!9.#)0TBW]U=I^3T
MM%V$T4\G\F*R6'$NB);GW29SG2=HNV=I@>>K<92G:KHAB>))6HUYGC VQ[K2
MU7 QYE,L2QRM7;@6B2WX5,).9X6BKBM,KS=A0.N(S185HUY=65*9OL/ 5[LH
M@.:,&%=)M KM1\>1HU,(!U(*(T #5G,05 '5E@U]>]XY%Y *65-G@XGFPW\C
MK_2.9=707I$?;M:<JX7Z*&.$BDY6#-X37N$#^^I3XP)7'&6,J-+)BL$_%LMB
M0OF[XD9R:&$G"ZV(:(V5?2<FICHW?!KA%U"'=87^NR F>M^G*O[)J92+E.HS
M1KPT)]RH$UC5 ":+@GM$@+WS<4N!X+C+^6! @NYQ>4:K=PJ!<9/=>(SH:$#Q
MN'+:*H1_B\@=4Q876>.SP@6?8ET^0&C&P%)+8M30(L@8 !ID.C0+RG+#: 4-
M32YE-EF/>+E*9HL?,<J63,TYA-\1&DA:"I1_)%%D05OS'K3R0)57)P[X4;,1
ML;I @XT)W:),?]O[S#%FGK6\&"1[K7E "6_!Y?4,:Q,&M(T[9FR999*NVQ03
M>9U'E#3/61E-'HH>!=8P@Z3QY0M:HE35,+%?7P^5LY-DK[,$D 0+#-S0>H1.
M9J%0J-Y2<WEK.MPY@$TK;XS&5FHZ@]4ZD@L>Q-?K,$KPWV5 *0X]UM&KQ7#0
MX*45"B>'+]UL&DW!F^KAX%3]E['ZS&*<38<Y$^QI98_1LC6J;WMPM!L_G&I.
MIWH.9S\#,O\*;W*"3ZT0S08Y$S1I9 ZH\$AE+!'6^FE,#B*S13L\"0:RF&K"
MH"$4I^93^X2R"GCO/[^[QVN<BU<-4*P1+)*4.#.N(@$_@HC<CY8!/7D2;I?!
M4IQC%*?UF2"H"1>,AI)T;OSD4+YC]1P1VC)W6."5[P==NVZ4HM/+H881+>I:
M<<IH,$OGR-P%=-V&T0]R?XD2!],27/,PQAFWZ>-6:1154PL:C'!FR&O+F4Y2
MY/_UVR'C[PD-V6]/?UF05V']*^%-G*#U&\+$?+K]^^0']03YYX>OB'#%WVV<
MN;P1K5#L[95?@A,Z[]75U8>W'R[>3_YGLI^%_)!/-,EF(C_N)IO0V29'TTW^
MJYCPO\G8:S^(!=RC4[\X,?I'/R73^0^]%RM0V+)CRSI7OMEKISP#NK@7%'4A
M(9$CTW<#JH \V;RC].@)<H[TV(VA"*V--*HR5: 5K"CSYZJEA<EXW1J .!4$
M(2-% 9%@Y"A\ )XK3OEGXT%*52 8EES5J04BWJ,"S(?/-0C%6]-K9.)M0BW7
MJ0+E7+1SJ"N?C=BN> !BUK/5-B5\\#G9RK4?AE/JH:E,5=!ATI]/;KDO81_>
MU3MR"U[@ ">('RHBWWM\L-#!@$Z>C>G&S+(K.M#$K/*AQJQ"_IT4HULKBJDG
MSZHU(T0&%'X'*$M=T7:B2!"00_P(S2:*@K 6$VLQ@2-':S&Q%A-K,1FFQ82Y
M\=092\2=H FW]=[:@-S!6T>8- MCUP4]!H$(5=.(*KVF:EX:O.I.P_4:)S2O
M@T;KY"$:2Q2X&*E?>"\OWIY>> ^&GSB!-W$/)X!_YQ5QI^X6W&@, JO+R\^?
MWK_]].G3YZO+CQ_>?>[\-."ND)?Z:+:81^$&1<EV[CM!0K[]YJ\49RE H@NT
M;'=H"J.]F!B'AC:\$"B3IL;2UMC@DO%E^TRF%=S1)7I"0T0KZ57!T)0#@\(!
MI41XQY?H"0T'306G ($:XO7<$WFNDL6"7%3IU<9Y"2/:;?NT<5R452>\ID\6
M+A']1N9EL,$(@Q%OC5!.72;MF0#$') ?>6\=-XNT%>CT:D-HLM6LPB4)%MP,
M>XM*/_YTH8IF-84F6$E)U(D0ONGU'B7D.CA;Y-\M-,BQFL*6FY(%3IH\()+[
MXO@T??UIA5!"K889E_G*E-<<F@0UJU0EL@6YV+T=A5D$"-4KOP,T42O)1DZT
M?1UR'Q&YN&/Z@N;4B6E!$_H/!>RKX],K_SYOB'_,51UC".*4/]]JH1[HHT#7
MKDMMNO'<V5+5-:U#@JC]N*2N3*DFKXBOS2$21\F!&B<_[54X^>&/*24/182/
MR?;!6;-,6+QFT"2M:6=6(E=3%8O.Q/V(-FGDKNB5?!FA[$)^2BMS\U;J"P48
M2I(\!D [6HUNY7=_O6+G+G#YZOFX!21IM&/KB6Z6(+/O_=:<H;DN?J&^(Q1<
M=.UND(IJ8-64*:]8'[L&P76$G-GB$3G^34S#<$K2.*+G-8<F\(82JHI:B6 #
M*J''HD%/B%PZJ"4);6@)")Y/^KC5:($@0Z?1W(S.@Q6R>B-[USU'_B>M1BM_
M&3H[J6=H,&#I'KOYTXJ^GSO:</:V(J4:12YV_-W)*IXO\-]9-1KE2*:/U4BF
M8MY_3MS#F8N@IG+NB;.;G'3)Y_\GS?IY8SS6B7-:+CX[X] AQ\KOY 0O*?4E
M./OX^>V'M^\_O;UX^^[=U<6GJ_Z"E@X^]?70[TJC>JB-BO/G9_)_L9-%] H+
MK.B?"(HV:B]RQH;4#;<D0F3TG$S.T9AD5'+MS$Y&7'S6@C1V"]+N7, W(9TT
M@20/K38D&3IA&I%JEFF6KY.]KDPV-(=L QQ=S&P'1=R]*F-YS@S-YU,2]".(
M-\C%"XP\KLKFMH6"$351G8A8B3B]+WGH\=NN,'K-*)\M;CWG>K.)PE?'%WEN
M13U R51)-A6WK3*9?6MY11%?!P%1<5'L1%MU:5<ZCU[P<A3WG=(H@X%I7O3W
MX$&B(^M/\2#1=^RC. D#%$NBH]FPX\2-1EX8L#::0M230^AIBAMFYU&C0YYB
M R^=='#-IT=GSIUA]S<H N[UGB#F!E<!="1"YC(^^2L4,=9SD\'YG@+A:WC_
MW?F%U^F:R_VCOX/CO^"SCB503P:09 0-^N"^)N)&YQ10$-&;8NV,J9HVY^-R
MGEI>?^51/@O0,UXC&GX^=[8,K[]J=VA@,R[SD]-=6U89C2CJ/)_G*0G=/^_B
M."4'Y#3"P3*O<_JT(G*+']#/[$\\'2C7^8P!IX%1FHP4O +$EYI\3&%"6$1N
MR[LK4K&$F.]N\EN?,5::< ;4:ZVM==%M5FCYGK"2OJ-&>(G)R2%[!#G^%H4Q
M3PO5=3MC3+5BD9&S4H_P*M_F*YYIXZ#II)4%CQ1'-+W-J@LKJH?LQW#K^,EV
M]N+CI9/?6E"T5CIHLX<X8_AH8Y?1EUS+ S>,$-XR'K'\18-(WG<:(GF++I/=
M=YQ9..\?W2=VV(#>O@-ZJ= 9-[>1A?2J%,PE8\\6!Z0(RKDPVT)!1N]F37GN
M +&?5UGBL+D@K-"D. HTN,A+K2IQ':0;#0J^^>7Z:4S@?7KDX <"U'2!)CX=
M(C@YS3;A0(]>21L4;(.";5"P#0H6!739H& ;%'PF@A]T4/ \C>+4(;M8*']@
MJ^LS&HDW(G1 L;HV^MN<@M ?_=U;Y*^-_@83_=W6$=9?"3(;.CFL:VK7H9-M
M]TO]H9,/*5V-L\7<27@!1R=-H(&F:Z^L##M %4ZS0;-0_?AJ0;-FRK#9H-E1
M 4Y?T*S>O<H&S<+#2HN@69W7-!NI-G@0:8Q4TWGYZW&7.XT4?D!)Y@#UB"K^
M%H;>3^S[_"#:VJYG#+C6;#(:$@FKJNDW%"Q\A)+G%1EO@]($N^I/-7^\>*\A
M+++\E,GAMXPZ--+&08X]#A)XT&/GFYX->@04]-CC Z(V G+L$9!U*I+O$Y/K
M"4V8!N(A6S"BQ[!(6[:ZV[+5HH>A]>SOMH;UL?][?#6L6;? IQ5!\<K!PLK6
M4ATAR4YKO>OFU/<8Z-KZ['8?!DMJHYL7C-P_$?-E.W42M RC[6Q!#35E"T]P
MRF\X&A1,]7X/T,D_37X=8*CD<$'XK';#T:"A4B<X5*"GSJ0A*\1'(E<B$_J,
M]6&<XWYM"R^QDKV' RUUX5>AU88IX*!DB\-V61R6Y7CN]CYD*\7:2K%CKA1K
M\V*AY<6V#8FP>;$V+];F40T@4T9C'A7H-%R;1]5)'A6T--R;7Q3.,?6*^OXS
M:8J^H>"6FEAG&[X[6*7K:.3?AMZ^<W-M%MV9'6J[SJ)C16XVM0$TC&_XL2$\
M#Q)!?I3:"- PU'4 N09N@7I:P":M $Q:,9- IREII6X%Q >7 RGTM!KPW &F
MGWGC>FV [Q^Z7M. "V7':][MC&'7BD5#R,JK75+']]M'Y"+\RDA":#?8&2/,
M ..,YNQUA3MZO8Y7H>]EI#^'SQ%>+E&D9Y.5'=SBTB0C.TGYZPFG18JM"92>
M#&TQ:HZ-!4(_#1JA<Q2Y% -+-%L41._6)^GUE+[D0^!@^4C.ST&Z6[4W099Q
MZOT("!MN?N$X(6U.ZQ$VP[;IC[*K J( BO7TV<AZ4DVHT[B>2./*EG?$IL)9
M].\TPK&'<WGJ6C>-)K?KHT]&%^O@"O(Z*"NJ?76V\6PQI\,_A EA&]E!R4T8
M!TZR7^YO6&!6&^'<$:F!6Z6Q_<((KCZ9QE5!)?GD6UI]XCF<IA'Z$B''7:G!
M2S"019DNII5@,UM.$4;%EB?DII'3H$;+!PTU6O+)QUR4Q99D&7=)%I9%W19D
ML059;$$66Y#%%F2Q!5EL019;D&4O=EN0Q19DZ:,@2W[/^H+#N\!]P]?,C&:0
MY**UV(HLK3UJ6IO)K363FQ4)9S.Y;2:WS>2VF=P#T7/*F=R]5Z^P&=IZ,[2[
MN+K?+;)PHIM?+D)>_/;BXCOV?9H.W/A*+QX1E'C;)%$:8 ,@(+S3#H33$<\4
M"%)LX%H#N@?">^U .!WQ3($@Q0;N;<;\9CZ/0B]UDUGTA*)70AGG_,9J!D6B
MO1[?I!DC2'/H]/16?#!E1?'),??TQFT+1?1*$F *3I(VHWOV--S@/Y/(V6N6
M1^23(ZF7/TK$U\A2'0'*2I+I)XJW.;4F+\BV)L5H];NM2='@%&AK4J@<%D=2
MDZ(V/OT1+5.?#K>MQ*2W3-*5&MG"T!@71U$70XK\'QO29;.)PE?'IWM0?AHQ
M!UKV?!;*'?/6:-&-KK+ E)ER&T;[T')JT.@&YY5I+=S[8;'1:B!=H=Y6 X&
M4%L-Q%8#@8A+6PW$5@,9*$9M-1!;#>2,5X6M!F*K@=CU8:N!V&H@0! )OAK(
MQ^Y??,SVG5LBEFD89'GEO^-D-4W)"ES3K<?U4X_L/=1W3?[SGIU?')=N@Y'.
M&(ZZN::K;L@KBEY"!C _]&@*VY<!:6T(0]X98TX[VTK0F76J&2Q60Y0_BLDQ
M@YKYE.O0?+IX>UJ')AMO4@QHO+9,:^5_2#ZGXHRHZ1^=EV+?A]8\K<(HH7OV
M5_22R!6+J7:!I@MX3*YN&\I4 0DMHQ]Y%Q#*TK(H!4=LU8;0A*4L@JH4)8D$
M]PQT8X%S$_;KFD,3OJ3DZD3>9V+^+8YB^BDI.4FXZ#8-Z#&3'\,K: Y;.&JY
M^:ID]OT$9?LM]5!YW=>$[;(;0Y._!LVL0&C?#U!J5M&WCHN$[]KPFA\QY^/G
MR\NKJWY1("_".C5=0Z31R-?.S]C'I-_1&B?D*OCH)"C+/_;V1ELI@(@&&#%D
ME,D&%9^JP:RX*8SW)TJ8:SSDM!\51-2H'-<K:L?+@RP&''K892=P2/49%3+4
M*07U#)I62Y2$!6I4LJ\EK)-80X-6UIOUQ@^W"'U! 5K@9.X[@;*Q]7/5V%H.
M.WG)QYULR,#PC:[3<+U!09S#D^:&)CC*+.][XCBV6*6>76OW!4&]E[FP\$M*
MOY"*>1J2$Q!RPV6 _ZYX<93Z0EGQ#:1WK.>;TFK*T&!PW?\?6<UA=(L#)W"I
M"W/OO7H,?1K?_].)/&5-<%75!/E$D]U,DX.IR)_I;)-%/EU?!?]/>2%3Z+^N
MSQ^=U]9^2C<;'Z/BF] \"I>1LYZ]^'B9(>5 KCP+DOP(4):\M"P89J26U.JU
M_/=XOJMC1$.T0(&(+GFK(^@,#%+=8>>M!<];;9:H37:)O0D\^ C:%5:<+0H-
M[_CS,,;T;S?T*!)C<C>["<CE/&H#.>5YK'[3PS)-IC3N/FKP$/V4OL3HKY0,
M<_-*+8>JYV7R]97S\G[,"<H&A7]K/F5#3;@2KWD/(4O'7R(,56(TA:<!^(QE
MK6Y)BH8<XG)*))E*$-C$:0U<SGS)U0M=1.'(Y"Z,;>*VARY[D0"EQ"\@<T0
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MU*T:(T=/7M_!)T<58T[- %^D,)[&,K2?'R#K&IZDTCI1?)Q,-UB*NU"P>9K
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MKM$R"DY3+FL->8!<?(,&H,\?Y?""ME\4PJ>/G2PK(\?E L]W+.!Z6P#O?7Z
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M,/2Q/2S(V# >I-CCCXQ^\([G>5$G!T\VRBE;]WI,0K($P$_H="EO5EY.<HV
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MN>QD5SVI!!]%8>ZQ/_LGFJ>K]/?V@KOCX?K[**>_J]42$JR@[UE2L[LIJ7E
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M-+#Q:L]#H8MBV8]2E@3H9H>O*-9GWNZ2NRG6*1;"):GKKT] 1;C!VV&F((J
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MZ':.@2Q #ZW([$@XP> G'G"EAN9* 6A7\&7@'!5*L$0?%IMQH(H= ==1V+T
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M,5X4;P <$!$%"\_#[I4\CRO\>%G=:>ULPSZJE !3,2$Y!AZIWEUT+]6;1O-
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M3 6?5?PPW%?0*=66O>0C*B9F*2;K?T%C1O',;O2K@K1PK'!W@T@, E.<J[X
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M3^&>(68B)RK)!J_>T=79^[I"!;%("6UBKG89QL*<GD.081K+F1@\)TT)W#L
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M2OI\%2=\8L*I76PA.+>7GUXIDY=?D>QG1UI-/:%KL,F+_K$8;J;-85F%KVU
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M<99X(VK9Q$YR"3"PVU5+.QO%N 5;N<H1"3L014+DWV&X1.M@P9^+4$D%-S;
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M/Q8R]\.%NKRZZ%X=OOE]S?S= #:.8JUI$.:?UA0I+*%EL8OQ9U3W!: _C)$
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MD;)=3!D7%GTQ7"-^>X-S9C%M<"!%;UV95$2MO01:>)K?[[[=2@+/P"X_ T9
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MVMT,9/&C>#\*4@Q8<8Z"-[$1;()*ITZIG+IBDV;RX)Z6#;[QHZ/0I[;5K'+
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MS!M.)117'00));JQJI\6 L#Z%/*&CW-_#:,X0\[E!'>&<1\LRB#521G$9^%
MLFBB7:)8NJ_]8;KK;^KXS.T&F*P1L+TUDW-*!].L)[6E.H:9*FU&>]1%) U
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MQ0^IW A&0-NBIDY@>)QIA;T#?V1)D(+%SQLZQ;KX6?XND"ZC@9]D*HYN#+L
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MD/9HYW\E@68Z= W$C73)9QZ6%C22TKHN)^C5$.W2PLNVZ>HBY(5(2;'2R"W
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MJ.E'ETD5.^UYQ8A^/>4#0CH0U%&S"C)T/:-SRXBFE!N*F;&11Q'>E[YA?10
M1DP1S; *4=K.+Q"HI/G:8;B>N4ANRO/)S%VPMJN9.H=VK.@.D2-3+C5N&;I(
M^A*",O;IG/6I)4?,&\>" V*@78N\KO>UFH%V;WSSV-MI8Y1=]?[\XK2Q@=.[
M2EFW\X?R+A9Y+>I6Y3P?8]93$XX_?WHVHHPI7NBRU(YV@3B&E1KU%VV?DD@9
M*\;Q\2)4Y@:?Q;@5)?/?BN\[YZ91,EG[@_"%"-3<GLV4#3*Y,6U+6RLP'3!
M?;6E"IB\GAC+2Y+4IK>(&E\*+6=MC\Q2H5.>9=<*1SL]/AXXMQN%)Q?2-H8@
M ZJ3YUL&'RA&@+H@N\\0 "E4AV9.A;CJQ&!2ZFVSPA.()R,XBTB^1MU::# C
M,16/TI%KD6&3:9LL0,?&*@W4!Q@6^]9'\A4)-VM7Q/92H(KC1DL<T#DW*-1S
M*H#S!#FKJ=UORD_GZQ=]FJ-:#6?92%#5O&9 @X 0N$<KHWI60#JH\)[(C+@;
M5-R226.ZI/!?FO=UZ9COZ5+P&AK;UB)QR1B13$J%7&7%$76*$H&;-'D&/T10
M#W:E<#TI];W!@_"7@$H:)D_9KT%]K7L/L*4( Z;=27%K]$:J4Q'91LR.5U,^
M.&(=P%_D^<. P,=/+#ON492EO,6?Y"'6]/*O!1X54B(-QEL),*=S MH9MT^9
MRY[,F7%@3EP"+)="?3?5P%>L!+,&CL_W@+TLT[_SW@Y@^I!H O]%O,CM;?TB
M5[2[SC+\1-.(C;[8##"Q[C3V&Z;H&R&K9B[4\[.X7\X%!207Q*5IJO=*6Y0$
MB:&05D]*[H23^;7/B #)% 1[NKD2Z>6R?L8@(E_"!N^SI/VL$;)OI_Y]6QBG
M1Q"YG[^E$@,\X7O'<&I/!F$/0=N7!N4<X$S/?OKTY.2_W4*+ST$ZIQX-'[@#
MB?I*-:> Z%1CV';,Z,)%BKS<>=^L_I*<T3K'^JL;.CP^03[X+'7_M7$&[(*H
M3>OA('E93(8D'OS$3415I= 6U=+ZUK?669XX5C#8\/H^SUL8@"RK!4X,R6,U
MM43;R,NV2*NJI'.RX7M;(_9R+< RU;NJJ<]T#E<[K\,\ZH&[[7$O2P#]2Q<B
M5*1U!<Y0&E\, VS/F+7<8+),/R03.@G6HB4J& G/ULLT/C'YFSEZ(AK//35M
M;$D[]90@QFX52=O$#^G:/<VOZ0=2=''NEG=<OWJ;R6@\IB,?'CC=C1U"<S[M
MS3<E-=(L>Q\QQXHAAG">P!F4:<-['QPM^"C)K6O$+1&L@NETTK4'#W/#4"*=
MKU=Q9WD1]I<)I:C6L)X[Y\&MPZ967\!W9/V,.DC$^TSC'O"]-<;$$&J,,#3/
MMOG%+'YK35WB< ?K>?B%K1^-])3 J_-E7SSF.U/;(?8F-S3$E:',6P\"'STD
MO!6T>UY1RU7RI"S?#SE*:8W:?($B/#"^DW ZM^OF4G .SBXEN)P3IA*&RH/4
M)I G6;3=2]*G<4:OG_HLSC!YH5$%:*+HLU#NFI6=;CA,L ]X:1W,TSKX 1U/
M-= =T,>U<UJ+R_6\]GI*2#:A5;QLUGQ Q[1.<G691!\1>#INZTJ-\S+3U[7V
M2_\3U+'=\W[$MZ_XRX:.(5 EF1R #'?(D]K:>*S3&S:?5\6N-/-@6PP-\[6M
MS[&:LS0J">.BY9#K$'/E5?0"!YZP.@V=&ZIK22_?3N@D"YKF3V.5@5SX*2GS
M%4DUM 0I9 %JN!?>52WKL6?Z1(W:U/Y"P9&W"NO<Y[47!15&CY4 Q40$4TV$
M\S>=*:4V2/..#EWF6XI[CP[%O4-Q[U9WF9.C&%M81D\8VTI;:Q;)@XCT.J>M
M-FT'0TU%N_^ZSX\PY[E/+@#4)9>$F\2 8W*#:O:#LE9$TWT \*VT'+MA\E;I
MU7!@QSTM3.,HS]I.5%M7CH[M@Y#G+4!T[;\(:SQ^60RV3XJ<*FY4HO.2M#.^
MOT5@P,/:^=IK1\RCK!Q:+2R-<5@FAV6R<YF049&EPKS.X%3COS"!HZUBJ"ZA
M#W I8TZAG)))R97Q>UBN[YU7?XN6X+\'O.A?9@6BG\^MH]PMOJ;(Z,";9.SV
M5H&*%_1L,W+5 N:_",3ZM[QJ/A+/3Y,]/@=O'B$\JSXH>Y!"?]_V=KV+&\UF
MG6B9C[$/\D=F>,$D,ZNJG6;J"T\A+9HF%VF57KIE-6=HULM?XH%[:LK@UX9"
M[9PNHL/NCDJ[*6VEK<^-EC(0?D@08I.?%,6]43M;;E>) 6. GUN:(5OC0:HT
M:!NB)#8QH03:]L4F[B<'+Q/;"C7(/*]4^.#&UV-BJ-[P@V5#2-C/358^\9*;
M'WE9)935HZ-<@/B_5#T1C#TH\74;>*+*_[OM5T1_*>6(/1-":AQB[ TDP1;I
M=8V:61%8466LG_2 "@)8^$3JKKM)<]3]!QU2#%Y,GACCYO>5-NY 2E6<5ZK
M >K6*@/[.0XD!<IFY.YVKT_'1%^;#WEEC@U11\3C<<. !^94C]/_ RBT+GP_
M ?:<3!C7.TPYDSZ,IA;ZJ-I:,4NORLK"Y^(]L3\F<+XO[9E=!J;86*H*2,VH
M ]2%42A\P7X&S4"P?7?-()T/$#UD?"O!;P8^ =)KM[S73_I47FG0=(<K7,1=
MWTC>S4H")W8'P%BWLM#A%>ARN:+.G(4YE*2RL"QSB/LRK(03*"/H0M&8-;-,
M8@=*9B)<P<A8N[<K<QR$CX1K'\GSP"<B ZK[MU@XB%CNWEA^%'24NK#NR"!)
MF^0RG5(*J*DZDQ.EJ&-() "C?3,N@"$_ZZR7PU=V_XP (7;B?#:,IX7Q:P&#
MTBHPC526:ATW,$M""XFNX#J9F[++_UQD+D%NOT,.&0NRA<X.-+9C5EU0[ GC
M1X5L!H^]#6 D]0-WDS5J](9J,>U=<'&A)*""0.$4BE>#;94K5 C'>>$!*!91
M$!"%3S*%53B7NX&AYA=Z-L\74[?Y&&=H-#W98/B7SR L/&,M^MI*+F!,12CC
MV:G97IHT)>0><2;#69T'>(&B>;V6FU%B$1"\X?ZV/?04 6J=1HF=DN?DG<=_
MK!6\8G[,QY#'V8A@\Z,!%''824%$21NA<%;$GA_0R6FQFO$N"$.W\T6M_.E:
M*V8%T5_)-'C =W2_Z"B3-U%6VTQXA\@]]$;;X;C?U>(S>645+(+NHK^MX(XS
MLS/>"=/(/L$=]OYK98"AS1WXYY;E-&7Z+88T$CF'] BHE/QUZ9M-1&H-5>BF
MYBUEM[_!:_:CXE[&!Y544<> ^>;,YA(9';5'],'*^0Y>]BW $4C/^P,9LK+.
MHL%XH\;06BZ7$'X5$-JJ;@2<VBYUV%E[TRRDN<;=]?0D.7O^QOF'Q\,'QQYG
M0#_GKRG6X)W\I66\NA,I)L?. #7!%Y>+:!I8# "E#8))N+DHU@$H&7AT58$J
M$WR6\H')I6BGQM>XDRY)+F2@W",3=X8I_/<N-S#A^)08VTYNKYZ4-AR;-G[%
M;QJ!*CX=O6" 8>[3-9K6'ONMT@G*Y6L1,,/D2]'KOX8:S")>VS*XF?M 2_"8
M%6?A+M%2/-NZ%MG*9Q]2ZN(*AIBD*]Q4_=.N$ 7/NS!@E8(5R:R$6G1(PH>K
M=/(^O12)27>) -%8DB6"GRWG-=P6-[7.U);^8<HJ:2&'<>S*RNS;XQ%DUASV
MXC82^/[D7GA&.<D.R(,MR(-O#\B# _+@5B,/+IM\B@95%B$C^*3GS(+-N<XJ
MSQ_F4X'PL:FEH&-"<S5W,TCG-.N:)5EB4]IO2-%FXG[JQ^2/V+9@)I/!@ZV,
MY#MQD+GA42]D_5URY^2NZ(,P11D?<#26;!TT0,V!'8:>JK0;]TI::4(ST.^3
M.Z=W,4P6K\L+(BS+O(QNT"$CW)>7:C,$7BKC%EWSWMVD7 5"+=.:XP[:.>3+
MJ%TOR]Z;4*@MJAA=DNY_Y_[=3DLN ^Q$Z4054;@_$,F]L;-O^DI>$/P.E[ZF
M5^G??03O[!RDQ!+?)C'1W#8[;.@@4_$[REXPO*/WJBBO42KBR 5-2$EP&S9W
MODY*Y]9<9H;MC< BQ27W0"'[MY$GO$1UCC2EFL4ZL/=*HDB$/*41BKK+&!(O
M"CO2CGHCM1[>'MJ]W#I"4Y?U%OX%PAE%$N\SG'GGW2;FK*HCRR"]J$:'&%R!
MG/G!,6RZGAA\K?W1V.5"@>U>%MD,[R0;:O_5?%,K)DESB<S'$KPNX\MSQQE[
M\YIQE(10)T@)_4(\5%YRSFPLB>'P[TV5UU-6%3&IJ<Y51%B2""7A-!,AHI=@
MRJ2/+' A&X3Z(*QQ42GB8<@V$/POBLB@T$%R37^!^_ /]I=3CL!IQ( H9VQW
MB?I([?SLPK?U&\%1R6+JO+L91-'JDR<_(H?O^8(?K@Q';^!"<,ZK3<2/9HSP
MJ/6!X/U!SE139DA4+D+V=#)G7D8X]-I\:S#^RO90Z:U8':)W&/YN\5]CGBC^
M0KTVRA'V?FE$^=P;FLMTMNY"??RJYK74U<S<W[6)?$U%C9*R*?1KMSYWO6,@
M^UFVYTC-<B8B:*/KDG*KDPGQE7%>L(U"C^4Y8M>;WSWOH-&2/(P?!YV9<A+3
M4+ 1@NR\BN1.!'.I6F:=:SM/+,W1 %/G;@+=4>IE?[;*:7MY>-9&M/M1VR[P
MN*SK+OT'HM.9A8]MWN'F>V&<(<?ZU59%2"A3T(UN[^2J7#3%FG8E4(N^R7I@
MTUYO1$T!](RV)5"T(XU8P8+\=E\LS2E]@2"#\_64JULUH/THI8!&_-%Y(52^
MVO8'IZEK+?4XWK':(FT#=XN_8S]J0E?OX"4+@TY$[%=%4I_FA[?583K')GD3
MG/0WAN)GGY[3J-AHD2/H=-/+]]IEO!&(G\AD1FV[?BWD/..(>T/2]"*53)8Y
M+QIFNE:^#E/$,*Q&SA5"6ZAVYA!']2"))+@XQJ5XDD5>J^G[+%OAMYSV=Z;.
M!R2#0$9-238-6*PV&ZFV(@E4ZZ>>F:0=W,SXJT(I4Y'X:F9:K_W";LN<P0S]
M3G6SH!K7$C#KYSWYJB)EZK1";(-%+E,B+AHSDB+FI(GUU;971KD,"XZ-WJRI
ME1!N1:W2N?7QVJ$=F<\>_5!2+>X*?G8$13LGS19%T*$U"/:ARX*2>Y>;<))R
M+==7D]GY4N;-O,.$27N3*^P"%B(^;E\SC7P+ZS,Q'Z4AZ3*T)'N";%F*\K:=
MJO@5\)9 ',7JTJA4^?C&_*"S\</JDGIWMRG8F2MDR.E:N;M-38GCO)[S8HVZ
MA;%DF'_]4D29L?%:FU,M% FO%V4#<$D0$*^CTB[7:4C\)KXNNMX#01SW)K]X
M=1%MI6%R%AN<6!Q1$PX8'Z0IT;"HK,^86KO,C%GQBU-(<'+:AQ!ZEYI&B,4Y
MY4:5 [V,>T&T&2\#7;2SX%50@2&XSQ2-O)S-(H06G@T5#K8EP2+CE9:3QM\]
MMB:@F6WD110TLWDU/2*P]::UE"1A&8E!@SS,&?,)G3$4KV\&K5]QSQ&?;IEJ
M"=);RXG%VUF'S!L ZEK6SFURWDU:0B<"-/AN9 ADR@5'.3F .#P%X9T?.C:W
MU4T>'^HFA[K)K:Z;G#-'7]3? =1-UJ*!BN@MP[=G'=L?,7&UQ&J#M(C P=6D
ML*.?PPJY&75^9#F9-%8>+_#,I).YIG7@4PV3GX #(NXQ<A<VTJ:O*+*FX'C4
M7QK#M!KTW@_S#C4C<PE-5Q!GY"1?X2 BVBS031'N+< 12DF%]AYJ&2<,9I:D
M=$E0H5VS-1 'DO*:#'CF''[78??^-^LEPE$7;\^T$P[XM/)^[!:AY!XF5G$P
MS65))[KVBO'^DK$SXT6EK=2T,"8F;TAINJ73\"KWY_!;""VQC\GR,!RCVII*
M4?/LP\L"&6E?L';HK/TW;#J*U<T+8RFD0A!OTW:-P4N4&+K7%K]JA]BWLC18
M!+TY-&$>5B.O1D*($6ETR@P';F6MT493H3<#"W0G&_9A)1U6DMJU65,'8Z0T
MTT+-2:&>X"@6-DM')%4+<<'"UZ?1]YA>M7%Q/Z.9F:FX5+Y&'QLF[A<9M5WY
M?.MA=1Y6)Z].G]G.\G^"4[Q")J_P_*2Z?#GO!#[O>2;%07!D?5 R-4TM'CK)
M#\M+EQ<\?JA'3JHL ^5?M2J!+J9R^B6BLO32?>:E*?YN]8QTK85X99)?Y4SA
M5D$4=D$F-%U0XO:6]Y=K0:.3*:V#GSOP@>&NBE('C00$T2*=!(R(QMA/;3,
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M=AYF519O_;V>$B3'7M0D$DLXH;SH$='&<WF>7G,Q=Z0V;B=MO@]()F?P)S)
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M=N.R=#Z&^!0HLJW+(_I?S5/U/UJ1799K\8AX/X26S! EM$B00G)L8U@TP^,
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MR=^(%AUU89"T)W=<I_( 3&-4B9(D%2?PWWY_!\8S9Y1-QMGCV0M.3^NQVD)
M2LJ6F1&93BM^&#X0 OL;*3;E'V3V68P@REZ$*2-PM2HYL6W@N?:CPI"E+#=U
ME[JF+"O90V[[+KIN$+$W*4%/6+9"-!);T8'UF:"E@.Y9*,_4V(-D?@:Q&P,H
MQ3BMW(X3+V><H7^W\@*9P/7", A\.""'HZ2.IY+1'3P0@5R.J(0N5EGFRNLC
MS*.R"#COZX,+1$-;[%469L9W\524T@TY5&%P2H.]0NN0-B05D$"0W2$ EDTP
M<_2'.7CP[ '8Q=E:PKWN2Q=4!:V967I5*EZKO?5\3WZ%?1[.(5.NWV_'<B]X
MH,?L")Q.HXB^[@#1D;)-,3<C#;0D]WD0!X-=(#'FXH&^JUE4X?I^!<#Q1E>C
MO],*?$7LM6X#,U6^K!;Q+QB-0M314*M(9!ERX4X1<&'IW(SBI_+F6I176FU
M:##JN98^1,]%*V_!QT:!*PB?<2_2GEHWQM$-XBX-NL%/1%^Q",HCH?>M_N]O
MQOOIQWBNY5<81PAT+<RP2'NW(K\'[1%KO!DI4JQ(D&4:!0IG97%9,84FG!=R
M)F,$F:P:A7DTVEJC]+MQJ[<7*#2:D9%D1LS;LH,U(79S<JK:G3P<A $KEPR2
MW>XO:)U/SL?I,DV$O!$2Y0O1'3H]^>^ZB=\-9OO1\(&;5J("U806,CI*T]VF
MQ2ZI*[NF!IQF]1=0XS5N/L[ CC)2='"Z!+.NE8JL51?/4_"?C=I%1O>03YV5
M4ZK>TX%YL"?T/[T/=D:BLPLXC]-DY &(N-F(-J6[U+WDS@_#-\/D].')H[OZ
MKA'.U49C&4VO2W#&95<BD<IC';5)SIX_/7_CA?UHF"MNA:YD6Y 4+D[O9QH?
M_9)73)/\S)EII"UH,[R;DU64R.J" K0EI9)&HN%LDPAT])N%/NC*\]$2]X8&
MB2S6_;N"#C*<.>DK#X4>4=XEH@:"O_J3/MX$/20!G.Z*FBQ? D\#XMP:V3AF
M#2$V"-^MH^*;_DDH:R%%9,6OZM+&$<@_:SWKP#?9#\(CVP=44AQ<6:XDC3JJ
MDJZ1+M^<NZR*S4!,\9ZTH=OK/X INS@ZF\&P6H7(8=:9-W&1.31,KK*^J>4P
M%ZTO9?M36.W >,"*@]$D:NX<ZYP9B?AB< 5]G!<G$0-KE)[*M8]+Z,^]YNVX
MQ[QA>PE$^R(F<AE1NG"*@_:,[DGF1W>D8>BE/SUS8U50 KD9SC-)/3+ACO)S
M4"_E0"MZHS-3XN29R#ZLTC810(!E21G1%\+P[5H'2X.*"9+4$AJ>U"4!/P0=
MV DO]4[*KHJW,FVK$>]P7SJA+:?R=C<>V%2:/(,1 A#0R2S+$!?&)3WWN<\Y
MQ<F>0_/8MJK;O4/5[5!UN]55MR?9IA1[YDRD,A+!W2@N2W5Q*:]9KX@UQQH5
M.8"XSD-.CW$0V<0B,X^J$,MHF!"NG/F$64S8VFJG?MJBX//?E;M;\B0=,N[8
MDUG<!F:[\Z>7;T9_NNM!;6*-:U:Y)!R(6&5+H.;V (ZV*A>"_@ZTD1\O;^%8
M:T&^/1TPD$C).5K'"5+E2@,>[L^']R1=P4*W(9@MN"#7)G; [L(X _A$<:T#
M 5JV[_$1P,L[SH$V*4-N &M?QQ]ME^DJ7$<Q0$PO80>H:"S)">-&EI()N;<:
M.L]]3_Q44=,>O37+JWH-F#XR<1[KY7_M]B?4$T P)V^3%Q@B%O$\X>R</KS+
M>4BWD"([@N-B2J1]&/D116;?(3P3#^/[]C?8Z" &<OM3Z89IF<\IN1N7N)@I
M0G.X<>RI1/F!TDZ^3AD/(^4J21[R/_?4:&*,CINO@75Z@K_EJZ \P?<)%4 \
M4.I&^F]*#P;ANI F#A?3I1%P]5A)6U!_ 3\W=AYW4?"+QLOE6&:1OP<]A\"X
M.."*:4\X3^TY3IVW1G'N+)+:I(:).-<KZ%OKZ'OGE&Y25BO"BF$S!%HKB2_<
M#!IX[,[]LI\H*+3R*"G/2N/^O$44(](BE@//+F\Q\4(-M[$G29N9M=TP%=G^
MD'=X5S7+%9/F4:[%Q?/9I,&;.^>LNCL0W%47K"W$>/IFL<[=9:2*@H I=5,S
MI=0CP:TK!46*C;#)!?<$ 9'PD6_)M$+XN![;))TX7Q><8BC0!L)+!!C._!TA
M=.N![5./A_UQ8$CRU67/7EJ[7;9(*V7DGP#::26C/*E&Y9SOA8M0\]FF]P1$
MM$%6WMDZHC C^'.EU16)>I3L$%,BN1N&0+H=\LK%[HS1W_H&&1;1?HU<4,VE
MZM+34LCI#@ 71-U9N"JI+:2F77%5$O"BT#?#"VU-<!2M>'<?]PY==5&6VE^Q
MB[D9[;CO6_QMM "0OBROH1DAL7VXM1Y#@%0RA.FN47'I4$NA.M0&1CD;5L_S
MF7^G&O!?@I>R/6SB+DZKR5P0O;[#5T-4SF]$BT7W"G74!-Y6QG<9N&8?<J [
M2T"1"$#%H&5\BY3D@>QK.S*O+<-*HF]<TW1+E-Y:,)K)9W&)S']HDB2Q>[MS
MT$P3[C7+>N9"E1JD9:?5',#+D_F3J2-D&N3\ O:\IZ<M<+;I>O5'6@>A8O5/
M<DWIH/,GNR9R\-2-?1Y1BH^41^TZ&[M Q:W<%:5J/Z+-KNMOX/G;D]@S3W26
M%^A13VM#O.[GUH"(_,:.026&H$F@POFB#(B?0/B8FE;)TNT[0:DP'D79D;<^
M9FGZPOQU;!.E[Q;#"]S5Q4H]6-D\7<R0T^QO[42*S7D"7,Q@32_N,D)SEG>M
MG7UR)C=/115CVTVM39;T8[\3K5V,F$-,$^>8D6XEE"4WA[$:&BXSD"GDB" +
M ",?;QR-T^AVT43I/Y0I*J@QNE_E-:/FW4<>QJ%'<'#F.&848V'P^FPTIB2N
MN!>WB,$16\/G1(1N*,]MB'Q3,'0&H9TX2RE-[T1H*O4G2\\O&#]ZL>YOOBMB
MUA!/KD0.DC;O&<2$=ME:A%8HZ8_MU@ZI-</+L_^DF=(A)<)(M&FI@+84G]WM
M)[N2M>0F?BP\KC%?H(K3NE&=Q#I7!EI'&P*P82Z^XSR2:;&6+I+L:R5;S0Q;
M<G +9=,81#(8&F 08B^?HJPM+,0F1 BG1E,P55I8D/OQR%^&G+2@<FS1U*I:
M .T205I2'X11,2*'<'M<-8ZPE;:"98L5"B/HKX^&9MTVD+*;]YXPCU .5'(;
M70G:%_;TW&#)*$X@^[3KO!ZP&I+8(3^24-:%?]0B^1:R4RMC%^$J.UI0^FDT
M*X&)QKB^[+2UB3#AG3>+]\:/VL_B^6&KQ3+0[]#;[.M8+5[G2>7FG@IR;OEP
M1HVE&[@BYO8/BX)RL9DA*("88 -+E='P-7ZY%BFVTS9F4(.(@TR<.\6H:A:(
MI$,'!L(J+OD@JJFJ;IT%]S %<X]EY4 G;MCSC8+!NW1Q03Z;^<YMKHZ2HP5W
M,C1^1R9)/?ZX@.1UKW@Q$AX&-$V03DCB',8T:=25%](D^AC.QJ+NO4#@@*7T
M5X\\"?OF[E"71Z+C@TZ@#1%IT"KS#@9#\"3VBR9-#J SL3:^4_GD!(8?BXN<
M$D;O!?1(7 >K-#L<9V_OJ*1@$'WS&.@ ?V+1RD-);$M)[/ZA)'8HB=WJDIBS
M%O?$[U@RI*A0*Z^H@-/C>Z>JUFR@\[$SG*I"AS-H[[/"&:TB N)PL8*=)F]O
MV.W/C<SD(#C-GLN0=;"HTZ!1DR\NZ#\]GL%TM1C6?@M)E"1#VAK6.OW 53G@
M %H_+B7_VFP[#T-)@DX^:=( )#?((7PEO\5"7B1KI+%\6:GP##J=I V%7_HT
M6TI7W, JA@%NT\_B:!B>/9$F^"4EIE(4%8V LLM+$3A:PV-8YQ!Z('_ 8YN\
M$@,_BB*SB:2@@\KNAIB(2>C&O8TUDM:)D&!!7FVO;38[$:L__/QJ]#HY&UV\
M?#?Z*7GS[.WYSV_.GKW=&U+U5W)V%[E;()BVS.VD<I-)RHDE$#01:5"(!%)E
M_P R!=*[@.JF^]G[# U"Z63NKHNWWI#OJ1131+(Z62M]]FA"VE\(RT#+RNV6
M=NNF:S#SE>!I=/^ %(POD'C5WG2AF&1#5?6N1,+*#5M:&$LX[YS[I&%Q^XI7
M%@GVQ:VRA2XF<FWSM2;%^"]5QA%6G=RY:"HR(;-F,4A^+J[3*Q&LI<I\PP4B
M^D=-[YUD26C@;S?+<5XZ7^:NGS8;0TDW*V7GHM>BSC8%^T=HPQC8!R3-,'>I
M3*9;U'.CAHEKTI/AP"MD4NBM%'/L-M:=6*RYIX)/!HV-?(5HF;[7//MU6;WG
ME +X'VKW7FN43@;NDI?II;XIQ,!$K?L5&/Z#Z_7=?\SP?RV&85E5R3_<JG'+
M+INJ1)-XP;\X>XJ^H[#F),6D+P9KEV<[=;_@Y"C7.]S1\1YY2^J1K15338$Y
MV=#4"U34<ZV'C,NB06Z>7ER5S863V---\@7EO?VCH=007G%1I[YTE@$^J>,;
M_M=_G#P\_OX)7=@=6K1>N#]\VR5\9(4LLCOER D67@U^O.CKG&9 5DN::BO@
MBVM)7<G]7>A"^1H\'QHY&B32_:]9,XO,AH<#NIVV*BO&EJH%,7!$-S*(D+FE
MJUH\R4>]^U"H7IKVFMC^U>MR\G[N#+5 !6W[F.Z-#H,G7>:97"9Y2U=(E 4@
MN5BDA2(U$5L(8%&:>NON,) PIC]%8QD+O)^U;'"/\KIPG\QS\,"D.A7.[3DB
M":2*@MN;YP7Y9QSJ2)W)5;0%!LN*1X:X>#+W3;4B:E/36DK1ET.N+IIO=2IX
M&%@X]@?-BAEL_,=*'/.0?ZZL"=%R$RO\5I"V]X]/[KR_2QM3< ]N8UVA$D7=
MWWM*A8]JIA:2YH![GHKM.@/(Y>3XE+/4Z NA/7>%(\O:$",F+[N, OU[[?7P
M:OAT2*[4Q9S^8YI1(4T[GZ^9E^:([Z*_&R;GLY GWS&"!P_MS<@=@Q7GI,+6
MJFG0N6./4-D ='$#NTP+8Y*"Y**[SCFW!LK$6C 5TRJ_XA1S!],O'@;VA>::
M7I/X3.\V]EJU2@RY2,<D]8XN567ZTL\"T)IZ'B_%N_"UROCY.!J0U##M/;]=
MVT]V69;36^!N/OGY[<O7SYA8[>3T^V?__[.SG]^]_.59<O[\^<NS9V_>NO](
MWOWPS'FB+UZ^??=F]/K=WEQ1RJ3-2NJ29'^.=GTMP 2I#Q.#XR#Q9)@FNP7B
M37W[OM0-, 0JX=B<S[-Q132)?!B=/L(.?<BO1>XGQA&> >5I%NFJSK[3_[ /
M0YD-R6I0@"^1CB:]D$9)FW6I?^ <"OX2I5J.D>NQ>9;C3H)D7>G M/V)W_1Z
MJG_?E1>[_WAX_.U_VGRPW$]RPS9K8:Y/FV+F7L9W\WPZS0K_;\A>?L>9*>?\
M36],"$G^#S?6KZ;CNEPTZZSUH%$&;3W]B"<TDIQ%"4%.N>+PVWM_U&?FG]\;
M?OOXC_J$_[9O]=[I\/')'_4)M[W5X^']TW_19_YF75GS_*DV6<X9&<')ZD,"
MB'2BI8'M<_*[#^-OVQVUP],'\<GT:'BJ=9 <A)??'?&?HLKB[GYL=UY[_^%S
M;/UM$Q9JUNN]3]K'3P?['?K_?WMZ?&_'/SYQWNRA<-N6U=9:VD?,V>CRL(+V
MN(+D /HCK: +,>J?:1GQ:?5'6$;QA'S"448,"_$Y9I))+AS/9K,O^?"((W>?
M7:&$KT=7%Q/SZ2*P!F M@>5W5N7ULYBG6S"3-\V2+D#".G)Z5WTP6EEB>CYV
M6L):TL/K%LR ,3>(R7=,R6>9A,/:N&%MZ+%TJV=@+TM!CI\_S$1\KF-':ABW
M_]AY2I2!B^37(7&&0%G@BQB(KS4?M^?P^%HSL/OP>'A?G:_#2_\"I\*MF '?
MV#E(SN9Y-DLZCN/A(/AB!\&_3/SQ*I_,4W<2_)@VLYF[Y1_*3]RW!_VO%D8D
MI\.3!Q&(_.'I'VH![.U]W];0('3W Q;BP1('TW^3Z9<;/!X^7NTN<_^A H*S
M=/$^)X[:@U_X[Q$,)*=Q$]&WAU?_QPT). YX[CL0/G<<<(O>[R=;_F^ O?K,
M #,%ED70N'Q[NK\_,9/_A243(,<%#@@"F&T)ZI(Z)P3]J+ELZC53.@/;SS\*
M_@!_[:]-0?P )X\[4DS0:"+0H;W;^4IYCO1N:$,U9-0G]^G'?VT6X!>Z-XA_
M_T3QD]'/Y=LG]^BG\;7,T'^AIG43U/Y G(EHAE-L]E,+!B5BNCR]+,IZ311,
MN-$KX$;=A4]%)]C?V4TWJ/3< /Y>,MJ2];;"3P;)JRJ\E>0:F'3PJ2S6+(J$
M;MAA M[UT^/CQZ:IC2A[.S\'R\.6>74/=EX<_<\1P=;[?QE>)3WKMM7@KD.0
MQJ>O1\F;;$5T>V>"'9_),!_*7-"(!RR=FZ_Y\28B,SG>F,%<$$]VV=34*@-J
M!V*"SPJ:/<;=*WX%K6 O7[T5CN$!R(??E=!N.B_.T( '>N(/8*6*'I(PYC2_
M3X:C(<WLD[Q<E)<RZ"?NG980>*&>*VT@0(>.\KJ])K1F1NT25?3%%U4ZA4##
M!=,6\%4C$K=#:W&WM?C!H;7XT%K\NUJ+TR2?_G]_^ML/B_>GIR>GCQX_?'CR
M)[[Z%X>B[SQOV_DOM#4,N*EAV\F[+:B6,]5*,SP093%SFB[HW&)&KC(T%I2D
ML.0%I4A;)CZ@'SH#*4,-O+PJ"'7315Z75_Y,/?6*3T0G4NM1GVGG4_<BTC;E
M#T@BDJC*!;JRMDT%CH;XC.N<38/ 7LFM@+AS>*37697E4_3CIBOPR]3)RV+"
M9X!YI%/X#?8/#\QQ3KP7@^2I.US\*]9Q3<I9*41&VXY/'"S<Z<E?>25ZEN9\
M_3&M-B5H<#IC)?J^T%*^=H</.,0"1PFZV:@',YO,"SZ,I+=K(+Y16E"S %P+
M>AS/H7DB2IHX>%E9%12@SO$M*W5W-OQ-8G_E_S[]N)G9^JSGQ>:#GIU*4C_8
M^J2['LR\+^<IL0MB?;_C83PTD74"MRA:C\":AMXCYQ\LW7IDH;RQ> K"N4D:
M@CFX>GDZR[GS2WXH5Y3E:'L0;:>C^_/1TKW@FEA0%HOL,FL-$=Q)W*3TDJG3
M%CR'Q,KB?*$GV7J>O*PKVL1/,^=\^%:B:IXURW0M(U^[MU77Z63>U-EZ72<O
M6"/"#5O4>87CLY8M0]0]W#!*>IQZ9Y'*VU>KZ\=$-9)=&I!AW1K1=,)3,6+G
MSACIAA\(\[5;Q=S'2,ZC7+UUT7;8P)?/^'V^S5;K(*-#EXOOH@/S(8;0WRRR
M*HXH3H_IQ_'E_,]'0IBU[ODY=O9CWJ%ZJ8$->]R/RPG8#Y^*01XD;Y^=D3<O
M5,OTY7>TS;!9J96]8<:P3FSV;; $)X^WACS1+P;1U,+9OTHK\O^-GP^N0$\X
M&S?=TG(^>_[B9?3 G4CO6S,:^G9\VW%VF18X=Z2QW%WSXOHL^>FG"Z49"DP-
M*[3F$SMI-'*_M]]B;[>GZ4FUH1?4L@BOMGQ[2WBQIR;/G:C*\Y_?)&?G;R[.
MWXS>/4M>OGY^_N;5Z-W+\]?[9'- SZ9;$KIOID$-F>2H?!_SV[7TV3YUKN(U
M:U>'U 6= >?@ 7&7RE=N<;>;ZKBU<E%.<(^4XH%'R8\N#*SRR7MW=;=8W)9_
MV^3KC)V8!\=N=[W.LND\70Y:9O;X]/[C^UZM:9TMLM6<VCF%9="MOCN/OCVY
M*WU[CT^/[KNCZQ:T4XZ>/GU)+WCTTUY>-[]AXN\! T'J66N)U/7Z>G@E- 5#
M=]ZC415DS%Z@EH[_#.^<)<C5[Y2K,"&&R.4PG3SH!Y^[2(5G_N3XZ,<!D214
M;O<M-EN_]#\#SY+>^Y5OCWYD.TN,E4J-)XR5I!*E/YKE"^8!FC55P=3AJZ:J
M&]$]D_9ON>V].^E=^N[)@SO3NWZ5NT5;L<[],V66%?ZTD\?W[EO^M.0._4"4
ME>R756*)OEN7U%U/["!I719N4C=J]!#%<<1Q392:;FQ56;"2%!ZD]6S4*3PP
MST;#7;JG8LHW=\R$-OQ/?(L0"HYFT/,KT^DUWFQIDAV8X(7>SLGQ?R81Z\#V
MN7]HC$PTSQ\[99-RE6=BFVB6W+C1OR\R3T0_ %Z4IF9>9OK."ODJD<K-"]!
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MOVF:%;V.;EAT=I?#&DKD @X<!<[D;14IOT:4(#GQH8L+B2*IE4Z1RV*,KHA
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ML+.?*%?,@V0J4FCYY,CJFQ'L>3U0%\>=G&%@> $C<*9#/::XM:^J\\Z 1YJ
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MFM?:3=8:YG>50)%=3%NB9!<I=>& AS#U8//I+>:0,'<4)Y'>*!WX(UFZL#W
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M,R2DEB2%WQ6)HKK+LUG7H%F6:%GP]+#G14[W108P/-1A(A%)#S%D'1@CV9C
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M,<-P,>X0KA;[8O'? KH60"D'2>C<4]L'OG6!14,=B 4]S[.7JG4[Q5^-LZ=
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M$R7^K^82_USBOP,E_@\FEO8'4&>]^:(6HX)V:W3  0'4LBVI$A'UL'AKLRW
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MQNSH\Z0B@8@?8GQHNOZ,,R]:A?B6O8]Y"?^;+.&H7>"P5G"()T2Y4(;A-C5
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MN3Q>/ A))D(+P6EC820]7,4^ =N7 ZZU1OTK=GOIK,!^]\[:*ZIKU6Y70^L
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M%S%)4""[2A =JU-ALLPCB6VUT1FI;%%EX],SF-VI:@^O7F:'AU5<V<>]@FG
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MUM$.:*UG9'"*CX]?.,B?:GL.T"<N[$,CEQY.R"X=J(W9X]UMBN27QYW"+!H
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MX^=\T#$8#]K%8DZI/$4HI1U1I$/K(77LI"NWNZ)LQXBVL):&M!0CM+LFD!/
MBGBRQ!0LGJR'EG]">Q.3<T+(6NZP#=\S8R8KFUPIXXYRNW=&:"[8;B$B,,>^
M/W><FO/LK]+#=ZTZ6PV O_Y\B&_F\:WRS3S^F+H.]+$'7YTCA\XM2K/P$/X=
MQ%G*];'EZ1I1(/$<5$"G?/)@0=^RYM;!Y?9X7FZWL-R@Z0T<PC$5Q+Q6YK7B
MUTKOZ2BP& :(>U:C\,'K/LF,0*WIZ.!Q=BU()OH\HR!8PCB4^A,!A@UU&-8K
M="*$&J:3[K">U_&\COTZ3J"D)CAQ-=QL$M(W+ZYY<1U<7 $:4.(\,I()*&"
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MSNF\XA2!X2VPM0'APLE?NU(N%VE5-$5W)=%WN$),:29#Q-S#@)+2<(1QA&P
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MI&"=(BU-ZJUI&V'>=(*)$/#URKT9H*<&\,G2"2D:FS&27*7'%,)<F>'TW[U
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M=_T(+]1V\:&4!+4+SG54F/A@T*Z(M&U39;,ZICQ#J\JV5I=[77D/FN2JZ!B
M<>'Z'2& 3?OEX+6Y<]0;+W)+5C9?J>>.@6K*IXQA65:KN5'Y166YT[.L?BF(
MG X3B-MDJ:1HKB*IJXFP8W.S::ZT?9L^.BY6Z>.@V]-)^Q&KJ.!U08DL,(NY
MB,?!7N_KETEH3(M]5I^7 "YTNQ4 8E0&.\B4ITZ"T%$% EUR3?--$>3I0+S5
MN)5 9&4&KYNN&\V6LDFP3_6'9FYH;F1J^-!N_O"L^,C#%4B/$%]VII(*>F>+
M4@C9F=M@$0ZTV>8FGM#[$:)_:%U<=\LLWC.[AF_?1MVQRR0'VL)?9.Y-X8[<
M%UN3)Z^CK4O+,#)<GC?0BT&TA=SP_6(MTEXX-D!*ODB98,.]:!JG(4DX-YYD
MCQ\Y]5?!*ZY()@,EF4.8<.X,_9O )A1JAHP$.?BM31MGEG=E_YR]SQC/GE)/
M0WB'#$H?UD13V3CWFC.,2A7-^7GF]).VB=_:8BO][JO"+=*599,(@^9#.!,/
MF)%T=+1]C@^>P(S0+2LG37"SL0GN7[H)KD]9KLC(<*"I 8XS&\P]FU5.%/*O
MBNW0]ZYO?TJ:6;@$4 HJM7$B96I;4!0FY]@T@Y!S656-/44.C#R+R5RR2&J+
MB!HP49P5)/V3;*0N!Z'LIY=I\&PP>F&'A4= E&Q>FS*)+.HW<&"1$Z2'I$C^
M2/O4E;.H9CTU;V<(4BO3.ZG2D^S3YCP?B:K>BIF!#,6O@@)6EAR1RHR(2EIX
MWM58%CA]6>\"_UCT?($#D*9/AY=JZ$1_:8E'G5 E<"([P"45*C]<7<D;VC9R
M"-6.F6MBDV-HD.0PLUV1>9;V,\J64WLEDS5P2WN\1'PN\<(D+1L[>"D7YXI+
M[1M62'DH6;0UG_DU<10A3/7C<UG,7*, =I:(%PT,<3W-S 5L,K="FH<S,<"R
M\NM+R)?TS]:#X0&ZED.\[=+]Q%PI4Z$G^BR![#F-(DIW47&WR0+\R637P[I5
MWM@'1;-IMRBA*&S>+.ZZL_(7>YX<HI^DUYG73%0MFT!$-AL-FQKKY(+C #1G
M%34NNGDX?VQ49#9G3JXS/6VR/Z/TF:0G@C;4=933(9@+E^T1K R@"/7A1"+.
MMA$'H!.4UTBLA-W:\'2':15%_(9T/5O8F#_/L3/VB;VGDRBPG03;*2@\(FEG
M&!XR<Q28<_<P61_@ON=#6'8*:I"_"U>L/X$^KMNU?/]D""+CL& _4BL"Z133
M <:?4/3BMRD'7AI?L%&8%E5*E[!?]2R&1]W< V@*MD[9 L('QY.S%54N+U#$
M$VB#-RH0C>]/JB 9I"R>%$,[#0JOJ>)#BDHT O0>*B3A9_:JJE\+>Y\E,=JS
MK*XT;]FX[O+JKZD]%M3&C1UZ J'Y&7Z3+*6(D[L'K&=GB2;$$)HBLK5VYL'O
M4.+PNZJ]7@A5=Z3,#[?7#$"1"I7YL)2^UFV("2.;6OF#9SJM$C]3Q#&0]A^E
M3!2=YY.W29ZQ!UJXCK<"20@EKY WBTCWL;]_7Z'PB[%0.!8*Q_[^T6_;3W5]
M#46,:C8"["92(91T3&&Y(?G;(QD*)T9 M16$&*&[3UB^J2F0!R>DR)_,A],C
MD%Y?&3%1E236K.24"YY$GS/!2K[L"4S9W4%BU$R#]UI(QM;0X4ORWA)N)7,!
M1S$(R1KZIUM-4D][K#9!YZ:=^J4VH3PTH1O7B@1C>J\ ^%MZ&T1OGWG'1(JW
M29A;%^MN=[QD1-<N9%O\R!,/4,T>L7^;U:Y1?-,E*+O!LHV,BGA3^@A<-=66
M5U/7TJ982[HT2">Q 6MXQ)QZ!XO((6>O16,\G7S[+B)RF:!%14XV@5F28GW5
MZ'36;M[.G(ZC[K:(I4]'R,"O H"! 1E-OB+O+^D:P2(IIBUC+0UPRS" "<0U
MZ%=%F*;1@='G2O7=E=^A.3@N?MS> L5[^-HW@_*&V%*QN_$=#8KWE[<$[?9Q
MQC;,Z*R26X-Y5<I,QH>GV3NK,W<\IF'^'8[S 21&Y,5SO33X$"U?1Y]"2E"L
MCG")K@*.+D/Y2OC"/_KI?3/F8-@0YUY;CA(DEXWY,04VQTGAVD&IH#M2,770
MEGPQ[P90=N-H65UE!@.>F;+*WG0"HEIO67)Q)(:&'589D(1T:BGITGTVU \R
M*B8@4A0JF K(%,/3)V8JK8]T2A]:;;U:5F*5+%YE'9/CO1I)O:G WI.P$&5!
M*K/!>4(N3/<;6DVQL.VZ5W:97Q9,.1G'M\_2@RF\MAHD=1A+EGK#6I .H3X7
M(32:3;%5OT,TS;*TI&R;"RBB!O=,4I41=QKIJU[C9K)TTN1>9R4(->(!-AI5
M6@I:;J'<P@_F0D$KZ8B@8>WDYG93\EZVWHI+AL[F=F;+)!,(XB1DB8(C$\ZP
M@A>!)3':IUNJCVH?K?.>EI%>RD8?!F'T,&@QYH)T"3A[E/96B A6.Y.E[+;7
M R5H9W1B-1^SKA;Q$)N^)57S/_:VBB$B @\</#2$#\?RR@<_Q!@/L9A[JD(=
MRJQ]I$C>6_?_631+1H"("<P3 Q@5OL0Z*D'9'EX=\97HO\1;2MJ/HI>M0<%>
MC7L>GPA*N:AXF1)L53GA4](:TVYM\OR=72E#(7%<-^^I^RU(++!2+4VKB/HJ
M'*CK?>_E".Z$;BI(7:.N!V/,RB(=86JZ".-6BZ!AW);Z#WL*V?<[GIR!51:#
M&UXVR,/>7AQV_RJC9%;2/06\U[2N\GEH/AGD'T:YA6-!/\Q<B0K(7,213+7'
M?3T27[D 6U8S9< \(J',-F98Y%?YKHD"(ZG<6,MH7'D!4=[X3:(A(?M^BY?8
MYW$,.'I_CDAB#!MN$3:$-45F55I_L<3*G&Y)1@#BVC&NEYU*N&"_NLL]IGW:
M%M3A17CFVA_W%R6O*6/#&\5D$,]Y7]THQ/\=>_XI*>0-](\^2<<SL++Q<&K3
MH&! F"A/6N@R@<9<<C2!S(YW'0A< @B1]Y3QMTX/@(&85HI=P;WA 6O\ EM9
MNPOD!4V2 @DL:CDU8''R =-EL9\47K1_(HZ% P.-2H87E< ]DP9ZG*9!$Z"1
MKQI^(0!%Z=%Z:\I;M%C&IH.X=%S<GK7^JFNI,D?7(5EXWF4W4FSZS.E0A:8@
M6>K^YD@N/B%?S)$V(!S3D IB:8<*SK&<E9S ,]>L.ELOK;D'TWM1T*F>^^]O
M?#RU;4OMWD9Z5AI=$27PW9AQ,%3/35^&WT7P ^$RUTZ_W>TH*,T;<'C$6 *6
M@\A)O8Y\[:+DWMA!/>ZL ]4E([+O1>B?%%[(:1]G(-63858/">$YI4$ LE54
M%^?198(FLW"?;,)Y1BO"_JBKRT#KL2 --RU>IYL@FBBSM'53>)_XLKB4T4W2
MFT->=O1[L9C'.O:>.O;]L8X]UK$_[8;7Y"!2,N3#3M6^:%@]?U.PN*U;].DZ
MZ*-(]3ORV1^V%/_FY;4]?%&I)7B;>KR3 X.P<(:2UYP4<1:%"_+'Y\R=*,*$
MX8[^6U7Y2>?[GS#XF-WG1%I&V[\^W/!]+JPKOSP]%XZ5O^P;4G6O5;"0W")R
M/]@%N?$C1P?TZ;D!_1>1&1^9AI56SH,PEV2=)=9;4W;M5C<>&BNXZE5Y!**E
M GU:@/2)TEEL6$^:O@4S@!>(G6UT97F#@#]]ZPE&TT1^617^67-.:EW[4)DD
MV 8FRCSX+^$R^$D>2.\[SQ;=?.[@IB>U,I3^=<O6QR]5V\2?!CTL(C=/X)>!
M'BC, G<>=._:VL>39XC9>M5UZZLO8_3)61]\EMFL0@\&#JT)!7(K*SK0N6L7
M_ZE=+X(L8'8N$ALY]#0'!B>;^#AKJ5+*_KLHLT1YR\XOJ-N78IPM-[JD/ GL
M(7*.;^HHBIG_VLYI'=&A^UR:ZO<^Z.&2_C#M>CCV#[:Z6^Y<ILKBSG?0X/+8
MH@4PZ[-P#2I'1WEHM@T#1%WOLGSRQ]5UY=R=)H\A!^6T6LW]A\^*QGM>SR(?
MU-EL63BTX#^+^NIG1HZ;SHZGPMAP[@< *X6'X@F6TH\ <9U'>_8346S7WF>=
M_OT :?R)/0$_4>]L!&*\<R &LJ9)N15@-Z9LJ/D[X*/@[!2^@<)=D >IXSI5
MV?@F).>46V065BJ7(^A0Z\<5QG P(M_\:L#4<,LBZL*7CF@ M<'0U-F45^/C
M^X-OK=+]1 <_C#-W>$Q^?G"F-'O>PH-88]<KO$9MJI GU-KK(__[)8X3RZ/0
M4.TF'*@8Y,*_+*I7>G_E. I4_T;*FB;+SUW.9&T6G$>8/[V"<>]"?@\7=C/O
MZ]#.RR;QOP(8K=FV\T+*_K4"Y:BTE3=-6\/LQ79+Y$R+M1;MC'Z7OOW0N\6Q
M]>.R+IJ&HXJ/=*X,Y/!?$!HC(BG]FU<S+LBC*)?W-U]H_DG F)TF_AYD@\J[
M3!9!D"'()W7$N)I\X:A5R=$<Y[-=AL1W/7_MW ;?7N53M\)_$? UOZ U*>.<
ML8^Q+1I\3F*=E52 \Y6LW10"FK:LIKI<8HPDWZ[3:^O0T5B9)'%2FX424,PE
M,\!@*]_4KMO@43[*BU5;6[A*1*^&M;2HADPAVZOKM'TT5]OY<10J(SLJN7ZS
M?('6H@>Q9=F@@-Q_%MS;#D_ZWG21)-JPHZ9/ FY/%:DA^^.'B+8BA72L8(QN
MY!:Y==V92;23M)Q=#(\FFQO67R4Z&^2R$)2\4:FQ@(<S-$X!L&4X."[R4A8\
MPX+])F=F';Q=T:B!\_XSL-S^*;">=)#%<C$C?303X)YYLY4U:6P9;S;]!ZQC
M9T0Z979=P;2 %(+E?0WT3U+M7 8NS=9;4J_^WN?-R@,F^W7?ZPFV<.\[VH?-
MIQ1?VEL/T^&1 AU7;.#$RY72[_K_$CR_WXR9#@)%DKW7LAG*D)$,6C58D.MJ
M[B1F,M^0ZAZ]*38O-V669.A$4YQP)%1_*XF1"J 3_CD5CJHW_C!+>UU].$O+
MRZ]Y;R)GAB,5\T\<IL@'A$-\P$S 2@@/4<T;R9@#:AG]Y X@RW)XX-7\F!W
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M[MJWBVIH0I,SY %8\ZW3E:*HY#)F"C!*4>0ZYAI1P]@VB>DU#X_TW]$M1BL
M#*54\JN(P0B[S8IZ/[05I+:$Z@$*U[#7TM:=SF'%7Z6QO:H U(%R ?24.<+>
MH2%&G1[-GZ;KV*HM.KE@?W)4%)T6G.$ %0>;P.6_Z\:QY/5C0F%,*-B$0L.X
MVBA80HLF;]">/7N=IA84)ZP%4*A=[,\Q* @%>P%F<M^%Y5HH%22@D^'$!44=
MV#2FTBZ^3_RQN4$F1=W9,KFM5BIS-(A3I=SE<\:^TH.ZE".KJ@=J,!8YHY6W
MDD*5BBS'-F&_U7R*/G"_I/+Q<QVWPC]174B8S.,\'YCB7 X*LO$,0I):[F
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M@7NBAJI&H"OL>C>(=9E\:%<X/YK4@4WI;\E+&2OZMP\E0$! 4SWI[QR?WO_
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M.T0"Y,;2#FTW?I,J0>)D 2G&Z,&CCAK($[ON/)C0RU*.R,"5-7>K0COH3=1
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M.<$9F/(,/I9Z:JPD3\D$:;'<3T! *EPF[<XP)2+4P(GTBBLB^L? G]UE_N;
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MZIK-RD<OT(0?4FFS&IK[5P:X%"#&AFZBU8J1QLF*PNMV?ZA"IN5B18!X/B%
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M]WZ'4ARWDM2PBY,X8UB9Y6_+8NX]<?AS7YV>W/W&JL[]"1SFT3N^J7?\+"_
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M>6+/!R-$#I"J3@PD*FT6]8==' "D*#G&T$=!-IEM)4X@Y&]&,WO6]W$^)SV
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MH&LER&=ATHK58?U'?A]KA=JH&4S1J <)/V/;0KLGR (,73P84)K(; *R0-4
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M2">0ZV9K.2<SZ^SA/%3-S[$&YP-VYQ@7"+94Q7MUU<(+K&6'"U;:R!*!6CD
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MGJA-Z*H<:1198Q_S!F/ZC)<,90-$*N2 Z?)QGG<:D;"1]ST-O3V,\HOH^5W
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M?CO#^"?)'G"!.0,D9C)&8N=">C6>DQUG>+\"Z=A0%Z4BA=0/%4YZLUZW+AF
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M1>2,<$T2D28YS!";[O$BH L?N7&2UJV36"^;C:8^*)=H%EX&:GS9,G\Q7E=
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MN_73,;T"F\]&CILRPBX1=;851S,G2'TDP%L<%C I<\>\1)LQ#S1V!]!BJI:
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MJS@! =*_HP#1O96)H3?7$FG+!1 *BX5"*'#":@E4WGXN3,@V6KCIRG6/A$"
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M9!;%XCH+',R>@H\W/BQ@H0&!G=>E;LT^[1&V92<?,EBO7[2TIBG0_:\R_L"
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MQA#6RY[Q[LD+4=P^Q:J,O5H)\CDJEJ&]<O ,&_RLFY0\/5(B4-B3#%]:?!&
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MT6AW&B>\G<T/#V(T0>YPH5X-.MD$UU&=H!$J$P3IV85ZG^6TB<<M3-U%B>#
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M.9'4G&#DYCD40A<0<O.\(O,)1.X37!DN@N-:A+=>BJFCAQ&T+)L#TY]V1V_
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M2+U&6K7I8CT,*_MS#7I(P[COQNK-XLA#HP+/R/8P1E"AQQ:'00P3EU2(AD.
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MTW%<!FAZ#PT!C=2'XA@P$R@@/<8DNP<'9CH&@^2!L3C35$2TX21MK$A_1_%
M2+MP^-:$B48+]6NX9.AV-$(>0FQ\23H1H4P7!]_'_?J1@<O/.",7KA0F+K*R
M;WX=K92'!%E',UUKDD*STBR+&< ;7'0K_'@(Q^F1YTT?$6)!N#+!EC.:_^IV
M3U?#&UED:TWTS^SVHDN;W05X&UP+^* !VN6QZ?>85J:18;K AF^VX!Y F@=#
MM$S:5( /71/.=F@!+[,37GQ5:AQKGDG6(I0?.Y,1S1XDDN7TH[D@W- AW+X
M3>:HXO_S($'94"]$W\DP54BF<_>;V+8$3X@<$0V$9!S*R.!! =]ZR\?2UCRX
M?P[A RS/O P#Y1L:H\8,"3['MK<#\1D.)$)P3!;H;0&4AS0=@_0J%#$>VI4
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M"-#,T$LTVTLOO$G>5.[N!Q5?NF3KZZATS=97)^F:K:_YT35;6TG[\)+)'\Q
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M$E71XF#TM8_Q>F6L5!3A^+C?'XUJMSG_;Z<S$#&O0QTNFU+$K7B>J:/N4\Z
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M@T.B;4B4*Z^P83[^_A?^"!^D6T!S$7WU?AFF-[2TR1%>^N#=H63AN0QJ/#.
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M"YOCD<W+G0T^'UC!#"OF4-[?(3I6-K0E^E"L)],@9JLF'1['+;%7DEJM6G_
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MMP)"I/!L+\_=@.'>^\1:S.DA.=[(?8:UM+9DM'8MG>*R$PM&LR,+?R)@^(G
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MKS)B2V;HL R'CO/IBU\X=&=8(RPCA&7D;E6?D(I<(:D(J7AY'^GYVXONTX;
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M 7'R$5L^.P158,S-HCZ>Y-DB;7/RGUWN@<73"'P/"0S._@F.@8+J=?K:PV)
M;2=9@^;FE?HR!X.0E(SN3HU#+4(_)^*0L]C#J!'8?)DC\?6^9Q0<B=37^U-7
MY$D0X(058[>J,%^Q"/XF?4ZY5^YM1YD2(Q5'L\5@VEVW5_WUI=>LU'QM+_0-
MMY! 47NH\8O\8+H3T)J%>'&2R7@ZDXRSJ8NM6@1[3R5W][YHA05T=VZ"WIO5
M_P+[\Q%><43)!5PO[,N)Q/W2F65[/FM85-$P1O6$5;:S3 O;'P[:'V)V+E]U
M>.]F)Q6%D.%>[,[;]8+U?)7-#B6V*04/&AMT!J:<6@J7MD&SSL+,5;/+CL1D
MLTUER2XVR@#'[:C"CV>X.,<2!^@3ROONW1+MB_5NU1*1J/TB!4/WCII]P5UD
M4?/;./E7M);L-O 5PP::J+@V8M?=K]4;HVPL4NF&08&I5FH,6MEZR_SC*S5_
M7JNA0.&#3BS:EET::WRC-*$J9F%9T*:VUQ%QX,"DX**=2L533/IHT?XW,3[$
M^)S7^'"13K1'S_@(6U;;4OEB2PSL=F;GIM.[7._L/OZK=B-32ZH]/I]2I4ZN
M+_4HHS"8][&SCRH%F4P\P[,7-!N$-"WZI&EUX,>JCG?N:\9NIC[T_.1H40II
M/OOH R$_^P7YV9W)X35RLWO&""$O(^1EER<ONV>$$7*R7Y"3W9D<7B4?NV>0
M$#?^37(QHAIWKQJODH?=.RO :^1@!#,$,Z^1?]T[9EXE]R*@N7O0O$H(=>^@
M>97PB8"&@(8@YO7ZD2@AYAT8.?<^[<\L,:D7+#&I\]2,)+)*"JP=A17[AKKL
MU&2K5//_I&:D#ORRK3IS@/;KWMKVU8/&5,[ZZLCLIYNV6$DIPY0\D1D.EXLP
M%!]/INE3^[[$!!$3] DFZ!56*V*"GIF@PBIA9+4V2%!;NEVM,OUV;YC_$Z*J
M=UN/!4NEVDTF1XLYFFVG-R-OQOMK;#TRGV0]",/4%S!,_6;A2&ZJV!,0,^R8
MKAAN;(7(RF*.'K,<>Y+P@3N'JCKV8XKON\8X\)6Q!6*^ ]M[OAN@-37F+:"F
MZH8:4UV@&7[,-3R37$SZYS4G]QS\? [#5-27V+"\Y-ZED+ZP!8@\&"+!&A5U
M+8D":U349116D=PSE#Z'<"CJ>A 6C-R[%,)RD7M&PZ?XUE%7 UP90K3@SK6
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M .(CQN=W+I)_\P#?*=-CO':!O&[F"WI[D-/-OJ0.Q*5;["1] =L@[ML/0OE
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M28;&A_OV@R9&AW!V$,Z.Z[(ZGW07TKDLD+<J!HHVV77%_LQ^L#N@DQ>#";9
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MAB6CAW^Q5KS^QY%0B+(@94D29?DL93DFO+@V96'/NA9_+E5XYFAU?FNPC05
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M^^]F??W"8N[7U]>TO=K18%@<BQU.:TSM5F[7LS%0\?4B3.9XY_@F-RZ@I-P
M/&U</-NB>$;"0?8I2 +C.E*5=Q$[(,16G]!YR&,T#E0ZS]X[8?J&:B6AU_KK
MI&B4BIE%U4B6FN6)S- HM&"IDU4S)(-YY0;@?C<O;NU*D@M8A&YKN2G9"ELQ
M WWD:DV3!=V@A2P"C%K2<9Z_X*4EQ"#<DD<0P2V-NXAV_@S_;5[I%MEFGS'G
M!6NU\2=U(^@*"/\X&.+9XZS%]6]S'#:#+A+GW*,)<UP-N(FP\5_T8A/S',O0
M8O^@\'_W)9*]'_1U(B&UQ?>F_]$FSXLZ(&YTZ^*PR+U<_U\_X]IZJ,U*256G
M<E79;)@&V]G8,!# UQ>R3)IL7MR2Q8B42/:1PUT;B"^('7[30%C]FB^O/2N0
M&NT\5ZSR^KB]F2 #@7AO3FR:G*\>ZHM#Y#KP8_A"R,"#,<-+XG(XU!79)R%9
MD2O*BM[$>0Z(R1R$9--U5H8&M.Q6@M@LVX]9#^$1F&_9M'FNNO6+;$$RBZ _
M*K=3?8ERH$W#-SS2;#J>HH[SGZ2F^]JA?K\[(C<1ZYP'^_Y8'I93'-V1$OFL
M2*\GP2ZE8>RC^]JI9#R=/B;S(]B_=NS?S>;'340MYX&ZD[.IF96>UJ0*E^(S
M:K+?W/5:".HP=,EP\>2)FYRO\#0'>N3XQ2/7 "D%[)6E_1TR&WE'8<OX/&B^
MTZV/NQKRQ8O,HS?DN\U0WM60B6+?PY#O4+$O?M[@8D.^[I1Q,W#5J8**ZAT]
MMG!1PMC?X@)[L R,Q5FO4B>1)*&(C62RB5"F$\6_2\6_B2QK4]FB9<KK.H(*
MURP7-/?+6--2;%^P-?&PDIW(N&0>.N)#7IQQ5$-V!X-@LS9<E%Q-8<;T2YZ$
MO7<X$*,0T7SLS1"F_^S>&C:T91-C;(%S4UO>E<K>871Z#Z05%Z^$.%JGRX]X
M?)7="DRJ0HUE,ZR9 #4WU1CK33W1DAE\X28?YY@D*?<DJ+Y25),##D1_(YTS
MO6/R]&/?$6U)X_6+Y$-)!'C;:2&2#R6*3Q2?*#Y1_'O)^=U$#>91@D%8*8:%
MR/4*CMM1+- !:N#B:L(\&)_:#=BQV4I#V2F>N1TPG8SVD'%KLXG,I%'])<_%
MD\DWCY=>46*TIOA[45S*N[TK2'_Y8=F+'PR+[*%7DD6Y-3W^W%-/D1WKK9'"
M-5T'NCF:5W"=^=/R@Z^]"-=MP=9RBF5Y#?WUA?O4^:AU&FS-(E6EYJ#7&LF;
M98/2!9G)H"U\CHI3)^X])];A:JW#1<]%$6/P6;[ZA8Q!:IUOIG+^6I$J7367
M=))UIIU=(V. KL-A?F$,KCMA_4C_\*\]_\._444O/H\6&V_W3CXA@[B9S 8A
M@[BV$HA73HD^GG=\)QE$>3RT%-EH44#,50OBK#F3.BV9X3^C*(( G5!!W+3K
M\U6L$*>-P,_8-Y3<:J#1VE;D^HK\X(Z8?)M=(^SCBSWC?/J"EVX1[-_2(D^V
M(3Z5"N(W%_GQ3ICGDQH0S$XATZ(\8=R8"'B1AX%,,GE#6Q%O4D$4#%NQ54(%
M08KDHEKD&;TAWVUF\JZ&3!3['H9\AXI-J""^J-YYGY*/Z:XSC_E3$#,\+X#>
M%T E(JHSGSM(1HYJ8GZ(A0L2.NPKT&)KQ745V_?B,1L0NHAKCC:C)P62D+K\
MP;QG>W'E/>0;>@X#OH/P?B(\S4L=L^&ENHK9T+R5P5'M<7,JH#XB0F*>B_-I
MCB2BB&D@IN&J<]4?,0W]\LZA2F.Z)#5Z#VM0ZJ7:[<$$]1'Q%2?C#'-,5TPL
M [$,MUUA?\L%/.^U#/5NRNCS"],PF<IBIR6T44%LKU$?47D]'4\R%RS.B4XH
M=0B72 Z;9$2BD>HC)?9$?^](?V_3*^_OEY43"^]6>TB/ATDG96XYE6)'AE[+
M5&&T'MZ9R,=3?(J4R!-T1S1??^<T)"]\R>=^9 =^%CXV&\LY-AX'8K9KNH<[
MP[$73E+R)+J^P[P;(6X@BD\4GR@^47R23[WF?.JC-X>=.<'6PA< ?/.U).LR
M _R$FE<ED3,[TR6;>Z!W91CKX3ODF$R<XH]OBKV!)"O8 %<U/))@)2$L25!%
MJ:)DGY82]_@\E9[B=Z.)+E$^9<[7H-1(YP8#%TQD-HF*25@VGN8O>*CIKA2=
M8/O6L?VIR>=W8!N8.:N[RN9+%"<ES88 F@+/K!&VN6\_,FF2=R; )GGGZ.>=
M+<>>)'S@SJ'A&).$,DDOW%E>[98\\J?T J92 MHK;*A5WJ >5N4%(P76?,6S
M>FV5$ 6932&W/)VZ++':O6."6(8KL0PDXTX4GV3<;R;C_O:2F$YDY_E1NSF5
MBIX<5/ADJM[,M]"2R..S#3Q]?&7H52;7VP<B1I1/OY#S'Q5 8YV'2N*$"IBP
M#!O\A4ZVNNBWH[?Q,_["Q*#W&-M'75I?G>_[^Q:("A_A[S7T*D1_%X+_%9/X
M,*K)!:K4KHO]G%*QM777+<_6,HNO:$PR\53Z>+_Q]NYHC#HJB VY)AMR+P<N
MHJX'!#4D(1^=A/Q^14;K.'3)H9; )=O6T&LD'T^2#R3K1K)N1/%O3O$_(YR\
M?,W(LV!2L7..=_*48B Q:5'?SATJ-VAD:6J>2"?&,)),8^*0U/%F$V&U)_"_
MLZ3[N7W:+\LI,Q2=B=4=_XQWT-R5KD8K-"59F1O*RA#])?I+])?H;]3R>Y\1
M"GUJU<'S73;L"L$X"5UT^-:](%5CD];E>3"2$@_L;%2B_0V-.-3P!8?LB8J\
M\UT*\M7YSY=$&+8'IPXQ82Q<,#>">4P_7!5"LJ$D*KSMI-"M5">O/'_^L@[K
M@.IF".K'ZW].6,)N0UQ4JE(V*3*!W&VW4^ZZT(&6$%^#2,?I#*E.)I:!6(;K
MS!S_D658=/--.B6T1J92G>>$ZJ8P&9DM9!E0(CG.\&\5:1++0"S#/622KS60
M^B/+,&F5@2J.2BDQ6([E:<>M6:, ^PRH?CN>9&^%@/I0*P(G]C,BI;L"]QVF
M?KXZ=7G51=6AQ3ID>NS?L5<6U0GT72JO2L5^)CL4Q?6FH[3D)/5ZC'-[M=4$
MU 34$0U0/@3JS<3L6L.BM9$8B;.S:V.>K1D" O6KX0D!-0$UV:3YI-CB0Z"N
M: ;(JG(P$RN3'-WK)D:%[7:-0/UJ9'&C.S/HNIOG;(SAE:'. HW9PU>'@OG"
M<K8 [-]:!*XZ53P4GS@35YF3_9M+YV+&CJL!-Q%^_B]ZL8GA8R*Q?U#XO_N2
MTJM9W"^44K1R.9_*3H-Y;1NAM3@0RVDG#&ZV..QRV<2V91898[D$=&O2]F!H
M%-Y 2I/;1XE9(68ETF;E4ZDJWVM6)B4K7ZCF:YZYW91LNB]W"].'-3(K,#AC
MDN3J4F)6(A#?14M*T3(KGUK"]UZSPIJ[WH2BU;68H-/-<9#8](:E"3(K,#Q,
MI6]CUZD._)BJ>%,4R*T,#6BQ\?9ILRF&AK8R?(,<^8AH-NMH0O_O'S1'G:-
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MX,$1[2<#=T(#R 2YF,/4"Q-B1FB;X,R@8VJX&W!I@9_;%T,X@8\N=O$PIA?
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M/?8DLQ@6&@RAC1__AI[3+V/8<E@[X&I/SB*TEO#Q815!Z"8@P^;MU<%[B4\
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M#=B=D@79$[-^IGLNZ2)WZJ-$$>ZDI#=Y&7<B<MH1&J@N+5S648LO"1@&2M-
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M/6!:#,1(L37,IO*"49YJO5:+#S?0G!XP-;AA=!1.=K1\,_*D\LPZR>WPUT_
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MO.37@HY"B"<*%(\"M _0'J.]1%(:J2D ^C\(G0+$"! #(0;D.,A;BQD8?YJ
M1Y3W_75L.RB)ZD[Q@H8L65BUD"2%.[J[[01#.R7QT,(!]8G#C^*,Q7WF@VXB
MZQTX*)?H0=#KU^?#(BVV<<)S1U$ A_?#H0'(9?G'''T/,2>5TG8=N_Y<>,@
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M%YL#7)T WE2;WH$3JMV)SP[N'L(17PBRBYP(/_;JM8-:MO*#&31Q6*(4>_L
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M(9+;I( N"I4$66T06C\XS<G==NS.ELGD)U%0=H\5;(:WMPU7JJ( &D?Z(((
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M4I ([WG8I]>0P&Y[!PAN.D0)@U@RC#E2.%#4P$Q!D7V_721Q7_X+/,X>(7_
M3&-B"A*/@YJ!P3W^_0#11@Z=>\76<> GV</@@X?C/[ [:XE037=G102.9O;.
MZ=8M-M@M"4Z$ C.9"+]K-Y!$T2JV?SUD*[><\]@-#3MB]=1?^W NXKQR<U2.
M5_(WM834C4AW'W#A\I6]**X?8\[!3IS-G?X *4TRYCB?60<JJ[G*IWUR9UXC
MHCMA(GL>I.+P=,Z.@^ %UTW@9B8]4GG(/S _1:P(LW2;.#VO$B@8SKK *TMZ
MI#HL25W#JN &M[QVC&:(S^'\B9.W/#4D?&:&ZY@!._<+$Z \DPY^/G]1'1CM
MCF6ZLU!%2K^=Y8'8VZF$=[0 OYTXR'%8(?\,YODC"D0GR2([.OV%,&.[W_C!
MTGQNF0D@SB+[ GQ+D,6^Z/=+26BL;B_+U@UOE7WP8@.-<\I@L2M5=F6^$:&7
MVV53&,H[J5CUB:KP'W>/414V(!Q1#./5U11)3UT4-T;"[OF JY\0&<\^"4J9
M$)7"D>!QSB>\-1'CG"D*CQ4/.^( \_6#FQC;W^U((=U%X#T![>M]'*9,<(:C
M8R+IR"/H&]AJYOGTR\IO@DX\4"]WL'!. D=!95UA"T_DMNM S2J.M&<XL:L]
MPV_M=347I(<G:RLJAU,? OLDAL7VYQ+([6OQHY:*<"- Q:Q"UY'8\AM>@W\[
MZHUUQ+3^@C<?_A+K?N<?./IT^*'S6)E(J'TM\;[(1[/A5^&[^WVB7P,W\@?<
MR/' C1RXD3_D1F;Q_3@N22)D1'0LFJ;I7V3V]SN8D^]R,*?..YA?OH/?<6-'
M/N&.AKQ-UNUD6>SL17QN_?=>&L1A0Z>#' GPS;P3R6A_P6GWAI>CB_<O9.B"
M[!H;+Y"0;U'(D*]/L?'DS&>.A6<D?![Y=]%M$<*WQ8$/PKV!R'6/5!$WMLJM
M#&:O *?3(S7<T3..[W#R-AXK$8'=>V'[7M<&@><4:*[*Y=Q/4*,R]D+WWDZ*
M3;9.,8C][SX13N>L>U@..+QCR15JP\J[2E?4L2?$JL6^\L:191;),F0&'/+F
M3(&4MS,(8H=3.TMPC+OX(T="UL&:\'8%Y,WE3O0F8VZ7V+)E.G8OUF&C+I')
MG! X+RZC<T<*@JL=.S8P@"(%<=JS_SZ\R'MF''(KV/C\29487A;Y6DB<>WF(
MIO FQ#%;.'R BS*P#!@Z CU*&=<IYJG.M*IEJL!41\-&A:&RS5"+R5:Q%DM)
MPA+WA3^(XD0!F*P$:4R=LQ!:G&,CW?^ 3AK'_BF:RTY0#C^<IXM<+K:-UW<F
M) -A[]_9=1$#I81=,G8.!$9DB6#,F64@&R!D"2_M=@[@:W,.AS<ZQ@K4D,Y&
MT5??=Q9#BO78_:]PV1%G(9@=N#WDB(#KO]X3>I=TA<)"F1,3Y,E,_"O\MVN.
MF2%3HTQ25V9 =D]HS6J"8B+^@-)"P$G&H:,@]'#YH18N/]2RW;>:&S1^F('A
MA*5,2;E);0:0Q(=YD>/NM5=G4Z-[]3A>8<3@SD"4L)F_(G]3=8#J5&K$?$+^
M$/BSZ[!AH,&U&,#W\P)*4Q*6$U/37>_?N57<HNZG1[]%H1NL1$)/SB(@9F?L
MBRHPL;=AWN" #P=.0.PP#D.V5460L0T?^ZS^VIOM<; 1O(\A5]4LJ#JV;$;C
MM'T]]G_8-S(."D+KAYHN"?9WBX \X"J6RJ%O"!.:MK;3R1#&XJ?'CC(,K+WI
MS'^4F[5&6C3O,=(QF&VP"_&!.D)XU@+'R(P#AYQW'PYIRT:Q!P>FJ)2MJ:$+
MDJ0(.0E:4P4>"CC^IN-U62L2G)?54#6HD,KBJUT@!N1]WCNU1OAD%[@Z+++C
M? &ET*'<*YQ.QBX/JHKAT(F])+ 7HB; V*#JED=L!KE7]UH]7(Z;!D*^A[*R
MB'?(;21,)'H4/G*41K8/FF*E%\D<7P7Z_MAQ])C;37,"(,@>O+EB1"R $ARK
MR<@0C00V+$)Q$BLL]^,<ZRXFGWT>&!P%P8P]JEC>0*>'>2 .T?>V\L:N7"?C
MRXT)<):^C]1'49N$01]C(DMA=HW-4 K\,I[3-#AE>9P/ 9<+UBBF#KF[T:UE
MH\G#GJQ= 1([/!^.4OH<UYR3$W>0JPY_F[&:FSZ^#X'CR3%32V&+*>X\.Q9E
M92-3J)DMI%F[SC IAX6"YM!*>+A(B,DH:I' &@7%<2RN:^=N8&):3A4LV\'E
M9.XA/RPJ)BQ)#W9RALL+;'/<.[(E]H*CQ_QMY[0>JP"G]P1AN$O(.3[O"MBO
M^66.YI(SZR,1VYY>]"(N.>:XIO2C8FP(1(CWDFV2-[$69I,Q*IK@V$+]5"WD
MC8"W%&)*,N'_&IS*F?E8:K>+<R-1_,2\N'-++1S:%Z&8A=P_^&HBOD^[Y+%/
MVI>+!:S,_O_LO6=SXDJ;,/Q]?X5J=N_W.:?*^ @! N;L3A49#)B,PQ=*2 W(
M" D4"/[U;R<E$)CQD#RCK7OGV+CI</755P[*AI:6,5' G*W_>FL#NIX1 ALS
MR/Y:= *! @HL&DP655F 3!'.0P6F8J;C1@1_JB@C5O".,N7N-^/:1;T@65<@
MI&=P@HEQ7'4OCR**?*<X!4=Q+Q5"S5'XL7/MT.TXRK/[(OW4G,2#>&-FMU'8
M\"R#8Q8@>49$S=+1MZ":35*1;1ZP\\11,7=:4\RAB$$)PSM)?O:.<?EPFO#L
M\7YAPP0YZQ)Q[(\G\H.95-K$X1J4OGD&$J)$G9=PGY *H?<Y]TM8),8(,CV(
M7\Z>*. QK\"$ T=&#0%B+X1J7XB$83DK[Y.S,H[,\]VG>](J98HCO'O\"=3%
MH"XU1)5<N>TH,1BA'[)"S$V'O;CRBT>.<\.KP)H$K<"]X(! ASX&A$/1-^GF
MD]NB+HE:H7*$]\7X[\@KDVQ?K;_?@%>'W"J6:L?*TEB8'35ZLU\=]P!Y1+LM
M('4-46!X]X(=QT<XN%=MI<G 5+DBT+2-1;N.< ]!P5CI,RNA9VW;@O:_H8_D
M1B<AX7.GWR%")!G4CK@A$71(Z_:7@-]_SQ[;W:^7U3N+"W5;R<FY2L[=UJLM
M@NWW"M9 M$Q@;#L"@XT%]NO"6<(X!$.1QUCJ=>/1#]VM8-J< $Y@!R\>UB7Q
M@S$0Q1,%7(?#2TZ0+1B?UO>0;$YE9Z"(P-&*5M2<O$$H@0?N"38/W87'N0OY
MT%T8N@LOG'6:^BFG8/I33D'NIYR"L0LX!?<351KQ9HO'=LE8OU=P#T'':C-A
MU<1QX#4FDHJ?6%''M-85[H98QH6H(1L35[ RA)E'(J)F0ELL"A2'[CQ-FK#.
MX>/!04)R@!D'6QOO/7S/42%V=^U5B<C^L"T4,WS,?RBX2+5Z9$C: SC4!LDU
MJ=EWL"L&XRW@Q#!&A(>3:;(;,0#-7%,ZT;@@GD ^-35<%9LLX8A/4,AR5<ZM
M"D_T.^0@-!W0:W3U63^W.BRYA5N=;3HW&! .10Z$)B5E:&AL%0K)1??H&(6@
ML ]I!@X*9AQ'KN2$1>H F3?=#+#]:]IEU W4%Q!N(/A6J#3K.2>>T!49L/Q'
M;8DH#ID$<NY&?MDIIAM@VA5E! J8>^9G4P2/D/A=$7Q'GB-WMU7QV0UQLPW.
M=F"J*^X3"S?*-'; ;%LV@V?#)05_0D0.TF-/)RY?+N6SY)K^V\3T[Y>195\Q
M%5_"(W$5.!JI-]R"V+]LUYS'O> 8\]U0\2*0G-K>&%*..\P9?>>XRSR&>V/;
MRN[77@/)\LDI,C4*$69@^]T"S.J>KFANRX"=%A[;U=:."#8.-ARZ*7YNF3K;
M>>BA=M0<X>:_T(XHD$081(N%;!1^ AF"COVTF*+@1T+L6/"-V-DT+BT15,?.
MX24E]HO""]WYC=OVDE1YL<%'UZ59:$[E"6JOHE_">[)))+)MV^82?%ETQX;[
MH-T$7=T.)4"TD.R=D''C5^CXA0IDX<XVD$H29UF'.LLJ..$))S5])\UO=OQI
MLCMDE^5@UYJ#HX<\>9['Z<GJLUNT>.H[N#FHGB_#O[M2!LIR0542D,P0P>DH
MV(-C1T$@E1RE.XFZ3(*/)-T:TPT1JNID@ TWU,%'2Q#0E"F/F1P_,;@7$O^[
M?29?I0#5K3SAHJC]Z'$GSSF@K^6@O&"'3_\D6F*L]. CT>H]01<HL$M%):A^
M%C^Q6\:387?#=/-L9/,B;[3IQ"QA'_IWI$?Z*DLX[D6:,03\,I(K2=-WZ;'U
M.5%,)+,7"_%HE0-H9MNII!T+)0-D:DNF84B8$)/.D"CWE*;P!*'?EJ74XS?V
M^<QP31.Z*V*A);VU[!1.M'7R@'UA^%300+B)ON$I0'0.\W3P0?R1$+XT6E)D
MPFU5Y7,7$Q<E$OI6MI'?X]CV%C_'X1!._V([KQ X+WOCR9L]0 DN'M?CR!L4
M-'.<+.1!6VPL-?S64AI0\J'#@V@<GA(?;MZ%+UW^^W5Z;?"G+_>=B(?EOH\S
MS+412YUCPB(),ZCS.4_[EEH%A"AR113I3&C-"J#KFJVZK'"5#"JMT&(?^.]V
M!VQ*V$(L"K$(8U%A/9=UC^!@A^8[ HNG82>5-X8 7I5*/D2E 6C0"M&D[5AA
M,IT;7(&6<1L6 %*,PY#7]K>Q,X@&,3E#D6 ;8FJ(J1A36Y9@Q_?[="YJV('T
M3?":-%!B$"XD,T**.,DOPK<!;JK;3HA25T0I6WWU&( 1[T1A\W] \YT03WX6
M3[:-8'<,#K0UD..*Q+SI@*B^$U_1>U%0?48 5_MSZKH'X%AP\ %/0$ <\V=O
ML;.WO7"0/\VAQ20C!FO!^^H]AB$XQX7@),,0G# $Y\(A..F?"L&)LI^*P;E$
M5,WA?-N.'9:,G#HXYQSY3>SJ83A?=\]]TBD":NPP$9N@%]U(W1%CM_4CY<8"
M5KNCBA=U2Z$OTGK!NK81%-+%S+6G.HU!W.!73P%HI[D73:#RV<%)-[.M^I[.
M(L1)C;X6T,=%=S-;@+]#"BDA1?N$2#YOYK:=W%T*Y^^3\SIU%.U 55Q6#]7:
M<ZL<N_6U<45 6D%^=ZD]NW<GFB'/EB)/4:H!W1>9#&<0')<W0])A:*K%5GX%
M ;BG<0TY,@EQ=F^.'",@PV<GM>(>/H0C[@<[EX&NR]15Y@M^T?%2A$N/D<L0
M&=UQ*_<E[M9&'-Y!UXOR8A02B1+T593&3^]]R[_@8-I67IR#>5MI4@;*KD,?
M["^(CI-B[W!4%ZXS1HX([**S-,S&KB2!12XHFMDHZ:F^[KS,7*-9J7;;&7^M
M4WP2 C)GDP@6;Y8T)D5PU269%S<=)%%G"+_LH_TZ%N'"%-NN3E2G$"PLDL?J
M]WIN]R1SP4_M,4/;XZCM=/1!]><\B.11ASQ)5[3HF^\9;]RR#QH!MR,!DO*Q
M*D!*N* C41D[9$GV@]?OC+:GD0S"(-3/H)H'&''V.71)\4XW74T43'$2L>:D
M"EU@DHZ;^KP_,P?!Q5GR6F7+<79.1I5PI /-4C/:3G#D5B? 659?3(Q>59AR
M3V;V^6T>X=K"^/)5Z'Z:;=HG8]J>N,]'8#)7:P[@55KG.HA@M=6ST:T 53OH
MB"0CT\A/R<X+],22!J7.VX2 1'G=,P&+T,8C=FZBP_4Q87'=D31.Q E9HP%[
M,1:]SS3+2%#.OV?J;A2AIZH,9EIVXI?708E"]I!YC5!_77%(._'6.BT_'>.;
MNVVW(S8BH5A&V(UZ=>-GG&9L=_;:A&3;2>XD=L*II>L,AV=BLMY,\YUP,40(
M34\1.S>I%(MB'M*(R%-@&#*J-;@7/)2W2JA(B.12/60?V%&>?>&/EZZ&6;$]
M[OOJ7H(%.XN)7+,RA3+^(/<J;6:5YZ] 0YR3791H5+RQ23JPDQ&IG8@D0M'>
MMBCFQ(WQ4W&[ 51K&K]O+ WZ!2AOI2D[((O$-#HK.D(MJ8;MT <TEGQ$)%LG
MA U);6LJ+'N: WNUAY&L&V9$AF\0_X2$,L))4;*6N[0=90G9-(2.K- (=13?
M/,?QS1"N%I+\B/\(5P[QGV\(QO"*(5;A.WTGU,2^0UI9 3T_'$.;S[@BYZ&*
M!^@,=6'#I.A;8YI>MY1OFH-E;-SFP;L-*+>.YI=6_Y\33V,0;ZPWQAK1>$''
M(:22KUFUKT+N)0O7.(4_$7G;(8]H[T@T<\FC<UU8]K5OBSH) \/Q:!-KR(Q0
MGTC(%5&T$(D@Q X:'.\\1!94$_B0VZG[XSZ:[0>S);+)WCJO,CR@K-LM*P@N
MNTT9[ID.$BH]@TAB 0JZGV!1T71:%-WYY4VG*@MYCT25P*PF^J_CE_I4J#RB
M"3A 'K\3I\2^'?[E*!<.W$F]?U?9<:#C=%)Q=>/AQI,^X$V6I\5!7&Z*CXN[
M,(R$I:;;&@SN/OY&='#?9'=.!@128] M1] E&UYJM=EI9N 5RX?;6=E^X$8<
ML)XB^^ RX<LH/&-NUTR!P),4APSZ(A@-&L:Q78;)TZ]]!]E<> BH)P<A3&3J
M;7+E)U4>USRMJX.[(=A7Y+F[Z]3JKJB0@^$HN@QNS5%$L=R@AE3*+57'W)B5
M=9^K)WO"T]NLI+Z8(W8\WC5<!H^[4'GN3\HQ-@P8 @1;G#EHS&2PO?),:>@?
M',*-[/P^D25(8K$C+\6QL7\O*8IU??8/$E$[P@@4461BJW$@2SN_>#HXV"E:
M7@878&8E@AUD2FX;!R?ORNTFXRF.3RV;N'R='>)J&6!D*0S:E;^HA</H?'6S
M($-"62(N4W;F<9M1H:I0.*Y\!)BM6BZ2NY[;J]/[53L?M+(#'_]9/+98CPIF
M6#.2M4 MLLB0YBE417-9'(N+XPNE+3'=0&1J/_1W$K G1;(N9AI #9K2J3H3
M,.LEZML[A55Q"NAAI,-=?#S"R0@KT:* ;:2XA"MM?4.R.M4Q(.DZGIA@QK#&
M8V#8X5KN9+A-QUI&E14*2]="(&(N2Z,"2=U\]TND$)LNPQEU_U\\$N&=8ZNG
M<J$=GNIA_2*\,6Q=A?-!-N'\2M,4O:7,MA5TG/'BR,VD"9>&,)JT&\6YE"CX
M!_)PDAP#F1=F_W<^HZH'7%1.5\F[T2S=;@9&DF2H$&(WP$([AE@0%I?_!5=U
M*G15AZ[J"[NJH^S/^:JC^U<Y*"F>7WKQEX2T::5=I<U1O(@"8.>1NJQ[Y&,I
MI^<G>]J%"-LF FQG'1**+3@Z!Y01;-+KD4I43\M;W,QYA)-I;&?703:*O<<H
MD4K0=2S%T#YQ1^035QP)*'!Y+&?(:I#]@QB1;>78J6_DW\-6^3C,>?TM3':;
M\1X^JITB1LKX^SDTL3Z/ O9QW-S(" ,D*K>X(NV5W%TY%#D)Z3FF"!FW7+9;
MGW%+#>R6V71FU!<R+*@U$_D7@4U4DE>P5A_JN^0[E*\(^,7:^+J%*;>".&C]
MW;T[=+SK=GN(S7:F&C(9Z+( 47R$3=7PY7@: ;.ICWHA^:&3\4%'_D&:#6%2
M1TOBVOT;Z(E(IST!]PQ =0G1*-HFGK[A-UP7V^V AL?*-!P#-R<Z. K/#]9S
MC38 WMH'J0SLF$=]'G[9F-*WNT)%2.]<K<ZVY&%!V:0B*5T0%Z00D6D4ZFSW
MJ$R(G0/NK1.,BO^B4@ X9!GM2245UTRW[:6; [1UP83E0B28R'.[7Q.= G=+
M-($@V>G*CDO/_8I;ED34(EXC-CT"CE4Z6&A1)ZU <7]4[4.C.$Z^IFTAE,VU
M#%.H+F=76 >ZS4I0HIT/],6+-GWGZE&6&SVOV&R\;,0?6[=%B\@Y2&?,BU$?
MGZ)LNU9)$W%W-YX\6)?KN6GR=H16'HP -HK"+SE6"L](VP_GJ3A@"TM4ED)?
M1!00Q]'@\I8F230F=F[-4UG07W#=]5.[+<@=ENNI:XOE):=!>,#VG-;$GG8G
M:%=#7&*16%F *I#J3?!STL 6I;20Z!7[0+AALL_GX=WZ=A$H&OH")Z29W CV
M]TP7+6R7K-^"G*=GSTQ#8@\)FL."#Z%;.*P)[=%IO^[4<H*D@Q2RILXAY&"R
M<,A[X!WJ;LU@G,I#0PPTK]<=RCE.$  JO8$_([*NG6]/=NOA</LW3JK&.&=W
M2E@[GI1+=8[9-ES21A(X%A!"B-RZ0;,YG2@W/]AQ&7!Y].%MR6; #1&^A%QP
MR(U+NC*:0)P0\PVBJ:1WN&. M#U\$JY3@%LEH>6]#1E_<@O4W[N4(3QIJBK&
M#@L^>SV@Q;@;WA8,$(,XLVF!'50>CK0D13X/IYCS5ADACW*TIW.]R_J0M8B&
M0Y+5=-)5&^I:)OW(/09&?_<D=_C;7H6/M/WPO!5R\6O!=O_YS5R0-:G2C#;=
M11F^-L5!WU*$%;9GX=!'R_8=XE'.=+A_) FJ=2O&VS1.P=/03@?TS@UD3#-)
M*QO#(3.FJP/9],_F^1127H)$BN7!ZZ,M 5SJ3TKI&*18?J!#ETSF<XC*M-"_
M70K/<UB$KBY:>-=QL -W\IJC6CZXC2X:3J)+29V+[9!5"%0;/<CMB;CA/ *U
M7>T%'0_>@4J3#K=.Z+E^W*@ F"8**G)#NC&JR#/ZHP[PG=DEL.EV/.V?O3JF
MI $2?N3:W0.MHE1E_@@R=I^!-2)2-#_WCO:=]T3H8NV;P(S:ET4!F5B/6 *Y
M6TC3-E^!]KN]/F&9T*1]GE[LNB =[2',_D'>5<@_%=I"PW'Q>/9B(_,6P]LM
MO>/YSD5C-%#PHZ>A--+R[28"CXV:TX, (Q\2:$@L&A9'(%G!^@:)1W)C>2EU
MQ3T\['XF;H2K3:XP)!$1L#L;=&C]0+=\W38^X[AV[-W'L/)F4R*.H*(@ US,
MQ^Z'04C/DH+8\;QY0GC]=GQM!543K*W(]CUOZ5I031&G$RCCHDO%/C>!9*='
ML)#DDA,W*SC!_H>VK2&**Y$_.X TE2'14[$4AT\72\7L-[T#GYP&WX-]-Y5V
MSNVYA4+=4=%5E L(CZ_ C1  .N0.,S4LKR",QS#:2I? L*8"JBWC4!<:)'?$
M34E 3-J :*,1$IY=6=<C[&$_#^(0KC!*:V7Y.G\$W)BO.+S/-^DS-3DU%6<S
MB(ZDF8.O+(![D>2&412.$]&^_4?2=)XVD'#$5\RUO;A$CXKN>4_4PB7E-T0D
M=!DQ/%14= P%2=,NA4Z5U*). ]Q1<56LHJ(N>P.[[\A@#D\SF)52F[6JJ+7I
MYKV^FIDQ\V6RH=W';<TV8PP:(Z\JVRZ,1VHVTY_V<H5>]"7##_/<$'Y) J(\
M$Q3C_[YQWQ@B=/S?-WEM?E>M6432S @=8"N]2T@1ON?P'514>K"&?3E-H"-G
MT#<&:K4(IA&.Z,"/D/0,AGQ#R((7J]3K-">C636A9XNIU;<?"=:^%/OT/_[C
M80'NS>][CTS02VSGCGEBW@H6F!@$=U>)DV8L6&PEO4]0,RW2OUY'"@O"X<.F
MK$<-+AR-(VZ$GUL7Z;7W3F!&Z$<\SH^8#OV(H1_QTG[$@#[1AX9SW\YO<RS0
MO"1(<3L3*,OMB]@WK-Q(YJ+Y-[;4ZR6'V:>!WN-OS.[X2"-;<451 YWF8M;'
M+%3\12>TEI0TU68SU)=H(M </UI&E=B><$(+XAC.=SS9.C@GCGS;*W)2X9D<
M&D@1 7D-(7-S._!ZUR1Z%&+XV(BR76&)<"(H!R"G RD?;-=Y]>[* >7=Y]:E
M 3V&;^>,/0.U->)2.R RLC#37&'?$#$&$?,!*FM+XFKL^L(T\!C*ER9IPJAN
M-U9T6KC0GJ18F*?[&_G NU6.?4]25EZ&JC^0?N:.J?_!AKL$4#B;BESF1URE
M)^2);ML39(43M7 U4B^LL<_& *)%528($,Q_B7"^A52NE0EOQ(8Y+54/Y:4'
M"PK62&:Y(U^ FB)M\HUT(TB-2%@T^@NNX$^,%(5.L\G\Y0;Q497%1("P] WY
M M5>J+T=*C$=@(/Q,XA8.UMNZK8)MT,VC.:G([.'1@:L+X\B%!I VEG=4JFK
M'><!4)14 ]X SD.&]%M"N "QZI[I.?Z$#Q>ZV[H/"$/+DU\'IX\@)CP!$7A'
M8$.\6P*\CADQ++AW[BS@,9>Z]=+L;KXTP93F+I-[Q>FR"#]1YJ^#8,J&A!/X
M;, ;5PVF-@F[,X)KOO1&&.!D&QDJ4J37.LK$6]+ZV!!VQ!(+<1JK=O"*J*ZF
M(L:&7P3=MA3TS CP/76H[QFH&=OB\C&1RT1JCMWC?,_:%H^0?V!J82N!5##W
M&G5(X(.O#/;N!B_K-,3Z$V1=;M2"TX@R(\&G:@>S[V/H);W.*UV!34QS^7%Q
M\SI<O_']S&TQ=)2HJZ)"RO1$P6TW>W/D(3B3IS&ZJSU45%>O@Q<5(X\'M?JT
MJ6>FTV,>M7O\UPB;OB-V'J_"QOQ%8A>2<?;O[TQEAC1):G2$Z.:.Q-W7()I!
M=9U:B]PNGSU[?K?3)S(2C"V9M"S%01+.(&041XM0EP_*@9\+R&B^V;) 2NZ*
MB$W9U@7XL3 >HZ QQP#N\2W8H4Q(*T:F3E64%=DMQ>CSP>)>!Y[I"+-\@US+
MD&21>@XF_LI/ D4 [%I!@A+-5W0.:SMV(85&A_9Y+_=V.G79! 2-ZR5%L)$]
MT>;WD.O0Y,=/Z.:(OI OVRUP19&<# M:FNF+-W$CR@(\P48 G;I.J(*/\#1U
M3=60-1[O\3#9@>)F[6DAM,JL7'NO3I>)]VI.S.SJ1<'C+I%2$_#B#Q"IP'8]
M#MVR&_^X9,MPR)9U8;)UC) +2=LC(D24M,7WD3;\QP@;PZ'UG$W9.C:>TH_;
MC@LWYTN0(\/IH (5+O)^^N*A>\Q?'6MH8G()"5\$4\S\#C7:W@-3L)-KMRBF
MO>^#%!,-(F5SW%8<=MT#C_4.2#YR*0Q1'K.W))\)QB3/%(=LV!MR'7*H';6V
M <!MY(3]L!* X!)EP>VO2A-D\"=_^ZKYV)X-6TJ#+X,XP&A$KFM&'PDBV/(:
M.J3E?OOD1!BT.VY0<ST1*@V/M$E*ZCJT-9K M)6_<ZI0Z?)L)UOWXPF2]TP!
M5X' A)^Z!^;(.6#B'![J4: >:L/.^[19 VW$X*'JQ'$12%,I9H^P.WM[HYZ2
MP0Y )*>H#.4V^)OF]F)(Z"6."7LR]T;DO=$^6R$(LELQ1M=LKY*G-(9)DY!%
MT]D1\AP[*$T#+3[D+.=KEQ4L074 Y.<VG4D<%*$2$99W1"@[LMB@Y*.D:1+I
MG@WQ#1>P<6@2<:%%>O!-=+21N4(ZA$M*8@E*2KHH(QN!95L*0UOR")P(/P(G
M#93+T*:]5$8VW,(J,PW**F[XC>!?0[;70'YNP]XX+HTRTW"= JSMDG 'W"'(
M;NJ#4-,3V0C7&U/'J1UO24@8#JFU,Q = DI2>S6$-']%__9V@<,"&''%OE,9
M#%D2\%/$K\I2G>@"9\,TFX 0@K^XOW>K53ECG$@=1 058,MY<T40R5.AW>4@
M3;"+,Y. 61J>XZTR1Y1T>A=>YZT7,IXB7G>VDFY;0RS5*>>E:JC$'3R=2/1D
M4MT9U\<R!3MK##F\D:N29BO@1T<Y!<:D.W@PU$@:RI* OEAL*/*!'WF1#63F
M<\@PPI^]9/@3]-1/D.VOT0("Y.Q[YKXCT;O 3XX]M-B]%($.H.YEASK[Z/#=
M-JW$@41$?A?0VR"\TR.%XV(:@CCY-&5T(H^<[7NI-]HV-JX<2RMIO#6Q#GCX
M_QF"-@*()^E'IF,1TTL[YCXIW#'XH/Y7=O,X!YGNG&)\WN!-FX$Z1FBONQW>
M$>GKB,):4#"^XC&5':>\X/ [ZDFW;R)8?0F]F$=Y,3DV]&*&7LQ+>S&Y_5\[
MJ+4?5Z%;P',-TND1*X&$,(AQ4FH0Y^+#00H,^4$\P?+P?_&4$$]\(V @W^B*
M QX(Q5:_H^5ZB_IP,,G67Q^CW3$R<VR/W'#+W&.K,7^<@@G'5TNY6;^Y:<&1
M.W-&B_QCM=X91%G0*:P>%EH\:I;1R-3V2#;3K6UB22/+6M,&9QJ#9SZ:S0RX
MW=4;Y8=:*Z99SVSN07]Y[H)UK%E<P9$[J[=F^<BX85K+7J23Z^?ZY;&LI,9P
MY,[J[VFS'1%C[33+2^MA+2DF7SK-\2"VNWKK+9TL<_%1;<KU2T!YZ('G[FL+
MCMQ9??%<Y=_+[71W^E30%XEJ+_=<?40C=U8?R,U<7TIP%387G2ZCD=6JD7UK
M#>*[J[/P1L;-@9HH--:+84TMR-EU!(W<67U>?X^,)QHG%W+)?C(GOTXR?&H%
M1^ZL7BQJU7<]R@[8TJ"7+]83\NNT@.;$F;A^T!?X2FY>F7,%>)9:Q7IN6,.G
M#!H:WQX:VSQFIL;B-=;;O*M644L7R_%19I 8L-LCM;*F)+E1)LGR5B2A-6.&
M.)N,X<B=T[\_+J/M7"FILG+R93/L#SN1\0#-&=L>67N-EIK%<6Q5*%EMW:KQ
MU;2BM.#('3BM^X-8_>4Q*K)5=M9=9@?YQ1N_@B/Y[9'@<5+JOKX::F'!C:SB
MR]MR\/J&YMR!Z+BL@;?NP^:)73P_-\TJ^QJOI=&)TCMO+IE6,]F7HC0M@>7[
M.U<VK&4:G6@7]B^Q'KOJ#ZW8M)13DJE>JMSJ5]#RT1TX >$EURR4UKE>J?[^
MPLXWT?K3$JV_>TVK^-/;R\3*OO5RD*I)N<>H5>_C67<@I:4>-]/^7#5[N=$Z
MD:R77]2QV!KPNS<*5JMWO3#,\RS_]%R)]E[26?:Y-4CNCAR(0Z64C#X\3R.1
M-)=ELYW737H%1^[<:&00R<16JAR?<LW.0^8MFM'UYPP<N7-/XTI9;J2D#<O*
M9752SL:?-D41K;X#_7DBGMW,1LM&;[$62XG7>5<9/(SAR%V0"I'8 (!:ILMV
MNIV7IQZOQ.)I-.DNG%)#>'L\*!9Z5FU2&B3'^<4PGQFD=D^_X/GWY',Y\5+@
M%Z-!I,9NN@5I#$?NKJ^/'I3&;+XN%KA5HB$^U;NS.22/Z=U)A_&'^&Q1?NBR
MC<>-VBZ^*_55'8W<F;/7;%6GTT(BRW(YK3IISV*;QL,*CMPYDF@T7A;1%->:
M=L;FR_!Q*JR?X.G3NZ@/Z9;5UC*/<T@A^-@@EM@,^?48CMQ%Z-:TGXV.HD.A
M8,7&[:?'?G4CM]%&'2P]J_./-@RA(<)M6MDUHTH9.Y?)<*VHNY;X_GBPS V7
MR6?6ZA?9QEA.=EO@S%G-CCISK <PAFHK^KN-NHW*D5G4.:IC1[\VS+'(M@MN
M<Y84U6QM52K(L[YBI)^>!X7AY0.H.C(R4.RT5W%JY. F,X9FZ<14O-WJU>F"
M2V)-[ +G>PME4@T=!1_CZ SD\2!JO)O=3=L<63-4XO.=U RE6<HJ*=)@AS1L
MMT!V<O:(0HXOPVMTM[V Y@HH2Z>'W!YW(#++,RCQQ8"S&7__=$-4 GVD=U"=
M XG?(A';_5H.ZW8DHBH.NZ.;F+J]*ITM2GLL.>V*]BBE^_H@Q5+WJ?A_O,6E
MMOH=>70(SY(HS0&5K+"+KMF_8X_1=Z(GKB!</E3//"VFG*'"$"=4@3/K9<'%
MY?! U%'JN,)R/B7;WSCJ)V\"JK/A/=S$/;"I\")NX"+2]\E8>!$W<!$A9;J5
M>XB%#^(F+H*[CX9"TTW<1$B:;N0>V/ B;N(BV/L4'][$+=Q$2)INY!Y"TG03
M%\'?I]/A1=S 1824Z5;N@0U9]2U<1/*>BX87<;J+^,?4O:Z*L_HG+@>1%/SC
MCB_R6!"=DV!_+1"(FH(^Q 6!/J_C<&<%"#KGWIC+(_S3N'6NXWH.+_^4EQ^[
MCQ_TSUS_\E$C2J:)&U$VA0W0F1 3SH()T?OT>5G#KV)""8D$*LXM"5'@=,SP
ML#[_)\#@(U7Z3X!!^!0^5"#_!!A\I+M](1B$:E-((?YHM<ENBF6$TM*?J3J1
M/N@H-=&X"W'@SU2:='C_IEW62E"E$ ]"S2G4G$*Y*-2<0LTIU)Q""A%J3@%"
M4R@G_;$Z4Z@T_^$*$V[3%EY^J"6%6E(H X5:4J@EG5!+"E6B2Y&#7Y4"B+W4
M_A<??O\O.]+"\7*25R&BE2]H_&ITOF9PJ4?&+B5XP^ *J! 3XL?I\(-H35\9
M/U2)&8$0.\Z"'42E^L+8@:HEJ;B+48@?I\>/%-; OC!ZM(%IZ6J(&V?!#>YK
MXT97,P7%#X73>R^\[6=$$8#1Z,+2^R$(9 6%5&<S=QLAG_+)7!T(7A7F4OIZ
M*O#<5WPONW#YGQ.<E-2&NL&3>D@#KN'G69")W2=\E=H9VI,D1/A?JXAT@VAP
M<H2G)8=N\*@AQE^8Q >?^]IH<'J,)Y5L;O"H(<:'&'\.C"=>MQL\:8CP%T;X
MVZ1[)T=XXEN[P9/^&L)_Y6A$IYD4C^=OZAK">4WUMCTG]=UI#7?1TG64X(Q:
M*G\!8]>-//#SAI1]A,..T>YDFOA-/4C:ZZ&H"[A#(V.I,NGT@/H-#.P.\8->
M)S_(1-3.,MGI#0N162NCL$MI\)Y8??NI_A"H \3 WP'";?N0426['41W,P>9
MM6P$?2&X902J(I*WP_M\?ZICL]E@4TB-IM7D0F#Y88Z7%WRVU^9:WQ@)B/),
M4(S_^Q:)?6-(/_;_^R:OS>^J-8M(FAFA(WZVBX5##]J$''2U#B(&%35'R, +
MI +?& .B#YPT]LUI</36:)8'3U6>%1Z%F6"MGBJ%6F; HW8XJ53*;O1GW]A7
ML)K?!B$Y7!#Z$H3D"J?^J/IR2'(^3W)0[1I<N@97KLFY^9A>.E0$#@5J;%Z4
M]>9!T=FG@:;7TU.@S">9VZ- O)'II,9=T9S*;X.%;I1?H^)@#"D0_^U'+)4,
M*= M!\O>' 7ZJ,AR2($^38'<FDEMD@@,_XI[&U><F M*>GI+A6\4A0>VMXB_
MF^_*XW2J%<:W1WHZE:8B1\KS9U9X%LO#<F)LCE\0Z4E_^Q&_BZ6YD/B$Q.?6
M8O-_=]KC>]@T7H?2E6*W!_6N1:S(/N7Z]78Y$:OJY1ND*Z7TX#6[G@K9*3#8
M:B+_-'SNUA%=05TV8TD^)"NWG/5P(?/,9=(7;IE:[&O?>6O/>9*M3(1Z9 IZ
MUFNYL9I-FZ^1_@H]Y\2W'_P=&X\=>-"_60C9EA4Z([U9$/BHT;W7#CW794UG
MYG N32)&Z=#I=/+0L=^$#NX-&+LITACZ3L\5$/:G:0G[X\5"A/^]$'Y/=,P?
MA_![P\5"A \1_C=$^+W18B&^_V;X?G-D[?0&BMLZWY\5XY73@21#S1JE/,^%
M#5&S9[B!36@O/%YUOMV0Q3/HT3=]6.:O+^B0^"H18'F 1D!@&$$VS"<KFLDE
MM5J/+XG9X5O[E<LUQH,4BO/B$[N.SK]#$O,S9HV;?G77LW'<-%A^(V)T\[%A
M!VG3^J%1EV)<0NT)[<K;>)5Z'UM@!6D3_^U'-)8(:=.O*>0W_0BO9XZZ:;#\
M/K3IAJ/&#A(EG>=R+_URI\A:K;<82#3R';V"B%(:$J6[&+\;F!J2I9 L_;+1
M\':A<G8+XN^/]C?/=DYM.[SIPUZ<QUX\WND@@UM41NT'\#AXFEJS:3Y17[2K
M8@TQ.!35Q-U%$_%#'.XW"VOZ]X/*6 45K<X,]Q?(2ORV!;)VP'%+%;-BD*A(
MFC54P'62[0]BS?^<"">.K*EU!5C\C+QP$%2GCCW-&(/&Z$8LP5$^]?PXF7&1
M M?HI<8#[4&/6.>D^P'4/KUX,<U-6BBSD5Y&&Y@Q+CY[RPS2R/[+Q8(BTD-J
M=OER:'\$-3NV8%I(SJY"SG[6EMS6FN7XU-K,"EQVLW@LLT)=$BY,W1*@H&<J
MN4JNUVELUAIX EQ^M8+4C8?4+<"[%5*W:Q0"^S.HVY'%\4+J=@WJ=KPUVEBO
MFM%*HI@K5$&Z4*B:Z8$X/J>++("LR<M\,3:*6NL"_Y85^/[K0^,QW8)D+?WM
M1^P.ZYPA80L)VV4(VY$U$$.Z=F:Z=B _.E$L),76TW.W5YT+D<[X<6P)3Q<6
MQ0RU\)P44Y7B=!&=/%;R3T)^/$:BV/[<YY!D7;Y&Y1]!LHZL8AF2K ,DJUT8
MC]1LIC_MY0J]Z$N&'^:YX:7EH$UO^5[1I5$O @;+8FF4WG!#) <A5T7L+I5*
M?T!5L+?B'U. 5_S#'OIHS>#5B"?#;EF-3,C5L/='$ ;\3?3'(ZG"2=]@E//$
MFI,=8C,FX[0LQC'GV + B*X) '_J&:,#1@<B>DP2(\#?X6_4XX2RP 61CH-C
M@+Q$T+]C5& R&BU0JJG8'XBSQFW7BC$!P#3N&;(?MQF<9T.H^]<=,W9$>3@_
MEN7O&-QPEW%[0.$OZ81'!NQ6U&9S344S:".T6]V"?P'K.5 -^-TC=GF1FSD-
M4]E">@&_K0$7'TEQ7HP. #\<#>)#^.J%))L<#"4!Q%B138A#%N[@'\'^!GR-
M\=I;JOPX+,RGI=DJ/7\O)'B]MD(NSYV1O7S1K$:SQ5[NI5XI5/@\FWH=PY&)
M[9$/Y2<SVL\OWMBG]6/D'>0M*]-;#;C!SNKOFVEB/4Y-RU.YWK+>9XVFN!#'
M<.3.ZH6> J6@2EF;\B6I61^5#$CRT)RQ[9'3Z6M95M/%>4&.)KJIIU2F44BT
MX,B=?;*O*ZZ4K,W9Z5-4?%8?\_J;E$4C^>V1N82>S3QT(R]LH]H?@>JJSJ6B
MXT%L]T2E6OI9+R7&\T*D^/;46V;YS2J5@2-WYARW6,/0JK74=%/L06RJ9ZOI
MYFH0WYT3+.)]O9](@!ZOFXWGMTU)Z<IHY,Z<H%]^GS3$3K]0?7M[ 8/!VZKT
MDADD=N>,=0:]>/\M:O6X57=M]=GG2B*"1NY /K<<)>5()L&R"^.5-9Y>>]5-
M:@Q'[L!S_MCC8\:P5^W-A.@Z-8Y'9@46S6GOTX>V)_&V$VYD&9&Q(,R_5U3(
MB4Q-WR#KIJ(9E@ZZ<(6LHHE3RG^&@V5+B3[+Z567Y:;IEZ=!K!691"#C!)!3
MS>%D)B0<Y\H&L@G"1X) _)YQSN(POW-#KR-.(,%70&/DK$U+J701M=^%9/L5
MQ"JEYG)>>*JGC'5Z# E"+G-Q2#J[Q=1=-B"/@AP 4?N1AC@.\O7_A<MH:Y8!
M>8CQ]W<,3RQ!V'NC0J0(OR',#?#=_L&[#93'1:6"F;".X!M0'9DRHH"1Z14R
M(SH1(. GMC61_0^Z>3?2@LX6)1CQ>=$8"BD'RP])\C)@2<1S1Q! -J^Q?X^@
MJ;\/=2!,(RL(EW_GFB$C_/J.J\) 7KPU)Q6]\<+V4&$(&:UE@JVS7ZZ'<?1X
M<>P?>!;GWU]24KA[C@LOX@8N(GH?#R_B%BXB'5[$;5Q$2)INY")"TG0K%\'=
MAU+335S$??1@RD!X$3]W$9^(YSY.C[C<\5'_Y^OX7#[BDU=O;7W11N H N:Z
MR=^_"JYSQ?:'>.+#D]A]@ONM\.1T3=(/,[>K']S.$]OQL9TF(X@RE6M[\]O"
MBID)$#*RH)RB@#%Y_M<^U34R'^,W<.[3-+>_TDFNE)<;8NQ7QUBBL/XY&$M8
MY[5O[M,8>WHF>M%S/VGZ%+6?G>N:"(S3\<RO<7EG,^]]J=3_CZSW7[^OR?EB
MY':B$M"#JJA-\IP"(N-RLT2?Y:;#%<NMQQ-1JAJ;AQJ*'8FA*C7)]%G:)X9O
M\JN]R8_,UK\!R_\:Z/C[*<E%696-"9"8L:9)H99\!IWCMJOHG%AN^%KG_YU$
M#?LAE] [#A U-KE&8I8?#;-LIS1<O@\'M<VRT!K$D:@16$ BI 0A)3BMS>*&
MSQ_:-'Y7F\9!1TA7,P6%D7<"K[^V@G6MS,7XCCOPCTA33-_&P?_ G,0=(>@1
MF &BSR 3*W=3U6:^9XF5SEH?@FQ;0ODLV,J2B@7U?PT)04@(/BGX7/O@IR,$
MC@ST-<(BSOD:PA3D/8FNGK2LC$ET"#NNAOQF!V'=H6Q@.T\KI\W@OC88P9+_
M&JX(QJP$;RMJ,D6F7\\TJQ6<#ES,5%]?'A\R*%^.J0L;.C>:M)C/,,)\KFM+
M^%W[._9X)M>(-#.YZAVJ_@IQ5)PP)CRH=S?,$(P%G/HL"G,92H;PT)"3H?0R
M^!D$CC6"_,'2P=[)[YDF;IT-A[N;$?"I#^P'@H6LXFG!C;;EKH@2VCQS>.%
M<Z3)%^UP%V8%X"Y)YC>>3@<&$'1X9IP!#I9 T>8X]YJF2S,RR9:F/;]E541Y
M@-(]\]&=>L$G ;@ZQ&*TY 1"6<#+ZDO@/9ASTV0F>-WD!U5#B> +2T;+'LIY
M3J;$J)!*\@,.\/%!/,IS@W24!8/A4$S%$FE!B/'#[3S53L42VLWLL\9&I/ZD
MN*Q7<I-U*RCGN3ZI:H7WAM2;;BPH:BP:.3/ZO@K*>2Z-V$S,6A8>>[E80U^*
MK%9-M3-!.<^=&MMYFJ1D=5KMK260F&NM%YP=O;-ZI,5'3;%<E=E.LZ?KY:+1
M'[^N@C*9._-H]$V6V'C!6EA-%226N6XD,#^YW%W,G[*YUJ+WU(ETV&I__-BP
MQD%9Q^E"M:TVFSVIEWOI]4?:D\2O6LA$9._S_-F\4+8<RY#&9@P#F,:AI-[G
M:+>6KNC/F\),R(!.>;IJ+VH9(GG*J@6DC'E@W  -B]Y6"G "D30;  R!P!52
M@9$AT00U&1+1[?O8DQ4LI_O")OEBY5FY5I7%58E_B;R,+P[<;B!?<0 JX"/8
M&<,?)@PSOUG&,)^^YV)ARL4-Y+Y K3"\AQNXA^A]+!U>Q U<1!*77 TOXNH7
M$5*FV[B':.(^?;!Q=7@3E\M3#4G3"2_BLWFJ'TJO?TB>ZA=(*[M0^B%$B.OV
M8[OA+-7?&$N.P S*/;\P:CSAWX 4R<!S"F/ M,%,D%5DI<C,-'CR=VSQ89K$
M6OO7"Q!TX^_3N6D.LKRK0^?,V:N4U5P[7B<C$ELXMMC+:D21162HEQAL,3I1
MI.[UCWF-\+Q8<"'\+Y<<F-S7JN26/,Q?+YKD@ &\I&N!>3R]8BV;++8BO:F5
MG?>?)U4XHI\AM6JCR;LHM]N,,WS OZ@=7Q?O [G6Z9TT'K2-&$#\+EGZ!C+[
M;92UF<4!U+5E"BI2] PPLI2:/ ($B1\%71_D9^7"*I&IQ7I<?P4JQ8@R'#RL
M( K'[U/;[E@&[>,4;(C(&U\6C4\O>5STW#5@&-]1\71K9A$?O>"1,+^ .G(3
M%(F(%+<;WG[*\'XJ==ST84_>&_RJ4D?&?9U>]2] #GG*"\\1*[54>J#,I\L]
M0^&BHQ;))^;3J4,=P<,'_BL&^4L@]37HVIE- 3?-AZ\NDAR3N;(5WH(;M)S2
MD'AU(-Q"//L>@\'5([TO'^*^U^1P=5C\P>DO!T2'X(08/IYO]T&LK4T%+3&N
M*J88[SV,22YPE+^+<V=K\Q?2E!NR87PD8UR+W-Z</>!/SQS9WC5QZ'OB%$0%
M"#JZV<F_DFS,%6'S'1^8;L1F"USTGO=O-\'>Q^?;L:^>B7VS142@*/\>KEU\
MRF"(O>8^+K[3Y:T8X:*[(0_HW__R!70X:(W"B#7]N\T>/1"DH.$PGH]!A,2+
M"".X@>^"LA(VALV,^?MXTE;%OSLL-H9V%8W>)_G_,)Z?$5QV+@[%*'M YPM3
MIE_S1RK;'WX0N$+OW=3FQU[Z6:+#8QZ>+S 3'?'C_^YJ8N"C0#]#-(=L5_$%
M>-"/H,R-@\&U$9,C4=V&\T8$;[A+\+O8AG00 &F&"RO&8C%IE!ZD.8D=Q--0
M=A 24FR03+."&)58*<:-MG,W7OF!SHWT?(3EDE9D8#T,7F9SE+>RD^4ACQ*1
M>;8;'_4ZI965&VS4F?P\#LJ%X2K#]KJZCB5Z?*R\>7L$TUD<=\O;F3,IB/EE
MS 3&M*$KT7)[S+XHJ\!LE*+(]KMB5+-ZN6&E^!I)SP>+46 /O$S5S Y6-6O6
MXV;Q3O4IWR\]QUI!G>TF6F'^4LSPI4)GKDBM>+^P>$V/!_SN2&6JQ_NIS*K&
M<H/^6ZZWSO471FN0#,B% =5I 8BO"58>R\5QM/SVT +C06IW))^MS,W>:X)C
M&ZONL*4.V]&!UH(C/5DS-"F%>.T/)K#0Q)2+9DO\/X,981$RHB 9,B!I O7>
M1-D2.C L!>=.P.T P]14P,R%#<HD,QC) E!6AJ0(#VV.X"9T)C/6 <"99G])
M8(1SPR9 ![+Z-W9LHY$UXMD^,/2>@9(TP&EU_RL'/%J<JR?"0SUJ)F"B_+T]
MYQV#<S0@A22@1TN*V@RR,1%ER0GVBO ERS^0R,V,+!TW(45=4BW#0%^BF2([
M!T*3[>S]_J+9.MJA;)VBA7(5O1;# DGVVY/&4TUF\YI@O?5Z&Y;CE_5FJ5_/
MGKFY7U :J0<S/0U?42KE6D8)CLJ&^9\3ZVB?O16/RI;X*94MIQEF8X1K-654
MJ0/T)40DHP-ERT ++^]QTA56SV]L3S<2A<6BWLH_Y8N;9F+\[0=[OULM$CU3
M!=,<%:>8(EPVX(P&2>V._NM[Z][0(CLOU).Y^0&-D$B:*GHJY@HH2\#,((0G
M!@-4=($[X6Z,9:#QAJD+B,W">2$QF0%SHDE0,AIO[IF"8>(+E^"KQ&FWOB-$
M/MP[?L\?$#;<.7)W;S+^$TD.,W[S7I*IQ'TJS R[A6AS[CX9)F#<PD5$PXNX
MC8M(AQ=Q$_D7E$=<.:;Z>'\'BHA&@@>2,+S<_61F[,-H>1%DL*?-P3T/=1E.
M4T9B%SH'FE)0C<CNO#^#/)_L"Q6]CW_M\'LH@ENJ>;8 <_LM7=G"#>5<_F1/
MX=J'N=[K^!4!(X3:9Z2!VW*:,;'?-]P]P';T"#?6Q>I]'6OW =[E9V714IZB
MYGNA,XY7<\*BG"M;*QH,?Q>-'FIJ<7HR>VF:F@S%B\L1T!!$OZ [A:3QM*01
MZ1S=E19 $6LO76%=BF2TJ95KE8I+WGQ\B[7L-C^7IHC7ECK@7:5"P3,4/+\0
MU$+!\S:HZT0'(("^MEEC5.=;=7-:BKZ6AYG1Z]LFLJ+QC+^]Q)D.)<Y0XKP)
M$(42Y^5I8E&S] "2^%!_YA^?1\JZ%WEK/CRR.4DMCU=VSX,_3^2,L:'(&8J<
M7PAJH<AY&^05C@WJIO=J&JG7]XC(=L3U>)Z<=_O-)Q1R^OM+G%T4E(FCT4.Y
M\X+D\\KY]E\:A.F; &%(6&W"FD'4XP!UY=^EZ%@8;)+LS-B4.ZUUJ2FPXT$2
M4U?V+A6/_E'2ZQ&)X#1 UE^[Y82A+E<'P>DHSK6R&O> \>J)TY=/(M\KVEX=
M%L>3Z#\]A3P> 6*W$>\N>HM7?M-[3:CYE('RHXY-(?>EQ5XV>/+3%& [#78K
ML^L"N3'[3L7]PK%HUB'@V23/BMQ 3*3B@WA*B ^$D1@=Q$;)&!>50)SC=C($
M\YE(_7D2?9JPI45K45O)#[&4$=A7J]R-)3K3!U.=EG*:-JMO2IMX/!/45VL#
M>IO1PU!:3RT]M1(F?&,%5N.@;EG/.2GWW*\8]9Z0 JG*;%"6^7@KJ%L6D)Y>
M<\_-_F8*>K6783J:>GPN9(+R$S?MU<-;5"^WV,7;=-!*K.>+2'8%1^ZL/FH)
MZ9Z6UWOLDSY:-)?-B%F?HSEW5H] "48WQM-<H0%A+S>;0C*;",QYA*=8Y<OR
M:V9:+43KM4$Z51DDQD$YCZ\%KM@9=JL/TQF(=<2W5JV:;@;F/%K/O#%NS-+/
MO<7+0V[*\V9S]=(BJJI_)#M(]2N50BK.1CJC;O]AG1;2?30GOW/V=T%X4R;O
MJRDW;L=7ZYA8Y\554';DTVML((C#2:0G)]]3RWIA7<Z45X/T[LC4:LQS.4G/
MLX*^R%E9RY+DS1B.W(%\>[G6.SS73Q:XV,-(!/G,1K/0R)T3%45!&N@U$YZ=
MU:/CV2"^>HN@D?8=G3M1KZEK<\@<-TU%4,V,*A46EHP;[QUJ;;8H-3-M<YQ/
M31>CX>OT9:T,NF"\V]HL>-PE6IL%DJ9#')%'G1$)*'#>)+#AX"]8=/QUQ'W7
M$1^LZ]*T^M8</[&EX6:3'3?K;WGV^.O8O81!ZC7::F\*3[W-\.TY6\UF5SU^
M=7FP!H/-U_716[U1 G,=LGB:[HI4@LNDL=&$?YS%)EBF9G] LMCP)]?/=$LF
M[A-_9%^5>]8I@.3\>&.9/E!!"F_F1F\FD0BOYB:O)G4?DK/;O)F0G-WNS83D
M[$:O)B1GMWHST?MH>#/GO)G/)F9_J-)<$R#7:Y7W ?L]<XKQ/BC=0O.\_4Z9
M]#7;?GT&9+ZR/2?K?A8B3H@XI^>0-PB%$_71"]G0]:C)!UVI+@^F4Y&3FZT>
M\IF'=L+FKB%"A0B%$2H>LJWSQ/Q13G;%@+<]0*D!P0 3" -&GLUUJ$O3PK6G
MH2FW=]YKM#M"EL';@\0I>L5BT]HM99.0 ]+.+-[3GCUXC@8##/8& V0WW<T<
M9-:RX8QU'E_%\_;J6(D8-*8OT999EUZF$6V1J]:;XU2JW?J%8+R]&]O7?G91
MXU*UN%S9]"+1U^BFK73?.D:&UI>(!T7BA40C)!HAT3B::,1/3C1>>L-ZKO:H
MU0NRW%_$P'M'*9;&ER0:V2K+";H6FQ4ZX\F2[;Z,A[*.B 9_1J(1O<6G<@L]
M!V_#@%*T=/A<<":)*C$CB';PYY/)F%_UFL_F:KX(M=R!P\DZ 7_@KOU-><'G
M!$CG9<%Q1?JN*"O(/#?>4N-:\F'*OTJ35S;36!GBZI*LH+M\C\U3\W:VQV6%
M=1.TAG5K0_L!IJ*'DNU"@A 2A#^=('Q..#Q $ HS=K@6EZGQE!??WU]K72G^
MLKJH;-A9YI/6>+%)%$H/D^=U.UUJYW"#4"@;IF+IL\F&7Y4@_ GV1]22R3*!
M[B8AA&:$W\",<%UF<7L'_BH"I?T<G3&4>92,E#3("#UEVN%+$?5]7(P\%GXE
M-?BGF8=2BG4>5HW\PQ2LAF_QW&C.=Z:T]!C/)T)K9$A&0C)R*V+H/C*R68)$
M[BT^T'N1B?E2K:[:$SY]41FT*"O19N\E&>M9KZ^M]WX[,RE9&4A&^#.2D= ^
M>=/V25*1@E$UD]D DYDK<)^HK2-CD Z:H6'BU_C&K5;(N@P3N>W3!W$4W,65
M.P4$0K2_V8L/T?Z<:!]:G6[:ZG0-FA#JDJ$N>4L'OH9)ZN05YGY:_XLJB58)
MC$&'Y7J1T<.$EQ8%WBX">L=S7&A("A]_^/C/84C*;&+2ALV76@5+;:?>]63R
M/=>_Z./GRV!FIO17@^WDIVTVMUQRVEL+/GX>/_X$&YI__D#S3PT8QO>]Y<Y"
M+3C4@G]7+7CG],Q?7TX"S+CO-N]YMO!G!: ?(%_PUHK?RS,"V,6Z)H#2$Y<=
M3GEUEGE)%<UF=&U7(PZ4%?\.J45(+4)J<;LBXQFIQ2;?[35,J?G$<J#8B4Y'
MK=[[ E4O)L)E-'4F:A&:&F_;U/AQFXWY$36,?W\#Q+5J:>RQ2%R]:\2OX-6I
M>FKLLUY<'3@_;]XXW%K#\?V$SRU\;N%S._=S^W)RXUY!,+B/C<JKR_I3YZG/
M/A649*\XF3U+?=0A LJ"L2 7P^FJKOS.9,?7W6>[;\Z)SB*K$5IL%!["<[@]
M1\'?1'\\\AR_ODO.W50T;L/[ +#=L^$NFPR*S134#0.5'T16)$8!AL&8$_@U
M>Z/>.2(&$"/R.D(.];V,_S-XBL]+\ E8M5Y5UA]$T%$'+UHF</W/W@3Y%4T$
MKQD^5,57]8E^!&DO>Q]U +R[_1T0,' W"GQT=Y\Z]^-*J[SKN<&"Y:;O<N>M
MLRPKE=77.C?2,G[BQ)RE#%>K3*2W6&8[\PTW7BVL\5<Z,8KD]#4P :1?)*+_
M\/X!LP&";C! 18_!5\0162SQOW$"-?A3[ X^'&,.1%106-G0C=P'=_+"A7@]
M%8=%!:Z$R/CD7TDVYHJP^8Z)&7W/-H/GHO>\GQ0EV'OXU+>*$GLF]LT6$8&B
M_'NHKN)IRQKO+<3%[9*G8@193;=+%:-__\M7FMEA8JAMC*9_MP4=#P0I:#C,
MU<8@0BH_XQ;"WP5E)6P,VS3 W\>3MG7MNR,LQ="NHE!4Y__#>'Y&<-FY.-23
MQ@,Z7\\9^C5_VQG[PP]*4--[-[7YL9=^ZIYV^&YB'OXA,!,=R53_W=7$0';R
MX3OMXN8_V@AR&MS%QW >K?##<_?![V(;TD$ W&J0=[C!%6U<]2.@KQYM4<<F
MA5B28U.#- ?EQW@L"@9".ID>#-/1I,ASTG"8WFD!%D^VWEZT$5=E<XG!2"NT
M:M'762:H11V;G[#5]KS<8#>IO%AJ1'CK:1G8HB[2SYF=5&*S*FPB@_G#<RN_
M%M554#NY05?NUOKF;-*35YE90ABNXX/%.*B=W*!=6:Z?QJ^5*2C-^ ;[4K74
MUBJHG=QHU&GFVV70+\BE$B=F&V:,ES)![>1F]1K7[2E/S1Y8Q_/C=*DK&'8:
MKW]DLJVNN:)I;::S5"\VZM7RNKD*;#S73S1;6NLUE^]%AN^Y>:^O%PNO@8WG
M&NU(-EI=)]4I-Z_/^;>15>"3JT%R=^3;V] 2WZ19CMV8L42LSJ\CR]0XJ)V<
MVDW/.X^SQ,/T28HL$_7W13YE9H+:R8W7;.I1T9MU-M(JYM:;F!9]7L#;9'>'
M\O5Q_:VL\3V6GS_5GKGWFBF_P*'1W:'-V7.L8X"7QE2N)*/\8QE$()M%0W<0
MKV.EWYK3RMN,+7&K)RUI;)IZJ85TGYU9"[.UQJW>C61/:.CCB?JX6)7+< ,!
M")6;3@>OS7RMTN.JD4:;XUZ>IN8*#=W!J-?"6EH,GI]?"US=M))5\Z71Z8[1
MT$MUO\N((N0,IM$4-HC2().]*.H6D&JR@"5P&1B'&N'E!N]]O3H?]Z:YNKJ)
MQIJ*]8P2X<_:@\UFA<>VMDO>,_14MKAB7*R?74>< ,E20&.T"UA,W'=A^OBT
M?-JTRX_S0B2A3[G(J#')CS+GA2F["])MD"'@&+)A(FZ$)#W2LPZRZ;!K'<_=
MI__(CC4'U>3C%?G3=4'A[I/A1=S"14"9_8_L%'2UBR!GBMVG_LBN9C>'_R$A
MN@K^AU3G&E#G_LQ6BC='=*+W\8.-?L*+N$S+MP_U@<L=_WJ==3[B@&=N7/&Q
M6>!2;;D(XB?N^>@--SGY&%P[WIP3>=I#//'A2?P^?MWPY5/CR>GZX!QF;E<_
M^)G;WER=J?P>7..#_EFWR4L_TFLN(D^<[=3'F2[^S)O_L]_#!9'_MD'P@8;]
M>X/@:A+!-:%R>LGABM&LGM@EWN=<%!5912=A3%V&_[KNV1,1SJN>^2H"%*&6
M5S_W)4+\J<AP2Q5!W #^+U@(:&F8L^_T9>;HP^RB=UF@SS)GZ7IPPN98["FI
M09$M%A;U=7;QGAWF2_6QW=_N+A;;S=@,WWCXQH\X*G>E_*\;>N(GS,'YA2?>
MB7#5?K8?D]A(,VXFE]V\\CBQN]&Q=^GHF0H^(QGOZJA^ UG9%[?_[!'9X+3
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MZO>S]YMDZ9 &PO_(^AZ6WL5_"N+H^Y60/X"O=W5!5N"U\G4XQ\1XTG1%@N@
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MET8F7)%638('%Z=W$.V=S#7\"7Y#,V&*=(PE("&B6X\W*.\ 5?C!*&&<[):
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MTN9(NR3:*A++UK%LLDG1_9G +HO%?AJ_F\VQ"$6D!%5+CMO1Z!NM;=9:(<$
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MLI)F]:*=G)%'._D8Q839L/,Y%A"#U7Z_FQE!/?@JI\&- L*0]P+X\._F4^;
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M^.B\DV@H&#\YAL\E#UV/A&U<(V"FV<:(_7L WOJ/J?-@-=E95>."TG NI8?
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M,;(RE\US]Z.OI>09D!4&E!QX[%_5-Y2!_H?7LKS",9JLJ+X)K9I/T+6)#!M
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M[5\DE-0J00_Z[6I??,N)A>8T,AG#+JY#W+4MI-H>Y[D!([<#(M <CP.-AQQ
M9[:%;T[SK%D=C*"1@KZJ=%+Y>?.M.PYZJ[#BE1FQ&ZAV<]/66PCCLM4%LZF,
ME:91OSJ^AY>5NC,A&$\6!D6N&!"BK2C?(NME(E,$HC>.)CCCT4-[Z-8Z<&^W
MK\-W;R)7*G&E<;E-4UIRNJX%0H)X_<F2YW:[-\#;E?(R.\,X<MI4^EACU,Q
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M"'[9U!?DG/O=N-]';,./SKYT)-A[9E^B1FH'C1!F#&Y4=[NEIKNX.*<(+%&
MY;)DH$]Q#+5BF%2KH84_WJCB2FU;L"*FV/6DMEF-Z0M80,$PKLF$>_2"3FYR
M$)C('PG'_9&$1R'4,1?BT5+A&YWCA:)"$6I:DQ.$*K5(BAG.>",BC>@8B0K"
M0\8?GQ3G&E7CA7YB!_V<T=JFG-G>SSGIG<ET=NCC",'<8PK=MZ:.Z^6)Q; F
MX,.Z&!*BA8@^3R654AL"27GGB5T'OU<6 $\<85(@=(0+:.V4EKAFB>.^D4NX
M/D.NVB<C#KMI$ :!4L"B,@1,8>(26>73^\C!IW9@'RZ85LTJO NA@D_=^LGQ
M@<U]0]B&1XJ3;@XF=L:K<"2"'0^F4.U>RB[L4^\A4ZI80Q_)@:0A9#<5D52U
MA=(3ZA\$)RO3:WZFSTC4:E =N<R(*CS&I&%"C&USP8=X9.H6U\P;B:S26-!,
M<K-<"=UP=R","Q%B@B/C]E(@LH-S/X4%>T/<5V9+IT..DSX! .N0]P78KU^0
M%B_$COTP9&R!H+%,8#2-M:L),14ER$0D .OA3E/-.T!BKPD+>UK:GX9^/81]
M?8G&+R,:[3N(HKR"P=2\)2[.BTP]%HA3G4*]T4X)3&$P(+!!CGH?>*,'6.QS
MQ!&MX:@GS!2(Y?68X:A/1L_<JERN\<EJ1 @PM5HHKRO"IKQ3(OBH^:@\71<J
M";ZRPIJ398/G<*9($T>+3(][H6;;PXT&4YTD,FA8O\9/767\E#73]D3L;Z=N
M;V<@&_R261$1]H.W9?>GVAY\\<A86Z\A:K[KP3B>)*4M))\-SWB:\K96Y#XP
M([ IWPG->/))3X"_>-H?O0O(XDG*O%; X:/:\#SK[ 46K+Y#]K#Q$+'*I9V'
MZ.+KMAZ>[#8T?SG9;F@S_RWZ#>U(S(U;#D^=H[V^3_4<GI6Q[VPZ))$?#&ZC
MFTH&[K,K7X1VT)0'3IS7+HX[@ LP!8'$:=L6-RA=H6(%=K!YZD^*%7 RABN4
M(YF\/!]CH4I2BN?"*2VUO :JT8&_4.& GW&^],SH=(C0H*C0U(*.9M:CTK ?
M#@/G((%[M"DZH%);[J7%&R79+CZ,DS:U$[3?.ES7LZAG[4FGVXEWRT*3Z9.M
M>('+$IU/ 1-]HNE&8:+#=:2Q(MNI2#=+U3>Q0FIZ:<K^H)3OM' X3+H^Z_G?
MV*=JU\N%A%RBP\*LL.QERU(X7E0?10%T>MR)B.MRFBJV\]@R+V6H%IR^]NY,
M[*/-F,NP9HACG<A A]KV[6DR=K*1MP%#NQ@$Y9$4W!H,FH7 9K7 C$ZA1 C+
MN3HG/I=R/D7!9L@+H4D[/6'>=06#C<[06*0.9PDN@;/12Z8IV$1X@II=B4%O
MPC8KCPZ"03>, 3W;<7/ 2*?#9+(H+)(->L)*1(/;D.\/:EX_"-1NT7Q6R8E3
M2B?9MWJ?2\8DU<H@GXP"?:R-^,7MG^/V#]B?><F4 9['K\_99+VZ7#>$:BX3
MDHU.:[CN.NP>\J* 8_W )/KL0%U &@ ^#7)L[H#%2!IAUL#2V3JE2XWX1HG%
M-JG.R8[L4\VU!]OK,-49',5^I;;N\+F 2,V66B5)]Z) [M8].VK/:$M7]A-&
M_U_=#1=W-X1>W0VO[H8[=S=$WM7=$/UBW0U-\&SP6DFXX8CMX?X#H37B4/,X
MTDO/D:"L2KX"#8Y-,7S08S%3$^Y8%Y(?=H">]FT'D_EJMHOM:/&=^NA+]N#T
M[9PB:A1LM;-1MF</?"KW5!J/KFUX'Q1!5U&F2&+- .VV>M>Y$6SP@,;V$F;$
M@-QF#I=3L_Y:L__JO-T=(@Q 7]M5"-M?8)-  Z(R(ML*_F;EX/?M,=NBLXSA
M/7O,/*>DZY2<0W+'HY;9LA1[RY/Y=C-9:J]3\U$*TSX42K -!M<S7 \G[4H\
MTQAKR4FN"9C*&X2Y7A#4,2D,L%F=Z2_S>75*3%<0R 4GX-@'#]CYK5$&X^@.
MC3(N&IT[-&HY97/:!KR\I2?VH'/-U+MY16G,&D*JJ4C%R28SEND/E)%LA[BX
M'U*CE:J"7M3$L@>^-CI7S^.,*;WE2*=:0RSUUI7$:;[6:4_'%[A8[Y8[-N^B
M[I +.5<#9B8SX09D(T85(K'J@EK$"XM<<Y.+#\AWLNYUC[ TC \H>=P<8G0'
M6\\EJJ<VF8^,IO3@3.0]V5,I6^86>'M(E#;KKHM\S&C3LWEBD2HG^46<_/57
M6WF8\O\_>^_5I+:R-@K?GU]!^=W[?'85FBT$"/!^SZHBB##D#'-#"2% *($"
M('[]UT$2 @3#S)#&YF)YV=!(W?WD;%^FCJ8$G!9 8T&RXUEI> DH?X#'%I0.
M-%PWL@U7X+WSP*+3@P%LS2.^7_*&3_'2L\33A^79\2VZX@)&,>WHD]WW8^[=
MM;;=M?3)7;L-19HP2]. 5PM^CG#-?8[A[E!B5X"$<%[#%\\8&/(<0"0[QQ3&
M&U$8$>8^NT;9==+=OY[>CC*U=@:;OG<96)((^H[P0&K2)7,6/V[C7XG+-*.1
M06)D&@))++(E*9.?Q$WV$W.B7=?<L??AB\5NFS; '[P0AFA]^4YAK)/5V6LA
MSRPR/8MF,F-N_(;:L$3#Y'FMW Y3KC]2+8IR.#AWDW#D+?3NC6%^KXX2;K8I
M5E"'QI,3W2A_@X<_Y!V%&*90N1-QU;F7NSFA!.0DM@(&H)"@-ZW+T9 ]?,.;
M_(12(3Q9-6A:ZA#U:)T*0\%P!KTXZ Q'.Y[##Q#*[Z:JC?&(4=O'Z>;O;"_)
M&QN!>5?'"R:"=@;.?MD%>/J[20SL4$4Y#Q[@#"7P!7PGMA<$W3/448?=_HT[
M9QP_B,;P@=SA+7VBM. #M1Y^D\+7;J<"^^<!*^JJF6Q-HF7&6@Y#P^XD0W:;
MR:^53G@%^'8W 7L[KDS>&=Z^6QL\Y14[KP?GAQRIL1BK,/'9"0MZ$,[!_2V*
MGD-4+X&\3>P?$?RH4G&; J2Z-1LV%]L_OU..C#/D8+X.*KB"Z2Q/*K@Z%4#9
MED-%.;CPPY\JM$H]%'N-CD<,'YJK_"C!DAEN\K7L>*26?: HYZ[0.+.\Y@/W
M?Z3.9EC.SHIMD<PR1*A%A.."%HY _O/.7=+DI0IMKC"M_K-9FN_ZT.R8Y5C0
M=,.QYK96V)ZK[.D<NV6>#:TN>O384!NBF0G'IJ^S06/61J%*ZDC_] \*)[L3
M@N.OQ4D*UVV"\+C>L4^T1M&=D#3F0L<=8I52NA:I#",5TIR$U,V8U><YU*@Z
M^N('Q9W"D_/\&S U=@G>BTV3FP#PL@!Z/^G 66%S)9<IV0]@)O/\B+8VJ;;)
M%N9]HM\/+WJK2_D_/=O?BJ'C_2[6)2O+%=@V32ZBB>Y2FS7JT1$00;$7,A[R
MF;1VM-3H%_;GG,F>.4E%=;T>5UP,N^)V)[6X><] ?.CZ-O/93;<]\WVWS)2^
M@>;R91Q,&9.%&&WTPR1=ZF34-3>S)KNY&!>9I'[T'+Z9UTLM,]O4+*7'%*--
M:QA]+0T*)>A7.37.-PCL=+!/WIMES_/N^)=M:(V=H#^/9]P'YJR%PM9V<P4'
M!W]^Q!WKW(-CZ%VSX\;779 [%5QG13*=EKUX$L[[:MA]_))_'#7>4)F;IF9#
MC>+*"U)8"YIIK,.1/ W[21P)<'[4O?D5?>^L=UU%IW@,R_2C2N"1\!IDSJTI
M.#ITA[[3$*LS3M "4>IVQ*I9;+"OL78O4H/C;D,OL=@GD>'+:N/]\.#;ZY;7
MM!X6J=?1."Z'YNVBU"@SBPF=RL96T)]ZY@BM=U!E1]\,"&-O7,)I0!^*!\ :
M8ZKO.TB!Q@G_;HNJ7;T1?O*'>:?\J9Y9SU'?K#2^C0./5#G7'/:+92$CFLL^
MJ<46O8HQ>]<C%2*)$6M]RA\56*J2":&'LMF@RQM<"FS-XO+\=POS847YPE0-
M;$]46'W$+G =-IPF*G&FA.<W6] )K<*[G?P".(5B/!JJ)P=H)/&L?J:Z\@?(
MEQMH+#<34-%R>D8,TUVC;64J\8G"=\EP"19YA5^B7^8Z=JS5</;RM2AKX">.
M <HL[$80&)L:LD3P<V P%/P46[VJ-F$58<-BS1Q8P7A*@/L).!*!*M2='AD[
M#3'@+_#+/1]N>P\X/3 @]]-M'(9]\%#[(SOW<=N>#JQ"L2>;4$>><9@P\^+1
MV.;54/M<OHM8ZMY(EX+21 :3G<Z$RL)M%IR%@LC^W%NE$&Z((8+KZ*)0G)0C
MN5@GN5ZNKLF(YVCCR%-R27;X]*1\;,CN25;HIJJV,%%V$$WZ.E-Z"2:<JY36
M9+OXMN2+^5PI8TV3T)/[29[H5+KO9J@A-X"-OCC_S?5\($?>N8X"04=^&,X.
M(R/_H*/27=*)\-=BX=<2,G>PT$:^#&OY>Q RA;<B/TE$5R(5'L])LE4F:[#U
MK0Z;+GT2^QPI! .?$(MDGG?;-NWA&/R'L!T@Y20=>;M1N;U%@@$.B%Y5AAYH
MQT+8_OXE4'!R(0[Q?.<]&I2&AJ##SB![GC3%$#AA#A.+;&\V?,<Q=_:YY'+@
MSWZRZF_J]"Y&VQP_?]6K#%61+"ICU2R)/N;T_A"GOKIG_(&R!\YR(@&B$O7
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M%5%ZRW3%+D-3N7II)NDE*@X'?UTF=S(80$C'*MXQPOO@PVC@],T>P1;8\ $
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MS.,>SR-94&";812@_ X>Z0?B\?=S +W')CU^CTN)@<<][+>P+NW69X@$<Y@
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M=K@^4.9Y)#_@(%&H#SK'!AI2F;7L65^^E^1=O7-)CKATCP$$FM_'/F/+#J\
M#HYW9YE"34[? F+[[.UR),!&/!X> U<"B0H$+)S4YL(+2U4\U1Z(0"#&""C4
M32 1K?TO;0D,S@<T(DR"B.OA&38&D'VX%;4KI\$7C6;;.V? J_WB)7C3"M*6
MD)AWA[GNC)(3@,XGL))DP5?Q&KQ?>"K!'KS@@;W/O4$5^*?PZUR-\O,S>[>3
M/.%[=R=<8%)Q*04N@+]P9@B6ZY,:EZ>8=KH0T[M\>S5?4%^;=N3?-%T#.#!!
MNE'*.FAVGX0@<317/!<I:1I358.=U7U55C+#R>7N2LDS32*]RM:M<!78>JC
M(1$*TC1]J+C.)1." \##. +Y=T=](VA+UFG:=W76]Z=G@-^09_ R6Z"AU5Y.
M!M["&M"  [HDX!!(U83C..$00Z!]ZFC^X0A-[(3D#4P= %<)O$*SM@?'FBH
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M;6P['-K]QW$WB8?;.3O==94D#'VD3>I5HEWLZ8UU)UH8-&>?;U7GSK"5A(D
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MM*NP%R:>I>QETJYR$%CQFA,/#;!X.C0R[V!W"'OQ2Z )>QN>>@!,D&4- JR
M7B#><HAR!\4A;>[A* LS>7F[P3LR\H'%)PD;1P_1!6!<X<:),CB%.L(]D75.
M$X:P%X02:#+I $#&\3B0W%)/RI2@2:8$6NI<X *AR$OFA8)2"P",,V%7>T?+
ML?5K(,@P38I@[ZRNFS(F,=LB2TDL()@F!_1R7D=\"[X%'(Z7D#C3>-A+<?=L
M^"!VL<E04%09#@(![S8@7-%O#W<T9@4ML&0ED]\7J]L+]\XA 5M1-=?7Y<*K
M=6P?NP?!G(G8.<\Y>_**Z6. WMT$FM6-69$#6FQYXTD"K*P"*WCCMI#T94K.
MW.[#&SFVARUAJ4YOD?<H[.#A:&:Z?V:WAEO\7YA1?B!1X%W.&*L-6'E3CQJ,
M'%N.H^L:O]E8.\D>!'WH# 3<\8@ST/$T-O'=^;/'BJI@?H);JK94('*\WZ=5
MW:BH1I\'Y[6ET\B;QN?+5R?S9B<S:$K+-JW&Z]E9/1<1&&!"*:I?HVM7[.W)
M-PY&@3UC+7R@?9LH^8&/\1,A\V>'F_,ZW,2?'6Z>'6XNT.&FQ0W8M*#WB4[:
M8.C732/3'@TFLC2!"JW=\6:[LL.6Z^%\06#,M^EKNQ6-Z0Q;!RLC^RM;.9X:
M)"+2AJ&+Z?@TT^X7(TFX,K:_<C[ODRJ5[Z?;9F?8++/Q5BE!)<'*Q/[*=F>9
MF@Q:<;Y=%90UEUYK75&M#Z@!N;]RO.X4^46=[3.4$#-$,=PI4G(2K#S8Y^IM
MTH\*E:DN"LMR]6TY'W4+%'SFP=MS6LK,#VB^32[$SF(2RG>[I)$$EO;AVXF*
M%,E;<I-<).B>,:MDN$HG.8@<KLP4PBFF2UF66&0:O<&P40\MS,D@ZO/,=*>M
M9XN3*DD1XT:ZTBAK\]5J0!^N%,,T,1$GN7G;&L@\,S 88YV8#&*'*ZD>/7F5
MFHNLN @GVLQZFJATXW#EP2U1C0K3#A?:%E/MT;-2?M.4-Q.X\N"6\MU4:E!L
MQ5G&RL:E1#56FT=GDT'<9Y_$)#DHLZD^8UE#/I&;+ZU$;056'KR]HZ=FL<0P
M2XJ+JEJ(F>ELM-JN@Y4';Q_EJHW!4*U'F>9*504V6C8+JB\FQ]><I-1I(DXN
MPOHLEE_2Z>QZ!4N9]U<FN+=$KB0OBTR7[Z_*+7(43Q0F8&5T?V4INLZ79UF>
M:;.IV5".AF;A5AZNC!^<**:)0CRLRF)76(N=LF#UZ@":/K@DUD=C*Y-,<FV"
MJ;:6@E&*E>=UL#*\OS)4J@_FR<JB)Q*Q5J57B:;H; ^NI ]@5)^NI'RR5B;9
M="E5'G53B9@%,?G@/B-RN;CH-Y?A-J4(E!D)E_+=2MT/D\?3?J.V(HD0F9M9
MQ4U=V_ =$N+\P3[GHW9IFN^%PZ0E%[K)F2AVJ.8$K#S8)]O*M_/A:D<DTS-V
MT<\WU.B<ABL/]EE_BXP4TU [#$%HXJRYE(91:^5'1T2WK)69C% 463Y**WRE
M*\[TB8>./M[=*_RA[EZ1:TD?;]?_ ##U9!A&.^*&VHER0@43()9E1PZQ&BDH
M6']VG#CP*6BL%_9[^I@. FINA!WN^F\DH<[/$HCL^$TB@W5Y)!9GM4F7S TM
M*S6IE6<9<G+@4.2F_,B4>-NM?*"S>_7OI'U*)%9;8!\I"7SYPX%O'#RH(*0$
MK9V+SR9584FI I'\$0!&.3L'KS0TD[\<Y+;:"?ER1EXN^B7\\DP=&NFOKA*(
M%#:H $KL7.=_.W_Q;@JJ3/:&H.; 88W#T:>1?D:0+]%XC";CX<B>YD8BU=&K
MMI$>?2OT$HHAE<O0G!W9;PKATQHCUT+PU[6GP*Y%G="@OK32V+G][&CH)0X>
M[;D[>Q?./7I4(\\KH?4\!CCJW*#S;P(^^C=6?Z&A^*[6:9L9Z,7.4G:HJY)I
M\%=6-X]C2>A\+-FQ'8S1%R !=.[X$Q / (C$2RST!,0# .))$0\#B&CX"8A'
M  10!")/2#P"))Z\Z3$ $7^AZ"<@'@ 03XIX&$"$HD] /  @$B^AI]KT"( @
M7R+4$Q"7 \1_#,WKBCK'_W2>L^EVQX_/?:8TG'L?5Y637[Z#^*DX^!EU2SA%
MT_D3G?[X/]QJIDOX7&POJTTOH?DZ (A$& 6<B/L#7QI.P+W0;?SA*,*I$B0F
ME/E\!M<(42]T[%LCAY-43; XJ]I-<;>SH6&R\UYB]!.3OLYL//;AGX0\V^Q(
M5.;,<@8:QP;S5'^B'-]?3^2Y!ALB7ZCXM\:DI%O2)P"\$11=X.SDW9^"@N_*
MF*JFSBJCB^'0>ZKWW2_%KD#;.>TG]-MWXJO;),+?_\-Q/#\>WU8+KIJ&#K.-
MT73$PZ3ER,6XQ;T/ZH#S4AKIX7%V&4 8,("1:L)4@1MP@/T<5Y0IX,UA"<.)
M=9X<U^MWJXM<I!E%L9<K1QNQ\HQ,=Q+*K*68O<'@/N6[=JJ+AV)PV>5^\5N+
M&^CI43PVD\L\F:YG2[+9E=H3*8GSWZA@))8(DCY-1/\86OM49OH% I&/2)0[
M%_.O2QP5A_H>\:P79$!?*<^].0OZ1*'N91C0J:)<'[;4:>5ELF28<Y'(,$H[
MP[?RR6P2)]O"JMS#CM9/EO3%^.-W)],O9)E>@O8DN5=4(UJFQ7357%:;IL=4
MAESY]J*"%N[%&E&]2VH-Q]9.;TWM%K"T*9?8UH-)?EB01C$FO>1;57H1JH?2
M,%\]!IA?_"6\WZ_J26I?#&P^(JE=7/KCT.$C'O4:UL<GZU]O)?>)\+T$?\'Q
MTW2@F\85]6&7^^0GO;=0CZ6'HCRHR$)J'6ZF"E#4A\@?_\2O(^FQ2^?;LI_O
M%+S,X48WW\&7>W57S'=D; \VM^=8R\^''M0"_2Q1/FD,THL\F;,V9HC.9J+]
MSF00AGZ66#3B.S/P>]+,O5PJ?_HAW\N;?C@6\CG'R&,PD0O[2?0/\9 /^DK2
MZ5PNU=@DB\PBO,J,ISP=UQ*PB#@*VXO35W25_.$D]UY>]A]QR+\"DN_E$_\1
MAWPO5_>/..35@_&/8Z;=VSQU!T[^I\%+/)1<?XSC[_HA]COJ:5 S.W=,S)]O
MW7UYO"K0L)CI9C3-]3B5R>77!8/25J-H%S8U <9;B K2L<,FL;_^&%IYH!#Y
MGW[NH_'RI]7W)UI]#LOYK.''%N-,<9![K;<74BB:K[/=S"(%^R(!PR_ZXC/U
M^<F3+A\C_\//_;?"^VB@]@\_]]&H[7T5VGL9FM\6 ;Y3B##KS"G_CSW?YQDN
MO'>X\&E#7C!":..WJ6TU/1]MSESE:B&ES;Z2B[D)-6:]OBK!'K#0R(PG@F&2
MOJ*5^3VXVC-$^ P1/@H7N;&QZ,-$/F@N=I/SMYPPTS32M&9=4PFQ\Z)9!PP&
MQ0GCSSCA,T[XMT/R&2?\4P[YC!/>,$Z(IO(^G4W7+M2]::7^TT*\H86XG29_
MRD)LE?)\7!(:9)M(ID+C9(1H"*WD@(86(DU%GS'(VY?IWIXD[WTO9];T/A2O
M>IJE5XQA'G"N#YJE!6D0"='K8I6D&3$=2R;&FT@73C0"9FDB^A*//\.8SS#F
M$][/,.:W"&,^A-G[;<]]^:Y5C]2B*OH]W7"73I;]$\N_/]]\ZC)Z87TM=N=B
MKU!IT_SJ;;2RA"JS>?CF4XL2:U@,%XVWV9F>CVQH+O<67@UBT* -!\DP&8R$
MJ6=8XFLF[+W)[6IMI>Y]L+L;G'?B)-^EAY0IC;-C14U'VTTQVC?3B]"2F4/N
M GM(D8 X_A#.<C'Y[-=G^,'IZ@--GV[ICOD&39^*]9@0,:=O&V:Q7I2:S6Y"
M'(W@*&?8]"GV$KM:TZ<_7NHBB_O>1'2M=D[W/M<#]6ZZE;Q]X-Y-8W8EI6)3
MH*D7Y]UFIA,>E90E9"*P=Q,5C(5#U^O>]#WXR)_7A[O#ZW P^%7]&_<^X[,%
M][-7U%'>^@6%#=,.]H?8P^K]FD7U>THMNW@KLFV3,=^JDTSY;5I9#>(H%3P8
MI>/!&'E%O\B]J>]AH_U_@A[W;,K]ESM4;+<)"R#[08>*-2S.AN%%:]-FPPDN
M*DX7N3D'V1)TJ% OL6>D_MF4^^F?.8O4COEG0MMD/YU;K:R"I;;IE)R+6O.R
M4- G@-BP?R;T;,K];,I]P;R(NQ_UZ=BYMO'AX4:[CIV0CV=''<S#8I(*\6*N
MRH?Y'+%.M$>0_4#/3BA(1:XB[/^$])7_&/"&_SG@SP\Y%_FBFPK%;2H-42ZI
MMJ9\8,P*FCVE3QT'>):;@K<"<@FH"#$#*U8/ ,,8X#QT+)DZ2I\)I"2 !D23
MFZH2V Q>2L YH_!K61WQ4F E&-.  =^@2I*Z@E^L]D=-LKINRI@ ?J,C?WY,
MR+H\$HNSVJ1+YH:6E9K4RK,,.3D@4V[*CTR)M^W[ S7<VW0,DA^FXNTN6Q!]
M6F!/*0DLM ER. A3R>E"6,Q>Q6+HE6/+PD(H)I(_P,5Q[!R\WM!,_G+D("B$
M/4:<?#D7[<CST0Z1B/,$6_1P (;L7.=_.W_Q;HH&S[8W)+-K D%-<;9%2/S8
M^,V:ANI\@"0(_L1F%WB-AW_8:^ GN_/+M\Y:SR#ULVNRZ/!+^&1UW7-0^\<&
MM7]:EIP,$3RA<",H $OE9!;F$Q W @30H9]P>  XA- (YB<@[@Z()V=Z$$ \
M.=-CP.')F1X$$+%W^LD\ 7$SSA1Y N*"@/ALHY-WC>K;'3\.OD3_PHXFL$]I
M=/9]7,^>_5X7P*D2_/#__8C_^"QE1E[H@S3;F_8<B._&+#A>,7AM[P:'.R_Q
M7MB/?_H\JP5X9<2/=O/H_O<_PPNT!GI2S!]*,=1G*29$XNCN]Z48G&$ZO 1F
MO*?J/I'C&R)'Y(D<UT*.&/7=D2-\4;EZ[PAU0]!%8JSQ?$" 5\'K1D!C#?XR
M,O/>A[M8\CWV\#W6+(-/Y[+,38T?R+FXM58DI21:F_)*-L)&?VHE'S&S/G*;
MG-8L*V@HA\430(?$D06T4;!)HP$HP\UP(;85D(96Y <=2MLPW9(0?0V/Q_%U
MOXY',H=?$E<I#T:^SGL3V+\QA5V,SK# O/>I;I\W^.0O?EDRE^ ODMPKJA$M
MTV*Z:BZK3=-C*D.NOAE_V70G9;/5F[(,(6<6W?BD'I-3]ESFR L9>_*7)W\Y
M(P[PM_.7\ Y_"5^$ORQ[TUE^,^[13+%$M);%3J*LE+X;?S$*HU<F-$G$Q9R<
M:W/$,$EH2A+PESC47V)7XB^1!^@?>83!?"=G:4>%(1_(0+ZAH_/"%MI?Q<[^
MB*[ 'V%GS'K.<P8_VF+\,8;&=<I*Y[4<T40S$JTLUK'^2IE.[#'+5]27'H%W
M?5MOY0TMK;^*3]S'K/H6?**;&,6Z;2[TRM#]-Z*8(P6I0ZWPW.-$XLDF_F(V
M<8M!7 _%)NYC'7T+-C%7ZI0VH_M))J>IR2IE&&V*20(V >RCQ%7:I[R7+_9M
M3*%[&WBX?8<R"E@"+UUBLM0SK/6G,;Z'L*/&PIH?$1M>4V_"\QRR.,;Q^E6N
M/BN8Z1E9)$N9=8*KO\GD"H\0AL(V1/WWCW4ZWZ-MQ-_JEG[RGP>QSQZ,_S09
M/C^T)#G23C?6(S6C+XU!QYXP_.0_3_[S#(O]88;?@_$?9C;**6G>J+>+L4J\
MH^7BI<T,ZC_Q*_.?1PB*W7S\\#W"9@XF! Q>DP,_8=,V_1)C3I\1M&?+OZ\U
MV3K%MW8[^Y7HSH;AEL!&JYK3]F 6F0U65AV/\0U$7Q)7Z.QW>__UO=2A/_R0
MWYK<;VDR/0ZYB[%<_G4=G7(,'^:UZ 8PO9F5Q/-M ;G'G^3^)/?O$]#Z +G?
MTD)Y''(?SS)LN3AC$TQ:R.FKA=BM3WN0W($-$J"OTK?W#F&GAVZ1>>7FA9?M
MF4GY]\R$^,DJ5D#C.5AW!U$#T *!$!-0W19Y _P:_ATUNE0Y ;701'TQ>9N*
M JPR"H!;)MP/O,TW==B2\U\7[J?[&+$:(OJA*'52DE0.7I^_ZX+!U^RZ'6A,
M\156TP99:F;U6R5ZW9;'N7[4:H97\CP)L_RC!_Z& $ 7"?PE>/5;OX^'^G:W
MGM<3ZWDS5UN(@CE)SA5.+;3B$WCK](E;A]1P[9N_CV_N=C=/Z_%\?R!DUR)A
MB*D&N2(&Q>0*WOQA6L7VYL'>4+->Y+3Q:WT!>0/Z,X+!!.\N"#B@#N6LL.0E
MZR4 >>-!C]\)D-]&8 0.L]=K>)?3H67@I8+R\7V@)L7OX,WGAHX\!K.\[0R2
M'(2$7E!J0#2JH[W9".C+# "FJW3MSR)!2!COT%1'I@=$NRKJR;?*NLP,M/J/
M?Z(O/KW)W^6VEX'=0P0%OP'L]%&RK"P:/-%.KQ6BK7+S^'*P@F4K81^)>0;+
MO@SX'B*F\@W 9XAR@^H4"E3;6HP+<E]^&[:&0/("\\9'],YY;8<1^['T4VS;
MF+)&8(FG#@*[#G9YOPK[_CO4W,N,L'/PQ\63D*^B8*;CQ%CKB!6RJ.>-X9"N
M9(0HHO/#:HZG8GP_.+'327&X7@]9AF@I66H54RF&F4 XG3)@GJKT/6 U;1I\
MFHW5WT@VF]::Z:3YJM8131T.V]W"ZI#ELI.)QD^@SBPXTV"V'-CAO;P]$FX4
M^"F\\"]!'+>$['<DC,>\QBL<'QCRQHKGL5(MLYK(&P$XIX.',V*=!R!D@0OP
M-W-6& 6&ENND %Q>W:Z%Z_ .?KW'\?&&GFS_1E,#>5=S:*D&*QT9$.U%5\E,
MD>UQ=#H0T^5"A,XN\Q$C E@+>1)=GR+@GC#C!YD0VTR2,7*A;DK]7L786-5W
M8?84!_>&6Z*]>AUM4G-+)(3&N)!;]2E)3T*XD>>*ALM[N,E#!W?29W8XY/ :
M?Q6&?:_Q;A_#&N==35Y; A'ICT1@3]@20EO7$6)XOT^KNE%1C3X/3LZI$P4
M8V?@E"_:O$5S\E*K"GV1& PZA>*,+&3X%?*D'$4;J"08\.T .)K[JMW(!*?"
MOG2PMS5,V%+!2MN*V[7O',W "7GP**Z&- +WR6"!H.,'PG;: 19\94_0/'0'
MSA'1P!U^[URDJV&$K6>JFOT17!?RNM8:S>BJQ:@=LBFRU>FZ:J9:X?J/?ZBM
M?]>)V6&E[#9LXV2/QP:X!+ AB%X($ '(*_3 3QC H\C_-IIM'?TU]-]?;BO(
M:V^8@:/NP)N!SFH(!AQC!_%\"C8,4!BC-P_8[KFYPK9G2RRG%$$?TO&VW."9
M1213*DB5B^BHSJ?;NT17B6X2',/&ZG%7*FY"3(DBFV:[&R4'Q4:WM2,O"Y7L
M(9(#]@>[WNN\XN Y)*;? )' 0^UA>3K 7%E5T%OSZ)I::@-?4G?**S[[@J:3
M[NND6J[*?8UG:5'L-I-OU8XV'.<R@*NI"G_(U=#5(IZV940H8SCV7\AVX*9L
MKK6:VI8.A"ND/!V;4Q#! A-> 2Q(DBST#;"9?@6 ::08%C&&< :,"?8N#?Q\
MC.*X\\#MK((W#=CMSB^/:#KH+4#;X:9\5>'MYV0*;]64.MU,VFE9R+06C60Y
M74U^T1'Z&:,;_6&?I@%9B%[#< &RXR"K'*$2-QK&\D8W0HG-TD(4]5E$?>T"
M5*(.O2/__G5YH?,8</(16GOT_&7]UPL9+*.\4FD5>6.CW6D\3>8XJTG*U6XL
M_39!!(VDT(%H&FNJC @1:@FZP6IVC! J'+JP1O]G PL3? 'X\5](G*V5:C\G
M7LHFC*R5L!@^L8HQT>1RT1U,OM@0[3;$.<VFNLSB34F(5&U"-9:5@A&OK6 P
MPI\\81@:SZ U.8[7=8\ _EXD^S[T[DZRC9[2()JU<84D4DT]+F>2Y2H-8&-,
M-9XG@% UI@=4B[7W(+8'V3$@S2 0I,*O<[4D ]_.(-F(,:_16'7!+.*OBWQS
MDX\#('T;TH0W9#]);M?Y6F%,BV1U'=8:J339G:\G7U6X"@I@B9($(:D#4\#>
M9G7L=RI?!4L8\$0NW%J,V\2\J6UBZQQ-#("58*S40P7+AHJ.R.\OXK ? N/#
M*D!L58Y,T]T>UQ9RFMPEH\*JW4O^^"=ZZ%?ZMZ-%L_ MVQ'= "-5*&_!?V-!
M8257,".1K&*=^GORX3-@?'=.O*X6.Y60,DBUY4V6R _BBVJ?6KGYW.^1HF#P
M\B"Z,(NAZ5MK*II4EQR62O.V.OHVI/@12^0S_#2I*$"5T'16$W@/0SV;G69K
MFYI:2KVVQ68M*0[>RI6ATD@>L5=]]5W6W8'E$*%#9-"$A;$ZB"V(XI!,/5^H
M/BPK1@ZY]X&?54W-?DJE.PEI$2Z?) FFFFHD^\*H/?P>=FBD:^@D(==&9#7V
MEM2-J*B^22O8'-/'O^_8,Y #"\HCL=;+P>SN;%7=, W*:(1),ETW5K5*?=B.
MA5=(!\*>T0,B?8\PD83\*2S_.-)T+G5[Y0Z< =-R'.;+S42Q5F21Z28VJI:/
MDHE%;"?L'7Y4VHQU27V4F7+]=@ZHU>'QLCY?$#"%)OQR.$G$59*0U]!6?L:"
MIAN!G?H4B-2$L"9P.<KO//K?H)^HRY%>8D:)Q51)Z]9[ECQJKGQK6S[KT\;_
MA \"^P;7+>W,H;(_LNTXMS8&_<\CA8 <=,ZYS=#V>$NARU4WAS.>,Z WG 7F
MN,1C'(6_<TC$3M?FEY!$P.<<KQDL^)";0BBB3\#>-%5"1H:.KQB'E3Q/1X^P
M RH>SZX"7F'R(_LKV6&8P0 P4W0<=P&_#NX$J* OV.2F.QKL2\"+86Y1CJ '
M/-$Q\ 4+P*.Q\!8)25#X , \X4;ADR38M2S;R@'T7L.;6@J&M9]C<SRI$AR'
MA2:<)*DK_3?:]>?+?]?ED5B<U29=,C>TK-2D5IYER,D!"0,.,3(EWHX0'+!P
M/[Z$2=@^70O6FK7 IE(2^-ZNTQL.JJ^)87>Q2LB,.3$:5*Q1;]2F-L=$*)$T
M3JP;P&5 $/" %<S!;@W-Y!^HTFZ_Q!#\VSX7NC-G**]GUC G <##2L/I?T>"
M/I=8ZS<JTK,WXXQ]HT(O]&Z)791\B8!/=L<1>QZ\\S0"4+CTWU--12X[T/CH
MT#@JLJUJM<DC2X03AV.+X9__9V<HL]OFA>!42=5^._/O/#=H7PV%2C$G/(%G
M/B-?UF]66K&6[M3WTB^1F#-:[[<[0R^,*#?T$J/_'?#\'=[+ >!D=DUXKLXN
M_20D?FS\MG_F?*;A$=7VA^\,G[;A;JCS<X%^%?X5]I0>LP$@;@!C^9^6ROD6
M<KXKKQ O@.PO#?F48N@NU;#>D=7^=+%_TWX7R#IEP.EN;I06Z&2)7$A<O-NL
MI"?":QTPPO /_#9W9:A7H*BVF>;:Z5BW,A;?HLM6*PE61O=7SMC7V(1*&:VV
M69.E@=!*O#&3^H :D/LKJ9GV5GFKKGHD:XR5-*<FFG)_ E8>/%/*EKCRO%4K
MDH)IS,JU0:73GL,A10?/G,_ZK]9R)'9%FILEF$@DLAJJ=3S.:'=E;SWLR8I!
M5QF!7!BINJ1&RQ/8>/?@F8G0.EQ*Q/B-R$]Y60Z5,I7%)HD[>>^N3)NY/KE*
M&*LV%>/:BU:+5#+"9! ]?"97)R-YIK)(DDU+(=O]E4'7E0EN0K>[LEY/3=N9
M-5LCJVJ-+14(GNJU82.6@V=69URLVILF%DR.;57EAAJK$_H*]W#879F)EP:*
MPK "TU25U*"<68=*8)\AV-QE=^5KJ+3)O2U*9CM'%+)S46[2_"H)8'2P,IYN
M#U[S@\F"9#=ES9IE)H"<DW[03%>D69O@K2:9"[&U*3$>%/-M"/?XP=DGY%A,
M9J(146#"?(($@K.GU_W@/J7-34E=E$4RW<MVDUJ[$PG%X9B9 TS.Y2NY9C]I
M+1@AM2QOID*DFQ7@2GI_I1KNI;D&.Z^UJZG$5"XL8[HJ3L#*Q/Y*Q:K,TL/^
M>LB8JW@S'"''G71FY8=+L6YA*:;D58&AM;:<3VY(LB##E0?[W'#<9J3-U6R;
MSK;R4K.L&NLIQ+J#?6:EJ<(N)[V12!C+-K_BQI5J!TZD.-AG,9\=Y4-+0,5F
M?]A2XN6*&)[ZXJ?5&D^+N5IQ3/+#\7P4;R\45D_B)JV[*PFQU:.KPT&-Z;+)
ME#)H<O59*.F'R0.+F4G\=%5D!"*1R*;S5G9 )G'CL]V5*[;&<J-HS1397)*2
M:_E58Q!)>G!^3U5PU"6R%1Z_6F_1&=F,4?E,+%.+FRNL!D4.E:83JZ,_CK[C
MI*KUS_\B#<(5PW@:+1#!$CO7^=_.7[SB! HM6V!!WLUAGK\K(CWM$FSY2!X(
MMFUO-/MI(2R//M_6(_P2.=EQS". /*^$F6]CH'D[NI_S;P(^^C=6,J#[XUW9
M;BMSZ,7.4G:HJY)I\%<6ZL<[,(3.[\"PHZ%]L8O,Z19V3T#<#! G^UH]X7 C
M."1>XD_.] B H%Z><'@$.#PEQ(, (O%"GNQJ]P3$S2@B](3#Y>#PV?;+[QH1
MMSM^W(D8>4LR+MH@\2Q6_"<=^*2>;!N_-BF$YNL P']A%'!<T5>\HO@IK_H9
M93K><57VY1S_AUNH<PF=]AM?&JZ-N=!MO*-8WOVP7\,03I4@J:$DGG-8"OD2
M3GQKW.B>UPQM[K1*0)5.%T*E=S2!N]^-TV7?>]A/B-MWW'CW'OQ0-0T=)@/!
M$#Y[6%D=N0B@'V$JX#V:3-]GTM5U9D78<O#/&)SS@6+8O?K_8]T^SLMTR\?:
MR^5X,E/:BX4T38<4(4843U:_7JU=!+,P ?K#.@[-1&4<55@STYJRBEWM[]:&
MXQSE_;3C%C<0PI/:.M]\2Y/-B6P.DLU*25VM!A0,FH6"9(@,4N'#]+5+:2'W
MIJQ[,)1'8*3_N@@S(>\S=>V"S.1S72-OS$YNU![R?&;RX9Z1@,^\9:A883%L
M%$BA5\E7AQF.M\8P,8%&A9I7&=J.M--[D]K-IW+=PRV4PXV5OYL_YW8JY'?6
M%[\1/__^G5+NQ]YW^P+[L/#*4!8FXH(CF&XG.I[2LZD0SJ]P'E@H& I3P7#L
ML%_4-W!8/0:7N#DKO)P2^(TXQ"U;]%^*1SR* OC%SN& A;2-43QAK:=<N_K*
M589C8;PTZW:":/0E=A5#\]H^RL=1^>ZMZN(NQI]3 N^]]Z=K\<]S+4)I<&XS
MIZ?"^&%QL-NTW(?;IZ*9$4=QFRY)5#/E ;N)&OWE!"?DT_%8D*0/AP!<9);S
MT[7X="T^%<WOJVCN<I;/*)KY]#*7RDPR3-O,=;/I2&20#'$K7.%#OX0/^<[3
MW?B-W(U951OS  JC_W"L BN*GZ['A\P5>X0[N'ONUU-+O:LL<7G%"44UOR!#
MM:16GY!5,R>J"2F[T8JP=A-Z-B.A(!TY'&MY,47U#Z<_6RM])"9T017U<=G*
M4U^].8\QP:U]1EFMB\5(9VP,R@P]ZD[#;67-6XTZ8#](6:4/1^X\O:)_=,)F
M](]Q!CR.5W674X<!IQZI)FPG\ "L^B9^V$>^@#OD@'Y--+%-RN"TJ&ZUBPM6
M7A/363=<>U %^/T<4+W=X_K):+1 $MRHHIC=&*$8DP&- _OA4#@83QQ.U'XZ
M:B_.F^].H[?SY-[]J'=7G6_,D!Y%5_Y2%JDHI-C*9JXJ9#/3B:ZY=&HY7L V
M7-?.'_BV3 HIS_]!G9/^\6D#>:&M;AL#DB^G][[])?SRS)-<]$*=AJ@!VJ7O
MEJ>W*^S6JHV<&84$:@R\.]70:>W*ZKK*"6BV(1IRX#2718UG 1(2[@>XR>_X
M00817\KZ_N!XRZ0DJ1R\+7_>PN!;]9U/.9@GU[,1GXN0:68MCNE99%F'@Y\B
M+X=YXX\V0OB\VVX.Q%9O&EMW2#F^F)!<I2W1[)UN>U0N3V.S1+;4;JJO0VK4
MUWDV.H'#'P_#9H\X_/>\&U=)^C7/2?FB:*9:%;/;TXG5E\:W?N'&96IIU(I2
MH4W*U;GXU@Q5<E8S"93O%_K$C<-!.L>FH@>.#43W&P2/Q[AZ:H4!J]*VTS3Q
MV$,33=,TIJP1L(>XOC.8_>@6T(A?=C[7U#6X1P-LX^]FC+>*HZ/)L(?:E1<1
MZ5F\G53848IAI[-->Y6MKV(%Q&B/#P+^RQGM T&/8QK]7)^L\R)AJ'K.2&QF
MV4X=LI$GX_X>$!17O?AHSM $62UU>&5 -]))??(>!!]C?GOP_@/<+V4K/\S@
M=O=)^$?[^.6+0]9B/*/GO56NW:5"PDJBZN56#_'PX\K$EX:YXU$>WVB&^]?D
M_*//;N\EQY1NU<HYDLIUAM7R>LJ49HB') YF$5UK=KMK8Y\[O-VY+5O9G)L:
M-P67%9A+K'+!:>W42:YVK+>;R_/0&$. UP(@%)GGT>P7@*!HSWBHNQX,3'D)
M#7IQ&60H#ADD_!/]WK,8:\%+'I,.7!-P+P+/L*\Y%U$#%^'.LL<KF[6:,]#^
M)5!5 J^F AZ"N'$H@5\V5.$(1K#%D0"HT% U?6_$>0#@+-+:(?U"G1]3M[L;
M\(Z@/9I'-14#V1S.^!WHXH#ZNP:O \_BT9U!.Q!N[I ==B0#(H=C;Q C^0D7
MV"=)>E[?<%[O<SQHIIQ>&X W*?S_['UIEZ)*MO;W^RM<U=WW[5XK\3 )6J=O
MK86(\ZPXY!<6 B*"H PB_OHW C333,VALC3%3,Z'.JD&0<0>GMA[1\3>,AB"
M8FBJ!D/)^_B+\UB$TEHN+=N%JU$ *61;GCH#\U8]0[132S&P+<, "X'L136$
MPKD_"&,4W'U7D7C@)>T#6*\*U<5*?%$"#C$0RT%$?/SP.B ^8!:<P[Z@):$L
M<OE-=:H/659E5R6I\.>G,#Y2D6NO"FV 7$IKRH;D#D>ZJ\QUNBS7L-WR*SV!
M"CBE/"@C7F>8-75@%&=/U(9^%\OV_#<4!P#,_E/H/0-HT17WT8F&/SP1BW^+
M_]D7^PKS<T4B&:7 =Z+$78I\E_)GFC2#WSQ6!9/%AY*.C^"X*Y0<%HR;//2L
M;  ]-$?9E7E\TIDA@KXFGJ.98/2O=/HNC5,5$ZS5!O#?Q; >5%3:]XQB__M%
M1S]1['^G1.B'78R'VJ)'10A/UQ#M=BA=I9LRK^,5-5/N#[;M_(HY79+Y79S:
M'TR(FK[#$KLX!ZY>\K&B\0@S5-VIKN547&3KM.Q3S%OF@Z-M]O7.=QL;SVIT
MO0XZS_33@?^/:K5-%&#.F+LZ>571]&"!-ZBQ5<\(HC)VL%:=!7V'AZ>!CR8K
M8.D&"S-0Z4FPAZI#<W^QT%Q745Y:[XYMBP@T]I8%&"VT*(#Y"]YP3E3X[4,?
M?R*%^KVQH!N][!)E$3R#D6R_3QFOEEY_:P$\6+A8<:D!BS_*[MG=T0I8]D4/
MGB6L.(X'KS><5/1UU9N[&JH#%[J[&3&C6;U$5V#(F*+N*.K8TWO?TO9HX3Q9
MMO:1YF>&W$XP7E\E(J%X&ES>O2;R$2-O<O*X!,F \< Z?D??8:P!T$;R(J\4
MKFM10#IOB)*.]"1@:(,7+2Q9,1Z-P*A\X4FO4P0T7T3.]<_#'<AK%#E\$FHZ
M%,T'2P@8V3"6%,':X\A/%3PL 5-W*;#$H-I&*AN="T ?F;&4G4H2<X$JAOC^
MA(4&V&>Z/PGJG;O"V$.[_=F0S.,WL!9=YOW;QK=7+RCLA<R%*6F3!.M73W2/
MIW-)IOLX,"*7SB8U..+ B$P"3?%@!)ZF$FB* R.H-$DEC(@!(P T91-&Q( 1
M>!I/UH@X, )#TW12,2L.G"#3N<1^/2,C/IJLY$W7^CM4D'K+J[TM&CS4^\F^
M5>_G1>6DT]1MEP :PWV $Z=O_[CP3:(T7UQIWBR2]:)MD4GCU\WK\:=*$UVT
MGYQ'.%YWQL]^8_'D9&,M+E@Z2]ZZN)#G*\#W"7AZT^*2N?4E&1YS/^OR>^T;
MJ%W-T9&IK2@I#9)"@8>!15<YV])Z[?F=,P/'=3*OO'JC_4/I-7[_V.&'SF&?
M.G=1KI",A4WH&B_6F%F!JE9&0Y\Y/'=!?LXECX<+&P<;[% 7BD 5*CM-Z )%
M.#I]V)>$W!2?:UZ3:O*BL58&]R17+RU@NGL<'L?'+Y*%-!,+M/C781'7LUE8
MUY[5YZ<*B787OC>8_-[UOU-@8K74 I_!<EMN9=&;=>!@A=+ZUL!D5&HXG4%E
MM>&#&9.=B PRWY = "89F/N"N$B6N&A/Y=IJ=WXPP6, D5?(.Q3M!WQO-/F]
MJZBGT&1=T_"NW9[JNI<1%[UZK[1=:?Z-H8G;F%%]AL_T4=9W,_U%;8;C#"SF
ME85H@ITZ0/K'\A?M@EQ;[UY DUN*C@XLN,T#T>(V(YMG]K6^$7I]AF/U29G"
M3J$7MSL1_BC@+^&7,ZD[2[I6LWB673K-%7)?X3:,0$+7*G<1]'KKZ-M-&#Z?
M$:>.A<OTC3#A,_RCF\ $G]8;=!V9#GAD:COST3C3X%:PWA3PD##L^+[GV1RD
M&P>%S]B-B(?K\XU0X3/\G)M !2>'MKB&K68YO.]2M<8B5U_G82DHX.E@^ 4=
MG3B@PHUO.D69=4TY%6B*\3LUGI*]IM@ 77AA&#_';*^VM?%Z[O[/7\VNMAL2
M-T+<PO;(6>7_.M'XN+']:@'\N!'B)B+ZYU. JP60+\3W6XHY<P_)&A1[D?IW
MF#GN/#7PDO#SN53M8ID2?R>0_,[\B!_. _::-]@'LHD]>'Y,>349*N(617M9
M=L0UNHL 'K^A8(PXA:8S1REX;B5('+=EZ-///\=BUG$+-/]!DIKSA8SCH_V\
MTR,1%5,J^K"YS13)C)UC;%C5*G-)[?^$:'#<].#3C[/'8M:QBRC_AOI?+C8<
M'_5O(5A)J@WX@-/:V"*S";![J0U+164OIOZ?$_:]I"]R6"CJD#;?N4S408+H
MXL<JKKA'61$?,JS#)+*PJ(H9LQ(,']L/^L2*4'74G!I9MZ[WAO/B:%WE,OB4
M^?'>%)*?4XGD8UOMGT?$S6B<]V=C,^ 0H=+$:_W^@&_[%R?B9YQA^CPB!OI6
M[#8[@H$NM ;.SK)D'RVI/WZAZ5,GLM_ZXK @PYL%Z!11FD4Y8-^;,#.=*GRP
M:--3%-/ Z@NSNIX]8>LU9.6W2_7"WBLA!2)J1BF"HRRN+R;J/)VO><*.F'&N
M4."X%LT6S7RM:Z\[/DSC>D>0QP*TRYQZ]PF4_PRHNR;EV_>*(3KF!$<I9F6-
MZ-I@T-K ,AF9._S$98I]SEJH#Y<G_F<LUM<D/MM49:]8H\?\BBU,ZM,"TBY7
MH-B3=SB-OBSVAY6.[DZF*5[:EJ0H\J>4VXRA2=7>3;]H6XOP1:V]CQ35!)!/
MUQ_LS>_1!3G4]6#";*K9 HFZ:_4[6E,?H]\0UX>MN2)J>@WK"FYO(*Q&C<O3
M+X:&U,?H9Y6$^CB?FU=TD=ZJ*[G4R)>,SA_;4)KY$1,I<HF/*B5'V:<.DFI)
M!N@6Q@1F?\N:LS3$X&?H/3]+7XUC:>JI[YM!T^3R><KH@XZ?](9(BF'\_=IF
MX'DS=[V8\P G'Z-->W<8(='C_%SPW_]YDGWL8;\69M^V[)_[] T'%-R1!@^#
M)JJ"1,G-Q"D8P$_1\,7 V<V6IM(DO<\,\?,A!001>NI8FJ;^E3KX&]+EB'$P
MM?<!Z9YD]]X]]C3!]_[+-[*L'20I?R?3+U*FCS@("8JIF0V1XQ]]2SH988%_
M ^4!^FT\2?NQ^^K'KS"7/%Q,62M,ANX\!%S$P]QLI_7B.:5/$?"9HD7ANXF
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M$^$0.%1- JM.TP(S@>N>IIH:D!81=GH\ @ OO]*_627P@R;(8Y7 9\9(Q8R
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M-CT25I2H;8OFHL9Q)8;#\HLL45!)%38]DE9Y@%AM#6DM.;S?::G93;TE(>$
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M^ )^/J'63&175!M-O\-,")^$/[Y3DB+>[GK8P9<$."\N'>7G_H_#05&@[]V
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M[,'^+AQ!Z^$SF RT8P&34I)BN\ C24G>PHL<LY04FK+.WO*T?%.QG9FV!%\
M05* \P*&Y&BJJ4TU283UVV#MW)EE@-F =64-YB1"K5 4)+1:ER&W87=0.9QP
MZ<F@_TJG@!D/AP ]FZ?&X(/_ LD!_'!5@5[2XT#V(XP(>$C\WR9Z.A56)TQ9
MYDFG"OA41N!H)U[UPHAW'I?S((XGN -__C#KQ-"- X("!CT)4L\E[QUB)IZV
MQR,L7%JV^TRASBEX(7E\P$Z +D"8%IH9H?3D<5(S$<C@1%',E ^@S%7@6*:O
M#]I6%D"&H2QY9HC[3_7YP./9-3VPK2!2[Q:'2%"=I^84].D_V>-XQ\F7LP!R
M&UXPZ%NMO5Y%/NQIV[:X%::([908O:34]#I"+86:!-9G GBOQ_O=IW Y=#Y5
MQ82C 2QZN-W@> !LCW4;F+:&YT \^@Q+];-(7MG/JC5]%]DW6&W>4VAIKBLF
ME<EL_W][7]Z;.M+L_570D5Z],U+(95_FN1H)"!#"OH?\$QELP-C8Q@L$/OVM
MZFZO&$(VDGGF2*,YYX!I]U)=ZZ^J<MVUL<!MC^4O%(=DV]\J$]\@ ?LBNGR0
M%]K>P3>^ZU][MJG)M#$ZW+<R,:N?;>P.NQ==2IP\VW?N[DF2N.!P;YAKD'!D
MZA.\C"O?1*:6&>$M8KDB:1#>3M29,*%-F8),'),NXP75 J0R?(@.SW\[;;'M
M@MUJ.%L92E1=1;D;:A5^6F[OXOE8K3<II^:@/\=OPZIL?HRD8+;4+VD[M?UN
M"5N!I-+5T97O7+((:EOH< [U*./#2'<"H3H@.5MM/5;>4=C;6DA ^>!%GI Q
MH6<D,1%>/S/MV1"E!OWGA*A5>A;,CH?U:+JP%!0BD60XGB_PG=H^TV!X 2R[
M2,DRZ=H>U*D1*<"L_\!M2\3^,R@]%,A?X__Y$]2;C056JH%'H7%[5,AA=3-.
M YI!+SX9@ENCDG= O<F XT-W$WS*@_XJJQH)(-ACLXUTAA>PV3?LI:4[VK?!
M+G(\FR*Z%!K12!0&< M8%-'*2"SOB$W$4=$"U5JW9(%$-H!DA/F<VO-T+ \[
MX!UC(>%7T& $MB#\GG*LF6H0*X=.1[-T334$9IOXR#T*TX^*+U$:#_[KGOSQ
M/.1?ZH_MK"3$2IE=LKKJY8PGL1L:7'[OD5\8@DL[(3?R!]M97)A-XT"FR%X$
MWKYNQ%C$ [UTM8N7^.JQ/6L/R]QD_VC-HOO%0/V6U<;?LEP5;H3("\Z:KQ++
M>"NO1$)M*T*D*"XB18$#NQYX'/P+^!RYP[_:Q6*Q\.O/R Y$J88Q.)Z<W1NN
M [.!9+AMALSBJ*B)\ *:7VL5GE))IRG7)+S!;82-P*M.>"ZYUP8.B.^QF>L4
MM!D%#78:&[QQ='/&,!U_ (_.:?)F5] 'Y'P\D_QC]2=."!@(9;(PBDA=4_@$
MZ"7DKKIV*UT%N]21A:Q.X1GX!<Q!1"D#PB$*/R&43^2-S;6JM<:@YO LW$Y,
MWA(7"@A='3:3]XX2^&WEKE;S<-,%T@DU]=TM VT =XLJ5?@5J@BZ*LN"\R;X
M"'@.$R#VV*5*R1E:5E4I:KL.D0/>H#*U$^ P. S6\L2Y0C4FMMVF+G F8<_P
MVI.LV\>B\1,8 HEJ"NS@U@MS^6E7I024JB.UT<6C7\"W:*3,RU8]W4<HAB.B
MP#KZKH J..$539-%P7BCP$K=^@8C%$&=&D!&:^!)(GI%W,L Q\0#;1FF.'/X
MEV^BJGX3H0%X1UX[NI @TU?=N-+;54>8P&,.0NIQ8VXV#)":P TXN)=SY!S!
MM>U BR&OI*%BY#4*J/S,M307=?BA&_.O,'H.G;\-Q6 >'%?-X'UZ!A-%\32=
M"_ KG5,H',1[WXFZYU%<!)&P+=1?[/=X!#U'8@F&[Z64Y>#:4"DBUPHW&8>@
MI^+S%+G3.W]*MAI+=L:FEDN()>A&(D=*_5UA*P(%<XMQ!7GO6]0K)+1E*W97
MYB,.1A645$UGCXC8^='LH*U$VC-3Q1U-D0U-WD2:((BXV1(,0A-.7E XNIT8
MT^%VCG2B5YS)0,I%.%[5["O)15#0 ><W."0/8 74Y4F9# P)!./*7?C- Z=8
MG+Z/."Y'F)ISVG1NJ>#<#&MJ@"H.0\)IVA,U+& [Q,( 0>:5UX3C[?'L?*/\
M_PMFBJY[VX4OZC-K#58,6$QPR0J&;0W8AU[HER+95"P(O("19S.\3%1\D6]]
MT"1J)AE4VHE&8,/M^\$HC3$S\@ J-6SQ##U$#2XF-H/C&':P#AFX9_00B_!+
M2=>/ZG(X,@H?'7W\-N-$N0SZ!V6<4SN,P#FN;2=^ RR7L#)DBDO@<6OB\D12
MQ"U@_!?^+@%GGOJ](+!\(F+@N;DH SD0AF:CZ8S3R"["D6T^[@GXP"I4V7(N
M [Q"4Q'<)P)-4JZT$)09"D<-%ZR8ON6R4V-3!O&@JVN\:H+FR"9;J3D!^/D-
ML7T#Q#;U&V+[&V)[98CM-4"S7M3?#W#1^O-&T4N";MH=7 )@@$%DRU!!B.]"
M0;XZX%Z*3'L.IHH2;^PXN2^DEM&'NUB[/>_.*E5K5<MU?_VMJ,>Q&\LSKI?)
M$H9O\^ +W#E93G[<B(W*=!B-3N:3^_%$[K4*W^'.L?T#?J<.C0F#"LO)",%!
MY4.W; 7!JY6@&(.31;V=P*D-T^+W>%?\06:_E]?O#08MR [NTE]CU .F9,DF
M2E;8#HY?608U,$\XI0-O\XW_'Q3G8(:"'0?ZDR@[LQ0-XC*6!=.VA1"9Y[X+
MOI<4=0?6W3^-_)W>]6 9#A6F>\(]Z-@J24M59A;HCLI1P6ER)689:=@I%Z*/
MY3;WI/<.N]E8VIRX$K:-1_0K@=E(J)/@IJ(['';+UGZ)\XC-@1[[B5@"DA8)
M9!'3DR#U[?#%JZ=/7/ W$7$>(!W1U;5OJ([L^7*G6C):V5[M-HSPPM1<N!06
M]3_!%C@#*6H@= $40(H!4'N>D\E"C:4 ;U-U-[#ABVL8Q\L@P Q[(?X+2=_M
M<*@("B#[ZKJ.0/_-]BB./N;F,#91L=UO>'K4">E'LSKG$'[0E#0\[Z'.#H(R
M84@/L,16 MTIX85SM/(I@<H+6\0OD?0+!ITCH$ WINT),B"_()$?'PMPIG(3
M?-Z-:IZ>@N.O9Z%9&UF#^R@C5-.[/YXI$CL-QO8XKV!ZS+<5,DDD2!OQ<GM"
M _]$!1>#R(KY5S)SN4?@PMP\7T+AI^2$^+D;G-]:))?!*"A\R6L/W8G&#'86
M9,D WEF$XY%^V>K4IK^M:)I856)<=VT:674B9^O 9 5@@!H,;\(UN8):=38I
M-9Z^C7B6Q\*:G@4ZV:K73)DB1A!E(2J2+LDMXA:Z(#A.7S_ZZD)Y:6SFYG.%
MGXJM3>ZN)0E<N[K9&N--*U,($Y@)K,^6B,5S#FJVHR.G-/<=8*8FT$(9N"+Q
M-1?W@[TF$(0M!NWAUW-Q1K#5W!0]_JJ^[V,.;P.74M!U]&+@[QC:]N5A%-UF
M*Z/T<%]./9E2?J%U9CYY''L3T+H IEQ[W@-#OTQXASUO1_C&/,)7>[)VA<FA
MM1CVUT4NEJP?]'JR\.OO1/8F%P])0C(V%G$*$T&"@7=<:H2D*"/#:0D"O^36
M >?7+:V%TZ%GJ:,G"5G?_XHAMA'Q<LX0A:L"V\O?1LBN&1&8RM\4F:<3SPDO
M .^74:0LX'3MF!"P4G%MK8%>%OB%Z>1'T%?/O-1^"C]84^AT@296(&0(3>U$
M$&[X N%%F#F^$OR@(DQUX@Q$6HD4UC0CBTPZ4G"H%J]62]W25Y'$O1-/'KOB
M7*4$(^L6@KEA\43(.(YH( [J/0+U$EW/B(>@RBE[@NI-5P#.I9SK4J1*1Q]U
M#DPR(,ERSAWI@7( #!N$=(DSELA9X0^\4:#SX/&X.B.[)?:P-(>@PLV(:/#!
MVAMD\>TY?23PNZ^ZO<#9"D^")J6D:/TNIM5K_+J6_$B>1)\=\AT]XU!,SRK5
M,O/QS,,HUM8RNYBZRS8'U<6OOZ^57_ O.5M+-S;YIM!KQ?9C);V8[AJ3^_9'
MLD8O.=M:*1E-Y&"/RI9F=2>6ME!?NB3OY;BJ^YE4HU,X/#MSF/'D@<L<1,,-
MD8CH,U:B[)C00&8G"EJDL;2Q\:>-C)/LU3.!ZP>90L-*%R:C&DQX,+/"P(A;
M4!$)0<]]#PC1T,WG$@G@Z!H'%Z,%5.C>@MIF*W(U9<:HW"@4$XJ2?)G&,O5:
M;U>/;7K+E_<@%ITD2130KF(92N7#33&GI5X.=^529UK/Q!_'>Q,4L;]3N=OX
M1;#$\T!$-^Y;ZXYJ!51'3((](9E.AD<R4Q/)>]9H=<XH&H6>,I.A"FQWQ-RI
MU,2&W]O!ZY,4Q.9]Y62!-QW^91R]0,.!1H?;H\%8\G'O<F=P]R*M,_RP6GZ>
M)%;Y14FH?H1+7D(_A=JN7EEGE_U8NS4<S(U!>SR0,0$S&9(>2%F=!_=,'#*N
M,NAC?:CJ88@13A[53;#-P1;"(+HK'A!&Q1P=S$7!\EI8V!2!6WOJQW^54=JZ
M,<@:BW-=/Q@O)&1EIQ92Q)9C!QE^_L2PVTYX%T:!*;AYB2XP!E,D%YC8!;+/
M!K*"[3S#:!_L$#!Z54&/1TTAD!GJR!!97%!7T?=J! * 7ON,^E\(Q6]9]!AC
MU1?-UIM!IJM[YC."+;0=MACT9DE)W-YV7[$)4,?@C>M^%0W7F#4CEL:.0IU1
MH4:K4M@;Q-Z ^9 X"&4*%!4<68+-##N(*\2?.'XGD[B>Z7CPEL^49U_L,PE6
M8?HJ'PJ!L#> X<(-*:FR3)4NY"SH2;')SN'%9QTJUJ8U*0^;2[$\YC96O=(I
MJ@FI<%S\)?PY$L>*_S#W2P:,6[HY-[ ,S_8$[Z5[NZ[FD3D5NF3F><AR.G,8
M%NX=R);O@Q&= @X]6/*>,MHXD<[Q0+9FT.E$C\7C=OH#GV:H3;I25X=P()S$
M2\"^_</WL/,(54PH?V%/+D"NF R6Y#K7=9G?@=E/\L=9VAL)CANT]@-%/=[8
MG/T&B_U8B !"-N8G'W3..YP;[P%#A=GN<V!B[B2):UU4EL!&0$(0"50IU&\\
MT%M>P-? $-,;U^D,L@GNE66*,YB2R"T4E0#4B/<?C+/E7L;?S#!SASBFEQ;,
M-R2ODN#6<)FX2K(QZ"MGQV%XU#I$U2Y4G _[DF?;<^-UKMM+M.T7#!!\-5#H
M=7H<HBPB%(?S)R2'2PJ255!F\BB,0#A'39@,M<-L,0@CL%\?^7N^S2AQ1$?V
M.8[2 J0&R [W'^?55+H<5T\MUDSQ;EZK*+'Q[/ZAL;D_)->;=Y<D\ BCK=?N
M-]J*@$>-#HL.W=M0[?/I4!>>M8Y0C@G"\SX;7\6T;;: .57'95TN/@"_EHI7
M1S0,U#$O'N%23_@2=#3C66H6%=&89G+#=4\H;U)WC9K<^N9#K+4J;W.H8*&!
M&MDF6CN %I+HDQ7"!29?&:&>[TYCF%&6TT%2$A1=CINYEZS9PC/,W,1B'[%!
MZ?;BW1--:F6H"JV(0+3J@J:+<HB+P2^"%#<O(G*"/] \:1+9Y+[;]Y!Z3L8N
ML3Z#%(%/]^U@=!\8.>KC7KMSB444\,OVO,)S!6)7<#+[M?G4W77%YG)2WDP[
M_++<[:;OR^^Q/ E3Z-BHQZ9M!C$6$)ZL.WF*K5:=>#1>MHSX0ZD3FVS3![!
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MFY0H98Q4:77WG-@?\A]QKM<8LJI,'8^AYZX/5U4S/CQ8PTSV<;X:KA*%J%S
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MB]SZ-Y\883:VNB,J) JES/:LN@E\LH5/[(J)GOE_C;<T6-Z39HSPOQWPUW/
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MZ&G3(6@R$(<*R>9&.>M4:O(FIFLZ; 5)DB/9;,1QX''QDW*U;*"Y)<O$U6/
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MWW+?]V]]GN,]GO_SO.][<3J.RYS7=7Z^G^]R?K[7#.3OY&G@E+ZVGC9 =0P
MJ"A? !D-7 .HCQW[^4TY:"C?M/2TM#0TM QT=,?IF1B8F!@9&!F93[*=8C[)
M>I*1\=3I4ZSL')R<G$PL7-RG.;C9.#@Y?MZ$BIIR#0WM"5K:$QS,C,P<_^&#
M_!%@I:=Z0HVDICH/'&.EHF:E(K<!( I.6JI?#^!/!]4Q"L;C=/0G&!@I$VI/
M <>HJ*F/T5#_1$UY-83R.D##2LMV3D;S.+O)/;KSWARRX<GY]()7W[5PWNK'
M",G=?_CX!,-I+FX>7N$+(J)B%^45%)4N*ZM<NZZEK:.KIV]ZV\S<XHZEE;V#
MHY.SBZN;SR-?/W]80&#$D\BHZ*<QL2FIS]/2,W[)?/&JH+#H=7%)Z9NJZIK:
MNOKW'QH^M;:U=W1^[NH>&!P:'AG]/C8^,SLWO["XM+RRBMW>V=W#[>,/#G_:
M10504_WY^+MVL5+L.D9#0TU#]],NJF/^/R>PTM">DSG.IFE"=\^;_;QL.#W'
MU>3\=RTG!.5N83CO/^QG."TD/R.,_6G:KY;]>X8]_D]9]A?#_FK7.,!$345Q
M'C4K  ;P?-FF!K=DVOU?>$;(]S0K#@2PN6]?K_S^/#Q%%KK'=X&A4M%(OJ+8
M9T=-^T(NC]AM9#$=,F%O.0\3O@+^D4<B [S@&>H!^ <PD:2P0@;NSJEV;L'G
MO>%N,T?@1M*)I:#E*;L8,D OD$KL(@-;V +2*761HU0R,#6G@SLIUQ2Z3](D
MED6OD[;P(CE;!2&!(H2S@<;[(F0 U9&$O[*;MVE,!N )H.^7OV*/I@[H<)6@
MZB/4=*[_/T(A#_\3!M#X^]"^33+P.&#R4&GT%?P372$9> @_(KB0@2<L>J1Y
M,K"/[R=&Q&^!FLG LW^(^"6,1:_O?RT"^7LH5JWR6FU/=TGH2W;M;*0[3<A,
MIVC3\5]^ _XK.)//[QY:&(&#R,#Y7-?HN&KC?P5K^,]&&/_7V_O_EX=>KZ!.
M[D*;M4?HK,-2NI-3JOFFWPKD[O%/M4X(3&["TCP8.@7/7K!/H6HWQIV6(M0G
M39*!SXB-&^H(YWUXBQHZY,Q:_V_6^(OY;JBWWCES^ZAMD2,+EC'B%,98=4K[
M<-?X-]!_ _)/<UDV;,"_WG;K']W6A=32X?\K!G"M%S%O@@S0[#3O>B*N_Y;M
MW])Z1,<S^3,$SI*&6W%P?P+[U_U^9#/[;]C^#:_K?,XPXA8AXK\<\C"1>J8R
MIG3-3S%5^'-L0!IW^3P?R.BB8_+].:X+<\59E! N>'%O?D#O)RJ)GZADIM6%
MPOR,/Y.!W(Z,OUIC]N=(2P;_#P_,TCO!"OT>Y;YBF1[7T-<3?\F>3CU?VB<0
M54(&_AIDYEIQ[H7_BQ]*BIO[!1[\,T_\7QF30_EXZ*NN5Q.V:1]VSN>*?F3G
M.]4]CR,##F:@O]Y$__,[CY7+*XL4&XI?W!NN^7\\_BV/>3.5L0U"2N$>P9WO
M4]C4YN(OYO.CQA5T_KJ<*5\<EV0V)4&TU 9/UO^_[>;O9;4=0:'??7=#9<9\
MOOF3[E>F3J LC7ONVV^#\<9#"9NTP5\#@1*,L^N#_W0AA3_+ _;_WH+F?YX$
M^V>(<Z.**J:XEM,;A.KBW/BOQ[;7(S>?P!/N(O2QT&^YO&4%IKYDX&3@[3<=
M-9RZ#SK4 []&4_+4%DQJ'B0#FISS?0/-SM<HBTOED0$[BH)]&7NHP4]2,#8>
MPNXDS;0.-6MQ6$SD27"8: &_&R=K;JI\.U[93"K3(P,(>C*P>Z'\S? H:M@5
MO#<#(CT93KLS@&<M,GZZ@60WF';$\B7C]XU':OD574;$'_6+Z#I8QI4PM>/%
MZ_VILV>1"?B6(S&8+<&[A*""OU< M0A5&"R?&2[^,*QP)S*SQKXVS1\PV'3@
M!]9Z@R/MO22EW9?$WVM=U*OA<V8Z"=8_U&F#U#$CZ['&G7:7DEHM%%O;<CE2
M6UT?2&>$5+_ESH)I/I/9UV9IABE'\GF."%HP3)3OHAJ#.D8M;)63H+36C.O"
MQFSI:]90J.J:\T@G>#8OO*$X&LGA6K<# QO:^A*,Y%-GX^"G),I4JV2L/<6?
M#NO0?9D8]@H<:I!>KYV%T.')P$>=CD#;M*4HA81 9JD "06:]T_?>;[@<LD2
M;:.>>K=8"E/"Q;W%='[*H\,KKGTJ+=?)A^4$:\HT9-[@<F'3NO1+=S:\G$Y$
M4'R@F:4#7H?+F86"3UIKSDA>I:])8D?#HHF"MV+VA:Q17N'W;\;MW/7RHE/N
M?7@[W?WXRE6NN(>-**,$.Z.)C2J5NU5CTJYB8T5GQ$-6QE4.]RZS\!"D,.N0
M.J;<8S4U02"FGEE5=WEKZR_H@DC"VQ;;.#Y"9^J+?64R<"^)4;HS 61<G6<R
MA.1?O331(O3L!QDHM)RR1O0RI;@OZPHYG'SBQW-0;84?/EEQI"/=3E78PT=M
M%6%.^B+W&!__VO0+.CXGQWNRV6<F;V/"%T,&9KD2]V*"U14+7L+2\:LFKI '
M9D'*7ZGN'M&?>PYHTTV8KF5[/_?Q=*2+\EC->=$P8M2U!H_QA(M#3&TD;>K'
M#2WTO_H;H:6W@ZS[/F]O,81^$5#"Q]D'E<+N?^W8[)+RN%O_V-:(HR&KZSZW
MQ/5-(4 E/"^_5(WQZ )!"Q\SDP.V&Y"0)P/K1RL+=6&3;B;6GQT3QG@49;ZN
M%WB/QH^^#CY'K-V%1Y($!LIUPE\'E8EM"K\(T3@4]T7N\&=:>=V36,]_J_$
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MM2MCX@;99FLD Y5]9""?-^-G(1NA%#*(#'SY_JLAU+RP/QFPI?SBJ@**T'S
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M/7]F64HA]54G;6X&KGD@A298;*)+(]O"-.B(K2[C'M;3,-%=IRU4!/-I3*]
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M2IZ\?<JJYWYS)1V!O7YVF0RD6RG]Q?KZWUG_*FFO58ZT]?-O?\##\73[2#*
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M$0$OW9G_T_6Q%C-'5<_=RG34WZX^_Y/'- WW@*A&CLN%>\ 'RUI5&T.)^FJ
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MJZR'78 :U2K-;]-6?)V7;.ZI(:V=*IC:]+N&>8![NVR%(2YA^3/%OK$"LKC
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M[O]S<E+_QD#7CWN0>XJ.;#@(MSG3^6NO38A9C1CT6.$>$!3@J7</2&\F>D@
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MRO7))/3,%.+M4NH5J8\ZIDK?\O0VO'7S#!231?F*?>.XXCL.T+]@W@5?RU"
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MKG I/G'LW%<!/ON2+*3<7[? L"]!$6<Y.#.*!IYFW09WE MDG3'L0O?T&;
MVEP,G7<>%O -"[A$6F O%H!:\>^1DSY*OF1N67-OP;W [Z).Z+-_/RC#)O>E
M%BL-O8$%O ._7($>;"+!JWZBEW)1TRCX!_A2V6VS *-=8E'NJPE8@.S%"8:
M"0M82CRA(P67UM>A,6@FC,Q%4!(6,%Q^2>)2]M;08@=*6$ VYAP+N!9WJ<CV
M2R],IJI?$)W,H3ACL8 8O6DW34SEZMS!^5[L*=[Q;4,L0 I*@;%NO]1ZVQX=
MAJT$2R](M3R0OVPW#OE:'7UX7 3^0PL("B#RQ!)S#OY!J'LIPNF[.IU>3D<!
M'72.QW6)!V D%L"_,/R'(;__ S[*O_S(O; <A*Z=7**<:(NV#N,?P(,>#OW#
M<#7_B(J6I9S8W_ M_=EE[O0(!3V0HKT4]DULI0^EY\#SE=(8485_0L1Y3(3T
MA!$" PX@Q@+N8=H&P&N3BUC 5Y3K/R\-PQ]WB!C;WR=Z\?_T/"F<4 _HW]4]
MI$"S3DY96@T?6_B'80&?,H]X_GG"9NJG^&U8@%'6*<3P[X/  OY_;/]GYJD(
MGD].5<(%MX-_.\5]?WZ*70-N[,%1PD]&JG$SRA*41R$.NA[&GV1(MFXI.&P/
M26[F%5_.Z+Z2]&8$^(>J[N9J :NHJ(J';T5$A*;AO9P(=N6;;#FO__BP_T[=
MT^$"+QV?7*Q<8E/.\.-UB8=,''P<?&NX47&IN(JT7^1N^]2*"IRQ716L#5>.
M([F:"PBFU>J[Y?+.F*Q7]-IKD8(1M:U;DM+M[_2]TC0G+>HS=\YVF.O4Q1T1
M-MI)Q-UD,FU6G$K,"3&O #2&%))X1H<%FFI:+IX6A84_0K: .[']\2+Q9#?#
M"G,KHV[ZD[$0LY3R]EJ\B+.0[B3%.?TV\:W:]Y;B<U&XMOE^D4V!!\?]N/8X
M-FTY.;JK4699<J0AORJU :;@MDLQ:]D6=4F/3 R2,5&UY4-'Y2-$*$X@.EJ:
M +PYH(4%C"2-G\[6'(N"SYL"P"G(T]!+TDYYP7&R>VRMDGLNBN;B'2#I]N/Y
M!"*D8B:J[!E;A5YA^#>,5WL/B=A/,+Z7)R3@<E.0*23Z8@&2\U@ ]'(31I2\
M_RG7/=\O!Z\U,9Q<DCFDMK<>]&"6Z/P0C"JNEP/\]Q91_O:NX_+N\..M1K9=
M8:-%&X7=&+"'/]ZYCG5_,Q:0N0>>R\4"NK1^L\ T>WCZ6ZL2)7.GNW@79])H
M':.<=_T!.KOHDR#,!0.&/?;7F>NQ?;SY/UQV"]&[&] C9?4VE@NZDG*(!?AD
M.-'M3BUV?ENRP0*2K&$7&U5_*IC(K,Q>,CLOZ=T1+&"QD'@VZ]0)[^+\<H(R
MB[;+M7L[19QJ9G%<EI;N&WGW[T6<[K9BQ,>:^+/MSIH*=%Y_1P5\%4HK!@H>
MUDU.7E%MVGL]](27\RU.7R]<R'4NM%V%&%^91\?R)#VQ@C=7D(IK%\4@=^KY
M-W0>_T1GX]_0^;,WOR.&*)Z5/=!PR,0EJ1K?=1 <%'VZLE+1V%SS)5%)8_=S
M;+HJO<OU<<W4;9Y='LB6V\SU;CIU^2]R7\9WXW<US[77G>Z(DPZL2I,H:YA[
MSNBM&PQ?81,7=4=S^9X@>OM%NK@N]WMH,P2!E%08:.XY0TGO3OV<\-2_[%'K
MRSU:GNP.#)-B9,"]).MTL8;-0.)UN)\/9*B8A7%1Y3[M\Z<K#:L*B6:LT&0N
M3P/FU.#9\L7-4XA[G]1@D9W2[4^"\5RFVGHWH%8'WC@ HIE,[Q.(=5)_NE$^
M2V-=!L0:4@<MC[O3T^VB&>7#,ZG6: C[>AS+_8]E'/YY8))_-Q@.%%GY+*KV
MQJ[[H/*JI.-H]PUP1>83<A%]TOP!\+!5,DW34% BY?TJIW9=Z;WT6@C$#KZ:
M;UN(L*L3ZK.T]?NF\/*=6G_82%#- &-)_$+5JO.;B-5,XM'WN:)^0NMS3LF9
M,^7Y)R$LVE&69-#ULU/_"W6E_=T_/4Q(0H8EXYX@-)6]X ;8X2NW(-5.5!VG
M(\FU,99PCT+Y>;96;LT (\=!-V*TY<0N6I8\PW0AS9:Q8<+)S5!_1Y"!QRVI
M?VM?+&QHC%$8ATH4)XIV?("GG/QP!&B87WN>0 NB8BDK@^LW'TM*_WH*-5=,
M?MN:)?W;4J(;!M7">F+@T/N^AG34A&:[VV(178RAMHF+<M]ER?89<!.?]S V
M,(0QD-*TSQ%1=#9X)'H7A6_+C3VDO?7DH<Y+RQ[V1^,);7I1XT(UC@C()=^3
MB\A97,V,-$Z9^O-3+OQT_';5)UDO$+?#LS2HLS=#,OM\7/_Q$/\A8[G>737N
MKQNJ@FZ_$AH=H%;,U@LCBJ0'JJ'WS>_%G4[D_V*DF(?[/?E\X%2S%KC+LZ)U
MT^"ZW-_>Y*? 3=!$%3G ?^A3JY[H..W9.[7C-IR+!%VA@8L5=#%-.>J\\E(2
M@!Y>+W&[0OZWJC26F'V,#A?I?^6G\F,L 'YG7]C;*2A&#/("P7.2O%]H\6MZ
M-D"D W06V!]].1IO,'M2Q'_Y=UXV%E!ML>RXGYSN'%7SCR'H89[$@R=)+QEX
M*N0;(]??*_\=-09L5/^%"$BC-A+<GDQDMN_?F7Z[O$V_^.E7;E,+19[[8BXU
M@!^,D&_7I/^:*Q:H%\$-OC*F;E#FB[1+O+Z+TBGVL-&3^S<@2MYK4:G_Y2DI
MGK6UN9KU.X#<7ROK]+/]+R[&V3_'$-RHY D/H,!/,<;T%+W,><>[:NB3 ,RT
M_^\-FPECRVD*[#A^_XTG0'Q#FC!@F-/5X/&6H*[[N40R/G4?,T[+BOQT0$B3
MF(A/S6D&VURB\2G+V(G=1(%",ES<59SG^>2/TH=^G@O?N2 [S),"AX&+3 )\
M@J/7XA^]TE?S!KSCXV#H!E,U4<WC0TPG!<]51!UYS&$3DN=3#]Y9R@8/M<6H
M" 'H5-F^E0@/4 I=X+&/S=?G,R<7P4?T'RXV4ZOJ5'>-.R TM0\("S/\OGT9
M\E@3Z1$M9EI4"-:GZ@D[K(P@33JW\+K2LGX^<ZY=K$,_ GXUH\@%%U/F8%_K
M,A#,S*?/DBJR)CP,7V5I',J1-[)^I>4:==75Q#\O8,2$!FD"R>Y8J,4@8$YE
M9=O<1S=6%..[/LJ;6>C=#P,57)/!O74(N1\"T125YQXH5RL')]0%O%5K9A/(
M9_&\""@HT302CFSAM/5A"'*/=I6W\5.7RJ!UJ8G)\J3XT#;U^#021"OD+?&F
M2V./J/N"H7N6$2D4R9J<#_QQ5F6K1#CXU7<GQ4R)("<H_6>2(JUV7;<9.;K+
M-0Y5/<N6D&,1O T"HAGV)1G?'>;G27*\^\'^FVA69'I2!MVL M_7C;WZFCSB
M]* ;6A./8NV68H7M2#"!W;.]7#"C'9KC\PVA)Z!782-Q^/>_^Z'FZ1-'-^:J
M0T+ST%ZP *KFTEU7SYM.8T%$C#2A\O$B-"W'3YG]Y7R<N+JF5!+DT^L,F=/0
MU#!_S;:C+<EI[P;$*@*8"G;>'-,;2E783LNV(P>36'P9*>?<D:!_P=6H& 4/
M>6"#EQBS^K@DZ +Y(BY@FO%<[7,S#$U8:-+UX UK6%G@W.-H$(BN\YWT+)/W
M]4>OFC)FN^OTA41KFS/AC@TE)UL6!Q*,=5!HN:_'CK^JG'=!1(M 3SX*KR.
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M_<VG>F['E3"3%H_3!/G2CQ!JH<:MLQ,8&J-0MR(OBB/Y</R@^:2CG*':X\X
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M>'";(H9-B5G-#4IHQ:?8E3?[%CSLY -&2Y0L)E]<1?-C :\3P,@-Z?%;L.J
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M W@WSSPS0/:>YB7K)?YD]4C):K:DD9! ?6H^>LLG"W$4GA\H3C[Z[Q"6J$?
MC[;@SZA#(+E>("O8Q(YXT0)_3V&O=;QDG-GC*S?"NF3,4_2H<%B_/5^\'2P=
MMCC"55!=_W9J>F98X#F3 B!\45</@,P2EL "W,:346\6@L"Y^EB O;Z*U*<A
MSB>*9<P6YPC%)::"==DB&I8M"?399DV#1YWC_,>=N5I,]0'4Y$1BEM"U\Z[?
M361^OU=TP:3#@S'8-B\B5FBZ1Z!1HVPIJ/HA?<1 6_<SGZRN0;/^LR-0330W
MLA0^R.EPK9[?/IR]V^"%OM%K? \=."4.%>?C]2TQJYI/=C!C!5-OD#LS4:U[
MH)Q9](_O$O3B8P\7">_,J=O4'0/MJ^2]S4@^H;1O*U'U1^FJ$-/;NFJU0 Y'
MC_<1ZCWUN1]/S0>TX(;E*J=8@*Y(.0VJIS/5*7H95NT6:*\B>75)W_>YXZBJ
M)Z<+2)&X#M!8-8F[1JN7Q=/#0XP%F"&F6PIR#64E=]*<'F0+*&[:67OJ:^;&
M>/P@O:/_/E!MI770=S9CD8Y#+] WDN;<\,M'%LMX?)WV.WPR]Y ]@JL^Y9U$
MN*A-P[V52#OB3YFE[@C[PTR1'._MU1?H3X1]S'WI[JV0SZ.11O&YO@8[\)/M
MR;/Z1*_JTUS=R:D NC.P+I\9JKYTP)TLJJ$[T3KOHM:+HFO4D*'2"#?D(;D
MD-_&?U0QOVY;2L4\X4U*H9\LLB=2@F<Q'%(.J7X*\Q.ESVZ9[8+;+L>5C4E8
MICMHU:XS+I/@!C:/'/D_X'K"=7]GFWQ?;H8N32S4DG:9U<AY76NP='WB+,_
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M103I3WX0:96&!1!<RIP@E&?]_,199=%@R8PX.#P 6FZ>$SL_'$[/&]XD^6G
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MY)L:PWO@UA.Q@!1SGK?5MEP"M=85P:7F' XJR0]X8Y,Y59SG4K?8/E60)<'
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M[_GBW!_[*IS01>KX[>J.N2X!M-_YX$VF:_I8%H4 0;1G1Q*'N97C+N/XX52
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M"JGJZ6RD\<?3'G>G(517CE33L35KK'*/._&?XP1XQGNUKZ4J!RMQ%)[Z=6_
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MHS^VF>;'SE2#1J##47HTV9SC4%"TVL!]QUK1T:5T6UHEU_LA0Z?&M.?PQF/
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MZBI:2^C>M;@UNAY*#T!F,M.6>!<>0'+D:-Z-""\NLM=+U_%VD8*67DE1 M=
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M/K+B:,&F$&=_=O3C4# BB&Q4Y)MESC,TY0E*R9?C^Y83*I+#*_39W411XA(
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M0&VZ9>16/WO;M3P+QJ@N;)NRZ_@XHK<]UE*O=ER O%.A,GMMDRYWC+^0#4'
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MD.L8>T>R%^\V]SI'#.VERJ2L4LD-VU?9!@$_\T]CE.9D2.%Q+E>:;XU@[/&
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MF!I>S^50E^#]#BE_(_>CC6^T%?'#"9QMH1C4TZOE';?.!9'M$&\WU!5\,N3
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M+/(%BO9W;AW_:UR%WK@?'*%6] TFT/;EL6[FW6^HA@^#6T39BX)P0:Y>(P2
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M#43XSJW';UF\P#[[Y13S3JMV02-\W;M4]>MO7<>G"3=\?&P(2)5%Y".8XES
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MD"X;5XXN/>I/0W,-XH'^@M(FLNML(LK]#;P&RBU@*%P^T+IP-'VQV'_A$+Q
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M>G0? 7@71*&5JXNP8 >8U*HD;#YOQ7+T&TOO&O\<O=Y"*P7:?=T_JHVI6;P
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M005)G5 LWS<A0C]*Y"+2M.+M9.'#DP?)EZ\+",M><H1S]PJI+'Y:5<ZX)]<
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M_^@Z+V.R[*_ 5<MD)J,W._B(<JU6Z,D\,]+D9N9P/C@ZC\MR7$!KX#)_P<.
MW*)-0GA#<K_6:S68^VO9=O.,KG(3.RV-+@67OID-BY<CH6UA6"O['AY!DXWN
M*5 9O^-JN,G,G'H4YZ3'Y,BF4VA' 8XOZS4;Q2Y^O& #;CE?&8@%,\B<=Q$4
M_Q@@=_Y4](K.(&8D)H]]_X!325P/)1]:4!/P61.XR#I3!:.S4)V[-+FF+2WV
MT44N44X)9>>/L1S1DKMW!CM=.2<LBHP54J2;H9*5@4*4=1-KX7>JPU-\]ZN2
M[QF:G-)"0=&C0()9)CI-7/6<P:G&EN2FPVU_1,/TPAS8(WIP3#TN_^<0;A?[
MUR":;05IN=V'IX;"C!31"(6FAVF^+BSF89-Z2FUIOLVY9*;OL)<MZ"#8BHRO
MK2O3*\X&?"B]PMO?ITXK%;PG/"<\:3;E/%9V)7^:\[O\FXF4.C;-F(*%7#^^
M[AZYG2$G]6))GU)M]"POK+8QS ZUD^#,MZ6BS:TQM.O0F>-G!R3UCM9SUB'+
M^%%6GR?;:D9C\E.%AQE7#E0[Y-X-(**]]%+JN^\N/A/KQ>.<C"CBI9I?>[S!
M$5D?]V^$)&URB,MQK"(N'JSRZ..#MSFJG)M:TJN4KFK3#Z__VD-6)&;OU!'O
ME#V0B\N *J/%S$K&KFM=W)<N,42\0[$_S+Z1W?4H;GN6E]**\W1^E.\7.0PZ
MO"A.2)(?;6^G4&^GE%Z6"F5,&KTN$1]9NK29*OQ GY@;_[=U Q/+.2G\$P'9
M64U&"#,ZX$BS[,M LQU+>2]=>-[5'=_-=%D3;F'RA[?K<U%-3>Q7A1&^S2\M
MOZ[7O1GR>GDNE:01U-KE//6-SQ[F^!KG]5$H]R- DJJ>>5K+),8]KP<W/OH=
M&39:3OJGD]9; WILEF/_% G2]UN8BTQ0MT< X0/)@32IP+V51I#.^+DOOXR1
M)\S^(CTED.4LHX_FP\^MS"62<$VG@H;\NKNWZS0SMB1+ZS,_,(@Q4]0IS.F^
M!2$8U S-;74_X/N98+\5CZS>^H:Q27&0C1SSV@+13KGJSM8\K6\E,5ZP&?&N
M.MY8/E8I<[>A>T- $\N(L5RWLQ@^YS^OI2M6VY+'1(V6!'\T!QJN'9!YNFG!
MVP/,S+:01^R8F#%:^O>F\;=@A$/SL@E$T _X"(#UGS%A>&!JH2,V;HF(]N56
MCU+$TVB.\Y_GO.<ZZ&/\?CX@R3ESD3VWV>>E6UQDM%^I#Z'4+8$R=+N_6C8?
M#!RDZ-]RV9JM^WNUAI=->.<Q6P.U^JM[@PB5'98R;MKZZ-C6)([OO\PFGA[)
M^,S+UR!?*+](?U^/MAEIU)N09"3^<5?FA>9[[B8F/A9&#ZRK'A]=SZS9(3Z^
MPM!J%;#.ZD[,3+W1#\>&42"7'%_]4&J^E5T*1-+!^R'3SQ+->BOM<;C>UOT(
M(/ (A "E#I5#UO!2N1T05V^;K88-L#5J2-_RQ_--I9VV14F]5''8""FYD3Q3
MS)M?K:_VR QY-G%&N+LS)K6D-[Y:0Q4XFKZ>:=1=V_A0N+[_^9N!4)(5C8>A
M/'>H(R$QHY[C?A(LFN=Y70B.F<%'^\@-BI?AT6^]35LRD@LO(Z5:=,>4K:$[
M4RTG4_:A4=VHATZUUYVB;QJ<FP;$]RV0B_*EB!(5QD? N@,![ AC+?.9IX^>
M18'- G/=97?=!(: 0T61A82%6@,@X8"S>;S-DC?X@398D/.$5&5#DD?9<7;V
M,)C4 6!>8\['&C,4Z49QUM<I2:4Z_?#2NM:P(.:^SH)[Z$\MR=(O2F"_4@IG
MY-'MHE<\YR$1X]VS4$U?:9V)8ZYS1*! U%?[Y4GJ#T1)B>Q8<8M(&)X$5(^M
MH%@](3SI;[P2 GYW);4;[#C'R)'>9^DRLVF]O'PF A7P.VKP=?7FQN>-EL*8
M%'0 S.W="*47[ G=O#1-$>ZI8U'*SY3HP8IWCE?]]GZG]1V89\7:+-9D*ZE3
M2"GLF5A"ULQ)8U^TCY4E[2)X-E?!7=G>X8=LSRA _/UM<R!Y !KQ([>@/XT<
MCW: 9YZ53I=44DZJ62^O$UZ*Z!R8==>;:),<2T;1\79NHP\X">/MA>)!AFPW
M/)<<?SZZSX6])ZBTXFB/5UR+]BQ<_*1KD.#F$UC)L[D=D%5?RDFF3/ZN]X^X
M7!%-HHEVEIJD3$%72SEUDIS![IO!;[AV]"0)8-O?Y6VP0ZU3><[">\@_DB;W
M")"(H.L>G%)PJHFL73VA1VG4*%CJ6AL*1[\[*'=N8J.G7]NH$1AB/X%SBC"[
MOO;AZ.WF/:$)#/SFO-+8XK]F%56C8M1->6I-A7":6[Z/WG@$J,'CC<S-%[-7
M[/IT,25<BS+R*!/K_+)G=RI^;&7DUH#:9ONPZUSB:SNKY70Q6'X99UR2 PWO
M"P3-Z<@5/DI-7%'!5+,-SYD8[\A08P'9!B&'7<*G2_MO^UR=)"B/N-3+PG'Y
MQ8H W_WQF90*LG%\'"OVPWW8RYH1E0ZA;IGL9QW G@3,G<VL=WP&Q9I)B'?N
MB)MK\OW9D')N\<6;ZPR%*JHGHJ\ [^>YDSHPZVA.#M6';$NYPJA-*PEEZ).E
M.SG'CQ]PT#7 +@?([P.OGN[+3M1F#3P-7,W.A?7M>Y[-8+:#URX<C(7.^S3N
M<N]W)3,]I=C@&R$Q6Q;;G!&3-+BVB7U:W")4XX^X*/9),KU0NWF CI_X8=@N
M#![&_+;I?3.Y>Q4_QLG$9X:YJRWRCZEXA[2M.Y>M#D H6QSP];#8A1+LB)]N
M\7W,;+\:!4AR=K9B+^3W]!9"R#F=_9*[2SGN;IV39<7KQQ@D.1LFFJ4E\Q]R
M*)ML2FV]H"LO*J-(%7))B'[U,']PQ& +2#A9:?7FBSG15+@N+KKUBE^8/3[9
M-9N_(UO3_^O'=.#V[>!D0U+5(*.EJQZWXA& ZX!=X M)1L5T6S\PHI5P7+G?
M>?='^&9*]=$F$R"(F#'0KJ6/ "*$\32<++\VLM'Y8\V0B8-+A62S)";],T+O
M6%7O&?\%PQ-E)+AK:/G)\<(I 5@;M[)D>+A<9BPUXPM $C*<1R7Q24NO:<]*
M-X./\&W2.C1=)9^G=LJJY7CF[X(4")V#4KK:4+E/-?*.XN@=)R&H2]\AWBVU
M;Q=E+BI_):EYL!CDSL$AI!'7/_>0MY*?I&-'<3?&0^'C^*>2(73SO!#/D_;9
M5]//?L>D[S''K69;>S-YS1ML]GP).%R*IK0WF5QM[L$HWBX49O?X7^U9^]BN
M,X*CC 1#+[V>,;*]@Y\\FTT!BM\2^IH2#KP0?"R!XCKO[/A%F%YMD2W&'-A@
M?9!/2OH<H,T[?(!QT?$ +RG6$6<73U7#_E&4EDF]..$/5-W\C-XL,_AKE"YN
M=$YHP4$&R?[,9#LQ*<6S=T6R7%N9/T".("TUG4J:(Y3SOMA=:1[Y#>9Z]^8Z
MY3BA_R9;R;2CI>Z8):[]Q69T/93R=3/H2M0J\0N;6_%IW3Q\=\^[&<2)+ QW
M*,NKF9ZE>4+)+O*&'.,[CN1-6OQJ5S'TH^!R<+<PW^"MGR+&_<*ITT7?(8B
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ML% CP4P7\N6(?/IRX/3<065D/<9%$58S4K)?HT1RE&&_(//9)N&G%>8,DUD
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M75!3^8JOF^CJ$X(C]K;:SW(K\^_$3<>\7KKMI<Q3WF0+=1@7:;5).7# -.6
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M%=7S?:**I7_GXC#ZZ3*^D\/GF^=J4+5P3, "1( F7EP[VUI CB[P005/=&N
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M2PV*KZ0*I)!Q3=4L*%.1W]'#[\T#4PAZ%-B?NHA<^^%3^7A[/F_0;=+%^W!
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M4L?F%_A(=M.:LK&0FE7+$T\XK?ET?MH:CB2]X[OM9R$\=IW\3N=77G:YLVN
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M'9/QP3<" 26>$'0@!*_O>]3W>:TQ^]6M6TIN)=S$#:!S &MU WB?"$+G-=X
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M]/K>]A7K/KSH-/U#.DOUXLBU"NO>QBL("6%D^G77#0 5<JV5B>?@B+XEJ!O
M*BL==]4)N[H3\=9P;Z!*X(\;P /G_:ZB&T!IY7BA^?42UYKL16HA*P/<)HX/
M+W7"* [92_O:? -X1P6?!1K#PU)G@RKK+U+QY>;I&/ZI-M6MGAN 77]?5B+^
ME&^>Q!4.B@O,!=GS!=>985 (.S()7S^J!]=VY*AB]%$?'HA[59SM<80J1]X
MYHHAY0:WQS$B1?MBA&_TV?77M#[D\+.C&$@QIH9&S_T&4%R78W:Y]43TB+K(
M$3'V6%5;-L\^Z=*A,N4&L%][&@"O3X^X'2<!0FRO@K_N?H6KUN:\AK,!(H'4
M_.?)VH0G%!,&MSX;P_JJM-KWX1+57@VP89"'.ZIF:+4<<ZP_4KGGNB_4,X.^
MN0+*H8:7U'.0?A@@[SWHPVG4<7 6FW_:XR_<A\*4B 0D$,WS%65!V" OJ+-
M*,1:T6T1_T'#YY5D QK6PD\C'^PQW1.[G%([LKS-(NAU#Y]BN (D4ZR5]2P
M&^OTZ080S7'Z5"!?*1[36]8<[D82/P?SQ)SOFQ6ML*>;DD^S*C0 KX.Q&8X#
M)WI70]@#ZHT)_**I9&I$>I&M.FGL#2"_?S&(S[0/PW?6AUX)+4M;>*N-X:@9
M+[9XXE@3%KGE?OI9BO:8^FBN333>*J9+0AM)[S^CO> *7H*#!%T5/?R<]OT;
MO9Z$(2/^%VWO&=14\#=L1U$I@JCTKH("TGN5* @("$@-/5($ @+2 P2B(+T)
M2)$6I?=([T1J!*3W3D+O"36T\/*_[WG?]YEY/M[/\V'/SMDY,V=GS_YVKVOG
MG+.E.\^6J\9-%%!4\0'%@Z=26.ZV:^."2=?M7RCG:$/N2D[NCIPD[7,<VU@
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M3VS(J!,Z";L"F%/.?6^$S-AW\2U3E['41%=5Z0(Z 38X4?\")!+^'CAUTKY
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MZ>6 .M^A4!>X$A0HC@K;A]JU@2F;>$[(:AMMQV'NK@7\<9TD,G8UX1JMC[I
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MJ#&>GUXLK(6M?#*BYD8INJ>26NV%$!\[^!Z=QK/U\9<W0?)_])CNW#W1YQY
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MB2]KX]V&D!VF6<O<\._L=&6CYI./EH_O20G* 12J#\?CSI^V8SDH": _TU>
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M(,VZ_6WWC6+J$*(8?B*H1(*L%'F88;G$;UL?9VT:W&74V;TI[%]<CD-_A=W
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M?=W9=AL-68/MJ^CH0$EL1:XMD\+8-Z:'JSOC\%[P\^&"V!Q?.[I,M 8WW[8
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M^M;WKY=CK?_I7:MBVO8]H)JCA\'0IDK74W]C[F[3Q^"K81<=5:",T]=ZSHC
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M92U##P:\HKT'^"ZY5GT7'73Z)@U@ #!PYX@5#<EG;ZEQERN<%#6TR:)]EH?
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M,XW=N]9A#S/JHS.&)&+S;IE#/"E<)OWFBIG70GP41&$L=.('A$&@:YA3CN\
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MH?E[9*Z 2 [C*?$*>FVFD1X_6$;$O);=HY!/U@9OVNUI.>>[TO34B20VX#?
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MGI$_DL8XRLM/S6[F$DQR%-U[TIN^U]<G^9W*/^P[Y9.&F=T'2@X;$PEY$^7
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M\?.33 BLMN,G$BX\E >-KM@Z@G)UNJJ,LE_VTH" T\0!_K4&-ZG.*ZUI&]4
M8P73U;E)4OBH5O:A[N7 [%>NSZ4\<<P&4J!I?=.5BQ:KPN<T1,-=R,O_9G>P
MS>T4"'^AOR3../.V.POU@F0J&BDT_F2YJ2W]F]Q!<R3E#2VVO.C7%X1K &L
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MD44;G/=?]5OY)>@',^4;0-<'/R$O45U<=3:.N$>.I^GO#(*%;29<(&V$^;%
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M6-IHE#XCL>UDUES &4VMHTSW<.5GXGI'=0IB2!?#EAG!@XG]JOZM9%>3O5Z
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M^ NU;DV7G([I8CO"/:$"A.UL;4+)EK:A4.6B7!JPV#;BZ"0)668:RUQU+@U
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M(^R.G;6I3C6G1O7<J)YYY9).#UC+G0XF&,;!3K MYDCE)'/0SAT!'TI7Z-^
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M+*;F8+*7-%Q6]O6&=!^10,,^A6AN<DP%"MM!W(.+($%/.%=QU/!2 \IE_GS
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MS9/4'SQ(>#1CS38QH'VV#><Y4B/< B_$%^790/,N-H![]94#0D3Y82Z=.!S
MBK:;>AB]JW#-2X!^X8(9LL8BH6)\L)9"@7?.SZID,O%I,"2DB(7X^%0"%./0
ME9Z$LY-(P@6S"L0O-&7])!2=3W<158G3:$9@*#_%:R#R**8%C03 YD7AF,6
M'@0H_L9Y%G"O#M V#QHG9WQ"</T-LP/^-E8L"./,U%WA@?Q#KL?B/.-6(PYZ
M]HC?" )G+'@ '$5E>*<,<H#.9V<'7S&=)> R)$D5@AY.A! A@B(SAAGBK&$D
MP&QY(]T$@)KA]C^&,^%R+G*E'%/"(1ZWYS"(%)8GU>TXI>$!#]5@G<F?L%'!
M4/S9/GBH,KKUYNN'[G7WE 1*C>6&6J&H>AXIJ@/N?!M&(0@R/(7_X&5H_X5)
MS*; 'E"H 8ER'Y 9_T:&3=@,M"MN9)@HW#M$1-Q/P!D<1"%S^$\B(\)..((W
M1 (>4'!(8"C-_P#/\(6:#?"4-PU$/!7"8+O>UYI9A>RYQ\X3#%TU0I0G_K6"
MMJP*H(EY3HR:3"RZE0C/[D*3B\NO-=9'7'EW>=W5V +38<,PU-S[AOL)'_BH
M: 5*@G9#BZDYBDH\3SH2Y-C,<'I'2!@7A,9T)%%YB825;K#<03CUA3M$29#9
M,U3W8+$1E5#M [U #(G%#'!SF!NF;\ -(+D#7"*<J@ZM<$S #<((0/M]J['%
M'.'[QI)/C]6$._;8K(5^ I'"YQ,E.O:/DT<93,8; *9R'([)2LKX!_"0P-WQ
M^0S(J>/)6^$NV]V,A:WAM 97',&/:^=@;CLR+H_8S5Y\%,8M8 IH!;%TN&\
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MRH,?4+ZO)\_N('1G\&L4C_TW_P]02P,$%     @ P(!D7-F;(PL_ @  D04
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MXH.LT$:@67M%U-O5X&EA;XF_ %!+ P04    " # @&1<G+0AY.@%  #03@
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M01JNPJ6DW*H,H*1!&#'3&E8#=LB@SQLMVQ@MPV@TXVT80X+"];^?_-P%KN\
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M#]GW)^ZA__AFJ-:\\DJUNG?MEM>V?P!02P,$%     @ P(!D7$@64B)C!0
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MYK50C7GE]6EUQ]HMKVA_ U!+ P04    " # @&1<01_)S<<O   VJ ( %P
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MH+E4JA,"U-RGSY2I5K[._04QQ2NMEQ@T(ZVG2:'^7L!V'+1].BIU ;MW]>8
M!JOP_0@GFF6\A?$+I?E&&M%8N]XVQ'J]W^PMC'0JS;5G5FD?%^;ZC&*-:-&
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M> 5HF4?!OOSJ_>LBDIO'H:\88ONBT8OU2DRW59JY7>$-MXJ\$684VXP_>X(
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M/RZ-]C,86K*R! PJK4;3F!.L.73'&34LZTR<</N@LS((Q0--:++[,,'\%X_
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M<7KS9A;Y:_9_BVP9W/\_4$L#!!0    ( ," 9%SY,6H1!%H  #T2!@ 8
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M-63"-$W9/YLN+5<Y%:Z8\CYSSHP1;FIC36S7@O5VD/1,D6C!GQ.HWV_LB7P
M6SJ,?#@"+U)8G[9'M3TZ*X\?Z#=PM?Z&8\46)^.S$ CA*LUGZ*A %.7.V!$H
M(Q_M3= ^^"<&9Z<#W)B#\A@<)1-0CCK!.+T\TS*4!&A0[5II5EZ;E44U.R(
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MG7!0G!.*;0H9NHBG2N54CGNBJZZNP%IY2'3:+Q\2UWX<.+P3V.->#@1?P:.
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MM/<R^$;2/PG8":Z9 I_BNRRYF\VPVS'(TE+^PS7H<'4E=-8'ZM%[H;"&S'7
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M1]Y5WU_:! AODI5XJ6:J+-2\&:JM$.G',R/(=W+J0CK$BW>;#6<C&HMV$^$
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MT>G>)W.++PFR>J?;'<#I<%XG5\\P**X.PZ/I40/^$2X"NT=SXS&)):;>$+Q
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M/J=4+[2SLQ.J3L!D_TZH3.2<4AZG:GNUIZ)&!4AV4)1AYZ124<?#Y#J9MET
M'-ND%(8PK$!*[7@X7B<%-^'RUM88@RJF!8^'RW5B<SM#QNATFSJU63FG4IW
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MN^JI_&/>N^(S\0I0ZZ".Z_;9NDHVYS\*!M>3!<IW7/>MS)48(J\ K^^4,5:
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M':<G3^8=UM)E\YY/ELMH@$PROIS]0P(-F5M<8VYEK4;F"[AL%&$(!5-E\J-
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ML%F0J$%S^HV$ONO8!&B$_]/G02G@*K5VI6IGQ'KXJU4TQA9UH)P#YD6:^\O
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M4$L! A0#%     @ P(!D7)9UJ@C7V0  @KD- !4              ( !PJ\
M '9S=&TM,C R-3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( ," 9%SQH2T.X)4
M *S%"P 5              "  <R) 0!V<W1M+3(P,C4Q,C,Q7W!R92YX;6Q0
M2P$"% ,4    " # @&1<HZ4Y2T.7!0 &/#4 %0              @ '?'P(
M=G-T;2TR,#(U,3(S,7@Q,&LN:'1M4$L! A0#%     @ P(!D7*RG/U7 &@$
ME5L! !@              ( !5;<' '9S=&TM,C R-3$R,S%X,3!K,# S+FIP
M9U!+ 0(4 Q0    ( ," 9%Q43KUG$+<! *?# 0 8              "  4O2
M" !V<W1M+3(P,C4Q,C,Q>#$P:S P-"YJ<&=02P$"% ,4    " # @&1<#2Q^
M9UBX  "?V@  &               @ &1B0H =G-T;2TR,#(U,3(S,7@Q,&LP
M,#4N:G!G4$L! A0#%     @ P(!D7$M:(+\M)@  @C0" !D
M ( !'T(+ '9S=&TM,C R-3$R,S%X97@Q,&0T.2YH=&U02P$"% ,4    " #
M@&1<4X)TCJ(6  #>V   &0              @ &#: L =G-T;2TR,#(U,3(S
M,7AE>#$P9#4P+FAT;5!+ 0(4 Q0    ( ," 9%S9FR,+/P(  )$%   8
M          "  5Q_"P!V<W1M+3(P,C4Q,C,Q>&5X,C%D,2YH=&U02P$"% ,4
M    " # @&1<G+0AY.@%  #03@  &               @ '1@0L =G-T;2TR
M,#(U,3(S,7AE>#(S9#$N:'1M4$L! A0#%     @ P(!D7/WEEZ%B"   *"@
M !@              ( ![X<+ '9S=&TM,C R-3$R,S%X97@S,60Q+FAT;5!+
M 0(4 Q0    ( ," 9%Q!LO2B] <  %4H   8              "  8>0"P!V
M<W1M+3(P,C4Q,C,Q>&5X,S%D,BYH=&U02P$"% ,4    " # @&1<_Y!.8F@%
M   U%@  &               @ &QF L =G-T;2TR,#(U,3(S,7AE>#,R9#$N
M:'1M4$L! A0#%     @ P(!D7$@64B)C!0  (18  !@              ( !
M3YX+ '9S=&TM,C R-3$R,S%X97@S,F0R+FAT;5!+ 0(4 Q0    ( ," 9%Q!
M'\G-QR\  #:H @ 7              "  >BC"P!V<W1M+3(P,C4Q,C,Q>&5X
M-&0R+FAT;5!+ 0(4 Q0    ( ," 9%SY,6H1!%H  #T2!@ 8
M  "  >33"P!V<W1M+3(P,C4Q,C,Q>&5X.3ED,2YH=&U02P4&     !, $P =
)!0  'BX,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>vstm-20251231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vstm="http://www.verastem.com/20251231"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vstm-20251231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_VeTMKHIwC0eLyAN6WUjVXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:PrivatePlacement2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_SkzoBDCVyE253YNoI4hWww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:November2025PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_wgrwxnERa0qwi96U9x_blQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:PrivatePlacement2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_Pf0AlvNsAkKhEKrfCVhX9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:November2025PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_9kM5FIopg02NBn8H3CtCvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_9_30_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_-TqHBbCtZkCiLS7Kdk667Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_5_30_2023_To_5_30_2023_us-gaap_TypeOfArrangementAxis_vstm_CertificateOfAmendmentMember_49ED66jM9E25MF3tUNgntg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:CertificateOfAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-30</startDate>
            <endDate>2023-05-30</endDate>
        </period>
    </context>
    <context id="Duration_5_30_2023_To_5_30_2023_oisDwP2U50elPdB2XZBoCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
        </entity>
        <period>
            <startDate>2023-05-30</startDate>
            <endDate>2023-05-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2013_To_12_31_2018_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_6UYIohPWOE6apXvvQXRZUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2013_To_12_31_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_InUwV157EEmuIs833j_9kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_a-kauTSQJEW4yLfm5-WSHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_1_2020_To_2_29_2020_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_KH8OwIiqFUWzZ49IgN-PQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueAndAllowancesReturnsMember_FTUadeq3F0WCVMRH53KrHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="vstm:ProductRevenueAllowancesAndReservesTypeAxis">vstm:ProductRevenueAndAllowancesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember_yE8fkK7qa06bC6iq6BUR2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="vstm:ProductRevenueAllowancesAndReservesTypeAxis">vstm:ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember_OyYlxyJlr0W_orM9kelphA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="vstm:ProductRevenueAllowancesAndReservesTypeAxis">vstm:ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember_Uvl6OFaJ0Uq4ztzlNkkoEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="vstm:ProductRevenueAllowancesAndReservesTypeAxis">vstm:ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember_168XNhm2-E2OU8g_oJr-ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="vstm:ProductRevenueAllowancesAndReservesTypeAxis">vstm:ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember_RoPH4kuymE2ByqNH0aMdag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="vstm:ProductRevenueAllowancesAndReservesTypeAxis">vstm:ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember_sxwP1I5FCEKe9EEKt9_cgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="vstm:ProductRevenueAllowancesAndReservesTypeAxis">vstm:ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueAndAllowancesReturnsMember_5FE7cQWXTUKpa-SgNguaWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="vstm:ProductRevenueAllowancesAndReservesTypeAxis">vstm:ProductRevenueAndAllowancesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_StatementScenarioAxis_vstm_AchievementOfCertainSalesMilestonesMember_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_zzkKq8OR_UOKfHUpO3ZAdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:AchievementOfCertainSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_srt_StatementScenarioAxis_vstm_AchievementOfFdaApprovalMember_tZQwQiMhYEqbPdhEQQ5HEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:AchievementOfFdaApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_srt_StatementScenarioAxis_vstm_AchievementOfFdaApprovalAnniversaryMember_xTJSoxkVBEah1aNhnYblRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:AchievementOfFdaApprovalAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_srt_StatementScenarioAxis_vstm_AchievementOfCertainSalesMilestonesMember_31ejtZ8BeEqgLwzBvmRC6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:AchievementOfCertainSalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_srt_StatementScenarioAxis_vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_o3q236vw0keqOsqNBTnifA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:AchievementOfCertainDevelopmentAndCommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="As_Of_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_vstm_ExerciseOfAllThreeGenFleetOptionsMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_o_C5UTUcQ0-Z9MtY_JiXjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:GenfleetTherapeuticsShanghaiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:ExerciseOfAllThreeGenFleetOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="As_Of_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_vstm_AchievementOfCertainSalesMilestonesMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_njuY9ME3DkeF5IZXfRJNAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:GenfleetTherapeuticsShanghaiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:AchievementOfCertainSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="As_Of_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_39lEE9M2vkGrczaWHlXE3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:GenfleetTherapeuticsShanghaiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:AchievementOfCertainDevelopmentAndCommercializationMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="As_Of_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_E2vhbuJLHEynsOukxWJq3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:GenfleetTherapeuticsShanghaiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-24</instant>
        </period>
    </context>
    <context id="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_pZ_a6EQacUaXNZDxp5JMNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_First100MillionNetSalesOfEachIncludedProductMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_yDuuqaiCa0qAYyrozwvzzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:First100MillionNetSalesOfEachIncludedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="As_Of_1_13_2025_srt_StatementScenarioAxis_vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_L9jTrBAWiUuY_e_CNM8bCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_-48AVsFUBEugaVAWJ90CjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_6_30_2025_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_ouTeCHDu4Ey5RJk0ycXIKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember_hrCFuYf1CEmedfPlJxDI9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-25</instant>
        </period>
    </context>
    <context id="Duration_1_17_2024_To_1_17_2024_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_9tsdrgQO-UKXsRxV5I_Sjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:StockOptionExchangeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-17</startDate>
            <endDate>2024-01-17</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_MajorCustomersAxis_vstm_MajorCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_kdCTYwGzK0Wb4YPT-CMQMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vstm:MajorCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2025_To_8_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_9R4yRxA400KtN3lsZ5eH2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:AtMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_gb-CSVl9SE2eIj1tdK0XYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:AtMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_O0Rufo-BykGzNlAstqrYkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_usrikRrbhk2qFlA8-ytCWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_mTaWPJHmCU-O7Tpo-6Loaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2023_To_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_dsxUwW56ZECoNMCxu8ilPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:GenfleetTherapeuticsShanghaiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-24</startDate>
            <endDate>2023-08-24</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_pEx0srU5Ak2GiczyEYhqRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_e8TDv-L8LUauwZTI1obpiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_8uqSrXDV0EmTZ1ByOF2jBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_4eTmUVOzd0mGjZsxlu90SQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_7_31_2024_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_ipNYPIX9lkyb7J4LRrkchw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_s7JVz9MorkeAVWRt5OMAbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_MdVGT0IgvUmbjCVDMtrXUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_5YDVN68wcUm0VSa7Wv493Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_m7dZCqcrSkuva19JwTUE4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_5ZISHrVDkE2EvnOvhrL_rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vstm:CopiktraLicenseAndRelatedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_K33i8h8swEuknRDePz8siA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_besuRyf8Y0a58JN5tevWUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_9WaY4ozWNUCB3Lci8zTJtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_1_31_2025_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_lGAzc-lkAkKmcWT8YEBiIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:GenfleetTherapeuticsShanghaiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_DF8qnE1w-kGq9_Ct4jgrAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:GenfleetTherapeuticsShanghaiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2025_To_1_13_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_ZP6M46McoESK6chF5ck0mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:First8QuartersFollowingNotePurchaseAgreementClosingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zCbuz_b2rkCKzl31gcidKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_02A2El0zNE6rdIdZB1KSUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermDLoanMember_0YiEHyy_qUmrRNBRC-bsYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermDLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-25</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <context id="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermCLoanMember_GwB-PS6Ju0-fUVSXWFqhUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermCLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-25</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_StatementScenarioAxis_vstm_SecondSaleMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_1vwgf71uzE-hN_Nsosf5bQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:SecondSaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_13_2025_srt_StatementScenarioAxis_vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_FQVi45q7jkSuA4lClWDejQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="As_Of_1_13_2025_srt_StatementScenarioAxis_vstm_SecondSaleMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_kgBvIxdJtkiqAwZH4jNFMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:SecondSaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="Duration_3_25_2022_To_3_25_2022_srt_StatementScenarioAxis_vstm_PrepaymentAfterSecondAnniversaryMember_1PALNeli40iSsLa7t8QfSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:PrepaymentAfterSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-25</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <context id="Duration_3_25_2022_To_3_25_2022_srt_StatementScenarioAxis_vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember_q8ti5S-pZU699rXFl4F2PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-25</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <context id="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember_hJCM6F5LHUKiyc_uSMcFDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-25</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_2MBviHog-02Q7tUt8Qeq9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Lb8_EogSb0aV0xpnEYsScg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-24</startDate>
            <endDate>2023-01-24</endDate>
        </period>
    </context>
    <context id="Duration_11_4_2022_To_11_4_2022_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_gfizhfrkqE64g9G7nBHm7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-04</startDate>
            <endDate>2022-11-04</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_StatementScenarioAxis_vstm_PursuantToLicenseAgreementMember_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_VDan3WYf1EevGGqNXzZ9hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:PursuantToLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_kZtv3Lbx3kGdnwrGa-1nxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_GkEC-M9QTUSgrlwCXKodVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_QfOCneyU3kuQfy4l3HkaFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_r6xwMcGjUkmR3Dp9MxTNuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_YFjHghTZW0Ch1fCZB71hlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_0A2hZA9RokujrbpWC0nGmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_7rlVb8oVn0S0Tnw4gAwhJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_5LADYlfrGUudV0Z1BYW7WA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_olbo--1GgkW245MgvwjaNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_18_2024_To_10_18_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fM5yxfUyOk2FmCtStYKMUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-18</startDate>
            <endDate>2024-10-18</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_T__SJ-zwq0yVJL4kvpsp4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_14_2025_To_11_14_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_WUufEo4u2kmXKrrBjVvTxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-14</startDate>
            <endDate>2025-11-14</endDate>
        </period>
    </context>
    <context id="Duration_4_25_2025_To_4_25_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_w6Qgr7wiUECKdrz2j0wQgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:PrivatePlacement2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-25</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_NZvKvAzq-k2_cBvWayCtvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_76lNElnqP0Ge645AbtZsrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_UQMJ9oLa3kmJvYGMn38KsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_L9scB89F9EeAgUmzCCgzrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:CantorFitzgeraldCo.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:AtMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_mUhVWV8WMkScZAT8JeG4VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_18_2024_To_10_18_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Kvj5joERQU2FBgyJpIJZgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-18</startDate>
            <endDate>2024-10-18</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_tpO1jPCeLkKmH0m8Lyeh1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:CantorFitzgeraldCo.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:AtMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_24_2023_To_1_24_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_vGMn7XIAIUSBLUxCpfC0tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-24</startDate>
            <endDate>2023-01-24</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_644V0cfv3U-29Mjt5jpGcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_2UfHf6a-7UekKeqNumvvTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:CantorFitzgeraldCo.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:AtMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_11_2012_To_7_11_2012_srt_CounterpartyNameAxis_vstm_PfizerIncMember_BItiDfIFn0WcHJLqHz3mqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-07-11</startDate>
            <endDate>2012-07-11</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7MnmvaWWgEePqWQTjdY9HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_TAPCsw8lgkWIgfJ_mbgurQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dp0SN57cD0KXZDKWXesKDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fuhD4w1zHUO3JOvClD8XNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7Z9PHqH2q0S7RrWVtY151Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xiIip57Oi0ehdHOXQBNQkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NDL3BYU3PUuJd3uSXk_5qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_w551gdo2ok6ZEMwgbJunYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C6prOwECYEmM37Ntixav9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8HWoELe-FUKs4q6zosK0_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lrgQGYbzQEm9cGGsaWCIRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ASFttFVznUOS8yMRpJAbxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MohRnXLqbEGEo5fjQezNRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_y9BYeLeimkGfbgD3G1n6_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IVIVyZ8H2UGZjpXhTwRvWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ba-9SwGbmkucpagN-WsZYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_rXXFIzj9hUybe-4ngReB2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_W4v_8l5EHEOk8tW_t3-29w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Y_mwN22A6kGbxpRR-EAdLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_V_Epz3gmqU27y1VxbWmrEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_14_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_u5xj-WOakUigG8lS-TAocg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-14</instant>
        </period>
    </context>
    <context id="As_Of_4_25_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_RmWH6lNih0uXM3yO2Zl1qQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:PrivatePlacement2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_UBix19n6xEadDF59Ya6BCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_vstm_PublicMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_y99DVEYGyUKxX-8hVBLWvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PublicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_KXGM5R7Mj0CV9njTnuX__g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_vVu2uuQvG06s9WNMj9GHKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Qle4ZI3AIEyBN5JnaC-kDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_XEXyJOXQwU6kwc_ldYtXQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_oquxji7W7kORBWim9QZqHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_11_2024_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_-AttFnMCSU6nI2v6Vkvu9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:StockOptionExchangeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-11</instant>
        </period>
    </context>
    <context id="As_Of_1_17_2024_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_6mVNyROOJkSrg0yW3Dje3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:StockOptionExchangeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-17</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_9MQgPcH2EUCI7sWeUwpq2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_19_2020_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_7ogkiNGxH0Cudi_sLSt8Sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-19</instant>
        </period>
    </context>
    <context id="As_Of_12_18_2018_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_VfDIZ_ny_0SEOGbgvYKH1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-18</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2014_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_HTpasKVhbEijVBMXmoAR3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_29_2012_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member__U1eFLyyYUinIuRMK__m6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-02-29</instant>
        </period>
    </context>
    <context id="Duration_9_1_2025_To_9_30_2025_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_cywh5amltUm6Kt3zBqYeYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2023_To_9_30_2023_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_D0hnNXSwOkqr4_93nEPQFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_kF5MtIMMKk-IM7zcfxe9ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_ZKoZ1HtmKEOVJFeHyY-zGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_6dsoZ6DBIU6g6FY7wcduKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_sFo85W5EcE2hWIXSctPLDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_12_31_2018_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_3QOHsDLjBU6VMM7clr-E_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_hb0DPVUMikKyDJikKyOjUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_29_2012_To_2_29_2012_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_I4P8dDbjHU-7QChhWz3WUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-02-29</startDate>
            <endDate>2012-02-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Thu2JVJXHE-NAiF2FbkbWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_H7UvvfgjnUqqlhC1ni7-Kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_PLQMRuTiiE6wbLtAwlEjMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:IncentivePlan2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member__JkWWHFFE02LfRdH8KCQ3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_AH-XF6rwGUWP_UuR-y8kTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_SRNGIXeB20ejdnPS4J6CHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_vstm_ShareBasedPaymentArrangementTrancheFiveMember_9vzgnyw0KEW9zorH509q7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">vstm:ShareBasedPaymentArrangementTrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_vstm_ShareBasedCompensationAwardTrancheFourMember_NWg1r4cHA0-EOBRAYidUbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">vstm:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8LF9tFy9yEe9w7E5AvqW_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_mUQePIf6k0Ox3rRBC0Wpxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DIZOBohzgUCmiDTqRAMCOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_21_2019_To_6_21_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_m3em9BxJfkWCCgCqGcDWTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-21</startDate>
            <endDate>2019-06-21</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_BalanceSheetLocationAxis_vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_ursq9MeRN0yWn5gbwLYHOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vstm:RestrictedCashAndCashEquivalentsNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceLeaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_BalanceSheetLocationAxis_vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_2MkKTScWkE6izafnUVQf4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vstm:RestrictedCashAndCashEquivalentsNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceInNeedhamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_BalanceSheetLocationAxis_vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_10pAZepk4k-KD0pKIdmI3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vstm:RestrictedCashAndCashEquivalentsNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceLeaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_BalanceSheetLocationAxis_vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_2wSiS_Brj0WdJYyQqH3Mow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vstm:RestrictedCashAndCashEquivalentsNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceInNeedhamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_11_13_2025_To_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_8KWsZFM4mEuCXxQ0JyrXPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:November2025PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-13</startDate>
            <endDate>2025-11-13</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_x-U4MebMkEusy4zb3w2UTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_VByLpZd3oUumXTdQ76R5ZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vstm:CopiktraLicenseAndRelatedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_zBiJ6bOlu0qlmuRS_OwhWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vstm:ResearchDevelopingAndCommercializationDrugsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_LArOb7j6NEaAnMIYXIPzkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_vstm_MajorCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_S7Vk9c7EfUOkiG3i3sRNMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vstm:MajorCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_ycCXXJQjykqCsZOvjuthHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vstm:CopiktraLicenseAndRelatedAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vstm:ResearchDevelopingAndCommercializationDrugsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_HA-hUtbuQkSrDIYOaGPRyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vstm:CopiktraLicenseAndRelatedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_C_jlzU3foUSnLHdbsgYZFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:SecuraBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vstm:CopiktraLicenseAndRelatedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4zRDVYOP-0K61PPNI3Uvhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_jTuekN8itU-PCSYuKMbIDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_OkY1QtMdYk-oqCKMPg88RQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_AXOj8gL7Jk6ZdhZ0AOwscw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Gs8d_AaUlkS6G-nzgF-NEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_YUbMCLNoMEiiVq3ezSlFGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_Em0bxcv8gk6czzZLTd4Ywg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_yve5Cj4_rU-htYKKwRh69g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7S9Co7osyUKPh1S2Fr2wNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="Duration_4_25_2025_To_4_25_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_t2jNkx3weEK3-E4-F4tIgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:PrivatePlacement2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-25</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="Duration_3_22_2023_To_3_22_2023_us-gaap_DebtInstrumentAxis_vstm_TermBLoanMember_Ko01k0D9G0CisdNqaY7CwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermBLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-22</startDate>
            <endDate>2023-03-22</endDate>
        </period>
    </context>
    <context id="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_n_qBs1SNYkedi6TPK_3kgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-25</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <context id="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Btgqk5RY306LVDoxcjygVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-24</startDate>
            <endDate>2023-01-24</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_edm9qWQjT0uGo3Ul1o6KTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_s_eRJ_IM-EC5I5guhHo3NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_8jcz-NhL0EGmNv5s7ylAMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_seqv11hd7kGtRU21nUUodw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_1iNwjL1LvUC8CJz-JY9pGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_FENbJ6e8LUCyQO0RcrlfFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_24_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_FQWIrrRmRkCSrnKhzFgoaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-24</instant>
        </period>
    </context>
    <context id="As_Of_11_4_2022_srt_CounterpartyNameAxis_vstm_BiotechnologyValueFundMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_ZbyWkvA4UE-y5mQ7pRm7Mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:BiotechnologyValueFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-04</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ykjfpsDf9EClxEq1QlGEFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_10_18_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_ACFKxOC2mUGBN1ufbr5J8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-18</instant>
        </period>
    </context>
    <context id="As_Of_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_EgpHd6yzBUuaIpY-YY3qXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-24</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_3L8cmMQep0K6q--7_1jqxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:PrivatePlacement2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_jUBqmRoabkGaS293dmEkgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:November2025PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2024_To_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_oG3TWOGlW0SJkm54UqDFTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-23</startDate>
            <endDate>2024-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2024_To_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_semVXOzt7UuTbjL3iSPnbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-23</startDate>
            <endDate>2024-07-23</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_h5EVJwZSEkaojEFbMUpw3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_NfyaVSuOXEOBvk_0IuL8CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_vstm_IqviaIncMember_us-gaap_BalanceSheetLocationAxis_vstm_AccountsPayableCurrentMember_EPTDxkm6dUGE_Y2j9gCeGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:IqviaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vstm:AccountsPayableCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_vstm_IqviaIncMember_sAB2nn3xb06KIRwK0qRhxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:IqviaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_EMxewkfryEW0MgeN6Ed9RQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_M65DxSkBeUWXwkv5yp4KTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2024_UMnI-wXQ0USHesrFhwgQ9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_nO8T_caZLkmO-wA1SFOP5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceInNeedhamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_15_2018_To_2_15_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_TZVH7IRG1kSvGhOZkG4XQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceInNeedhamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-15</startDate>
            <endDate>2018-02-15</endDate>
        </period>
    </context>
    <context id="Duration_2_15_2018_To_2_15_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_PZfr7HL6HkyNjzMRM2PTpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceInNeedhamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-15</startDate>
            <endDate>2018-02-15</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_SnnAtXkpqkWQ3yAjnYmU6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:FirstInsuranceFundingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-Ba5ewoa3EWicqSM_lHMtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TtA8P5RxPEqhMQS4CQul_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yQk4kITunkGYKm5hIqAzWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2023_To_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_us-gaap_ResearchAndDevelopmentArrangementMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_tYSyxNxH1Uuvalr8k9zyHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:GenfleetTherapeuticsShanghaiIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-24</startDate>
            <endDate>2023-08-24</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_MkLIiJaJsUiWkMQbaTnydg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_fqBR8I39AkaH9nxabK_ZXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_13_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_xbPXD0-44U2IqHm7qVghXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="As_Of_1_13_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_OGwNsXA5AUWD7GEFLnYUtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_yUvfHNVxFkOmrE7fRHax3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_13_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_kwGm2G1ANE6CxfNPRBiayA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_QSij2lq4ik6s4CjD_2yz9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_Uj6ZHm1iCka91Tq8-q7rTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_us-gaap_GovernmentAssistanceTypeAxis_us-gaap_GovernmentAssistanceOtherMember_GBuPX_U0g0azpKLEVKIehg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">us-gaap:GovernmentAssistanceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_0S7CWDwAHkCwzDSQQTfHkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember__WavrOlweUuRmxKfUY_vSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember_RAkPieYklE2it_DAfMg6bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_6KQR_VTJyEGtpgOTeeNfig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_l6H3Xy5qKk-1R-nWGp4lrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6mJXVPDki0CwWIMRXdTM3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_14_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_0BoN3371-EmgElNU_GJ5pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-14</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_fGAFkO2I5k6tbgjWbUyMMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_FvCF6Wd2sUa1Ka_dpTtMeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_M3ZzNPTGjEyOJy5c4k1gkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_vstm_PublicMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_Jr05H4l9L0uUqAYKxs4qxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:PublicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_7P_amzQ5tEm7vf5xPezzyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:StockOptionExchangeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_QxkWpkXINU6ewZdwyiOEzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aS2tcr5syUKqamx-hjW3Pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_22_2023_To_3_22_2023_CVN1xwustEOhPxcy3fNk7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
        </entity>
        <period>
            <startDate>2023-03-22</startDate>
            <endDate>2023-03-22</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_RedemptionPriorToThirdAnniversaryMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_E6tvvCsPZ0mBoCk6DsCySg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:RedemptionPriorToThirdAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_RedemptionPriorToSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_YpTuBpiScUuxKI1zr7VhQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:RedemptionPriorToSecondAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_RedemptionAfterYearThirdAnniversaryMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_E6iz-U49E0K1SJSRv0h8aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:RedemptionAfterYearThirdAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_1_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_cQjwjoVWG0yneJwH7D4Q0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:FirstInsuranceFundingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_Un8b41l_pEirHv8lmaIPmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="As_Of_3_22_2023_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_75mzb7bZKkioJTv-axGvyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_8S_QmEHi20-3Bt7pN3KrWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_UhCOi_V-Yk--a9CzLZu_Og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:FirstInsuranceFundingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_13_2025_srt_StatementScenarioAxis_vstm_InitialSaleMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_TGIhGhuPoUWERtDGZhnrlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vstm:InitialSaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_zrQB4qKfyEqQTrK2VnX_yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermELoanMember_oqIeKfAl3E-mBRkyj-y-iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermELoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermDLoanMember_w57GQ0GBSEaZmkdvKKZD1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermDLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermCLoanMember_LB9vQfFWtUOb5dJuYRvwQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermCLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-25</instant>
        </period>
    </context>
    <context id="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_iZI7Ie7K00GLdoRZJcm5tA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="Duration_3_22_2023_To_3_22_2023_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_5nolpa91pE-eWxvWNTzoIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vstm:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-22</startDate>
            <endDate>2023-03-22</endDate>
        </period>
    </context>
    <context id="As_Of_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_S54_9duti0-qFLlDHg8uag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-24</instant>
        </period>
    </context>
    <context id="As_Of_11_4_2022_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_zoyOL8-GYk65yM8gGKkE-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-04</instant>
        </period>
    </context>
    <context id="Duration_11_4_2022_To_11_4_2022_srt_CounterpartyNameAxis_vstm_BiotechnologyValueFundMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_tMPnHLFbrkuMv8YVveCukQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:BiotechnologyValueFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-04</startDate>
            <endDate>2022-11-04</endDate>
        </period>
    </context>
    <context id="Duration_11_4_2022_To_11_4_2022_srt_CounterpartyNameAxis_vstm_BiotechnologyValueFundMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fvPNrQJtrkWkJoV_MdT_gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vstm:BiotechnologyValueFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-04</startDate>
            <endDate>2022-11-04</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_MajorCustomersAxis_vstm_MajorCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_plJG3megQ0iGNmTnOb-Uvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vstm:MajorCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_6XXSqLAvakekgauvuyfFBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_KS1tXWlGL0mDHAAYpEFAqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-13</instant>
        </period>
    </context>
    <context id="As_Of_5_30_2023_us-gaap_TypeOfArrangementAxis_vstm_CertificateOfAmendmentMember_Q_y7EUi3X0K_kq-y8s1gbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vstm:CertificateOfAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_PreFundedWarrantMember_KnGNGKDd4UaRuVatC6F9Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_v94nix69zkGeGJg-ULbs-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_WarrantMember_wbTMM7gk_U6IJSEizGwY4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_jgUB4qLkMESjHNyit_jWJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_o3QykpaT9kO0MVdafyJpUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_vstm_SeriesaConvertiblePreferredStockMember_h2EwK_J3D0yrYJTXRulnyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_vstm_PreFundedWarrantMember_Fay4PRvQWEyTg9vyJimtfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_VwswXPy6N0iYiVDwlnG78g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_WarrantMember_3vY0IAdGpE23ucHgSc6EPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_hNJYkO5IlkSxNYbhWOjEug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_LdWz0v453kS4CX1tFFGG_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_xgsOVZqDvUy1HFomyzF7Hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-23</instant>
        </period>
    </context>
    <context id="As_Of_6_21_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_kZlm7MS8p0C-2514CTT6lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-21</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_W-OWHjTX20eGOqczNgrSyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_XleLLeLgMUaEtBjxP-2klw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_n96ND7-6FkaDWs_KK9qUrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:November2025PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-13</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_NVq59xSXbE6uvQXjAgxbQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_4_25_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_ehT0HA0cvUW9AwZHGjQ9nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:PrivatePlacement2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-25</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_eegaa3ABKkqBRahdn4RezA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_9uZ0RStEKUaT5_5fRWamIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-23</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_qoqGwn8YFkepdjxAScNrxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-23</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_ewMMPiBO5k-cPP2IurkzMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_9JY_1UA-ZEecEwccCTRt3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_Uyhdm4_rYEOg-NEKFqTeBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_z5GNzJxej0aeNGqmRjwWLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_CashAndCashEquivalentsAxis_vstm_CashAndMoneyMarketAccountsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_vstm_CorporateBondsAndCommercialPaperMember_RPkjFi0xNEyDFZjufdCC-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vstm:CashAndMoneyMarketAccountsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vstm:CorporateBondsAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7jjnAioBzkCDhttauz0FHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_vstm_CashAndMoneyMarketAccountsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d4Dr_eG7_EGh26Hx67k-HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vstm:CashAndMoneyMarketAccountsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_eBqr6h4vlUOpwptV_czZMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_CashAndCashEquivalentsAxis_vstm_CashAndMoneyMarketAccountsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_vstm_CorporateBondsAndCommercialPaperMember_MWAiV7Cxnk2tfkH3USoRZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vstm:CashAndMoneyMarketAccountsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vstm:CorporateBondsAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_12Jwxj-GpUyMjUlJbpGHrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_vstm_CashAndMoneyMarketAccountsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_2k6kDSuJ90Spe63C0ts7DA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">vstm:CashAndMoneyMarketAccountsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_-gOCxHhMf0WnaIxAheCqPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0ZkUR0_jhUeO6Ak4kIOPSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AjLSxccsFEupWVwt4xkeYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5WLmwNvOF0u7-gwsjUY1fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5TQU9p2reEqK8sueEagIGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_15_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_xJV-v7FV5UyE4Ztk9gpPcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceLeaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-15</instant>
        </period>
    </context>
    <context id="As_Of_2_15_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_X8QqK4Hmd06KwW35Ix-WEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceInNeedhamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2014_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_xnA_Kvwj70evJoubr3vJJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vstm:OfficeAndLaboratorySpaceInNeedhamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-04-15</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_haNRViJSzEOTdDWixSwWZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_2Bs0lZ91y0Cmf6Th8FtUgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_YnZ3x6uu-0Wme4Fzg28ezw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_GHWd8K1WG0u-Q7uzXgEt8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_V8o_TMafXU69pWaNyC7oHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_nET5C9dUgUCwg9L0-kWvkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_YJkjgHtK7UWwDuHpo_dJVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_NV4P7J5B-UKwUVnwqEP6NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_Z7vMySuKckCsJVbZ8qZDQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_UVwviP4qFk2O79hJ4CkV4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_eu_9_6CHf0y-Lj52IH4byw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vstm:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Q-P8zB2YJ0Gd2Zv66vU9Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_xY-UvU2IMkukHRCrwlS71A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_-x24TYsG3USzRfi7iWlv3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_P0DHBOoSh0iaybDJceiPYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vstm:StockOptionExchangeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_vstm_SellingGeneralAndAdministrativeExpenseMember_GF1wQLe1cEepBDtan8hiOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">vstm:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vstm:ResearchDevelopingAndCommercializationDrugsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_81vFum6e40qPRWAKzAeYEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_HI4Ao1b7KUaKAhD6JIXWwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_vstm_SellingGeneralAndAdministrativeExpenseMember_sCAZBIHJT0aFnxlMm6H5GQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">vstm:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vstm:ResearchDevelopingAndCommercializationDrugsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_S_kTXh7xV0m8qg0cNUl6aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2rH54lHkjUGemFEv-HKuhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_oOgDU519zEqo7xvys1DGvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_vstm_SellingGeneralAndAdministrativeExpenseMember_F3TTaRhxYEqLX5MuwsstiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">vstm:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vstm:ResearchDevelopingAndCommercializationDrugsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vstm:EmployeeAndNonEmployeesStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_o06JHclHKkuBTNuWXs-wzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_M0_H0x6EIkiEVk025KKwUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_vKi2RrPfkku5amSLSGzqiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2024_To_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_hbgxBNPYbUyJb5vXdalJvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vstm:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:July2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-23</startDate>
            <endDate>2024-07-23</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Nx7kZA6zXkqD1bBA5afBeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_6SeiJlC4WkGCPvAYgU6Y5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vstm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H2d2wIpatEOMddtM_uXHjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_smxFsQJeIEe8LC1hRLDuYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GZ0fEHkwU0OYcLlJwZ7pfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2025_To_12_31_2025_9WuRZ5oiCEytQ-4llKR_8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2025_U2l50NSmAkq0-Oxfvm-ugA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_27_2026_QrdMVJO2fkqYAmK0L974Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
        </entity>
        <period>
            <instant>2026-02-27</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_customer_sDaO4Ago9kCUEtrMUagxqg">
        <measure>vstm:customer</measure>
    </unit>
    <unit id="Unit_Standard_tranche_AR7EJ57OqEq8JqHSzH8_Aw">
        <measure>vstm:tranche</measure>
    </unit>
    <unit id="Unit_Standard_Vote_tReSOj-zJkipnhJ_-h7uBA">
        <measure>vstm:Vote</measure>
    </unit>
    <unit id="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_sqft_FdbiNq8DNkeaOGqvsWqN6A">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_5quK1hZThku2W0bLLpUodA">
        <measure>vstm:item</measure>
    </unit>
    <unit id="Unit_Standard_segment_zofEUC3Xr0eG4_rh7aLMNg">
        <measure>vstm:segment</measure>
    </unit>
    <unit id="Unit_Standard_Y_QWKc7mjBxEydJx6eMjqhZA">
        <measure>vstm:Y</measure>
    </unit>
    <unit id="Unit_Standard_installment_8U3XYH-pF0m6Z5I545EDwQ">
        <measure>vstm:installment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tc_z3XtzHMRmU2aqTv8dK6c_A_2_1">0001526119</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tc_95ca6b8oQ0OaAzvy6R0oFg_3_1">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tc_2A0M9ug7nEOGXe-m_FUbpQ_4_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tc_7qTXQ40-Zk-5gKhT5f-boQ_5_1">false</dei:AmendmentFlag>
    <vstm:PreferredStockSharesDesignated
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_seqv11hd7kGtRU21nUUodw"
      decimals="-3"
      id="Hidden_ysfm7Z_m_EuRZVq3lctHYw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">944000</vstm:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_seqv11hd7kGtRU21nUUodw"
      decimals="-3"
      id="Hidden_eYsU4ZNv00232JjNRkZteQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_edm9qWQjT0uGo3Ul1o6KTA"
      decimals="-3"
      id="Hidden_qHhHCzO2QUaDq3kIsGr8-A"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_seqv11hd7kGtRU21nUUodw"
      decimals="-3"
      id="Hidden_VjEul_4ydEymIByn90mfmg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      id="Hidden_4fkcjdqq20K-eWbfNX-_fQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w"
      xsi:nil="true"/>
    <us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      id="Hidden_sTNsB9LO6EuYGC4ZcgJfMw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      id="Hidden_QmHIF05vtkW-Lf37Rt1dAg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      id="Hidden_YfginUZE2EOloL1Am_w-Fw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Hidden_f0PNnUvzCUyNJXe3HQWfrg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">77740000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Hidden_A0c_18zVRUq0bhgTAuwcJA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">44784000</us-gaap:CommonStockSharesOutstanding>
    <vstm:StockholdersEquityReverseStockSplitConversionRatio
      contextRef="Duration_5_30_2023_To_5_30_2023_us-gaap_TypeOfArrangementAxis_vstm_CertificateOfAmendmentMember_49ED66jM9E25MF3tUNgntg"
      decimals="4"
      id="Hidden_mxFYjHBtZEODqcY96vbZbg"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0833</vstm:StockholdersEquityReverseStockSplitConversionRatio>
    <vstm:StockholdersEquityReverseStockSplitConversionRatio
      contextRef="Duration_5_30_2023_To_5_30_2023_oisDwP2U50elPdB2XZBoCg"
      decimals="4"
      id="Hidden_UDYzqQ6S1E630AMzLLYW3A"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0833</vstm:StockholdersEquityReverseStockSplitConversionRatio>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_5_1_2022_To_5_31_2022_0S7CWDwAHkCwzDSQQTfHkw"
      id="Hidden_q90ZIR8th0OGZ8dK-5vu4A">http://fasb.org/us-gaap/2025#ResearchAndDevelopmentExpense</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      id="Hidden_LYd0gLsYTUK5twLVxNTSUw">http://www.verastem.com/20251231#GrantsReceivableNet</us-gaap:GovernmentAssistanceCurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Hidden_W4pGquiuLUKirJceSn_YoA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">30000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Hidden_NwoIzrC_q02kziSjSvHlIw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">26000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Hidden_N2ulbwwA-UqvBSpy2gwqug"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">62000</us-gaap:Depreciation>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_iZI7Ie7K00GLdoRZJcm5tA"
      id="Hidden_Jq6EAhHjvU6lCRswi0Rx2Q">http://fasb.org/us-gaap/2025#SecuredOvernightFinancingRateSofrMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_1_14_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_0BoN3371-EmgElNU_GJ5pw"
      id="Hidden__aGtVmkn9kuWPabZ5DVUXg">http://www.verastem.com/20251231#FairValueAdjustmentOfNotes</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList
      contextRef="Duration_1_14_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_0BoN3371-EmgElNU_GJ5pw"
      id="Hidden_-3F5ri1upkSXeC-rPJHM9A">http://www.verastem.com/20251231#FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="Duration_3_22_2023_To_3_22_2023_CVN1xwustEOhPxcy3fNk7A"
      id="Hidden_YOPMCZqEsUS3-osVGkAxWQ">http://fasb.org/us-gaap/2025#SecuredOvernightFinancingRateSofrMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_vstm_ShareBasedPaymentArrangementTrancheFiveMember_9vzgnyw0KEW9zorH509q7Q"
      id="Hidden_Y9Qm4X9j2kKBLrWQXymdSw">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Hidden_0gfH3kQvRkeG5SIGukyrFQ">http://xbrl.sec.gov/country/2025#US</us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration>
    <vstm:CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_kZtv3Lbx3kGdnwrGa-1nxQ"
      id="Hidden_UdxKXO7ke0C6w3GjR8sZiQ">P5Y</vstm:CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod>
    <vstm:CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_GkEC-M9QTUSgrlwCXKodVw"
      id="Hidden_gx1jXOcOUEaYyXuc-ygToQ">P15Y</vstm:CapitalizedResearchAndDevelopmentExpensesAmortizationPeriod>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Hidden_7alXqiLFbU--YfYHWYlRNA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <vstm:NumberOfDaysOfPriorNoticeToTerminateAgreement.
      contextRef="Duration_8_24_2023_To_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_dsxUwW56ZECoNMCxu8ilPA"
      id="Hidden_JU_oIydDdkuR8-FICIEckw">P90D</vstm:NumberOfDaysOfPriorNoticeToTerminateAgreement.>
    <vstm:NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach
      contextRef="Duration_8_24_2023_To_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_dsxUwW56ZECoNMCxu8ilPA"
      id="Hidden_AfA5SF6tv0-rw53ZSmEEFw">P60D</vstm:NumberOfDaysOfPriorNoticeTerminationFailsToCureBreach>
    <us-gaap:SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      id="Hidden_gxfwXUi5dECGg1py2bW53w">http://fasb.org/us-gaap/2025#SupplierFinanceProgramObligationCurrent http://fasb.org/us-gaap/2025#SupplierFinanceProgramObligationNoncurrent</us-gaap:SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration>
    <dei:DocumentType
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_m1aKTUZTAEipb9avVxcmtQ">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tc_QZOsYGLlXk2coQJKgqUwzw_1_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_uT9824eMZEyELjqihYatOQ">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_j92kn5s44UGunC1S_N6V3A">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tc_MCUIjnWK90mY0Mx8-4e9RA_4_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_EHiwa2qlzUaTLTZN8nIrug">001-35403</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_q64GgQ5sq0yplVX-NHb07g">Verastem,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_7939X_drx02_yFD1OfYfOg">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_T7Nuc_ns80mc4LVppx3JiQ">27-3269467</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_oJw7X6zfCkamqwE6xqV31w">117 Kendrick Street, Suite&#160;500</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_BAtBUl14FESnylwnWFJFGQ">Needham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_C4GbbPJJoEyJdZl4qT2j1A">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_ty531AN7M0yIoX5tJSh1Hg">02494</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_xsonCEK1lEuMJNJXw8kyVQ">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_Oh2VH1o7IESAnxTn-x83iQ">292-4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tc_MaopwaNSpUm-K6GIB1NgUw_1_0">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tc_0zhkkvvkjUKOEALDO_jbaw_1_1">VSTM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_LLW66hU9VEe0BpgGX83j5g">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_osw-H4MfRUiMY9M1x4xcRw">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_TZY3PK1AWkeCO6n5BvA8JQ">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_T0RwRmzcKkWxhoR64_JzkQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_33VYti6IyUa9CtQX_MNBbA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_dxzk3qHhR0uHZL06iJhjOw">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_88T9ZX6gqU2mW7jTqAkx7Q">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_Bwh66ASiOk2krNqUW7TJ7g">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_C7VZ66t2Rk2BKG4WAgcGzg">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_cKYvsEkW7E6nQMHgXU40MQ">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_2Ir7zo-4xk-NlmI0NwYXvQ">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2025_U2l50NSmAkq0-Oxfvm-ugA"
      decimals="0"
      id="Narr_u3NJr1E-tUiGMU8QKjWeLA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">253804995</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_27_2026_QrdMVJO2fkqYAmK0L974Jw"
      decimals="INF"
      id="Narr_qTUTmJOuyUeb3XeVGiAzBA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">87835106</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_kNmPeiFSL0qJLcyXzSfaTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"&gt;Portions of the definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A relating to the Registrant&#x2019;s Annual General Meeting of Shareholders, to be held on May 21, 2026 will be incorporated by reference in this Form 10-K in response to Items 10, 11, 12, 13 and 14 of Part III. The definitive proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year ended December&#160;31, 2025.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_3hJp2G6BW0Ob2zTRkKcThA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In the ordinary course of our business, we and our third-party service providers, such as contract research organizations, contract manufacturing organizations, and managed service providers collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research and development data and personal information). The secure maintenance of this confidentiality, availability and integrity of this information is critical to our business and reputation.  In addition, we are heavily dependent on the functioning of our information technology applications and services to carry out our business processes. While we have adopted administrative, technical and physical safeguards to protect such systems and data, our systems and those of third-party service providers may be vulnerable to a cyber-attack. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;We have adopted &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;processes&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; designed to identify, assess and manage material risks from cybersecurity threats.  Those processes include assessment of, and response to internal and external threats to the security, confidentiality, integrity and availability of our data and information systems, along with other material risks to our operations, at least annually or whenever there are material changes to our systems or operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Our risk management team collaborates with our &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Chief Information Officer (&#x201c;CIO&#x201d;)&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;, our internal information technology (&#x201c;IT&#x201d;) department, our Compliance team and our third-party IT managed service providers to evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.  We have established processes to detect potential vulnerabilities and anomalies through technical safeguards and have adopted policies and procedures around internal and external notification of cybersecurity incidents. Our CIO and IT Department implement processes around security monitoring and vulnerability testing.  We also have in place an incident response process for responding to and escalating cybersecurity events and incidents.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;As part of our risk management process, we &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;engage outside providers&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; to conduct periodic internal and external penetration testing of our systems, networks and web properties. We also employ internal security testing solutions and security awareness training for all employees. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We engage a security operations platform provider to assist us in monitoring, assessing and managing potential cyber events. We also perform periodic cyber maturity assessments to measure our cybersecurity profile against industry peers and standards. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;We rely on third parties, including software-as-a-service and platform-as-a-services cloud vendors, for various business functions.  Our third-party services providers have access to our information systems and data, and we rely on such third parties for the continuous operation of our business.  &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;We oversee these third-party&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; service providers by conducting vendor diligence during contracting and onboarding and through ongoing monitoring.  Vendors are assessed for risk based on the nature of their service, access to data and systems, and the level to which those systems and data impact our business. Based on that assessment, we conduct diligence that may include completing security questionnaires, onsite audits, and other technical and data security evaluations.&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_geEKSoFj60eWIsBRZik4cw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;We have adopted &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;processes&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; designed to identify, assess and manage material risks from cybersecurity threats.  Those processes include assessment of, and response to internal and external threats to the security, confidentiality, integrity and availability of our data and information systems, along with other material risks to our operations, at least annually or whenever there are material changes to our systems or operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Our risk management team collaborates with our &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Chief Information Officer (&#x201c;CIO&#x201d;)&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;, our internal information technology (&#x201c;IT&#x201d;) department, our Compliance team and our third-party IT managed service providers to evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.  We have established processes to detect potential vulnerabilities and anomalies through technical safeguards and have adopted policies and procedures around internal and external notification of cybersecurity incidents. Our CIO and IT Department implement processes around security monitoring and vulnerability testing.  We also have in place an incident response process for responding to and escalating cybersecurity events and incidents.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;As part of our risk management process, we &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;engage outside providers&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; to conduct periodic internal and external penetration testing of our systems, networks and web properties. We also employ internal security testing solutions and security awareness training for all employees. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We engage a security operations platform provider to assist us in monitoring, assessing and managing potential cyber events. We also perform periodic cyber maturity assessments to measure our cybersecurity profile against industry peers and standards. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;We rely on third parties, including software-as-a-service and platform-as-a-services cloud vendors, for various business functions.  Our third-party services providers have access to our information systems and data, and we rely on such third parties for the continuous operation of our business.  &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;We oversee these third-party&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; service providers by conducting vendor diligence during contracting and onboarding and through ongoing monitoring.  Vendors are assessed for risk based on the nature of their service, access to data and systems, and the level to which those systems and data impact our business. Based on that assessment, we conduct diligence that may include completing security questionnaires, onsite audits, and other technical and data security evaluations.&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_WnYH_eH_W0aA-v33lnW53Q">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_JlJ0qb8ggUCw_BCOr1VEUA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Our risk management team collaborates with our &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Chief Information Officer (&#x201c;CIO&#x201d;)&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;, our internal information technology (&#x201c;IT&#x201d;) department, our Compliance team and our third-party IT managed service providers to evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.  We have established processes to detect potential vulnerabilities and anomalies through technical safeguards and have adopted policies and procedures around internal and external notification of cybersecurity incidents. Our CIO and IT Department implement processes around security monitoring and vulnerability testing.  We also have in place an incident response process for responding to and escalating cybersecurity events and incidents.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_fWUFsJWvb0uhbLSRTwplgQ">&lt;span style="font-size:10pt;"&gt;Chief Information Officer (&#x201c;CIO&#x201d;)&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_eL6Zii9EEE2oKoV1yLrdtQ">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_J4pzx0o7GUeXX2hxJDE6kA">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_K6VQyQ3xzUyzzqgRHjr_2w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Our Board of Directors provides oversight of the Company&#x2019;s cybersecurity risk management program and integrates this oversight into its overall evaluation of enterprise risk. Our &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Audit Committee&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; has primary responsibility for oversight of cybersecurity and is briefed on cybersecurity risks at least once each year and following any material cybersecurity incidents.&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;At the management level, our cybersecurity program is managed by our &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;CIO&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, reporting into the executive leadership team. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Our CIO has over 30 years of experience managing IT operations and cybersecurity within the pharmaceutical, biotechnology and high-tech industries.&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Our &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;CIO reports at least annually to the Audit Committee&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; and such reporting includes an overall assessment of compliance with our cybersecurity policies and procedures as well as topics that may include risk assessments, risk management and control decisions, service provider arrangements, test results, security incidents and responses and recommendations for changes and updates to policies and procedures. In the event of a cybersecurity incident, the CIO reports the incident to the executive leadership team. If the cybersecurity incident is determined to be material, the executive leadership team will report the incident to the Audit Committee or Board of Directors as appropriate.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_hgxF2-PzzUaAHyexU5l1tQ">&lt;span style="font-size:10pt;"&gt;Our Board of Directors provides oversight of the Company&#x2019;s cybersecurity risk management program and integrates this oversight into its overall evaluation of enterprise risk. Our &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Audit Committee&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; has primary responsibility for oversight of cybersecurity and is briefed on cybersecurity risks at least once each year and following any material cybersecurity incidents.&lt;/span&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_WszhNT3VEkiJ-yUFuIbYng">&lt;span style="font-size:10pt;"&gt;Audit Committee&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_qMmwXg5RGEe9L28txtrmWw">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_TdjtE6vAsUyCq8DpTCNa9g">&lt;span style="font-size:10pt;"&gt;Our CIO has over 30 years of experience managing IT operations and cybersecurity within the pharmaceutical, biotechnology and high-tech industries.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_tcS-QGtMh0eSiHcxwKPzyQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Our &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;CIO reports at least annually to the Audit Committee&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; and such reporting includes an overall assessment of compliance with our cybersecurity policies and procedures as well as topics that may include risk assessments, risk management and control decisions, service provider arrangements, test results, security incidents and responses and recommendations for changes and updates to policies and procedures. In the event of a cybersecurity incident, the CIO reports the incident to the executive leadership team. If the cybersecurity incident is determined to be material, the executive leadership team will report the incident to the Audit Committee or Board of Directors as appropriate.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_oC0jAy0WCEW4bTIwJnnDFA">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_LT4ELb8k30mKPowqfzl6dQ">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_VLVZYCM5jEOpph7iiGFkcA">42</dei:AuditorFirmId>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_9WuRZ5oiCEytQ-4llKR_8g"
      id="Narr_AVgM4ZKXFEWKph9EyYIMuQ">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_9WuRZ5oiCEytQ-4llKR_8g"
      id="Narr_-DQSGDa_6EeuJQfpuyJPYA">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_9WuRZ5oiCEytQ-4llKR_8g"
      id="Narr_bx2Q_gm7HUSCmYB5iVTJ3A">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_9WuRZ5oiCEytQ-4llKR_8g"
      id="Narr_rgjSmPUeM0yx4NL5SftwJg">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_7bmOI-zq8k6yFCWGM7R-0Q">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorName
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_7J1YrTvk3U29ZEv6NLGayg">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr__rcKIJ-UYk2s7pOF4Px-Lg">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_BkuOBXgIKk-lwd-8UStJ-A_6_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">204990000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_lFF6pNJQdUKUQAri1sGfew_6_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">88818000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNet
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_drdGd5IhGkSAZClrwpppkw_7_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">8813000</us-gaap:AccountsReceivableNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_Hcvw8XBzqEaIW_82cJU9ig_8_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1833000</us-gaap:InventoryNet>
    <vstm:GrantsReceivableNet
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_9LNC0aUIS0uiXKgzcTHU7w_9_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">200000</vstm:GrantsReceivableNet>
    <vstm:GrantsReceivableNet
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_DVBFz1Bx5UWz_dk4fpnT4Q_9_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">200000</vstm:GrantsReceivableNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_0jGb1DcGqUKcOlajNEInUg_10_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7577000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_Nw9N93BBkkuuPW7tZffm4g_10_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5943000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_svwWKDFmn0yv23lBmq8oag_11_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">223413000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_l2AkSoKreE-81GdG10vNsA_11_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">94961000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_dDPuckJ6PkawP8s3APXx6Q_12_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">32000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_9OxMcI1wUEq6q4-pA0bLNQ_13_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">491000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_3Bj25nz6k06tYoaYCk3xPg_13_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1405000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_AQV_WPzmNUOi1m8T3PPfwg_14_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">241000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_kWm3dXsFFEGQr5xp5IbUkQ_15_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">16426000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_sGl21-3pCUqLVoyElTvlFA_16_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6112000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_X0QICoi5-kSWE0n7iio8Pw_16_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4899000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_N0eWcn-mGEm1V_xhIepSfg_17_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">246442000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_5IYyhQo5WUSH99lcPbMEsw_17_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">101538000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_hdsRu5U_iUiqWawXzOABlA_20_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">12448000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_jf2RGVA8_0CiHaxv8bA_BA_20_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4026000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_O2moTwH3gEKPOpQIPLjzSQ_21_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">53981000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_Nt8aKqa8IEOHTjSLXZA6Og_21_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">25952000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:SupplierFinanceProgramObligationCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_V0E30_AKAkq3hNRRgl3AmA_22_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5304000</us-gaap:SupplierFinanceProgramObligationCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_pBBraDUXjku-TJERlDfsJA_23_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">535000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_vjLBl1WO3U-eU77DZC4u8A_23_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">995000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_MQQZVRgwJ0mYkU0j5ih6uA_24_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">72268000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_PD7eFwGuSUaLoxoLhHlCYQ_24_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">30973000</us-gaap:LiabilitiesCurrent>
    <us-gaap:SecuredLongTermDebt
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_vyGFRZ6UOkmuW1MJpW-XSQ_26_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">76330000</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_LI4gcbiat0qSb3Mwp_yyaA_26_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">40724000</us-gaap:SecuredLongTermDebt>
    <us-gaap:SupplierFinanceProgramObligationNoncurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_GgvtH9960EKd8BaQi7bzTw_27_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5000000</us-gaap:SupplierFinanceProgramObligationNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_Ri2dI3V1P0GM-Ov5XxL1RQ_28_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">535000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_eQTa6-n_QUSWJwz4gubVVQ_29_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">35647000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_ID4Yqv7YrEmQpaR7foHOaw_29_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">58199000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_jMj8G9O-5kC51l4zk3gbLQ_30_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">189245000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_xVBNLGvIT02fq3opyHNKAw_30_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">130431000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_seqv11hd7kGtRU21nUUodw"
      decimals="4"
      id="Narr_7StbHx7kyE2UtWJwQkE8lw"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_edm9qWQjT0uGo3Ul1o6KTA"
      decimals="4"
      id="Narr_iBFGWlhA_0ioC7HBxtjcLA"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <vstm:PreferredStockSharesDesignated
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_edm9qWQjT0uGo3Ul1o6KTA"
      decimals="-3"
      id="Narr_Ts9bGgaOWEy3xIu2Il6ICQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">944000</vstm:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_edm9qWQjT0uGo3Ul1o6KTA"
      decimals="-3"
      id="Narr_gkS04_bz30-LlkfquD8WRA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_FENbJ6e8LUCyQO0RcrlfFw"
      decimals="4"
      id="Narr_ASYqUqOIj0Sbuksd46TriA"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_8jcz-NhL0EGmNv5s7ylAMg"
      decimals="4"
      id="Narr_yeoXWcyuTUajPf_76GboXg"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_FENbJ6e8LUCyQO0RcrlfFw"
      decimals="-3"
      id="Narr_M9g8S88UyUStP8iRv-2KsA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_8jcz-NhL0EGmNv5s7ylAMg"
      decimals="-3"
      id="Narr_VD_j32MToEOwAIPyCr_G3w"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_1iNwjL1LvUC8CJz-JY9pGg"
      decimals="4"
      id="Narr_2qB-kSZqmUu48zr4pwEZFQ"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_s_eRJ_IM-EC5I5guhHo3NA"
      decimals="4"
      id="Narr_NF_6AovDFkaZLuTgHrWz7g"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_s_eRJ_IM-EC5I5guhHo3NA"
      decimals="INF"
      id="Narr_SJN-SONdx0KJpjyXttoLkw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_1iNwjL1LvUC8CJz-JY9pGg"
      decimals="INF"
      id="Narr_Mp-9XYds-UyUgW7aT2ezlQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_s_eRJ_IM-EC5I5guhHo3NA"
      decimals="INF"
      id="Narr_Z6iWZjBWg0-Uxh0ZYsDLlg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_s_eRJ_IM-EC5I5guhHo3NA"
      decimals="INF"
      id="Narr_wtOHY_8Ji0m1I-CSjGilkg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_1iNwjL1LvUC8CJz-JY9pGg"
      decimals="INF"
      id="Narr_ly308anebUGzAkOAEMAuVA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_1iNwjL1LvUC8CJz-JY9pGg"
      decimals="INF"
      id="Narr_seRc-c_CPUG4GI91ah759w"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="4"
      id="Narr_MQs_U7zWH0SPHc2ddF9u5A"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="4"
      id="Narr_0iC9oiKnHEiidhctatDIuA"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Narr_4oVthLFd6EGUV7B60uoRIg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Narr_tV8BpZRUs02HQ3SdJV8q8w"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Narr_4qVoqmVo60e0gztXQ4RNsA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">77740000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Narr_KWtryN6_VEOt9XfUbOxDMw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">44784000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_QhpXh2jGC0K9bYjd3So1qA_36_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_BMh7B1A6TEa8_oqlDglLiw_36_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_iPx4944-7U2ocV2KStqzzA_37_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1216958000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_eec50A0dBUyXpXc19bHGtA_37_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">926630000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_pblSO3hnWkCkIyk5VJm4lQ_38_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5229000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_cQoHA-KBH0uAZlCy0TMrvQ_39_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-1164998000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_hJPfC4o_sUSFKn91fQUg5w_39_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-955527000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_2Or6VaKd_E6kv3JDY9dv_A_40_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">57197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_PyX1OIld9kyD8LOvmHO1-g_40_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-28893000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_9kIzj_0rKkeSGAbgS4aXLQ_41_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">246442000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_vhTRI6TAFUezdF2ehpi-lA_41_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">101538000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_LArOb7j6NEaAnMIYXIPzkQ"
      decimals="-3"
      id="Tc_FPZa2ZIXeEmLKBx-Zt4bhw_4_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">30914000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_HA-hUtbuQkSrDIYOaGPRyw"
      decimals="-3"
      id="Tc_RoR3AhiUuUaeZbsrvDUXww_5_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_uNkt7ECQo0azu-N13Jcr3A_6_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">30914000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_KfOX6GHV10aucbxeSjpQag_6_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">10000000</us-gaap:Revenues>
    <vstm:CostOfGoodsSoldExcludingAmortization
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_4ULroi5tAkK4B2hnLoeeww_8_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4600000</vstm:CostOfGoodsSoldExcludingAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_LddFVfspP0OIS_KcoN2dHA_9_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">698000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_V9T1lu02CUWe_8OABJbadw_10_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">114599000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_pm1kOU93vU2nSlhveVsi7g_10_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">81334000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_H9azphMTcEGJRlwy4QpJfw_10_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">61356000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_TSMumxh9gEW_8NvdOI7ZCA_11_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">81146000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_ASfUJzrEr0i0PbLUMqmcyA_11_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">43622000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_PmrU3BxRDUyHgaYBVjemoA_11_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">30728000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_gPrO0pIsYE6YbwBX-AOTQQ_12_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">201043000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_05vluhis1UyaUcLexd7DTw_12_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">124956000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_Xfso6RcCSUqFCfDrgqcQ2A_12_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">92084000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_WApXnh0WQUafkB8DBSOQKA_13_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-170129000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_tVVEy1KPmU60mBczTW-lZQ_13_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-114956000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_IQ_K1nJhtUCfxmOkK08ogQ_13_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-92084000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_1bDeAKAA20eGPjXXX7JILw_14_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-203000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_xnu2pF2w00W2MAw0Nqa6SA_14_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-123000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_35jhi3ghLUmNeKoX8fimcw_14_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-109000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_wbm5QtHwhkKTcIsjT8K4Ag_15_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4068000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_LjdYM1D0tECa3iFdDlbi1A_15_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4149000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_Sw2NYtksLUqqYP-ODyj8yQ_15_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6214000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_-xglPlUj-Eyu6zfZYytdiQ_16_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1138000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc___Y3dh2mfkq1axLs-GleTQ_16_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4562000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_YfNcIjbqk06TeJrsn_vzCA_16_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4139000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_CC2Cr0Hx0UWhjZb8mVewbA_17_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-1826000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <vstm:IncomeLossFromPreferredStockTrancheLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_9Tn3DHBASEuAaQ7zkEYDYA_18_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4189000</vstm:IncomeLossFromPreferredStockTrancheLiability>
    <vstm:IncomeLossFromPreferredStockTrancheLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_epZTKzTiw0Shw45v6csgzA_18_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2751000</vstm:IncomeLossFromPreferredStockTrancheLiability>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_OoAp1reShkOxy-G9dn9wUw_19_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">27492000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_Pd1qBM0SXE-Qqjo0Lhom6w_19_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">19149000</us-gaap:FairValueAdjustmentOfWarrants>
    <vstm:FairValueAdjustmentOfNotes
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc__9H1VnOiWkW98BA3_GSzYg_20_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">12751000</vstm:FairValueAdjustmentOfNotes>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_OeZPjaFGkUKrMUsS5_mm_w_21_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-209471000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_BFObnxRZ-EWK2IkH4j6zUA_21_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-130452000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_rXP3ehx-n0Kn_0xuYpLz_w_21_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-87367000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_1Se-IVy-Y0qn_Sk4Gd0lew_22_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">185000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_zeLpv87N3EyG9n5CtJ1t9g_23_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-209471000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_1k-RD6M9AkGsSHI4NB5guA_23_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-130637000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_99lji8rq8U6KtcUq45r_Ag_23_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-87367000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="2"
      id="Tc_oEPzmFXkd0KU5fYbhbZ81w_24_4"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">-3.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="2"
      id="Tc_oEPzmFXkd0KU5fYbhbZ81w_24_4_2"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">-3.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="2"
      id="Tc_-l3WKQcGjEeINW-AlKuGJg_24_7"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">-3.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="2"
      id="Tc_-l3WKQcGjEeINW-AlKuGJg_24_7_2"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">-3.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="2"
      id="Tc_5587DH55s0KCIUcW__ypwA_24_10"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">-3.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="2"
      id="Tc_5587DH55s0KCIUcW__ypwA_24_10_2"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">-3.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_FokHkR7e_k6SVr_Sv9Trtw_26_4"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">69309000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_FokHkR7e_k6SVr_Sv9Trtw_26_4_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">69309000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_NeWFg4qI7UKfanuksqgB4w_26_7"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">35713000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_NeWFg4qI7UKfanuksqgB4w_26_7_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">35713000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_JH3lKKLVR0Ok7t_D3lJ_lw_26_10"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">22054000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_JH3lKKLVR0Ok7t_D3lJ_lw_26_10_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">22054000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_rwx1s5lcSk673BiYu4185Q_28_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-209471000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_OExwCtJQp0K9M38RM5TDFw_28_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-130637000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_s1Ancd16aE6iNJiIragENA_28_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-87367000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_r7sMrE4E70-xC7yv8q3Wyw_29_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-13000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_tt3C8VShV0Gxz0MTDhJ0kA_29_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">13000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <vstm:FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_FukEbAk7qEWDjqhL9u7-TA_30_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-5229000</vstm:FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_uiBZuFAitUyW8ejU5eqOsQ_31_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-204242000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_c_qxXKF9Qka5eyDxdSCpBA_31_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-130650000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_TZqa-sDaMUe7O6RTVSQULw_31_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-87354000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Y_mwN22A6kGbxpRR-EAdLw"
      decimals="INF"
      id="Tc_tWq-eW51bUKbWAfu-a4KAw_6_8"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1000000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_V_Epz3gmqU27y1VxbWmrEQ"
      decimals="INF"
      id="Tc_XWCM9PpbKEOieGagFvFfAQ_6_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">16711761</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_V_Epz3gmqU27y1VxbWmrEQ"
      decimals="-3"
      id="Tc_QIGRV722bESvriY0wUFouA_6_16"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ASFttFVznUOS8yMRpJAbxg"
      decimals="-3"
      id="Tc_Zo8MkSXGl0yhFcGhyKaqAw_6_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">784912000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lrgQGYbzQEm9cGGsaWCIRg"
      decimals="-3"
      id="Tc_DeSBPuSQkkC_Yh4rZR0yXg_6_25"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-737523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_z5GNzJxej0aeNGqmRjwWLg"
      decimals="-3"
      id="Tc_pi9y5KBIqk-Z0Y6LbpP1kQ_6_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">47391000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yQk4kITunkGYKm5hIqAzWQ"
      decimals="-3"
      id="Tc_Xmu5rLHmQEmXDpE6G_7Thg_7_25"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-87367000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_spT7QvgklUeOw_jk1byisw_7_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-87367000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_NfyaVSuOXEOBvk_0IuL8CA"
      decimals="-3"
      id="Tc_GUYb7yCsrUeLeS8UTqfJfQ_8_22"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">13000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_wPOs7h3WxEioa88LzGmhAw_8_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">13000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_6SeiJlC4WkGCPvAYgU6Y5w"
      decimals="-3"
      id="Narr_fH0HSJbpZ0GqrKbsiH9svw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1901000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <vstm:IssuanceOfPreferredStockTrancheLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Narr_RThfjA-XUke9xmfkFe7mcA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6940000</vstm:IssuanceOfPreferredStockTrancheLiability>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_644V0cfv3U-29Mjt5jpGcg"
      decimals="INF"
      id="Tc_s_4rJN7F3EmJN2X3DN4A6Q_9_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_644V0cfv3U-29Mjt5jpGcg"
      decimals="-3"
      id="Tc_vI9cJOawDkq6C-45GHe9qQ_9_5"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">21159000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Narr_NWcBHi9lKUSfhsSxeHCddA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6351000</us-gaap:PaymentsOfStockIssuanceCosts>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4zRDVYOP-0K61PPNI3Uvhg"
      decimals="INF"
      id="Tc_k7oYWN9jHEyNlQiTSNNWTQ_10_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">8489409</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4zRDVYOP-0K61PPNI3Uvhg"
      decimals="-3"
      id="Tc_Xtt1rF5S8kmHOUG7m5kjrg_10_16"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1000</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GZ0fEHkwU0OYcLlJwZ7pfQ"
      decimals="-3"
      id="Tc_8sN-r_jZr06OaQ6FdUQL9A_10_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">91419000</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_va3K-xzzrU2bOLWVH-xVow_10_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">91420000</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4zRDVYOP-0K61PPNI3Uvhg"
      decimals="INF"
      id="Tc_FKxIWK-7aE6440ahYTqpWw_11_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">14270</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GZ0fEHkwU0OYcLlJwZ7pfQ"
      decimals="-3"
      id="Tc_kmOSulKHGEiTXvxV1DB3Aw_11_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">57000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_6EA2TPDQWUS1a9RuuVfOzw_11_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">57000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4zRDVYOP-0K61PPNI3Uvhg"
      decimals="INF"
      id="Tc_oMXVzuhPy0eMsWN4WrIgfQ_12_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">65710</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GZ0fEHkwU0OYcLlJwZ7pfQ"
      decimals="-3"
      id="Tc_-kLp4by7AkCAL1fVAVXH7A_13_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5860000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_k9JyExpDHkGOdxvzYhZUZw_13_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5860000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ba-9SwGbmkucpagN-WsZYg"
      decimals="INF"
      id="Tc_GsZOhepio0Cv56vD90iS1w_14_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ba-9SwGbmkucpagN-WsZYg"
      decimals="-3"
      id="Tc_EtYPNUnay0eehaQcC-SyZw_14_5"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">21159000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_rXXFIzj9hUybe-4ngReB2A"
      decimals="INF"
      id="Tc_OakRvXkkkkaUJJkqUlwCHA_14_8"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1000000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_W4v_8l5EHEOk8tW_t3-29w"
      decimals="INF"
      id="Tc_VQuLsAU6AU-hCAGsJ4OgEA_14_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">25281150</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_W4v_8l5EHEOk8tW_t3-29w"
      decimals="-3"
      id="Tc_VWDQvJ7Pxk6vCjQX0agoig_14_16"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C6prOwECYEmM37Ntixav9g"
      decimals="-3"
      id="Tc_gEH5XOg0kES7x09eTdBbOA_14_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">882248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8HWoELe-FUKs4q6zosK0_w"
      decimals="-3"
      id="Tc_ZoZrg-g11E2n2f80GOCSdA_14_22"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_w551gdo2ok6ZEMwgbJunYg"
      decimals="-3"
      id="Tc_IdyHjCcIqkmQ6M0olVnevA_14_25"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-824890000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_Uyhdm4_rYEOg-NEKFqTeBA"
      decimals="-3"
      id="Tc_m6j9z8YebEm_AdEXYDvykA_14_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">57374000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TtA8P5RxPEqhMQS4CQul_w"
      decimals="-3"
      id="Tc_pfpXm33lgESu06Ph3SYhJw_15_25"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-130637000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_8CUzJkAcKEejgdc9hTUtyQ_15_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-130637000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_h5EVJwZSEkaojEFbMUpw3A"
      decimals="-3"
      id="Tc_9JgKhHEFl0e_lv6OMesfLg_16_22"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-13000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_M2dNgYrKxU-43JSF3QSpHw_16_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-13000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Nx7kZA6zXkqD1bBA5afBeQ"
      decimals="-3"
      id="Narr_Ff-4_H1gckGJ-4CY7PUoTQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1179000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA"
      decimals="INF"
      id="Tc_GIkw3O6QGUWe9nMcEXGSvQ_17_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">13333334</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA"
      decimals="-3"
      id="Tc_gfXqdkcKS0yEUZhJ9FubgQ_17_16"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1000</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_smxFsQJeIEe8LC1hRLDuYQ"
      decimals="-3"
      id="Tc_4Ma4o9tPS0mwqFfEMtaryA_17_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">14220000</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_5QpuRHp-rUaYEF8NEkb2xg_17_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">14221000</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_TAPCsw8lgkWIgfJ_mbgurQ"
      decimals="INF"
      id="Tc_CQ0WL4DhtEyeKUyw_VVJfA_18_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">-1200000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_TAPCsw8lgkWIgfJ_mbgurQ"
      decimals="-3"
      id="Tc_9klHhRg900qC_yOoWoNV8g_18_5"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-21159000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA"
      decimals="INF"
      id="Tc_U1UChWSujE6ILbEbLqCdKA_18_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">4236568</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_smxFsQJeIEe8LC1hRLDuYQ"
      decimals="-3"
      id="Tc_TByRptbo80OkZ83W1LN4RA_18_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">21159000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_eb4a3mcbWE66diW2LjAgxg_18_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">21159000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <vstm:SharesIssuedFromPreFundedWarrantExercises
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA"
      decimals="INF"
      id="Tc_nfaWqWU010WF5yvaUvf_2w_19_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1538201</vstm:SharesIssuedFromPreFundedWarrantExercises>
    <vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA"
      decimals="INF"
      id="Tc_NcafDQeG0EyCU02FfEwmSQ_20_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">250000</vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <vstm:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_smxFsQJeIEe8LC1hRLDuYQ"
      decimals="-3"
      id="Tc_0psg2GeG9UGRozI873lPVA_20_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-1420000</vstm:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <vstm:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_r7bU_vmQp0SjJXkVJk1wug_20_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-1420000</vstm:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA"
      decimals="INF"
      id="Tc_bOmi8qx7sUW-pGyCotL2EQ_21_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">21978</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_smxFsQJeIEe8LC1hRLDuYQ"
      decimals="-3"
      id="Tc_pRR1rYuHekS9eOXYt6vxag_21_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">172000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_BHLUuJdWLUmnR6ro1nQdvQ_21_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">172000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA"
      decimals="INF"
      id="Tc_TB3jtnX2sESijtU_gQiGhQ_22_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">15231</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_smxFsQJeIEe8LC1hRLDuYQ"
      decimals="-3"
      id="Tc_sEYPhAIZb0OPY6KPJAzUHw_22_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">69000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_OxjHb6Wpw0GsK6N5W8R9sQ_22_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">69000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dWQSNbHri0qjQ6yCba30oA"
      decimals="INF"
      id="Tc_OSNmMdXMy0ySK3TNFF7MlQ_23_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">107888</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_smxFsQJeIEe8LC1hRLDuYQ"
      decimals="-3"
      id="Tc_Xg3RLobkTUuIBp9Sxm0vjQ_24_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7342000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_w6w9qwj97EegXrHUMhE7ug_24_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7342000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_y9BYeLeimkGfbgD3G1n6_A"
      decimals="INF"
      id="Tc_FcsSWdJpX0ygBi16mKNqCg_25_8"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1000000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IVIVyZ8H2UGZjpXhTwRvWw"
      decimals="INF"
      id="Tc_5mwnpfx6pUeGdJM9pDXhzA_25_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">44784350</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IVIVyZ8H2UGZjpXhTwRvWw"
      decimals="-3"
      id="Tc_qojBVt3il0GiiZN-lInB2Q_25_16"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NDL3BYU3PUuJd3uSXk_5qA"
      decimals="-3"
      id="Tc_jSpkCLBqSU2BBPaq3pxaXg_25_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">926630000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xiIip57Oi0ehdHOXQBNQkQ"
      decimals="-3"
      id="Tc_lnHbd9OHg0KkFqFdhnsSEQ_25_25"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-955527000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_8M4cV9D5cUSCWUV0iFXmWg_25_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-28893000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-Ba5ewoa3EWicqSM_lHMtQ"
      decimals="-3"
      id="Tc_fuOh_BtcZkW7PnEK5aY5_g_26_25"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-209471000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_p305RP2C1EC13R7xZsj9tw_26_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-209471000</us-gaap:NetIncomeLoss>
    <vstm:FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zCbuz_b2rkCKzl31gcidKg"
      decimals="-3"
      id="Tc_qzIYz66TtE6KMYST0QS4_A_27_22"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-5229000</vstm:FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk>
    <vstm:FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_Iqk-ukyu4U-9V0D9TcoqzQ_27_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-5229000</vstm:FairValueAdjustmentOfNotesInstrumentSpecificCreditRisk>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H2d2wIpatEOMddtM_uXHjg"
      decimals="-3"
      id="Tc_uVku1gc_g0ulnmla91jKpQ_28_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">9404000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_w8TklVvuckixeWg0SF78qQ_28_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">9404000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw"
      decimals="INF"
      id="Tc_LHVlL6IXIEiHmgC5w1xZVQ_29_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">16341</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H2d2wIpatEOMddtM_uXHjg"
      decimals="-3"
      id="Tc_Ml1UYgeTJUu2aBA46dJMew_29_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">51000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_-5vv2tGKAkSSk_ZeITozBQ_29_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">51000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw"
      decimals="INF"
      id="Tc_hSWVWtMPNUeZWvJlUIKEgw_30_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">687093</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw"
      decimals="INF"
      id="Tc_WcepCGAP50yAzQmrUkAsOg_31_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">9654168</vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <vstm:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw"
      decimals="-3"
      id="Tc_fkDFfRXCfkWUcXEqrGS4tA_31_16"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-1000</vstm:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <vstm:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H2d2wIpatEOMddtM_uXHjg"
      decimals="-3"
      id="Tc_9M_ScUUXYUqYG9MMm38zwQ_31_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-83835000</vstm:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <vstm:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_gO1u_t9Z-kOkX18lSzzCWA_31_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-83836000</vstm:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw"
      decimals="INF"
      id="Tc_YM95tk-jZUSDopZ9uejaBA_32_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">12674</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H2d2wIpatEOMddtM_uXHjg"
      decimals="-3"
      id="Tc_I4COBgYwQ0SfQQqDs7cvBw_32_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">65000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_Rhhx-snlJk6_3r8IMMPMDA_32_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">65000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7MnmvaWWgEePqWQTjdY9HA"
      decimals="INF"
      id="Tc_hxpbt8K-t0-77QoKpvyp9Q_33_8"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">-1000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw"
      decimals="INF"
      id="Tc_AJfBDGXcQ0WxwfWoBBzAZQ_33_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">833332</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <vstm:SharesIssuedFromPreFundedWarrantExercises
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw"
      decimals="INF"
      id="Tc_KbY_UF-H3EW0N-LHAo9vfA_34_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">2499665</vstm:SharesIssuedFromPreFundedWarrantExercises>
    <vstm:StockIssuedDuringPeriodSharesAtMarketTransactions
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw"
      decimals="INF"
      id="Tc_N7yP7LsnO0e5fl4DtjKRaQ_35_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">4000000</vstm:StockIssuedDuringPeriodSharesAtMarketTransactions>
    <vstm:StockIssuedDuringPeriodValueAtMarketTransactions
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw"
      decimals="-3"
      id="Tc_F2CQH6yojk-zX7xpajG24Q_35_16"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1000</vstm:StockIssuedDuringPeriodValueAtMarketTransactions>
    <vstm:StockIssuedDuringPeriodValueAtMarketTransactions
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H2d2wIpatEOMddtM_uXHjg"
      decimals="-3"
      id="Tc_svGuadgzTEWjnJnSeSDEug_35_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">22736000</vstm:StockIssuedDuringPeriodValueAtMarketTransactions>
    <vstm:StockIssuedDuringPeriodValueAtMarketTransactions
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_XkUr-Hr1K0OpSugA47_U3A_35_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">22737000</vstm:StockIssuedDuringPeriodValueAtMarketTransactions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Narr_1OWrT9Fu4UCQkj8KVirRIA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">74000</us-gaap:PaymentsOfStockIssuanceCosts>
    <vstm:StockIssuedDuringPeriodSharesStockPurchaseAgreement
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_I7sRIEusV0KevLEgq_qncw"
      decimals="INF"
      id="Tc_i1vymRu-H0q9AxEdV08SQg_36_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1416939</vstm:StockIssuedDuringPeriodSharesStockPurchaseAgreement>
    <vstm:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H2d2wIpatEOMddtM_uXHjg"
      decimals="-3"
      id="Tc_CXX1YDrSVk6muHkFK-8D4Q_36_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7426000</vstm:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <vstm:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_ZQo6AOIxUESVDxrPxGh62A_36_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7426000</vstm:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_3L8cmMQep0K6q--7_1jqxA"
      decimals="-3"
      id="Narr_hbfVkkd0e0emxW072MVwgg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5072000</us-gaap:PaymentsOfStockIssuanceCosts>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_VeTMKHIwC0eLyAN6WUjVXA"
      decimals="INF"
      id="Tc_isHfBfHiIkyx9AsO_awAkw_37_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">3429287</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_VeTMKHIwC0eLyAN6WUjVXA"
      decimals="-3"
      id="Tc_BrROHLVTLU2--m3RYawBbA_37_16"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1000</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_wgrwxnERa0qwi96U9x_blQ"
      decimals="-3"
      id="Tc_H8K9YAUvs0ajrd-1YHc7Kw_37_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">69932000</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_3L8cmMQep0K6q--7_1jqxA"
      decimals="-3"
      id="Tc_oSHthQIjHkO3ScS7jlqL_w_37_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">69933000</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_jUBqmRoabkGaS293dmEkgw"
      decimals="-3"
      id="Narr_Qnrmlfqco0SP_k38L9rNBg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6617000</us-gaap:PaymentsOfStockIssuanceCosts>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_SkzoBDCVyE253YNoI4hWww"
      decimals="INF"
      id="Tc_TuuC8h7SM0uM_D1482Hc_w_38_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">10405863</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_SkzoBDCVyE253YNoI4hWww"
      decimals="-3"
      id="Tc_QQ1VQhLPpECyb7wz2C1hFw_38_16"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1000</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_Pf0AlvNsAkKhEKrfCVhX9w"
      decimals="-3"
      id="Tc_VdLaT6fDSUaCpnN5Ibg3MA_38_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">96879000</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_jUBqmRoabkGaS293dmEkgw"
      decimals="-3"
      id="Tc_ZMx_3iEj90ifizxJ-zokDQ_38_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">96880000</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MohRnXLqbEGEo5fjQezNRw"
      decimals="INF"
      id="Tc_iS3KjXRrxUu4mzG4bESIOg_39_13"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">77739712</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MohRnXLqbEGEo5fjQezNRw"
      decimals="-3"
      id="Tc_kWXGdS2gh0635vU6dnrnCw_39_16"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fuhD4w1zHUO3JOvClD8XNw"
      decimals="-3"
      id="Tc_qliHnNq1UUSQFNGeElaZrQ_39_19"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1216958000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7Z9PHqH2q0S7RrWVtY151Q"
      decimals="-3"
      id="Tc_57-dGx3Q_Uij5h3B8uDHIg_39_22"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5229000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dp0SN57cD0KXZDKWXesKDw"
      decimals="-3"
      id="Tc_ZEj422Jcvkq5pzKDVJe0HQ_39_25"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-1164998000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_hTuCCvxfh0u1CrDnib6HyQ_39_28"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">57197000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_0SSzR22y0E2OZ1yMWKqdYQ_4_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-209471000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_gIU1VK3xIEWstKMWNf22Jw_4_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-130637000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_ZITObUFFrkmTFL5E-8H11A_4_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-87367000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_qcqgXELq502-9yamdCV-cw_6_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">30000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_ByjUupzhU0SPZ9vlinyxZw_6_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">26000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc__Z5w7iOxfUmhvnrhnnCR0g_6_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">62000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc__Unt3cXEHUG2fQNN4JGebA_7_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">698000</us-gaap:AmortizationOfIntangibleAssets>
    <vstm:OperatingLeaseNonCashCost
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc__fmE771aSUarUSvA5fVUog_8_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-81000</vstm:OperatingLeaseNonCashCost>
    <vstm:OperatingLeaseNonCashCost
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_fOG2ORt-wkCmhvGyHkh1fg_8_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-175000</vstm:OperatingLeaseNonCashCost>
    <vstm:OperatingLeaseNonCashCost
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_HZ9WSXH0IUiGLQM3D3dHzQ_8_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-175000</vstm:OperatingLeaseNonCashCost>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_CWx3ZVq9iUCdmPd-JtjVDg_9_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">9404000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_VEJD7x1kxkSWn8mdOnEedg_9_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7342000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_oUc4UoLIA0qM8r7W26savA_9_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5860000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_XWg6ElZY40eRYRGZp7KMmg_10_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">29000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_vE-VA8qWhEefNEPJOsxibQ_10_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-5000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_czL8QIcEokKJDoeX8Lk_Qw_10_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-1132000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <vstm:ChangeInFairValueOfOfPreferredStockTrancheLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_0Aygby4rt0KbezifCqqIAQ_11_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-4189000</vstm:ChangeInFairValueOfOfPreferredStockTrancheLiability>
    <vstm:ChangeInFairValueOfOfPreferredStockTrancheLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_rGUNjO7spkevSBu0lq16oA_11_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-2751000</vstm:ChangeInFairValueOfOfPreferredStockTrancheLiability>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_NccuQqC2JU6PwjMCg-T4Bw_12_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">27492000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_Jh9TC0XiKkCtd1VzFiBv-w_12_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">19149000</us-gaap:FairValueAdjustmentOfWarrants>
    <vstm:FairValueAdjustmentOfNotesNoncash
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_hhviwa0CzUmJ_Sulae1fVg_13_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6560000</vstm:FairValueAdjustmentOfNotesNoncash>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_zUFr2EZ8WESteR8uvSkF4A_14_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-1826000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_lIf22UU3m0ys6NbaONzoYA_16_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">8813000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_MoQoasyqOU28RyPQRibAHg_16_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-31000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <vstm:IncreaseDecreaseInGrantsReceivableNet
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_vTHmpR2QnUWbcOO55pFuEg_17_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-200000</vstm:IncreaseDecreaseInGrantsReceivableNet>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_RJ2T3AbMW02dq9R3G-ahWg_18_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1833000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_wShj8x_GmkuXleLyKWw1FQ_19_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2605000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_qOBklsmatkOTcPlThLqeYg_19_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">596000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_SxtGzRlimU-VQtWuHLX_Pg_19_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5826000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_OV2wSHebBku8tTwqHyh4HA_20_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">8422000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_xqD3MKJvAU6uz9r_IUvVqA_20_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-3158000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_7nvz1eYGbES6dOhnQCzVnA_20_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2283000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_YcK-fMWw4EiHG8pLi4HPIg_21_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">30833000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_TQqxHna3KkufZrdPk3eTuQ_21_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7999000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_R9aTG3PW2kmFlvxtgNiuTA_21_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2938000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_vQJMjH4cf0CL_kOki3SxnQ_22_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-327000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_lWMt_wsluUORD6GL9fbRxg_22_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-383000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_mCLytG3FUkGeWZIR5WU0og_23_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-137509000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_tb_YI561SU-DBE1wguz5dg_23_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-104771000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_oCn0jl7hMUK6598c4WPzVQ_23_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-86460000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_8JSEJDEj60O_rXXuxwirdg_25_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">28000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_egLAM3383k-eMr5ObfPf-Q_26_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">9624000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_z3BKOazaskyX2S8dJ8rMjg_27_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">96447000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_tw7eykG0L0meVQZ_xqO0fA_28_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">60000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_5wDP5CtwaUKTcC4o4N2RBw_28_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">52000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_mIbYla_iQ0eECLFEjPjUSQ_29_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-9624000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_iaCvXd1dyE6Wa_JrZ2DR3w_29_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">59972000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_bzAmD4deAkSF8Q0sAbOgAQ_29_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-44447000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_DUSkOs5TakOdsvi60RbPhA_31_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">196976000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_WIzo0Hb1HUOVJweHV5RRXg_31_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">14221000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_NT5iW9pkik2Kpzd-dZFERw_31_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">91420000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_ydJ7bY4o5ky6c03ZifM8LA_32_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">39595000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_q8et-cDcUE6kShq3CJ1zIA_33_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">28099000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_9zZgfU0t0kmweHO7CXXreg_34_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">33792000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_ekClTvBDH06U4kOAePA92w_34_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">875000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_L9i0JvIp2Uulmv93fMv-EA_35_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">75000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_7-BmDZRPhUGs_uK945NPDQ_35_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">14918000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_JZM_F0HRNEWCaKndwTrIjw_36_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">42579000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfLoanCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_uU27Efymo0CXOB10m-7-bw_37_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">150000</us-gaap:PaymentsOfLoanCosts>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_Lix7f_muZU-J3jZH1tx1Rw_38_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-300000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <vstm:ProceedsFromInsurancePremiumFinancing
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_TOEpKLUB4E2u_TRR5rwFSw_39_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1180000</vstm:ProceedsFromInsurancePremiumFinancing>
    <vstm:ProceedsFromInsurancePremiumFinancing
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_pTDP15AQZkaLmCALxFgZkQ_39_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1298000</vstm:ProceedsFromInsurancePremiumFinancing>
    <vstm:ProceedsFromInsurancePremiumFinancing
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_gQIecEZH5Euqb_hSrMlZuw_39_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1430000</vstm:ProceedsFromInsurancePremiumFinancing>
    <vstm:PaymentsOnInsurancePremiumFinancing
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_l0Sufz5DcUGW8BYEEwxSaQ_40_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1180000</vstm:PaymentsOnInsurancePremiumFinancing>
    <vstm:PaymentsOnInsurancePremiumFinancing
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_xgkTlYGlxU2U6nBwimBMiA_40_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1298000</vstm:PaymentsOnInsurancePremiumFinancing>
    <vstm:PaymentsOnInsurancePremiumFinancing
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_KdieBc_ujEKgC1VT-ZFyyw_40_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1430000</vstm:PaymentsOnInsurancePremiumFinancing>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_BGYT6B-yQkG2iqqe1QgRsQ_41_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">116000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_gHlDFLDMskyxHn1W_TFhJw_41_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">241000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_3kzVg01cwE-17Pbu-xVYHg_41_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">57000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_5Ygco0InOE-cUDDwTVUYfQ_42_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">263305000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_UdsJbS9b0ESFpAXuFpa2Ew_42_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">54782000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_jAQ3xUsIJE6RuIeJrpyDFQ_42_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">134194000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_i9npdRxKvU6-QjhU1bc6_g_43_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">116172000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_4s0KjEMZOECgTsAfMLWpoQ_43_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">9983000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_tj0rydcPekuhAxAhxpnkjg_43_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3287000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_aLI5p74MTk2BNKcLiRQFBQ_44_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">89059000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_Uyhdm4_rYEOg-NEKFqTeBA"
      decimals="-3"
      id="Tc_RxPyRjaXKEaW7lvLzdusXA_44_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">79076000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_z5GNzJxej0aeNGqmRjwWLg"
      decimals="-3"
      id="Tc_3JbSZzSXGUGkUFekdq6UZw_44_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">75789000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_cMBNSL73AkWvl9EDjFbEJw_45_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">205231000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_I30byK9BBkSLmoxOwpBMVw_45_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">89059000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_Uyhdm4_rYEOg-NEKFqTeBA"
      decimals="-3"
      id="Tc_mb0tZGcnaU65vk_49qWFXg_45_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">79076000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_uXb-DsDuiEeTwx84HrnOjA_47_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6364000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_o5SPG7cR3Uy-S47CvKp8Kg_47_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3774000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_z_HBuQ3xXkO1cWbKuYl4ig_47_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3361000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_heqHyCvMEUantsVzOyXTHw_48_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">185000</us-gaap:IncomeTaxesPaidNet>
    <vstm:IssuanceOfPreferredStockTrancheLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_Ba8FqWDVNUKCa053DjxUWg_50_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6940000</vstm:IssuanceOfPreferredStockTrancheLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_T5EBnN3IvEibTpOjCz9opw_51_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_G2Oq6SjkJEeUFFkQFDoqXQ_52_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">32000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_bPhZieDPSEqAXRDTnngc_A_53_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">21159000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <vstm:FairValueAdjustmentOfWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_EmTK5_V6qkqkYpPFsl4Rew_54_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">50044000</vstm:FairValueAdjustmentOfWarrantsExercised>
    <vstm:FairValueAdjustmentOfWarrantsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_myi5jYo6MUS9yK6PPG0l4g_54_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">545000</vstm:FairValueAdjustmentOfWarrantsExercised>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_CLmZubx_AEq2NVuYsLCsjQ_55_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">988000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_TvfDxgGB5UuLCZmeQculJQ_56_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7500000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_5hdxbLf36k6bqkhfmJMERg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1. Nature of business&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Verastem, Inc. (the &#x201c;Company&#x201d;)&lt;span style="background:#ffffff;"&gt; is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with &lt;/span&gt;challenging RAS/MAPK pathway-driven cancers. The Company markets AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the U.S., the first treatment specifically FDA-approved for adults with KRAS-mutated recurrent LGSOC who have received prior systemic therapy. AVMAPKI FAKZYNJA CO-PACK received accelerated approval in the U.S. on May 8, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s pipeline is focused on novel small molecule drugs developed both as monotherapy and in combination, which inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including targeting RAS directly with KRAS G12D inhibition, targeting the pathway downstream with RAF/MEK inhibition, and targeting the parallel pathway that drives resistance with FAK inhibition. The Company&#x2019;s focus is to expeditiously develop and deliver transformative therapies that truly change outcomes for people living with RAS/MAPK pathway-driven cancers. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements include the accounts of Verastem Securities Company and Verastem Europe GmbH, wholly-owned subsidiaries of the Company.&#160;All financial information presented has been consolidated and includes the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to the risks associated with other life science companies, including, but not limited to, possible failure of preclinical testing or clinical trials, competitors developing new technological innovations, commercial success of the Company&#x2019;s marketed product AVMAPKI FAKZYNJA CO-PACK, inability to obtain marketing approval of the Company&#x2019;s product candidates, market acceptance and commercial success of the Company&#x2019;s product candidates following receipt of regulatory approval, and, protection of proprietary technology and the continued ability to obtain adequate financing to fund the Company&#x2019;s future operations. Until such time, if ever, that the Company can generate substantial product revenues or achieve profitability, it may need to raise additional capital.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025, the Company had cash and cash equivalents of $205.0 million and an additional $29.4 million in proceeds in January 2026 from the exercise of Warrants (see &lt;i style="font-style:italic;"&gt;Note 20. Subsequent Events&lt;/i&gt;). &lt;span style="background:#ffffff;"&gt;In accordance with applicable accounting standards, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within 12 months after the date of the issuance of these consolidated financial statements. &lt;/span&gt;The Company expects its existing cash resources, including the proceeds from the exercise of Warrants in January 2026, along with revenue it expects to generate from sales of AVMAPKI FAKZYNJA CO-PACK and the availability to draw down $25.0 million under the Second Purchase (defined herein) pursuant to the Company&#x2019;s Note Purchase Agreement (defined herein) (see &lt;i style="font-style:italic;"&gt;Note 8. Long-term debt&lt;/i&gt;) will be sufficient to fund its planned operations through 12 months from the date of issuance of these consolidated financial statements. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, the Company had concluded that there was substantial doubt about its ability to continue as a going concern primarily due to anticipated operating losses for the foreseeable future since the Company did not yet have regulatory approval to sell any of its product candidates, and the Company continued to incur operating costs to execute its strategic plan, including costs related to research and development of its product candidates and commercial readiness activities. The Company&#x2019;s increased cash and cash equivalents position as of December 31, 2025, forecasted net product revenue following regulatory approval of AVMAPKI FAKZYNJA CO-PACK on May 8, 2025, and ability to draw down on the Second Purchase pursuant to the Note Purchase Agreement, alleviated the substantial doubt. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company expects to finance its operations with its existing cash and&#160;cash equivalents, through revenue generated from sales of AVMAPKI FAKZYNJA CO-PACK, through potential future milestones and royalties received pursuant to the Company&#x2019;s Asset Purchase Agreement (&#x201c;Secura APA&#x201d;) with Secura Bio, Inc. (&#x201c;Secura&#x201d;), note drawdowns pursuant to the Note Purchase Agreement, or through other strategic financing opportunities that could include, but are not limited to collaboration agreements, future offerings of its equity, or the incurrence of debt. However, there is no guarantee that any of these strategic or financing opportunities will be executed or executed on favorable terms, and some could be dilutive to existing stockholders. If the Company fails to obtain additional future capital or generate sufficient net product revenue, it may be unable to complete its planned preclinical studies and clinical trials and obtain approval of certain investigational product candidates from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) or foreign regulatory authorities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reverse Stock Split&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:14pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;On May 30, 2023, the Company filed a Certificate of Amendment to the Company&#x2019;s Restated Certificate of Incorporation, as amended to date, with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company&#x2019;s issued and outstanding common stock, par value &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.0001&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;at a ratio of&#160;&lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_mxFYjHBtZEODqcY96vbZbg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1-for-12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;(the &#x201c;Reverse Stock Split&#x201d;), as authorized at the Company&#x2019;s 2023 annual meeting of stockholders held on May 15, 2023. The Company effected the Reverse Stock Split on May 31, 2023. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise were entitled to a fractional share of common stock were entitled to receive a price equal to the closing price of the common stock on the Nasdaq Capital Market on the date immediately preceding the Reverse Stock Split, as adjusted by the ratio of&#160;&lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_UDYzqQ6S1E630AMzLLYW3A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;share of common stock for every 12 shares of common stock, multiplied by the applicable fraction of a share. The number of shares of common stock that the Company is authorized to issue remains at&#160;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;300,000,000&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;shares and the par value of its common stock remains unchanged at &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.0001&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;The Company has retroactively restated the share and per share amounts in the consolidated financial statements for the year ended December 31, 2023, to give retroactive effect to the Reverse Stock Split. The consolidated statements of convertible preferred stock and stockholders&#x2019; equity reflect the impact of the Reverse Stock Split by reclassifying from &#x201c;common stock&#x201d; to &#x201c;additional paid-in capital&#x201d; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split the year ended December 31, 2023.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-5"
      id="Narr_s6erLGsY80GbHzVhGoRqmw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">205000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7S9Co7osyUKPh1S2Fr2wNQ"
      decimals="-5"
      id="Narr_vcVDVSg3aE-Dk4erlVP0Gw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">29400000</us-gaap:ProceedsFromWarrantExercises>
    <vstm:DebtInstrumentIssuanceOfAdditionalNotes
      contextRef="As_Of_12_31_2025_srt_StatementScenarioAxis_vstm_SecondSaleMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_1vwgf71uzE-hN_Nsosf5bQ"
      decimals="-5"
      id="Narr_ztsTd6dt1Eur941rvZ3eRA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">25000000</vstm:DebtInstrumentIssuanceOfAdditionalNotes>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_5_30_2023_us-gaap_TypeOfArrangementAxis_vstm_CertificateOfAmendmentMember_Q_y7EUi3X0K_kq-y8s1gbw"
      decimals="4"
      id="Narr_NcSiU9W8i02x7FSS8iTUiA"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_5_30_2023_us-gaap_TypeOfArrangementAxis_vstm_CertificateOfAmendmentMember_Q_y7EUi3X0K_kq-y8s1gbw"
      decimals="INF"
      id="Narr_mw0C8Odav02DyDt1Df5bTw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_5_30_2023_us-gaap_TypeOfArrangementAxis_vstm_CertificateOfAmendmentMember_Q_y7EUi3X0K_kq-y8s1gbw"
      decimals="4"
      id="Narr_G2U-4tOEYUOUFXjTznRIxg"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_vWyN4-5fukus7nNiyj-pYw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2. Significant accounting policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Basis of presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) under the assumption that the Company will continue as a going concern for the next 12 months. Accordingly, they do not include any adjustments that might result from the uncertainty related to the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Use of estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The preparation of the Company&#x2019;s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including but not limited to estimates related to revenue recognition, accrued and prepaid clinical trial expense and other general accruals, stock-based compensation expense, long-term debt, and its warrant liability. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable. Actual results could differ from such estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Segment and geographic information&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available and regularly reviewed by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;one operating segment, which is the business of researching, developing and commercializing drugs for the treatment of patients with cancer. All material long-lived assets of the Company reside in the U.S.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Proceeds from grants&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;In May 2022, the Company was awarded the &#x201c;Therapeutic Accelerator Award&#x201d; grant from Pancreatic Cancer Network (&#x201c;PanCAN&#x201d;) for up to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$3.8&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;million (the &#x201c;&lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_q90ZIR8th0OGZ8dK-5vu4A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PanCAN Grant&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#x201d;). In August 2022, PanCAN agreed to provide the Company with an additional &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.5&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;million for the collection and analysis of patient samples. The grant is supporting a Phase 1b/2 clinical trial of GEMZAR (gemcitabine) and ABRAXANE (Nab-paclitaxel) in combination with avutometinib and defactinib entitled RAMP 205. The RAMP 205 trial is evaluating whether combining avutometinib (to target KRAS mutant, which is found in more than 90% of pancreatic adenocarcinomas), and defactinib (to reduce stromal density and adaptive resistance to avutometinib) to the standard GEMZAR/ABRAXANE regimen improves outcomes for patients with such pancreatic cancers. The Company recognizes grants as contra research and development expense in the consolidated statement of operations and comprehensive loss on a systematic basis over the periods in which the Company recognizes as expenses the related costs for which the grants are intended to compensate. Eligible expenses incurred in excess of grant payments received up to the total amount of the PanCAN Grant are recorded as a grant receivable. Through December 31, 2025, the Company has received &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$4.1&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;million of cash proceeds that were initially recorded as deferred liabilities on the balance sheet. The Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$2.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$2.0&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; million of the proceeds as a reduction of research and development expense during the years ended December 31, 2025, 2024, and 2023, respectively.  As of December 31, 2025, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.2&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million as a &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_LYd0gLsYTUK5twLVxNTSUw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;grant receivable&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;no&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; deferred liabilities related to the PanCAN Grant recognized on the consolidated balance sheet.&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash, cash equivalents and restricted cash&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist of a U.S. Government money market funds and corporate bonds and commercial paper of publicly traded companies. Cash equivalents are reported at fair value. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 204,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 88,818&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total cash, cash equivalents and restricted cash&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 205,231&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 89,059&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;Amounts included in restricted cash as of December 31, 2025 and December 31, 2024 represent cash held to collateralize outstanding letters of credit provided as a security deposit for the Company&#x2019;s office space located in Needham, Massachusetts in the amount of $0.2&#160;million. The letters of credit are included in&lt;span style="color:#212529;"&gt;&#160;prepaid expenses and other current assets &lt;/span&gt;on the consolidated balance sheet as of December 31, 2025, and in non-current restricted cash as of December 31, 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;There were no realized gains or losses on cash equivalents for the years ended December 31, 2025, 2024 or 2023. Accrued interest receivable is excluded from the amortized cost and estimated fair value of the Company&#x2019;s cash equivalents. Accrued interest receivable of $0.2 million is presented within prepaid expenses and other current assets on the consolidated balance sheets on December 31, 2025. There was no accrued interest receivable as of December &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;31, 2024. There were no debt securities in an unrealized loss position as of December 31, 2025, or December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash, cash equivalents and restricted cash consist of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Cash, cash equivalents &amp;amp; restricted cash:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Cash and money market accounts&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 205,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 205,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Total cash, cash equivalents &amp;amp; restricted cash&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; 205,231&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; 205,231&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Cash, cash equivalents &amp;amp; restricted cash:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Cash and money market accounts&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 89,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 89,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Total cash, cash equivalents &amp;amp; restricted cash&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; 89,059&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; 89,059&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value of financial instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines the fair value of its financial instruments based upon the fair value hierarchy, which prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"&gt;Level&#160;1 inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Quoted prices in active markets for identical assets or liabilities that the Company can access at the measurement date.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"&gt;Level&#160;2 inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"&gt;Level&#160;3 inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Items measured at fair value on a recurring basis&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are measured at fair value on a recurring basis (in thousands) &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 106,830&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 106,830&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,647&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,647&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76,330&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 111,977&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 111,977&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 63,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 63,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 63,304&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 63,304&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,199&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,199&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 58,199&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 58,199&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 12pt 0pt;"&gt;The investments and cash equivalents have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. The Company validates the prices provided by third party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active. After completing its validation procedures, the Company did not adjust or override any fair value measurements provided by the pricing services as of December 31, 2025 and 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Warrant liability&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;A warrant liability was recorded in connection with the July 2024 Offering (defined herein) (see&#160;&lt;i style="font-style:italic;"&gt;Note 10. Capital Stock&lt;/i&gt;). The fair value measurement of the warrant liability is classified as Level 3 under the fair value hierarchy. The fair value of the warrant liability at December 31, 2025 and December 31, 2024, was determined using the Black-Scholes valuation model. The inputs to the Black-Scholes valuation model include the risk-free rate, stock price volatility, expected dividends and remaining term. Significant increases or decreases in any of those inputs in isolation could result in a significantly lower or higher fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Below are the inputs used to value the warrant liability at December 31, 2025 and December 31, 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 3.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 4.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Remaining term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;1.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table represents a reconciliation of the warrant liability (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 58,199&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Fair value of warrants exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (50,044)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Fair value adjustment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 27,492&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 35,647&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Note Purchase Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"&gt;The fair value of the Notes pursuant to the Note Purchase Agreement represents the present value of estimated future payments, including interest, principal, Repayment Amount, and Revenue Participation Payments (each as defined in the Note Purchase Agreement) &lt;span style="background:#ffffff;"&gt;(see &lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Note 8. Long-term debt&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;)&lt;/span&gt;. The fair value measurement is based on significant Level 3 unobservable inputs such as the probability and timing of Revenue Participation Payments, Repayment Amount, and the discount rate. The Company determined the fair value of the Notes utilizing a discounted cash flow model of estimated future payments including interest, principal, Repayment Amount and Revenue Participation Payments utilizing a discount rate calculated as the term matched risk-free rate plus credit spread. At January 13, 2025, the Company utilized a discount rate between 11.9%-12.4% and at December 31, 2025, the Company utilized a discount rate between 12.6%-13.0%. The fair value of the Notes at December 31, 2025 was determined to be $76.3 million which differed from the contractual principal amount of $75.0 million by $1.3 &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;million. Significant increases or decreases in any of these inputs in isolation could result in a significantly lower or higher fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Oxford Loan Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The fair value of the Company&#x2019;s Term Loans (as defined herein) pursuant to the Loan Agreement (as defined herein) (see &lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Note 10. Long-term debt&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;)&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; was determined using a discounted cash flow analysis with current applicable rates for similar instruments as of the consolidated balance sheet dates. The Company estimated that the fair value of its Term Loans was approximately &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$41.1&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million at December 31, 2024 which differed from its carrying value of approximately &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$40.7&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million. The fair value of the Company&#x2019;s long-term debt was determined using Level&#160;3 inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Concentrations of credit risk and off-balance sheet risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents and trade accounts receivable are financial instruments that potentially subject the Company to concentrations of credit risk. The Company mitigates this risk by maintaining its cash and cash equivalents with high quality, accredited financial institutions. The management of the Company&#x2019;s investments is not discretionary on the part of these financial institutions. As of December 31, 2025, the Company&#x2019;s cash, cash equivalents were deposited at four financial institutions and it has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:12pt 0pt 0pt 0pt;"&gt;As of December 31, 2025 there were five customers that cumulatively made up 100% of the Company&#x2019;s trade accounts receivable balance and two customers who cumulatively made up more than 60% of the Company&#x2019;s trade accounts receivable balance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2025, there were&#160;two&#160;customers who each individually accounted for greater than&#160;10% of the Company&#x2019;s total revenues, for a total of $27.4 million. For the year ended December 31, 2024, there was&#160;one&#160;customer, Secura, who individually accounted for all of the Company&#x2019;s revenue. Refer to&#160;&lt;i style="font-style:italic;"&gt;Note 16. License, collaboration, and commercial agreements&lt;/i&gt;&#160;for a detailed discussion of the Secura APA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Property and equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment consist of laboratory equipment, office furniture, computer equipment and leasehold improvements. Expenditures for repairs and maintenance are recorded to expense as incurred, whereas major betterments are capitalized as additions to property and equipment. Depreciation and amortization are calculated using the straight-line method over the following estimated useful lives of the assets:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;5&#160;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;5&#160;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3&#160;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lesser of useful life or life of lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying value of assets may not be recoverable. Recoverability is measured by comparison of the asset&#x2019;s book value to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. No impairment losses have been recorded through December 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cloud Computing Implementation Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurs costs to implement cloud computing arrangements that are hosted by third-party vendors. In accordance with Accounting Standard Codification (&#x201c;ASC&#x201d;) 350-40,&#160;Goodwill and Other, Internal-Use Software, for cloud computing arrangements that meet the definition of a service contract, the Company capitalizes qualifying implementation costs incurred during the application development stage as a component of prepaid expenses and other current assets and other assets. Capitalization of these costs concludes once the project is substantially complete, and the software is ready for the Company's intended use. Once available for its intended use, the capitalized costs are amortized on a straight-line basis over the term of the associated hosting arrangement, and are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss. Costs related to data conversion, overhead, general and administrative activities, and training are expensed as incurred. Post-configuration training and maintenance costs will be expensed as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025, prepaid expenses and other current assets, and other long-term assets, included approximately $0.4&#160;million each of capitalized implementation costs on the consolidated balance sheet.&#160;For the year ended December 31, 2025, the Company recorded amortization expense associated with cloud computing implementation costs of approximately $0.3 million recorded within selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Research and development costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company expenses research and development costs to operations as incurred. Research and development expenses consist of: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;external research and development expenses incurred under arrangements with third parties, such as contract research organizations, clinical trial sites, manufacturing organizations and consultants, including the scientific advisory board;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;license fees; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, and laboratory supplies.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;Costs for certain development activities, such as clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendor on their actual costs incurred or level of effort expended. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid expenses and other current assets or accrued expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-based compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;For service-based equity awards, the Company recognizes stock-based compensation expense for stock options, and restricted stock units (&#x201c;RSUs&#x201d;) issued to employees, directors, and consultants based on the grant date fair value of the awards on a straight-line basis over the requisite service period, which typically is the vest period. The Company recognized stock-based compensation for shares issued to employees under the Company&#x2019;s employee stock purchase plan (&#x201c;ESPP&#x201d;) plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company has granted performance-based RSUs and stock options with terms that allow the recipients to vest in a specific number of shares based upon the achievement of performance-based milestones as specified in the grants. Stock-based compensation expense associated with these performance-based RSUs and stock options is recognized if the performance condition is considered probable of achievement using the Company&#x2019;s best estimates of the time to vesting for the achievement of the performance-based milestones. &lt;/span&gt;Awards subject to performance-based vesting requirements are expensed utilizing an accelerated attribution model if achievement of the performance criteria is determined to be probable. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The grant date fair value of stock options is estimated using the Black-Scholes option pricing model that takes into account the fair value of its common stock, the exercise price, the expected life of the option, the expected volatility of its common stock, expected dividends on its common stock, and the risk-free interest rate over the expected life of the option. The Company applies the simplified method described in the Securities and Exchange Commission (&#x201c;SEC&#x201d;) Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 14.D.2 to calculate the expected term as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term for options granted to employees. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its population. The Company has not paid and do not anticipate paying cash dividends on the Company&#x2019;s shares of common stock; therefore, the expected dividend yield is assumed to be zero. The computation of expected volatility is based on the historical volatility of the Company&#x2019;s common stock. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options.&lt;span style="background:#ffffff;"&gt; The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;The Company issues shares under the Company&#x2019;s ESPP to employees. Stock-based compensation expense for discounted purchases under the ESPP is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Leases are accounted for in accordance with ASC Topic 842, Leases (&#x201c;ASC 842&#x201d;).&#160;This standard requires lessees to recognize in the statement of financial position a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term for both finance and operating leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances within the arrangement.&#160;A lease is identified where an arrangement conveys the right to control the use of identified property, plant, and equipment for a period of time in exchange for consideration.&#160;Leases which are identified within the scope of ASC 842 and which have a term greater than one year are recognized on the Company&#x2019;s consolidated balance sheets as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize leases with terms of one year or less on its consolidated balance sheets. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates to calculate the present value of lease payments.&#160;Incremental borrowing rates are the rates the Company incurs to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with ASC 842, components of a lease are split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, maintenance, consumables, etc.), and non-components (e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on fair values to the lease components and non-lease components. Although separation of lease and non-lease components is required, certain practical expedients are available. Entities may elect the practical expedient to not separate lease and non-lease components. Rather, they would account for each lease component and the related non-lease component together as a single component. The Company has elected to account for the lease and non-lease components of each of its operating leases as a single lease component and allocate all of the contract consideration to the lease component only. The lease component results in an operating right-of-use asset being recorded on the consolidated balance sheets and amortized on a straight-line basis as lease expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services in accordance with ASC Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;). To determine revenue recognition for contracts with its customers, the Company performs the following five step assessment: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception and once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines which goods and services are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;P&lt;/i&gt;&lt;i style="font-style:italic;"&gt;roduct Revenue, Net&lt;/i&gt; - The Company sells AVMAPKI FAKZYNJA CO-PACK to a limited number of specialty pharmacies and specialty distributors in the United States. The specialty pharmacies dispense AVMAPKI FAKZYNJA CO-PACK directly to patients while the specialty distributors resell AVMAPKI FAKZYNJA CO-PACK to healthcare entities who then resell AVMAPKI FAKZYNJA CO-PACK to patients. In addition to distribution agreements with specialty distributors, the Company also enters into arrangements with (1) certain government agencies and various private organizations (&#x201c;Third-Party Purchasers&#x201d;), which may provide for chargebacks or discounts with respect to the purchase of AVMAPKI FAKZYNJA CO-PACK, and (2) Medicare and Medicaid, which may provide for certain rebates with respect to their reimbursement of AVMAPKI FAKZYNJA CO-PACK.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue on sales of AVMAPKI FAKZYNJA CO-PACK when a customer obtains control of the product, which occurs at a specific point in time (typically upon delivery). Product revenues are recorded at the wholesale acquisition costs, net of applicable reserves for variable consideration. Components of variable consideration include trade discounts and allowances, Third-Party Payer chargebacks and discounts, government rebates, product returns, other patient focused allowances, such as voluntary co-pay assistance, benefits verification, and other patient support programs that are offered within contracts between the Company and customers, payors, and other indirect customers relating to the Company&#x2019;s sale of AVMAPKI FAKZYNJA CO-PACK. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable or a current liability. These estimates take into consideration a range of possible outcomes based upon relevant factors such as, customer contract terms, information received from third parties regarding the anticipated payor mix for AVMAPKI FAKZYNJA CO-PACK, known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled with respect to sales made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The amount of variable consideration included within a transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under contracts will not occur in a future period. The Company&#x2019;s analyses contemplate the application of the constraint in accordance with Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) Accounting Standard Codification (&#x201c;ASC&#x201d;) 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). For the twelve months ended December 31, 2025, the Company determined a material reversal of revenue would not occur in a future period for the estimates detailed below and, therefore, transaction prices would not be reduced further. Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates. If actual results in the future vary from the Company&#x2019;s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Trade Discounts and Allowances: The Company generally provides customers with invoice discounts on sales of AVMAPKI FAKZYNJA CO-PACK for prompt payment and other discounts, which are explicitly stated in the Company&#x2019;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates its specialty pharmacy and specialty distributor customers for sales order management, data, distribution, and certain other services. The Company has determined such services are not distinct from the Company&#x2019;s sale of AVMAPKI FAKZYNJA CO-PACK to the specialty pharmacy and specialty distributor customers and, therefore, these payments have also been recorded as a reduction of revenue within the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-Party Payer Chargebacks, Discounts and Fees: The Company executes contracts with Third-Party Purchasers which allow for eligible purchases of AVMAPKI FAKZYNJA CO-PACK at prices lower than the wholesale acquisition cost. In some cases, customers will charge the Company for the difference between what they pay for &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;AVMAPKI FAKZYNJA CO-PACK and the ultimate selling price to the Third-Party Purchasers to whom they sell the product. Reserves will generally be established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable, net. Chargeback amounts will generally be determined at the time of resale to the qualified Third-Party Purchasers by customers, and the Company generally will issue credits for such amounts within a few weeks of the customer&#x2019;s notification to the Company of the resale. The reserves for chargebacks are expected to consist of credits that the Company expects to issue for units that remain in customer inventories at the end of each reporting period that the Company expects will be sold to Third-Party Purchasers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. &lt;span style="color:#212529;background:#ffffff;"&gt;In addition, the Company compensated certain Third-Party Payers for administrative services, such as account management and data reporting. These administrative service fees have also been recorded as a reduction of net product revenue within the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Government Rebates: The Company is subject to discount and rebate payment obligations under various government programs including Federal and state Medicaid programs, Medicare, and others. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses on the consolidated balance sheets. The Company&#x2019;s liability for these rebates consist of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in customer inventories at the end of each reporting period. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Other Patient Support Initiatives: Other patient support initiatives that the Company offers include voluntary co-pay assistance programs, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payors. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive for product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses on the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Product Returns: Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company either directly or through one of its distribution channels. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s return policy generally allows for eligible returns of AVMAPKI FAKZYNJA CO-PACK for credit under the following circumstances:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Receipt of damaged product;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Shipment errors that were a result of an error by the Company;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Expired product that is returned during the period beginning three months prior to the product&#x2019;s expiration and ending six months after the expiration date;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Quantities of product received by a customer in excess of quantity ordered;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Product subject to a recall; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Product that the Company, at its sole discretion, has specified can be returned for credit. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;As of December 31, 2025, the Company has not received any returns.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Sales of intellectual property&lt;/i&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt; - &lt;/span&gt;For sales of license and intellectual property, that include sale-based royalties, including milestone payments based on a level of sales, the Company evaluates whether the royalties and sales-based milestones are considered probable of being achieved and estimates the amount of royalties to include over the contractual term using the expected value method and estimates the sales-based milestones using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated royalty and milestone value is included in the transaction price. Royalties and sales-based milestones for territories for which there is not regulatory approval are not considered probable until such regulatory approval is achieved. The Company evaluates factors such as whether consideration is outside of the Company&#x2019;s control, timeline for when the uncertainty will be resolved and historical sales of COPIKTRA if applicable. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and amount of royalty revenue to be received and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounts Receivable, Net &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Accounts receivable, net consists of amounts due from customers, net of applicable revenue reserves. Accounts receivable have standard payments that generally require payment within 30 to 90 days. Management determines the allowance for credit loss by regularly evaluating individual customer receivables and considering a customer&#x2019;s financial condition, credit history and current economic conditions.  Based on the Company&#x2019;s latest assessment of the collectability of its accounts receivable, an allowance for credit loss is not deemed necessary at December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Inventory &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventories are stated at the lower of cost or estimated net realizable value. The Company determined the cost of inventories using the&#160;standard cost&#160;method, which approximates actual cost based on a first-in, first out basis. Inventories consist primarily of third-party manufacturing costs. The Company began capitalizing inventory upon receiving FDA approval for AVMAPKI FAKZYNJA CO-PACK on May 8, 2025. Prior to the FDA approval of AVMAPKI FAKZYNJA CO-PACK, expenses associated with the manufacturing of the Company's products were recorded as research and development expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, are recorded within cost of sales &#x2013; product within the consolidated statements of operations and net loss. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required which would be recorded as a cost of sales - product in the consolidated statements of operations and comprehensive loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Shipping and handling costs for product shipments are recorded as incurred in cost of sales - product along with costs associated with manufacturing the product, and any inventory write-downs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;i style="font-style:italic;"&gt; &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company records finite-lived intangible assets related to certain capitalized milestone payments at their fair value. These assets are amortized over their remaining useful lives, which are estimated based on the shorter of the remaining underlying patent life or the estimated useful life of the underlying product. Intangible assets are amortized using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when future revenues cannot be reasonably estimated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company assesses its finite-lived intangible assets for impairment if indicators are present or changes in circumstance suggest that impairment may exist. Events that could result in an impairment, or trigger an impairment assessment, include the receipt of additional clinical or nonclinical data regarding the Company&#x2019;s drug products or a potentially competitive drug candidate, significant changes in the manner of our use of the acquired assets, or new &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;information regarding future projected sales for the product. If impairment indicators are present or changes in circumstance suggest that impairment may exist, the Company performs a recoverability test by comparing the sum of the estimated undiscounted cash flows of each finite-lived intangible asset to its carrying value on the consolidated balance sheets. If the undiscounted cash flows used in the recoverability test are less than the carrying value, the Company would determine the fair value of the finite-lived intangible asset and recognize an impairment loss if the carrying value of the finite-lived intangible asset exceeds its fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Collaborative arrangements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Contracts are considered to be collaborative arrangements when they satisfy the following criteria defined in ASC Topic 808, &lt;i style="font-style:italic;"&gt;Collaborative Arrangements&lt;/i&gt;: (i) the parties to the contract must actively participate in the joint operating activity and (ii) the joint operating activity must expose the parties to the possibility of significant risk and rewards, based on whether or not the activity is successful. Payments received from or made to a partner that are the result of a collaborative relationship with a partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction or increase to research and development expense, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes the tax effects of an uncertain tax position only if it is more likely than not that it will be sustained based solely on its technical merits as of the reporting date and only in an amount more likely than not that it will be sustained upon review by the tax authorities. The Company evaluates uncertain tax positions on a quarterly basis and adjust the liability for changes in facts and circumstances, such as new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, significant amendment to an existing tax law, or resolution of an examination. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the income tax provision in the period in which such determination is made. The resolution of its uncertain income tax positions is dependent on uncontrollable factors such as law changes, new case law, and the willingness of the income tax authorities to settle, including the timing thereof and other factors. Although the Company does not anticipate significant changes to its uncertain income tax positions in the next 12 months, items outside of its control could cause its uncertain income tax positions to change in the future, which would be recorded in its statements of operations. Interest and/or penalties related to income tax matters are recognized as a component of income tax expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Net operating loss (&#x201c;NOL&#x201d;) and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the Internal Revenue Code (&#x201c;IRC&#x201d;), as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company experienced a greater than 50% change in ownership as defined under Section 382 and 383 of the IRC as well as similar state provisions during the year ended December 31, 2024. For more details, please refer to &lt;i style="font-style:italic;"&gt;Note 14. Income Taxes.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss per share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per common share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period. For purposes of calculating net loss per share, weighted-average number of common shares outstanding includes the weighted average effect of pre-funded warrants as the exercise of which requires little or no consideration for the delivery of shares of common stock. &lt;span style="white-space:pre-wrap;"&gt;Diluted net loss per common share is calculated by increasing the denominator by the weighted-average number of additional shares that could have been outstanding from securities convertible into common stock, such as the warrants issued in July 2024, stock options, restricted stock units, and ESPP (using the &#x201c;treasury stock&#x201d; method), Series A Convertible Preferred Stock, and Series B Convertible Preferred Stock (using the &#x201c;if-converted&#x201d; method), unless their effect on net loss per share is antidilutive. Under the &#x201c;if-converted&#x201d; method, convertible instruments that are-in-the-money, are assumed to have been converted as of the beginning of the period or when issued, if later. Additionally, the effects of any interest expense and changes in fair value of any bifurcated derivatives shall be added back to the numerator of the diluted net loss per share calculation.  Refer to &lt;/span&gt;&lt;i style="font-style:italic;"&gt;Note 13. Net Loss per share&lt;/i&gt; for further details related to the calculation of net loss per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recently Adopted Accounting Standards Updates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"&gt;In December 2023, the FASB issued ASU No. 2023-09,&#160;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#160;(&#x201c;ASU 2023-09&#x201d;). The guidance in ASU 2023-09 improves the transparency of income tax disclosures by greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The Company has adopted and applied the guidance under this ASU for the year ended December 31, 2025, using the prospective transition method. See&#160;&lt;i style="font-style:italic;"&gt;Note 14. Income Taxes&lt;/i&gt;&#160;in the accompanying notes to the consolidated financial statements for further detail.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;Recently issued accounting standards updates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In November 2024, the FASB issued ASU No 2024-03&#x2014;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;). The guidance in ASU 2024-03 is intended to require more detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted.  The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to all prior periods presented in the financial statements. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"&gt;In September 2025, the FASB issued ASU No. 2025-06,&#160;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software&#160;(&#x201c;ASU 2025-06&#x201d;). This standard modernizes the accounting for internal-use software by removing references to prescriptive development stages and instead requiring capitalization of costs once (1) management has authorized and committed to funding the software project, and (2) it is probable the project will be completed and placed in service. Entities must evaluate whether there is &#x201c;significant development uncertainty,&#x201d; such as unresolved novel functionality or substantially revised performance requirements, before meeting this capitalization threshold. ASU 2025-06 is effective for annual reporting periods beginning after December 15, 2027, and interim periods within such annual reporting periods, with early adoption permitted. Entities may adopt the amendments prospectively, retrospectively, or under a modified transition approach. The Company is in the process of evaluating the impact that the adoption of this ASU may have on its consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"&gt;Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_6vUlRVoHPkOhpLP7yAY-0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Basis of presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) under the assumption that the Company will continue as a going concern for the next 12 months. Accordingly, they do not include any adjustments that might result from the uncertainty related to the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_V1xph460H0qslkUP6Cx7ew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Use of estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The preparation of the Company&#x2019;s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including but not limited to estimates related to revenue recognition, accrued and prepaid clinical trial expense and other general accruals, stock-based compensation expense, long-term debt, and its warrant liability. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable. Actual results could differ from such estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_PTYBhBdm_kWeQq0Lp8dnRA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Segment and geographic information&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available and regularly reviewed by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;one operating segment, which is the business of researching, developing and commercializing drugs for the treatment of patients with cancer. All material long-lived assets of the Company reside in the U.S.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="INF"
      id="Narr_jTbTgmTMs0KhIoa5YQGTww"
      unitRef="Unit_Standard_item_5quK1hZThku2W0bLLpUodA">1</us-gaap:NumberOfOperatingSegments>
    <vstm:ProceedsFromGrantsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_i4l6yR-JRU6wuSq4oHUFzA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Proceeds from grants&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;In May 2022, the Company was awarded the &#x201c;Therapeutic Accelerator Award&#x201d; grant from Pancreatic Cancer Network (&#x201c;PanCAN&#x201d;) for up to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$3.8&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;million (the &#x201c;&lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_q90ZIR8th0OGZ8dK-5vu4A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PanCAN Grant&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#x201d;). In August 2022, PanCAN agreed to provide the Company with an additional &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.5&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;million for the collection and analysis of patient samples. The grant is supporting a Phase 1b/2 clinical trial of GEMZAR (gemcitabine) and ABRAXANE (Nab-paclitaxel) in combination with avutometinib and defactinib entitled RAMP 205. The RAMP 205 trial is evaluating whether combining avutometinib (to target KRAS mutant, which is found in more than 90% of pancreatic adenocarcinomas), and defactinib (to reduce stromal density and adaptive resistance to avutometinib) to the standard GEMZAR/ABRAXANE regimen improves outcomes for patients with such pancreatic cancers. The Company recognizes grants as contra research and development expense in the consolidated statement of operations and comprehensive loss on a systematic basis over the periods in which the Company recognizes as expenses the related costs for which the grants are intended to compensate. Eligible expenses incurred in excess of grant payments received up to the total amount of the PanCAN Grant are recorded as a grant receivable. Through December 31, 2025, the Company has received &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$4.1&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;million of cash proceeds that were initially recorded as deferred liabilities on the balance sheet. The Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$2.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$2.0&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; million of the proceeds as a reduction of research and development expense during the years ended December 31, 2025, 2024, and 2023, respectively.  As of December 31, 2025, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.2&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million as a &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_LYd0gLsYTUK5twLVxNTSUw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;grant receivable&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;no&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; deferred liabilities related to the PanCAN Grant recognized on the consolidated balance sheet.&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; &lt;/span&gt;&lt;/p&gt;</vstm:ProceedsFromGrantsPolicyPolicyTextBlock>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="Duration_5_1_2022_To_5_31_2022_0S7CWDwAHkCwzDSQQTfHkw"
      decimals="-5"
      id="Narr_FUmzD7awh0SZxrZanPCWOQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3800000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_GovernmentAssistanceTypeAxis_us-gaap_GovernmentAssistanceOtherMember_GBuPX_U0g0azpKLEVKIehg"
      decimals="-5"
      id="Narr_lfsO337R_kqJQ3_gezCSsQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">500000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-5"
      id="Narr_cfWSq9bxzkaQexDztsE4uQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4100000</us-gaap:GovernmentAssistanceAmount>
    <vstm:ReductionInResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-5"
      id="Narr_8RuY6B-3O0-jmti92CPx9Q"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</vstm:ReductionInResearchAndDevelopmentExpense>
    <vstm:ReductionInResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-5"
      id="Narr_QnHNbUlPc0yxe_7y6u3TOg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2000000</vstm:ReductionInResearchAndDevelopmentExpense>
    <vstm:ReductionInResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-5"
      id="Narr_jQZTnTMDjUiZ5aRTOXsyDw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2000000</vstm:ReductionInResearchAndDevelopmentExpense>
    <us-gaap:GovernmentAssistanceAmountCumulativeCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-5"
      id="Narr_J-YS-VIUekmJgpd9OdU_zg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">200000</us-gaap:GovernmentAssistanceAmountCumulativeCurrent>
    <us-gaap:GovernmentAssistanceLiabilityCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-5"
      id="Narr_C-u0OopesEmxEYN3cBzddA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</us-gaap:GovernmentAssistanceLiabilityCurrent>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_w-Hp0iEF902Q3VOTW6qcwA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash, cash equivalents and restricted cash&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist of a U.S. Government money market funds and corporate bonds and commercial paper of publicly traded companies. Cash equivalents are reported at fair value. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 204,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 88,818&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total cash, cash equivalents and restricted cash&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 205,231&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 89,059&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;Amounts included in restricted cash as of December 31, 2025 and December 31, 2024 represent cash held to collateralize outstanding letters of credit provided as a security deposit for the Company&#x2019;s office space located in Needham, Massachusetts in the amount of $0.2&#160;million. The letters of credit are included in&lt;span style="color:#212529;"&gt;&#160;prepaid expenses and other current assets &lt;/span&gt;on the consolidated balance sheet as of December 31, 2025, and in non-current restricted cash as of December 31, 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;There were no realized gains or losses on cash equivalents for the years ended December 31, 2025, 2024 or 2023. Accrued interest receivable is excluded from the amortized cost and estimated fair value of the Company&#x2019;s cash equivalents. Accrued interest receivable of $0.2 million is presented within prepaid expenses and other current assets on the consolidated balance sheets on December 31, 2025. There was no accrued interest receivable as of December &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;31, 2024. There were no debt securities in an unrealized loss position as of December 31, 2025, or December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash, cash equivalents and restricted cash consist of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Cash, cash equivalents &amp;amp; restricted cash:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Cash and money market accounts&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 205,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 205,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Total cash, cash equivalents &amp;amp; restricted cash&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; 205,231&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; 205,231&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Cash, cash equivalents &amp;amp; restricted cash:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Cash and money market accounts&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 89,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 89,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Total cash, cash equivalents &amp;amp; restricted cash&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; 89,059&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; 89,059&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Group_fYOq2HoFf0mcEyrJJAQJHw">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 204,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 88,818&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total cash, cash equivalents and restricted cash&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 205,231&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 89,059&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_HpaPY8r520GCwrL5qOc_8g_2_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">204990000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_CyangAmxL02iS49YHdg7jA_2_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">88818000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_2Hup17hfEUmpISeX2UGBmw_3_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">241000</us-gaap:SecurityDeposit>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_MmAyQgT8XUK9MflgCxnRWg_3_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">241000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_OwOxeCY1Q0udWMpp9nClHw_4_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">205231000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_e8hKDsF-ikaxDfWh9SPE7A_4_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">89059000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2024_us-gaap_BalanceSheetLocationAxis_vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_2wSiS_Brj0WdJYyQqH3Mow"
      decimals="-5"
      id="Narr_ZpNCbGCFCESfQujDs9qzIQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">200000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2025_us-gaap_BalanceSheetLocationAxis_vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_2MkKTScWkE6izafnUVQf4g"
      decimals="-5"
      id="Narr__ruCEY-roEuZIZ7zj8VQ-Q"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">200000</us-gaap:SecurityDeposit>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-5"
      id="Narr_c0P-5uJBeU68nJx0by4NOg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-5"
      id="Narr_OqR9JdERVEqdl7Quuvj3Ow"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-5"
      id="Narr_DOt0Q7QgyEG4jJdibZAm7w"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:InterestReceivable
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-5"
      id="Narr_l3jVtQna20KfYgIxrkV3Nw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">200000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-5"
      id="Narr_AAoM4T8Gkkiq02xt1d1ttQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</us-gaap:InterestReceivable>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_g96AeisdXEGGzC4LMgflAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;31, 2024. There were no debt securities in an unrealized loss position as of December 31, 2025, or December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash, cash equivalents and restricted cash consist of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Cash, cash equivalents &amp;amp; restricted cash:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Cash and money market accounts&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 205,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 205,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Total cash, cash equivalents &amp;amp; restricted cash&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; 205,231&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; 205,231&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Cash, cash equivalents &amp;amp; restricted cash:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Cash and money market accounts&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 89,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 89,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;Total cash, cash equivalents &amp;amp; restricted cash&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; 89,059&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt; 89,059&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-5"
      id="Narr_FEmPyzgVCUexQ-V3MMn7zQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-5"
      id="Narr_O7QCbhYark2Q-smB-DSqzQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2025_us-gaap_CashAndCashEquivalentsAxis_vstm_CashAndMoneyMarketAccountsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_vstm_CorporateBondsAndCommercialPaperMember_MWAiV7Cxnk2tfkH3USoRZg"
      decimals="-3"
      id="Tc_FlwakQom6EupBfx6mBGS1A_6_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">205231000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_CashAndCashEquivalentsAxis_vstm_CashAndMoneyMarketAccountsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_vstm_CorporateBondsAndCommercialPaperMember_RPkjFi0xNEyDFZjufdCC-Q"
      decimals="-3"
      id="Tc_ujA6IcaScEW8aS4tnX18QQ_6_12"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">205231000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_12Jwxj-GpUyMjUlJbpGHrw"
      decimals="-3"
      id="Tc_ZMLQ8anH4EuK31UVvX2Ldw_7_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">205231000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7jjnAioBzkCDhttauz0FHg"
      decimals="-3"
      id="Tc_jc0CeL2pAEConfGHG5t8Yw_7_12"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">205231000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_vstm_CashAndMoneyMarketAccountsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_2k6kDSuJ90Spe63C0ts7DA"
      decimals="-3"
      id="Tc_7EXDdBfje0-b7TJ87hyrzA_6_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">89059000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_vstm_CashAndMoneyMarketAccountsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d4Dr_eG7_EGh26Hx67k-HQ"
      decimals="-3"
      id="Tc_Ny9IKeAGLkOYMtd5lY0IPQ_6_12"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">89059000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_-gOCxHhMf0WnaIxAheCqPA"
      decimals="-3"
      id="Tc_GK1CXk0tTk-mtg7CgDin2g_7_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">89059000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_eBqr6h4vlUOpwptV_czZMg"
      decimals="-3"
      id="Tc_78SNQ9-syUG5W68um_YroQ_7_12"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">89059000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_P2ZpDJlLd0e0ISqwUFX6Fw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value of financial instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines the fair value of its financial instruments based upon the fair value hierarchy, which prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"&gt;Level&#160;1 inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Quoted prices in active markets for identical assets or liabilities that the Company can access at the measurement date.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"&gt;Level&#160;2 inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"&gt;Level&#160;3 inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:83.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Items measured at fair value on a recurring basis&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are measured at fair value on a recurring basis (in thousands) &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 106,830&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 106,830&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,647&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,647&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76,330&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 111,977&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 111,977&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 63,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 63,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 63,304&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 63,304&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,199&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,199&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 58,199&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 58,199&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 12pt 0pt;"&gt;The investments and cash equivalents have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. The Company validates the prices provided by third party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active. After completing its validation procedures, the Company did not adjust or override any fair value measurements provided by the pricing services as of December 31, 2025 and 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Warrant liability&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;A warrant liability was recorded in connection with the July 2024 Offering (defined herein) (see&#160;&lt;i style="font-style:italic;"&gt;Note 10. Capital Stock&lt;/i&gt;). The fair value measurement of the warrant liability is classified as Level 3 under the fair value hierarchy. The fair value of the warrant liability at December 31, 2025 and December 31, 2024, was determined using the Black-Scholes valuation model. The inputs to the Black-Scholes valuation model include the risk-free rate, stock price volatility, expected dividends and remaining term. Significant increases or decreases in any of those inputs in isolation could result in a significantly lower or higher fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Below are the inputs used to value the warrant liability at December 31, 2025 and December 31, 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 3.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 4.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Remaining term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;1.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table represents a reconciliation of the warrant liability (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 58,199&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Fair value of warrants exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (50,044)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Fair value adjustment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 27,492&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 35,647&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Note Purchase Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"&gt;The fair value of the Notes pursuant to the Note Purchase Agreement represents the present value of estimated future payments, including interest, principal, Repayment Amount, and Revenue Participation Payments (each as defined in the Note Purchase Agreement) &lt;span style="background:#ffffff;"&gt;(see &lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Note 8. Long-term debt&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;)&lt;/span&gt;. The fair value measurement is based on significant Level 3 unobservable inputs such as the probability and timing of Revenue Participation Payments, Repayment Amount, and the discount rate. The Company determined the fair value of the Notes utilizing a discounted cash flow model of estimated future payments including interest, principal, Repayment Amount and Revenue Participation Payments utilizing a discount rate calculated as the term matched risk-free rate plus credit spread. At January 13, 2025, the Company utilized a discount rate between 11.9%-12.4% and at December 31, 2025, the Company utilized a discount rate between 12.6%-13.0%. The fair value of the Notes at December 31, 2025 was determined to be $76.3 million which differed from the contractual principal amount of $75.0 million by $1.3 &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;million. Significant increases or decreases in any of these inputs in isolation could result in a significantly lower or higher fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Oxford Loan Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The fair value of the Company&#x2019;s Term Loans (as defined herein) pursuant to the Loan Agreement (as defined herein) (see &lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Note 10. Long-term debt&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;)&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; was determined using a discounted cash flow analysis with current applicable rates for similar instruments as of the consolidated balance sheet dates. The Company estimated that the fair value of its Term Loans was approximately &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$41.1&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million at December 31, 2024 which differed from its carrying value of approximately &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$40.7&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million. The fair value of the Company&#x2019;s long-term debt was determined using Level&#160;3 inputs.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_kvU0daP8_kuy5EyGVDlO7Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are measured at fair value on a recurring basis (in thousands) &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 106,830&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 106,830&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,647&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,647&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76,330&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 111,977&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 111,977&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 63,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 63,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 63,304&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 63,304&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,199&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,199&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 58,199&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 58,199&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AjLSxccsFEupWVwt4xkeYw"
      decimals="-3"
      id="Tc_IRsYnCXrjUy4MMaSZ1IjNQ_4_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">106830000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0ZkUR0_jhUeO6Ak4kIOPSQ"
      decimals="-3"
      id="Tc_j2EXmIeA-0G7matYdJcWGw_4_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">106830000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AjLSxccsFEupWVwt4xkeYw"
      decimals="-3"
      id="Tc_z0DYXqyIDkCFnCLLd3RUgg_5_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">106830000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0ZkUR0_jhUeO6Ak4kIOPSQ"
      decimals="-3"
      id="Tc_sh7tGwZcWkm_8i9WyzCJBg_5_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">106830000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AjLSxccsFEupWVwt4xkeYw"
      decimals="-3"
      id="Tc_tCBBzXKRAESFDtGy-vynUg_6_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">35647000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_olbo--1GgkW245MgvwjaNA"
      decimals="-3"
      id="Tc_D8Eyqp85b06V1i7Jyf72jw_6_12"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">35647000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_pHPKgAvMQEWiqkJrPvsR8w_7_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">76330000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_l6H3Xy5qKk-1R-nWGp4lrA"
      decimals="-3"
      id="Tc_UfIjsakQEEiL809O7d_aYw_7_12"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">76330000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_spHgPYbpK0iKbmoGoGyL6Q_8_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">111977000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_l6H3Xy5qKk-1R-nWGp4lrA"
      decimals="-3"
      id="Tc_tFZ84PZvCkmRikGqXpk2Jw_8_12"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">111977000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5TQU9p2reEqK8sueEagIGw"
      decimals="-3"
      id="Tc_x6dekFqQDEKHqZD5q7Ruog_4_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">63304000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5WLmwNvOF0u7-gwsjUY1fw"
      decimals="-3"
      id="Tc_WzPfXgJhgkSoYmewHOZtDg_4_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">63304000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5TQU9p2reEqK8sueEagIGw"
      decimals="-3"
      id="Tc_AUrbpNv4uk-9j07BjEY2nQ_5_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">63304000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5WLmwNvOF0u7-gwsjUY1fw"
      decimals="-3"
      id="Tc_CJBYADFy60WANNpi95ZRmw_5_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">63304000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5TQU9p2reEqK8sueEagIGw"
      decimals="-3"
      id="Tc_dUySIErBdUeiu9isxg-UJA_6_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">58199000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6mJXVPDki0CwWIMRXdTM3Q"
      decimals="-3"
      id="Tc_eaF9TrQ3gEufPz4hvgDYZQ_6_12"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">58199000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5TQU9p2reEqK8sueEagIGw"
      decimals="-3"
      id="Tc_FadcZCN0uEySCLSXhmuK6w_7_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">58199000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6mJXVPDki0CwWIMRXdTM3Q"
      decimals="-3"
      id="Tc_WUfuo9hGCkuJcKoRM1UsWg_7_12"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">58199000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_1Qz6cFAFeka5wxofCcaAqA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 3.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 4.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Remaining term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;1.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2025_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_QfOCneyU3kuQfy4l3HkaFA"
      decimals="2"
      id="Tc_YRv2Ng295kKuCP7Ci23L6g_2_2"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">3.74</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_0A2hZA9RokujrbpWC0nGmA"
      decimals="2"
      id="Tc_2KZ9XbpknUmBH4nrdElEBw_2_5"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">4.17</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2025_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_r6xwMcGjUkmR3Dp9MxTNuA"
      decimals="0"
      id="Tc_FRi20lcPSUGvAt3JOMSlug_3_2"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">53</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_7rlVb8oVn0S0Tnw4gAwhJg"
      decimals="0"
      id="Tc_vb-1aalOu0aVTB08sQd64g_3_5"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">137</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2025_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_YFjHghTZW0Ch1fCZB71hlw"
      decimals="1"
      id="Tc_u8khxqE-tU2kk9T4zQYZoA_5_2"
      unitRef="Unit_Standard_Y_QWKc7mjBxEydJx6eMjqhZA">0.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_5LADYlfrGUudV0Z1BYW7WA"
      decimals="1"
      id="Tc_6ZcL8BAzI0Kzm_s3Cy48Yg_5_5"
      unitRef="Unit_Standard_Y_QWKc7mjBxEydJx6eMjqhZA">1.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <vstm:ReconciliationOfWarrantLiabilityTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_04GyNOS9RUOJexwWhYL6ug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table represents a reconciliation of the warrant liability (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 58,199&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Fair value of warrants exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (50,044)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Fair value adjustment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 27,492&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 35,647&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</vstm:ReconciliationOfWarrantLiabilityTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_yUvfHNVxFkOmrE7fRHax3g"
      decimals="-3"
      id="Tc_4rMJYZuNDU6l0zAVxeynwQ_1_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">58199000</us-gaap:WarrantsAndRightsOutstanding>
    <vstm:FairValueAdjustmentOfWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_FvCF6Wd2sUa1Ka_dpTtMeA"
      decimals="-3"
      id="Tc_sa556__OkE-MoEqjaIkMew_2_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-50044000</vstm:FairValueAdjustmentOfWarrantsExercised>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_FvCF6Wd2sUa1Ka_dpTtMeA"
      decimals="-3"
      id="Tc_Paa9Xge5ok6-z6en7D82tw_3_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">27492000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_l6H3Xy5qKk-1R-nWGp4lrA"
      decimals="-3"
      id="Tc_QWyfKzabT0-_rZTOh60S8Q_4_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">35647000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LongTermDebtMeasurementInput
      contextRef="As_Of_1_13_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_xbPXD0-44U2IqHm7qVghXg"
      decimals="1"
      id="Narr_cZFXCLTC50WxaL3zyJdC9A"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">11.9</us-gaap:LongTermDebtMeasurementInput>
    <us-gaap:LongTermDebtMeasurementInput
      contextRef="As_Of_1_13_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_OGwNsXA5AUWD7GEFLnYUtw"
      decimals="1"
      id="Narr_8LIAhSQlikWOyfJflZiZuQ"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">12.4</us-gaap:LongTermDebtMeasurementInput>
    <us-gaap:LongTermDebtMeasurementInput
      contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_MkLIiJaJsUiWkMQbaTnydg"
      decimals="1"
      id="Narr_d-lXxstKK0qrE7d8Hqi0sQ"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">12.6</us-gaap:LongTermDebtMeasurementInput>
    <us-gaap:LongTermDebtMeasurementInput
      contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_fqBR8I39AkaH9nxabK_ZXg"
      decimals="1"
      id="Narr_W-rsrcchAE-YHLr7cGFbbg"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">13</us-gaap:LongTermDebtMeasurementInput>
    <us-gaap:DebtInstrumentFairValue
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_8S_QmEHi20-3Bt7pN3KrWg"
      decimals="-5"
      id="Narr_eATqRZvPG0e5e76cF6FTeA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">76300000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_8S_QmEHi20-3Bt7pN3KrWg"
      decimals="-5"
      id="Narr_L-YPu64YZU-bYxeDyQmZ0w"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">75000000</us-gaap:DebtInstrumentFaceAmount>
    <vstm:DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_8S_QmEHi20-3Bt7pN3KrWg"
      decimals="-5"
      id="Narr_kqb_o2cvJk68_Ed0zmOX-w"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1300000</vstm:DifferenceInFairValueToCarryingValueDebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_yUvfHNVxFkOmrE7fRHax3g"
      decimals="-5"
      id="Narr_xMfxh41gwUCqojvKDlDydw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">41100000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_yUvfHNVxFkOmrE7fRHax3g"
      decimals="-5"
      id="Narr_NbMjLy0FLUiZJu9VQCjGnw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">40700000</us-gaap:LongTermDebt>
    <vstm:ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_vnDembETl06N9caG_u73kQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Concentrations of credit risk and off-balance sheet risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents and trade accounts receivable are financial instruments that potentially subject the Company to concentrations of credit risk. The Company mitigates this risk by maintaining its cash and cash equivalents with high quality, accredited financial institutions. The management of the Company&#x2019;s investments is not discretionary on the part of these financial institutions. As of December 31, 2025, the Company&#x2019;s cash, cash equivalents were deposited at four financial institutions and it has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:12pt 0pt 0pt 0pt;"&gt;As of December 31, 2025 there were five customers that cumulatively made up 100% of the Company&#x2019;s trade accounts receivable balance and two customers who cumulatively made up more than 60% of the Company&#x2019;s trade accounts receivable balance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2025, there were&#160;two&#160;customers who each individually accounted for greater than&#160;10% of the Company&#x2019;s total revenues, for a total of $27.4 million. For the year ended December 31, 2024, there was&#160;one&#160;customer, Secura, who individually accounted for all of the Company&#x2019;s revenue. Refer to&#160;&lt;i style="font-style:italic;"&gt;Note 16. License, collaboration, and commercial agreements&lt;/i&gt;&#160;for a detailed discussion of the Secura APA.&lt;/p&gt;</vstm:ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_a127Ugz1d0ybURrbCu9nJA">As of December 31, 2025, the Company&#x2019;s cash, cash equivalents were deposited at four financial institutions and it has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk>
    <vstm:NumberOfCustomers
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_6XXSqLAvakekgauvuyfFBQ"
      decimals="INF"
      id="Narr_OXQHfa1D10KkaUMZCYKZYA"
      unitRef="Unit_Standard_customer_sDaO4Ago9kCUEtrMUagxqg">5</vstm:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_6XXSqLAvakekgauvuyfFBQ"
      decimals="2"
      id="Narr_Uh1Foy87zUqmJQs-pzsTPw"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">1</us-gaap:ConcentrationRiskPercentage1>
    <vstm:NumberOfCustomers
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_MajorCustomersAxis_vstm_MajorCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_plJG3megQ0iGNmTnOb-Uvw"
      decimals="INF"
      id="Narr_sC6C_97VWUm22e17sgNT-g"
      unitRef="Unit_Standard_customer_sDaO4Ago9kCUEtrMUagxqg">2</vstm:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_MajorCustomersAxis_vstm_MajorCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_plJG3megQ0iGNmTnOb-Uvw"
      decimals="2"
      id="Narr_-uvmIXRaRk6f8n3vn64lTQ"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.60</us-gaap:ConcentrationRiskPercentage1>
    <vstm:NumberOfCustomers
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_MajorCustomersAxis_vstm_MajorCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_kdCTYwGzK0Wb4YPT-CMQMA"
      decimals="INF"
      id="Narr_8YLf3YDq4UydGrSygKE12A"
      unitRef="Unit_Standard_customer_sDaO4Ago9kCUEtrMUagxqg">2</vstm:NumberOfCustomers>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_vstm_MajorCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_S7Vk9c7EfUOkiG3i3sRNMQ"
      decimals="-5"
      id="Narr_pae14sMXnE-sjkRxFsr9NQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">27400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <vstm:NumberOfCustomers
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_vstm_MajorCustomerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_S7Vk9c7EfUOkiG3i3sRNMQ"
      decimals="INF"
      id="Narr_9iQxMW4rDUSszvjzkVzAUA"
      unitRef="Unit_Standard_customer_sDaO4Ago9kCUEtrMUagxqg">1</vstm:NumberOfCustomers>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_VctoEM2zJkG_DjGybaYH6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Property and equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment consist of laboratory equipment, office furniture, computer equipment and leasehold improvements. Expenditures for repairs and maintenance are recorded to expense as incurred, whereas major betterments are capitalized as additions to property and equipment. Depreciation and amortization are calculated using the straight-line method over the following estimated useful lives of the assets:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;5&#160;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;5&#160;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3&#160;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lesser of useful life or life of lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying value of assets may not be recoverable. Recoverability is measured by comparison of the asset&#x2019;s book value to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. No impairment losses have been recorded through December 31, 2025.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <vstm:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_TC1QgEHlwEStnboBxD1qLQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;5&#160;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;5&#160;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3&#160;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lesser of useful life or life of lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</vstm:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_jTuekN8itU-PCSYuKMbIDQ"
      id="Tc_VF5Ih0-Q-kCTOBK947n8nQ_1_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_AXOj8gL7Jk6ZdhZ0AOwscw"
      id="Tc_PJot5k4IikCSo1umIGq4PQ_2_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Gs8d_AaUlkS6G-nzgF-NEA"
      id="Tc_zQJgdcp5kkCoUJZKKBPSvg_3_2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Narr_hzp-B4zSu0yjGy4ncm3I1w"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <vstm:CloudComputingImplementationCostsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_qhAxZuGQokSi9H_qFS1UnA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cloud Computing Implementation Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurs costs to implement cloud computing arrangements that are hosted by third-party vendors. In accordance with Accounting Standard Codification (&#x201c;ASC&#x201d;) 350-40,&#160;Goodwill and Other, Internal-Use Software, for cloud computing arrangements that meet the definition of a service contract, the Company capitalizes qualifying implementation costs incurred during the application development stage as a component of prepaid expenses and other current assets and other assets. Capitalization of these costs concludes once the project is substantially complete, and the software is ready for the Company's intended use. Once available for its intended use, the capitalized costs are amortized on a straight-line basis over the term of the associated hosting arrangement, and are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss. Costs related to data conversion, overhead, general and administrative activities, and training are expensed as incurred. Post-configuration training and maintenance costs will be expensed as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025, prepaid expenses and other current assets, and other long-term assets, included approximately $0.4&#160;million each of capitalized implementation costs on the consolidated balance sheet.&#160;For the year ended December 31, 2025, the Company recorded amortization expense associated with cloud computing implementation costs of approximately $0.3 million recorded within selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;</vstm:CloudComputingImplementationCostsPolicyPolicyTextBlock>
    <us-gaap:CapitalizedContractCostNetCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-5"
      id="Narr_SbALcSbJb0ijljnsyQPk0Q"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">400000</us-gaap:CapitalizedContractCostNetCurrent>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-5"
      id="Narr_i3x8pzUPrkm-idpCKW7ZQA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_t0jUeLOC0E6d_DVoQk5-fA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Research and development costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company expenses research and development costs to operations as incurred. Research and development expenses consist of: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;external research and development expenses incurred under arrangements with third parties, such as contract research organizations, clinical trial sites, manufacturing organizations and consultants, including the scientific advisory board;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;license fees; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, and laboratory supplies.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;Costs for certain development activities, such as clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendor on their actual costs incurred or level of effort expended. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid expenses and other current assets or accrued expenses. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_65mHHqWvgE6c7UbYuINveA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-based compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;For service-based equity awards, the Company recognizes stock-based compensation expense for stock options, and restricted stock units (&#x201c;RSUs&#x201d;) issued to employees, directors, and consultants based on the grant date fair value of the awards on a straight-line basis over the requisite service period, which typically is the vest period. The Company recognized stock-based compensation for shares issued to employees under the Company&#x2019;s employee stock purchase plan (&#x201c;ESPP&#x201d;) plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company has granted performance-based RSUs and stock options with terms that allow the recipients to vest in a specific number of shares based upon the achievement of performance-based milestones as specified in the grants. Stock-based compensation expense associated with these performance-based RSUs and stock options is recognized if the performance condition is considered probable of achievement using the Company&#x2019;s best estimates of the time to vesting for the achievement of the performance-based milestones. &lt;/span&gt;Awards subject to performance-based vesting requirements are expensed utilizing an accelerated attribution model if achievement of the performance criteria is determined to be probable. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The grant date fair value of stock options is estimated using the Black-Scholes option pricing model that takes into account the fair value of its common stock, the exercise price, the expected life of the option, the expected volatility of its common stock, expected dividends on its common stock, and the risk-free interest rate over the expected life of the option. The Company applies the simplified method described in the Securities and Exchange Commission (&#x201c;SEC&#x201d;) Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 14.D.2 to calculate the expected term as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term for options granted to employees. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its population. The Company has not paid and do not anticipate paying cash dividends on the Company&#x2019;s shares of common stock; therefore, the expected dividend yield is assumed to be zero. The computation of expected volatility is based on the historical volatility of the Company&#x2019;s common stock. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options.&lt;span style="background:#ffffff;"&gt; The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;The Company issues shares under the Company&#x2019;s ESPP to employees. Stock-based compensation expense for discounted purchases under the ESPP is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period&lt;/span&gt;.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_Ze25__gBeEW--apWZbM5NA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Leases are accounted for in accordance with ASC Topic 842, Leases (&#x201c;ASC 842&#x201d;).&#160;This standard requires lessees to recognize in the statement of financial position a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term for both finance and operating leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances within the arrangement.&#160;A lease is identified where an arrangement conveys the right to control the use of identified property, plant, and equipment for a period of time in exchange for consideration.&#160;Leases which are identified within the scope of ASC 842 and which have a term greater than one year are recognized on the Company&#x2019;s consolidated balance sheets as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize leases with terms of one year or less on its consolidated balance sheets. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates to calculate the present value of lease payments.&#160;Incremental borrowing rates are the rates the Company incurs to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with ASC 842, components of a lease are split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, maintenance, consumables, etc.), and non-components (e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on fair values to the lease components and non-lease components. Although separation of lease and non-lease components is required, certain practical expedients are available. Entities may elect the practical expedient to not separate lease and non-lease components. Rather, they would account for each lease component and the related non-lease component together as a single component. The Company has elected to account for the lease and non-lease components of each of its operating leases as a single lease component and allocate all of the contract consideration to the lease component only. The lease component results in an operating right-of-use asset being recorded on the consolidated balance sheets and amortized on a straight-line basis as lease expense.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_GSlJzIdN20mxmOiYnzlGKA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services in accordance with ASC Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;). To determine revenue recognition for contracts with its customers, the Company performs the following five step assessment: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception and once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines which goods and services are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;P&lt;/i&gt;&lt;i style="font-style:italic;"&gt;roduct Revenue, Net&lt;/i&gt; - The Company sells AVMAPKI FAKZYNJA CO-PACK to a limited number of specialty pharmacies and specialty distributors in the United States. The specialty pharmacies dispense AVMAPKI FAKZYNJA CO-PACK directly to patients while the specialty distributors resell AVMAPKI FAKZYNJA CO-PACK to healthcare entities who then resell AVMAPKI FAKZYNJA CO-PACK to patients. In addition to distribution agreements with specialty distributors, the Company also enters into arrangements with (1) certain government agencies and various private organizations (&#x201c;Third-Party Purchasers&#x201d;), which may provide for chargebacks or discounts with respect to the purchase of AVMAPKI FAKZYNJA CO-PACK, and (2) Medicare and Medicaid, which may provide for certain rebates with respect to their reimbursement of AVMAPKI FAKZYNJA CO-PACK.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue on sales of AVMAPKI FAKZYNJA CO-PACK when a customer obtains control of the product, which occurs at a specific point in time (typically upon delivery). Product revenues are recorded at the wholesale acquisition costs, net of applicable reserves for variable consideration. Components of variable consideration include trade discounts and allowances, Third-Party Payer chargebacks and discounts, government rebates, product returns, other patient focused allowances, such as voluntary co-pay assistance, benefits verification, and other patient support programs that are offered within contracts between the Company and customers, payors, and other indirect customers relating to the Company&#x2019;s sale of AVMAPKI FAKZYNJA CO-PACK. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable or a current liability. These estimates take into consideration a range of possible outcomes based upon relevant factors such as, customer contract terms, information received from third parties regarding the anticipated payor mix for AVMAPKI FAKZYNJA CO-PACK, known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled with respect to sales made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The amount of variable consideration included within a transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under contracts will not occur in a future period. The Company&#x2019;s analyses contemplate the application of the constraint in accordance with Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) Accounting Standard Codification (&#x201c;ASC&#x201d;) 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). For the twelve months ended December 31, 2025, the Company determined a material reversal of revenue would not occur in a future period for the estimates detailed below and, therefore, transaction prices would not be reduced further. Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates. If actual results in the future vary from the Company&#x2019;s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Trade Discounts and Allowances: The Company generally provides customers with invoice discounts on sales of AVMAPKI FAKZYNJA CO-PACK for prompt payment and other discounts, which are explicitly stated in the Company&#x2019;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates its specialty pharmacy and specialty distributor customers for sales order management, data, distribution, and certain other services. The Company has determined such services are not distinct from the Company&#x2019;s sale of AVMAPKI FAKZYNJA CO-PACK to the specialty pharmacy and specialty distributor customers and, therefore, these payments have also been recorded as a reduction of revenue within the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-Party Payer Chargebacks, Discounts and Fees: The Company executes contracts with Third-Party Purchasers which allow for eligible purchases of AVMAPKI FAKZYNJA CO-PACK at prices lower than the wholesale acquisition cost. In some cases, customers will charge the Company for the difference between what they pay for &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;AVMAPKI FAKZYNJA CO-PACK and the ultimate selling price to the Third-Party Purchasers to whom they sell the product. Reserves will generally be established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable, net. Chargeback amounts will generally be determined at the time of resale to the qualified Third-Party Purchasers by customers, and the Company generally will issue credits for such amounts within a few weeks of the customer&#x2019;s notification to the Company of the resale. The reserves for chargebacks are expected to consist of credits that the Company expects to issue for units that remain in customer inventories at the end of each reporting period that the Company expects will be sold to Third-Party Purchasers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. &lt;span style="color:#212529;background:#ffffff;"&gt;In addition, the Company compensated certain Third-Party Payers for administrative services, such as account management and data reporting. These administrative service fees have also been recorded as a reduction of net product revenue within the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Government Rebates: The Company is subject to discount and rebate payment obligations under various government programs including Federal and state Medicaid programs, Medicare, and others. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses on the consolidated balance sheets. The Company&#x2019;s liability for these rebates consist of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in customer inventories at the end of each reporting period. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Other Patient Support Initiatives: Other patient support initiatives that the Company offers include voluntary co-pay assistance programs, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payors. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive for product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses on the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Product Returns: Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company either directly or through one of its distribution channels. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s return policy generally allows for eligible returns of AVMAPKI FAKZYNJA CO-PACK for credit under the following circumstances:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Receipt of damaged product;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Shipment errors that were a result of an error by the Company;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Expired product that is returned during the period beginning three months prior to the product&#x2019;s expiration and ending six months after the expiration date;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Quantities of product received by a customer in excess of quantity ordered;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Product subject to a recall; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Product that the Company, at its sole discretion, has specified can be returned for credit. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;As of December 31, 2025, the Company has not received any returns.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Sales of intellectual property&lt;/i&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt; - &lt;/span&gt;For sales of license and intellectual property, that include sale-based royalties, including milestone payments based on a level of sales, the Company evaluates whether the royalties and sales-based milestones are considered probable of being achieved and estimates the amount of royalties to include over the contractual term using the expected value method and estimates the sales-based milestones using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated royalty and milestone value is included in the transaction price. Royalties and sales-based milestones for territories for which there is not regulatory approval are not considered probable until such regulatory approval is achieved. The Company evaluates factors such as whether consideration is outside of the Company&#x2019;s control, timeline for when the uncertainty will be resolved and historical sales of COPIKTRA if applicable. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and amount of royalty revenue to be received and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_mBrqhsUKak2WtBXjp-2Rag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounts Receivable, Net &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Accounts receivable, net consists of amounts due from customers, net of applicable revenue reserves. Accounts receivable have standard payments that generally require payment within 30 to 90 days. Management determines the allowance for credit loss by regularly evaluating individual customer receivables and considering a customer&#x2019;s financial condition, credit history and current economic conditions.  Based on the Company&#x2019;s latest assessment of the collectability of its accounts receivable, an allowance for credit loss is not deemed necessary at December 31, 2025.&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_eq0m3c2PIkyj-_CZdymIXg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Inventory &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventories are stated at the lower of cost or estimated net realizable value. The Company determined the cost of inventories using the&#160;standard cost&#160;method, which approximates actual cost based on a first-in, first out basis. Inventories consist primarily of third-party manufacturing costs. The Company began capitalizing inventory upon receiving FDA approval for AVMAPKI FAKZYNJA CO-PACK on May 8, 2025. Prior to the FDA approval of AVMAPKI FAKZYNJA CO-PACK, expenses associated with the manufacturing of the Company's products were recorded as research and development expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, are recorded within cost of sales &#x2013; product within the consolidated statements of operations and net loss. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required which would be recorded as a cost of sales - product in the consolidated statements of operations and comprehensive loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Shipping and handling costs for product shipments are recorded as incurred in cost of sales - product along with costs associated with manufacturing the product, and any inventory write-downs.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_tytIxV2M7UaWjmGnYtf0gg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;i style="font-style:italic;"&gt; &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company records finite-lived intangible assets related to certain capitalized milestone payments at their fair value. These assets are amortized over their remaining useful lives, which are estimated based on the shorter of the remaining underlying patent life or the estimated useful life of the underlying product. Intangible assets are amortized using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when future revenues cannot be reasonably estimated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company assesses its finite-lived intangible assets for impairment if indicators are present or changes in circumstance suggest that impairment may exist. Events that could result in an impairment, or trigger an impairment assessment, include the receipt of additional clinical or nonclinical data regarding the Company&#x2019;s drug products or a potentially competitive drug candidate, significant changes in the manner of our use of the acquired assets, or new &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;information regarding future projected sales for the product. If impairment indicators are present or changes in circumstance suggest that impairment may exist, the Company performs a recoverability test by comparing the sum of the estimated undiscounted cash flows of each finite-lived intangible asset to its carrying value on the consolidated balance sheets. If the undiscounted cash flows used in the recoverability test are less than the carrying value, the Company would determine the fair value of the finite-lived intangible asset and recognize an impairment loss if the carrying value of the finite-lived intangible asset exceeds its fair value.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_TH09AfVaA0eLP5DYa05I7g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Collaborative arrangements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Contracts are considered to be collaborative arrangements when they satisfy the following criteria defined in ASC Topic 808, &lt;i style="font-style:italic;"&gt;Collaborative Arrangements&lt;/i&gt;: (i) the parties to the contract must actively participate in the joint operating activity and (ii) the joint operating activity must expose the parties to the possibility of significant risk and rewards, based on whether or not the activity is successful. Payments received from or made to a partner that are the result of a collaborative relationship with a partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction or increase to research and development expense, respectively.&lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Group_rqYokz2M102fXw0B4Hs4NQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes the tax effects of an uncertain tax position only if it is more likely than not that it will be sustained based solely on its technical merits as of the reporting date and only in an amount more likely than not that it will be sustained upon review by the tax authorities. The Company evaluates uncertain tax positions on a quarterly basis and adjust the liability for changes in facts and circumstances, such as new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, significant amendment to an existing tax law, or resolution of an examination. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the income tax provision in the period in which such determination is made. The resolution of its uncertain income tax positions is dependent on uncontrollable factors such as law changes, new case law, and the willingness of the income tax authorities to settle, including the timing thereof and other factors. Although the Company does not anticipate significant changes to its uncertain income tax positions in the next 12 months, items outside of its control could cause its uncertain income tax positions to change in the future, which would be recorded in its statements of operations. Interest and/or penalties related to income tax matters are recognized as a component of income tax expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Net operating loss (&#x201c;NOL&#x201d;) and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the Internal Revenue Code (&#x201c;IRC&#x201d;), as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <vstm:ChangeInCompanyOwnershipPercent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="2"
      id="Narr_b6OaBeYuGUSPhfmK5rBF8w"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.50</vstm:ChangeInCompanyOwnershipPercent>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_suCfi21Dj0GUU7bBW_rU6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss per share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per common share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period. For purposes of calculating net loss per share, weighted-average number of common shares outstanding includes the weighted average effect of pre-funded warrants as the exercise of which requires little or no consideration for the delivery of shares of common stock. &lt;span style="white-space:pre-wrap;"&gt;Diluted net loss per common share is calculated by increasing the denominator by the weighted-average number of additional shares that could have been outstanding from securities convertible into common stock, such as the warrants issued in July 2024, stock options, restricted stock units, and ESPP (using the &#x201c;treasury stock&#x201d; method), Series A Convertible Preferred Stock, and Series B Convertible Preferred Stock (using the &#x201c;if-converted&#x201d; method), unless their effect on net loss per share is antidilutive. Under the &#x201c;if-converted&#x201d; method, convertible instruments that are-in-the-money, are assumed to have been converted as of the beginning of the period or when issued, if later. Additionally, the effects of any interest expense and changes in fair value of any bifurcated derivatives shall be added back to the numerator of the diluted net loss per share calculation.  Refer to &lt;/span&gt;&lt;i style="font-style:italic;"&gt;Note 13. Net Loss per share&lt;/i&gt; for further details related to the calculation of net loss per share.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <vstm:NewAccountingStandardsAdoptedPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_GrM6lTa05kCDgFyZbxj6VA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recently Adopted Accounting Standards Updates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"&gt;In December 2023, the FASB issued ASU No. 2023-09,&#160;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#160;(&#x201c;ASU 2023-09&#x201d;). The guidance in ASU 2023-09 improves the transparency of income tax disclosures by greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The Company has adopted and applied the guidance under this ASU for the year ended December 31, 2025, using the prospective transition method. See&#160;&lt;i style="font-style:italic;"&gt;Note 14. Income Taxes&lt;/i&gt;&#160;in the accompanying notes to the consolidated financial statements for further detail.&lt;/p&gt;</vstm:NewAccountingStandardsAdoptedPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_rpoLWqaQH0iLzKkv5zKCcA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;Recently issued accounting standards updates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In November 2024, the FASB issued ASU No 2024-03&#x2014;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;). The guidance in ASU 2024-03 is intended to require more detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted.  The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to all prior periods presented in the financial statements. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"&gt;In September 2025, the FASB issued ASU No. 2025-06,&#160;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software&#160;(&#x201c;ASU 2025-06&#x201d;). This standard modernizes the accounting for internal-use software by removing references to prescriptive development stages and instead requiring capitalization of costs once (1) management has authorized and committed to funding the software project, and (2) it is probable the project will be completed and placed in service. Entities must evaluate whether there is &#x201c;significant development uncertainty,&#x201d; such as unresolved novel functionality or substantially revised performance requirements, before meeting this capitalization threshold. ASU 2025-06 is effective for annual reporting periods beginning after December 15, 2027, and interim periods within such annual reporting periods, with early adoption permitted. Entities may adopt the amendments prospectively, retrospectively, or under a modified transition approach. The Company is in the process of evaluating the impact that the adoption of this ASU may have on its consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"&gt;Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <vstm:ProductRevenueReservesAndAllowancesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_Vg_vCbv7X0uVF0Ogi7TQeg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3. Product revenue reserves and allowances&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Since 2025, the Company&#x2019;s sole source of product revenue has been from sales of AVMAPKI FAKZYNJA CO-PACK in the United States. The following table summarizes activity in each of the product revenue allowance and reserve categories for the twelve months ended December 31, 2025 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Trade&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Third Party Payer &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Government &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;discounts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;chargebacks,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;rebates&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;discounts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:38.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;allowances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and fees&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;incentives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Provision related to sales in the current year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 888&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 387&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,392&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,043&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Adjustments related to prior period sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Credits and payments made&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (652)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (135)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,367)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,154)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Ending balance at December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 236&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 252&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 376&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,889&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"&gt;Trade discounts and Payer chargebacks and discounts are recorded as a reduction to accounts receivable, net on the consolidated balance sheets. Trade allowances and Payer fees, government rebates, other incentives and returns are recorded as a component of accrued expenses on the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</vstm:ProductRevenueReservesAndAllowancesDisclosureTextBlock>
    <vstm:ProductRevenueReservesAndAllowancesTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_tm7cnBLwGEimVls9WX_EbQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Since 2025, the Company&#x2019;s sole source of product revenue has been from sales of AVMAPKI FAKZYNJA CO-PACK in the United States. The following table summarizes activity in each of the product revenue allowance and reserve categories for the twelve months ended December 31, 2025 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Trade&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Third Party Payer &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Government &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;discounts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;chargebacks,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;rebates&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;discounts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:38.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;allowances&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and fees&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;incentives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Provision related to sales in the current year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 888&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 387&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,392&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,043&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Adjustments related to prior period sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Credits and payments made&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (652)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (135)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,367)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,154)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Ending balance at December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 236&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 252&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 376&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,889&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</vstm:ProductRevenueReservesAndAllowancesTableTextBlock>
    <vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear
      contextRef="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember_yE8fkK7qa06bC6iq6BUR2Q"
      decimals="-3"
      id="Tc_zjOPH_WK60aNamauwWIELA_6_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">888000</vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear>
    <vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear
      contextRef="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember_OyYlxyJlr0W_orM9kelphA"
      decimals="-3"
      id="Tc_6sAS8gTctkij_qrsHZ1c_g_6_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">387000</vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear>
    <vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear
      contextRef="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember_Uvl6OFaJ0Uq4ztzlNkkoEg"
      decimals="-3"
      id="Tc_SIPli-HpX0aXcHbH5gtgYg_6_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4392000</vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear>
    <vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear
      contextRef="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueAndAllowancesReturnsMember_FTUadeq3F0WCVMRH53KrHg"
      decimals="-3"
      id="Tc_G9_ZBxkaBkes0K5DWbXTMg_6_12"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">376000</vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear>
    <vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_hBIhaM-keUuZHOwmkPZ-Vw_6_15"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6043000</vstm:ProductRevenueReservesAndAllowancesProvisionRelatedToSalesInCurrentYear>
    <vstm:ProductRevenueReservesAndAllowancesDeductions
      contextRef="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember_yE8fkK7qa06bC6iq6BUR2Q"
      decimals="-3"
      id="Tc_hWu1AC7oLU6GcBbjRZ2COg_8_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">652000</vstm:ProductRevenueReservesAndAllowancesDeductions>
    <vstm:ProductRevenueReservesAndAllowancesDeductions
      contextRef="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember_OyYlxyJlr0W_orM9kelphA"
      decimals="-3"
      id="Tc_xJOMd325nUaRIjgw8zguew_8_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">135000</vstm:ProductRevenueReservesAndAllowancesDeductions>
    <vstm:ProductRevenueReservesAndAllowancesDeductions
      contextRef="Duration_1_1_2025_To_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember_Uvl6OFaJ0Uq4ztzlNkkoEg"
      decimals="-3"
      id="Tc_r62CYVHSF0uQj3e5ODSrIw_8_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1367000</vstm:ProductRevenueReservesAndAllowancesDeductions>
    <vstm:ProductRevenueReservesAndAllowancesDeductions
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_qIfRJeN_WkumkD5MqRKcLw_8_15"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2154000</vstm:ProductRevenueReservesAndAllowancesDeductions>
    <vstm:ProductRevenueReservesAndAllowances
      contextRef="As_Of_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesTradeDiscountsAndAllowancesMember_168XNhm2-E2OU8g_oJr-ug"
      decimals="-3"
      id="Tc_9qYtty9aH0-UAo_t324mjA_9_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">236000</vstm:ProductRevenueReservesAndAllowances>
    <vstm:ProductRevenueReservesAndAllowances
      contextRef="As_Of_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesThirdPartyPayerChargebacksDiscountsAndFeesMember_RoPH4kuymE2ByqNH0aMdag"
      decimals="-3"
      id="Tc_5eErAICICUSOyxoeWe2Dww_9_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">252000</vstm:ProductRevenueReservesAndAllowances>
    <vstm:ProductRevenueReservesAndAllowances
      contextRef="As_Of_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueReservesAndAllowancesGovernmentRebatesAndOtherIncentivesMember_sxwP1I5FCEKe9EEKt9_cgA"
      decimals="-3"
      id="Tc_ivDF3f1uxE6jBa6VZJON9Q_9_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3025000</vstm:ProductRevenueReservesAndAllowances>
    <vstm:ProductRevenueReservesAndAllowances
      contextRef="As_Of_12_31_2025_vstm_ProductRevenueAllowancesAndReservesTypeAxis_vstm_ProductRevenueAndAllowancesReturnsMember_5FE7cQWXTUKpa-SgNguaWg"
      decimals="-3"
      id="Tc_snEX7c8IFkq1hNIDWaDggw_9_12"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">376000</vstm:ProductRevenueReservesAndAllowances>
    <vstm:ProductRevenueReservesAndAllowances
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_iyUvzIrdfU-e_vFGf9y2bQ_9_15"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3889000</vstm:ProductRevenueReservesAndAllowances>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_vQl1Xi9wT02k9YW_3Q-h-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. Inventory&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory consists of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,797&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total inventory&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,833&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;At&#160;December&#160;31, 2025, all of the Company&#x2019;s inventory was related to&#160;AVMAPKI and FAKZYNJA. In May 2025, the FDA approved AVMAPKI FAKZYNJA CO-PACK, at which time the Company began to capitalize costs to manufacture AVMAPKI FAKZYNJA CO-PACK. Prior to FDA approval of AVMAPKI FAKZYNJA CO-PACK, all costs related to the manufacturing of AVMAPKI and FAKZYNJA and related material were charged to research and development expense in the period incurred. At&#160;December&#160;31, 2025, the Company determined that a reserve related to inventory&#160;was&#160;not required.&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_RZe3IGPvpEWM8sx9g08ZCA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory consists of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,797&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total inventory&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,833&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_Cm5V02kbw02xghcdKsyJLA_3_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1797000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_yCO5mDfbB0SGbvzb_LyvEQ_4_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">36000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc__A3HT8KPDUucISxrbeBRdg_5_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1833000</us-gaap:InventoryNet>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_X1TL9IrXyEmaAeSHkwRqLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5. Intangible Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s intangible assets consist of the following (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average Remaining Amortization Period (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired and in-licensed rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 17,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;14.8 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (698)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total intangible assets, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 16,426&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company's finite-lived intangible assets are the result of milestone payments due under the Pfizer Agreement (defined herein) and the License Agreement (defined herein). Refer to &lt;i style="font-style:italic;"&gt;Note 16. License, collaboration and commercial agreements&lt;/i&gt; for further discussion of the Pfizer Agreement and License Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company recorded approximately $0.7 million in cost of sales &#x2013; intangible amortization expense related to finite-lived intangible assets during the twelve months ended December 31, 2025 using straight-line methodology. Estimated future cost of sales- intangible amortization expense for finite-lived intangible assets as of December 31, 2025 is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:85.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ending December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,841&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total future amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 16,426&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_i9Vay7YuD0iLKicwG6Y-Yg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s intangible assets consist of the following (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average Remaining Amortization Period (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired and in-licensed rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 17,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;14.8 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (698)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total intangible assets, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 16,426&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_UFLB7FQ-UkuBpVXhKscaVA_2_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">17124000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Narr_DmHEw5AL3U2VweIF-lb_Jw">P14Y9M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_WDaX-u8vlUeH69HUsl21fQ_3_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">698000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_64DRVe3Rokao5gKltc4UJg_4_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">16426000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_K7BDoaujUUy026vMPGVMBA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company recorded approximately $0.7 million in cost of sales &#x2013; intangible amortization expense related to finite-lived intangible assets during the twelve months ended December 31, 2025 using straight-line methodology. Estimated future cost of sales- intangible amortization expense for finite-lived intangible assets as of December 31, 2025 is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:85.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ending December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,841&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total future amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 16,426&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-5"
      id="Narr_EwXj0Urs5EqqMQDWDFyP5g"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">700000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_XlqQlW1tzESg4KCaqHCHuw_2_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1117000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_LYTaxG-AokuCQGFv6tNj3Q_3_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1117000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_R0sfM6QMtkG1ZHbAfZjy-w_4_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1117000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_JMX6NXflxU-jPJN0CdnHgw_5_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1117000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_yZts8Zz-c0Scxgp7pTVPWg_6_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1117000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_6zd1ga_y70msyHSQxGPa0g_7_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">10841000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_4-ecTO4TqUqZ6yUZ5nD8sg_8_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">16426000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_qGPARtgD8kqfbZkYxl_Teg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;6. Property and equipment, net&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;Property and equipment and related accumulated depreciation are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 811&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 839&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Assets not yet placed in service&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 1,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 1,650&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1,622)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1,618)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total property and equipment, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 32&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The Company recorded less than &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_W4pGquiuLUKirJceSn_YoA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million, less than &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_NwoIzrC_q02kziSjSvHlIw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million, and &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_N2ulbwwA-UqvBSpy2gwqug;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million in depreciation expense for the years ended December 31, 2025, 2024, and 2023, respectively&lt;/span&gt;.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      id="Tb__8Z1QRyEWUybjXBKBBwU6w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;Property and equipment and related accumulated depreciation are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 811&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 839&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Assets not yet placed in service&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 1,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 1,650&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1,622)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1,618)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total property and equipment, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 32&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_OkY1QtMdYk-oqCKMPg88RQ"
      decimals="-3"
      id="Tc_qL28L4iIyU-1Z1yRlTjSsA_3_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">146000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_YUbMCLNoMEiiVq3ezSlFGg"
      decimals="-3"
      id="Tc_BK02aro3mESghv0TYgbirA_3_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">146000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_AXOj8gL7Jk6ZdhZ0AOwscw"
      decimals="-3"
      id="Tc_Tvz3p8pRBU2BaxPeQbMuyg_4_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">811000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_Em0bxcv8gk6czzZLTd4Ywg"
      decimals="-3"
      id="Tc_SvD7ugqy5EGJhXxR9GRCJg_4_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">839000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Gs8d_AaUlkS6G-nzgF-NEA"
      decimals="-3"
      id="Tc_lG3SJwODJkewbj4Cfp6Skw_5_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">665000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_yve5Cj4_rU-htYKKwRh69g"
      decimals="-3"
      id="Tc_Fil1PUY73UuZZQzVRAhGuA_5_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">665000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_1l5QGegeS02U-fJh6dqE6g_7_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1622000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_6Hemt8rZs0SDkR0Cvv2ojQ_7_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1650000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_xLaeGW2Bbk6nmAY8FtP1xg_8_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1622000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_yDTUOtdPW02eFS1kfQUzqw_8_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1618000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_n6nvMWSWV0WEl7UFhmXdVg_9_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">32000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_C_zVrKpgUkCMny13PluXwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. Accrued expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses consist of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:62.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:15.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued clinical trial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,915&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued milestone payments &amp;amp; royalties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued compensation and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,860&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued commercialization costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,205&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 803&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued contract manufacturing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued other research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,015&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued consulting fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,287&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 316&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 492&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total accrued expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 53,981&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25,952&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      id="Tb_NWvWyRHNpE-5rk2-fOhDfA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses consist of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:62.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:15.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued clinical trial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,915&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued milestone payments &amp;amp; royalties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued compensation and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,860&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued commercialization costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,205&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 803&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued contract manufacturing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued other research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,015&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued consulting fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,287&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 316&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 492&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total accrued expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 53,981&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25,952&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <vstm:AccruedClinicalTrialExpensesCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_gcUl8_F0FEqMxBqzBbDGMg_3_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">14338000</vstm:AccruedClinicalTrialExpensesCurrent>
    <vstm:AccruedClinicalTrialExpensesCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_S-2KVBV3d0-P4t7vTDlNhA_3_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">10915000</vstm:AccruedClinicalTrialExpensesCurrent>
    <vstm:AccruedMilestonePaymentsCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_wiziICe3h0mhk9WUIUAeRw_4_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">11767000</vstm:AccruedMilestonePaymentsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_1F6TU5BGA0iaD3TQKRVZOw_5_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">10860000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_31lTDo1g606zafXsRa_e4g_5_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6245000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <vstm:AccruedCommercializationCostsCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_T7muSmej0Uy48ySamyY1Ow_6_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">8205000</vstm:AccruedCommercializationCostsCurrent>
    <vstm:AccruedCommercializationCostsCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_wrai1Hz7NUK6eu3tnJITVw_6_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">803000</vstm:AccruedCommercializationCostsCurrent>
    <vstm:AccruedContractManufacturingExpensesCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_hbpKBCCRmkihj63WQ7laNQ_7_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3224000</vstm:AccruedContractManufacturingExpensesCurrent>
    <vstm:AccruedContractManufacturingExpensesCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_3Ib3KTrKZE-cklo4QacVMg_7_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3748000</vstm:AccruedContractManufacturingExpensesCurrent>
    <vstm:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_vIbYFGmdKUir3M3Lki_nRQ_8_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3015000</vstm:AccruedResearchAndDevelopmentExpensesCurrent>
    <vstm:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_Ph7fj6rOFkWVD0d819YJSw_8_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1359000</vstm:AccruedResearchAndDevelopmentExpensesCurrent>
    <vstm:AccruedConsultingFeesCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_9gsqEyaXIECSjYIofb4QGA_9_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1287000</vstm:AccruedConsultingFeesCurrent>
    <vstm:AccruedConsultingFeesCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc__uMWcssey02sPO_C7g3EmA_9_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1613000</vstm:AccruedConsultingFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_xRhv8_Ys3kSeMsqPaUF55w_10_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">793000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_B-mNYojIV0iYGyTGReP4jg_10_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">620000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_IFNq9PpyWEiKDX4X78rMhw_11_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">316000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_lUdhfzWjM0KCSg89l8RSdA_12_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">492000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_LkVo89_xyEC7gB9_HYCmDw_12_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">333000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_ktQ2pivqUUaI70Skszdlpw_13_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">53981000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_5w_0BaHtzkuqoxCwCznjxg_13_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">25952000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_D4tklFxlIEKqbRToFcrtsQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8. Long-term debt&lt;/b&gt; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Note Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On January&#160;13, 2025 (the &#x201c;Note Purchase Agreement Closing Date&#x201d;), the Company entered into the &lt;/span&gt;Note Purchase Agreement (the &#x201c;Note Purchase Agreement&#x201d;) with RGCM SA LLC, as purchaser agent, Oberland Capital Management LLC (&#x201c;Oberland&#x201d;) and certain funds managed by Oberland, as purchasers (together with the other purchasers party thereto referred as the &#x201c;Note Purchase Agreement Purchasers&#x201d;) &lt;span style="background:#ffffff;"&gt;pursuant to which the Company may sell to the Purchasers, and the Purchasers may buy from the Company, notes (the &#x201c;Notes&#x201d;) in an aggregate principal amount not to exceed &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$150.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million. On the Note Purchase Agreement Closing Date, the Company issued and sold an initial Note in an aggregate principal amount &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$75.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million. In addition, the Company may issue and sell additional Notes with aggregate principal amount of up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$75.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million as follows&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-top:14pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt 0pt 6pt 0pt;"&gt;iii.&lt;/td&gt;&lt;td style="text-align:right;width:18pt;padding:0pt 0pt 6pt 0pt;"&gt;&lt;/td&gt;&lt;td style="padding:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;at the option of the Company, the a second purchase (the &#x201c;Second Purchase&#x201d;) of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$25.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million principal amount of Notes, at any time prior to December 31, 2025, upon the FDA&#x2019;s approval sufficient for the promotion and sale of avutometinib and defactinib for the treatment of LGSOC and subject to certain other customary conditions precedent. In March 2026, the Company amended the Note Purchase Agreement to extend the date by which it may draw down the Second Purchase from December 31, 2025 to June 30, 2026 (see &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Note 20. Subsequent Events&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;). and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:31.5pt;padding:0pt;"&gt;iv.&lt;/td&gt;&lt;td style="text-align:right;width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;at the option of the Company, the, a third purchase (the &#x201c;Third Purchase&#x201d;) of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$50.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million principal amount of Notes, at any time prior to December 31, 2026, provided that trailing six-month worldwide net sales of avutometinib and defactinib are at least &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$55.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million and subject to certain other customary conditions precedent.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:14pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:14pt;background:#ffffff;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The outstanding principal amount of the Notes bear interest at a rate per annum equal to the sum of (i)&#160;the greater of the Term &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_Jq6EAhHjvU6lCRswi0Rx2Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;SOFR&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; (as defined in the Note Purchase Agreement) and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;4.29%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, and (ii)&#160;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;3.71%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, subject to adjustment in certain circumstances set forth in the Note Purchase Agreement and an overall cap of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;9.75%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, payable quarterly in arrears until the seventh anniversary of the Note Purchase Agreement Closing Date or the date on which all amounts owing to the Note Purchase Agreement Purchasers under the Note Purchase Agreement have been paid in full (the &#x201c;Note Purchase Agreement Maturity Date&#x201d;). For the first eight quarters following the Note Purchase Agreement Closing Date, at the Company&#x2019;s option, up to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;50%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of the interest due may be paid-in-kind and added to the then-outstanding principal balance of the Notes. Through December 31, 2025, the Company has not elected to defer any interest through its paid-in-kind option. Upon the occurrence and during the continuance of an Event of Default (as defined in the Note Purchase Agreement) under the Note Purchase Agreement, the then-applicable interest rate on all outstanding obligations may be increased by an additional &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5.00%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:0pt;"&gt;Beginning on January&#160;13, 2025 and continuing until the Note Purchase Agreement Maturity Date, the Note Purchase Agreement Purchasers will receive 1.00% (the &#x201c;Revenue Participation Percentage&#x201d;) of the first $100.0 million of net sales of each Included Product (as defined in the Note Purchase Agreement) by the Company or its affiliates or licensees in each calendar year, payable quarterly. &#x201c;Included Products&#x201d; is defined in the Note Purchase Agreement to include (a)&#160;avutometinib and defactinib, including any product that contains either one of the foregoing in combination with any other active ingredient(s), and (b)&#160;all other compounds, chemical entities or pharmaceutical products being designed, developed, licensed, manufactured or commercialized by the Company or its subsidiaries from time to time. The Revenue Participation Percentage will increase&#160;pro rata&#160;immediately upon the occurrence of the Second Purchase and the Third Purchase, such that the Revenue Participation Percentage shall increase to a maximum of 2.00% in the event that $150 million in aggregate principal amount of Notes has been purchased pursuant to the Note Purchase Agreement following the Third Purchase. The outstanding principal amount of the Notes, interest accrued thereon and any other amounts owing to the Note Purchase Agreement Purchasers under the Note Purchase Agreement will be due in two equal instalments on (a)&#160;the sixth anniversary of the Note Purchase Agreement Closing Date, and (b)&#160;the Note Purchase Agreement Maturity Date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;All of the Notes may be redeemed prior to the Note Purchase Agreement Maturity Date at the option of the Company, subject to payment of the Repayment Amount (as defined in the Note Purchase Agreement). The Note Purchase Agreement Purchasers may demand redemption of the Notes prior to the Note Purchase Agreement Maturity Date in the event of a Change of Control (as defined in the Note Purchase Agreement) of the Company or an Event of Default (as defined in the Note Purchase Agreement) under the Note Purchase Agreement, subject to payment of the Repayment Amount. The Repayment Amount is due at the earlier of the Maturity Date and when payment of all obligations under the Note Purchase Agreement are otherwise due. The Repayment Amount is: (a)&#160;135% of the principal amount of the Notes if redemption occurs before the second anniversary of the Note Purchase Agreement Closing Date upon a Change of Control; (b)&#160;if the preceding clause (a)&#160;does not apply, 175% of the principal amount of the Notes if redemption occurs prior to the third anniversary the Note Purchase Agreement Closing date; and (c)&#160;thereafter, 195% of the principal amount of the Notes if redemption occurs after the third anniversary the Note Purchase Agreement Closing Date, minus, in each case, the sum of regularly scheduled interest paid in cash, payments of principal in cash, and payments of revenue participation in cash prior to such redemption date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 10pt 0pt;"&gt;The Note Purchase Agreement contains no financial covenants. The Company&#x2019;s obligations under the Note Purchase Agreement are subject to customary covenants, including limitations on the Company&#x2019;s ability to dispose of assets, undergo a change of control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of its capital stock, repurchase stock and make investments, in each case subject to certain exceptions. The Company&#x2019;s obligations under the Note Purchase Agreement are secured by a security interest on substantially all of the Company&#x2019;s and its subsidiaries&#x2019; assets, including its intellectual property related to avutometinib and defactinib, and a negative pledge on intellectual property related to the &lt;span style="background:#ffffff;"&gt;Company&#x2019;s collaboration and option agreement with GenFleet (the &#x201c;GenFleet Agreement&#x201d;), subject to certain exceptions relating to the Company&#x2019;s development of its intellectual property.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;A portion of the proceeds of the Note Purchase Agreement were used to repay the Company&#x2019;s obligations under the Loan Agreement in full. The Loan Agreement was terminated concurrently with entry into the Note Purchase Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"&gt;The Company assessed the terms and features of the Note Purchase Agreement and determined that the Company is eligible to elect the fair value option under ASC 825, &lt;i style="font-style:italic;"&gt;Financial Instruments&lt;/i&gt;. The Note Purchase Agreement contains various embedded features and the election of the fair value option allows the Company to bypass analysis of potential embedded derivatives and further analysis of bifurcation of any recognized financial liabilities. Under the fair value option, the financial liability is initially measured at its fair value on the issuance date and subsequently remeasured at estimated fair value on a recurring basis at each reporting date. Changes in the fair value of the Note Purchase Agreement, which include accrued interest, if any, are recorded as a component of change in fair value of Notes in the consolidated statements of operations. The Company has not elected to present interest expense separately from changes in fair value and therefore will not separately present interest expense associated with the Note Purchase Agreement. Changes in fair value caused by instrument-specific credit risk are presented separately in other comprehensive income or loss within the consolidated statements of equity (deficit). The portion of total &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;changes in fair value of Notes attributable to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive loss. Under the fair value option, debt issuance costs are expensed as incurred. The Company incurred $0.8 million of debt issuance costs which were recorded within selling, general and administrative expense in the consolidated statements of operations for the year ended December 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The Company determined the fair value of the Notes on January 13, 2025 was &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$75.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;million. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;The following table reconciles the change in fair value of the Notes during the years ended December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Beginning fair value balance at January 13, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;75,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden__aGtVmkn9kuWPabZ5DVUXg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value reported in statements of operations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12,751&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-3F5ri1upkSXeC-rPJHM9A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value reported in comprehensive loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,229)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest and revenue participation payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,192)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Ending fair value at December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;76,330&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;As of December 31, 2025, future principal payments under the Note Purchase Agreement are due as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2031&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2032&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total principal payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 75,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Loan Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On March 25, 2022 (the &#x201c;Loan Agreement Closing Date&#x201d;), the Company entered into a loan and security agreement (the &#x201c;Original Loan Agreement&#x201d;) with Oxford Finance, LLC (&#x201c;Oxford&#x201d;), as collateral agent and a lender, and Oxford Finance Credit Fund III LP, as a lender (&#x201c;OFCF III&#x201d; and together with Oxford, the &#x201c;Lenders&#x201d;), pursuant to which the Lenders agreed to lend the Company up to an aggregate principal amount of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$150.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million in a series of term loans (the &#x201c;Term Loans&#x201d;). On January 4, 2024, the Company amended the Original Loan Agreement (as amended, the &#x201c;Loan Agreement&#x201d;) to extend the date by which it may draw down the Term C Loan from March 31, 2024, to March 31, 2025. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Pursuant to the Loan Agreement, the Company received an initial Term Loan of&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$25.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million on the Loan Agreement Closing Date, and drew down the second term loan of&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$15.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million (the &#x201c;Term B Loan&#x201d;) on March 22, 2023, and could have borrowed an additional&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$110.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million of Term Loans at its option upon the satisfaction of certain conditions as follows:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;i.&lt;/td&gt;&lt;td style="text-align:right;width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;$25.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; million (the &#x201c;Term C Loan&#x201d;), when the Company has received accelerated or full approval from the FDA of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;avutometinib &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;for the treatment of LGSOC (the &#x201c;Term C Milestone&#x201d;). The Company could have drawn the Term C Loan within &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;60 days&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; after the occurrence of the Term C Milestone, but no later than March 31, 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;ii.&lt;/td&gt;&lt;td style="text-align:right;width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;$35.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; million (the &#x201c;Term D Loan&#x201d;), when the Company has achieved at least &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;$50.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; million in gross product revenue calculated on a trailing six-month basis (the &#x201c;Term D Milestone&#x201d;). The Company could have drawn the Term D Loan within &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;30 days&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; after the occurrence of the Term D Milestone, but no later than March 31, 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;iii.&lt;/td&gt;&lt;td style="text-align:right;width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;$50.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; million (the &#x201c;Term E Loan&#x201d;), at the sole discretion of the Lenders.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Term Loans bore interest at a floating rate equal to (a) the greater of (i) the one-month &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_YOPMCZqEsUS3-osVGkAxWQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;CME Secured Overnight Financing Rate&lt;/span&gt;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and (ii) &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;0.13%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; plus (b) &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;7.37%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;, subject to an overall floor and cap. Interest was payable monthly in arrears on the first calendar day of each calendar month. As a result of the Term B Loan drawdown, beginning (i) April 1, 2025, or (ii) April 1, 2026, if either (A) &lt;/span&gt;avutometinib h&lt;span style="background:#ffffff;"&gt;as received FDA approval for the treatment of LGSOC or (B) COPIKTRA has received FDA approval for the treatment of peripheral T-cell lymphoma, the Company would have been required to repay the Term Loans in consecutive equal monthly payments of principal, together with applicable interest, in arrears. All unpaid principal and accrued and unpaid interest with respect to each Term Loan were due and payable in full on March 1, 2027.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company was required to make a final payment of&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;5.0%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of the original principal amount of the Term Loans that are drawn, payable at maturity or upon any earlier acceleration or prepayment of the Term Loans (the &#x201c;Final Payment Fee&#x201d;). The Company could have prepaid all, but not less than all, of the Term Loans, subject to a prepayment fee equal to (i)&#160;3.0% of the principal amount of the applicable Term Loan if prepaid on or before the first anniversary date of the funding date of such Term Loan, (ii)&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;2.0%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of the principal amount of the applicable Term Loan if prepaid after the first anniversary and on or before the second anniversary of the funding date of such Term Loan, and (iii) &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;1.0%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of the principal amount of the applicable Term Loan if prepaid after the second anniversary of the applicable funding date of such Term Loan. All Term Loans were subject to a facility fee of&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;0.5%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of the principal amount.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Loan Agreement contained &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;no&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; financial covenants. The Loan Agreement included customary events of default, including, among others, payment defaults, breach of representations and warrants, covenant defaults, judgment defaults, insolvency and bankruptcy defaults, and a material adverse change. The occurrence of an event of default could have resulted in the acceleration of the obligations under the Loan Agreement, termination of the Term Loan commitments and the right to foreclose on the collateral securing the obligations. During the existence of an event of default, the Term Loans would have accrued interest at a rate per annum equal to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;5.0%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; above the otherwise applicable interest rate.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;In connection with the Loan Agreement, the Company granted Oxford a security interest in all of the Company&#x2019;s personal property now owned or hereafter acquired, excluding intellectual property (but including the right to payments and proceeds of intellectual property), and a negative pledge on intellectual property.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;The Company assessed all terms and features of the Loan Agreement in order to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the Loan Agreement, including put and call features. The Company determined that all features of the Loan Agreement were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's financial statements. The Company reassesses the features on a quarterly basis to determine if they require separate accounting. There have been no changes to the Company&lt;/span&gt;&#x2019;s &lt;span style="font-family:'Times';"&gt;assessment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Concurrently with the closing of the Note Purchase Agreement, on January&#160;13, 2025, the Company terminated its Loan Agreement and repaid in full the balance of its obligations under the Loan Agreement of approximately &lt;/span&gt;&lt;span style="font-family:'Times';"&gt;$42.7&lt;/span&gt;&lt;span style="font-family:'Times';"&gt;&#160;million (the &#x201c;Payoff Amount&#x201d;). The Payoff Amount included the Final Payment Fee of &lt;/span&gt;&lt;span style="font-family:'Times';"&gt;$2.0&lt;/span&gt;&lt;span style="font-family:'Times';"&gt;&#160;million, which was due at the earlier of prepayment or loan maturity, and certain prepayment fees as set forth in the Loan Agreement, a prepayment penalty fee of &lt;/span&gt;&lt;span style="font-family:'Times';"&gt;$0.6&lt;/span&gt;&lt;span style="font-family:'Times';"&gt;&#160;million, and unpaid interest of &lt;/span&gt;&lt;span style="font-family:'Times';"&gt;$0.1&lt;/span&gt;&lt;span style="font-family:'Times';"&gt;&#160;million.&#160;Upon the Lender&#x2019;s receipt of the Payoff Amount, the Loan Agreement was terminated along with the Lender&#x2019;s commitment to provide funding under any future term loans.&#160; All liens on the Company&#x2019;s assets to secure the loans under the Loan Agreement have been terminated and released. The Payoff Amount, excluding accrued interest, exceeded the carrying amount of the Term Loan on January 13, 2025 by&#160;&lt;/span&gt;&lt;span style="font-family:'Times';"&gt;$1.8&lt;/span&gt;&lt;span style="font-family:'Times';"&gt;&#160;million. As a result the Company recorded a loss on debt extinguishment of&#160;&lt;/span&gt;&lt;span style="font-family:'Times';"&gt;$1.8&lt;/span&gt;&lt;span style="font-family:'Times';"&gt;&#160;million included in the consolidated statements of operations and comprehensive loss for the twelve months ended December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;The debt issuance costs and the Final Payment Fee were recorded as a debt discount which were accreted to interest expense through the maturity date of the Term Loan using the effective interest method.&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;The components of the carrying value of the Term Loan as of December 31, 2024, are detailed below (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"&gt;&lt;span style="color:#212529;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal loan balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Final Payment Fee&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,172&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Debt issuance costs, net of accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (448)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Long-term debt, net of discount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 40,724&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The following table sets forth total interest expense for the years ended December 31, 2025, 2024, and 2023 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:52.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Contractual Interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 3,774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 3,472&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Amortization of debt discount and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 277&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 230&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Amortization of Final Payment Fee&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 511&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,138&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,562&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,139&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:1pt;font-style:italic;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_1_13_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_kwGm2G1ANE6CxfNPRBiayA"
      decimals="-5"
      id="Narr_ZbP1wZN5ekGxshuyROwjmg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_13_2025_srt_StatementScenarioAxis_vstm_InitialSaleMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_TGIhGhuPoUWERtDGZhnrlA"
      decimals="-5"
      id="Narr__TX3RtjEXUCWJtRKUfgpZQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">75000000</us-gaap:DebtInstrumentFaceAmount>
    <vstm:DebtInstrumentIssuanceOfAdditionalNotes
      contextRef="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_Un8b41l_pEirHv8lmaIPmw"
      decimals="-5"
      id="Narr_0_D4cc69AUqFHeFyPKgOGA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">75000000</vstm:DebtInstrumentIssuanceOfAdditionalNotes>
    <vstm:DebtInstrumentIssuanceOfAdditionalNotes
      contextRef="As_Of_1_13_2025_srt_StatementScenarioAxis_vstm_SecondSaleMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_kgBvIxdJtkiqAwZH4jNFMw"
      decimals="-5"
      id="Narr_RuleXFH0-02UUdcZFrcEOg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">25000000</vstm:DebtInstrumentIssuanceOfAdditionalNotes>
    <vstm:DebtInstrumentIssuanceOfAdditionalNotes
      contextRef="As_Of_1_13_2025_srt_StatementScenarioAxis_vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_FQVi45q7jkSuA4lClWDejQ"
      decimals="-5"
      id="Narr_HTkgKY4af0ifBVuIDXKhAQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">50000000</vstm:DebtInstrumentIssuanceOfAdditionalNotes>
    <vstm:CovenantWorldwideNetSalesOfAvutometinibAndDefactinib
      contextRef="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_Trailing6MonthsWorldwideNetSalesOfAvutometinibAndDefactinibAtLeast55MillionMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_2MBviHog-02Q7tUt8Qeq9g"
      decimals="-5"
      id="Narr_eassn7D4n0SQASdqG4k-AQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">55000000</vstm:CovenantWorldwideNetSalesOfAvutometinibAndDefactinib>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_iZI7Ie7K00GLdoRZJcm5tA"
      decimals="4"
      id="Narr_rsELOuPP102e7Nx_2yv6jQ"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0429</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <vstm:DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate
      contextRef="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_Un8b41l_pEirHv8lmaIPmw"
      decimals="4"
      id="Narr_n5pVhfZthUmhFQB5ZqL8mw"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0371</vstm:DebtInstrumentInterestRateStatedPercentageAdditionalInterestRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_Un8b41l_pEirHv8lmaIPmw"
      decimals="4"
      id="Narr_HlgWWbhw40ip1yzLixbrFw"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0975</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <vstm:InterestDuePaidInKindPercentage
      contextRef="Duration_1_13_2025_To_1_13_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_vstm_First8QuartersFollowingNotePurchaseAgreementClosingDateMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_ZP6M46McoESK6chF5ck0mg"
      decimals="2"
      id="Narr_6Cqp14-S9UuvwQmtuyIZNQ"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.50</vstm:InterestDuePaidInKindPercentage>
    <vstm:AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage
      contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_iZI7Ie7K00GLdoRZJcm5tA"
      decimals="4"
      id="Narr_k9rROQLBgECPcP6t75ILaw"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.05</vstm:AdditionalIncreaseInInterestRateAtEventOfDefaultPercentage>
    <vstm:ParticipationInNetSalesPercentage
      contextRef="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_First100MillionNetSalesOfEachIncludedProductMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_yDuuqaiCa0qAYyrozwvzzw"
      decimals="4"
      id="Narr_nCdAVi1LZUac5EpJv6PF_g"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.01</vstm:ParticipationInNetSalesPercentage>
    <vstm:ParticipationInNetSalesSalesAmount
      contextRef="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_First100MillionNetSalesOfEachIncludedProductMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_yDuuqaiCa0qAYyrozwvzzw"
      decimals="-5"
      id="Narr_AboF4msjFkaVrb7TZNFAqg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">100000000</vstm:ParticipationInNetSalesSalesAmount>
    <vstm:ParticipationInNetSalesPercentage
      contextRef="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_pZ_a6EQacUaXNZDxp5JMNA"
      decimals="4"
      id="Narr_EgTWiLBcMEe0-xJVS76zDQ"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.02</vstm:ParticipationInNetSalesPercentage>
    <vstm:ParticipationInNetSalesAggregatePrincipalAmountOfDebt
      contextRef="As_Of_1_13_2025_srt_StatementScenarioAxis_vstm_PurchaseOfFull150MillionAggregatePrincipalAmountOfNoteMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_L9jTrBAWiUuY_e_CNM8bCQ"
      decimals="-6"
      id="Narr_3ep19niInEaIMfNvV8M2gg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">150000000</vstm:ParticipationInNetSalesAggregatePrincipalAmountOfDebt>
    <vstm:DebtInstrumentNumberOfEqualInstallments
      contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_iZI7Ie7K00GLdoRZJcm5tA"
      decimals="INF"
      id="Narr_YQ8ZqAy7WEqEYAHEuZkyVQ"
      unitRef="Unit_Standard_installment_8U3XYH-pF0m6Z5I545EDwQ">2</vstm:DebtInstrumentNumberOfEqualInstallments>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_RedemptionPriorToSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_YpTuBpiScUuxKI1zr7VhQg"
      decimals="2"
      id="Narr_bn-xX6AkHk-pIJYm-VUPKQ"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">1.35</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_RedemptionPriorToThirdAnniversaryMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_E6tvvCsPZ0mBoCk6DsCySg"
      decimals="2"
      id="Narr_A7B0jax8IE2-_GpLWoOgag"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">1.75</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="Duration_1_13_2025_To_1_13_2025_srt_StatementScenarioAxis_vstm_RedemptionAfterYearThirdAnniversaryMember_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_E6iz-U49E0K1SJSRv0h8aQ"
      decimals="2"
      id="Narr_nG0votsf_kOFNvK1LXl5RA"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">1.95</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentCovenantDescription
      contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_iZI7Ie7K00GLdoRZJcm5tA"
      id="Narr_BBWmYiAGCkarAuXCSmJlvw">The Note Purchase Agreement contains no financial covenants</us-gaap:DebtInstrumentCovenantDescription>
    <vstm:DebtIssuanceCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_02A2El0zNE6rdIdZB1KSUg"
      decimals="-5"
      id="Narr_fIRKSHTPbEqj3gb5d9QEaQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">800000</vstm:DebtIssuanceCosts>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_Un8b41l_pEirHv8lmaIPmw"
      decimals="-5"
      id="Narr_48s8YAAGrUub7cCghocKvw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">75000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Group_zgaJxhLT3k6o8-qjLrTcCw">&lt;span style="font-size:10pt;"&gt;The following table reconciles the change in fair value of the Notes during the years ended December 31, 2025&lt;/span&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Beginning fair value balance at January 13, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;75,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden__aGtVmkn9kuWPabZ5DVUXg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value reported in statements of operations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12,751&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-3F5ri1upkSXeC-rPJHM9A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value reported in comprehensive loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,229)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest and revenue participation payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,192)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Ending fair value at December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;76,330&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_Un8b41l_pEirHv8lmaIPmw"
      decimals="-3"
      id="Tc_2z_VmJ9V70ygzG0ywIRbdg_1_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">75000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_14_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_0BoN3371-EmgElNU_GJ5pw"
      decimals="-3"
      id="Tc_T77DokhqhkGU0aBCsPcWGQ_2_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-12751000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="Duration_1_14_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_0BoN3371-EmgElNU_GJ5pw"
      decimals="-3"
      id="Tc_S4NPfFsm5ky2nWRKUTts_w_3_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5229000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="Duration_1_14_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_0BoN3371-EmgElNU_GJ5pw"
      decimals="-3"
      id="Tc_u_462H2p4kqWnFV73iTt6g_4_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6192000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_8S_QmEHi20-3Bt7pN3KrWg"
      decimals="-3"
      id="Tc__4VRWzQaAEKV0C_3NHrjkQ_5_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">76330000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_-YdQ7h0dPUaScC-RCaPWDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;As of December 31, 2025, future principal payments under the Note Purchase Agreement are due as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2031&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2032&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total principal payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 75,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <vstm:LongTermDebtMaturityYearSix
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_yEjjVqDXqUGcQZm11rg45g_6_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">37500000</vstm:LongTermDebtMaturityYearSix>
    <vstm:LongTermDebtMaturityYearSeven
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_UyDN7Lf3dkm13i0_yhb_Yg_7_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">37500000</vstm:LongTermDebtMaturityYearSeven>
    <vstm:LongTermDebtMaturitiesAggregatePrincipalDue
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_xw7iDOrubEOJh6QKvWJQnA_8_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">75000000</vstm:LongTermDebtMaturitiesAggregatePrincipalDue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_zrQB4qKfyEqQTrK2VnX_yg"
      decimals="-5"
      id="Narr_7r98nrI6Z0eDHR99ei-FNw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_n_qBs1SNYkedi6TPK_3kgw"
      decimals="-5"
      id="Narr_d1cCuacnc0OX9RPXTLbIIA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">25000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_3_22_2023_To_3_22_2023_us-gaap_DebtInstrumentAxis_vstm_TermBLoanMember_Ko01k0D9G0CisdNqaY7CwQ"
      decimals="-5"
      id="Narr_41PZAYhXOkyS8qR7VDbr9A"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">15000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <vstm:DebtInstrumentCurrentBorrowingCapacity
      contextRef="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_zrQB4qKfyEqQTrK2VnX_yg"
      decimals="-5"
      id="Narr_P-NPAqrIbk-Cuf-rOxyz8Q"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">110000000</vstm:DebtInstrumentCurrentBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermCLoanMember_LB9vQfFWtUOb5dJuYRvwQw"
      decimals="-5"
      id="Narr_dHnFqqSXy0mLiB6zNSAMJg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">25000000</us-gaap:DebtInstrumentFaceAmount>
    <vstm:DebtInstrumentPeriodToDrawLoanMinimum
      contextRef="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermCLoanMember_GwB-PS6Ju0-fUVSXWFqhUQ"
      id="Narr_sOj1dxOnPEKTEFClbDjcOg">P60D</vstm:DebtInstrumentPeriodToDrawLoanMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermDLoanMember_w57GQ0GBSEaZmkdvKKZD1w"
      decimals="-5"
      id="Narr_q25n9EPBgU66XatzxtJ9cg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">35000000</us-gaap:DebtInstrumentFaceAmount>
    <vstm:GrossProductRevenueToBeAchieved
      contextRef="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermDLoanMember_0YiEHyy_qUmrRNBRC-bsYg"
      decimals="-5"
      id="Narr_PwvO-v-6n0WKztgahFWSYw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">50000000</vstm:GrossProductRevenueToBeAchieved>
    <vstm:DebtInstrumentPeriodToDrawLoanMinimum
      contextRef="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermDLoanMember_0YiEHyy_qUmrRNBRC-bsYg"
      id="Narr_DybtlcIVdU6ST2nb4KZbcg">P30D</vstm:DebtInstrumentPeriodToDrawLoanMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermELoanMember_oqIeKfAl3E-mBRkyj-y-iA"
      decimals="-5"
      id="Narr_nh8IkfLdX0C9y5Ezg9K-tA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_3_22_2023_To_3_22_2023_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_5nolpa91pE-eWxvWNTzoIA"
      decimals="4"
      id="Narr__f1leL7SS0adoXBw2co-ow"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0013</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_22_2023_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_75mzb7bZKkioJTv-axGvyQ"
      decimals="4"
      id="Narr_6A27Rlw5LUuoYcKXw1ji6g"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0737</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <vstm:DebtInstrumentFinalPaymentFeePercentage
      contextRef="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_n_qBs1SNYkedi6TPK_3kgw"
      decimals="3"
      id="Narr_Uri3-8L090WGTwmPcfK1YA"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.05</vstm:DebtInstrumentFinalPaymentFeePercentage>
    <vstm:DebtInstrumentFinalPaymentFeePercentage
      contextRef="Duration_3_25_2022_To_3_25_2022_srt_StatementScenarioAxis_vstm_PrepaymentAfterFirstAnniversaryAndOnOrBeforeSecondAnniversaryMember_q8ti5S-pZU699rXFl4F2PQ"
      decimals="3"
      id="Narr_HkvC5fnKDUOfu7ltK5xAYQ"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.02</vstm:DebtInstrumentFinalPaymentFeePercentage>
    <vstm:DebtInstrumentFinalPaymentFeePercentage
      contextRef="Duration_3_25_2022_To_3_25_2022_srt_StatementScenarioAxis_vstm_PrepaymentAfterSecondAnniversaryMember_1PALNeli40iSsLa7t8QfSA"
      decimals="3"
      id="Narr_zUTTHgVPrkuU2fUgHyCh2A"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.01</vstm:DebtInstrumentFinalPaymentFeePercentage>
    <vstm:DebtInstrumentAdditionalInterestRateInEventOfDefault
      contextRef="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_TermLoanFacilityMember_zrQB4qKfyEqQTrK2VnX_yg"
      decimals="3"
      id="Narr_lXC7al8q-0CqGQLF725yoQ"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.005</vstm:DebtInstrumentAdditionalInterestRateInEventOfDefault>
    <vstm:NumberOfFinancialCovenants
      contextRef="As_Of_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember_hrCFuYf1CEmedfPlJxDI9w"
      decimals="INF"
      id="Narr_9aLgePVMWUWfpuB0PdmPPA"
      unitRef="Unit_Standard_item_5quK1hZThku2W0bLLpUodA">0</vstm:NumberOfFinancialCovenants>
    <vstm:DebtInstrumentAccruedInterestRate
      contextRef="Duration_3_25_2022_To_3_25_2022_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember_hJCM6F5LHUKiyc_uSMcFDQ"
      decimals="3"
      id="Narr_wi8UJvY90EalNSs1oG8XJw"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.05</vstm:DebtInstrumentAccruedInterestRate>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember__WavrOlweUuRmxKfUY_vSg"
      decimals="-5"
      id="Narr_dCUplrOMGEKwhq2mqLiiVA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">42700000</us-gaap:RepaymentsOfLongTermDebt>
    <vstm:RepaymentsOfLongTermDebtFinalPaymentFee
      contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember__WavrOlweUuRmxKfUY_vSg"
      decimals="-5"
      id="Narr_MJFgj2oC90-OuuaMwlfDHQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2000000</vstm:RepaymentsOfLongTermDebtFinalPaymentFee>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember__WavrOlweUuRmxKfUY_vSg"
      decimals="-5"
      id="Narr_T1Pe00dMd0uUR31E4TAuRQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">600000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <vstm:RepaymentsOfLongTermDebtUnpaidInterest
      contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember__WavrOlweUuRmxKfUY_vSg"
      decimals="-5"
      id="Narr_TFlGjwjQ-0CsQtVteVXBHA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">100000</vstm:RepaymentsOfLongTermDebtUnpaidInterest>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember__WavrOlweUuRmxKfUY_vSg"
      decimals="-5"
      id="Narr_sY38XIi8UE6GUH2tnF-wTw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-1800000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_LoanAndSecurityAgreementMember_RAkPieYklE2it_DAfMg6bg"
      decimals="-5"
      id="Narr_x9nDOq1Df0SwMi3Fw3OLAw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-1800000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Group_36ypkJHP3Uy9Q78n_xzZrg">&lt;span style="color:#212529;"&gt;The components of the carrying value of the Term Loan as of December 31, 2024, are detailed below (in thousands):&lt;/span&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"&gt;&lt;span style="color:#212529;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal loan balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Final Payment Fee&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,172&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Debt issuance costs, net of accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (448)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Long-term debt, net of discount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 40,724&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_-4E3cJFf8kK0hmjS6Cdtzw_2_2"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">40000000</us-gaap:DebtInstrumentCarryingAmount>
    <vstm:DebtInstrumentFinalPaymentFee
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_5vhyVcHqKk6r3GVpqkO3zA_3_2"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1172000</vstm:DebtInstrumentFinalPaymentFee>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_G9szStQLZUCCbiCi0sw9hw_4_2"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">448000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_-jeF0e8-TU2oPGCFEoRPHg_5_2"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">40724000</us-gaap:LongTermDebt>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_zbMcuypbiUSIYEyMMNAB6A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The following table sets forth total interest expense for the years ended December 31, 2025, 2024, and 2023 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:52.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Contractual Interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 3,774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 3,472&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Amortization of debt discount and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 277&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 230&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Amortization of Final Payment Fee&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 511&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,138&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,562&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,139&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:1pt;font-style:italic;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <vstm:ContractualInterestExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_TD6s7rZdC0yU1KoVqt34QA_3_2"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1109000</vstm:ContractualInterestExpense>
    <vstm:ContractualInterestExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_9mFPMP4ImE6uUcsjjs-DYg_3_5"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3774000</vstm:ContractualInterestExpense>
    <vstm:ContractualInterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_0pHm6ssqy0ehc2yDXVmU_w_3_8"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3472000</vstm:ContractualInterestExpense>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_kuT2U_t8REmRTqNSwwxDiQ_4_2"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">11000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_Xq3draT7NUScJNtizT5E-w_4_5"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">277000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_6w1yIaFpo0SLF1vgBo_DJg_4_8"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">230000</us-gaap:AmortizationOfFinancingCosts>
    <vstm:AmortizationOfFinalPaymentFee
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_tnr3SV1g80iFkNz1XQ0NTQ_5_2"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">18000</vstm:AmortizationOfFinalPaymentFee>
    <vstm:AmortizationOfFinalPaymentFee
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_8Plr9_lg9Uqs0JADaRnQow_5_5"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">511000</vstm:AmortizationOfFinalPaymentFee>
    <vstm:AmortizationOfFinalPaymentFee
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_WB_Gat1yA0e8hUeOXvp8wQ_5_8"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">437000</vstm:AmortizationOfFinalPaymentFee>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_h0nrU6NJxkOJKTYrLdysow_6_2"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1138000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_1SSCqlFgIk-VjJrRUYv8Pw_6_5"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4562000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_gs9Elj_EcUaO_ZVlLxrvSg_6_8"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4139000</us-gaap:InterestExpense>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_g_lvTasI6U2EkV9g7vUTKA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;9. Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 15, 2014, the Company entered into a lease agreement for approximately 15,197 square feet of office and laboratory space in Needham, Massachusetts. The lease term commenced on April 15, 2014 and it was scheduled to expire on September 30, 2019. Effective February 15, 2018, the Company amended its lease agreement to relocate within the facility to another location consisting of 27,810 square feet of office space (the &#x201c;February 2018 Amended Lease Agreement&#x201d;). The February 2018 Amended Lease Agreement extended the expiration date of the lease from September 2019 through June 2025. Pursuant to the February 2018 Amended Lease Agreement, the initial annual base rent amount was approximately $0.7 million, which increased during the lease term to $1.1 million for the last 12-month period. Effective November 1, 2024, the Company amended the February 2018 Amended Lease Agreement to extend the expiration date from June 2025 to June 2026 (the &#x201c;November 2024 Amended Lease Agreement&#x201d;). The payment terms of the November 2024 Amended Lease Agreement are $1.1 million per annum through the expiration date in June 2026. As a result of the November 2024 Amended Lease Agreement, the Company recorded an incremental $1.0 million right-of-use asset and corresponding lease liability during the year ended December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has accounted for its Needham, Massachusetts office space as an operating lease. The Company&#x2019;s lease contains an option to renew and extend the lease terms and an option to terminate the lease prior to the expiration date. The Company has not included the lease extension or the termination options within the right-of-use asset and lease liability on the consolidated balance sheets as neither option is reasonably certain to be exercised. The Company&#x2019;s lease includes variable non-lease components (e.g., common area maintenance, maintenance, consumables, etc.) that are not included in the right-of-use asset and lease liability and are reflected as an expense in the period incurred. The Company does not have any other operating or finance leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025, a right-of-use asset of $0.5 million and lease liability of $0.5 million are reflected on the consolidated balance sheets. The elements of lease expense were as follows (dollar amounts in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:53.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:43.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease Expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Operating lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 885&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:43.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Lease Expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 906&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 885&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other Information - Operating Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:43.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Operating cash flows paid for amounts included in measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,092&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,081&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,060&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other Balance Sheet Information - Operating Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Weighted average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;9.8%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity Analysis&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 546&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Less: Present value discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease Liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 535&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_4_15_2014_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_xnA_Kvwj70evJoubr3vJJQ"
      decimals="INF"
      id="Narr_Rm-pGXKFKkeqRvo26baZUA"
      unitRef="Unit_Standard_sqft_FdbiNq8DNkeaOGqvsWqN6A">15197</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_2_15_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_X8QqK4Hmd06KwW35Ix-WEQ"
      decimals="INF"
      id="Narr_DX7r-rVtbUOS0aAqBJlPEg"
      unitRef="Unit_Standard_sqft_FdbiNq8DNkeaOGqvsWqN6A">27810</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_2_15_2018_To_2_15_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_TZVH7IRG1kSvGhOZkG4XQA"
      decimals="-5"
      id="Narr_pOK9LKQI1U-VfBO_AJ-niw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_2_15_2018_To_2_15_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_PZfr7HL6HkyNjzMRM2PTpg"
      decimals="-5"
      id="Narr_C7-c2yaI_0OYRvt5WUeUvg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceInNeedhamMassachusettsMember_nO8T_caZLkmO-wA1SFOP5w"
      decimals="-5"
      id="Narr_BG3N6jkKHkC4_tKhq_KPrw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_11_30_2024_UMnI-wXQ0USHesrFhwgQ9g"
      decimals="-5"
      id="Narr_dh02gn0gTUebMB1DeYXdlQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-5"
      id="Narr_D_eiIEgAKEanzibepjmnhg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-5"
      id="Narr_mWp8oh1MwEiHFFM2UJ3n7g"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Group_0ac6m0T6VUWty6P-ZVTmAQ">The elements of lease expense were as follows (dollar amounts in thousands):&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:53.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:43.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease Expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Operating lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 885&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:43.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Lease Expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 906&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 885&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:43.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other Information - Operating Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:43.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Operating cash flows paid for amounts included in measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,092&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,081&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,060&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other Balance Sheet Information - Operating Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Weighted average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;9.8%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:48.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity Analysis&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 546&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Less: Present value discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease Liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 535&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_QNYh1lrqo0CBmRdh2mVqpA_4_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1011000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_gbhrokiKlkGFsLpEwZuxxg_4_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">906000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_7seh7d2DMEiyKNwfLQGeEQ_4_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">885000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_kwz8DxlpIkuNTSjxHrjAyA_5_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1011000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_Pju4MnW-DUWCpi7N1SPUrg_5_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">906000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_jQ08-duQMEmjqfyKEGh9fQ_5_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">885000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_49hSRf4W90-YsL4TTftnSg_7_4"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1092000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_18DhkDvW3Emjspl8MzWhRw_7_7"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1081000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_RBuyXEgjA0S5vfrNiiBB-A_7_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1060000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      id="Tc_HGz4yfbBCEyTvKQT8f556g_3_6">P0Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="3"
      id="Tc_5m5pmhC500O1xbsHKAhH1A_4_6"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.098</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_N4nQ0cGzUEis_5M9tcTViA_6_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">546000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_hKiWZ0QNkkqaNs-5RXMf-A_7_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">546000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_6av96c3afkSwqL4KW-5wmg_8_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">11000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_26lGiZ3eyEmZdjeeoawq8Q_9_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">535000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_yszt-HnrEUq05F5ATMrHgw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10. Capital Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;Under the amended and restated certificate of incorporation, the Company&#x2019;s board of directors has the authority, without further action by the stockholders, to issue up to&#160;5,000,000&#160;shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025 and 2024, the Company had reserved the following shares of common stock for the issuance of common stock for vested restricted stock units, the exercise of stock options, employee stock purchase plan, Series A Convertible Preferred Stock conversions to shares of common stock, and exercise of warrants and pre-funded warrants (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares reserved under Equity Compensation Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,232&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,925&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares reserved for Inducement Grants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,195&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 802&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares reserved for ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares reserved for Series A Convertible Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 833&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares reserved for Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares reserved for pre-funded warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,656&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total shares reserved&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 28,555&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 30,702&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:12pt 0pt 0pt 0pt;"&gt;Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;November 2025 Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 13, 2025, the Company entered into an Underwriting Agreement (the &#x201c;November 2025 Public Offering&#x201d;) with several Underwriters to sell in a public offering 8,543,794 shares of the Company&#x2019;s common stock, at a price to the public of $7.25 per share, less the underwriting discounts and commissions, and, in lieu of shares of common stock to certain investors, pre-funded warrants (the &#x201c;November 2025 Pre-Funded Warrants&#x201d;) to purchase up to an aggregate of 3,870,000 shares of common stock at a price to the public of $7.2499 per share of common stock underlying a pre-funded warrant, which represents the per share public offering price for the shares of common stock &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;less the $0.001 per share exercise price for each such share of common stock underlying a November 2025 Pre-Funded Warrant. Furthermore, as part of the Underwriting Agreement, Greenshoe Options (&#x201c;November 2025 Overallotment Options&#x201d;) were granted to the Underwriters to purchase up to an aggregate of 1,862,069 shares of the Company&#x2019;s Common Stock, par value $0.0001 per share, at a price to the Underwriters of $7.25 per share, less the underwriting discounts and commissions. On November 14, 2025, the underwriters exercised their Overallotment Options in full and the Company issued 1,862,069 additional shares of common stock at the price of $7.25 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;The exercise price of each November 2025 Pre-Funded Warrant equals&#160;$0.0001&#160;per underlying share of common stock.&#160;The exercise price and the number of shares of common stock issuable upon exercise of each November 2025 Pre-Funded Warrant is subject to appropriate adjustment in the event of certain stock dividends, stock splits, stock combinations, or similar events affecting the Company&#x2019;s common stock. The November 2025 Pre-Funded Warrants are exercisable in cash or by means of a cashless exercise and will not expire until the date the November 2025 Pre-Funded Warrants are fully exercised.&#160;The November 2025 Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof (together with its affiliates) immediately following such exercise would exceed a specified beneficial ownership limitation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;The November 2025 Pre-Funded Warrants cannot require cash settlement, are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its common stock shares and permit the holders to receive a fixed number of shares of common stock upon exercise. Additionally, the November 2025 Pre-Funded Warrants do not provide any guarantee of value or return. Accordingly, the November 2025 Pre-Funded Warrants are classified as a component of permanent equity. The net proceeds of the 2025 Public Offering were approximately $96.9&#160;million, after deducting underwriting fees and other expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;April 2025 PIPE Transaction&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;On April 25, 2025, the Company entered into a securities purchase agreement with certain institutional accredited investors (the &#x201c;PIPE Investors&#x201d;), pursuant to which the Company sold to the PIPE Investors, in a private placement (the &#x201c;2025 Private Placement&#x201d;), an aggregate of&#160;3,429,287&#160;shares of the Company&#x2019;s common stock at an offering price of $7.00&#160;per share and,&#160;in lieu of common stock to certain PIPE Investors, pre-funded warrants to purchase an aggregate of&#160;7,285,713&#160;shares of common stock (the &#x201c;April 2025 Pre-Funded Warrants,&#x201d;) at an offering price of $6.9999&#160;per April 2025 Pre-Funded Warrant. The 2025 Private Placement closed on April 28, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The exercise price of each April 2025 Pre-Funded Warrant equals&#160;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.0001&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;per underlying share of common stock.&#160;The exercise price and the number of shares of common stock issuable upon exercise of each April 2025 Pre-Funded Warrant is subject to appropriate adjustment in the event of certain stock dividends, stock splits, stock combinations, or similar events affecting the Company&#x2019;s common stock. The April 2025 Pre-Funded Warrants are exercisable in cash or by means of a cashless exercise and will not expire until the date the April 2025 Pre-Funded Warrants are fully exercised.&#160;The April 2025 Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof (together with its affiliates) immediately following such exercise would exceed a specified beneficial ownership limitation; provided, however, that a holder may increase or decrease the beneficial ownership limitation by giving&#160;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;61 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#x2019; notice to the Company, but not to any percentage in excess of&#160;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;19.99%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;. I&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;n addition, upon the occurrence of a fundamental transaction (as described in the April 2025 Pre-Funded Warrant), each April 2025 Pre-Funded Warrant will have the right to receive, upon exercise of such April 2025 Pre-Funded Warrant, the kind and amount of securities, cash or other property that such holders would have received had they exercised such April 2025 Pre-Funded Warrant immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the April 2025 Pre-Funded Warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;The April 2025 Pre-Funded Warrants cannot require cash settlement, are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its common stock shares and permit the holders to receive a fixed number of shares of common stock upon exercise. Additionally, the April 2025 Pre-Funded Warrants do not provide any guarantee of value or return. Accordingly, the April 2025 Pre-Funded Warrants are classified as a component of permanent equity. The net proceeds of the 2025 Private Placement were approximately $69.9&#160;million, after deducting placement agent fees and other expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;In connection with the Note Purchase Agreement, on January&#160;13, 2025, the Company entered into a Stock Purchase Agreement (the &#x201c;Stock Purchase Agreement&#x201d;) with the certain funds managed by Oberland and affiliates thereof (the &#x201c;SPA Investors&#x201d;), pursuant to which the SPA Investors purchased an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;1,416,939&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares of the Company&#x2019;s common stock, at a price of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$5.2931&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per share, based on the trailing 30-trading day volume-weighted average price of the Company&#x2019;s common stock, as of the date of the Stock Purchase Agreement. The Company received net proceeds of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$7.4&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million after deducting for offering costs which was recorded as component of permanent equity during the year ended December 31, 2025. In addition, pursuant to the Stock Purchase Agreement, the Company granted the SPA Investors, for a period of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;three years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; following the closing on January 13, 2025, a right to participate in any equity offerings consummated by the Company in an amount up to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$2.5&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million, subject to certain limitations and exclusions set out in the Stock Purchase Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;July 2024 Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;On July&#160;23, 2024, the Company entered into an underwriting agreement with Guggenheim Securities, LLC and Cantor Fitzgerald&#160;&amp;amp; Co. (&#x201c;Cantor&#x201d;), as representatives of the several underwriters relating to the underwritten offering, issuance and sale by the Company of: (i)&#160;13,333,334&#160;shares of the Company&#x2019;s common stock, and accompanying warrants (the &#x201c;Warrants&#x201d;) to purchase up to&#160;13,333,334&#160;shares of common stock; and (ii)&#160;to certain investors, pre-funded warrants (the &#x201c;July 2024 Pre-Funded Warrants&#x201d;) to purchase up to&#160;5,000,000&#160;shares of common stock and accompanying Warrants to purchase&#160;5,000,000&#160;shares of common stock (collectively, the &#x201c;July 2024 Offering&#x201d;). Each share of common stock was sold with an accompanying Warrant at a combined price of $3.00, and each July 2024 Pre-Funded Warrant was sold together with an accompanying Warrant at a combined price of $2.999, which is equal to the combined offering price per share of common stock and accompanying Warrant less the $0.001&#160;exercise price of each July 2024 Pre-Funded Warrant. The July 2024 Offering closed on July 25, 2024. The Company received approximately $50.8&#160;million in net proceeds, after deducting underwriting discounts and commissions and offering expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;Each July 2024 Pre-Funded Warrant has an exercise price equal to $0.001&#160;per underlying share of common stock. The July 2024 Pre-Funded Warrants are exercisable as of July 25, 2024, do not expire and are exercisable in cash or by means of cashless exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;Each Warrant has an exercise price equal to&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;$3.50&lt;/span&gt;&lt;span style="color:#212529;"&gt;. Each Warrant is exercisable for&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;one&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;share of the Company&#x2019;s common stock (or, in certain limited circumstances in lieu of a share of common stock, a pre-funded warrant for&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;one&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;share of the Company&#x2019;s common stock at the warrant exercise price less the exercise price of the pre-funded warrant purchased). The Warrants are exercisable as of July 25, 2024 until their expiration on January 25, 2026. The Warrants are exercisable in cash or, in certain limited circumstances only, by means of a cashless exercise.&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;span style="color:#212529;"&gt;The exercise price and the number of shares of common stock issuable upon exercise of each Warrant or July 2024 Pre-Funded Warrant, as applicable, is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Company&#x2019;s common stock as well as upon any distribution of assets, including cash, stock or other property, to the Company&#x2019;s stockholders.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;The Company may not effect the exercise of any Warrant or July 2024 Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Warrant or July 2024 Pre-Funded Warrant if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) would exceed&#160;&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;4.99%&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;&#160;(or such higher percentage up to&#160;&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;19.99%&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;, at the election of the holder) of the number of shares of the Company&#x2019;s common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder&#x2019;s election upon&#160;&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;61 days&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;&#x2019; notice to the Company subject to the terms of such Warrants or July 2024 Pre-Funded Warrants, as applicable, provided that such percentage may in no event exceed&#160;&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;19.99%&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;. In the event that the exercise of a Warrant would cause the holder to beneficially own in excess of&#160;&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;4.99%&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;&#160;(or such higher percentage up to&#160;&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;19.99%&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;, at the election of the holder) of the total number shares of the Company&#x2019;s common stock outstanding immediately after giving effect to such exercise, the holder of a Warrant may elect to purchase a pre-funded warrant for&#160;&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;one&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;&#160;share of the Company&#x2019;s common Stock, rather than a share of common stock, at the Warrant exercise price less the exercise price of the pre-funded warrant purchased.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;In addition, upon the consummation of an acquisition (as described in the Warrants agreements and July 2024 Pre-Funded Warrants agreements, as applicable), each Warrant and July 2024 Pre-Funded Warrant will automatically be converted into the right of the holder of such Warrant or July 2024 Pre-Funded Warrant, as applicable, to receive the kind and amount of securities, cash or other property that such holders would have received had they exercised such Warrant or July 2024 Pre-Funded Warrant, as applicable, immediately prior to such acquisition, without regard to any limitations on exercise contained in the Warrant agreements or July 2024 Pre-Funded Warrant agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;The Warrants meet the definition of a derivative pursuant to FASB Accounting Standard Codification 815,&#160;&lt;i style="font-style:italic;"&gt;Derivatives and Hedging&lt;/i&gt;, and do not meet the derivative scope exception given the Warrants do not qualify under the indexation guidance. As a result, the Warrants were initially recognized as liabilities and measured at fair value using the Black-Scholes valuation model with subsequent changes in fair value recorded in earnings. The warrants were recorded at a fair value of $39.6&#160;million upon issuance and the Company allocated $39.6&#160;million of the proceeds to this liability and recorded this amount as warrant liability. During the year ended December 31, 2025 and 2024, 9,654,168 Warrants and 250 Warrants, respectively, were exercised for shares of common stock and the fair value of the Warrants on the respective exercise dates was $50.0 million and $0.5 million, respectively, which was reclassified from warrant liability to additional paid in capital. On December 31, 2025 and 2024, the fair value of the outstanding 8,429,166 Warrants and 18,083,334 Warrants, respectively, was determined to be $35.6&#160;million and $58.2 million, respectively and the Company recorded this amount as warrant liability on the consolidated balance sheets. During the year ended December 31, 2025 and 2024, the Company recorded the mark-to-market adjustment of $27.5&#160;million and $19.1 million, respectively, under change in fair value of warrant liability within the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;The July 2024 Pre-Funded Warrants cannot require cash settlement, are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock and Warrants with which they were issued, are immediately exercisable, and do not embody an obligation for the Company to repurchase its common stock shares and permit the holders to receive a fixed number of shares of common stock upon exercise. Additionally, the July 2024 Pre-Funded Warrants do not provide any guarantee of value or return. Accordingly, the July 2024 Pre-Funded Warrants are classified as a component of permanent equity. The Company allocated&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;$15.4&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;million of the proceeds to the July 2024 Pre-Funded Warrants and shares of common stock issued. During the second quarter of 2025, the holders exercised &lt;/span&gt;&lt;span style="color:#212529;"&gt;2,500,000&lt;/span&gt;&lt;span style="color:#212529;"&gt; July 2024 Pre-Funded Warrants, exercise price &lt;/span&gt;&lt;span style="color:#212529;"&gt;$0.001&lt;/span&gt;&lt;span style="color:#212529;"&gt; per share, via cashless exercise resulting in the issuance of &lt;/span&gt;&lt;span style="color:#212529;"&gt;2,499,665&lt;/span&gt;&lt;span style="color:#212529;"&gt; shares of common stock. During the third quarter of 2025, &lt;/span&gt;&lt;span style="color:#212529;"&gt;no&lt;/span&gt;&lt;span style="color:#212529;"&gt; July 2024 Pre-Funded Warrants were exercised.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;The Company incurred a total of&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;$4.2&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;million in issuance costs, which the Company allocated to the Warrants, and 2024 Pre-Funded Warrants and shares of common stock consistent with the allocation of proceeds.&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;$3.0&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;million of issuance costs were allocated to the Warrants and expensed within selling, general and administrative expenses in the statements of operations and comprehensive loss for the year ended December 31, 2024.&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;$1.2&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;million of the issuance costs were allocated to the July 2024 Pre-Funded Warrants and shares of common stock and applied against additional paid-in capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;June 2023 Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;In June 2023, in an underwritten offering, the Company offered 8,489,409 shares of the Company&#x2019;s common stock, at a price to the public of $9.75 per share, less the underwriting discounts and commissions, and, in lieu of shares of common stock to certain investors, pre-funded warrants (the &#x201c;June 2023 Pre-Funded Warrants&#x201d;) to purchase up to an aggregate of 1,538,591 shares of common stock at a price to the public of $9.749 per share of common stock underlying a pre-funded warrant, which represents the per share public offering price for the shares of common stock less the $0.001 per share exercise price for each such share of common stock underlying a June 2023 Pre-Funded Warrant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:14pt;padding-top:2pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The Company could not have effected the exercise of any June 2023 Pre-Funded Warrant, and a holder was not entitled to exercise any portion of any June 2023 Pre-Funded Warrant if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) would have exceeded &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;9.99%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of the number of shares of common stock outstanding immediately after giving effect to the exercise, which percentage could have been increased or decreased at the holder&#x2019;s election upon &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;61 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#x2019; notice to the Company subject to the terms of such June 2023 Pre-Funded Warrant, provided that such percentage in no event exceeded &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;19.99%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;Each June 2023 Pre-Funded Warrant had an exercise price equal to $0.001 per share of common stock. The exercise price and the number of shares of common stock issuable upon exercise of each June 2023 Pre-Funded Warrant was subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Company&#x2019;s common stock as well as upon any distribution of assets, including cash, stock or other property, to the Company&#x2019;s stockholders. The June 2023 Pre-Funded Warrants were exercisable as of June 21, 2023, did not expire and were exercisable in cash or by means of a cashless exercise. In addition, upon the consummation of an acquisition (as described in the June 2023 Pre-Funded Warrant agreements), each June 2023 Pre-Funded Warrant would have automatically been converted into the right of the holder of such June 2023 Pre-Funded Warrant to receive the kind and amount of securities, cash or other property that such holders would have received had they exercised such June 2023 Pre-Funded Warrant immediately prior to such acquisition, without regard to any limitations on exercise contained in the June 2023 Pre-Funded Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;The June 2023 Pre-Funded Warrants could not have required cash settlement, were freestanding financial instruments that were legally detachable and separately exercisable from the shares of common stock with which they were issued, were immediately exercisable, and did not embody an obligation for the Company to repurchase its common stock shares and permitted the holders to receive a fixed number of shares of common stock upon exercise. Additionally, the June 2023 Pre-Funded Warrants did not provide any guarantee of value or return. Accordingly, the June 2023 Pre-Funded Warrants were classified as a component of permanent equity. After deducting for commissions and other offering expenses, the Company received net proceeds of approximately $91.4 million from the sale of 8,489,409 shares of common stock and June 2023 Pre-Funded Warrants to purchase up to 1,538,591 shares of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;During the year ended December 31, 2024, the holders exercised all of the June 2023 Pre-Funded Warrants representing 1,538,591 underlying shares of common stock, at an exercise price $0.0001 per share, via cashless exercise resulting in the issuance of 1,538,201 shares of common stock. As of December 31, 2024 there were no June 2023 Pre-Funded Warrants outstanding. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;On January 24, 2023, the Company entered into a Securities Purchase Agreement (the &#x201c;Series B Convertible Preferred Stock Securities Purchase Agreement&#x201d;) with certain purchasers pursuant to which the Company agreed to sell and issue to the purchasers in a private placement (the &#x201c;Private Placement&#x201d;) up to 2,144,160 shares of its Series B convertible preferred stock, par value $0.0001 per share (the &#x201c;Series B Convertible Preferred Stock&#x201d;), in two tranches. On January 24, 2023, the Company filed the Certificate of Designation of the Preferences, Rights and Limitations of the Series B Convertible Preferred Stock (the &#x201c;Series B Convertible Preferred Stock Certificate of Designation&#x201d;) setting forth the preferences, rights and limitations of the Series B Convertible Preferred Stock with the Secretary of State of the State of Delaware. The Series B Convertible Preferred Stock Certificate of Designation became effective upon filing. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Each share of the Series B Convertible Preferred Shares is convertible into &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;3.5305&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares of the Company&#x2019;s common stock, such conversion rate reflects an adjustment to account for the Reverse Stock Split, at the option of the holders at any time, subject to certain limitations, including that the holder will be prohibited from converting Series B Convertible Preferred Stock into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares of common stock above a conversion blocker, which is initially set at &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;9.99%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; (the &#x201c;Conversion Blocker&#x201d;) of the total common stock then issued and outstanding immediately following the conversion of such shares of Series B Convertible Preferred Stock. Holders of the Series B Convertible Preferred Stock are permitted to increase the Conversion Blocker to an amount not to exceed &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;19.99%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; upon&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; 60 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#x2019; notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;The Company agreed to sell and issue in the first tranche of the Private Placement 1,200,000 shares of Series B Convertible Preferred Stock at a purchase price of $25.00 per share of Series B Convertible Preferred Stock (equivalent to $7.0812 per share of common stock). The first tranche of the Private Placement closed on January 27, 2023. The Company received gross proceeds from the first tranche of the Private Placement of approximately $30.0 million, before deducting fees to the placement agent and other offering expenses payable by the Company (&#x201c;Series B Convertible Preferred Stock Proceeds&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;In addition, the Company agreed to sell and issue in the second tranche of the Private Placement &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;944,160&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares of Series B Convertible Preferred Stock at a purchase price of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$31.77&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per share of Series B Convertible Preferred Stock (equivalent to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$9.00&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per share of common stock) if at any time within 18 months following the closing of the first tranche the &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;10-day&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; volume weighted average price of the Company&#x2019;s common stock (as quoted on Nasdaq and as calculated by Bloomberg) should reach at least &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$13.50&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per share, such threshold reflects an adjustment to account for the Reverse Stock Split (which may be further adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction as needed) with aggregate trading volume during the same &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;10-day&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; period of at least &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$25&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million (the &#x201c;Second Tranche Right&#x201d;). The second tranche of the Private Placement is expected to close within &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;seven&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; trading days of meeting the second tranche conditions and will be subject to additional, customary closing conditions. If the Second Tranche Right conditions are satisfied, the Company anticipates receiving gross proceeds from the second tranche of the Private Placement of approximately &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$30.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million, before deducting fees to the placement agent and other offering expenses payable by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;The Series B Convertible Preferred Stock ranks (i) senior to the common stock; (ii) senior to all other classes and series of equity securities of the Company that by their terms do not rank senior to the Series B Convertible Preferred Stock; (iii) senior to all shares of the Company&#x2019;s Series A Convertible Preferred Stock the equity securities described in (i)-(iii), the &#x201c;Junior Stock&#x201d;); (iv) on parity with any class or series of capital stock of the Company hereafter created specifically ranking by its terms on parity with the Series B Convertible Preferred Stock (the &#x201c;Parity Stock&#x201d;); (v) junior to any class or series of capital stock of the Company hereafter created specifically ranking by its terms senior to any Series B Convertible Preferred Stock (&#x201c;Senior Stock&#x201d;); and (vi) junior to all of the Company&#x2019;s existing and future debt obligations, including convertible or exchangeable debt securities, in each case, as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily and as to the right to receive dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;In the event of the liquidation, dissolution or winding up of the affairs of the Company, whether voluntary or involuntary, after payment or provision for payment of the debts and other liabilities of the Company, and subject to the prior and superior rights of any Senior Stock, each holder of shares of Series B Convertible Preferred Stock will be entitled to receive, in preference to any distributions of any of the assets or surplus funds of the Company to the holders of the common stock and any of the Company&#x2019;s securities that are Junior Stock and pari passu with any distribution to the holders of any Parity Stock, an amount equal to $1.00 per share of Series B Convertible Preferred Stock, plus an additional amount equal to any dividends declared but unpaid on such shares, before any payments shall be made or any assets distributed to holders of the common stock or any of the Company&#x2019;s securities that are Junior Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;So long as any shares of the Series B Convertible Preferred Stock remain outstanding, the Company cannot without the affirmative vote or consent of the holders of majority of the shares of the Series B Convertible Preferred Stock then-outstanding, in which the holders of the Series B Convertible Preferred Stock vote separately as a class: (a) amend, alter, modify or repeal (whether by merger, consolidation or otherwise) the Series B Convertible Preferred Stock Certificate of Designation, the Company&#x2019;s certificate of incorporation, or the Company&#x2019;s bylaws in any manner that adversely affects the rights, preferences, privileges or the restrictions provided for the benefit of, the Series B Convertible Preferred Stock; (b) issue further shares of Series B Convertible Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series B Convertible Preferred Stock; (c) authorize or issue any Senior Stock; or (d) enter into any agreement to do any of the foregoing that is not expressly made conditional on obtaining the affirmative vote or written consent of the majority of then-outstanding Series B Convertible Preferred Stock. Holders of Series B Convertible Preferred Stock are entitled to receive when, as and if dividends are declared and paid on the common stock, an equivalent dividend, calculated on an as-converted basis. Shares of Series B Convertible Preferred Stock are otherwise not entitled to dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;The Company initially classified the first tranche of the Series B Convertible Preferred Stock as temporary equity in the consolidated balance sheets as the Company could have been required to redeem the Series B Convertible Preferred Stock if the Company could not convert the Series B Convertible Preferred Stock into shares of common stock for any reason including due to any applicable laws or by the rules or regulations of any stock exchange, interdealer quotation system, or other self-regulatory organization with jurisdiction over the Company which is not solely in the control of the Company. If the Company was required to redeem the Series B Convertible Preferred Stock, it would have been based upon the volume-weighted-average price of common stock on an as converted basis on the date the holders provided a conversion notice to the Company. &lt;span style="color:#212529;"&gt;On October 18, 2024, holders of the Series B Convertible Preferred Stock elected to convert&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;1,200,000&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;shares of Series B Convertible Preferred Stock for&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;4,236,568&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;shares of the Company&#x2019;s common stock and consequently, the Company issued&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;4,236,568&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;shares of its common stock to holders of the Series B Convertible Preferred Stock. During the year ended December 31, 2024, the&#160;Company did not adjust the carrying value of the Series B Convertible Preferred Stock since it was not probable the holders would be unable to convert the Series B Convertible Preferred Stock into shares of common stock due to any reason including due to any applicable laws or by the rules or regulations of any stock exchange, interdealer quotation system, or other self-regulatory organization with jurisdiction over the Company. Upon conversion, the Company reclassified &lt;/span&gt;&lt;span style="color:#212529;"&gt;$21.2&lt;/span&gt;&lt;span style="color:#212529;"&gt; million from Series B Convertible Preferred Stock to common stock and additional paid in capital on the consolidated balance sheet. As of December 31, 2025 and 2024, there are&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;0&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;shares of Series B Convertible Preferred Stock outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;The Company evaluated the Second Tranche Right under ASC 480, &lt;i style="font-style:italic;"&gt;Distinguishing Liabilities from Equity&lt;/i&gt; (&#x201c;ASC 480&#x201d;) and determined that it met the requirements for separate accounting from the initial issuance of Series B Convertible Preferred Stock as a freestanding financial instrument. The Company then determined the Second Tranche Right should be liability classified pursuant to ASC 480. As a result, the Company classified the Second Tranche Right as a non-current liability within the consolidated balance sheets and the Second Tranche Right was initially recorded at fair value and is subsequently re-measured at fair value at the end of each reporting period. The fair value of the Second Tranche Right on the date of issuance was determined to be $6.9 million based on a Monte-Carlo valuation and the Company allocated $6.9 million of the Series B Convertible Preferred Stock Proceeds to this liability and recorded this amount as preferred stock tranche liability. On December 31, 2023, the fair value of the Second Tranche Right was determined to be $4.2 million and the Company recorded this amount as preferred stock tranche liability on the consolidated balance sheets. The Second Tranche Right expired in July 2024 and is no longer outstanding. The Company recorded the mark-to-market adjustment of $4.2 million for the year ended December 31, 2024, under change in fair value of preferred stock tranche liability within the consolidated statements of operations and loss. The Company recorded the mark-to-market adjustment of $2.8 million for the year ended December 31, 2023, under change in fair value of preferred stock tranche liability within the consolidated statements of operations and loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;padding-top:2pt;background:#ffffff;margin:0pt;"&gt;The Company determined that all other features of the securities offered pursuant to the Series B Convertible Preferred Stock Securities Purchase Agreement were clearly and closely associated with the equity host and did not require bifurcation or the fair value of the feature was immaterial to the Company's consolidated financial statements. The Company reassesses the features on a quarterly basis to determine if they require separate accounting. There were no changes to the Company&#x2019;s original assessment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:12pt 0pt 0pt 0pt;"&gt;On November 4, 2022, the Company e&lt;span style="background:#ffffff;"&gt;ntered into an exchange agreement (the &#x201c;Exchange Agreement&#x201d;) with Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP and MSI BVF SPV, LLC (collectively referred to as &#x201c;BVF&#x201d;), pursuant to which BVF exchanged &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;833,333&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of the Company&#x2019;s common stock for &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;1,000,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of newly designated Series A convertible preferred stock, par value &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.0001&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; per share (the &#x201c;Series A Convertible Preferred Stock&#x201d;) (the &#x201c;Exchange&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Each share of the Series A Convertible Preferred Stock was convertible into &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;0.833&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares of the Company&#x2019;s common stock at the option of the holder at any time, subject to certain limitations, including that the holder was prohibited from converting the Series A Convertible Preferred Stock into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares of common stock above the Conversion Blocker, initially set at &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;9.99%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, of the total common stock then issued and outstanding immediately following the conversion of such shares of the Series A Convertible Preferred Stock. Holders of the Series A Convertible Preferred Stock were permitted to increase the Conversion Blocker to an amount not to exceed &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;19.99%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; upon &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;60 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#x2019; notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;Shares of Series A Convertible Preferred Stock generally had no voting rights, except as required by law and except that the consent of a majority of the holders of the outstanding Series A Convertible Preferred Stock was required to amend the terms of the Series A Convertible Preferred Stock. In the event of the Company&#x2019;s liquidation, dissolution or winding up, holders of Series A Convertible Preferred Stock would have participated pari passu with any distribution of proceeds to holders of common stock. Holders of Series A Convertible Preferred Stock were entitled to receive when, as and if dividends were declared and paid on the common stock, an equivalent dividend, calculated on an as-converted basis. Shares of Series A Convertible Preferred Stock were otherwise not entitled to dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The Series A Convertible Preferred Stock were (i) senior to any class or series of capital stock of the Company hereafter created specifically ranking by its terms junior to the Series A Convertible Preferred Stock; (ii) on parity with the common stock and any class or series of capital stock of the Company created specifically ranking by its terms on parity with the Series A Convertible Preferred Stock; and (iii) junior to the Series B Convertible Preferred Stock and to any class or series of capital stock of the Company created specifically ranking by its terms senior to any Series A Convertible Preferred Stock, in each case, as to distributions of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:0pt;"&gt;The Company evaluated the Series A Convertible Preferred Stock for liability or equity classification under ASC 480 and determined that equity treatment was appropriate because the Series A Convertible Preferred Stock did not meet the definition of the liability under ASC 480. Additionally, the Series A Convertible Preferred Stock were not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, or (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Company recorded the Series A Convertible Preferred Stock as permanent equity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;In June 2025, holders of the Series A Convertible Preferred Stock elected to convert all&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;shares of Series A Convertible Preferred Stock for&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;833,332&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;shares of the Company&#x2019;s common stock and consequently, the Company issued&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;833,332&lt;/span&gt;&lt;span style="color:#212529;"&gt; shares of its common stock to holders of the Series A Convertible Preferred Stock. As of December 31, 2025, there were &lt;/span&gt;&lt;span style="color:#212529;"&gt;no&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;shares of Series A Convertible Preferred Stock outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;At-the-market equity offering programs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;In August 2021, the Company entered into a sales agreement with Cantor pursuant to which the Company can offer and sell up to&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$&lt;/span&gt;100.0&lt;span style="background:#ffffff;"&gt;&#160;million of its common stock at the current market prices from time to time through Cantor as sales agent (the &#x201c;August 2021 ATM&#x201d;). In August 2025, the Company entered into a separate sales agreement with Cantor pursuant to which the Company can offer and sell up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$100.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million of its common stock at the current market prices from time to time through Cantor as sales agent (the &#x201c;August 2025 ATM&#x201d; and together with the August 2021 ATM, the &#x201c;ATM Programs&#x201d;). During the years ended December 31, 2025, 2024, and 2023, the Company sold &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;4,000,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares,&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares, and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares, respectively, under the ATM Programs for net proceeds of approximately &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$22.7&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million, &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million, and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million, respectively, (after deducting commissions and other offering expenses)&lt;/span&gt;.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="INF"
      id="Narr_QHsY7To7NUyr8DsRNiGS2Q"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">5000000</us-gaap:PreferredStockSharesAuthorized>
    <vstm:ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_0nf6NAqK4EWE1WyIBDr18w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025 and 2024, the Company had reserved the following shares of common stock for the issuance of common stock for vested restricted stock units, the exercise of stock options, employee stock purchase plan, Series A Convertible Preferred Stock conversions to shares of common stock, and exercise of warrants and pre-funded warrants (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares reserved under Equity Compensation Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,232&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,925&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares reserved for Inducement Grants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,195&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 802&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares reserved for ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares reserved for Series A Convertible Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 833&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares reserved for Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares reserved for pre-funded warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,656&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total shares reserved&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 28,555&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 30,702&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</vstm:ScheduleOfSharesOfCommonStockReservedForPotentialConversionTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_jgUB4qLkMESjHNyit_jWJw"
      decimals="-3"
      id="Tc_Siw5l8K1WEi7akrGY0olGA_3_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">5232000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_hNJYkO5IlkSxNYbhWOjEug"
      decimals="-3"
      id="Tc_HxNn5iEA-Eq5Q2EWfZSXLQ_3_4"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">5925000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_v94nix69zkGeGJg-ULbs-w"
      decimals="-3"
      id="Tc_Egz3mi-1E0WZHgg_gxHcUg_4_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1195000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_VwswXPy6N0iYiVDwlnG78g"
      decimals="-3"
      id="Tc_8hRqMOXqwEe9YCgKKdg0rQ_4_4"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">802000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_o3QykpaT9kO0MVdafyJpUg"
      decimals="-3"
      id="Tc_UTYQ2HBYIEOG3hzzyLw78w_5_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">43000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_LdWz0v453kS4CX1tFFGG_Q"
      decimals="-3"
      id="Tc_QlnzbqXkPUiVIofI4T8bTw_5_4"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">59000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_vstm_SeriesaConvertiblePreferredStockMember_h2EwK_J3D0yrYJTXRulnyg"
      decimals="-3"
      id="Tc_2oCjhxE3LkutLwpgasQcYQ_6_4"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">833000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_WarrantMember_wbTMM7gk_U6IJSEizGwY4w"
      decimals="-3"
      id="Tc_of7HL8lbEUqoHt3fTNivzA_7_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">8429000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_WarrantMember_3vY0IAdGpE23ucHgSc6EPA"
      decimals="-3"
      id="Tc_qhvnZEh9JUykBLKhwAHqeQ_7_4"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">18083000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_PreFundedWarrantMember_KnGNGKDd4UaRuVatC6F9Bg"
      decimals="-3"
      id="Tc_1ThEsF6Xm0qN3TY6joCrZA_8_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">13656000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_vstm_PreFundedWarrantMember_Fay4PRvQWEyTg9vyJimtfA"
      decimals="-3"
      id="Tc_Q9M7KrfKg0alHay9pj_TPA_8_4"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">5000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_pm7R8nOdR0aON7NKkhelPw_9_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">28555000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_egP815A2wEqrbbKbjtvFpA_9_4"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">30702000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <vstm:NumberOfVotesPerEachShareOfCommonStock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="INF"
      id="Narr_dUl7CoYWq0mvaRAMKdAagQ"
      unitRef="Unit_Standard_Vote_tReSOj-zJkipnhJ_-h7uBA">1</vstm:NumberOfVotesPerEachShareOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_13_2025_To_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_8KWsZFM4mEuCXxQ0JyrXPg"
      decimals="INF"
      id="Narr_DP6sHyPkrEOWK09m8-xy8g"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">8543794</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_n96ND7-6FkaDWs_KK9qUrw"
      decimals="2"
      id="Narr_oU4Jjp27nUq-GqYKyvR_nA"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">7.25</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_n96ND7-6FkaDWs_KK9qUrw"
      decimals="INF"
      id="Narr_5s5UxHTe60KU3HzGsXO7ow"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">3870000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_n96ND7-6FkaDWs_KK9qUrw"
      decimals="INF"
      id="Narr_E5FMx6azo0yXEbf7SYoE8A"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">7.2499</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_n96ND7-6FkaDWs_KK9qUrw"
      decimals="INF"
      id="Narr_Zdo7g-_YzEescFo34Lz4Hw"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vstm:SaleOfStockOptionToPurchaseMaximumNumberOfShares
      contextRef="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_KS1tXWlGL0mDHAAYpEFAqQ"
      decimals="INF"
      id="Narr_wx76mietGUqlqjz1DYWQ_g"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1862069</vstm:SaleOfStockOptionToPurchaseMaximumNumberOfShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_KS1tXWlGL0mDHAAYpEFAqQ"
      decimals="INF"
      id="Narr_QwAT3ZRLjkac_67Jq9_T5g"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharePrice
      contextRef="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_KS1tXWlGL0mDHAAYpEFAqQ"
      decimals="2"
      id="Narr_-e9kBHQHaUy6eusIflINAg"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">7.25</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_14_2025_To_11_14_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_WUufEo4u2kmXKrrBjVvTxA"
      decimals="INF"
      id="Narr_JkxYpGi9SkyE_KVmYXAyew"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1862069</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_14_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_u5xj-WOakUigG8lS-TAocg"
      decimals="2"
      id="Narr_2v0az4jhI0O-jKh8y-Jd3A"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">7.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_KS1tXWlGL0mDHAAYpEFAqQ"
      decimals="INF"
      id="Narr_p4ISp3QyWUqvdGdWHf3hGQ"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_11_13_2025_To_11_13_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_November2025PublicOfferingMember_8KWsZFM4mEuCXxQ0JyrXPg"
      decimals="-5"
      id="Narr_jyxICwk4qkWpAlUKDZfD-A"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">96900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_25_2025_To_4_25_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_w6Qgr7wiUECKdrz2j0wQgw"
      decimals="INF"
      id="Narr_jWv6cyo9H0mnh1JwE1GSsQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">3429287</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_4_25_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_RmWH6lNih0uXM3yO2Zl1qQ"
      decimals="2"
      id="Narr_QrzIijEtBEywTyhuecoplw"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">7</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_4_25_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_ehT0HA0cvUW9AwZHGjQ9nw"
      decimals="INF"
      id="Narr_v75MpIYoBkyfZOUHrwOWhQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">7285713</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_4_25_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_ehT0HA0cvUW9AwZHGjQ9nw"
      decimals="INF"
      id="Narr_qcTF4oM6hUKCuEFsJutFOA"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">6.9999</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_4_25_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_ehT0HA0cvUW9AwZHGjQ9nw"
      decimals="INF"
      id="Narr_CncMOKVb50yjPfuZXsSVGQ"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vstm:WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod
      contextRef="Duration_4_25_2025_To_4_25_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_t2jNkx3weEK3-E4-F4tIgA"
      id="Narr_7nw1yNddyk-DwsarU0suTg">P61D</vstm:WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod>
    <vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder
      contextRef="As_Of_4_25_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_ehT0HA0cvUW9AwZHGjQ9nw"
      decimals="4"
      id="Narr_CGRLTInQ8kiit7xs-_AY3A"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.1999</vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_4_25_2025_To_4_25_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_PrivatePlacement2025Member_t2jNkx3weEK3-E4-F4tIgA"
      decimals="-5"
      id="Narr_UrykjkY3J0e4XZd0SdlqoA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">69900000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_76lNElnqP0Ge645AbtZsrA"
      decimals="INF"
      id="Narr_XjTOTh6aaUqgey66w0sR1Q"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1416939</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_UBix19n6xEadDF59Ya6BCw"
      decimals="INF"
      id="Narr_A-jHTFdOQ0m1ZjYFYAoITg"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">5.2931</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_x-U4MebMkEusy4zb3w2UTg"
      decimals="-5"
      id="Narr_C7hcEbe9bUyD8qZTCdwk7g"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <vstm:StockPurchaseRightPeriod
      contextRef="Duration_1_13_2025_To_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_76lNElnqP0Ge645AbtZsrA"
      id="Narr_0ITESEsRmkSC6qdpnmuTnA">P3Y</vstm:StockPurchaseRightPeriod>
    <vstm:StockPurchaseRightMaximumAmount
      contextRef="As_Of_1_13_2025_us-gaap_DebtInstrumentAxis_vstm_NotePurchaseAgreementMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_StockPurchaseAgreementMember_UBix19n6xEadDF59Ya6BCw"
      decimals="-5"
      id="Narr_Bk0u8tftd0e_YieMn2IhNg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2500000</vstm:StockPurchaseRightMaximumAmount>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_xgsOVZqDvUy1HFomyzF7Hg"
      decimals="INF"
      id="Narr_xR8bqa4TpUGXi2LVx-pGWA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">13333334</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_qoqGwn8YFkepdjxAScNrxA"
      decimals="INF"
      id="Narr_UFVycn5_IkKq00vMDPHrCA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">13333334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_9uZ0RStEKUaT5_5fRWamIg"
      decimals="INF"
      id="Narr_TbyPQ3V5T0uCSKSCv1wuQQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_9uZ0RStEKUaT5_5fRWamIg"
      decimals="INF"
      id="Narr_HuPbCkgEUkKHmV8d1N_Saw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_qoqGwn8YFkepdjxAScNrxA"
      decimals="2"
      id="Narr_1DvAeJnX5kCqa6vKFthzyw"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">3</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_9uZ0RStEKUaT5_5fRWamIg"
      decimals="3"
      id="Narr_fg6Z8-O-wUqKx1iAAWRNWg"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">2.999</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_9uZ0RStEKUaT5_5fRWamIg"
      decimals="3"
      id="Narr_wbDbvPC9lECZ4anKftrcEw"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_7_23_2024_To_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_semVXOzt7UuTbjL3iSPnbw"
      decimals="-5"
      id="Narr_XpzCZFmRsEiBncptZr58fA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">50800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_9uZ0RStEKUaT5_5fRWamIg"
      decimals="3"
      id="Narr_GFZk9ZVR4kKE5DDpcOKzow"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_qoqGwn8YFkepdjxAScNrxA"
      decimals="2"
      id="Narr_8RqACoxj40KZiRjrOGa7MQ"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">3.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_qoqGwn8YFkepdjxAScNrxA"
      decimals="INF"
      id="Narr_VIsn8K0ymkCf9vf19FQQzQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_9uZ0RStEKUaT5_5fRWamIg"
      decimals="INF"
      id="Narr_co24gIPEbkuFBhFogRQTDA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants
      contextRef="As_Of_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_xgsOVZqDvUy1HFomyzF7Hg"
      decimals="4"
      id="Narr_5TiNUwW7F0arTNZDh3VDOA"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0499</vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants>
    <vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder
      contextRef="As_Of_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_xgsOVZqDvUy1HFomyzF7Hg"
      decimals="4"
      id="Narr_qhz2p27GZ06akRzJxFggrg"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.1999</vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder>
    <vstm:WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod
      contextRef="Duration_7_23_2024_To_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_semVXOzt7UuTbjL3iSPnbw"
      id="Narr_HB7Sa1Xdh0OpRCEQobMJow">P61D</vstm:WarrantOrPreFundedWarrantElectionToExerciseNoticePeriod>
    <vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder
      contextRef="As_Of_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_xgsOVZqDvUy1HFomyzF7Hg"
      decimals="4"
      id="Narr_RykXjZMeOEGKW9n9pgrDdw"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.1999</vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder>
    <vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants
      contextRef="As_Of_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_xgsOVZqDvUy1HFomyzF7Hg"
      decimals="4"
      id="Narr_Z1Oxx5tgWk28jrFjaNuR-Q"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0499</vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrants>
    <vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder
      contextRef="As_Of_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_xgsOVZqDvUy1HFomyzF7Hg"
      decimals="4"
      id="Narr_YTbINblqikuEP9lDpheBWA"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.1999</vstm:ThresholdPercentageHeldToSharesOutstandingToExerciseWarrantsOrPreFundedWarrantsAtElectionOfHolder>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_9uZ0RStEKUaT5_5fRWamIg"
      decimals="INF"
      id="Narr_wEh8GtMuVUyEHoteiiHY7A"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_xgsOVZqDvUy1HFomyzF7Hg"
      decimals="-5"
      id="Narr_bDnVG0OnKkGP_uDR27p2DA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">39600000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_7_23_2024_To_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_semVXOzt7UuTbjL3iSPnbw"
      decimals="-5"
      id="Narr_mCk_CMqYKk6g0c0E24Gq_w"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">39600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_fGAFkO2I5k6tbgjWbUyMMg"
      decimals="INF"
      id="Narr_f1PUiRM5iUCKPe1ET5d2Jg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">9654168</vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_M3ZzNPTGjEyOJy5c4k1gkw"
      decimals="INF"
      id="Narr_FpWxBFZmmky_eFZw4JUHcQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">250</vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <vstm:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_fGAFkO2I5k6tbgjWbUyMMg"
      decimals="-5"
      id="Narr_p3vMWw9RU0mx2pxAHy1UFA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">50000000</vstm:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <vstm:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_M3ZzNPTGjEyOJy5c4k1gkw"
      decimals="-5"
      id="Narr_q9rCw9a_ZUOZlXHlJSj5hg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">500000</vstm:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_W-OWHjTX20eGOqczNgrSyQ"
      decimals="INF"
      id="Narr_Q1BJ_KeK-k6T6iTAQM4FKQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">8429166</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_XleLLeLgMUaEtBjxP-2klw"
      decimals="INF"
      id="Narr_Y_1UNMvGm0eAjSrZ0RfSFQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">18083334</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_W-OWHjTX20eGOqczNgrSyQ"
      decimals="-5"
      id="Narr_AI9B3Dg70kmwG-b0hYrz2w"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">35600000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_XleLLeLgMUaEtBjxP-2klw"
      decimals="-5"
      id="Narr_b0JULhJny0aq88GpcLxEkA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">58200000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_fGAFkO2I5k6tbgjWbUyMMg"
      decimals="-5"
      id="Narr_zCASMGfxqEaa5qFencbBCg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">27500000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_M3ZzNPTGjEyOJy5c4k1gkw"
      decimals="-5"
      id="Narr_ic8VmWkcZUKwIes0lr1bvg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">19100000</us-gaap:FairValueAdjustmentOfWarrants>
    <vstm:ProceedsFromIssuanceOfWarrantsAndCommonStock
      contextRef="Duration_7_23_2024_To_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_semVXOzt7UuTbjL3iSPnbw"
      decimals="-5"
      id="Narr_ccCdG8BDwk650x7MUR5W4g"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">15400000</vstm:ProceedsFromIssuanceOfWarrantsAndCommonStock>
    <vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_NZvKvAzq-k2_cBvWayCtvA"
      decimals="INF"
      id="Narr_BB1KvsIgKEiyP6C_w8pagQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">2500000</vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_NVq59xSXbE6uvQXjAgxbQg"
      decimals="INF"
      id="Narr_WcC2KW1X_kSKi68x4QLdXw"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_NZvKvAzq-k2_cBvWayCtvA"
      decimals="INF"
      id="Narr_H-_OclWg5ky7PZE5cNUIzg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">2499665</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_-TqHBbCtZkCiLS7Kdk667Q"
      decimals="INF"
      id="Narr_np4BPLqJkku7zGYuAIWZMw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">0</vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_7_23_2024_To_7_23_2024_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_semVXOzt7UuTbjL3iSPnbw"
      decimals="-5"
      id="Narr_YcUzs2jk6kKLbsjL0kYphw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_7_23_2024_To_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_oG3TWOGlW0SJkm54UqDFTQ"
      decimals="-5"
      id="Narr_d2mBhE6Kd0yIzZ27ac8f5g"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_7_23_2024_To_7_23_2024_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_July2024PublicOfferingMember_hbgxBNPYbUyJb5vXdalJvg"
      decimals="-5"
      id="Narr_OtfIV8kp2kSjhAEAI8SEYQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_vstm_PublicMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_Jr05H4l9L0uUqAYKxs4qxw"
      decimals="INF"
      id="Narr_GqEmFH6kJ0iJXhnSNVMErQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">8489409</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:SharePrice
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_vstm_PublicMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_y99DVEYGyUKxX-8hVBLWvQ"
      decimals="2"
      id="Narr_OhY9ChI3MkCxEzO3EhRrPQ"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">9.75</us-gaap:SharePrice>
    <vstm:CommonStockSharesOffered
      contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_9JY_1UA-ZEecEwccCTRt3w"
      decimals="INF"
      id="Narr_mPcZk0-r00eSc3YaqaBzHw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1538591</vstm:CommonStockSharesOffered>
    <us-gaap:SharePrice
      contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_9JY_1UA-ZEecEwccCTRt3w"
      decimals="INF"
      id="Narr_rkPtSekkOEqBlFeyX45R6g"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">9.749</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_9JY_1UA-ZEecEwccCTRt3w"
      decimals="INF"
      id="Narr_l3tk1bQl2k6J5upCBrLU-Q"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vstm:MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage
      contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_O0Rufo-BykGzNlAstqrYkQ"
      decimals="4"
      id="Narr_NRqacBzvwkW3W_kgJ54h1Q"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0999</vstm:MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsAsPercentage>
    <vstm:PreFundedWarrantElectionToExerciseNoticePeriod
      contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_O0Rufo-BykGzNlAstqrYkQ"
      id="Narr_J4a0F-fj7UO9lC64A95-gQ">P61D</vstm:PreFundedWarrantElectionToExerciseNoticePeriod>
    <vstm:MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage
      contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_O0Rufo-BykGzNlAstqrYkQ"
      decimals="4"
      id="Narr_u7-8EVJQRUCkcJ__40_HEA"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.1999</vstm:MaximumAmountOfCommonStockOwnedByHolderExerciseOfPreFundedWarrantsMaximumAllowableIncreaseAsPercentage>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_ewMMPiBO5k-cPP2IurkzMA"
      decimals="3"
      id="Narr_iaQkN9iNw0ShvRie1cKa4w"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_9kM5FIopg02NBn8H3CtCvw"
      decimals="-5"
      id="Narr_yVV42_KraEqa6FxfLbZ33A"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">91400000</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_mUhVWV8WMkScZAT8JeG4VQ"
      decimals="INF"
      id="Narr_rc6bx5RwAUC5WGEQz7JCjQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">8489409</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_UQMJ9oLa3kmJvYGMn38KsQ"
      decimals="INF"
      id="Narr_aDgV5lxMDEKUI0vInFETOA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1538591</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_T__SJ-zwq0yVJL4kvpsp4w"
      decimals="INF"
      id="Narr__zuca05QF0arvkinYBDEzg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1538591</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_eegaa3ABKkqBRahdn4RezA"
      decimals="4"
      id="Narr_UTaiGrHljEuAdXQZeB7nsQ"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_vstm_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_UnderwritingAgreementMember_T__SJ-zwq0yVJL4kvpsp4w"
      decimals="INF"
      id="Narr_updBQOvxRkOHF2oyVTbxWg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1538201</vstm:StockIssuedPreFundedWarrantsNetOfIssuanceCostsInShares>
    <vstm:PreFundedWarrantsWarrantsOutstanding
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="INF"
      id="Narr_ZNPxViH-lEmvtNBaY6sExQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">0</vstm:PreFundedWarrantsWarrantsOutstanding>
    <vstm:PreferredStockConvertibleAggregateSharesToBeSold
      contextRef="Duration_1_24_2023_To_1_24_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_vGMn7XIAIUSBLUxCpfC0tQ"
      decimals="INF"
      id="Narr_YQJksgAk_0mQcZvIIsj4jw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">2144160</vstm:PreferredStockConvertibleAggregateSharesToBeSold>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_1_24_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_FQWIrrRmRkCSrnKhzFgoaQ"
      decimals="4"
      id="Narr_7rYvfuETb0CXWnljIPVUjg"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <vstm:PreferredStockIssueNumberOfTranches
      contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Lb8_EogSb0aV0xpnEYsScg"
      decimals="INF"
      id="Narr_EtmWxKi7yUamp9qCMBiq8A"
      unitRef="Unit_Standard_tranche_AR7EJ57OqEq8JqHSzH8_Aw">2</vstm:PreferredStockIssueNumberOfTranches>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_S54_9duti0-qFLlDHg8uag"
      decimals="4"
      id="Narr_Ifs0OjJIHEqDXy6EDfcfZg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">3.5305</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <vstm:ConversionOfPreferredStockConversionBlockerPercent
      contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Lb8_EogSb0aV0xpnEYsScg"
      decimals="4"
      id="Narr_nowSATg5MEyvb1bWgD0WSA"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0999</vstm:ConversionOfPreferredStockConversionBlockerPercent>
    <vstm:ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice
      contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Lb8_EogSb0aV0xpnEYsScg"
      decimals="4"
      id="Narr_rNQ17J5fdEe1poed9a0Dcg"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.1999</vstm:ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice>
    <vstm:ConversionOfPreferredStockConversionBlockerNoticePeriod
      contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Lb8_EogSb0aV0xpnEYsScg"
      id="Narr_bMFjKUk0FE-1T-38ir34SA">P60D</vstm:ConversionOfPreferredStockConversionBlockerNoticePeriod>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_24_2023_To_1_24_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_vGMn7XIAIUSBLUxCpfC0tQ"
      decimals="INF"
      id="Narr_6oqX6ftoRkuD37hJj_RjUg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_1_24_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_FQWIrrRmRkCSrnKhzFgoaQ"
      decimals="2"
      id="Narr_NLCP4Nb4N0ug1ozfaspGzg"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_EgpHd6yzBUuaIpY-YY3qXw"
      decimals="4"
      id="Narr_xLyFcIaU60q59WvrjRQ5dA"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">7.0812</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Btgqk5RY306LVDoxcjygVA"
      decimals="-5"
      id="Narr_vrDjzPynXEK5Syb5JL_ILg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">30000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Btgqk5RY306LVDoxcjygVA"
      decimals="INF"
      id="Narr_hBjbr2cMq0ixirutx34H6Q"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">944160</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vstm:PreferredStockIssuanceThresholdSharePrice
      contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Lb8_EogSb0aV0xpnEYsScg"
      decimals="2"
      id="Narr_Vf96i-LWVkOuKRaJ7UX4Pw"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">31.77</vstm:PreferredStockIssuanceThresholdSharePrice>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_EgpHd6yzBUuaIpY-YY3qXw"
      decimals="2"
      id="Narr_qBJdf8m1pUKlRMEqg6BF7w"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">9</us-gaap:SharesIssuedPricePerShare>
    <vstm:PreferredStockIssuanceExpectedClosingPeriod
      contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Lb8_EogSb0aV0xpnEYsScg"
      id="Narr_MGSbYKMiDkuvY0r7qXNtjA">P10D</vstm:PreferredStockIssuanceExpectedClosingPeriod>
    <vstm:PreferredStockIssuanceThresholdSharePrice
      contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Btgqk5RY306LVDoxcjygVA"
      decimals="2"
      id="Narr_5MCj-bCWtUyDN8gneW03LA"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">13.5</vstm:PreferredStockIssuanceThresholdSharePrice>
    <vstm:PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche
      contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Btgqk5RY306LVDoxcjygVA"
      id="Narr_Z3Rk1-cVskiKgM4G7VAxvw">P10D</vstm:PeriodOfStockIssuanceInSecondTrancheAfterClosingFirstTranche>
    <vstm:PreferredStockIssuanceThresholdAggregateTradingVolume
      contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Btgqk5RY306LVDoxcjygVA"
      decimals="-5"
      id="Narr_X9E3GNLx0UKZveKHGLDyhA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">25000000</vstm:PreferredStockIssuanceThresholdAggregateTradingVolume>
    <vstm:PreferredStockIssuanceThresholdTradingDays
      contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Btgqk5RY306LVDoxcjygVA"
      decimals="INF"
      id="Narr_DIZKeg95wk23fp00TM0P-Q"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7</vstm:PreferredStockIssuanceThresholdTradingDays>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_1_24_2023_To_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Btgqk5RY306LVDoxcjygVA"
      decimals="-5"
      id="Narr_K5UcepJsOE2Nly2DyPyl6g"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">30000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_S54_9duti0-qFLlDHg8uag"
      decimals="2"
      id="Narr_qnklZDWkWE62GQLjlsL28w"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">1</us-gaap:PreferredStockLiquidationPreference>
    <vstm:NumberOfPreferredStockConvertibleIntoCommonStock
      contextRef="As_Of_10_18_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_ACFKxOC2mUGBN1ufbr5J8w"
      decimals="INF"
      id="Narr_HgHMmi0Hy0SsV9vAhdx12Q"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1200000</vstm:NumberOfPreferredStockConvertibleIntoCommonStock>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="As_Of_10_18_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_ACFKxOC2mUGBN1ufbr5J8w"
      decimals="INF"
      id="Narr_VTxpHDGR7ECilOqSI3py_A"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">4236568</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_18_2024_To_10_18_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_Kvj5joERQU2FBgyJpIJZgQ"
      decimals="INF"
      id="Narr_JsXKzWExQUarWm-f4YPHbw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">4236568</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_10_18_2024_To_10_18_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fM5yxfUyOk2FmCtStYKMUQ"
      decimals="-5"
      id="Narr_fA0d3FTWjk2O-gRbm8WadA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">21200000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_edm9qWQjT0uGo3Ul1o6KTA"
      decimals="INF"
      id="Narr_04olCHd8akCEAz6c4dx-6g"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">0</us-gaap:PreferredStockSharesOutstanding>
    <vstm:SecondTrancheRightLiabilityNonCurrentFairValue
      contextRef="As_Of_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_S54_9duti0-qFLlDHg8uag"
      decimals="-5"
      id="Narr_5d6KjbathECA4S3eVn1BJQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6900000</vstm:SecondTrancheRightLiabilityNonCurrentFairValue>
    <vstm:PreferredStockTrancheLiability
      contextRef="As_Of_1_24_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_S54_9duti0-qFLlDHg8uag"
      decimals="-5"
      id="Narr_flixRbg8lEyYz_2HCEi0Cg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6900000</vstm:PreferredStockTrancheLiability>
    <vstm:SecondTrancheRightLiabilityNonCurrentFairValue
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_a-kauTSQJEW4yLfm5-WSHA"
      decimals="-5"
      id="Narr_iQtx0kvl9kuw4jMjOk1K4w"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4200000</vstm:SecondTrancheRightLiabilityNonCurrentFairValue>
    <vstm:MarketToMarketAdjustmentOfPreferredStockTrancheLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_mTaWPJHmCU-O7Tpo-6Loaw"
      decimals="-5"
      id="Narr_MTGDTTmed0imwrmCk0CswA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4200000</vstm:MarketToMarketAdjustmentOfPreferredStockTrancheLiability>
    <vstm:MarketToMarketAdjustmentOfPreferredStockTrancheLiability
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_usrikRrbhk2qFlA8-ytCWA"
      decimals="-5"
      id="Narr_4sWFfM6DtkeyLOC7HnepEA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2800000</vstm:MarketToMarketAdjustmentOfPreferredStockTrancheLiability>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_11_4_2022_To_11_4_2022_srt_CounterpartyNameAxis_vstm_BiotechnologyValueFundMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fvPNrQJtrkWkJoV_MdT_gw"
      decimals="INF"
      id="Narr_gXMK5gkcG02f2R2bmI8O_A"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">833333</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_11_4_2022_To_11_4_2022_srt_CounterpartyNameAxis_vstm_BiotechnologyValueFundMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_tMPnHLFbrkuMv8YVveCukQ"
      decimals="INF"
      id="Narr_4ABkSYzv7023xezLZHkrig"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1000000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_11_4_2022_srt_CounterpartyNameAxis_vstm_BiotechnologyValueFundMember_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_ZbyWkvA4UE-y5mQ7pRm7Mw"
      decimals="4"
      id="Narr_BG2bUdPzwkyGX8mig5nemA"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_11_4_2022_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_zoyOL8-GYk65yM8gGKkE-g"
      decimals="INF"
      id="Narr_T0MkWC0KvkCkWHwikpsmKA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">0.833</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <vstm:ConversionOfPreferredStockConversionBlockerPercent
      contextRef="Duration_11_4_2022_To_11_4_2022_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_gfizhfrkqE64g9G7nBHm7w"
      decimals="4"
      id="Narr__EzJZfHZ9Uu5PFbBdW1GmA"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0999</vstm:ConversionOfPreferredStockConversionBlockerPercent>
    <vstm:ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice
      contextRef="Duration_11_4_2022_To_11_4_2022_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_gfizhfrkqE64g9G7nBHm7w"
      decimals="4"
      id="Narr_DiqQ4JI7pke9fdKCEneGZg"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.1999</vstm:ConversionOfPreferredStockConversionBlockerPercentUponGivingNotice>
    <vstm:ConversionOfPreferredStockConversionBlockerNoticePeriod
      contextRef="Duration_11_4_2022_To_11_4_2022_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_gfizhfrkqE64g9G7nBHm7w"
      id="Narr_8n1W8tQVOk-2gAJZk0dz9w">P60D</vstm:ConversionOfPreferredStockConversionBlockerNoticePeriod>
    <vstm:NumberOfPreferredStockConvertibleIntoCommonStock
      contextRef="As_Of_6_30_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_-48AVsFUBEugaVAWJ90CjA"
      decimals="INF"
      id="Narr_NLpmmbzs3ESz2TICgAlBHg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1000000</vstm:NumberOfPreferredStockConvertibleIntoCommonStock>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ykjfpsDf9EClxEq1QlGEFQ"
      decimals="INF"
      id="Narr_uaSbiq7vfUWjTmDPH8FTSw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">833332</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ykjfpsDf9EClxEq1QlGEFQ"
      decimals="INF"
      id="Narr_4iWMe6FREEqXggyp36JFwA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">833332</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_s_eRJ_IM-EC5I5guhHo3NA"
      decimals="INF"
      id="Narr__MVRpDDhQUKOU3BQ5RhF5Q"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">0</us-gaap:PreferredStockSharesOutstanding>
    <vstm:MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_gb-CSVl9SE2eIj1tdK0XYA"
      decimals="-5"
      id="Narr_WYdvg7O9oE-HI3Elyf9Fqg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">100000000</vstm:MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram>
    <vstm:MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram
      contextRef="Duration_8_1_2025_To_8_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_9R4yRxA400KtN3lsZ5eH2A"
      decimals="-5"
      id="Narr_mlVRvOOh0USbDSICFFyscQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">100000000</vstm:MaximumValueOfCommonStockOfferedThroughMarketEquityOfferingProgram>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_L9scB89F9EeAgUmzCCgzrA"
      decimals="INF"
      id="Narr_LfBUiuuuTUmS4hHGT4gj4Q"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_tpO1jPCeLkKmH0m8Lyeh1A"
      decimals="INF"
      id="Narr_vc_QRfyztEGNCWRVvAVcpw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_2UfHf6a-7UekKeqNumvvTw"
      decimals="INF"
      id="Narr_pVncBMs810W4pqR3RbyIJg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vstm:ProceedsFromIssuanceOfCommonStockNet
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_L9scB89F9EeAgUmzCCgzrA"
      decimals="-5"
      id="Narr_hcN7XxI93UKa1_IB3hxfoA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">22700000</vstm:ProceedsFromIssuanceOfCommonStockNet>
    <vstm:ProceedsFromIssuanceOfCommonStockNet
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_tpO1jPCeLkKmH0m8Lyeh1A"
      decimals="-5"
      id="Narr_jUguNPEbDUGrvoO3kzFChQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</vstm:ProceedsFromIssuanceOfCommonStockNet>
    <vstm:ProceedsFromIssuanceOfCommonStockNet
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_vstm_CantorFitzgeraldCoMember_us-gaap_SubsidiarySaleOfStockAxis_vstm_AtMarketEquityOfferingProgramMember_2UfHf6a-7UekKeqNumvvTw"
      decimals="-5"
      id="Narr_PYnz8_dCRUqCuyVWRBDWvw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</vstm:ProceedsFromIssuanceOfCommonStockNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_0T3fJyZ5j0S72HD7DP8uwA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;11. Stock-based compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense as reflected in the Company&#x2019;s consolidated statements of operations and comprehensive loss was as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,134&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,987&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,873&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total stock-based compensation expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,405&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,342&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,860&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;width:192.9pt;"&gt;&lt;/span&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;All of the $9.4 million, $7.3 million, and $5.9 million of stock-based compensation expense recorded during the years ended December 31, 2025, 2024 and 2023, respectively, was recorded to additional paid-in capital.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has awards outstanding under two equity compensation plans, the Amended and Restated 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;), and the Amended and Restated 2012 Incentive Plan (the &#x201c;2012 Plan&#x201d;), as well as the inducement award program. Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the individual plans. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021 Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During 2021, the Company&#x2019;s stockholders approved the 2021 Equity Incentive Plan (the &#x201c;Original 2021 Plan&#x201d;). Upon effectiveness of the Original 2021 Plan, the Company ceased making awards under the 2012 Plan. At the Company&#x2019;s 2024 Annual General Meeting of Shareholders in May 2024, the Company&#x2019;s shareholders approved the Amended 2021 Plan. The Amended 2021 Plan together with the Original 2021 Plan is referred to as the 2021 Plan. The 2021 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs and other stock-based awards. The number of shares of common stock initially reserved for issuance under the Original 2021 Plan was (i) 1,991,666 plus (ii) the number of shares of the Company&#x2019;s common stock underlying awards under the 2012 Plan and the &lt;span style="background:#ffffff;"&gt;2010 Equity Incentive Plan (the &#x201c;&lt;/span&gt;2010 Plan&#x201d;) that expire, terminate or are surrendered without delivery of shares, are forfeited to or repurchased by the Company, or otherwise become available again for grant under the terms of the 2012 Plan or the 2010 Plan, as applicable. The Amended 2021 Plan increased the maximum number of shares available for issuance by 3,200,000 shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025, under the 2021 Plan, the Company has granted stock options for 2,590,423 shares of common stock, of which 418,541 have been forfeited and 34,402 have been exercised, and granted RSUs for 2,268,761 shares of common stock, of which 105,361 have been forfeited and 852,679 have vested. As of December 31, 2025, 1,567,799 shares remain available for future issuance under the 2021 Plan. The exercise price of each option has been equal to the closing price of a share of the Company&#x2019;s common stock on the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2012 Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2012 Plan became effective immediately upon the closing of the Company&#x2019;s initial public offering in February 2012. Upon effectiveness of the 2012 Plan, the Company ceased making awards under the 2010 Plan. The 2012 Plan initially allowed the Company to grant awards for up to 285,714 shares of common stock, plus the number of shares of common stock available for grant under the 2010 Plan as of the effectiveness of the 2012 Plan (which was an additional 2,508 shares), plus that number of shares of common stock related to awards outstanding under the 2010 Plan which terminate by expiration, forfeiture, cancellation or otherwise. The 2012 Plan included an &#x201c;evergreen provision&#x201d; that allowed for an annual increase in the number of shares of common stock available for issuance under the 2012 Plan. The annual increase was added on the first day of each year from 2013 through 2018 and was equal to the lesser of 107,412 shares of common stock and 4.0% of the number of shares of common stock outstanding, or a lesser amount as determined by the board of directors. On each of January 1, 2018, January 1, 2017 and January 1, 2016, the number of shares available for issuance under the 2012 Plan increased by 107,412 under this provision. On December 18, 2018, the shareholders of the Company approved the Amended and Restated 2012 Incentive Plan which increased the maximum number of shares available for issuance under the 2012 Plan to 1,385,702 and eliminated the evergreen provision. On May 19, 2020, the shareholders of the Company approved the Amended and Restated 2012 Incentive Plan which increased the maximum number of shares available for issuance by 1,083,333 shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Awards under the 2012 Plan may include the following award types: incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, RSUs, other stock-based or cash-based awards and any combination of the foregoing. As of December 31, 2025, under the 2012 Plan, the Company has granted stock options for 1,841,188 shares of common stock, of which 1,201,898 have been forfeited, 238,203 have expired, and 191,342 have been exercised, and granted RSUs for 556,432 shares of common stock, of which 87,547 have been forfeited and 468,885 have vested. The exercise price of each stock option has been equal to the closing price of a share of the Company&#x2019;s common stock on the grant date. Upon adoption of the Original 2021 Plan, the Company ceased issuing awards from the 2012 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Inducement Award Program&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In December&#160;2014, the Company established an inducement award program (in accordance with Nasdaq Listing Rule&#160;5635(c)(4)) under which it may grant non-statutory stock options to purchase, and RSUs in respect of up to an aggregate of&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;62,500 shares of common stock to new or prospective employees as inducement to enter into employment with the Company. In December 2016, the Board of Directors authorized and reserved 48,333 additional shares of common stock under this program. In December 2017, the Board of Directors authorized and reserved 208,333 additional shares of common stock under this program. In June and December 2018, the Board of Directors authorized and reserved 141,666 and 104,166 additional shares of common stock under this program, respectively. In February 2020, the Board of Directors authorized the reduction of 169,447 shares available for issuance under this program. In September 2023, the Board of Directors authorized and reserved 500,000 additional shares of common stock under this program. In September 2025, the Board of Directors authorized and reserved 400,000 additional shares of common stock under this program. The program is governed by the terms of the 2021 Plan, but shares issued pursuant to the program are not issued under the 2021 Plan. As of December 31, 2025, the Company had granted options for 1,459,605 shares of common stock under the program, of which 725,488 have been forfeited, 1,997 have expired and 48,913 have been exercised, and granted RSUs for 164,137 shares, of which 45,658 have been forfeited and 115,302 have vested. As of December 31, 2025, 508,330 shares remain available for future issuance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock Options&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Most options granted by the Company vest twenty-five percent (25%) one year from vesting start date and six and a quarter percent (6.25%) for each successive three-month period, thereafter (subject to acceleration of vesting in the event of certain change of control transactions) subject to the employee&#x2019;s continued employment with, or service to, the Company on such vesting date and are exercisable for a period of ten years from the date of grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Option Exchange Program&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 17, 2024, the Company&#x2019;s stockholders, upon recommendation of the board of directors, approved a one-time stock option exchange program (the &#x201c;Option Exchange Program&#x201d;) for certain employees, executive officers and non-employee directors of the Company who held certain underwater options and remained employed or otherwise engaged by the Company through the completion of the Exchange Offer. The Company&#x2019;s offer to participate in the Option Exchange Program commenced on February 8, 2024, and expired on March 8, 2024 (the &#x201c;Exchange Offer&#x201d;). Pursuant to the Exchange Offer,&#160;42&#160;eligible holders elected to exchange, and the Company accepted for cancellation, eligible options to purchase an aggregate of&#160;603,330&#160;shares of the Company&#x2019;s common stock (the &#x201c;Exchanged Options&#x201d;). On March 11, 2024, promptly following the expiration of the Exchange Offer, the Company granted new options to purchase&#160;603,330&#160;shares of common stock (the &#x201c;New Options&#x201d;), pursuant to the terms of the Exchange Offer and the Amended 2021 Plan. The exercise price of the New Options granted was $11.44&#160;per share, which was the closing price of the Company&#x2019;s common stock on the Nasdaq Capital Market on the grant date of the New Options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The exchange of stock options was treated as a modification for accounting purposes. As a result of the Option Exchange Program, the Company will recognize incremental stock-based compensation expense of $1.7 million over the requisite service period of the New Options, which is two or four years depending on whether the Exchanged Options were vested at the time of exchange. Since the Exchanged Options were not at-the-money on the modification date, the Company was precluded from utilizing the simplified method as described in SEC Staff Accounting Bulletin Topic 14.D.2 to calculate the expected term as a key assumption in the Black-Scholes pricing model. Therefore, the Company utilized the binomial lattice model to calculate the fair value of the Exchanged Options immediately prior to the exchange. The Company utilized the Black-Scholes option-pricing model to calculate the fair value of the New Options on the modification date. The Company is recognizing the remaining unamortized stock compensation expense for the Exchanged Options on the modification date over the original requisite service period of the Exchanged Options. At December 31, 2025, there was no unrecognized compensation cost related to Exchanged Options. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;A summary of the Company&#x2019;s stock option activity and related information for the year ended December 31, 2025, is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.58760834%;padding-left:0pt;padding-right:0pt;width:101.17%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average exercise&#160;price&#160;per share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average remaining contractual term (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate intrinsic value (in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,479,037&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 843&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 754,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised/Released&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,674)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited/cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (189,306)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (625)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 95.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,030,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,731&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested at December 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,568,702&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,248&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:18pt 0pt 12pt 0pt;"&gt;The fair value of each stock option was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 107&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company recorded stock-based compensation expense associated with employee and non-employee stock options of $4.5 million, $4.6 million, and $4.2 million, for the years ended December 31, 2025, 2024, and 2023, respectively. The weighted-average grant date fair value of stock options granted in the years ended December 31, 2025, 2024, and 2023 was $5.48, $3.35 and $6.16 per stock option, respectively. The fair value of stock options that vested during the years ended December 31, 2025, 2024, and 2023 was $3.7 million, $3.5 million, and $3.1 million, respectively. The aggregate intrinsic value of options exercised (i.e.,&#160;the difference between the market price at exercise and the price paid by employees to exercise the option) during the years ended December&#160;31, 2025, 2024, and 2023 was $0.1 million, $0.1 million, and $0.0 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;At December 31, 2025 there was $5.4 million of total unrecognized compensation cost related to unvested stock options and the Company expects to recognize this cost over a remaining weighted-average period of 2.2 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restricted Stock Units (&#x201c;RSUs&#x201d;)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Each RSU entitles the holder to receive one share of the Company&#x2019;s common stock when the RSU vests. The RSUs generally vest (i) twenty-five percent (25%) one year from vesting start date and six and a quarter percent (6.25%) for each successive three-month period, thereafter, (ii) two tranches for 50% of the award with the second and final vesting date on the one year anniversary of the vesting commencement date, (iii) 100 percent within two years of the vesting commencement date and (iv) 33.3% of the RSUs on the first &lt;span style="-sec-ix-hidden:Hidden_Y9Qm4X9j2kKBLrWQXymdSw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; anniversaries of the grant date. The RSUs are subject to acceleration of vesting in the event of certain change of control transactions and subject to the employee&#x2019;s continued employment with, or service to, the Company on such vesting date. Compensation expense is recognized on a straight-line basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;A summary of RSU activity during the year ended December 31, 2025, is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average grant date fair value per&#160;share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,010,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,132,374&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (687,067)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited/cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (141,642)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,313,898&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 6pt 0pt;"&gt;The Company recorded stock-based compensation expense associated with employee and non-employee RSUs of $4.9 million, $2.7 million, and $1.6 million, for the years ended December 31, 2025, 2024, and 2023, respectively. The total fair value of restricted stock units that vested during the years ended December 31, 2025, 2024, and 2023 was approximately $4.4 million, $1.7 million, and $1.7 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;At December 31, 2025, there was $4.6 million of total unrecognized compensation cost related to unvested RSUs and the Company expects to recognize this cost over a remaining weighted-average period of 1.9 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Employee stock purchase plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;At the special meeting of stockholders, held on December 18, 2018, the stockholders approved the 2018 Employee Stock Purchase Plan (&#x201c;2018 ESPP&#x201d;). On June 21, 2019, the board of directors of the Company amended and restated the 2018 ESPP, to account for certain non-material changes to the plan&#x2019;s administration (the &#x201c;Amended and Restated 2018 ESPP&#x201d;). The Amended and Restated 2018 ESPP provides eligible employees with the opportunity, through regular payroll deductions, to purchase shares of the Company&#x2019;s common stock at &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;85%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of the lesser of the fair market value of the common stock (a) on the date the option is granted, which is the first day of the purchase period, and (b) on the exercise date, which is the last business day of the purchase period. The Amended and Restated 2018 ESPP generally allows for &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;two&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;six-month&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; purchase periods per year beginning in January and July, or such other periods as determined by the compensation committee of the Company&#x2019;s board of directors. The Company has reserved &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;166,666&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares of common stock for the administration of the Amended and Restated 2018 ESPP. The fair value of shares expected to be purchased under the Amended and Restated 2018 ESPP was calculated using the Black-Scholes model with the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:49.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:49.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;For the years ended December 31, 2025, 2024, and 2023, the Company has recognized less than $0.1 million of stock-based compensation expense each year under the Amended and Restated 2018 ESPP. During the years ended December 31, 2025, 2024, and 2023, the Company issued 16,341 shares, 15,231 shares and 14,270 shares, respectively, of common stock for proceeds of $0.1 million in each year under the Amended and Restated 2018 ESPP.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      id="Tb_LrDYNpo9nEWzGpBGuJxQfQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense as reflected in the Company&#x2019;s consolidated statements of operations and comprehensive loss was as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,134&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,987&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,873&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total stock-based compensation expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,405&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,342&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,860&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_81vFum6e40qPRWAKzAeYEA"
      decimals="-3"
      id="Tc_A86HJSzzVk6cr368gDfprA_3_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2527000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2rH54lHkjUGemFEv-HKuhQ"
      decimals="-3"
      id="Tc_Tp72rHsB1E-LvorS9TIerA_3_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2134000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_M0_H0x6EIkiEVk025KKwUw"
      decimals="-3"
      id="Tc_7EfyvuGP-kWMwSjlGhdhQA_3_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1987000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_vstm_SellingGeneralAndAdministrativeExpenseMember_GF1wQLe1cEepBDtan8hiOg"
      decimals="-3"
      id="Tc_XmTjsHyboUyy0xfaR7yhdA_4_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6878000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_vstm_SellingGeneralAndAdministrativeExpenseMember_sCAZBIHJT0aFnxlMm6H5GQ"
      decimals="-3"
      id="Tc_IGdQfXNrCEedkRDDWi4MaA_4_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5208000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_vstm_SellingGeneralAndAdministrativeExpenseMember_F3TTaRhxYEqLX5MuwsstiQ"
      decimals="-3"
      id="Tc_JrsX3odlcUOnhpWSts2BGQ_4_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3873000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_Ui3OVlHj5Uu63w2AELuqsw_5_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">9405000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_aqsfIL-GnEO0F6Q-SDCmBw_5_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7342000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-3"
      id="Tc_FobVnM48aESwcFFc8ylgMg_5_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5860000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-5"
      id="Narr_h2eMDvl7M0SOOHK4BLmy8A"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">9400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-5"
      id="Narr_YhKFNgnZM026IqmONOUirQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-5"
      id="Narr_fbPalMgOYUOMI7NKZ87WrQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <vstm:NumberOfEquityCompensationPlans
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="INF"
      id="Narr_hLW7ZSl7zEGsXqEz0_-c5g"
      unitRef="Unit_Standard_item_5quK1hZThku2W0bLLpUodA">2</vstm:NumberOfEquityCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_9MQgPcH2EUCI7sWeUwpq2w"
      decimals="INF"
      id="Narr_0DcmMWwnHES-CwFQy3OD_A"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1991666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_kF5MtIMMKk-IM7zcfxe9ng"
      decimals="INF"
      id="Narr_wfQlLhkBvkGPng4Q7qdvDg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_vVu2uuQvG06s9WNMj9GHKQ"
      decimals="INF"
      id="Narr_S88e4j0uPEWKKdOG66XVQA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">2590423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_vVu2uuQvG06s9WNMj9GHKQ"
      decimals="INF"
      id="Narr_7vV_ZesYFkaKyhNKlgabqA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">418541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_vVu2uuQvG06s9WNMj9GHKQ"
      decimals="INF"
      id="Narr__LDdOY2a2E-iOpXtCWxaUg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">34402</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member__JkWWHFFE02LfRdH8KCQ3w"
      decimals="INF"
      id="Narr_Bey8n5TnsUKh0zq9RzgqVw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">2268761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member__JkWWHFFE02LfRdH8KCQ3w"
      decimals="INF"
      id="Narr_Bj8X20pS6EyRbIUQyoe8YQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">105361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member__JkWWHFFE02LfRdH8KCQ3w"
      decimals="INF"
      id="Narr_ENx3occDb0elJ75DV3-ZDw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">852679</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_vstm_EquityIncentivePlan2021Member_oquxji7W7kORBWim9QZqHQ"
      decimals="INF"
      id="Narr_UGumss9mPEKR-mTxQfYQ9Q"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1567799</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_2_29_2012_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member__U1eFLyyYUinIuRMK__m6g"
      decimals="INF"
      id="Narr_i4X32TXhGkSVrjXlu4fk8Q"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">285714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_2_29_2012_To_2_29_2012_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_I4P8dDbjHU-7QChhWz3WUw"
      decimals="INF"
      id="Narr_WtlPLEp9WkSv2FyuEAqvAA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">2508</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <vstm:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized
      contextRef="Duration_1_1_2013_To_12_31_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_InUwV157EEmuIs833j_9kA"
      decimals="INF"
      id="Narr_VMij6G1pYECyyXkkXZt68g"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">107412</vstm:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized>
    <vstm:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved
      contextRef="Duration_1_1_2013_To_12_31_2018_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_6UYIohPWOE6apXvvQXRZUg"
      decimals="INF"
      id="Narr_gVoLgUrydkOy1ffUwz5pBg"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.04</vstm:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingCommonStockForComputationOfAnnualIncreaseInNumberOfSharesReserved>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2016_To_12_31_2018_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_3QOHsDLjBU6VMM7clr-E_Q"
      decimals="INF"
      id="Narr_8DUilHNr_EKrdak-2u-PXA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">107412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_18_2018_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_VfDIZ_ny_0SEOGbgvYKH1A"
      decimals="INF"
      id="Narr_xlauqyC4oUmxlt_TyB3msQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1385702</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_5_19_2020_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_7ogkiNGxH0Cudi_sLSt8Sg"
      decimals="INF"
      id="Narr_u2nVw3bqnk6yFmwYm0AmTg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1083333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_XEXyJOXQwU6kwc_ldYtXQA"
      decimals="INF"
      id="Narr_bqkgfj3XgkWhVy6KfmeL0A"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1841188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_XEXyJOXQwU6kwc_ldYtXQA"
      decimals="INF"
      id="Narr_i9QjoLV7fE-h0Dc1xTFKgQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1201898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_XEXyJOXQwU6kwc_ldYtXQA"
      decimals="INF"
      id="Narr_dJi3TJ0dGUiXwLApMCPELA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">238203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_XEXyJOXQwU6kwc_ldYtXQA"
      decimals="INF"
      id="Narr_dxr3a0gCn0-ETqK5UVlGdg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">191342</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_PLQMRuTiiE6wbLtAwlEjMw"
      decimals="INF"
      id="Narr_NHbpYSQuXkO0d3Wkh48pSg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">556432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_PLQMRuTiiE6wbLtAwlEjMw"
      decimals="INF"
      id="Narr_mKhQAIkRnE-CAo9zevgjMQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">87547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_IncentivePlan2012Member_PLQMRuTiiE6wbLtAwlEjMw"
      decimals="INF"
      id="Narr_ty9h3eJZTk-Zc8mBeVZoIw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">468885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2014_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_HTpasKVhbEijVBMXmoAR3g"
      decimals="INF"
      id="Narr_oobw3oADkEqQ0LHc-BJgJA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">62500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_hb0DPVUMikKyDJikKyOjUQ"
      decimals="INF"
      id="Narr_gTT2jM95REKFJMws-5merg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">48333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_sFo85W5EcE2hWIXSctPLDg"
      decimals="INF"
      id="Narr_2RwFaXUX9U-Os5p9qJRDJg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">208333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_6dsoZ6DBIU6g6FY7wcduKw"
      decimals="INF"
      id="Narr_Sw32TGkJ-kejl6hd1xJzVA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">141666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_12_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_ZKoZ1HtmKEOVJFeHyY-zGQ"
      decimals="INF"
      id="Narr_iWMCY-gz_k6B_gNh97pkFw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">104166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <vstm:ReductionOfSharesAvailableForIssuance
      contextRef="Duration_2_1_2020_To_2_29_2020_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_KH8OwIiqFUWzZ49IgN-PQQ"
      decimals="INF"
      id="Narr_JdbhxoCxsUesKlZt2XjL9g"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">169447</vstm:ReductionOfSharesAvailableForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_9_1_2023_To_9_30_2023_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_D0hnNXSwOkqr4_93nEPQFw"
      decimals="INF"
      id="Narr_jleSOILf8kKbZtRrh6TLZg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_9_1_2025_To_9_30_2025_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_cywh5amltUm6Kt3zBqYeYw"
      decimals="INF"
      id="Narr_1UsQhW6xa06PuNWbGXBVEA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Qle4ZI3AIEyBN5JnaC-kDw"
      decimals="INF"
      id="Narr_a5exA9ABWkmITLXi81OmZg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1459605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Qle4ZI3AIEyBN5JnaC-kDw"
      decimals="INF"
      id="Narr_wRQouAHYi0S4aYkQraGOJQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">725488</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Qle4ZI3AIEyBN5JnaC-kDw"
      decimals="INF"
      id="Narr_Sz8zkmkbxkCsKc5Sfgot0g"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1997</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Qle4ZI3AIEyBN5JnaC-kDw"
      decimals="INF"
      id="Narr_whjVv2mCwU21kZhzIAZw_A"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">48913</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Thu2JVJXHE-NAiF2FbkbWQ"
      decimals="INF"
      id="Narr_wRYayRigIUG4JRB6SyRlCQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">164137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Thu2JVJXHE-NAiF2FbkbWQ"
      decimals="INF"
      id="Narr_sQLBvPbZ9kelORZmE2TZ0A"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">45658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_Thu2JVJXHE-NAiF2FbkbWQ"
      decimals="INF"
      id="Narr_XTUU_1vLL0WndGtfFLRBeQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">115302</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_vstm_InducementAwardProgramMember_v94nix69zkGeGJg-ULbs-w"
      decimals="INF"
      id="Narr_smZLPT2W6EOtbYo8vjv9Dw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">508330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_SRNGIXeB20ejdnPS4J6CHA"
      decimals="2"
      id="Narr_YaLyH8LlGkK7iR78DTvDnQ"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_SRNGIXeB20ejdnPS4J6CHA"
      id="Narr_Iyp7OpVLFE-eO27vV20A6g">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_AH-XF6rwGUWP_UuR-y8kTA"
      decimals="4"
      id="Narr_VNjyHbyr7k-znwmnYZLafw"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_AH-XF6rwGUWP_UuR-y8kTA"
      id="Narr_nag1e6fgHESNGzw7xO6olA">P3M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      id="Narr_SC2H8g5dvk6Zm5BthjLl9g">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <vstm:NumberOfEligibleStockholders
      contextRef="Duration_1_17_2024_To_1_17_2024_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_9tsdrgQO-UKXsRxV5I_Sjg"
      decimals="INF"
      id="Narr_BCZDQI21qUu4ZooI-hn8Tw"
      unitRef="Unit_Standard_item_5quK1hZThku2W0bLLpUodA">42</vstm:NumberOfEligibleStockholders>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_1_17_2024_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_6mVNyROOJkSrg0yW3Dje3g"
      decimals="INF"
      id="Narr_u2uc7-_C9ka0ujwdKOKQ-w"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">603330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_3_11_2024_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_-AttFnMCSU6nI2v6Vkvu9A"
      decimals="INF"
      id="Narr_obEIqggHjECi40kRmuqDPA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">603330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_3_11_2024_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_-AttFnMCSU6nI2v6Vkvu9A"
      decimals="2"
      id="Narr_z3WOhGGj5UKXl41jInQHcA"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">11.44</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_P0DHBOoSh0iaybDJceiPYw"
      decimals="-5"
      id="Narr_5E-xTVFTFUevk3G-2f5R_A"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_vstm_StockOptionExchangeProgramMember_7P_amzQ5tEm7vf5xPezzyQ"
      decimals="-6"
      id="Narr_gpSVD_SlvU6o8QFjQG4iEw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      id="Tb_8eduIiBirUG8jgOiv2oi-A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.58760834%;padding-left:0pt;padding-right:0pt;width:101.17%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average exercise&#160;price&#160;per share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average remaining contractual term (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate intrinsic value (in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,479,037&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 843&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 754,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised/Released&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,674)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited/cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (189,306)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (625)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 95.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,030,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,731&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested at December 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,568,702&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,248&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_KXGM5R7Mj0CV9njTnuX__g"
      decimals="INF"
      id="Tc_sCd87jmMe0CQFLmuWlUglA_2_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">2479037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_KXGM5R7Mj0CV9njTnuX__g"
      decimals="2"
      id="Tc_VTHm0Ltupk-DEnUDeTHAFA_2_5"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">11.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w"
      id="Tc_x_gHbIld7ECveTO6q1Q1Cg_2_7">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_KXGM5R7Mj0CV9njTnuX__g"
      decimals="-3"
      id="Tc_HgXZ1Xa6bkm_NmiBx3SBIA_2_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">843000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      decimals="INF"
      id="Tc_s5eAt_CqH0Gyzu16FD5YVg_3_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">754000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      decimals="2"
      id="Tc_CCGGBRzAKEq3wDfhe68r9w_3_5"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">6.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      decimals="INF"
      id="Tc_EhzdhGXcoEGHxIt2rwd5WA_4_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">12674</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      decimals="2"
      id="Tc_aK8EK_GJQUql15HQaWDqBg_4_5"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">5.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      decimals="INF"
      id="Tc_uwGP1nUaJ0qpuAWjIsQwLg_5_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">189306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      decimals="2"
      id="Tc_WApZGijrr0uyjWun1apKuQ_5_5"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">6.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      decimals="INF"
      id="Tc_TLHe8liR0U-AB1fA4-RiTA_6_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      decimals="2"
      id="Tc_Il_416xKO06EkC7A9fz4Ww_6_5"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">95.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_QxkWpkXINU6ewZdwyiOEzg"
      decimals="INF"
      id="Tc_qLatyEc58UajsH4z6cGZ3w_7_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">3030432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_QxkWpkXINU6ewZdwyiOEzg"
      decimals="2"
      id="Tc_ulfFfnoC5USk5YuCq1vEpw_7_5"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">10.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      id="Tc_KQ7i4uhZzEqxqLSSW9kddg_7_7">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_QxkWpkXINU6ewZdwyiOEzg"
      decimals="-3"
      id="Tc_fawlB7h030KpWSDV3dLnvg_7_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2731000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      decimals="INF"
      id="Tc_YXnPFqZKaUuEuZOgDMZhNw_8_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1568702</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_QxkWpkXINU6ewZdwyiOEzg"
      decimals="2"
      id="Tc_ybKjb3qTzUa39c5khqGpcw_8_5"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">12.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      id="Tc_TscwwyIyoU6BmG5ypMiIsg_8_7">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_QxkWpkXINU6ewZdwyiOEzg"
      decimals="-3"
      id="Tc_o_p3kA21ekGOe3eG-x9Udg_8_10"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1248000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      id="Tb_32AhqiqjJkK1JcaMiqiK9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 107&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      decimals="4"
      id="Tc_trKe_V2rzEWLi5J3ff8xYQ_3_2"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w"
      decimals="4"
      id="Tc_zWgMuTXhaE-mDqW8gQ7mBw_3_5"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw"
      decimals="4"
      id="Tc_tIdJE1g98kGmGUc-bA-rnA_3_8"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      decimals="2"
      id="Tc_cVMnVJM4rku45Nqx7Ywnhg_4_2"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w"
      decimals="2"
      id="Tc_W9d7WUc1JE6YZ-KG0ilV2w_4_5"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw"
      decimals="2"
      id="Tc_pnQ2rj6YAEGroAO2ttU2EA_4_8"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      decimals="2"
      id="Tc_YOcQjIuCj0K0LDx9cQZm0w_5_2"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w"
      decimals="2"
      id="Tc_SEeHbylm4UCRxdoDsvt_VQ_5_5"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw"
      decimals="2"
      id="Tc_EjdGnCetQUK7N8VrG8Lzjw_5_8"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      id="Tc_L6VzEcv0K0OuhU_j4j_wyQ_6_2">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w"
      id="Tc_k7GHJx5hcEe3er5z5_TjyA_6_5">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw"
      id="Tc_fjDaMKja9ECiGswqkWQhXA_6_8">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      decimals="-5"
      id="Narr_F2jyYTL6xUmfGY5yS3wmpA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w"
      decimals="-5"
      id="Narr_Hs9xpSGPqkiugApncoIT8g"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw"
      decimals="-5"
      id="Narr_6s8HY_iFxk-tkBR0w-_KAw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      decimals="2"
      id="Narr_8V62Vm6_-UOksAZNxME_rQ"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">5.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w"
      decimals="2"
      id="Narr_sdAMnqRe-UCxn-Uocp8v_w"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">3.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw"
      decimals="2"
      id="Narr_tkmR2VII2UyqfImYmZbTbg"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">6.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      decimals="-5"
      id="Narr_uC8-frVkN0KsHtbb6NDi5w"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w"
      decimals="-5"
      id="Narr_ahgKbxxbaE-TnF2w7o2EEg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw"
      decimals="-5"
      id="Narr_hSteCa7QZ0aFCrSCAuJoQw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      decimals="-5"
      id="Narr_luB0Uf5h_kCMI46FvH4t4g"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_lmXKo4rDTEWoGFrhCf2D0w"
      decimals="-5"
      id="Narr_e_D1aSA070qozLYXNtzyOg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_vXhjHzfX6EKL-TvKV9MnLw"
      decimals="-5"
      id="Narr_9UwJdzBpyk-iRfIGwY2lsA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_QxkWpkXINU6ewZdwyiOEzg"
      decimals="-5"
      id="Narr_Z5GmvrOiYk-__VIKj0IDew"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_vstm_EmployeeAndNonEmployeesStockOptionMember_9owsisj6VE-pq2_wYKtH-Q"
      id="Narr_8RS5wTEoV0SkaOhxOuBT3Q">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <vstm:NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw"
      decimals="INF"
      id="Narr_vwMYrea6kkWSAZOVrbfGDw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1</vstm:NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DIZOBohzgUCmiDTqRAMCOA"
      decimals="2"
      id="Narr_cdb7HtW42kSLqkksj4oJWw"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DIZOBohzgUCmiDTqRAMCOA"
      id="Narr_w4Za5Wh8C0GcyS0mOW7CZg">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8LF9tFy9yEe9w7E5AvqW_g"
      decimals="4"
      id="Narr_hFBWEqZn9k2Pg2RvNIt8Pw"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8LF9tFy9yEe9w7E5AvqW_g"
      id="Narr_RXnR-SPfN0-BSs8mDAMO6w">P3M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <vstm:NumberOfInstallmentsForVestingOfRestrictedStockUnits
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_mUQePIf6k0Ox3rRBC0Wpxg"
      decimals="INF"
      id="Narr_i_e-G3TqfU-pSrz7xG6-_Q"
      unitRef="Unit_Standard_tranche_AR7EJ57OqEq8JqHSzH8_Aw">2</vstm:NumberOfInstallmentsForVestingOfRestrictedStockUnits>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_mUQePIf6k0Ox3rRBC0Wpxg"
      decimals="2"
      id="Narr_aOm4hCWXcUiGrmW05iwUXA"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_mUQePIf6k0Ox3rRBC0Wpxg"
      id="Narr_xOKVN1n_BUmzF-H_8qOY2w">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <vstm:NumberOfAnniversariesForVestingRestrictedStockUnits
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DIZOBohzgUCmiDTqRAMCOA"
      decimals="INF"
      id="Narr_FPzPoLBJUkSPAk_ZMNbnRA"
      unitRef="Unit_Standard_item_5quK1hZThku2W0bLLpUodA">1</vstm:NumberOfAnniversariesForVestingRestrictedStockUnits>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_vstm_ShareBasedCompensationAwardTrancheFourMember_NWg1r4cHA0-EOBRAYidUbA"
      decimals="2"
      id="Narr_4Wts0-mPd0O7ZAst5koZlw"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_vstm_ShareBasedCompensationAwardTrancheFourMember_NWg1r4cHA0-EOBRAYidUbA"
      id="Narr_ozER2tR300CQtwPNQbU73w">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_vstm_ShareBasedPaymentArrangementTrancheFiveMember_9vzgnyw0KEW9zorH509q7Q"
      decimals="3"
      id="Narr_7W0sdDhcYUGtal3fvQpq-g"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      id="Tb_OJ9bWqw9mEugtR27RQRPhA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average grant date fair value per&#160;share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,010,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,132,374&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (687,067)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited/cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (141,642)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,313,898&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_H7UvvfgjnUqqlhC1ni7-Kw"
      decimals="INF"
      id="Tc_i3gPxHSZC0Sgmu_ASNLoww_2_3"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1010233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_H7UvvfgjnUqqlhC1ni7-Kw"
      decimals="2"
      id="Tc_ZD27IqbRI0iXNHObDceyfg_2_6"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">6.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw"
      decimals="INF"
      id="Tc_Nbmigkqc-EWV5fh6jhi3Hw_3_3"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1132374</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw"
      decimals="2"
      id="Tc_Utd89yxhcUOJcNbfifvuQA_3_6"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">5.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw"
      decimals="INF"
      id="Tc_B5Ddc2czW0-ODM_az5tYvg_4_3"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">687067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw"
      decimals="2"
      id="Tc_HCvGBDgDEUuGWFC44_A1cw_4_6"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">6.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw"
      decimals="INF"
      id="Tc_Hq01PArQg0OuGko9lFzrKg_5_3"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">141642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw"
      decimals="2"
      id="Tc_QkK4Vft_ME6dWh3UnxeyRQ_5_6"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">6.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aS2tcr5syUKqamx-hjW3Pw"
      decimals="INF"
      id="Tc_sUXcYA55I0-cdNnuW7-ntg_6_3"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1313898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aS2tcr5syUKqamx-hjW3Pw"
      decimals="2"
      id="Tc_kiBaNzpon0SDV5xcCBvfqw_6_6"
      unitRef="Unit_Divide_USD_shares_oeAWjI_4TUGv3fzpr3QLVw">5.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw"
      decimals="-5"
      id="Narr__pAxjdeG40CExkf6j4vQZg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_S_kTXh7xV0m8qg0cNUl6aw"
      decimals="-5"
      id="Narr_dMMh7j9FLUSoJb2dYsea5g"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_o06JHclHKkuBTNuWXs-wzg"
      decimals="-5"
      id="Narr_m2vtPKlIU0mOpkZS1NGySA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw"
      decimals="-5"
      id="Narr_6j8UAnadBEahjzUwFQw7Ig"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_S_kTXh7xV0m8qg0cNUl6aw"
      decimals="-5"
      id="Narr_cERYGY0Qek-tosGt9zjFVQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_o06JHclHKkuBTNuWXs-wzg"
      decimals="-5"
      id="Narr_kwX8dpE6-0OLVen_6RCAsg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aS2tcr5syUKqamx-hjW3Pw"
      decimals="-5"
      id="Narr_yqfj6pXwGUW21iwl2QMTXg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_fWlKz1EL20SuUW50_KRWTw"
      id="Narr_XAf2syPMG02GVbOMxhELjg">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_6_21_2019_To_6_21_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_m3em9BxJfkWCCgCqGcDWTw"
      decimals="2"
      id="Narr_WPOwIS_6yEeHVH-uQW8nkQ"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <vstm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods
      contextRef="Duration_6_21_2019_To_6_21_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_m3em9BxJfkWCCgCqGcDWTw"
      decimals="INF"
      id="Narr_RQ6kg7NdUk2Ig5HTVzPBqA"
      unitRef="Unit_Standard_item_5quK1hZThku2W0bLLpUodA">2</vstm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAwardVestingPeriods>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_21_2019_To_6_21_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_m3em9BxJfkWCCgCqGcDWTw"
      id="Narr_IiU-AWgtfki9g2aCL7dw6A">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_6_21_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_kZlm7MS8p0C-2514CTT6lg"
      decimals="INF"
      id="Narr_vJujti0k_USRxXAXhLG7IA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">166666</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      id="Group_C3VJP-IxkEyurc5Yc8fccA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:49.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:49.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:49.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_HI4Ao1b7KUaKAhD6JIXWwA"
      decimals="4"
      id="Tc_9f2jiuN6NUalveVZ4ELGmA_3_2"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_oOgDU519zEqo7xvys1DGvA"
      decimals="4"
      id="Tc_XGMsQVIqxUyhA8baA-jx4Q_3_5"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0531</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_vKi2RrPfkku5amSLSGzqiw"
      decimals="4"
      id="Tc_tMh6TAU5T0Cwt5TmKh22Aw_3_8"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_HI4Ao1b7KUaKAhD6JIXWwA"
      decimals="2"
      id="Tc_sbLsp7KKoUCCpsNq-ZIExA_4_2"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_oOgDU519zEqo7xvys1DGvA"
      decimals="2"
      id="Tc_w7kM7L-fVU-frsjXY5MEqg_4_5"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">1.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_vKi2RrPfkku5amSLSGzqiw"
      decimals="2"
      id="Tc_s90OEMrg8E2Tt6KMm9LvBw_4_8"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_HI4Ao1b7KUaKAhD6JIXWwA"
      id="Tc_AHqbWeaz00S8CXEMRmyGmA_6_2">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_oOgDU519zEqo7xvys1DGvA"
      id="Tc_UsS4-g1eIkWNz5F45r9Arg_6_5">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_vKi2RrPfkku5amSLSGzqiw"
      id="Tc_O-1GcKVUyEiP1m5xy1ZcPw_6_8">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_vKi2RrPfkku5amSLSGzqiw"
      decimals="-5"
      id="Narr__L0nfl8tLkSWjFXvJE52fA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_oOgDU519zEqo7xvys1DGvA"
      decimals="-5"
      id="Narr_xXYBwhYnyE-_IN2KTTVUPw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_HI4Ao1b7KUaKAhD6JIXWwA"
      decimals="-5"
      id="Narr_ykzaRNQ_l0miM2Ch84T0Gg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_HI4Ao1b7KUaKAhD6JIXWwA"
      decimals="INF"
      id="Narr_bCXAY9DDEEO7CFnBKRrvQw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">16341</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_oOgDU519zEqo7xvys1DGvA"
      decimals="INF"
      id="Narr_PZelasnb206AqoX7KVVOxg"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">15231</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_vKi2RrPfkku5amSLSGzqiw"
      decimals="INF"
      id="Narr_CNgduFK7YUqCDbLfD-PHIw"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">14270</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_vKi2RrPfkku5amSLSGzqiw"
      decimals="-5"
      id="Narr_mSjZ0m4WkkybAxJ8D40tvg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_oOgDU519zEqo7xvys1DGvA"
      decimals="-5"
      id="Narr_W2kWOjeaikK1R_tSV_qXMg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_HI4Ao1b7KUaKAhD6JIXWwA"
      decimals="-5"
      id="Narr_oG_LYB9jIka7zgqdGMBGlQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_axZHcbOlgkSwmoorxCroZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12. Segment Reporting&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has&#160;one&#160;operating segment which is the business of researching, developing and commercializing drugs for the treatment of patients with cancer. While the Company group consists of entities incorporated in both the U.S. and Germany, the Company manages all business activities on a consolidated basis for the purposes of assessing performance, making operating decisions, and allocating Company resources. The Company&#x2019;s Chief Operating Decision Maker (the &#x201c;CODM&#x201d;) is its President and Chief Executive Officer. The measure of segment assets is the same as reported on the consolidated balance sheets as total assets. The CODM assesses performance based on consolidated net loss that is also reported on the statements of operations and comprehensive loss. The CODM uses net loss to monitor budget versus actual results and to determine how to allocate resources and capital in line with the Company&#x2019;s overall strategy and goals. The accounting policies of the Company's segment are the same as those described in &lt;i style="font-style:italic;"&gt;Note 2. Significant accounting policies&lt;/i&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The table below is a summary of segment net loss including significant segment expenses for the years ended December 31, 2025, 2024 and 2023 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Product revenue, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,914&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Sale of COPIKTRA license and related assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expenses:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cost of sales - product&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cost of sales - intangible amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 698&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Research and development expenses&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 112,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78,648&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,137&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Commercial expenses&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,316&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,164&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Medical affairs expenses&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,231&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,907&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;General and administrative expenses&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,512&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,785&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,755&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,342&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,860&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Depreciation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,068)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,149)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,214)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,138&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,139&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Loss on debt extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Change in fair value of preferred stock tranche liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,189)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,751)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Change in fair value of warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,492&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,149&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Change in fair value of Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,751&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Other segment items&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 185&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (209,471)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (130,637)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (87,367)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;This category is exclusive of non-cash stock-based compensation and severance expense.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other segment items primarily include severance expense and transactions losses and gains due to foreign currency fluctuations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="INF"
      id="Narr_u2Abk89eZkSQNdSi7Y6Cqg"
      unitRef="Unit_Standard_segment_zofEUC3Xr0eG4_rh7aLMNg">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="INF"
      id="Narr_W_mwjeGCgkeoyH2r4NxgxA"
      unitRef="Unit_Standard_segment_zofEUC3Xr0eG4_rh7aLMNg">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_YiH62p3iCkWn9fd-jHp4DA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The table below is a summary of segment net loss including significant segment expenses for the years ended December 31, 2025, 2024 and 2023 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Product revenue, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,914&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Sale of COPIKTRA license and related assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expenses:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cost of sales - product&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cost of sales - intangible amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 698&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Research and development expenses&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 112,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78,648&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,137&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Commercial expenses&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,316&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,164&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Medical affairs expenses&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,231&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,907&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;General and administrative expenses&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,512&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,785&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,755&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,342&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,860&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Depreciation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,068)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,149)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,214)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,138&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,139&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Loss on debt extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Change in fair value of preferred stock tranche liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,189)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,751)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Change in fair value of warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,492&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,149&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Change in fair value of Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,751&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Other segment items&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 185&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:58.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (209,471)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (130,637)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (87,367)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;This category is exclusive of non-cash stock-based compensation and severance expense.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other segment items primarily include severance expense and transactions losses and gains due to foreign currency fluctuations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_zBiJ6bOlu0qlmuRS_OwhWQ"
      decimals="-3"
      id="Tc__1O2uhj6RkeMTVjCyCSlbQ_4_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">30914000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_ycCXXJQjykqCsZOvjuthHg"
      decimals="-3"
      id="Tc_rNk346YeHESQ16LGyuc5nA_5_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <vstm:CostOfGoodsSoldExcludingAmortization
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"
      decimals="-3"
      id="Tc_MtYWEA5ZMUK-2a-w2T8yzg_7_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4600000</vstm:CostOfGoodsSoldExcludingAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"
      decimals="-3"
      id="Tc_nsrInbpXJkqx8bsitzONvQ_8_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">698000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <vstm:ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"
      decimals="-3"
      id="Tc_GMqUV3gAmEe7LjHEOc4-Sw_9_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">112065000</vstm:ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense>
    <vstm:ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA"
      decimals="-3"
      id="Tc_p0VERsawskqmCaGd9L4FdQ_9_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">78648000</vstm:ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense>
    <vstm:ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q"
      decimals="-3"
      id="Tc_lXT_8t3j-UaYRKHtWj-EzQ_9_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">59137000</vstm:ResearchAndDevelopmentExpenseExcludingNonCashStockBasedCompensationAndSeveranceExpense>
    <vstm:CommercialExpenditure
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"
      decimals="-3"
      id="Tc_HrRLAfFsSk6BWYM-A261gw_10_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">34316000</vstm:CommercialExpenditure>
    <vstm:CommercialExpenditure
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA"
      decimals="-3"
      id="Tc_Pwe3LTZueUiJ3UdfHdGSOQ_10_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">10934000</vstm:CommercialExpenditure>
    <vstm:CommercialExpenditure
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q"
      decimals="-3"
      id="Tc_hPNOtgTRzUSdEw6owja-fQ_10_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4164000</vstm:CommercialExpenditure>
    <vstm:MedicalAffairExpenditure
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"
      decimals="-3"
      id="Tc_ORU9MWVyhEeoRFXUNldJug_11_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">11046000</vstm:MedicalAffairExpenditure>
    <vstm:MedicalAffairExpenditure
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA"
      decimals="-3"
      id="Tc_iLoZhsahZ0aFwNHaLtpQYw_11_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5231000</vstm:MedicalAffairExpenditure>
    <vstm:MedicalAffairExpenditure
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q"
      decimals="-3"
      id="Tc_UjPL9jh7GUOddiJ4FoS2Ug_11_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2907000</vstm:MedicalAffairExpenditure>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"
      decimals="-3"
      id="Tc_EGTVfrgL0EaRqrLJNJhvnA_12_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">28512000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA"
      decimals="-3"
      id="Tc__bJ44L0Z-0qUFsgybHfZMw_12_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">21785000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q"
      decimals="-3"
      id="Tc_loR9D8iDs0SRMJQ_feBBZA_12_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">19755000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"
      decimals="-3"
      id="Tc_SEFVKiXiS0KlsNTHlmd0VQ_13_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">9405000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA"
      decimals="-3"
      id="Tc_CciP6t9B4EOuzli0dPqvrw_13_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7342000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q"
      decimals="-3"
      id="Tc_vEns4urpgki0kB7LsgJZig_13_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5860000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"
      decimals="-3"
      id="Tc_D-E3LlnB70m27qTREBkqjw_14_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">32000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA"
      decimals="-3"
      id="Tc_7CcnGyidM06ZvaVorJIdWw_14_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">26000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q"
      decimals="-3"
      id="Tc_b3c1qW6mD0ixFRfaBnGnag_14_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">62000</us-gaap:Depreciation>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"
      decimals="-3"
      id="Tc_13Y8A-61OUam9NPuPkfw_Q_15_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4068000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA"
      decimals="-3"
      id="Tc_Ymdw5TlXDEK0StltKofdFQ_15_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4149000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q"
      decimals="-3"
      id="Tc_gY-YKFQ_v0uqnASCicyDrQ_15_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6214000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"
      decimals="-3"
      id="Tc_zDEcHcBIEk2YVlHjwLmM4g_16_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1138000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA"
      decimals="-3"
      id="Tc_q3G-zoxKvUSKPc8NJOhKsA_16_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4562000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q"
      decimals="-3"
      id="Tc_b8TrASQKg0u3sqkIJ_SqjQ_16_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4139000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"
      decimals="-3"
      id="Tc_DSBFpvSQRUO6-YEL3U5akA_17_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-1826000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <vstm:IncomeLossFromPreferredStockTrancheLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA"
      decimals="-3"
      id="Tc_kvjvBjhg-keGcDjc17ZLvw_18_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">4189000</vstm:IncomeLossFromPreferredStockTrancheLiability>
    <vstm:IncomeLossFromPreferredStockTrancheLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q"
      decimals="-3"
      id="Tc_ala7IRR3o0621qZvJY_M4w_18_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2751000</vstm:IncomeLossFromPreferredStockTrancheLiability>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"
      decimals="-3"
      id="Tc_1hg1P4gE_UaNwbjEHNB6-w_19_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">27492000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA"
      decimals="-3"
      id="Tc_NBiTQoB1zkGO5szeAysNWA_19_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">19149000</us-gaap:FairValueAdjustmentOfWarrants>
    <vstm:FairValueAdjustmentOfNotes
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"
      decimals="-3"
      id="Tc_WJePc459bUynUF8LB4UQog_20_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">12751000</vstm:FairValueAdjustmentOfNotes>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"
      decimals="-3"
      id="Tc_lV6OThNLUka459E0K8DJEw_21_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">572000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA"
      decimals="-3"
      id="Tc_TE31y9lh4U-Lstzyx_ntDQ_21_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1113000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q"
      decimals="-3"
      id="Tc_jy6N9rS1pU-JdkZRPkdmsQ_21_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">308000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA"
      decimals="-3"
      id="Tc_DnzqTHDYG0Sen1T6WSM9lw_22_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">185000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"
      decimals="-3"
      id="Tc_vtObeuLDIEGkFesDmzVmiA_23_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-209471000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA"
      decimals="-3"
      id="Tc_r_19QD-kWk6dO-oqFBk4kg_23_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-130637000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q"
      decimals="-3"
      id="Tc_JP9lBpLjyUSByY3Yiuu24w_23_9"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-87367000</us-gaap:NetIncomeLoss>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_8FKqRr4FlUuHqtupIRgG5Q"
      id="Narr_FbFXiW040kaEn2tmYpAOeA">Other segment items primarily include severance expense and transactions losses and gains due to foreign currency fluctuations.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_sVzP3y1-90GU-wKyXGYyiA"
      id="Narr_-EqtGj3DqUG7IaaT7xzGBw">Other segment items primarily include severance expense and transactions losses and gains due to foreign currency fluctuations.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_vstm_ResearchDevelopingAndCommercializationDrugsSegmentMember_-wljI1WJwkeXqjIFQ5VTcg"
      id="Narr_Z4S1r6lINUORzcvYub4qwA">Other segment items primarily include severance expense and transactions losses and gains due to foreign currency fluctuations.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_4ucU2zRLhkagdEOsOg_bjg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;13. Net Loss per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC Topic 260, &lt;i style="font-style:italic;"&gt;Earnings Per Share,&lt;/i&gt; requires the Company to calculate its net loss per share based on basic and diluted net loss per share, as defined. Basic EPS excludes dilution and is computed by dividing net loss by the weighted average number of shares outstanding for the period. For the years ended December 31, 2025, 2024, and 2023 net loss, basic and diluted EPS are the same as the assumed exercise of stock options, RSUs, ESPP, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Warrants are anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:50.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,030,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,479,037&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,270,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,313,898&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,010,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 209,289&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,429,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,083,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,475&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A Convertible Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 833,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 833,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B Convertible Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,236,570&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total potentially dilutive securities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,783,736&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 22,413,970&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,557,026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_HnXq2GXmlk6seKtHHwQddA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:50.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,030,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,479,037&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,270,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,313,898&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,010,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 209,289&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,429,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,083,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,475&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series A Convertible Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 833,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 833,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Series B Convertible Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,236,570&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total potentially dilutive securities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,783,736&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 22,413,970&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,557,026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_YnZ3x6uu-0Wme4Fzg28ezw"
      decimals="INF"
      id="Tc_sbalBEZVSU6qfXydAiXmRw_3_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">3030432</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_NV4P7J5B-UKwUVnwqEP6NQ"
      decimals="INF"
      id="Tc_cTSfVlQNJEuzS6WN_rrJKw_3_4"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">2479037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_xY-UvU2IMkukHRCrwlS71A"
      decimals="INF"
      id="Tc_fgp-C1K1GEef0uKCOlOZdw_3_6"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">2270359</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_2Bs0lZ91y0Cmf6Th8FtUgg"
      decimals="INF"
      id="Tc_lTUhwSMHRkK-BL-yyBdVKQ_4_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1313898</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_YJkjgHtK7UWwDuHpo_dJVg"
      decimals="INF"
      id="Tc_keyBdZNHZ0aeyYEDli7Jxw_4_4"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">1010233</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Q-P8zB2YJ0Gd2Zv66vU9Sw"
      decimals="INF"
      id="Tc_eo1A8eienU-Q8w4ws5xO2Q_4_6"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">209289</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_haNRViJSzEOTdDWixSwWZQ"
      decimals="INF"
      id="Tc_32NyF2Z9a0a_P2iHwVohCQ_5_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">8429166</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_nET5C9dUgUCwg9L0-kWvkg"
      decimals="INF"
      id="Tc_PQ6EHYQJlkqhUPQ2Q8ncXQ_5_4"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">18083334</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_GHWd8K1WG0u-Q7uzXgEt8A"
      decimals="INF"
      id="Tc_Vh_nwz_liEeNP4tg_dB_0Q_6_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">10240</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_Z7vMySuKckCsJVbZ8qZDQg"
      decimals="INF"
      id="Tc_G7_gBsdnqEee2VhZvXaujQ_6_4"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">8033</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_-x24TYsG3USzRfi7iWlv3A"
      decimals="INF"
      id="Tc_ySlHuF5WPkSRPUX5FES0Mw_6_6"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">7475</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_V8o_TMafXU69pWaNyC7oHA"
      decimals="INF"
      id="Tc_-gPa2DrPkEWb39t0uwuzEw_7_4"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">833333</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesaConvertiblePreferredStockMember_eu_9_6CHf0y-Lj52IH4byw"
      decimals="INF"
      id="Tc_VqivyjaYvkCz3d8RQa4biA_7_6"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">833333</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_vstm_SeriesBConvertiblePreferredStockMember_UVwviP4qFk2O79hJ4CkV4Q"
      decimals="INF"
      id="Tc_4GM7yK7V5UuB1JyzqmSn7A_8_6"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">4236570</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="INF"
      id="Tc_qQwQPxSrNUW7hV-5oOAa1A_9_2"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">12783736</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="INF"
      id="Tc_tJ1oyf8rfUCkLR45vQ-Saw_9_4"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">22413970</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="INF"
      id="Tc_sM7aXEdHPEq2KgY-y0prpQ_9_6"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">7557026</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_Xkma-fCafUWRkdh6gcPUyg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;14. Income Taxes &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;There was no income tax expense for the years ended December 31, 2025 and 2023. The Company recorded income tax expense of &lt;/span&gt;&lt;span style="color:#212529;"&gt;$0.2&lt;/span&gt;&lt;span style="color:#212529;"&gt; million for the year ended December 31, 2024 comprised of a federal income tax payment due to interest under IRC section 453A related to the &lt;/span&gt;&lt;span style="color:#212529;"&gt;$10.0&lt;/span&gt;&lt;span style="color:#212529;"&gt; million milestone payment from Secura because it was an installment sale. This payment was made in 2025. Refer to &lt;/span&gt;&lt;i style="color:#212529;font-style:italic;"&gt;Note. 16. License collaboration and commercial agreements&lt;/i&gt;&lt;span style="color:#212529;"&gt; for further discussion of the Secura APA&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;For the years ended December 31, 2025, 2024, and 2023 income tax expense consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:45.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current income tax expense:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 185&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total current income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 185&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total income tax expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 185&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;As further described in&#160;&lt;a href="https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm" style="-sec-extract:exhibit;color:#000000;font-family:&amp;quot;&amp;quot;'Times New Roman','Times','serif'&amp;quot;&amp;quot;;font-size:10pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Note&#160;&lt;/i&gt;&lt;/a&gt;&lt;a href="https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm" style="-sec-extract:exhibit;color:#000000;font-family:&amp;quot;&amp;quot;'Times New Roman','Times','serif'&amp;quot;&amp;quot;;font-size:10pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;2,&lt;/i&gt;&lt;/a&gt;&lt;a href="https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm" style="-sec-extract:exhibit;color:#000000;font-family:&amp;quot;&amp;quot;'Times New Roman','Times','serif'&amp;quot;&amp;quot;;font-size:10pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;&#160;Summary of Significant Accounting Policies&lt;/i&gt;&lt;/a&gt;, the Company elected to prospectively adopt the guidance in ASU 2023-09.&#160;The following table is a reconciliation of our effective income tax&#160;rate to the statutory federal income tax&#160;rate for the year ended December&#160;31, 2025 in accordance with the guidance in ASU 2023-09:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Pretax loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (209,471)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,989)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State and local income tax benefit, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,710)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in the valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Nontaxable or nondeductible items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Change in fair value of warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 698&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,828&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_0gfH3kQvRkeG5SIGukyrFQ;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Effective income tax rate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table is a reconciliation of the Company&#x2019;s effective&#160;income tax&#160;rate to the statutory federal&#160;income tax&#160;rate for the year ended December&#160;31, 2024 in accordance with the guidance prior to the adoption of&#160;ASU 2023-09:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Income tax benefit using U.S. federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State tax benefit, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.91)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.88)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in the valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax law change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;NOL and tax credit expiration under Section 382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (44.44)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.18)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effective income tax rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (0.14)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 101,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Capitalized research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,786&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,902&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Installment sale&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,187&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Other deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,408&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 462&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 179,447&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,686&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (119)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (362)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (119)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (362)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax asset prior to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 179,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (179,328)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (133,324)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net deferred tax asset&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has recorded a valuation allowance against its deferred tax assets at December 31, 2025 and 2024 because the Company&#x2019;s management believes that it is more likely than not that these assets will not be fully realized. The increase in the valuation allowance of approximately $46.0 million in the year ended December 31, 2025, primarily relates to federal and state NOLs and credits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025, the Company had federal and state NOL carryforwards of approximately $460.5 million and $99.5 million, respectively, which are available to reduce future taxable income. The Company also had federal and state tax credits of $12.3 million and $0.7 million, respectively, which may be used to offset future tax liabilities. The NOL and tax credit carryforwards will expire at various dates through 2045, except for $423.3 million of federal &lt;span style="color:#212529;background:#ffffff;"&gt;NOL carryforwards which may be carried forward indefinitely. &lt;/span&gt;Section 382 and 383 of the IRC and similar provisions under state law limit the utilization of U.S. NOL carryforwards, state NOL carryforwards, R&amp;amp;D credits, and OD credits following certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%. During 2024, the Company believes it triggered ownership changes under Section 382 of the IRC and similar provisions under state law. Based on the Company&#x2019;s analysis under Section 382, the Company believes that its federal NOL carryforwards, its state NOL carryforwards, R&amp;amp;D credits, and OD credits are limited by Section 382 and similar provisions under state law as of December 31, 2025. The portion of federal NOL carryforwards, state NOL carryforwards, R&amp;amp;D credits, and OD credits that were determined to be limited have been written off as of December 31, 2025. The remaining unused carryforwards and credits remain available for future periods. The Company has approximately $346.4 million of federal NOLs generated prior to such ownership changes inclusive of $309.3 million of federal NOLs &lt;span style="color:#212529;background:#ffffff;"&gt;which may be carried forward indefinitely. Since the &lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;$309.3&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt; million of federal NOLs may be carried forward indefinitely, these have not been written off as of December 31, 2025, but due to the limitations under Section 382 generally the Company can only use &lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;$1.6&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt; million per year against taxable income in the future. &lt;/span&gt;Due to the Company&#x2019;s full valuation allowance the write off of certain NOL carryforwards and R&amp;amp;D and OD credits did not have any impact to the statements of operation and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;) requires taxpayers to capitalize and amortize research and development (&#x201c;R&amp;amp;D&#x201d;) expenditures under section 174 for tax years beginning after December 31, 2021. This rule became effective for the Company during 2022. The Company is amortizing these costs for tax purposes over &lt;span style="-sec-ix-hidden:Hidden_UdxKXO7ke0C6w3GjR8sZiQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;5&lt;/span&gt;&lt;/span&gt; years for R&amp;amp;D performed in the U.S. and over &lt;span style="-sec-ix-hidden:Hidden_gx1jXOcOUEaYyXuc-ygToQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;15&lt;/span&gt;&lt;/span&gt; years for R&amp;amp;D performed outside the U.S.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;The One Big Beautiful Bill Act ("OBBBA") was passed and became effective for the Company during 2025. The legislation includes, among other provisions, permanent full expensing for certain business assets, changes to the interest deduction limitation under Section 163(j), amendments to international tax provisions including the global intangible low-taxed income (&#x201c;GILTI&#x201d;) and foreign-derived intangible income (&#x201c;FDII&#x201d;) regimes, the permanent extension of the controlled foreign corporation (&#x201c;CFC&#x201d;) look-through rule, as well as modifications to the treatment of research and development expenditures mentioned above.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;Congress modified the treatment for research and development expenditures by adding new Section 174A, which applies for tax years beginning after December 31, 2024. Section 174A permits the immediate deduction of domestic R&amp;amp;D expenditures or, at the taxpayer&#x2019;s election, capitalization and amortization over a period of at least five years beginning when the related benefits are first realized. Foreign R&amp;amp;D expenditures continue to be capitalized and amortized over 15 years. Transition provisions allow taxpayers either to continue amortizing amounts capitalized under the TCJA rules or to deduct remaining unamortized domestic R&amp;amp;D expenditures in the first tax year beginning after December 31, 2024. The Company has elected to continue amortizing previously capitalized domestic R&amp;amp;D expenditures over the remaining amortization period permitted under OBBBA.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;On October 4, 2023, Massachusetts enacted tax law changes which included the adoption of a single sales apportionment factor effective on January 1, 2025. On December 4, 2024, Massachusetts subsequently enacted supplemental legislation modifying Massachusetts' single sales apportionment factor in certain circumstances. As required under ASC 740, the Company has accounted for the deferred tax impacts of this tax law change in the period the tax law was enacted. The impact of the tax law change is offset by a change in valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company&#x2019;s reserves related to taxes are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. From inception and through December 31, 2025, the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Company had no unrecognized tax benefits or related &lt;span style="-sec-ix-hidden:Hidden_7alXqiLFbU--YfYHWYlRNA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;interest&lt;/span&gt;&lt;/span&gt;, and penalties accrued. The Company has not conducted a study of R&amp;amp;D credit and OD credit carryforwards. A future study may result in an adjustment to the Company&#x2019;s R&amp;amp;D credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s R&amp;amp;D credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or statement of operations if an adjustment were required. The Company would recognize both accrued interest and penalties related to unrecognized benefits in income tax expense. The Company&#x2019;s uncertain tax positions are related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-5"
      id="Narr_X9s9h67n2Umyci3F1L5Mdw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">200000</us-gaap:IncomeTaxExpenseBenefit>
    <vstm:LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_5ZISHrVDkE2EvnOvhrL_rA"
      decimals="-5"
      id="Narr_b_N1ThXiN0yBSbc0VJI0Ag"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">10000000</vstm:LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_lqIBBuCLSUu8tYEvgf__VA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;For the years ended December 31, 2025, 2024, and 2023 income tax expense consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:45.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current income tax expense:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 185&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total current income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 185&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total income tax expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 185&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_PMOCTKftCUiVmMl8pTLFpg_4_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">185000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_qIP_xcdoAEqogIDXHBR6hw_6_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">185000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-3"
      id="Tc_JtJaDQay4k2pJ3Wad0fMgA_11_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">185000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Group_ALVbksKW-UCZgvbAvdz9-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Pretax loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (209,471)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,989)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State and local income tax benefit, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,710)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in the valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Nontaxable or nondeductible items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Change in fair value of warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 698&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,828&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_0gfH3kQvRkeG5SIGukyrFQ;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Effective income tax rate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Income tax benefit using U.S. federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State tax benefit, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.91)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.88)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in the valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax law change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;NOL and tax credit expiration under Section 382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (44.44)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.18)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effective income tax rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (0.14)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_yDvz-B7Zsk-DjvRs7g5_Yg_5_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-209471000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_T_SlRC1Oy0mjuDOzRWVHCg_7_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">-43989000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="3"
      id="Tc_7rab0HbaG0-ojjX1JkLz4w_7_5"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_MZ9yOG-NeUuhmo38S090yw_10_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">9710000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="3"
      id="Tc_voIN49gRnkmN9mWOTikIIg_10_5"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">-0.046</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_OcsX9iUIDEmHls1racs4tQ_11_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">45400000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="3"
      id="Tc_4vMwqHf-jU6R4LOAJAXCkg_11_5"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">-0.217</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <vstm:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_LM1pVITVr0CTSf9jmPVCEA_13_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">5773000</vstm:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityAmount>
    <vstm:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="3"
      id="Tc_gDW4dQZznk6qHu1hqjAgiQ_13_5"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">-0.028</vstm:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_0ID9cQGUkUeeAD9LDKfFvg_14_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">698000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="3"
      id="Tc_2KNiTIgVC0uNFqOm3GsVsw_14_5"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-3"
      id="Tc_nRiqIIz41E6z9EgfOva9dQ_15_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1828000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="3"
      id="Tc_Ozhrkyiqo0mZ-bm0x-puIQ_15_5"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="4"
      id="Tc_qC8lJzlemkOnwQYvklmHoQ_2_3"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="4"
      id="Tc_LhSF8zbXYE2lhb4N9dolQQ_3_3"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.0292</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="4"
      id="Tc_VLxbOLstmEexvcdGm2EMvA_4_3"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">-0.0456</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="4"
      id="Tc_F_DXnNnQ4E2UBQ2uxSjZ9w_5_3"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">-0.0191</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="4"
      id="Tc_J4tmjwdAbEmXc0hXGge-pg_6_3"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">-0.0288</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="4"
      id="Tc_8ljs_cAQj0qRrfGS-kD2Sw_7_3"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.1459</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="4"
      id="Tc_tYLkxIsFZUGKKL-TXR_n1w_8_3"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.062</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <vstm:EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="4"
      id="Tc_GXljHGvg2kiZycWZF4QutA_9_3"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">-0.4444</vstm:EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="4"
      id="Tc_eloNALWgMkqW-Avuq9DW7Q_10_3"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">-0.0018</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="4"
      id="Tc_JEgnAd0zUUiwsnVo3FwMcw_11_3"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">-0.0014</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_S8ml_et65ESBt073FgcCZQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 101,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Capitalized research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,786&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,902&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Installment sale&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,187&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Other deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,408&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 462&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 179,447&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,686&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (119)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (362)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (119)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (362)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax asset prior to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 179,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (179,328)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (133,324)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:75.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net deferred tax asset&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_4QPGauZQLkeqL5csqLmy_w_4_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">101083000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_Pz5u2nYbu0ugUm1maN3sqA_4_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">81151000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <vstm:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_Xxs3U30TPkKBs_I4CJ_YWA_5_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">52887000</vstm:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <vstm:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_eTqku-iSg0m-Tow70sKIag_5_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">38478000</vstm:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_9YVwLhwLgEe74f3SrZBwWA_6_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">12850000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_01GIOnYMVECcr_9KLtc1LA_6_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2786000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_rmRKyMfQnUyDBIK-E_3TXQ_7_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2902000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_msW5NFgQlkuPbPekFzb2Tw_7_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2762000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <vstm:DeferredTaxAssetsInstallmentSale
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_-SWX9U2iSUWW8G9M7rvPSA_8_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7187000</vstm:DeferredTaxAssetsInstallmentSale>
    <vstm:DeferredTaxAssetsInstallmentSale
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_p8BKvKKl9UWNHDYuWgVQHg_8_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7652000</vstm:DeferredTaxAssetsInstallmentSale>
    <vstm:DeferredTaxAssetsLeaseLiability
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_JUu6k2HKrkeE7iX9tJbHUA_9_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">130000</vstm:DeferredTaxAssetsLeaseLiability>
    <vstm:DeferredTaxAssetsLeaseLiability
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_rHCsUet8gkSm9veOzhIs7A_9_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">395000</vstm:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_lPVJWqx76UuITXY8LUMgyA_10_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2408000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_UW_IJeOma0OA2yGUbs9CQQ_10_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">462000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_1Or8C6DjC0-eo7yRNvefag_11_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">179447000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_mjTgerJywECYYYS2SOpsrw_11_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">133686000</us-gaap:DeferredTaxAssetsGross>
    <vstm:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_KkhqT60Bdk6vFMKyGyE1rA_13_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">119000</vstm:DeferredTaxLiabilitiesRightOfUseAsset>
    <vstm:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_VZN4WvpQA0OYxiB3Uoe9Sg_13_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">362000</vstm:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_cqpSVs6QNEGRLE1JofQUYA_14_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">119000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_UVSAKUYJ6Em6FAvNSqCx1g_14_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">362000</us-gaap:DeferredIncomeTaxLiabilities>
    <vstm:DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_EApijdg5hkWvySOyOHwUzw_15_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">179328000</vstm:DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance>
    <vstm:DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_L0dX8_50LUOf7J572tZWTA_15_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">133324000</vstm:DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Tc_yyahlFJ1Q0G6J7Vbxmyi7A_16_3"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">179328000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2024_Ay3dy0DGQEunR8zr77zCVA"
      decimals="-3"
      id="Tc_W_DCXFAx2kuxYzv7wqwQnw_16_6"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">133324000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-5"
      id="Narr_BEM8HDjGpE2WvgsZNetx2Q"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">46000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_M65DxSkBeUWXwkv5yp4KTw"
      decimals="-5"
      id="Narr_5bOFCCgFEku18e2fCmOcvQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">460500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_EMxewkfryEW0MgeN6Ed9RQ"
      decimals="-5"
      id="Narr_tRqw2re8dkC_X0z1UgKN6Q"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">99500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_M65DxSkBeUWXwkv5yp4KTw"
      decimals="-5"
      id="Narr_z-2GNnnfnUKwvY0loOOZ3g"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">12300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_EMxewkfryEW0MgeN6Ed9RQ"
      decimals="-5"
      id="Narr_A3aVj0SMjEW7g2xuLNHqwg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">700000</us-gaap:TaxCreditCarryforwardAmount>
    <vstm:OperatingLossCarryforwardsIndefinitePeriod
      contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_M65DxSkBeUWXwkv5yp4KTw"
      decimals="-5"
      id="Narr_n_CjYcCqekakmBMo3WpPwQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">423300000</vstm:OperatingLossCarryforwardsIndefinitePeriod>
    <vstm:OperatingLossCarryforwardsPriorToOwnershipChanges
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-5"
      id="Narr_Fz_f-rsGAkGeKkL-6p_Kcg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">346400000</vstm:OperatingLossCarryforwardsPriorToOwnershipChanges>
    <vstm:OperatingLossCarryforwardsInclusiveOfOwnershipChanges
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-5"
      id="Narr_x1KjSe7cjken655z8Qmsgg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">309300000</vstm:OperatingLossCarryforwardsInclusiveOfOwnershipChanges>
    <vstm:OperatingLossCarryforwardsInclusiveOfOwnershipChanges
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-5"
      id="Narr_4YbLVzHN60uS7Lwzwxrk2g"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">309300000</vstm:OperatingLossCarryforwardsInclusiveOfOwnershipChanges>
    <vstm:OperatingLossCarryforwardsSection382Limitation
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-5"
      id="Narr_QnnDUpFdbEOw190IRYE4fQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1600000</vstm:OperatingLossCarryforwardsSection382Limitation>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Narr_W3yA4h-JD0OOfQcFGujI8Q"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-3"
      id="Narr_c6kUPEA-XEOaZrRzwcWkqQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_qSvFppiGn0aQmts7oYl7KA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;15. Commitments and contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into a lease agreement for approximately 27,810 square feet of office space in Needham, Massachusetts.&#160;Please refer to &lt;i style="font-style:italic;"&gt;Note 9. Leases &lt;/i&gt;for further details regarding the minimum aggregate future lease commitments as of December 31, 2025. In&#160;conjunction with the execution of the February 2018 Amended Lease Agreement and November 2024 Amended Lease Agreement, the Company has provided a security deposit in the form of a letter of credit in the amount of $0.2 million as of December 31, 2025, and 2024.&#160;The amount is included in non-current restricted cash on the consolidated balance sheets as of December 31, 2025, and 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;As of December 31, 2025, the Company has committed to spend approximately &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$48.1&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million under the IQVIA Master Services Agreement which the Company expects to spend in the next two to three years. As of December 31, 2025, &lt;/span&gt;approximately $13.7&#160;million of this commitment is included within vendor financing arrangements, accrued expenses, and accounts payable on the consolidated balance sheets.&#160;Pursuant to the terms of various other agreements, the Company may be required to pay various development, regulatory and commercial milestones. In addition, if any products related to these agreements are approved for sale, the Company may be required to pay significant royalties on future sales. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurring.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_2_15_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_xJV-v7FV5UyE4Ztk9gpPcA"
      decimals="0"
      id="Narr_pZuwAYzNgUSmBa03KzrK3A"
      unitRef="Unit_Standard_sqft_FdbiNq8DNkeaOGqvsWqN6A">27810</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2024_us-gaap_BalanceSheetLocationAxis_vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_10pAZepk4k-KD0pKIdmI3Q"
      decimals="-5"
      id="Narr_j4Nt916JV0Op6w0ow7MTGg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">200000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2025_us-gaap_BalanceSheetLocationAxis_vstm_RestrictedCashAndCashEquivalentsNoncurrentMember_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_vstm_OfficeAndLaboratorySpaceLeaseArrangementMember_ursq9MeRN0yWn5gbwLYHOg"
      decimals="-5"
      id="Narr_IC3-28NonEupuQYupgoxQg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">200000</us-gaap:SecurityDeposit>
    <us-gaap:OtherCommitment
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_vstm_IqviaIncMember_sAB2nn3xb06KIRwK0qRhxA"
      decimals="-5"
      id="Narr_UqB8p4xzDECPbK61XWyt6A"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">48100000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_vstm_IqviaIncMember_us-gaap_BalanceSheetLocationAxis_vstm_AccountsPayableCurrentMember_EPTDxkm6dUGE_Y2j9gCeGg"
      decimals="-5"
      id="Narr_AIwKFm7hS0ONUTfsTOWTlg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">13700000</us-gaap:OtherCommitment>
    <vstm:LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_uqNYEUMhiEWaquKFPBo2kA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;16. License, collaboration and commercial agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Pfizer, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On July&#160;11, 2012, the Company entered into a license agreement (the &#x201c;Pfizer Agreement&#x201d;) with Pfizer (&#x201c;Pfizer&#x201d;) under which Pfizer granted the Company worldwide, exclusive rights to research, develop, manufacture and commercialize products containing certain of Pfizer&#x2019;s inhibitors of FAK, including defactinib, for all therapeutic, diagnostic and prophylactic uses in humans. The Company has the right to grant sublicenses under the foregoing licensed rights, subject to certain restrictions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Upon entering into the Pfizer Agreement, the Company made a one-time cash payment to Pfizer in the amount of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.5&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million and issued &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;16,001&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of its common stock. In April 2025, the Company entered into an amendment to the Pfizer Agreement such that a &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$7.5&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million milestone became payable upon FDA approval of AVMAPKI FAKZYNJA CO-PACK on May 8, 2025 (the &#x201c;First Pfizer Milestone&#x201d;), and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$8.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million milestone (the &#x201c;Second Pfizer Milestone&#x201d;) is payable upon the one-year anniversary of the FDA approval of AVMAPKI FAKZYNJA CO-PACK. The Company recorded a &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$15.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million intangible asset related to these payments on the consolidated balance sheets and will record &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.5&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million of interest expense related to the Second Pfizer Milestone. &lt;/span&gt;Pfizer is also eligible to receive up to $2.0&#160;million in developmental milestones and up to an additional $110.0&#160;million based on the successful attainment of regulatory and commercial sales milestones. &lt;span style="color:#212529;background:#ffffff;"&gt;The future milestone payments are contingent in nature and will be recognized if and when the respective contingencies are resolved. &lt;/span&gt;Pfizer is also eligible to receive high single to mid-double-digit royalties on future net sales of the products. The Company&#x2019;s &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;royalty obligations with respect to each product in each country begin on the date of first commercial sale of the product in that country, and end on the later of 10 years after the date of first commercial sale of the product in that country or the date of expiration or abandonment of the last claim contained in any issued patent or patent application licensed by Pfizer to the Company that covers the product in that country.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In the second quarter of 2025, the Company entered into an agreement with a third party to obtain an exclusive license for certain patents and intellectual property related to avutometinib and defactinib (the &#x201c;License Agreement&#x201d;). This agreement covers one of the four patent families that the Company has exclusively licensed and are owned by either Chugai or the third party. Pursuant to the License Agreement, the Company became obligated to pay $2.1 million in the year ended December 31, 2025 and is further obligated to pay up to $2.3 million upon achievement of certain milestones. &lt;span style="background:#ffffff;"&gt;The Company recorded &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$2.1&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million within intangible assets related to these payments on the consolidated balance sheets. &lt;/span&gt;The future milestone payments are contingent in nature and will be recognized if and when the respective contingencies are resolved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;GenFleet Therapeutics (Shanghai), Inc. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;On August 24, 2023, the Company entered into the GenFleet Agreement, pursuant to which GenFleet granted the Company the option to obtain exclusive development and commercialization rights worldwide outside of mainland China, Hong Kong, Macau, and Taiwan (the &#x201c;Territory&#x201d;) for up to three oncology programs targeting RAS pathway driven cancers (the &#x201c;GenFleet Options&#x201d;). The Company may exercise its GenFleet Options on a program-by-program basis.&lt;/span&gt; In January 2025, the Company exercised its GenFleet Option with respect to VS-7375 and made a $6.0 million payment to GenFleet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company made an upfront payment of $2.0 million to GenFleet in September 2023 and will provide $1.5 million of research support over the first three years of the GenFleet Agreement. In addition, pursuant to the GenFleet Agreement, upon achievement of certain milestones, and upon the Company exercising its GenFleet Options, GenFleet will be entitled to receive payments of up to $622.0 million, inclusive of (i) up to $154.0 million upon achievement of certain development and commercialization milestones, (ii) up to $450.0 million upon achievement of certain sales milestones, and (iii) up to $18.0 million upon exercise of all three GenFleet Options. The Company paid GenFleet a $3.0 million milestone in the year ended December 31, 2024, upon GenFleet achieving a development milestone. The Company has also agreed to pay GenFleet royalties on net sales of licensed products in the Territory ranging from the mid to high single digits. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company may terminate the GenFleet Agreement in its entirety or on a program-by-program basis by providing &lt;span style="-sec-ix-hidden:Hidden_JU_oIydDdkuR8-FICIEckw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;90 days&lt;/span&gt;&lt;/span&gt; written notice to GenFleet. Either party may terminate the GenFleet Agreement in its entirety or on a program-by-program and country-by-country basis, with &lt;span style="-sec-ix-hidden:Hidden_AfA5SF6tv0-rw53ZSmEEFw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;60 days&lt;/span&gt;&lt;/span&gt;&#x2019; written notice for the other party&#x2019;s material breach if such party fails to cure the breach. Either party may also terminate the GenFleet Agreement in its entirety upon certain insolvency events involving the other party.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company expensed $6.0 million in January 2025, related to the GenFleet Option payment within&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;research and development expense in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2025. The other future milestone payments are contingent in nature and will be recognized if and when the respective contingencies are resolved. If the Company elects to exercise further GenFleet Options, the related payment will be recognized if and when each respective GenFleet Option is elected.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Secura Bio, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;On August 10, 2020, the Company and Secura signed the Secura APA and on September 30, 2020, the transaction closed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;Pursuant to the Secura APA, the Company sold to Secura its exclusive worldwide license, including related assets, for the research, development, commercialization, and manufacture in oncology indications of products containing duvelisib. The sale included certain intellectual property related to duvelisib in oncology indications, certain existing duvelisib inventory, claims and rights under certain contracts pertaining to duvelisib. Pursuant to the Secura APA, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;Secura assumed all operational and financial responsibility for activities that were part of the Company&#x2019;s duvelisib oncology program, including all commercialization efforts related to duvelisib in the United States and Europe, as well as the Company&#x2019;s ongoing duvelisib clinical trials. Further, Secura assumed all obligations with existing collaboration partners developing and commercializing duvelisib, which include Yakult, Honsha Co., Ltd. (&#x201c;Yakult&#x201d;), CSPC Pharmaceutical Group Limited (&#x201c;CSPC&#x201d;) and Sanofi. Additionally, Secura assumed all royalty payment obligations due under the amended and restated license agreement with Infinity Pharmaceuticals, Inc.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;Pursuant to the terms of the Secura APA, Secura has paid the Company an up-front payment of $70.0 million in September 2020 and has agreed to pay the Company (i) regulatory milestone payments up to $45.0 million, consisting of a payment of $35.0 million upon receipt of regulatory approval of COPIKTRA in the United States for the treatment of peripheral T-cell lymphoma and a payment of $10.0 million upon receipt of the first regulatory approval for the commercial sale of COPIKTRA in the European Union for the treatment of peripheral T-cell lymphoma, (ii)&#160;sales milestone payments of up to $50.0 million, consisting of $10.0 million when total worldwide net sales of COPIKTRA exceed $100.0 million, $15.0 million when total worldwide net sales of COPIKTRA exceed $200.0 million and $25.0 million when total worldwide net sales of COPIKTRA exceed $300.0 million, (iii)&#160;low double-digit royalties on the annual aggregate net sales above $100.0 million in the United States, European Union, and the United Kingdom of Great Britain and Northern Ireland and (iv)&#160;50% of all royalty, milestone and sublicense revenue payments payable to Secura under the Company&#x2019;s existing license agreements with Sanofi, Yakult, and CSPC, and 50% of all royalty and milestone payments payable to Secura under any license or sublicense agreement entered into by Secura in certain jurisdictions.&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;The Company evaluated the Secura APA in accordance with ASC 606 as the Company concluded that the counterparty, Secura, is a customer. The Company identified a bundled performance obligation consisting of delivery of the duvelisib global license and intellectual property, certain existing duvelisib inventory, certain duvelisib contracts and clinical trials, certain regulatory approvals, and certain regulatory documentation and books and records (the &#x201c;Bundled Secura Performance Obligation&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;The Company concluded that the duvelisib global license and intellectual property were not distinct within the context of the contract (i.e. separately identifiable) because the other assets including certain existing duvelisib inventory, certain duvelisib contracts and clinical trials, certain regulatory approval, and certain regulatory documentation and books and records do not have stand-alone value from other duvelisib global license and intellectual property and Secura could not benefit from them without the duvelisib global license and intellectual property. Consistent with the guidance under ASC 606-10-25-16A, the Company disregarded immaterial promised goods and services when determining performance obligations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;The Company determined that the upfront payment of $70.0 million, future potential milestone payments and royalties including from Secura&#x2019;s sublicensees should be allocated to the delivery of the Bundled Secura Performance Obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:2pt;background:#ffffff;margin:0pt;"&gt;During the years ended December 31, 2025 and 2023, the Company has not recognized any revenue associated with the Secura APA. During the year end ended December 31, 2024, Secura achieved $100.0 million of total worldwide net sales of COPIKTRA which triggered a $10.0 million sales milestone payment to the Company under the Secura APA. The Company received the $10.0 million milestone payment in July 2024. The Company determined all future potential milestones and royalties were excluded from the transaction price, as all other milestone amounts were fully constrained under the guidance as of December 31, 2025. As part of the Company&#x2019;s evaluation of the constraint, the Company considered several factors in determining whether there is significant uncertainty associated with the future events that would result in the milestone payments. Those factors included: the likelihood and magnitude of revenue reversals related to future milestones, the amount of variable consideration that is highly susceptible to factors outside of the Company&#x2019;s influence and the uncertainty about the consideration is not expected to be resolved for an extended period of time. All future potential milestone payments were fully constrained as the risk of significant revenue reversal related to these amounts has not yet been resolved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</vstm:LicenseCollaborationAndCommercialAgreementsDisclosureTextBlock>
    <vstm:CollaborativeArrangementsOneTimeCashPayment
      contextRef="Duration_7_11_2012_To_7_11_2012_srt_CounterpartyNameAxis_vstm_PfizerIncMember_BItiDfIFn0WcHJLqHz3mqw"
      decimals="-5"
      id="Narr_ZzKe_pPeE0ee_y71j0pv7A"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1500000</vstm:CollaborativeArrangementsOneTimeCashPayment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_11_2012_To_7_11_2012_srt_CounterpartyNameAxis_vstm_PfizerIncMember_BItiDfIFn0WcHJLqHz3mqw"
      decimals="INF"
      id="Narr_PLU6nhbT3kenrl1t8x7tNA"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">16001</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vstm:PotentialMilestonePayments
      contextRef="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_srt_StatementScenarioAxis_vstm_AchievementOfFdaApprovalMember_tZQwQiMhYEqbPdhEQQ5HEg"
      decimals="-5"
      id="Narr_YZ0jjP1-1Eus1JCP0Yv5zg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">7500000</vstm:PotentialMilestonePayments>
    <vstm:PotentialMilestonePayments
      contextRef="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_srt_StatementScenarioAxis_vstm_AchievementOfFdaApprovalAnniversaryMember_xTJSoxkVBEah1aNhnYblRg"
      decimals="-5"
      id="Narr_Ou3APzVRxkeHI-fE4E--kA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">8000000</vstm:PotentialMilestonePayments>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_6KQR_VTJyEGtpgOTeeNfig"
      decimals="-5"
      id="Narr_XIn-mKgYYUC0lzF4XPb6_w"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">15000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:InterestExpense
      contextRef="Duration_4_1_2025_To_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_QSij2lq4ik6s4CjD_2yz9A"
      decimals="-5"
      id="Narr_rUjGt1UzuU67XfjUj2A-lA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">500000</us-gaap:InterestExpense>
    <vstm:PotentialMilestonePayments
      contextRef="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_srt_StatementScenarioAxis_vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_o3q236vw0keqOsqNBTnifA"
      decimals="-5"
      id="Narr__9CtRLmHFEWuhUQ9N7EM2g"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2000000</vstm:PotentialMilestonePayments>
    <vstm:PotentialMilestonePayments
      contextRef="As_Of_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_srt_StatementScenarioAxis_vstm_AchievementOfCertainSalesMilestonesMember_31ejtZ8BeEqgLwzBvmRC6g"
      decimals="-5"
      id="Narr_ub-U_3HMuUesuNF6q3Q8mw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">110000000</vstm:PotentialMilestonePayments>
    <vstm:CollaborativeArrangementsRoyaltyObligationsTerm
      contextRef="Duration_4_1_2025_To_4_30_2025_srt_CounterpartyNameAxis_vstm_PfizerIncMember_QSij2lq4ik6s4CjD_2yz9A"
      id="Narr__1n89cEUfEGU6nOQKs3Vpw">P10Y</vstm:CollaborativeArrangementsRoyaltyObligationsTerm>
    <vstm:NumberOfPatents
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_ouTeCHDu4Ey5RJk0ycXIKQ"
      decimals="INF"
      id="Narr_nH9fU2iWSUCY3yJFtMupyQ"
      unitRef="Unit_Standard_item_5quK1hZThku2W0bLLpUodA">1</vstm:NumberOfPatents>
    <vstm:CollaborativeArrangementsOneTimeCashPayment
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_StatementScenarioAxis_vstm_PursuantToLicenseAgreementMember_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_VDan3WYf1EevGGqNXzZ9hw"
      decimals="-5"
      id="Narr_G2SJlGQ4SkaxzMo176C02g"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2100000</vstm:CollaborativeArrangementsOneTimeCashPayment>
    <vstm:PotentialMilestonePayments
      contextRef="As_Of_12_31_2025_srt_StatementScenarioAxis_vstm_AchievementOfCertainSalesMilestonesMember_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_zzkKq8OR_UOKfHUpO3ZAdw"
      decimals="-5"
      id="Narr_D7P71K3VUE2knSI4meYg0Q"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2300000</vstm:PotentialMilestonePayments>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_vstm_ExclusiveLicenseAgreementMember_Uj6ZHm1iCka91Tq8-q7rTA"
      decimals="-5"
      id="Narr_8CwrDyWre0uOwGtQEzcChA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <vstm:LicenseAndCollaborationAgreementsDevelopmentMilestonePayments
      contextRef="Duration_1_1_2025_To_1_31_2025_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_lGAzc-lkAkKmcWT8YEBiIg"
      decimals="-5"
      id="Narr_i4eOvFsclkKiR1sqOuQmEQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6000000</vstm:LicenseAndCollaborationAgreementsDevelopmentMilestonePayments>
    <vstm:LicenseAndCollaborationAgreementUpfrontPayment
      contextRef="Duration_8_24_2023_To_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_dsxUwW56ZECoNMCxu8ilPA"
      decimals="-5"
      id="Narr_bzOWYvAawEyFoeMOd_OWsw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">2000000</vstm:LicenseAndCollaborationAgreementUpfrontPayment>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="Duration_8_24_2023_To_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_us-gaap_ResearchAndDevelopmentArrangementMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_tYSyxNxH1Uuvalr8k9zyHg"
      decimals="-5"
      id="Narr_A6tbtSTC30qgC7poTyxQkA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1500000</us-gaap:LongTermPurchaseCommitmentAmount>
    <vstm:PotentialMilestonePayments
      contextRef="As_Of_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_E2vhbuJLHEynsOukxWJq3A"
      decimals="-5"
      id="Narr_I42TUiXmVUOpoNT6fW3xJQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">622000000</vstm:PotentialMilestonePayments>
    <vstm:PotentialMilestonePayments
      contextRef="As_Of_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_vstm_AchievementOfCertainDevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_39lEE9M2vkGrczaWHlXE3Q"
      decimals="-5"
      id="Narr_lLVuopybTUOytKReUaOe_Q"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">154000000</vstm:PotentialMilestonePayments>
    <vstm:PotentialMilestonePayments
      contextRef="As_Of_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_vstm_AchievementOfCertainSalesMilestonesMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_njuY9ME3DkeF5IZXfRJNAw"
      decimals="-5"
      id="Narr_3MbZifsPyUqFTFOst0QyPQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">450000000</vstm:PotentialMilestonePayments>
    <vstm:PotentialMilestonePayments
      contextRef="As_Of_8_24_2023_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_vstm_ExerciseOfAllThreeGenFleetOptionsMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_o_C5UTUcQ0-Z9MtY_JiXjQ"
      decimals="-5"
      id="Narr_1LYqd2Z1okmjST72I88ILA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">18000000</vstm:PotentialMilestonePayments>
    <vstm:LicenseAndCollaborationAgreementsDevelopmentMilestonePayments
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_DF8qnE1w-kGq9_Ct4jgrAw"
      decimals="-5"
      id="Narr_pHaDAEy95UCHLcjk7wgUIw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">3000000</vstm:LicenseAndCollaborationAgreementsDevelopmentMilestonePayments>
    <vstm:LicenseAndCollaborationAgreementUpfrontPayment
      contextRef="Duration_1_1_2025_To_1_31_2025_srt_CounterpartyNameAxis_vstm_GenfleetTherapeuticsShanghaiIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_lGAzc-lkAkKmcWT8YEBiIg"
      decimals="-5"
      id="Narr_V5LivzhygEuiMIKbBcZcQQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">6000000</vstm:LicenseAndCollaborationAgreementUpfrontPayment>
    <vstm:LicenseAndCollaborationAgreementUpfrontPayment
      contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_9WaY4ozWNUCB3Lci8zTJtg"
      decimals="-5"
      id="Narr_65u5y9BM7UmPEpH8WOD1CA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">70000000</vstm:LicenseAndCollaborationAgreementUpfrontPayment>
    <vstm:LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_besuRyf8Y0a58JN5tevWUA"
      decimals="-5"
      id="Narr_kYmAE6QIUEGwIl3DY4woaA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">45000000</vstm:LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivable>
    <vstm:LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_K33i8h8swEuknRDePz8siA"
      decimals="-5"
      id="Narr_xHlCCe7Zok-7rQnvoIMqVA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">35000000</vstm:LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalOfCopiktra>
    <vstm:LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_K33i8h8swEuknRDePz8siA"
      decimals="-5"
      id="Narr_ArzA6gUC7UGBtOYPEWWrhg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">10000000</vstm:LicenseAndCollaborationAgreementsRegulatoryMilestonePaymentsReceivableUponApprovalForCommercialSale>
    <vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceivable
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_besuRyf8Y0a58JN5tevWUA"
      decimals="-5"
      id="Narr_rjU_onl1y0qC1jog8NM6Cg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">50000000</vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceivable>
    <vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceivable
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_m7dZCqcrSkuva19JwTUE4A"
      decimals="-5"
      id="Narr_kk3DiRmR70WZNF38pp9i_A"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">10000000</vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceivable>
    <vstm:LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments
      contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_4eTmUVOzd0mGjZsxlu90SQ"
      decimals="-5"
      id="Narr_z45xOCDmEk2_9_AB70pRBA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">100000000</vstm:LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments>
    <vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceivable
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_5YDVN68wcUm0VSa7Wv493Q"
      decimals="-5"
      id="Narr_aan3tHkYlUyGhT-t6716gw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">15000000</vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceivable>
    <vstm:LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments
      contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds200MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_8uqSrXDV0EmTZ1ByOF2jBA"
      decimals="-5"
      id="Narr_aVjlPO5q1kWa0T1iFn13vA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">200000000</vstm:LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments>
    <vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceivable
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_MdVGT0IgvUmbjCVDMtrXUg"
      decimals="-5"
      id="Narr_5AMju06YAkG6hW2BrqXoCw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">25000000</vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceivable>
    <vstm:LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments
      contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds300MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_e8TDv-L8LUauwZTI1obpiw"
      decimals="-5"
      id="Narr_zIrxnzpG5E2V1pbpYuJ2IQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">300000000</vstm:LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments>
    <vstm:LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments
      contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_9WaY4ozWNUCB3Lci8zTJtg"
      decimals="-5"
      id="Narr_rx1-rz4oh0Ky1rgHmsLanA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">100000000</vstm:LicenseAndCollaborationAgreementsThresholdSalesToTriggerRoyaltyPayments>
    <vstm:LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements
      contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_9WaY4ozWNUCB3Lci8zTJtg"
      decimals="2"
      id="Narr_fu3zGolnDEqxuhEXDKuwiQ"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.50</vstm:LicenseAndCollaborationAgreementsPercentageOfRoyaltyMilestoneAndSubLicensingRevenuePaymentsEntitledUnderExistingLicenseAgreements>
    <vstm:LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions
      contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_9WaY4ozWNUCB3Lci8zTJtg"
      decimals="2"
      id="Narr_-cJtIjIFYEuMfDJRK8VKDw"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.50</vstm:LicenseAndCollaborationAgreementsPercentageOfRoyaltyAndMilestonePaymentsEntitledUnderCertainJurisdictions>
    <vstm:LicenseAndCollaborationAgreementUpfrontPayment
      contextRef="Duration_9_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_9WaY4ozWNUCB3Lci8zTJtg"
      decimals="-5"
      id="Narr_oM0ljkvrmkCpuHQhARTX8A"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">70000000</vstm:LicenseAndCollaborationAgreementUpfrontPayment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_C_jlzU3foUSnLHdbsgYZFQ"
      decimals="-5"
      id="Narr_UHLrNE9FL0Of3kuI8YTcqQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_ProductOrServiceAxis_vstm_CopiktraLicenseAndRelatedAssetsMember_VByLpZd3oUumXTdQ76R5ZA"
      decimals="-5"
      id="Narr_3qs7hlQl80mWqkv3AXhwOA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <vstm:LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_pEx0srU5Ak2GiczyEYhqRA"
      decimals="-5"
      id="Narr__RKHjmk9U0a4gnN6SUPcJQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">100000000</vstm:LicenseAndCollaborationAgreementsThresholdSalesToTriggerMilestonePayments>
    <vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceivable
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_s7JVz9MorkeAVWRt5OMAbQ"
      decimals="-5"
      id="Narr_HfRulA2hOEGfp3m6N7hKLQ"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">10000000</vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceivable>
    <vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceived
      contextRef="As_Of_7_31_2024_srt_CounterpartyNameAxis_vstm_SecuraBioIncMember_srt_StatementScenarioAxis_vstm_LicenseAndCollaborationAgreementIfSalesExceeds100MillionMember_us-gaap_TypeOfArrangementAxis_vstm_LicenseAndCollaborationAgreementMember_ipNYPIX9lkyb7J4LRrkchw"
      decimals="-5"
      id="Narr_BelGm00V8UiElbcg5CRptA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">10000000</vstm:LicenseAndCollaborationAgreementsSalesMilestoneReceived>
    <us-gaap:LongTermDebtTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_NJxOhUJO1EmeGUIZ3kLQFQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;17. Notes Payable&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2025, the&#160;Company entered into a finance agreement with FIRST Insurance Funding (&#x201c;First Insurance&#x201d;). Pursuant to the terms of the agreement, First Insurance loaned the Company the principal amount of $1.2&#160;million, which accrued interest at&#160;6.9% per annum, to fund a portion of the Company&#x2019;s insurance policies. Pursuant to the agreement with First Insurance, the Company made an initial payment of $0.3&#160;million and made monthly payments of $0.1&#160;million through November 2025 including principal and interest. The agreement assigned First Insurance a first priority lien and security interest in the financed insurance policies. The outstanding balance at December 31, 2025 was $0.0 million.&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_UhCOi_V-Yk--a9CzLZu_Og"
      decimals="-5"
      id="Narr_eSvBjsigkkqMMNMOz8CBVA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_UhCOi_V-Yk--a9CzLZu_Og"
      decimals="3"
      id="Narr_j3O5WTG_3kKYoAOn8n99Zw"
      unitRef="Unit_Standard_pure_mG8yxnlnLkyzMwmt3tYhyA">0.069</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="Duration_1_1_2025_To_1_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_cQjwjoVWG0yneJwH7D4Q0A"
      decimals="-5"
      id="Narr_5uvVG5paxUe11kMirM4Btg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">300000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_1_1_2025_To_1_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_cQjwjoVWG0yneJwH7D4Q0A"
      decimals="-5"
      id="Narr_ivLEuVvX6ESBRh6zmLU0Xg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">100000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2025_us-gaap_DebtInstrumentAxis_vstm_FirstInsuranceFundingMember_SnnAtXkpqkWQ3yAjnYmU6A"
      decimals="-5"
      id="Narr_BE3jKUEIUk6CPYLR7LprJw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">0</us-gaap:NotesPayable>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_Y5Qe83xppUWu55zjh9d0nQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;18. Employee benefit Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2011, the Company adopted a 401(k) retirement and savings plan (the 401(k) Plan) covering all employees. The 401(k) Plan allows employees to make pre-tax or post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. Under the 401(k) Plan, the Company may make discretionary contributions as approved by the board of directors. The Company made contributions to the 401(k) Plan of approximately $1.3 million, $1.0 million and $0.8 million in each of the years ended December 31, 2025, 2024, and 2023.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      decimals="-5"
      id="Narr_vkGRqBYgT0ucgR3_P4wMhA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2024_To_12_31_2024_xMdkKjPgW0GbyyBgPMjD0g"
      decimals="-5"
      id="Narr_b3vC4Rx4g0aqYLsThWiVMg"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">1000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2023_To_12_31_2023_XTHLzQwWOkG5ktM-9QIXRw"
      decimals="-5"
      id="Narr_l1fXgCptBka33IQJbCNMpA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:SupplierFinanceProgramTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_9vvzqG6QEEKSb1jacUaQnQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;19. Vendor Financing Arrangement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the IQVIA Master Services Agreement, the Company has extended payment terms with respect to a portion of the services provided and has recorded a vendor financing arrangement liability of $10.3 million as of December 31, 2025. The Company expects to pay the amounts recorded as &lt;span style="-sec-ix-hidden:Hidden_gxfwXUi5dECGg1py2bW53w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;vendor financing arrangement&lt;/span&gt;&lt;/span&gt; liabilities during 2026 and 2027.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplierFinanceProgramTextBlock>
    <us-gaap:SupplierFinanceProgramObligation
      contextRef="As_Of_12_31_2025_REgfnBAVkUCEU1YA6bD2bA"
      decimals="-5"
      id="Narr_teAUrGtRdEmmKG_LInDAQw"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">10300000</us-gaap:SupplierFinanceProgramObligation>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_Fv-iBdRe-0y1RLL2WRVYDg"
      id="Tb_-K8JldTAMU2fTRCmVk-xKg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;20. Subsequent events &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"&gt;The Company reviews all activity subsequent to year end but prior to the issuance of the consolidated financial statements for events that could require disclosure or that could impact the carrying value of assets or liabilities as of the consolidated balance sheet date. The Company is not aware of any material subsequent events other than the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants exercise&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:0pt;"&gt;In January 2026, 8,391,666 Warrants were exercised. As a result, the Company issued 8,391,666 shares of common stock and received net proceeds of $29.4 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note Purchase Agreement amendment&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;In March 2026, the Company amended the Note Purchase Agreement to extend the date the Company may draw the Second Purchase from December 31, 2025 to June 30, 2026. Refer to&#160;&lt;i style="font-style:italic;"&gt;Note 8. Long-term debt&lt;/i&gt;&#160;for additional details on the Note Purchase Agreement.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <vstm:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7S9Co7osyUKPh1S2Fr2wNQ"
      decimals="INF"
      id="Narr_AhFzGskOdkWVFeV8CyXZ_A"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">8391666</vstm:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7S9Co7osyUKPh1S2Fr2wNQ"
      decimals="INF"
      id="Narr_BlOYbgwzkk6PQkVV5uIfWQ"
      unitRef="Unit_Standard_shares_kMBnisb68UmReEq4DLIlNw">8391666</vstm:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7S9Co7osyUKPh1S2Fr2wNQ"
      decimals="-5"
      id="Narr_WTJKQbbpZk6M4Lo_HMR-mA"
      unitRef="Unit_Standard_USD_A-nSv7SUbE-mQAl0vd_z5w">29400000</us-gaap:ProceedsFromWarrantExercises>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
